@prefix xsd:<http://www.w3.org/2001/XMLSchema#> .
@prefix civic: <http://purl.jp/bio/10/civic/> .
@prefix civico: <http://purl.jp/bio/10/civic/ontology#> .
@prefix civicg: <https://civic.genome.wustl.edu/links/genes/> .
@prefix civicv: <https://civic.genome.wustl.edu/links/variants/> .
@prefix civice: <https://civic.genome.wustl.edu/links/evidence_items/> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix ensembl: <http://identifiers.org/ensembl/> .
@prefix faldo: <http://biohackathon.org/resource/faldo#> .
@prefix hco: <http://identifiers.org/hco/> .
@prefix m2r: <http://med2rdf/org/ontology/med2rdf#> .
@prefix pbm: <http://identifiers.org/pubmed/> .
@prefix sio: <http://semanticscience.org/resource/> .
@prefix dct:<http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .

civicg:28
    rdfs:seeAlso <http://identifiers.org/ncbigene/3717> ;
    dcterms:identifier "28" ;
    m2r:variation civicv:64,civicv:571,civicv:615,civicv:1681 ;
    rdfs:label "JAK2" ;
    a m2r:Gene .

civicg:38
    rdfs:seeAlso <http://identifiers.org/ncbigene/5156> ;
    dcterms:identifier "38" ;
    m2r:variation civicv:99,civicv:98,civicv:100,civicv:101,civicv:102,civicv:247,civicv:567,civicv:574,civicv:577,civicv:716,civicv:774,civicv:862,civicv:863,civicv:864,civicv:865 ;
    rdfs:label "PDGFRA" ;
    a m2r:Gene .

civicg:18
    rdfs:seeAlso <http://identifiers.org/ncbigene/1788> ;
    dcterms:identifier "18" ;
    m2r:variation civicv:32,civicv:189 ;
    rdfs:label "DNMT3A" ;
    a m2r:Gene .

civicg:30
    rdfs:seeAlso <http://identifiers.org/ncbigene/3845> ;
    dcterms:identifier "30" ;
    m2r:variation civicv:76,civicv:77,civicv:75,civicv:425,civicv:81,civicv:78,civicv:79,civicv:148,civicv:80,civicv:203,civicv:254,civicv:322,civicv:336,civicv:479,civicv:530,civicv:592,civicv:906,civicv:905,civicv:913,civicv:907 ;
    rdfs:label "KRAS" ;
    a m2r:Gene .

civicg:36
    rdfs:seeAlso <http://identifiers.org/ncbigene/4893> ;
    dcterms:identifier "36" ;
    m2r:variation civicv:94,civicv:93,civicv:95,civicv:96,civicv:208,civicv:92,civicv:427,civicv:596,civicv:878,civicv:1654 ;
    rdfs:label "NRAS" ;
    a m2r:Gene .

civicg:31
    rdfs:seeAlso <http://identifiers.org/ncbigene/5604> ;
    dcterms:identifier "31" ;
    m2r:variation civicv:82,civicv:83,civicv:627,civicv:655,civicv:1272 ;
    rdfs:label "MAP2K1" ;
    a m2r:Gene .

civicg:3
    rdfs:seeAlso <http://identifiers.org/ncbigene/369> ;
    dcterms:identifier "3" ;
    m2r:variation civicv:10,civicv:825 ;
    rdfs:label "ARAF" ;
    a m2r:Gene .

civicg:29
    rdfs:seeAlso <http://identifiers.org/ncbigene/3815> ;
    dcterms:identifier "29" ;
    m2r:variation civicv:65,civicv:72,civicv:66,civicv:69,civicv:73,civicv:67,civicv:201,civicv:202,civicv:256,civicv:388,civicv:429,civicv:482,civicv:509,civicv:586,civicv:986,civicv:978,civicv:1263,civicv:989,civicv:1264,civicv:1265,civicv:1266,civicv:983,civicv:1267,civicv:968 ;
    rdfs:label "KIT" ;
    a m2r:Gene .

civicg:5
    rdfs:seeAlso <http://identifiers.org/ncbigene/673> ;
    dcterms:identifier "5" ;
    m2r:variation civicv:17,civicv:13,civicv:12,civicv:14,civicv:11,civicv:184,civicv:285,civicv:286,civicv:287,civicv:288,civicv:399,civicv:426,civicv:522,civicv:563,civicv:579,civicv:580,civicv:581,civicv:582,civicv:583,civicv:584,civicv:585,civicv:611,civicv:617,civicv:618,civicv:656,civicv:657,civicv:658,civicv:694,civicv:1269,civicv:2408,civicv:1106,civicv:992,civicv:2221,civicv:1186,civicv:2222,civicv:1627,civicv:2223,civicv:2224,civicv:2225,civicv:2226,civicv:2227,civicv:2228,civicv:2229,civicv:993,civicv:2361,civicv:2398 ;
    rdfs:label "BRAF" ;
    a m2r:Gene .

civicg:1
    rdfs:seeAlso <http://identifiers.org/ncbigene/238> ;
    dcterms:identifier "1" ;
    m2r:variation civicv:8,civicv:9,civicv:7,civicv:608,civicv:5,civicv:170,civicv:171,civicv:172,civicv:173,civicv:307,civicv:308,civicv:6,civicv:352,civicv:499,civicv:500,civicv:501,civicv:503,civicv:512,civicv:513,civicv:514,civicv:520,civicv:527,civicv:528,civicv:549,civicv:550,civicv:551,civicv:552,civicv:588,civicv:589,civicv:839,civicv:2220 ;
    rdfs:label "ALK" ;
    a m2r:Gene .

civicg:24
    rdfs:seeAlso <http://identifiers.org/ncbigene/2322> ;
    dcterms:identifier "24" ;
    m2r:variation civicv:55,civicv:519,civicv:56,civicv:437,civicv:540,civicv:603,civicv:612,civicv:613,civicv:1302 ;
    rdfs:label "FLT3" ;
    a m2r:Gene .

civicg:42
    rdfs:seeAlso <http://identifiers.org/ncbigene/5979> ;
    dcterms:identifier "42" ;
    m2r:variation civicv:113,civicv:112,civicv:273,civicv:295,civicv:597,civicv:626,civicv:1260,civicv:1687 ;
    rdfs:label "RET" ;
    a m2r:Gene .

civicg:37
    rdfs:seeAlso <http://identifiers.org/ncbigene/5290> ;
    dcterms:identifier "37" ;
    m2r:variation civicv:103,civicv:106,civicv:105,civicv:107,civicv:104,civicv:212,civicv:294,civicv:311,civicv:883,civicv:1653,civicv:2336,civicv:2337 ;
    rdfs:label "PIK3CA" ;
    a m2r:Gene .

civicg:35
    rdfs:seeAlso <http://identifiers.org/ncbigene/4869> ;
    dcterms:identifier "35" ;
    m2r:variation civicv:86,civicv:87 ;
    rdfs:label "NPM1" ;
    a m2r:Gene .

civicg:15
    rdfs:seeAlso <http://identifiers.org/ncbigene/1050> ;
    dcterms:identifier "15" ;
    m2r:variation civicv:29,civicv:28,civicv:594 ;
    rdfs:label "CEBPA" ;
    a m2r:Gene .

civicg:49
    rdfs:seeAlso <http://identifiers.org/ncbigene/7490> ;
    dcterms:identifier "49" ;
    m2r:variation civicv:129,civicv:130 ;
    rdfs:label "WT1" ;
    a m2r:Gene .

civicg:23
    rdfs:seeAlso <http://identifiers.org/ncbigene/2261> ;
    dcterms:identifier "23" ;
    m2r:variation civicv:53,civicv:196,civicv:325,civicv:628,civicv:827,civicv:830 ;
    rdfs:label "FGFR3" ;
    a m2r:Gene .

civicg:46
    rdfs:seeAlso <http://identifiers.org/ncbigene/7248> ;
    dcterms:identifier "46" ;
    m2r:variation civicv:124,civicv:125,civicv:714 ;
    rdfs:label "TSC1" ;
    a m2r:Gene .

civicg:26
    rdfs:seeAlso <http://identifiers.org/ncbigene/3417> ;
    dcterms:identifier "26" ;
    m2r:variation civicv:58,civicv:59,civicv:420,civicv:645,civicv:880,civicv:928 ;
    rdfs:label "IDH1" ;
    a m2r:Gene .

civicg:34
    rdfs:seeAlso <http://identifiers.org/ncbigene/4255> ;
    dcterms:identifier "34" ;
    m2r:variation civicv:85,civicv:338,civicv:1255 ;
    rdfs:label "MGMT" ;
    a m2r:Gene .

civicg:6
    rdfs:seeAlso <http://identifiers.org/ncbigene/672> ;
    dcterms:identifier "6" ;
    m2r:variation civicv:131,civicv:185,civicv:397,civicv:403,civicv:477,civicv:709,civicv:1236,civicv:1237,civicv:1238,civicv:1239,civicv:1240,civicv:1241,civicv:1242,civicv:1243,civicv:1244,civicv:1245,civicv:1246,civicv:1555 ;
    rdfs:label "BRCA1" ;
    a m2r:Gene .

civicg:7
    rdfs:seeAlso <http://identifiers.org/ncbigene/675> ;
    dcterms:identifier "7" ;
    m2r:variation civicv:132,civicv:186,civicv:661,civicv:708,civicv:1247,civicv:1248,civicv:1249,civicv:1250,civicv:1251,civicv:1252,civicv:1253 ;
    rdfs:label "BRCA2" ;
    a m2r:Gene .

civicg:4
    rdfs:seeAlso <http://identifiers.org/ncbigene/25> ;
    dcterms:identifier "4" ;
    m2r:variation civicv:1,civicv:3,civicv:2,civicv:241,civicv:892,civicv:1021,civicv:1022,civicv:1023,civicv:1024,civicv:1025,civicv:1026,civicv:1027,civicv:1029,civicv:1030,civicv:1152,civicv:1173,civicv:1183,civicv:1184,civicv:1230,civicv:1231,civicv:1232,civicv:1233,civicv:1487,civicv:1488,civicv:1506,civicv:1507,civicv:1509,civicv:1523,civicv:1526,civicv:1528,civicv:1529,civicv:1530,civicv:1531,civicv:1532,civicv:1534,civicv:1535,civicv:1537,civicv:1657,civicv:2335,civicv:1525,civicv:2340,civicv:1625,civicv:2343,civicv:2359,civicv:1609,civicv:2370,civicv:2371,civicv:2375,civicv:2376 ;
    rdfs:label "ABL1" ;
    a m2r:Gene .

civicg:48
    rdfs:seeAlso <http://identifiers.org/ncbigene/7307> ;
    dcterms:identifier "48" ;
    m2r:variation civicv:127,civicv:128,civicv:521 ;
    rdfs:label "U2AF1" ;
    a m2r:Gene .

civicg:9
    rdfs:seeAlso <http://identifiers.org/ncbigene/894> ;
    dcterms:identifier "9" ;
    m2r:variation civicv:22,civicv:21 ;
    rdfs:label "CCND2" ;
    a m2r:Gene .

civicg:8
    rdfs:seeAlso <http://identifiers.org/ncbigene/595> ;
    dcterms:identifier "8" ;
    m2r:variation civicv:20,civicv:19,civicv:18 ;
    rdfs:label "CCND1" ;
    a m2r:Gene .

civicg:19
    rdfs:seeAlso <http://identifiers.org/ncbigene/1956> ;
    dcterms:identifier "19" ;
    m2r:variation civicv:33,civicv:34,civicv:133,civicv:134,civicv:190,civicv:191,civicv:193,civicv:252,civicv:453,civicv:312,civicv:317,civicv:354,civicv:375,civicv:390,civicv:415,civicv:443,civicv:454,civicv:455,civicv:460,civicv:562,civicv:442,civicv:712,civicv:718,civicv:720,civicv:723,civicv:724,civicv:736,civicv:726,civicv:1854,civicv:999,civicv:2174,civicv:1020,civicv:994,civicv:995,civicv:996,civicv:1001,civicv:1420,civicv:1891,civicv:1892,civicv:1894,civicv:1895,civicv:1896,civicv:1897,civicv:1457,civicv:1899,civicv:1463,civicv:1466,civicv:1012,civicv:1445,civicv:1446,civicv:1017,civicv:1018,civicv:1866,civicv:1482,civicv:1181,civicv:1513,civicv:1514,civicv:1187,civicv:1188,civicv:1515,civicv:1566,civicv:1571,civicv:1572,civicv:1573,civicv:1574,civicv:1575,civicv:1579,civicv:1477,civicv:1863,civicv:1664,civicv:1665,civicv:1666,civicv:1667,civicv:1668,civicv:1765,civicv:2333,civicv:2334 ;
    rdfs:label "EGFR" ;
    a m2r:Gene .

civicg:2
    rdfs:seeAlso <http://identifiers.org/ncbigene/207> ;
    dcterms:identifier "2" ;
    m2r:variation civicv:4,civicv:169,civicv:2360 ;
    rdfs:label "AKT1" ;
    a m2r:Gene .

civicg:20
    rdfs:seeAlso <http://identifiers.org/ncbigene/2064> ;
    dcterms:identifier "20" ;
    m2r:variation civicv:39,civicv:35,civicv:36,civicv:37,civicv:38,civicv:40,civicv:41,civicv:42,civicv:43,civicv:44,civicv:45,civicv:306,civicv:413,civicv:414,civicv:416,civicv:496,civicv:497,civicv:666,civicv:816,civicv:817,civicv:818,civicv:871,civicv:872,civicv:873,civicv:874,civicv:875 ;
    rdfs:label "ERBB2" ;
    a m2r:Gene .

civicg:21
    rdfs:seeAlso <http://identifiers.org/ncbigene/2099> ;
    dcterms:identifier "21" ;
    m2r:variation civicv:46,civicv:47,civicv:48,civicv:49,civicv:50,civicv:607,civicv:692 ;
    rdfs:label "ESR1" ;
    a m2r:Gene .

civicg:10
    rdfs:seeAlso <http://identifiers.org/ncbigene/896> ;
    dcterms:identifier "10" ;
    m2r:variation civicv:23 ;
    rdfs:label "CCND3" ;
    a m2r:Gene .

civicg:13
    rdfs:seeAlso <http://identifiers.org/ncbigene/1019> ;
    dcterms:identifier "13" ;
    m2r:variation civicv:25,civicv:553,civicv:556 ;
    rdfs:label "CDK4" ;
    a m2r:Gene .

civicg:51
    rdfs:seeAlso <http://identifiers.org/ncbigene/4921> ;
    dcterms:identifier "51" ;
    m2r:variation civicv:141,civicv:142,civicv:144,civicv:143,civicv:140,civicv:139,civicv:145 ;
    rdfs:label "DDR2" ;
    a m2r:Gene .

civicg:22
    rdfs:seeAlso <http://identifiers.org/ncbigene/2263> ;
    dcterms:identifier "22" ;
    m2r:variation civicv:52,civicv:54,civicv:511,civicv:545,civicv:629,civicv:782,civicv:783,civicv:828,civicv:2202,civicv:2206 ;
    rdfs:label "FGFR2" ;
    a m2r:Gene .

civicg:25
    rdfs:seeAlso <http://identifiers.org/ncbigene/2624> ;
    dcterms:identifier "25" ;
    m2r:variation civicv:57 ;
    rdfs:label "GATA2" ;
    a m2r:Gene .

civicg:39
    rdfs:seeAlso <http://identifiers.org/ncbigene/5371> ;
    dcterms:identifier "39" ;
    m2r:variation civicv:108,civicv:461,civicv:462,civicv:463 ;
    rdfs:label "PML" ;
    a m2r:Gene .

civicg:41
    rdfs:seeAlso <http://identifiers.org/ncbigene/5728> ;
    dcterms:identifier "41" ;
    m2r:variation civicv:110,civicv:213,civicv:214,civicv:313,civicv:510,civicv:605,civicv:636,civicv:838 ;
    rdfs:label "PTEN" ;
    a m2r:Gene .

civicg:45
    rdfs:seeAlso <http://identifiers.org/ncbigene/7157> ;
    dcterms:identifier "45" ;
    m2r:variation civicv:116,civicv:117,civicv:118,civicv:119,civicv:121,civicv:122,civicv:221,civicv:222,civicv:223,civicv:242,civicv:369,civicv:504,civicv:531,civicv:918,civicv:922,civicv:1306,civicv:1068,civicv:1307,civicv:1108,civicv:1109,civicv:1300,civicv:879,civicv:1066,civicv:1695,civicv:1092,civicv:1696,civicv:1697,civicv:1698,civicv:1699 ;
    rdfs:label "TP53" ;
    a m2r:Gene .

civicg:27
    rdfs:seeAlso <http://identifiers.org/ncbigene/3418> ;
    dcterms:identifier "27" ;
    m2r:variation civicv:62,civicv:570,civicv:63,civicv:199 ;
    rdfs:label "IDH2" ;
    a m2r:Gene .

civicg:44
    rdfs:seeAlso <http://identifiers.org/ncbigene/23451> ;
    dcterms:identifier "44" ;
    m2r:variation civicv:215,civicv:565,civicv:114 ;
    rdfs:label "SF3B1" ;
    a m2r:Gene .

civicg:11
    rdfs:seeAlso <http://identifiers.org/ncbigene/898> ;
    dcterms:identifier "11" ;
    m2r:variation civicv:24,civicv:187 ;
    rdfs:label "CCNE1" ;
    a m2r:Gene .

civicg:14
    rdfs:seeAlso <http://identifiers.org/ncbigene/1029> ;
    dcterms:identifier "14" ;
    m2r:variation civicv:27,civicv:272,civicv:554,civicv:641 ;
    rdfs:label "CDKN2A" ;
    a m2r:Gene .

civicg:50
    rdfs:seeAlso <http://identifiers.org/ncbigene/4851> ;
    dcterms:identifier "50" ;
    m2r:variation civicv:135,civicv:136,civicv:138,civicv:137,civicv:206,civicv:207,civicv:330,civicv:601 ;
    rdfs:label "NOTCH1" ;
    a m2r:Gene .

civicg:33
    rdfs:seeAlso <http://identifiers.org/ncbigene/1436> ;
    dcterms:identifier "33" ;
    m2r:variation civicv:30 ;
    rdfs:label "CSF1R" ;
    a m2r:Gene .

civicg:17
    rdfs:seeAlso <http://identifiers.org/ncbigene/5566> ;
    dcterms:identifier "17" ;
    m2r:variation civicv:31 ;
    rdfs:label "PRKACA" ;
    a m2r:Gene .

civicg:59
    rdfs:seeAlso <http://identifiers.org/ncbigene/596> ;
    dcterms:identifier "59" ;
    m2r:variation civicv:151,civicv:152,civicv:2233 ;
    rdfs:label "BCL2" ;
    a m2r:Gene .

civicg:56
    rdfs:seeAlso <http://identifiers.org/ncbigene/27086> ;
    dcterms:identifier "56" ;
    m2r:variation civicv:153 ;
    rdfs:label "FOXP1" ;
    a m2r:Gene .

civicg:57
    rdfs:seeAlso <http://identifiers.org/ncbigene/5966> ;
    dcterms:identifier "57" ;
    m2r:variation civicv:154 ;
    rdfs:label "REL" ;
    a m2r:Gene .

civicg:43
    rdfs:seeAlso <http://identifiers.org/ncbigene/861> ;
    dcterms:identifier "43" ;
    m2r:variation civicv:155,civicv:802,civicv:803,civicv:804,civicv:806,civicv:807,civicv:810 ;
    rdfs:label "RUNX1" ;
    a m2r:Gene .

civicg:60
    rdfs:seeAlso <http://identifiers.org/ncbigene/3481> ;
    dcterms:identifier "60" ;
    m2r:variation civicv:156 ;
    rdfs:label "IGF2" ;
    a m2r:Gene .

civicg:55
    rdfs:seeAlso <http://identifiers.org/ncbigene/54790> ;
    dcterms:identifier "55" ;
    m2r:variation civicv:157 ;
    rdfs:label "TET2" ;
    a m2r:Gene .

civicg:61
    rdfs:seeAlso <http://identifiers.org/ncbigene/6790> ;
    dcterms:identifier "61" ;
    m2r:variation civicv:158,civicv:180,civicv:181 ;
    rdfs:label "AURKA" ;
    a m2r:Gene .

civicg:58
    rdfs:seeAlso <http://identifiers.org/ncbigene/7428> ;
    dcterms:identifier "58" ;
    m2r:variation civicv:160,civicv:159,civicv:436,civicv:631,civicv:764,civicv:766,civicv:771,civicv:793,civicv:794,civicv:820,civicv:829,civicv:843,civicv:844,civicv:845,civicv:846,civicv:847,civicv:848,civicv:849,civicv:850,civicv:851,civicv:852,civicv:1733,civicv:1741,civicv:1742,civicv:1743,civicv:1744,civicv:1745,civicv:1746,civicv:1747,civicv:1739,civicv:1748,civicv:1750,civicv:1787,civicv:1752,civicv:2015,civicv:1754,civicv:1755,civicv:1756,civicv:1757,civicv:1758,civicv:1760,civicv:1761,civicv:1762,civicv:1763,civicv:1764,civicv:1766,civicv:1767,civicv:1768,civicv:1769,civicv:1770,civicv:1771,civicv:1772,civicv:1773,civicv:1774,civicv:1775,civicv:1776,civicv:1777,civicv:1778,civicv:1785,civicv:1788,civicv:1790,civicv:1791,civicv:1792,civicv:1793,civicv:1797,civicv:1798,civicv:1800,civicv:1801,civicv:1802,civicv:1782,civicv:1803,civicv:1806,civicv:1807,civicv:1826,civicv:1820,civicv:1833,civicv:1811,civicv:1834,civicv:1835,civicv:1838,civicv:1839,civicv:1840,civicv:1796,civicv:1841,civicv:1842,civicv:1843,civicv:1844,civicv:1804,civicv:1845,civicv:1846,civicv:1847,civicv:1809,civicv:1848,civicv:1849,civicv:1850,civicv:1852,civicv:1853,civicv:1867,civicv:1810,civicv:1869,civicv:2114,civicv:1859,civicv:1871,civicv:1738,civicv:1873,civicv:2125,civicv:1856,civicv:1794,civicv:1795,civicv:1885,civicv:1886,civicv:1887,civicv:1888,civicv:1889,civicv:1893,civicv:1786,civicv:1902,civicv:1903,civicv:1904,civicv:1816,civicv:1905,civicv:1906,civicv:1780,civicv:1907,civicv:1908,civicv:1909,civicv:1935,civicv:1912,civicv:1913,civicv:1916,civicv:1918,civicv:1919,civicv:1921,civicv:1923,civicv:1808,civicv:1924,civicv:1926,civicv:1928,civicv:1948,civicv:1819,civicv:1949,civicv:1883,civicv:1953,civicv:1954,civicv:1955,civicv:1734,civicv:1956,civicv:1957,civicv:1958,civicv:1960,civicv:1872,civicv:1961,civicv:1962,civicv:1963,civicv:1874,civicv:1964,civicv:1966,civicv:1967,civicv:1946,civicv:1968,civicv:1969,civicv:1970,civicv:1825,civicv:1857,civicv:1827,civicv:1986,civicv:1987,civicv:1988,civicv:1990,civicv:1992,civicv:1915,civicv:1993,civicv:1974,civicv:1994,civicv:1995,civicv:1996,civicv:1997,civicv:1837,civicv:1784,civicv:1998,civicv:1999,civicv:2000,civicv:2007,civicv:1855,civicv:2008,civicv:2009,civicv:1836,civicv:2010,civicv:1814,civicv:2011,civicv:2012,civicv:2013,civicv:2014,civicv:1815,civicv:2020,civicv:1920,civicv:2021,civicv:1813,civicv:2022,civicv:2023,civicv:2024,civicv:2026,civicv:2027,civicv:2028,civicv:2029,civicv:2030,civicv:2078,civicv:2032,civicv:2033,civicv:1865,civicv:1851,civicv:2034,civicv:2035,civicv:2036,civicv:2037,civicv:1824,civicv:2039,civicv:2040,civicv:2041,civicv:2042,civicv:2055,civicv:2056,civicv:2057,civicv:2058,civicv:2089,civicv:2090,civicv:2091,civicv:2092,civicv:2097,civicv:2098,civicv:2099,civicv:2129,civicv:2130,civicv:2131,civicv:2132,civicv:2133,civicv:2134,civicv:2136,civicv:2137,civicv:2138,civicv:2139,civicv:2140,civicv:2141,civicv:2142,civicv:2143,civicv:2144,civicv:2145,civicv:2077,civicv:1939,civicv:2148,civicv:2150,civicv:2151,civicv:2152,civicv:2160,civicv:2162,civicv:2264,civicv:1861,civicv:2265,civicv:2290,civicv:2292,civicv:2299,civicv:2367,civicv:2368,civicv:2369,civicv:2373,civicv:2488 ;
    rdfs:label "VHL" ;
    a m2r:Gene .

civicg:62
    rdfs:seeAlso <http://identifiers.org/ncbigene/55193> ;
    dcterms:identifier "62" ;
    m2r:variation civicv:161 ;
    rdfs:label "PBRM1" ;
    a m2r:Gene .

civicg:63
    rdfs:seeAlso <http://identifiers.org/ncbigene/2146> ;
    dcterms:identifier "63" ;
    m2r:variation civicv:163,civicv:165,civicv:257,civicv:291 ;
    rdfs:label "EZH2" ;
    a m2r:Gene .

civicg:53
    rdfs:seeAlso <http://identifiers.org/ncbigene/2313> ;
    dcterms:identifier "53" ;
    m2r:variation civicv:164,civicv:197 ;
    rdfs:label "FLI1" ;
    a m2r:Gene .

civicg:64
    rdfs:seeAlso <http://identifiers.org/ncbigene/8085> ;
    dcterms:identifier "64" ;
    m2r:variation civicv:167 ;
    rdfs:label "KMT2D" ;
    a m2r:Gene .

civicg:65
    rdfs:seeAlso <http://identifiers.org/ncbigene/695> ;
    dcterms:identifier "65" ;
    m2r:variation civicv:168,civicv:870,civicv:2169 ;
    rdfs:label "BTK" ;
    a m2r:Gene .

civicg:66
    rdfs:seeAlso <http://identifiers.org/ncbigene/324> ;
    dcterms:identifier "66" ;
    m2r:variation civicv:174 ;
    rdfs:label "APC" ;
    a m2r:Gene .

civicg:67
    rdfs:seeAlso <http://identifiers.org/ncbigene/367> ;
    dcterms:identifier "67" ;
    m2r:variation civicv:175,civicv:176,civicv:359,civicv:362,civicv:600 ;
    rdfs:label "AR" ;
    a m2r:Gene .

civicg:68
    rdfs:seeAlso <http://identifiers.org/ncbigene/171023> ;
    dcterms:identifier "68" ;
    m2r:variation civicv:177,civicv:557 ;
    rdfs:label "ASXL1" ;
    a m2r:Gene .

civicg:69
    rdfs:seeAlso <http://identifiers.org/ncbigene/472> ;
    dcterms:identifier "69" ;
    m2r:variation civicv:178,civicv:179,civicv:243,civicv:244 ;
    rdfs:label "ATM" ;
    a m2r:Gene .

civicg:70
    rdfs:seeAlso <http://identifiers.org/ncbigene/8314> ;
    dcterms:identifier "70" ;
    m2r:variation civicv:182,civicv:183,civicv:2211 ;
    rdfs:label "BAP1" ;
    a m2r:Gene .

civicg:71
    rdfs:seeAlso <http://identifiers.org/ncbigene/2078> ;
    dcterms:identifier "71" ;
    m2r:variation civicv:194,civicv:195 ;
    rdfs:label "ERG" ;
    a m2r:Gene .

civicg:72
    rdfs:seeAlso <http://identifiers.org/ncbigene/668> ;
    dcterms:identifier "72" ;
    m2r:variation civicv:198 ;
    rdfs:label "FOXL2" ;
    a m2r:Gene .

civicg:73
    rdfs:seeAlso <http://identifiers.org/ncbigene/10320> ;
    dcterms:identifier "73" ;
    m2r:variation civicv:200 ;
    rdfs:label "IKZF1" ;
    a m2r:Gene .

civicg:74
    rdfs:seeAlso <http://identifiers.org/ncbigene/8202> ;
    dcterms:identifier "74" ;
    m2r:variation civicv:204,civicv:205 ;
    rdfs:label "NCOA3" ;
    a m2r:Gene .

civicg:75
    rdfs:seeAlso <http://identifiers.org/ncbigene/7849> ;
    dcterms:identifier "75" ;
    m2r:variation civicv:209,civicv:683 ;
    rdfs:label "PAX8" ;
    a m2r:Gene .

civicg:76
    rdfs:seeAlso <http://identifiers.org/ncbigene/5241> ;
    dcterms:identifier "76" ;
    m2r:variation civicv:210 ;
    rdfs:label "PGR" ;
    a m2r:Gene .

civicg:77
    rdfs:seeAlso <http://identifiers.org/ncbigene/4089> ;
    dcterms:identifier "77" ;
    m2r:variation civicv:216,civicv:282,civicv:533,civicv:564,civicv:646 ;
    rdfs:label "SMAD4" ;
    a m2r:Gene .

civicg:78
    rdfs:seeAlso <http://identifiers.org/ncbigene/6597> ;
    dcterms:identifier "78" ;
    m2r:variation civicv:217,civicv:218,civicv:349 ;
    rdfs:label "SMARCA4" ;
    a m2r:Gene .

civicg:79
    rdfs:seeAlso <http://identifiers.org/ncbigene/7015> ;
    dcterms:identifier "79" ;
    m2r:variation civicv:219,civicv:220,civicv:248,civicv:421 ;
    rdfs:label "TERT" ;
    a m2r:Gene .

civicg:80
    rdfs:seeAlso <http://identifiers.org/ncbigene/7270> ;
    dcterms:identifier "80" ;
    m2r:variation civicv:224 ;
    rdfs:label "TTF1" ;
    a m2r:Gene .

civicg:8950
    rdfs:seeAlso <http://identifiers.org/ncbigene/11200> ;
    dcterms:identifier "8950" ;
    m2r:variation civicv:230,civicv:785,civicv:787,civicv:788 ;
    rdfs:label "CHEK2" ;
    a m2r:Gene .

civicg:12112
    rdfs:seeAlso <http://identifiers.org/ncbigene/51755> ;
    dcterms:identifier "12112" ;
    m2r:variation civicv:236 ;
    rdfs:label "CDK12" ;
    a m2r:Gene .

civicg:9189
    rdfs:seeAlso <http://identifiers.org/ncbigene/22978> ;
    dcterms:identifier "9189" ;
    m2r:variation civicv:238,civicv:239,civicv:240 ;
    rdfs:label "NT5C2" ;
    a m2r:Gene .

civicg:3870
    rdfs:seeAlso <http://identifiers.org/ncbigene/4771> ;
    dcterms:identifier "3870" ;
    m2r:variation civicv:245,civicv:279,civicv:659,civicv:697 ;
    rdfs:label "NF2" ;
    a m2r:Gene .

civicg:6144
    rdfs:seeAlso <http://identifiers.org/ncbigene/7515> ;
    dcterms:identifier "6144" ;
    m2r:variation civicv:249,civicv:261 ;
    rdfs:label "XRCC1" ;
    a m2r:Gene .

civicg:2473
    rdfs:seeAlso <http://identifiers.org/ncbigene/2950> ;
    dcterms:identifier "2473" ;
    m2r:variation civicv:250,civicv:259 ;
    rdfs:label "GSTP1" ;
    a m2r:Gene .

civicg:14842
    rdfs:seeAlso <http://identifiers.org/ncbigene/79444> ;
    dcterms:identifier "14842" ;
    m2r:variation civicv:251 ;
    rdfs:label "BIRC7" ;
    a m2r:Gene .

civicg:1741
    rdfs:seeAlso <http://identifiers.org/ncbigene/2073> ;
    dcterms:identifier "1741" ;
    m2r:variation civicv:255 ;
    rdfs:label "ERCC5" ;
    a m2r:Gene .

civicg:3672
    rdfs:seeAlso <http://identifiers.org/ncbigene/4524> ;
    dcterms:identifier "3672" ;
    m2r:variation civicv:258 ;
    rdfs:label "MTHFR" ;
    a m2r:Gene .

civicg:7451
    rdfs:seeAlso <http://identifiers.org/ncbigene/9429> ;
    dcterms:identifier "7451" ;
    m2r:variation civicv:260 ;
    rdfs:label "ABCG2" ;
    a m2r:Gene .

civicg:4244
    rdfs:seeAlso <http://identifiers.org/ncbigene/5243> ;
    dcterms:identifier "4244" ;
    m2r:variation civicv:262,civicv:263,civicv:404,civicv:451 ;
    rdfs:label "ABCB1" ;
    a m2r:Gene .

civicg:1736
    rdfs:seeAlso <http://identifiers.org/ncbigene/2068> ;
    dcterms:identifier "1736" ;
    m2r:variation civicv:264 ;
    rdfs:label "ERCC2" ;
    a m2r:Gene .

civicg:5971
    rdfs:seeAlso <http://identifiers.org/ncbigene/7298> ;
    dcterms:identifier "5971" ;
    m2r:variation civicv:265,civicv:347,civicv:379,civicv:382,civicv:779 ;
    rdfs:label "TYMS" ;
    a m2r:Gene .

civicg:12146
    rdfs:seeAlso <http://identifiers.org/ncbigene/53353> ;
    dcterms:identifier "12146" ;
    m2r:variation civicv:266,civicv:647 ;
    rdfs:label "LRP1B" ;
    a m2r:Gene .

civicg:1885
    rdfs:seeAlso <http://identifiers.org/ncbigene/2260> ;
    dcterms:identifier "1885" ;
    m2r:variation civicv:267,civicv:268,civicv:466,civicv:515,civicv:569 ;
    rdfs:label "FGFR1" ;
    a m2r:Gene .

civicg:4941
    rdfs:seeAlso <http://identifiers.org/ncbigene/6098> ;
    dcterms:identifier "4941" ;
    m2r:variation civicv:269,civicv:465,civicv:516,civicv:517,civicv:518,civicv:576,civicv:1271 ;
    rdfs:label "ROS1" ;
    a m2r:Gene .

civicg:52
    rdfs:seeAlso <http://identifiers.org/ncbigene/4233> ;
    dcterms:identifier "52" ;
    m2r:variation civicv:270,civicv:324,civicv:323,civicv:464,civicv:621,civicv:649,civicv:798 ;
    rdfs:label "MET" ;
    a m2r:Gene .

civicg:524
    rdfs:seeAlso <http://identifiers.org/ncbigene/545> ;
    dcterms:identifier "524" ;
    m2r:variation civicv:271 ;
    rdfs:label "ATR" ;
    a m2r:Gene .

civicg:2747
    rdfs:seeAlso <http://identifiers.org/ncbigene/3265> ;
    dcterms:identifier "2747" ;
    m2r:variation civicv:274,civicv:275 ;
    rdfs:label "HRAS" ;
    a m2r:Gene .

civicg:11335
    rdfs:seeAlso <http://identifiers.org/ncbigene/29126> ;
    dcterms:identifier "11335" ;
    m2r:variation civicv:276 ;
    rdfs:label "CD274" ;
    a m2r:Gene .

civicg:2073
    rdfs:seeAlso <http://identifiers.org/ncbigene/2475> ;
    dcterms:identifier "2073" ;
    m2r:variation civicv:277,civicv:283,civicv:284,civicv:470,civicv:542,civicv:543,civicv:544,civicv:572,civicv:609,civicv:610 ;
    rdfs:label "MTOR" ;
    a m2r:Gene .

civicg:254
    rdfs:seeAlso <http://identifiers.org/ncbigene/208> ;
    dcterms:identifier "254" ;
    m2r:variation civicv:278,civicv:635 ;
    rdfs:label "AKT2" ;
    a m2r:Gene .

civicg:12903
    rdfs:seeAlso <http://identifiers.org/ncbigene/55294> ;
    dcterms:identifier "12903" ;
    m2r:variation civicv:281,civicv:637 ;
    rdfs:label "FBXW7" ;
    a m2r:Gene .

civicg:1733
    rdfs:seeAlso <http://identifiers.org/ncbigene/2065> ;
    dcterms:identifier "1733" ;
    m2r:variation civicv:289,civicv:361,civicv:701,civicv:702,civicv:703,civicv:781 ;
    rdfs:label "ERBB3" ;
    a m2r:Gene .

civicg:3976
    rdfs:seeAlso <http://identifiers.org/ncbigene/4907> ;
    dcterms:identifier "3976" ;
    m2r:variation civicv:290 ;
    rdfs:label "NT5E" ;
    a m2r:Gene .

civicg:3742
    rdfs:seeAlso <http://identifiers.org/ncbigene/4615> ;
    dcterms:identifier "3742" ;
    m2r:variation civicv:292,civicv:424 ;
    rdfs:label "MYD88" ;
    a m2r:Gene .

civicg:4875
    rdfs:seeAlso <http://identifiers.org/ncbigene/6016> ;
    dcterms:identifier "4875" ;
    m2r:variation civicv:296,civicv:297 ;
    rdfs:label "RIT1" ;
    a m2r:Gene .

civicg:3741
    rdfs:seeAlso <http://identifiers.org/ncbigene/4613> ;
    dcterms:identifier "3741" ;
    m2r:variation civicv:298 ;
    rdfs:label "MYCN" ;
    a m2r:Gene .

civicg:5365
    rdfs:seeAlso <http://identifiers.org/ncbigene/6608> ;
    dcterms:identifier "5365" ;
    m2r:variation civicv:299,civicv:300,civicv:1570 ;
    rdfs:label "SMO" ;
    a m2r:Gene .

civicg:4645
    rdfs:seeAlso <http://identifiers.org/ncbigene/5727> ;
    dcterms:identifier "4645" ;
    m2r:variation civicv:301,civicv:302 ;
    rdfs:label "PTCH1" ;
    a m2r:Gene .

civicg:5534
    rdfs:seeAlso <http://identifiers.org/ncbigene/6794> ;
    dcterms:identifier "5534" ;
    m2r:variation civicv:303,civicv:304,civicv:485,civicv:634,civicv:715 ;
    rdfs:label "STK11" ;
    a m2r:Gene .

civicg:5572
    rdfs:seeAlso <http://identifiers.org/ncbigene/6850> ;
    dcterms:identifier "5572" ;
    m2r:variation civicv:305 ;
    rdfs:label "SYK" ;
    a m2r:Gene .

civicg:1734
    rdfs:seeAlso <http://identifiers.org/ncbigene/2066> ;
    dcterms:identifier "1734" ;
    m2r:variation civicv:310,civicv:364,civicv:365 ;
    rdfs:label "ERBB4" ;
    a m2r:Gene .

civicg:2593
    rdfs:seeAlso <http://identifiers.org/ncbigene/3084> ;
    dcterms:identifier "2593" ;
    m2r:variation civicv:314,civicv:2178,civicv:2179,civicv:2286 ;
    rdfs:label "NRG1" ;
    a m2r:Gene .

civicg:389
    rdfs:seeAlso <http://identifiers.org/ncbigene/374> ;
    dcterms:identifier "389" ;
    m2r:variation civicv:315 ;
    rdfs:label "AREG" ;
    a m2r:Gene .

civicg:5742
    rdfs:seeAlso <http://identifiers.org/ncbigene/7039> ;
    dcterms:identifier "5742" ;
    m2r:variation civicv:316 ;
    rdfs:label "TGFA" ;
    a m2r:Gene .

civicg:1737
    rdfs:seeAlso <http://identifiers.org/ncbigene/2069> ;
    dcterms:identifier "1737" ;
    m2r:variation civicv:318 ;
    rdfs:label "EREG" ;
    a m2r:Gene .

civicg:4532
    rdfs:seeAlso <http://identifiers.org/ncbigene/5594> ;
    dcterms:identifier "4532" ;
    m2r:variation civicv:320,civicv:321 ;
    rdfs:label "MAPK1" ;
    a m2r:Gene .

civicg:9705
    rdfs:seeAlso <http://identifiers.org/ncbigene/23624> ;
    dcterms:identifier "9705" ;
    m2r:variation civicv:326 ;
    rdfs:label "CBLC" ;
    a m2r:Gene .

civicg:4692
    rdfs:seeAlso <http://identifiers.org/ncbigene/5789> ;
    dcterms:identifier "4692" ;
    m2r:variation civicv:327,civicv:792 ;
    rdfs:label "PTPRD" ;
    a m2r:Gene .

civicg:1428
    rdfs:seeAlso <http://identifiers.org/ncbigene/1667> ;
    dcterms:identifier "1428" ;
    m2r:variation civicv:328 ;
    rdfs:label "DEFA1" ;
    a m2r:Gene .

civicg:1735
    rdfs:seeAlso <http://identifiers.org/ncbigene/2067> ;
    dcterms:identifier "1735" ;
    m2r:variation civicv:329 ;
    rdfs:label "ERCC1" ;
    a m2r:Gene .

civicg:6104
    rdfs:seeAlso <http://identifiers.org/ncbigene/7465> ;
    dcterms:identifier "6104" ;
    m2r:variation civicv:331 ;
    rdfs:label "WEE1" ;
    a m2r:Gene .

civicg:1950
    rdfs:seeAlso <http://identifiers.org/ncbigene/2342> ;
    dcterms:identifier "1950" ;
    m2r:variation civicv:332 ;
    rdfs:label "FNTB" ;
    a m2r:Gene .

civicg:8878
    rdfs:seeAlso <http://identifiers.org/ncbigene/11122> ;
    dcterms:identifier "8878" ;
    m2r:variation civicv:333 ;
    rdfs:label "PTPRT" ;
    a m2r:Gene .

civicg:6071
    rdfs:seeAlso <http://identifiers.org/ncbigene/7422> ;
    dcterms:identifier "6071" ;
    m2r:variation civicv:334 ;
    rdfs:label "VEGFA" ;
    a m2r:Gene .

civicg:1510
    rdfs:seeAlso <http://identifiers.org/ncbigene/1786> ;
    dcterms:identifier "1510" ;
    m2r:variation civicv:335 ;
    rdfs:label "DNMT1" ;
    a m2r:Gene .

civicg:10573
    rdfs:seeAlso <http://identifiers.org/ncbigene/27250> ;
    dcterms:identifier "10573" ;
    m2r:variation civicv:337 ;
    rdfs:label "PDCD4" ;
    a m2r:Gene .

civicg:5737
    rdfs:seeAlso <http://identifiers.org/ncbigene/7033> ;
    dcterms:identifier "5737" ;
    m2r:variation civicv:339 ;
    rdfs:label "TFF3" ;
    a m2r:Gene .

civicg:9171
    rdfs:seeAlso <http://identifiers.org/ncbigene/22943> ;
    dcterms:identifier "9171" ;
    m2r:variation civicv:340 ;
    rdfs:label "DKK1" ;
    a m2r:Gene .

civicg:855
    rdfs:seeAlso <http://identifiers.org/ncbigene/960> ;
    dcterms:identifier "855" ;
    m2r:variation civicv:341 ;
    rdfs:label "CD44" ;
    a m2r:Gene .

civicg:1634
    rdfs:seeAlso <http://identifiers.org/ncbigene/1950> ;
    dcterms:identifier "1634" ;
    m2r:variation civicv:342 ;
    rdfs:label "EGF" ;
    a m2r:Gene .

civicg:3465
    rdfs:seeAlso <http://identifiers.org/ncbigene/4193> ;
    dcterms:identifier "3465" ;
    m2r:variation civicv:343,civicv:495,civicv:642 ;
    rdfs:label "MDM2" ;
    a m2r:Gene .

civicg:2657
    rdfs:seeAlso <http://identifiers.org/ncbigene/3162> ;
    dcterms:identifier "2657" ;
    m2r:variation civicv:344 ;
    rdfs:label "HMOX1" ;
    a m2r:Gene .

civicg:7041
    rdfs:seeAlso <http://identifiers.org/ncbigene/8877> ;
    dcterms:identifier "7041" ;
    m2r:variation civicv:345 ;
    rdfs:label "SPHK1" ;
    a m2r:Gene .

civicg:761
    rdfs:seeAlso <http://identifiers.org/ncbigene/841> ;
    dcterms:identifier "761" ;
    m2r:variation civicv:346,civicv:650 ;
    rdfs:label "CASP8" ;
    a m2r:Gene .

civicg:13276
    rdfs:seeAlso <http://identifiers.org/ncbigene/55872> ;
    dcterms:identifier "13276" ;
    m2r:variation civicv:348,civicv:439 ;
    rdfs:label "PBK" ;
    a m2r:Gene .

civicg:10024
    rdfs:seeAlso <http://identifiers.org/ncbigene/26040> ;
    dcterms:identifier "10024" ;
    m2r:variation civicv:350,civicv:351 ;
    rdfs:label "SETBP1" ;
    a m2r:Gene .

civicg:913
    rdfs:seeAlso <http://identifiers.org/ncbigene/1026> ;
    dcterms:identifier "913" ;
    m2r:variation civicv:355 ;
    rdfs:label "CDKN1A" ;
    a m2r:Gene .

civicg:259
    rdfs:seeAlso <http://identifiers.org/ncbigene/214> ;
    dcterms:identifier "259" ;
    m2r:variation civicv:356 ;
    rdfs:label "ALCAM" ;
    a m2r:Gene .

civicg:3255
    rdfs:seeAlso <http://identifiers.org/ncbigene/3925> ;
    dcterms:identifier "3255" ;
    m2r:variation civicv:357 ;
    rdfs:label "STMN1" ;
    a m2r:Gene .

civicg:12121
    rdfs:seeAlso <http://identifiers.org/ncbigene/51773> ;
    dcterms:identifier "12121" ;
    m2r:variation civicv:358 ;
    rdfs:label "RSF1" ;
    a m2r:Gene .

civicg:914
    rdfs:seeAlso <http://identifiers.org/ncbigene/1027> ;
    dcterms:identifier "914" ;
    m2r:variation civicv:360,civicv:372 ;
    rdfs:label "CDKN1B" ;
    a m2r:Gene .

civicg:6023
    rdfs:seeAlso <http://identifiers.org/ncbigene/7361> ;
    dcterms:identifier "6023" ;
    m2r:variation civicv:363 ;
    rdfs:label "UGT1A" ;
    a m2r:Gene .

civicg:16872
    rdfs:seeAlso <http://identifiers.org/ncbigene/91607> ;
    dcterms:identifier "16872" ;
    m2r:variation civicv:366 ;
    rdfs:label "SLFN11" ;
    a m2r:Gene .

civicg:4753
    rdfs:seeAlso <http://identifiers.org/ncbigene/5879> ;
    dcterms:identifier "4753" ;
    m2r:variation civicv:367 ;
    rdfs:label "RAC1" ;
    a m2r:Gene .

civicg:355
    rdfs:seeAlso <http://identifiers.org/ncbigene/332> ;
    dcterms:identifier "355" ;
    m2r:variation civicv:368,civicv:578 ;
    rdfs:label "BIRC5" ;
    a m2r:Gene .

civicg:3586
    rdfs:seeAlso <http://identifiers.org/ncbigene/4361> ;
    dcterms:identifier "3586" ;
    m2r:variation civicv:370,civicv:428 ;
    rdfs:label "MRE11" ;
    a m2r:Gene .

civicg:5845
    rdfs:seeAlso <http://identifiers.org/ncbigene/7150> ;
    dcterms:identifier "5845" ;
    m2r:variation civicv:371,civicv:384 ;
    rdfs:label "TOP1" ;
    a m2r:Gene .

civicg:8407
    rdfs:seeAlso <http://identifiers.org/ncbigene/10551> ;
    dcterms:identifier "8407" ;
    m2r:variation civicv:373 ;
    rdfs:label "AGR2" ;
    a m2r:Gene .

civicg:17016
    rdfs:seeAlso <http://identifiers.org/ncbigene/93100> ;
    dcterms:identifier "17016" ;
    m2r:variation civicv:374 ;
    rdfs:label "NAPRT" ;
    a m2r:Gene .

civicg:5649
    rdfs:seeAlso <http://identifiers.org/ncbigene/6935> ;
    dcterms:identifier "5649" ;
    m2r:variation civicv:376 ;
    rdfs:label "ZEB1" ;
    a m2r:Gene .

civicg:5777
    rdfs:seeAlso <http://identifiers.org/ncbigene/7076> ;
    dcterms:identifier "5777" ;
    m2r:variation civicv:377 ;
    rdfs:label "TIMP1" ;
    a m2r:Gene .

civicg:8908
    rdfs:seeAlso <http://identifiers.org/ncbigene/11156> ;
    dcterms:identifier "8908" ;
    m2r:variation civicv:378 ;
    rdfs:label "PTP4A3" ;
    a m2r:Gene .

civicg:2899
    rdfs:seeAlso <http://identifiers.org/ncbigene/3480> ;
    dcterms:identifier "2899" ;
    m2r:variation civicv:380,civicv:391 ;
    rdfs:label "IGF1R" ;
    a m2r:Gene .

civicg:1721
    rdfs:seeAlso <http://identifiers.org/ncbigene/2050> ;
    dcterms:identifier "1721" ;
    m2r:variation civicv:381 ;
    rdfs:label "EPHB4" ;
    a m2r:Gene .

civicg:5848
    rdfs:seeAlso <http://identifiers.org/ncbigene/7153> ;
    dcterms:identifier "5848" ;
    m2r:variation civicv:383 ;
    rdfs:label "TOP2A" ;
    a m2r:Gene .

civicg:4503
    rdfs:seeAlso <http://identifiers.org/ncbigene/5563> ;
    dcterms:identifier "4503" ;
    m2r:variation civicv:385 ;
    rdfs:label "PRKAA2" ;
    a m2r:Gene .

civicg:2778
    rdfs:seeAlso <http://identifiers.org/ncbigene/3309> ;
    dcterms:identifier "2778" ;
    m2r:variation civicv:386 ;
    rdfs:label "HSPA5" ;
    a m2r:Gene .

civicg:1655
    rdfs:seeAlso <http://identifiers.org/ncbigene/1978> ;
    dcterms:identifier "1655" ;
    m2r:variation civicv:387 ;
    rdfs:label "EIF4EBP1" ;
    a m2r:Gene .

civicg:8262
    rdfs:seeAlso <http://identifiers.org/ncbigene/10381> ;
    dcterms:identifier "8262" ;
    m2r:variation civicv:389 ;
    rdfs:label "TUBB3" ;
    a m2r:Gene .

civicg:7009
    rdfs:seeAlso <http://identifiers.org/ncbigene/8837> ;
    dcterms:identifier "7009" ;
    m2r:variation civicv:392 ;
    rdfs:label "CFLAR" ;
    a m2r:Gene .

civicg:7014
    rdfs:seeAlso <http://identifiers.org/ncbigene/8842> ;
    dcterms:identifier "7014" ;
    m2r:variation civicv:393 ;
    rdfs:label "PROM1" ;
    a m2r:Gene .

civicg:11587
    rdfs:seeAlso <http://identifiers.org/ncbigene/50943> ;
    dcterms:identifier "11587" ;
    m2r:variation civicv:394 ;
    rdfs:label "FOXP3" ;
    a m2r:Gene .

civicg:5013
    rdfs:seeAlso <http://identifiers.org/ncbigene/6194> ;
    dcterms:identifier "5013" ;
    m2r:variation civicv:395 ;
    rdfs:label "RPS6" ;
    a m2r:Gene .

civicg:3090
    rdfs:seeAlso <http://identifiers.org/ncbigene/3716> ;
    dcterms:identifier "3090" ;
    m2r:variation civicv:396,civicv:614,civicv:822 ;
    rdfs:label "JAK1" ;
    a m2r:Gene .

civicg:1567
    rdfs:seeAlso <http://identifiers.org/ncbigene/1848> ;
    dcterms:identifier "1567" ;
    m2r:variation civicv:398 ;
    rdfs:label "DUSP6" ;
    a m2r:Gene .

civicg:2784
    rdfs:seeAlso <http://identifiers.org/ncbigene/3315> ;
    dcterms:identifier "2784" ;
    m2r:variation civicv:400 ;
    rdfs:label "HSPB1" ;
    a m2r:Gene .

civicg:1463
    rdfs:seeAlso <http://identifiers.org/ncbigene/1728> ;
    dcterms:identifier "1463" ;
    m2r:variation civicv:401,civicv:402 ;
    rdfs:label "NQO1" ;
    a m2r:Gene .

civicg:6329
    rdfs:seeAlso <http://identifiers.org/ncbigene/7852> ;
    dcterms:identifier "6329" ;
    m2r:variation civicv:405 ;
    rdfs:label "CXCR4" ;
    a m2r:Gene .

civicg:11261
    rdfs:seeAlso <http://identifiers.org/ncbigene/28986> ;
    dcterms:identifier "11261" ;
    m2r:variation civicv:406 ;
    rdfs:label "MAGEH1" ;
    a m2r:Gene .

civicg:6906
    rdfs:seeAlso <http://identifiers.org/ncbigene/8714> ;
    dcterms:identifier "6906" ;
    m2r:variation civicv:407 ;
    rdfs:label "ABCC3" ;
    a m2r:Gene .

civicg:16656
    rdfs:seeAlso <http://identifiers.org/ncbigene/89845> ;
    dcterms:identifier "16656" ;
    m2r:variation civicv:408 ;
    rdfs:label "ABCC10" ;
    a m2r:Gene .

civicg:446
    rdfs:seeAlso <http://identifiers.org/ncbigene/440> ;
    dcterms:identifier "446" ;
    m2r:variation civicv:409 ;
    rdfs:label "ASNS" ;
    a m2r:Gene .

civicg:927
    rdfs:seeAlso <http://identifiers.org/ncbigene/1045> ;
    dcterms:identifier "927" ;
    m2r:variation civicv:410 ;
    rdfs:label "CDX2" ;
    a m2r:Gene .

civicg:5516
    rdfs:seeAlso <http://identifiers.org/ncbigene/6774> ;
    dcterms:identifier "5516" ;
    m2r:variation civicv:411 ;
    rdfs:label "STAT3" ;
    a m2r:Gene .

civicg:4419
    rdfs:seeAlso <http://identifiers.org/ncbigene/5460> ;
    dcterms:identifier "4419" ;
    m2r:variation civicv:412 ;
    rdfs:label "POU5F1" ;
    a m2r:Gene .

civicg:5761
    rdfs:seeAlso <http://identifiers.org/ncbigene/7058> ;
    dcterms:identifier "5761" ;
    m2r:variation civicv:417 ;
    rdfs:label "THBS2" ;
    a m2r:Gene .

civicg:3983
    rdfs:seeAlso <http://identifiers.org/ncbigene/4914> ;
    dcterms:identifier "3983" ;
    m2r:variation civicv:419,civicv:800,civicv:860,civicv:1278,civicv:1280,civicv:1282,civicv:2288,civicv:2289,civicv:2393,civicv:2394,civicv:2395 ;
    rdfs:label "NTRK1" ;
    a m2r:Gene .

civicg:8553
    rdfs:seeAlso <http://identifiers.org/ncbigene/10735> ;
    dcterms:identifier "8553" ;
    m2r:variation civicv:422,civicv:669 ;
    rdfs:label "STAG2" ;
    a m2r:Gene .

civicg:2622
    rdfs:seeAlso <http://identifiers.org/ncbigene/3122> ;
    dcterms:identifier "2622" ;
    m2r:variation civicv:423 ;
    rdfs:label "HLA-DRA" ;
    a m2r:Gene .

civicg:776
    rdfs:seeAlso <http://identifiers.org/ncbigene/865> ;
    dcterms:identifier "776" ;
    m2r:variation civicv:431 ;
    rdfs:label "CBFB" ;
    a m2r:Gene .

civicg:3537
    rdfs:seeAlso <http://identifiers.org/ncbigene/4297> ;
    dcterms:identifier "3537" ;
    m2r:variation civicv:432 ;
    rdfs:label "KMT2A" ;
    a m2r:Gene .

civicg:2596
    rdfs:seeAlso <http://identifiers.org/ncbigene/3091> ;
    dcterms:identifier "2596" ;
    m2r:variation civicv:433,civicv:434,civicv:660 ;
    rdfs:label "HIF1A" ;
    a m2r:Gene .

civicg:1705
    rdfs:seeAlso <http://identifiers.org/ncbigene/2034> ;
    dcterms:identifier "1705" ;
    m2r:variation civicv:435 ;
    rdfs:label "EPAS1" ;
    a m2r:Gene .

civicg:4616
    rdfs:seeAlso <http://identifiers.org/ncbigene/5696> ;
    dcterms:identifier "4616" ;
    m2r:variation civicv:438 ;
    rdfs:label "PSMB8" ;
    a m2r:Gene .

civicg:7297
    rdfs:seeAlso <http://identifiers.org/ncbigene/9232> ;
    dcterms:identifier "7297" ;
    m2r:variation civicv:440 ;
    rdfs:label "PTTG1" ;
    a m2r:Gene .

civicg:3274
    rdfs:seeAlso <http://identifiers.org/ncbigene/3953> ;
    dcterms:identifier "3274" ;
    m2r:variation civicv:441 ;
    rdfs:label "LEPR" ;
    a m2r:Gene .

civicg:3852
    rdfs:seeAlso <http://identifiers.org/ncbigene/4739> ;
    dcterms:identifier "3852" ;
    m2r:variation civicv:444 ;
    rdfs:label "NEDD9" ;
    a m2r:Gene .

civicg:1763
    rdfs:seeAlso <http://identifiers.org/ncbigene/2114> ;
    dcterms:identifier "1763" ;
    m2r:variation civicv:445 ;
    rdfs:label "ETS2" ;
    a m2r:Gene .

civicg:3215
    rdfs:seeAlso <http://identifiers.org/ncbigene/3875> ;
    dcterms:identifier "3215" ;
    m2r:variation civicv:446 ;
    rdfs:label "KRT18" ;
    a m2r:Gene .

civicg:1883
    rdfs:seeAlso <http://identifiers.org/ncbigene/2258> ;
    dcterms:identifier "1883" ;
    m2r:variation civicv:447 ;
    rdfs:label "FGF13" ;
    a m2r:Gene .

civicg:5500
    rdfs:seeAlso <http://identifiers.org/ncbigene/6756> ;
    dcterms:identifier "5500" ;
    m2r:variation civicv:448 ;
    rdfs:label "SSX1" ;
    a m2r:Gene .

civicg:5501
    rdfs:seeAlso <http://identifiers.org/ncbigene/6757> ;
    dcterms:identifier "5501" ;
    m2r:variation civicv:449 ;
    rdfs:label "SSX2" ;
    a m2r:Gene .

civicg:5503
    rdfs:seeAlso <http://identifiers.org/ncbigene/6759> ;
    dcterms:identifier "5503" ;
    m2r:variation civicv:450 ;
    rdfs:label "SSX4" ;
    a m2r:Gene .

civicg:1842
    rdfs:seeAlso <http://identifiers.org/ncbigene/2212> ;
    dcterms:identifier "1842" ;
    m2r:variation civicv:456 ;
    rdfs:label "FCGR2A" ;
    a m2r:Gene .

civicg:1844
    rdfs:seeAlso <http://identifiers.org/ncbigene/2214> ;
    dcterms:identifier "1844" ;
    m2r:variation civicv:457 ;
    rdfs:label "FCGR3A" ;
    a m2r:Gene .

civicg:1843
    rdfs:seeAlso <http://identifiers.org/ncbigene/2213> ;
    dcterms:identifier "1843" ;
    m2r:variation civicv:458 ;
    rdfs:label "FCGR2B" ;
    a m2r:Gene .

civicg:3153
    rdfs:seeAlso <http://identifiers.org/ncbigene/3791> ;
    dcterms:identifier "3153" ;
    m2r:variation civicv:467,civicv:468,civicv:502 ;
    rdfs:label "KDR" ;
    a m2r:Gene .

civicg:47
    rdfs:seeAlso <http://identifiers.org/ncbigene/7249> ;
    dcterms:identifier "47" ;
    m2r:variation civicv:469 ;
    rdfs:label "TSC2" ;
    a m2r:Gene .

civicg:4765
    rdfs:seeAlso <http://identifiers.org/ncbigene/5892> ;
    dcterms:identifier "4765" ;
    m2r:variation civicv:471 ;
    rdfs:label "RAD51D" ;
    a m2r:Gene .

civicg:7024
    rdfs:seeAlso <http://identifiers.org/ncbigene/8854> ;
    dcterms:identifier "7024" ;
    m2r:variation civicv:472,civicv:473 ;
    rdfs:label "ALDH1A2" ;
    a m2r:Gene .

civicg:13948
    rdfs:seeAlso <http://identifiers.org/ncbigene/57650> ;
    dcterms:identifier "13948" ;
    m2r:variation civicv:474,civicv:475 ;
    rdfs:label "KIAA1524" ;
    a m2r:Gene .

civicg:24938
    rdfs:seeAlso <http://identifiers.org/ncbigene/407000> ;
    dcterms:identifier "24938" ;
    m2r:variation civicv:476,civicv:498 ;
    rdfs:label "MIR218-1" ;
    a m2r:Gene .

civicg:13005
    rdfs:seeAlso <http://identifiers.org/ncbigene/55510> ;
    dcterms:identifier "13005" ;
    m2r:variation civicv:481 ;
    rdfs:label "DDX43" ;
    a m2r:Gene .

civicg:11322
    rdfs:seeAlso <http://identifiers.org/ncbigene/29110> ;
    dcterms:identifier "11322" ;
    m2r:variation civicv:483 ;
    rdfs:label "TBK1" ;
    a m2r:Gene .

civicg:16394
    rdfs:seeAlso <http://identifiers.org/ncbigene/84868> ;
    dcterms:identifier "16394" ;
    m2r:variation civicv:486 ;
    rdfs:label "HAVCR2" ;
    a m2r:Gene .

civicg:3549
    rdfs:seeAlso <http://identifiers.org/ncbigene/4313> ;
    dcterms:identifier "3549" ;
    m2r:variation civicv:487 ;
    rdfs:label "MMP2" ;
    a m2r:Gene .

civicg:3553
    rdfs:seeAlso <http://identifiers.org/ncbigene/4318> ;
    dcterms:identifier "3553" ;
    m2r:variation civicv:488 ;
    rdfs:label "MMP9" ;
    a m2r:Gene .

civicg:128
    rdfs:seeAlso <http://identifiers.org/ncbigene/58> ;
    dcterms:identifier "128" ;
    m2r:variation civicv:546 ;
    rdfs:label "ACTA1" ;
    a m2r:Gene .

civicg:8614
    rdfs:seeAlso <http://identifiers.org/ncbigene/10808> ;
    dcterms:identifier "8614" ;
    m2r:variation civicv:490,civicv:491 ;
    rdfs:label "HSPH1" ;
    a m2r:Gene .

civicg:26599
    rdfs:seeAlso <http://identifiers.org/ncbigene/641700> ;
    dcterms:identifier "26599" ;
    m2r:variation civicv:492 ;
    rdfs:label "ECSCR" ;
    a m2r:Gene .

civicg:12367
    rdfs:seeAlso <http://identifiers.org/ncbigene/54538> ;
    dcterms:identifier "12367" ;
    m2r:variation civicv:493 ;
    rdfs:label "ROBO4" ;
    a m2r:Gene .

civicg:4286
    rdfs:seeAlso <http://identifiers.org/ncbigene/5292> ;
    dcterms:identifier "4286" ;
    m2r:variation civicv:494 ;
    rdfs:label "PIM1" ;
    a m2r:Gene .

civicg:2317
    rdfs:seeAlso <http://identifiers.org/ncbigene/2776> ;
    dcterms:identifier "2317" ;
    m2r:variation civicv:505,civicv:507,civicv:604 ;
    rdfs:label "GNAQ" ;
    a m2r:Gene .

civicg:2308
    rdfs:seeAlso <http://identifiers.org/ncbigene/2767> ;
    dcterms:identifier "2308" ;
    m2r:variation civicv:506,civicv:558 ;
    rdfs:label "GNA11" ;
    a m2r:Gene .

civicg:4371
    rdfs:seeAlso <http://identifiers.org/ncbigene/5395> ;
    dcterms:identifier "4371" ;
    m2r:variation civicv:508 ;
    rdfs:label "PMS2" ;
    a m2r:Gene .

civicg:34321
    rdfs:seeAlso <http://identifiers.org/ncbigene/100288687> ;
    dcterms:identifier "34321" ;
    m2r:variation civicv:524 ;
    rdfs:label "DUX4" ;
    a m2r:Gene .

civicg:2239
    rdfs:seeAlso <http://identifiers.org/ncbigene/2683> ;
    dcterms:identifier "2239" ;
    m2r:variation civicv:525 ;
    rdfs:label "B4GALT1" ;
    a m2r:Gene .

civicg:7953
    rdfs:seeAlso <http://identifiers.org/ncbigene/10018> ;
    dcterms:identifier "7953" ;
    m2r:variation civicv:526 ;
    rdfs:label "BCL2L11" ;
    a m2r:Gene .

civicg:9538
    rdfs:seeAlso <http://identifiers.org/ncbigene/23411> ;
    dcterms:identifier "9538" ;
    m2r:variation civicv:529 ;
    rdfs:label "SIRT1" ;
    a m2r:Gene .

civicg:15013
    rdfs:seeAlso <http://identifiers.org/ncbigene/79728> ;
    dcterms:identifier "15013" ;
    m2r:variation civicv:532,civicv:541 ;
    rdfs:label "PALB2" ;
    a m2r:Gene .

civicg:1811
    rdfs:seeAlso <http://identifiers.org/ncbigene/2176> ;
    dcterms:identifier "1811" ;
    m2r:variation civicv:534 ;
    rdfs:label "FANCC" ;
    a m2r:Gene .

civicg:4176
    rdfs:seeAlso <http://identifiers.org/ncbigene/5159> ;
    dcterms:identifier "4176" ;
    m2r:variation civicv:535,civicv:568 ;
    rdfs:label "PDGFRB" ;
    a m2r:Gene .

civicg:4795
    rdfs:seeAlso <http://identifiers.org/ncbigene/5925> ;
    dcterms:identifier "4795" ;
    m2r:variation civicv:537,civicv:547,civicv:606,civicv:632,civicv:638,civicv:799 ;
    rdfs:label "RB1" ;
    a m2r:Gene .

civicg:3532
    rdfs:seeAlso <http://identifiers.org/ncbigene/4292> ;
    dcterms:identifier "3532" ;
    m2r:variation civicv:538,civicv:662,civicv:725,civicv:728,civicv:730,civicv:731,civicv:733,civicv:735,civicv:741,civicv:743,civicv:744,civicv:745,civicv:746,civicv:747,civicv:748,civicv:749,civicv:750,civicv:751,civicv:752,civicv:753,civicv:754,civicv:756,civicv:757,civicv:758,civicv:759,civicv:760,civicv:769 ;
    rdfs:label "MLH1" ;
    a m2r:Gene .

civicg:4685
    rdfs:seeAlso <http://identifiers.org/ncbigene/5781> ;
    dcterms:identifier "4685" ;
    m2r:variation civicv:539 ;
    rdfs:label "PTPN11" ;
    a m2r:Gene .

civicg:9722
    rdfs:seeAlso <http://identifiers.org/ncbigene/23645> ;
    dcterms:identifier "9722" ;
    m2r:variation civicv:548 ;
    rdfs:label "PPP1R15A" ;
    a m2r:Gene .

civicg:916
    rdfs:seeAlso <http://identifiers.org/ncbigene/1030> ;
    dcterms:identifier "916" ;
    m2r:variation civicv:555,civicv:784 ;
    rdfs:label "CDKN2B" ;
    a m2r:Gene .

civicg:732
    rdfs:seeAlso <http://identifiers.org/ncbigene/811> ;
    dcterms:identifier "732" ;
    m2r:variation civicv:559,civicv:2388 ;
    rdfs:label "CALR" ;
    a m2r:Gene .

civicg:1239
    rdfs:seeAlso <http://identifiers.org/ncbigene/1441> ;
    dcterms:identifier "1239" ;
    m2r:variation civicv:560,civicv:2387 ;
    rdfs:label "CSF3R" ;
    a m2r:Gene .

civicg:4546
    rdfs:seeAlso <http://identifiers.org/ncbigene/5609> ;
    dcterms:identifier "4546" ;
    m2r:variation civicv:566 ;
    rdfs:label "MAP2K7" ;
    a m2r:Gene .

civicg:20480
    rdfs:seeAlso <http://identifiers.org/ncbigene/253260> ;
    dcterms:identifier "20480" ;
    m2r:variation civicv:573 ;
    rdfs:label "RICTOR" ;
    a m2r:Gene .

civicg:3867
    rdfs:seeAlso <http://identifiers.org/ncbigene/4763> ;
    dcterms:identifier "3867" ;
    m2r:variation civicv:587,civicv:698 ;
    rdfs:label "NF1" ;
    a m2r:Gene .

civicg:353
    rdfs:seeAlso <http://identifiers.org/ncbigene/330> ;
    dcterms:identifier "353" ;
    m2r:variation civicv:590 ;
    rdfs:label "BIRC3" ;
    a m2r:Gene .

civicg:4767
    rdfs:seeAlso <http://identifiers.org/ncbigene/5894> ;
    dcterms:identifier "4767" ;
    m2r:variation civicv:591 ;
    rdfs:label "RAF1" ;
    a m2r:Gene .

civicg:5210
    rdfs:seeAlso <http://identifiers.org/ncbigene/6427> ;
    dcterms:identifier "5210" ;
    m2r:variation civicv:595 ;
    rdfs:label "SRSF2" ;
    a m2r:Gene .

civicg:1285
    rdfs:seeAlso <http://identifiers.org/ncbigene/1493> ;
    dcterms:identifier "1285" ;
    m2r:variation civicv:599 ;
    rdfs:label "CTLA4" ;
    a m2r:Gene .

civicg:12
    rdfs:seeAlso <http://identifiers.org/ncbigene/1021> ;
    dcterms:identifier "12" ;
    m2r:variation civicv:602 ;
    rdfs:label "CDK6" ;
    a m2r:Gene .

civicg:537
    rdfs:seeAlso <http://identifiers.org/ncbigene/567> ;
    dcterms:identifier "537" ;
    m2r:variation civicv:616 ;
    rdfs:label "B2M" ;
    a m2r:Gene .

civicg:4659
    rdfs:seeAlso <http://identifiers.org/ncbigene/5743> ;
    dcterms:identifier "4659" ;
    m2r:variation civicv:619 ;
    rdfs:label "PTGS2" ;
    a m2r:Gene .

civicg:9935
    rdfs:seeAlso <http://identifiers.org/ncbigene/25913> ;
    dcterms:identifier "9935" ;
    m2r:variation civicv:623 ;
    rdfs:label "POT1" ;
    a m2r:Gene .

civicg:3529
    rdfs:seeAlso <http://identifiers.org/ncbigene/4288> ;
    dcterms:identifier "3529" ;
    m2r:variation civicv:624 ;
    rdfs:label "MKI67" ;
    a m2r:Gene .

civicg:4760
    rdfs:seeAlso <http://identifiers.org/ncbigene/5887> ;
    dcterms:identifier "4760" ;
    m2r:variation civicv:625 ;
    rdfs:label "RAD23B" ;
    a m2r:Gene .

civicg:1873
    rdfs:seeAlso <http://identifiers.org/ncbigene/2248> ;
    dcterms:identifier "1873" ;
    m2r:variation civicv:630 ;
    rdfs:label "FGF3" ;
    a m2r:Gene .

civicg:4289
    rdfs:seeAlso <http://identifiers.org/ncbigene/5295> ;
    dcterms:identifier "4289" ;
    m2r:variation civicv:633 ;
    rdfs:label "PIK3R1" ;
    a m2r:Gene .

civicg:3094
    rdfs:seeAlso <http://identifiers.org/ncbigene/3725> ;
    dcterms:identifier "3094" ;
    m2r:variation civicv:639 ;
    rdfs:label "JUN" ;
    a m2r:Gene .

civicg:1955
    rdfs:seeAlso <http://identifiers.org/ncbigene/2353> ;
    dcterms:identifier "1955" ;
    m2r:variation civicv:640,civicv:739 ;
    rdfs:label "FOS" ;
    a m2r:Gene .

civicg:779
    rdfs:seeAlso <http://identifiers.org/ncbigene/868> ;
    dcterms:identifier "779" ;
    m2r:variation civicv:643 ;
    rdfs:label "CBLB" ;
    a m2r:Gene .

civicg:593
    rdfs:seeAlso <http://identifiers.org/ncbigene/639> ;
    dcterms:identifier "593" ;
    m2r:variation civicv:644 ;
    rdfs:label "PRDM1" ;
    a m2r:Gene .

civicg:525
    rdfs:seeAlso <http://identifiers.org/ncbigene/546> ;
    dcterms:identifier "525" ;
    m2r:variation civicv:648 ;
    rdfs:label "ATRX" ;
    a m2r:Gene .

civicg:533
    rdfs:seeAlso <http://identifiers.org/ncbigene/558> ;
    dcterms:identifier "533" ;
    m2r:variation civicv:651 ;
    rdfs:label "AXL" ;
    a m2r:Gene .

civicg:2186
    rdfs:seeAlso <http://identifiers.org/ncbigene/2621> ;
    dcterms:identifier "2186" ;
    m2r:variation civicv:652 ;
    rdfs:label "GAS6" ;
    a m2r:Gene .

civicg:1767
    rdfs:seeAlso <http://identifiers.org/ncbigene/2118> ;
    dcterms:identifier "1767" ;
    m2r:variation civicv:653 ;
    rdfs:label "ETV4" ;
    a m2r:Gene .

civicg:8552
    rdfs:seeAlso <http://identifiers.org/ncbigene/10734> ;
    dcterms:identifier "8552" ;
    m2r:variation civicv:654 ;
    rdfs:label "STAG3" ;
    a m2r:Gene .

civicg:12555
    rdfs:seeAlso <http://identifiers.org/ncbigene/54880> ;
    dcterms:identifier "12555" ;
    m2r:variation civicv:663 ;
    rdfs:label "BCOR" ;
    a m2r:Gene .

civicg:888
    rdfs:seeAlso <http://identifiers.org/ncbigene/999> ;
    dcterms:identifier "888" ;
    m2r:variation civicv:664 ;
    rdfs:label "CDH1" ;
    a m2r:Gene .

civicg:399
    rdfs:seeAlso <http://identifiers.org/ncbigene/387> ;
    dcterms:identifier "399" ;
    m2r:variation civicv:665 ;
    rdfs:label "RHOA" ;
    a m2r:Gene .

civicg:3485
    rdfs:seeAlso <http://identifiers.org/ncbigene/4221> ;
    dcterms:identifier "3485" ;
    m2r:variation civicv:667 ;
    rdfs:label "MEN1" ;
    a m2r:Gene .

civicg:14089
    rdfs:seeAlso <http://identifiers.org/ncbigene/58508> ;
    dcterms:identifier "14089" ;
    m2r:variation civicv:668 ;
    rdfs:label "KMT2C" ;
    a m2r:Gene .

civicg:3738
    rdfs:seeAlso <http://identifiers.org/ncbigene/4610> ;
    dcterms:identifier "3738" ;
    m2r:variation civicv:670 ;
    rdfs:label "MYCL" ;
    a m2r:Gene .

civicg:2591
    rdfs:seeAlso <http://identifiers.org/ncbigene/3082> ;
    dcterms:identifier "2591" ;
    m2r:variation civicv:671 ;
    rdfs:label "HGF" ;
    a m2r:Gene .

civicg:5418
    rdfs:seeAlso <http://identifiers.org/ncbigene/6663> ;
    dcterms:identifier "5418" ;
    m2r:variation civicv:672 ;
    rdfs:label "SOX10" ;
    a m2r:Gene .

civicg:1872
    rdfs:seeAlso <http://identifiers.org/ncbigene/2247> ;
    dcterms:identifier "1872" ;
    m2r:variation civicv:673 ;
    rdfs:label "FGF2" ;
    a m2r:Gene .

civicg:1646
    rdfs:seeAlso <http://identifiers.org/ncbigene/1964> ;
    dcterms:identifier "1646" ;
    m2r:variation civicv:674 ;
    rdfs:label "EIF1AX" ;
    a m2r:Gene .

civicg:12271
    rdfs:seeAlso <http://identifiers.org/ncbigene/54206> ;
    dcterms:identifier "12271" ;
    m2r:variation civicv:691 ;
    rdfs:label "ERRFI1" ;
    a m2r:Gene .

civicg:5225
    rdfs:seeAlso <http://identifiers.org/ncbigene/6446> ;
    dcterms:identifier "5225" ;
    m2r:variation civicv:693 ;
    rdfs:label "SGK1" ;
    a m2r:Gene .

civicg:5356
    rdfs:seeAlso <http://identifiers.org/ncbigene/6598> ;
    dcterms:identifier "5356" ;
    m2r:variation civicv:695,civicv:696 ;
    rdfs:label "SMARCB1" ;
    a m2r:Gene .

civicg:7954
    rdfs:seeAlso <http://identifiers.org/ncbigene/10019> ;
    dcterms:identifier "7954" ;
    m2r:variation civicv:699 ;
    rdfs:label "SH2B3" ;
    a m2r:Gene .

civicg:7502
    rdfs:seeAlso <http://identifiers.org/ncbigene/9493> ;
    dcterms:identifier "7502" ;
    m2r:variation civicv:700 ;
    rdfs:label "KIF23" ;
    a m2r:Gene .

civicg:1411
    rdfs:seeAlso <http://identifiers.org/ncbigene/1647> ;
    dcterms:identifier "1411" ;
    m2r:variation civicv:705 ;
    rdfs:label "GADD45A" ;
    a m2r:Gene .

civicg:54
    rdfs:seeAlso <http://identifiers.org/ncbigene/2130> ;
    dcterms:identifier "54" ;
    m2r:variation civicv:706 ;
    rdfs:label "EWSR1" ;
    a m2r:Gene .

civicg:8351
    rdfs:seeAlso <http://identifiers.org/ncbigene/10481> ;
    dcterms:identifier "8351" ;
    m2r:variation civicv:772 ;
    rdfs:label "HOXB13" ;
    a m2r:Gene .

civicg:32083
    rdfs:seeAlso <http://identifiers.org/ncbigene/100144748> ;
    dcterms:identifier "32083" ;
    m2r:variation civicv:711 ;
    rdfs:label "KLLN" ;
    a m2r:Gene .

civicg:11761
    rdfs:seeAlso <http://identifiers.org/ncbigene/51185> ;
    dcterms:identifier "11761" ;
    m2r:variation civicv:713 ;
    rdfs:label "CRBN" ;
    a m2r:Gene .

civicg:1413
    rdfs:seeAlso <http://identifiers.org/ncbigene/1649> ;
    dcterms:identifier "1413" ;
    m2r:variation civicv:717,civicv:722 ;
    rdfs:label "DDIT3" ;
    a m2r:Gene .

civicg:9588
    rdfs:seeAlso <http://identifiers.org/ncbigene/23476> ;
    dcterms:identifier "9588" ;
    m2r:variation civicv:719 ;
    rdfs:label "BRD4" ;
    a m2r:Gene .

civicg:1342
    rdfs:seeAlso <http://identifiers.org/ncbigene/1565> ;
    dcterms:identifier "1342" ;
    m2r:variation civicv:721 ;
    rdfs:label "CYP2D6" ;
    a m2r:Gene .

civicg:3628
    rdfs:seeAlso <http://identifiers.org/ncbigene/4436> ;
    dcterms:identifier "3628" ;
    m2r:variation civicv:727,civicv:762,civicv:763,civicv:770,civicv:773,civicv:808 ;
    rdfs:label "MSH2" ;
    a m2r:Gene .

civicg:12422
    rdfs:seeAlso <http://identifiers.org/ncbigene/54658> ;
    dcterms:identifier "12422" ;
    m2r:variation civicv:729,civicv:732 ;
    rdfs:label "UGT1A1" ;
    a m2r:Gene .

civicg:1526
    rdfs:seeAlso <http://identifiers.org/ncbigene/1806> ;
    dcterms:identifier "1526" ;
    m2r:variation civicv:737,civicv:738,civicv:740 ;
    rdfs:label "DPYD" ;
    a m2r:Gene .

civicg:9952
    rdfs:seeAlso <http://identifiers.org/ncbigene/25937> ;
    dcterms:identifier "9952" ;
    m2r:variation civicv:742 ;
    rdfs:label "WWTR1" ;
    a m2r:Gene .

civicg:2478
    rdfs:seeAlso <http://identifiers.org/ncbigene/2956> ;
    dcterms:identifier "2478" ;
    m2r:variation civicv:761,civicv:765,civicv:767,civicv:775,civicv:776,civicv:809 ;
    rdfs:label "MSH6" ;
    a m2r:Gene .

civicg:8450
    rdfs:seeAlso <http://identifiers.org/ncbigene/10599> ;
    dcterms:identifier "8450" ;
    m2r:variation civicv:777,civicv:778 ;
    rdfs:label "SLCO1B1" ;
    a m2r:Gene .

civicg:2279
    rdfs:seeAlso <http://identifiers.org/ncbigene/2735> ;
    dcterms:identifier "2279" ;
    m2r:variation civicv:780 ;
    rdfs:label "GLI1" ;
    a m2r:Gene .

civicg:5051
    rdfs:seeAlso <http://identifiers.org/ncbigene/6240> ;
    dcterms:identifier "5051" ;
    m2r:variation civicv:795,civicv:1257 ;
    rdfs:label "RRM1" ;
    a m2r:Gene .

civicg:5052
    rdfs:seeAlso <http://identifiers.org/ncbigene/6241> ;
    dcterms:identifier "5052" ;
    m2r:variation civicv:796 ;
    rdfs:label "RRM2" ;
    a m2r:Gene .

civicg:4386
    rdfs:seeAlso <http://identifiers.org/ncbigene/5426> ;
    dcterms:identifier "4386" ;
    m2r:variation civicv:797,civicv:1830,civicv:1831,civicv:1832 ;
    rdfs:label "POLE" ;
    a m2r:Gene .

civicg:3985
    rdfs:seeAlso <http://identifiers.org/ncbigene/4916> ;
    dcterms:identifier "3985" ;
    m2r:variation civicv:801,civicv:805,civicv:1277,civicv:1281,civicv:2422 ;
    rdfs:label "NTRK3" ;
    a m2r:Gene .

civicg:11932
    rdfs:seeAlso <http://identifiers.org/ncbigene/51428> ;
    dcterms:identifier "11932" ;
    m2r:variation civicv:814 ;
    rdfs:label "DDX41" ;
    a m2r:Gene .

civicg:4690
    rdfs:seeAlso <http://identifiers.org/ncbigene/5787> ;
    dcterms:identifier "4690" ;
    m2r:variation civicv:819 ;
    rdfs:label "PTPRB" ;
    a m2r:Gene .

civicg:2608
    rdfs:seeAlso <http://identifiers.org/ncbigene/3107> ;
    dcterms:identifier "2608" ;
    m2r:variation civicv:821 ;
    rdfs:label "HLA-C" ;
    a m2r:Gene .

civicg:3364
    rdfs:seeAlso <http://identifiers.org/ncbigene/4072> ;
    dcterms:identifier "3364" ;
    m2r:variation civicv:823 ;
    rdfs:label "EPCAM" ;
    a m2r:Gene .

civicg:2319
    rdfs:seeAlso <http://identifiers.org/ncbigene/2778> ;
    dcterms:identifier "2319" ;
    m2r:variation civicv:826,civicv:876,civicv:877,civicv:1319 ;
    rdfs:label "GNAS" ;
    a m2r:Gene .

civicg:7936
    rdfs:seeAlso <http://identifiers.org/ncbigene/10000> ;
    dcterms:identifier "7936" ;
    m2r:variation civicv:1301,civicv:1227 ;
    rdfs:label "AKT3" ;
    a m2r:Gene .

civicg:3659
    rdfs:seeAlso <http://identifiers.org/ncbigene/4507> ;
    dcterms:identifier "3659" ;
    m2r:variation civicv:867 ;
    rdfs:label "MTAP" ;
    a m2r:Gene .

civicg:18353
    rdfs:seeAlso <http://identifiers.org/ncbigene/137492> ;
    dcterms:identifier "18353" ;
    m2r:variation civicv:868 ;
    rdfs:label "VPS37A" ;
    a m2r:Gene .

civicg:1396
    rdfs:seeAlso <http://identifiers.org/ncbigene/1630> ;
    dcterms:identifier "1396" ;
    m2r:variation civicv:1284 ;
    rdfs:label "DCC" ;
    a m2r:Gene .

civicg:1290
    rdfs:seeAlso <http://identifiers.org/ncbigene/1499> ;
    dcterms:identifier "1290" ;
    m2r:variation civicv:1285,civicv:1286,civicv:1287,civicv:1296 ;
    rdfs:label "CTNNB1" ;
    a m2r:Gene .

civicg:6559
    rdfs:seeAlso <http://identifiers.org/ncbigene/8289> ;
    dcterms:identifier "6559" ;
    m2r:variation civicv:1293,civicv:1510,civicv:1682,civicv:2108 ;
    rdfs:label "ARID1A" ;
    a m2r:Gene .

civicg:8331
    rdfs:seeAlso <http://identifiers.org/ncbigene/10461> ;
    dcterms:identifier "8331" ;
    m2r:variation civicv:1299 ;
    rdfs:label "MERTK" ;
    a m2r:Gene .

civicg:3737
    rdfs:seeAlso <http://identifiers.org/ncbigene/4609> ;
    dcterms:identifier "3737" ;
    m2r:variation civicv:1303 ;
    rdfs:label "MYC" ;
    a m2r:Gene .

civicg:4384
    rdfs:seeAlso <http://identifiers.org/ncbigene/5424> ;
    dcterms:identifier "4384" ;
    m2r:variation civicv:1647,civicv:1648 ;
    rdfs:label "POLD1" ;
    a m2r:Gene .

civicg:4290
    rdfs:seeAlso <http://identifiers.org/ncbigene/5296> ;
    dcterms:identifier "4290" ;
    m2r:variation civicv:1652,civicv:2363 ;
    rdfs:label "PIK3R2" ;
    a m2r:Gene .

civicg:154
    rdfs:seeAlso <http://identifiers.org/ncbigene/90> ;
    dcterms:identifier "154" ;
    m2r:variation civicv:2061,civicv:1686,civicv:2283 ;
    rdfs:label "ACVR1" ;
    a m2r:Gene .

civicg:981
    rdfs:seeAlso <http://identifiers.org/ncbigene/1111> ;
    dcterms:identifier "981" ;
    m2r:variation civicv:1693 ;
    rdfs:label "CHEK1" ;
    a m2r:Gene .

civicg:9533
    rdfs:seeAlso <http://identifiers.org/ncbigene/23405> ;
    dcterms:identifier "9533" ;
    m2r:variation civicv:2050,civicv:2051,civicv:2052,civicv:2195,civicv:2196 ;
    rdfs:label "DICER1" ;
    a m2r:Gene .

civicg:8032
    rdfs:seeAlso <http://identifiers.org/ncbigene/10111> ;
    dcterms:identifier "8032" ;
    m2r:variation civicv:2168 ;
    rdfs:label "RAD50" ;
    a m2r:Gene .

civicg:4327
    rdfs:seeAlso <http://identifiers.org/ncbigene/5336> ;
    dcterms:identifier "4327" ;
    m2r:variation civicv:2170 ;
    rdfs:label "PLCG2" ;
    a m2r:Gene .

civicg:549
    rdfs:seeAlso <http://identifiers.org/ncbigene/580> ;
    dcterms:identifier "549" ;
    m2r:variation civicv:2219 ;
    rdfs:label "BARD1" ;
    a m2r:Gene .

civicg:450
    rdfs:seeAlso <http://identifiers.org/ncbigene/445> ;
    dcterms:identifier "450" ;
    m2r:variation civicv:2230 ;
    rdfs:label "ASS1" ;
    a m2r:Gene .

civicg:4791
    rdfs:seeAlso <http://identifiers.org/ncbigene/5921> ;
    dcterms:identifier "4791" ;
    m2r:variation civicv:2235 ;
    rdfs:label "RASA1" ;
    a m2r:Gene .

civicg:8787
    rdfs:seeAlso <http://identifiers.org/ncbigene/11011> ;
    dcterms:identifier "8787" ;
    m2r:variation civicv:2240 ;
    rdfs:label "TLK2" ;
    a m2r:Gene .

civicg:3984
    rdfs:seeAlso <http://identifiers.org/ncbigene/4915> ;
    dcterms:identifier "3984" ;
    m2r:variation civicv:2287,civicv:2396 ;
    rdfs:label "NTRK2" ;
    a m2r:Gene .

civicg:15344
    rdfs:seeAlso <http://identifiers.org/ncbigene/80243> ;
    dcterms:identifier "15344" ;
    m2r:variation civicv:2364 ;
    rdfs:label "PREX2" ;
    a m2r:Gene .

civicg:5177
    rdfs:seeAlso <http://identifiers.org/ncbigene/6390> ;
    dcterms:identifier "5177" ;
    m2r:variation civicv:2411 ;
    rdfs:label "SDHB" ;
    a m2r:Gene .

civicg:4517
    rdfs:seeAlso <http://identifiers.org/ncbigene/5579> ;
    dcterms:identifier "4517" ;
    m2r:variation civicv:2468 ;
    rdfs:label "PRKCB" ;
    a m2r:Gene .

civicv:1                 # so:gene_fusion
    rdfs:label "BCR-ABL" ;
    m2r:evidence civice:213,civice:220,civice:232,civice:259,civice:260,civice:261,civice:344 ;
    sio:SIO_000974 civic:22_5partner1, civic:9_3partner1 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000305877.8 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors." ;
    civico:variantID "1" ;
    m2r:disease civic:ChronicMyeloidLeukemia,civic:AcuteMyeloidLeukemia ;   
    a obo:transcript_fusion, m2r:Variation .

civic:22_5partner1                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "23522397" ;
                      faldo:reference hco:22#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "23632600" ;
                      faldo:reference hco:22#GRCh37
        ]
     ] .


civic:9_3partner1 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 133729451 ;
                       faldo:reference hco:9#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 133763063 ;
                       faldo:reference hco:9#GRCh37
        ]
     ] .


civicv:2
    rdfs:label "BCR-ABL T315I" ;
    m2r:evidence civice:234,civice:235,civice:1390,civice:2667,civice:2669,civice:2670,civice:4364,civice:4365,civice:6192,civice:6196,civice:6234,civice:6235,civice:6285 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748283 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748283 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases." ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "2" ;
    civico:variantGroups "Imatinib Resistance" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:3
    rdfs:label "BCR-ABL E255K" ;
    m2r:evidence civice:233,civice:2659,civice:2661,civice:2662,civice:4348,civice:4350,civice:6193,civice:6194,civice:6214,civice:6282 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133738363 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133738363 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases." ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "3" ;
    civico:variantGroups "Imatinib Resistance" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:4
    rdfs:label "E17K" ;
    m2r:evidence civice:231,civice:707,civice:709,civice:3039,civice:4029 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 105246551 ;
            faldo:reference hco:14#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 105246551 ;
            faldo:reference hco:14#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000407796.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics." ;
    m2r:disease civic:BreastCancer,civic:Melanoma,civic:Cancer ;
    dcterms:identifier "4" ;
    a obo:missense_variant, m2r:Variation .


civicv:5                 # so:gene_fusion
    rdfs:label "EML4-ALK" ;
    m2r:evidence civice:262,civice:1121,civice:1188,civice:1203,civice:1206,civice:1207,civice:1332 ;
    sio:SIO_000974 civic:2_5partner5, civic:2_3partner5 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000318522.5 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors." ;
    civico:variantID "5" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:LungAcinarAdenocarcinoma ;
    civico:variantGroups "ALK Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:2_5partner5                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42396490" ;
                      faldo:reference hco:2#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42522656" ;
                      faldo:reference hco:2#GRCh37
        ]
     ] .


civic:2_3partner5 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29415640 ;
                       faldo:reference hco:2#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29446394 ;
                       faldo:reference hco:2#GRCh37
        ]
     ] .


civicv:6
    rdfs:label "EML4-ALK C1156Y" ;
    m2r:evidence civice:841,civice:842,civice:1346 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29445258 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29445258 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, C1156Y has been shown to confer resistance to crizotinib. Case reports indicate that secondary mutations can modulate drug sensitivity. EML4-ALK C1156Y/L1196M maintained crizotinib resistance while the lorlatinib resistant combination EML4-ALK C1156Y/L1198F re-sensitized the tumor to crizotinib treatment." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "6" ;
    civico:variantGroups "ALK Fusions,Crizotinib Resistance" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:7
    rdfs:label "EML4-ALK L1196M" ;
    m2r:evidence civice:141,civice:237,civice:442,civice:1341 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29443631 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29443631 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, L1196M has been shown to confer resistance to crizotinib. This was also true in a patient with both EML4-ALK C1156Y & L1196M." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "7" ;
    civico:variantGroups "ALK Fusions,Crizotinib Resistance" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:8
    rdfs:label "F1174L" ;
    m2r:evidence civice:32,civice:33,civice:37,civice:38,civice:125,civice:142,civice:1271,civice:1327,civice:1329 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29443695 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29443695 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells." ;
    m2r:disease civic:InflammatoryMyofibroblasticTumor,civic:Non-smallCellLungCarcinoma,civic:Neuroblastoma ;
    dcterms:identifier "8" ;
    civico:variantGroups "Crizotinib Resistance" ;
    a obo:missense_variant, m2r:Variation .


civicv:9
    rdfs:label "R1275Q" ;
    m2r:evidence civice:39,civice:48,civice:143,civice:1269,civice:1270,civice:1331 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29432664 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29432664 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines." ;
    m2r:disease civic:Neuroblastoma ;
    dcterms:identifier "9" ;
    a obo:missense_variant, m2r:Variation .


civicv:10
    rdfs:label "S214C" ;
    m2r:evidence civice:17,civice:40,civice:41 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 47426121 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 47426121 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000377045.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "10" ;
    a obo:missense_variant, m2r:Variation .


civicv:11
    rdfs:label "V600D" ;
    m2r:evidence civice:94,civice:4488,civice:4489 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453135 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453136 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "CA" ;
    m2r:alternative_allele "AT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry." ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "11" ;
    civico:variantGroups "Other V600's" ;
    a obo:missense_variant, m2r:Variation .


civicv:12
    rdfs:label "V600E" ;
    m2r:evidence civice:79,civice:80,civice:82,civice:86,civice:89,civice:90,civice:91,civice:95,civice:96,civice:97,civice:98,civice:99,civice:102,civice:103,civice:104,civice:105,civice:106,civice:107,civice:126,civice:463,civice:656,civice:757,civice:816,civice:1005,civice:1127,civice:1141,civice:1398,civice:1405,civice:1406,civice:1408,civice:1409,civice:1410,civice:1411,civice:1413,civice:1414,civice:1421,civice:1428,civice:1430,civice:1552,civice:1579,civice:1589,civice:1591,civice:1698,civice:1699,civice:1749,civice:1902,civice:1940,civice:2115,civice:2117,civice:2118,civice:2121,civice:2135,civice:2137,civice:2503,civice:3017,civice:3739,civice:3750,civice:3755,civice:3757,civice:3758,civice:3777,civice:3787,civice:5902,civice:5903,civice:5904,civice:5906,civice:5958,civice:5959,civice:5960,civice:5961,civice:5962,civice:6045,civice:6123,civice:6124,civice:6178 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453136 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453136 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment." ;
    m2r:disease civic:ThyroidCancer,civic:PapillaryThyroidCarcinoma,civic:Melanoma,civic:ColorectalCancer,civic:Non-smallCellLungCarcinoma,civic:Myeloma,civic:HairyCellLeukemia,civic:Cancer,civic:SkinMelanoma,civic:GastrointestinalNeuroendocrineTumor,civic:MultipleMyeloma,civic:Ganglioglioma,civic:OvarianCystadenocarcinoma,civic:Cholangiocarcinoma,civic:OvarianCancer,civic:AnaplasticThyroidCarcinoma,civic:LaryngealSquamousCellCarcinoma,civic:AnaplasticThyroidCancer,civic:ColorectalAdenocarcinoma ;
    dcterms:identifier "12" ;
    a obo:missense_variant, m2r:Variation .


civicv:13
    rdfs:label "V600E+V600M" ;
    m2r:evidence civice:73 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453135 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453137 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response." ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "13" ;
    civico:variantGroups "Other V600's" ;
    a obo:missense_variant, m2r:Variation .


civicv:14
    rdfs:label "V600E AMPLIFICATION" ;
    m2r:evidence civice:92 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140434279 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140624564 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Amplification of BRAF V600E has been shown to confer resistance to MEK inhibitors. For more information on the V600 locus, see the V600E entry." ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "14" ;
    a obo:transcript_amplification,obo:missense_variant, m2r:Variation .


civicv:17
    rdfs:label "V600" ;
    m2r:evidence civice:30,civice:88,civice:93,civice:994,civice:1000,civice:1407,civice:1415,civice:1574,civice:1575,civice:1576,civice:1598,civice:1750,civice:5905,civice:6044,civice:6046,civice:6047,civice:6180 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453136 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453137 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations." ;
    m2r:disease civic:Melanoma,civic:ColorectalCancer,civic:Non-smallCellLungCarcinoma,civic:Langerhans-CellHistiocytosis,civic:Cholangiocarcinoma ;
    dcterms:identifier "17" ;
    civico:variantGroups "Other V600's" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:18
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:354,civice:858,civice:1495,civice:1560,civice:1562,civice:1599 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 69455855 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 69469242 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000227507.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer." ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:BreastCancer,civic:SkinMelanoma,civic:RenalCellCarcinoma,civic:OvarianCancer ;
    dcterms:identifier "18" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:19
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:342,civice:355 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 69455855 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 69469242 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000227507.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "19" ;
    a m2r:Variation .


civicv:20
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:221,civice:356,civice:357,civice:358,civice:856,civice:1536,civice:1563 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 69455855 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 69469242 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000227507.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies." ;
    m2r:disease civic:BreastCancer,civic:HeadAndNeckSquamousCellCarcinoma,civic:MantleCellLymphoma,civic:Estrogen-receptorPositiveBreastCancer ;
    dcterms:identifier "20" ;
    a m2r:Variation .


civicv:21
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:359,civice:360,civice:361,civice:362 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 4382938 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 4414516 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000261254.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies." ;
    m2r:disease civic:StomachCancer ;
    dcterms:identifier "21" ;
    a m2r:Variation .


civicv:22
    rdfs:label "PROMOTER DEMETHYLATION" ;
    m2r:evidence civice:219 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 4381437 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 4382937 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000261254.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies." ;
    m2r:disease civic:StomachCancer ;
    dcterms:identifier "22" ;
    a m2r:Variation .


civicv:23
    rdfs:label "LOSS" ;
    m2r:evidence civice:263 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41902671 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41909586 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000372991.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL." ;
    m2r:disease civic:T-cellLeukemia ;
    dcterms:identifier "23" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:24
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:363,civice:364,civice:365,civice:1734 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 30302805 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 30315215 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000262643.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts." ;
    m2r:disease civic:BreastCancer,civic:GastricAdenosquamousCarcinoma,civic:OvarianCancer ;
    dcterms:identifier "24" ;
    a m2r:Variation .


civicv:25
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:264,civice:4872 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 58141510 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 58146304 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257904.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors." ;
    m2r:disease civic:Estrogen-receptorPositiveBreastCancer,civic:Sarcoma ;
    dcterms:identifier "25" ;
    a m2r:Variation .


civicv:27
    rdfs:label "PROMOTER HYPERMETHYLATION" ;
    m2r:evidence civice:367 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 21974827 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 21994591 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000498124.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "27" ;
    a m2r:Variation .


civicv:28
    rdfs:label "N-TERMINAL FRAME SHIFT" ;
    m2r:evidence civice:1103 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 33792961 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 33793470 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000498907.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "CEBPA N-terminal frame shift mutations that result in a premature stop codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML). CEBPA mutations are associated with a favorable prognosis; however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications. N-terminal frame shift mutations within amino acids 1-120 have been shown to disrupt expression of the full-length 42kDa isoform while maintaining expression of a 30kDa isoform (translated from the AUG at full-length protein isoform amino acid M120). This 30kDa isoform exhibits dominant negative activity." ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "28" ;
    a obo:dominant_negative_variant,obo:frameshift_truncation, m2r:Variation .


civicv:29
    rdfs:label "MUTATION" ;
    m2r:evidence civice:122,civice:166,civice:167,civice:168,civice:467,civice:468 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 33790840 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 33793470 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000498907.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications." ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "29" ;
    a obo:loss_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:30                 # so:gene_fusion
    rdfs:label "MEF2D-CSF1R" ;
    m2r:evidence civice:403 ;
    sio:SIO_000974 civic:1_5partner30, civic:5_3partner30 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000348159.4 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity." ;
    civico:variantID "30" ;
    m2r:disease civic:AcuteLymphocyticLeukemia ;   
    a obo:transcript_fusion, m2r:Variation .

civic:1_5partner30                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "156446804" ;
                      faldo:reference hco:1#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "156470620" ;
                      faldo:reference hco:1#GRCh37
        ]
     ] .


civic:5_3partner30 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 149433787 ;
                       faldo:reference hco:5#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 149441412 ;
                       faldo:reference hco:5#GRCh37
        ]
     ] .


civicv:31                 # so:gene_fusion
    rdfs:label "DNAJB1-PRKACA" ;
    m2r:evidence civice:405,civice:532,civice:754,civice:1643 ;
    sio:SIO_000974 civic:19_5partner31, civic:19_3partner31 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000254322.2 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type." ;
    civico:variantID "31" ;
    m2r:disease civic:HepatocellularFibrolamellarCarcinoma,civic:HepatocellularMixedFibrolamellarCarcinoma ;   
    a obo:transcript_fusion, m2r:Variation .

civic:19_5partner31                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "14628951" ;
                      faldo:reference hco:19#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "14629232" ;
                      faldo:reference hco:19#GRCh37
        ]
     ] .


civic:19_3partner31 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 14202500 ;
                       faldo:reference hco:19#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 14218221 ;
                       faldo:reference hco:19#GRCh37
        ]
     ] .


civicv:32
    rdfs:label "R882" ;
    m2r:evidence civice:3,civice:4,civice:11,civice:18,civice:24,civice:25,civice:31,civice:49,civice:50,civice:51,civice:61,civice:62,civice:63,civice:64,civice:65,civice:66,civice:67,civice:68,civice:110,civice:112,civice:113,civice:114,civice:115,civice:157,civice:170,civice:186,civice:187,civice:189 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25457241 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25457243 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000264709.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML." ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "32" ;
    a obo:missense_variant, m2r:Variation .


civicv:33
    rdfs:label "L858R" ;
    m2r:evidence civice:229,civice:275,civice:276,civice:347,civice:879,civice:883,civice:885,civice:968,civice:982,civice:1665,civice:2621,civice:2624,civice:2625,civice:2626,civice:2627,civice:2628,civice:2629,civice:2631,civice:2632,civice:2633,civice:2634,civice:2994,civice:2997,civice:3811,civice:4265,civice:4284,civice:4285,civice:4286,civice:4287,civice:4288,civice:4290,civice:4291,civice:4292,civice:4293,civice:4294,civice:4295,civice:4860,civice:6183 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55259515 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55259515 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies." ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:LungAdenocarcinoma,civic:Cancer,civic:LungSmallCellCarcinoma,civic:HematologicCancer,civic:MalignantGlioma ;
    dcterms:identifier "33" ;
    a obo:missense_variant, m2r:Variation .


civicv:34
    rdfs:label "T790M" ;
    m2r:evidence civice:238,civice:239,civice:240,civice:277,civice:278,civice:369,civice:370,civice:642,civice:646,civice:762,civice:963,civice:965,civice:966,civice:967,civice:1391,civice:1397,civice:1592,civice:1667,civice:1863,civice:1867,civice:2157,civice:2158,civice:2159,civice:2160,civice:2161,civice:2162,civice:2163,civice:2164,civice:2165,civice:3810 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55249071 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249071 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing." ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:LungCancer,civic:LungAdenocarcinoma,civic:Cancer ;
    dcterms:identifier "34" ;
    civico:variantGroups "EGFR TKI Resistance" ;
    a obo:missense_variant, m2r:Variation .


civicv:35
    rdfs:label "D769H" ;
    m2r:evidence civice:279 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37880261 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37880261 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines were shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "35" ;
    civico:variantGroups "HER2 Activating" ;
    a obo:missense_variant, m2r:Variation .


civicv:36
    rdfs:label "D769Y" ;
    m2r:evidence civice:280 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37880261 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37880261 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "36" ;
    civico:variantGroups "HER2 Activating" ;
    a obo:missense_variant, m2r:Variation .


civicv:37
    rdfs:label "DEL 755-759" ;
    m2r:evidence civice:281 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37880219 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37880233 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "TTGAGGGAAAACACA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "37" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:38
    rdfs:label "G309A" ;
    m2r:evidence civice:282 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37868205 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37868205 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "38" ;
    civico:variantGroups "HER2 Activating" ;
    a obo:missense_variant, m2r:Variation .


civicv:39
    rdfs:label "L755S" ;
    m2r:evidence civice:241,civice:283,civice:1176 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37880220 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37880220 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines." ;
    m2r:disease civic:BreastCancer,civic:ColonCancer ;
    dcterms:identifier "39" ;
    a obo:missense_variant, m2r:Variation .


civicv:40
    rdfs:label "L755W" ;
    m2r:evidence civice:284 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37880220 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37880220 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "40" ;
    a obo:missense_variant, m2r:Variation .


civicv:41
    rdfs:label "P780INS" ;
    m2r:evidence civice:285,civice:1048 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37881011 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37881012 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:alternative_allele "GGCTCCCCA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research." ;
    m2r:disease civic:BreastCancer,civic:LungAdenocarcinoma ;
    dcterms:identifier "41" ;
    civico:variantGroups "HER2 Activating" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:42
    rdfs:label "R678Q" ;
    m2r:evidence civice:286 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37879658 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37879658 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "42" ;
    a obo:missense_variant, m2r:Variation .


civicv:43
    rdfs:label "R896C" ;
    m2r:evidence civice:287 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37881616 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37881616 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "43" ;
    civico:variantGroups "HER2 Activating" ;
    a obo:missense_variant, m2r:Variation .


civicv:44
    rdfs:label "V777L" ;
    m2r:evidence civice:288,civice:1177 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37881000 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37881000 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research." ;
    m2r:disease civic:BreastCancer,civic:ColonCancer ;
    dcterms:identifier "44" ;
    civico:variantGroups "HER2 Activating" ;
    a obo:missense_variant, m2r:Variation .


civicv:45
    rdfs:label "V842I" ;
    m2r:evidence civice:289,civice:1174 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37881332 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37881332 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research." ;
    m2r:disease civic:BreastCancer,civic:ColonCancer ;
    dcterms:identifier "45" ;
    civico:variantGroups "HER2 Activating" ;
    a obo:missense_variant, m2r:Variation .


civicv:46
    rdfs:label "L536Q" ;
    m2r:evidence civice:242,civice:290 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 152419920 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 152419921 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    m2r:reference_allele "TC" ;
    m2r:alternative_allele "AG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000440973.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "46" ;
    civico:variantGroups "ESR1 Ligand-Binding Domain" ;
    a obo:missense_variant, m2r:Variation .


civicv:47
    rdfs:label "D538G" ;
    m2r:evidence civice:243,civice:291,civice:4814 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 152419926 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 152419926 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000206249.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "47" ;
    civico:variantGroups "ESR1 Ligand-Binding Domain" ;
    a obo:missense_variant, m2r:Variation .


civicv:48
    rdfs:label "Y537C" ;
    m2r:evidence civice:244,civice:292 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 152419923 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 152419923 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000206249.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "48" ;
    civico:variantGroups "ESR1 Ligand-Binding Domain" ;
    a obo:missense_variant, m2r:Variation .


civicv:49
    rdfs:label "Y537N" ;
    m2r:evidence civice:245,civice:293 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 152419922 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 152419922 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000206249.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "49" ;
    civico:variantGroups "ESR1 Ligand-Binding Domain" ;
    a obo:missense_variant, m2r:Variation .


civicv:50
    rdfs:label "Y537S" ;
    m2r:evidence civice:246,civice:294 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 152419923 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 152419923 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000206249.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "50" ;
    civico:variantGroups "ESR1 Ligand-Binding Domain" ;
    a obo:missense_variant, m2r:Variation .


civicv:52                 # so:gene_fusion
    rdfs:label "FGFR2-MGEA5" ;
    m2r:evidence civice:295 ;
    sio:SIO_000974 civic:10_5partner52, civic:10_3partner52 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000457416.2 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts." ;
    civico:variantID "52" ;
    m2r:disease civic:Cholangiocarcinoma ;
    civico:variantGroups "FGFR fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:10_5partner52                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "123243212" ;
                      faldo:reference hco:10#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "123357917" ;
                      faldo:reference hco:10#GRCh37
        ]
     ] .


civic:10_3partner52 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 103544209 ;
                       faldo:reference hco:10#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 103552700 ;
                       faldo:reference hco:10#GRCh37
        ]
     ] .


civicv:53                 # so:gene_fusion
    rdfs:label "FGFR3-BAIAP2L1" ;
    m2r:evidence civice:144 ;
    sio:SIO_000974 civic:4_5partner53, civic:7_3partner53 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000340107.4 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts." ;
    civico:variantID "53" ;
    m2r:disease civic:BladderCarcinoma ;
    civico:variantGroups "FGFR fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:4_5partner53                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "1795039" ;
                      faldo:reference hco:4#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "1810599" ;
                      faldo:reference hco:4#GRCh37
        ]
     ] .


civic:7_3partner53 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 97991744 ;
                       faldo:reference hco:7#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 97920963 ;
                       faldo:reference hco:7#GRCh37
        ]
     ] .


civicv:54                 # so:gene_fusion
    rdfs:label "FGFR2-TACC3" ;
    m2r:evidence civice:296 ;
    sio:SIO_000974 civic:4_5partner54, civic:4_3partner54 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000358487.5 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "In a clinical sequencing program for advanced stage cancers, Wu et al has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts." ;
    civico:variantID "54" ;
    m2r:disease civic:Cholangiocarcinoma ;
    civico:variantGroups "FGFR fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:4_5partner54                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "123243212" ;
                      faldo:reference hco:4#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "123357598" ;
                      faldo:reference hco:4#GRCh37
        ]
     ] .


civic:4_3partner54 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 1723266 ;
                       faldo:reference hco:4#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 1741505 ;
                       faldo:reference hco:4#GRCh37
        ]
     ] .


civicv:55
    rdfs:label "ITD" ;
    m2r:evidence civice:52,civice:69,civice:127,civice:128,civice:129,civice:130,civice:131,civice:158,civice:159,civice:190,civice:191,civice:192,civice:193,civice:195,civice:198,civice:222,civice:297,civice:298,civice:299,civice:371,civice:372,civice:1040,civice:1109,civice:1112,civice:1137,civice:1515,civice:1555 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 28608219 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 28608351 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000241453.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:AcutePromyelocyticLeukemia ;
    dcterms:identifier "55" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:56
    rdfs:label "TKD MUTATION" ;
    m2r:evidence civice:171,civice:214,civice:247,civice:248,civice:322,civice:373,civice:1295 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 28592642 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 28592642 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000241453.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor." ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "56" ;
    a obo:nonsynonymous_variant, m2r:Variation .


civicv:57
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:301 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 128198270 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 128212028 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000341105.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "GATA2 misregulation has been observed in a number of hematologic malignancies, as well as non-small cell lung cancer. Treatment of over-active GATA2 pathways using the proteasome inhibitor bortezomib has shown dramatic tumor regression in lung cancer." ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "57" ;
    a m2r:Variation .


civicv:58
    rdfs:label "R132" ;
    m2r:evidence civice:160,civice:223,civice:323,civice:348,civice:349,civice:374,civice:480,civice:481 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 209113111 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 209113113 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000415913.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:Astrocytoma,civic:GlioblastomaMultiforme,civic:MyelodysplasticSyndrome ;
    dcterms:identifier "58" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:59
    rdfs:label "R132C" ;
    m2r:evidence civice:224,civice:324,civice:732,civice:2327,civice:2329,civice:2330,civice:2331,civice:2332,civice:4032 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 209113113 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 209113113 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000415913.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:BrainGlioma,civic:MalignantGlioma,civic:GlioblastomaMultiforme ;
    dcterms:identifier "59" ;
    a obo:missense_variant, m2r:Variation .


civicv:62
    rdfs:label "R140" ;
    m2r:evidence civice:327,civice:329,civice:330,civice:350,civice:1542 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 90631934 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 90631934 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000330062.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:MyelodysplasticSyndrome ;
    dcterms:identifier "62" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:63
    rdfs:label "R172K" ;
    m2r:evidence civice:331,civice:332,civice:375 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 90631838 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 90631838 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000330062.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:MyelodysplasticSyndrome ;
    dcterms:identifier "63" ;
    a obo:missense_variant, m2r:Variation .


civicv:64
    rdfs:label "V617F" ;
    m2r:evidence civice:1,civice:5,civice:7,civice:19,civice:20 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 5073770 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 5073770 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000381652.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success." ;
    m2r:disease civic:LymphoidLeukemia,civic:ChronicMyeloidLeukemia,civic:BoneMarrowCancer,civic:PolycythemiaVera ;
    dcterms:identifier "64" ;
    a obo:gain_of_function_variant,obo:missense_variant, m2r:Variation .


civicv:65
    rdfs:label "D816V" ;
    m2r:evidence civice:26,civice:1725,civice:1726 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55599321 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55599321 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:SystemicMastocytosis ;
    dcterms:identifier "65" ;
    civico:variantGroups "KIT Exon 17" ;
    a obo:missense_variant, m2r:Variation .


civicv:66
    rdfs:label "EXON 11 MUTATION" ;
    m2r:evidence civice:53,civice:58,civice:225,civice:333,civice:334,civice:376,civice:654,civice:1224 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55593582 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55593708 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib." ;
    m2r:disease civic:GastrointestinalStromalTumor,civic:Melanoma,civic:LungCancer ;
    dcterms:identifier "66" ;
    civico:variantGroups "KIT Exon 11" ;
    a obo:coding_sequence_variant, m2r:Variation .


civicv:67
    rdfs:label "INTERNAL DUPLICATION" ;
    m2r:evidence civice:302 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55593582 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55593708 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "c-KIT internal duplications have been observed in exon 11, within the juxtamembrane domain. In a case study of an anal melanoma patient harboring this event, imatinib confered marked response. Also, cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year." ;
    m2r:disease civic:MalignantAnusMelanoma ;
    dcterms:identifier "67" ;
    civico:variantGroups "KIT Exon 11" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:69
    rdfs:label "EXON 14 MUTATION" ;
    m2r:evidence civice:70 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55595501 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55595651 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "c-KIT exon 14 mutations lie within the tyrosine kinase domain of the protein. While relatively rare in primary gastrointestinal tumors, they are notably more prevalent in refractory disease, suggesting a role in imatinib resistance. Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma." ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "69" ;
    a obo:exon_variant, m2r:Variation .


civicv:72
    rdfs:label "L576P" ;
    m2r:evidence civice:34,civice:42,civice:303 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55593661 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55593661 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib." ;
    m2r:disease civic:Melanoma,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "72" ;
    civico:variantGroups "KIT Exon 11" ;
    a obo:missense_variant, m2r:Variation .


civicv:73
    rdfs:label "V654A" ;
    m2r:evidence civice:249,civice:304 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55594258 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55594258 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response." ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "73" ;
    civico:variantGroups "KIT Exon 11" ;
    a obo:missense_variant, m2r:Variation .


civicv:75
    rdfs:label "EXON 2 MUTATION" ;
    m2r:evidence civice:87,civice:250,civice:916,civice:917,civice:993,civice:1208,civice:1219,civice:1326 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398208 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398329 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS." ;
    m2r:disease civic:ColorectalCancer,civic:PancreaticCarcinoma,civic:PancreaticCancer ;
    dcterms:identifier "75" ;
    a obo:missense_variant, m2r:Variation .


civicv:76
    rdfs:label "G12" ;
    m2r:evidence civice:8,civice:215,civice:336,civice:337,civice:377,civice:378,civice:487 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398284 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398285 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients." ;
    m2r:disease civic:AcuteLeukemia,civic:Non-smallCellLungCarcinoma,civic:ColorectalCancer,civic:MultipleMyeloma ;
    dcterms:identifier "76" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:77
    rdfs:label "G12/G13" ;
    m2r:evidence civice:35,civice:134,civice:135,civice:194,civice:622,civice:990,civice:6292,civice:6293,civice:6294,civice:6295,civice:6296,civice:6363 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398280 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398285 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients." ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:ColorectalCancer,civic:PancreaticAdenocarcinoma ;
    dcterms:identifier "77" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:78
    rdfs:label "G12C" ;
    m2r:evidence civice:227,civice:1142,civice:1173,civice:1216,civice:1217,civice:2212,civice:2253,civice:2257,civice:2258,civice:2261,civice:2262,civice:2263,civice:3973 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398285 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398285 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients." ;
    m2r:disease civic:LungCancer,civic:Non-smallCellLungCarcinoma,civic:Cancer,civic:ColorectalCancer,civic:MultipleMyeloma ;
    dcterms:identifier "78" ;
    civico:variantGroups "EGFR TKI Resistance" ;
    a obo:missense_variant, m2r:Variation .


civicv:79
    rdfs:label "G12D" ;
    m2r:evidence civice:228,civice:305,civice:937,civice:1215,civice:1300,civice:1311,civice:1580,civice:1732,civice:1898,civice:2218,civice:2236,civice:2240,civice:2247,civice:2250,civice:2251,civice:2252,civice:3946,civice:3957,civice:3958,civice:6316 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398284 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398284 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided." ;
    m2r:disease civic:LungCancer,civic:Non-smallCellLungCarcinoma,civic:PancreaticCarcinoma,civic:ColorectalCancer,civic:PancreaticCancer,civic:TumorOfExocrinePancreas,civic:HairyCellLeukemia,civic:PancreaticDuctalCarcinoma,civic:MultipleMyeloma,civic:Melanoma,civic:OvarianCancer ;
    dcterms:identifier "79" ;
    civico:variantGroups "EGFR TKI Resistance" ;
    a obo:missense_variant, m2r:Variation .


civicv:80
    rdfs:label "G13" ;
    m2r:evidence civice:488 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398281 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398282 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients." ;
    m2r:disease civic:MultipleMyeloma ;
    dcterms:identifier "80" ;
    a obo:inframe_insertion,obo:missense_variant, m2r:Variation .


civicv:81
    rdfs:label "G13D" ;
    m2r:evidence civice:145,civice:306,civice:806,civice:1180,civice:1181,civice:2183,civice:2231,civice:3878,civice:3882,civice:6320,civice:6322 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398281 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398281 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing." ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "81" ;
    a obo:missense_variant, m2r:Variation .


civicv:82
    rdfs:label "P124S" ;
    m2r:evidence civice:12 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 66729162 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 66729162 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000307102.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart." ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "82" ;
    a obo:missense_variant, m2r:Variation .


civicv:83
    rdfs:label "Q56P" ;
    m2r:evidence civice:13 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 66727451 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 66727451 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000307102.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines." ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "83" ;
    a obo:missense_variant, m2r:Variation .


civicv:85
    rdfs:label "PROMOTER METHYLATION" ;
    m2r:evidence civice:172,civice:307,civice:308,civice:309,civice:490,civice:491 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 131264495 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 131265656 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000306010.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients." ;
    m2r:disease civic:GlioblastomaMultiforme,civic:AnaplasticOligodendroglioma ;
    dcterms:identifier "85" ;
    a m2r:Variation .


civicv:86
    rdfs:label "EXON 12 MUTATION" ;
    m2r:evidence civice:108,civice:111,civice:116,civice:117,civice:118,civice:119,civice:120,civice:137,civice:146,civice:147,civice:148,civice:149,civice:150,civice:151,civice:173,civice:174,civice:175,civice:176,civice:177,civice:179,civice:180,civice:181,civice:182,civice:183,civice:184,civice:185,civice:196,civice:199,civice:1102,civice:1369 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 170837531 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 170837569 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000517671.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy." ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "86" ;
    civico:variantGroups "NPM1 Exon 12" ;
    a obo:exon_variant, m2r:Variation .


civicv:87
    rdfs:label "W288FS" ;
    m2r:evidence civice:109,civice:121,civice:152,civice:153 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 170837547 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 170837548 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    m2r:alternative_allele "TCTG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000517671.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information)." ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "87" ;
    civico:variantGroups "NPM1 Exon 12" ;
    a obo:frameshift_elongation, m2r:Variation .


civicv:92
    rdfs:label "G12" ;
    m2r:evidence civice:57 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 115258747 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 115258748 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000369535.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated." ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "92" ;
    a obo:missense_variant, m2r:Variation .


civicv:93
    rdfs:label "G13D" ;
    m2r:evidence civice:21 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 115258744 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 115258744 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000369535.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated." ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "93" ;
    a obo:missense_variant, m2r:Variation .


civicv:94
    rdfs:label "Q61" ;
    m2r:evidence civice:10,civice:14,civice:36,civice:124,civice:497,civice:1226,civice:1473 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 115256528 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 115256530 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000369535.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study." ;
    m2r:disease civic:Melanoma,civic:ColorectalCancer,civic:FollicularThyroidCarcinoma,civic:SkinMelanoma ;
    dcterms:identifier "94" ;
    a obo:missense_variant, m2r:Variation .


civicv:95
    rdfs:label "Q61L" ;
    m2r:evidence civice:22 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 115256529 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 115256529 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000369535.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study." ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "95" ;
    a obo:missense_variant, m2r:Variation .


civicv:96
    rdfs:label "Q61R" ;
    m2r:evidence civice:23 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 115256529 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 115256529 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000369535.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study." ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "96" ;
    a obo:missense_variant, m2r:Variation .


civicv:98
    rdfs:label "D842I" ;
    m2r:evidence civice:43 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55152092 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55152093 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "GA" ;
    m2r:alternative_allele "AT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412)." ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "98" ;
    civico:variantGroups "Imatinib Resistance" ;
    a obo:missense_variant, m2r:Variation .


civicv:99
    rdfs:label "D842V" ;
    m2r:evidence civice:2,civice:15,civice:16,civice:44,civice:651,civice:738,civice:4060 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55152093 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55152093 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412)." ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "99" ;
    civico:variantGroups "Imatinib Resistance" ;
    a obo:missense_variant, m2r:Variation .


civicv:100
    rdfs:label "D842Y" ;
    m2r:evidence civice:45 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55152092 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55152092 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412)." ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "100" ;
    civico:variantGroups "Imatinib Resistance" ;
    a obo:missense_variant, m2r:Variation .


civicv:101
    rdfs:label "I843DEL" ;
    m2r:evidence civice:46,civice:1309 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55152095 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55152097 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "ATC" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412)." ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "101" ;
    civico:variantGroups "Imatinib Resistance" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:102
    rdfs:label "DI842-843VM" ;
    m2r:evidence civice:47 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55152093 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55152097 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "ACATC" ;
    m2r:alternative_allele "TCATG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412)." ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "102" ;
    civico:variantGroups "Imatinib Resistance" ;
    a obo:missense_variant, m2r:Variation .


civicv:103
    rdfs:label "E542K" ;
    m2r:evidence civice:83,civice:256,civice:310,civice:311,civice:384,civice:385,civice:1549,civice:1626 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 178936082 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 178936082 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with other PIK3CA variants or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases." ;
    m2r:disease civic:ColorectalCancer,civic:BreastCancer,civic:HeadAndNeckSquamousCellCarcinoma,civic:ThyroidCancer ;
    dcterms:identifier "103" ;
    a obo:missense_variant, m2r:Variation .


civicv:104
    rdfs:label "E545K" ;
    m2r:evidence civice:387,civice:710,civice:1171,civice:1453,civice:1550,civice:1670,civice:2034,civice:2035,civice:2036,civice:2037,civice:2038,civice:2040,civice:3722 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 178936091 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 178936091 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases." ;
    m2r:disease civic:ColorectalCancer,civic:BreastCancer,civic:LungAdenocarcinoma,civic:Her2-receptorPositiveBreastCancer,civic:Cancer,civic:Non-smallCellLungCarcinoma,civic:Melanoma ;
    dcterms:identifier "104" ;
    a obo:missense_variant, m2r:Variation .


civicv:105
    rdfs:label "EXON 21 MUTATION" ;
    m2r:evidence civice:138 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 178951882 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 178952495 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases." ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "105" ;
    a obo:exon_variant, m2r:Variation .


civicv:106
    rdfs:label "EXON 10 MUTATION" ;
    m2r:evidence civice:123 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 178935998 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 178936122 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases." ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "106" ;
    a obo:exon_variant, m2r:Variation .


civicv:107
    rdfs:label "H1047R" ;
    m2r:evidence civice:258,civice:314,civice:388,civice:1361,civice:1362,civice:1363,civice:1401,civice:1447,civice:1465,civice:1505,civice:1506,civice:1623,civice:1625,civice:2098,civice:2100,civice:2102,civice:2103,civice:2105,civice:2106,civice:2110 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 178952085 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 178952085 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases." ;
    m2r:disease civic:ColorectalCancer,civic:BreastCancer,civic:HeadAndNeckCancer,civic:LungAdenocarcinoma,civic:HeadAndNeckSquamousCellCarcinoma,civic:Her2-receptorPositiveBreastCancer,civic:ThyroidCancer,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "107" ;
    a obo:missense_variant, m2r:Variation .


civicv:108                 # so:gene_fusion
    rdfs:label "PML-RARA" ;
    m2r:evidence civice:316,civice:1090,civice:1091,civice:1519 ;
    sio:SIO_000974 civic:15_5partner108, civic:17_3partner108 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000268058.3 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising." ;
    civico:variantID "108" ;
    m2r:disease civic:AcutePromyelocyticLeukemia ;   
    a obo:transcript_fusion, m2r:Variation .

civic:15_5partner108                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "74287058" ;
                      faldo:reference hco:15#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "74325755" ;
                      faldo:reference hco:15#GRCh37
        ]
     ] .


civic:17_3partner108 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 38504568 ;
                       faldo:reference hco:17#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 38513048 ;
                       faldo:reference hco:17#GRCh37
        ]
     ] .


civicv:110
    rdfs:label "R233*" ;
    m2r:evidence civice:317,civice:343 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 89717672 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 89717672 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371953.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis." ;
    m2r:disease civic:BreastCancer,civic:GlioblastomaMultiforme ;
    dcterms:identifier "110" ;
    civico:variantGroups "PTEN Loss-of-Function" ;
    a obo:stop_gained,obo:loss_of_function_variant, m2r:Variation .


civicv:112
    rdfs:label "C634W" ;
    m2r:evidence civice:75 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 43609950 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 43609950 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000355710.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib." ;
    m2r:disease civic:ThyroidMedullaryCarcinoma ;
    dcterms:identifier "112" ;
    civico:variantGroups "Motesanib Resistance" ;
    a obo:missense_variant, m2r:Variation .


civicv:113
    rdfs:label "M918T" ;
    m2r:evidence civice:74,civice:76,civice:77,civice:78,civice:1365 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 43617416 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 43617416 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000355710.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis." ;
    m2r:disease civic:ThyroidMedullaryCarcinoma ;
    dcterms:identifier "113" ;
    civico:variantGroups "Motesanib Resistance" ;
    a obo:missense_variant, m2r:Variation .


civicv:114
    rdfs:label "K666N" ;
    m2r:evidence civice:1418 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 198267359 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 198267359 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000335508.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "114" ;
    civico:variantGroups "HEAT domain mutation" ;
    a obo:missense_variant, m2r:Variation .


civicv:116
    rdfs:label "R175H" ;
    m2r:evidence civice:319,civice:389,civice:2310,civice:4880 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7578406 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7578406 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant." ;
    m2r:disease civic:BreastCancer,civic:StomachCarcinoma,civic:Cancer ;
    dcterms:identifier "116" ;
    a obo:missense_variant, m2r:Variation .


civicv:117
    rdfs:label "R248Q" ;
    m2r:evidence civice:390,civice:391,civice:3042 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7577538 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7577538 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant." ;
    m2r:disease civic:BreastCancer,civic:Cancer ;
    dcterms:identifier "117" ;
    a obo:missense_variant, m2r:Variation .


civicv:118
    rdfs:label "R248W" ;
    m2r:evidence civice:392,civice:4879 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7577539 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7577539 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival." ;
    m2r:disease civic:BreastCancer,civic:Cancer ;
    dcterms:identifier "118" ;
    a obo:missense_variant, m2r:Variation .


civicv:119
    rdfs:label "R249" ;
    m2r:evidence civice:393,civice:399 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7577535 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7577535 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "119" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:121
    rdfs:label "R273C" ;
    m2r:evidence civice:395,civice:396,civice:2292,civice:4881 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7577121 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7577121 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type." ;
    m2r:disease civic:BreastCancer,civic:StomachCarcinoma,civic:Cancer ;
    dcterms:identifier "121" ;
    a obo:missense_variant, m2r:Variation .


civicv:122
    rdfs:label "R273H" ;
    m2r:evidence civice:397,civice:398,civice:4882 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7577120 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7577120 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type." ;
    m2r:disease civic:BreastCancer,civic:Cancer ;
    dcterms:identifier "122" ;
    a obo:missense_variant, m2r:Variation .


civicv:124
    rdfs:label "FRAMESHIFT TRUNCATION" ;
    m2r:evidence civice:154,civice:320 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 135766735 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 135820008 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000298552.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells." ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:InvasiveBladderTransitionalCellCarcinoma ;
    dcterms:identifier "124" ;
    civico:variantGroups "TSC Loss" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:125
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:155 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 135766735 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 135820008 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000298552.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells." ;
    m2r:disease civic:BladderCarcinoma ;
    dcterms:identifier "125" ;
    civico:variantGroups "TSC Loss" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:127
    rdfs:label "Q157P/R" ;
    m2r:evidence civice:217,civice:338,civice:339,civice:400 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 44514777 ;
            faldo:reference hco:21#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 44514777 ;
            faldo:reference hco:21#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000291552.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:MyelodysplasticSyndrome ;
    dcterms:identifier "127" ;
    a obo:missense_variant, m2r:Variation .


civicv:128
    rdfs:label "S34Y/F" ;
    m2r:evidence civice:218,civice:340,civice:401 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 44524456 ;
            faldo:reference hco:21#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 44524456 ;
            faldo:reference hco:21#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000291552.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:MyelodysplasticSyndrome ;
    dcterms:identifier "128" ;
    a obo:missense_variant, m2r:Variation .


civicv:129
    rdfs:label "EXON 7 MUTATION" ;
    m2r:evidence civice:139,civice:162,civice:163,civice:201,civice:202,civice:203,civice:204,civice:205,civice:206 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32417803 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32417953 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000332351.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors." ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "129" ;
    a obo:exon_variant, m2r:Variation .


civicv:130
    rdfs:label "EXON 9 MUTATION" ;
    m2r:evidence civice:165,civice:210 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32413518 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32413610 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000332351.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "WT1 exon 9 mutations have been shown to be recurrent in acute myeloid leukemia, although at a less frequent rate than their exon 7 counterparts. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 9 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors." ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "130" ;
    a obo:exon_variant, m2r:Variation .


civicv:131
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:211,civice:845,civice:1523,civice:1924,civice:4838,civice:4876,civice:5815,civice:6075 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41196312 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41277387 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000357654.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    dcterms:description "BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response." ;
    m2r:disease civic:OvarianCancer,civic:ProstateCancer,civic:BreastCancer,civic:Her2-receptorNegativeBreastCancer,civic:PancreaticCancer ;
    dcterms:identifier "131" ;
    civico:variantGroups "BRCA Germline Variants" ;
    a obo:loss_of_function_variant,obo:loss_of_heterozygosity, m2r:Variation .


civicv:132
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:212,civice:650,civice:1308,civice:1524,civice:1925,civice:4839,civice:4875,civice:5816,civice:6076 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32889611 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32973347 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000380152.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    dcterms:description "BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response." ;
    m2r:disease civic:OvarianCancer,civic:ProstateCancer,civic:PancreaticCancer,civic:BreastCancer,civic:Her2-receptorNegativeBreastCancer ;
    dcterms:identifier "132" ;
    civico:variantGroups "BRCA Germline Variants" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:133
    rdfs:label "EXON 19 DELETION" ;
    m2r:evidence civice:273,civice:413,civice:880,civice:881,civice:882,civice:884,civice:969,civice:981,civice:983,civice:1666,civice:2519,civice:2995,civice:2996,civice:4766,civice:4859 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55242415 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55242513 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma." ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:LungAdenocarcinoma ;
    dcterms:identifier "133" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:134
    rdfs:label "G719S" ;
    m2r:evidence civice:274,civice:787,civice:1736,civice:4190 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55241707 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55241707 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib." ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:ColorectalCancer ;
    dcterms:identifier "134" ;
    a obo:missense_variant, m2r:Variation .


civicv:135
    rdfs:label "D1642H" ;
    m2r:evidence civice:380 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 139399219 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 139399219 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000277541.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Activating mutations in NOTCH1, including D1642H, have been shown to be poor prognostic markers in lung cancer." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "135" ;
    a obo:missense_variant, m2r:Variation .


civicv:136
    rdfs:label "R2327W" ;
    m2r:evidence civice:381 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 139391212 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 139391212 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000277541.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Activating mutations in NOTCH1, including R2327W, have been shown to be poor prognostic markers in lung cancer." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "136" ;
    a obo:missense_variant, m2r:Variation .


civicv:137
    rdfs:label "V2444FS" ;
    m2r:evidence civice:383 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 139390861 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 139390861 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "TGT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000277541.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Activating mutations in NOTCH1, including a frameshift insertion at V2444, have been shown to be poor prognostic markers in lung cancer." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "137" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:138
    rdfs:label "S2275FS" ;
    m2r:evidence civice:382 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 139391369 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 139391370 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000277541.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Activating mutations in NOTCH1, including a frameshift insertion at S2275, have been shown to be poor prognostic markers in lung cancer." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "138" ;
    a obo:plus_1_frameshift_variant, m2r:Variation .


civicv:139
    rdfs:label "L63V" ;
    m2r:evidence civice:271 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 162724415 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 162724415 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000367922.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "139" ;
    a obo:missense_variant, m2r:Variation .


civicv:140
    rdfs:label "L239R" ;
    m2r:evidence civice:270 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 162729630 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 162729630 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000367922.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "140" ;
    a obo:missense_variant, m2r:Variation .


civicv:141
    rdfs:label "G253C" ;
    m2r:evidence civice:266 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 162729671 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 162729671 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000367922.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Activating mutations in DDR2, including G253C, has been shown to be sensitive to dasatinib in cell lines." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "141" ;
    a obo:missense_variant, m2r:Variation .


civicv:142
    rdfs:label "G505S" ;
    m2r:evidence civice:267 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 162741822 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 162741822 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000367922.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "142" ;
    a obo:missense_variant, m2r:Variation .


civicv:143
    rdfs:label "I638F" ;
    m2r:evidence civice:269 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 162745497 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 162745497 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000367922.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "143" ;
    a obo:missense_variant, m2r:Variation .


civicv:144
    rdfs:label "G774V" ;
    m2r:evidence civice:268 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 162748407 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 162748407 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000367922.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "144" ;
    a obo:missense_variant, m2r:Variation .


civicv:145
    rdfs:label "S768R" ;
    m2r:evidence civice:272 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 162748390 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 162748390 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000367922.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Activating mutations in DDR2, including S768R, has been shown to be sensitive to dasatinib in cell lines." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "145" ;
    a obo:missense_variant, m2r:Variation .


civicv:148
    rdfs:label "G12A" ;
    m2r:evidence civice:251,civice:2004,civice:2008,civice:2009,civice:2012,civice:2013,civice:2014,civice:3710,civice:6319 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398284 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398284 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma." ;
    m2r:disease civic:LungAdenocarcinoma,civic:ColorectalCancer,civic:LungCancer,civic:MultipleMyeloma ;
    dcterms:identifier "148" ;
    civico:variantGroups "EGFR TKI Resistance" ;
    a obo:missense_variant, m2r:Variation .


civicv:151                 # so:gene_fusion
    rdfs:label "IGH-BCL2" ;
    m2r:evidence civice:407 ;
    sio:SIO_000974 civic:14_5partner151, civic:18_3partner151 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The typically reciprocal t(14;18)(q32;q21) translocation involves rearrangement between the immunoglobulin heavy chain locus on chromosome 14 and the 3' UTR of BCL2 on chromosome 18, leading to the overexpression of BCL2. This rearrangment is observed in >80% of patients with follicular lymphoma." ;
    civico:variantID "151" ;
    m2r:disease civic:DiffuseLargeB-cellLymphoma ;   
    a obo:transcript_regulatory_region_fusion, m2r:Variation .

civic:14_5partner151                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "106032614" ;
                      faldo:reference hco:14#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "107288051" ;
                      faldo:reference hco:14#GRCh37
        ]
     ] .


civic:18_3partner151 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 60794268 ;
                       faldo:reference hco:18#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 60987019 ;
                       faldo:reference hco:18#GRCh37
        ]
     ] .


civicv:152
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:423,civice:424 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 60790579 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 60987361 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000398117.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:DiffuseLargeB-cellLymphoma ;
    dcterms:identifier "152" ;
    a m2r:Variation .


civicv:153
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:408 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 71003844 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 71633140 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318789.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Amplication in FOXP1 has been shown to be associated with the ABC subtype of DLBCL." ;
    m2r:disease civic:DiffuseLargeB-cellLymphoma ;
    dcterms:identifier "153" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:154
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:409 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 61108709 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 61149800 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000295025.8" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:DiffuseLargeB-cellLymphoma ;
    dcterms:identifier "154" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:155
    rdfs:label "MUTATION" ;
    m2r:evidence civice:411,civice:429,civice:430,civice:508,civice:509,civice:1558 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 36160098 ;
            faldo:reference hco:21#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 36421641 ;
            faldo:reference hco:21#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000300305.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:AcuteLymphocyticLeukemia ;
    dcterms:identifier "155" ;
    a obo:loss_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:156
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:412,civice:414 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 2150348 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 2170833 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000300632.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "156" ;
    a m2r:Variation .


civicv:157
    rdfs:label "MUTATION" ;
    m2r:evidence civice:415,civice:417,civice:419,civice:421,civice:426,civice:427 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 106067450 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 106200973 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000513237.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving \"CN AML\" and \"de novo AML\" however have been unable to elucidate a clinical impact." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:MyelodysplasticSyndrome ;
    dcterms:identifier "157" ;
    a obo:gene_variant,obo:loss_of_function_variant, m2r:Variation .


civicv:158
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:416,civice:1653 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 54944446 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 54967393 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000395913.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCarcinoma,civic:EsophagusSquamousCellCarcinoma ;
    dcterms:identifier "158" ;
    a m2r:Variation .


civicv:159
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:428 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10182692 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10193904 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ClearCellRenalCellCarcinoma ;
    dcterms:identifier "159" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:160
    rdfs:label "MUTATION" ;
    m2r:evidence civice:418,civice:422,civice:1672,civice:4832,civice:5323 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10182692 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10193904 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ClearCellRenalCellCarcinoma,civic:RenalCellCarcinoma ;
    dcterms:identifier "160" ;
    a obo:gene_variant,obo:loss_of_function_variant, m2r:Variation .


civicv:161
    rdfs:label "MUTATION" ;
    m2r:evidence civice:420,civice:499 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 52581857 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 52719852 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000394830.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ClearCellRenalCellCarcinoma,civic:RenalCellCarcinoma ;
    dcterms:identifier "161" ;
    a obo:loss_of_function_variant,obo:transcription_variant, m2r:Variation .


civicv:163
    rdfs:label "MUTATION" ;
    m2r:evidence civice:425,civice:1015 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 148504477 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 148581370 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000320356.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MyelodysplasticSyndrome,civic:FollicularLymphoma ;
    dcterms:identifier "163" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:164                 # so:gene_fusion
    rdfs:label "EWSR1-FLI1 Type 1" ;
    m2r:evidence civice:431 ;
    sio:SIO_000974 civic:22_5partner164, civic:11_3partner164 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000397938.2 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Although multiple fusion transcripts have been described, type 1 consists of EWSR1 exon 7 fused to FLI1 exon 6, the most common arrangement in Ewings Sarcoma." ;
    civico:variantID "164" ;
    m2r:disease civic:EwingSarcoma ;   
    a obo:transcript_fusion, m2r:Variation .

civic:22_5partner164                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "29664007" ;
                      faldo:reference hco:22#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "29683123" ;
                      faldo:reference hco:22#GRCh37
        ]
     ] .


civic:11_3partner164 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 128675261 ;
                       faldo:reference hco:11#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 128683162 ;
                       faldo:reference hco:11#GRCh37
        ]
     ] .


civicv:165
    rdfs:label "Y646" ;
    m2r:evidence civice:432,civice:433,civice:1494 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 148508726 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 148508728 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000320356.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Mutations of Y646 are associated with a diagnosis of Germinal Center B type DLBCL and Follicular non-Hodgkin Lymphoma. In vitro experimental findings suggest that this may be due to reduced methyltransferase activity of EZH2 on protein H3K27 (Morin et al., 2010)." ;
    m2r:disease civic:DiffuseLargeB-cellLymphoma,civic:FollicularLymphoma,civic:SkinMelanoma ;
    dcterms:identifier "165" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:167
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:435 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 49412758 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 49449107 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000301067.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:FollicularLymphoma ;
    dcterms:identifier "167" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:168
    rdfs:label "C481S" ;
    m2r:evidence civice:436,civice:1770 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 100611165 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 100611165 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000308731.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicLymphocyticLeukemia ;
    dcterms:identifier "168" ;
    a obo:missense_variant, m2r:Variation .


civicv:169
    rdfs:label "Q79K" ;
    m2r:evidence civice:439,civice:4498,civice:6260 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 105243048 ;
            faldo:reference hco:14#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 105243048 ;
            faldo:reference hco:14#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000407796.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "169" ;
    a obo:missense_variant, m2r:Variation .


civicv:170                 # so:gene_fusion
    rdfs:label "EML4-ALK AMPLIFICATION" ;
    m2r:evidence civice:440,civice:766,civice:767 ;
    sio:SIO_000974 civic:2_5partner170, civic:2_3partner170 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000318522.5 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "170" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;   
    a obo:transcript_fusion,obo:transcript_amplification, m2r:Variation .

civic:2_5partner170                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42396490" ;
                      faldo:reference hco:2#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42528380" ;
                      faldo:reference hco:2#GRCh37
        ]
     ] .


civic:2_3partner170 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29415640 ;
                       faldo:reference hco:2#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29446394 ;
                       faldo:reference hco:2#GRCh37
        ]
     ] .


civicv:171
    rdfs:label "ALK FUSION G1202R" ;
    m2r:evidence civice:441,civice:1345,civice:1350,civice:1351,civice:1352,civice:1357 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29443613 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29443613 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor  17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein." ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:Cancer,civic:LungAdenocarcinoma ;
    dcterms:identifier "171" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:172
    rdfs:label "EML4-ALK S1206Y" ;
    m2r:evidence civice:443,civice:1343 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29443600 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29443600 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:Cancer ;
    dcterms:identifier "172" ;
    civico:variantGroups "Crizotinib Resistance" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:173
    rdfs:label "EML4-ALK T1151INST" ;
    m2r:evidence civice:444,civice:1347,civice:1348,civice:1349 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29445271 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29445272 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:alternative_allele "CGT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The ALK fusion variant with insertion of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment. The mutation was absent in tumor sample taken before crizotinib treatment. Characterization of the variant using cell lines expressing EML4-ALK with 1151 T insert found the variant to be highly crizotinib resistant, and other work demonstrated resistance to next generation inhibitor alectinib, while resistance to tool compound TAE684 indicates potential resistance to the next generation ALK inhibitor ceritinib which is derived from TAE684. Other experiments suggest theraputic potential for HSP90 inhibitors, as EML4-ALK T1151 Tins sensitivity to 17-AAG has been observed." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "173" ;
    a obo:transcript_fusion,obo:inframe_insertion, m2r:Variation .


civicv:174
    rdfs:label "MUTATION" ;
    m2r:evidence civice:445,civice:446 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 112043218 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 112181936 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000457016.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColonCarcinoma,civic:ColorectalCancer ;
    dcterms:identifier "174" ;
    a m2r:Variation .


civicv:175
    rdfs:label "F877L" ;
    m2r:evidence civice:447 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 66943549 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 66943549 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000374690.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "175" ;
    a obo:missense_variant, m2r:Variation .


civicv:176
    rdfs:label "W742" ;
    m2r:evidence civice:448 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 66937370 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 66937372 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000374690.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ProstateCarcinoma ;
    dcterms:identifier "176" ;
    a obo:missense_variant, m2r:Variation .


civicv:177
    rdfs:label "MUTATION" ;
    m2r:evidence civice:449,civice:450,civice:451,civice:1378,civice:1508,civice:1513 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 30946155 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 31027122 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000375687.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:Myelofibrosis ;
    dcterms:identifier "177" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:178
    rdfs:label "MUTATION" ;
    m2r:evidence civice:452,civice:453,civice:455,civice:1539,civice:1907,civice:1960,civice:2927 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 108093559 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 108239826 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000278616.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GlioblastomaMultiforme,civic:Melanoma,civic:HematologicCancer,civic:ChronicLymphocyticLeukemia,civic:MantleCellLymphoma,civic:ProstateCancer ;
    dcterms:identifier "178" ;
    a obo:loss_of_function_variant,obo:transcription_variant, m2r:Variation .


civicv:179
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:454,civice:878,civice:1292,civice:1564,civice:5215 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 108093559 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 108239826 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000278616.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer,civic:GastricAdenocarcinoma,civic:PancreaticCancer,civic:ChronicLymphocyticLeukemia,civic:StomachCancer ;
    dcterms:identifier "179" ;
    a m2r:Variation .


civicv:180
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:456 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 54944446 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 54967393 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000395913.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:EsophagusAdenocarcinoma ;
    dcterms:identifier "180" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:181
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:457,civice:871,civice:1650 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 54944446 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 54967393 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000395913.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:CervicalAdenocarcinoma,civic:Non-smallCellLungCarcinoma,civic:OvarianSerousCarcinoma ;
    dcterms:identifier "181" ;
    a m2r:Variation .


civicv:182
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:458 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 52435029 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 52444366 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000460680.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UvealMelanoma ;
    dcterms:identifier "182" ;
    a m2r:Variation .


civicv:183
    rdfs:label "MUTATION" ;
    m2r:evidence civice:459,civice:461,civice:1234,civice:1235,civice:5339 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 52435029 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 52444366 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000460680.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "BAP1 is a tumor suppressor gene, mutations in this gene have been observed in a number of cancers including melanoma, and renal cancers. These mutations generally lead to loss-of-function and mutations in the UHC domain of BAP1 have been shown to lead to structural instability and β-amyloid aggregation in models. Germline mutations are associated with an increased risk of tumorgenesis and can lead to the development of \"atypical Spitz tumours (ASTs), cutaneous melanoma (CM), epithelioid malignant mesothelioma (MM) and clear cell RCC\"." ;
    m2r:disease civic:ClearCellRenalCellCarcinoma,civic:UvealMelanoma,civic:MalignantMesothelioma,civic:RenalCellCarcinoma ;
    dcterms:identifier "183" ;
    a obo:loss_of_function_variant,obo:protein_altering_variant, m2r:Variation .


civicv:184                 # so:gene_fusion
    rdfs:label "AKAP9-BRAF" ;
    m2r:evidence civice:462 ;
    sio:SIO_000974 civic:7_5partner184, civic:7_3partner184 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000356239.3 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "184" ;
    m2r:disease civic:PapillaryThyroidCarcinoma ;
    civico:variantGroups "BRAF Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:7_5partner184                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "91570181" ;
                      faldo:reference hco:7#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "91625114" ;
                      faldo:reference hco:7#GRCh37
        ]
     ] .


civic:7_3partner184 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140434279 ;
                       faldo:reference hco:7#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140487384 ;
                       faldo:reference hco:7#GRCh37
        ]
     ] .


civicv:185
    rdfs:label "MUTATION" ;
    m2r:evidence civice:464,civice:1370,civice:1529,civice:1531,civice:1675,civice:1677,civice:1684,civice:1772,civice:1775,civice:1897,civice:5830,civice:5914,civice:5915,civice:5932,civice:5934 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41196312 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41277387 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000357654.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:EpithelialOvarianCancer,civic:Cancer,civic:OvarianCarcinoma,civic:OvarianCancer,civic:Triple-receptorNegativeBreastCancer,civic:BreastCancer,civic:PancreaticCancer ;
    dcterms:identifier "185" ;
    a obo:gene_variant,obo:loss_of_function_variant, m2r:Variation .


civicv:186
    rdfs:label "MUTATION" ;
    m2r:evidence civice:465,civice:1371,civice:1530,civice:1532,civice:1676,civice:1678,civice:1685,civice:1773,civice:1776,civice:5831,civice:5913,civice:5916,civice:5933,civice:5935 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32889611 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32973347 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000380152.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:EpithelialOvarianCancer,civic:Cancer,civic:OvarianCarcinoma,civic:OvarianCancer,civic:Triple-receptorNegativeBreastCancer,civic:BreastCancer,civic:PancreaticCancer ;
    dcterms:identifier "186" ;
    a obo:gene_variant,obo:loss_of_function_variant, m2r:Variation .


civicv:187
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:466,civice:1629,civice:1735 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 30302805 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 30315215 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000262643.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCarcinoma,civic:Estrogen-receptorPositiveBreastCancer,civic:OvarianSerousCystadenocarcinoma ;
    dcterms:identifier "187" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:189
    rdfs:label "MUTATION" ;
    m2r:evidence civice:188,civice:469,civice:1238,civice:1585,civice:1586,civice:1587,civice:2926 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25455845 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25565459 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000264709.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy." ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:T-cellAcuteLymphoblasticLeukemia,civic:MyelodysplasticSyndrome,civic:Cancer ;
    dcterms:identifier "189" ;
    a obo:transcript_variant, m2r:Variation .


civicv:190
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:470,civice:471,civice:473,civice:691,civice:854,civice:911,civice:948,civice:977,civice:3015 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55086794 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55279321 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Barrett%27sAdenocarcinoma,civic:CervicalSquamousCellCarcinoma,civic:HeadAndNeckSquamousCellCarcinoma,civic:ColorectalCancer,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "190" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:191
    rdfs:label "COPY NUMBER VARIATION" ;
    m2r:evidence civice:472,civice:5924,civice:5925 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55086794 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55279321 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "191" ;
    a obo:copy_number_change, m2r:Variation .


civicv:193
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:474,civice:692,civice:693,civice:737,civice:782,civice:783,civice:784,civice:954 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55086794 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55279321 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SupratentorialGlioblastomaMultiforme,civic:HeadAndNeckSquamousCellCarcinoma,civic:Non-smallCellLungCarcinoma,civic:EsophagusSquamousCellCarcinoma ;
    dcterms:identifier "193" ;
    a m2r:Variation .


civicv:194                 # so:gene_fusion
    rdfs:label "EWSR1-ERG" ;
    m2r:evidence civice:475 ;
    sio:SIO_000974 civic:22_5partner194, civic:21_3partner194 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000397938.2 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "EWSR1-ERG is found in 5% of patients with Ewing Sarcoma and considered to be diagnostic of this disease, a small tumor more often found in bone, but less frequently in soft tissue. To better identify EWSR1-ERG in patients, conventional cytogenetics methods were analyzed: FISH and RT-PCR. Ultimately concluding that more than one method is needed to accurately diagnose patients due to the strengths and weaknesses of each individual method." ;
    civico:variantID "194" ;
    m2r:disease civic:EwingSarcoma ;   
    a obo:transcript_fusion, m2r:Variation .

civic:22_5partner194                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "29664007" ;
                      faldo:reference hco:22#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "29683123" ;
                      faldo:reference hco:22#GRCh37
        ]
     ] .


civic:21_3partner194 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 39751949 ;
                       faldo:reference hco:21#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 39755845 ;
                       faldo:reference hco:21#GRCh37
        ]
     ] .


civicv:195                 # so:gene_fusion
    rdfs:label "TMPRSS2-ERG" ;
    m2r:evidence civice:476 ;
    sio:SIO_000974 civic:21_5partner195, civic:21_3partner195 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000398585.3 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "TMPRSS2 fusions are prevalent in Prostate Cancer. TMPRSS2 fusion with ETS family members such as ERG are among the most common. Fusion of TMPRSS2 with ERG may result in overexpression of ERG driven by the TMPRSS2 androgen-responsive promoter elements. Due to the high prevalence of this fusion, it may have diagnostic utility for prostate cancer, especially ERG expression positive prostate cancer." ;
    civico:variantID "195" ;
    m2r:disease civic:ProstateCarcinoma ;   
    a obo:transcript_fusion, m2r:Variation .

civic:21_5partner195                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42879877" ;
                      faldo:reference hco:21#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42879992" ;
                      faldo:reference hco:21#GRCh37
        ]
     ] .


civic:21_3partner195 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 39751949 ;
                       faldo:reference hco:21#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 39817544 ;
                       faldo:reference hco:21#GRCh37
        ]
     ] .


civicv:196
    rdfs:label "Y375C" ;
    m2r:evidence civice:477 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1806099 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1806099 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000340107.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BladderCarcinoma ;
    dcterms:identifier "196" ;
    a obo:missense_variant, m2r:Variation .


civicv:197                 # so:gene_fusion
    rdfs:label "EWSR1-FLI1" ;
    m2r:evidence civice:478 ;
    sio:SIO_000974 civic:22_5partner197, civic:11_3partner197 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000397938.2 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "197" ;
    m2r:disease civic:EwingSarcoma ;   
    a obo:transcript_fusion, m2r:Variation .

civic:22_5partner197                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "29664007" ;
                      faldo:reference hco:22#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "29683123" ;
                      faldo:reference hco:22#GRCh37
        ]
     ] .


civic:11_3partner197 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 128651853 ;
                       faldo:reference hco:11#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 128683162 ;
                       faldo:reference hco:11#GRCh37
        ]
     ] .


civicv:198
    rdfs:label "C134W" ;
    m2r:evidence civice:479,civice:6034 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 138665163 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 138665163 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000330315.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown." ;
    m2r:disease civic:OvarianGranulosaCellTumor,civic:OvarianSexCord-stromalTumours ;
    dcterms:identifier "198" ;
    a obo:missense_variant, m2r:Variation .


civicv:199
    rdfs:label "R172" ;
    m2r:evidence civice:482,civice:483,civice:627,civice:628,civice:1511 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 90631837 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 90631839 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000330062.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "IDH2 R172 is a gain-of-function mutation commonly observed in acute myeloid leukemia and is enriched in those patients which are cytogenetically normal. R172 is analogous to IDH1 R132 mutations and leads to neomorphic enzymatic activity. Specifically this mutation \"catalyzes the conversion of alpha ketoglurarate to beta-hydrozyglutarate\" leading to increased levels of beta-hydrozyglutarate. This in turn leads to hypermethylation of target genes and an inhibition of cellular differentiation. R172 mutations generally lead to worse overall survival and higher rates of relapse compared to the most common IDH2 mutations in AML (R140)." ;
    m2r:disease civic:GlioblastomaMultiforme,civic:Astrocytoma,civic:PeripheralT-cellLymphoma,civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "199" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:200
    rdfs:label "DELETION" ;
    m2r:evidence civice:484,civice:624,civice:625,civice:626,civice:629 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 50344378 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 50472799 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000331340.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for \"normal  hematopoiesis\". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease.  Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones." ;
    m2r:disease civic:PrecursorBLymphoblasticLymphoma-leukemia,civic:AcuteLymphocyticLeukemia ;
    dcterms:identifier "200" ;
    a obo:transcript_ablation, m2r:Variation .


civicv:201
    rdfs:label "M541L" ;
    m2r:evidence civice:485,civice:1423 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55593464 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55593464 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia,civic:ChronicLeukemia ;
    dcterms:identifier "201" ;
    a obo:missense_variant, m2r:Variation .


civicv:202
    rdfs:label "V560DEL" ;
    m2r:evidence civice:486 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55593612 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55593614 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "GTT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ThymicCarcinoma ;
    dcterms:identifier "202" ;
    a obo:inframe_deletion,obo:amino_acid_deletion, m2r:Variation .


civicv:203
    rdfs:label "Q61" ;
    m2r:evidence civice:489 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25380275 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25380277 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MultipleMyeloma ;
    dcterms:identifier "203" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:204
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:492 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 46130646 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 46285621 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000372004.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "204" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:205
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:493 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 46130646 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 46285621 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000372004.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "205" ;
    a m2r:Variation .


civicv:206
    rdfs:label "MUTATION" ;
    m2r:evidence civice:494,civice:1479,civice:1486,civice:1538 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 139388896 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 139440314 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000277541.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MantleCellLymphoma,civic:ChronicLymphocyticLeukemia ;
    dcterms:identifier "206" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:207
    rdfs:label "P2514FS" ;
    m2r:evidence civice:495,civice:1014 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 139390649 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 139390650 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000277541.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "This mutation disrupts the C-terminal PEST domain that in normal conditions promotes degradation,  resulting in accumulation of an active NOTCH1 isoform sustaining deregulated signaling." ;
    m2r:disease civic:ChronicLymphocyticLeukemia ;
    dcterms:identifier "207" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:208
    rdfs:label "MUTATION" ;
    m2r:evidence civice:27,civice:56,civice:71,civice:496,civice:996,civice:1225,civice:1227,civice:1230,civice:1429,civice:1472,civice:1476,civice:1509,civice:1703,civice:2931,civice:2937,civice:5344,civice:6263 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 115247090 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 115259515 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000369535.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer,civic:AcuteMyeloidLeukemia,civic:Melanoma,civic:MultipleMyeloma,civic:SkinMelanoma,civic:Cancer ;
    dcterms:identifier "208" ;
    a obo:gain_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:209                 # so:gene_fusion
    rdfs:label "PAX8-PPARG" ;
    m2r:evidence civice:498 ;
    sio:SIO_000974 civic:2_5partner209, civic:3_3partner209 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000429538.3 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PAX8-PPAR gamma is a oncogene caused by a translocation between 2q13 and 3p25 resulting in an in-frame fusion between the two genes. It has been observed in Follicular Thyroid Cancer (FTC) and is one of two known fusion products involving PPAR gamma in FTC indicating this region may be a breakpoint hotspot. Studies have indicated that the fusion product increases cell viability and proliferation and decreases apoptosis." ;
    civico:variantID "209" ;
    m2r:disease civic:FollicularThyroidCarcinoma ;   
    a obo:transcript_fusion, m2r:Variation .

civic:2_5partner209                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "114036521" ;
                      faldo:reference hco:2#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "113992971" ;
                      faldo:reference hco:2#GRCh37
        ]
     ] .


civic:3_3partner209 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 12329400 ;
                       faldo:reference hco:3#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 12475810 ;
                       faldo:reference hco:3#GRCh37
        ]
     ] .


civicv:210
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:500,civice:501,civice:502,civice:503 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 100900355 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 101001255 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000325455.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "210" ;
    a m2r:Variation .


civicv:212
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:504,civice:756,civice:1403,civice:1464,civice:6275 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 178866311 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 178957881 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastricAdenocarcinoma,civic:EpithelialOvarianCancer,civic:StomachCarcinoma,civic:HeadAndNeckSquamousCellCarcinoma,civic:Melanoma ;
    dcterms:identifier "212" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:213
    rdfs:label "DELETION" ;
    m2r:evidence civice:505,civice:1231,civice:1741 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 89622870 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 89731687 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371953.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ProstateAdenocarcinoma,civic:ProstateCancer ;
    dcterms:identifier "213" ;
    a obo:transcript_ablation, m2r:Variation .


civicv:214
    rdfs:label "LOSS" ;
    m2r:evidence civice:506,civice:507,civice:643,civice:644,civice:645,civice:708,civice:711,civice:714,civice:716,civice:864,civice:893,civice:938,civice:1297,civice:1383,civice:1385,civice:1386,civice:1455,civice:1492,civice:1493,civice:1500,civice:1502,civice:1611,civice:1614,civice:5840,civice:5957,civice:6271,civice:6315 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 89622870 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 89731687 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371953.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer,civic:ProstateCancer,civic:BladderCarcinoma,civic:BreastCancer,civic:Melanoma,civic:Cancer,civic:GastricAdenocarcinoma,civic:EndometrialCancer,civic:PancreaticCarcinoma,civic:Her2-receptorPositiveBreastCancer,civic:OvarianCancer,civic:StomachCarcinoma,civic:StomachCancer,civic:SolidTumor ;
    dcterms:identifier "214" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:215
    rdfs:label "MUTATION" ;
    m2r:evidence civice:352,civice:510,civice:1480,civice:1487,civice:1540 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 198254508 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 198299815 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000335508.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MyelodysplasticSyndrome,civic:ChronicLymphocyticLeukemia ;
    dcterms:identifier "215" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:216
    rdfs:label "MUTATION" ;
    m2r:evidence civice:511,civice:719 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48556583 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48611409 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342988.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PancreaticAdenocarcinoma,civic:ColorectalCancer ;
    dcterms:identifier "216" ;
    a obo:loss_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:217
    rdfs:label "MUTATION" ;
    m2r:evidence civice:512 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11071598 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11172958 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000358026.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SmallCellCarcinomaOfTheOvaryHypercalcemicType ;
    dcterms:identifier "217" ;
    a obo:gene_variant,obo:loss_of_function_variant, m2r:Variation .


civicv:218
    rdfs:label "INACTIVATING MUTATION" ;
    m2r:evidence civice:513 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11071598 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11172958 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000358026.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "218" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:219
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:514 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1253282 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1295162 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000310581.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcralLentiginousMelanoma ;
    dcterms:identifier "219" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:220
    rdfs:label "PROMOTER MUTATION" ;
    m2r:evidence civice:515,civice:516,civice:657,civice:658,civice:976 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1295161 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1295373 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000310581.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspots, termed C228T and C250T are observed in many cancer types and have a particularly high prevalence in glioblastoma (83%), melanoma (71%), bladder cancer (66%) and hepatocelluar carcinoma (HCC) (47%). The two mutations are usually heterozygous and mutually exclusive and result in an increased similarity to an ETS binding domain and may act as a binding site to an ETS transcription factor. These mutations are thought to be early events in tumorgenesis and aid in cellular immortality. Decreased overall survival in patients with these mutations have been observed in medulloblastoma, thyroid cancer, urogenital cancer, melanoma, and laryngeal tumors. The presence of these mutations has also been shown to be predictive of malignant/premalignant nodules in HCC and meningiomas." ;
    m2r:disease civic:SkinMelanoma,civic:GlioblastomaMultiforme,civic:ThyroidCancer,civic:BrainGlioma ;
    dcterms:identifier "220" ;
    a obo:regulatory_region_variant, m2r:Variation .


civicv:221
    rdfs:label "DELETERIOUS MUTATION" ;
    m2r:evidence civice:517,civice:1147,civice:1148,civice:1170,civice:2966,civice:2967,civice:2968 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7571720 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7590856 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors." ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma,civic:Non-smallCellLungCarcinoma,civic:Sarcoma,civic:Leukemia,civic:Cancer ;
    dcterms:identifier "221" ;
    a m2r:Variation .


civicv:222
    rdfs:label "MUTATION" ;
    m2r:evidence civice:518,civice:519,civice:520,civice:521,civice:522,civice:523,civice:524,civice:640,civice:850,civice:851,civice:1018,civice:1028,civice:1145,civice:1146,civice:1450,civice:1451,civice:1452,civice:1478,civice:1481,civice:1485,civice:1507,civice:2784,civice:2820,civice:2999 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7571720 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7590856 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma,civic:EsophagusSquamousCellCarcinoma,civic:PrecursorBLymphoblasticLymphoma-leukemia,civic:MyelodysplasticSyndrome,civic:Myeloma,civic:GastricAdenocarcinoma,civic:BreastCancer,civic:AcuteMyeloidLeukemia,civic:AdrenocorticalCarcinoma,civic:Non-smallCellLungCarcinoma,civic:ChronicLymphocyticLeukemia,civic:StomachCarcinoma ;
    dcterms:identifier "222" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:223
    rdfs:label "TRUNCATING MUTATION" ;
    m2r:evidence civice:525,civice:526 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7573998 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7579714 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "223" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:224
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:527 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 135251008 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 135282209 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000334270.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "224" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:230
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:531 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29083732 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29137832 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000328354.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "230" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:236
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:623 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37618292 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37691399 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000447079.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianSerousCarcinoma ;
    dcterms:identifier "236" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:238
    rdfs:label "R367Q" ;
    m2r:evidence civice:630,civice:633 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 104852955 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 104852955 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000343289.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:T-cellAcuteLymphoblasticLeukemia ;
    dcterms:identifier "238" ;
    a obo:missense_variant, m2r:Variation .


civicv:239
    rdfs:label "K359Q" ;
    m2r:evidence civice:631,civice:636,civice:667 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 104852980 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 104852980 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000343289.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:T-cellAcuteLymphoblasticLeukemia,civic:AcuteLymphocyticLeukemia ;
    dcterms:identifier "239" ;
    a obo:missense_variant, m2r:Variation .


civicv:240
    rdfs:label "D407A" ;
    m2r:evidence civice:632,civice:635 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 104850745 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 104850745 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000343289.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:T-cellAcuteLymphoblasticLeukemia ;
    dcterms:identifier "240" ;
    a obo:missense_variant, m2r:Variation .


civicv:241
    rdfs:label "BCR-ABL F317L" ;
    m2r:evidence civice:637,civice:638,civice:639,civice:2674,civice:2676,civice:2680,civice:4381,civice:6215,civice:6252,civice:6270,civice:6309 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748288 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748288 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors." ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "241" ;
    civico:variantGroups "Imatinib Resistance" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:242
    rdfs:label "DNA BINDING DOMAIN MUTATION" ;
    m2r:evidence civice:641,civice:2783 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7577149 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7578443 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OralSquamousCellCarcinoma,civic:BreastCancer ;
    dcterms:identifier "242" ;
    a obo:DNA_binding_site, m2r:Variation .


civicv:243
    rdfs:label "V2288FS*1" ;
    m2r:evidence civice:647 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 108196840 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 108196841 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    m2r:reference_allele "TC" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000278616.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "A frameshift mutation predicted to cause truncation before the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain." ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "243" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:244
    rdfs:label "N2875H" ;
    m2r:evidence civice:648 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 108218044 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 108218044 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000278616.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "A missense mutation within the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "244" ;
    a obo:missense_variant, m2r:Variation .


civicv:245
    rdfs:label "Y177FS" ;
    m2r:evidence civice:649 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 30051593 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 30051594 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000338641.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PeritonealMesothelioma ;
    dcterms:identifier "245" ;
    a obo:frameshift_elongation, m2r:Variation .


civicv:247
    rdfs:label "V561A" ;
    m2r:evidence civice:652 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55141036 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55141036 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "247" ;
    a obo:missense_variant, m2r:Variation .


civicv:248
    rdfs:label "C228T" ;
    m2r:evidence civice:655,civice:1646 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1295228 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1295228 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000310581.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PapillaryThyroidCarcinoma,civic:ThyroidCancer ;
    dcterms:identifier "248" ;
    a obo:regulatory_region_variant, m2r:Variation .


civicv:249
    rdfs:label "R194W" ;
    m2r:evidence civice:659 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 44057574 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 44057574 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000262887.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "249" ;
    a obo:missense_variant, m2r:Variation .


civicv:250
    rdfs:label "DELETION" ;
    m2r:evidence civice:660 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 67351066 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 67354131 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000398606.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCarcinoma ;
    dcterms:identifier "250" ;
    a obo:transcript_ablation, m2r:Variation .


civicv:251
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:661 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 61867235 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 61871859 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000217169.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColonCancer ;
    dcterms:identifier "251" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:252
    rdfs:label "EXON 4 DELETION" ;
    m2r:evidence civice:662 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55214299 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55214433 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:EpithelialOvarianCancer ;
    dcterms:identifier "252" ;
    a obo:exon_loss_variant, m2r:Variation .


civicv:253
    rdfs:label "3' UTR MUTATION" ;
    dcterms:identifier "253" ;
    a m2r:Variation .


civicv:254
    rdfs:label "RS61764370" ;
    m2r:evidence civice:664,civice:872 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25360224 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25360224 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000311936.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    dcterms:description "Germline variant in the 3' UTR of KRAS that predicts resistance to platinum-based therapy." ;
    m2r:disease civic:EpithelialOvarianCancer,civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "254" ;
    a obo:3_prime_UTR_variant, m2r:Variation .


civicv:255
    rdfs:label "RS751402" ;
    m2r:evidence civice:665 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 103498198 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 103498199 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000355739.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:ParietalLobeEpendymoma ;
    dcterms:identifier "255" ;
    a obo:SNP,obo:5_prime_UTR_variant, m2r:Variation .


civicv:256
    rdfs:label "3' UTR MUTATION" ;
    m2r:evidence civice:666 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55604724 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55606881 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:AcralLentiginousMelanoma ;
    dcterms:identifier "256" ;
    a obo:3_prime_UTR_variant, m2r:Variation .


civicv:257
    rdfs:label "INTRON 6 MUTATION" ;
    m2r:evidence civice:668 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 148524359 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 148525831 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000320356.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "257" ;
    a obo:intron_variant, m2r:Variation .


civicv:258
    rdfs:label "A222V" ;
    m2r:evidence civice:669,civice:1756,civice:1757 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11856378 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11856378 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000376592.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:StomachCancer,civic:PancreaticCancer,civic:RectumCancer ;
    dcterms:identifier "258" ;
    a obo:missense_variant, m2r:Variation .


civicv:259
    rdfs:label "I105V" ;
    m2r:evidence civice:670 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 67352689 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 67352689 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000398606.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "259" ;
    a obo:missense_variant, m2r:Variation .


civicv:260
    rdfs:label "Q141K" ;
    m2r:evidence civice:671 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 89052323 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 89052323 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000237612.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "260" ;
    a obo:missense_variant, m2r:Variation .


civicv:261
    rdfs:label "Q399R" ;
    m2r:evidence civice:672,civice:673 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 44055726 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 44055726 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000262887.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:CervicalCancer ;
    dcterms:identifier "261" ;
    a obo:missense_variant, m2r:Variation .


civicv:262
    rdfs:label "S893T" ;
    m2r:evidence civice:674 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 87160618 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 87160618 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000265724.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "262" ;
    a obo:missense_variant, m2r:Variation .


civicv:263
    rdfs:label "I1145I" ;
    m2r:evidence civice:675,civice:1076 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 87138645 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 87138645 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000265724.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:BreastCancer ;
    dcterms:identifier "263" ;
    a obo:synonymous_variant, m2r:Variation .


civicv:264
    rdfs:label "K751Q" ;
    m2r:evidence civice:676,civice:677 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 45854919 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 45854919 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000391945.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:Osteosarcoma,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "264" ;
    a obo:missense_variant, m2r:Variation .


civicv:265
    rdfs:label "5' TANDEM REPEAT" ;
    m2r:evidence civice:678 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 657604 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 657742 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000323274.10" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "265" ;
    a obo:short_tandem_repeat_variation,obo:5_prime_UTR_variant, m2r:Variation .


civicv:266
    rdfs:label "EXON 12–22 DELETION" ;
    m2r:evidence civice:679 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 141665446 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 141777671 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389484.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "266" ;
    a obo:exon_loss_variant, m2r:Variation .


civicv:267
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:680,civice:682,civice:683,civice:684,civice:685,civice:686,civice:687,civice:1105,civice:1247,civice:1604,civice:1767,civice:1908,civice:1909,civice:1911,civice:1991,civice:3027 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 38268656 ;
            faldo:reference hco:8#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 38325363 ;
            faldo:reference hco:8#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000425967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224)." ;
    m2r:disease civic:LungSquamousCellCarcinoma,civic:Non-smallCellLungCarcinoma,civic:Cancer,civic:BreastCancer,civic:BoneEwing%27sSarcoma,civic:Estrogen-receptorPositiveBreastCancer,civic:BladderCarcinoma ;
    dcterms:identifier "267" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:268
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:681,civice:793,civice:798,civice:799,civice:800,civice:801,civice:896,civice:970,civice:2915 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 38268656 ;
            faldo:reference hco:8#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 38325363 ;
            faldo:reference hco:8#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000425967.3" ;
    civico:ensemblVersion "75" ;
    dcterms:description "FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Göke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Göke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Göke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011)." ;
    m2r:disease civic:LungCancer,civic:BreastCancer,civic:HeadAndNeckSquamousCellCarcinoma,civic:GastricAdenocarcinoma,civic:BladderCarcinoma,civic:ColorectalCancer,civic:Sarcoma ;
    dcterms:identifier "268" ;
    a m2r:Variation .


civicv:269
    rdfs:label "REARRANGEMENT" ;
    m2r:evidence civice:688,civice:1030,civice:1248,civice:1301,civice:1443,civice:1690,civice:2951 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 117609463 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 117747018 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000368508.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014)." ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:LungAdenocarcinoma,civic:ColorectalAdenocarcinoma,civic:Bronchiolo-alveolarAdenocarcinoma,civic:Cancer ;
    dcterms:identifier "269" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:270
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:689,civice:733,civice:735,civice:836,civice:890,civice:1392,civice:1565,civice:1566,civice:1588,civice:1692,civice:1713,civice:1714,civice:1971,civice:1979 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 116312459 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 116436396 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318493.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastricAdenocarcinoma,civic:Non-smallCellLungCarcinoma,civic:LungAdenocarcinoma,civic:LungSquamousCellCarcinoma,civic:GlioblastomaMultiforme,civic:ColorectalCancer,civic:Cancer ;
    dcterms:identifier "270" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:271
    rdfs:label "I774FS" ;
    m2r:evidence civice:690 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 142274740 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 142274740 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000350721.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Single A insertion or deletion in the 10 A mononucleotide run in exon 10 of ATR results in a frameshift of codon I774. In patients with endometrial cancer, this mutation has only been observed in patients with microsatellite instability." ;
    m2r:disease civic:EndometrialCancer ;
    dcterms:identifier "271" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:272
    rdfs:label "p16 EXPRESSION" ;
    m2r:evidence civice:694,civice:695,civice:696,civice:697,civice:753,civice:758,civice:759,civice:804,civice:1155,civice:1314 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 21968055 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 21974865 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000498124.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding." ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma,civic:OropharynxCancer,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "272" ;
    a m2r:Variation .


civicv:273                 # so:gene_fusion
    rdfs:label "KIF5B-RET" ;
    m2r:evidence civice:698,civice:1622 ;
    sio:SIO_000974 civic:10_5partner273, civic:10_3partner273 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000302418.4 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "In a study by Takeuchi et. al. a fusion screen was performed in 1529 lung cancer samples. 14 adenocarcinomas with KIF5B-RET and CCDC6-RET fusions were identified. (Takeuchi K et. al., 2012)" ;
    civico:variantID "273" ;
    m2r:disease civic:LungAdenocarcinoma ;   
    a obo:transcript_fusion, m2r:Variation .

civic:10_5partner273                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "32306071" ;
                      faldo:reference hco:10#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "32345359" ;
                      faldo:reference hco:10#GRCh37
        ]
     ] .


civic:10_3partner273 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 43609928 ;
                       faldo:reference hco:10#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 43625799 ;
                       faldo:reference hco:10#GRCh37
        ]
     ] .


civicv:274
    rdfs:label "G13D" ;
    m2r:evidence civice:699,civice:3851,civice:3852 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 534285 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 534285 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000451590.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer,civic:SkinSquamousCellCarcinoma ;
    dcterms:identifier "274" ;
    a obo:missense_variant, m2r:Variation .


civicv:275
    rdfs:label "MUTATION" ;
    m2r:evidence civice:700 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 533873 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 534289 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000451590.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "275" ;
    a obo:coding_transcript_variant, m2r:Variation .


civicv:276
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:701,civice:702,civice:703,civice:704,civice:743,civice:975,civice:1167,civice:1172,civice:1274,civice:1275,civice:1517,civice:1578,civice:1615,civice:1733,civice:3000,civice:4844,civice:4855,civice:4856,civice:4857,civice:5507,civice:5811 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 5450525 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 5470547 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000381577.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:LungSquamousCellCarcinoma,civic:OvarianSerousCarcinoma,civic:Melanoma,civic:PapillaryThyroidCarcinoma,civic:StomachCarcinoma,civic:Cancer,civic:MerkelCellCarcinoma,civic:HeadAndNeckSquamousCellCarcinoma,civic:BreastCancer ;
    dcterms:identifier "276" ;
    a m2r:Variation .


civicv:277
    rdfs:label "MUTATION" ;
    m2r:evidence civice:705,civice:712 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11166592 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11322564 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361445.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BladderCarcinoma,civic:Melanoma ;
    dcterms:identifier "277" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:278
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:706 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 40736224 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 40791302 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000392038.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "278" ;
    a m2r:Variation .


civicv:279
    rdfs:label "K159FS*16" ;
    m2r:evidence civice:715 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 30050673 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 30050675 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000338641.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "279" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:281
    rdfs:label "MUTATION" ;
    m2r:evidence civice:718,civice:1631 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 153245446 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 153332714 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000281708.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer,civic:Cancer ;
    dcterms:identifier "281" ;
    a obo:loss_of_function_variant,obo:protein_altering_variant, m2r:Variation .


civicv:282
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:720 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48556583 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48611409 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342988.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "282" ;
    a m2r:Variation .


civicv:283
    rdfs:label "H1968Y" ;
    m2r:evidence civice:713 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11188519 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11188519 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361445.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "283" ;
    a obo:gain_of_function_variant,obo:missense_variant, m2r:Variation .


civicv:284
    rdfs:label "P2213S" ;
    m2r:evidence civice:722 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11184580 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11184580 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361445.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "284" ;
    a obo:gain_of_function_variant,obo:missense_variant, m2r:Variation .


civicv:285                 # so:gene_fusion
    rdfs:label "AGK-BRAF" ;
    m2r:evidence civice:723,civice:724 ;
    sio:SIO_000974 civic:7_5partner285, civic:7_3partner285 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000355413.4 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "285" ;
    m2r:disease civic:Melanoma ;
    civico:variantGroups "BRAF Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:7_5partner285                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "141250989" ;
                      faldo:reference hco:7#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "141255367" ;
                      faldo:reference hco:7#GRCh37
        ]
     ] .


civic:7_3partner285 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140434279 ;
                       faldo:reference hco:7#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140494267 ;
                       faldo:reference hco:7#GRCh37
        ]
     ] .


civicv:286                 # so:gene_fusion
    rdfs:label "PAPSS1-BRAF" ;
    m2r:evidence civice:725,civice:726 ;
    sio:SIO_000974 civic:4_5partner286, civic:7_3partner286 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000265174.4 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "286" ;
    m2r:disease civic:Melanoma ;
    civico:variantGroups "BRAF Fusions" ;   
    a obo:transcript_fusion,obo:gene_fusion, m2r:Variation .

civic:4_5partner286                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "108603171" ;
                      faldo:reference hco:4#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "108641608" ;
                      faldo:reference hco:4#GRCh37
        ]
     ] .


civic:7_3partner286 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140434279 ;
                       faldo:reference hco:7#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140487384 ;
                       faldo:reference hco:7#GRCh37
        ]
     ] .


civicv:287                 # so:gene_fusion
    rdfs:label "TRIM24-BRAF" ;
    m2r:evidence civice:727,civice:1416 ;
    sio:SIO_000974 civic:7_5partner287, civic:7_3partner287 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000343526.4 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "287" ;
    m2r:disease civic:Melanoma,civic:SkinMelanoma ;
    civico:variantGroups "BRAF Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:7_5partner287                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "138145079" ;
                      faldo:reference hco:7#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "138239711" ;
                      faldo:reference hco:7#GRCh37
        ]
     ] .


civic:7_3partner287 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140434279 ;
                       faldo:reference hco:7#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140487384 ;
                       faldo:reference hco:7#GRCh37
        ]
     ] .


civicv:288
    rdfs:label "L597R" ;
    m2r:evidence civice:728,civice:1458 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453145 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453145 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma,civic:SkinMelanoma ;
    dcterms:identifier "288" ;
    civico:variantGroups "Other V600's" ;
    a obo:missense_variant, m2r:Variation .


civicv:289
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:729,civice:1152,civice:1153 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 56473645 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 56497289 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000267101.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer,civic:Cancer ;
    dcterms:identifier "289" ;
    a m2r:Variation .


civicv:290
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:730 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 86159809 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 86205496 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257770.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "290" ;
    a m2r:Variation .


civicv:291
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:731 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 148504477 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 148581370 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000320356.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "291" ;
    a m2r:Variation .


civicv:292
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:734 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 38179969 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 38184510 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000417037.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "292" ;
    a m2r:Variation .


civicv:294
    rdfs:label "P471L" ;
    m2r:evidence civice:739 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 178928226 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 178928226 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MerkelCellCarcinoma ;
    dcterms:identifier "294" ;
    a obo:missense_variant, m2r:Variation .


civicv:295
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:740 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 43572475 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 43625799 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000355710.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "295" ;
    a m2r:Variation .


civicv:296
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:741 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 155870065 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 155880706 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000368322.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:EndometrialCancer ;
    dcterms:identifier "296" ;
    a m2r:Variation .


civicv:297
    rdfs:label "MUTATION" ;
    m2r:evidence civice:742 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 155870065 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 155880706 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000368322.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "297" ;
    a obo:transcript_variant, m2r:Variation .


civicv:298
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:744,civice:1328 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 16080686 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 16087129 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000281043.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Neuroblastoma ;
    dcterms:identifier "298" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:299
    rdfs:label "D473H" ;
    m2r:evidence civice:745,civice:755,civice:1099 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 128849189 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 128849189 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000249373.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BrainMedulloblastoma,civic:BasalCellCarcinoma ;
    dcterms:identifier "299" ;
    a obo:missense_variant, m2r:Variation .


civicv:300
    rdfs:label "MUTATION" ;
    m2r:evidence civice:746,civice:747,civice:1477,civice:5979 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 128828713 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 128853386 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000249373.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BasalCellCarcinoma,civic:Cancer ;
    dcterms:identifier "300" ;
    a obo:coding_transcript_variant, m2r:Variation .


civicv:301
    rdfs:label "MUTATION" ;
    m2r:evidence civice:748,civice:5978 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 98205262 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 98270943 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000331920.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BrainMedulloblastoma,civic:Cancer ;
    dcterms:identifier "301" ;
    a obo:gene_variant,obo:loss_of_function_variant, m2r:Variation .


civicv:302
    rdfs:label "LOH" ;
    m2r:evidence civice:749 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 98205262 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 98270943 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000331920.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BrainMedulloblastoma ;
    dcterms:identifier "302" ;
    a obo:loss_of_heterozygosity, m2r:Variation .


civicv:303
    rdfs:label "EXON 1-2 MUTATION" ;
    m2r:evidence civice:750 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1205740 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1218499 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000326873.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "303" ;
    a obo:exon_variant, m2r:Variation .


civicv:304
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:751 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1205740 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1228428 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000326873.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "304" ;
    a m2r:Variation .


civicv:305
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:752 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 93564069 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 93660831 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000375754.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "305" ;
    a m2r:Variation .


civicv:306
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:528,civice:529,civice:760,civice:761,civice:886,civice:887,civice:895,civice:961,civice:962,civice:1006,civice:1007,civice:1008,civice:1009,civice:1010,civice:1011,civice:1012,civice:1013,civice:1022,civice:1023,civice:1041,civice:1042,civice:1044,civice:1050,civice:1077,civice:1096,civice:1097,civice:1098,civice:1113,civice:1122,civice:1132,civice:1133,civice:1159,civice:1160,civice:1380,civice:1381,civice:1382,civice:1393,civice:1432,civice:1437,civice:1439,civice:1448,civice:1499,civice:1561,civice:1613,civice:1686,civice:1687,civice:1688,civice:1689,civice:1693,civice:1764,civice:1891,civice:1993,civice:5981,civice:5982,civice:5983,civice:5984,civice:5985,civice:5986 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37856333 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37884915 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer." ;
    m2r:disease civic:Her2-receptorPositiveBreastCancer,civic:BreastCancer,civic:UterineCorpusEndometrialCarcinoma,civic:ColorectalCancer,civic:PancreaticAdenocarcinoma,civic:GastricAdenocarcinoma,civic:Non-smallCellLungCarcinoma,civic:LungSmallCellCarcinoma,civic:UterineCorpusSerousAdenocarcinoma,civic:EndometrialCancer,civic:LungAdenocarcinoma,civic:ScrotumPaget%27sDisease,civic:BladderCarcinoma,civic:BiliaryTractCancer,civic:SalivaryGlandCarcinoma,civic:PancreaticCancer,civic:UterineCancer ;
    dcterms:identifier "306" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:307
    rdfs:label "EML4-ALK L1152R" ;
    m2r:evidence civice:763 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29445270 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29445270 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "307" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:308
    rdfs:label "EML4-ALK G1269A" ;
    m2r:evidence civice:764,civice:765 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29432682 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29432682 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The EML4-ALK G1269A mutation has been identified in non-small cell lung cancer patients resistant to crizotinib. Cell line data from multiple groups have shown this mutation enhances resistance to crizotinib treatment in vitro." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "308" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:309
    rdfs:label "AUTOCRINE ACTIVATION" ;
    dcterms:identifier "309" ;
    a m2r:Variation .


civicv:310
    rdfs:label "MUTATION" ;
    m2r:evidence civice:770 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 212295697 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 212578308 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342788.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB4 mutations have been identified in melanoma, lung adenocarcinoma and medulloblastoma. In-vitro studies suggest that melanoma cell lines harboring an ERBB4 mutation are sensitive to ERBB4 inhibition with lapatinib." ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "310" ;
    a obo:gain_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:311
    rdfs:label "MUTATION" ;
    m2r:evidence civice:771,civice:892,civice:915,civice:1296,civice:1358,civice:1360,civice:1364,civice:1384,civice:1402,civice:1490,civice:1501,civice:1503,civice:1504,civice:1600,civice:1607,civice:1610,civice:1616,civice:1705,civice:3040,civice:6188,civice:6189,civice:6191,civice:6297,civice:6298,civice:6299,civice:6300,civice:6301,civice:6362,civice:6375 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 178866311 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 178957881 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations." ;
    m2r:disease civic:ColorectalCancer,civic:EndometrialCancer,civic:Her2-receptorPositiveBreastCancer,civic:Cancer,civic:HeadAndNeckCancer,civic:HeadAndNeckSquamousCellCarcinoma,civic:StomachCancer,civic:BreastCancer,civic:Estrogen-receptorPositiveBreastCancer ;
    dcterms:identifier "311" ;
    a obo:gain_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:312
    rdfs:label "VIII" ;
    m2r:evidence civice:772,civice:773,civice:848,civice:971,civice:1017,civice:1128,civice:4500 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55087058 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55223523 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)" ;
    m2r:disease civic:GlioblastomaMultiforme,civic:HeadAndNeckSquamousCellCarcinoma,civic:BrainGlioma,civic:MalignantGlioma ;
    dcterms:identifier "312" ;
    a obo:disruptive_inframe_deletion, m2r:Variation .


civicv:313
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:774,civice:775,civice:955,civice:1129,civice:1624 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 89622870 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 89731687 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371953.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GlioblastomaMultiforme,civic:BreastCancer,civic:Her2-receptorPositiveBreastCancer ;
    dcterms:identifier "313" ;
    a m2r:Variation .


civicv:314
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:776,civice:777,civice:778,civice:779,civice:813,civice:861 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 31497942 ;
            faldo:reference hco:8#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32622294 ;
            faldo:reference hco:8#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000523534.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma,civic:ColorectalCancer,civic:OvarianCancer,civic:Non-smallCellLungCarcinoma,civic:Cancer ;
    dcterms:identifier "314" ;
    a m2r:Variation .


civicv:315
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:780,civice:781,civice:788,civice:846,civice:1020 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 75310851 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 75320726 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000395748.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:ColorectalCancer,civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "315" ;
    a m2r:Variation .


civicv:316
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:785 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 70674412 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 70781147 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000295400.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "316" ;
    a m2r:Variation .


civicv:317
    rdfs:label "G724S" ;
    m2r:evidence civice:786 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55241722 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55241722 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "317" ;
    a obo:missense_variant, m2r:Variation .


civicv:318
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:789,civice:1021,civice:1055 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 75230860 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 75254468 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000244869.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer,civic:LungAdenocarcinoma ;
    dcterms:identifier "318" ;
    a m2r:Variation .


civicv:319
    rdfs:label "EXPRESSION" ;
    dcterms:identifier "319" ;
    a m2r:Variation .


civicv:320
    rdfs:label "E322K" ;
    m2r:evidence civice:791 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 22127164 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 22127164 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000215832.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "320" ;
    a obo:gain_of_function_variant,obo:missense_variant, m2r:Variation .


civicv:321
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:792 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 22108789 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 22221919 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000215832.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "321" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:322
    rdfs:label "A146V" ;
    m2r:evidence civice:794,civice:2209 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25378561 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25378561 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:ColorectalCancer ;
    dcterms:identifier "322" ;
    a obo:missense_variant, m2r:Variation .


civicv:323
    rdfs:label "MUTATION" ;
    m2r:evidence civice:796 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 116312459 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 116436396 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318493.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:PapillaryRenalCellCarcinoma ;
    dcterms:identifier "323" ;
    a obo:gain_of_function_variant,obo:transcription_variant, m2r:Variation .


civicv:324
    rdfs:label "EXON 14 SKIPPING MUTATION" ;
    m2r:evidence civice:736,civice:797,civice:1185,civice:1186,civice:1651,civice:4786 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 116411903 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 116412043 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318493.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021))." ;
    m2r:disease civic:Cancer,civic:LungAdenocarcinoma ;
    dcterms:identifier "324" ;
    a obo:exon_loss_variant, m2r:Variation .


civicv:325
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:803 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1795039 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1810599 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000440486.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BladderCarcinoma ;
    dcterms:identifier "325" ;
    a m2r:Variation .


civicv:326
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:805 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 45281126 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 45303891 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000270279.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "326" ;
    a m2r:Variation .


civicv:327
    rdfs:label "MUTATION" ;
    m2r:evidence civice:807 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 8314246 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10033790 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000381196.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckCarcinoma ;
    dcterms:identifier "327" ;
    a obo:loss_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:328
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:808 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 6835172 ;
            faldo:reference hco:8#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 6837602 ;
            faldo:reference hco:8#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000382692.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "328" ;
    a m2r:Variation .


civicv:329
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:809,civice:810 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 45916692 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 45926824 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000013807.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BladderCarcinoma ;
    dcterms:identifier "329" ;
    a m2r:Variation .


civicv:330
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:811,civice:812 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 139388896 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 139440314 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000277541.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "330" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:331
    rdfs:label "RS3910384" ;
    m2r:evidence civice:814 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 9599943 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 9599943 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000450114.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "331" ;
    a obo:polymorphic_sequence_variant,obo:intron_variant, m2r:Variation .


civicv:332
    rdfs:label "RS11623866" ;
    m2r:evidence civice:815 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 65453063 ;
            faldo:reference hco:14#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 65453063 ;
            faldo:reference hco:14#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000246166.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "332" ;
    a obo:regulatory_region_variant, m2r:Variation .


civicv:333
    rdfs:label "PROMOTER HYPERMETHYLATION" ;
    m2r:evidence civice:817 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "333" ;
    a m2r:Variation .


civicv:334
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:818 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 43738444 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 43752346 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000372055.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "334" ;
    a m2r:Variation .


civicv:335
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:819,civice:946 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10244022 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10305811 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000340748.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:OvarianCancer,civic:GastricAdenocarcinoma ;
    dcterms:identifier "335" ;
    a m2r:Variation .


civicv:336
    rdfs:label "MUTATION" ;
    m2r:evidence civice:820,civice:894,civice:935,civice:943,civice:947,civice:988,civice:989,civice:991,civice:992,civice:997,civice:998,civice:999,civice:1001,civice:1003,civice:1004,civice:1139,civice:1140,civice:1182,civice:1183,civice:1218,civice:1220,civice:1596,civice:1642,civice:1700,civice:1702,civice:2998,civice:3715,civice:3895,civice:4842,civice:4862,civice:4863,civice:4864,civice:4866,civice:4867,civice:4868,civice:4869,civice:4996,civice:4997,civice:5345,civice:6264 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25362365 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25403737 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer,civic:EndometrialCancer,civic:Cancer,civic:ColorectalCancer,civic:Non-smallCellLungCarcinoma,civic:PancreaticAdenocarcinoma,civic:LungAdenocarcinoma,civic:PseudomyxomaPeritonei,civic:HepatocellularCarcinoma,civic:Melanoma ;
    dcterms:identifier "336" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:337
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:821 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 112631596 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 112659763 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000393104.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "A new study, a retrospective analysis of 77 patients, has implicated PDCD4 expression in the sensitivity to paclitaxel. However, this finding came from a large proteome screen and has not yet been replicated in independent patient sets." ;
    m2r:disease civic:LungCancer ;
    dcterms:identifier "337" ;
    a m2r:Variation .


civicv:338
    rdfs:label "RS16906252" ;
    m2r:evidence civice:822 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 131265545 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 131265545 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000306010.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:GlioblastomaMultiforme ;
    dcterms:identifier "338" ;
    a obo:synonymous_variant, m2r:Variation .


civicv:339
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:823 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 43731777 ;
            faldo:reference hco:21#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 43735761 ;
            faldo:reference hco:21#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000518498.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "339" ;
    a m2r:Variation .


civicv:340
    rdfs:label "NUCLEAR EXPRESSION" ;
    m2r:evidence civice:824 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 54074056 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 54077417 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000373970.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "340" ;
    a m2r:Variation .


civicv:341
    rdfs:label "ISOFORM EXPRESSION" ;
    m2r:evidence civice:825 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 35160728 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 35251574 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000428726.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "341" ;
    a m2r:Variation .


civicv:342
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:826 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 110834047 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 110933422 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000265171.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "342" ;
    a m2r:Variation .


civicv:343
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:827,civice:828 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 69201956 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 69239214 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000462284.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:MalignantPleuralMesothelioma ;
    dcterms:identifier "343" ;
    a m2r:Variation .


civicv:344
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:829 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 35776828 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 35790207 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000216117.8" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:RenalCellCarcinoma ;
    dcterms:identifier "344" ;
    a m2r:Variation .


civicv:345
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:830 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 74380731 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 74383936 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000323374.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:CervicalCancer ;
    dcterms:identifier "345" ;
    a m2r:Variation .


civicv:346
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:831 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 202122759 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 202152434 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000358485.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BoneEwing%27sSarcoma ;
    dcterms:identifier "346" ;
    a m2r:Variation .


civicv:347
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:832,civice:922,civice:929 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 657604 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 673578 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000323274.10" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:GastricAdenocarcinoma ;
    dcterms:identifier "347" ;
    a m2r:Variation .


civicv:348
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:835 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 27667137 ;
            faldo:reference hco:8#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 27695612 ;
            faldo:reference hco:8#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000301905.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "348" ;
    a m2r:Variation .


civicv:349
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:837,civice:838 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11071598 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11172958 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000358026.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "349" ;
    a m2r:Variation .


civicv:350
    rdfs:label "EXON 4 MUTATION" ;
    m2r:evidence civice:839 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 42531877 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 42531918 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000282030.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "350" ;
    a obo:exon_variant, m2r:Variation .


civicv:351
    rdfs:label "G870S" ;
    m2r:evidence civice:840 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 42531913 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 42531913 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000282030.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "351" ;
    a obo:missense_variant, m2r:Variation .


civicv:352
    rdfs:label "EML4-ALK C1156Y–L1198F" ;
    m2r:evidence civice:843,civice:844 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29443625 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29445258 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "EML4-ALK C1156Y alone is resistant to crizotinib in non-small cell lung cancer (NSCLC) which has been shown to be modulated (both increased sensitivity and resistance) by additional ALK mutations. A case report showed that an NSCLC harboring EML4-ALK C1156Y–L1198F was resistant to lorlatinib but this second mutation re-sensitized this tumor to crizotinib." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "352" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:354
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:849,civice:1572,civice:1708,civice:1709,civice:1984,civice:4877 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55086794 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55279321 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma,civic:ColorectalCancer,civic:Chordoma,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "354" ;
    a m2r:Variation .


civicv:355
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:852 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 36646487 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 36655108 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000405375.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "355" ;
    a m2r:Variation .


civicv:356
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:853 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 105085753 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 105295744 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000306107.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "356" ;
    a m2r:Variation .


civicv:357
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:855 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 26211931 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 26232957 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000426559.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:EndometrialCarcinoma ;
    dcterms:identifier "357" ;
    a m2r:Variation .


civicv:358
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:857 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 77371041 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 77532063 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000308488.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "358" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:359
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:859 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 66764465 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 66950461 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000374690.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "359" ;
    a m2r:Variation .


civicv:360
    rdfs:label "CYTOPLASMIC MISLOCALIZATION" ;
    m2r:evidence civice:860 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 12870058 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 12875305 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000228872.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "360" ;
    a m2r:Variation .


civicv:361
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:862,civice:865 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 56473645 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 56497289 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000267101.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Cancer,civic:PancreaticDuctalAdenocarcinoma ;
    dcterms:identifier "361" ;
    a m2r:Variation .


civicv:362
    rdfs:label "SPLICE VARIANT 7" ;
    m2r:evidence civice:863 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 66764662 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 66915917 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000504326.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "362" ;
    a m2r:Variation .


civicv:363
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:866 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 234526291 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 234681956 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000373450.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "363" ;
    a m2r:Variation .


civicv:364
    rdfs:label "NUCLEAR TRANSLOCATION" ;
    m2r:evidence civice:867 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 212240446 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 213403565 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342788.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "364" ;
    a m2r:Variation .


civicv:365
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:868,civice:869 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 212240446 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 213403565 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342788.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "365" ;
    a m2r:Variation .


civicv:366
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:870 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 33677324 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 33700639 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000394566.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "366" ;
    a m2r:Variation .


civicv:367
    rdfs:label "P29S" ;
    m2r:evidence civice:873 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 6426892 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 6426892 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000356142.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "367" ;
    a obo:missense_variant, m2r:Variation .


civicv:368
    rdfs:label "NUCLEAR EXPRESSION" ;
    m2r:evidence civice:874 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 76210267 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 76221717 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000301633.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "368" ;
    a m2r:Variation .


civicv:369
    rdfs:label "WILD TYPE" ;
    m2r:evidence civice:875,civice:906,civice:1149,civice:2963,civice:2964,civice:2965 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7571720 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7590856 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer,civic:EsophagealCarcinoma,civic:Non-smallCellLungCarcinoma,civic:Cancer,civic:Leukemia ;
    dcterms:identifier "369" ;
    a obo:wild_type, m2r:Variation .


civicv:370
    rdfs:label "LOSS" ;
    m2r:evidence civice:876 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 94152895 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 94227074 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000323929.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:EndometrialCancer ;
    dcterms:identifier "370" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:371
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:888 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 39657458 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 39753127 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361337.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "371" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:372
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:889 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 12870058 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 12875305 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000228872.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "372" ;
    a m2r:Variation .


civicv:373
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:891 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 16831435 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 16844704 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000419304.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "373" ;
    a m2r:Variation .


civicv:374
    rdfs:label "PROMOTER HYPERMETHYLATION" ;
    m2r:evidence civice:897 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "374" ;
    a m2r:Variation .


civicv:375
    rdfs:label "EXON 18 OVEREXPRESSION" ;
    m2r:evidence civice:898 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55237999 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55238735 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000344576.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "375" ;
    a obo:exon_variant, m2r:Variation .


civicv:376
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:899,civice:900 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 31608101 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 31818741 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361642.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:MantleCellLymphoma ;
    dcterms:identifier "376" ;
    a m2r:Variation .


civicv:377
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:901,civice:927 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 47441712 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 47446188 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000218388.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "377" ;
    a m2r:Variation .


civicv:378
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:902 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 142402093 ;
            faldo:reference hco:8#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 142441394 ;
            faldo:reference hco:8#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000521578.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "378" ;
    a m2r:Variation .


civicv:379
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:903 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 657604 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 673578 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000323274.10" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "379" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:380
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:904 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 99192200 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 99507759 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000268035.6" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "380" ;
    a m2r:Variation .


civicv:381
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:905 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 100400187 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 100425121 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000358173.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "381" ;
    a m2r:Variation .


civicv:382
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:907,civice:908 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 657604 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 673578 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000323274.10" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:ProstateCancer ;
    dcterms:identifier "382" ;
    a m2r:Variation .


civicv:383
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:909 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 38544768 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 38574202 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000423485.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "383" ;
    a m2r:Variation .


civicv:384
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:910,civice:912 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 39657458 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 39753127 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361337.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:OvarianCancer,civic:ColorectalCancer ;
    dcterms:identifier "384" ;
    a m2r:Variation .


civicv:385
    rdfs:label "T172 PHOSPHORYLATION" ;
    m2r:evidence civice:913 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 57159476 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 57159478 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371244.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "385" ;
    a m2r:Variation .


civicv:386
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:914 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 127997132 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 128003609 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000324460.6" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "386" ;
    a m2r:Variation .


civicv:387
    rdfs:label "PHOSPHORYLATION" ;
    m2r:evidence civice:918,civice:932 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37888200 ;
            faldo:reference hco:8#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37914663 ;
            faldo:reference hco:8#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000338825.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:GastricAdenocarcinoma,civic:ColorectalCancer ;
    dcterms:identifier "387" ;
    a m2r:Variation .


civicv:388
    rdfs:label "MUTATION" ;
    m2r:evidence civice:919,civice:1222 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55524085 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55606881 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastrointestinalStromalTumor,civic:Melanoma ;
    dcterms:identifier "388" ;
    a obo:gain_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:389
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:920,civice:921 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 89989687 ;
            faldo:reference hco:16#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 90002505 ;
            faldo:reference hco:16#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000315491.7" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Cancer,civic:BreastCancer ;
    dcterms:identifier "389" ;
    a m2r:Variation .


civicv:390
    rdfs:label "Y1092 PHOSPHORYLATION" ;
    m2r:evidence civice:923 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55272951 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55272953 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    dcterms:description "Although referred to as Y1068 in the literature, based on the recognition peptide described, this tyrosine occurs at Y1039 (ENST00000454757.2 v75) or Y1092 (ENST00000275493.2 v75)." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "390" ;
    a m2r:Variation .


civicv:391
    rdfs:label "NUCLEAR EXPRESSION" ;
    m2r:evidence civice:924 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 99192200 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 99507759 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000268035.6" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Sarcoma ;
    dcterms:identifier "391" ;
    a m2r:Variation .


civicv:392
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:925 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 201980827 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 202041410 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000309955.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "392" ;
    a m2r:Variation .


civicv:393
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:926 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 15969857 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 16085324 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000510224.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:HepatocellularCarcinoma ;
    dcterms:identifier "393" ;
    a m2r:Variation .


civicv:394
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:928 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 49106897 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 49121288 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000376207.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "394" ;
    a m2r:Variation .


civicv:395
    rdfs:label "PHOSPHORYLATION" ;
    m2r:evidence civice:930 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 19376309 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 19376323 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000380394.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:GastricAdenocarcinoma ;
    dcterms:identifier "395" ;
    a m2r:Variation .


civicv:396
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:931 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 65298912 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 65432187 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342505.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "396" ;
    a m2r:Variation .


civicv:397
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:933 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41196312 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41277387 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000357654.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:MalignantMesothelioma ;
    dcterms:identifier "397" ;
    a m2r:Variation .


civicv:398
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:934 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 89741009 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 89747048 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000279488.7" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "398" ;
    a m2r:Variation .


civicv:399
    rdfs:label "MUTATION" ;
    m2r:evidence civice:936,civice:1404,civice:1704,civice:6302,civice:6303,civice:6304,civice:6305,civice:6306,civice:6307 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453136 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140481403 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer,civic:ColorectalCancer ;
    dcterms:identifier "399" ;
    a obo:gene_variant,obo:gain_of_function_variant, m2r:Variation .


civicv:400
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:939 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 75931861 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 75933612 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000248553.6" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:PancreaticDuctalAdenocarcinoma ;
    dcterms:identifier "400" ;
    a m2r:Variation .


civicv:401
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:940 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 69743304 ;
            faldo:reference hco:16#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 69760854 ;
            faldo:reference hco:16#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000320623.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:LungCancer ;
    dcterms:identifier "401" ;
    a m2r:Variation .


civicv:402
    rdfs:label "P187S" ;
    m2r:evidence civice:941 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 69745145 ;
            faldo:reference hco:16#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 69745145 ;
            faldo:reference hco:16#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000320623.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:LungCancer ;
    dcterms:identifier "402" ;
    a obo:missense_variant, m2r:Variation .


civicv:403
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:942 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41196312 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41277387 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000357654.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "403" ;
    a m2r:Variation .


civicv:404
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:944 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 87133175 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 87342564 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000265724.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "404" ;
    a m2r:Variation .


civicv:405
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:949 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 136871919 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 136873813 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000409817.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:GastricAdenocarcinoma ;
    dcterms:identifier "405" ;
    a m2r:Variation .


civicv:406
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:950 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55478538 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55479998 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342972.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BileDuctAdenocarcinoma ;
    dcterms:identifier "406" ;
    a m2r:Variation .


civicv:407
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:951 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48712218 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48769613 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000285238.8" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "407" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:408
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:952 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 43395292 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 43418168 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000372530.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "408" ;
    a m2r:Variation .


civicv:409
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:953 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 97481430 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 97501854 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000175506.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "409" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:410
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:956 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 28536274 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 28545276 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000381020.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "410" ;
    a m2r:Variation .


civicv:411
    rdfs:label "SH2 DOMAIN MUTATION" ;
    m2r:evidence civice:957 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 40465342 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 40475372 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000264657.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:T-cellLargeGranularLymphocyteLeukemia ;
    dcterms:identifier "411" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:412
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:958 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 31132120 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 31138470 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000259915.8" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColonCancer ;
    dcterms:identifier "412" ;
    a m2r:Variation .


civicv:413
    rdfs:label "KINASE DOMAIN MUTATION" ;
    m2r:evidence civice:959,civice:1043 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37879863 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37882870 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "413" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:414
    rdfs:label "Y772_A775DUP" ;
    m2r:evidence civice:960,civice:1045,civice:1047,civice:1125,civice:1888,civice:1893 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37880996 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37880997 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:alternative_allele "TACGTGATGGCT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies." ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:LungAdenocarcinoma,civic:LungCarcinoma ;
    dcterms:identifier "414" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:415
    rdfs:label "C797S" ;
    m2r:evidence civice:964,civice:1396 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55249091 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249091 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:LungAdenocarcinoma ;
    dcterms:identifier "415" ;
    a obo:missense_variant, m2r:Variation .


civicv:416
    rdfs:label "SERUM LEVELS" ;
    m2r:evidence civice:972,civice:973 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37856333 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37884915 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "416" ;
    a m2r:Variation .


civicv:417
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:974 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 169615875 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 169654139 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000366787.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "417" ;
    a m2r:Variation .


civicv:419
    rdfs:label "NTRK1 FUSIONS" ;
    m2r:evidence civice:978,civice:1019,civice:2948,civice:2956,civice:6567,civice:6569 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 156844175 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 156851434 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000524377.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer,civic:LungAdenocarcinoma,civic:Cancer,civic:Sarcoma ;
    dcterms:identifier "419" ;
    civico:variantGroups "NTRK1 Fusions" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:420
    rdfs:label "R132H" ;
    m2r:evidence civice:979,civice:5987 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 209113112 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 209113112 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000415913.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions." ;
    m2r:disease civic:AnaplasticOligodendroglioma,civic:PancreaticDuctalAdenocarcinoma ;
    dcterms:identifier "420" ;
    a obo:missense_variant, m2r:Variation .


civicv:421
    rdfs:label "RS2736100" ;
    m2r:evidence civice:980 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1286516 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1286516 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000310581.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:BrainGlioma ;
    dcterms:identifier "421" ;
    a obo:polymorphic_sequence_variant,obo:coding_transcript_intron_variant, m2r:Variation .


civicv:422
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:984,civice:1659 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 123095568 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 123236506 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371157.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BladderCarcinoma,civic:Melanoma ;
    dcterms:identifier "422" ;
    a m2r:Variation .


civicv:423
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:985 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32407619 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32412823 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000395388.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "423" ;
    a m2r:Variation .


civicv:424
    rdfs:label "L265P" ;
    m2r:evidence civice:986,civice:1489,civice:1641 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 38182641 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 38182641 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000396334.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Waldenstr%C3%B6m%27sMacroglobulinemia,civic:ChronicLymphocyticLeukemia ;
    dcterms:identifier "424" ;
    a obo:gain_of_function_variant,obo:missense_variant, m2r:Variation .


civicv:425
    rdfs:label "G12V" ;
    m2r:evidence civice:136,civice:795,civice:987,civice:1143,civice:1715,civice:2001,civice:2232,civice:2268,civice:3924,civice:6323 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398284 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398284 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions" ;
    m2r:disease civic:ColorectalCancer,civic:Non-smallCellLungCarcinoma,civic:Cancer,civic:LungCancer ;
    dcterms:identifier "425" ;
    a obo:missense_variant, m2r:Variation .


civicv:426
    rdfs:label "WILD TYPE" ;
    m2r:evidence civice:995 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140434279 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140624564 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "426" ;
    a obo:wild_type, m2r:Variation .


civicv:427
    rdfs:label "Q61K" ;
    m2r:evidence civice:1002,civice:1474,civice:1475,civice:2192,civice:2907 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 115256530 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 115256530 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000369535.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Neuroblastoma,civic:SkinMelanoma,civic:ColorectalCancer,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "427" ;
    a obo:missense_variant, m2r:Variation .


civicv:428
    rdfs:label "FRAMESHIFT MUTATION" ;
    m2r:evidence civice:1016 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 94152895 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 94227074 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000323929.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "428" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:429
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1024,civice:1025 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55524085 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55606881 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:EndometrialCancer ;
    dcterms:identifier "429" ;
    a m2r:Variation .


civicv:431                 # so:gene_fusion
    rdfs:label "CBFB-MYH11" ;
    m2r:evidence civice:1027 ;
    sio:SIO_000974 civic:16_5partner431, civic:16_3partner431 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000412916.2 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "CBFB-MYH11 is the result of inv(16)(p13q22) or t(16;16)(p13;q22) and is sufficient for the diagnosis of acute myeloid leukemia (in the correct setting) according to WHO criteria, even when blast counts are <20% (Vardiman et al, Blood 2008). This fusion is typically associated with favorable prognosis relative to other AML subtypes (including cytogenetically normal); however, the impact of additional mutations in the context of this fusion is incompletely understood. AMLs with this fusion are often grouped with other rearrangements affecting genes encoding core binding factor subunits, referred to as CBF AMLs." ;
    civico:variantID "431" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;   
    a obo:transcript_fusion, m2r:Variation .

civic:16_5partner431                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "67063148" ;
                      faldo:reference hco:16#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "67116211" ;
                      faldo:reference hco:16#GRCh37
        ]
     ] .


civic:16_3partner431 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 15797029 ;
                       faldo:reference hco:16#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 15820911 ;
                       faldo:reference hco:16#GRCh37
        ]
     ] .


civicv:432
    rdfs:label "MLL-MLLT3" ;
    m2r:evidence civice:1029 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "432" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:433
    rdfs:label "3' UTR Polymorphism" ;
    m2r:evidence civice:1031 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 62213848 ;
            faldo:reference hco:14#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 62213848 ;
            faldo:reference hco:14#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000394997.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:PancreaticAdenocarcinoma ;
    dcterms:identifier "433" ;
    a obo:SNP,obo:3_prime_UTR_variant, m2r:Variation .


civicv:434
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1032,civice:1034 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 62162258 ;
            faldo:reference hco:14#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 62214976 ;
            faldo:reference hco:14#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000394997.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer,civic:Sarcoma ;
    dcterms:identifier "434" ;
    a m2r:Variation .


civicv:435
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1033,civice:1673 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 46524541 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 46613836 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263734.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer,civic:RenalCellCarcinoma ;
    dcterms:identifier "435" ;
    a m2r:Variation .


civicv:436
    rdfs:label "LOSS" ;
    m2r:evidence civice:1035,civice:4830 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10182692 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10193904 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:RenalCarcinoma,civic:RenalCellCarcinoma ;
    dcterms:identifier "436" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:437
    rdfs:label "D835" ;
    m2r:evidence civice:1036,civice:1037,civice:1038,civice:1039 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 28592642 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 28592642 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000241453.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "437" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:438
    rdfs:label "NUCLEAR EXPRESSION" ;
    m2r:evidence civice:1051 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32808494 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32812480 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000374881.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:GastricAdenocarcinoma ;
    dcterms:identifier "438" ;
    a m2r:Variation .


civicv:439
    rdfs:label "NUCLEAR EXPRESSION" ;
    m2r:evidence civice:1052 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 27667137 ;
            faldo:reference hco:8#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 27695612 ;
            faldo:reference hco:8#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000301905.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:GastricAdenocarcinoma ;
    dcterms:identifier "439" ;
    a m2r:Variation .


civicv:440
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1053 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 159848829 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 159855748 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000352433.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Meningioma ;
    dcterms:identifier "440" ;
    a m2r:Variation .


civicv:441
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:1054 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 65886335 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 66107242 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000349533.6" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Meningioma ;
    dcterms:identifier "441" ;
    a m2r:Variation .


civicv:442
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1701,civice:1728,civice:1937,civice:2148,civice:2153,civice:2559,civice:2939,civice:3016,civice:3792,civice:3794,civice:4201,civice:5923 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55086794 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55279321 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma,civic:Non-smallCellLungCarcinoma,civic:LungCancer,civic:PeritonealMesothelioma ;
    dcterms:identifier "442" ;
    a obo:inframe_variant, m2r:Variation .


civicv:443
    rdfs:label "G465R" ;
    m2r:evidence civice:1057,civice:1058 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55227926 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55227926 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "443" ;
    a obo:missense_variant, m2r:Variation .


civicv:444
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1059 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11185051 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11382581 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000504387.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:HepatocellularCarcinoma ;
    dcterms:identifier "444" ;
    a m2r:Variation .


civicv:445
    rdfs:label "RS461155" ;
    m2r:evidence civice:1060 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 40191638 ;
            faldo:reference hco:21#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 40191638 ;
            faldo:reference hco:21#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000360214.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "445" ;
    a obo:synonymous_variant, m2r:Variation .


civicv:446
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:1061 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 53342655 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 53346684 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000388837.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "446" ;
    a m2r:Variation .


civicv:447
    rdfs:label "CYTOPLASMIC EXPRESSION" ;
    m2r:evidence civice:1062 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 137715011 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 138286269 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000370603.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "447" ;
    a m2r:Variation .


civicv:448
    rdfs:label "SS18-SSX1" ;
    m2r:evidence civice:1063,civice:1065,civice:1068,civice:1069,civice:1070,civice:1071,civice:1072 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SynovialSarcoma,civic:MalignantPeripheralNerveSheathTumor ;
    dcterms:identifier "448" ;
    civico:variantGroups "SYT-SSX fusions" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:449
    rdfs:label "SS18-SSX2" ;
    m2r:evidence civice:1064,civice:1066,civice:1067,civice:1073 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SynovialSarcoma ;
    dcterms:identifier "449" ;
    civico:variantGroups "SYT-SSX fusions" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:450                 # so:gene_fusion
    rdfs:label "SS18-SSX4" ;
    m2r:evidence civice:1074 ;
    sio:SIO_000974 civic:18_5partner450, civic:X_3partner450 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000415083.2 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "450" ;
    m2r:disease civic:SynovialSarcoma ;
    civico:variantGroups "SYT-SSX fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:18_5partner450                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "23612363" ;
                      faldo:reference hco:18#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "23670589" ;
                      faldo:reference hco:18#GRCh37
        ]
     ] .


civic:X_3partner450 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 48261524 ;
                       faldo:reference hco:X#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 48265521 ;
                       faldo:reference hco:X#GRCh37
        ]
     ] .


civicv:451
    rdfs:label "S893A/T" ;
    m2r:evidence civice:1075 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 87160618 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 87160618 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000265724.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    dcterms:description "Refer to  https://www.pharmgkb.org/rsid/rs2032582  for more information." ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "451" ;
    a obo:missense_variant, m2r:Variation .


civicv:453
    rdfs:label "S492R" ;
    m2r:evidence civice:717,civice:1078,civice:1079,civice:1080 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55228009 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55228009 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "453" ;
    a obo:missense_variant, m2r:Variation .


civicv:454
    rdfs:label "R451C" ;
    m2r:evidence civice:1081 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55227884 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55227884 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "454" ;
    a obo:missense_variant, m2r:Variation .


civicv:455
    rdfs:label "K467T" ;
    m2r:evidence civice:1082,civice:1083 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55227933 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55227933 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "455" ;
    a obo:missense_variant, m2r:Variation .


civicv:456
    rdfs:label "H167R" ;
    m2r:evidence civice:1084,civice:1088 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 161479745 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 161479745 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000271450.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "456" ;
    a obo:missense_variant, m2r:Variation .


civicv:457
    rdfs:label "F212V" ;
    m2r:evidence civice:1085,civice:1087 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 161514542 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 161514542 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000367969.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "457" ;
    a obo:missense_variant, m2r:Variation .


civicv:458
    rdfs:label "I232T" ;
    m2r:evidence civice:1086 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 161643798 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 161643798 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000358671.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "458" ;
    a obo:missense_variant, m2r:Variation .


civicv:460
    rdfs:label "P753S" ;
    m2r:evidence civice:1089 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55242487 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55242487 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinSquamousCellCarcinoma ;
    dcterms:identifier "460" ;
    a obo:missense_variant, m2r:Variation .


civicv:461
    rdfs:label "B2 DOMAIN MUTATION" ;
    m2r:evidence civice:1092 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 74315213 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 74315219 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000268058.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The B2 domain in PML is the binding site for ATRA. Point mutations in this region have been associated with ATRA resistance in patients with APL." ;
    m2r:disease civic:AcutePromyelocyticLeukemia ;
    dcterms:identifier "461" ;
    civico:variantGroups "PML-RARa B2 Domain" ;
    a obo:missense_variant, m2r:Variation .


civicv:462
    rdfs:label "PML-RARA A216V" ;
    m2r:evidence civice:1093 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 74315213 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 74315213 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000268058.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "A216V in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL." ;
    m2r:disease civic:AcutePromyelocyticLeukemia ;
    dcterms:identifier "462" ;
    civico:variantGroups "PML-RARa B2 Domain" ;
    a obo:missense_variant, m2r:Variation .


civicv:463
    rdfs:label "PML-RARA L218P" ;
    m2r:evidence civice:1094 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 74315219 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 74315219 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000268058.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "L218P in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL." ;
    m2r:disease civic:AcutePromyelocyticLeukemia ;
    dcterms:identifier "463" ;
    civico:variantGroups "PML-RARa B2 Domain" ;
    a obo:missense_variant, m2r:Variation .


civicv:464
    rdfs:label "EXON 14 MUTATION + AMPLIFICATION" ;
    m2r:evidence civice:1095 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 116312459 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 116436396 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318493.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "464" ;
    a obo:transcript_amplification,obo:exon_loss_variant, m2r:Variation .


civicv:465
    rdfs:label "CD74-ROS1 G2032R" ;
    m2r:evidence civice:1100,civice:1101,civice:1249,civice:1250,civice:1251,civice:1254,civice:1255 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 117638347 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 117638347 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000368508.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro." ;
    m2r:disease civic:LungAdenocarcinoma,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "465" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:466
    rdfs:label "ZNF198-FGFR1" ;
    m2r:evidence civice:1104 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloproliferativeDisease ;
    dcterms:identifier "466" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:467
    rdfs:label "A1065T" ;
    m2r:evidence civice:1106 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55955969 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55955969 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263923.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Angiosarcoma ;
    dcterms:identifier "467" ;
    a obo:missense_variant, m2r:Variation .


civicv:468
    rdfs:label "D717V" ;
    m2r:evidence civice:1107 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55968180 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55968180 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263923.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Angiosarcoma ;
    dcterms:identifier "468" ;
    a obo:missense_variant, m2r:Variation .


civicv:469
    rdfs:label "Q1178*" ;
    m2r:evidence civice:1108 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 2130300 ;
            faldo:reference hco:16#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 2130300 ;
            faldo:reference hco:16#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000219476.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ThyroidCarcinoma ;
    dcterms:identifier "469" ;
    a obo:stop_gained, m2r:Variation .


civicv:470
    rdfs:label "F2108L" ;
    m2r:evidence civice:1110,civice:1543 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11187094 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11187094 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361445.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ThyroidCarcinoma,civic:BreastCancer ;
    dcterms:identifier "470" ;
    a obo:missense_variant, m2r:Variation .


civicv:471
    rdfs:label "R186*" ;
    m2r:evidence civice:1111 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 33433425 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 33433425 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000345365.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "471" ;
    a obo:stop_gained, m2r:Variation .


civicv:472
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1114,civice:1116 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 58245622 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 58358616 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000249750.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "472" ;
    a m2r:Variation .


civicv:473
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:1115 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 58245622 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 58358616 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000249750.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "473" ;
    a m2r:Variation .


civicv:474
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1117 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 108268716 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 108308299 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000295746.8" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PancreaticDuctalAdenocarcinoma ;
    dcterms:identifier "474" ;
    a m2r:Variation .


civicv:475
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:1118 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 108268716 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 108308299 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000295746.8" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PancreaticDuctalAdenocarcinoma ;
    dcterms:identifier "475" ;
    a m2r:Variation .


civicv:476
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1119 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 20529898 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 20530007 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000384999.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "476" ;
    a m2r:Variation .


civicv:477
    rdfs:label "P968FS" ;
    m2r:evidence civice:1123,civice:1124 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41244645 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41244646 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:alternative_allele "GA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000471181.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:BreastCancer,civic:OvarianCancer ;
    dcterms:identifier "477" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:479
    rdfs:label "Q22*" ;
    m2r:evidence civice:1131 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398255 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398255 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColonMucinousAdenocarcinoma ;
    dcterms:identifier "479" ;
    a obo:stop_gained, m2r:Variation .


civicv:480
    rdfs:label "P904L" ;
    civico:hgvs "NC_000002.11:g.25457176G>A" ;
    dcterms:identifier "480" ;
    a m2r:Variation .


civicv:481
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1135 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 74104471 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 74127292 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000370336.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UvealMelanoma ;
    dcterms:identifier "481" ;
    a m2r:Variation .


civicv:482
    rdfs:label "RS3733542" ;
    m2r:evidence civice:1136 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55602765 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55602765 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "482" ;
    a obo:synonymous_variant, m2r:Variation .


civicv:483
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1138 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 64845660 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 64895888 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000331710.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "483" ;
    a m2r:Variation .


civicv:485
    rdfs:label "LOSS" ;
    m2r:evidence civice:1144,civice:1618,civice:1619,civice:1620,civice:1737 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1205740 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1228428 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000326873.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:Peutz-JeghersSyndrome ;
    dcterms:identifier "485" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:486
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1150,civice:1151 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 156512843 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 156536725 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000307851.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "486" ;
    a m2r:Variation .


civicv:487
    rdfs:label "SERUM LEVELS" ;
    m2r:evidence civice:1156,civice:1158 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55512883 ;
            faldo:reference hco:16#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55540603 ;
            faldo:reference hco:16#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000219070.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:InflammatoryBreastCarcinoma,civic:BrainGlioma ;
    dcterms:identifier "487" ;
    a m2r:Variation .


civicv:488
    rdfs:label "SERUM LEVELS" ;
    m2r:evidence civice:1157 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 44637547 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 44645200 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000372330.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:InflammatoryBreastCarcinoma ;
    dcterms:identifier "488" ;
    a m2r:Variation .


civicv:490
    rdfs:label "NUCLEAR EXPRESSION" ;
    m2r:evidence civice:1162,civice:1163 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 31710765 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 31736064 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000320027.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:GastricAdenocarcinoma ;
    dcterms:identifier "490" ;
    a m2r:Variation .


civicv:491
    rdfs:label "T17 DELETION" ;
    m2r:evidence civice:1164 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 31722621 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 31722637 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000320027.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "491" ;
    a obo:short_tandem_repeat_variation, m2r:Variation .


civicv:492
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1165 ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "492" ;
    a m2r:Variation .


civicv:493
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1166 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 124753587 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 124768177 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000306534.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "493" ;
    a m2r:Variation .


civicv:494
    rdfs:label "NUCLEAR EXPRESSION" ;
    m2r:evidence civice:1168 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37137979 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37143202 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000373509.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "494" ;
    a m2r:Variation .


civicv:495
    rdfs:label "SNP309" ;
    m2r:evidence civice:1169 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 69202580 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 69202580 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000462284.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:HeadAndNeckCancer ;
    dcterms:identifier "495" ;
    a obo:coding_transcript_intron_variant, m2r:Variation .


civicv:496
    rdfs:label "L866M" ;
    m2r:evidence civice:1178 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37881404 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37881404 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "This mutation was shown to be an activating mutation and conferred sensitivity to a combination of trastuzumab with neratinib or lapatinib in colorectal cancer patient-derived xenografts." ;
    m2r:disease civic:ColonCancer ;
    dcterms:identifier "496" ;
    a obo:missense_variant, m2r:Variation .


civicv:497
    rdfs:label "S310F/Y" ;
    m2r:evidence civice:1179 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37868208 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37868208 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "ERBB2 S310F/Y was one of the first ERBB2 variants to be functionally classified (Greulich et al. 2012). This mutation was shown to be an activating mutation (through hyperphosphorylation) in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in murine Ba/F3 cells have been shown to be sensitive to the ERBB2 inhibitors (afatinib, lapatinib and neratinib). More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research." ;
    m2r:disease civic:ColonCancer ;
    dcterms:identifier "497" ;
    a obo:missense_variant, m2r:Variation .


civicv:498
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:1184 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 20529898 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 20530007 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000384999.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PancreaticCancer ;
    dcterms:identifier "498" ;
    a m2r:Variation .


civicv:499
    rdfs:label "ALK FUSIONS" ;
    m2r:evidence civice:945,civice:1175,civice:1187,civice:1198,civice:1199,civice:1200,civice:1201,civice:1202,civice:1240,civice:1243,civice:1264,civice:1272,civice:1273,civice:1279,civice:1282,civice:1334,civice:1335,civice:1419,civice:1577,civice:1691,civice:1783,civice:2952,civice:4835,civice:4858,civice:6042,civice:6043 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29415640 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29446394 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib – a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC." ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:AnaplasticLargeCellLymphoma,civic:InflammatoryMyofibroblasticTumor,civic:DiffuseLargeB-cellLymphoma,civic:ColorectalAdenocarcinoma,civic:BreastCancer,civic:LungAdenocarcinoma,civic:Cancer,civic:VaginaSarcoma,civic:EpithelioidInflammatoryMyofibroblasticSarcoma ;
    dcterms:identifier "499" ;
    civico:variantGroups "ALK Fusions" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:500                 # so:gene_fusion
    rdfs:label "EML4-ALK E20;A20" ;
    m2r:evidence civice:1189,civice:1196,civice:1204,civice:1245 ;
    sio:SIO_000974 civic:2_5partner500, civic:2_3partner500 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000318522.5 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition." ;
    civico:variantID "500" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:Cancer ;
    civico:variantGroups "ALK Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:2_5partner500                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42396490" ;
                      faldo:reference hco:2#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42552694" ;
                      faldo:reference hco:2#GRCh37
        ]
     ] .


civic:2_3partner500 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29415640 ;
                       faldo:reference hco:2#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29446394 ;
                       faldo:reference hco:2#GRCh37
        ]
     ] .


civicv:501                 # so:gene_fusion
    rdfs:label "EML4-ALK E2;A20" ;
    m2r:evidence civice:1190,civice:1266 ;
    sio:SIO_000974 civic:2_5partner501, civic:2_3partner501 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000318522.5 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "501" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:RenalCellCarcinoma ;
    civico:variantGroups "ALK Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:2_5partner501                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42396490" ;
                      faldo:reference hco:2#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42472827" ;
                      faldo:reference hco:2#GRCh37
        ]
     ] .


civic:2_3partner501 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29415640 ;
                       faldo:reference hco:2#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29446394 ;
                       faldo:reference hco:2#GRCh37
        ]
     ] .


civicv:502
    rdfs:label "R961W" ;
    m2r:evidence civice:1191 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55961059 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55961059 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263923.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalAdenocarcinoma ;
    dcterms:identifier "502" ;
    a obo:missense_variant, m2r:Variation .


civicv:503                 # so:gene_fusion
    rdfs:label "EML4-ALK E6;A20" ;
    m2r:evidence civice:1192,civice:1193,civice:1194,civice:1195,civice:1197,civice:1205,civice:1340 ;
    sio:SIO_000974 civic:2_5partner503, civic:2_3partner503 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000318522.5 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition." ;
    civico:variantID "503" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    civico:variantGroups "ALK Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:2_5partner503                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42396490" ;
                      faldo:reference hco:2#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "42491871" ;
                      faldo:reference hco:2#GRCh37
        ]
     ] .


civic:2_3partner503 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29415640 ;
                       faldo:reference hco:2#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29446394 ;
                       faldo:reference hco:2#GRCh37
        ]
     ] .


civicv:504
    rdfs:label "P47S" ;
    m2r:evidence civice:1209 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7579548 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7579548 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "504" ;
    a obo:missense_variant, m2r:Variation .


civicv:505
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1210,civice:1229,civice:1953,civice:5068 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 80331003 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 80646374 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000286548.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UvealMelanoma ;
    dcterms:identifier "505" ;
    a m2r:Variation .


civicv:506
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1211,civice:1228,civice:1952,civice:3049 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 3094408 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 3124002 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000078429.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UvealMelanoma ;
    dcterms:identifier "506" ;
    a m2r:Variation .


civicv:507
    rdfs:label "Q209" ;
    m2r:evidence civice:1213,civice:1233 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 80409487 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 80409489 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000286548.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UvealMelanoma ;
    dcterms:identifier "507" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:508
    rdfs:label "K706FS*19" ;
    m2r:evidence civice:1214 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 6022512 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 6022512 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000265849.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:GlioblastomaMultiforme ;
    dcterms:identifier "508" ;
    a obo:minus_1_frameshift_variant, m2r:Variation .


civicv:509
    rdfs:label "EXON 9 MUTATION" ;
    m2r:evidence civice:1221,civice:1223,civice:1424 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55592023 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55592216 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations." ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "509" ;
    a obo:exon_variant, m2r:Variation .


civicv:510
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1232,civice:1359,civice:1467,civice:1491,civice:1522,civice:1931 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 89622870 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 89731687 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371953.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:EndometrialCarcinoma,civic:HeadAndNeckCancer,civic:HeadAndNeckSquamousCellCarcinoma,civic:Cancer,civic:ProstateCancer,civic:GlioblastomaMultiforme ;
    dcterms:identifier "510" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:511
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1236,civice:1912 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 123239371 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 123357917 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000457416.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:EndometrialCancer,civic:Cholangiocarcinoma ;
    dcterms:identifier "511" ;
    a obo:gain_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:512
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1237 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29415640 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 30144432 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "512" ;
    a obo:gene_variant,obo:gain_of_function_variant, m2r:Variation .


civicv:513                 # so:gene_fusion
    rdfs:label "NPM-ALK" ;
    m2r:evidence civice:1239,civice:1241,civice:1356 ;
    sio:SIO_000974 civic:5_5partner513, civic:2_3partner513 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000517671.1 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "513" ;
    m2r:disease civic:AnaplasticLargeCellLymphoma,civic:Cancer ;
    civico:variantGroups "ALK Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:5_5partner513                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "170814120" ;
                      faldo:reference hco:5#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "170818803" ;
                      faldo:reference hco:5#GRCh37
        ]
     ] .


civic:2_3partner513 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29415640 ;
                       faldo:reference hco:2#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29446394 ;
                       faldo:reference hco:2#GRCh37
        ]
     ] .


civicv:514                 # so:gene_fusion
    rdfs:label "RANBP2-ALK" ;
    m2r:evidence civice:1244 ;
    sio:SIO_000974 civic:2_5partner514, civic:2_3partner514 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000283195.6 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "514" ;
    m2r:disease civic:InflammatoryMyofibroblasticTumor ;
    civico:variantGroups "ALK Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:2_5partner514                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "109335937" ;
                      faldo:reference hco:2#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "109375004" ;
                      faldo:reference hco:2#GRCh37
        ]
     ] .


civic:2_3partner514 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29415640 ;
                       faldo:reference hco:2#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29446394 ;
                       faldo:reference hco:2#GRCh37
        ]
     ] .


civicv:515
    rdfs:label "N546K" ;
    m2r:evidence civice:1246 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 38274849 ;
            faldo:reference hco:8#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 38274849 ;
            faldo:reference hco:8#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000341462.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BoneEwing%27sSarcoma ;
    dcterms:identifier "515" ;
    a obo:missense_variant, m2r:Variation .


civicv:516
    rdfs:label "CD74-ROS1 L2026M" ;
    m2r:evidence civice:1252,civice:1253,civice:1257,civice:1258 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 117638365 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 117638365 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000368508.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The L2026M mutation is considered a gatekeeper mutation located in the inhibitor binding pocket of ROS1 and corresponding to L1196M in ALK and T790M in EGFR. This mutation has not been reportedly observed in a patient but inferred as a variant likely to emerge in crizotinib-resistant tumors. In vitro kinase activity, structural predictions and growth inhibition assays indicate the L2026M mutation in the CD74-ROS1 fusion provides crizotinib resistance. Additional preclinical assays have indicated that crizotinib resistant cells harboring this mutation are sensitive to PF-06463922 and foretinib." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "516" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:517
    rdfs:label "CD74-ROS1 L2155S" ;
    m2r:evidence civice:1256 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 117630062 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 117630062 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000368508.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "517" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:518
    rdfs:label "CD74-ROS1 G2101A" ;
    m2r:evidence civice:1259,civice:1260 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 117631376 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 117631376 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000368508.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "518" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:519
    rdfs:label "MUTATION" ;
    m2r:evidence civice:156,civice:5261 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 28577411 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 28674729 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000241453.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "519" ;
    a obo:gain_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:520                 # so:gene_fusion
    rdfs:label "CLTC-ALK" ;
    m2r:evidence civice:1261,civice:1263,civice:1265 ;
    sio:SIO_000974 civic:17_5partner520, civic:2_3partner520 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000269122.3 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion)." ;
    civico:variantID "520" ;
    m2r:disease civic:DiffuseLargeB-cellLymphoma ;
    civico:variantGroups "ALK Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:17_5partner520                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "57697219" ;
                      faldo:reference hco:17#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "57768072" ;
                      faldo:reference hco:17#GRCh37
        ]
     ] .


civic:2_3partner520 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29415640 ;
                       faldo:reference hco:2#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 29446394 ;
                       faldo:reference hco:2#GRCh37
        ]
     ] .


civicv:521
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1262 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 44513066 ;
            faldo:reference hco:21#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 44527697 ;
            faldo:reference hco:21#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000291552.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Myelofibrosis ;
    dcterms:identifier "521" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:522
    rdfs:label "DEL 485-490" ;
    m2r:evidence civice:1267 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140477838 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140477855 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "AGGTGCTGTCACATTCAA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "522" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:524
    rdfs:label "DUX4 FUSIONS" ;
    m2r:evidence civice:1276,civice:1277 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteLymphocyticLeukemia ;
    dcterms:identifier "524" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:525
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1278 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 33110635 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 33167354 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000379731.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:RenalCellCarcinoma ;
    dcterms:identifier "525" ;
    a m2r:Variation .


civicv:526
    rdfs:label "DELETION POLYMORPHISM" ;
    m2r:evidence civice:1280,civice:1281 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 111883195 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 111886097 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000393256.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:ChronicMyeloidLeukemia,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "526" ;
    a obo:polymorphic_sequence_variant, m2r:Variation .


civicv:527
    rdfs:label "ALK FUSION I1171" ;
    m2r:evidence civice:1283,civice:1284,civice:1285,civice:1287,civice:1344,civice:1367,civice:1368 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29445213 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29445213 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "527" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:528
    rdfs:label "EML4-ALK  V1180L" ;
    m2r:evidence civice:1286,civice:1288,civice:1289,civice:1290,civice:1291 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29443679 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29443679 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "528" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:529
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1293,civice:1294 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 69644427 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 69678147 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000212015.6" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:PancreaticDuctalCarcinoma,civic:PancreaticCancer ;
    dcterms:identifier "529" ;
    a m2r:Variation .


civicv:530
    rdfs:label "G12R" ;
    m2r:evidence civice:1298,civice:2264,civice:3989,civice:3991 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398285 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398285 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PancreaticCancer,civic:ColorectalCancer ;
    dcterms:identifier "530" ;
    a obo:missense_variant, m2r:Variation .


civicv:531
    rdfs:label "P72R" ;
    m2r:evidence civice:1302,civice:1303,civice:1304 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7579472 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7579472 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    dcterms:description "This polymorphism is relatively widely studied across cancer types, but meta-analyses in breast, lung and cervical cancer cohorts have so far been inconclusive as to the significance of a patient's genotype at this locus as it relates to cancer susceptibility and prognosis." ;
    m2r:disease civic:BreastCancer,civic:LungCarcinoma,civic:CervicalCancer ;
    dcterms:identifier "531" ;
    a obo:missense_variant, m2r:Variation .


civicv:532
    rdfs:label "BIALLELIC INACTIVATION" ;
    m2r:evidence civice:1305,civice:1963 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 23614491 ;
            faldo:reference hco:16#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 23652631 ;
            faldo:reference hco:16#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000261584.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PancreaticCancer,civic:ProstateCancer ;
    dcterms:identifier "532" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:533
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1306 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48556583 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48611409 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342988.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:PancreaticDuctalAdenocarcinoma ;
    dcterms:identifier "533" ;
    a m2r:Variation .


civicv:534
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:1307 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 97861336 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 98079984 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000289081.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Unknown" ;
    m2r:disease civic:PancreaticCancer ;
    dcterms:identifier "534" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:535
    rdfs:label "EBF1-PDGFRB" ;
    m2r:evidence civice:1310 ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment." ;
    m2r:disease civic:AcuteLymphocyticLeukemia ;
    dcterms:identifier "535" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:536
    rdfs:label "SNP" ;
    dcterms:identifier "536" ;
    a m2r:Variation .


civicv:537
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1313 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48877911 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 49056122 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000267163.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "537" ;
    a m2r:Variation .


civicv:538
    rdfs:label "METHYLATION" ;
    m2r:evidence civice:1315 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:StomachCarcinoma ;
    dcterms:identifier "538" ;
    a m2r:Variation .


civicv:539
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1316 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 112856718 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 112947717 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000351677.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LaryngealCarcinoma ;
    dcterms:identifier "539" ;
    a m2r:Variation .


civicv:540
    rdfs:label "T227M" ;
    m2r:evidence civice:1317 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 28624294 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 28624294 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000241453.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    dcterms:description "FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib." ;
    m2r:disease civic:RenalCellCarcinoma ;
    dcterms:identifier "540" ;
    a obo:SNP,obo:missense_variant, m2r:Variation .


civicv:541
    rdfs:label "L531FS*30" ;
    m2r:evidence civice:1318 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 23646276 ;
            faldo:reference hco:16#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 23646276 ;
            faldo:reference hco:16#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000261584.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "541" ;
    a obo:SNP,obo:minus_1_frameshift_variant, m2r:Variation .


civicv:542
    rdfs:label "S2215Y" ;
    m2r:evidence civice:1319 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11184573 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11184573 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361445.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:EndometrialAdenocarcinoma ;
    dcterms:identifier "542" ;
    a obo:missense_variant, m2r:Variation .


civicv:543
    rdfs:label "C1483Y" ;
    m2r:evidence civice:1320 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11217230 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11217230 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361445.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:T-cellAcuteLymphoblasticLeukemia ;
    dcterms:identifier "543" ;
    a obo:missense_variant, m2r:Variation .


civicv:544
    rdfs:label "E1799K" ;
    m2r:evidence civice:1321 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11190804 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11190804 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361445.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ClearCellRenalCellCarcinoma ;
    dcterms:identifier "544" ;
    a obo:missense_variant, m2r:Variation .


civicv:545
    rdfs:label "N550K" ;
    m2r:evidence civice:1322 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 123258034 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 123258034 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000457416.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:EndometrialCancer ;
    dcterms:identifier "545" ;
    a obo:gain_of_function_variant,obo:missense_variant, m2r:Variation .


civicv:546
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1161 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 229566992 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 229569841 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000366684.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "546" ;
    a m2r:Variation .


civicv:547
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1324 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48877911 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 49056122 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000267163.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PancreaticAdenocarcinoma ;
    dcterms:identifier "547" ;
    a m2r:Variation .


civicv:548
    rdfs:label "RS557806" ;
    m2r:evidence civice:1325 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 49377242 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 49377242 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000200453.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "548" ;
    a obo:polymorphic_sequence_variant,obo:missense_variant, m2r:Variation .


civicv:549
    rdfs:label "F1245C" ;
    m2r:evidence civice:1330,civice:1333 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29436859 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29436859 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Neuroblastoma ;
    dcterms:identifier "549" ;
    a obo:missense_variant, m2r:Variation .


civicv:550
    rdfs:label "DEL4-11" ;
    m2r:evidence civice:1336 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29497965 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29754982 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Neuroblastoma ;
    dcterms:identifier "550" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:551
    rdfs:label "ALK FUSION F1245C" ;
    m2r:evidence civice:1337,civice:1338,civice:1339 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29436859 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29436859 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "In neuroblastoma, F1245 is one of three hotspot ALK mutations found at a high frequency. In a case study, a pretreated non-small cell lung cancer (NSCLC) patient with EML4-ALK F1245C mutation responded well to ceritinib after slow disease progression during crizotinib treatment. Crizotinib resistance was attributed to the F1245C mutation, although the ALK-rearrangement was not sequenced prior to crizotinib treatment. The patient's slow onset of disease progression during crizotinib treatment mirrors preclinical findings that indicate ALK-fusion with F1245C has moderate resistance to crizotinib compared to the fusion alone." ;
    m2r:disease civic:Cancer,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "551" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:552
    rdfs:label "ALK FUSION G1269A" ;
    m2r:evidence civice:1342,civice:1353,civice:1354,civice:1355 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29432682 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29432682 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:Cancer ;
    dcterms:identifier "552" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:553
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:1366,civice:4841 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 58141510 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 58146304 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257904.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Liposarcoma ;
    dcterms:identifier "553" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:554
    rdfs:label "LOSS" ;
    m2r:evidence civice:1372,civice:1373,civice:1375,civice:1377,civice:1765,civice:1879,civice:1881 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 21967752 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 21994623 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000579755.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma,civic:RenalCellCarcinoma,civic:OvarianCancer,civic:Her2-receptorNegativeBreastCancer,civic:EwingSarcoma,civic:DermatofibrosarcomaProtuberans ;
    dcterms:identifier "554" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:555
    rdfs:label "LOSS" ;
    m2r:evidence civice:1374,civice:1880 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 22002902 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 22009362 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000276925.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:RenalCellCarcinoma,civic:EwingSarcoma ;
    dcterms:identifier "555" ;
    a obo:transcript_ablation, m2r:Variation .


civicv:556
    rdfs:label "R24C" ;
    m2r:evidence civice:1376 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 58145431 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 58145431 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257904.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "556" ;
    a obo:missense_variant, m2r:Variation .


civicv:557
    rdfs:label "EXON 12 MUTATION" ;
    m2r:evidence civice:1379 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 31021087 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 31021720 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000375687.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "557" ;
    a obo:exon_variant, m2r:Variation .


civicv:558
    rdfs:label "Q209" ;
    m2r:evidence civice:1212 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 3118942 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 3118942 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000078429.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UvealMelanoma ;
    dcterms:identifier "558" ;
    a obo:missense_variant, m2r:Variation .


civicv:559
    rdfs:label "EXON 9 FRAMESHIFT" ;
    m2r:evidence civice:1387,civice:1482,civice:1649 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 13054527 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 13054727 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000316448.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Exon 9 insertions and deletions have become part of the WHO diagnostic criteria for essential thrombocythemia (ET) and primary myelofibrosis (PMF) (Arber et al, 2016). These mutations are typically heterozygous and in the absence of JAK2 and MPL mutations. Approximately 80% of observed mutations are type 1 (p.L367fs*46), the result of a 52 bp deletion, or type 2 (p.K385fs*47), the result of a 5-bp TTGTC insertion, and studies have suggested phenotypic and prognostic differences between them. In PMF patients, CALR exon 9 mutations have been associated with improved median survival." ;
    m2r:disease civic:Myelofibrosis,civic:ChronicMyeloproliferativeDisease ;
    dcterms:identifier "559" ;
    a obo:exon_variant, m2r:Variation .


civicv:560
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1388,civice:1389 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 36932096 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 36933444 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000373106.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicNeutrophilicLeukemia,civic:AtypicalChronicMyeloidLeukemia ;
    dcterms:identifier "560" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:562
    rdfs:label "S768I" ;
    m2r:evidence civice:1394,civice:1395,civice:2906,civice:4273,civice:4274 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55249005 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249005 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "562" ;
    a obo:missense_variant, m2r:Variation .


civicv:563
    rdfs:label "V600K" ;
    m2r:evidence civice:1399,civice:1400,civice:1422,civice:2505,civice:2506,civice:4180,civice:4181,civice:6179 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453136 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453137 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "AC" ;
    m2r:alternative_allele "TT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma,civic:SkinMelanoma ;
    dcterms:identifier "563" ;
    civico:variantGroups "Other V600's" ;
    a obo:missense_variant, m2r:Variation .


civicv:564
    rdfs:label "LOSS" ;
    m2r:evidence civice:1412 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48556583 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48611409 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342988.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PancreaticCancer ;
    dcterms:identifier "564" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:565
    rdfs:label "K700E" ;
    m2r:evidence civice:1417 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 198266834 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 198266834 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000335508.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "565" ;
    civico:variantGroups "HEAT domain mutation" ;
    a obo:missense_variant, m2r:Variation .


civicv:566
    rdfs:label "E116K" ;
    m2r:evidence civice:1420 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7975157 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7975157 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000397979.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:LungCancer ;
    dcterms:identifier "566" ;
    a obo:missense_variant, m2r:Variation .


civicv:567
    rdfs:label "PDGFRA FUSIONS" ;
    m2r:evidence civice:1425,civice:1433 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyelomonocyticLeukemia,civic:MyeloidAndLymphoidNeoplasmsWithEosinophiliaAndAbnormalitiesOfPDGFRA%2CPDGFRB%2CAndFGFR1 ;
    dcterms:identifier "567" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:568
    rdfs:label "PDGFRB FUSIONS" ;
    m2r:evidence civice:1426,civice:1434,civice:1498 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyelomonocyticLeukemia,civic:HematologicCancer,civic:ChronicMyeloproliferativeDisease ;
    dcterms:identifier "568" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:569
    rdfs:label "FGFR1 FUSIONS" ;
    m2r:evidence civice:1427,civice:1435 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 38268656 ;
            faldo:reference hco:8#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 38325363 ;
            faldo:reference hco:8#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000425967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyelomonocyticLeukemia,civic:HematologicCancer ;
    dcterms:identifier "569" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:570
    rdfs:label "MUTATION" ;
    m2r:evidence civice:328,civice:1640,civice:4833,civice:5069 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 90626277 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 90645736 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000330062.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia,civic:BrainGlioma ;
    dcterms:identifier "570" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:571
    rdfs:label "PCM1-JAK2" ;
    m2r:evidence civice:1436 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HematologicCancer ;
    dcterms:identifier "571" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:572
    rdfs:label "E2014K + E2419K" ;
    m2r:evidence civice:1438 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11174420 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11187857 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361445.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UrothelialCarcinoma ;
    dcterms:identifier "572" ;
    a obo:missense_variant, m2r:Variation .


civicv:573
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:1440 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 38938021 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 39074510 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000357387.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "573" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:574                 # so:gene_fusion
    rdfs:label "FIP1L1-PDGFRA" ;
    m2r:evidence civice:1441,civice:1445,civice:1774,civice:1777 ;
    sio:SIO_000974 civic:4_5partner574, civic:4_3partner574 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000337488.6 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase&quot; (NDA021588)." ;
    civico:variantID "574" ;
    m2r:disease civic:MyeloidAndLymphoidNeoplasmsWithEosinophiliaAndAbnormalitiesOfPDGFRA%2CPDGFRB%2CAndFGFR1 ;   
    a obo:transcript_fusion, m2r:Variation .

civic:4_5partner574                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "54243812" ;
                      faldo:reference hco:4#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "54294350" ;
                      faldo:reference hco:4#GRCh37
        ]
     ] .


civic:4_3partner574 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 55141008 ;
                       faldo:reference hco:4#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 55164414 ;
                       faldo:reference hco:4#GRCh37
        ]
     ] .


civicv:576                 # so:gene_fusion
    rdfs:label "TFG-ROS1" ;
    m2r:evidence civice:1444 ;
    sio:SIO_000974 civic:3_5partner576, civic:6_3partner576 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000240851.4 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "576" ;
    m2r:disease civic:InflammatoryMyofibroblasticTumor ;   
    a obo:transcript_fusion, m2r:Variation .

civic:3_5partner576                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "100428269" ;
                      faldo:reference hco:3#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "100447702" ;
                      faldo:reference hco:3#GRCh37
        ]
     ] .


civic:6_3partner576 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 117609463 ;
                       faldo:reference hco:6#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 117642557 ;
                       faldo:reference hco:6#GRCh37
        ]
     ] .


civicv:577
    rdfs:label "FIP1L1-PDGFRA T674I" ;
    m2r:evidence civice:1446,civice:1779 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55144547 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55144547 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "A case study of relapsed myeloproliferative hypereosinophilic syndrome suggests that a T674I mutation in the PDGFRA split kinase domain of FIP1L1-PDGFRA fusions may confer resistance to imatinib." ;
    m2r:disease civic:MyeloidAndLymphoidNeoplasmsWithEosinophiliaAndAbnormalitiesOfPDGFRA%2CPDGFRB%2CAndFGFR1 ;
    dcterms:identifier "577" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:578
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1449 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 76210267 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 76221717 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000301633.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Her2-receptorPositiveBreastCancer ;
    dcterms:identifier "578" ;
    a m2r:Variation .


civicv:579
    rdfs:label "D594A" ;
    m2r:evidence civice:1454 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453154 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453154 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "579" ;
    civico:variantGroups "Kinase Dead BRAF Mutation" ;
    a obo:missense_variant, m2r:Variation .


civicv:580
    rdfs:label "D594V" ;
    m2r:evidence civice:1456 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453154 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453154 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "580" ;
    civico:variantGroups "Kinase Dead BRAF Mutation" ;
    a obo:missense_variant, m2r:Variation .


civicv:581
    rdfs:label "K483M" ;
    m2r:evidence civice:1457 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140477859 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140477860 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "TT" ;
    m2r:alternative_allele "CA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "The K483M variant is a kinase dead loss-of-function variant in the catalytic site of BRAF. This engineered variant is often used as a control when evaluating other BRAF variants." ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "581" ;
    civico:variantGroups "Kinase Dead BRAF Mutation" ;
    a obo:loss_of_function_variant,obo:missense_variant, m2r:Variation .


civicv:582
    rdfs:label "L597S" ;
    m2r:evidence civice:1459,civice:1460 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453145 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453146 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "AG" ;
    m2r:alternative_allele "GA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "582" ;
    a obo:missense_variant, m2r:Variation .


civicv:583
    rdfs:label "L597Q" ;
    m2r:evidence civice:1461,civice:4905,civice:5971 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453145 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453145 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma,civic:Cancer ;
    dcterms:identifier "583" ;
    a obo:missense_variant, m2r:Variation .


civicv:584
    rdfs:label "K601E" ;
    m2r:evidence civice:1462 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453134 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453134 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "584" ;
    a obo:missense_variant, m2r:Variation .


civicv:585
    rdfs:label "L597V" ;
    m2r:evidence civice:1463 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453146 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453146 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "585" ;
    a obo:missense_variant, m2r:Variation .


civicv:586
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:1466 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55524085 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55606881 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:MucosalMelanoma ;
    dcterms:identifier "586" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:587
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1468,civice:1469,civice:1470,civice:1471,civice:1958 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29421945 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29704695 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000358273.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma,civic:PlexiformNeurofibroma ;
    dcterms:identifier "587" ;
    a obo:loss_of_function_variant,obo:protein_altering_variant, m2r:Variation .


civicv:588
    rdfs:label "HIP1-ALK I1171N" ;
    m2r:evidence civice:1483 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29445213 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29445213 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "588" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:589
    rdfs:label "EML4-ALK I1171S" ;
    m2r:evidence civice:1484 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29445213 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29445213 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "589" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:590
    rdfs:label "TRUNCATING MUTATION" ;
    m2r:evidence civice:1488 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 102201730 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 102207833 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263464.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicLymphocyticLeukemia ;
    dcterms:identifier "590" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:591
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:1496 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 12625100 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 12705725 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000251849.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "591" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:592
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:1497,civice:5836,civice:6317 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25362365 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25403737 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:SkinMelanoma,civic:EndometrialCancer,civic:Melanoma ;
    dcterms:identifier "592" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:594
    rdfs:label "BIALLELIC INACTIVATION" ;
    m2r:evidence civice:1512 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 33790840 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 33793470 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000498907.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "594" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:595
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1514 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 74732402 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 74733113 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000392485.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "595" ;
    a obo:gene_variant, m2r:Variation .


civicv:596
    rdfs:label "G12/G13" ;
    m2r:evidence civice:1516 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 115258744 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 115258748 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000369535.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "596" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:597
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1518 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 43572475 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 43625799 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000355710.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PapillaryAdenocarcinoma ;
    dcterms:identifier "597" ;
    a m2r:Variation .


civicv:599                 # so:gene_fusion
    rdfs:label "CTLA4-CD28" ;
    m2r:evidence civice:1520 ;
    sio:SIO_000974 civic:2_5partner599, civic:2_3partner599 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000302823.3 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "A survey of 115 T-cell lymphoma samples of diverse subtypes identified this fusion in 26 of 45 cases of angioimmunoblastic T-cell lymphomas (58%), nine of 39 peripheral T-cell lymphomas, not otherwise specified (23%), and nine of 31 extranodal NK/T cell lymphomas (29%)." ;
    civico:variantID "599" ;
    m2r:disease civic:Sezary%27sDisease ;   
    a obo:transcript_fusion, m2r:Variation .

civic:2_5partner599                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "204732509" ;
                      faldo:reference hco:2#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "204736210" ;
                      faldo:reference hco:2#GRCh37
        ]
     ] .


civic:2_3partner599 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 204599507 ;
                       faldo:reference hco:2#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 204603635 ;
                       faldo:reference hco:2#GRCh37
        ]
     ] .


civicv:600
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1521 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 66764465 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 66950461 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000374690.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "600" ;
    a obo:transcript_variant, m2r:Variation .


civicv:601
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:1525 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 139388896 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 139440314 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000277541.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "601" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:602
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1526,civice:1527 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 92234235 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 92463231 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000265734.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Estrogen-receptorPositiveBreastCancer ;
    dcterms:identifier "602" ;
    a m2r:Variation .


civicv:603
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1528 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 28577411 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 28674729 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000241453.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AdultB-LymphoblasticLeukemia ;
    dcterms:identifier "603" ;
    a m2r:Variation .


civicv:604
    rdfs:label "Q209P" ;
    m2r:evidence civice:1533,civice:1537 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 80409488 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 80409488 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000286548.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "604" ;
    a obo:missense_variant, m2r:Variation .


civicv:605
    rdfs:label "V317FS" ;
    m2r:evidence civice:1534 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 89720799 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 89720802 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "TACT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371953.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "605" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:606
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:1535,civice:1595 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48877911 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 49056122 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000267163.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer,civic:GlioblastomaMultiforme ;
    dcterms:identifier "606" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:607
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1541 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 152128686 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 152424406 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000206249.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "607" ;
    a m2r:Variation .


civicv:608
    rdfs:label "EML4-ALK C1156Y–L1196M" ;
    m2r:evidence civice:236 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29443631 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29445258 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389048.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "608" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:609
    rdfs:label "M2327I" ;
    m2r:evidence civice:1544,civice:1545 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11177096 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11177096 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361445.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "609" ;
    a obo:missense_variant, m2r:Variation .


civicv:610
    rdfs:label "A2034V" ;
    m2r:evidence civice:1547,civice:1548 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 11187796 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 11187796 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000361445.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "610" ;
    a obo:missense_variant, m2r:Variation .


civicv:611
    rdfs:label "D594G" ;
    m2r:evidence civice:1551,civice:1553,civice:1554,civice:4472,civice:6001,civice:6002 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453154 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453154 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding." ;
    m2r:disease civic:ColorectalCancer,civic:SkinMelanoma ;
    dcterms:identifier "611" ;
    a obo:missense_variant, m2r:Variation .


civicv:612
    rdfs:label "D835H" ;
    m2r:evidence civice:1556 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 28592642 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 28592642 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000241453.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "612" ;
    a obo:missense_variant, m2r:Variation .


civicv:613
    rdfs:label "D835H/Y" ;
    m2r:evidence civice:1557 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 28592642 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 28592642 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G/A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000241453.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "613" ;
    a obo:missense_variant, m2r:Variation .


civicv:614
    rdfs:label "Q503*" ;
    m2r:evidence civice:1567 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 65321333 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 65321333 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342505.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "614" ;
    a obo:stop_gained, m2r:Variation .


civicv:615
    rdfs:label "Exon 12 splice site insertion" ;
    m2r:evidence civice:1568 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 5070053 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 5070054 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000381652.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "615" ;
    a m2r:Variation .


civicv:616
    rdfs:label "S14FS" ;
    m2r:evidence civice:1569 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 45003786 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 45003789 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    m2r:reference_allele "TCTT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000558401.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "616" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:617                 # so:gene_fusion
    rdfs:label "PPFIBP2-BRAF" ;
    m2r:evidence civice:1570 ;
    sio:SIO_000974 civic:11_5partner617, civic:7_3partner617 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000299492.4 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "617" ;
    m2r:disease civic:SkinMelanoma ;
    civico:variantGroups "BRAF Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:11_5partner617                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "7535001" ;
                      faldo:reference hco:11#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "7586998" ;
                      faldo:reference hco:11#GRCh37
        ]
     ] .


civic:7_3partner617 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140434279 ;
                       faldo:reference hco:7#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140481493 ;
                       faldo:reference hco:7#GRCh37
        ]
     ] .


civicv:618                 # so:gene_fusion
    rdfs:label "KIAA1549-BRAF" ;
    m2r:evidence civice:1571,civice:1664 ;
    sio:SIO_000974 civic:7_5partner618, civic:7_3partner618 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000440172.1 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "618" ;
    m2r:disease civic:SkinMelanoma,civic:Sarcoma ;
    civico:variantGroups "BRAF Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:7_5partner618                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "138545885" ;
                      faldo:reference hco:7#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "138666064" ;
                      faldo:reference hco:7#GRCh37
        ]
     ] .


civic:7_3partner618 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140434279 ;
                       faldo:reference hco:7#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140487384 ;
                       faldo:reference hco:7#GRCh37
        ]
     ] .


civicv:619
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1573 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 186640923 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 186649559 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000367468.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "619" ;
    a m2r:Variation .


civicv:621
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1581,civice:1583,civice:1584,civice:3038,civice:5835 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 116312459 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 116436396 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318493.6" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:SkinMelanoma,civic:UvealMelanoma,civic:StomachCarcinoma ;
    dcterms:identifier "621" ;
    a m2r:Variation .


civicv:623
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1590 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 124462440 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 124570035 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000357628.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicLymphocyticLeukemia ;
    dcterms:identifier "623" ;
    a obo:loss_of_function_variant,obo:protein_altering_variant, m2r:Variation .


civicv:624
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1593,civice:1594 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 129894923 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 129924649 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000368654.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer,civic:ProstateCancer ;
    dcterms:identifier "624" ;
    a m2r:Variation .


civicv:625
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1597 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 110045560 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 110094475 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000358015.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Sarcoma ;
    dcterms:identifier "625" ;
    a m2r:Variation .


civicv:626
    rdfs:label "CCDC6-RET" ;
    m2r:evidence civice:1601 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "626" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:627
    rdfs:label "C121S" ;
    m2r:evidence civice:1602 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 66729154 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 66729154 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000307102.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "627" ;
    a obo:missense_variant, m2r:Variation .


civicv:628
    rdfs:label "S249C" ;
    m2r:evidence civice:1603 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1803568 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1803568 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000340107.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UrothelialCarcinoma ;
    dcterms:identifier "628" ;
    a obo:missense_variant, m2r:Variation .


civicv:629
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:1605,civice:1990 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 123239371 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 123357917 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000457416.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer,civic:StomachCarcinoma ;
    dcterms:identifier "629" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:630
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:1606 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 69624992 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 69633792 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000334134.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "630" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:631
    rdfs:label "R200W (c.598C>T)" ;
    m2r:evidence civice:1608 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191605 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191605 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:ChuvashPolycythemia ;
    dcterms:identifier "631" ;
    a obo:missense_variant, m2r:Variation .


civicv:632
    rdfs:label "PHOSPHORYLATION" ;
    m2r:evidence civice:1609 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48877911 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 49056122 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000267163.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "632" ;
    a m2r:Variation .


civicv:633
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1612 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 67511548 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 67597649 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000521381.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "633" ;
    a obo:gain_of_function_variant,obo:missense_variant, m2r:Variation .


civicv:634
    rdfs:label "D194E" ;
    m2r:evidence civice:1617 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1220489 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1220489 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000326873.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:PancreaticCancer ;
    dcterms:identifier "634" ;
    a obo:loss_of_heterozygosity,obo:missense_variant, m2r:Variation .


civicv:635
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:1621 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 40736224 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 40791302 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000392038.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "635" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:636
    rdfs:label "R130*" ;
    m2r:evidence civice:1627 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 89692904 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 89692904 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371953.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ThyroidCancer ;
    dcterms:identifier "636" ;
    a obo:stop_gained, m2r:Variation .


civicv:637
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:1628,civice:1632 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 153242410 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 153457253 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000281708.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:RenalCellCarcinoma,civic:Cancer ;
    dcterms:identifier "637" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:638
    rdfs:label "M695FS*26" ;
    m2r:evidence civice:1630 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 49033946 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 49033947 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000267163.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Estrogen-receptorPositiveBreastCancer ;
    dcterms:identifier "638" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:639
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1633 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 59246465 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 59249785 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371222.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalAdenocarcinoma ;
    dcterms:identifier "639" ;
    a m2r:Variation .


civicv:640
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1634 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 75745477 ;
            faldo:reference hco:14#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 75748933 ;
            faldo:reference hco:14#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000303562.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColonAdenocarcinoma ;
    dcterms:identifier "640" ;
    a m2r:Variation .


civicv:641
    rdfs:label "RS3814960" ;
    m2r:evidence civice:1635 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 21975017 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 21975017 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000498124.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:EsophagusSquamousCellCarcinoma ;
    dcterms:identifier "641" ;
    a obo:5_prime_UTR_exon_variant, m2r:Variation .


civicv:642
    rdfs:label "RS34886328" ;
    m2r:evidence civice:1636 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 69234988 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 69234988 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000462284.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:EsophagusSquamousCellCarcinoma ;
    dcterms:identifier "642" ;
    a obo:3_prime_UTR_truncation, m2r:Variation .


civicv:643
    rdfs:label "RS2305035" ;
    m2r:evidence civice:1637 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 105439026 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 105439026 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000264122.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "643" ;
    a obo:polymorphic_sequence_variant,obo:synonymous_variant, m2r:Variation .


civicv:644
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1638,civice:1717 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 106534195 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 106557813 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000369096.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:DiffuseLargeB-cellLymphoma ;
    dcterms:identifier "644" ;
    a obo:loss_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:645
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1639,civice:2933 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 209101803 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 209116275 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000415913.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BrainGlioma ;
    dcterms:identifier "645" ;
    a obo:transcript_variant, m2r:Variation .


civicv:646
    rdfs:label "DELETION" ;
    m2r:evidence civice:1644 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48556583 ;
            faldo:reference hco:18#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48611409 ;
            faldo:reference hco:18#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342988.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "646" ;
    a obo:transcript_ablation, m2r:Variation .


civicv:647
    rdfs:label "DELETION" ;
    m2r:evidence civice:1645 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140988992 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 142889270 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000389484.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:GlioblastomaMultiforme ;
    dcterms:identifier "647" ;
    a obo:transcript_ablation, m2r:Variation .


civicv:648
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:1647,civice:1648 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 76760356 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 77041702 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000373344.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Astrocytoma,civic:GlioblastomaMultiforme ;
    dcterms:identifier "648" ;
    a m2r:Variation .


civicv:649
    rdfs:label "D1228N" ;
    m2r:evidence civice:1652 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 116423407 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 116423407 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000397752.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "649" ;
    a obo:missense_variant, m2r:Variation .


civicv:650
    rdfs:label "D302H" ;
    m2r:evidence civice:1654 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 202149589 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 202149589 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000264275.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Neuroblastoma ;
    dcterms:identifier "650" ;
    a obo:polymorphic_sequence_variant,obo:missense_variant, m2r:Variation .


civicv:651
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1655 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41725108 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41767671 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000301178.4" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:EsophagusSquamousCellCarcinoma ;
    dcterms:identifier "651" ;
    a m2r:Variation .


civicv:652
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1656,civice:1657 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 114523524 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 114567046 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000357389.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ProstateCancer,civic:OralSquamousCellCarcinoma ;
    dcterms:identifier "652" ;
    a m2r:Variation .


civicv:653
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1658 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41605212 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41623800 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000319349.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "653" ;
    a m2r:Variation .


civicv:654
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:1660 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 99775186 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 99812003 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000426455.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "654" ;
    a m2r:Variation .


civicv:655
    rdfs:label "Q56_V60del" ;
    m2r:evidence civice:1661 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 66727449 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 66727463 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    m2r:reference_allele "CCAGAAGCAGAAGGT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000307102.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianSerousCarcinoma ;
    dcterms:identifier "655" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:656                 # so:gene_fusion
    rdfs:label "BRAF-CUL1" ;
    m2r:evidence civice:1662 ;
    sio:SIO_000974 civic:7_5partner656, civic:7_3partner656 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000288602.6 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "656" ;
    m2r:disease civic:OvarianSerousCarcinoma ;
    civico:variantGroups "BRAF Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:7_5partner656                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "140434279" ;
                      faldo:reference hco:7#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "140487384" ;
                      faldo:reference hco:7#GRCh37
        ]
     ] .


civic:7_3partner656 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 148395737 ;
                       faldo:reference hco:7#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 148457588 ;
                       faldo:reference hco:7#GRCh37
        ]
     ] .


civicv:657                 # so:gene_fusion
    rdfs:label "ZKSCAN1-BRAF" ;
    m2r:evidence civice:1663 ;
    sio:SIO_000974 civic:7_5partner657, civic:7_3partner657 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000426572.1 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "657" ;
    m2r:disease civic:Melanoma ;
    civico:variantGroups "BRAF Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:7_5partner657                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "99613222" ;
                      faldo:reference hco:7#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "99627575" ;
                      faldo:reference hco:7#GRCh37
        ]
     ] .


civic:7_3partner657 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140434279 ;
                       faldo:reference hco:7#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 140482957 ;
                       faldo:reference hco:7#GRCh37
        ]
     ] .


civicv:658
    rdfs:label "L505H" ;
    m2r:evidence civice:1668,civice:1669 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140477794 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140477794 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "658" ;
    a obo:missense_variant, m2r:Variation .


civicv:659
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1671 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29999547 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 30094587 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000338641.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AcousticNeuroma ;
    dcterms:identifier "659" ;
    a obo:transcript_variant, m2r:Variation .


civicv:660
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1674 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 62164340 ;
            faldo:reference hco:14#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 62214489 ;
            faldo:reference hco:14#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000539097.1" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:RenalCellCarcinoma ;
    dcterms:identifier "660" ;
    a m2r:Variation .


civicv:661
    rdfs:label "D3095E" ;
    m2r:evidence civice:1679 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32968854 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32968854 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000544455.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "661" ;
    a obo:missense_variant, m2r:Variation .


civicv:662
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1680 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37034823 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37092409 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:StomachCarcinoma ;
    dcterms:identifier "662" ;
    a m2r:Variation .


civicv:663
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1681 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 39910501 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 40036582 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342274.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:StomachCancer ;
    dcterms:identifier "663" ;
    a obo:transcript_variant, m2r:Variation .


civicv:664
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1682 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 68771128 ;
            faldo:reference hco:16#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 68869451 ;
            faldo:reference hco:16#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000261769.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:StomachCarcinoma ;
    dcterms:identifier "664" ;
    a obo:transcription_variant, m2r:Variation .


civicv:665
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1683 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 49412898 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 49405977 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000418115.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:StomachCarcinoma ;
    dcterms:identifier "665" ;
    a obo:gain_of_function_variant,obo:transcription_variant, m2r:Variation .


civicv:666
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1694,civice:5338,civice:5980 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37868196 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37881332 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BladderCarcinoma,civic:BreastCancer,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "666" ;
    a obo:missense_variant, m2r:Variation .


civicv:667
    rdfs:label "FRAMESHIFT TRUNCATION" ;
    m2r:evidence civice:1695 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 64572092 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 64572092 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000337652.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ThyroidHurthleCellCarcinoma ;
    dcterms:identifier "667" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:668
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1696 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 151832010 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 152133090 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000262189.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinSquamousCellCarcinoma ;
    dcterms:identifier "668" ;
    a obo:loss_of_function_variant,obo:transcription_variant, m2r:Variation .


civicv:669
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1697 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 123176418 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 123217308 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000218089.9" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:BoneEwing%27sSarcoma ;
    dcterms:identifier "669" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:670
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1706 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 40361098 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 40367685 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000397332.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:MultipleMyeloma ;
    dcterms:identifier "670" ;
    a m2r:Variation .


civicv:671
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1707 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 81328322 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 81399514 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000222390.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:GlioblastomaMultiforme ;
    dcterms:identifier "671" ;
    a m2r:Variation .


civicv:672
    rdfs:label "LOSS" ;
    m2r:evidence civice:1710 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 38368307 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 38380544 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000396884.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "672" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:673
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1711 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 123747863 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 123819391 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000264498.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "673" ;
    a m2r:Variation .


civicv:674
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1712 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 20156713 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 20159754 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000379607.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UvealMelanoma ;
    dcterms:identifier "674" ;
    a obo:transcript_variant, m2r:Variation .


civicv:683
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1716 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 113973574 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 114036527 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000429538.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:FemaleReproductiveOrganCancer ;
    dcterms:identifier "683" ;
    a m2r:Variation .


civicv:691
    rdfs:label "E384*" ;
    m2r:evidence civice:1724 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 8073509 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 8073509 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000377482.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cholangiocarcinoma ;
    dcterms:identifier "691" ;
    a obo:stop_gained,obo:loss_of_function_variant, m2r:Variation .


civicv:692
    rdfs:label "S463P" ;
    m2r:evidence civice:1727 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 152415537 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 152415537 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000440973.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Estrogen-receptorPositiveBreastCancer ;
    dcterms:identifier "692" ;
    a obo:missense_variant, m2r:Variation .


civicv:693
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1729,civice:1730,civice:1731 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 134490384 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 134639196 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000367858.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "693" ;
    a m2r:Variation .


civicv:694
    rdfs:label "G596C" ;
    m2r:evidence civice:1738 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453149 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453149 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "694" ;
    a obo:missense_variant, m2r:Variation .


civicv:695
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:1739 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 24129150 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 24176703 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000344921.6" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:SynovialSarcoma ;
    dcterms:identifier "695" ;
    a m2r:Variation .


civicv:696
    rdfs:label "DELETION" ;
    m2r:evidence civice:1740 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 24129150 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 24176703 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000344921.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:RhabdoidCancer ;
    dcterms:identifier "696" ;
    a obo:transcript_ablation, m2r:Variation .


civicv:697
    rdfs:label "LOSS" ;
    m2r:evidence civice:1742 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29999547 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 30094587 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000338641.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ThyroidCarcinoma ;
    dcterms:identifier "697" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:698
    rdfs:label "LOSS" ;
    m2r:evidence civice:1743 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29421945 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29704695 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000358273.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantPeripheralNerveSheathTumor ;
    dcterms:identifier "698" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:699
    rdfs:label "RS3184504" ;
    m2r:evidence civice:1744 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 111884608 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 111884608 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000341259.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "699" ;
    a obo:polymorphic_sequence_variant,obo:missense_variant, m2r:Variation .


civicv:700
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1745 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 69706688 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 69740756 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000260363.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HepatocellularCarcinoma ;
    dcterms:identifier "700" ;
    a m2r:Variation .


civicv:701
    rdfs:label "V104M" ;
    m2r:evidence civice:1746 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 56478854 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 56478854 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000267101.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UrothelialCarcinoma ;
    dcterms:identifier "701" ;
    a obo:missense_variant, m2r:Variation .


civicv:702
    rdfs:label "R103G" ;
    m2r:evidence civice:1747 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 56478851 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 56478851 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000267101.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UrothelialCarcinoma ;
    dcterms:identifier "702" ;
    a obo:missense_variant, m2r:Variation .


civicv:703
    rdfs:label "G284R" ;
    m2r:evidence civice:1748 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 56481922 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 56481922 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000267101.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UrothelialCarcinoma ;
    dcterms:identifier "703" ;
    a obo:missense_variant, m2r:Variation .


civicv:705
    rdfs:label "rs681673" ;
    m2r:evidence civice:1751 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 68152388 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 68152388 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000370986.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "705" ;
    a obo:coding_transcript_intron_variant, m2r:Variation .


civicv:706                 # so:gene_fusion
    rdfs:label "EWSR1-FLI1" ;
    m2r:evidence civice:1752,civice:1753,civice:1754 ;
    sio:SIO_000974 civic:22_5partner706, civic:11_3partner706 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000414183.2 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "In approximately 90% of Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) a translocation t(11;22)(q24; q12) is identified, fusing the 5’ exons (containing the transactivatin domain, at least exon 1-7) of EWSR1, with the 3’ exons (from exon 9, coding the DNA binding domain) of FLI1." ;
    civico:variantID "706" ;
    m2r:disease civic:BoneEwing%27sSarcoma ;   
    a obo:transcript_fusion, m2r:Variation .

civic:22_5partner706                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "29664307" ;
                      faldo:reference hco:22#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "29688158" ;
                      faldo:reference hco:22#GRCh37
        ]
     ] .


civic:11_3partner706 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 128638013 ;
                       faldo:reference hco:11#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 128683162 ;
                       faldo:reference hco:11#GRCh37
        ]
     ] .


civicv:707
    rdfs:label "TMPRSS2-ERG" ;
    dcterms:identifier "707" ;
    a m2r:Variation .


civicv:708
    rdfs:label "TRUNCATING MUTATION" ;
    m2r:evidence civice:1758 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "708" ;
    a obo:feature_truncation, m2r:Variation .


civicv:709
    rdfs:label "Alu insertion" ;
    m2r:evidence civice:1759 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "709" ;
    a m2r:Variation .


civicv:711
    rdfs:label "PROMOTER METHYLATION" ;
    m2r:evidence civice:1761,civice:1762 ;
    m2r:disease civic:BreastCancer,civic:RenalCellCarcinoma ;
    dcterms:identifier "711" ;
    a obo:gene_silenced_by_DNA_methylation, m2r:Variation .


civicv:712
    rdfs:label "D761Y" ;
    m2r:evidence civice:1763 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55242511 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55242511 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "712" ;
    a obo:missense_variant, m2r:Variation .


civicv:713
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1766 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 3191695 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 3221394 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231948.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MultipleMyeloma ;
    dcterms:identifier "713" ;
    a m2r:Variation .


civicv:714
    rdfs:label "R1062W" ;
    m2r:evidence civice:1768,civice:1921 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 135771933 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 135771933 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000298552.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:TuberousSclerosis ;
    dcterms:identifier "714" ;
    a obo:missense_variant, m2r:Variation .


civicv:715
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1769 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 1205740 ;
            faldo:reference hco:19#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 1223074 ;
            faldo:reference hco:19#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000326873.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:Peutz-JeghersSyndrome ;
    dcterms:identifier "715" ;
    a obo:gene_variant, m2r:Variation .


civicv:716
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:1771 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55095264 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55164414 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "716" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:717                 # so:gene_fusion
    rdfs:label "EWSR1-DDIT3" ;
    m2r:evidence civice:1778 ;
    sio:SIO_000974 civic:22_5partner717, civic:12_3partner717 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000414183.2 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "717" ;
    m2r:disease civic:MyxoidLiposarcoma ;   
    a obo:transcript_fusion, m2r:Variation .

civic:22_5partner717                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "29664307" ;
                      faldo:reference hco:22#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "29687588" ;
                      faldo:reference hco:22#GRCh37
        ]
     ] .


civic:12_3partner717 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 57910376 ;
                       faldo:reference hco:12#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 57911536 ;
                       faldo:reference hco:12#GRCh37
        ]
     ] .


civicv:718
    rdfs:label "G719" ;
    m2r:evidence civice:1780,civice:4189 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55241707 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55241708 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "718" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:719
    rdfs:label "BRD4-NUTM1" ;
    m2r:evidence civice:1781 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:NUTMidlineCarcinoma ;
    dcterms:identifier "719" ;
    a m2r:Variation .


civicv:720
    rdfs:label "S720" ;
    m2r:evidence civice:1782 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55241710 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55241711 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "720" ;
    a obo:protein_altering_variant, m2r:Variation .


civicv:721
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:1784 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 42522501 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 42526908 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000360608.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "721" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:722
    rdfs:label "FUS-DDIT3" ;
    m2r:evidence civice:1785 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MyxoidLiposarcoma ;
    dcterms:identifier "722" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:723
    rdfs:label "K757R" ;
    m2r:evidence civice:1786 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55242500 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55242500 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "723" ;
    a obo:missense_variant, m2r:Variation .


civicv:724
    rdfs:label "E746G" ;
    m2r:evidence civice:1787 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55242467 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55242467 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "724" ;
    a obo:missense_variant, m2r:Variation .


civicv:725
    rdfs:label "E13FS*3" ;
    m2r:evidence civice:1788 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37035075 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37035075 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "725" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:726
    rdfs:label "EXON 20 INSERTION" ;
    m2r:evidence civice:1809,civice:4650 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55248991 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249022 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "726" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:727
    rdfs:label "R383*" ;
    m2r:evidence civice:1790 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 47656951 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 47656951 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000233146.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "727" ;
    a obo:stop_gained, m2r:Variation .


civicv:728
    rdfs:label "V534R" ;
    m2r:evidence civice:1791 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37081718 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37081719 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "GT" ;
    m2r:alternative_allele "AG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "728" ;
    a obo:missense_variant, m2r:Variation .


civicv:729
    rdfs:label "UGT1A1*28" ;
    m2r:evidence civice:1792 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 234668881 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 234668882 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:alternative_allele "TATATATATATATA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000305208.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "729" ;
    a obo:microsatellite, m2r:Variation .


civicv:730
    rdfs:label "G606FS*2" ;
    m2r:evidence civice:1793 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37089094 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37089095 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "GG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "730" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:731
    rdfs:label "C.790+1G>A" ;
    m2r:evidence civice:1794 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37056036 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37056036 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST0000023170.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "731" ;
    a obo:splice_donor_variant, m2r:Variation .


civicv:732
    rdfs:label "UGT1A1*60" ;
    m2r:evidence civice:1795 ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "732" ;
    a obo:microsatellite, m2r:Variation .


civicv:733
    rdfs:label "K618DEL" ;
    m2r:evidence civice:1796 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37089130 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37089132 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "AAG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "733" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:734
    rdfs:label "P138T" ;
    dcterms:identifier "734" ;
    a m2r:Variation .


civicv:735
    rdfs:label "R687FS" ;
    m2r:evidence civice:1798 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37090464 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37090464 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "735" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:736
    rdfs:label "V769_770insASV" ;
    m2r:evidence civice:1799 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55249009 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249010 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:alternative_allele "GCCAGCGTG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "736" ;
    a obo:direct_tandem_duplication, m2r:Variation .


civicv:737
    rdfs:label "DPYD*2A HOMOZYGOSITY" ;
    m2r:evidence civice:1800 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 97915614 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 97915614 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000370192.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "737" ;
    a obo:splice_donor_variant, m2r:Variation .


civicv:738
    rdfs:label "DPYD*13 HOMOZYGOSITY" ;
    m2r:evidence civice:1801 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 97981343 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 97981343 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000370192.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "738" ;
    a obo:missense_variant, m2r:Variation .


civicv:739
    rdfs:label "TRUNCATING FUSION" ;
    m2r:evidence civice:1802 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 75745477 ;
            faldo:reference hco:14#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 75748127 ;
            faldo:reference hco:14#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000303562.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BoneEpithelioidHemangioma ;
    dcterms:identifier "739" ;
    a obo:transcript_fusion,obo:stop_gained, m2r:Variation .


civicv:740
    rdfs:label "RS67376798 HOMOZYGOSITY" ;
    m2r:evidence civice:1803 ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "740" ;
    a obo:polymorphic_sequence_variant, m2r:Variation .


civicv:741
    rdfs:label "R100*" ;
    m2r:evidence civice:1804 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37042536 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37042536 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "741" ;
    a obo:stop_gained, m2r:Variation .


civicv:742                 # so:gene_fusion
    rdfs:label "WWTR1-CAMTA1" ;
    m2r:evidence civice:1805 ;
    sio:SIO_000974 civic:3_5partner742, civic:1_3partner742 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000465804.1 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "742" ;
    m2r:disease civic:EpithelioidHemangioendothelioma ;   
    a obo:transcript_fusion, m2r:Variation .

civic:3_5partner742                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "149235022" ;
                      faldo:reference hco:3#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "149290787" ;
                      faldo:reference hco:3#GRCh37
        ]
     ] .


civic:1_3partner742 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 7721786 ;
                       faldo:reference hco:1#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 7829766 ;
                       faldo:reference hco:1#GRCh37
        ]
     ] .


civicv:743
    rdfs:label "T117M" ;
    m2r:evidence civice:1806 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37045935 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37045935 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "743" ;
    a obo:missense_variant, m2r:Variation .


civicv:744
    rdfs:label "Q426FS" ;
    m2r:evidence civice:1807 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37067365 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37067365 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "744" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:745
    rdfs:label "V49A" ;
    m2r:evidence civice:1808 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37038139 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37038139 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "745" ;
    a obo:missense_variant, m2r:Variation .


civicv:746
    rdfs:label "D667FS" ;
    m2r:evidence civice:1810 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37090406 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37090406 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "746" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:747
    rdfs:label "M1L" ;
    m2r:evidence civice:1811 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37035039 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37035039 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "747" ;
    a obo:missense_variant, m2r:Variation .


civicv:748
    rdfs:label "*757L" ;
    m2r:evidence civice:1812 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37092143 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37092143 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "748" ;
    a obo:stop_lost, m2r:Variation .


civicv:749
    rdfs:label "R265G" ;
    m2r:evidence civice:1813 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37058999 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37058999 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "749" ;
    a obo:missense_variant, m2r:Variation .


civicv:750
    rdfs:label "V213FS" ;
    m2r:evidence civice:1814 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37053551 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37053551 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "750" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:751
    rdfs:label "N551T" ;
    m2r:evidence civice:1815 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37081770 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37081770 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "751" ;
    a obo:missense_variant, m2r:Variation .


civicv:752
    rdfs:label "A424T" ;
    m2r:evidence civice:1816 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37067359 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37067359 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "752" ;
    a obo:missense_variant, m2r:Variation .


civicv:753
    rdfs:label "Q149*" ;
    m2r:evidence civice:1817 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37048546 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37048546 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "753" ;
    a obo:stop_gained, m2r:Variation .


civicv:754
    rdfs:label "R226*" ;
    m2r:evidence civice:1818 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37053589 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37053589 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "754" ;
    a obo:stop_gained, m2r:Variation .


civicv:755
    rdfs:label "I972F" ;
    civico:hgvs "ENST00000234420.5:c.2914A>T,NC_000002.11:g.48028036A>T" ;
    dcterms:identifier "755" ;
    a m2r:Variation .


civicv:756
    rdfs:label "P536FS" ;
    m2r:evidence civice:1820 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37081726 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37081726 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "756" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:757
    rdfs:label "G67R" ;
    m2r:evidence civice:1821 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37038192 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37038192 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "757" ;
    a obo:missense_variant, m2r:Variation .


civicv:758
    rdfs:label "I68S" ;
    m2r:evidence civice:1822 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37038196 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37038196 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "758" ;
    a obo:missense_variant, m2r:Variation .


civicv:759
    rdfs:label "G65D" ;
    m2r:evidence civice:1823 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37038187 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37038187 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "759" ;
    a obo:missense_variant, m2r:Variation .


civicv:760
    rdfs:label "A681V" ;
    m2r:evidence civice:1824 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37090447 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37090447 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "760" ;
    a obo:missense_variant, m2r:Variation .


civicv:761
    rdfs:label "P138T" ;
    m2r:evidence civice:1825 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48018217 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48018217 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000234420.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "761" ;
    a obo:missense_variant, m2r:Variation .


civicv:762
    rdfs:label "V273FS" ;
    m2r:evidence civice:1826 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 47641433 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 47641433 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000233146.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "762" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:763
    rdfs:label "E28FS" ;
    m2r:evidence civice:1827 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 47630413 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 47630414 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000233146.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "763" ;
    a obo:frameshift_elongation, m2r:Variation .


civicv:764
    rdfs:label "E55FS (c.163_164delGA)" ;
    m2r:evidence civice:1828 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183694 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183695 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "GA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "764" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:765
    rdfs:label "I891FS" ;
    m2r:evidence civice:1829 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48027794 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48027795 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "TC" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000234420.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "765" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:766
    rdfs:label "E55RfsTer11 (c.163delG)" ;
    m2r:evidence civice:1830 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183694 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183694 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "766" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:767
    rdfs:label "R1242H" ;
    m2r:evidence civice:1831 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48033421 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48033421 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000234420.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "767" ;
    a obo:missense_variant, m2r:Variation .


civicv:768
    rdfs:label "R315*" ;
    civico:hgvs "NM_000535.6:c.943C>T,NP_000526.2:p.Arg315Ter,NC_000007.13:g.6031649G>A" ;
    dcterms:identifier "768" ;
    a m2r:Variation .


civicv:769
    rdfs:label "M490T" ;
    m2r:evidence civice:1833 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37070334 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37070334 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000231790.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "769" ;
    a obo:missense_variant, m2r:Variation .


civicv:770
    rdfs:label "K172*" ;
    m2r:evidence civice:1834 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 47637380 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 47637380 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000233146.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "770" ;
    a obo:stop_gained, m2r:Variation .


civicv:771
    rdfs:label "A56FS (c.164_165insG)" ;
    m2r:evidence civice:1835 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183695 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183696 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "771" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:772
    rdfs:label "G84E" ;
    m2r:evidence civice:1760,civice:1836 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 46805705 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 46805705 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000290295.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "772" ;
    a obo:missense_variant, m2r:Variation .


civicv:773
    rdfs:label "E483G" ;
    m2r:evidence civice:1837 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 47690231 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 47690231 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000233146.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "773" ;
    a obo:missense_variant, m2r:Variation .


civicv:774                 # so:gene_fusion
    rdfs:label "TNKS2-PDGFRA" ;
    m2r:evidence civice:1838 ;
    sio:SIO_000974 civic:10_5partner774, civic:4_3partner774 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000371627.4 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "774" ;
    m2r:disease civic:MyeloidAndLymphoidNeoplasmsWithEosinophiliaAndAbnormalitiesOfPDGFRA%2CPDGFRB%2CAndFGFR1 ;   
    a obo:transcript_fusion, m2r:Variation .

civic:10_5partner774                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "93558069" ;
                      faldo:reference hco:10#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "93619405" ;
                      faldo:reference hco:10#GRCh37
        ]
     ] .


civic:4_3partner774 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 55141008 ;
                       faldo:reference hco:4#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 55164414 ;
                       faldo:reference hco:4#GRCh37
        ]
     ] .


civicv:775
    rdfs:label "V352I" ;
    m2r:evidence civice:1839 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48026176 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48026176 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000234420.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "775" ;
    a obo:missense_variant, m2r:Variation .


civicv:776
    rdfs:label "R1242C" ;
    m2r:evidence civice:1840 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48033420 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48033420 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000234420.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "776" ;
    a obo:missense_variant, m2r:Variation .


civicv:777
    rdfs:label "RS4149056" ;
    m2r:evidence civice:1841 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 21331549 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 21331549 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256958.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "777" ;
    a obo:polymorphic_sequence_variant,obo:missense_variant, m2r:Variation .


civicv:778
    rdfs:label "N130D" ;
    m2r:evidence civice:1842 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 21329738 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 21329738 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256958.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "778" ;
    a obo:missense_variant, m2r:Variation .


civicv:779
    rdfs:label "RS34743033" ;
    m2r:evidence civice:1843 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 657646 ;
            faldo:reference hco:18#
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 657646 ;
            faldo:reference hco:18#
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:transcript "ENST00000323274.10" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "779" ;
    a m2r:Variation .


civicv:780
    rdfs:label "ACTB-GLI1" ;
    m2r:evidence civice:1844 ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Fusion of the hedgehog pathway component gene GLI1 to the β-actin gene (ACTB)  has been described as a mechanism of GLI1,and by extension hedgehog pathway, activation. These fusions have been described in histologically distinctive soft tissue tumours showing a pericytic phenotype.  Gene fusions retain the DNA-binding zinc finger domains of GLI1 and it is likely that the replacement of the promoter region of GLI1with that of the ubiquitously expressed ACTB gene leads to deregulation of GLI expression and its downstream target genes." ;
    m2r:disease civic:Pericytoma ;
    dcterms:identifier "780" ;
    a obo:gene_fusion, m2r:Variation .


civicv:781
    rdfs:label "V855A" ;
    m2r:evidence civice:1845 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 56491672 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 56491672 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST000000267101.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "781" ;
    a obo:missense_variant, m2r:Variation .


civicv:782                 # so:gene_fusion
    rdfs:label "FGFR2-BICC1" ;
    m2r:evidence civice:1846,civice:1851,civice:1917,civice:1920 ;
    sio:SIO_000974 civic:10_5partner782, civic:10_3partner782 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000457416.2 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "782" ;
    m2r:disease civic:Cholangiocarcinoma,civic:UrothelialCarcinoma,civic:EndometrialCancer ;   
    a obo:transcript_fusion, m2r:Variation .

civic:10_5partner782                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "123239371" ;
                      faldo:reference hco:10#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "123357917" ;
                      faldo:reference hco:10#GRCh37
        ]
     ] .


civic:10_3partner782 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 60461834 ;
                       faldo:reference hco:10#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 60591195 ;
                       faldo:reference hco:10#GRCh37
        ]
     ] .


civicv:783                 # so:gene_fusion
    rdfs:label "FGFR2-AHCYL1" ;
    m2r:evidence civice:1847,civice:1853 ;
    sio:SIO_000974 civic:10_5partner783, civic:1_3partner783 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000457416.2 ;
    civico:ensemblVersion "75" ;
    civico:variantID "783" ;
    m2r:disease civic:Cholangiocarcinoma ;   
    a obo:transcript_fusion, m2r:Variation .

civic:10_5partner783                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "123239371" ;
                      faldo:reference hco:10#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "123357917" ;
                      faldo:reference hco:10#GRCh37
        ]
     ] .


civic:1_3partner783 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 110554984 ;
                       faldo:reference hco:1#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 110566357 ;
                       faldo:reference hco:1#GRCh37
        ]
     ] .


civicv:784
    rdfs:label "METHYLATION" ;
    m2r:evidence civice:1848 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 22009121 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 22009172 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000276925.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcutePromyelocyticLeukemia ;
    dcterms:identifier "784" ;
    a m2r:Variation .


civicv:785
    rdfs:label "1100DELC" ;
    m2r:evidence civice:1850 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29091857 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29091857 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000328354.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "785" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:787
    rdfs:label "I157T" ;
    m2r:evidence civice:1852 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 29121087 ;
            faldo:reference hco:22#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 29121087 ;
            faldo:reference hco:22#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000328354.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "787" ;
    a obo:missense_variant, m2r:Variation .


civicv:788
    rdfs:label "IVS2+1G>A" ;
    m2r:evidence civice:1854 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:ProstateCancer ;
    dcterms:identifier "788" ;
    a m2r:Variation .


civicv:792
    rdfs:label "V253I" ;
    m2r:evidence civice:1856 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 8521481 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 8521481 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000381196.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:BoneEwing%27sSarcoma ;
    dcterms:identifier "792" ;
    a obo:missense_variant, m2r:Variation .


civicv:793
    rdfs:label "A56FS (c.164_165insA)" ;
    m2r:evidence civice:1857 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183695 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183696 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "793" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:794
    rdfs:label "E55E (c.165G>A)" ;
    m2r:evidence civice:1858 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183696 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183696 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "794" ;
    a obo:silent_mutation, m2r:Variation .


civicv:795
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1859 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 4116039 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 4160106 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000300738.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:PancreaticCancer ;
    dcterms:identifier "795" ;
    a m2r:Variation .


civicv:796
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1860 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10262455 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10271545 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000360566.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:PancreaticCancer ;
    dcterms:identifier "796" ;
    a m2r:Variation .


civicv:797
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1861,civice:1862 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133202900 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133256623 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000320574.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:GlioblastomaMultiforme,civic:EndometrialCancer ;
    dcterms:identifier "797" ;
    a obo:gene_variant, m2r:Variation .


civicv:798
    rdfs:label "D1228V" ;
    m2r:evidence civice:1864,civice:1865 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 116423408 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 116423408 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000397752.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "798" ;
    a obo:missense_variant, m2r:Variation .


civicv:799
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1866 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48877911 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 49056122 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000267163.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungSmallCellCarcinoma ;
    dcterms:identifier "799" ;
    a obo:gene_variant, m2r:Variation .


civicv:800
    rdfs:label "SQSTM1-NTRK1" ;
    m2r:evidence civice:1868,civice:2950,civice:6103 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:PediatricFibrosarcoma ;
    dcterms:identifier "800" ;
    civico:variantGroups "NTRK1 Fusions" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:801                 # so:gene_fusion
    rdfs:label "ETV6-NTRK3" ;
    m2r:evidence civice:1869,civice:1870,civice:6099,civice:6474,civice:6475,civice:6930 ;
    sio:SIO_000974 civic:12_5partner801, civic:15_3partner801 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000396373.4 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "801" ;
    m2r:disease civic:SalivaryGlandCarcinoma,civic:PediatricFibrosarcoma,civic:PapillaryThyroidCarcinoma,civic:BreastSecretoryCarcinoma,civic:PediatricB-lymphoblasticLeukemia ;   
    a obo:transcript_fusion, m2r:Variation .

civic:12_5partner801                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "11802788" ;
                      faldo:reference hco:12#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "12022903" ;
                      faldo:reference hco:12#GRCh37
        ]
     ] .


civic:15_3partner801 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 88483984 ;
                       faldo:reference hco:15#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 88418230 ;
                       faldo:reference hco:15#GRCh37
        ]
     ] .


civicv:802
    rdfs:label "K83E" ;
    m2r:evidence civice:1871 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 36259163 ;
            faldo:reference hco:21#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 36259163 ;
            faldo:reference hco:21#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000344691.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "802" ;
    a obo:missense_variant, m2r:Variation .


civicv:803
    rdfs:label "Y260*" ;
    m2r:evidence civice:1872 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 36171704 ;
            faldo:reference hco:21#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 36171704 ;
            faldo:reference hco:21#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000344691.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "803" ;
    a obo:stop_gained, m2r:Variation .


civicv:804
    rdfs:label "R135FSX177" ;
    m2r:evidence civice:1873 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "804" ;
    a m2r:Variation .


civicv:805
    rdfs:label "ETV6-NTRK3 G623R" ;
    m2r:evidence civice:1874 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 88476265 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 88476265 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000394480.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "805" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:806
    rdfs:label "D198Y" ;
    m2r:evidence civice:1875 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 36231792 ;
            faldo:reference hco:21#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 36231792 ;
            faldo:reference hco:21#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000300305.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    dcterms:description "D198Y was observed in a pedigree with a history of Familial platelet disorder with predisposition to acute myeloid leukemia. It occurs within the Runt domain of RUNX1, known to be associated with the disease." ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "806" ;
    a obo:loss_of_function_variant,obo:missense_variant, m2r:Variation .


civicv:807
    rdfs:label "A107P" ;
    m2r:evidence civice:1876 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 36252962 ;
            faldo:reference hco:21#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 36252962 ;
            faldo:reference hco:21#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000344691.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "807" ;
    a obo:missense_variant, m2r:Variation .


civicv:808
    rdfs:label "LOSS" ;
    m2r:evidence civice:1877 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 47630108 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 47710367 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000233146.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UrothelialCarcinoma ;
    dcterms:identifier "808" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:809
    rdfs:label "LOSS" ;
    m2r:evidence civice:1878 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 48010221 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 48037240 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000234420.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:UrothelialCarcinoma ;
    dcterms:identifier "809" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:810
    rdfs:label "T148HFSX9" ;
    m2r:evidence civice:1882 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 36252913 ;
            faldo:reference hco:21#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 36252920 ;
            faldo:reference hco:21#GRCh37
        ]
    ] ;
    m2r:reference_allele "GCTGCGGT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000300305.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "810" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:811
    rdfs:label "R399C" ;
    civico:hgvs "NM_001987.4:c.1195C>T,NP_001978.1:p.Arg399Cys,ENST00000396373.4:c.1195C>T,NC_000012.11:g.12038902C>T" ;
    dcterms:identifier "811" ;
    a m2r:Variation .


civicv:812
    rdfs:label "R369Q" ;
    civico:hgvs "NM_001987.4:c.1106G>A,NP_001978.1:p.Arg369Gln,ENST00000396373.4:c.1106G>A,NC_000012.11:g.12037475G>A" ;
    dcterms:identifier "812" ;
    a m2r:Variation .


civicv:813
    rdfs:label "P214L" ;
    dcterms:identifier "813" ;
    a m2r:Variation .


civicv:814
    rdfs:label "R164W" ;
    m2r:evidence civice:1887 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 176942767 ;
            faldo:reference hco:5#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 176942767 ;
            faldo:reference hco:5#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000507955.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:HematologicCancer ;
    dcterms:identifier "814" ;
    a obo:missense_variant, m2r:Variation .


civicv:816
    rdfs:label "G776L" ;
    m2r:evidence civice:1889 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37880997 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37880998 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "GG" ;
    m2r:alternative_allele "CT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "816" ;
    a obo:missense_variant, m2r:Variation .


civicv:817
    rdfs:label "G778_P780DUP" ;
    m2r:evidence civice:1890,civice:1892 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37881011 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37881012 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:alternative_allele "GGCTCCCCA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma,civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "817" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:818
    rdfs:label "M774DELINSWLV" ;
    m2r:evidence civice:1894 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37880991 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37880991 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "TGGCTGG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "818" ;
    a obo:inframe_indel, m2r:Variation .


civicv:819
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:1895 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 70910630 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 71031220 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000334414.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Angiosarcoma ;
    dcterms:identifier "819" ;
    a obo:loss_of_function_variant, m2r:Variation .


civicv:820
    rdfs:label "A149S (c.445G>T)" ;
    m2r:evidence civice:1896,civice:5679 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188302 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188302 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "820" ;
    a obo:missense_variant, m2r:Variation .


civicv:821
    rdfs:label "COPY-NEUTRAL LOSS OF HETEROZYGOSITY" ;
    m2r:evidence civice:1899 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "821" ;
    a m2r:Variation .


civicv:822
    rdfs:label "S703I" ;
    m2r:evidence civice:1900 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 65311203 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 65311203 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000342505.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HepatocellularCarcinoma ;
    dcterms:identifier "822" ;
    a obo:missense_variant, m2r:Variation .


civicv:823
    rdfs:label "3' EXON DELETION" ;
    m2r:evidence civice:1901 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 47612305 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 47614173 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263735" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:LynchSyndrome ;
    dcterms:identifier "823" ;
    a obo:disruptive_inframe_deletion, m2r:Variation .


civicv:824
    rdfs:label "K57T" ;
    dcterms:identifier "824" ;
    a m2r:Variation .


civicv:825
    rdfs:label "S490T" ;
    m2r:evidence civice:1905 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 47429340 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 47429340 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000377045.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "825" ;
    a obo:missense_variant, m2r:Variation .


civicv:826
    rdfs:label "R201C" ;
    m2r:evidence civice:1906 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 57484420 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 57484420 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371085.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "826" ;
    a obo:missense_variant, m2r:Variation .


civicv:827
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1910 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BladderCarcinoma ;
    dcterms:identifier "827" ;
    a m2r:Variation .


civicv:828
    rdfs:label "FUSION" ;
    m2r:evidence civice:1913,civice:1918 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cholangiocarcinoma,civic:Cancer ;
    dcterms:identifier "828" ;
    a m2r:Variation .


civicv:829
    rdfs:label "M54IFS (c.162_166delGGAGG)" ;
    m2r:evidence civice:1914 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183693 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183697 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "GGAGG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "829" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:830
    rdfs:label "FGFR3-TACC3" ;
    m2r:evidence civice:1919 ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "830" ;
    a m2r:Variation .


civicv:837
    rdfs:label "W535L" ;
    civico:hgvs "NM_005631.4:c.1604G>T,NP_005622.1:p.Trp535Leu,ENST00000249373.3:c.1604G>T,NC_000007.13:g.128850341G>T" ;
    dcterms:identifier "837" ;
    a m2r:Variation .


civicv:838
    rdfs:label "R173C" ;
    m2r:evidence civice:1930,civice:1934,civice:1935 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 89711899 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 89711899 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371953.3" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Cancer,civic:EndometrialHyperplasia,civic:PTENHarmatomaTumorSyndrome ;
    dcterms:identifier "838" ;
    a obo:missense_variant, m2r:Variation .


civicv:839
    rdfs:label "ALTERNATIVE TRANSCRIPT (ATI)" ;
    m2r:evidence civice:1936 ;
    dcterms:description "This novel ALK transcript (alternative isoform) initiates from a de novo alternative transcription initiation (ATI) site in ALK intron 19." ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "839" ;
    a m2r:Variation .


civicv:840
    rdfs:label "G469R" ;
    civico:hgvs "NM_004333.4:c.1405G>C,NP_004324.2:p.Gly469Arg,NC_000007.13:g.140481403C>G,ENST00000288602.6c.1405G>C" ;
    dcterms:identifier "840" ;
    a m2r:Variation .


civicv:841
    rdfs:label "G469V" ;
    civico:hgvs "NM_004333.4:c.1406G>T,NP_004324.2:p.Gly469Val,ENST00000288602.6:c.1406G>T,NC_000007.13:g.140481402C>A" ;
    dcterms:identifier "841" ;
    a m2r:Variation .


civicv:842
    rdfs:label "APC" ;
    dcterms:identifier "842" ;
    a m2r:Variation .


civicv:843
    rdfs:label "EXON 1-3 DELETION" ;
    m2r:evidence civice:1942 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183532 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191649 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "843" ;
    a obo:exon_loss_variant, m2r:Variation .


civicv:844
    rdfs:label "EXON 1 DELETION" ;
    m2r:evidence civice:1943,civice:5249 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183532 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183871 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "844" ;
    a obo:exon_loss_variant, m2r:Variation .


civicv:845
    rdfs:label "EXON 1-2 DELETION" ;
    m2r:evidence civice:1944 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183532 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188320 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "845" ;
    a obo:exon_loss_variant, m2r:Variation .


civicv:846
    rdfs:label "M1FS (c.1_17del17)" ;
    m2r:evidence civice:1945 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183532 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183548 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "ATGCCCCGGAGGGCGGA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "846" ;
    a obo:start_lost, m2r:Variation .


civicv:847
    rdfs:label "M1? (c.1-1_20del21)" ;
    m2r:evidence civice:1946 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183531 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183551 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "AATGCCCCGGAGGGCGGAGAA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "847" ;
    a obo:start_lost, m2r:Variation .


civicv:848
    rdfs:label "M1? (c.3G>A)" ;
    m2r:evidence civice:1947 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183534 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183534 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "848" ;
    a obo:start_lost, m2r:Variation .


civicv:849
    rdfs:label "N7D (c.19A>G)" ;
    m2r:evidence civice:1948 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183550 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183550 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "849" ;
    a obo:missense_variant, m2r:Variation .


civicv:850
    rdfs:label "P25L (c.74C>T)" ;
    m2r:evidence civice:1949 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183605 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183605 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "850" ;
    a obo:missense_variant, m2r:Variation .


civicv:851
    rdfs:label "P59fs (c.173_174insC)" ;
    m2r:evidence civice:1950 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183704 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183705 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "851" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:852
    rdfs:label "Y98FS (c.291_310del20)" ;
    m2r:evidence civice:1951 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183822 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183841 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "CTACCCAACGCTGCCGCCTG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "852" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:853
    rdfs:label "LOSS" ;
    dcterms:identifier "853" ;
    a m2r:Variation .


civicv:854
    rdfs:label "Q61L" ;
    civico:hgvs "NM_005343.3:c.182A>T,NP_005334.1:p.Gln61Leu,ENST00000451590.1:c.182A>T,NC_000011.9:g.533874T>A" ;
    dcterms:identifier "854" ;
    a m2r:Variation .


civicv:855
    rdfs:label "EXON 8 MUTATION" ;
    dcterms:identifier "855" ;
    a m2r:Variation .


civicv:856
    rdfs:label "DELETION" ;
    dcterms:identifier "856" ;
    a m2r:Variation .


civicv:857
    rdfs:label "EXPRESSION" ;
    dcterms:identifier "857" ;
    a m2r:Variation .


civicv:858
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "858" ;
    a m2r:Variation .


civicv:859
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "859" ;
    a m2r:Variation .


civicv:860
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:1972 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 156830686 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 156851434 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000524377.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Neuroblastoma ;
    dcterms:identifier "860" ;
    a m2r:Variation .


civicv:861
    rdfs:label "T725M" ;
    civico:hgvs "ENST00000275493.2:c.2174C>T,NC_000007.13:g.55241726C>T" ;
    dcterms:identifier "861" ;
    a m2r:Variation .


civicv:862
    rdfs:label "P577S" ;
    m2r:evidence civice:1974 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55141083 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55141083 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "862" ;
    a obo:missense_variant, m2r:Variation .


civicv:863
    rdfs:label "R841K" ;
    m2r:evidence civice:1975 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55152090 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55152090 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "863" ;
    a obo:missense_variant, m2r:Variation .


civicv:864
    rdfs:label "H845Y" ;
    m2r:evidence civice:1976 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55152101 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55152101 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "864" ;
    a obo:missense_variant, m2r:Variation .


civicv:865
    rdfs:label "G853D" ;
    m2r:evidence civice:1977 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55152126 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55152126 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000257290.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "865" ;
    a obo:missense_variant, m2r:Variation .


civicv:866
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "866" ;
    a m2r:Variation .


civicv:867
    rdfs:label "DELETION" ;
    m2r:evidence civice:1980 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "867" ;
    a m2r:Variation .


civicv:868
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:1981 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 17104080 ;
            faldo:reference hco:8#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 17155533 ;
            faldo:reference hco:8#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000324849.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "868" ;
    a m2r:Variation .


civicv:869
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "869" ;
    a m2r:Variation .


civicv:870
    rdfs:label "T316A" ;
    m2r:evidence civice:1985 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 100613633 ;
            faldo:reference hco:X#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 100613633 ;
            faldo:reference hco:X#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000308731.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicLymphocyticLeukemia ;
    dcterms:identifier "870" ;
    a obo:missense_variant, m2r:Variation .


civicv:871
    rdfs:label "T862A" ;
    m2r:evidence civice:1986 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37881392 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37881392 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:StomachCarcinoma ;
    dcterms:identifier "871" ;
    a obo:missense_variant, m2r:Variation .


civicv:872
    rdfs:label "V773A" ;
    m2r:evidence civice:1987 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37880989 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37880989 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma ;
    dcterms:identifier "872" ;
    a obo:missense_variant, m2r:Variation .


civicv:873
    rdfs:label "N857S" ;
    m2r:evidence civice:1988 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37881378 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37881378 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "873" ;
    a obo:missense_variant, m2r:Variation .


civicv:874
    rdfs:label "H878Y" ;
    m2r:evidence civice:1989 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 37881440 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 37881440 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269571.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HepatocellularCarcinoma ;
    dcterms:identifier "874" ;
    a obo:missense_variant, m2r:Variation .


civicv:875
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1992,civice:4840,civice:5955,civice:5956,civice:6170,civice:6171 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HeadAndNeckSquamousCellCarcinoma,civic:Her2-receptorPositiveBreastCancer,civic:PancreaticCancer,civic:SalivaryGlandCancer ;
    dcterms:identifier "875" ;
    a m2r:Variation .


civicv:876
    rdfs:label "MUTATION" ;
    m2r:evidence civice:1994 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PseudomyxomaPeritonei ;
    dcterms:identifier "876" ;
    a m2r:Variation .


civicv:877
    rdfs:label "T393C" ;
    m2r:evidence civice:1995,civice:1996,civice:1997,civice:2892,civice:2893,civice:2895,civice:2896,civice:2897,civice:2898 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 57428713 ;
            faldo:reference hco:20#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 57428713 ;
            faldo:reference hco:20#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000371100" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Polymorphism" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:IntrahepaticCholangiocarcinoma,civic:BreastCarcinoma,civic:BladderUrothelialCarcinoma,civic:ColorectalCancer,civic:EsophagealCancer,civic:ClearCellRenalCellCarcinoma,civic:ChronicLymphocyticLeukemia,civic:Melanoma ;
    dcterms:identifier "877" ;
    a obo:missense_variant, m2r:Variation .


civicv:878
    rdfs:label "G12D" ;
    m2r:evidence civice:3693 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 115258747 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 115258747 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000369535.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "878" ;
    a obo:missense_variant, m2r:Variation .


civicv:879
    rdfs:label "G245S" ;
    m2r:evidence civice:4883 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "879" ;
    a m2r:Variation .


civicv:880
    rdfs:label "R132L" ;
    m2r:evidence civice:2020 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 209113112 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 209113112 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000415913.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantGlioma ;
    dcterms:identifier "880" ;
    a obo:missense_variant, m2r:Variation .


civicv:881
    rdfs:label "E545Q" ;
    civico:hgvs "NM_006218.3:c.1633G>C,NP_006209.2:p.Glu545Gln,NC_000003.11:g.178936091G>C,ENST00000263967.3:c.1633G>C" ;
    dcterms:identifier "881" ;
    a m2r:Variation .


civicv:882
    rdfs:label "E545A" ;
    civico:hgvs "NM_006218.3:c.1634A>C,NP_006209.2:p.Glu545Ala,NC_000003.11:g.178936092A>C,ENST00000263967.3:c.1634A>C" ;
    dcterms:identifier "882" ;
    a m2r:Variation .


civicv:883
    rdfs:label "E545G" ;
    m2r:evidence civice:3724 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 178936092 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 178936092 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "883" ;
    a obo:missense_variant, m2r:Variation .


civicv:884
    rdfs:label "E545V" ;
    civico:hgvs "NM_006218.3:c.1634A>T,NP_006209.2:p.Glu545Val,NC_000003.11:g.178936092A>T,ENST00000263967.3:c.1634A>T" ;
    dcterms:identifier "884" ;
    a m2r:Variation .


civicv:885
    rdfs:label "Q546K" ;
    civico:hgvs "NM_006218.3:c.1636C>A,NP_006209.2:p.Gln546Lys,NC_000003.11:g.178936094C>A,ENST00000263967.3:c.1636C>A" ;
    dcterms:identifier "885" ;
    a m2r:Variation .


civicv:886
    rdfs:label "Q546E" ;
    civico:hgvs "NM_006218.3:c.1636C>G,NP_006209.2:p.Gln546Glu,NC_000003.11:g.178936094C>G,ENST00000263967.3:c.1636C>G" ;
    dcterms:identifier "886" ;
    a m2r:Variation .


civicv:890
    rdfs:label "L747_S752del" ;
    dcterms:identifier "890" ;
    a m2r:Variation .


civicv:891
    rdfs:label "S752_I759delSPKANKEI" ;
    dcterms:identifier "891" ;
    a m2r:Variation .


civicv:892
    rdfs:label "BCR-ABL F359V" ;
    m2r:evidence civice:2167,civice:2169,civice:2170,civice:3815,civice:3819,civice:6256 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748414 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748414 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "892" ;
    a obo:missense_variant, m2r:Variation .


civicv:893
    rdfs:label "Q61H" ;
    civico:hgvs "NM_002524.4:c.183A>C,NP_002515.1:p.Gln61His,NC_000001.10:g.115256528T>G,ENST00000369535.4:c.183A>C" ;
    dcterms:identifier "893" ;
    a m2r:Variation .


civicv:895
    rdfs:label "G13C" ;
    civico:hgvs "NM_002524.4:c.37G>T,NP_002515.1:p.Gly13Cys,NC_000001.10:g.115258745C>A,ENST00000369535.4:c.37G>T" ;
    dcterms:identifier "895" ;
    a m2r:Variation .


civicv:896
    rdfs:label "G13R" ;
    civico:hgvs "NM_002524.4:c.37G>C,NP_002515.1:p.Gly13Arg,NC_000001.10:g.115258745C>G,ENST00000369535.4:c.37G>C" ;
    dcterms:identifier "896" ;
    a m2r:Variation .


civicv:897
    rdfs:label "G12C" ;
    civico:hgvs "NM_002524.4:c.34G>T,NP_002515.1:p.Gly12Cys,NC_000001.10:g.115258748C>A,ENST00000369535.4:c.34G>T" ;
    dcterms:identifier "897" ;
    a m2r:Variation .


civicv:898
    rdfs:label "G12S" ;
    civico:hgvs "NM_002524.4:c.34G>A,NP_002515.1:p.Gly12Ser,NC_000001.10:g.115258748C>T,ENST00000369535.4:c.34G>A" ;
    dcterms:identifier "898" ;
    a m2r:Variation .


civicv:901
    rdfs:label "T2666A" ;
    civico:hgvs "NC_000011.9:g.108204681A>G" ;
    dcterms:identifier "901" ;
    a m2r:Variation .


civicv:902
    rdfs:label "L2890V" ;
    civico:hgvs "NM_000051.3:c.8668C>G,NP_000042.3:p.Leu2890Val,NC_000011.9:g.108218089C>G,ENST00000278616.4:c.8668C>G" ;
    dcterms:identifier "902" ;
    a m2r:Variation .


civicv:903
    rdfs:label "R3008C" ;
    civico:hgvs "NC_000011.9:g.108236086C>T" ;
    dcterms:identifier "903" ;
    a m2r:Variation .


civicv:904
    rdfs:label "R3008H" ;
    civico:hgvs "NC_000011.9:g.108236087G>A" ;
    dcterms:identifier "904" ;
    a m2r:Variation .


civicv:905
    rdfs:label "A146P" ;
    m2r:evidence civice:2225 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25378562 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25378562 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "905" ;
    a obo:missense_variant, m2r:Variation .


civicv:906
    rdfs:label "A146T" ;
    m2r:evidence civice:2206,civice:2943,civice:3858 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25378562 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25378562 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "906" ;
    a obo:missense_variant, m2r:Variation .


civicv:907
    rdfs:label "Q61H" ;
    m2r:evidence civice:3862 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25380275 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25380275 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "907" ;
    a obo:missense_variant, m2r:Variation .


civicv:908
    rdfs:label "Q61L" ;
    civico:hgvs "NM_004985.4:c.182A>T,NP_004976.2:p.Gln61Leu,NC_000012.11:g.25380276T>A,ENST00000256078.4:c.182A>T" ;
    dcterms:identifier "908" ;
    a m2r:Variation .


civicv:909
    rdfs:label "Q61R" ;
    civico:hgvs "NM_004985.4:c.182A>G,NP_004976.2:p.Gln61Arg,NC_000012.11:g.25380276T>C,ENST00000256078.4:c.182A>G" ;
    dcterms:identifier "909" ;
    a m2r:Variation .


civicv:910
    rdfs:label "Q61K" ;
    civico:hgvs "NM_004985.4:c.181C>A,NP_004976.2:p.Gln61Lys,NC_000012.11:g.25380277G>T,ENST00000256078.4:c.181C>A" ;
    dcterms:identifier "910" ;
    a m2r:Variation .


civicv:911
    rdfs:label "G13C" ;
    civico:hgvs "NM_004985.4:c.37G>T,NP_004976.2:p.Gly13Cys,NC_000012.11:g.25398282C>A,ENST00000256078.4:c.37G>T" ;
    dcterms:identifier "911" ;
    a m2r:Variation .


civicv:913
    rdfs:label "G12S" ;
    m2r:evidence civice:2269,civice:2273,civice:2274,civice:2277,civice:2278,civice:2279,civice:4012,civice:6314,civice:6324 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 25398285 ;
            faldo:reference hco:12#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 25398285 ;
            faldo:reference hco:12#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256078.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer,civic:LungCancer,civic:MultipleMyeloma ;
    dcterms:identifier "913" ;
    a obo:missense_variant, m2r:Variation .


civicv:918
    rdfs:label "R273L" ;
    m2r:evidence civice:2286 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7577120 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7577120 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "918" ;
    a obo:missense_variant, m2r:Variation .


civicv:922
    rdfs:label "Y220C" ;
    m2r:evidence civice:2306,civice:4884 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7578190 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7578190 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:StomachCarcinoma,civic:Cancer ;
    dcterms:identifier "922" ;
    a obo:missense_variant, m2r:Variation .


civicv:925
    rdfs:label "LKB1" ;
    dcterms:identifier "925" ;
    a m2r:Variation .


civicv:927
    rdfs:label "R132G" ;
    civico:hgvs "NM_001282386.1:c.394C>G,NP_001269315.1:p.Arg132Gly,NC_000002.11:g.209113113G>C,ENST00000415913.1:c.394C>G" ;
    dcterms:identifier "927" ;
    a m2r:Variation .


civicv:928
    rdfs:label "R132S" ;
    m2r:evidence civice:2339 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 209113113 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 209113113 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000415913.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantGlioma ;
    dcterms:identifier "928" ;
    a obo:missense_variant, m2r:Variation .


civicv:930
    rdfs:label "N345K" ;
    civico:hgvs "NM_006218.3:c.1035T>A,NP_006209.2:p.Asn345Lys,NC_000003.11:g.178921553T>A,ENST00000263967.3:c.1035T>A" ;
    dcterms:identifier "930" ;
    a m2r:Variation .


civicv:931
    rdfs:label "C420R" ;
    civico:hgvs "NM_006218.3:c.1258T>C,NP_006209.2:p.Cys420Arg,NC_000003.11:g.178927980T>C,ENST00000263967.3:c.1258T>C" ;
    dcterms:identifier "931" ;
    a m2r:Variation .


civicv:933
    rdfs:label "E542Q" ;
    civico:hgvs "NM_006218.3:c.1624G>C,NP_006209.2:p.Glu542Gln,NC_000003.11:g.178936082G>C,ENST00000263967.3:c.1624G>C" ;
    dcterms:identifier "933" ;
    a m2r:Variation .


civicv:934
    rdfs:label "E545D" ;
    civico:hgvs "NM_006218.3:c.1635G>C,NP_006209.2:p.Glu545Asp,NC_000003.11:g.178936093G>C,ENST00000263967.3:c.1635G>C" ;
    dcterms:identifier "934" ;
    a m2r:Variation .


civicv:935
    rdfs:label "Y1021C" ;
    civico:hgvs "NM_006218.3:c.3062A>G,NP_006209.2:p.Tyr1021Cys,NC_000003.11:g.178952007A>G,ENST00000263967.3:c.3062A>G" ;
    dcterms:identifier "935" ;
    a m2r:Variation .


civicv:937
    rdfs:label "M1043I" ;
    civico:hgvs "NM_006218.3:c.3129G>T,NP_006209.2:p.Met1043Ile,NC_000003.11:g.178952074G>T,ENST00000263967.3:c.3129G>T" ;
    dcterms:identifier "937" ;
    a m2r:Variation .


civicv:938
    rdfs:label "H1047Y" ;
    civico:hgvs "NM_006218.3:c.3139C>T,NP_006209.2:p.His1047Tyr,NC_000003.11:g.178952084C>T,ENST00000263967.3:c.3139C>T" ;
    dcterms:identifier "938" ;
    a m2r:Variation .


civicv:939
    rdfs:label "G1049S" ;
    civico:hgvs "NM_006218.3:c.3145G>A,NP_006209.2:p.Gly1049Ser,NC_000003.11:g.178952090G>A,ENST00000263967.3:c.3145G>A" ;
    dcterms:identifier "939" ;
    a m2r:Variation .


civicv:940
    rdfs:label "G1049R" ;
    civico:hgvs "NM_006218.3:c.3145G>C,NP_006209.2:p.Gly1049Arg,NC_000003.11:g.178952090G>C,ENST00000263967.3:c.3145G>C" ;
    dcterms:identifier "940" ;
    a m2r:Variation .


civicv:941
    rdfs:label "V561D" ;
    civico:hgvs "NM_006206.5:c.1682T>A,NP_006197.1:p.Val561Asp,NC_000004.11:g.55141036T>A,ENST00000257290.5:c.1682T>A" ;
    dcterms:identifier "941" ;
    a m2r:Variation .


civicv:946
    rdfs:label "Y503_F504insAY" ;
    civico:hgvs "NC_000004.11:g.55592185_55592186insGCCTAT" ;
    dcterms:identifier "946" ;
    a m2r:Variation .


civicv:948
    rdfs:label "K550_W557del" ;
    dcterms:identifier "948" ;
    a m2r:Variation .


civicv:949
    rdfs:label "K550_K558DEL" ;
    civico:hgvs "NM_000222.2:c.1648_1674del27,NP_000213.1:p.Lys550_Lys558del,NC_000004.11:g.55593582_55593608del27,ENST00000288135.5:c.1648_1674del27" ;
    dcterms:identifier "949" ;
    a m2r:Variation .


civicv:950
    rdfs:label "P551L" ;
    civico:hgvs "ENST00000288135.5:c.1652C>T" ;
    dcterms:identifier "950" ;
    a m2r:Variation .


civicv:951
    rdfs:label "M552_W557DEL" ;
    civico:hgvs "ENST00000288135.5:c.1654_1671delATGTATGAAGTACAGTGG" ;
    dcterms:identifier "951" ;
    a m2r:Variation .


civicv:952
    rdfs:label "Y553D" ;
    civico:hgvs "ENST00000288135.5:c.1657T>G,NC_000004.11:g.55593591T>G" ;
    dcterms:identifier "952" ;
    a m2r:Variation .


civicv:953
    rdfs:label "Y553_K558DEL" ;
    dcterms:identifier "953" ;
    a m2r:Variation .


civicv:954
    rdfs:label "DEL 554-558" ;
    civico:hgvs "ENST00000288135.5:c.1660_1674delGAAGTACAGTGGAAG" ;
    dcterms:identifier "954" ;
    a m2r:Variation .


civicv:955
    rdfs:label "E554D" ;
    civico:hgvs "ENST00000288135.5:c.1662A>C,NC_000004.11:g.55593596A>C" ;
    dcterms:identifier "955" ;
    a m2r:Variation .


civicv:956
    rdfs:label "V555_Q556DEL" ;
    civico:hgvs "ENST00000288135.5:c.1663_1668delGTACAG" ;
    dcterms:identifier "956" ;
    a m2r:Variation .


civicv:957
    rdfs:label "V555-P573DELVQWKVVEEINGNNYVYIDP" ;
    dcterms:identifier "957" ;
    a m2r:Variation .


civicv:958
    rdfs:label "W557R" ;
    civico:hgvs "NM_000222.2:c.1669T>C,NP_000213.1:p.Trp557Arg,NC_000004.11:g.55593603T>C,ENST00000288135.5:c.1669T>C" ;
    dcterms:identifier "958" ;
    a m2r:Variation .


civicv:959
    rdfs:label "W557G" ;
    civico:hgvs "NM_000222.2:c.1669T>G,NP_000213.1:p.Trp557Gly,NC_000004.11:g.55593603T>G,ENST00000288135.5:c.1669T>G" ;
    dcterms:identifier "959" ;
    a m2r:Variation .


civicv:960
    rdfs:label "W557T" ;
    civico:hgvs "ENST00000288135.5:c.1669_1670delinsAC,NC_000004.11:g.55593603_55593604delinsAC" ;
    dcterms:identifier "960" ;
    a m2r:Variation .


civicv:961
    rdfs:label "W557_K558DELWK" ;
    dcterms:identifier "961" ;
    a m2r:Variation .


civicv:962
    rdfs:label "W557_E561DEL" ;
    dcterms:identifier "962" ;
    a m2r:Variation .


civicv:963
    rdfs:label "K558Q" ;
    civico:hgvs "NM_000222.2:c.1672A>C,NP_000213.1:p.Lys558Gln,NC_000004.11:g.55593606A>C,ENST00000288135.5:c.1672A>C" ;
    dcterms:identifier "963" ;
    a m2r:Variation .


civicv:964
    rdfs:label "K558_V559DEL" ;
    civico:hgvs "ENST00000288135.5:c.1672_1677delAAGGTT" ;
    dcterms:identifier "964" ;
    a m2r:Variation .


civicv:965
    rdfs:label "K558R" ;
    civico:hgvs "ENST00000288135.5:c.1673A>G,NC_000004.11:g.55593607A>G" ;
    dcterms:identifier "965" ;
    a m2r:Variation .


civicv:966
    rdfs:label "V559DEL" ;
    civico:hgvs "ENST00000288135.5:c.1675_1677delGTT,NM_000222.2:c.1675_1677delGTT,NP_000213.1:p.Val559del,NC_000004.11:g.55593609_55593611delGTT" ;
    dcterms:identifier "966" ;
    a m2r:Variation .


civicv:967
    rdfs:label "V559_V560DEL" ;
    civico:hgvs "ENST00000288135.5:c.1675_1680delGTTGTT" ;
    dcterms:identifier "967" ;
    a m2r:Variation .


civicv:968
    rdfs:label "V559D" ;
    m2r:evidence civice:3028,civice:3029 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55593610 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55593610 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastrointestinalStromalTumor,civic:Cancer ;
    dcterms:identifier "968" ;
    a obo:missense_variant, m2r:Variation .


civicv:969
    rdfs:label "V559A" ;
    civico:hgvs "NM_000222.2:c.1676T>C,NP_000213.1:p.Val559Ala,NC_000004.11:g.55593610T>C,ENST00000288135.5:c.1676T>C" ;
    dcterms:identifier "969" ;
    a m2r:Variation .


civicv:970
    rdfs:label "V559G" ;
    civico:hgvs "NM_000222.2:c.1676T>G,NP_000213.1:p.Val559Gly,NC_000004.11:g.55593610T>G,ENST00000288135.5:c.1676T>G" ;
    dcterms:identifier "970" ;
    a m2r:Variation .


civicv:971
    rdfs:label "V560D" ;
    civico:hgvs "ENST00000288135.5:c.1679T>A,NM_000222.2:c.1679T>A,NP_000213.1:p.Val560Asp,NC_000004.11:g.55593613T>A" ;
    dcterms:identifier "971" ;
    a m2r:Variation .


civicv:972
    rdfs:label "V560G" ;
    civico:hgvs "NM_000222.2:c.1679T>G,NP_000213.1:p.Val560Gly,NC_000004.11:g.55593613T>G,ENST00000288135.5:c.1679T>G" ;
    dcterms:identifier "972" ;
    a m2r:Variation .


civicv:974
    rdfs:label "T574A" ;
    civico:hgvs "ENST00000288135.5:c.1720A>G,NC_000004.11:g.55593654A>G" ;
    dcterms:identifier "974" ;
    a m2r:Variation .


civicv:975
    rdfs:label "Q575L" ;
    civico:hgvs "ENST00000288135.5:c.1724A>T,NC_000004.11:g.55593658A>T" ;
    dcterms:identifier "975" ;
    a m2r:Variation .


civicv:976
    rdfs:label "P577L" ;
    civico:hgvs "ENST00000288135.5:c.1730C>T,NC_000004.11:g.55593664C>T" ;
    dcterms:identifier "976" ;
    a m2r:Variation .


civicv:977
    rdfs:label "D579DEL" ;
    civico:hgvs "ENST00000288135.5:c.1735_1737delGAT" ;
    dcterms:identifier "977" ;
    a m2r:Variation .


civicv:978
    rdfs:label "K642E" ;
    m2r:evidence civice:2889 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55594221 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55594221 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "978" ;
    a obo:missense_variant, m2r:Variation .


civicv:979
    rdfs:label "T661I" ;
    civico:hgvs "ENST00000288135.5:c.1982C>T,NC_000004.11:g.55594279C>T" ;
    dcterms:identifier "979" ;
    a m2r:Variation .


civicv:980
    rdfs:label "S692L" ;
    civico:hgvs "ENST00000288135.5:c.2075C>T,NP_000213.1:p.Ser692Leu,NC_000004.11:g.55595585C>T,NM_000222.2:c.2075C>T" ;
    dcterms:identifier "980" ;
    a m2r:Variation .


civicv:981
    rdfs:label "Q694K" ;
    civico:hgvs "ENST00000288135.5:c.2080C>A,NC_000004.11:g.55595590C>A" ;
    dcterms:identifier "981" ;
    a m2r:Variation .


civicv:983
    rdfs:label "D816H" ;
    m2r:evidence civice:2923 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55599320 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55599320 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "983" ;
    a obo:missense_variant, m2r:Variation .


civicv:984
    rdfs:label "D816Y" ;
    dcterms:identifier "984" ;
    a m2r:Variation .


civicv:986
    rdfs:label "D820Y" ;
    m2r:evidence civice:2886,civice:2888 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55599332 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55599332 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "986" ;
    a obo:missense_variant, m2r:Variation .


civicv:989
    rdfs:label "Y823D" ;
    m2r:evidence civice:2919 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55599341 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55599341 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "989" ;
    a obo:missense_variant, m2r:Variation .


civicv:990
    rdfs:label "A829P" ;
    dcterms:identifier "990" ;
    a m2r:Variation .


civicv:991
    rdfs:label "V600R" ;
    dcterms:identifier "991" ;
    a m2r:Variation .


civicv:992
    rdfs:label "G469A" ;
    m2r:evidence civice:5965 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140481402 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140481402 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "992" ;
    a obo:missense_variant, m2r:Variation .


civicv:993
    rdfs:label "G469E" ;
    m2r:evidence civice:6003,civice:6004 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140481402 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140481402 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:SkinMelanoma ;
    dcterms:identifier "993" ;
    a obo:missense_variant, m2r:Variation .


civicv:994
    rdfs:label "R108K" ;
    m2r:evidence civice:4186 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantGlioma ;
    dcterms:identifier "994" ;
    a m2r:Variation .


civicv:995
    rdfs:label "T263P" ;
    m2r:evidence civice:4187 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantGlioma ;
    dcterms:identifier "995" ;
    a m2r:Variation .


civicv:996
    rdfs:label "A289V" ;
    m2r:evidence civice:4188 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55221822 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55221822 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantGlioma ;
    dcterms:identifier "996" ;
    a obo:missense_variant, m2r:Variation .


civicv:999
    rdfs:label "G719A" ;
    m2r:evidence civice:2508,civice:6181 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55241708 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55241708 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "999" ;
    a obo:missense_variant, m2r:Variation .


civicv:1001
    rdfs:label "V742A" ;
    m2r:evidence civice:4197 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1001" ;
    a m2r:Variation .


civicv:1002
    rdfs:label "E746_A750delELREA" ;
    dcterms:identifier "1002" ;
    a m2r:Variation .


civicv:1003
    rdfs:label "E746_T751>I" ;
    dcterms:identifier "1003" ;
    a m2r:Variation .


civicv:1004
    rdfs:label "E746_T751delinsA" ;
    dcterms:identifier "1004" ;
    a m2r:Variation .


civicv:1005
    rdfs:label "E746V" ;
    dcterms:identifier "1005" ;
    a m2r:Variation .


civicv:1006
    rdfs:label "L747_A750>P" ;
    dcterms:identifier "1006" ;
    a m2r:Variation .


civicv:1007
    rdfs:label "L747_T751delLREAT" ;
    dcterms:identifier "1007" ;
    a m2r:Variation .


civicv:1008
    rdfs:label "L747_T751>Q" ;
    dcterms:identifier "1008" ;
    a m2r:Variation .


civicv:1009
    rdfs:label "E746_S752>D" ;
    dcterms:identifier "1009" ;
    a m2r:Variation .


civicv:1010
    rdfs:label "L747_T751>P" ;
    dcterms:identifier "1010" ;
    a m2r:Variation .


civicv:1011
    rdfs:label "L747_P753>Q" ;
    dcterms:identifier "1011" ;
    a m2r:Variation .


civicv:1012
    rdfs:label "L747_P753delinsS" ;
    m2r:evidence civice:4266 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55242470 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55242487 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1012" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:1013
    rdfs:label "D761N" ;
    dcterms:identifier "1013" ;
    a m2r:Variation .


civicv:1016
    rdfs:label "G810S" ;
    dcterms:identifier "1016" ;
    a m2r:Variation .


civicv:1017
    rdfs:label "R831H" ;
    m2r:evidence civice:4279 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55259434 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55259434 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantMesothelioma ;
    dcterms:identifier "1017" ;
    a obo:missense_variant, m2r:Variation .


civicv:1018
    rdfs:label "L838V" ;
    m2r:evidence civice:4280 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1018" ;
    a m2r:Variation .


civicv:1020
    rdfs:label "L861Q" ;
    m2r:evidence civice:3802,civice:4299 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:MalignantGlioma ;
    dcterms:identifier "1020" ;
    a m2r:Variation .


civicv:1021
    rdfs:label "BCR-ABL M244V" ;
    m2r:evidence civice:2638,civice:4302,civice:4307,civice:6242 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133738330 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133738330 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1021" ;
    a obo:missense_variant, m2r:Variation .


civicv:1022
    rdfs:label "BCR-ABL L248V" ;
    m2r:evidence civice:2641,civice:2644,civice:4310,civice:6236,civice:6308 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133738342 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133738342 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1022" ;
    a obo:missense_variant, m2r:Variation .


civicv:1023
    rdfs:label "BCR-ABL G250E" ;
    m2r:evidence civice:2645,civice:2647,civice:2648,civice:4313,civice:4316,civice:6244,civice:6267 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133738349 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133738349 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1023" ;
    a obo:missense_variant, m2r:Variation .


civicv:1024
    rdfs:label "Q252H" ;
    m2r:evidence civice:2650,civice:4327,civice:6219,civice:6245,civice:6274 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133738356 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133738356 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1024" ;
    a obo:missense_variant, m2r:Variation .


civicv:1025
    rdfs:label "BCR-ABL Y253H" ;
    m2r:evidence civice:2654,civice:4331,civice:4335,civice:6237 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133738357 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133738357 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1025" ;
    a obo:missense_variant, m2r:Variation .


civicv:1026
    rdfs:label "Y253F" ;
    m2r:evidence civice:2655,civice:2657,civice:4340 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133738358 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133738358 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1026" ;
    a obo:missense_variant, m2r:Variation .


civicv:1027
    rdfs:label "BCR-ABL D276G" ;
    m2r:evidence civice:2663,civice:2666,civice:4357,civice:4359,civice:6246 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133747520 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133747520 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1027" ;
    a obo:missense_variant, m2r:Variation .


civicv:1029
    rdfs:label "M351T" ;
    m2r:evidence civice:2682,civice:2684,civice:2685,civice:4396,civice:6254 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748391 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748391 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1029" ;
    a obo:missense_variant, m2r:Variation .


civicv:1030
    rdfs:label "BCR-ABL H396R" ;
    m2r:evidence civice:2687,civice:2689,civice:4411,civice:4413,civice:6258 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133750356 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133750356 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1030" ;
    a obo:missense_variant, m2r:Variation .


civicv:1031
    rdfs:label "L1600P" ;
    civico:hgvs "ENST00000277541.6:c.4799T>C,NC_000009.11:g.139399344A>G" ;
    dcterms:identifier "1031" ;
    a m2r:Variation .


civicv:1032
    rdfs:label "L1574P" ;
    civico:hgvs "ENST00000277541.6:c.4721T>C,NC_000009.11:g.139399422A>G" ;
    dcterms:identifier "1032" ;
    a m2r:Variation .


civicv:1033
    rdfs:label "R1598P" ;
    civico:hgvs "ENST00000277541.6:c.4793G>C,NC_000009.11:g.139399350C>G" ;
    dcterms:identifier "1033" ;
    a m2r:Variation .


civicv:1034
    rdfs:label "L1678P" ;
    civico:hgvs "ENST00000277541.6:c.5033T>C,NC_000009.11:g.139397768A>G" ;
    dcterms:identifier "1034" ;
    a m2r:Variation .


civicv:1049
    rdfs:label "P278S" ;
    dcterms:identifier "1049" ;
    a m2r:Variation .


civicv:1066
    rdfs:label "M237I" ;
    m2r:evidence civice:4885 ;
    civico:referenceBuild "GRCh37" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1066" ;
    a m2r:Variation .


civicv:1068
    rdfs:label "Y234C" ;
    m2r:evidence civice:2745 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7577580 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7577580 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1068" ;
    a obo:missense_variant, m2r:Variation .


civicv:1092
    rdfs:label "V157F" ;
    m2r:evidence civice:4887 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7578461 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7578461 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1092" ;
    a obo:missense_variant, m2r:Variation .


civicv:1103
    rdfs:label "Q61P" ;
    civico:hgvs "NM_004985.4:c.182A>C,NP_004976.2:p.Gln61Pro,NC_000012.11:g.25380276T>G,ENST00000256078.4:c.182A>C" ;
    dcterms:identifier "1103" ;
    a m2r:Variation .


civicv:1104
    rdfs:label "Q61E" ;
    civico:hgvs "NM_004985.4:c.181C>G,NP_004976.2:p.Gln61Glu,NC_000012.11:g.25380277G>C,ENST00000256078.4:c.181C>G" ;
    dcterms:identifier "1104" ;
    a m2r:Variation .


civicv:1105
    rdfs:label "Q61FS" ;
    dcterms:identifier "1105" ;
    a m2r:Variation .


civicv:1106
    rdfs:label "G464V" ;
    m2r:evidence civice:5964 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140481417 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140481417 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1106" ;
    a obo:missense_variant, m2r:Variation .


civicv:1107
    rdfs:label "D594N" ;
    civico:hgvs "NM_004333.4:c.1780G>A,NP_004324.2:p.Asp594Asn,NC_000007.13:g.140453155C>T,ENST00000288602.6:c.1780G>A" ;
    dcterms:identifier "1107" ;
    a m2r:Variation .


civicv:1108
    rdfs:label "R282L" ;
    m2r:evidence civice:2818 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7577093 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7577093 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:StomachCarcinoma ;
    dcterms:identifier "1108" ;
    a obo:missense_variant, m2r:Variation .


civicv:1109
    rdfs:label "R213P" ;
    m2r:evidence civice:2819 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7578211 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7578211 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:StomachCarcinoma ;
    dcterms:identifier "1109" ;
    a obo:missense_variant, m2r:Variation .


civicv:1120
    rdfs:label "K117N" ;
    civico:hgvs "NM_004985.4:c.351A>T,NP_004976.2:p.Lys117Asn,NC_000012.11:g.25378647T>A,ENST00000256078.4:c.351A>T" ;
    dcterms:identifier "1120" ;
    a m2r:Variation .


civicv:1121
    rdfs:label "F595L" ;
    civico:hgvs "NM_004333.4:c.1785T>G,NP_004324.2:p.Phe595Leu,NC_000007.13:g.140453150A>C,ENST00000288602.6:c.1785T>G" ;
    dcterms:identifier "1121" ;
    a m2r:Variation .


civicv:1127
    rdfs:label "F1592S" ;
    civico:hgvs "ENST00000277541.6:c.4775T>C,NC_000009.11:g.139399368A>G" ;
    dcterms:identifier "1127" ;
    a m2r:Variation .


civicv:1140
    rdfs:label "L1600Q" ;
    civico:hgvs "ENST00000277541.6:c.4799T>A,NC_000009.11:g.139399344A>T" ;
    dcterms:identifier "1140" ;
    a m2r:Variation .


civicv:1142
    rdfs:label "L1585R" ;
    civico:hgvs "ENST00000277541.6:c.4754T>G,NC_000009.11:g.139399389A>C" ;
    dcterms:identifier "1142" ;
    a m2r:Variation .


civicv:1143
    rdfs:label "V1577A" ;
    civico:hgvs "ENST00000277541.6:c.4730T>G,NC_000009.11:g.139399413A>G" ;
    dcterms:identifier "1143" ;
    a m2r:Variation .


civicv:1144
    rdfs:label "V1577E" ;
    civico:hgvs "ENST00000277541.6:c.4730T>A,NC_000009.11:g.139399413A>T" ;
    dcterms:identifier "1144" ;
    a m2r:Variation .


civicv:1145
    rdfs:label "L1574Q" ;
    civico:hgvs "ENST00000277541.6:c.4721T>A,NC_000009.11:g.139399422A>T" ;
    dcterms:identifier "1145" ;
    a m2r:Variation .


civicv:1151
    rdfs:label "H1047L" ;
    civico:hgvs "NM_006218.3:c.3140A>T,NP_006209.2:p.His1047Leu,NC_000003.11:g.178952085A>T,ENST00000263967.3:c.3140A>T" ;
    dcterms:identifier "1151" ;
    a m2r:Variation .


civicv:1152
    rdfs:label "BCR-ABL F486S" ;
    m2r:evidence civice:2829,civice:4571 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133755488 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133755488 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1152" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:1153
    rdfs:label "P292R" ;
    civico:hgvs "ENST00000278616.4:c.875C>G,NC_000011.9:g.108115727C>G" ;
    dcterms:identifier "1153" ;
    a m2r:Variation .


civicv:1154
    rdfs:label "M1FS" ;
    dcterms:identifier "1154" ;
    a m2r:Variation .


civicv:1155
    rdfs:label "K293*" ;
    civico:hgvs "ENST00000278616.4:c.877A>T,NM_000051.3:c.877A>T,NP_000042.3:p.Lys293Ter,NC_000011.9:g.108115729A>T" ;
    dcterms:identifier "1155" ;
    a m2r:Variation .


civicv:1156
    rdfs:label "R2459C" ;
    civico:hgvs "NC_000011.9:g.108201008C>T" ;
    dcterms:identifier "1156" ;
    a m2r:Variation .


civicv:1157
    rdfs:label "Q984E" ;
    civico:hgvs "ENST00000278616.4:c.2950C>G,NC_000011.9:g.108142006C>G" ;
    dcterms:identifier "1157" ;
    a m2r:Variation .


civicv:1158
    rdfs:label "F1025L" ;
    civico:hgvs "ENST00000278616.4:c.3075T>G,NC_000011.9:g.108142131T>G" ;
    dcterms:identifier "1158" ;
    a m2r:Variation .


civicv:1159
    rdfs:label "Q1084*" ;
    civico:hgvs "ENST00000278616.4:c.3250C>T,NC_000011.9:g.108143545C>T" ;
    dcterms:identifier "1159" ;
    a m2r:Variation .


civicv:1160
    rdfs:label "D1930V" ;
    civico:hgvs "ENST00000278616.4:c.5789A>T,NC_000011.9:g.108180913A>T" ;
    dcterms:identifier "1160" ;
    a m2r:Variation .


civicv:1161
    rdfs:label "R2034P" ;
    civico:hgvs "NC_000011.9:g.108186743G>C" ;
    dcterms:identifier "1161" ;
    a m2r:Variation .


civicv:1162
    rdfs:label "E2187*" ;
    civico:hgvs "ENST00000278616.4:c.6559G>T,NC_000011.9:g.108192134G>T" ;
    dcterms:identifier "1162" ;
    a m2r:Variation .


civicv:1163
    rdfs:label "L2427P" ;
    civico:hgvs "ENST00000278616.4:c.7280T>C,NC_000011.9:g.108199938T>C" ;
    dcterms:identifier "1163" ;
    a m2r:Variation .


civicv:1164
    rdfs:label "F2732V" ;
    civico:hgvs "ENST00000278616.4:c.8194T>G,NC_000011.9:g.108206614T>G,NM_000051.3:c.8194T>G,NP_000042.3:p.Phe2732Val" ;
    dcterms:identifier "1164" ;
    a m2r:Variation .


civicv:1165
    rdfs:label "R777FS" ;
    dcterms:identifier "1165" ;
    a m2r:Variation .


civicv:1166
    rdfs:label "K468FS" ;
    civico:hgvs "NM_000051.3:c.1402_1403delAA,NP_000042.3:p.Lys468Glufs,NC_000011.9:g.108121594_108121595delAA,ENST00000278616.4:c.1402_1403delAA,NC_000011.9:g.108121594_108121595del" ;
    dcterms:identifier "1166" ;
    a m2r:Variation .


civicv:1167
    rdfs:label "V1268FS" ;
    dcterms:identifier "1167" ;
    a m2r:Variation .


civicv:1168
    rdfs:label "D1682H" ;
    civico:hgvs "NM_000051.3:c.5044G>C,NP_000042.3:p.Asp1682His,NC_000011.9:g.108170479G>C,ENST00000278616.4:c.5044G>C" ;
    dcterms:identifier "1168" ;
    a m2r:Variation .


civicv:1169
    rdfs:label "A2062V" ;
    civico:hgvs "ENST00000278616.4:c.6185C>T,NC_000011.9:g.108186827C>T" ;
    dcterms:identifier "1169" ;
    a m2r:Variation .


civicv:1170
    rdfs:label "R1575H" ;
    civico:hgvs "NC_000011.9:g.108164152G>A" ;
    dcterms:identifier "1170" ;
    a m2r:Variation .


civicv:1171
    rdfs:label "A2274T" ;
    civico:hgvs "NM_000051.3:c.6820G>A,NP_000042.3:p.Ala2274Thr,NC_000011.9:g.108196797G>A,ENST00000278616.4:c.6820G>A" ;
    dcterms:identifier "1171" ;
    a m2r:Variation .


civicv:1172
    rdfs:label "C2488Y" ;
    civico:hgvs "NM_000051.3:c.7463G>A,NP_000042.3:p.Cys2488Tyr,NC_000011.9:g.108201096G>A,ENST00000278616.4:c.7463G>A" ;
    dcterms:identifier "1172" ;
    a m2r:Variation .


civicv:1173
    rdfs:label "BCR-ABL E255V" ;
    m2r:evidence civice:2850,civice:2851,civice:4443,civice:4447 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133738364 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133738364 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1173" ;
    a obo:missense_variant, m2r:Variation .


civicv:1174
    rdfs:label "F1592C" ;
    civico:hgvs "NM_017617.4:c.4775T>G,NP_060087.3:p.Phe1592Cys,NC_000009.11:g.139399368A>C,ENST00000277541.6:c.4775T>G" ;
    dcterms:identifier "1174" ;
    a m2r:Variation .


civicv:1175
    rdfs:label "G12V" ;
    dcterms:identifier "1175" ;
    a m2r:Variation .


civicv:1178
    rdfs:label "R93W" ;
    civico:hgvs "ENST00000263967.3:c.277C>T,NC_000003.11:g.178916890C>T,NM_006218.2:c.277C>T,NP_006209.2:p.Arg93Trp" ;
    dcterms:identifier "1178" ;
    a m2r:Variation .


civicv:1181
    rdfs:label "R776C" ;
    m2r:evidence civice:4468 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1181" ;
    a m2r:Variation .


civicv:1182
    rdfs:label "S784F" ;
    dcterms:identifier "1182" ;
    a m2r:Variation .


civicv:1183
    rdfs:label "E292V" ;
    m2r:evidence civice:2853 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133747568 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133747568 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1183" ;
    a obo:missense_variant, m2r:Variation .


civicv:1184
    rdfs:label "BCR-ABL F359C" ;
    m2r:evidence civice:2854,civice:4482,civice:6239 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748415 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748415 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1184" ;
    a obo:missense_variant, m2r:Variation .


civicv:1186
    rdfs:label "N581S" ;
    m2r:evidence civice:5967 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453193 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453193 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1186" ;
    a obo:missense_variant, m2r:Variation .


civicv:1187
    rdfs:label "A864T" ;
    m2r:evidence civice:4495 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55259532 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55259532 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1187" ;
    a obo:missense_variant, m2r:Variation .


civicv:1188
    rdfs:label "N826S" ;
    m2r:evidence civice:4496 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1188" ;
    a m2r:Variation .


civicv:1196
    rdfs:label "G466A" ;
    civico:hgvs "NM_004333.4:c.1397G>C,NP_004324.2:p.Gly466Ala,NC_000007.13:g.140481411C>G,ENST00000288602.6:c.1397G>C" ;
    dcterms:identifier "1196" ;
    a m2r:Variation .


civicv:1206
    rdfs:label "S501_A502INSAY" ;
    civico:hgvs "NC_000004.11:g.55592179_55592180insGCCTAT" ;
    dcterms:identifier "1206" ;
    a m2r:Variation .


civicv:1214
    rdfs:label "E746_T751delinsVA" ;
    civico:hgvs "NC_000007.13:g.55242467_55242483delinsTTGCT,NM_005228.3:c.2237_2253delinsTTGCT,NP_005219.2:p.Glu746_Thr751delinsValAla" ;
    dcterms:identifier "1214" ;
    a m2r:Variation .


civicv:1227
    rdfs:label "E17K" ;
    m2r:evidence civice:4521 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 243859016 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 243859016 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000366539.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "1227" ;
    a obo:missense_variant, m2r:Variation .


civicv:1230
    rdfs:label "L384M" ;
    m2r:evidence civice:2861,civice:4527 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133750319 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133750319 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1230" ;
    a obo:missense_variant, m2r:Variation .


civicv:1231
    rdfs:label "BCR-ABL V299L" ;
    m2r:evidence civice:2862,civice:4540,civice:6216,civice:6241,civice:6247 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133747588 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133747588 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1231" ;
    a obo:missense_variant, m2r:Variation .


civicv:1232
    rdfs:label "L387F" ;
    m2r:evidence civice:2863 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133750330 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133750330 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1232" ;
    a obo:missense_variant, m2r:Variation .


civicv:1233
    rdfs:label "BCR-ABL G398R" ;
    m2r:evidence civice:2864,civice:4561 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133750361 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133750361 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1233" ;
    a obo:transcript_fusion,obo:missense_variant, m2r:Variation .


civicv:1234
    rdfs:label "K111N" ;
    civico:hgvs "NM_006218.3:c.333G>C,NP_006209.2:p.Lys111Asn,NC_000003.11:g.178916946G>C,ENST00000263967.3:c.333G>C" ;
    dcterms:identifier "1234" ;
    a m2r:Variation .


civicv:1235
    rdfs:label "I391M" ;
    civico:hgvs "NM_006218.3:c.1173A>G,NP_006209.2:p.Ile391Met,NC_000003.11:g.178927410A>G,ENST00000263967.3:c.1173A>G" ;
    dcterms:identifier "1235" ;
    a m2r:Variation .


civicv:1236
    rdfs:label "M1V" ;
    m2r:evidence civice:2868 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41276113 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41276113 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000471181.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1236" ;
    a obo:start_lost, m2r:Variation .


civicv:1237
    rdfs:label "M1I" ;
    m2r:evidence civice:2869 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41276111 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41276111 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000471181.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1237" ;
    a obo:start_lost, m2r:Variation .


civicv:1238
    rdfs:label "C61G" ;
    m2r:evidence civice:2870 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41258504 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41258504 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000471181.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1238" ;
    a obo:missense_variant, m2r:Variation .


civicv:1239
    rdfs:label "C64Y" ;
    m2r:evidence civice:2871 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41258494 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41258494 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000471181.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1239" ;
    a obo:missense_variant, m2r:Variation .


civicv:1240
    rdfs:label "R71G" ;
    m2r:evidence civice:2872 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41258474 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41258474 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000471181.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1240" ;
    a obo:missense_variant, m2r:Variation .


civicv:1241
    rdfs:label "R71K" ;
    m2r:evidence civice:2873 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41258473 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41258473 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000471181.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1241" ;
    a obo:missense_variant, m2r:Variation .


civicv:1242
    rdfs:label "R1495M" ;
    m2r:evidence civice:2874 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41228505 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41228505 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000357654.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1242" ;
    a obo:missense_variant, m2r:Variation .


civicv:1243
    rdfs:label "E1559K" ;
    m2r:evidence civice:2875 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41226348 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41226348 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000357654.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1243" ;
    a obo:missense_variant, m2r:Variation .


civicv:1244
    rdfs:label "D1692N" ;
    m2r:evidence civice:2876 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41219625 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41219625 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000357654.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1244" ;
    a obo:missense_variant, m2r:Variation .


civicv:1245
    rdfs:label "R1443*" ;
    m2r:evidence civice:2877 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41234451 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41234451 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000471181.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1245" ;
    a obo:stop_gained, m2r:Variation .


civicv:1246
    rdfs:label "Q1467*" ;
    m2r:evidence civice:2878 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41228590 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41228590 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000357654.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1246" ;
    a obo:stop_gained, m2r:Variation .


civicv:1247
    rdfs:label "M1R" ;
    m2r:evidence civice:2879 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32890599 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32890599 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000544455.1" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1247" ;
    a obo:missense_variant, m2r:Variation .


civicv:1248
    rdfs:label "M1I" ;
    m2r:evidence civice:2880 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32890600 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32890600 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000544455.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1248" ;
    a obo:missense_variant, m2r:Variation .


civicv:1249
    rdfs:label "V159M" ;
    m2r:evidence civice:2881 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32900287 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32900287 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000544455.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1249" ;
    a obo:missense_variant, m2r:Variation .


civicv:1250
    rdfs:label "V211L" ;
    m2r:evidence civice:2882 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32900751 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32900751 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1250" ;
    a obo:missense_variant, m2r:Variation .


civicv:1251
    rdfs:label "V211I" ;
    m2r:evidence civice:2883 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32900751 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32900751 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1251" ;
    a obo:missense_variant, m2r:Variation .


civicv:1252
    rdfs:label "R2336P" ;
    m2r:evidence civice:2884 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32921033 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32921033 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000544455.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1252" ;
    a obo:missense_variant, m2r:Variation .


civicv:1253
    rdfs:label "R2336H" ;
    m2r:evidence civice:2885 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 32921033 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 32921033 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000544455.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1253" ;
    a obo:missense_variant, m2r:Variation .


civicv:1254
    rdfs:label "V143A" ;
    civico:hgvs "ENST00000269305.4:c.428T>C,NC_000017.10:g.7578502A>G" ;
    dcterms:identifier "1254" ;
    a m2r:Variation .


civicv:1255
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:2899,civice:2901,civice:2902,civice:2903,civice:2904 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 131265448 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 131566271 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000306010.7" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:GlioblastomaMultiforme,civic:MalignantGlioma,civic:Oligodendroglioma,civic:NeuroendocrineTumor ;
    dcterms:identifier "1255" ;
    a m2r:Variation .


civicv:1256
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "1256" ;
    a m2r:Variation .


civicv:1257
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:2905,civice:5506,civice:5508,civice:5530,civice:5599 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 4116039 ;
            faldo:reference hco:11#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 4160106 ;
            faldo:reference hco:11#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000300738.5" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:PancreaticCancer ;
    dcterms:identifier "1257" ;
    a m2r:Variation .


civicv:1258
    rdfs:label "EXPRESSION" ;
    dcterms:identifier "1258" ;
    a m2r:Variation .


civicv:1259
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "1259" ;
    a m2r:Variation .


civicv:1260
    rdfs:label "C609Y" ;
    m2r:evidence civice:2913 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 43609070 ;
            faldo:reference hco:10#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 43609070 ;
            faldo:reference hco:10#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000355710.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    dcterms:description "There is some functional evidence that this variant leads to reduced RET activity (PMID: 9230192) and increased cell proliferation and resistance to apoptosis (PMID: 16715139). It has been widely reported in both familial and sporadic cases of multiple endocrine neoplasia type 2 with medullary thyroid cancers. Despite extensive WGS and Exome coverage for a combined total of ~150k alleles in the GNOMAD browser, this variant has never been observed." ;
    m2r:disease civic:ThyroidMedullaryCarcinoma ;
    dcterms:identifier "1260" ;
    a obo:missense_variant, m2r:Variation .


civicv:1261
    rdfs:label "AMPLIFICATION" ;
    dcterms:identifier "1261" ;
    a m2r:Variation .


civicv:1262
    rdfs:label "EXPRESSION" ;
    dcterms:identifier "1262" ;
    a m2r:Variation .


civicv:1263
    rdfs:label "N822K" ;
    m2r:evidence civice:2918 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55599340 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55599340 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "1263" ;
    a obo:missense_variant, m2r:Variation .


civicv:1264
    rdfs:label "C809G" ;
    m2r:evidence civice:2920 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55599299 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55599299 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "1264" ;
    a obo:missense_variant, m2r:Variation .


civicv:1265
    rdfs:label "D820A" ;
    m2r:evidence civice:2921 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55599333 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55599333 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "1265" ;
    a obo:missense_variant, m2r:Variation .


civicv:1266
    rdfs:label "D820G" ;
    m2r:evidence civice:2922 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55599333 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55599333 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "1266" ;
    a obo:missense_variant, m2r:Variation .


civicv:1267
    rdfs:label "T670I" ;
    m2r:evidence civice:2924 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55595519 ;
            faldo:reference hco:4#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55595519 ;
            faldo:reference hco:4#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288135.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:GastrointestinalStromalTumor ;
    dcterms:identifier "1267" ;
    a obo:missense_variant, m2r:Variation .


civicv:1268
    rdfs:label "AMPLIFICATION" ;
    dcterms:identifier "1268" ;
    a m2r:Variation .


civicv:1269
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:2929 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140434279 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140624564 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "1269" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:1270
    rdfs:label "F53L" ;
    civico:hgvs "NM_002755.3:c.157T>C,NP_002746.1:p.Phe53Leu,NC_000015.9:g.66727441T>C,ENST00000307102.5:c.157T>C" ;
    dcterms:identifier "1270" ;
    a m2r:Variation .


civicv:1271
    rdfs:label "G2032R" ;
    m2r:evidence civice:2934 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 117638347 ;
            faldo:reference hco:6#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 117638347 ;
            faldo:reference hco:6#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000368508.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "1271" ;
    a obo:missense_variant, m2r:Variation .


civicv:1272
    rdfs:label "K57N" ;
    m2r:evidence civice:2935,civice:2936 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 66727455 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 66727455 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000307102.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "1272" ;
    a obo:missense_variant, m2r:Variation .


civicv:1273
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "1273" ;
    a m2r:Variation .


civicv:1274
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "1274" ;
    a m2r:Variation .


civicv:1275
    rdfs:label "L1198F" ;
    civico:hgvs "ENST00000389048.3:c.3592C>T,NC_000002.11:g.29443625G>A" ;
    dcterms:identifier "1275" ;
    a m2r:Variation .


civicv:1276
    rdfs:label "AMPLIFICATION" ;
    dcterms:identifier "1276" ;
    a m2r:Variation .


civicv:1277
    rdfs:label "NTRK3 FUSIONS" ;
    m2r:evidence civice:2949,civice:6568 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1277" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:1278                 # so:gene_fusion
    rdfs:label "LMNA-NTRK1" ;
    m2r:evidence civice:2955,civice:2960,civice:6100 ;
    sio:SIO_000974 civic:1_5partner1278, civic:1_3partner1278 ;    # sio:has-ordered-part
    civico:referenceBuild "GRCh37" ;
    rdfs:seeAlso ensembl:ENST00000368300.4 ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    civico:variantID "1278" ;
    m2r:disease civic:Sarcoma,civic:ColorectalAdenocarcinoma ;
    civico:variantGroups "NTRK1 Fusions" ;   
    a obo:transcript_fusion, m2r:Variation .

civic:1_5partner1278                              
    sio:SIO_000300 "1" ; 
    faldo:location [
      a faldo:Region ;
        faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "156084498" ;
                      faldo:reference hco:1#GRCh37 
                      ] ;
        faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                      faldo:position "156108548" ;
                      faldo:reference hco:1#GRCh37
        ]
     ] .


civic:1_3partner1278 
    sio:SIO_000300 "2" ;                             
     faldo:location [
       a faldo:Region ;
         faldo:begin [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 156844363 ;
                       faldo:reference hco:1#GRCh37
                       ] ;
         faldo:end   [ a faldo:ExactPosition, faldo:ForwardStrandPosition ;
                       faldo:position 156851434 ;
                       faldo:reference hco:1#GRCh37
        ]
     ] .


civicv:1279
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "1279" ;
    a m2r:Variation .


civicv:1280
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:2958 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 156830686 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 156851434 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000524377.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1280" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:1281
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:2959 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 88418230 ;
            faldo:reference hco:15#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 88799978 ;
            faldo:reference hco:15#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000394480.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1281" ;
    a obo:transcript_amplification, m2r:Variation .


civicv:1282
    rdfs:label "LMNA-NTRK1 G595R AND G667C" ;
    m2r:evidence civice:2961 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 156846342 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 156849107 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000524377.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalAdenocarcinoma ;
    dcterms:identifier "1282" ;
    a obo:missense_variant, m2r:Variation .


civicv:1283
    rdfs:label "CYTOPLASMIC EXPRESSION" ;
    dcterms:identifier "1283" ;
    a m2r:Variation .


civicv:1284
    rdfs:label "EXPRESSION" ;
    m2r:evidence civice:2972 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "1284" ;
    a m2r:Variation .


civicv:1285
    rdfs:label "T41A" ;
    m2r:evidence civice:2973,civice:3044,civice:5070 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41266124 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41266124 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000349496.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:DesmoidFibromatosis ;
    dcterms:identifier "1285" ;
    a obo:missense_variant, m2r:Variation .


civicv:1286
    rdfs:label "S45F" ;
    m2r:evidence civice:2974,civice:2976,civice:5071,civice:6049 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41266137 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41266137 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000349496.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:DesmoidFibromatosis ;
    dcterms:identifier "1286" ;
    a obo:missense_variant, m2r:Variation .


civicv:1287
    rdfs:label "S45P" ;
    m2r:evidence civice:2975,civice:3043,civice:5072 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41266136 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41266136 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000349496.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:DesmoidFibromatosis ;
    dcterms:identifier "1287" ;
    a obo:missense_variant, m2r:Variation .


civicv:1288
    rdfs:label "M511I" ;
    civico:hgvs "ENST00000458235.1:c.1533G>A,NM_000215.3:c.1533G>A,NP_000206.2:p.Met511Ile,NC_000019.9:g.17949108C>T" ;
    dcterms:identifier "1288" ;
    a m2r:Variation .


civicv:1289
    rdfs:label "V722I" ;
    civico:hgvs "NM_000215.3:c.2164G>A,NP_000206.2:p.Val722Ile,NC_000019.9:g.17945696C>T,ENST00000458235.1:c.2164G>A" ;
    dcterms:identifier "1289" ;
    a m2r:Variation .


civicv:1290
    rdfs:label "S61C" ;
    civico:hgvs "ENST00000458235.1:c.181A>T,NC_000019.9:g.17955046T>A,NM_000215.3:c.181A>T,NP_000206.2:p.Ser61Cys" ;
    dcterms:identifier "1290" ;
    a m2r:Variation .


civicv:1291
    rdfs:label "P429S" ;
    civico:hgvs "ENST00000342505.4:c.1285C>T,NC_000001.10:g.65325837G>A" ;
    dcterms:identifier "1291" ;
    a m2r:Variation .


civicv:1292
    rdfs:label "W690*" ;
    dcterms:identifier "1292" ;
    a m2r:Variation .


civicv:1293
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:2982,civice:2983 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianClearCellCarcinoma ;
    dcterms:identifier "1293" ;
    a m2r:Variation .


civicv:1294
    rdfs:label "W8* (c.24G>A)" ;
    civico:hgvs "NM_000551.3:c.24G>A,ENST00000256474.2:c.24G>A,NC_000003.11:g.10183555G>A,NP_000542.1:p.Trp8Ter" ;
    dcterms:identifier "1294" ;
    a m2r:Variation .


civicv:1295
    rdfs:label "F1245V" ;
    civico:hgvs "NM_004304.4:c.3733T>G,NP_004295.2:p.Phe1245Val,NC_000002.11:g.29436860A>C,ENST00000389048.3:c.3733T>G" ;
    dcterms:identifier "1295" ;
    a m2r:Variation .


civicv:1296
    rdfs:label "ACTIVATING MUTATION" ;
    m2r:evidence civice:2988 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41240930 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41281936 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000349496.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "1296" ;
    a obo:gain_of_function_variant,obo:transcript_variant, m2r:Variation .


civicv:1298
    rdfs:label "599INST" ;
    dcterms:identifier "1298" ;
    a m2r:Variation .


civicv:1299
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:2991 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 112656056 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 112787138 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000295408.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "1299" ;
    a m2r:Variation .


civicv:1300
    rdfs:label "CONSERVED DOMAIN MUT" ;
    m2r:evidence civice:2993 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7577062 ;
            faldo:reference hco:17#
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7579398 ;
            faldo:reference hco:17#
        ]
    ] ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "This conserved domain mutation variant covers mutations in regions of p53 reported to be highly conserved during evolution. These regions span codons 117-143 (region II), 171-181 (region III), 234-258 (region (IV), and 270-286 (region V). Region I covers approximately codons 10 through 25 but does not appear in all studies on conserved domain mutations. There is overlap with these regions and reported regions of hotspot p53 mutations, where it is observed that hotspots for detrimental mutation correspond to more highly evolutionary conserved regions. While there is agreement and overlap between different reports, the literature does not seem to indicate an exact consensus on these regions of human p53 at this time, but the four highly conserved regions are part of the DNA binding domain, and are reported to exist within codons 97 to 292." ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1300" ;
    a m2r:Variation .


civicv:1301
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:1922,civice:1923,civice:6261 ;
    m2r:disease civic:BreastCancer,civic:Triple-receptorNegativeBreastCancer,civic:Melanoma ;
    dcterms:identifier "1301" ;
    a m2r:Variation .


civicv:1302
    rdfs:label "D835V" ;
    m2r:evidence civice:3007,civice:3008,civice:3009,civice:3010,civice:3012,civice:3034,civice:4022 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 28592641 ;
            faldo:reference hco:13#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 28592641 ;
            faldo:reference hco:13#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000241453.7" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AcuteMyeloidLeukemia ;
    dcterms:identifier "1302" ;
    a obo:missense_variant, m2r:Variation .


civicv:1303
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:3003,civice:5505 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungSmallCellCarcinoma,civic:MultipleMyeloma ;
    dcterms:identifier "1303" ;
    a m2r:Variation .


civicv:1304
    rdfs:label "L755P" ;
    civico:hgvs "NP_004439.2:p.Leu755Pro,NM_004448.3:c.2263_2264delinsCC,NC_000017.13:g.37880219_37880220delinsCC" ;
    dcterms:identifier "1304" ;
    a m2r:Variation .


civicv:1305
    rdfs:label "T798M" ;
    civico:hgvs "ENST00000269571.5:c.2393_2394delCAinsTG,NC_000017.10:g.37881064_37881065delinsTG" ;
    dcterms:identifier "1305" ;
    a m2r:Variation .


civicv:1306
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:2697,civice:2799,civice:3013 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 7571720 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 7590856 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000269305.4" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer,civic:StomachCancer ;
    dcterms:identifier "1306" ;
    a m2r:Variation .


civicv:1307
    rdfs:label "ALTERATION" ;
    m2r:evidence civice:2771,civice:3014 ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "P53 ALTERATION is a bucket type variant used in studies which is constructed by combining all cases of p53 mutation together with p53 overexpression. This includes cases which have p53 mutation or overexpression alone or as well as cases where both occur in combination." ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1307" ;
    a m2r:Variation .


civicv:1308
    rdfs:label "L768S" ;
    civico:hgvs "ENST00000269571.5:c.2303T>C" ;
    dcterms:identifier "1308" ;
    a m2r:Variation .


civicv:1309
    rdfs:label "L638S" ;
    dcterms:identifier "1309" ;
    a m2r:Variation .


civicv:1310
    rdfs:label "V773" ;
    dcterms:identifier "1310" ;
    a m2r:Variation .


civicv:1311
    rdfs:label "V773L" ;
    dcterms:identifier "1311" ;
    a m2r:Variation .


civicv:1312
    rdfs:label "K753E" ;
    civico:hgvs "ENST00000269571.5:c.2257A>G" ;
    dcterms:identifier "1312" ;
    a m2r:Variation .


civicv:1313
    rdfs:label "L753E" ;
    dcterms:identifier "1313" ;
    a m2r:Variation .


civicv:1314
    rdfs:label "K755S" ;
    dcterms:identifier "1314" ;
    a m2r:Variation .


civicv:1316
    rdfs:label "V559" ;
    dcterms:identifier "1316" ;
    a m2r:Variation .


civicv:1317
    rdfs:label "G13V" ;
    dcterms:identifier "1317" ;
    a m2r:Variation .


civicv:1318
    rdfs:label "L3 Domain Mutation" ;
    dcterms:identifier "1318" ;
    a m2r:Variation .


civicv:1319
    rdfs:label "R201H" ;
    m2r:evidence civice:3045 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:FollicularThyroidCarcinoma ;
    dcterms:identifier "1319" ;
    a m2r:Variation .


civicv:1320
    rdfs:label "NON-AMPLIFICATION" ;
    dcterms:identifier "1320" ;
    a m2r:Variation .


civicv:1387
    rdfs:label "G12D" ;
    dcterms:identifier "1387" ;
    a m2r:Variation .


civicv:1390
    rdfs:label "E884K" ;
    dcterms:identifier "1390" ;
    a m2r:Variation .


civicv:1391
    rdfs:label "Q61R" ;
    dcterms:identifier "1391" ;
    a m2r:Variation .


civicv:1392
    rdfs:label "Q61K" ;
    dcterms:identifier "1392" ;
    a m2r:Variation .


civicv:1393
    rdfs:label "G13R" ;
    dcterms:identifier "1393" ;
    a m2r:Variation .


civicv:1394
    rdfs:label "G12V" ;
    dcterms:identifier "1394" ;
    a m2r:Variation .


civicv:1395
    rdfs:label "G13R" ;
    civico:hgvs "NM_004985.4:c.37G>C,NP_004976.2:p.Gly13Arg,NC_000012.11:g.25398282C>G,ENST00000256078.4:c.37G>C" ;
    dcterms:identifier "1395" ;
    a m2r:Variation .


civicv:1396
    rdfs:label "G13S" ;
    civico:hgvs "NM_004985.4:c.37G>A,NP_004976.2:p.Gly13Ser,NC_000012.11:g.25398282C>T,ENST00000256078.4:c.37G>A" ;
    dcterms:identifier "1396" ;
    a m2r:Variation .


civicv:1397
    rdfs:label "D835E" ;
    dcterms:identifier "1397" ;
    a m2r:Variation .


civicv:1398
    rdfs:label "F57C" ;
    dcterms:identifier "1398" ;
    a m2r:Variation .


civicv:1400
    rdfs:label "K650E" ;
    dcterms:identifier "1400" ;
    a m2r:Variation .


civicv:1402
    rdfs:label "D816G" ;
    dcterms:identifier "1402" ;
    a m2r:Variation .


civicv:1413
    rdfs:label "E709Q" ;
    dcterms:identifier "1413" ;
    a m2r:Variation .


civicv:1420
    rdfs:label "G719D" ;
    m2r:evidence civice:4210 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1420" ;
    a m2r:Variation .


civicv:1433
    rdfs:label "E746_S752>A" ;
    dcterms:identifier "1433" ;
    a m2r:Variation .


civicv:1443
    rdfs:label "S768N" ;
    dcterms:identifier "1443" ;
    a m2r:Variation .


civicv:1445
    rdfs:label "D770_N771insSVD" ;
    m2r:evidence civice:4275 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55249013 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249014 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:alternative_allele "GCGTGGACA" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1445" ;
    a m2r:Variation .


civicv:1446
    rdfs:label "H773_V774insH" ;
    m2r:evidence civice:4276 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1446" ;
    a m2r:Variation .


civicv:1457
    rdfs:label "L838P" ;
    m2r:evidence civice:4252 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1457" ;
    a m2r:Variation .


civicv:1463
    rdfs:label "T847I" ;
    m2r:evidence civice:4260 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1463" ;
    a m2r:Variation .


civicv:1465
    rdfs:label "P848L" ;
    dcterms:identifier "1465" ;
    a m2r:Variation .


civicv:1466
    rdfs:label "V851I" ;
    m2r:evidence civice:4264 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1466" ;
    a m2r:Variation .


civicv:1467
    rdfs:label "T854A" ;
    dcterms:identifier "1467" ;
    a m2r:Variation .


civicv:1474
    rdfs:label "A859T" ;
    civico:hgvs "ENST00000275493.2:c.2575G>A" ;
    dcterms:identifier "1474" ;
    a m2r:Variation .


civicv:1477
    rdfs:label "L861R" ;
    m2r:evidence civice:4669 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1477" ;
    a m2r:Variation .


civicv:1482
    rdfs:label "E868G" ;
    m2r:evidence civice:4301 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantMesothelioma ;
    dcterms:identifier "1482" ;
    a m2r:Variation .


civicv:1487
    rdfs:label "BCR-ABL E355G" ;
    m2r:evidence civice:4400,civice:4403,civice:6255 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748403 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748403 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1487" ;
    a obo:missense_variant, m2r:Variation .


civicv:1488
    rdfs:label "BCR-ABL L387M" ;
    m2r:evidence civice:4406 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133750328 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133750328 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1488" ;
    a obo:missense_variant, m2r:Variation .


civicv:1489
    rdfs:label "G13V" ;
    dcterms:identifier "1489" ;
    a m2r:Variation .


civicv:1491
    rdfs:label "A59T" ;
    civico:hgvs "NM_004985.4:c.175G>A,NP_004976.2:p.Ala59Thr,NC_000012.11:g.25380283C>T,ENST00000256078.4:c.175G>A" ;
    dcterms:identifier "1491" ;
    a m2r:Variation .


civicv:1492
    rdfs:label "F1174C" ;
    civico:hgvs "ENST00000389048.3:c.3521T>G" ;
    dcterms:identifier "1492" ;
    a m2r:Variation .


civicv:1493
    rdfs:label "T1151M" ;
    civico:hgvs "NM_004304.4:c.3452C>T,NP_004295.2:p.Thr1151Met,NC_000002.11:g.29445273G>A,ENST00000389048.3:c.3452C>T" ;
    dcterms:identifier "1493" ;
    a m2r:Variation .


civicv:1494
    rdfs:label "T277A" ;
    civico:hgvs "ENST00000318560.5:c.829A>G" ;
    dcterms:identifier "1494" ;
    a m2r:Variation .


civicv:1495
    rdfs:label "S438C" ;
    civico:hgvs "ENST00000318560.5:c.1313C>G" ;
    dcterms:identifier "1495" ;
    a m2r:Variation .


civicv:1496
    rdfs:label "E450G" ;
    civico:hgvs "ENST00000318560.5:c.1349A>G,NC_000009.11:g.133753880A>G,NM_005157.5:c.1349A>G,NP_005148.2:p.Glu450Gly" ;
    dcterms:identifier "1496" ;
    a m2r:Variation .


civicv:1497
    rdfs:label "P551_E554DELPMYE" ;
    dcterms:identifier "1497" ;
    a m2r:Variation .


civicv:1498
    rdfs:label "W557_V559INSC" ;
    dcterms:identifier "1498" ;
    a m2r:Variation .


civicv:1499
    rdfs:label "S158L" ;
    civico:hgvs "ENST00000263967.3:c.473C>T,NC_000003.11:g.178917598C>T,NM_006218.2:c.473C>T,NP_006209.2:p.Ser158Leu" ;
    dcterms:identifier "1499" ;
    a m2r:Variation .


civicv:1500
    rdfs:label "E81K" ;
    civico:hgvs "NM_006218.3:c.241G>A,NP_006209.2:p.Glu81Lys,NC_000003.11:g.178916854G>A,ENST00000263967.3:c.241G>A" ;
    dcterms:identifier "1500" ;
    a m2r:Variation .


civicv:1503
    rdfs:label "R505C" ;
    civico:hgvs "NM_033632.3:c.1513C>T,NP_361014.1:p.Arg505Cys,NC_000004.11:g.153247289G>A,ENST00000281708.4:c.1513C>T" ;
    dcterms:identifier "1503" ;
    a m2r:Variation .


civicv:1504
    rdfs:label "R505H" ;
    dcterms:identifier "1504" ;
    a m2r:Variation .


civicv:1505
    rdfs:label "F1174V" ;
    civico:hgvs "ENST00000389048.3:c.3520T>G" ;
    dcterms:identifier "1505" ;
    a m2r:Variation .


civicv:1506
    rdfs:label "L298V" ;
    m2r:evidence civice:4475 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133747585 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133747585 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1506" ;
    a obo:missense_variant, m2r:Variation .


civicv:1507
    rdfs:label "BCR-ABL F311I" ;
    m2r:evidence civice:4478 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748270 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748270 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1507" ;
    a obo:missense_variant, m2r:Variation .


civicv:1508
    rdfs:label "L364I" ;
    civico:hgvs "ENST00000318560.5:c.1090C>A" ;
    dcterms:identifier "1508" ;
    a m2r:Variation .


civicv:1509
    rdfs:label "BCR-ABL E453Q" ;
    m2r:evidence civice:4486 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133753888 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133753888 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1509" ;
    a obo:missense_variant, m2r:Variation .


civicv:1510
    rdfs:label "Q456X" ;
    m2r:evidence civice:4487 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianClearCellCarcinoma ;
    dcterms:identifier "1510" ;
    a m2r:Variation .


civicv:1511
    rdfs:label "S768_D770dup" ;
    dcterms:identifier "1511" ;
    a m2r:Variation .


civicv:1513
    rdfs:label "H773_V774insNPH" ;
    m2r:evidence civice:4493 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55249012 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249013 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:alternative_allele "AACCCCCAC" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "1513" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:1514
    rdfs:label "D770_N771insGL" ;
    m2r:evidence civice:4494 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55249012 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249013 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:alternative_allele "GGGTTA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "1514" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:1515
    rdfs:label "A763_Y764insFQEA" ;
    m2r:evidence civice:4497 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55248992 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55248993 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:alternative_allele "TCCAGGAAGCCT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1515" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:1517
    rdfs:label "G13V" ;
    civico:hgvs "NC_000012.11:g.25398280_25398281delinsAA,ENST00000256078.4:c.38_39delinsTT,NM_004985.4:c.38_39delinsTT,NP_004976.2:p.Gly13Val" ;
    dcterms:identifier "1517" ;
    a m2r:Variation .


civicv:1518
    rdfs:label "DIM842_844DEL" ;
    dcterms:identifier "1518" ;
    a m2r:Variation .


civicv:1520
    rdfs:label "Q2223K" ;
    dcterms:identifier "1520" ;
    a m2r:Variation .


civicv:1521
    rdfs:label "W110*" ;
    civico:hgvs "NP_000068.1:p.Trp110Ter,NC_000009.11:g.21971028C>T,NM_000077.4:c.330G>A,ENST00000498124.1:c.330G>A" ;
    dcterms:identifier "1521" ;
    a m2r:Variation .


civicv:1522
    rdfs:label "A20P" ;
    civico:hgvs "ENST00000498124.1:c.58G>C" ;
    dcterms:identifier "1522" ;
    a m2r:Variation .


civicv:1523
    rdfs:label "BCR-ABL F359I" ;
    m2r:evidence civice:4530,civice:4532 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748414 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748414 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1523" ;
    a obo:missense_variant, m2r:Variation .


civicv:1524
    rdfs:label "M343T" ;
    civico:hgvs "ENST00000318560.5:c.1028T>C,NC_000009.11:g.133748367T>C,NM_005157.5:c.1028T>C,NP_005148.2:p.Met343Thr" ;
    dcterms:identifier "1524" ;
    a m2r:Variation .


civicv:1525
    rdfs:label "BCR-ABL F317V" ;
    m2r:evidence civice:6208,civice:6253 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748288 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748288 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1525" ;
    a obo:missense_variant, m2r:Variation .


civicv:1526
    rdfs:label "E279K" ;
    m2r:evidence civice:4543 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133747528 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133747528 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1526" ;
    a obo:missense_variant, m2r:Variation .


civicv:1527
    rdfs:label "Q300R" ;
    civico:hgvs "ENST00000318560.5:c.899A>G" ;
    dcterms:identifier "1527" ;
    a m2r:Variation .


civicv:1528
    rdfs:label "BCR-ABL F311L" ;
    m2r:evidence civice:4546,civice:6238 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748270 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748270 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1528" ;
    a obo:missense_variant, m2r:Variation .


civicv:1529
    rdfs:label "BCR-ABL N331S" ;
    m2r:evidence civice:4549 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748331 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748331 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1529" ;
    a obo:missense_variant, m2r:Variation .


civicv:1530
    rdfs:label "BCR-ABL L364P" ;
    m2r:evidence civice:4551 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133750260 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133750260 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1530" ;
    a obo:missense_variant, m2r:Variation .


civicv:1531
    rdfs:label "BCR-ABL H396P" ;
    m2r:evidence civice:4554,civice:6240 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133750356 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133750356 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1531" ;
    a obo:missense_variant, m2r:Variation .


civicv:1532
    rdfs:label "D421G" ;
    m2r:evidence civice:4559 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133750431 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133750431 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1532" ;
    a obo:missense_variant, m2r:Variation .


civicv:1533
    rdfs:label "I432T" ;
    civico:hgvs "ENST00000318560.5:c.1295T>C" ;
    dcterms:identifier "1533" ;
    a m2r:Variation .


civicv:1534
    rdfs:label "BCR-ABL E450V" ;
    m2r:evidence civice:4563 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133753880 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133753880 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1534" ;
    a obo:missense_variant, m2r:Variation .


civicv:1535
    rdfs:label "BCR-ABL E453K" ;
    m2r:evidence civice:4565 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133753888 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133753888 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1535" ;
    a obo:missense_variant, m2r:Variation .


civicv:1536
    rdfs:label "E453A" ;
    civico:hgvs "ENST00000318560.5:c.1358A>C,NC_000009.11:g.133753889A>C,NM_005157.5:c.1358A>C,NP_005148.2:p.Glu453Ala" ;
    dcterms:identifier "1536" ;
    a m2r:Variation .


civicv:1537
    rdfs:label "BCR-ABL P480A" ;
    m2r:evidence civice:4568 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133755469 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133755469 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1537" ;
    a obo:missense_variant, m2r:Variation .


civicv:1538
    rdfs:label "F486Y" ;
    civico:hgvs "ENST00000318560.5:c.1457T>A,NC_000009.11:g.133755488T>A,NM_005157.5:c.1457T>A,NP_005148.2:p.Phe486Tyr" ;
    dcterms:identifier "1538" ;
    a m2r:Variation .


civicv:1539
    rdfs:label "W559_R560DELWR" ;
    dcterms:identifier "1539" ;
    a m2r:Variation .


civicv:1540
    rdfs:label "L579M" ;
    civico:hgvs "ENST00000257290.5:c.2455C>A" ;
    dcterms:identifier "1540" ;
    a m2r:Variation .


civicv:1541
    rdfs:label "Q556_I571DEL" ;
    dcterms:identifier "1541" ;
    a m2r:Variation .


civicv:1542
    rdfs:label "Y553_W557DELYEVQW" ;
    dcterms:identifier "1542" ;
    a m2r:Variation .


civicv:1543
    rdfs:label "V555_I571DEL" ;
    dcterms:identifier "1543" ;
    a m2r:Variation .


civicv:1544
    rdfs:label "E611_F612INS25" ;
    dcterms:identifier "1544" ;
    a m2r:Variation .


civicv:1545
    rdfs:label "K550_W557DELKPMYEVQW" ;
    dcterms:identifier "1545" ;
    a m2r:Variation .


civicv:1546
    rdfs:label "T417_D419DELTYDINSI" ;
    dcterms:identifier "1546" ;
    a m2r:Variation .


civicv:1547
    rdfs:label "D579_H580INSIDPTQLPYD" ;
    dcterms:identifier "1547" ;
    a m2r:Variation .


civicv:1548
    rdfs:label "Y570_L576DEL" ;
    dcterms:identifier "1548" ;
    a m2r:Variation .


civicv:1549
    rdfs:label "K558NP" ;
    dcterms:identifier "1549" ;
    a m2r:Variation .


civicv:1550
    rdfs:label "V560_L576DEL" ;
    dcterms:identifier "1550" ;
    a m2r:Variation .


civicv:1551
    rdfs:label "V569_L576DEL" ;
    dcterms:identifier "1551" ;
    a m2r:Variation .


civicv:1552
    rdfs:label "E278E" ;
    civico:hgvs "ENST00000544786.1:c.834G>A" ;
    dcterms:identifier "1552" ;
    a m2r:Variation .


civicv:1553
    rdfs:label "L1196Q" ;
    civico:hgvs "ENST00000389048.3:c.3587T>A" ;
    dcterms:identifier "1553" ;
    a m2r:Variation .


civicv:1554
    rdfs:label "L1152P" ;
    civico:hgvs "ENST00000389048.3:c.3455T>C" ;
    dcterms:identifier "1554" ;
    a m2r:Variation .


civicv:1555
    rdfs:label "W1815X" ;
    m2r:evidence civice:4623 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 41199682 ;
            faldo:reference hco:17#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 41199682 ;
            faldo:reference hco:17#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianCancer ;
    dcterms:identifier "1555" ;
    a obo:stop_gained, m2r:Variation .


civicv:1556
    rdfs:label "L1198P" ;
    civico:hgvs "ENST00000389048.3:c.3593T>C" ;
    dcterms:identifier "1556" ;
    a m2r:Variation .


civicv:1557
    rdfs:label "ERBB2 G776INSV_G/C" ;
    dcterms:identifier "1557" ;
    a m2r:Variation .


civicv:1558
    rdfs:label "A502_Y503INSAY" ;
    dcterms:identifier "1558" ;
    a m2r:Variation .


civicv:1559
    rdfs:label "D816E" ;
    dcterms:identifier "1559" ;
    a m2r:Variation .


civicv:1560
    rdfs:label "D473G" ;
    dcterms:identifier "1560" ;
    a m2r:Variation .


civicv:1561
    rdfs:label "D473Y" ;
    dcterms:identifier "1561" ;
    a m2r:Variation .


civicv:1562
    rdfs:label "S278I" ;
    dcterms:identifier "1562" ;
    a m2r:Variation .


civicv:1563
    rdfs:label "W281C" ;
    dcterms:identifier "1563" ;
    a m2r:Variation .


civicv:1564
    rdfs:label "Q477E" ;
    dcterms:identifier "1564" ;
    a m2r:Variation .


civicv:1566
    rdfs:label "D770_N771insGT" ;
    m2r:evidence civice:4643 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55249012 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249013 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:alternative_allele "GGCACA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "1566" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:1567
    rdfs:label "V774_C775insHV" ;
    dcterms:identifier "1567" ;
    a m2r:Variation .


civicv:1569
    rdfs:label "D770_N771insNPG" ;
    dcterms:identifier "1569" ;
    a m2r:Variation .


civicv:1570
    rdfs:label "L412F" ;
    m2r:evidence civice:4653,civice:4654 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 128846398 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 128846398 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000249373.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BasalCellCarcinoma ;
    dcterms:identifier "1570" ;
    a obo:missense_variant, m2r:Variation .


civicv:1571
    rdfs:label "W731L" ;
    m2r:evidence civice:4655 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantMesothelioma ;
    dcterms:identifier "1571" ;
    a m2r:Variation .


civicv:1572
    rdfs:label "E734Q" ;
    m2r:evidence civice:4656 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantMesothelioma ;
    dcterms:identifier "1572" ;
    a obo:missense_variant, m2r:Variation .


civicv:1573
    rdfs:label "T785A" ;
    m2r:evidence civice:4657 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantMesothelioma ;
    dcterms:identifier "1573" ;
    a m2r:Variation .


civicv:1574
    rdfs:label "C797Y" ;
    m2r:evidence civice:4658 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55249092 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249092 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantMesothelioma ;
    dcterms:identifier "1574" ;
    a obo:missense_variant, m2r:Variation .


civicv:1575
    rdfs:label "Y801H" ;
    m2r:evidence civice:4659 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantMesothelioma ;
    dcterms:identifier "1575" ;
    a m2r:Variation .


civicv:1576
    rdfs:label "V321M" ;
    dcterms:identifier "1576" ;
    a m2r:Variation .


civicv:1577
    rdfs:label "E709_T710>D" ;
    dcterms:identifier "1577" ;
    a m2r:Variation .


civicv:1578
    rdfs:label "V769A" ;
    dcterms:identifier "1578" ;
    a m2r:Variation .


civicv:1579
    rdfs:label "A767_V769dupASV" ;
    m2r:evidence civice:4665 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55249000 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249001 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:alternative_allele "GCCAGCGTG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "1579" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:1580
    rdfs:label "L747_S752INSQ" ;
    dcterms:identifier "1580" ;
    a m2r:Variation .


civicv:1581
    rdfs:label "N771>GY" ;
    dcterms:identifier "1581" ;
    a m2r:Variation .


civicv:1582
    rdfs:label "P546S" ;
    dcterms:identifier "1582" ;
    a m2r:Variation .


civicv:1583
    rdfs:label "W281L" ;
    dcterms:identifier "1583" ;
    a m2r:Variation .


civicv:1584
    rdfs:label "G497W" ;
    dcterms:identifier "1584" ;
    a m2r:Variation .


civicv:1585
    rdfs:label "I408V" ;
    dcterms:identifier "1585" ;
    a m2r:Variation .


civicv:1586
    rdfs:label "C469Y" ;
    dcterms:identifier "1586" ;
    a m2r:Variation .


civicv:1587
    rdfs:label "T241M" ;
    dcterms:identifier "1587" ;
    a m2r:Variation .


civicv:1588
    rdfs:label "A459V" ;
    dcterms:identifier "1588" ;
    a m2r:Variation .


civicv:1589
    rdfs:label "S533N" ;
    dcterms:identifier "1589" ;
    a m2r:Variation .


civicv:1590
    rdfs:label "W170X" ;
    dcterms:identifier "1590" ;
    a m2r:Variation .


civicv:1591
    rdfs:label "W712X" ;
    dcterms:identifier "1591" ;
    a m2r:Variation .


civicv:1592
    rdfs:label "Q787X" ;
    dcterms:identifier "1592" ;
    a m2r:Variation .


civicv:1593
    rdfs:label "Q17X" ;
    dcterms:identifier "1593" ;
    a m2r:Variation .


civicv:1595
    rdfs:label "H201L" ;
    civico:hgvs "ENST00000318560.5:c.602A>T" ;
    dcterms:identifier "1595" ;
    a m2r:Variation .


civicv:1596
    rdfs:label "Y232S" ;
    civico:hgvs "ENST00000318560.5:c.695A>C,NC_000009.11:g.133738295A>C,NM_005157.5:c.695A>C,NP_005148.2:p.Tyr232Ser" ;
    dcterms:identifier "1596" ;
    a m2r:Variation .


civicv:1597
    rdfs:label "M237V" ;
    civico:hgvs "ENST00000318560.5:c.709A>G" ;
    dcterms:identifier "1597" ;
    a m2r:Variation .


civicv:1598
    rdfs:label "I242T" ;
    civico:hgvs "ENST00000318560.5:c.725T>C" ;
    dcterms:identifier "1598" ;
    a m2r:Variation .


civicv:1599
    rdfs:label "G250V" ;
    civico:hgvs "ENST00000318560.5:c.749G>T,NC_000009.11:g.133738349G>T,NM_005157.5:c.749G>T,NP_005148.2:p.Gly250Val" ;
    dcterms:identifier "1599" ;
    a m2r:Variation .


civicv:1600
    rdfs:label "Q252R" ;
    civico:hgvs "ENST00000318560.5:c.755A>G" ;
    dcterms:identifier "1600" ;
    a m2r:Variation .


civicv:1601
    rdfs:label "E258D" ;
    civico:hgvs "ENST00000318560.5:c.774G>T,NC_000009.11:g.133738374G>T,NM_005157.5:c.774G>T,NP_005148.2:p.Glu258Asp" ;
    dcterms:identifier "1601" ;
    a m2r:Variation .


civicv:1602
    rdfs:label "L273M" ;
    civico:hgvs "ENST00000318560.5:c.817T>A" ;
    dcterms:identifier "1602" ;
    a m2r:Variation .


civicv:1603
    rdfs:label "E281K" ;
    civico:hgvs "ENST00000318560.5:c.841G>A,NC_000009.11:g.133747534G>A,NM_005157.5:c.841G>A,NP_005148.2:p.Glu281Lys" ;
    dcterms:identifier "1603" ;
    a m2r:Variation .


civicv:1604
    rdfs:label "V289I" ;
    civico:hgvs "ENST00000318560.5:c.865G>A,NC_000009.11:g.133747558G>A,NM_005157.5:c.865G>A,NP_005148.2:p.Val289Ile" ;
    dcterms:identifier "1604" ;
    a m2r:Variation .


civicv:1605
    rdfs:label "Y342H" ;
    civico:hgvs "ENST00000318560.5:c.1024T>C,NC_000009.11:g.133748363T>C,NM_005157.5:c.1024T>C,NP_005148.2:p.Tyr342His" ;
    dcterms:identifier "1605" ;
    a m2r:Variation .


civicv:1606
    rdfs:label "D363Y" ;
    civico:hgvs "ENST00000318560.5:c.1087G>T,NC_000009.11:g.133750256G>T,NM_005157.5:c.1087G>T,NP_005148.2:p.Asp363Tyr" ;
    dcterms:identifier "1606" ;
    a m2r:Variation .


civicv:1607
    rdfs:label "A365V" ;
    civico:hgvs "ENST00000318560.5:c.1094C>T,NC_000009.11:g.133750263C>T,NM_005157.5:c.1094C>T,NP_005148.2:p.Ala365Val" ;
    dcterms:identifier "1607" ;
    a m2r:Variation .


civicv:1608
    rdfs:label "A366G" ;
    civico:hgvs "ENST00000318560.5:c.1097C>G,NC_000009.11:g.133750266C>G,NM_005157.5:c.1097C>G,NP_005148.2:p.Ala366Gly" ;
    dcterms:identifier "1608" ;
    a m2r:Variation .


civicv:1609
    rdfs:label "BCR-ABL V379I" ;
    m2r:evidence civice:6257 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133750304 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133750304 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1609" ;
    a obo:missense_variant, m2r:Variation .


civicv:1610
    rdfs:label "M388L" ;
    civico:hgvs "ENST00000318560.5:c.1162A>T" ;
    dcterms:identifier "1610" ;
    a m2r:Variation .


civicv:1611
    rdfs:label "Y393C" ;
    civico:hgvs "ENST00000318560.5:c.1178A>G,NC_000009.11:g.133750347A>G,NM_005157.5:c.1178A>G,NP_005148.2:p.Tyr393Cys" ;
    dcterms:identifier "1611" ;
    a m2r:Variation .


civicv:1612
    rdfs:label "A397P" ;
    civico:hgvs "ENST00000318560.5:c.1189G>C,NC_000009.11:g.133750358G>C,NM_005157.5:c.1189G>C,NP_005148.2:p.Ala397Pro" ;
    dcterms:identifier "1612" ;
    a m2r:Variation .


civicv:1613
    rdfs:label "S417Y" ;
    civico:hgvs "ENST00000318560.5:c.1250C>A" ;
    dcterms:identifier "1613" ;
    a m2r:Variation .


civicv:1614
    rdfs:label "I418V" ;
    civico:hgvs "ENST00000318560.5:c.1252A>G" ;
    dcterms:identifier "1614" ;
    a m2r:Variation .


civicv:1615
    rdfs:label "I418S" ;
    civico:hgvs "ENST00000318560.5:c.1253T>G" ;
    dcterms:identifier "1615" ;
    a m2r:Variation .


civicv:1616
    rdfs:label "P441L" ;
    civico:hgvs "ENST00000318560.5:c.1322C>T" ;
    dcterms:identifier "1616" ;
    a m2r:Variation .


civicv:1617
    rdfs:label "E450K" ;
    civico:hgvs "ENST00000318560.5:c.1348G>A,NC_000009.11:g.133753879G>A,NM_005157.5:c.1348G>A,NP_005148.2:p.Glu450Lys" ;
    dcterms:identifier "1617" ;
    a m2r:Variation .


civicv:1618
    rdfs:label "E450Q" ;
    civico:hgvs "ENST00000318560.5:c.1348G>C,NC_000009.11:g.133753879G>C,NM_005157.5:c.1348G>C,NP_005148.2:p.Glu450Gln" ;
    dcterms:identifier "1618" ;
    a m2r:Variation .


civicv:1619
    rdfs:label "E450A" ;
    civico:hgvs "ENST00000318560.5:c.1349A>C,NC_000009.11:g.133753880A>C,NM_005157.5:c.1349A>C,NP_005148.2:p.Glu450Ala" ;
    dcterms:identifier "1619" ;
    a m2r:Variation .


civicv:1620
    rdfs:label "E453V" ;
    civico:hgvs "ENST00000318560.5:c.1358A>T,NC_000009.11:g.133753889A>T,NM_005157.5:c.1358A>T,NP_005148.2:p.Glu453Val" ;
    dcterms:identifier "1620" ;
    a m2r:Variation .


civicv:1621
    rdfs:label "E459G" ;
    civico:hgvs "ENST00000318560.5:c.1376A>G,NC_000009.11:g.133753907A>G,NM_005157.5:c.1376A>G,NP_005148.2:p.Glu459Gly" ;
    dcterms:identifier "1621" ;
    a m2r:Variation .


civicv:1622
    rdfs:label "M472I" ;
    civico:hgvs "ENST00000318560.5:c.1416G>A" ;
    dcterms:identifier "1622" ;
    a m2r:Variation .


civicv:1623
    rdfs:label "P480L" ;
    civico:hgvs "ENST00000318560.5:c.1439C>T" ;
    dcterms:identifier "1623" ;
    a m2r:Variation .


civicv:1624
    rdfs:label "G514S" ;
    civico:hgvs "ENST00000318560.5:c.1540G>A" ;
    dcterms:identifier "1624" ;
    a m2r:Variation .


civicv:1625
    rdfs:label "BCR-ABL F317I" ;
    m2r:evidence civice:6217,civice:6251 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748288 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748288 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "1625" ;
    a obo:missense_variant, m2r:Variation .


civicv:1626
    rdfs:label "E203K" ;
    civico:hgvs "NM_002755.3:c.607G>A,NP_002746.1:p.Glu203Lys,NC_000015.9:g.66774131G>A,ENST00000307102.5:c.607G>A" ;
    dcterms:identifier "1626" ;
    a m2r:Variation .


civicv:1627
    rdfs:label "G596R" ;
    m2r:evidence civice:5969 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453149 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453149 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1627" ;
    a obo:missense_variant, m2r:Variation .


civicv:1628
    rdfs:label "R163X" ;
    dcterms:identifier "1628" ;
    a m2r:Variation .


civicv:1630
    rdfs:label "Y591_V592INSVDFREYE" ;
    dcterms:identifier "1630" ;
    a m2r:Variation .


civicv:1631
    rdfs:label "E588_Y589INSKYFYVDFRE" ;
    dcterms:identifier "1631" ;
    a m2r:Variation .


civicv:1632
    rdfs:label "V592_D593INSDFREY" ;
    dcterms:identifier "1632" ;
    a m2r:Variation .


civicv:1635
    rdfs:label "E746_A750>IP" ;
    dcterms:identifier "1635" ;
    a m2r:Variation .


civicv:1638
    rdfs:label "K745_E749delKELRE" ;
    dcterms:identifier "1638" ;
    a m2r:Variation .


civicv:1639
    rdfs:label "C475V" ;
    dcterms:identifier "1639" ;
    a m2r:Variation .


civicv:1640
    rdfs:label "N336S" ;
    civico:hgvs "ENST00000318560.5:c.1007A>G" ;
    dcterms:identifier "1640" ;
    a m2r:Variation .


civicv:1641
    rdfs:label "D2033N" ;
    dcterms:identifier "1641" ;
    a m2r:Variation .


civicv:1642
    rdfs:label "Y956N" ;
    dcterms:identifier "1642" ;
    a m2r:Variation .


civicv:1643
    rdfs:label "Q225X" ;
    dcterms:identifier "1643" ;
    a m2r:Variation .


civicv:1644
    rdfs:label "P1460T" ;
    dcterms:identifier "1644" ;
    a m2r:Variation .


civicv:1645
    rdfs:label "Y1520X" ;
    dcterms:identifier "1645" ;
    a m2r:Variation .


civicv:1646
    rdfs:label "A59E" ;
    dcterms:identifier "1646" ;
    a m2r:Variation .


civicv:1647
    rdfs:label "C284Y" ;
    m2r:evidence civice:4776 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "1647" ;
    a m2r:Variation .


civicv:1648
    rdfs:label "E374K" ;
    m2r:evidence civice:4777 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1648" ;
    a m2r:Variation .


civicv:1649
    rdfs:label "D1010Y" ;
    dcterms:identifier "1649" ;
    a m2r:Variation .


civicv:1650
    rdfs:label "G596V" ;
    dcterms:identifier "1650" ;
    a m2r:Variation .


civicv:1651
    rdfs:label "D1010N" ;
    dcterms:identifier "1651" ;
    a m2r:Variation .


civicv:1652
    rdfs:label "N561D" ;
    m2r:evidence civice:4783 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "1652" ;
    a m2r:Variation .


civicv:1653
    rdfs:label "D350G" ;
    m2r:evidence civice:4784 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 178921567 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 178921567 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000263967.3" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "1653" ;
    a obo:missense_variant, m2r:Variation .


civicv:1654
    rdfs:label "Q179X" ;
    m2r:evidence civice:4785 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "1654" ;
    a m2r:Variation .


civicv:1656
    rdfs:label "R351W" ;
    civico:hgvs "ENST00000372348.2:c.1051C>T" ;
    dcterms:identifier "1656" ;
    a m2r:Variation .


civicv:1657
    rdfs:label "G340L" ;
    m2r:evidence civice:4788 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133748300 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133748301 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "GG" ;
    m2r:alternative_allele "CT" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1657" ;
    a obo:coding_sequence_variant, m2r:Variation .


civicv:1658
    rdfs:label "V600_K601DELINSD" ;
    dcterms:identifier "1658" ;
    a m2r:Variation .


civicv:1659
    rdfs:label "S628N" ;
    dcterms:identifier "1659" ;
    a m2r:Variation .


civicv:1660
    rdfs:label "D1010H" ;
    dcterms:identifier "1660" ;
    a m2r:Variation .


civicv:1661
    rdfs:label "R1192P" ;
    civico:hgvs "NM_004304.4:c.3575G>C,NP_004295.2:p.Arg1192Pro,NC_000002.11:g.29443642C>G,ENST00000389048.3:c.3575G>C" ;
    dcterms:identifier "1661" ;
    a m2r:Variation .


civicv:1662
    rdfs:label "N771DELinsVH" ;
    dcterms:identifier "1662" ;
    a m2r:Variation .


civicv:1663
    rdfs:label "DELNVTAP" ;
    dcterms:identifier "1663" ;
    a m2r:Variation .


civicv:1664
    rdfs:label "M766_A767insAI" ;
    m2r:evidence civice:4799 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1664" ;
    a m2r:Variation .


civicv:1665
    rdfs:label "Y764_V765insHH" ;
    m2r:evidence civice:4800 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1665" ;
    a m2r:Variation .


civicv:1666
    rdfs:label "D770_N771insGY" ;
    m2r:evidence civice:4801 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "1666" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:1667
    rdfs:label "P772_H773insYNP" ;
    m2r:evidence civice:4802 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1667" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:1668
    rdfs:label "P772_V774insPHV" ;
    m2r:evidence civice:4803 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "1668" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:1669
    rdfs:label "Y508F" ;
    dcterms:identifier "1669" ;
    a m2r:Variation .


civicv:1670
    rdfs:label "S1986Y" ;
    dcterms:identifier "1670" ;
    a m2r:Variation .


civicv:1671
    rdfs:label "S1986F" ;
    dcterms:identifier "1671" ;
    a m2r:Variation .


civicv:1672
    rdfs:label "Y69FS*11" ;
    dcterms:identifier "1672" ;
    a m2r:Variation .


civicv:1673
    rdfs:label "G1109C" ;
    civico:hgvs "ENST00000342788.4:c.3325G>T" ;
    dcterms:identifier "1673" ;
    a m2r:Variation .


civicv:1674
    rdfs:label "E380Q" ;
    dcterms:identifier "1674" ;
    a m2r:Variation .


civicv:1675
    rdfs:label "L536R" ;
    dcterms:identifier "1675" ;
    a m2r:Variation .


civicv:1676
    rdfs:label "S668FS*39" ;
    dcterms:identifier "1676" ;
    a m2r:Variation .


civicv:1677
    rdfs:label "L403FS*34" ;
    dcterms:identifier "1677" ;
    a m2r:Variation .


civicv:1678
    rdfs:label "G579W" ;
    dcterms:identifier "1678" ;
    a m2r:Variation .


civicv:1679
    rdfs:label "R658Q" ;
    dcterms:identifier "1679" ;
    a m2r:Variation .


civicv:1680
    rdfs:label "R391W" ;
    dcterms:identifier "1680" ;
    a m2r:Variation .


civicv:1681
    rdfs:label "F547 SPLICE SITE MUTATION" ;
    m2r:evidence civice:4825 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 5070054 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 5070054 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "1681" ;
    a obo:splice_donor_variant, m2r:Variation .


civicv:1682
    rdfs:label "P1175FS*5" ;
    m2r:evidence civice:4826 ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:OvarianClearCellCarcinoma ;
    dcterms:identifier "1682" ;
    a m2r:Variation .


civicv:1683
    rdfs:label "R214H" ;
    dcterms:identifier "1683" ;
    a m2r:Variation .


civicv:1684
    rdfs:label "AMPLIFICATION" ;
    dcterms:identifier "1684" ;
    a m2r:Variation .


civicv:1685
    rdfs:label "AMPLIFICATION" ;
    dcterms:identifier "1685" ;
    a m2r:Variation .


civicv:1686
    rdfs:label "G328V" ;
    m2r:evidence civice:4846,civice:6955 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 158622516 ;
            faldo:reference hco:2#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 158622516 ;
            faldo:reference hco:2#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000434821.1" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:DiffuseIntrinsicPontineGlioma ;
    dcterms:identifier "1686" ;
    civico:variantGroups "ACVR1 kinase domain mutation" ;
    a obo:missense_variant, m2r:Variation .


civicv:1687
    rdfs:label "FUSION" ;
    m2r:evidence civice:4847,civice:4848,civice:4849,civice:4850 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1687" ;
    a m2r:Variation .


civicv:1688
    rdfs:label "KIF5B-RET V804L" ;
    dcterms:identifier "1688" ;
    a m2r:Variation .


civicv:1689
    rdfs:label "KIF5B-RET G810A" ;
    dcterms:identifier "1689" ;
    a m2r:Variation .


civicv:1690
    rdfs:label "MUTATION" ;
    dcterms:identifier "1690" ;
    a m2r:Variation .


civicv:1691
    rdfs:label "FGFR3 Fusion" ;
    dcterms:identifier "1691" ;
    a m2r:Variation .


civicv:1692
    rdfs:label "G691R" ;
    dcterms:identifier "1692" ;
    a m2r:Variation .


civicv:1693
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:4874 ;
    m2r:disease civic:LungSmallCellCarcinoma ;
    dcterms:identifier "1693" ;
    a m2r:Variation .


civicv:1694
    rdfs:label "E12D (c.36G>C)" ;
    civico:hgvs "NM_000551.3:c.36G>C,NP_000542.1:p.Glu12Asp,NC_000003.11:g.10183567G>C,ENST00000256474.2:c.36G>C" ;
    dcterms:identifier "1694" ;
    a m2r:Variation .


civicv:1695
    rdfs:label "R158H" ;
    m2r:evidence civice:4886 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1695" ;
    a m2r:Variation .


civicv:1696
    rdfs:label "R249S" ;
    m2r:evidence civice:4888 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1696" ;
    a m2r:Variation .


civicv:1697
    rdfs:label "R280K" ;
    m2r:evidence civice:4889 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1697" ;
    a m2r:Variation .


civicv:1698
    rdfs:label "R280T" ;
    m2r:evidence civice:4890 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1698" ;
    a m2r:Variation .


civicv:1699
    rdfs:label "R158L" ;
    m2r:evidence civice:4891 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "1699" ;
    a m2r:Variation .


civicv:1700
    rdfs:label "C634R" ;
    dcterms:identifier "1700" ;
    a m2r:Variation .


civicv:1733
    rdfs:label "E46* (c.136G>T)" ;
    m2r:evidence civice:4895 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183667 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183667 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1733" ;
    a obo:stop_gained, m2r:Variation .


civicv:1734
    rdfs:label "E52K (c.154G>A)" ;
    m2r:evidence civice:5272 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183685 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183685 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1734" ;
    a obo:missense_variant, m2r:Variation .


civicv:1735
    rdfs:label "E52fs* (c.156G>T)" ;
    dcterms:identifier "1735" ;
    a m2r:Variation .


civicv:1736
    rdfs:label "E55* (c.163G>T)" ;
    dcterms:identifier "1736" ;
    a m2r:Variation .


civicv:1737
    rdfs:label "G39AfsTer26 (c.327delC)" ;
    dcterms:identifier "1737" ;
    a m2r:Variation .


civicv:1738
    rdfs:label "L158P (c.473T>C)" ;
    m2r:evidence civice:5103,civice:5281 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191480 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191480 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST0" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1738" ;
    a obo:missense_variant, m2r:Variation .


civicv:1739
    rdfs:label "R167Q (c.500G>A)" ;
    m2r:evidence civice:4913,civice:5062,civice:5264,civice:5354,civice:5402,civice:5469,civice:5485,civice:5487,civice:5546,civice:6222 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191507 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191507 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    dcterms:description "R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2α. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2α and suprressed tumorgenesis." ;
    m2r:disease civic:VonHippel-LindauDisease,civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "1739" ;
    a obo:missense_variant, m2r:Variation .


civicv:1741
    rdfs:label "Y98H (c.292T>C)" ;
    m2r:evidence civice:4906,civice:4967,civice:5372,civice:5418,civice:5451,civice:5474 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183823 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183823 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease,civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "1741" ;
    a obo:missense_variant, m2r:Variation .


civicv:1742
    rdfs:label "H115Q (c.345C>A)" ;
    m2r:evidence civice:4907 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188202 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188202 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1742" ;
    a obo:missense_variant, m2r:Variation .


civicv:1743
    rdfs:label "F119L (c.357C>G)" ;
    m2r:evidence civice:4908,civice:5411,civice:5436,civice:5454 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188214 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188214 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease,civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "1743" ;
    a obo:missense_variant, m2r:Variation .


civicv:1744
    rdfs:label "A149T (c.445G>A)" ;
    m2r:evidence civice:4909 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188302 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188302 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1744" ;
    a obo:missense_variant, m2r:Variation .


civicv:1745
    rdfs:label "T157I (c.470C>T)" ;
    m2r:evidence civice:4910,civice:5294 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191477 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191477 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1745" ;
    a obo:missense_variant, m2r:Variation .


civicv:1746
    rdfs:label "R161Q (c.482G>A)" ;
    m2r:evidence civice:4911,civice:5061,civice:5125,civice:5179,civice:5262,civice:5400,civice:5466,civice:5481 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191489 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191489 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease,civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "1746" ;
    a obo:missense_variant, m2r:Variation .


civicv:1747
    rdfs:label "R167W (c.499C>T)" ;
    m2r:evidence civice:4912,civice:5052,civice:5184,civice:5265,civice:5468,civice:5484,civice:5545,civice:5769 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191506 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191506 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1747" ;
    a obo:missense_variant, m2r:Variation .


civicv:1748
    rdfs:label "L178P (c.533T>C)" ;
    m2r:evidence civice:4914,civice:4983,civice:5149,civice:5198,civice:5470 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191540 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191540 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST0" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1748" ;
    a obo:missense_variant, m2r:Variation .


civicv:1749
    rdfs:label "F76I (c.226T>A)" ;
    civico:hgvs "ENST00000256474.2:c.226T>A,NC_000003.11:g.10183757T>A,NM_000551.3:c.226T>A,NP_000542.1:p.Phe76Ile" ;
    dcterms:identifier "1749" ;
    a m2r:Variation .


civicv:1750
    rdfs:label "V62C (c.180delG)" ;
    m2r:evidence civice:4916 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183711 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183711 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1750" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:1752
    rdfs:label "Q73* (c.217C>T)" ;
    m2r:evidence civice:4918,civice:5135,civice:5270 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183748 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183748 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1752" ;
    a obo:stop_gained, m2r:Variation .


civicv:1754
    rdfs:label "N78H (c.232A>C)" ;
    m2r:evidence civice:4920,civice:4962,civice:5130,civice:5341 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183763 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183763 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST0000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease,civic:RenalCellCarcinoma ;
    dcterms:identifier "1754" ;
    a obo:missense_variant, m2r:Variation .


civicv:1755
    rdfs:label "N78S (c.233A>G)" ;
    m2r:evidence civice:4921,civice:5020,civice:5027,civice:5250,civice:5376,civice:5491 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183764 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183764 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1755" ;
    a obo:missense_variant, m2r:Variation .


civicv:1756
    rdfs:label "N78T (c.233A>C)" ;
    m2r:evidence civice:4922 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183764 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183764 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1756" ;
    a obo:missense_variant, m2r:Variation .


civicv:1757
    rdfs:label "S80I (c.239G>T)" ;
    m2r:evidence civice:4923,civice:5428 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183770 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183770 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1757" ;
    a obo:missense_variant, m2r:Variation .


civicv:1758
    rdfs:label "N131* (c.255insC)" ;
    m2r:evidence civice:4924 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1758" ;
    a m2r:Variation .


civicv:1759
    rdfs:label "P86A (c.256C>G)" ;
    civico:hgvs "NM_000551.3:c.256C>G,NP_000542.1:p.Pro86Ala,NC_000003.11:g.10183787C>G,ENST00000256474.2:c.256C>G" ;
    dcterms:identifier "1759" ;
    a m2r:Variation .


civicv:1760
    rdfs:label "P86L (c.257C>T)" ;
    m2r:evidence civice:4926,civice:5157 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183788 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183788 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1760" ;
    a obo:missense_variant, m2r:Variation .


civicv:1761
    rdfs:label "W88R (c.262T>A)" ;
    m2r:evidence civice:4927,civice:5168 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183793 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183793 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1761" ;
    a obo:missense_variant, m2r:Variation .


civicv:1762
    rdfs:label "S111FS (c.331delA)" ;
    m2r:evidence civice:4928 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1762" ;
    a m2r:Variation .


civicv:1763
    rdfs:label "S111N (c.332G>A)" ;
    m2r:evidence civice:4929 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183863 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183863 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1763" ;
    a obo:missense_variant, m2r:Variation .


civicv:1764
    rdfs:label "S111R (c.333C>G)" ;
    m2r:evidence civice:4930,civice:5498 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183864 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183864 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1764" ;
    a obo:missense_variant, m2r:Variation .


civicv:1765
    rdfs:label "Gain-of-function" ;
    m2r:evidence civice:4931 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1765" ;
    a m2r:Variation .


civicv:1766
    rdfs:label "Y112* (c.336C>A)" ;
    m2r:evidence civice:4932 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183867 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183867 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1766" ;
    a obo:stop_gained, m2r:Variation .


civicv:1767
    rdfs:label "W117C (c.351G>T)" ;
    m2r:evidence civice:4933,civice:5044,civice:5295 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188208 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188208 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1767" ;
    a obo:missense_variant, m2r:Variation .


civicv:1768
    rdfs:label "L129Q (c.386insAGA)" ;
    m2r:evidence civice:4934 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1768" ;
    a m2r:Variation .


civicv:1769
    rdfs:label "L135* (c.404T>A)" ;
    m2r:evidence civice:4935 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188261 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188261 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1769" ;
    a obo:stop_gained, m2r:Variation .


civicv:1770
    rdfs:label "N150I (c.448delA)" ;
    m2r:evidence civice:4936 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1770" ;
    a m2r:Variation .


civicv:1771
    rdfs:label "P154fs (c.462delA)" ;
    m2r:evidence civice:4937 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188319 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188319 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1771" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:1772
    rdfs:label "C162R (c.484T>C)" ;
    m2r:evidence civice:4939,civice:5175,civice:5349 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191491 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191491 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1772" ;
    a obo:missense_variant, m2r:Variation .


civicv:1773
    rdfs:label "C162F (c.485G>T)" ;
    m2r:evidence civice:4940,civice:5050,civice:5189 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191492 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191492 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1773" ;
    a obo:missense_variant, m2r:Variation .


civicv:1774
    rdfs:label "C162W (c.486C>G)" ;
    m2r:evidence civice:4941,civice:5267,civice:5355 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191493 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191493 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1774" ;
    a obo:missense_variant, m2r:Variation .


civicv:1775
    rdfs:label "V166D (c.497T>A)" ;
    m2r:evidence civice:4942 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191504 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191504 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1775" ;
    a obo:missense_variant, m2r:Variation .


civicv:1776
    rdfs:label "L184P (c.551T>C)" ;
    m2r:evidence civice:4943,civice:5055 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191558 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191558 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1776" ;
    a obo:missense_variant, m2r:Variation .


civicv:1777
    rdfs:label "E186* (c.556G>T)" ;
    m2r:evidence civice:4944,civice:5057 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191563 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191563 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1777" ;
    a obo:stop_gained, m2r:Variation .


civicv:1778
    rdfs:label "E186K (c.556G>A)" ;
    m2r:evidence civice:4945 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191563 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191563 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1778" ;
    a obo:missense_variant, m2r:Variation .


civicv:1779
    rdfs:label "R167fs (c.502insTTGTTCGT)" ;
    dcterms:identifier "1779" ;
    a m2r:Variation .


civicv:1780
    rdfs:label "Y175fs (c.526delA)" ;
    m2r:evidence civice:5166 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191533 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191533 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:RenalCellCarcinoma ;
    dcterms:identifier "1780" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:1781
    rdfs:label "Q145H (c.435_436delGC)" ;
    civico:hgvs "NM_000551.3:c.435_436delGC,NP_000542.1:p.Gln145Hisfs,NC_000003.11:g.10188292_10188293delGC,ENST00000256474.2:c.435_436delGC" ;
    dcterms:identifier "1781" ;
    a m2r:Variation .


civicv:1782
    rdfs:label "P154L (c.461C>T)" ;
    m2r:evidence civice:4976,civice:5154,civice:5461 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188318 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188318 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1782" ;
    a obo:missense_variant, m2r:Variation .


civicv:1783
    rdfs:label "T157fs (c.472insT)" ;
    dcterms:identifier "1783" ;
    a m2r:Variation .


civicv:1784
    rdfs:label "S183* (c.548C>A)" ;
    m2r:evidence civice:5370,civice:5471 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191555 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191555 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:RenalCellCarcinoma,civic:VonHippel-LindauDisease ;
    dcterms:identifier "1784" ;
    a obo:stop_gained, m2r:Variation .


civicv:1785
    rdfs:label "A56fs (c.167insA)" ;
    m2r:evidence civice:4956 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1785" ;
    a m2r:Variation .


civicv:1786
    rdfs:label "P59R (c.175delC)" ;
    m2r:evidence civice:5155 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183706 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183706 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1786" ;
    a obo:missense_variant, m2r:Variation .


civicv:1787
    rdfs:label "S65W (c.194C>G)" ;
    m2r:evidence civice:4917,civice:4958,civice:5026,civice:5034,civice:5161,civice:5765 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183725 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183725 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1787" ;
    a obo:missense_variant, m2r:Variation .


civicv:1788
    rdfs:label "S65L (c.194C>T)" ;
    m2r:evidence civice:4959,civice:5104,civice:5159,civice:5287,civice:5499,civice:5582 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183725 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183725 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1788" ;
    a obo:missense_variant, m2r:Variation .


civicv:1789
    rdfs:label "V66* (c.196delG)" ;
    civico:hgvs "ENST00000256474.2:c.196delG,NC_000003.11:g.10183727delG,NM_000551.3:c.196delG,NP_000542.1:p.Val66Ter" ;
    dcterms:identifier "1789" ;
    a m2r:Variation .


civicv:1790
    rdfs:label "C77FS (c.228_229insC)" ;
    m2r:evidence civice:4961 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183759 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183760 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1790" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:1791
    rdfs:label "R79P (c.236G>C)" ;
    m2r:evidence civice:4963 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183767 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183767 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1791" ;
    a obo:missense_variant, m2r:Variation .


civicv:1792
    rdfs:label "S80R (c.240T>G)" ;
    m2r:evidence civice:4964,civice:5448 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183771 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183771 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1792" ;
    a obo:missense_variant, m2r:Variation .


civicv:1793
    rdfs:label "L89P (c.266T>C)" ;
    m2r:evidence civice:4965,civice:5150,civice:5368,civice:5449 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183797 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183797 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST0000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1793" ;
    a obo:missense_variant, m2r:Variation .


civicv:1794
    rdfs:label "E94* (c.280G>T)" ;
    m2r:evidence civice:5137,civice:5405,civice:5433,civice:5550,civice:5561,civice:5771 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183811 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183811 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1794" ;
    a obo:stop_gained, m2r:Variation .


civicv:1795
    rdfs:label "P103FS (c.309_310delTG)" ;
    m2r:evidence civice:5138 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183840 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183841 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "TG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1795" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:1796
    rdfs:label "R113* (c.337C>T)" ;
    m2r:evidence civice:5043,civice:5260,civice:5352 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183868 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183868 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1796" ;
    a obo:missense_variant, m2r:Variation .


civicv:1797
    rdfs:label "G114C (c.340G>T)" ;
    m2r:evidence civice:4970,civice:5139 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183871 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183871 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1797" ;
    a obo:missense_variant, m2r:Variation .


civicv:1798
    rdfs:label "L118P (c.353T>C)" ;
    m2r:evidence civice:4971,civice:5143,civice:5276,civice:5435,civice:5477 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188210 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188210 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1798" ;
    a obo:missense_variant, m2r:Variation .


civicv:1800
    rdfs:label "N131P (c.390_391delTA)" ;
    m2r:evidence civice:4973,civice:5128 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188247 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188248 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "TA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1800" ;
    a obo:missense_variant, m2r:Variation .


civicv:1801
    rdfs:label "F136S (c.407T>C)" ;
    m2r:evidence civice:4974,civice:5152,civice:5202,civice:5284,civice:5543 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188264 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188264 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1801" ;
    a obo:missense_variant, m2r:Variation .


civicv:1802
    rdfs:label "L153C (c.457delC)" ;
    m2r:evidence civice:4975,civice:5145 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1802" ;
    a m2r:Variation .


civicv:1803
    rdfs:label "L158V (c.472C>G)" ;
    m2r:evidence civice:4977,civice:5146,civice:5464 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191479 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191479 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST0" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1803" ;
    a obo:missense_variant, m2r:Variation .


civicv:1804
    rdfs:label "R161* (c.481C>T)" ;
    m2r:evidence civice:5049,civice:5263,civice:5375,civice:5483 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191488 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191488 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease,civic:RenalCellCarcinoma ;
    dcterms:identifier "1804" ;
    a obo:missense_variant, m2r:Variation .


civicv:1805
    rdfs:label "R167G (c.499C>G)" ;
    civico:hgvs "NM_000551.3:c.499C>G,NP_000542.1:p.Arg167Gly,NC_000003.11:g.10191506C>G,ENST00000256474.2:c.499C>G" ;
    dcterms:identifier "1805" ;
    a m2r:Variation .


civicv:1806
    rdfs:label "V170F (c.508G>T)" ;
    m2r:evidence civice:4982 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191515 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191515 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1806" ;
    a obo:missense_variant, m2r:Variation .


civicv:1807
    rdfs:label "I180V (c.538A>G)" ;
    m2r:evidence civice:4984 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191545 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191545 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST0" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1807" ;
    a obo:missense_variant, m2r:Variation .


civicv:1808
    rdfs:label "L184R (c.551T>G)" ;
    m2r:evidence civice:5199 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191558 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191558 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1808" ;
    a obo:missense_variant, m2r:Variation .


civicv:1809
    rdfs:label "Y185* (c.555C>G)" ;
    m2r:evidence civice:5056,civice:5170 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191562 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191562 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1809" ;
    a obo:stop_gained, m2r:Variation .


civicv:1810
    rdfs:label "Q195* (c.583C>T)" ;
    m2r:evidence civice:5097,civice:5134,civice:5360,civice:5404,civice:5472 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191590 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191590 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1810" ;
    a obo:stop_gained, m2r:Variation .


civicv:1811
    rdfs:label "S65* (c.194C>A)" ;
    m2r:evidence civice:5033,civice:5422 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183725 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183725 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1811" ;
    a obo:stop_gained, m2r:Variation .


civicv:1812
    rdfs:label "G93fs (c.278delG)" ;
    civico:hgvs "ENST00000256474.2:c.277delG,ENST00000256474.2:c.278delG" ;
    dcterms:identifier "1812" ;
    a m2r:Variation .


civicv:1813
    rdfs:label "D121G (c.362A>G)" ;
    m2r:evidence civice:5437,civice:5455 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188219 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188219 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1813" ;
    a obo:missense_variant, m2r:Variation .


civicv:1814
    rdfs:label "F136C (c.407T>G)" ;
    m2r:evidence civice:5412,civice:5480 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188264 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188264 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AdrenalGlandPheochromocytoma,civic:VonHippel-LindauDisease ;
    dcterms:identifier "1814" ;
    a obo:missense_variant, m2r:Variation .


civicv:1815
    rdfs:label "V84L (c.250G>T)" ;
    m2r:evidence civice:5430 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183781 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183781 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1815" ;
    a obo:missense_variant, m2r:Variation .


civicv:1816
    rdfs:label "S72P (c.214delT)" ;
    m2r:evidence civice:5163 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183745 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183745 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1816" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:1818
    rdfs:label "Q96P (c.287A>C)" ;
    civico:hgvs "ENST00000256474.2:c.287A>C,NC_000003.11:g.10183818A>C,NM_000551.3:c.287A>C,NP_000542.1:p.Gln96Pro" ;
    dcterms:identifier "1818" ;
    a m2r:Variation .


civicv:1819
    rdfs:label "G185S (c.340+5G>C)" ;
    m2r:evidence civice:5246 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1819" ;
    a m2r:Variation .


civicv:1820
    rdfs:label "L116V (c.346C>G)" ;
    m2r:evidence civice:5022 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188203 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188203 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST0" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1820" ;
    a obo:missense_variant, m2r:Variation .


civicv:1821
    rdfs:label "W117* (c.351G>A)" ;
    civico:hgvs "ENST00000256474.2:c.351G>A,NC_000003.11:g.10188208G>A,NM_000551.3:c.351G>A,NP_000542.1:p.Trp117Ter" ;
    dcterms:identifier "1821" ;
    a m2r:Variation .


civicv:1822
    rdfs:label "L118R (c.353T>G)" ;
    civico:hgvs "NM_000551.3:c.353T>G,NP_000542.1:p.Leu118Arg,NC_000003.11:g.10188210T>G,ENST00000256474.2:c.353T>G" ;
    dcterms:identifier "1822" ;
    a m2r:Variation .


civicv:1823
    rdfs:label "N141FS (c.421delA)" ;
    civico:hgvs "ENST00000256474.2:c.421delA" ;
    dcterms:identifier "1823" ;
    a m2r:Variation .


civicv:1824
    rdfs:label "C162Y (c.485G>A)" ;
    m2r:evidence civice:5493 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191492 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191492 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1824" ;
    a obo:missense_variant, m2r:Variation .


civicv:1825
    rdfs:label "V166F (c.496G>T)" ;
    m2r:evidence civice:5302 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191503 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191503 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1825" ;
    a obo:missense_variant, m2r:Variation .


civicv:1826
    rdfs:label "V170D (c.509T>A)" ;
    m2r:evidence civice:5013,civice:5029,civice:5092,civice:5863 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191516 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191516 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1826" ;
    a obo:missense_variant, m2r:Variation .


civicv:1827
    rdfs:label "R177* (c.529A>T)" ;
    m2r:evidence civice:5331 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191536 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191536 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1827" ;
    a obo:stop_gained, m2r:Variation .


civicv:1828
    rdfs:label "L188R (c.563delT)" ;
    civico:hgvs "ENST00000256474.2:c.563delT,NC_000003.11:g.10191570del,NM_000551.3:c.563delT,NP_000542.1:p.Leu188ArgfsTer14" ;
    dcterms:identifier "1828" ;
    a m2r:Variation .


civicv:1829
    rdfs:label "E186del (c.558_560delAGA)" ;
    civico:hgvs "ENST00000256474.2:c.558_560delAGA,NC_000003.11:g.10191565_10191567del,NM_000551.3:c.558_560delAGA,NP_000542.1:p.Glu186del" ;
    dcterms:identifier "1829" ;
    a m2r:Variation .


civicv:1830
    rdfs:label "P286R" ;
    m2r:evidence civice:5017 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "1830" ;
    a m2r:Variation .


civicv:1831
    rdfs:label "V411L" ;
    m2r:evidence civice:5018 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "1831" ;
    a m2r:Variation .


civicv:1832
    rdfs:label "S459F" ;
    m2r:evidence civice:5019 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "1832" ;
    a m2r:Variation .


civicv:1833
    rdfs:label "V166F (c.498C>G)" ;
    m2r:evidence civice:5024 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1833" ;
    a m2r:Variation .


civicv:1834
    rdfs:label "E70* (c.208G>T)" ;
    m2r:evidence civice:5035,civice:5361,civice:5445,civice:6059 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183739 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183739 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1834" ;
    a obo:stop_gained, m2r:Variation .


civicv:1835
    rdfs:label "F76S (c.227T>C)" ;
    m2r:evidence civice:5037 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183758 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183758 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1835" ;
    a obo:missense_variant, m2r:Variation .


civicv:1836
    rdfs:label "L188V (c.562C>G)" ;
    m2r:evidence civice:5409 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191569 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191569 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "1836" ;
    a obo:missense_variant, m2r:Variation .


civicv:1837
    rdfs:label "P81S (c.241C>T)" ;
    m2r:evidence civice:5369 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183772 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183772 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1837" ;
    a obo:missense_variant, m2r:Variation .


civicv:1838
    rdfs:label "L101G (c.301C>G)" ;
    m2r:evidence civice:5040 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1838" ;
    a m2r:Variation .


civicv:1839
    rdfs:label "T105P (c.313A>C)" ;
    m2r:evidence civice:5041,civice:5293 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183844 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183844 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1839" ;
    a obo:missense_variant, m2r:Variation .


civicv:1840
    rdfs:label "R107P (c.320G>C)" ;
    m2r:evidence civice:5042 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183851 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183851 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1840" ;
    a obo:missense_variant, m2r:Variation .


civicv:1841
    rdfs:label "L118T (c.352insA)" ;
    m2r:evidence civice:5045 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1841" ;
    a m2r:Variation .


civicv:1842
    rdfs:label "N167T (c.392A>C)" ;
    m2r:evidence civice:5046 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1842" ;
    a m2r:Variation .


civicv:1843
    rdfs:label "L132fs (c.395delA)" ;
    m2r:evidence civice:5047 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1843" ;
    a m2r:Variation .


civicv:1844
    rdfs:label "D143fs (c.430delG)" ;
    m2r:evidence civice:5048 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1844" ;
    a m2r:Variation .


civicv:1845
    rdfs:label "Q164* (c.490C>T)" ;
    m2r:evidence civice:5051,civice:5096,civice:5359,civice:5403 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191497 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191497 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1845" ;
    a obo:stop_gained, m2r:Variation .


civicv:1846
    rdfs:label "Y175D (c.523T>G)" ;
    m2r:evidence civice:5053 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191530 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191530 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1846" ;
    a obo:missense_variant, m2r:Variation .


civicv:1847
    rdfs:label "V181G (c.540_543delCGTC)" ;
    m2r:evidence civice:5054 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1847" ;
    a m2r:Variation .


civicv:1848
    rdfs:label "Q96* (c.286C>T)" ;
    m2r:evidence civice:5058,civice:5271 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183817 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183817 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST0" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1848" ;
    a obo:stop_gained, m2r:Variation .


civicv:1849
    rdfs:label "P86R (c.257C>G)" ;
    m2r:evidence civice:5059,civice:5156 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183788 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183788 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1849" ;
    a obo:missense_variant, m2r:Variation .


civicv:1850
    rdfs:label "G144* (c.430G>T)" ;
    m2r:evidence civice:5064 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188287 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188287 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1850" ;
    a obo:stop_gained, m2r:Variation .


civicv:1851
    rdfs:label "L128F (c.381_382GC>TT)" ;
    m2r:evidence civice:5478 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1851" ;
    a m2r:Variation .


civicv:1852
    rdfs:label "L188P (c.563T>C)" ;
    m2r:evidence civice:5066,civice:5282 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191570 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191570 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1852" ;
    a obo:missense_variant, m2r:Variation .


civicv:1853
    rdfs:label "S111C (c.330CA>TT)" ;
    m2r:evidence civice:5067 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1853" ;
    a m2r:Variation .


civicv:1854
    rdfs:label "Ex19 del L858R" ;
    m2r:evidence civice:2156,civice:3791,civice:4759 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma,civic:LungAdenocarcinoma ;
    dcterms:identifier "1854" ;
    a obo:missense_variant,obo:inframe_deletion, m2r:Variation .


civicv:1855
    rdfs:label "R161P (c.482G>C)" ;
    m2r:evidence civice:5401 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191489 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191489 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "1855" ;
    a obo:missense_variant, m2r:Variation .


civicv:1856
    rdfs:label "Q164R (c.491A>G)" ;
    m2r:evidence civice:5133 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191498 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191498 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1856" ;
    a obo:missense_variant, m2r:Variation .


civicv:1857
    rdfs:label "G114R (c.340G>C)" ;
    m2r:evidence civice:5305,civice:5476 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183871 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183871 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1857" ;
    a obo:missense_variant, m2r:Variation .


civicv:1858
    rdfs:label "G93D (c.278G>A)" ;
    civico:hgvs "ENST00000256474.2:c.278G>A,NC_000003.11:g.10183809G>A,NM_000551.3:c.278G>A,NP_000542.1:p.Gly93Asp" ;
    dcterms:identifier "1858" ;
    a m2r:Variation .


civicv:1859
    rdfs:label "G93S (c.277G>A)" ;
    m2r:evidence civice:5100,civice:5407 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183808 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183808 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease,civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "1859" ;
    a obo:missense_variant, m2r:Variation .


civicv:1860
    rdfs:label "L101R (c.302T>G)" ;
    civico:hgvs "ENST00000256474.2:c.302T>G,NC_000003.11:g.10183833T>G,NM_000551.3:c.302T>G,NP_000542.1:p.Leu101Arg" ;
    dcterms:identifier "1860" ;
    a m2r:Variation .


civicv:1861
    rdfs:label "L188Q (c.563T>A)" ;
    m2r:evidence civice:6061 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191570 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191570 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1861" ;
    a obo:missense_variant, m2r:Variation .


civicv:1862
    rdfs:label "K159E (c.475A>G)" ;
    civico:hgvs "ENST00000256474.2:c.475A>G" ;
    dcterms:identifier "1862" ;
    a m2r:Variation .


civicv:1863
    rdfs:label "RARE EX 18-21 MUT" ;
    m2r:evidence civice:4755,civice:4762 ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "Rare exon 18-21 mutations in EGFR consist of all EGFR mutations excluding sensitizing L858R substitutions and exon 19 deletions, as well as resistance mutation T790M." ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1863" ;
    a obo:exon_variant, m2r:Variation .


civicv:1864
    rdfs:label "P192fs (c.575delC)" ;
    civico:hgvs "ENST00000256474.2:c.573delC,ENST00000256474.2:c.575delC,NC_000003.11:g.10191582del,NM_000551.3:c.575del,NP_000542.1:p.Pro192GlnfsTer10" ;
    dcterms:identifier "1864" ;
    a m2r:Variation .


civicv:1865
    rdfs:label "Y112H (c.334T>C)" ;
    m2r:evidence civice:5475 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183865 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183865 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1865" ;
    a obo:missense_variant, m2r:Variation .


civicv:1866
    rdfs:label "L861" ;
    m2r:evidence civice:4298 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1866" ;
    a m2r:Variation .


civicv:1867
    rdfs:label "R64P (c.191G>C)" ;
    m2r:evidence civice:5094 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183722 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183722 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1867" ;
    a obo:missense_variant, m2r:Variation .


civicv:1868
    rdfs:label "N131fs (c.393CC>A)" ;
    dcterms:identifier "1868" ;
    a m2r:Variation .


civicv:1869
    rdfs:label "E189L (c.565delG)" ;
    m2r:evidence civice:5098 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1869" ;
    a m2r:Variation .


civicv:1871
    rdfs:label "I151T (c.452T>C)" ;
    m2r:evidence civice:5101,civice:5141,civice:5720 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188309 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188309 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1871" ;
    a obo:missense_variant, m2r:Variation .


civicv:1872
    rdfs:label "L158fs (c.473insT)" ;
    m2r:evidence civice:5280 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1872" ;
    a m2r:Variation .


civicv:1873
    rdfs:label "S68P (c.202T>C)" ;
    m2r:evidence civice:5105 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183733 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183733 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1873" ;
    a obo:missense_variant, m2r:Variation .


civicv:1874
    rdfs:label "S80N (c.239G>A)" ;
    m2r:evidence civice:5289,civice:5371,civice:5415,civice:5427 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183770 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183770 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease,civic:RenalCellCarcinoma,civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "1874" ;
    a obo:missense_variant, m2r:Variation .


civicv:1875
    rdfs:label "V130F (c.388G>T)" ;
    civico:hgvs "ENST00000256474.2:c.388G>T,NC_000003.11:g.10188245G>T,NM_000551.3:c.388G>T,NP_000542.1:p.Val130Phe" ;
    dcterms:identifier "1875" ;
    a m2r:Variation .


civicv:1876
    rdfs:label "LOSS" ;
    dcterms:identifier "1876" ;
    a m2r:Variation .


civicv:1877
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "1877" ;
    a m2r:Variation .


civicv:1878
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "1878" ;
    a m2r:Variation .


civicv:1879
    rdfs:label "LOSS" ;
    dcterms:identifier "1879" ;
    a m2r:Variation .


civicv:1880
    rdfs:label "LOSS" ;
    dcterms:identifier "1880" ;
    a m2r:Variation .


civicv:1881
    rdfs:label "F858L" ;
    dcterms:identifier "1881" ;
    a m2r:Variation .


civicv:1883
    rdfs:label "Q145* (c.433C>T)" ;
    m2r:evidence civice:5248,civice:5798 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188290 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188290 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1883" ;
    a obo:stop_gained, m2r:Variation .


civicv:1884
    rdfs:label "E134* (c.400G>T)" ;
    civico:hgvs "ENST00000256474.2:c.400G>T,NC_000003.11:g.10188257G>T,NM_000551.3:c.400G>T,NP_000542.1:p.Glu134Ter" ;
    dcterms:identifier "1884" ;
    a m2r:Variation .


civicv:1885
    rdfs:label "H115P (c.344A>C)" ;
    m2r:evidence civice:5140 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188201 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188201 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1885" ;
    a obo:missense_variant, m2r:Variation .


civicv:1886
    rdfs:label "L128R (c.383T>G)" ;
    m2r:evidence civice:5144 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188240 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188240 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1886" ;
    a obo:missense_variant, m2r:Variation .


civicv:1887
    rdfs:label "L169P (c.506T>C)" ;
    m2r:evidence civice:5147,civice:5197 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191513 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191513 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1887" ;
    a obo:missense_variant, m2r:Variation .


civicv:1888
    rdfs:label "L178R (c.533T>G)" ;
    m2r:evidence civice:5148,civice:5774 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191540 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191540 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1888" ;
    a obo:missense_variant, m2r:Variation .


civicv:1889
    rdfs:label "M54* (c.162insT)" ;
    m2r:evidence civice:5151 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1889" ;
    a m2r:Variation .


civicv:1891
    rdfs:label "L747P" ;
    m2r:evidence civice:4220 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1891" ;
    a m2r:Variation .


civicv:1892
    rdfs:label "V774A" ;
    m2r:evidence civice:4226 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1892" ;
    a m2r:Variation .


civicv:1893
    rdfs:label "F91* (c.272T>A)" ;
    m2r:evidence civice:5153 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1893" ;
    a m2r:Variation .


civicv:1894
    rdfs:label "V774M" ;
    m2r:evidence civice:4231 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1894" ;
    a m2r:Variation .


civicv:1895
    rdfs:label "K806E" ;
    m2r:evidence civice:4239 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 55249118 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 55249118 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000275493.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1895" ;
    a obo:missense_variant, m2r:Variation .


civicv:1896
    rdfs:label "N826Y" ;
    m2r:evidence civice:4244 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1896" ;
    a m2r:Variation .


civicv:1897
    rdfs:label "V834I" ;
    m2r:evidence civice:4248 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1897" ;
    a m2r:Variation .


civicv:1899
    rdfs:label "N842S" ;
    m2r:evidence civice:4256 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "1899" ;
    a m2r:Variation .


civicv:1902
    rdfs:label "P86S (c.256C>T)" ;
    m2r:evidence civice:5158,civice:5286,civice:5775 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183787 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183787 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1902" ;
    a obo:missense_variant, m2r:Variation .


civicv:1903
    rdfs:label "S65P (c.193T>C)" ;
    m2r:evidence civice:5160 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183724 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183724 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1903" ;
    a obo:missense_variant, m2r:Variation .


civicv:1904
    rdfs:label "S72P (c.214T>C)" ;
    m2r:evidence civice:5162 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183745 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183745 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1904" ;
    a obo:missense_variant, m2r:Variation .


civicv:1905
    rdfs:label "G123FS (c.367delG)" ;
    m2r:evidence civice:5164 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188224 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188224 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1905" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:1906
    rdfs:label "L135FS (c.404delT)" ;
    m2r:evidence civice:5165 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188261 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188261 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1906" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:1907
    rdfs:label "R176fs (c.528delG)" ;
    m2r:evidence civice:5167,civice:5643 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191535 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191535 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1907" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:1908
    rdfs:label "W88* (c.264G>A)" ;
    m2r:evidence civice:5169 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183795 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183795 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1908" ;
    a obo:stop_gained, m2r:Variation .


civicv:1909
    rdfs:label "V155E (c.464T>A)" ;
    m2r:evidence civice:5171 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191471 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191471 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1909" ;
    a obo:missense_variant, m2r:Variation .


civicv:1910
    rdfs:label "V170A (c.509T>C)" ;
    civico:hgvs "NM_000551.3:c.509T>C,NP_000542.1:p.Val170Ala,NC_000003.11:g.10191516T>C,ENST00000256474.2:c.509T>C" ;
    dcterms:identifier "1910" ;
    a m2r:Variation .


civicv:1911
    rdfs:label "R58fs (c.173_174insC)" ;
    civico:hgvs "ENST00000256474.2:c.173_174insC,NM_000551.3:c.173_174insC,NC_000003.11:g.10183704_10183705insC,NP_000542.1:p.Pro59AlafsTer?" ;
    dcterms:identifier "1911" ;
    a m2r:Variation .


civicv:1912
    rdfs:label "F76fs (c.223_224insT)" ;
    m2r:evidence civice:5174 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183754 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183755 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1912" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:1913
    rdfs:label "K196* (c.586A>T)" ;
    m2r:evidence civice:5176 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191593 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191593 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1913" ;
    a obo:stop_gained, m2r:Variation .


civicv:1914
    rdfs:label "R120G (c.358A>G)" ;
    civico:hgvs "NM_000551.3:c.358A>G,NP_000542.1:p.Arg120Gly,NC_000003.11:g.10188215A>G,ENST00000256474.2:c.358A>G" ;
    dcterms:identifier "1914" ;
    a m2r:Variation .


civicv:1915
    rdfs:label "R161G (c.481C>G)" ;
    m2r:evidence civice:5353 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191488 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191488 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1915" ;
    a obo:missense_variant, m2r:Variation .


civicv:1916
    rdfs:label "R167L (c.500G>T)" ;
    m2r:evidence civice:5183 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191507 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191507 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1916" ;
    a obo:missense_variant, m2r:Variation .


civicv:1917
    rdfs:label "N141fs (c.422_440del19)" ;
    civico:hgvs "ENST00000256474.2:c.422_440delATGTTGACGGACAGCCTAT,NC_000003.11:g.10188279_10188297del,NM_000551.3:c.422_440del,NP_000542.1:p.Asn141IlefsTer12" ;
    dcterms:identifier "1917" ;
    a m2r:Variation .


civicv:1918
    rdfs:label "D126FS (c.375_376insC)" ;
    m2r:evidence civice:5188 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188232 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188233 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1918" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:1919
    rdfs:label "E160FS (c.479_480delAG)" ;
    m2r:evidence civice:5191 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191486 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191487 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "AG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1919" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:1920
    rdfs:label "G93R (c.277G>C)" ;
    m2r:evidence civice:5432,civice:5450 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183808 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183808 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1920" ;
    a obo:missense_variant, m2r:Variation .


civicv:1921
    rdfs:label "H115Y (c.343C>T)" ;
    m2r:evidence civice:5193,civice:5363 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188200 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188200 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1921" ;
    a obo:missense_variant, m2r:Variation .


civicv:1922
    rdfs:label "I109FS (c.326delT)" ;
    civico:hgvs "ENST00000256474.2:c.326delT" ;
    dcterms:identifier "1922" ;
    a m2r:Variation .


civicv:1923
    rdfs:label "L153P (c.458T>C)" ;
    m2r:evidence civice:5196 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188315 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188315 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1923" ;
    a obo:missense_variant, m2r:Variation .


civicv:1924
    rdfs:label "L188R (c.563T>G)" ;
    m2r:evidence civice:5200 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191570 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191570 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1924" ;
    a obo:missense_variant, m2r:Variation .


civicv:1925
    rdfs:label "L85fs (c.253_254ins38)" ;
    dcterms:identifier "1925" ;
    a m2r:Variation .


civicv:1926
    rdfs:label "F76del (c.227_229delTCT)" ;
    m2r:evidence civice:5203,civice:5340,civice:5426,civice:5447,civice:5641,civice:5682,civice:5744,civice:5749,civice:5766,civice:6121 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183758 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183760 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "TCT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1926" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:1927
    rdfs:label "P103A (c.307C>G)" ;
    civico:hgvs "NM_000551.3:c.307C>G,NP_000542.1:p.Pro103Ala,NC_000003.11:g.10183838C>G,ENST00000256474.2:c.307C>G" ;
    dcterms:identifier "1927" ;
    a m2r:Variation .


civicv:1928
    rdfs:label "P138T (c.412C>A)" ;
    m2r:evidence civice:5205 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188269 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188269 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1928" ;
    a obo:missense_variant, m2r:Variation .


civicv:1929
    rdfs:label "P59fs (c.176delC)" ;
    civico:hgvs "ENST00000256474.2:c.176delC,NC_000003.11:g.10183707del,NM_000551.3:c.176del,NP_000542.1:p.Pro59ArgfsTer8" ;
    dcterms:identifier "1929" ;
    a m2r:Variation .


civicv:1930
    rdfs:label "P59S (c.175C>T)" ;
    civico:hgvs "NM_000551.3:c.175C>T,NP_000542.1:p.Pro59Ser,NC_000003.11:g.10183706C>T,ENST00000256474.2:c.175C>T" ;
    dcterms:identifier "1930" ;
    a m2r:Variation .


civicv:1931
    rdfs:label "P61P (c.183C>G)" ;
    civico:hgvs "NM_000551.3:c.183C>G,NP_000542.1:p.Pro61=,NC_000003.11:g.10183714C>G,ENST00000256474.2:c.183C>G" ;
    dcterms:identifier "1931" ;
    a m2r:Variation .


civicv:1932
    rdfs:label "Y175* (c.525C>A)" ;
    civico:hgvs "ENST00000256474.2:c.525C>A,NP_000542.1:p.Tyr175Ter,NC_000003.11:g.10191532C>A,NM_000551.3:c.525C>A" ;
    dcterms:identifier "1932" ;
    a m2r:Variation .


civicv:1933
    rdfs:label "Y98C  (c.293A>G)" ;
    civico:hgvs "NM_000551.3:c.293A>G,NP_000542.1:p.Tyr98Cys,NC_000003.11:g.10183824A>G,ENST00000256474.2:c.293A>G" ;
    dcterms:identifier "1933" ;
    a m2r:Variation .


civicv:1934
    rdfs:label "V155G (c.464T>G)" ;
    civico:hgvs "ENST00000256474.2:c.464T>G,NC_000003.11:g.10191471T>G,NM_000551.3:c.464T>G,NP_000542.1:p.Val155Gly" ;
    dcterms:identifier "1934" ;
    a m2r:Variation .


civicv:1935
    rdfs:label "V170G (c.509T>G)" ;
    m2r:evidence civice:5172,civice:5303 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191516 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191516 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1935" ;
    a obo:missense_variant, m2r:Variation .


civicv:1936
    rdfs:label "V66G (c.197T>G)" ;
    civico:hgvs "ENST00000256474.2:c.197T>G,NC_000003.11:g.10183728T>G,NM_000551.3:c.197T>G,NP_000542.1:p.Val66Gly" ;
    dcterms:identifier "1936" ;
    a m2r:Variation .


civicv:1937
    rdfs:label "V84L (c.250G>C)" ;
    civico:hgvs "NP_000542.1:p.Val84Leu,NM_000551.3:c.250G>C,NC_000003.11:g.10183781G>C,ENST00000256474.2:c.250G>C" ;
    dcterms:identifier "1937" ;
    a m2r:Variation .


civicv:1938
    rdfs:label "EXON 2 DELETION" ;
    dcterms:identifier "1938" ;
    a m2r:Variation .


civicv:1939
    rdfs:label "EXON 3 DELETION" ;
    m2r:evidence civice:5767 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1939" ;
    a m2r:Variation .


civicv:1940
    rdfs:label "EXON 2-3 DELETION" ;
    dcterms:identifier "1940" ;
    a m2r:Variation .


civicv:1941
    rdfs:label "S168T (c.503G>C)" ;
    civico:hgvs "ENST00000256474.2:c.503G>C,NC_000003.11:g.10191510G>C,NM_000551.3:c.503G>C,NP_000542.1:p.Ser168Thr" ;
    dcterms:identifier "1941" ;
    a m2r:Variation .


civicv:1942
    rdfs:label "P86S (c.257C>T)" ;
    dcterms:identifier "1942" ;
    a m2r:Variation .


civicv:1943
    rdfs:label "Q164H (c.492G>C)" ;
    civico:hgvs "ENST00000256474.2:c.492G>C" ;
    dcterms:identifier "1943" ;
    a m2r:Variation .


civicv:1944
    rdfs:label "L63P (c.188T>C)" ;
    civico:hgvs "NM_000551.3:c.188T>C,NP_000542.1:p.Leu63Pro,NC_000003.11:g.10183719T>C,ENST00000256474.2:c.188T>C" ;
    dcterms:identifier "1944" ;
    a m2r:Variation .


civicv:1945
    rdfs:label "p.Phe119Glnfs*12 (c.354_355delCT)" ;
    dcterms:identifier "1945" ;
    a m2r:Variation .


civicv:1946
    rdfs:label "Y156C (c.467A>G)" ;
    m2r:evidence civice:5298,civice:5417,civice:5463 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191474 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191474 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease,civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "1946" ;
    a obo:missense_variant, m2r:Variation .


civicv:1947
    rdfs:label "Null (Partial deletion of 4.6 Kb)" ;
    dcterms:identifier "1947" ;
    a m2r:Variation .


civicv:1948
    rdfs:label "R69fs (c.204insG)" ;
    m2r:evidence civice:5245 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1948" ;
    a m2r:Variation .


civicv:1949
    rdfs:label "G144fs (c.432insG)" ;
    m2r:evidence civice:5247 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1949" ;
    a m2r:Variation .


civicv:1951
    rdfs:label "Null (Partial deletion of Exon 2)" ;
    dcterms:identifier "1951" ;
    a m2r:Variation .


civicv:1952
    rdfs:label "Null (Partial deletion of Exon 3)" ;
    dcterms:identifier "1952" ;
    a m2r:Variation .


civicv:1953
    rdfs:label "N131K (c.393C>A)" ;
    m2r:evidence civice:5266,civice:5457 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188250 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188250 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1953" ;
    a obo:missense_variant, m2r:Variation .


civicv:1954
    rdfs:label "T105fs (c.315insAC)" ;
    m2r:evidence civice:5268 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1954" ;
    a m2r:Variation .


civicv:1955
    rdfs:label "P71fs (c.211insT)" ;
    m2r:evidence civice:5269 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1955" ;
    a m2r:Variation .


civicv:1956
    rdfs:label "E70K (c.208G>A)" ;
    m2r:evidence civice:5273,civice:5780 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183739 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183739 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1956" ;
    a obo:missense_variant, m2r:Variation .


civicv:1957
    rdfs:label "H115Q (c.345C>G)" ;
    m2r:evidence civice:5274 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188202 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188202 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1957" ;
    a obo:missense_variant, m2r:Variation .


civicv:1958
    rdfs:label "H191FS (c.571delC)" ;
    m2r:evidence civice:5275 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191578 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191578 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1958" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:1959
    rdfs:label "Null (c.1-?_463+?del)" ;
    dcterms:identifier "1959" ;
    a m2r:Variation .


civicv:1960
    rdfs:label "L140fs (c.417_to_418delTC)" ;
    m2r:evidence civice:5279 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1960" ;
    a m2r:Variation .


civicv:1961
    rdfs:label "M54fs (c.161insT)" ;
    m2r:evidence civice:5283 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1961" ;
    a m2r:Variation .


civicv:1962
    rdfs:label "P154P (c.462A>C)" ;
    m2r:evidence civice:5285 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188319 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188319 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1962" ;
    a obo:synonymous_variant, m2r:Variation .


civicv:1963
    rdfs:label "S80R (c.238A>C)" ;
    m2r:evidence civice:5288,civice:5547,civice:5548 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183769 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183769 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1963" ;
    a obo:missense_variant, m2r:Variation .


civicv:1964
    rdfs:label "R60fs (c.179delG)" ;
    m2r:evidence civice:5290 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183710 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183710 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1964" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:1965
    rdfs:label "I109TfsX50 (c.326delT)" ;
    civico:hgvs "ENST00000256474.2:c.326delT" ;
    dcterms:identifier "1965" ;
    a m2r:Variation .


civicv:1966
    rdfs:label "W88S (c.263G>C)" ;
    m2r:evidence civice:5296 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183794 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183794 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1966" ;
    a obo:missense_variant, m2r:Variation .


civicv:1967
    rdfs:label "Y156D (c.466T>G)" ;
    m2r:evidence civice:5297 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191473 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191473 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1967" ;
    a obo:missense_variant, m2r:Variation .


civicv:1968
    rdfs:label "Y156* (c.468T>G)" ;
    m2r:evidence civice:5299 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191475 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191475 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1968" ;
    a obo:stop_gained, m2r:Variation .


civicv:1969
    rdfs:label "Y175* (c.525C>G)" ;
    m2r:evidence civice:5300,civice:5440 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191532 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191532 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1969" ;
    a obo:stop_gained, m2r:Variation .


civicv:1970
    rdfs:label "V130L (c.388G>C)" ;
    m2r:evidence civice:5301 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188245 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188245 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1970" ;
    a obo:missense_variant, m2r:Variation .


civicv:1971
    rdfs:label "Null (c.341-?_642+?del)" ;
    dcterms:identifier "1971" ;
    a m2r:Variation .


civicv:1972
    rdfs:label "Splicing alteration (c.463+1G>A)" ;
    civico:hgvs "NM_000551.3:c.463+1G>A,NC_000003.11:g.10188321G>A,ENST00000256474.2:c.463+1G>A" ;
    dcterms:identifier "1972" ;
    a m2r:Variation .


civicv:1973
    rdfs:label "Null (c.464-?_642+?del)" ;
    dcterms:identifier "1973" ;
    a m2r:Variation .


civicv:1974
    rdfs:label "Splicing alteration (c.464-1G>A)" ;
    m2r:evidence civice:5357 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191470 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191470 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1974" ;
    a obo:splice_acceptor_variant, m2r:Variation .


civicv:1975
    rdfs:label "R167fsX4 (c.499_504delinsT)" ;
    civico:hgvs "ENST00000256474.2:c.499_504delinsT" ;
    dcterms:identifier "1975" ;
    a m2r:Variation .


civicv:1976
    rdfs:label "E173* (c.517G>T)" ;
    civico:hgvs "ENST00000256474.2:c.517G>T,NC_000003.11:g.10191524G>T,NM_000551.3:c.517G>T,NP_000542.1:p.Glu173Ter" ;
    dcterms:identifier "1976" ;
    a m2r:Variation .


civicv:1977
    rdfs:label "V194fs (c.579_580delTG)" ;
    civico:hgvs "ENST00000256474.2:c.579_580delTG" ;
    dcterms:identifier "1977" ;
    a m2r:Variation .


civicv:1978
    rdfs:label "Null (c.-678-?_340+?del)" ;
    dcterms:identifier "1978" ;
    a m2r:Variation .


civicv:1979
    rdfs:label "Null (c.-678-?_642+?del)" ;
    dcterms:identifier "1979" ;
    a m2r:Variation .


civicv:1980
    rdfs:label "R82P (c.245G>C)" ;
    civico:hgvs "NM_000551.3:c.245G>C,NP_000542.1:p.Arg82Pro,NC_000003.11:g.10183776G>C,ENST00000256474.2:c.245G>C" ;
    dcterms:identifier "1980" ;
    a m2r:Variation .


civicv:1981
    rdfs:label "N100fsX131 (c.298_299InsA)" ;
    dcterms:identifier "1981" ;
    a m2r:Variation .


civicv:1982
    rdfs:label "DELETION" ;
    dcterms:identifier "1982" ;
    a m2r:Variation .


civicv:1983
    rdfs:label "DELETION" ;
    dcterms:identifier "1983" ;
    a m2r:Variation .


civicv:1986
    rdfs:label "*214L (c.641G>T)" ;
    m2r:evidence civice:5334 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191648 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191648 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1986" ;
    a obo:stop_lost, m2r:Variation .


civicv:1987
    rdfs:label "*214W (c.642A>G)" ;
    m2r:evidence civice:5335 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191649 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191649 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1987" ;
    a obo:stop_lost, m2r:Variation .


civicv:1988
    rdfs:label "*214C (c.642A>T)" ;
    m2r:evidence civice:5336 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191649 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191649 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1988" ;
    a obo:stop_lost, m2r:Variation .


civicv:1989
    rdfs:label "G144fs (c.431delG)" ;
    civico:hgvs "NM_000551.3:c.431delG,NP_000542.1:p.Gly144Aspfs,NC_000003.11:g.10188288delG,ENST00000256474.2:c.431delG" ;
    dcterms:identifier "1989" ;
    a m2r:Variation .


civicv:1990
    rdfs:label "Splicing alteration (c.464-1G>T)" ;
    m2r:evidence civice:5343,civice:5642 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191470 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191470 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1990" ;
    a obo:splice_acceptor_variant, m2r:Variation .


civicv:1991
    rdfs:label "EXON 9 + EXON 20 MUTATIONS" ;
    dcterms:identifier "1991" ;
    a m2r:Variation .


civicv:1992
    rdfs:label "Splicing alteration (c.464-2A>T)" ;
    m2r:evidence civice:5351 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191469 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191469 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1992" ;
    a obo:splice_acceptor_variant, m2r:Variation .


civicv:1993
    rdfs:label "Splicing alteration (c.463+2C>T)" ;
    m2r:evidence civice:5356 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1993" ;
    a m2r:Variation .


civicv:1994
    rdfs:label "Q132* (c.394C>T)" ;
    m2r:evidence civice:5358,civice:5458 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188251 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188251 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1994" ;
    a obo:stop_gained, m2r:Variation .


civicv:1995
    rdfs:label "C77ins (c.230_insTCT)" ;
    m2r:evidence civice:5364 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1995" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:1996
    rdfs:label "L129fs (c.384delT)" ;
    m2r:evidence civice:5365 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188241 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188241 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1996" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:1997
    rdfs:label "L178Q (c.533T>A)" ;
    m2r:evidence civice:5366 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191540 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191540 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST000002564742" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1997" ;
    a obo:missense_variant, m2r:Variation .


civicv:1998
    rdfs:label "Splicing alteration (c.463+1G>C)" ;
    m2r:evidence civice:5373 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188321 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188321 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:RenalCellCarcinoma ;
    dcterms:identifier "1998" ;
    a obo:splice_donor_variant, m2r:Variation .


civicv:1999
    rdfs:label "V74G (c.221T>G)" ;
    m2r:evidence civice:5374,civice:5424,civice:5446 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183752 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183752 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "1999" ;
    a obo:missense_variant, m2r:Variation .


civicv:2000
    rdfs:label "H115R (c.344A>G)" ;
    m2r:evidence civice:5377,civice:5772 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188201 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188201 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2000" ;
    a obo:missense_variant, m2r:Variation .


civicv:2001
    rdfs:label "R131S (c.392A>G)" ;
    dcterms:identifier "2001" ;
    a m2r:Variation .


civicv:2002
    rdfs:label "Q73fs (c.215delC)" ;
    civico:hgvs "ENST00000256474.2:c.215delC" ;
    dcterms:identifier "2002" ;
    a m2r:Variation .


civicv:2003
    rdfs:label "S111R (c.333C>A)" ;
    civico:hgvs "NP_000542.1:p.Ser111Arg,ENST00000256474.2:c.333C>A,NC_000003.11:g.10183864C>A,NM_000551.3:c.333C>A" ;
    dcterms:identifier "2003" ;
    a m2r:Variation .


civicv:2004
    rdfs:label "S168fs (c.503delG)" ;
    civico:hgvs "ENST00000256474.2:c.503delG,NC_000003.11:g.10191510delG,NM_000551.3:c.503delG,NP_000542.1:p.Ser168ThrfsTer2" ;
    dcterms:identifier "2004" ;
    a m2r:Variation .


civicv:2005
    rdfs:label "P172fs  (c.516delT)" ;
    civico:hgvs "ENST00000256474.2:c.516delT" ;
    dcterms:identifier "2005" ;
    a m2r:Variation .


civicv:2006
    rdfs:label "Y112N (c.334T>A)" ;
    civico:hgvs "NM_000551.3:c.334T>A,NP_000542.1:p.Tyr112Asn,NC_000003.11:g.10183865T>A,ENST00000256474.2:c.334T>A" ;
    dcterms:identifier "2006" ;
    a m2r:Variation .


civicv:2007
    rdfs:label "R107G  (c.319C>G)" ;
    m2r:evidence civice:5399 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183850 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183850 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2007" ;
    a obo:missense_variant, m2r:Variation .


civicv:2008
    rdfs:label "G93C (c.277G>T)" ;
    m2r:evidence civice:5406 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183808 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183808 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "2008" ;
    a obo:missense_variant, m2r:Variation .


civicv:2009
    rdfs:label "G93V (c.278G>T)" ;
    m2r:evidence civice:5408 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183809 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183809 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "2009" ;
    a obo:missense_variant, m2r:Variation .


civicv:2010
    rdfs:label "L198Q  (c.593T>A)" ;
    m2r:evidence civice:5410,civice:5473 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191600 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191600 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AdrenalGlandPheochromocytoma,civic:VonHippel-LindauDisease ;
    dcterms:identifier "2010" ;
    a obo:missense_variant, m2r:Variation .


civicv:2011
    rdfs:label "S65A (c.193T>G)" ;
    m2r:evidence civice:5413 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183724 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183724 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "2011" ;
    a obo:missense_variant, m2r:Variation .


civicv:2012
    rdfs:label "S68W (c.203C>G)" ;
    m2r:evidence civice:5414 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "2012" ;
    a m2r:Variation .


civicv:2013
    rdfs:label "Y156N (c.466T>A)" ;
    m2r:evidence civice:5416 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191473 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191473 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "2013" ;
    a obo:missense_variant, m2r:Variation .


civicv:2014
    rdfs:label "P61fs (c.183insC)" ;
    m2r:evidence civice:5420 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2014" ;
    a m2r:Variation .


civicv:2015
    rdfs:label "F76del (c.226_228delTTC)" ;
    m2r:evidence civice:4919,civice:5650,civice:5654 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183757 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183759 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "TTC" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2015" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:2016
    rdfs:label "Null (Complete deletion)" ;
    dcterms:identifier "2016" ;
    a m2r:Variation .


civicv:2017
    rdfs:label "Splicing alteration (IVS1-1G>A)" ;
    dcterms:identifier "2017" ;
    a m2r:Variation .


civicv:2019
    rdfs:label "Splicing alteration (IVS2-1G>C)" ;
    dcterms:identifier "2019" ;
    a m2r:Variation .


civicv:2020
    rdfs:label "L85P (c.254T>C)" ;
    m2r:evidence civice:5431 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183785 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183785 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2020" ;
    a obo:missense_variant, m2r:Variation .


civicv:2021
    rdfs:label "R108ins (c.324InsCGC)" ;
    m2r:evidence civice:5434 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2021" ;
    a m2r:Variation .


civicv:2022
    rdfs:label "V194fs (c.581_582delTG)" ;
    m2r:evidence civice:5441 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191588 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191589 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "TG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2022" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2023
    rdfs:label "A149fs (c.449del14-nt)" ;
    m2r:evidence civice:5442 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2023" ;
    a m2r:Variation .


civicv:2024
    rdfs:label "3'UTR alteration (c.639+10C>G)" ;
    m2r:evidence civice:5443 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2024" ;
    a m2r:Variation .


civicv:2026
    rdfs:label "G114S (c.340G>A)" ;
    m2r:evidence civice:5452 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183871 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183871 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2026" ;
    a obo:missense_variant, m2r:Variation .


civicv:2027
    rdfs:label "W117fs (c.349dupT)" ;
    m2r:evidence civice:5453 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188206 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188207 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2027" ;
    a obo:inframe_insertion, m2r:Variation .


civicv:2028
    rdfs:label "A122I (c.364_365GC>AT)" ;
    m2r:evidence civice:5456,civice:6417 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188221 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188222 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "GC" ;
    m2r:alternative_allele "AT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2028" ;
    a obo:missense_variant, m2r:Variation .


civicv:2029
    rdfs:label "N150fs (c.445_458del)" ;
    m2r:evidence civice:5459 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188302 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188315 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "GCCAATATCACACT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2029" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:2030
    rdfs:label "I151M (c.453C>G)" ;
    m2r:evidence civice:5460 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188310 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188310 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2030" ;
    a obo:missense_variant, m2r:Variation .


civicv:2032
    rdfs:label "E160FS (c.478_479delGA)" ;
    m2r:evidence civice:5465 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191485 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191486 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "GA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2032" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2033
    rdfs:label "L163H (c.488T>A)" ;
    m2r:evidence civice:5467 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191495 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191495 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2033" ;
    a obo:missense_variant, m2r:Variation .


civicv:2034
    rdfs:label "L129P (c.386T>C)" ;
    m2r:evidence civice:5479 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188243 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188243 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2034" ;
    a obo:missense_variant, m2r:Variation .


civicv:2035
    rdfs:label "C162FS (c.483delA)" ;
    m2r:evidence civice:5482 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191490 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191490 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2035" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2036
    rdfs:label "Null (Partial deletion of Exons 2 & 3)" ;
    m2r:evidence civice:5486 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2036" ;
    a m2r:Variation .


civicv:2037
    rdfs:label "N78I (c.233A>T)" ;
    m2r:evidence civice:5489 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183764 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183764 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2037" ;
    a obo:missense_variant, m2r:Variation .


civicv:2038
    rdfs:label "I147V (c.439A>G)" ;
    civico:hgvs "NM_000551.3:c.439A>G,NP_000542.1:p.Ile147Val,NC_000003.11:g.10188296A>G,ENST00000256474.2:c.439A>G" ;
    dcterms:identifier "2038" ;
    a m2r:Variation .


civicv:2039
    rdfs:label "W88fs (c.263_265delGGCinsTT)" ;
    m2r:evidence civice:5495 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183794 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183796 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "GGC" ;
    m2r:alternative_allele "TT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2039" ;
    a obo:indel,obo:frameshift_variant, m2r:Variation .


civicv:2040
    rdfs:label "K159fs (c.477_478insCA)" ;
    m2r:evidence civice:5496 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191484 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191485 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:alternative_allele "CA" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2040" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:2041
    rdfs:label "Q73fs (c.217delC)" ;
    m2r:evidence civice:5500 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183748 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183748 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2041" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2042
    rdfs:label "A149fs (c.445delG)" ;
    m2r:evidence civice:5501 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188302 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188302 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2042" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:2043
    rdfs:label "G104A (c.311G>C)" ;
    civico:hgvs "NM_000551.3:c.311G>C,NP_000542.1:p.Gly104Ala,NC_000003.11:g.10183842G>C,ENST00000256474.2:c.311G>C" ;
    dcterms:identifier "2043" ;
    a m2r:Variation .


civicv:2044
    rdfs:label "R107H (c.320G>A)" ;
    civico:hgvs "NM_000551.3:c.320G>A,NP_000542.1:p.Arg107His,NC_000003.11:g.10183851G>A,ENST00000256474.2:c.320G>A" ;
    dcterms:identifier "2044" ;
    a m2r:Variation .


civicv:2045
    rdfs:label "S111C (c.331A>T)" ;
    dcterms:identifier "2045" ;
    a m2r:Variation .


civicv:2046
    rdfs:label "V155L (c.463G>C)" ;
    dcterms:identifier "2046" ;
    a m2r:Variation .


civicv:2047
    rdfs:label "EXON 3 DELETION" ;
    dcterms:identifier "2047" ;
    a m2r:Variation .


civicv:2048
    rdfs:label "Splicing alteration (c.463+1G>T)" ;
    civico:hgvs "NM_000551.3:c.463+1G>T,NC_000003.11:g.10188321G>T,ENST00000256474.2:c.463+1G>T" ;
    dcterms:identifier "2048" ;
    a m2r:Variation .


civicv:2049
    rdfs:label "Null (Deletion of Exon 2)" ;
    dcterms:identifier "2049" ;
    a m2r:Variation .


civicv:2050
    rdfs:label "E1705K" ;
    m2r:evidence civice:5533 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantSertoli-LeydigCellTumor ;
    dcterms:identifier "2050" ;
    a m2r:Variation .


civicv:2051
    rdfs:label "D1709N" ;
    m2r:evidence civice:5534,civice:5886,civice:5899 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantSertoli-LeydigCellTumor,civic:GlandularPatternOvarianYolkSacTumor ;
    dcterms:identifier "2051" ;
    a m2r:Variation .


civicv:2052
    rdfs:label "E1813Q" ;
    m2r:evidence civice:5535,civice:5892 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantSertoli-LeydigCellTumor ;
    dcterms:identifier "2052" ;
    a m2r:Variation .


civicv:2053
    rdfs:label "D126Y (c.376G>T)" ;
    civico:hgvs "NM_000551.3:c.376G>T,NP_000542.1:p.Asp126Tyr,NC_000003.11:g.10188233G>T,ENST00000256474.2:c.376G>T" ;
    dcterms:identifier "2053" ;
    a m2r:Variation .


civicv:2054
    rdfs:label "T124I (c.371C>T)" ;
    civico:hgvs "NM_000551.3:c.371C>T,NP_000542.1:p.Thr124Ile,NC_000003.11:g.10188228C>T,ENST00000256474.2:c.371C>T" ;
    dcterms:identifier "2054" ;
    a m2r:Variation .


civicv:2055
    rdfs:label "P146fs (c.436delC)" ;
    m2r:evidence civice:5544 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188293 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188293 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2055" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2056
    rdfs:label "W88R (c.262T>C)" ;
    m2r:evidence civice:5549 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183793 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183793 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2056" ;
    a obo:missense_variant, m2r:Variation .


civicv:2057
    rdfs:label "H115FS (c.344delA)" ;
    m2r:evidence civice:5553 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188201 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188201 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2057" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2058
    rdfs:label "P102fs (c.305delC)" ;
    m2r:evidence civice:5554 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183836 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183836 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2058" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2059
    rdfs:label "G144R (c.430G>A)" ;
    civico:hgvs "ENST00000256474.2:c.430G>A,NC_000003.11:g.10188287G>A,NM_000551.3:c.430G>A,NP_000542.1:p.Gly144Arg" ;
    dcterms:identifier "2059" ;
    a m2r:Variation .


civicv:2060
    rdfs:label "H125P (c.374A>C)" ;
    civico:hgvs "NM_000551.3:c.374A>C,NP_000542.1:p.His125Pro,NC_000003.11:g.10188231A>C,ENST00000256474.2:c.374A>C" ;
    dcterms:identifier "2060" ;
    a m2r:Variation .


civicv:2061
    rdfs:label "Gain-of-Function" ;
    m2r:evidence civice:4845 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Astrocytoma ;
    dcterms:identifier "2061" ;
    a m2r:Variation .


civicv:2063
    rdfs:label "F354L" ;
    dcterms:identifier "2063" ;
    a m2r:Variation .


civicv:2064
    rdfs:label "P192S (c.574C>T)" ;
    civico:hgvs "NM_000551.3:c.574C>T,NP_000542.1:p.Pro192Ser,NC_000003.11:g.10191581C>T,ENST00000256474.2:c.574C>T" ;
    dcterms:identifier "2064" ;
    a m2r:Variation .


civicv:2065
    rdfs:label "Splicing alteration (IVS2+3A>G)" ;
    dcterms:identifier "2065" ;
    a m2r:Variation .


civicv:2066
    rdfs:label "Y175N (c.523T>A)" ;
    civico:hgvs "ENST00000256474.2:c.523T>A,NC_000003.11:g.10191530T>A,NM_000551.3:c.523T>A,NP_000542.1:p.Tyr175Asn" ;
    dcterms:identifier "2066" ;
    a m2r:Variation .


civicv:2067
    rdfs:label "Y175C (c.524A>G)" ;
    civico:hgvs "NM_000551.3:c.524A>G,NP_000542.1:p.Tyr175Cys,NC_000003.11:g.10191531A>G,ENST00000256474.2:c.524A>G" ;
    dcterms:identifier "2067" ;
    a m2r:Variation .


civicv:2068
    rdfs:label "V87A (c.260T>C)" ;
    civico:hgvs "ENST00000256474.2:c.260T>C,NC_000003.11:g.10183791T>C,NM_000551.3:c.260T>C,NP_000542.1:p.Val87Ala" ;
    dcterms:identifier "2068" ;
    a m2r:Variation .


civicv:2069
    rdfs:label "P97L (c.290C>T)" ;
    civico:hgvs "ENST00000256474.2:c.290C>T" ;
    dcterms:identifier "2069" ;
    a m2r:Variation .


civicv:2070
    rdfs:label "L184H (c.551T>A)" ;
    civico:hgvs "ENST00000256474.2:c.551T>A" ;
    dcterms:identifier "2070" ;
    a m2r:Variation .


civicv:2073
    rdfs:label "G106fs (c.316insA)" ;
    dcterms:identifier "2073" ;
    a m2r:Variation .


civicv:2074
    rdfs:label "Splicing alteration (c.340+1G>T)" ;
    civico:hgvs "ENST00000256474.2:c.340+1G>T,NC_000003.11:g.10183872G>T,NM_198156.2:c.340+1G>T" ;
    dcterms:identifier "2074" ;
    a m2r:Variation .


civicv:2075
    rdfs:label "Splicing alteration (c.463+2T>C)" ;
    civico:hgvs "NM_000551.3:c.463+2T>C,NC_000003.11:g.10188322T>C,ENST00000256474.2:c.463+2T>C" ;
    dcterms:identifier "2075" ;
    a m2r:Variation .


civicv:2076
    rdfs:label "V155M (c.463G>A)" ;
    civico:hgvs "NM_000551.3:c.463G>A,NP_000542.1:p.Val155Met,NC_000003.11:g.10188320G>A,ENST00000256474.2:c.463G>A" ;
    dcterms:identifier "2076" ;
    a m2r:Variation .


civicv:2077
    rdfs:label "Splicing alteration (c.464-1G>C)" ;
    m2r:evidence civice:5745 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191470 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191470 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2077" ;
    a obo:splice_acceptor_variant, m2r:Variation .


civicv:2078
    rdfs:label "Splicing alteration (c.464-2A>G)" ;
    m2r:evidence civice:5462,civice:5724,civice:5851 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191469 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191469 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2078" ;
    a obo:splice_acceptor_variant, m2r:Variation .


civicv:2079
    rdfs:label "Q164L (c.491A>T)" ;
    civico:hgvs "ENST00000256474.2:c.491A>T,NC_000003.11:g.10191498A>T,NM_000551.3:c.491A>T,NP_000542.1:p.Gln164Leu" ;
    dcterms:identifier "2079" ;
    a m2r:Variation .


civicv:2080
    rdfs:label "R176fs (c.527delG)" ;
    civico:hgvs "ENST00000256474.2:c.527delG" ;
    dcterms:identifier "2080" ;
    a m2r:Variation .


civicv:2081
    rdfs:label "V194fs (c.581_582delGT)" ;
    dcterms:identifier "2081" ;
    a m2r:Variation .


civicv:2082
    rdfs:label "Null (Partial deletion of Exon 1)" ;
    dcterms:identifier "2082" ;
    a m2r:Variation .


civicv:2083
    rdfs:label "Null (Partial deletion of Exons 1 & 2)" ;
    dcterms:identifier "2083" ;
    a m2r:Variation .


civicv:2084
    rdfs:label "P81L (c.242C>T)" ;
    civico:hgvs "NM_000551.3:c.242C>T,NP_000542.1:p.Pro81Leu,NC_000003.11:g.10183773C>T,ENST00000256474.2:c.242C>T" ;
    dcterms:identifier "2084" ;
    a m2r:Variation .


civicv:2085
    rdfs:label "T152I (c.455C>T)" ;
    civico:hgvs "ENST00000256474.2:c.455C>T,NC_000003.11:g.10188312C>T,NM_000551.3:c.455C>T,NP_000542.1:p.Thr152Ile" ;
    dcterms:identifier "2085" ;
    a m2r:Variation .


civicv:2086
    rdfs:label "V130I (c.388G>A)/ R200W (c.598C>T)" ;
    dcterms:identifier "2086" ;
    a m2r:Variation .


civicv:2087
    rdfs:label "L63fs (c.189_192delGCGC)" ;
    dcterms:identifier "2087" ;
    a m2r:Variation .


civicv:2088
    rdfs:label "F76del (c.224_226delTCT)" ;
    civico:hgvs "ENST00000256474.2:c.224_226delTCT" ;
    dcterms:identifier "2088" ;
    a m2r:Variation .


civicv:2089
    rdfs:label "P81delRVV (c.243_251delGCGCGTCGT)" ;
    m2r:evidence civice:5637,civice:5726 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2089" ;
    a m2r:Variation .


civicv:2090
    rdfs:label "P40fs (c.118ins)" ;
    m2r:evidence civice:5638 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2090" ;
    a m2r:Variation .


civicv:2091
    rdfs:label "T152fs (c.455insA)" ;
    m2r:evidence civice:5639,civice:5734 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2091" ;
    a m2r:Variation .


civicv:2092
    rdfs:label "T157fs (c.472ins)" ;
    m2r:evidence civice:5640 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2092" ;
    a m2r:Variation .


civicv:2093
    rdfs:label "Splicing alteration (c.464-2A>C)" ;
    civico:hgvs "NM_000551.3:c.464-2A>C,NC_000003.11:g.10191469A>C,ENST00000256474.2:c.464-2A>C" ;
    dcterms:identifier "2093" ;
    a m2r:Variation .


civicv:2094
    rdfs:label "T157fs (c.472ins1-nt)" ;
    dcterms:identifier "2094" ;
    a m2r:Variation .


civicv:2095
    rdfs:label "I151fs (c.452insA)" ;
    dcterms:identifier "2095" ;
    a m2r:Variation .


civicv:2096
    rdfs:label "F158ins (c.472insTTT)" ;
    dcterms:identifier "2096" ;
    a m2r:Variation .


civicv:2097
    rdfs:label "D92fs (c.275del18-nt)" ;
    m2r:evidence civice:5649 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2097" ;
    a m2r:Variation .


civicv:2098
    rdfs:label "K159fs (c.475delA)" ;
    m2r:evidence civice:5651 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191482 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191482 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2098" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2099
    rdfs:label "V66del (c.197_220del)" ;
    m2r:evidence civice:5653 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2099" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:2100
    rdfs:label "S183fs (c.548delC)" ;
    civico:hgvs "ENST00000256474.2:c.548delC" ;
    dcterms:identifier "2100" ;
    a m2r:Variation .


civicv:2101
    rdfs:label "V84M (c.250G>A)" ;
    civico:hgvs "NM_000551.3:c.250G>A,NP_000542.1:p.Val84Met,NC_000003.11:g.10183781G>A,ENST00000256474.2:c.250G>A" ;
    dcterms:identifier "2101" ;
    a m2r:Variation .


civicv:2103
    rdfs:label "Null (Partial deletion)" ;
    dcterms:identifier "2103" ;
    a m2r:Variation .


civicv:2104
    rdfs:label "Splicing alteration (c.340+5G>C)" ;
    civico:hgvs "NM_000551.3:c.340+5G>C,NC_000003.11:g.10183876G>C,ENST00000256474.2:c.340+5G>C" ;
    dcterms:identifier "2104" ;
    a m2r:Variation .


civicv:2105
    rdfs:label "D197N (c.589G>A)" ;
    civico:hgvs "ENST00000256474.2:c.589G>A,NC_000003.11:g.10191596G>A,NM_000551.3:c.589G>A,NP_000542.1:p.Asp197Asn" ;
    dcterms:identifier "2105" ;
    a m2r:Variation .


civicv:2106
    rdfs:label "S80G (c.238A>G)" ;
    civico:hgvs "NM_000551.3:c.238A>G,NP_000542.1:p.Ser80Gly,NC_000003.11:g.10183769A>G,ENST00000256474.2:c.238A>G" ;
    dcterms:identifier "2106" ;
    a m2r:Variation .


civicv:2107
    rdfs:label "F76L (c.228C>G)" ;
    civico:hgvs "ENST00000256474.2:c.228C>G,NC_000003.11:g.10183759C>G,NM_000551.3:c.228C>G,NP_000542.1:p.Phe76Leu" ;
    dcterms:identifier "2107" ;
    a m2r:Variation .


civicv:2108
    rdfs:label "UNDEREXPRESSION" ;
    m2r:evidence civice:5675,civice:5676,civice:5787 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 27022524 ;
            faldo:reference hco:1#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 27108595 ;
            faldo:reference hco:1#GRCh37
        ]
    ] ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000324856.7" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:StomachCancer,civic:ClearCellRenalCellCarcinoma,civic:OvarianClearCellCarcinoma ;
    dcterms:identifier "2108" ;
    a m2r:Variation .


civicv:2109
    rdfs:label "Y646 or Y641" ;
    dcterms:identifier "2109" ;
    a m2r:Variation .


civicv:2110
    rdfs:label "R82L (c.245G>T)" ;
    civico:hgvs "ENST00000256474.2:c.245G>T,NC_000003.11:g.10183776G>T,NM_000551.3:c.245G>T,NP_000542.1:p.Arg82Leu" ;
    dcterms:identifier "2110" ;
    a m2r:Variation .


civicv:2112
    rdfs:label "N78D (c.232A>G)" ;
    civico:hgvs "ENST00000256474.2:c.232A>G" ;
    dcterms:identifier "2112" ;
    a m2r:Variation .


civicv:2113
    rdfs:label "N78Y (c.232A>T)" ;
    civico:hgvs "NM_000551.3:c.232A>T,NP_000542.1:p.Asn78Tyr,NC_000003.11:g.10183763A>T,ENST00000256474.2:c.232A>T" ;
    dcterms:identifier "2113" ;
    a m2r:Variation .


civicv:2114
    rdfs:label "Splicing alteration (c.340+1G>A)" ;
    m2r:evidence civice:5099,civice:5332,civice:5689,civice:5845 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183872 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183872 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2114" ;
    a obo:splice_donor_variant, m2r:Variation .


civicv:2115
    rdfs:label "Y185* (c.555C>A)" ;
    civico:hgvs "NP_000542.1:p.Tyr185Ter,ENST00000256474.2:c.555C>A,NC_000003.11:g.10191562C>A,NM_000551.3:c.555C>A" ;
    dcterms:identifier "2115" ;
    a m2r:Variation .


civicv:2116
    rdfs:label "R167Q (c.499C>T)" ;
    dcterms:identifier "2116" ;
    a m2r:Variation .


civicv:2117
    rdfs:label "P95R (c.284C>G)" ;
    civico:hgvs "ENST00000256474.2:c.284C>G" ;
    dcterms:identifier "2117" ;
    a m2r:Variation .


civicv:2118
    rdfs:label "P103L (c.308C>T)" ;
    civico:hgvs "ENST00000256474.2:c.308C>T" ;
    dcterms:identifier "2118" ;
    a m2r:Variation .


civicv:2119
    rdfs:label "F119S (c.356T>C)" ;
    civico:hgvs "ENST00000256474.2:c.356T>C,NC_000003.11:g.10188213T>C,NM_000551.3:c.356T>C,NP_000542.1:p.Phe119Ser" ;
    dcterms:identifier "2119" ;
    a m2r:Variation .


civicv:2120
    rdfs:label "P138L (c.413C>T)" ;
    civico:hgvs "ENST00000256474.2:c.413C>T" ;
    dcterms:identifier "2120" ;
    a m2r:Variation .


civicv:2121
    rdfs:label "P61fs (c.181delCCGT)" ;
    dcterms:identifier "2121" ;
    a m2r:Variation .


civicv:2122
    rdfs:label "S65* (c.203C>A)" ;
    civico:hgvs "ENST00000256474.2:c.203C>A,NM_000551.3:c.203C>A,NP_000542.1:p.Ser68Ter,NC_000003.11:g.10183734C>A" ;
    dcterms:identifier "2122" ;
    a m2r:Variation .


civicv:2123
    rdfs:label "C77del (c.229_231delTGC)" ;
    civico:hgvs "ENST00000256474.2:c.229_231delTGC,NC_000003.11:g.10183760_10183762del,NM_000551.3:c.229_231del,NP_000542.1:p.Cys77del" ;
    dcterms:identifier "2123" ;
    a m2r:Variation .


civicv:2124
    rdfs:label "W88C (c.264G>C)" ;
    civico:hgvs "ENST00000256474.2:c.264G>C,NC_000003.11:g.10183795G>C,NM_000551.3:c.264G>C,NP_000542.1:p.Trp88Cys" ;
    dcterms:identifier "2124" ;
    a m2r:Variation .


civicv:2125
    rdfs:label "Q132P (c.395A>C)" ;
    m2r:evidence civice:5131 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188252 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188252 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2125" ;
    a obo:missense_variant, m2r:Variation .


civicv:2126
    rdfs:label "D198fs (c.592_593delCT)" ;
    civico:hgvs "ENST00000256474.2:c.592_593delCT" ;
    dcterms:identifier "2126" ;
    a m2r:Variation .


civicv:2127
    rdfs:label "G93FS (c.279delC)" ;
    civico:hgvs "ENST00000256474.2:c.279delC" ;
    dcterms:identifier "2127" ;
    a m2r:Variation .


civicv:2128
    rdfs:label "P97P (c.291C>G)" ;
    civico:hgvs "ENST00000256474.2:c.291C>G" ;
    dcterms:identifier "2128" ;
    a m2r:Variation .


civicv:2129
    rdfs:label "G114dup (c.342dupGGT)" ;
    m2r:evidence civice:5725 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2129" ;
    a m2r:Variation .


civicv:2130
    rdfs:label "S65FS (c.194delC)" ;
    m2r:evidence civice:5727 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183725 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183725 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2130" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2131
    rdfs:label "Q73fs (c.214insGCCC)" ;
    m2r:evidence civice:5728 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2131" ;
    a m2r:Variation .


civicv:2132
    rdfs:label "F76fs (c.227insC)" ;
    m2r:evidence civice:5729 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2132" ;
    a m2r:Variation .


civicv:2133
    rdfs:label "Splicing alteration (c.341-2A>C)" ;
    m2r:evidence civice:5730,civice:5748 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188196 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188196 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:RenalCellCarcinoma,civic:VonHippel-LindauDisease ;
    dcterms:identifier "2133" ;
    a obo:splice_acceptor_variant, m2r:Variation .


civicv:2134
    rdfs:label "G114fs (c.341delCGTTTCCAACAATTTCTCGGTGT)" ;
    m2r:evidence civice:5731 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2134" ;
    a m2r:Variation .


civicv:2135
    rdfs:label "G123fs (c.369_375delGACACAC)" ;
    civico:hgvs "ENST00000256474.2:c.369_375delGACACAC" ;
    dcterms:identifier "2135" ;
    a m2r:Variation .


civicv:2136
    rdfs:label "H125fs (c.374insA)" ;
    m2r:evidence civice:5733 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2136" ;
    a m2r:Variation .


civicv:2137
    rdfs:label "L158fs (c.474_476delGAAinsC)" ;
    m2r:evidence civice:5735 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191481 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191483 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "GAA" ;
    m2r:alternative_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2137" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:2138
    rdfs:label "Y175fs (c.525delC)" ;
    m2r:evidence civice:5736 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191532 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191532 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2138" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2139
    rdfs:label "L188fs (c.562delC)" ;
    m2r:evidence civice:5737 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191569 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191569 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2139" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2140
    rdfs:label "Q195fs (c.584_585delAG)" ;
    m2r:evidence civice:5738 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191591 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191592 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "AG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2140" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:2141
    rdfs:label "D197FS (c.589delG)" ;
    m2r:evidence civice:5739 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191596 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191596 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2141" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2142
    rdfs:label "T202fs (c.606insA)" ;
    m2r:evidence civice:5740 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2142" ;
    a m2r:Variation .


civicv:2143
    rdfs:label "R113FS (c.337delC)" ;
    m2r:evidence civice:5741 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183868 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183868 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2143" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2144
    rdfs:label "E55fs (c.165_166dupG)" ;
    m2r:evidence civice:5742 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2144" ;
    a m2r:Variation .


civicv:2145
    rdfs:label "P61FS (c.182_185delCCGT)" ;
    m2r:evidence civice:5743 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183713 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183716 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "CCGT" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2145" ;
    a obo:frameshift_variant, m2r:Variation .


civicv:2146
    rdfs:label "Splicing alteration (c.463+3A>T)" ;
    civico:hgvs "NM_000551.3:c.463+3A>T,NC_000003.11:g.10188323A>T,ENST00000256474.2:c.463+3A>T" ;
    dcterms:identifier "2146" ;
    a m2r:Variation .


civicv:2147
    rdfs:label "K196E (c.586A>G)" ;
    civico:hgvs "NM_000551.3:c.586A>G,NP_000542.1:p.Lys196Glu,NC_000003.11:g.10191593A>G,ENST00000256474.2:c.586A>G" ;
    dcterms:identifier "2147" ;
    a m2r:Variation .


civicv:2148
    rdfs:label "R161R (c.481C>A)" ;
    m2r:evidence civice:5768 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2148" ;
    a m2r:Variation .


civicv:2149
    rdfs:label "N90I (c.269A>T)" ;
    civico:hgvs "NM_000551.3:c.269A>T,NP_000542.1:p.Asn90Ile,NC_000003.11:g.10183800A>T,ENST00000256474.2:c.269A>T" ;
    dcterms:identifier "2149" ;
    a m2r:Variation .


civicv:2150
    rdfs:label "I151F (c.451A>T)" ;
    m2r:evidence civice:5773 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2150" ;
    a m2r:Variation .


civicv:2151
    rdfs:label "W88* (c.263G>A)" ;
    m2r:evidence civice:5776 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183794 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183794 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2151" ;
    a obo:stop_gained, m2r:Variation .


civicv:2152
    rdfs:label "3'UTR alteration (c.642+70C>A)" ;
    m2r:evidence civice:5777 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191719 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191719 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2152" ;
    a m2r:Variation .


civicv:2153
    rdfs:label "G114fs (c.326_339dupTCCACAGCTACCGA)" ;
    dcterms:identifier "2153" ;
    a m2r:Variation .


civicv:2154
    rdfs:label "D121H (c.361G>C)" ;
    civico:hgvs "ENST00000256474.2:c.361G>C,NC_000003.11:g.10188218G>C,NM_000551.3:c.361G>C,NP_000542.1:p.Asp121His" ;
    dcterms:identifier "2154" ;
    a m2r:Variation .


civicv:2155
    rdfs:label "R145fs (c.432_433insA)" ;
    civico:hgvs "ENST00000256474.2:c.432_433insA" ;
    dcterms:identifier "2155" ;
    a m2r:Variation .


civicv:2156
    rdfs:label "S111R (c.331A>C)" ;
    civico:hgvs "NP_000542.1:p.Ser111Arg,ENST00000256474.2:c.331A>C,NC_000003.11:g.10183862A>C,NM_000551.3:c.331A>C" ;
    dcterms:identifier "2156" ;
    a m2r:Variation .


civicv:2157
    rdfs:label "L128P (c.383T>C)" ;
    civico:hgvs "ENST00000256474.2:c.383T>C" ;
    dcterms:identifier "2157" ;
    a m2r:Variation .


civicv:2158
    rdfs:label "F76fs (c.222_225dupCATC)" ;
    dcterms:identifier "2158" ;
    a m2r:Variation .


civicv:2159
    rdfs:label "V9, truncated variant, contiguous splicing of exons 1, 2, 3, and CE5" ;
    dcterms:identifier "2159" ;
    a m2r:Variation .


civicv:2160
    rdfs:label "Y98FS (c.291delC)" ;
    m2r:evidence civice:5794 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183822 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183822 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2160" ;
    a obo:frameshift_truncation, m2r:Variation .


civicv:2161
    rdfs:label "S183L (c.548C>T)" ;
    civico:hgvs "NM_000551.3:c.548C>T,NP_000542.1:p.Ser183Leu,NC_000003.11:g.10191555C>T,ENST00000256474.2:c.548C>T" ;
    dcterms:identifier "2161" ;
    a m2r:Variation .


civicv:2162
    rdfs:label "N150S (c.449A>G)" ;
    m2r:evidence civice:5799 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188306 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188306 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2162" ;
    a obo:missense_variant, m2r:Variation .


civicv:2163
    rdfs:label "EXPRESSION" ;
    dcterms:identifier "2163" ;
    a m2r:Variation .


civicv:2164
    rdfs:label "UNDEREXPRESSION" ;
    dcterms:identifier "2164" ;
    a m2r:Variation .


civicv:2165
    rdfs:label "S1088F" ;
    civico:hgvs "NM_000135.2:c.3263C>T,NP_000126.2:p.Ser1088Phe,NC_000016.9:g.89815152G>A,ENST00000568369.1:c.3263C>T" ;
    dcterms:identifier "2165" ;
    a m2r:Variation .


civicv:2166
    rdfs:label "SLC3A2-NRG1" ;
    dcterms:identifier "2166" ;
    a m2r:Variation .


civicv:2167
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "2167" ;
    a m2r:Variation .


civicv:2168
    rdfs:label "L1237F" ;
    m2r:evidence civice:5829 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:UreterSmallCellCarcinoma ;
    dcterms:identifier "2168" ;
    a m2r:Variation .


civicv:2169
    rdfs:label "MUTATION" ;
    m2r:evidence civice:5833 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicLymphocyticLeukemia ;
    dcterms:identifier "2169" ;
    a m2r:Variation .


civicv:2170
    rdfs:label "MUTATION" ;
    m2r:evidence civice:5834 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicLymphocyticLeukemia ;
    dcterms:identifier "2170" ;
    a m2r:Variation .


civicv:2171
    rdfs:label "LOSS-OF-FUNCTION" ;
    dcterms:identifier "2171" ;
    a m2r:Variation .


civicv:2172
    rdfs:label "Gain-of-Function" ;
    dcterms:identifier "2172" ;
    a m2r:Variation .


civicv:2173
    rdfs:label "E94K (c.280G>A)" ;
    civico:hgvs "NM_000551.3:c.280G>A,NP_000542.1:p.Glu94Lys,NC_000003.11:g.10183811G>A,ENST00000256474.2:c.280G>A" ;
    dcterms:identifier "2173" ;
    a m2r:Variation .


civicv:2174
    rdfs:label "WILDTYPE" ;
    m2r:evidence civice:2512 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "2174" ;
    a m2r:Variation .


civicv:2175
    rdfs:label "R79C (c.235C>T)" ;
    dcterms:identifier "2175" ;
    a m2r:Variation .


civicv:2176
    rdfs:label "Y175C (c.523A>G)" ;
    dcterms:identifier "2176" ;
    a m2r:Variation .


civicv:2177
    rdfs:label "M54I (c.162G>C)" ;
    civico:hgvs "ENST00000256474.2:c.162G>C" ;
    dcterms:identifier "2177" ;
    a m2r:Variation .


civicv:2178
    rdfs:label "ATP1B1-NRG1 fusion" ;
    m2r:evidence civice:5858 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cholangiocarcinoma ;
    dcterms:identifier "2178" ;
    civico:variantGroups "NRG1 gene fusions" ;
    a m2r:Variation .


civicv:2179
    rdfs:label "SDC4-NRG1" ;
    m2r:evidence civice:5859 ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "2179" ;
    civico:variantGroups "NRG1 gene fusions" ;
    a m2r:Variation .


civicv:2180
    rdfs:label "rs3828743" ;
    dcterms:identifier "2180" ;
    a m2r:Variation .


civicv:2181
    rdfs:label "R177ins (c.531insCTGAGAGTAAAGCCTGAA)" ;
    dcterms:identifier "2181" ;
    a m2r:Variation .


civicv:2182
    rdfs:label "Null (Large deletion)" ;
    dcterms:identifier "2182" ;
    a m2r:Variation .


civicv:2184
    rdfs:label "Partial deletion of 0.7 Kb" ;
    dcterms:identifier "2184" ;
    a m2r:Variation .


civicv:2185
    rdfs:label "Partial deletion of 1 Kb" ;
    dcterms:identifier "2185" ;
    a m2r:Variation .


civicv:2186
    rdfs:label "Partial deletion of 1.2 Kb" ;
    dcterms:identifier "2186" ;
    a m2r:Variation .


civicv:2187
    rdfs:label "Partial deletion of 1.5 Kb" ;
    dcterms:identifier "2187" ;
    a m2r:Variation .


civicv:2188
    rdfs:label "Partial deletion of 11 Kb" ;
    dcterms:identifier "2188" ;
    a m2r:Variation .


civicv:2189
    rdfs:label "Partial deletion of 12 Kb" ;
    dcterms:identifier "2189" ;
    a m2r:Variation .


civicv:2190
    rdfs:label "Partial deletion of 3.5 Kb" ;
    dcterms:identifier "2190" ;
    a m2r:Variation .


civicv:2191
    rdfs:label "Partial deletion of 3 Kb" ;
    dcterms:identifier "2191" ;
    a m2r:Variation .


civicv:2192
    rdfs:label "Partial deletion of 7.5 Kb" ;
    dcterms:identifier "2192" ;
    a m2r:Variation .


civicv:2193
    rdfs:label "Partial deletion of 7 Kb" ;
    dcterms:identifier "2193" ;
    a m2r:Variation .


civicv:2194
    rdfs:label "Partial deletion of 8.2 Kb" ;
    dcterms:identifier "2194" ;
    a m2r:Variation .


civicv:2195
    rdfs:label "D1709G" ;
    m2r:evidence civice:5887,civice:5897 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:MalignantSertoli-LeydigCellTumor,civic:OvarianGranulosaCellTumor ;
    dcterms:identifier "2195" ;
    a m2r:Variation .


civicv:2196
    rdfs:label "D1709E" ;
    m2r:evidence civice:5888,civice:5900 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:MalignantSertoli-LeydigCellTumor,civic:GlandularPatternOvarianYolkSacTumor ;
    dcterms:identifier "2196" ;
    a m2r:Variation .


civicv:2197
    rdfs:label "D1810H" ;
    dcterms:identifier "2197" ;
    a m2r:Variation .


civicv:2198
    rdfs:label "D1810Y" ;
    dcterms:identifier "2198" ;
    a m2r:Variation .


civicv:2199
    rdfs:label "D1810N" ;
    dcterms:identifier "2199" ;
    a m2r:Variation .


civicv:2200
    rdfs:label "E1813G" ;
    dcterms:identifier "2200" ;
    a m2r:Variation .


civicv:2201
    rdfs:label "E1813K" ;
    dcterms:identifier "2201" ;
    a m2r:Variation .


civicv:2202
    rdfs:label "FGFR2 fusions" ;
    m2r:evidence civice:5908 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cholangiocarcinoma ;
    dcterms:identifier "2202" ;
    a m2r:Variation .


civicv:2203
    rdfs:label "EGFR-RAD51 fusion" ;
    dcterms:identifier "2203" ;
    a m2r:Variation .


civicv:2204
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "2204" ;
    a m2r:Variation .


civicv:2205
    rdfs:label "AMPLIFICATION" ;
    dcterms:identifier "2205" ;
    a m2r:Variation .


civicv:2206
    rdfs:label "FGFR2 mutations" ;
    m2r:evidence civice:5912 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cholangiocarcinoma ;
    dcterms:identifier "2206" ;
    a m2r:Variation .


civicv:2207
    rdfs:label "EXPRESSION" ;
    dcterms:identifier "2207" ;
    a m2r:Variation .


civicv:2208
    rdfs:label "EXPRESSION" ;
    dcterms:identifier "2208" ;
    a m2r:Variation .


civicv:2209
    rdfs:label "EXPRESSION" ;
    dcterms:identifier "2209" ;
    a m2r:Variation .


civicv:2210
    rdfs:label "KMT2E-ASNS fusion (promoter swap)" ;
    dcterms:identifier "2210" ;
    a m2r:Variation .


civicv:2211
    rdfs:label "ALTERNATIVE TRANSCRIPT (ATI)" ;
    m2r:evidence civice:5929 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:MalignantMesothelioma ;
    dcterms:identifier "2211" ;
    a m2r:Variation .


civicv:2212
    rdfs:label "LOSS" ;
    dcterms:identifier "2212" ;
    a m2r:Variation .


civicv:2213
    rdfs:label "M766_A767insASV" ;
    dcterms:identifier "2213" ;
    a m2r:Variation .


civicv:2214
    rdfs:label "delD770insGY" ;
    dcterms:identifier "2214" ;
    a m2r:Variation .


civicv:2215
    rdfs:label "delL747_P753insS" ;
    dcterms:identifier "2215" ;
    a m2r:Variation .


civicv:2216
    rdfs:label "delE746_A750" ;
    dcterms:identifier "2216" ;
    a m2r:Variation .


civicv:2217
    rdfs:label "P772_H773insH" ;
    dcterms:identifier "2217" ;
    a m2r:Variation .


civicv:2218
    rdfs:label "STRN-ALK" ;
    dcterms:identifier "2218" ;
    a m2r:Variation .


civicv:2219
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:5953 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "2219" ;
    a m2r:Variation .


civicv:2220
    rdfs:label "ALK FUSION" ;
    m2r:evidence civice:5954 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ThyroidCarcinoma ;
    dcterms:identifier "2220" ;
    a m2r:Variation .


civicv:2221
    rdfs:label "G496A" ;
    m2r:evidence civice:5966 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "2221" ;
    a m2r:Variation .


civicv:2222
    rdfs:label "G466V" ;
    m2r:evidence civice:5968 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140481411 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140481411 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "2222" ;
    a obo:missense_variant, m2r:Variation .


civicv:2223
    rdfs:label "G606E" ;
    m2r:evidence civice:5970 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140453118 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140453118 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "2223" ;
    a obo:missense_variant, m2r:Variation .


civicv:2224
    rdfs:label "P731T" ;
    m2r:evidence civice:5972 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 140434507 ;
            faldo:reference hco:7#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 140434507 ;
            faldo:reference hco:7#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000288602.6" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "2224" ;
    a obo:missense_variant, m2r:Variation .


civicv:2225
    rdfs:label "intron 9 rearrangement" ;
    m2r:evidence civice:5973,civice:6401 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer,civic:Melanoma ;
    dcterms:identifier "2225" ;
    a m2r:Variation .


civicv:2226
    rdfs:label "intron 10 rearrangement" ;
    m2r:evidence civice:5974,civice:6400 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer,civic:Melanoma ;
    dcterms:identifier "2226" ;
    a m2r:Variation .


civicv:2227
    rdfs:label "MACF1-BRAF Fusion" ;
    m2r:evidence civice:5975 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "2227" ;
    a m2r:Variation .


civicv:2228
    rdfs:label "WASFL-BRAF Fusion" ;
    m2r:evidence civice:5976 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Cancer ;
    dcterms:identifier "2228" ;
    a m2r:Variation .


civicv:2229
    rdfs:label "CUX1-BRAF" ;
    m2r:evidence civice:5977 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PancreaticCancer ;
    dcterms:identifier "2229" ;
    civico:variantGroups "BRAF Fusions" ;
    a obo:transcript_fusion, m2r:Variation .


civicv:2230
    rdfs:label "LOSS" ;
    m2r:evidence civice:5988,civice:5989 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Sarcoma,civic:OvarianCancer ;
    dcterms:identifier "2230" ;
    a m2r:Variation .


civicv:2231
    rdfs:label "MUTATION" ;
    dcterms:identifier "2231" ;
    a m2r:Variation .


civicv:2232
    rdfs:label "LOSS" ;
    dcterms:identifier "2232" ;
    a m2r:Variation .


civicv:2233
    rdfs:label "MUTATION" ;
    m2r:evidence civice:5992 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:FollicularLymphoma ;
    dcterms:identifier "2233" ;
    a m2r:Variation .


civicv:2234
    rdfs:label "LOSS" ;
    dcterms:identifier "2234" ;
    a m2r:Variation .


civicv:2235
    rdfs:label "LOSS-OF-FUNCTION" ;
    m2r:evidence civice:5994 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "2235" ;
    a m2r:Variation .


civicv:2236
    rdfs:label "LOSS-OF-FUNCTION" ;
    dcterms:identifier "2236" ;
    a m2r:Variation .


civicv:2237
    rdfs:label "MUTATION" ;
    dcterms:identifier "2237" ;
    a m2r:Variation .


civicv:2238
    rdfs:label "ISOFORM EXPRESSION" ;
    dcterms:identifier "2238" ;
    a m2r:Variation .


civicv:2239
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "2239" ;
    a m2r:Variation .


civicv:2240
    rdfs:label "AMPLIFICATION" ;
    m2r:evidence civice:6000 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "2240" ;
    a m2r:Variation .


civicv:2241
    rdfs:label "R82C (c.244C>T)" ;
    civico:hgvs "NC_000003.11:g.10183775C>T,ENST00000256474.2:c.244C>T,NM_000551.3:c.244C>T,NP_000542.1:p.Arg82Cys" ;
    dcterms:identifier "2241" ;
    a m2r:Variation .


civicv:2242
    rdfs:label "W88L (c.263G>T)" ;
    civico:hgvs "NC_000003.11:g.10183794G>T,ENST00000256474.2:c.263G>T,NM_000551.3:c.263G>T,NP_000542.1:p.Trp88Leu" ;
    dcterms:identifier "2242" ;
    a m2r:Variation .


civicv:2243
    rdfs:label "S111G (c.331A>G)" ;
    civico:hgvs "NC_000003.11:g.10183862A>G,ENST00000256474.2:c.331A>G,NM_000551.3:c.331A>G,NP_000542.1:p.Ser111Gly" ;
    dcterms:identifier "2243" ;
    a m2r:Variation .


civicv:2244
    rdfs:label "I151M (c.453C>G)" ;
    civico:hgvs "ENST00000256474.2:c.453C>G,NC_000003.11:g.10188310C>G,NM_000551.3:c.453C>G,NP_000542.1:p.Ile151Met" ;
    dcterms:identifier "2244" ;
    a m2r:Variation .


civicv:2245
    rdfs:label "E160* (c.478G>T)" ;
    civico:hgvs "NC_000003.11:g.10191485G>T,ENST00000256474.2:c.478G>T,NM_000551.3:c.478G>T,NP_000542.1:p.Glu160Ter" ;
    dcterms:identifier "2245" ;
    a m2r:Variation .


civicv:2246
    rdfs:label "I180N (c.539T>A)" ;
    civico:hgvs "NC_000003.11:g.10191546T>A,ENST00000256474.2:c.539T>A,NM_000551.3:c.539T>A,NP_000542.1:p.Ile180Asn" ;
    dcterms:identifier "2246" ;
    a m2r:Variation .


civicv:2247
    rdfs:label "L198R (c.593T>G)" ;
    civico:hgvs "NC_000003.11:g.10191600T>G,ENST00000256474.2:c.593T>G,NM_000551.3:c.593T>G,NP_000542.1:p.Leu198Arg" ;
    dcterms:identifier "2247" ;
    a m2r:Variation .


civicv:2248
    rdfs:label "T100A(c.298A>G)" ;
    dcterms:identifier "2248" ;
    a m2r:Variation .


civicv:2249
    rdfs:label "W117* (c.350G>A)" ;
    dcterms:identifier "2249" ;
    a m2r:Variation .


civicv:2250
    rdfs:label "I151S (c.452T>G)" ;
    dcterms:identifier "2250" ;
    a m2r:Variation .


civicv:2251
    rdfs:label "Q96fs (c.286insT)" ;
    dcterms:identifier "2251" ;
    a m2r:Variation .


civicv:2252
    rdfs:label "G104fs (c.309delT)" ;
    dcterms:identifier "2252" ;
    a m2r:Variation .


civicv:2253
    rdfs:label "N174fs (c.520delA)" ;
    dcterms:identifier "2253" ;
    a m2r:Variation .


civicv:2254
    rdfs:label "PROMOTER DEMETHYLATION" ;
    dcterms:identifier "2254" ;
    a m2r:Variation .


civicv:2255
    rdfs:label "A702S" ;
    dcterms:identifier "2255" ;
    a m2r:Variation .


civicv:2256
    rdfs:label "E709K and G719A" ;
    dcterms:identifier "2256" ;
    a m2r:Variation .


civicv:2257
    rdfs:label "Exon 18 deletion" ;
    dcterms:identifier "2257" ;
    a m2r:Variation .


civicv:2258
    rdfs:label "E 709A and G719C" ;
    dcterms:identifier "2258" ;
    a m2r:Variation .


civicv:2259
    rdfs:label "I744_K745insKIPVAI" ;
    dcterms:identifier "2259" ;
    a m2r:Variation .


civicv:2260
    rdfs:label "D1028N" ;
    dcterms:identifier "2260" ;
    a m2r:Variation .


civicv:2261
    rdfs:label "Q132fs (c.395delA)" ;
    dcterms:identifier "2261" ;
    a m2r:Variation .


civicv:2262
    rdfs:label "L63fs (c.187delC)" ;
    dcterms:identifier "2262" ;
    a m2r:Variation .


civicv:2263
    rdfs:label "P61fs (c.181delC)" ;
    dcterms:identifier "2263" ;
    a m2r:Variation .


civicv:2264
    rdfs:label "R82_V84del (c.244_252del)" ;
    m2r:evidence civice:6060 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183775 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183783 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "CGCGTCGTG" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2264" ;
    a obo:inframe_deletion, m2r:Variation .


civicv:2265
    rdfs:label "A56_P59del (c.166_178del)" ;
    m2r:evidence civice:6062 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:RenalCellCarcinoma ;
    dcterms:identifier "2265" ;
    a m2r:Variation .


civicv:2266
    rdfs:label "G104fs (c.310delG)" ;
    dcterms:identifier "2266" ;
    a m2r:Variation .


civicv:2267
    rdfs:label "Q132fs (c.395_396delAA)" ;
    dcterms:identifier "2267" ;
    a m2r:Variation .


civicv:2268
    rdfs:label "V194fs (c.579_580delTG)" ;
    dcterms:identifier "2268" ;
    a m2r:Variation .


civicv:2269
    rdfs:label "M54_A56del (c.159_168del)" ;
    dcterms:identifier "2269" ;
    a m2r:Variation .


civicv:2270
    rdfs:label "P71_78del (c.213_232del)" ;
    dcterms:identifier "2270" ;
    a m2r:Variation .


civicv:2271
    rdfs:label "F76_N78del (c.226_232del)" ;
    dcterms:identifier "2271" ;
    a m2r:Variation .


civicv:2272
    rdfs:label "N141fs (c.421_422delAA)" ;
    dcterms:identifier "2272" ;
    a m2r:Variation .


civicv:2273
    rdfs:label "R161fs (c.481insC)" ;
    dcterms:identifier "2273" ;
    a m2r:Variation .


civicv:2274
    rdfs:label "P172fs (c.514delC)" ;
    dcterms:identifier "2274" ;
    a m2r:Variation .


civicv:2275
    rdfs:label "p.R258G" ;
    dcterms:identifier "2275" ;
    a m2r:Variation .


civicv:2276
    rdfs:label "p.R358X" ;
    dcterms:identifier "2276" ;
    a m2r:Variation .


civicv:2277
    rdfs:label "V2del" ;
    dcterms:identifier "2277" ;
    a m2r:Variation .


civicv:2279
    rdfs:label "G24R" ;
    dcterms:identifier "2279" ;
    a m2r:Variation .


civicv:2280
    rdfs:label "p.G328W" ;
    dcterms:identifier "2280" ;
    a m2r:Variation .


civicv:2281
    rdfs:label "p.S37C" ;
    dcterms:identifier "2281" ;
    a m2r:Variation .


civicv:2282
    rdfs:label "E518K" ;
    dcterms:identifier "2282" ;
    a m2r:Variation .


civicv:2283
    rdfs:label "G328E" ;
    m2r:evidence civice:6091 ;
    civico:variantOrigin "Somatic Mutation" ;
    dcterms:description "This mutation occurs within the kinase domain of ACVR1 and has been shown to be activating of downstream BMP signaling with increased cell proliferation in cells overexpressing this variant." ;
    m2r:disease civic:DiffuseIntrinsicPontineGlioma ;
    dcterms:identifier "2283" ;
    civico:variantGroups "ACVR1 kinase domain mutation" ;
    a obo:gain_of_function_variant,obo:missense_variant, m2r:Variation .


civicv:2285
    rdfs:label "F232C" ;
    dcterms:identifier "2285" ;
    a m2r:Variation .


civicv:2286
    rdfs:label "NRG1 fusion" ;
    m2r:evidence civice:6273 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:PancreaticAdenocarcinoma ;
    dcterms:identifier "2286" ;
    a m2r:Variation .


civicv:2287
    rdfs:label "NTRK2-STRN fusion" ;
    m2r:evidence civice:6098 ;
    m2r:disease civic:Sarcoma ;
    dcterms:identifier "2287" ;
    a m2r:Variation .


civicv:2288
    rdfs:label "TMP3-NTRK1" ;
    m2r:evidence civice:6101 ;
    m2r:disease civic:Sarcoma ;
    dcterms:identifier "2288" ;
    a m2r:Variation .


civicv:2289
    rdfs:label "PDE4DIP-NTRK1" ;
    m2r:evidence civice:6102 ;
    m2r:disease civic:Sarcoma ;
    dcterms:identifier "2289" ;
    a m2r:Variation .


civicv:2290
    rdfs:label "G144Q (c.431G>A)" ;
    m2r:evidence civice:6106 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "2290" ;
    a m2r:Variation .


civicv:2291
    rdfs:label "I147T (c.440T>C)" ;
    dcterms:identifier "2291" ;
    a m2r:Variation .


civicv:2292
    rdfs:label "Splicing alteration (c.463+8C>T)" ;
    m2r:evidence civice:6108 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10188328 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10188328 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "C" ;
    m2r:alternative_allele "T" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:AdrenalGlandPheochromocytoma ;
    dcterms:identifier "2292" ;
    a m2r:Variation .


civicv:2293
    rdfs:label "G104G (c.312C>G)" ;
    dcterms:identifier "2293" ;
    a m2r:Variation .


civicv:2294
    rdfs:label "F91L (c.273C>G)" ;
    dcterms:identifier "2294" ;
    a m2r:Variation .


civicv:2298
    rdfs:label "L128fs (c.382delC)" ;
    dcterms:identifier "2298" ;
    a m2r:Variation .


civicv:2299
    rdfs:label "W88fs (c.261dupA)" ;
    m2r:evidence civice:6122 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2299" ;
    a m2r:Variation .


civicv:2300
    rdfs:label "L63P (c.188T>C)" ;
    civico:hgvs "NM_000551.3:c.188T>C,NP_000542.1:p.Leu63Pro,NC_000003.11:g.10183719T>C,ENST00000256474.2:c.188T>C" ;
    dcterms:identifier "2300" ;
    a m2r:Variation .


civicv:2301
    rdfs:label "E55fs (c.162delG)" ;
    dcterms:identifier "2301" ;
    a m2r:Variation .


civicv:2302
    rdfs:label "R60fs (c.176_177delCG)" ;
    dcterms:identifier "2302" ;
    a m2r:Variation .


civicv:2303
    rdfs:label "P61_S65del (c.183_195del)" ;
    dcterms:identifier "2303" ;
    a m2r:Variation .


civicv:2304
    rdfs:label "E70fs (c.209_210delAG)" ;
    dcterms:identifier "2304" ;
    a m2r:Variation .


civicv:2305
    rdfs:label "L85fs (c.253delC)" ;
    dcterms:identifier "2305" ;
    a m2r:Variation .


civicv:2306
    rdfs:label "P86fs (c.255_256delGC)" ;
    dcterms:identifier "2306" ;
    a m2r:Variation .


civicv:2307
    rdfs:label "P86H (c.257C>A)" ;
    civico:hgvs "NC_000003.11:g.10183788C>A,ENST00000256474.2:c.257C>A,NM_000551.3:c.257C>A,NP_000542.1:p.Pro86His" ;
    dcterms:identifier "2307" ;
    a m2r:Variation .


civicv:2308
    rdfs:label "L89H (c.266T>A)" ;
    civico:hgvs "NC_000003.11:g.10183797T>A,ENST00000256474.2:c.266T>A,NM_000551.3:c.266T>A,NP_000542.1:p.Leu89His" ;
    dcterms:identifier "2308" ;
    a m2r:Variation .


civicv:2309
    rdfs:label "N90fs (c.269delA)" ;
    dcterms:identifier "2309" ;
    a m2r:Variation .


civicv:2310
    rdfs:label "E94_P97del (c.281_291del)" ;
    dcterms:identifier "2310" ;
    a m2r:Variation .


civicv:2311
    rdfs:label "K114fs (c.339_340delAG)" ;
    dcterms:identifier "2311" ;
    a m2r:Variation .


civicv:2312
    rdfs:label "L116fs (c.347delT)" ;
    dcterms:identifier "2312" ;
    a m2r:Variation .


civicv:2313
    rdfs:label "L118fs (c.349_350insG)" ;
    dcterms:identifier "2313" ;
    a m2r:Variation .


civicv:2314
    rdfs:label "T124fs (c.370_371insTGCAGGA)" ;
    dcterms:identifier "2314" ;
    a m2r:Variation .


civicv:2315
    rdfs:label "N131fs (c.389delT)" ;
    dcterms:identifier "2315" ;
    a m2r:Variation .


civicv:2316
    rdfs:label "S139fs (c.415insC)" ;
    dcterms:identifier "2316" ;
    a m2r:Variation .


civicv:2317
    rdfs:label "L140fs (c.420delC)" ;
    dcterms:identifier "2317" ;
    a m2r:Variation .


civicv:2318
    rdfs:label "N141_D142del (c.422_428del)" ;
    dcterms:identifier "2318" ;
    a m2r:Variation .


civicv:2319
    rdfs:label "G144fs (c.429_430insGGAC)" ;
    dcterms:identifier "2319" ;
    a m2r:Variation .


civicv:2320
    rdfs:label "G144fs (c.430_433delGGAC)" ;
    dcterms:identifier "2320" ;
    a m2r:Variation .


civicv:2321
    rdfs:label "Q145H (c.435G>T)" ;
    dcterms:identifier "2321" ;
    a m2r:Variation .


civicv:2322
    rdfs:label "I147fs (c.439insT)" ;
    dcterms:identifier "2322" ;
    a m2r:Variation .


civicv:2323
    rdfs:label "T157fs (c.469delA)" ;
    dcterms:identifier "2323" ;
    a m2r:Variation .


civicv:2324
    rdfs:label "L158_K159del (c.472_477del)" ;
    dcterms:identifier "2324" ;
    a m2r:Variation .


civicv:2325
    rdfs:label "V166fs (c.498delC)" ;
    dcterms:identifier "2325" ;
    a m2r:Variation .


civicv:2326
    rdfs:label "S168_L169del (c.504_509del)" ;
    dcterms:identifier "2326" ;
    a m2r:Variation .


civicv:2327
    rdfs:label "K171fs (c.512_516delAGCCT)" ;
    dcterms:identifier "2327" ;
    a m2r:Variation .


civicv:2328
    rdfs:label "H191fs (c.570_574delCCACC)" ;
    dcterms:identifier "2328" ;
    a m2r:Variation .


civicv:2329
    rdfs:label "R205fs (c.615delC)" ;
    dcterms:identifier "2329" ;
    a m2r:Variation .


civicv:2330
    rdfs:label "L869R" ;
    civico:hgvs "NC_000017.10:g.37881414T>G,NM_004448.3:c.2606T>G,NP_004439.2:p.Leu869Arg,ENST00000269571.5:c.2606T>G" ;
    dcterms:identifier "2330" ;
    a m2r:Variation .


civicv:2331
    rdfs:label "T798I" ;
    dcterms:identifier "2331" ;
    a m2r:Variation .


civicv:2332
    rdfs:label "A750T" ;
    dcterms:identifier "2332" ;
    a m2r:Variation .


civicv:2333
    rdfs:label "R705K" ;
    m2r:evidence civice:6182 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Non-smallCellLungCarcinoma ;
    dcterms:identifier "2333" ;
    a m2r:Variation .


civicv:2334
    rdfs:label "RARE EGRF MUT" ;
    m2r:evidence civice:6186 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:LungAdenocarcinoma ;
    dcterms:identifier "2334" ;
    a m2r:Variation .


civicv:2335
    rdfs:label "BCR-ABL T315A" ;
    m2r:evidence civice:6190 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "2335" ;
    a m2r:Variation .


civicv:2336
    rdfs:label "EXON 20 MUTATION" ;
    m2r:evidence civice:6198 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "2336" ;
    a m2r:Variation .


civicv:2337
    rdfs:label "EXON 9 MUTATION" ;
    m2r:evidence civice:6199 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:BreastCancer ;
    dcterms:identifier "2337" ;
    a m2r:Variation .


civicv:2340
    rdfs:label "BCR-ABL L248R" ;
    m2r:evidence civice:6210,civice:6243 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "2340" ;
    a m2r:Variation .


civicv:2343
    rdfs:label "BCR-ABL F317S" ;
    m2r:evidence civice:6218 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "2343" ;
    a m2r:Variation .


civicv:2347
    rdfs:label "S185C" ;
    dcterms:identifier "2347" ;
    a m2r:Variation .


civicv:2348
    rdfs:label "V253G" ;
    dcterms:identifier "2348" ;
    a m2r:Variation .


civicv:2349
    rdfs:label "exon 6 mutations" ;
    dcterms:identifier "2349" ;
    a m2r:Variation .


civicv:2350
    rdfs:label "P2RY8-CRLF2 fusion" ;
    dcterms:identifier "2350" ;
    a m2r:Variation .


civicv:2351
    rdfs:label "BCR-ABL E255" ;
    dcterms:identifier "2351" ;
    a m2r:Variation .


civicv:2352
    rdfs:label "BCR-ABL F359" ;
    dcterms:identifier "2352" ;
    a m2r:Variation .


civicv:2358
    rdfs:label "BCR-ABL F311V" ;
    dcterms:identifier "2358" ;
    a m2r:Variation .


civicv:2359
    rdfs:label "BCR-ABL F317C" ;
    m2r:evidence civice:6250 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "2359" ;
    a m2r:Variation .


civicv:2360
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:6259 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "2360" ;
    a m2r:Variation .


civicv:2361
    rdfs:label "V600E/K AMPLIFICATION" ;
    m2r:evidence civice:6262 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "2361" ;
    a m2r:Variation .


civicv:2362
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "2362" ;
    a m2r:Variation .


civicv:2363
    rdfs:label "OVEREXPRESSION" ;
    m2r:evidence civice:6266 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "2363" ;
    a m2r:Variation .


civicv:2364
    rdfs:label "R172I" ;
    m2r:evidence civice:6268 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "2364" ;
    a m2r:Variation .


civicv:2366
    rdfs:label "WILD TYPE" ;
    dcterms:identifier "2366" ;
    a m2r:Variation .


civicv:2367
    rdfs:label "3p26.3-25.3 11Mb del" ;
    m2r:evidence civice:6287 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2367" ;
    a m2r:Variation .


civicv:2368
    rdfs:label "c.208G > A" ;
    m2r:evidence civice:6288 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2368" ;
    a m2r:Variation .


civicv:2369
    rdfs:label "c.233 A>G" ;
    m2r:evidence civice:6289 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10183764 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10183764 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "A" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2369" ;
    a m2r:Variation .


civicv:2370
    rdfs:label "BCR-ABL E459K" ;
    m2r:evidence civice:6310 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 133753906 ;
            faldo:reference hco:9#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 133753906 ;
            faldo:reference hco:9#GRCh37
        ]
    ] ;
    m2r:reference_allele "G" ;
    m2r:alternative_allele "A" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000318560.5" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "2370" ;
    a obo:missense_variant, m2r:Variation .


civicv:2371
    rdfs:label "TKD MUTATION" ;
    m2r:evidence civice:6311,civice:6335 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "2371" ;
    a m2r:Variation .


civicv:2372
    rdfs:label "EGFR T790M" ;
    dcterms:identifier "2372" ;
    a m2r:Variation .


civicv:2373
    rdfs:label "c.128−?_250+?" ;
    m2r:evidence civice:6329 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2373" ;
    a m2r:Variation .


civicv:2374
    rdfs:label "c.251−?_429 +?" ;
    dcterms:identifier "2374" ;
    a m2r:Variation .


civicv:2375
    rdfs:label "P-Loop Mutation" ;
    m2r:evidence civice:6336 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "2375" ;
    a m2r:Variation .


civicv:2376
    rdfs:label "Non-P-Loop Mutation" ;
    m2r:evidence civice:6337 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicMyeloidLeukemia ;
    dcterms:identifier "2376" ;
    a m2r:Variation .


civicv:2377
    rdfs:label "Y35N" ;
    dcterms:identifier "2377" ;
    a m2r:Variation .


civicv:2378
    rdfs:label "COPY-NEUTRAL LOSS OF HETEROZYGOSITY" ;
    dcterms:identifier "2378" ;
    a m2r:Variation .


civicv:2379
    rdfs:label "COPY-NEUTRAL LOSS OF HETEROZYGOSITY" ;
    dcterms:identifier "2379" ;
    a m2r:Variation .


civicv:2380
    rdfs:label "V130I (c.388G>A)" ;
    dcterms:identifier "2380" ;
    a m2r:Variation .


civicv:2381
    rdfs:label "L118P (c.353T>C) / R107G  (c.319C>G)" ;
    dcterms:identifier "2381" ;
    a m2r:Variation .


civicv:2382
    rdfs:label "Null (c.1-?_340+?del)" ;
    dcterms:identifier "2382" ;
    a m2r:Variation .


civicv:2383
    rdfs:label "Q203TfsX53 (c.606dupA)" ;
    dcterms:identifier "2383" ;
    a m2r:Variation .


civicv:2384
    rdfs:label "UNDEREXPRESSION" ;
    dcterms:identifier "2384" ;
    a m2r:Variation .


civicv:2385
    rdfs:label "EWSR1-NR4A3" ;
    dcterms:identifier "2385" ;
    a m2r:Variation .


civicv:2386
    rdfs:label "UNDEREXPRESSION" ;
    dcterms:identifier "2386" ;
    a m2r:Variation .


civicv:2387
    rdfs:label "T618I" ;
    m2r:evidence civice:6380,civice:6381 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ChronicNeutrophilicLeukemia ;
    dcterms:identifier "2387" ;
    a m2r:Variation .


civicv:2388
    rdfs:label "MUTATION" ;
    m2r:evidence civice:6382 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:EssentialThrombocythemia ;
    dcterms:identifier "2388" ;
    a m2r:Variation .


civicv:2389
    rdfs:label "MUTATION" ;
    dcterms:identifier "2389" ;
    a m2r:Variation .


civicv:2390
    rdfs:label "56_61QKQKVG>R" ;
    dcterms:identifier "2390" ;
    a m2r:Variation .


civicv:2391
    rdfs:label "C121S + G128D" ;
    dcterms:identifier "2391" ;
    a m2r:Variation .


civicv:2392
    rdfs:label "EXPRESSION" ;
    dcterms:identifier "2392" ;
    a m2r:Variation .


civicv:2393
    rdfs:label "NTRK1-TRIM63" ;
    m2r:evidence civice:6392 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "2393" ;
    a m2r:Variation .


civicv:2394
    rdfs:label "NTRK1-DDR2" ;
    m2r:evidence civice:6393 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "2394" ;
    a m2r:Variation .


civicv:2395
    rdfs:label "NTRK1-GON4L" ;
    m2r:evidence civice:6394 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:Melanoma ;
    dcterms:identifier "2395" ;
    a m2r:Variation .


civicv:2396
    rdfs:label "ETV6-NTRK2" ;
    m2r:evidence civice:6396 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:HematologicCancer ;
    dcterms:identifier "2396" ;
    a m2r:Variation .


civicv:2397
    rdfs:label "AMPLIFICATION" ;
    dcterms:identifier "2397" ;
    a m2r:Variation .


civicv:2398
    rdfs:label "D594K" ;
    m2r:evidence civice:6402,civice:6403 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "2398" ;
    a m2r:Variation .


civicv:2399
    rdfs:label "V443L" ;
    dcterms:identifier "2399" ;
    a m2r:Variation .


civicv:2400
    rdfs:label "V443M" ;
    dcterms:identifier "2400" ;
    a m2r:Variation .


civicv:2401
    rdfs:label "V496V" ;
    dcterms:identifier "2401" ;
    a m2r:Variation .


civicv:2402
    rdfs:label "V555M" ;
    dcterms:identifier "2402" ;
    a m2r:Variation .


civicv:2403
    rdfs:label "R248C" ;
    dcterms:identifier "2403" ;
    a m2r:Variation .


civicv:2404
    rdfs:label "Y373C" ;
    dcterms:identifier "2404" ;
    a m2r:Variation .


civicv:2405
    rdfs:label "G380R" ;
    dcterms:identifier "2405" ;
    a m2r:Variation .


civicv:2406
    rdfs:label "G370C" ;
    dcterms:identifier "2406" ;
    a m2r:Variation .


civicv:2407
    rdfs:label "F386L" ;
    dcterms:identifier "2407" ;
    a m2r:Variation .


civicv:2408
    rdfs:label "Non-V600" ;
    m2r:evidence civice:3046 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:ColorectalCancer ;
    dcterms:identifier "2408" ;
    a m2r:Variation .


civicv:2409
    rdfs:label "UNDEREXPRESSION" ;
    dcterms:identifier "2409" ;
    a m2r:Variation .


civicv:2410
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "2410" ;
    a m2r:Variation .


civicv:2411
    rdfs:label "c. 589_600dup, p. Cys196 Cys200dup, exon 6, frame shift, loss-of-funtion" ;
    m2r:evidence civice:6442 ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:Paraganglioma ;
    dcterms:identifier "2411" ;
    a m2r:Variation .


civicv:2412
    rdfs:label "UNDEREXPRESSION" ;
    dcterms:identifier "2412" ;
    a m2r:Variation .


civicv:2413
    rdfs:label "FRAMESHIFT MUTATION" ;
    dcterms:identifier "2413" ;
    a m2r:Variation .


civicv:2414
    rdfs:label "E102_I103delEI" ;
    dcterms:identifier "2414" ;
    a m2r:Variation .


civicv:2415
    rdfs:label "LOSS-OF-FUNCTION" ;
    dcterms:identifier "2415" ;
    a m2r:Variation .


civicv:2416
    rdfs:label "K27M" ;
    dcterms:identifier "2416" ;
    a m2r:Variation .


civicv:2417
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "2417" ;
    a m2r:Variation .


civicv:2418
    rdfs:label "UNDEREXPRESSION" ;
    dcterms:identifier "2418" ;
    a m2r:Variation .


civicv:2419
    rdfs:label "OVEREXPRESSION" ;
    dcterms:identifier "2419" ;
    a m2r:Variation .


civicv:2420
    rdfs:label "K36M" ;
    dcterms:identifier "2420" ;
    a m2r:Variation .


civicv:2421
    rdfs:label "G34W" ;
    dcterms:identifier "2421" ;
    a m2r:Variation .


civicv:2422
    rdfs:label "ETV6-NTRK3 FUSION" ;
    m2r:evidence civice:6473 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:CongenitalFibrosarcoma ;
    dcterms:identifier "2422" ;
    a m2r:Variation .


civicv:2423
    rdfs:label "F136fs (c.407delC)" ;
    dcterms:identifier "2423" ;
    a m2r:Variation .


civicv:2424
    rdfs:label "LOSS-OF-FUNCTION" ;
    dcterms:identifier "2424" ;
    a m2r:Variation .


civicv:2425
    rdfs:label "H191D (c.571C>G)" ;
    dcterms:identifier "2425" ;
    a m2r:Variation .


civicv:2426
    rdfs:label "Splicing alteration (IVS1 1G>T)" ;
    dcterms:identifier "2426" ;
    a m2r:Variation .


civicv:2427
    rdfs:label "P54S (c.460C>T)" ;
    dcterms:identifier "2427" ;
    a m2r:Variation .


civicv:2428
    rdfs:label "G104V (c.311G>T)" ;
    dcterms:identifier "2428" ;
    a m2r:Variation .


civicv:2429
    rdfs:label "t(1;3)(q32;q13.3)" ;
    dcterms:identifier "2429" ;
    a m2r:Variation .


civicv:2430
    rdfs:label "P40R (c.119C>G)" ;
    dcterms:identifier "2430" ;
    a m2r:Variation .


civicv:2431
    rdfs:label "c.−213− ?_463 ?del" ;
    dcterms:identifier "2431" ;
    a m2r:Variation .


civicv:2432
    rdfs:label "V87fs (c.259_260insA)" ;
    dcterms:identifier "2432" ;
    a m2r:Variation .


civicv:2433
    rdfs:label "c.89c297 " ;
    dcterms:identifier "2433" ;
    a m2r:Variation .


civicv:2434
    rdfs:label "Splicing alteration (c.340 1G>A)" ;
    dcterms:identifier "2434" ;
    a m2r:Variation .


civicv:2435
    rdfs:label "c.341-59_341-14del" ;
    dcterms:identifier "2435" ;
    a m2r:Variation .


civicv:2436
    rdfs:label "Splicing alteration (c.463 2T>C)" ;
    dcterms:identifier "2436" ;
    a m2r:Variation .


civicv:2437
    rdfs:label "V166A (c.497T>C)" ;
    dcterms:identifier "2437" ;
    a m2r:Variation .


civicv:2438
    rdfs:label "235 (CAG-TAG)" ;
    dcterms:identifier "2438" ;
    a m2r:Variation .


civicv:2439
    rdfs:label "REARRANGEMENT" ;
    dcterms:identifier "2439" ;
    a m2r:Variation .


civicv:2440
    rdfs:label "P138R (c.413C>G)" ;
    dcterms:identifier "2440" ;
    a m2r:Variation .


civicv:2441
    rdfs:label "Splicing alteration (c.340-1G>A)" ;
    dcterms:identifier "2441" ;
    a m2r:Variation .


civicv:2442
    rdfs:label "A50A (c.150C>G); Splicing alteration (c.463-1G>T)" ;
    dcterms:identifier "2442" ;
    a m2r:Variation .


civicv:2443
    rdfs:label "Q132Hfs*45 (c.343_395dup)" ;
    dcterms:identifier "2443" ;
    a m2r:Variation .


civicv:2444
    rdfs:label "Q73Pfs*59 (c.217dupC)" ;
    dcterms:identifier "2444" ;
    a m2r:Variation .


civicv:2445
    rdfs:label "V74Sfs*53 (c.219_232delGGTCATCTTCTGCA)" ;
    dcterms:identifier "2445" ;
    a m2r:Variation .


civicv:2446
    rdfs:label "D121Mfs*38 (c.361delG)" ;
    dcterms:identifier "2446" ;
    a m2r:Variation .


civicv:2447
    rdfs:label "V66Gfs*89 (c.197_209del)" ;
    dcterms:identifier "2447" ;
    a m2r:Variation .


civicv:2448
    rdfs:label "R79_S80del (c.236_241delGCAGTC)" ;
    dcterms:identifier "2448" ;
    a m2r:Variation .


civicv:2449
    rdfs:label "D92G (c.275A>G)" ;
    dcterms:identifier "2449" ;
    a m2r:Variation .


civicv:2450
    rdfs:label "Y98C (c.293A>G)" ;
    dcterms:identifier "2450" ;
    a m2r:Variation .


civicv:2451
    rdfs:label "V141fs (c.422_440del19)" ;
    dcterms:identifier "2451" ;
    a m2r:Variation .


civicv:2452
    rdfs:label "Splicing alteration (c.463 1G>T)" ;
    dcterms:identifier "2452" ;
    a m2r:Variation .


civicv:2453
    rdfs:label "Y156_T157del (c.465_470del6)" ;
    dcterms:identifier "2453" ;
    a m2r:Variation .


civicv:2454
    rdfs:label "Splicing alteration (c.554-1G>T)" ;
    dcterms:identifier "2454" ;
    a m2r:Variation .


civicv:2455
    rdfs:label "G114Vfs*45 (c.339delA)" ;
    dcterms:identifier "2455" ;
    a m2r:Variation .


civicv:2456
    rdfs:label "T133Lfs*26 (c.397delA)" ;
    dcterms:identifier "2456" ;
    a m2r:Variation .


civicv:2457
    rdfs:label "Splicing alteration (c.464-2G>A)" ;
    dcterms:identifier "2457" ;
    a m2r:Variation .


civicv:2458
    rdfs:label "R167P (c.500G>C)" ;
    dcterms:identifier "2458" ;
    a m2r:Variation .


civicv:2459
    rdfs:label "L178P (c.532C>T)" ;
    dcterms:identifier "2459" ;
    a m2r:Variation .


civicv:2460
    rdfs:label "N131K (c.393C>G)" ;
    dcterms:identifier "2460" ;
    a m2r:Variation .


civicv:2461
    rdfs:label "Splicing alteration (c.463 3A>C)" ;
    dcterms:identifier "2461" ;
    a m2r:Variation .


civicv:2462
    rdfs:label "S72fs (c.216delC)" ;
    dcterms:identifier "2462" ;
    a m2r:Variation .


civicv:2463
    rdfs:label "H110P (c.329A>C)" ;
    dcterms:identifier "2463" ;
    a m2r:Variation .


civicv:2464
    rdfs:label "Splicing alteration (IVS2-1G>T)" ;
    dcterms:identifier "2464" ;
    a m2r:Variation .


civicv:2465
    rdfs:label "exon1 151nt del; Null (Partial deletion of Exon 1)" ;
    dcterms:identifier "2465" ;
    a m2r:Variation .


civicv:2466
    rdfs:label "E52* (c.154G>T)" ;
    dcterms:identifier "2466" ;
    a m2r:Variation .


civicv:2467
    rdfs:label "L158E (c.473T>A)" ;
    dcterms:identifier "2467" ;
    a m2r:Variation .


civicv:2468
    rdfs:label "D427N" ;
    m2r:evidence civice:6654 ;
    civico:variantOrigin "Somatic Mutation" ;
    m2r:disease civic:AdultT-cellLeukemia ;
    dcterms:identifier "2468" ;
    a m2r:Variation .


civicv:2469
    rdfs:label "R176fs (c.526_528delA)" ;
    dcterms:identifier "2469" ;
    a m2r:Variation .


civicv:2470
    rdfs:label "W117C (c.351G>X)" ;
    dcterms:identifier "2470" ;
    a m2r:Variation .


civicv:2471
    rdfs:label "T104fs (c.313_315delC)" ;
    dcterms:identifier "2471" ;
    a m2r:Variation .


civicv:2472
    rdfs:label "EXON 1-2 DELETION; BRK1 DELETION" ;
    dcterms:identifier "2472" ;
    a m2r:Variation .


civicv:2473
    rdfs:label "M54fs (c.160delA)" ;
    dcterms:identifier "2473" ;
    a m2r:Variation .


civicv:2474
    rdfs:label "P59fs (c.176insAGCAdelTCCTGCGCT)" ;
    dcterms:identifier "2474" ;
    a m2r:Variation .


civicv:2475
    rdfs:label "F119L (c.355T>C)" ;
    dcterms:identifier "2475" ;
    a m2r:Variation .


civicv:2476
    rdfs:label "I151N (c.452T>A)" ;
    dcterms:identifier "2476" ;
    a m2r:Variation .


civicv:2477
    rdfs:label "V155fs (c.464_468delTGTAT)" ;
    dcterms:identifier "2477" ;
    a m2r:Variation .


civicv:2478
    rdfs:label "L163P (c.488T>C)" ;
    dcterms:identifier "2478" ;
    a m2r:Variation .


civicv:2479
    rdfs:label "D197Rfs* (c.588_588dupA)" ;
    dcterms:identifier "2479" ;
    a m2r:Variation .


civicv:2480
    rdfs:label "Y98S (c.293A>C)" ;
    dcterms:identifier "2480" ;
    a m2r:Variation .


civicv:2481
    rdfs:label "I151T (c.453T>C)" ;
    dcterms:identifier "2481" ;
    a m2r:Variation .


civicv:2482
    rdfs:label "A149fs (c.446delG)" ;
    dcterms:identifier "2482" ;
    a m2r:Variation .


civicv:2483
    rdfs:label "F76del (c.226delTTC)" ;
    dcterms:identifier "2483" ;
    a m2r:Variation .


civicv:2484
    rdfs:label "Y98N (c.292T>A)" ;
    dcterms:identifier "2484" ;
    a m2r:Variation .


civicv:2485
    rdfs:label "Splicing alteration (c.IVS2-1G>T)" ;
    dcterms:identifier "2485" ;
    a m2r:Variation .


civicv:2486
    rdfs:label "R167fs (c.501insTTGTCCGT)" ;
    dcterms:identifier "2486" ;
    a m2r:Variation .


civicv:2487
    rdfs:label "I75del (c.221delTCA)" ;
    dcterms:identifier "2487" ;
    a m2r:Variation .


civicv:2488
    rdfs:label "*214G (c.641T>G)" ;
    m2r:evidence civice:6723 ;
    faldo:location [ 
    a faldo:Region ;
        faldo:begin [
            a faldo:ExactPosition ;
            faldo:position 10191647 ;
            faldo:reference hco:3#GRCh37
        ];
	    faldo:end [
            a faldo:ExactPosition ;
            faldo:position 10191647 ;
            faldo:reference hco:3#GRCh37
        ]
    ] ;
    m2r:reference_allele "T" ;
    m2r:alternative_allele "G" ;
    civico:referenceBuild "GRCh37" ;
    civico:transcript "ENST00000256474.2" ;
    civico:ensemblVersion "75" ;
    civico:variantOrigin "Germline Mutation" ;
    m2r:disease civic:VonHippel-LindauDisease ;
    dcterms:identifier "2488" ;
    a obo:stop_lost, m2r:Variation .


civicv:2489
    rdfs:label "*214C (c.641insC)" ;
    dcterms:identifier "2489" ;
    a m2r:Variation .


civicv:2490
    rdfs:label "N131S (c.392A>G)" ;
    dcterms:identifier "2490" ;
    a m2r:Variation .


civicv:2491
    rdfs:label "G114V (c.341G>T)" ;
    dcterms:identifier "2491" ;
    a m2r:Variation .


civicv:2492
    rdfs:label "Partial deletion of 4 Kb" ;
    dcterms:identifier "2492" ;
    a m2r:Variation .


civicv:2493
    rdfs:label "V194G (c.581T>G)" ;
    dcterms:identifier "2493" ;
    a m2r:Variation .


civicv:2494
    rdfs:label "R120T (c.359G>C)" ;
    dcterms:identifier "2494" ;
    a m2r:Variation .


civicv:2495
    rdfs:label "H208fs (c.623insTTTTGTTG)" ;
    dcterms:identifier "2495" ;
    a m2r:Variation .


civicv:2496
    rdfs:label "P86S (c.256C>T); Splicing alteration (c.340 5G>C)" ;
    dcterms:identifier "2496" ;
    a m2r:Variation .


civicv:2497
    rdfs:label "M54Gfs*77 (c.160_161delAT)" ;
    dcterms:identifier "2497" ;
    a m2r:Variation .


civicv:2498
    rdfs:label "L198Wfs*4 (c.592delC)" ;
    dcterms:identifier "2498" ;
    a m2r:Variation .


civicv:2499
    rdfs:label "K196fs (c.588insA)" ;
    dcterms:identifier "2499" ;
    a m2r:Variation .


civicv:2500
    rdfs:label "Y98S (c.293A>C) (Novel)" ;
    dcterms:identifier "2500" ;
    a m2r:Variation .


civicv:2501
    rdfs:label "L198P (c.593T>C)" ;
    dcterms:identifier "2501" ;
    a m2r:Variation .


civicv:2502
    rdfs:label "E160V (c.479A>T)" ;
    civico:hgvs "NM_000551.3:c.479A>T,NP_000542.1:p.Glu160Val,NC_000003.11:g.10191486A>T,ENST00000256474.2:c.479A>T" ;
    dcterms:identifier "2502" ;
    a m2r:Variation .


civicv:2503
    rdfs:label "S183W (c.548C>G)" ;
    dcterms:identifier "2503" ;
    a m2r:Variation .


civicv:2504
    rdfs:label "Splicing alteration (c.341-2A>G)" ;
    dcterms:identifier "2504" ;
    a m2r:Variation .


civicv:2505
    rdfs:label "L163F (c.487C>T)" ;
    dcterms:identifier "2505" ;
    a m2r:Variation .


civicv:2506
    rdfs:label "L85_E94del (c.254_283del30bp)" ;
    dcterms:identifier "2506" ;
    a m2r:Variation .


civicv:2507
    rdfs:label "c.516_517dupGTCAAGCCT; c.532_542delCTGGACATCGTinsATTA" ;
    dcterms:identifier "2507" ;
    a m2r:Variation .


civicv:2508
    rdfs:label "L129P (c.386T>G)" ;
    dcterms:identifier "2508" ;
    a m2r:Variation .


civicv:2509
    rdfs:label "V62Efs*71 (c.185_193delTGCTGCGCTinsAGCA)" ;
    dcterms:identifier "2509" ;
    a m2r:Variation .


civicv:2510
    rdfs:label "R69Afs*63 (c.204_205insG)" ;
    dcterms:identifier "2510" ;
    a m2r:Variation .


civicv:2511
    rdfs:label "S80Ifs*79 (c.239delG)" ;
    dcterms:identifier "2511" ;
    a m2r:Variation .


civicv:2512
    rdfs:label "S80fs (c.239_245delGTCCGCG)" ;
    dcterms:identifier "2512" ;
    a m2r:Variation .


civicv:2513
    rdfs:label "V87E (c.260T>A)" ;
    dcterms:identifier "2513" ;
    a m2r:Variation .


civicv:2514
    rdfs:label "D92fs (c.275delAinsCC)" ;
    dcterms:identifier "2514" ;
    a m2r:Variation .


civicv:2515
    rdfs:label "P97Afs*35 (c.287_288insA)" ;
    dcterms:identifier "2515" ;
    a m2r:Variation .


civicv:2516
    rdfs:label "H110Pfs*49 (c.329delA)" ;
    dcterms:identifier "2516" ;
    a m2r:Variation .


civicv:2517
    rdfs:label "S111Tfs*48 (c.332delG)" ;
    dcterms:identifier "2517" ;
    a m2r:Variation .


civicv:2518
    rdfs:label "Splicing alteration (c.340 3_340 10delACGGGCCCinsCG)" ;
    dcterms:identifier "2518" ;
    a m2r:Variation .


civicv:2519
    rdfs:label "Splicing alteration (c.340 5G>C)" ;
    dcterms:identifier "2519" ;
    a m2r:Variation .


civicv:2520
    rdfs:label "H115fs (c.343delC)" ;
    dcterms:identifier "2520" ;
    a m2r:Variation .


civicv:2521
    rdfs:label "W117G (c.349T>G)" ;
    dcterms:identifier "2521" ;
    a m2r:Variation .


civicv:2522
    rdfs:label "W117R (c.349T>A)" ;
    dcterms:identifier "2522" ;
    a m2r:Variation .


civicv:2523
    rdfs:label "W117S (c.350G>C)" ;
    dcterms:identifier "2523" ;
    a m2r:Variation .


civicv:2524
    rdfs:label "E134Dfs*72 (c.402_428delATTATTTGTGCCATCTCTCAATGTTGA)" ;
    dcterms:identifier "2524" ;
    a m2r:Variation .


civicv:2525
    rdfs:label "Q145fs (c.433_437delCAGCC)" ;
    dcterms:identifier "2525" ;
    a m2r:Variation .


civicv:2526
    rdfs:label "P146Gfs*14 (c.435_436insGG)" ;
    dcterms:identifier "2526" ;
    a m2r:Variation .


civicv:2527
    rdfs:label "E160fs (c.480delG)" ;
    dcterms:identifier "2527" ;
    a m2r:Variation .


civicv:2528
    rdfs:label "C162* (c.486C>A)" ;
    dcterms:identifier "2528" ;
    a m2r:Variation .


civicv:2529
    rdfs:label "E189_D190del (c.565_570delGAAGAC)" ;
    dcterms:identifier "2529" ;
    a m2r:Variation .


civicv:2530
    rdfs:label "Splicing alteration (c.642 70C>A)" ;
    dcterms:identifier "2530" ;
    a m2r:Variation .


civicv:2531
    rdfs:label "c.(?_－213)_(*3705_?)del (Exon1, 2, 3 deletion)" ;
    dcterms:identifier "2531" ;
    a m2r:Variation .


civicv:2532
    rdfs:label "R82G (c.244C>G)" ;
    dcterms:identifier "2532" ;
    a m2r:Variation .


civicv:2533
    rdfs:label "D126N (c.376G>A)" ;
    dcterms:identifier "2533" ;
    a m2r:Variation .


civicv:2534
    rdfs:label "Splicing alteration (IVSI 3insCGdelACGGGCCC)" ;
    dcterms:identifier "2534" ;
    a m2r:Variation .


civicv:2535
    rdfs:label "MS/TS" ;
    dcterms:identifier "2535" ;
    a m2r:Variation .


civicv:2536
    rdfs:label "L1016 (c.302T>G)" ;
    dcterms:identifier "2536" ;
    a m2r:Variation .


civicv:2537
    rdfs:label "R108fs (c.323delGC)" ;
    dcterms:identifier "2537" ;
    a m2r:Variation .


civicv:2538
    rdfs:label "E70K (c.208G>A); Splicing alteration (c.340+5G>C)" ;
    dcterms:identifier "2538" ;
    a m2r:Variation .


civicv:2539
    rdfs:label "V114R (c.341T>C)" ;
    dcterms:identifier "2539" ;
    a m2r:Variation .


civicv:2540
    rdfs:label "H115Q (c.346C>A)" ;
    dcterms:identifier "2540" ;
    a m2r:Variation .


civicv:2541
    rdfs:label "S139F (c.416C>T)" ;
    dcterms:identifier "2541" ;
    a m2r:Variation .


civicv:2542
    rdfs:label "F190L (c.568T>C)" ;
    dcterms:identifier "2542" ;
    a m2r:Variation .


civicv:2543
    rdfs:label "L198fs (c.592delC)" ;
    dcterms:identifier "2543" ;
    a m2r:Variation .


civicv:2544
    rdfs:label "Del/FS" ;
    dcterms:identifier "2544" ;
    a m2r:Variation .


civicv:2545
    rdfs:label "M54fs (c.160_175del)" ;
    dcterms:identifier "2545" ;
    a m2r:Variation .


civicv:2546
    rdfs:label "P61fs Stop at 121(c.180_208del)" ;
    dcterms:identifier "2546" ;
    a m2r:Variation .


civicv:2547
    rdfs:label "Asn67fs (c.197_213del)" ;
    dcterms:identifier "2547" ;
    a m2r:Variation .


civicv:2548
    rdfs:label "V84fs (c.249_255del)" ;
    dcterms:identifier "2548" ;
    a m2r:Variation .


civicv:2549
    rdfs:label "L89R(c.266T>G)" ;
    dcterms:identifier "2549" ;
    a m2r:Variation .


civicv:2550
    rdfs:label "AMPLIFICATION" ;
    dcterms:identifier "2550" ;
    a m2r:Variation .


civicv:2551
    rdfs:label "G104fs*158 (c.311delC)" ;
    dcterms:identifier "2551" ;
    a m2r:Variation .


civicv:2552
    rdfs:label "R120fs*158 (c.359delG)" ;
    dcterms:identifier "2552" ;
    a m2r:Variation .


civicv:2553
    rdfs:label "D121_A122del (c.361_366del)" ;
    dcterms:identifier "2553" ;
    a m2r:Variation .


civicv:2554
    rdfs:label "D126G (c.377A>G)" ;
    dcterms:identifier "2554" ;
    a m2r:Variation .


civicv:2555
    rdfs:label "G127fs (c.381delG)" ;
    dcterms:identifier "2555" ;
    a m2r:Variation .


civicv:2556
    rdfs:label "T133fs*157 (c.397_400delACTG)" ;
    dcterms:identifier "2556" ;
    a m2r:Variation .


civicv:2557
    rdfs:label "L135fs (c.405delA)" ;
    dcterms:identifier "2557" ;
    a m2r:Variation .


civicv:2558
    rdfs:label "F137fs (c.408insT)" ;
    dcterms:identifier "2558" ;
    a m2r:Variation .


civicv:2559
    rdfs:label "L140fs*158 (c.419delT)" ;
    dcterms:identifier "2559" ;
    a m2r:Variation .


civicv:2560
    rdfs:label "G144fs*158 (c.431delG)" ;
    dcterms:identifier "2560" ;
    a m2r:Variation .


civicv:2561
    rdfs:label "A149fs*158 (c.446delC)" ;
    dcterms:identifier "2561" ;
    a m2r:Variation .


civicv:2562
    rdfs:label "T157fs*158 (c.469delA)" ;
    dcterms:identifier "2562" ;
    a m2r:Variation .


civicv:2563
    rdfs:label "L163fs*169 (c.488delT)" ;
    dcterms:identifier "2563" ;
    a m2r:Variation .


civicv:2564
    rdfs:label "AMPLIFICATION" ;
    dcterms:identifier "2564" ;
    a m2r:Variation .


civicv:2565
    rdfs:label "LOSS-OF-FUNCTION" ;
    dcterms:identifier "2565" ;
    a m2r:Variation .


civicv:2566
    rdfs:label "ABL1 fusions" ;
    dcterms:identifier "2566" ;
    a m2r:Variation .


civicv:2567
    rdfs:label "MUTATION" ;
    dcterms:identifier "2567" ;
    a m2r:Variation .


civicv:2568
    rdfs:label "V804M" ;
    dcterms:identifier "2568" ;
    a m2r:Variation .


civicv:2569
    rdfs:label "EZH2 Y641F" ;
    dcterms:identifier "2569" ;
    a m2r:Variation .


civicv:2570
    rdfs:label "Q61" ;
    dcterms:identifier "2570" ;
    a m2r:Variation .


civicv:2571
    rdfs:label "ABL2 fusions" ;
    dcterms:identifier "2571" ;
    a m2r:Variation .


civicv:2572
    rdfs:label "JAK2 fusions" ;
    dcterms:identifier "2572" ;
    a m2r:Variation .


civice:1
    dct:references pbm:16081687 ;
    civico:citation "Levine et al., 2005, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Negative" ;
    civico:evidenceLevel "B" ;
    dcterms:description "JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL)." ;
    a m2r:Evidence .

civice:2
    dct:references pbm:15146165 ;
    civico:citation "Lasota et al., 2004, Lab. Invest." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Negative" ;
    civico:evidenceLevel "B" ;
    dcterms:description "GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant." ;
    a m2r:Evidence .

civice:3
    dct:references pbm:22081665 ;
    civico:citation "LaRochelle et al., 2011, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk)." ;
    a m2r:Evidence .

civice:4
    dct:references pbm:22490330 ;
    civico:citation "Ribeiro et al., 2012, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A." ;
    a m2r:Evidence .

civice:5
    dct:references pbm:16081687 ;
    civico:citation "Levine et al., 2005, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML)." ;
    a m2r:Evidence .

civice:7
    dct:references pbm:19287384 ;
    civico:citation "Kilpivaara et al., 2009, Nat. Genet." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The SNP rs10974944 in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer." ;
    a m2r:Evidence .

civice:8
    dct:references pbm:24571676 ;
    civico:citation "Andrade et al., 2014, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation." ;
    a m2r:Evidence .

civice:10
    dct:references pbm:23861977 ;
    civico:citation "Tschandl et al., 2013, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk." ;
    a m2r:Evidence .

civice:11
    dct:references pbm:22081665 ;
    civico:citation "LaRochelle et al., 2011, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Daunorubicin ;
    dcterms:description "Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation." ;
    a m2r:Evidence .

civice:12
    dct:references pbm:19915144 ;
    civico:citation "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1 or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells." ;
    a m2r:Evidence .

civice:13
    dct:references pbm:19915144 ;
    civico:citation "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1, or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells." ;
    a m2r:Evidence .

civice:14
    dct:references pbm:23569304 ;
    civico:citation "Trunzer et al., 2013, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Vemurafenib resistance is associated with gain of Q61 mutation in NRAS." ;
    a m2r:Evidence .

civice:15
    dct:references pbm:15928335 ;
    civico:citation "Corless et al., 2005, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "GIST cancer with D842V mutation is resistant to imatinib." ;
    a m2r:Evidence .

civice:16
    dct:references pbm:16954519 ;
    civico:citation "Heinrich et al., 2006, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib." ;
    a m2r:Evidence .

civice:17
    dct:references pbm:24569458 ;
    civico:citation "Imielinski et al., 2014, J. Clin. Invest." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission." ;
    a m2r:Evidence .

civice:18
    dct:references pbm:22081665 ;
    civico:citation "LaRochelle et al., 2011, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Idarubicin ;
    dcterms:description "Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation." ;
    a m2r:Evidence .

civice:19
    dct:references pbm:16709929 ;
    civico:citation "Kiladjian et al., 2006, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PegylatedIFN-alpha-2a ;
    dcterms:description "In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F." ;
    a m2r:Evidence .

civice:20
    dct:references pbm:18394554 ;
    civico:citation "Wernig et al., 2008, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_TG101348 ;
    dcterms:description "TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells." ;
    a m2r:Evidence .

civice:21
    dct:references pbm:18375819 ;
    civico:citation "Banerji et al., 2008, Mol. Cancer Ther." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_17-AAG ;
    dcterms:description "Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation." ;
    a m2r:Evidence .

civice:22
    dct:references pbm:21576590 ;
    civico:citation "Soon et al., 2011, Arch Dermatol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months." ;
    a m2r:Evidence .

civice:23
    dct:references pbm:21576590 ;
    civico:citation "Soon et al., 2011, Arch Dermatol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months." ;
    a m2r:Evidence .

civice:24
    dct:references pbm:22081665 ;
    civico:citation "LaRochelle et al., 2011, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "There is no difference in the complete remission rate of de novo AML patients with DNMT3A mutation compared to those who are wild type for DNMT3A." ;
    a m2r:Evidence .

civice:25
    dct:references pbm:21067377 ;
    civico:citation "Ley et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation." ;
    a m2r:Evidence .

civice:26
    dct:references pbm:16384925 ;
    civico:citation "Cairoli et al., 2006, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In acute myloid leukemia patients, D816 mutation is associated with earlier relapse and poorer prognosis than wildtype KIT." ;
    a m2r:Evidence .

civice:27
    dct:references pbm:24666267 ;
    civico:citation "Therkildsen et al., 2014, Acta Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS." ;
    a m2r:Evidence .

civice:30
    dct:references pbm:21166657 ;
    civico:citation "Lee et al., 2011, Br. J. Dermatol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "BRAF mutations are associated with melanoma arising in non-chronic sun damaged skin and with superficial spreading melanoma." ;
    a m2r:Evidence .

civice:31
    dct:references pbm:24512939 ;
    civico:citation "El Ghannam et al., Blood Cells Mol. Dis." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "DNMT3A R882 mutations were associated with older age, higher white blood cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of cytogenetically normal AML patients." ;
    a m2r:Evidence .

civice:32
    dct:references pbm:21030459 ;
    civico:citation "Sasaki et al., 2010, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation." ;
    a m2r:Evidence .

civice:33
    dct:references pbm:21030459 ;
    civico:citation "Sasaki et al., 2010, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation." ;
    a m2r:Evidence .

civice:34
    dct:references pbm:19671763 ;
    civico:citation "Woodman et al., 2009, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib,civic:drug_Nilotinib,civic:drug_Sorafenib ;
    dcterms:description "The melanoma cell line WM3211, which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L576P mutation alters the conformation of KIT and reduces the binding affinity of imatinib." ;
    a m2r:Evidence .

civice:35
    dct:references pbm:15696205 ;
    civico:citation "Pao et al., 2005, PLoS Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9/38 refractory vs 0/21 sensitive patients; P=0.0201)." ;
    a m2r:Evidence .

civice:36
    dct:references pbm:20619739 ;
    civico:citation "De Roock et al., 2010, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Chemotherapy-refractory patients with colorectal cancer harboring NRAS mutation (primarily Q61) have a significantly lower response rate to cetuximab than patients wildtype for NRAS." ;
    a m2r:Evidence .

civice:37
    dct:references pbm:21575866 ;
    civico:citation "Sakamoto et al., 2011, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "CH5424802 is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells." ;
    a m2r:Evidence .

civice:38
    dct:references pbm:21948233 ;
    civico:citation "Heuckmann et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation." ;
    a m2r:Evidence .

civice:39
    dct:references pbm:18923525 ;
    civico:citation "George et al., 2008, Nature" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_TAE684 ;
    dcterms:description "TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L." ;
    a m2r:Evidence .

civice:40
    dct:references pbm:24569458 ;
    civico:citation "Imielinski et al., 2014, J. Clin. Invest." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro." ;
    a m2r:Evidence .

civice:41
    dct:references pbm:24569458 ;
    civico:citation "Imielinski et al., 2014, J. Clin. Invest." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro." ;
    a m2r:Evidence .

civice:42
    dct:references pbm:19671763 ;
    civico:citation "Woodman et al., 2009, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib." ;
    a m2r:Evidence .

civice:43
    dct:references pbm:22745105 ;
    civico:citation "Heinrich et al., 2012, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crenolanib ;
    dcterms:description "In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib." ;
    a m2r:Evidence .

civice:44
    dct:references pbm:22745105 ;
    civico:citation "Heinrich et al., 2012, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crenolanib ;
    dcterms:description "In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib." ;
    a m2r:Evidence .

civice:45
    dct:references pbm:22745105 ;
    civico:citation "Heinrich et al., 2012, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crenolanib ;
    dcterms:description "In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib." ;
    a m2r:Evidence .

civice:46
    dct:references pbm:22745105 ;
    civico:citation "Heinrich et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crenolanib ;
    dcterms:description "In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib sensitivity, crenolanib showed no significant difference from imatinib in kinase activity inhibition." ;
    a m2r:Evidence .

civice:47
    dct:references pbm:22745105 ;
    civico:citation "Heinrich et al., 2012, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crenolanib ;
    dcterms:description "In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib." ;
    a m2r:Evidence .

civice:48
    dct:references pbm:18923525 ;
    civico:citation "George et al., 2008, Nature" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_TAE684 ;
    dcterms:description "The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684." ;
    a m2r:Evidence .

civice:49
    dct:references pbm:23632886 ;
    civico:citation "Gaidzik et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a large cohort of AML patients (mean = 48 years), DNMT3A mutation (64.5% of which were R882) had no prognostic value on overall, relapse free and event free survival." ;
    a m2r:Evidence .

civice:50
    dct:references pbm:23632886 ;
    civico:citation "Gaidzik et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a large cohort (n=1770) of AML patients (18-60 years old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value for overall, relapse free and event free survival. This was true for cytogenetically normal AML and the entire cohort." ;
    a m2r:Evidence .

civice:51
    dct:references pbm:22490330 ;
    civico:citation "Ribeiro et al., 2012, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD." ;
    a m2r:Evidence .

civice:52
    dct:references pbm:22490330 ;
    civico:citation "Ribeiro et al., 2012, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD." ;
    a m2r:Evidence .

civice:53
    dct:references pbm:16551858 ;
    civico:citation "Wardelmann et al., 2006, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "There is no significant association between wildtype KIT or KIT mutations in exon 9 or 11 in survival among GIST patients." ;
    a m2r:Evidence .

civice:56
    dct:references pbm:15951308 ;
    civico:citation "Bowen et al., 2005, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The presence of NRAS mutation in AML patients does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death)." ;
    a m2r:Evidence .

civice:57
    dct:references pbm:16434492 ;
    civico:citation "Bacher et al., 2006, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NRAS mutation status does not impact overall, event-free or disease-free survival in patients with AML." ;
    a m2r:Evidence .

civice:58
    dct:references pbm:23775962 ;
    civico:citation "Hodi et al., 2013, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients." ;
    a m2r:Evidence .

civice:61
    dct:references pbm:23632886 ;
    civico:citation "Gaidzik et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "A" ;
    dcterms:description "In a large cohort of young AML patients (18-60 years old), DNMT3A R882 mutations were associated with reduced relapse free survival in the entire cohort as well as the subset of patients with cytogenetically normal AML." ;
    a m2r:Evidence .

civice:62
    dct:references pbm:21067377 ;
    civico:citation "Ley et al., 2010, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation." ;
    a m2r:Evidence .

civice:63
    dct:references pbm:23632886 ;
    civico:citation "Gaidzik et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable, cytogenetically normal AMLs." ;
    a m2r:Evidence .

civice:64
    dct:references pbm:21067377 ;
    civico:citation "Ley et al., 2010, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation." ;
    a m2r:Evidence .

civice:65
    dct:references pbm:24512939 ;
    civico:citation "El Ghannam et al., Blood Cells Mol. Dis." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In cytogenetically normal AML patients, DNMT3A R882 mutations are associated with lower overall and disease free survival as compared to patients with wild type DNMT3A." ;
    a m2r:Evidence .

civice:66
    dct:references pbm:22291079 ;
    civico:citation "Marcucci et al., 2012, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In older cytogenetically normal AML patients (>59 years), DNMT3A R882 mutation is prognostic for shorter disease free survival and overall survival compared to patients without the mutation." ;
    a m2r:Evidence .

civice:67
    dct:references pbm:22490330 ;
    civico:citation "Ribeiro et al., 2012, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3." ;
    a m2r:Evidence .

civice:68
    dct:references pbm:22291079 ;
    civico:citation "Marcucci et al., 2012, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations other than R882 are prognostic for shorter disease free survival and overall survival compared to patients without the mutation." ;
    a m2r:Evidence .

civice:69
    dct:references pbm:21067377 ;
    civico:citation "Ley et al., 2010, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation." ;
    a m2r:Evidence .

civice:70
    dct:references pbm:16551858 ;
    civico:citation "Wardelmann et al., 2006, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "GIST patients with exon 14 KIT mutations had reduced overall survival compared to patients wiltype for KIT." ;
    a m2r:Evidence .

civice:71
    dct:references pbm:22180178 ;
    civico:citation "Jakob et al., 2012, Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS." ;
    a m2r:Evidence .

civice:73
    dct:references pbm:23031422 ;
    civico:citation "Ponti et al., 2012, J Hematol Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dabrafenib ;
    dcterms:description "A single patient with BRAF V600E/V600M bi-allelic mutation responded to the V600E drug dabrafenib." ;
    a m2r:Evidence .

civice:74
    dct:references pbm:18073307 ;
    civico:citation "Elisei et al., 2008, J. Clin. Endocrinol. Metab." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases." ;
    a m2r:Evidence .

civice:75
    dct:references pbm:21422803 ;
    civico:citation "Coxon et al., 2012, J. Endocrinol. Invest." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Motesanib ;
    dcterms:description "Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET." ;
    a m2r:Evidence .

civice:76
    dct:references pbm:21422803 ;
    civico:citation "Coxon et al., 2012, J. Endocrinol. Invest." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Motesanib ;
    dcterms:description "Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET." ;
    a m2r:Evidence .

civice:77
    dct:references pbm:23056499 ;
    civico:citation "Couto et al., 2012, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD1480 ;
    dcterms:description "The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth." ;
    a m2r:Evidence .

civice:78
    dct:references pbm:9839497 ;
    civico:citation "Egawa et al., 1998, Jpn. J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Compared to those who harbor a wild type RET, patients with RET M918T mutation develop larger and more aggressive medullary thyroid cancer." ;
    a m2r:Evidence .

civice:79
    dct:references pbm:21594703 ;
    civico:citation "Howell et al., 2011, Ann. Surg. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer." ;
    a m2r:Evidence .

civice:80
    dct:references pbm:24570209 ;
    civico:citation "Crescenzi et al., 2014, Horm. Metab. Res." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer." ;
    a m2r:Evidence .

civice:82
    dct:references pbm:24586605 ;
    civico:citation "Meckbach et al., 2014, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dacarbazine,civic:drug_Temozolomide ;
    dcterms:description "BRAF status does not predict outcome in patients treated with dacarbazine or temozolomide." ;
    a m2r:Evidence .

civice:83
    dct:references pbm:24559322 ;
    civico:citation "Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Regorafenib ;
    dcterms:description "PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment." ;
    a m2r:Evidence .

civice:86
    dct:references pbm:24576830 ;
    civico:citation "Nissan et al., 2014, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib,civic:drug_PD0325901 ;
    dcterms:description "In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors." ;
    a m2r:Evidence .

civice:87
    dct:references pbm:24559322 ;
    civico:citation "Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Regorafenib ;
    dcterms:description "KRAS mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment." ;
    a m2r:Evidence .

civice:88
    dct:references pbm:23325582 ;
    civico:citation "Peeters et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone)." ;
    a m2r:Evidence .

civice:89
    dct:references pbm:19001320 ;
    civico:citation "Di Nicolantonio et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Sorafenib,civic:drug_Panitumumab ;
    dcterms:description "Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced." ;
    a m2r:Evidence .

civice:90
    dct:references pbm:24576830 ;
    civico:citation "Nissan et al., 2014, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors." ;
    a m2r:Evidence .

civice:91
    dct:references pbm:23524406 ;
    civico:citation "Rudin et al., 2013, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dabrafenib ;
    dcterms:description "In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib." ;
    a m2r:Evidence .

civice:92
    dct:references pbm:21098728 ;
    civico:citation "Corcoran et al., 2010, Sci Signal" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF V600E gene." ;
    a m2r:Evidence .

civice:93
    dct:references pbm:23020132 ;
    civico:citation "Flaherty et al., 2012, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Trametinib ;
    dcterms:description "Melanoma patients with BRAF V600E/K mutations had longer progression-free survival, increased tumor regression,  and increased duration of response to combined dabrafenib and trametinib treatment compared to dabrafenib alone." ;
    a m2r:Evidence .

civice:94
    dct:references pbm:23463675 ;
    civico:citation "Ponti et al., 2013, J. Clin. Pathol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib ;
    dcterms:description "Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib." ;
    a m2r:Evidence .

civice:95
    dct:references pbm:24583796 ;
    civico:citation "Menzies et al., 2014, Clin. Cancer Res." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Trametinib ;
    dcterms:description "Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma." ;
    a m2r:Evidence .

civice:96
    dct:references pbm:23845441 ;
    civico:citation "Rad et al., 2013, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PLX4720,civic:drug_GDC0941 ;
    dcterms:description "Combined MEK inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation." ;
    a m2r:Evidence .

civice:97
    dct:references pbm:23812671 ;
    civico:citation "Ji et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PLX4720,civic:drug_Nutlin-3 ;
    dcterms:description "Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy." ;
    a m2r:Evidence .

civice:98
    dct:references pbm:22180495 ;
    civico:citation "Yang et al., 2012, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Capecitabine,civic:drug_Vemurafenib,civic:drug_Bevacizumab ;
    dcterms:description "Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased survival and reduced tumor burden compared to single and double agent therapies." ;
    a m2r:Evidence .

civice:99
    dct:references pbm:22180495 ;
    civico:citation "Yang et al., 2012, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation." ;
    a m2r:Evidence .

civice:102
    dct:references pbm:24354346 ;
    civico:citation "Walczyk et al., 2014, Clin. Endocrinol. (Oxf)" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer." ;
    a m2r:Evidence .

civice:103
    dct:references pbm:24594804 ;
    civico:citation "Chen et al., 2014, PLoS ONE" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as a marker of poor prognosis." ;
    a m2r:Evidence .

civice:104
    dct:references pbm:24388723 ;
    civico:citation "Nagore et al., 2014, J. Am. Acad. Dermatol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients." ;
    a m2r:Evidence .

civice:105
    dct:references pbm:21594703 ;
    civico:citation "Howell et al., 2011, Ann. Surg. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts." ;
    a m2r:Evidence .

civice:106
    dct:references pbm:24396464 ;
    civico:citation "He et al., 2014, Oncol Lett" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases." ;
    a m2r:Evidence .

civice:107
    dct:references pbm:21594703 ;
    civico:citation "Howell et al., 2011, Ann. Surg. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo)." ;
    a m2r:Evidence .

civice:108
    dct:references pbm:16455956 ;
    civico:citation "Thiede et al., 2006, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NPM1 mutations were not associated with the M3 acute myeloid leukemia FAB subtype (0/55)." ;
    a m2r:Evidence .

civice:109
    dct:references pbm:21067377 ;
    civico:citation "Ley et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "No NPM1 mutations were identified in patients with favorable risk cytogenetics (79/215 patients)." ;
    a m2r:Evidence .

civice:110
    dct:references pbm:23632886 ;
    civico:citation "Gaidzik et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Negative" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients." ;
    a m2r:Evidence .

civice:111
    dct:references pbm:16076867 ;
    civico:citation "Schnittger et al., 2005, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Negative" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid leukemia." ;
    a m2r:Evidence .

civice:112
    dct:references pbm:21067377 ;
    civico:citation "Ley et al., 2010, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes." ;
    a m2r:Evidence .

civice:113
    dct:references pbm:21067377 ;
    civico:citation "Ley et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype)." ;
    a m2r:Evidence .

civice:114
    dct:references pbm:23632886 ;
    civico:citation "Gaidzik et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients." ;
    a m2r:Evidence .

civice:115
    dct:references pbm:23632886 ;
    civico:citation "Gaidzik et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients." ;
    a m2r:Evidence .

civice:116
    dct:references pbm:19357394 ;
    civico:citation "Vardiman et al., 2009, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "AML with mutated NPM1 is a provisional entity in the World Health Organization (WHO) classification of acute myeloid leukemia (AML). This mutation should be tested for in clinical trials and is recommended for testing in patients with cytogentically normal AML." ;
    a m2r:Evidence .

civice:117
    dct:references pbm:17957027 ;
    civico:citation "Gale et al., 2008, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NPM1 mutations were associated with de novo AML as well as M4 and M5 FAB subtypes." ;
    a m2r:Evidence .

civice:118
    dct:references pbm:16076867 ;
    civico:citation "Schnittger et al., 2005, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NPM1 mutations were associated with M4, M5a and M5b FAB subtypes of acute myeloid leukemia." ;
    a m2r:Evidence .

civice:119
    dct:references pbm:16455956 ;
    civico:citation "Thiede et al., 2006, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NPM1 mutations were associated with M5a and M5b FAB subtypes of acute myeloid leukemia." ;
    a m2r:Evidence .

civice:120
    dct:references pbm:19059939 ;
    civico:citation "Schlenk et al., 2009, Haematologica" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NPM1 mutations were associated with normal karyotype in older (>60) patients." ;
    a m2r:Evidence .

civice:121
    dct:references pbm:21067377 ;
    civico:citation "Ley et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NPM1 mutations were associated with intermediate risk cytogenetics (including normal karyotype)." ;
    a m2r:Evidence .

civice:122
    dct:references pbm:19965647 ;
    civico:citation "Burnett et al., 2010, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_All-transRetinoicAcid ;
    dcterms:description "In a randomized trial of previously untreated younger (<60) patients with acute myeloid leukemia (excluding acute promyelocytic leukemia) and high-risk myelodysplastic syndrome CEBPA mutation status had no significant impact on patient response to ATRA (N=20) compared to randomized control (N=15)." ;
    a m2r:Evidence .

civice:123
    dct:references pbm:20619739 ;
    civico:citation "De Roock et al., 2010, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In chemotherapy-refractory patients with colorectal cancer, Exon 9 PIK3CA mutations (Exon 9) had no significant impact on response rate, disease control rate, progression free surivival or overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA." ;
    a m2r:Evidence .

civice:124
    dct:references pbm:20619739 ;
    civico:citation "De Roock et al., 2010, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61) was not informative for disease control rate, progression free survival or overall survival following cetuximab plus chemotherapy." ;
    a m2r:Evidence .

civice:125
    dct:references pbm:22072639 ;
    civico:citation "Bresler et al., 2011, Sci Transl Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation. The authors conclude that this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors." ;
    a m2r:Evidence .

civice:126
    dct:references pbm:20619739 ;
    civico:citation "De Roock et al., 2010, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Chemotherapy-refractory patients with colorectal cancer harboring BRAF mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype BRAF." ;
    a m2r:Evidence .

civice:127
    dct:references pbm:19965647 ;
    civico:citation "Burnett et al., 2010, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_All-transRetinoicAcid ;
    dcterms:description "ATRA treatment did not effect overall survival in patients <60 years old with FLT3-ITD mutation." ;
    a m2r:Evidence .

civice:128
    dct:references pbm:17957027 ;
    civico:citation "Gale et al., 2008, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "FLT3-ITD mutation without NPM1 was associated with increased relapse risk and reduced overall survival in young adult AML patients (median age 43)." ;
    a m2r:Evidence .

civice:129
    dct:references pbm:17957027 ;
    civico:citation "Gale et al., 2008, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Increasing level of FLT3-ITD mutant correlated with reduced disease-free and overall survival as well as increased relapse rate." ;
    a m2r:Evidence .

civice:130
    dct:references pbm:15626738 ;
    civico:citation "Bagrintseva et al., 2005, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Daunorubicin ;
    dcterms:description "Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone." ;
    a m2r:Evidence .

civice:131
    dct:references pbm:15626738 ;
    civico:citation "Bagrintseva et al., 2005, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_SU5614 ;
    dcterms:description "Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles." ;
    a m2r:Evidence .

civice:134
    dct:references pbm:20619739 ;
    civico:citation "De Roock et al., 2010, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Chemotherapy-refractory patients with colorectal cancer harboring KRAS mutations (primarily G12/G13) had lower response and disease control rates and shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype KRAS." ;
    a m2r:Evidence .

civice:135
    dct:references pbm:18202412 ;
    civico:citation "Lièvre et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "KRAS mutations were significantly associated with lack of response to cetuximab in patients with advanced colorectal cancer." ;
    a m2r:Evidence .

civice:136
    dct:references pbm:20978259 ;
    civico:citation "De Roock et al., 2010, JAMA" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model." ;
    a m2r:Evidence .

civice:137
    dct:references pbm:19965647 ;
    civico:citation "Burnett et al., 2010, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_All-transRetinoicAcid ;
    dcterms:description "ATRA treatment did not effect overall survival in patients <60 years old with NPM1 mutation regardless of FLT3-ITD status." ;
    a m2r:Evidence .

civice:138
    dct:references pbm:20619739 ;
    civico:citation "De Roock et al., 2010, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Chemotherapy-refractory patients with colorectal cancer harboring Exon 20 PIK3CA mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA." ;
    a m2r:Evidence .

civice:139
    dct:references pbm:18591546 ;
    civico:citation "Virappane et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Daunorubicin,civic:drug_Cytarabine ;
    dcterms:description "WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML." ;
    a m2r:Evidence .

civice:141
    dct:references pbm:21575866 ;
    civico:citation "Sakamoto et al., 2011, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or EML4-ALK with the L1196M mutation." ;
    a m2r:Evidence .

civice:142
    dct:references pbm:18923525 ;
    civico:citation "George et al., 2008, Nature" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_TAE684 ;
    dcterms:description "SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition." ;
    a m2r:Evidence .

civice:143
    dct:references pbm:22072639 ;
    civico:citation "Bresler et al., 2011, Sci Transl Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation." ;
    a m2r:Evidence .

civice:144
    dct:references pbm:23558953 ;
    civico:citation "Wu et al., 2013, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PD173074 ;
    dcterms:description "Following identification of this fusion in a patient, this fusion was expressed in HEK 293T cells leading to oligomerization in the absence of ligand, induced morphologic changes in the cell and increased cellular proliferation consistent with FGFR activation. Mouse xenografts using the bladder cell line SW780 which harbors an FGFR3-BAIAP2L1 fusion showed reduced tumor burden when treated with the FGFR inhibitor PD173074." ;
    a m2r:Evidence .

civice:145
    dct:references pbm:20978259 ;
    civico:citation "De Roock et al., 2010, JAMA" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model." ;
    a m2r:Evidence .

civice:146
    dct:references pbm:19059939 ;
    civico:citation "Schlenk et al., 2009, Haematologica" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_All-transRetinoicAcid ;
    dcterms:description "ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD." ;
    a m2r:Evidence .

civice:147
    dct:references pbm:22417203 ;
    civico:citation "Patel et al., 2012, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Daunorubicin ;
    dcterms:description "Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11." ;
    a m2r:Evidence .

civice:148
    dct:references pbm:24797300 ;
    civico:citation "Tassara et al., 2014, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_ValproicAcid ;
    dcterms:description "For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid." ;
    a m2r:Evidence .

civice:149
    dct:references pbm:21719597 ;
    civico:citation "Balusu et al., 2011, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_All-transRetinoicAcid,civic:drug_NSC348884 ;
    dcterms:description "NSC348884 combined with ATRA treatment induces apoptosis in primary AML cells harboring mutant NPM1 but not in cells with wildtype NPM1 or both mutant NPM1 and FLT3-ITD." ;
    a m2r:Evidence .

civice:150
    dct:references pbm:24927407 ;
    civico:citation "Ehninger et al., 2014, Blood Cancer J" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Anti-CD33,civic:drug_Anti-CD123 ;
    dcterms:description "CD33 and CD123 expression was significantly increased in patients with NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33 and anti-CD123 therapy." ;
    a m2r:Evidence .

civice:151
    dct:references pbm:24927407 ;
    civico:citation "Ehninger et al., 2014, Blood Cancer J" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Anti-CD33 ;
    dcterms:description "CD33 expression was significantly increased in patients with NPM1 mutation with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy." ;
    a m2r:Evidence .

civice:152
    dct:references pbm:21719597 ;
    civico:citation "Balusu et al., 2011, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_NSC348884 ;
    dcterms:description "NSC348884 induced apoptosis in OPI-AML3 cells harboring an NPM1 mutation." ;
    a m2r:Evidence .

civice:153
    dct:references pbm:15659725 ;
    civico:citation "Falini et al., 2005, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_InductionTherapy ;
    dcterms:description "NPM1 mutation (Type A, W288fs) causes cytoplasmic localization of NPM when transfected into a non-hematopoietic cell line (293T cells). Cytoplasmic localization of NPM in AML patients was associated with good response to induction therapy." ;
    a m2r:Evidence .

civice:154
    dct:references pbm:19966866 ;
    civico:citation "Liang et al., 2010, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "Following rapamycin treatment of mice with KrasG12D-induced lung tumors, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, increased apoptosis, reduced proliferation and reduced tumor burden compared to Tsc1 wildtype mice." ;
    a m2r:Evidence .

civice:155
    dct:references pbm:22923433 ;
    civico:citation "Iyer et al., 2012, Science" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts." ;
    a m2r:Evidence .

civice:156
    dct:references pbm:14726504 ;
    civico:citation "Fröhling et al., 2004, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "FLT3 mutations did not alter overall survival or remission duration in younger (16-60), cytogenetically normal AML patients with CEBPA mutations. 10/36 patients with CEBPA mutations also had FLT3 mutations (8 FLT3-ITD, 2 FLT3-D835)." ;
    a m2r:Evidence .

civice:157
    dct:references pbm:22291079 ;
    civico:citation "Marcucci et al., 2012, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Complete remission rates did not differ between patients with wildtype or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML." ;
    a m2r:Evidence .

civice:158
    dct:references pbm:21537333 ;
    civico:citation "Schnittger et al., 2011, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "FLT3-ITD duplication length did not effect prognosis in patients with an NPM1 mutation." ;
    a m2r:Evidence .

civice:159
    dct:references pbm:17957027 ;
    civico:citation "Gale et al., 2008, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Size of the FLT3-ITD mutant duplication had no impact on overall survival or relapse rate." ;
    a m2r:Evidence .

civice:160
    dct:references pbm:20805365 ;
    civico:citation "Schnittger et al., 2010, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation." ;
    a m2r:Evidence .

civice:162
    dct:references pbm:19221039 ;
    civico:citation "Gaidzik et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML." ;
    a m2r:Evidence .

civice:163
    dct:references pbm:19221039 ;
    civico:citation "Gaidzik et al., 2009, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML." ;
    a m2r:Evidence .

civice:165
    dct:references pbm:19221039 ;
    civico:citation "Gaidzik et al., 2009, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML." ;
    a m2r:Evidence .

civice:166
    dct:references pbm:19965647 ;
    civico:citation "Burnett et al., 2010, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a group of young (<60 years old) acute myeloid leukemia (exclude acute promyelocytic leukemia) and high-risk MDS patients, those with CEBPA mutations (35/423) showed marginally improved overall survival (36% vs 31%; P = .04) than those with wildtype CEBPA." ;
    a m2r:Evidence .

civice:167
    dct:references pbm:18450602 ;
    civico:citation "Schlenk et al., 2008, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, CEBPA mutation was significantly associated with complete remission in multivariate analysis (odds ratio, 1.33; 95% confidence interval [CI], 1.01 to 1.74). Multivariate analysis was performed on all patients  that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. Only 509 patients in the study were evaluated for CEBPA, 67 of which had a mutation." ;
    a m2r:Evidence .

civice:168
    dct:references pbm:14726504 ;
    civico:citation "Fröhling et al., 2004, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Overall survival and remission duration were significantly longer (p=0.01 and p=0.05, respectively) in younger (16-60), cytogenetically normal acute myeloid leukemia patients with CEBPA mutations (21/236 patients)." ;
    a m2r:Evidence .

civice:170
    dct:references pbm:23632886 ;
    civico:citation "Gaidzik et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "DNMT3A mutations were associated with achievement of complete remission in a large cohort of younger (18-60) AML patients." ;
    a m2r:Evidence .

civice:171
    dct:references pbm:17965322 ;
    civico:citation "Bacher et al., 2008, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis 3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal karyotype patients were analyzed." ;
    a m2r:Evidence .

civice:172
    dct:references pbm:11070098 ;
    civico:citation "Esteller et al., 2000, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas." ;
    a m2r:Evidence .

civice:173
    dct:references pbm:17957027 ;
    civico:citation "Gale et al., 2008, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NPM1 mutation without FLT3-ITD was associated with reduced relapse risk and increased overall survival in young adult acute myeloid leukemia patients (median age 43)." ;
    a m2r:Evidence .

civice:174
    dct:references pbm:19059939 ;
    civico:citation "Schlenk et al., 2009, Haematologica" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with NPM1 mutations were associated with improved complete remission rates as well as overall and disease free survival when all ages and karyotype were analyzed; however, when only normal karyotype patients were analyzed, only complete remission rates were improved." ;
    a m2r:Evidence .

civice:175
    dct:references pbm:16455956 ;
    civico:citation "Thiede et al., 2006, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Complete remission rates were higher (P<0.001) and both disease-free survival (N=205 vs 352, P=0.041) and overall survival (N=372 vs 956, P=0.022) were longer for AML patients with Exon 12 NPM1 mutations (irrespective of FLT3 status) than those with wildtype NPM1. Improved CR rates were also higher for those with NPM1 exon 12 mutations and normal karyotype. In multivariate analysis, NPM1 mutation alone (FLT3 wildtype) was associated with improved overall survival (but not DFS) in the entire cohort and in normal karyotype patients <60 years old." ;
    a m2r:Evidence .

civice:176
    dct:references pbm:16076867 ;
    civico:citation "Schnittger et al., 2005, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Complete remission rates were higher (70.5% vs 54.7%, P = 0.003) and event-free survival was longer (median, 428 vs 336 days; P = 0.012) for normal karyotype AML patients (median age 60.3 years) with Exon 12 NPM1 mutations (N=212) compared to those with wildtype NPM1 (N=189)." ;
    a m2r:Evidence .

civice:177
    dct:references pbm:15659725 ;
    civico:citation "Falini et al., 2005, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Cytoplasmic localization of NPM in AML patients was an independent prognositic factor associated with complete remission in response to induction therapy in a multivariate analysis (p=0.019) but not in a univariate analysis (p=0.07)." ;
    a m2r:Evidence .

civice:179
    dct:references pbm:22417203 ;
    civico:citation "Patel et al., 2012, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Intermediate risk patients with mutant NPM1 had improved overall survival with the presence of either IDH1 or IDH2 mutations than those wildtype for both IDH1 and IDH2." ;
    a m2r:Evidence .

civice:180
    dct:references pbm:19047294 ;
    civico:citation "Büchner et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Normal karyotype patients with NPM1 mutation and without FLT3-ITD had improved overall and relapse-free survival, complete remission rates and remission duration compared to all other combinations of mutants." ;
    a m2r:Evidence .

civice:181
    dct:references pbm:24855211 ;
    civico:citation "Linch et al., 2014, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NPM1 mutation (N=724) was associated with higher complete remission rates (92% vs 82%; P < 0.0001), lower cumulative incidence of relapse (42% vs 58%; P < 0.0001) and higher overall survival (48% vs 27%; P < .0001) than NPM1 wildtype status (N=885) in intermediate risk, young adult AML patients (median age 46 years)." ;
    a m2r:Evidence .

civice:182
    dct:references pbm:22430270 ;
    civico:citation "Gaidzik et al., 2012, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NPM1 mutation was associated with increased overall, event-free and relapse-free survival and remission after induction therapy in the entire cohort and in the cytogenetically normal subset of patients." ;
    a m2r:Evidence .

civice:183
    dct:references pbm:18450602 ;
    civico:citation "Schlenk et al., 2008, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, NPM1 mutation without FLT3-ITD was significantly associated with complete remission in multivariate analysis (odds ratio, 1.48; 95% CI, 1.21 to 1.80). Multivariate analysis was performed on all patients that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. 130 patients had NPM1 mutations without FLT3-ITD. NPM1 mutations were evaluated in 570 patients (310 mutated).  FLT3-ITD was evaluated in 531 patients (164 mutated)." ;
    a m2r:Evidence .

civice:184
    dct:references pbm:20026798 ;
    civico:citation "Becker et al., 2010, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NPM1 mutations were associated with increased complete remission rates as well as longer overall disease free survival in normal karyotype AML patients >59 years old, particularly in those >69 years old." ;
    a m2r:Evidence .

civice:185
    dct:references pbm:16051734 ;
    civico:citation "Döhner et al., 2005, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Younger (16-60), normal karyotype AML patients with Exon 12 NPM1 mutation and without FLT3-ITD have increased overall survival (N=74, P = .001), relapse-free survival (N=86, P < .001) and response to induction chemotherapy. Multivariate analysis identified NPM1 mutation in the absence of FLT3-ITD as a prognostic marker for the achievement of CR (P=0.004)." ;
    a m2r:Evidence .

civice:186
    dct:references pbm:22490330 ;
    civico:citation "Ribeiro et al., 2012, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882)." ;
    a m2r:Evidence .

civice:187
    dct:references pbm:22291079 ;
    civico:citation "Marcucci et al., 2012, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "DNMT3A mutations (62% of which were R882) were associated with reduced disease-free survival in patients with cytogenetically normal AML." ;
    a m2r:Evidence .

civice:188
    dct:references pbm:22490330 ;
    civico:citation "Ribeiro et al., 2012, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Young AML patients (415 patients; <60 years old) with any DNMT3A mutation (n=96) have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A." ;
    a m2r:Evidence .

civice:189
    dct:references pbm:22490330 ;
    civico:citation "Ribeiro et al., 2012, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Young AML patients (415 patients; <60 years old) with DNMT3A R882 mutations (n=58) have shorter overall and relapse-free survival than patients with wildtype DNMT3A." ;
    a m2r:Evidence .

civice:190
    dct:references pbm:24801015 ;
    civico:citation "Port et al., 2014, Ann. Hematol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "A" ;
    dcterms:description "Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD." ;
    a m2r:Evidence .

civice:191
    dct:references pbm:21537333 ;
    civico:citation "Schnittger et al., 2011, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A ratio of >0.49 FLT3-ITD/FLT3 wildtype level was associated with reduced event-free and overall survival in old (>59) and younger patients (<60) with an NPM1 mutation." ;
    a m2r:Evidence .

civice:192
    dct:references pbm:21537333 ;
    civico:citation "Schnittger et al., 2011, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3." ;
    a m2r:Evidence .

civice:193
    dct:references pbm:21537333 ;
    civico:citation "Schnittger et al., 2011, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation." ;
    a m2r:Evidence .

civice:194
    dct:references pbm:18202412 ;
    civico:citation "Lièvre et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "D" ;
    dcterms:description "KRAS mutations were significantly associated with reduced progression-free and overall survival in patients with advanced colorectal cancer." ;
    a m2r:Evidence .

civice:195
    dct:references pbm:16455956 ;
    civico:citation "Thiede et al., 2006, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Coocurrence of FLT3-ITD mutations significantly reduced overall (N=74 vs 95, P=0.003) and disease-free survival (N=43 vs 67, P=0.02) of normal karyotype AML patients (<60 years old) compared to patients with NPM1 mutations alone." ;
    a m2r:Evidence .

civice:196
    dct:references pbm:19587375 ;
    civico:citation "Schnittger et al., 2009, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Monitoring NPM1 mutation by cDNA-based RT-PCR effectively predicted relapse in 62/93 patients by >1 log increase in NPM1 levels (N=57) or lack of reduction in NPM1 levels following first line therapy (N=15)." ;
    a m2r:Evidence .

civice:198
    dct:references pbm:24855211 ;
    civico:citation "Linch et al., 2014, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with NPM1 mutations and low (<25%, N=63), intermediate (25-50%, N=156) or high (>50%, N=66) levels of FLT3-ITD have worse overall survival (P<0.0001 for trend) and cumulative incidence of relapse (P<0.001) than those with NPM1 mutations alone (N=387) in young adult, intermediate risk AML patients." ;
    a m2r:Evidence .

civice:199
    dct:references pbm:24859829 ;
    civico:citation "Tian et al., 2014, Int. J. Hematol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "TET2 mutation reduces overall survival of normal karyotype patients with either an NPM1 mutation or NPM1 mutation without FLT3-ITD." ;
    a m2r:Evidence .

civice:201
    dct:references pbm:19536888 ;
    civico:citation "Renneville et al., 2009, Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Mutations  in WT1 were associated with increased risk of recurrence in young patients (15-50) with cytogenetically normal AML." ;
    a m2r:Evidence .

civice:202
    dct:references pbm:19536888 ;
    civico:citation "Renneville et al., 2009, Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Mutations in WT1 were associated with a worse overall prognosis than patients wildtype for WT1 in young patients (15-50), primarily because of increased risk of disease recurrence." ;
    a m2r:Evidence .

civice:203
    dct:references pbm:19221039 ;
    civico:citation "Gaidzik et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD following induction therapy in young (16-60) patients with cytogenetically normal AML." ;
    a m2r:Evidence .

civice:204
    dct:references pbm:18559874 ;
    civico:citation "Paschka et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients." ;
    a m2r:Evidence .

civice:205
    dct:references pbm:18591546 ;
    civico:citation "Virappane et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML." ;
    a m2r:Evidence .

civice:206
    dct:references pbm:18591546 ;
    civico:citation "Virappane et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML." ;
    a m2r:Evidence .

civice:210
    dct:references pbm:18559874 ;
    civico:citation "Paschka et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "WT1 mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients." ;
    a m2r:Evidence .

civice:211
    dct:references pbm:23346317 ;
    civico:citation "Goff, 2013, J Gynecol Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer." ;
    a m2r:Evidence .

civice:212
    dct:references pbm:23346317 ;
    civico:citation "Goff, 2013, J Gynecol Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undifferentiated ovarian cancer." ;
    a m2r:Evidence .

civice:213
    dct:references pbm:25212276 ;
    civico:citation "Schmidt et al., 2014, Leukemia" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML." ;
    a m2r:Evidence .

civice:214
    dct:references pbm:11290608 ;
    civico:citation "Yamamoto et al., 2001, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "WBC counts were not significantly different in AML patients with FLT3 D835 mutations compared to wild type." ;
    a m2r:Evidence .

civice:215
    dct:references pbm:18794081 ;
    civico:citation "Riely et al., 2008, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "KRAS mutations in lung cancer patients are not associated with smoking history, age or gender." ;
    a m2r:Evidence .

civice:217
    dct:references pbm:23029227 ;
    civico:citation "Qian et al., 2012, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF Q157P/R mutations and those who harbor wild type U2AF." ;
    a m2r:Evidence .

civice:218
    dct:references pbm:23029227 ;
    civico:citation "Qian et al., 2012, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF." ;
    a m2r:Evidence .

civice:219
    dct:references pbm:14612939 ;
    civico:citation "Oshimo et al., 2003, Int. J. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Negative" ;
    civico:evidenceLevel "D" ;
    dcterms:description "CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II." ;
    a m2r:Evidence .

civice:220
    dct:references pbm:20537386 ;
    civico:citation "An et al., 2010, Leuk. Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease." ;
    a m2r:Evidence .

civice:221
    dct:references pbm:15961768 ;
    civico:citation "Arnold et al., 2005, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer." ;
    a m2r:Evidence .

civice:222
    dct:references pbm:11290608 ;
    civico:citation "Yamamoto et al., 2001, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "WBC counts were higher in AML patients with internal tandem repeat of Flt3 compared to wild type." ;
    a m2r:Evidence .

civice:223
    dct:references pbm:20376086 ;
    civico:citation "Ho et al., 2010, Leukemia" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In leukemia patients, IDH1 R132 mutation is associated with adults and normal karyotype." ;
    a m2r:Evidence .

civice:224
    dct:references pbm:20538800 ;
    civico:citation "Abbas et al., 2010, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation." ;
    a m2r:Evidence .

civice:225
    dct:references pbm:10485475 ;
    civico:citation "Taniguchi et al., 1999, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "KIT mutation is associated with larger, more invasive tumors, greater pathologic histology and older patients compared to tumors with wildtype KIT." ;
    a m2r:Evidence .

civice:227
    dct:references pbm:23014527 ;
    civico:citation "Dogan et al., 2012, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "KRAS G12C occur more frequently in women than men." ;
    a m2r:Evidence .

civice:228
    dct:references pbm:23014527 ;
    civico:citation "Dogan et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "KRAS G12D mutation occurs in never smokers significantly more often than in smokers." ;
    a m2r:Evidence .

civice:229
    dct:references pbm:24736073 ;
    civico:citation "Lim et al., 2014, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate: P=0.250) compared to patients with Exon 19 mutations (N=170)." ;
    a m2r:Evidence .

civice:231
    dct:references pbm:23888070 ;
    civico:citation "Beaver et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_MK-2206 ;
    dcterms:description "Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations." ;
    a m2r:Evidence .

civice:232
    dct:references pbm:12476305 ;
    civico:citation "Nimmanapalli et al., 2002, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines." ;
    a m2r:Evidence .

civice:233
    dct:references pbm:15194504 ;
    civico:citation "Yamamoto et al., 2004, Biochem. Biophys. Res. Commun." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "COS7 cell lines transfected with BCR-ABL constructs harboring E255K mutations were shown to be resistant to imatinib and exhibited increased kinase activity." ;
    a m2r:Evidence .

civice:234
    dct:references pbm:20537386 ;
    civico:citation "An et al., 2010, Leuk. Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In chronic myeloid leukemia patients with the ABL T315I mutation, tumors have shown to be resistant to imatinib treatment." ;
    a m2r:Evidence .

civice:235
    dct:references pbm:15194504 ;
    civico:citation "Yamamoto et al., 2004, Biochem. Biophys. Res. Commun." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "COS7 cell lines transfected with BCR-ABL constructs harboring T315I mutations were shown to be resistant to imatinib and exhibited increased kinase activity." ;
    a m2r:Evidence .

civice:236
    dct:references pbm:20979473 ;
    civico:citation "Choi et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A 28 year old patient with T4N3M1 stage lung adenocarcinoma harboring an EML4-ALK variant 1 fusion was treated with crizotinib after failing conventional therapy. The patient achieved a partial response but progressed after 5 months of treatment. Molecular analysis at this time identified two missense mutations in ALK C1156Y and L1196M. Ba/F3 cells expressing EML4-ALK L1196M or EML4-ALK C1156Y were more resistant to crizontinib treatment than those expressing EML4-ALK wildtype." ;
    a m2r:Evidence .

civice:237
    dct:references pbm:20979473 ;
    civico:citation "Choi et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In patients with non-small cell lung cancer harboring EML4-ALK fusion, the L1196M variant has been shown to confer resistance to crizotinib." ;
    a m2r:Evidence .

civice:238
    dct:references pbm:25668228 ;
    civico:citation "Denis et al., 2015, Clin. Chim. Acta" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse." ;
    a m2r:Evidence .

civice:239
    dct:references pbm:15728811 ;
    civico:citation "Kobayashi et al., 2005, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib." ;
    a m2r:Evidence .

civice:240
    dct:references pbm:21430269 ;
    civico:citation "Sequist et al., 2011, Sci Transl Med" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dacomitinib ;
    dcterms:description "In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance." ;
    a m2r:Evidence .

civice:241
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2." ;
    a m2r:Evidence .

civice:242
    dct:references pbm:24185512 ;
    civico:citation "Toy et al., 2013, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_HormoneTherapy ;
    dcterms:description "MCF7 cell lines harboring the L536Q mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy." ;
    a m2r:Evidence .

civice:243
    dct:references pbm:24185512 ;
    civico:citation "Toy et al., 2013, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_HormoneTherapy ;
    dcterms:description "MCF7 cell lines harboring the D538G mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy." ;
    a m2r:Evidence .

civice:244
    dct:references pbm:24185512 ;
    civico:citation "Toy et al., 2013, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_HormoneTherapy ;
    dcterms:description "MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy." ;
    a m2r:Evidence .

civice:245
    dct:references pbm:24185512 ;
    civico:citation "Toy et al., 2013, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_HormoneTherapy ;
    dcterms:description "MCF7 cell lines harboring the Y537N mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy." ;
    a m2r:Evidence .

civice:246
    dct:references pbm:24185512 ;
    civico:citation "Toy et al., 2013, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_HormoneTherapy ;
    dcterms:description "MCF7 cell lines harboring the L537S mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy." ;
    a m2r:Evidence .

civice:247
    dct:references pbm:22368270 ;
    civico:citation "Man et al., 2012, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "Emergence of D835 mutation in AML patients with FLT3 tandem repeat is associated with sorafenib resistance." ;
    a m2r:Evidence .

civice:248
    dct:references pbm:18230792 ;
    civico:citation "Zhang et al., 2008, J. Natl. Cancer Inst." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "Sorafenib is effective in patients with FLT3 internal tandem repeat mutations, but not in patients with wild type or D835 mutation." ;
    a m2r:Evidence .

civice:249
    dct:references pbm:16954519 ;
    civico:citation "Heinrich et al., 2006, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "KIT V654A results in imatinib resistance in GIST patient-derived cell lines." ;
    a m2r:Evidence .

civice:250
    dct:references pbm:16618717 ;
    civico:citation "Lièvre et al., 2006, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab." ;
    a m2r:Evidence .

civice:251
    dct:references pbm:19794967 ;
    civico:citation "Marchetti et al., 2009, Neoplasia" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) were significantly shorter in mutated patients." ;
    a m2r:Evidence .

civice:256
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "The presence of a PIK3CA mutation in exon 9 (such as E542K) or exon 20 were associated with lack of panitumumab or cetuximab response." ;
    a m2r:Evidence .

civice:258
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "The presence of a PIK3CA mutation in exon 9 or exon 20 (such as H1047R) were associated with lack of panitumumab or cetuximab response." ;
    a m2r:Evidence .

civice:259
    dct:references pbm:12476305 ;
    civico:citation "Nimmanapalli et al., 2002, Oncogene" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML." ;
    a m2r:Evidence .

civice:260
    dct:references pbm:20537386 ;
    civico:citation "An et al., 2010, Leuk. Res." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML." ;
    a m2r:Evidence .

civice:261
    dct:references pbm:20537386 ;
    civico:citation "An et al., 2010, Leuk. Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Nilotinib,civic:drug_Dasatinib ;
    dcterms:description "The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval." ;
    a m2r:Evidence .

civice:262
    dct:references pbm:20979473 ;
    civico:citation "Choi et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In patients with non-small cell lung cancer harboring the EML4-ALK fusion, treatment with crizotinib has shown to be effective in acheiving stable disease." ;
    a m2r:Evidence .

civice:263
    dct:references pbm:23079656 ;
    civico:citation "Sawai et al., 2012, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with Palbociclib (PD-0332991) significantly increased median survival." ;
    a m2r:Evidence .

civice:264
    dct:references pbm:25002028 ;
    civico:citation "Vora et al., 2014, Cancer Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BYL719%28Alpelisib%29 ;
    dcterms:description "In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions." ;
    a m2r:Evidence .

civice:266
    dct:references pbm:22328973 ;
    civico:citation "Hammerman et al., 2011, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib." ;
    a m2r:Evidence .

civice:267
    dct:references pbm:22328973 ;
    civico:citation "Hammerman et al., 2011, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib." ;
    a m2r:Evidence .

civice:268
    dct:references pbm:22328973 ;
    civico:citation "Hammerman et al., 2011, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib." ;
    a m2r:Evidence .

civice:269
    dct:references pbm:22328973 ;
    civico:citation "Hammerman et al., 2011, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib." ;
    a m2r:Evidence .

civice:270
    dct:references pbm:22328973 ;
    civico:citation "Hammerman et al., 2011, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib." ;
    a m2r:Evidence .

civice:271
    dct:references pbm:22328973 ;
    civico:citation "Hammerman et al., 2011, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib." ;
    a m2r:Evidence .

civice:272
    dct:references pbm:22328973 ;
    civico:citation "Hammerman et al., 2011, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dasatinib,civic:drug_Erlotinib ;
    dcterms:description "In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response." ;
    a m2r:Evidence .

civice:273
    dct:references pbm:16730237 ;
    civico:citation "Ji et al., 2006, Cancer Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "Exon 19 deletion has been shown to be correlated with gefitinib response." ;
    a m2r:Evidence .

civice:274
    dct:references pbm:15118125 ;
    civico:citation "Paez et al., 2004, Science" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations." ;
    a m2r:Evidence .

civice:275
    dct:references pbm:24457318 ;
    civico:citation "Fukihara et al., 2014, Oncology" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival." ;
    a m2r:Evidence .

civice:276
    dct:references pbm:15118125 ;
    civico:citation "Paez et al., 2004, Science" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations." ;
    a m2r:Evidence .

civice:277
    dct:references pbm:24636847 ;
    civico:citation "Li et al., 2014, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pemetrexed,civic:drug_Erlotinib ;
    dcterms:description "In an NSCLC patient initially with L858R mutation, pemetrexed and cisplatin combination treatment was followed by erlotinib treatment. A slow progression developed which was found to be positive for L858R as well as T790M mutation which confers resistance to tyrosine kinase inhibitors. Due to slow tumor growth erlotinib was continued despite T790M, with re-addition of premetrexed, and this reduced tumor size and resulted in stable disease." ;
    a m2r:Evidence .

civice:278
    dct:references pbm:24658966 ;
    civico:citation "Ai et al., 2014, Amino Acids" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Staurosporine ;
    dcterms:description "In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present." ;
    a m2r:Evidence .

civice:279
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib,civic:drug_Neratinib ;
    dcterms:description "In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib." ;
    a m2r:Evidence .

civice:280
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib." ;
    a m2r:Evidence .

civice:281
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib,civic:drug_Neratinib ;
    dcterms:description "In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib." ;
    a m2r:Evidence .

civice:282
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib." ;
    a m2r:Evidence .

civice:283
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "The L755S mutation showed mild response to neratinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2." ;
    a m2r:Evidence .

civice:284
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay." ;
    a m2r:Evidence .

civice:285
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "In MCF10A cell lines, the in-frame insertion of a single amino acid at position 780 was shown to be sensitive to neratinib." ;
    a m2r:Evidence .

civice:286
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib,civic:drug_Lapatinib ;
    dcterms:description "MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony forming assay." ;
    a m2r:Evidence .

civice:287
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib." ;
    a m2r:Evidence .

civice:288
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib." ;
    a m2r:Evidence .

civice:289
    dct:references pbm:23220880 ;
    civico:citation "Bose et al., 2013, Cancer Discov" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib." ;
    a m2r:Evidence .

civice:290
    dct:references pbm:24185510 ;
    civico:citation "Robinson et al., 2013, Nat. Genet." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Tamoxifen,civic:drug_Fulvestrant ;
    dcterms:description "Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the L536Q ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines." ;
    a m2r:Evidence .

civice:291
    dct:references pbm:24185510 ;
    civico:citation "Robinson et al., 2013, Nat. Genet." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Tamoxifen,civic:drug_Fulvestrant ;
    dcterms:description "Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the N538G ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines." ;
    a m2r:Evidence .

civice:292
    dct:references pbm:24185510 ;
    civico:citation "Robinson et al., 2013, Nat. Genet." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Tamoxifen,civic:drug_Fulvestrant ;
    dcterms:description "Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537C ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines." ;
    a m2r:Evidence .

civice:293
    dct:references pbm:24185510 ;
    civico:citation "Robinson et al., 2013, Nat. Genet." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Tamoxifen,civic:drug_Fulvestrant ;
    dcterms:description "Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537N ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines." ;
    a m2r:Evidence .

civice:294
    dct:references pbm:24185510 ;
    civico:citation "Robinson et al., 2013, Nat. Genet." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Tamoxifen,civic:drug_Fulvestrant ;
    dcterms:description "Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537S ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines." ;
    a m2r:Evidence .

civice:295
    dct:references pbm:24550739 ;
    civico:citation "Borad et al., 2014, PLoS Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Ponatinib ;
    dcterms:description "In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease. However, this response did not meet criteria for RECIST partial response." ;
    a m2r:Evidence .

civice:296
    dct:references pbm:24550739 ;
    civico:citation "Borad et al., 2014, PLoS Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pazopanib,civic:drug_Ponatinib ;
    dcterms:description "In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurrent in multiple other cancer types." ;
    a m2r:Evidence .

civice:297
    dct:references pbm:14726387 ;
    civico:citation "Smith et al., 2004, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Lestaurtinib%28CEP-701%29 ;
    dcterms:description "CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated AML patients with FLT3 mutations." ;
    a m2r:Evidence .

civice:298
    dct:references pbm:18230792 ;
    civico:citation "Zhang et al., 2008, J. Natl. Cancer Inst." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "Sorafenib is effective in patients with FLT3 internal tandem repeats, but not in wild type or D835 mutation." ;
    a m2r:Evidence .

civice:299
    dct:references pbm:12357354 ;
    civico:citation "Tse et al., 2002, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AG1296 ;
    dcterms:description "AG1296 is effective in triggering apoptosis in Ba/F3 and primary AML cells with FLT3 internal tandem repeat." ;
    a m2r:Evidence .

civice:301
    dct:references pbm:22541434 ;
    civico:citation "Kumar et al., 2012, Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Bortezomib,civic:drug_Fasudil ;
    dcterms:description "Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression." ;
    a m2r:Evidence .

civice:302
    dct:references pbm:18421059 ;
    civico:citation "Hodi et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In a case study, a patient with anal melanoma harboring a 7 codon duplication in the juxtamambrane region (exon 11) of KIT showed marked response 4 months after imatinib treatment." ;
    a m2r:Evidence .

civice:303
    dct:references pbm:17372901 ;
    civico:citation "Antonescu et al., 2007, Int. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib,civic:drug_Imatinib,civic:drug_Nilotinib ;
    dcterms:description "Ba/F3 cells harboring the KIT L576P mutation were sensitive to dasatinib, nilotinib and imatinib. In these assays, dasatinib was more efficacious than nilotinib or imatinib, showing results most similar to the known sensitive KIT mutation V559D." ;
    a m2r:Evidence .

civice:304
    dct:references pbm:16638875 ;
    civico:citation "Prenen et al., 2006, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sunitinib ;
    dcterms:description "In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib." ;
    a m2r:Evidence .

civice:305
    dct:references pbm:19029981 ;
    civico:citation "Engelman et al., 2008, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BEZ235%28NVP-BEZ235,civic:drug_Dactolisib%29,civic:drug_ARRY-142886 ;
    dcterms:description "The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy, in a lung cancer model with KRAS G12D mutation led to marked tumor regression." ;
    a m2r:Evidence .

civice:306
    dct:references pbm:20978259 ;
    civico:citation "De Roock et al., 2010, JAMA" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS." ;
    a m2r:Evidence .

civice:307
    dct:references pbm:15758010 ;
    civico:citation "Hegi et al., 2005, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "In a randomized clinical trial, patients with MGMT promoter methyaltion benefitted from temozolomide. This benefit was also methylation status dependent, as those without methylation did not see increased survival." ;
    a m2r:Evidence .

civice:308
    dct:references pbm:11070098 ;
    civico:citation "Esteller et al., 2000, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Carmustine ;
    dcterms:description "MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells." ;
    a m2r:Evidence .

civice:309
    dct:references pbm:11070098 ;
    civico:citation "Esteller et al., 2000, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_O%286%29-benzylguanine ;
    dcterms:description "In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with initial resistance to alkylating agents." ;
    a m2r:Evidence .

civice:310
    dct:references pbm:21558396 ;
    civico:citation "Tanaka et al., 2011, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_CH5132799 ;
    dcterms:description "Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene." ;
    a m2r:Evidence .

civice:311
    dct:references pbm:15647370 ;
    civico:citation "Kang et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "Rapamycin inhibits transformation induced by mutation in PIK3CA." ;
    a m2r:Evidence .

civice:314
    dct:references pbm:21558396 ;
    civico:citation "Tanaka et al., 2011, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_CH5132799 ;
    dcterms:description "Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene." ;
    a m2r:Evidence .

civice:316
    dct:references pbm:8674046 ;
    civico:citation "Yoshida et al., 1996, Cancer Res." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_All-transRetinoicAcid ;
    dcterms:description "Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations." ;
    a m2r:Evidence .

civice:317
    dct:references pbm:20085938 ;
    civico:citation "Courtney et al., 2010, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_MTORInhibitors ;
    dcterms:description "Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors." ;
    a m2r:Evidence .

civice:319
    dct:references pbm:22698404 ;
    civico:citation "Jackson et al., 2012, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Doxorubicin ;
    dcterms:description "Breast tumors in a mouse model with R172H mutation (homologous to human R175H) are more responsive to doxorubicin than breast tumors with wild type TP53." ;
    a m2r:Evidence .

civice:320
    dct:references pbm:22923433 ;
    civico:citation "Iyer et al., 2012, Science" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "A patient with metastatic bladder cancer that responded well to the mTOR inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del, p.Glu636fs) and a nonsense NF2 mutation. 2/3 additional patients with TSC1 mutations also had mild responses to everolimus." ;
    a m2r:Evidence .

civice:322
    dct:references pbm:11290608 ;
    civico:citation "Yamamoto et al., 2001, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "AML patients with D835 mutation of FLT3 did not have worse overall survival than patients with wild type FLT3." ;
    a m2r:Evidence .

civice:323
    dct:references pbm:20368538 ;
    civico:citation "Wagner et al., 2010, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The complete remission and overall survival rates in patients with IDH1 R132 mutation is not significantly different from those who do not have this mutation." ;
    a m2r:Evidence .

civice:324
    dct:references pbm:20538800 ;
    civico:citation "Abbas et al., 2010, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1." ;
    a m2r:Evidence .

civice:327
    dct:references pbm:22616558 ;
    civico:citation "Zhou et al., 2012, Leuk. Lymphoma" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this meta-analysis of adult non-promyelocytic AML (11 studies), patients with IDH2 R140 or R172 mutations had event free survival and overall survival similar to those with wild-type IDH2." ;
    a m2r:Evidence .

civice:328
    dct:references pbm:20421455 ;
    civico:citation "Thol et al., 2010, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with IDH2 R140 and R172 mutation, the presence of mutation does not impact overall survival or disease free survival." ;
    a m2r:Evidence .

civice:329
    dct:references pbm:21997850 ;
    civico:citation "Lin et al., 2012, Ann. Hematol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with myelodysplastic syndrome, the presence of IDH2 R140Q (N=3) or IDH1 R132 (N=2) mutations did not confer prognostic value (overall survival) compared to wild-type IDH1/2 patients (N=61; P=0.794)." ;
    a m2r:Evidence .

civice:330
    dct:references pbm:22033490 ;
    civico:citation "Patnaik et al., 2012, Leukemia" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "R140Q mutation in IDH2 does not have prognostic value in patients with MDS." ;
    a m2r:Evidence .

civice:331
    dct:references pbm:22616558 ;
    civico:citation "Zhou et al., 2012, Leuk. Lymphoma" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "AML patients with IDH2 mutations such as R172K have event free survival and overall survival similar to those with wild-type IDH2." ;
    a m2r:Evidence .

civice:332
    dct:references pbm:21997850 ;
    civico:citation "Lin et al., 2012, Ann. Hematol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients suffering from MDS, the presence of IDH2 mutations such as R172K do not confer prognostic value (overall survival)." ;
    a m2r:Evidence .

civice:333
    dct:references pbm:12000708 ;
    civico:citation "Corless et al., 2002, Am. J. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "KIT mutations were identified in morphologically benign, incidentally discovered GISTs at a rate similar to that seen in advanced, metastatic GIST patients indicating is not a prognostic marker for GIST." ;
    a m2r:Evidence .

civice:334
    dct:references pbm:15217946 ;
    civico:citation "Boldrini et al., 2004, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer." ;
    a m2r:Evidence .

civice:336
    dct:references pbm:19934290 ;
    civico:citation "Ogino et al., 2009, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with stage III colorectal cancer undergoing chemotherapy, KRAS G12 mutation did not impact overall or disease free survival." ;
    a m2r:Evidence .

civice:337
    dct:references pbm:11208838 ;
    civico:citation "Schiller et al., 2001, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "There is no strong association between KRAS mutation status and overall or progression free survival in patients with NSCLC." ;
    a m2r:Evidence .

civice:338
    dct:references pbm:23029227 ;
    civico:citation "Qian et al., 2012, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with AML, those who harbor Q157P/R mutation of U2AF1 do not show a statistically significant difference in complete remission rate compared to those who harbor wild type U2AF1." ;
    a m2r:Evidence .

civice:339
    dct:references pbm:23029227 ;
    civico:citation "Qian et al., 2012, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with MDS, those who harbor Q157P/R mutation of U2AF do not show statistical significance in complete remission rate compared to those who harbor wild type U2AF." ;
    a m2r:Evidence .

civice:340
    dct:references pbm:23029227 ;
    civico:citation "Qian et al., 2012, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1." ;
    a m2r:Evidence .

civice:342
    dct:references pbm:17070615 ;
    civico:citation "Gautschi et al., 2007, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Three studies have found no significant survival impact for CCND1 in lung cancer." ;
    a m2r:Evidence .

civice:343
    dct:references pbm:22479427 ;
    civico:citation "Carico et al., 2012, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "PTEN nonsense mutations, including R233*, have been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients." ;
    a m2r:Evidence .

civice:344
    dct:references pbm:20537386 ;
    civico:citation "An et al., 2010, Leuk. Res." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens." ;
    a m2r:Evidence .

civice:347
    dct:references pbm:24662454 ;
    civico:citation "Douillard et al., 2014, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR." ;
    a m2r:Evidence .

civice:348
    dct:references pbm:19933982 ;
    civico:citation "Dubbink et al., 2009, Neurology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with astrocytoma, the presence of IDH1 R132 mutation is prognostic for better survival compared to patients who harbor wild type mutation." ;
    a m2r:Evidence .

civice:349
    dct:references pbm:20127344 ;
    civico:citation "Bleeker et al., 2010, Acta Neuropathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with glioblastoma, those harboring IDH1 R132 mutation has higher overall survival compared to those who do not have IDH1 mutation." ;
    a m2r:Evidence .

civice:350
    dct:references pbm:21596855 ;
    civico:citation "Green et al., 2011, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In AML, patients with IDH2 R140 mutation have improved overall survival compared to those with wild-type IDH2." ;
    a m2r:Evidence .

civice:352
    dct:references pbm:21995386 ;
    civico:citation "Papaemmanuil et al., 2011, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with SF3B1 mutations had a statistically significant longer overall survival as well as event free-survival. Both before and after adjustment for age, karyotype and sex." ;
    a m2r:Evidence .

civice:354
    dct:references pbm:17070615 ;
    civico:citation "Gautschi et al., 2007, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Inceased copy number of CCND1 is associated with poorer overall survival." ;
    a m2r:Evidence .

civice:355
    dct:references pbm:17070615 ;
    civico:citation "Gautschi et al., 2007, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Three studies have associated CCND1 expression with poorer survival." ;
    a m2r:Evidence .

civice:356
    dct:references pbm:15961768 ;
    civico:citation "Arnold et al., 2005, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis." ;
    a m2r:Evidence .

civice:357
    dct:references pbm:16309541 ;
    civico:citation "Thomas et al., 2005, Int J Exp Pathol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma." ;
    a m2r:Evidence .

civice:358
    dct:references pbm:17891190 ;
    civico:citation "Jares et al., 2007, Nat. Rev. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma." ;
    a m2r:Evidence .

civice:359
    dct:references pbm:10547574 ;
    civico:citation "Takano et al., 1999, J. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "D" ;
    dcterms:description "Cyclin D2 overexpression is associated with poor prognosis in gastric cancers." ;
    a m2r:Evidence .

civice:360
    dct:references pbm:10547574 ;
    civico:citation "Takano et al., 1999, J. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "D" ;
    dcterms:description "Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers." ;
    a m2r:Evidence .

civice:361
    dct:references pbm:10547574 ;
    civico:citation "Takano et al., 1999, J. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "D" ;
    dcterms:description "Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers." ;
    a m2r:Evidence .

civice:362
    dct:references pbm:10547574 ;
    civico:citation "Takano et al., 1999, J. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "D" ;
    dcterms:description "Cyclin D2 overexpression is associated with vascular invasion by cancer cells in gastric cancers." ;
    a m2r:Evidence .

civice:363
    dct:references pbm:12432043 ;
    civico:citation "Keyomarsi et al., 2002, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times higher than those with normal cyclin E levels." ;
    a m2r:Evidence .

civice:364
    dct:references pbm:10224221 ;
    civico:citation "Donnellan et al., 1999, FASEB J." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma." ;
    a m2r:Evidence .

civice:365
    dct:references pbm:10224221 ;
    civico:citation "Donnellan et al., 1999, FASEB J." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma." ;
    a m2r:Evidence .

civice:367
    dct:references pbm:23111194 ;
    civico:citation "Bradly et al., 2012, Diagn. Mol. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence and shorter overall survival." ;
    a m2r:Evidence .

civice:369
    dct:references pbm:24623981 ;
    civico:citation "Ding et al., 2014, Onco Targets Ther" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation." ;
    a m2r:Evidence .

civice:370
    dct:references pbm:24729716 ;
    civico:citation "Li et al., 2014, Onco Targets Ther" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations." ;
    a m2r:Evidence .

civice:371
    dct:references pbm:11290608 ;
    civico:citation "Yamamoto et al., 2001, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "AML patients with internal tandem repeat of FLT3 has worse overall survival than patients with wild type FLT3." ;
    a m2r:Evidence .

civice:372
    dct:references pbm:11585760 ;
    civico:citation "Whitman et al., 2001, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Simultaneous tandem repeat of FLT3 with loss of wild type FLT3 leads to poor survival and inferior disease free survival in patients with AML." ;
    a m2r:Evidence .

civice:373
    dct:references pbm:17940205 ;
    civico:citation "Whitman et al., 2008, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3." ;
    a m2r:Evidence .

civice:374
    dct:references pbm:20494930 ;
    civico:citation "Thol et al., 2010, Haematologica" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "IDH1 R132 mutation in patients suffering from myelodysplastic syndromes is associated with worse overall survival." ;
    a m2r:Evidence .

civice:375
    dct:references pbm:21596855 ;
    civico:citation "Green et al., 2011, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In AML, patients with an IDH2 R172K mutation have worse overall survival compared to those with wild-type IDH2." ;
    a m2r:Evidence .

civice:376
    dct:references pbm:10485475 ;
    civico:citation "Taniguchi et al., 1999, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "KIT mutation is associated with worse overall and cause-specific prognosis in patients with GIST compared to patients with wildtype KIT." ;
    a m2r:Evidence .

civice:377
    dct:references pbm:18528420 ;
    civico:citation "Chng et al., 2008, Leukemia" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival." ;
    a m2r:Evidence .

civice:378
    dct:references pbm:15597105 ;
    civico:citation "Mascaux et al., 2005, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A meta-analysis showed KRAS mutation is associated with worse outcome in patients with NSCLC." ;
    a m2r:Evidence .

civice:380
    dct:references pbm:20007775 ;
    civico:citation "Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NOTCH1 gain-of-function mutations, including D1642H (called D1643H in publication), have shown to be correlated with poor prognosis in lung cancer. This is in a TP53 wild-type context." ;
    a m2r:Evidence .

civice:381
    dct:references pbm:20007775 ;
    civico:citation "Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NOTCH1 gain-of-function mutations, including R2327W (called R2328W in publication), have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context." ;
    a m2r:Evidence .

civice:382
    dct:references pbm:20007775 ;
    civico:citation "Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NOTCH1 gain-of-function mutations, including S2275fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context." ;
    a m2r:Evidence .

civice:383
    dct:references pbm:20007775 ;
    civico:citation "Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NOTCH1 gain-of-function mutations, including V2444fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context." ;
    a m2r:Evidence .

civice:384
    dct:references pbm:22357840 ;
    civico:citation "Liao et al., 2012, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "E" ;
    dcterms:description "Coexistence of exon 9 (E542K or E545K) and exon 20 mutations but not either alone, is prognostic for worse overall survival and cancer specific survival." ;
    a m2r:Evidence .

civice:385
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The presence of exon 9 (such as E542K) or exon 20 mutations were associated with poorer survival compared to those with wild-type PIK3CA mutation (P = 0.035)." ;
    a m2r:Evidence .

civice:387
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation, and 1 patient (patient 95, see supplemental table 1) had PIK3CA E545K in the primary tumor without co-occurring mutations in the other tested genes. This response was consistent with observations made of the larger cohort, where patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. However, there was one patient (Patient 55, Table S1) who had E545K as the only noted variant, but experienced partial response." ;
    a m2r:Evidence .

civice:388
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab,civic:drug_Cetuximab ;
    dcterms:description "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). PIK3CA H1047R was the only variant noted in the primary tumors of four patients, and the metastatic tumor of one patient, who experienced disease progression following treatment. In the larger cohort, patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors." ;
    a m2r:Evidence .

civice:389
    dct:references pbm:16489069 ;
    civico:citation "Olivier et al., 2006, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Breast cancer patients who harbor R175H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation." ;
    a m2r:Evidence .

civice:390
    dct:references pbm:16489069 ;
    civico:citation "Olivier et al., 2006, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Breast cancer patients who harbor a R248Q mutation (N=18) have worse overall survival than those with wild type TP53 (N=1460), but have better prognosis than those with a R248W mutation (N=8)." ;
    a m2r:Evidence .

civice:391
    dct:references pbm:9569050 ;
    civico:citation "Berns et al., 1998, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R248 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53." ;
    a m2r:Evidence .

civice:392
    dct:references pbm:16489069 ;
    civico:citation "Olivier et al., 2006, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In breast cancer patients harboring R248W mutation, the prognosis is worse than any other hotspot TP53 mutation, as well as worse than patients with wild type TP53." ;
    a m2r:Evidence .

civice:393
    dct:references pbm:9569050 ;
    civico:citation "Berns et al., 1998, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53." ;
    a m2r:Evidence .

civice:395
    dct:references pbm:16489069 ;
    civico:citation "Olivier et al., 2006, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation." ;
    a m2r:Evidence .

civice:396
    dct:references pbm:9569050 ;
    civico:citation "Berns et al., 1998, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In breast cancer patients  harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53." ;
    a m2r:Evidence .

civice:397
    dct:references pbm:16489069 ;
    civico:citation "Olivier et al., 2006, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Breast cancer patients who harbor R273H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation." ;
    a m2r:Evidence .

civice:398
    dct:references pbm:9569050 ;
    civico:citation "Berns et al., 1998, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53." ;
    a m2r:Evidence .

civice:399
    dct:references pbm:9569050 ;
    civico:citation "Berns et al., 1998, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Doxorubicin ;
    dcterms:description "Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53." ;
    a m2r:Evidence .

civice:400
    dct:references pbm:23861105 ;
    civico:citation "Wu et al., 2013, Am. J. Hematol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "After adjusting for age and cancer stage, presence of U2AF mutation such as Q157P/R is prognostic for poorer survival outcomes in patients with MDS." ;
    a m2r:Evidence .

civice:401
    dct:references pbm:23861105 ;
    civico:citation "Wu et al., 2013, Am. J. Hematol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "After adjusting for age and cancer stage, the presence of U2AF mutations such as S34Y/F are prognostic for poorer survival outcomes in patients with MDS." ;
    a m2r:Evidence .

civice:403
    dct:references pbm:24186003 ;
    civico:citation "Lilljebjörn et al., 2014, Leukemia" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib,civic:drug_GW-2580 ;
    dcterms:description "Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580." ;
    a m2r:Evidence .

civice:405
    dct:references pbm:24578576 ;
    civico:citation "Honeyman et al., 2014, Science" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity." ;
    a m2r:Evidence .

civice:407
    dct:references pbm:12075054 ;
    civico:citation "Rosenwald et al., 2002, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The t(14;18) transloaction of BCL2 is shown to be associated with germinal-center B-cell–like diffuse large-B-cell lymphomas." ;
    a m2r:Evidence .

civice:408
    dct:references pbm:18765795 ;
    civico:citation "Lenz et al., 2008, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Amplification of FOXP1 is shown to be associated with ABC DLBCL." ;
    a m2r:Evidence .

civice:409
    dct:references pbm:12075054 ;
    civico:citation "Rosenwald et al., 2002, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Amplification of REL is shown to be associated with germinal-center B-cell–like diffuse large-B-cell lymphomas." ;
    a m2r:Evidence .

civice:411
    dct:references pbm:21343560 ;
    civico:citation "Gaidzik et al., 2011, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cytarabine ;
    dcterms:description "In non-APL patients with AML (age 18-60), those who had mutations in RUNX1 had significantly shorter relapse-free survival following conventional post-remission treatment (repetitive cycles of high-dose cytarabine) than those treated with an allogeneic hematopoietic stem-cell transplantation (N=32) at first remission (4-year RFS; 0% vs 52%; P<0.0001)." ;
    a m2r:Evidence .

civice:412
    dct:references pbm:25670080 ;
    civico:citation "Vidal et al., 2015, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_OSI-906%28Linsitinib%29 ;
    dcterms:description "OSI-906, an IGF1R/INSR inhibitor, does not have a significant effect on chemotherapy resistant castration-resistant prostate cancer cell lines." ;
    a m2r:Evidence .

civice:413
    dct:references pbm:16818686 ;
    civico:citation "Jackman et al., 2006, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib or erlotinib (38 versus 17 months; P = 0.04)." ;
    a m2r:Evidence .

civice:414
    dct:references pbm:25670080 ;
    civico:citation "Vidal et al., 2015, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_OSI-906%28Linsitinib%29,civic:drug_Docetaxel,civic:drug_Cabazitaxel ;
    dcterms:description "OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate cancer cell lines." ;
    a m2r:Evidence .

civice:415
    dct:references pbm:22430270 ;
    civico:citation "Gaidzik et al., 2012, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death." ;
    a m2r:Evidence .

civice:416
    dct:references pbm:19157502 ;
    civico:citation "Mendiola et al., 2009, Hum. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with ovarian carcinomas, those with Aurora kinase A expression (as measured by immunohistochemistry) had increased progression-free and overall survival compared to those without expression." ;
    a m2r:Evidence .

civice:417
    dct:references pbm:19666869 ;
    civico:citation "Kosmider et al., 2009, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations." ;
    a m2r:Evidence .

civice:418
    dct:references pbm:18464292 ;
    civico:citation "Patard et al., 2008, Int. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with renal clear cell carcinoma, patients with VHL mutations had longer cancer-specific survival." ;
    a m2r:Evidence .

civice:419
    dct:references pbm:22430270 ;
    civico:citation "Gaidzik et al., 2012, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission." ;
    a m2r:Evidence .

civice:420
    dct:references pbm:23620406 ;
    civico:citation "Hakimi et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In renal clear cell carcinoma, patients with PBRM1 mutations did not have a significantly different cancer specific survival." ;
    a m2r:Evidence .

civice:421
    dct:references pbm:21343549 ;
    civico:citation "Metzeler et al., 2011, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations did not have significantly different rates of event-free survival, complete remission, disease-free survival, or overall survival." ;
    a m2r:Evidence .

civice:422
    dct:references pbm:23620406 ;
    civico:citation "Hakimi et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In renal clear cell carcinoma, patients with VHL mutations did not have a significant impact on cancer specific survival." ;
    a m2r:Evidence .

civice:423
    dct:references pbm:9207459 ;
    civico:citation "Gascoyne et al., 1997, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased overall, disease-free, and relapse-free survival." ;
    a m2r:Evidence .

civice:424
    dct:references pbm:9207459 ;
    civico:citation "Gascoyne et al., 1997, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased OS, DFS, and RFS." ;
    a m2r:Evidence .

civice:425
    dct:references pbm:20601954 ;
    civico:citation "Nikoloski et al., 2010, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In myelodysplastic syndrome, patients with point mutations in EZH2 have worse overall survival that their wild-type counterparts." ;
    a m2r:Evidence .

civice:426
    dct:references pbm:21828143 ;
    civico:citation "Chou et al., 2011, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients classified as intermediate-risk via cytogenetics, TET2 mutations have been shown to be correlated with poor prognosis." ;
    a m2r:Evidence .

civice:427
    dct:references pbm:21343549 ;
    civico:citation "Metzeler et al., 2011, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with cytogenetically normal acute myeloid leukemia, those in the ELN favorable-risk group with TET2 mutations had shorter event-free survival, lower rates of complete remission, and shorter disease-free survival." ;
    a m2r:Evidence .

civice:428
    dct:references pbm:11793370 ;
    civico:citation "Schraml et al., 2002, J. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with renal clear cell carcinoma, patients with loss of function VHL mutations had shorter tumor-specific survival." ;
    a m2r:Evidence .

civice:429
    dct:references pbm:21343560 ;
    civico:citation "Gaidzik et al., 2011, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 878 non-APL patients with AML, those who had mutations in RUNX1 (N=53) had higher rates of refractory disease than those without (30% versus 19%; P = 0.047)." ;
    a m2r:Evidence .

civice:430
    dct:references pbm:21343560 ;
    civico:citation "Gaidzik et al., 2011, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 878 non-APL patients with AML (18-60 years), those who had mutations in RUNX1 (N=53) had shorter event-free survival (8% vs 30%, P<0.0001) and relapse-free survival (26% vs 44%, P=0.022) relative to wild-type. EFS was also shorter for the cytogenetically normal (CN) subgroup with RUNX1 mutations (N=34; 10% vs 34%; P<0.0001) compared to wild-type (N=499), but only trending for relapse-free survival (29% vs 43%; P=0.21). For multivariate analysis, RUNX1 was a significant marker of inferior EFS in the entire cohort (P=0.011) and the intermediate-risk (P=0.005) subgroup but not the CN subgroup." ;
    a m2r:Evidence .

civice:431
    dct:references pbm:9552022 ;
    civico:citation "de Alava et al., 1998, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with Ewing's sarcoma, those with type 1 EWS-FLI1 fusions had longer overall survival than those with other types of EWS-FLI1 fusions." ;
    a m2r:Evidence .

civice:432
    dct:references pbm:20081860 ;
    civico:citation "Morin et al., 2010, Nat. Genet." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of GCB-DLBCL in 35 / 320 patient samples. In contrast, mutations in EZH2 Y641 are not observed in centroblast samples from healthy controls." ;
    a m2r:Evidence .

civice:433
    dct:references pbm:20081860 ;
    civico:citation "Morin et al., 2010, Nat. Genet." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of Follicular non-Hodgkin Lymphoma in 18 / 251 patient samples. In contrast, mutations in EZH2 Y641 are not observed in centroblast samples from healthy controls." ;
    a m2r:Evidence .

civice:435
    dct:references pbm:21796119 ;
    civico:citation "Morin et al., 2011, Nature" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "MLL2 was found to be the most frequently mutated gene in a sample of 31/35 follicular lymphoma patients and was not mutated in normal centroblast samples. Furthermore, MLL2 mutations were as frequently observed as t(14;18) Igh-BCL2 translocations, which are the most common clinically significant genetic event observed in follicular lymphoma. Mutations were predicted to be loss-of-function." ;
    a m2r:Evidence .

civice:436
    dct:references pbm:24869598 ;
    civico:citation "Woyach et al., 2014, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Ibrutinib ;
    dcterms:description "Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK." ;
    a m2r:Evidence .

civice:439
    dct:references pbm:24265152 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229." ;
    a m2r:Evidence .

civice:440
    dct:references pbm:22277784 ;
    civico:citation "Katayama et al., 2012, Sci Transl Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Amplification of wild-type EML4-ALK in the non-small cell lung carcinoma cell line, H3122, caused resistance to crizotinib." ;
    a m2r:Evidence .

civice:441
    dct:references pbm:22277784 ;
    civico:citation "Katayama et al., 2012, Sci Transl Med" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "The G1202R mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells." ;
    a m2r:Evidence .

civice:442
    dct:references pbm:22277784 ;
    civico:citation "Katayama et al., 2012, Sci Transl Med" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "The L1196M mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells." ;
    a m2r:Evidence .

civice:443
    dct:references pbm:22277784 ;
    civico:citation "Katayama et al., 2012, Sci Transl Med" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "The S1206Y mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells." ;
    a m2r:Evidence .

civice:444
    dct:references pbm:22277784 ;
    civico:citation "Katayama et al., 2012, Sci Transl Med" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A lung adenocarcinoma patient responded to crizotinib treatment for 12 months, after which the cancer relapsed and sequencing of the ALK tyrosine kinase domain revealed a 1151insT mutation. This mutation was not found in the pre-crizotinib biopsy. EML4-ALK T1151insT was expressed In Ba/F3 cells and an IC50 of 431.8 nM was obtained, which was 16 times higher than for EML4-ALK wild-type, indicating strong crizotinib resistance. EML4-ALK containing H3122 NSCLC cells were incubated in increasing levels of crizotinib inducing resistance. The resulting cell line H3122 CR2 had IC50 10x greater to crizotinib than parental H3122, and was found to contain 1151 insT mutation. In western blots, pALK levels in H3122 CR2 cells remained apparent under 1000 nM crizotinib, whereas pALK signal was ablated under these conditions in parental H3122 cells." ;
    a m2r:Evidence .

civice:445
    dct:references pbm:22440753 ;
    civico:citation "Waaler et al., 2012, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_JW55 ;
    dcterms:description "Canonical Wnt signaling in colon carcinoma cells with APC mutation was inhibited by JW55 treatment." ;
    a m2r:Evidence .

civice:446
    dct:references pbm:23539443 ;
    civico:citation "Lau et al., 2013, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_G007-LK ;
    dcterms:description "G007-LK inhibits in vivo tumor growth in a subset of APC-mutant colorectal cancers xenograft models but may be limited by intestinal toxicity." ;
    a m2r:Evidence .

civice:447
    dct:references pbm:23779130 ;
    civico:citation "Joseph et al., 2013, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Enzalutamide,civic:drug_ARN-509 ;
    dcterms:description "Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer cell lines." ;
    a m2r:Evidence .

civice:448
    dct:references pbm:12517791 ;
    civico:citation "Hara et al., 2003, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Bicalutamide ;
    dcterms:description "LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion." ;
    a m2r:Evidence .

civice:449
    dct:references pbm:25412851 ;
    civico:citation "Ohgami et al., 2015, Mod. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with acute myeloid leukemia, in a univariate analysis those with mutations in ASXL1 had worse overall survival than wild-type." ;
    a m2r:Evidence .

civice:450
    dct:references pbm:25412851 ;
    civico:citation "Ohgami et al., 2015, Mod. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Among patients with AML, those with mutations in ASXL1 were more likely to have the AML with myelodysplasia-related changes (AML-MRC) subtype." ;
    a m2r:Evidence .

civice:451
    dct:references pbm:25308295 ;
    civico:citation "Shivarov et al., 2015, Leuk. Lymphoma" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a meta-analysis of six studies totalling 3311 patients with non-M3 acute myeloid leukemia, those with mutations in ASXL1 had worse overall survival than wild-type patients (Hazard ratio 1.86, 95% CI 1.49-2.33)." ;
    a m2r:Evidence .

civice:452
    dct:references pbm:23960094 ;
    civico:citation "Eich et al., 2013, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "Glioblastoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied." ;
    a m2r:Evidence .

civice:453
    dct:references pbm:23960094 ;
    civico:citation "Eich et al., 2013, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "Melanoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied." ;
    a m2r:Evidence .

civice:454
    dct:references pbm:23761041 ;
    civico:citation "Riabinska et al., 2013, Sci Transl Med" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_KU-0060648,civic:drug_NU7441 ;
    dcterms:description "ATM-deficient H1395 and HT144 cancer cell lines showed growth inhibition when treated with DNA PKcs inhibitors KU-0060648 and NU7441. These agents also increased the lifespan of mice transfused with ATM-deficient lymphoma cells when compared with etoposide or control." ;
    a m2r:Evidence .

civice:455
    dct:references pbm:20739657 ;
    civico:citation "Weston et al., 2010, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Olaparib was found to inhibit cancer cell growth in ATM mutant cell lines of several blood cancers including Lymphoblastoid Leukemia, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and in a murine xenograft model of Mantle Cell Lymphoma." ;
    a m2r:Evidence .

civice:456
    dct:references pbm:22302096 ;
    civico:citation "Sehdev et al., 2012, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Alisertib ;
    dcterms:description "Antitumour effect of alisertib treatment in esophageal adenocarcinomas can be intensified in combination with cisplatin." ;
    a m2r:Evidence .

civice:457
    dct:references pbm:12559175 ;
    civico:citation "Anand et al., 2003, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Paclitaxel ;
    dcterms:description "In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol." ;
    a m2r:Evidence .

civice:458
    dct:references pbm:25147369 ;
    civico:citation "van Essen et al., 2014, Br J Ophthalmol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with uveal melanoma, those with BAP1 expression (determined by immunohistochemical staining) had better survival." ;
    a m2r:Evidence .

civice:459
    dct:references pbm:23797736 ;
    civico:citation "Sato et al., 2013, Nat. Genet." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type." ;
    a m2r:Evidence .

civice:461
    dct:references pbm:23792563 ;
    civico:citation "2013, Nature" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with clear cell renal cell carcinoma, those with nonsilent mutations of BAP1 had worse overall survival than wild-type." ;
    a m2r:Evidence .

civice:462
    dct:references pbm:15630448 ;
    civico:citation "Ciampi et al., 2005, J. Clin. Invest." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The AKAP9-BRAF fusion gene was found in 3/28 tumor samples of radiation-associated papillary thyroid carcinoma, and no samples of non-radiation associated papillary thyroid carcinoma. This fusion was associated with elevated BRAF kinase activity, similar to the V600E variant." ;
    a m2r:Evidence .

civice:463
    dct:references pbm:23612012 ;
    civico:citation "Andrulis et al., 2013, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type." ;
    a m2r:Evidence .

civice:464
    dct:references pbm:22274685 ;
    civico:citation "Bolton et al., 2012, JAMA" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival." ;
    a m2r:Evidence .

civice:465
    dct:references pbm:22274685 ;
    civico:citation "Bolton et al., 2012, JAMA" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival." ;
    a m2r:Evidence .

civice:466
    dct:references pbm:20336784 ;
    civico:citation "Nakayama et al., 2010, Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival." ;
    a m2r:Evidence .

civice:467
    dct:references pbm:19304957 ;
    civico:citation "Ho et al., 2009, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In children with acute myeloid leukemia, those with mutations in CEBPA had better overall and event-free survival and decreased cummulative incidence of relapse." ;
    a m2r:Evidence .

civice:468
    dct:references pbm:25014773 ;
    civico:citation "Matsuo et al., 2014, Blood Cancer J" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a set of 315 pediatric patients with acute myeloid leukemia, 47 had mutations in CEBPA. Those with mutations had better overall survival than wild-type patients." ;
    a m2r:Evidence .

civice:469
    dct:references pbm:23341344 ;
    civico:citation "Grossmann et al., 2013, Genes Chromosomes Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In adult patients with early (n = 30), cortical (n = 30), mature (n = 3) or unknown (n = 8) T-cell acute lymphoblastic leukemia, those with mutations in DNMT3A (n=12) had shorter overall survival than wild-type patients (n=59; p=0.011). This was also true for the subset of patients with early T-ALL DNMT3A-mutated (n = 8) compared to wild-type patients (n = 22; p=0.005)." ;
    a m2r:Evidence .

civice:470
    dct:references pbm:20840671 ;
    civico:citation "Marx et al., 2010, Histopathology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial." ;
    a m2r:Evidence .

civice:471
    dct:references pbm:21730982 ;
    civico:citation "Iida et al., 2011, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival." ;
    a m2r:Evidence .

civice:472
    dct:references pbm:17538160 ;
    civico:citation "Temam et al., 2007, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 134 patients with head and neck squamous cancer 32 had copy number variations. Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and disease-free survival." ;
    a m2r:Evidence .

civice:473
    dct:references pbm:16943533 ;
    civico:citation "Chung et al., 2006, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tumors." ;
    a m2r:Evidence .

civice:474
    dct:references pbm:14583498 ;
    civico:citation "Shinojima et al., 2003, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with glioblastoma multiforme, those with overespression of wild-type EGFR had shorter overall survival." ;
    a m2r:Evidence .

civice:475
    dct:references pbm:23706910 ;
    civico:citation "Warren et al., 2013, Hum. Pathol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "t(21;22) rearrangements of EWSR1-ERG are associated with a diagnosis of Ewing sarcoma and are the second most common gene fusion reported in this disease." ;
    a m2r:Evidence .

civice:476
    dct:references pbm:16254181 ;
    civico:citation "Tomlins et al., 2005, Science" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples." ;
    a m2r:Evidence .

civice:477
    dct:references pbm:20542753 ;
    civico:citation "Bodoor et al., 2010, Cancer Epidemiol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Y375C mutation results in activation of FGFR3 and is associated with bladder carcinoma. Patients with low-grade tumors were more likely to have FGFR3 mutations than those with high-grade tumors." ;
    a m2r:Evidence .

civice:478
    dct:references pbm:23706910 ;
    civico:citation "Warren et al., 2013, Hum. Pathol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "t(11;22) rearrangements of EWSR1-FLI1 are diagnostic of ewing sarcoma, and are observed in 90% of cytogenetic samples." ;
    a m2r:Evidence .

civice:479
    dct:references pbm:20693978 ;
    civico:citation "Jamieson et al., 2010, Mod. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "FOXL2 C134W mutation was found in 52 / 56 adult granulosa cell tumors, and is absent in other types of sex-cord stromal tumors, and juvenile granulosa tumors." ;
    a m2r:Evidence .

civice:480
    dct:references pbm:19228619 ;
    civico:citation "Yan et al., 2009, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with a glioblastoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients." ;
    a m2r:Evidence .

civice:481
    dct:references pbm:19228619 ;
    civico:citation "Yan et al., 2009, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with anaplastic astrocytoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients." ;
    a m2r:Evidence .

civice:482
    dct:references pbm:19228619 ;
    civico:citation "Yan et al., 2009, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with a glioblastoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients." ;
    a m2r:Evidence .

civice:483
    dct:references pbm:19228619 ;
    civico:citation "Yan et al., 2009, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with anaplastic astrocytoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients." ;
    a m2r:Evidence .

civice:484
    dct:references pbm:22699455 ;
    civico:citation "Krentz et al., 2013, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, those with deletions of IKZF1 had worse event-free and overall survival than patients without deletions." ;
    a m2r:Evidence .

civice:485
    dct:references pbm:16307017 ;
    civico:citation "Krüger et al., 2006, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Negative" ;
    civico:evidenceLevel "B" ;
    dcterms:description "M541L mutation was not associated with CML in caucasian patients, and was common among healthy controls (8.1%), in contrast to a previous study in a Japanese CML patient population in which M541L was strongly associated with CML disease." ;
    a m2r:Evidence .

civice:486
    dct:references pbm:15201427 ;
    civico:citation "Ströbel et al., 2004, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib." ;
    a m2r:Evidence .

civice:487
    dct:references pbm:18528420 ;
    civico:citation "Chng et al., 2008, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (median 19.9 vs 44.3 months, p=0.005) and progression free survival (median 14.7 vs 30.3 months, p<0.001) than those without mutations." ;
    a m2r:Evidence .

civice:488
    dct:references pbm:18528420 ;
    civico:citation "Chng et al., 2008, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (median 19.9 vs 44.3 months, p=0.005) and progression free survival (median 14.7 vs 30.3 months, p<0.001) than those without mutations." ;
    a m2r:Evidence .

civice:489
    dct:references pbm:18528420 ;
    civico:citation "Chng et al., 2008, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those without mutations." ;
    a m2r:Evidence .

civice:490
    dct:references pbm:19901104 ;
    civico:citation "van den Bent et al., 2009, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation. Those with promoter methylation had better progression-free and overall survival." ;
    a m2r:Evidence .

civice:491
    dct:references pbm:15758010 ;
    civico:citation "Hegi et al., 2005, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with glioblastoma, those with methylated MGMT promoters have better overall survival than those with unmethylated promoters." ;
    a m2r:Evidence .

civice:492
    dct:references pbm:23322234 ;
    civico:citation "Burandt et al., 2013, Breast Cancer Res. Treat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with breast cancer, those with amplification of NCOA3 had shorter disease-specific survival." ;
    a m2r:Evidence .

civice:493
    dct:references pbm:23322234 ;
    civico:citation "Burandt et al., 2013, Breast Cancer Res. Treat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "High expression determined by immunohistochemistry of NCOA3 was found in 571 out of 1,836 breast cancer samples. Those with high expression had worse overall and disease-specific survival." ;
    a m2r:Evidence .

civice:494
    dct:references pbm:22210878 ;
    civico:citation "Kridel et al., 2012, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "14 out of 121 patient samples contained mutations in NOTCH1. Those with mutations had worse overall survival than wild-type (median OS, 1.43 years vs. 3.86 years)." ;
    a m2r:Evidence .

civice:495
    dct:references pbm:21670202 ;
    civico:citation "Fabbri et al., 2011, J. Exp. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a cohort of 120 patients with chronic lymphoytic leukemia, those with P2515 frameshift deletions in NOTCH1 at diagnosis had worse overall and treatment free survival. NOTCH1 mutations were also found to be an independent poor predictor of survival regardless of TP53 and IGHV status." ;
    a m2r:Evidence .

civice:496
    dct:references pbm:18528420 ;
    civico:citation "Chng et al., 2008, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with multiple myeloma, the presence of a mutation in NRAS was not significantly associated with progression-free or overall survival." ;
    a m2r:Evidence .

civice:497
    dct:references pbm:22650231 ;
    civico:citation "Fukahori et al., 2012, Thyroid" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with follicular thyroid carcinoma, those with mutations in NRAS at codon 61 did not have significantly different overall survival than patients with wild-type NRAS (p=0.36)." ;
    a m2r:Evidence .

civice:498
    dct:references pbm:12727991 ;
    civico:citation "Nikiforova et al., 2003, J. Clin. Endocrinol. Metab." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "PAX8–PPARG gene fusions were found in 12/33 follicular thyroid carcinoma tumor samples, but were rarely found in thyroid Hürthle cell tumors." ;
    a m2r:Evidence .

civice:499
    dct:references pbm:23333114 ;
    civico:citation "Kapur et al., 2013, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with sporatic clear cell renal cell carcinoma, those with mutations in PBRM1 had better overall survival than patients with BAP1 mutations." ;
    a m2r:Evidence .

civice:500
    dct:references pbm:16497822 ;
    civico:citation "Dowsett et al., 2006, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with breast cancer, those with expression of PgR (determined by immunohistochemical staining) had better relapse-free survival than those without expression." ;
    a m2r:Evidence .

civice:501
    dct:references pbm:23280579 ;
    civico:citation "Patani et al., 2013, Int. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Tamoxifen ;
    dcterms:description "In patients with ER-Positive breast cancer, expression of PgR does not effect the outcome of treatment with tamoxifen." ;
    a m2r:Evidence .

civice:502
    dct:references pbm:21422407 ;
    civico:citation "Bartlett et al., 2011, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Tamoxifen,civic:drug_Exemestane ;
    dcterms:description "In patients with breast cancer, those with low expression of PgR treated with tamoxifen had the same disease-free survial as those with high expression of PgR." ;
    a m2r:Evidence .

civice:503
    dct:references pbm:21422407 ;
    civico:citation "Bartlett et al., 2011, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with breast cancer, those with low expression of PgR had worse disease-free survival than those with high expression." ;
    a m2r:Evidence .

civice:504
    dct:references pbm:22292935 ;
    civico:citation "Shi et al., 2012, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification." ;
    a m2r:Evidence .

civice:505
    dct:references pbm:17700571 ;
    civico:citation "Yoshimoto et al., 2007, Br. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those without deletions." ;
    a m2r:Evidence .

civice:506
    dct:references pbm:21163703 ;
    civico:citation "De Roock et al., 2011, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response." ;
    a m2r:Evidence .

civice:507
    dct:references pbm:11504908 ;
    civico:citation "Neshat et al., 2001, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Temsirolimus ;
    dcterms:description "In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779)." ;
    a m2r:Evidence .

civice:508
    dct:references pbm:23341344 ;
    civico:citation "Grossmann et al., 2013, Genes Chromosomes Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In univariate analysis, mutations in RUNX1 were significantly associated with shorter overall survival compared to wildtype RUNX1 in adult (18-87 years old) T-cell acute lymphoblastic leukemia (N=9 mutated, 62 wild type patients; P=0.014) and the early subtype (N=7 mutated, 23 wild type patients; P=0.027). RUNX1 mutations were associated with other poor-risk parameters, early subtype and older age." ;
    a m2r:Evidence .

civice:509
    dct:references pbm:22753902 ;
    civico:citation "Mendler et al., 2012, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of patients with cytogenically normal acute myeloid leukemia, RUNX1 mutations were more frequent in patients 60 years old or older. Patients with RUNX1 mutations had shorter disease-free (younger, P = 0.058; older, P < 0.001), event-free (both, P < 0.001), and overall survival (younger, P = 0.003; older, P < 0.001) as well as lower complete remission rates (younger, P = 0.005; older, P = 0.006)." ;
    a m2r:Evidence .

civice:510
    dct:references pbm:23568491 ;
    civico:citation "Wan et al., 2013, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with chronic lymphocytic leukemia, those with mutations in SF3B1 had shorter time to treatment, progression-free survival, and overall survival. A majority of the mutations are in the C-terminal domain with the most frequent location being K700E (50% of reported cases)." ;
    a m2r:Evidence .

civice:511
    dct:references pbm:19584151 ;
    civico:citation "Blackford et al., 2009, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild-type patients." ;
    a m2r:Evidence .

civice:512
    dct:references pbm:24658004 ;
    civico:citation "Jelinic et al., 2014, Nat. Genet." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Nonsense mutations in SMARCA4 were associated with small cell carcinoma of the ovary, hypercalcemic type in 10/10 tumor samples, and were rarely found in other solid tumor types catalogued by TCGA." ;
    a m2r:Evidence .

civice:513
    dct:references pbm:24658004 ;
    civico:citation "Jelinic et al., 2014, Nat. Genet." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with lung adenocarcinoma, those with loss-of-function mutations in SMARCA4 had worse overall survival than those with only missense or no mutations." ;
    a m2r:Evidence .

civice:514
    dct:references pbm:25219713 ;
    civico:citation "Diaz et al., 2014, J. Am. Acad. Dermatol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with acral lentiginous melanoma, those with amplification of TERT had shorter overall survival." ;
    a m2r:Evidence .

civice:515
    dct:references pbm:25217772 ;
    civico:citation "Griewank et al., 2014, J. Natl. Cancer Inst." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with nonacral cutaneous melanoma, those with mutations in the TERT promoter had shorter overall survival than wild-type patients." ;
    a m2r:Evidence .

civice:516
    dct:references pbm:23955565 ;
    civico:citation "Nonoguchi et al., 2013, Acta Neuropathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 187 patients with glioblastoma, those with TERT promoter mutations had worse cummulative survival than wild-type patients. The most common mutation was C228T (73% of mutants) followed by C250T (27% of mutants). However, most of the Prognostic value of TERT mutations is thought to be derived from their inverse coorelation with IDH1 mutations." ;
    a m2r:Evidence .

civice:517
    dct:references pbm:22090360 ;
    civico:citation "Skinner et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those without mutations or with nondisruptive mutations." ;
    a m2r:Evidence .

civice:518
    dct:references pbm:8901856 ;
    civico:citation "Koch et al., 1996, J. Natl. Cancer Inst." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Unlike other studies, in this study of 110 patients with head and neck squamous cell carcinoma, there was no significant difference in the overall survival of patients with and without any TP53 mutations." ;
    a m2r:Evidence .

civice:519
    dct:references pbm:19941080 ;
    civico:citation "Yamasaki et al., 2010, Ann. Surg. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival." ;
    a m2r:Evidence .

civice:520
    dct:references pbm:22699455 ;
    civico:citation "Krentz et al., 2013, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, in multivariate analysis those with mutations in TP53 had worse event-free survival than patients without mutations." ;
    a m2r:Evidence .

civice:521
    dct:references pbm:24836762 ;
    civico:citation "Bally et al., 2014, Leuk. Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with myelodysplastic syndrome, in a multivariate analysis those with mutations in TP53 had shorter overall survival than wild-type patients." ;
    a m2r:Evidence .

civice:522
    dct:references pbm:17215851 ;
    civico:citation "Chng et al., 2007, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with myeloma, those with mutations in TP53 had worse overall survival than those without." ;
    a m2r:Evidence .

civice:523
    dct:references pbm:11325447 ;
    civico:citation "Alsner et al., 2001, Radiother Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery. Unlike those treated with radiotherapy, those treated with surgery did not show a significant difference in rates of loco-regional control between those with and without mutations in TP53." ;
    a m2r:Evidence .

civice:524
    dct:references pbm:11325447 ;
    civico:citation "Alsner et al., 2001, Radiother Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations. Of the 93 patients treated with radiotherapy, patients with mutations in TP53 had lower rates of loco-regional control and shorter disease-free, disease-specific, and overall survival." ;
    a m2r:Evidence .

civice:525
    dct:references pbm:21467160 ;
    civico:citation "Lindenbergh-van der Plas et al., 2011, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with head and neck squamous cell carcinoma, in a multivariate analysis those with truncating mutations in TP53 had worse progression-free and overall survival than wild-type patients." ;
    a m2r:Evidence .

civice:526
    dct:references pbm:21467160 ;
    civico:citation "Lindenbergh-van der Plas et al., 2011, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with head and neck squamous cell carcinoma, when comparing patients with any mutation in TP53 to wild-type, there was not a significant difference in overall survival in a multivariate analysis." ;
    a m2r:Evidence .

civice:527
    dct:references pbm:19040416 ;
    civico:citation "Barletta et al., 2009, J. Cell. Mol. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "6 of 89 patients with lung adenocarcinoma had amplification of TTF1. There was no statistical difference in overall survival between patients with and without gene amplification." ;
    a m2r:Evidence .

civice:528
    dct:references pbm:11248153 ;
    civico:citation "Slamon et al., 2001, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "A randomized clinical trial of 469 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved time to disease progression, objective response rate, and duration of response for patients who received trastuzumab in addition to chemotherapy compared to chemotherapy alone." ;
    a m2r:Evidence .

civice:529
    dct:references pbm:15911866 ;
    civico:citation "Marty et al., 2005, J. Clin. Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "A randomized clinical trial of 186 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved overall survival, response rate, response duration, time to progression, and time to treatment failure for patients who received trastuzumab in addition to chemotherapy (docetaxel) compared to chemotherapy alone." ;
    a m2r:Evidence .

civice:531
    dct:references pbm:10617473 ;
    civico:citation "Bell et al., 1999, Science" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Heterozygous germline truncating (frameshift) and missense mutations confer highly penetrant predisposition to multiple cancer types including sarcoma, breast cancer, and brain tumors. Screening of individuals with Li-Fraumeni syndrome but lacking TP53 mutations identified 1/4 classical and 2/18 LFS variant presentation. This included 1 large family pedigree with strong co-segregation of the mutation with cancer development." ;
    a m2r:Evidence .

civice:532
    dct:references pbm:25698061 ;
    civico:citation "Graham et al., 2015, Mod. Pathol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus. A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional hepatocellular carcinomas, 25 cholangiocarcinomas, 25 hepatic adenomas, and 5 hepatoblastomas). FISH was tested in 19 fibrolamellar carcinomas and in 6 scirrhous hepatocellular carcinomas. Evidence of the DNAJB1-PRKACA fusion was found in all fibrolamellar cases but not in other tumor types for both methods indicating that detection of DNAJB1-PRKACA is a very sensitive and specific finding in support of the diagnosis of fibrolamellar carcinoma." ;
    a m2r:Evidence .

civice:622
    dct:references pbm:24915778 ;
    civico:citation "Infante et al., 2014, Eur. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gemcitabine,civic:drug_Trametinib ;
    dcterms:description "Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastatic adenocarcinoma of the pancreas." ;
    a m2r:Evidence .

civice:623
    dct:references pbm:24240700 ;
    civico:citation "Bajrami et al., 2014, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1." ;
    a m2r:Evidence .

civice:624
    dct:references pbm:24366361 ;
    civico:citation "van der Veer et al., 2014, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "IKZF1 deletions are associated with poor outcome in patients with childhood BCR-ABL–positive B-cell precursor acute lymphoblastic leukemia even when treated with imatinib. This phenomenon was observed in patients treated in the pre-TKI era as well as those treated with imatinib when compared to wild-type patients undergoing similar treatment." ;
    a m2r:Evidence .

civice:625
    dct:references pbm:19770381 ;
    civico:citation "Martinelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "IKZF1 deletions in patients with BCR-ABL–positive adult acute lymphoblastic leukemia were associated with reduced disease-free survival compared to wild type patients." ;
    a m2r:Evidence .

civice:626
    dct:references pbm:20445578 ;
    civico:citation "Kuiper et al., 2010, Leukemia" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A targeted copy number screen of 131 precursor B-ALL cases revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates. Furthermore non-high-risk patients with IKZF1 deletions exhibited a ~12-fold higher relative relapse rate than those without IKZF1 deletions." ;
    a m2r:Evidence .

civice:627
    dct:references pbm:26268241 ;
    civico:citation "Wang et al., 2015, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with angioimmunoblastic T-cell lymphoma (a subtype of peripheral T-cell lymphoma), IDH2 R172 mutations (N=16) had no impact on overall survival when compared to patients with wildtype IDH2 (N=24)." ;
    a m2r:Evidence .

civice:628
    dct:references pbm:22215888 ;
    civico:citation "Cairns et al., 2012, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "IDH2 R172 mutations were frequently observed in patients with the angioimmunoblastic T-cell lymphoma subtype of peripheral T-cell lymphomas but not observed in other subtypes." ;
    a m2r:Evidence .

civice:629
    dct:references pbm:24740809 ;
    civico:citation "Beldjord et al., 2014, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with Philadelphia Chromosome negative B-cell precursor acute lymphoblastic leukemia, focal deletion involving 3-5 exons of IKZF1 was associated with higher cumulative incidence of relapse (CIR) than wildtype IKZF1." ;
    a m2r:Evidence .

civice:630
    dct:references pbm:23377281 ;
    civico:citation "Tzoneva et al., 2013, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_6-thioguanine,civic:drug_6-mercaptopurine ;
    dcterms:description "CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 R367Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins." ;
    a m2r:Evidence .

civice:631
    dct:references pbm:23377281 ;
    civico:citation "Tzoneva et al., 2013, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_6-mercaptopurine,civic:drug_6-thioguanine ;
    dcterms:description "CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 K359Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins." ;
    a m2r:Evidence .

civice:632
    dct:references pbm:23377281 ;
    civico:citation "Tzoneva et al., 2013, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_6-mercaptopurine,civic:drug_6-thioguanine ;
    dcterms:description "CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 D407A mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype protein." ;
    a m2r:Evidence .

civice:633
    dct:references pbm:23377281 ;
    civico:citation "Tzoneva et al., 2013, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Arabinosylguanine,civic:drug_Nelarabine ;
    dcterms:description "CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone." ;
    a m2r:Evidence .

civice:635
    dct:references pbm:23377281 ;
    civico:citation "Tzoneva et al., 2013, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nelarabine,civic:drug_Arabinosylguanine ;
    dcterms:description "CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone." ;
    a m2r:Evidence .

civice:636
    dct:references pbm:23377281 ;
    civico:citation "Tzoneva et al., 2013, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nelarabine,civic:drug_Arabinosylguanine ;
    dcterms:description "CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone." ;
    a m2r:Evidence .

civice:637
    dct:references pbm:18818391 ;
    civico:citation "Jabbour et al., 2008, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "BCR-ABL F317L has been shown to confer resistance to dasatinib in patients with CML." ;
    a m2r:Evidence .

civice:638
    dct:references pbm:24236021 ;
    civico:citation "Tanneeru et al., 2013, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ponatinib ;
    dcterms:description "Molecular dynamics simulations and calculated solvated interaction energies indicate BCR-ABL F317L mutations are Ponatinib sensitive." ;
    a m2r:Evidence .

civice:639
    dct:references pbm:25349473 ;
    civico:citation "Miller et al., 2014, Biologics" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Ponatinib ;
    dcterms:description "Ponatinib has shown to be effective in patients with BCR-ABL kinase domain mutations like F317L." ;
    a m2r:Evidence .

civice:640
    dct:references pbm:21747090 ;
    civico:citation "Hof et al., 2011, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In relapsed B-ALL patients, TP53 mutations were associated with morphologic nonresponse to therapy (>5% blasts in the bone marrow after 9 weeks of treatment) as well as reduced event free and overall survival when compared to TP53 wildtype patients." ;
    a m2r:Evidence .

civice:641
    dct:references pbm:12509970 ;
    civico:citation "Yamazaki et al., 2003, Oral Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutations outside of this DNA binding domain. These mutations were also significantly associated with locoregional failure, cervical lymph node metastasis and distant metastasis, likely contributing to this finding." ;
    a m2r:Evidence .

civice:642
    dct:references pbm:18227510 ;
    civico:citation "Yun et al., 2008, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gefitinib,civic:drug_AEE788 ;
    dcterms:description "Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie. erlotinib). In response, tumors may accumulate an additional 'gatekeeper' mutation in EGFR, T790M. Authors show that T790M retain low affinity for gefitinib and that introduction of T790M in the presence of L858R mutant increases the ATP affinity of L858R and activates wild-type EGFR, thus showing that increased ATP affinity is the primary mode of resistance in tumors with T790M, though irreversible ATP inhibitors (ie. HKI-272) are able to overcome this resistance via covalent bonding." ;
    a m2r:Evidence .

civice:643
    dct:references pbm:17700571 ;
    civico:citation "Yoshimoto et al., 2007, Br. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "PTEN Loss (by FISH) is associated with poorer prognosis in patients with prostate cancer." ;
    a m2r:Evidence .

civice:644
    dct:references pbm:23989949 ;
    civico:citation "Seront et al., 2013, Br. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer." ;
    a m2r:Evidence .

civice:645
    dct:references pbm:24387334 ;
    civico:citation "Dillon et al., 2014, Curr Drug Targets" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival." ;
    a m2r:Evidence .

civice:646
    dct:references pbm:25923550 ;
    civico:citation "Sequist et al., 2015, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Rociletinib ;
    dcterms:description "In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC." ;
    a m2r:Evidence .

civice:647
    dct:references pbm:26510020 ;
    civico:citation "Mateo et al., 2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic frameshift mutation (ATM V2288fs*1) predicted to result in truncation prior to the PI3K catalytic domain and other domains for p53 recognition and response to DNA damage. No other alterations in ATM were observed; however, this patient also had frameshift mutations in MLH3, MRE11 and NBN." ;
    a m2r:Evidence .

civice:648
    dct:references pbm:26510020 ;
    civico:citation "Mateo et al., 2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic missense mutation (ATM N2875H) and no other alterations in ATM or other DNA repair genes." ;
    a m2r:Evidence .

civice:649
    dct:references pbm:25798586 ;
    civico:citation "Sheffield et al., 2015, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Carboplatin,civic:drug_Cisplatin ;
    dcterms:description "A frameshift mutation in NF2 at position Y177 was found in a patient who did not respond to the standard platinum doublet chemotherapy regimen." ;
    a m2r:Evidence .

civice:650
    dct:references pbm:26510020 ;
    civico:citation "Mateo et al., 2015, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function alleles (biallelic somatic loss or germline mutations in combination with somatic copy loss or copy neutral LOH) demonstrated a clinical response." ;
    a m2r:Evidence .

civice:651
    dct:references pbm:12949711 ;
    civico:citation "Hirota et al., 2003, Gastroenterology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor." ;
    a m2r:Evidence .

civice:652
    dct:references pbm:12949711 ;
    civico:citation "Hirota et al., 2003, Gastroenterology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "293T cells stably transduced with PDGFRA V561A showed constitutive tyrosine phosphorylation in the absense of ligand; however, when treated with imatinib, this phosphorylation was inhibited similarly to that of wildtype PDGFRA, consistent with sensitivity to this inhibitor." ;
    a m2r:Evidence .

civice:654
    dct:references pbm:14645423 ;
    civico:citation "Heinrich et al., 2003, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In a Phase II trial for the treatment of GIST patients with imatinib, patients with Exon 11 Kit mutations (N=85) had significantly better event-free and overall survival than patients with Exon 9 Kit mutations (N=23) or no Kit mutations (N=9)." ;
    a m2r:Evidence .

civice:655
    dct:references pbm:25024077 ;
    civico:citation "Xing et al., 2014, J. Clin. Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no mutations in either gene." ;
    a m2r:Evidence .

civice:656
    dct:references pbm:25024077 ;
    civico:citation "Xing et al., 2014, J. Clin. Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T (N=35), recurrence-free survival is worse than in patients harboring one of these mutations (N=159 BRAF, N=26 TERT promoter mutated) or no mutations in either gene (N=287)(P<0.001)." ;
    a m2r:Evidence .

civice:657
    dct:references pbm:23766237 ;
    civico:citation "Liu et al., 2013, Endocr. Relat. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "TERT promoter mutations are prevalent in aggressive sub-types of thyroid cancers. This work showed that TERT promoter mutations were significantly more prevalent in the tall cell papillary thyroid carcinoma (PTC) samples than in the conventional PTC and follicular variant PTC samples." ;
    a m2r:Evidence .

civice:658
    dct:references pbm:23766237 ;
    civico:citation "Liu et al., 2013, Endocr. Relat. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "TERT promoter mutation C228T is significantly associated with BRAF V600E mutation, a marker of more aggressive tumors, in papillary thyroid cancer (PTC). Conversely, the BRAF V600E mutation is significantly more common in PTC cases with the TERT C228T mutation than in cases with the wild-type allele of TERT. TERT promoter mutations were also enriched in the more aggressive tall cell PTC compared to follicular or conventional PTC (30.8% vs 10.3%, P=0.046) and in the worse outcome anaplastic thyroid cancer than differentiated thyroid cancers (46.3% vs 12.2%, P=3×10−8)." ;
    a m2r:Evidence .

civice:659
    dct:references pbm:19157633 ;
    civico:citation "Sun et al., 2009, Lung Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gemcitabine,civic:drug_Vinorelbine,civic:drug_Docetaxel ;
    dcterms:description "The XRCC1 R194W variant was shown to be correlated with increased chance of response to platinum-based chemotherapy in Stage IV Non-small Cell Lung Carcinoma (NSCLC). 82 patients with Stage IV NSCLC who had not previously been treated with chemotherapy were used in this study." ;
    a m2r:Evidence .

civice:660
    dct:references pbm:25010864 ;
    civico:citation "Sawers et al., 2014, Br. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Carboplatin,civic:drug_Paclitaxel ;
    dcterms:description "Stable GSTP1 knockdown in ovarian carcinoma A2780 cell lines showed increased sensitivity to platinum-based chemotherapy drugs carboplatin, cisplatinum, carboplatin, and paclitaxel. For each drug, 3 biological replicates were performed for this study, and effectiveness was evaluated using an MTT assay. There was not a significant difference in sensitivity to other chemotherapy drugs such as gemcitabine, topotecan, and doxorubicin." ;
    a m2r:Evidence .

civice:661
    dct:references pbm:23188704 ;
    civico:citation "Ding et al., 2013, Tumour Biol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cisplatin ;
    dcterms:description "Livin (BIRC7) overexpression in two colon cancer cell lines (RKO and SW620) increased resistance of these cells to cisplatin. siRNA knockdown of Livin rendered the cells more sensitive to cisplatin. The study also further showed that cytoplasmic Livin levels increased in four colon cancer cell lines (RKO, SW620, HCT116, and KM12C) after cisplatin treatment in a dose-dependent manner. This study highlighted Livin as a potential player in colon cancer therapy." ;
    a m2r:Evidence .

civice:662
    dct:references pbm:23764753 ;
    civico:citation "Zhang et al., 2013, Carcinogenesis" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cisplatin ;
    dcterms:description "A variant of EGFR with exon 4 deletion (de4 EGFR) enhanced the invasiveness and cisplatin resistance of epithelial ovarian cancer cell lines (SKOV3, CAOV3, ES2) in vitro when compared with wild-type EGFR. The three cell lines were infected with lentivirus for either EGFR or de4 EGFR, and lentivirus-infected cells were used to perform transwell migration assays, invasion assays, and cisplatin sensitivity assays." ;
    a m2r:Evidence .

civice:664
    dct:references pbm:22139083 ;
    civico:citation "Ratner et al., 2012, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Carboplatin,civic:drug_Paclitaxel ;
    dcterms:description "The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EOC patients without BRCA mutations were used in this study. Furthermore, the researchers tested a KRAS-variant EOC cell line (BG1) and found it has much greater platinum-based chemotherapy resistance than a non-KRAS-variant cell line (CAOV3)." ;
    a m2r:Evidence .

civice:665
    dct:references pbm:26338418 ;
    civico:citation "Somers et al., 2015, Genes Dev." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The rs751402 polymorphism in the 5' UTR of ERCC5 was correlated with reduced progression free-survival in children with ependymoma that had been treated with platinum-based therapies. 55 post-operative frozen samples were used in this study. The results were also confirmed in vitro by treating neuroblastoma and B-cell lines expressing the wild-type or rs751402 polymorphism and finding that the rs751402 polymorphism was correlated with higher survival." ;
    a m2r:Evidence .

civice:666
    dct:references pbm:21119596 ;
    civico:citation "Godshalk et al., 2011, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The rs17084733 variant in the 3' UTR of KIT was correlated with susceptibility to melanoma when comparing 70 melanoma patients to 94 healthy individuals from the same community. This variant was most strongly correlated with acral lentigious melanoma." ;
    a m2r:Evidence .

civice:667
    dct:references pbm:23377281 ;
    civico:citation "Tzoneva et al., 2013, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The K359Q somatic mutation was significantly correlated with early disease recurrence and relapse in 103 T-cell ALL regardless of treatment course. The data was obtained from Berlin Frankfurt Münster Clinical Trials." ;
    a m2r:Evidence .

civice:668
    dct:references pbm:21926398 ;
    civico:citation "Crea et al., 2012, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The rs3757441 variant in Intron 6 of EZH2 (C/C versus C/T or T/T) was significantly correlated with lower progression free survival and overall survival in patients with metastatic Colorectal Cancer (mCRC). Blood samples from 106 patients with mCRC before and after treatment were used for this study." ;
    a m2r:Evidence .

civice:669
    dct:references pbm:18704422 ;
    civico:citation "Huang et al., 2009, Cancer Chemother. Pharmacol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_5-fluorouracil ;
    dcterms:description "The MTHFR C667T variant was associated with significantly lower relapse-free survival and overall survival in stomach cancer patients treated with 5-Fluorouracil-based therapies. 116 Chinese patients with histologically confirmed gastric cancer were used in this study, and all patients had radical surgery before treatment." ;
    a m2r:Evidence .

civice:670
    dct:references pbm:19922504 ;
    civico:citation "Chen et al., 2010, Cancer Sci." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_FolfoxProtocol ;
    dcterms:description "Patients with the GSTP1 I105V variant had greater response to FOLFOX-4 treatment, longer progression-free survival, and longer overall survival. 166 Chinese patients with metastatic colorectal carcinoma who had been treated with FOLFOX-4 were used in this study." ;
    a m2r:Evidence .

civice:671
    dct:references pbm:22112610 ;
    civico:citation "Tian et al., 2012, Gynecol. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The ABCG2 Q141K variant was correlated with  higher progression-free survival and overall survival in 511 ovarian cancer patients treated with platinum + taxane-based chemotherapy." ;
    a m2r:Evidence .

civice:672
    dct:references pbm:22551904 ;
    civico:citation "Liao et al., 2012, J Thorac Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The XRCC1 R399Q variant was significantly correlated with higher overall survival in non-small cell lung carcinoma (NSCLC) patients treated with gemcitabine and platinum. 62 patients with either Stage IIIB or Stage IV NSCLC were used for this study." ;
    a m2r:Evidence .

civice:673
    dct:references pbm:16875718 ;
    civico:citation "Chung et al., 2006, Gynecol. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Carboplatin ;
    dcterms:description "The XRCC1 R399Q variant was correlated with increased response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer. Tumor samples from 36 patients with Stage IB or IIA bulky (greater than 4 cm in size) cervical carcinomas were used in this study." ;
    a m2r:Evidence .

civice:674
    dct:references pbm:16467099 ;
    civico:citation "Gréen et al., 2006, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Paclitaxel ;
    dcterms:description "The ABCB1 G2677T/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients. 51 epithelial and 2 fallopian tube frozen tumors were analyzed for this study." ;
    a m2r:Evidence .

civice:675
    dct:references pbm:22296372 ;
    civico:citation "Yan et al., 2011, Asian Pac. J. Cancer Prev." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Carboplatin ;
    dcterms:description "The mutation at codon 3435 (C>T) correlated with a significantly higher response rate to platinum-based chemotherapy in patients with advanced non small cell lung cancer (NSCLC).  103 Chinese patients with NSCLC were evaluated in this study. However, there was not a significant correlation between the mutation and overall survival." ;
    a m2r:Evidence .

civice:676
    dct:references pbm:19434073 ;
    civico:citation "Caronia et al., 2009, Pharmacogenomics J." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin ;
    dcterms:description "The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival. 91 osteosarcoma patients with a median age of 15 years were followed in this study." ;
    a m2r:Evidence .

civice:677
    dct:references pbm:19470925 ;
    civico:citation "Gandara et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Paclitaxel,civic:drug_Carboplatin ;
    dcterms:description "The ERCC2 K751Q variant is significantly correlated with increased response to paclitaxel and carboplatin therapies in non small cell lung cancer (NSCLC). The researchers utilized data from three previous clinical trials in Japan and the United States with a total of 526 NSCLC patients." ;
    a m2r:Evidence .

civice:678
    dct:references pbm:20628391 ;
    civico:citation "Martinez-Balibrea et al., 2010, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_5-fluorouracil,civic:drug_Irinotecan ;
    dcterms:description "The TYMS 5' 3TPR germline variant was significantly correlated with lower response to irinotecan plus 5-fluorouracil treatment in colorectal cancer patients. 149 metastatic CRC patients treated with irinotecan/5FU as first-line chemotherapy were followed in this study." ;
    a m2r:Evidence .

civice:679
    dct:references pbm:22896685 ;
    civico:citation "Cowin et al., 2012, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Doxorubicin ;
    dcterms:description "A minimum common region of deletion of 0.19Mb, encompassing exons 12–22 of LRP1B4 was observed in 4 patients exhibiting acquired treatment resistance. Transfection of mLRP1B4, a fully functional minigene of LRP1B, in IGROV1 and OVCAR4 ovarian cell lines with low expression of LRP1B4 increased sensitivity to liposomal doxorubicin but not doxorubicin. siRNA knockdown of LRP1B4 in JHOS3 and Kuramochi ovarian cancer cell lines decreased sensitivity to liposomal doxorubicin but not doxorubicin." ;
    a m2r:Evidence .

civice:680
    dct:references pbm:21160078 ;
    civico:citation "Weiss et al., 2010, Sci Transl Med" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PD173074 ;
    dcterms:description "Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors. 4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were highly sensitive to PD173074. This sensitivity was confirmed in a mouse xenograft. Clinical trials are currently ongoing." ;
    a m2r:Evidence .

civice:681
    dct:references pbm:24771645 ;
    civico:citation "Wynes et al., 2014, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ponatinib ;
    dcterms:description "Preclinical evidence (in-vitro) for predictive value of FGFR1 mRNA and protein expression as well as mRNA expression of FGF2 and FGF9 for sensitivity to FGFR1 inhibition. The authors suggested that FGFR1 expression is a better predictive marker than FGFR1 amplification and proposes a connection between KRAS and PIK3CA mutations. This study used 58 cell lines, of which 14 exhibited ponatinib sensitivity. This sensitivity was correlated with FGFR1 mRNA and protein expression." ;
    a m2r:Evidence .

civice:682
    dct:references pbm:23182986 ;
    civico:citation "Kim et al., 2013, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates with cigarette smoking." ;
    a m2r:Evidence .

civice:683
    dct:references pbm:25086725 ;
    civico:citation "Seo et al., 2014, Virchows Arch." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis." ;
    a m2r:Evidence .

civice:684
    dct:references pbm:23806793 ;
    civico:citation "Tran et al., 2013, Lung Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6. No difference in survival is seen between amplified and non-amplified patients in general." ;
    a m2r:Evidence .

civice:685
    dct:references pbm:25171497 ;
    civico:citation "Chang et al., 2014, PLoS ONE" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification. However, larger studies are warranted for confirmation." ;
    a m2r:Evidence .

civice:686
    dct:references pbm:21666749 ;
    civico:citation "Dutt et al., 2011, PLoS ONE" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PD173074 ;
    dcterms:description "Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line." ;
    a m2r:Evidence .

civice:687
    dct:references pbm:25433983 ;
    civico:citation "Jiang et al., 2015, Lung Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metastasis." ;
    a m2r:Evidence .

civice:688
    dct:references pbm:25264305 ;
    civico:citation "Shaw et al., 2014, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "An expansion cohort of a phase-1 Crizotinib study found a 72% objective response rate among 50 patients with ROS1 rearrangement. The study did not compare to patients without rearrangement that were treated with Crizotinib.  Several different ROS1 fusion partners were identified, but no clinical differences in outcome were associated with the identity of the 5' partner." ;
    a m2r:Evidence .

civice:689
    dct:references pbm:22389872 ;
    civico:citation "Catenacci et al., 2011, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Onartuzumab ;
    dcterms:description "A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine HGF-production (the growth factor ligand of MET). The patient initially achieved a complete response on MET-Inhibitor MetMAb (Onartuzumab) for 2 years and mixed response after recurrence with resistance in some of the newly developing metastases." ;
    a m2r:Evidence .

civice:690
    dct:references pbm:19470935 ;
    civico:citation "Zighelboim et al., 2009, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Extension and reduction of the ATR exon 10 A10 repeat (alters codon I774) was associated with poorer overall and disease-free survival in patients with endometrioid endometrial cancer when compared to patients with wildtype ATR and with or without microsatellite instability. These ATR mutations were observed in 12 of 248 patients (4.8%, 3 insertions, 9 deletions)." ;
    a m2r:Evidence .

civice:691
    dct:references pbm:21048039 ;
    civico:citation "Licitra et al., 2011, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PLATINUM,civic:drug_Cetuximab,civic:drug_5-fluorouracil ;
    dcterms:description "EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study." ;
    a m2r:Evidence .

civice:692
    dct:references pbm:23265711 ;
    civico:citation "Licitra et al., 2013, Eur. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcinoma." ;
    a m2r:Evidence .

civice:693
    dct:references pbm:22056021 ;
    civico:citation "Pirker et al., 2012, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_EGFRInhibitor ;
    dcterms:description "EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone." ;
    a m2r:Evidence .

civice:694
    dct:references pbm:24577117 ;
    civico:citation "Vermorken et al., 2014, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_EGFRInhibitor ;
    dcterms:description "In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 patient tumors)." ;
    a m2r:Evidence .

civice:695
    dct:references pbm:24799460 ;
    civico:citation "Argiris et al., 2014, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma." ;
    a m2r:Evidence .

civice:696
    dct:references pbm:23746666 ;
    civico:citation "Vermorken et al., 2013, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab) in combination with chemotherapy compared to chemotherapy alone." ;
    a m2r:Evidence .

civice:697
    dct:references pbm:24577089 ;
    civico:citation "Pogorzelski et al., 2014, Cell Death Dis" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In this study response to EGFR-inhibition by cetuximab was independent of HPV-status, represented by expression of p16 (CDKN2A, an established biomarker of HPV infection). Expression of p16 was assayed in 69 HNSCC patients by IHC." ;
    a m2r:Evidence .

civice:698
    dct:references pbm:23584301 ;
    civico:citation "Gautschi et al., 2013, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vandetanib ;
    dcterms:description "A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission in the patient." ;
    a m2r:Evidence .

civice:699
    dct:references pbm:26561417 ;
    civico:citation "Boidot et al., 2016, Int J Colorectal Dis" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_EGFRInhibitor ;
    dcterms:description "Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study." ;
    a m2r:Evidence .

civice:700
    dct:references pbm:26544513 ;
    civico:citation "Kiessling et al., 2015, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Binimetinib%28MEK162%29,civic:drug_PD0325901,civic:drug_Everolimus,civic:drug_Selumetinib%28AZD6244%29,civic:drug_AZD8055 ;
    dcterms:description "A pre-clinical study in 10 solid cancer cell lines. HRAS mutations (Q61L, Q61R and G12V) sensitized cell lines toward MEK inhibitors (AZD6244/selumetinib, MEK162 and PD0325901) and mTOR inhibitors (Everolimus and AZD8055)." ;
    a m2r:Evidence .

civice:701
    dct:references pbm:26664143 ;
    civico:citation "Zhong et al., 2015, Onco Targets Ther" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC." ;
    a m2r:Evidence .

civice:702
    dct:references pbm:26313362 ;
    civico:citation "Schmidt et al., 2015, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study)." ;
    a m2r:Evidence .

civice:703
    dct:references pbm:26625204 ;
    civico:citation "Darb-Esfahani et al., 2016, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases)." ;
    a m2r:Evidence .

civice:704
    dct:references pbm:26086854 ;
    civico:citation "Carbognin et al., 2015, PLoS ONE" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Nivolumab,civic:drug_Pembrolizumab ;
    dcterms:description "Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included melanoma, PD-L1 expression was associated with a higher ORR rate in patients with melanoma. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies." ;
    a m2r:Evidence .

civice:705
    dct:references pbm:24625776 ;
    civico:citation "Wagle et al., 2014, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Everolimus,civic:drug_Pazopanib ;
    dcterms:description "A case-study of a patient with urothelial carcinoma reported exceptional response (14 months) in a phase 1 study of Everolimus and Pazopanib. Mutations E2014K and E2419K were shown to be activating in-vitro." ;
    a m2r:Evidence .

civice:706
    dct:references pbm:22842582 ;
    civico:citation "Grell et al., 2012, Int. J. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "In HER2+ metastatic breast cancer treated with trastuzumab (n = 74 patients), the expression of AKT2 and pAkt-Thr308 and/or pAkt-Ser473 localized in nucleus+cytoplasm was associated with an improved time to progression (TTP) and overall survival (OS) compared to AKT2 negative tumors as measured by immunohistochemistry." ;
    a m2r:Evidence .

civice:707
    dct:references pbm:24735930 ;
    civico:citation "Lassen et al., 2014, Mol. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_GSK2141795 ;
    dcterms:description "A cell line with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B  in this study." ;
    a m2r:Evidence .

civice:708
    dct:references pbm:24735930 ;
    civico:citation "Lassen et al., 2014, Mol. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_GSK2141795 ;
    dcterms:description "Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B." ;
    a m2r:Evidence .

civice:709
    dct:references pbm:26351323 ;
    civico:citation "Davies et al., 2015, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_AZD5363 ;
    dcterms:description "In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been published, this paper highlights in vitro results that further confirm the role of AKT E17K mutation." ;
    a m2r:Evidence .

civice:710
    dct:references pbm:23888070 ;
    civico:citation "Beaver et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_MK-2206,civic:drug_Pictilisib ;
    dcterms:description "PIK3CA E545K mutation increased sensitivity to AKT inhibitor MK-2206 and PI3K inhibitor GDC-0941 in a breast cancer cell line model." ;
    a m2r:Evidence .

civice:711
    dct:references pbm:25398829 ;
    civico:citation "Hancox et al., 2015, Mol. Cancer Ther." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD8186 ;
    dcterms:description "Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency." ;
    a m2r:Evidence .

civice:712
    dct:references pbm:26490311 ;
    civico:citation "Kong et al., 2016, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Median overall survival of patients with nonsynonymous mutations in mTOR was shorter." ;
    a m2r:Evidence .

civice:713
    dct:references pbm:26490311 ;
    civico:citation "Kong et al., 2016, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_LY294002,civic:drug_AZD5363 ;
    dcterms:description "In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth." ;
    a m2r:Evidence .

civice:714
    dct:references pbm:25672916 ;
    civico:citation "Hyman et al., 2015, Cancer Chemother. Pharmacol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Buparlisib,civic:drug_Carboplatin,civic:drug_Paclitaxel ;
    dcterms:description "All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers." ;
    a m2r:Evidence .

civice:715
    dct:references pbm:25878190 ;
    civico:citation "Moulder et al., 2015, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Temsirolimus ;
    dcterms:description "23 patients were treated with temsirolimus containing regimens. 1 patient with a complete response >3 years had a K159fs*16 mutation in NF2. 2 patients were tested for NF2 mutations." ;
    a m2r:Evidence .

civice:716
    dct:references pbm:25409150 ;
    civico:citation "Juric et al., 2015, Nature" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BYL719%28Alpelisib%29 ;
    dcterms:description "A case report described a responder to PI3K inhibitor BYL719 for a tumor with PIK3CA E542K mutation. After partial response for 9.5 months, resistance developed. Sequencing in this and other patients as well as preclinical models showed loss of PTEN as the probable mechanism of resistance." ;
    a m2r:Evidence .

civice:717
    dct:references pbm:22270724 ;
    civico:citation "Montagut et al., 2012, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro and in one patient." ;
    a m2r:Evidence .

civice:718
    dct:references pbm:26508446 ;
    civico:citation "Lupini et al., 2015, BMC Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab,civic:drug_Cetuximab ;
    dcterms:description "65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab). FBXW7 mutation was found to be more prevalent in non-responders (5 mutations) than responders (1 mutation)." ;
    a m2r:Evidence .

civice:719
    dct:references pbm:26508446 ;
    civico:citation "Lupini et al., 2015, BMC Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab,civic:drug_Cetuximab ;
    dcterms:description "In a retrospective analysis of 65 patients with metastatic colorectal cancer, SMAD4 mutations were more common among patients with no benefit from EGFR-inhibition (cetuximab or panitumumab) (4 patients) than with patients with response to EGFR directed treatment (1 patient)." ;
    a m2r:Evidence .

civice:720
    dct:references pbm:26046389 ;
    civico:citation "Cheng et al., 2015, Cancer Biol. Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In this study, SMAD4 underexpression was associated with an epithelial-to-mesenchymal transition and resistance to EGFR-directed treatment with Cetuximab." ;
    a m2r:Evidence .

civice:722
    dct:references pbm:26490311 ;
    civico:citation "Kong et al., 2016, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD5363,civic:drug_LY294002 ;
    dcterms:description "In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth." ;
    a m2r:Evidence .

civice:723
    dct:references pbm:23890088 ;
    civico:citation "Botton et al., 2013, Pigment Cell Melanoma Res" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib." ;
    a m2r:Evidence .

civice:724
    dct:references pbm:23890088 ;
    civico:citation "Botton et al., 2013, Pigment Cell Melanoma Res" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines." ;
    a m2r:Evidence .

civice:725
    dct:references pbm:24345920 ;
    civico:citation "Hutchinson et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "BRAF-fusion in \"pan-negative\" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib." ;
    a m2r:Evidence .

civice:726
    dct:references pbm:24345920 ;
    civico:citation "Hutchinson et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "BRAF-fusion in \"pan-negative\" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This fusion is believed to activate MAPK pathway signaling." ;
    a m2r:Evidence .

civice:727
    dct:references pbm:24345920 ;
    civico:citation "Hutchinson et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was \"pan-negative\" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was found to be sensitive to the MEK-inhibitor Trametinib." ;
    a m2r:Evidence .

civice:728
    dct:references pbm:23715574 ;
    civico:citation "Bahadoran et al., 2013, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "A case report of a patient with BRAF L597R mutation and clinical response to BRAF-inhibition (Vemurafenib) that correlated to in-vitro models." ;
    a m2r:Evidence .

civice:729
    dct:references pbm:25520391 ;
    civico:citation "Cushman et al., 2015, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "High expression of ERBB3 (her3) was associated with shorter overall survival (OS) from Cetuximab treatment in patients with metastatic colorectal cancer. Gene expression measures (qRT-PCR) were available for 103 patients." ;
    a m2r:Evidence .

civice:730
    dct:references pbm:25520391 ;
    civico:citation "Cushman et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "CD73 high expression was identified as a potential marker of improved PFS from cetuximab treatment in patients with metastatic CRC." ;
    a m2r:Evidence .

civice:731
    dct:references pbm:26683709 ;
    civico:citation "Jiang et al., 2016, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "High expression of EZH2 was associated with poorer outcome in a meta-analysis encompassing 51 studies and 9444 patients." ;
    a m2r:Evidence .

civice:732
    dct:references pbm:26436839 ;
    civico:citation "Okoye-Okafor et al., 2015, Nat. Chem. Biol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_GSK321 ;
    dcterms:description "Newly developed allosteric inhibitors (GSK321) of IDH1 led to granulocytic differentiation in-vitro and in-vivo." ;
    a m2r:Evidence .

civice:733
    dct:references pbm:17463250 ;
    civico:citation "Engelman et al., 2007, Science" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In this study a gefitinib-sensitive cell-line (HCC827), acquired gefitinib resistance (HCC827 GR) by a focal amplification of MET.  Resistance was conferred by the MET amplification driving ERBB3 (HER3)-dependent activation of PI3K." ;
    a m2r:Evidence .

civice:734
    dct:references pbm:26596839 ;
    civico:citation "Xiang et al., 2016, Tumour Biol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Paclitaxel ;
    dcterms:description "In this retrospective analysis of 211 breast cancer tissues, MYD88 overexpression was correlated  with poor survival. In-vitro experiments showed a decrease in sensitivity towards paclitaxel in cell-lines with high MYD88 expression." ;
    a m2r:Evidence .

civice:735
    dct:references pbm:21623265 ;
    civico:citation "Ou et al., 2011, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A case-study of an ALK-negative patient with MET amplification (MET/CEP7 ratio >5.0) who achieved a durable partial response to MET/ALK-inhibitor crizotinib." ;
    a m2r:Evidence .

civice:736
    dct:references pbm:26547802 ;
    civico:citation "Togashi et al., 2015, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "The creation of a cell line model (HEK293) with MET exon 14 deletion (using the CRISPR/Cas9 system) led to enhanced cellular growth and sensitivity to the MET inhibitor crizotinib. MET exon 14 deletion results in an in-frame deletion in the MET protein. Recurrent splice site mutations that result in exon 14 skipping have been observed in ~3% of all lung cancers." ;
    a m2r:Evidence .

civice:737
    dct:references pbm:26439803 ;
    civico:citation "Park et al., 2015, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_EGFRInhibitor ;
    dcterms:description "In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison to MET expression were correlated with longer PFS." ;
    a m2r:Evidence .

civice:738
    dct:references pbm:26130666 ;
    civico:citation "Yoo et al., 2016, Cancer Res Treat" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "823 patients with GIST under therapy with imatinib were genotyped for this study. 18 patients (2%) with PDGFRA mutations were identified. In D842V-mutant GISTs, PFS (median 3.8 months) and OS (median 25.2 months) were significantly poorer than Non-D842V mutated (PFS median 29.5 months OS median 59.8 months)." ;
    a m2r:Evidence .

civice:739
    dct:references pbm:26466009 ;
    civico:citation "Shiver et al., 2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Idelalisib ;
    dcterms:description "A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib." ;
    a m2r:Evidence .

civice:740
    dct:references pbm:26686064 ;
    civico:citation "Hatem et al., 2016, Int. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vandetanib ;
    dcterms:description "Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandetanib slowed tumor growth." ;
    a m2r:Evidence .

civice:741
    dct:references pbm:26617739 ;
    civico:citation "Xu et al., 2015, Int J Clin Exp Pathol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "After preliminary studies in cell lines, GEO datasets and fresh frozen tissues, RIT1 expression was determined in 257 tumors and 31 normal tissues. Elevated expression of RIT1 was correlated with poorer overall survival, pathological type, clinical stage, grade and vascular invasion." ;
    a m2r:Evidence .

civice:742
    dct:references pbm:24469055 ;
    civico:citation "Berger et al., 2014, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_Pictilisib ;
    dcterms:description "RIT1 mutations were identified in approx. 2% of lung adenocarcinomas (5/87 in the \"oncogene negative\" samples of TCGA - no RIT1 mutations were observed in 143 samples with a known driver mutation). GDC-0941 impaired tumor growth of NCI-H2110 (RIT1 M90I mutated) xenografts in nude mice. GDC-0941 and AZD-6244 (selumetinib) impaired colony formation in-vitro. Combined PI3K/MEK inhibition was more effective than single agent treatment in-vitro." ;
    a m2r:Evidence .

civice:743
    dct:references pbm:26086854 ;
    civico:citation "Carbognin et al., 2015, PLoS ONE" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Nivolumab,civic:drug_Pembrolizumab ;
    dcterms:description "Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies." ;
    a m2r:Evidence .

civice:744
    dct:references pbm:26537256 ;
    civico:citation "Carter et al., 2015, Sci Transl Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_CBL0137 ;
    dcterms:description "The drug CBL0137 (a drug that interacts with SSRP1 aka FACT) exhibited a synergistic effect with standard chemotherapy (cyclophosphamide, etoposide, cisplatin, vincristine, etc.) by blocking repair of DNA damage caused by genotoxic drugs, thus creating a synthetic lethal environment in MYCN-amplified neuroblastoma cells. High MYCN expression was found to sensitize neuroblastoma cells to CBL0137." ;
    a m2r:Evidence .

civice:745
    dct:references pbm:19726788 ;
    civico:citation "Yauch et al., 2009, Science" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vismodegib ;
    dcterms:description "In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib)." ;
    a m2r:Evidence .

civice:746
    dct:references pbm:25759020 ;
    civico:citation "Atwood et al., 2015, Cancer Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vismodegib ;
    dcterms:description "In basal cell carcinoma, H231R, D473G, W281C and Q477E mutations conferred resistance to SMO-inhibitor vismodegib. SMO mutations were identified in 22 of 44 resistant basal cell carcinomas in 15 patients." ;
    a m2r:Evidence .

civice:747
    dct:references pbm:25759020 ;
    civico:citation "Atwood et al., 2015, Cancer Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ArsenicTrioxide,civic:drug_PSI ;
    dcterms:description "Basal cell carcinomas with ligand-binding pocket or constitutively active mutations in the SMO gene were sensitive to inhibition of downstream hedgehog signaling with PSI (aPKC-ι/λ/GLI inhibitor) or arsenic trioxide." ;
    a m2r:Evidence .

civice:748
    dct:references pbm:24651015 ;
    civico:citation "Kool et al., 2014, Cancer Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vismodegib ;
    dcterms:description "133 sonic-hedghog driven medulloblastomas were sequenced for alterations (WGS or WES). 60 cases exhibited PTCH1 mutations, most of which were likely loss-of-function (spread across the gene and of types including: stop gain, splice site, frameshift, etc.). Functional models also showed PTCH1 mutant xenografts to be sensitive to SHH inhibition with vismodegib." ;
    a m2r:Evidence .

civice:749
    dct:references pbm:26169613 ;
    civico:citation "Robinson et al., 2015, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vismodegib ;
    dcterms:description "Loss-of-heterozygosity in SHH-driven medulloblastoma was associated with increased PFS under therapy with vismodegib (AKA HhAntag691, GDC0449, GDC-0449). 43 patients total were enrolled for this study." ;
    a m2r:Evidence .

civice:750
    dct:references pbm:26625312 ;
    civico:citation "Pécuchet et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a retrospective analysis of 567 non-squamous, non-small cell lung cancer patients, Exon 1-2 mutations in STK11 were significantly associated with shorter OS (24 vs. 69 months) also after multivariate analysis. Results were validated in public datasets." ;
    a m2r:Evidence .

civice:751
    dct:references pbm:26391455 ;
    civico:citation "Grossi et al., 2015, Autophagy" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_SB202190 ;
    dcterms:description "STK11-deficient cells were sensitive to treatment with MAPK11 inhibitor SB202190." ;
    a m2r:Evidence .

civice:752
    dct:references pbm:26096845 ;
    civico:citation "Yu et al., 2015, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Paclitaxel ;
    dcterms:description "Overexpression and high p-SYK/SYK ratio were associated with resistance to paclitaxel. Inhibition of SYK with R406 resensitized cell lines to paclitaxel." ;
    a m2r:Evidence .

civice:753
    dct:references pbm:23746666 ;
    civico:citation "Vermorken et al., 2013, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone." ;
    a m2r:Evidence .

civice:754
    dct:references pbm:25557953 ;
    civico:citation "Cornella et al., 2015, Gastroenterology" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The DNAJB1-PRKACA fusion was detected in 79% (58/73) of fibrolamellar hepatocellular carcinomas assayed." ;
    a m2r:Evidence .

civice:755
    dct:references pbm:25759020 ;
    civico:citation "Atwood et al., 2015, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vismodegib ;
    dcterms:description "D473 mutations were identified in 5/30 resistant basal cell carcinomas. Crystal structure indicated this mutation interacts with a water molecule in the ligand binding pocket, putatively altering its interaction with the SMO inhibitor vismodegib. SMO-/- mouse embryonic fibroblasts expressing the SMO D473G mutant maintained hedgehog signaling in the presence of the drug and had IC50 values >40 fold higher than cells expressing wildtype SMO." ;
    a m2r:Evidence .

civice:756
    dct:references pbm:25370471 ;
    civico:citation "Sarker et al., 2015, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pictilisib ;
    dcterms:description "One platinum-refractory epithelial ovarian cancer patient with PTEN loss and PIK3CA amplification had a partial response on treatment with PI3K inhibitor pictilisib (GDC-0941) in this phase 1 study. A total of 60 patients with advanced solid tumors were enrolled in this study." ;
    a m2r:Evidence .

civice:757
    dct:references pbm:25370471 ;
    civico:citation "Sarker et al., 2015, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pictilisib ;
    dcterms:description "One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 with 60 patients enrolled." ;
    a m2r:Evidence .

civice:758
    dct:references pbm:20530316 ;
    civico:citation "Ang et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "A" ;
    dcterms:description "720 patients with stage III/IV oropharyngeal cancer were retrospectively analyzed for p16 and HPV status. p16 and HPV-positivity correlated well and both showed improved overall-survival compared to patients with HPV-negative/p16 negative tumors. HPV/p16 status was shown to be a strong and independent risk factor in oropharyngeal carcinoma." ;
    a m2r:Evidence .

civice:759
    dct:references pbm:26712222 ;
    civico:citation "Rosenthal et al., 2016, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "This study shows that benefit of EGFR inhibition in addition to radiotherapy was independent of p16/HPV status. 182 patients were evaluated." ;
    a m2r:Evidence .

civice:760
    dct:references pbm:18725974 ;
    civico:citation "She et al., 2008, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AKTi-1-2 ;
    dcterms:description "Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (AKTi-1/2; naphthyridinone)." ;
    a m2r:Evidence .

civice:761
    dct:references pbm:20142587 ;
    civico:citation "Burstein et al., 2010, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab and trastuzumab-naive cohorts in a Phase II trial with a primary endpoint of 16-week progression free survival." ;
    a m2r:Evidence .

civice:762
    dct:references pbm:24065731 ;
    civico:citation "Walter et al., 2013, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Rociletinib ;
    dcterms:description "CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR." ;
    a m2r:Evidence .

civice:763
    dct:references pbm:21791641 ;
    civico:citation "Sasaki et al., 2011, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Case-report of a patient with an acquired ALK L1152R mutation and resistance to crizotinib treatment. A cell line model also showed resistance against ALK inhibition." ;
    a m2r:Evidence .

civice:764
    dct:references pbm:22235099 ;
    civico:citation "Doebele et al., 2012, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "11 patients with crizotinib-resistant NSCLC were analyzed for this study. Two harbored the G1269A mutation that also led to crizotinib-resistance in-vitro." ;
    a m2r:Evidence .

civice:765
    dct:references pbm:23344087 ;
    civico:citation "Kim et al., 2013, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "2 out of 7 patients with an acquired resistance to crizotinib had a G1269A mutation. One of these patients also harbored a L1196M mutation. In vitro follow-up showed reduced crizotinib-induced ALK dephosphorylation (293T) and apoptosis (Ba/F3) when EML4-ALK G1269A overexpression was compared to EML4-ALK overexpression in these cell lines." ;
    a m2r:Evidence .

civice:766
    dct:references pbm:22235099 ;
    civico:citation "Doebele et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Two out of 11 patients with an acquired crizotinib resistance showed new ALK copy-number gain (defined as more than 2-fold increase in the mean of the rearranged gene per cell in the posttreatment specimen compared with the pretreatment specimen), both with >4 fold increase. One of them also harbored a resistance mutation (G1269A)." ;
    a m2r:Evidence .

civice:767
    dct:references pbm:23344087 ;
    civico:citation "Kim et al., 2013, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "One patient with ALK-rearranged non-small cell lung cancer and an acquired resistance to crizotinib showed new ALK amplification (4.1 fold increase compared to pre-crizotinib specimen as measured by FISH) and harbored an EGFR L858R mutation." ;
    a m2r:Evidence .

civice:770
    dct:references pbm:19718025 ;
    civico:citation "Prickett et al., 2009, Nat. Genet." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "ERBB4 was the most commonly mutated protein tyrosine kinase in this study in melanoma (19% in 79 patients). Seven of the identified mutations in ERBB4 (E317K, E452K, E542K, R544W, E563K, E836K and E872K) were transforming and activating in-vitro. ERBB4 inhibition with shRNA or lapatinib led to reduced cell growth." ;
    a m2r:Evidence .

civice:771
    dct:references pbm:25242168 ;
    civico:citation "Song et al., 2015, Int. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cabozantinib ;
    dcterms:description "20 patient-derived colorectal cancer xenografts were treated with cabozantinib, a c-MET and VEGFR2 inhibitor. 16 xenografts showed sensitivity (as defined by TGII: tumor growth of treated compared to control ≤ 20%). Among the genes tested for mutations (KRAS, TP53, PIK3CA, MET, VEGFR2, RET and AXL), PIK3CA mutations (4 PDTX) showed a significant enrichment in sensitive xenografts. PIK3CA mutations were observed in 4/5 of the most responsive tumors. Treating xenografts derived from isogenic PIK3CA wildtype or mutant cell lines corroborated this finding with PIK3CA mutant xenografts showing greater sensitivity to cabozantinib." ;
    a m2r:Evidence .

civice:772
    dct:references pbm:16282176 ;
    civico:citation "Mellinghoff et al., 2005, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_EGFRInhibitor ;
    dcterms:description "49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort of 33 patients. EGFRvIII and PTEN coexpression were associated with responsiveness to EGFR TKI." ;
    a m2r:Evidence .

civice:773
    dct:references pbm:26423602 ;
    civico:citation "Alshami et al., 2015, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Case report of a 58-year old patient with disease progression after radiotherapy and three temozolomide cycles. Afatinib and temozolomide led to disease regression. At last assessment 63 treatment cycles had been completed and the patient had survived for about 5 years since recurrence. Identified EGFR aberrations included EGFRvIII positivity, EGFR gene amplification and three somatic EGFR mutations." ;
    a m2r:Evidence .

civice:774
    dct:references pbm:16282176 ;
    civico:citation "Mellinghoff et al., 2005, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_EGFRInhibitor ;
    dcterms:description "49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort of 33 patients. EGFRvIII and PTEN coexpression were associated with responsiveness to EGFR TKI." ;
    a m2r:Evidence .

civice:775
    dct:references pbm:25939761 ;
    civico:citation "Zahonero et al., 2015, Mol. Cancer Ther." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dacomitinib ;
    dcterms:description "In this preclinical study, the EGFR inhibitor dacomitinib had an effect on cell viability, self-renewal and proliferation in EGFR amplified GBM cells in-vitro and in-vivo (with or without the EGFRvIII mutation). It was less effective in one cell-line with PTEN deletion." ;
    a m2r:Evidence .

civice:776
    dct:references pbm:21840482 ;
    civico:citation "Wilson et al., 2011, Cancer Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation. This aberration was mainly identified in head and neck cancer cell lines." ;
    a m2r:Evidence .

civice:777
    dct:references pbm:21900593 ;
    civico:citation "Yonesaka et al., 2011, Sci Transl Med" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "NRG1 upregulation or ERBB2 amplification were the main causes of resistance to cetuximab in-vivo and in-vitro in this study. Inhibition of ERBB2/ERBB3 signaling restored cetuximab sensitivity." ;
    a m2r:Evidence .

civice:778
    dct:references pbm:20227043 ;
    civico:citation "Sheng et al., 2010, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Anti-ERBB3Agents ;
    dcterms:description "An NRG1-ERBB3 autocrine signal-transducing loop was identified in a subset of ovarian cancers and cell lines. Disruption of this loop led to decreased cell-growth in-vitro and prolonged survival in-vivo. An ERBB3 directed antibody (MM-121) inhibited tumor-growth in-vivo." ;
    a m2r:Evidence .

civice:779
    dct:references pbm:23390248 ;
    civico:citation "Hegde et al., 2013, Sci Transl Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Carboplatin,civic:drug_Gemcitabine,civic:drug_Cisplatin,civic:drug_Paclitaxel ;
    dcterms:description "In-vivo studies of residual NSCLC tumors (xenografts of 5 cell lines) after chemotherapy found increased EGFR-family signaling and NRG1 expression. NRG1 inhibition (YW538.24.71 antibody) led to decreased tumor growth and enhanced magnitude and response to chemotherapy." ;
    a m2r:Evidence .

civice:780
    dct:references pbm:21791641 ;
    civico:citation "Sasaki et al., 2011, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A cell line (DFCI076) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibition of both pathways led to decreased cell-growth. Amphiregulin (AREG) production was identified as a potential mediator of EGFR-activation (no other alterations detectable). The same mechanism could be reproduced in a cell line (H3122) without EML1-ALK mutation and resistance to crizotinib that was acquired in-vitro." ;
    a m2r:Evidence .

civice:781
    dct:references pbm:23344087 ;
    civico:citation "Kim et al., 2013, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions." ;
    a m2r:Evidence .

civice:782
    dct:references pbm:9625170 ;
    civico:citation "Rubin Grandis et al., 1998, J. Natl. Cancer Inst." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival." ;
    a m2r:Evidence .

civice:783
    dct:references pbm:26459251 ;
    civico:citation "Jia et al., 2016, Clin Transl Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Nimotuzumab ;
    dcterms:description "55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to moderate groups (37 pts)." ;
    a m2r:Evidence .

civice:784
    dct:references pbm:26459251 ;
    civico:citation "Jia et al., 2016, Clin Transl Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "55 tumor samples were analyzed for EGFR expression using IHC. PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8 ± 0.5 vs. 11.0 ± 2.8 months, P = 0.007; OS: 9.7 ± 0.5 vs. 21.5 ± 1.5 months, P = 0.03." ;
    a m2r:Evidence .

civice:785
    dct:references pbm:9625170 ;
    civico:citation "Rubin Grandis et al., 1998, J. Natl. Cancer Inst." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival." ;
    a m2r:Evidence .

civice:786
    dct:references pbm:24894453 ;
    civico:citation "Cho et al., 2014, Mol. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules." ;
    a m2r:Evidence .

civice:787
    dct:references pbm:24894453 ;
    civico:citation "Cho et al., 2014, Mol. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules. The same in-vitro results could be reproduced for the G719S mutation." ;
    a m2r:Evidence .

civice:788
    dct:references pbm:23374602 ;
    civico:citation "Pentheroudakis et al., 2013, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "226 cetuximab-treated patients with colorectal cancer (CRC) were analyzed for mRNA expression (by qPCR) of EGFR and its ligands (EGF, TGFA, AREG and EREG). High AREG mRNA expression in KRAS wild type tumours was a favorable predictor in a multivariate analysis (median survival 33 vs. 15 months, p=0.0005).   Cetuximab-treated patients with AREG-low KRAS wild type CRC had poor survival, similar to KRAS mutated CRC." ;
    a m2r:Evidence .

civice:789
    dct:references pbm:23374602 ;
    civico:citation "Pentheroudakis et al., 2013, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high EREG mRNA and low Ephrin A2 receptor mRNA." ;
    a m2r:Evidence .

civice:791
    dct:references pbm:26181029 ;
    civico:citation "Van Allen et al., 2015, JAMA Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mutation (allelic fraction 0.13). In-vitro studies in two HNSCC cell lines showed enhanced EGFR phosphorylation and erlotinib sensitivity in the mutant line compared with the wild-type line." ;
    a m2r:Evidence .

civice:792
    dct:references pbm:22961667 ;
    civico:citation "Ercan et al., 2012, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_WZ4002 ;
    dcterms:description "Resistance to WZ4002 was induced in cell lines. Amplification of MAPK1 or downregulation of ERK-pathway inhibitors led to resistance to EGFR inhibition with WZ4002. Chemical inhibition (MEK inhibition with either CI-1040 or GSK1120212) or shRNA knockdown of MAPK1 resensitized cells to EGFR inhibition with WZ4002 in-vitro. Additionally, MAPK1 amplification was identified in 1/21 erlotinib-resistant NSCLC patients. MAPK1 amplification was not observed in the pretreatment tumor, only the post-treatment resistant tumor which lacked other more common drug-resistance mechanisms EGFR T790M or MET amplification." ;
    a m2r:Evidence .

civice:793
    dct:references pbm:26673008 ;
    civico:citation "Shi et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "FGFR1 expression, was assessed by IHC in 1,086 invasive breast cancers. FGFR1 expression was mainly associated with luminal cancer subtypes. Multivariate Cox regression analysis showed FGFR1 to be an independent poor prognostic marker in luminal A cancers for disease free survival (hazard ratio = 3.341, p = 0.008). In luminal A cancers, FGFR1 expression was also significantly associated with higher pN (lymph node metastases; p = 0.023) and pT (unfavorable tumor characteristics; p = 0.003) stages and lymphovascular invasion (p = 0.010)." ;
    a m2r:Evidence .

civice:794
    dct:references pbm:24836576 ;
    civico:citation "Van Allen et al., 2014, Nat. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_LY2835219 ;
    dcterms:description "Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led to administration of CDK4 inhibitor LY2835219. Specifically, the PHIAL algorithm nominated this variant as actionable on the basis of a predicted synthetic lethal relationship between activated KRAS and CDK4. The patient achieved stable disease and was on treatment for 16 weeks which was the patients best and only clinical response to any cancer-directed therapy." ;
    a m2r:Evidence .

civice:795
    dct:references pbm:20609353 ;
    civico:citation "Puyol et al., 2010, Cancer Cell" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PD0332991 ;
    dcterms:description "In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors. 17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treated with vehicle developed lesions at the end of the treatment." ;
    a m2r:Evidence .

civice:796
    dct:references pbm:23213094 ;
    civico:citation "Choueiri et al., 2013, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Foretinib ;
    dcterms:description "In a retrospective analysis of 74 patients with papillary renal cell carcinoma, treated with foretinib, MET germline mutation was associated with improved response rate.  A response was observed in 5 of 10 (50%) vs. 5 of 57 (8.8%) patients with and without germline MET mutations, respectively." ;
    a m2r:Evidence .

civice:797
    dct:references pbm:25971939 ;
    civico:citation "Paik et al., 2015, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping." ;
    a m2r:Evidence .

civice:798
    dct:references pbm:26115874 ;
    civico:citation "Ipenburg et al., 2016, Target Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This review identified 12 studies that addressed the prognostic role of FGFRs in HNSSC. Evidence was found for the expression of FGFR1 in cancer-associated fibroblasts, other results were conflicting. Significant risk of bias was reported for the included studies." ;
    a m2r:Evidence .

civice:799
    dct:references pbm:26015511 ;
    civico:citation "Göke et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BGJ398 ;
    dcterms:description "FGFR1 mRNA expression, rather than copy number alterations, were predictive of response to FGFR inhibitor BGJ398 in cell lines and patient derived xenografts." ;
    a m2r:Evidence .

civice:800
    dct:references pbm:26637881 ;
    civico:citation "Schmidt et al., 2015, Anticancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BGJ398 ;
    dcterms:description "FGFR inhibitor BGJ398 was most effective in a gastric cancer cell line model with high expression of FGFR1 and FGFR2IIIc." ;
    a m2r:Evidence .

civice:801
    dct:references pbm:21119661 ;
    civico:citation "Lamont et al., 2011, Br. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_DovitinibDilacticAcid%28TKI258DilacticAcid%29,civic:drug_PD173074 ;
    dcterms:description "One urothelial cell line (JMSU1) with high expression of FGFR1 was sensitive to treatment with FGFR inhibitors  (SU5402, TKI258 or PD173074)." ;
    a m2r:Evidence .

civice:803
    dct:references pbm:21119661 ;
    civico:citation "Lamont et al., 2011, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dovitinib,civic:drug_SU-5402,civic:drug_PD173074 ;
    dcterms:description "The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression." ;
    a m2r:Evidence .

civice:804
    dct:references pbm:25267748 ;
    civico:citation "Chung et al., 2014, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH). p16 expression in non-oropharyngeal HNSSC was also prognostic and associated with a better outcome. However, p16-positive oropharyngeal HNSSC still had better PFS and OS than p16-positive non-oropharyngeal HNSSC." ;
    a m2r:Evidence .

civice:805
    dct:references pbm:25883215 ;
    civico:citation "Frankum et al., 2015, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "The E3 ubiquitin ligase, CBLC, was identified as a candidate biomarker for olaparib sensitivity in a siRNA screen and further validated in-vitro. In other words, expression of CBLC is predicted to confer resistance to olaparib." ;
    a m2r:Evidence .

civice:806
    dct:references pbm:26623049 ;
    civico:citation "Osumi et al., 2015, Mol Clin Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "This is a retrospective analysis of 98 patients with metastatic colorectal cancer and KRAS mutations. 23 (23.5%) had KRAS p.G13D-mutated tumors. Of the 98 patients, 31 patients received cetuximab, of these, 9 (29.0%) had KRAS p.G13D mutations. Univariate analysis did not show any differences between these groups. Multivariate analysis showed a trend towards better PFS among patients with a G13D mutation (PFS: HR=0.29; 95% CI: 0.08-1.10; P=0.07; OS: HR=0.23; 95% CI: 0.04-1.54; P=0.13)." ;
    a m2r:Evidence .

civice:807
    dct:references pbm:26267899 ;
    civico:citation "Peyser et al., 2015, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_JSI-124 ;
    dcterms:description "In this preclinical study, loss-of-function of PTPRD was mainly caused by mutation in head and neck cancer, as identified in TCGA data. PTPRD mutated cell-lines were more sensitive to STAT3 inhibition (JSI-124) than wild-type cells. The authors generated several representative HNSCC-derived PTPRD mutants by site-directed mutagenesis (S384R, K1502M, T1100M and L1147F)." ;
    a m2r:Evidence .

civice:808
    dct:references pbm:26261420 ;
    civico:citation "Kohli et al., 2015, Onco Targets Ther" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Docetaxel ;
    dcterms:description "Blood mRNA levels of DEFA1, DEFA1B and DEFA3 were associated with response to docetaxel treatment in castration resistant prostate cancer. The discovery cohort consisted of 6 patients, results were validated in 10 patients." ;
    a m2r:Evidence .

civice:809
    dct:references pbm:26162296 ;
    civico:citation "Klatte et al., 2015, J. Urol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin ;
    dcterms:description "Immunhistochemistry of ERCC1 expression in 432 patients revealed no correlation to response to cisplatin based chemotherapy. In-vitro studies also did not show any effects." ;
    a m2r:Evidence .

civice:810
    dct:references pbm:26162296 ;
    civico:citation "Klatte et al., 2015, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "ERCC1 expression as evaluated by IHC in 432 patients was associated with better disease-free survival (HR 0.70, p = 0.028) and cancer specific survival (HR 0.70, p = 0.032) on multivariable analysis." ;
    a m2r:Evidence .

civice:811
    dct:references pbm:26152787 ;
    civico:citation "Arcaroli et al., 2016, Int. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_NOTCH1Antibody ;
    dcterms:description "NOTCH1 copy-number gain in a patient-derived tumor xenograft model of colorectal cancer, was associated with increased NOTCH1 and JAG1 activity and response to a NOTCH1-targeting antibody (PF-06293622)." ;
    a m2r:Evidence .

civice:812
    dct:references pbm:26152787 ;
    civico:citation "Arcaroli et al., 2016, Int. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NOTCH1 amplifications (as determined by FISH) were significantly (log-rank p = 0.025) associated with worse survival in a cohort of 116 patients with colorectal cancer." ;
    a m2r:Evidence .

civice:813
    dct:references pbm:26137564 ;
    civico:citation "Mendell et al., 2015, EBioMedicine" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Patritumab ;
    dcterms:description "In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab. HRG (NRG1) expression was retrospectively defined as predictive biomarker but prospectively assessed in 102 patients before unblinding. NRG1-high groups demonstrated clinical benefit from additional patritumab with hazard ratios of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively." ;
    a m2r:Evidence .

civice:814
    dct:references pbm:26057002 ;
    civico:citation "Liu et al., 2015, Sci Rep" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PLATINUM,civic:drug_Gemcitabine ;
    dcterms:description "The presence of the WEE1 polymorphism rs3910384 correlated with OS and PFS of NSCLC patients treated with platinum-based chemotherapy. Especially the combination of two DNA-damaging agents was associated with efficacy. 663 patients were tested. The authors showed that rs3910384 is closely linked with the putative functional WEE1 promoter at SNPs rs6486433, rs3763869 and rs3763868." ;
    a m2r:Evidence .

civice:815
    dct:references pbm:26033044 ;
    civico:citation "Bachmann et al., 2015, Br J Clin Pharmacol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Lonafarnib ;
    dcterms:description "57 from 105 patients in the AGo-OVAR-15 trial were retrospectively genotyped for FNTB polymorphisms. Resistance to lonafarnib-containing treatment was limited to patients with a FNTB rs11623866 (c.-609G > C) GG genotype (HRPFS 6.2, 95%CI = 2.01, 19.41, P = 0.002; HROS 9.6, 95%CI = 1.89, 48.54, P = 0.006)." ;
    a m2r:Evidence .

civice:816
    dct:references pbm:25989278 ;
    civico:citation "Rowland et al., 2015, Br. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progression free survival) could not definitely state that survival benefit of anti-EGFR monoclonal antibodies is limited to patients with wild type BRAF. In other words, the authors believe that there is insufficient data to justify the exclusion of anti-EGFR monoclonal antibody therapy for patients with mutant BRAF. In these studies, mutant BRAF specifically meant the V600E mutation." ;
    a m2r:Evidence .

civice:817
    dct:references pbm:25982282 ;
    civico:citation "Peyser et al., 2016, Oncogene" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Stattic,civic:drug_JSI-124 ;
    dcterms:description "PTPRT promoter hypermethylation was associated with increased sensitivity to STAT3 inhibition in this preclinical study in HNSCC. The authors found that PTPRT promoter methylation and sensitivity to Stattic (a STAT3 SH2 domain inhibitor) or JSI-124 (a JAK/STAT3 pathway inhibitor) are significantly correlated (P<0.05)." ;
    a m2r:Evidence .

civice:818
    dct:references pbm:25973082 ;
    civico:citation "Tsai et al., 2015, Int J Clin Exp Pathol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_L-FolinicAcid,civic:drug_Bevacizumab,civic:drug_Irinotecan,civic:drug_5-fluorouracil ;
    dcterms:description "Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC." ;
    a m2r:Evidence .

civice:819
    dct:references pbm:25968887 ;
    civico:citation "Stewart et al., 2015, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Decitabine ;
    dcterms:description "DNMT1 expression (mRNA expression from an independent study) correlated with sensitivity to decitabine (ρ, −0.443, Pearson regression analysis) in this preclinical study of 45 solid tumor cell lines. DNMT1 protein expression was also evaluated in two KRAS-mutant ovarian cancer cell lines pre and post-decitabine treatment showing downregulation following treatment." ;
    a m2r:Evidence .

civice:820
    dct:references pbm:25968887 ;
    civico:citation "Stewart et al., 2015, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Decitabine ;
    dcterms:description "KRAS mutation or amplification predicted sensitivity to decitabine in ovarian cancer cell lines. The authors profiled the response of 45 ovarian, melanoma, and breast cancer cell lines over 9 days of treatment with decitabine. 4 ovarian lines with KRAS mutation were among the most sensitive to decitabine." ;
    a m2r:Evidence .

civice:821
    dct:references pbm:25928036 ;
    civico:citation "Xu et al., 2015, J. Proteome Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Paclitaxel ;
    dcterms:description "PDCD4 expression was associated with response to paclitaxel in a retrospective analysis of 77 patients after preclinical validation and mechanistic analysis of the biomarker." ;
    a m2r:Evidence .

civice:822
    dct:references pbm:25910840 ;
    civico:citation "Rapkins et al., 2015, Neuro-oncology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "The T allele of the rs16906252 SNP was associated with MGMT methylation and low protein expression. Germline presence of the T allele increased the risk of glioblastoma development (adjusted odds ratio, 1.96; P = .013). Temozolomide treatment led to better survival in patients with the rs16906252 T genotype irrespective of methylation status." ;
    a m2r:Evidence .

civice:823
    dct:references pbm:25900183 ;
    civico:citation "May et al., 2015, Endocr. Relat. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Aminoglutethimide,civic:drug_Tamoxifen ;
    dcterms:description "TFF3 expression was assessed by IHC in 75 patients, 187 patients were identified for the validation cohort. TFF3 expression was associated with response to endocrine therapy (tamoxifen, aminoglutethimide or oophorectomy) and outperformed ER, PR and TFF1 as biomarkers." ;
    a m2r:Evidence .

civice:824
    dct:references pbm:25788273 ;
    civico:citation "Aguilera et al., 2015, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Irinotecan,civic:drug_L-FolinicAcid,civic:drug_5-fluorouracil,civic:drug_Oxaliplatin ;
    dcterms:description "Nuclear expression of DICKKOPF-1 was identified in 15% of 699 patients with colorectal cancer and was associated with decreased progression-free survival (PFS) and overall survival (OS) after chemotherapy (FOLFOX, FOLFIRI, or 5-FU) [adjusted HR, 1.65; 95% confidence interval (CI), 1.23-2.21; P = 0.002)]." ;
    a m2r:Evidence .

civice:825
    dct:references pbm:25762343 ;
    civico:citation "Birzele et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_RG7356 ;
    dcterms:description "CD44 isoform expression (especially CD44s) was identified to predict response to CD44 antibody RG7356 preclinically. Retrospective evaluation of 13 patients from a phase 1 study, treated with RG7356, identified 3 patients with CD44s isoform. 2/3 patients with CD44s had SD as best response. Overall, 5 patients had an OR." ;
    a m2r:Evidence .

civice:826
    dct:references pbm:25677871 ;
    civico:citation "Ansell et al., 2016, J. Oral Pathol. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "3 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amphiregulin and epiregulin were inconclusive." ;
    a m2r:Evidence .

civice:827
    dct:references pbm:25668009 ;
    civico:citation "Walter et al., 2015, Br. J. Cancer" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Pemetrexed ;
    dcterms:description "72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with cisplatin and pemetrexed (standard of care therapy)." ;
    a m2r:Evidence .

civice:828
    dct:references pbm:25668009 ;
    civico:citation "Walter et al., 2015, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with standard of care therapy (cisplatin and pemetrexed)." ;
    a m2r:Evidence .

civice:829
    dct:references pbm:26309414 ;
    civico:citation "Zheng et al., 2015, Onco Targets Ther" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sorafenib,civic:drug_Sunitinib ;
    dcterms:description "In 66 patients with advanced renal cell carcinoma, high expression of heme oxygenase-1 (HO-1) was associated with poor overall response rate (2.6% versus 53.6%, P<0.01), clinical benefit rate (47.4% versus 92.9%, P<0.01), shorter progression-free survival (4.4 versus 42 months, P=0.022) and poor overall survival (χ (2)=4.775, P=0.029) in patients receiving sorafenib or sunitinib." ;
    a m2r:Evidence .

civice:830
    dct:references pbm:26311741 ;
    civico:citation "Kim et al., 2015, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "SPHK1 protein expression was assessed in 287 cervical cancer and 5 normal cervical tissue samples using IHC. Univariate analysis for OS showed SPHK1 expression (p = 0.033; Figure 1C), tumor size (p = 0.033), and lymph node metastasis (p = 0.008) as associated with OS. SPHK1 expression did not directly predict OS. High SPHK1 expression was also associated with larger tumor size (p < 0.001), deeper invasion depth (p < 0.001), presence of lymph node metastasis (p = 0.029), higher FIGO stage (p = 0.029), presence of lymphovascular invasion (p = 0.045), and higher preoperative squamous cell carcinoma (SCC) antigen level (p = 0.009)." ;
    a m2r:Evidence .

civice:831
    dct:references pbm:26291055 ;
    civico:citation "Kang et al., 2015, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Conatumumab ;
    dcterms:description "In-vitro and in-vivo sensitivity to DR5 antibody conatumumab was correlated with expression of caspase-8." ;
    a m2r:Evidence .

civice:832
    dct:references pbm:26502926 ;
    civico:citation "Chamizo et al., 2015, BMC Pulm Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pemetrexed ;
    dcterms:description "mRNA expression of thymidylate synthase (TYMS) in 62 NSCLC patients correlated with response rate to pemetrexed mono- or combination therapy. Response rate with low TYMS expression was 0.29 compared with 0.03 in patients with overexpression (P = 0.025). Patients with low expression exhibited a benefit in time to progression (average TTP = 56 vs. 23 months, P = 0.001) and in overall survival (average OS = 60 vs. 25 months, P = 0.002)." ;
    a m2r:Evidence .

civice:835
    dct:references pbm:26745678 ;
    civico:citation "Li et al., 2016, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "TOPK (PBK) silencing sensitized lung cancer cells to gefitinib in preclinical xenograft models. Over-expression was also associated with resistance in various lung cancer cell lines." ;
    a m2r:Evidence .

civice:836
    dct:references pbm:26724472 ;
    civico:citation "Zhang et al., 2016, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Case report of a patient with MET amplification without high-level MET/CEP7 ratio, MET exon 14 mutation or overexpression who achieved rapid response to crizotinib." ;
    a m2r:Evidence .

civice:837
    dct:references pbm:26671993 ;
    civico:citation "Bell et al., 2016, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Vinorelbine ;
    dcterms:description "SMARCA4 expression was determined with gene expression microarray in 133 patients. Improved five-year disease-specific survival (DSS) was noted only in patients with low SMARCA4 expression when treated with adjuvant cisplatin/vinorelbine (n=36) (HR=0.1, 95% CI: 0.0-0.5, P=0.002 [low]; HR 1.0, 95% CI: 0.5-2.3, P=0.92 [high]) compared to patients in the observation arm (N=30)." ;
    a m2r:Evidence .

civice:838
    dct:references pbm:26671993 ;
    civico:citation "Bell et al., 2016, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "SMARCA4 expression was determined with gene expression microarray in 133 patients. Reduced overall survival was observed in patients with low SMARCA4 expression compared to intermediate (P<0 .001) or high expression (P=0.009). In multivariate analysis, compared to low, high SMARCA4 expression predicted a decrease in risk of death (HR=0.6, 95% CI: 0.4-0.8, P=0.002)." ;
    a m2r:Evidence .

civice:839
    dct:references pbm:23222956 ;
    civico:citation "Piazza et al., 2013, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion. Targeted sequencing of 70 aCML patients identified SETBP1 mutations between codons 858 and 871 in 24.3% of the patients. Patients with this mutation had a 22 month median survival compared to 77 months in aCML patients without the mutation (P=.01)." ;
    a m2r:Evidence .

civice:840
    dct:references pbm:23222956 ;
    civico:citation "Piazza et al., 2013, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "D" ;
    dcterms:description "Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion. The researchers transfected 293T cells with SETBP1 G870S, a variant found to be associated with poor prognosis in aCML, and found those cells had higher proliferation and higher expression of SET and SETBP1 proteins. This may be linked to the mutation abrogating a ubiquitination site." ;
    a m2r:Evidence .

civice:841
    dct:references pbm:26698910 ;
    civico:citation "Shaw et al., 2016, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_AUY922,civic:drug_Crizotinib,civic:drug_Ceritinib ;
    dcterms:description "In this case report, a patient with metastatic, ALK-rearranged NSCLC with C1156Y mutation had tumor progression under sequential treatment with first crizotinib, then ceritinib and finally AUY922. Subsequent chemotherapy (carboplatin–pemetrexed) was administered and the patient had a response for 6 months before progression. Exome sequencing revealed the C1156Y mutation was present in <7% of the pretreatment tumor and in ~50% of the crizotinib tumor prior to ceritinib therapy." ;
    a m2r:Evidence .

civice:842
    dct:references pbm:26698910 ;
    civico:citation "Shaw et al., 2016, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Lorlatinib ;
    dcterms:description "Case report of a patient with metastatic ALK-rearranged NSCLC after progression under sequential crizotinib, ceritinib, HSP90 inhibitor AUY922 and chemotherapy followed by crizotinib again. Third generation ALK inhibitor lorlatinib led to a partial response that lasted for 8 months. The C1156Y mutation was confirmed in a sample prior to initial crizotinib (<7% of cells), following crizotinib treatment (~50% of cells) and following lorlatinib resistance (100% of cells). However, a second ALK mutation (C1156Y & L1198F) was detected in the lorlatinib resistant tumor." ;
    a m2r:Evidence .

civice:843
    dct:references pbm:26698910 ;
    civico:citation "Shaw et al., 2016, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Lorlatinib ;
    dcterms:description "Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response with the third generation ALK-inhibitor lorlatinib. The patient progressed on lorlatinib after 8 months, at which point whole exome sequencing revealed an EML4-ALK C1156Y–L1198F double mutation. In vitro, the double mutation was resistant to lorlatinib but sensitive to crizotinib. The patient was started on crizotinib again and had a clinical response that lasted for 6 months." ;
    a m2r:Evidence .

civice:844
    dct:references pbm:26698910 ;
    civico:citation "Shaw et al., 2016, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response with the third generation ALK-inhibitor lorlatinib. The patient progressed on lorlatinib after 8 months, at which point whole exome sequencing revealed an EML4-ALK C1156Y–L1198F double mutation. In vitro, the double mutation was resistant to lorlatinib but sensitive to crizotinib. The patient was started on crizotinib again and had a clinical response that lasted for 6 months." ;
    a m2r:Evidence .

civice:845
    dct:references pbm:26510020 ;
    civico:citation "Mateo et al., 2015, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study." ;
    a m2r:Evidence .

civice:846
    dct:references pbm:21653686 ;
    civico:citation "Tinhofer et al., 2011, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Docetaxel ;
    dcterms:description "47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tumor cells was associated with reduced overall survival  (hazard ratio: 2.2, P = 0.002) and progression free survival (hazard ratio: 2.2, P = 0.016) compared to patients with low AREG expression score. AREG was an independent prognosticator of OS in multivariate Cox analysis. High EGFRvIII and AREG expression levels identified SCCHN (squamous cell carcinoma, head and neck) patients that were less likely to benefit from combination treatment with cetuximab and docetaxel." ;
    a m2r:Evidence .

civice:848
    dct:references pbm:21653686 ;
    civico:citation "Tinhofer et al., 2011, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Docetaxel ;
    dcterms:description "47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression was associated with reduced disease control rate (DCR) and shortened progression free survival (PFS) (HR: 3.3, P = 0.005) but not with OS." ;
    a m2r:Evidence .

civice:849
    dct:references pbm:21653686 ;
    civico:citation "Tinhofer et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Docetaxel ;
    dcterms:description "47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFRvIII. EGFR expression had no impact on PFS or OS." ;
    a m2r:Evidence .

civice:850
    dct:references pbm:24740294 ;
    civico:citation "Xu et al., 2014, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Chemotherapy ;
    dcterms:description "In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.704; 95% confidence intervals [CI] = 0.550-0.903; P = 0.006)." ;
    a m2r:Evidence .

civice:851
    dct:references pbm:22698404 ;
    civico:citation "Jackson et al., 2012, Cancer Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Doxorubicin ;
    dcterms:description "In this preclinical study, MMTV-Wnt1 mammary tumors with mutant TP53 showed a better clinical response to chemotherapy (doxorubicin) than TP53 wild-type tumors. This was mediated by wild-type TP53-induced cell-arrest under chemotherapy even in the context of heterozygous TP53 point mutations or absence of p21. Thus the status of both TP53 alleles should be assessed because even one copy of wild-type TP53 may contribute to poor response to chemotherapy." ;
    a m2r:Evidence .

civice:852
    dct:references pbm:24708484 ;
    civico:citation "Sim et al., 2014, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_5-fluorouracil ;
    dcterms:description "112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1α and ALDH1. High pretreatment p21 (CDKN1A) expression was significantly associated with non-pCR (p = 0.022) and poor disease free survival (median DFS - low vs high p21: 75.8 vs 58.1 months, p = 0.002). Multivariate analysis was also significant (p = 0.001, HR 6.14; 95% CI 2.03, 18.55)." ;
    a m2r:Evidence .

civice:853
    dct:references pbm:24708484 ;
    civico:citation "Sim et al., 2014, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_5-fluorouracil ;
    dcterms:description "112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1α and ALDH1. Pretreatment CD166 (ALCAM) expression level was associated with poor disease free survival (p = 0.003; HR 5.61; 95% CI 1.81, 17.35)." ;
    a m2r:Evidence .

civice:854
    dct:references pbm:24653627 ;
    civico:citation "Shen et al., 2014, Chin. J. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regardless of KRAS status. For the pooled analysis, the objective response rate (ORR) was 65.2% (167/256) in patients with high EFGR GCN, while in patients with low EFGR GCN, the pooled ORR was 12.2% (44/361). The odds ratio (OR) was 6.905 (95% CI: 4.489-10.620; Z=8.79, P=0.000). In wild type KRAS patients, the pooled OR was 8.133 (95% CI: 4.316-15.326; Z=6.48, P=0.000)." ;
    a m2r:Evidence .

civice:855
    dct:references pbm:24587245 ;
    civico:citation "Werner et al., 2014, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Paclitaxel ;
    dcterms:description "33 patients were retrospectively analyzed for Stathmin expression by IHC. High protein expression was correlated with poor response to paclitaxel but not other chemotherapy. The authors supported this conclusion with pre-clinical studies that showed that knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel." ;
    a m2r:Evidence .

civice:856
    dct:references pbm:15138475 ;
    civico:citation "Stendahl et al., 2004, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Tamoxifen ;
    dcterms:description "The authors performed a tissue microarray analysis of 167 postmenopausal breast cancers that had been randomized to treatment with or without tamoxifen.  ER +ve patients with high CCND1 tumor expression did not show any difference in survival between tamoxifen and no treatment." ;
    a m2r:Evidence .

civice:857
    dct:references pbm:24367492 ;
    civico:citation "Keilty et al., 2013, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Tamoxifen ;
    dcterms:description "In retrospective study, 413 patients were assessed for RSF1 amplification. 28 patients with RSF1 amplification did not show a benefit from adjuvant tamoxifen compared to placebo (12 treated vs 16 placebo). 381 patients without amplification did show a benefit compared to placebo (187 treated vs 194 placebo)." ;
    a m2r:Evidence .

civice:858
    dct:references pbm:24367492 ;
    civico:citation "Keilty et al., 2013, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Tamoxifen ;
    dcterms:description "In this retrospective analysis, CCND1 amplification was analyzed in 442 patients. No interaction with treatment was observed." ;
    a m2r:Evidence .

civice:859
    dct:references pbm:24356815 ;
    civico:citation "Wang et al., 2014, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BEZ235%28NVP-BEZ235,civic:drug_Dactolisib%29 ;
    dcterms:description "In-vitro and xenograft studies of response of breast cancer cell lines to PI3K/mTOR inhibitor NVP-BEZ235 showed that sensitivity correlated with expression of the androgen receptor (AR). Reintroduction of AR expression resensitized nonresponsive AR-negative cells to NVP-BEZ235. A dihydrotestosterone (DHT) and NVP-BEZ235 combination achieved tumor regression and complete response in AR/ER expressing tumors (xenografts)." ;
    a m2r:Evidence .

civice:860
    dct:references pbm:25587029 ;
    civico:citation "Zhao et al., 2014, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "Cytoplasmic localization of p27 (CDKN1B) leads to lapatinib resistance in HER2+ breast cancer cell lines. p27 knockout resensitiuzed cells to lapatinib." ;
    a m2r:Evidence .

civice:861
    dct:references pbm:25542901 ;
    civico:citation "Meetze et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AV-203 ;
    dcterms:description "This screening study in various tumor xenografts identified NRG1 expression to correlate with sensivity to ERBB3 inhibitory antibody AV-203. ERBB3 expression was not predictive of response." ;
    a m2r:Evidence .

civice:862
    dct:references pbm:25542901 ;
    civico:citation "Meetze et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AV-203 ;
    dcterms:description "The authors conducted an in vivo efficacy study of AV-203 (ERBB3 inhibitory antibody) using a panel of 32 xenograft models representing 12 human cancer types. To identify biomarkers that can predict response to AV-203, the relationship between tumor growth inhibition (TGI) by AV-203 and the expression levels of ERBB3 and NRG1 were evaluated in these tumor models. ERBB3 expression was not predictive of response." ;
    a m2r:Evidence .

civice:863
    dct:references pbm:25184630 ;
    civico:citation "Antonarakis et al., 2014, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Abiraterone,civic:drug_Enzalutamide ;
    dcterms:description "Detection of AR-V7 in circulating tumor cells of 62 patients treated with either enzalitamide (n=31) or arbiraterone (n=31), was correlated with lower PSA response rates and PSA PFS in men receiving enzalutamide or abiraterone." ;
    a m2r:Evidence .

civice:864
    dct:references pbm:25300346 ;
    civico:citation "Zhang et al., 2015, Oncology" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Lapatinib,civic:drug_Trastuzumab ;
    dcterms:description "In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) to HER2-targeted therapy (trastuzumab, N=39; lapatinib, N=9). Response rates did not differ between groups." ;
    a m2r:Evidence .

civice:865
    dct:references pbm:25216528 ;
    civico:citation "Thomas et al., 2014, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Pertuzumab,civic:drug_9F7-F11 ;
    dcterms:description "In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time. Sensitivity to single-agent pertuzumab might also be increased through ERBB3 expression." ;
    a m2r:Evidence .

civice:866
    dct:references pbm:25210794 ;
    civico:citation "Landmann et al., 2014, Cell Death Dis" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ganetespib ;
    dcterms:description "Colorectal cancer cell lines were evaluated for response to the HSP90 inhibitor ganetespib.  Correlating cell line-specific IC50s with the corresponding gene expression patterns revealed a possible relationship to UGT1A expression. High UGT1A expression was correlated with ganetespib resistance. Knockdown of UGT1A sensitized HT29 cells to HSP90 inhibition. HCT116 and SW480 cell lines became resistant through UGT1A overexpression." ;
    a m2r:Evidence .

civice:867
    dct:references pbm:25153719 ;
    civico:citation "Mohd Nafi et al., 2014, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "HER4 nuclear translocation was identified as a mediator of trastuzumab resistance in HER2 positive breast cancer cell lines. Increased nuclear staining was also identified in xenograft and patient samples after trastuzumab treatment." ;
    a m2r:Evidence .

civice:868
    dct:references pbm:25153719 ;
    civico:citation "Mohd Nafi et al., 2014, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "siRNA knockdown of HER4 or inhibition with neratinib enhanced trastuzumab response in breast cancer cell lines." ;
    a m2r:Evidence .

civice:869
    dct:references pbm:25590338 ;
    civico:citation "Canfield et al., 2015, Cell Cycle" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "ERBB4 protein expression was identified in breast cancer cell lines with acquired lapatinib resistance. Genetic ablation of ERBB4 (not ERBB1-3) led to apoptosis in trastuzumab- and lapatinib resistant cells, probably through a decrease in the PI3K/Akt pathway." ;
    a m2r:Evidence .

civice:870
    dct:references pbm:25089570 ;
    civico:citation "Tian et al., 2014, Anticancer Drugs" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_SN-38 ;
    dcterms:description "In this study, SLFN11 expression was associated with sensitivity to SN-38 (an active metabolite of topoisomerase inhibitor irinotecan)." ;
    a m2r:Evidence .

civice:871
    dct:references pbm:25082261 ;
    civico:citation "Xu et al., 2014, J Transl Med" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin ;
    dcterms:description "High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisplatin-based chemotherapy. In-vitro data confirmed these results and overexpression or knockdown of AURKA decreased or increased in-vitro sensitivity to cisplatin." ;
    a m2r:Evidence .

civice:872
    dct:references pbm:25081901 ;
    civico:citation "Chung et al., 2014, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin ;
    dcterms:description "In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was added to their platinum-based regimen (log-rank P = 0.04)." ;
    a m2r:Evidence .

civice:873
    dct:references pbm:25056119 ;
    civico:citation "Watson et al., 2014, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Vemurafenib ;
    dcterms:description "Melanoma cell lines harboring the RAC1 P29S hotspot mutation were shown to be resistant to BRAF inhibition with vemurafenib or dabrafenib and knock-in or knock-out of this mutation decreased and increased sensitivity to these drugs." ;
    a m2r:Evidence .

civice:874
    dct:references pbm:24961465 ;
    civico:citation "Wu et al., 2014, Med. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Taxane,civic:drug_PLATINUM ;
    dcterms:description "Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective analysis of 48 patients with non-small cell lung cancer." ;
    a m2r:Evidence .

civice:875
    dct:references pbm:24957073 ;
    civico:citation "Sclafani et al., 2014, J. Natl. Cancer Inst." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Capecitabine,civic:drug_Cetuximab,civic:drug_Oxaliplatin ;
    dcterms:description "In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild-type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P = .02 by Cox regression) and overall survival (OS) (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P = .02 by Cox regression) when treated with Cetuximab + CAPOX (Capecitabine, Oxaliplatin) than in the control arm without Cetuximab." ;
    a m2r:Evidence .

civice:876
    dct:references pbm:24927325 ;
    civico:citation "Koppensteiner et al., 2014, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BMN-673 ;
    dcterms:description "One endometrial cell line with decreased MRE11 expression caused by a homozygous poly(T) mutation exhibited increased sensitivity to the PARP inhibitor BMN-673. Loss of MRE11 was identified in 30.7% of endometrial tumors (N=521)." ;
    a m2r:Evidence .

civice:878
    dct:references pbm:24841718 ;
    civico:citation "Kubota et al., 2014, Cell Cycle" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Low ATM protein expression led to sensitivity to PARP inhibitors in TP53 -ve gastric cancer cell lines (8 lines were used for various aspects of this study)." ;
    a m2r:Evidence .

civice:879
    dct:references pbm:23816960 ;
    civico:citation "Sequist et al., 2013, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001)." ;
    a m2r:Evidence .

civice:880
    dct:references pbm:23816960 ;
    civico:citation "Sequist et al., 2013, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001). 308 patients had either exon 19 or L858 mutations." ;
    a m2r:Evidence .

civice:881
    dct:references pbm:25862853 ;
    civico:citation "Banno et al., 2015, Anticancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Stable HEK293 cell lines expressing mutant EGFR cDNAs were created (using a pQCLIN retroviral vector) and their drug sensitivities to afatinib were examined by MTT assay. Phorphorylation of EGFR was assayed by Western blot. The 50% inhibitory concentration (IC50) of afatinib was significantly lower in cells harboring EGFR exon 19 deletion than in cells harboring EGFR L858R." ;
    a m2r:Evidence .

civice:882
    dct:references pbm:22452895 ;
    civico:citation "Yang et al., 2012, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In total, 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (exon 19 deletion or L858R) had an objective response compared to 39% of 23 patients with less common EGFR mutations." ;
    a m2r:Evidence .

civice:883
    dct:references pbm:22452895 ;
    civico:citation "Yang et al., 2012, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations." ;
    a m2r:Evidence .

civice:884
    dct:references pbm:22285168 ;
    civico:citation "Rosell et al., 2012, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "A randomized phase 3 trial involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group." ;
    a m2r:Evidence .

civice:885
    dct:references pbm:22285168 ;
    civico:citation "Rosell et al., 2012, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group." ;
    a m2r:Evidence .

civice:886
    dct:references pbm:25268372 ;
    civico:citation "Schwab et al., 2014, Br. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Eight uterine cancer cell lines (four with ERBB2 amplification and four without) were treated with scalar concentrations of afatinib. Primary chemotherapy-resistant USC cell lines harbouring ERBB2 gene amplification were sensitive to afatinib exposure and significantly more sensitive than non-amplified cell lines." ;
    a m2r:Evidence .

civice:887
    dct:references pbm:25537159 ;
    civico:citation "Rimawi et al., 2015, Clin. Breast Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Lapatinib,civic:drug_Trastuzumab,civic:drug_Afatinib ;
    dcterms:description "In this phase 2 trial, treatment-naive, ERBB2-positive (by IHC) breast cancer patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to afatinib (n = 10), lapatinib (n = 8), or trastuzumab (n = 11). The primary end point was objective response rate. Objective response was seen in 8 afatinib-, 6 lapatinib-, and 4 trastuzumab-treated patients. Afatinib demonstrated clinical activity that compared favorably to trastuzumab and lapatinib for neoadjuvant treatment of HER2-positive breast cancer." ;
    a m2r:Evidence .

civice:888
    dct:references pbm:24256029 ;
    civico:citation "Nygård et al., 2014, Scand. J. Gastroenterol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Irinotecan ;
    dcterms:description "FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe. TOP1 gain was nonsignificantly associated with objective response to irinotecan Odds ratio (OR): 1.62; p = 0.07." ;
    a m2r:Evidence .

civice:889
    dct:references pbm:24239278 ;
    civico:citation "Moreno-Galindo et al., 2014, Oral Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_5-fluorouracil,civic:drug_Cisplatin ;
    dcterms:description "41 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response after multivariate analysis (p=0.025; n=41 patients)." ;
    a m2r:Evidence .

civice:890
    dct:references pbm:24192513 ;
    civico:citation "Schwab et al., 2014, Lung Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested negative for EGFR, KRAS and PIK3CA mutations and ALK and ROS1 rearrangements. c-MET amplification was detected by FISH. Crizotinib led to a partial response." ;
    a m2r:Evidence .

civice:891
    dct:references pbm:24167368 ;
    civico:citation "Hrstka et al., 2013, Dis. Markers" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Tamoxifen ;
    dcterms:description "mRNA expression of AGR2 in 61 patients with tamoxifen treated postmenopausal breast cancer was determined by qRT-PCR and was inversely associated with treatment response and progression free survival (p= 0.0011, p = 0.0366 respectively). AGR2 protein expression as assessed by IHC was not significantly associated with treatment outcome." ;
    a m2r:Evidence .

civice:892
    dct:references pbm:24166148 ;
    civico:citation "Mackay et al., 2014, Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Temsirolimus,civic:drug_Ridaforolimus ;
    dcterms:description "94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, including PIK3CA mutations (N=21/73), KRAS mutations (10/73) or PTEN loss." ;
    a m2r:Evidence .

civice:893
    dct:references pbm:24166148 ;
    civico:citation "Mackay et al., 2014, Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Temsirolimus,civic:drug_Ridaforolimus ;
    dcterms:description "94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss." ;
    a m2r:Evidence .

civice:894
    dct:references pbm:24166148 ;
    civico:citation "Mackay et al., 2014, Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Temsirolimus,civic:drug_Ridaforolimus ;
    dcterms:description "94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. Mutations were found in 32 of 73 analyzed tumors, 10 of which were KRAS mutations. No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss." ;
    a m2r:Evidence .

civice:895
    dct:references pbm:24146218 ;
    civico:citation "Sclafani et al., 2013, Ann. Oncol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Oxaliplatin,civic:drug_Cetuximab,civic:drug_Capecitabine ;
    dcterms:description "141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and chemoradiotherapy, with or without cetuximab." ;
    a m2r:Evidence .

civice:896
    dct:references pbm:24135816 ;
    civico:citation "Göke et al., 2013, Digestion" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BGJ398 ;
    dcterms:description "In vitro studies showed efficacy of FGFR inhibitor NVP-BGJ398 in cell lines exhibiting high FGFR1 protein. Three cell lines (SNU-C1, HDC9, HCT116) were analyzed. FGFR1 amplification (24/454, assessed by FISH) and/or activated pFGFR1 protein (18/99, assessed by mRNA in situ hybridization) was identified in primary CRC tissue samples." ;
    a m2r:Evidence .

civice:897
    dct:references pbm:24097869 ;
    civico:citation "Shames et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_GNE-617 ;
    dcterms:description "Tumor-specific promoter hypermethylation of NAPRT1 led to loss of NAPRT1 expression in most tumor types sensitive to treatment with Nampt inhibitor GNE-617 and nicotinic acid." ;
    a m2r:Evidence .

civice:898
    dct:references pbm:24039832 ;
    civico:citation "Baty et al., 2013, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab,civic:drug_Erlotinib ;
    dcterms:description "Overexpression of EGFR exon 18 (Affymetrix Human Exon 1.0 ST) in tumor or blood samples was associated with tumor shrinkage, independently of EGFR mutational status in NSCLC treated with bevacizumab and erlotinib. 76 patients were analyzed for this study." ;
    a m2r:Evidence .

civice:899
    dct:references pbm:24013721 ;
    civico:citation "Sánchez-Tilló et al., 2014, Cell Death Differ." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Doxorubicin,civic:drug_Cytarabine,civic:drug_Gemcitabine ;
    dcterms:description "Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine." ;
    a m2r:Evidence .

civice:900
    dct:references pbm:24013721 ;
    civico:citation "Sánchez-Tilló et al., 2014, Cell Death Differ." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Salinomycin,civic:drug_Doxorubicin ;
    dcterms:description "Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine. the combination of salinomycin (downregulating ZEB1) and doxorubicin was syngergistic." ;
    a m2r:Evidence .

civice:901
    dct:references pbm:23881388 ;
    civico:citation "Bjerre et al., 2013, Tumour Biol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Fulvestrant ;
    dcterms:description "TIMP1 overexpression was associated with resistance to fulvestrant in breast cancer cell lines." ;
    a m2r:Evidence .

civice:902
    dct:references pbm:23867504 ;
    civico:citation "Al-Aidaroos et al., 2013, J. Clin. Invest." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In-vitro studies linked PRL-3 (PP4A3) expression to hyperactivation and dependence on EGFR signaling (through downregulation of PTP1B, an inhibitory phosphatase of EGFR). Retrospective analysis of 68 patients showed improved clinical response to the EGFR inhibitor cetuximab in tumors expressing PRL-3." ;
    a m2r:Evidence .

civice:903
    dct:references pbm:23645741 ;
    civico:citation "Kasai et al., 2013, Anticancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pemetrexed ;
    dcterms:description "TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25). The same was found in 17 cell lines." ;
    a m2r:Evidence .

civice:904
    dct:references pbm:23619944 ;
    civico:citation "Peled et al., 2013, Cell Oncol (Dordr)" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "Expression of IGF1R in NSCLC cell lines (n=17) was associated with resistance to EGFR inhibitor gefitinib, however, knock-in or knock-out of IGF1R did not affect gefitinib sensitivity. IGF1R expression was also higher in patients with disease progression after gefitinib therapy in a clinical cohort (n=98)." ;
    a m2r:Evidence .

civice:905
    dct:references pbm:23579861 ;
    civico:citation "Guijarro-Muñoz et al., 2013, Med. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab ;
    dcterms:description "EPHB4 expression, as assessed by quantitative RT-PCR in 13 colorectal cancer patients treated with bevacizumab, was higher in non-responders (p = 0.048). No difference was observed in a control group without bevacizumab treatment. qRT-PCR results were also shown to correlate with protein expression measured by IHC." ;
    a m2r:Evidence .

civice:906
    dct:references pbm:23515910 ;
    civico:citation "Zhang et al., 2013, Ann. Surg. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Chemotherapy ;
    dcterms:description "Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 % CI = 1.03-1.16, P = .003; pathological MR: RR = 1.15, 95 % CI = 1.06-1.25, P = .001; total complete response [CR]: RR = 1.08, 95 % CI = 1.00-1.17, P = .040) in this meta-analysis (28 studies, 1497 cases)." ;
    a m2r:Evidence .

civice:907
    dct:references pbm:21367480 ;
    civico:citation "Chen et al., 2011, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pemetrexed ;
    dcterms:description "49 tumor specimens from 268 NSCLC patients treated with pemetrexed were evaluated for expression of TYMS and DHFR by IHC and compared to treatment outcomes. Patients with low TS (≤150) expression had a longer median progression-free survival (PFS) than those with high TS (>150) expression (4.8 vs. 3.4 months; p=0.01)." ;
    a m2r:Evidence .

civice:908
    dct:references pbm:24782778 ;
    civico:citation "Russell et al., 2014, Front Pharmacol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pemetrexed ;
    dcterms:description "Case report of a patient with metastatic prostate cancer and underexpression of TYMS who showed a nonspecified response to pemetrexed for at least 4 months." ;
    a m2r:Evidence .

civice:909
    dct:references pbm:15486187 ;
    civico:citation "Durbecq et al., 2004, Mol. Cancer Ther." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Doxorubicin ;
    dcterms:description "In a retrospective study, TOP2A expression was assessed by IHC for 108 breast cancer patients (from TAX 303 trial). TOP2A expression was associated with a higher probability of response in doxorubicin treated but not in docetaxel treated breast cancer patients." ;
    a m2r:Evidence .

civice:910
    dct:references pbm:19648970 ;
    civico:citation "Litzow et al., 2010, Bone Marrow Transplant." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cyclophosphamide,civic:drug_Carboplatin,civic:drug_Topotecan ;
    dcterms:description "Shorter progression free survival was observed in patients with low expression (IHC) of topoisomerase 1 in 16 patients with relapsed or persistent ovarian or peritoneal carcinoma after treatment with topotecan, cyclophosphamide and carboplatin followed by an autologous hematopoietic stem cell transplant." ;
    a m2r:Evidence .

civice:911
    dct:references pbm:18794099 ;
    civico:citation "Personeni et al., 2008, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and overall survival independent of KRAS status." ;
    a m2r:Evidence .

civice:912
    dct:references pbm:19775480 ;
    civico:citation "Kostopoulos et al., 2009, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Irinotecan ;
    dcterms:description "498 patients were retrospectively analyzed for topoisomerase 1 expression (IHC). In the subgroup of patients treated with irinotecan (38% of the 498), those patients expressing Topoisomerase I had a better overall survival according to multivariate analysis (HR = 0.47, 95% CI 0.23-0.94, p = 0.033)." ;
    a m2r:Evidence .

civice:913
    dct:references pbm:23506848 ;
    civico:citation "Migita et al., 2013, Am. J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_ACLYSiRNA ;
    dcterms:description "Low levels of baseline p-AMPK (PRKAA2, measured at Thr172) were predictive of efficacy of ACLY inhibition by siRNA in cell lines of various cancer histologies." ;
    a m2r:Evidence .

civice:914
    dct:references pbm:23456958 ;
    civico:citation "Thornton et al., 2013, Int. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_5-fluorouracil ;
    dcterms:description "Expression of GRP78 (HSPA5) in colorectal cancer patients (n=396, by IHC) showed improved benefit from adjuvant chemotherapy in stage III patients (52% vs. 28%; p = 0.026). In vitro, GRP78 inhibition reduced response to 5-FU." ;
    a m2r:Evidence .

civice:915
    dct:references pbm:23435830 ;
    civico:citation "Wu et al., 2013, J. Cancer Res. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Anti-EGFRMonoclonalAntibody ;
    dcterms:description "A meta-analysis of 8 metastatic colorectal cancer studies (839 patients) was performed. PIK3CA mutations were significantly associated with shorter PFS and OS following therapy with anti-EGFR monoclonal antibodies (PFS: 8 studies, 839 patients; HR = 1.53; 95 % confidence interval (CI) 1.28-1.84; P < 0.001; OS: 5 studies; 587 patients; HR = 1.28; 95 % CI 1.05-1.56; P = 0.015)." ;
    a m2r:Evidence .

civice:916
    dct:references pbm:23435671 ;
    civico:citation "Boeck et al., 2013, J. Gastroenterol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment." ;
    a m2r:Evidence .

civice:917
    dct:references pbm:23435671 ;
    civico:citation "Boeck et al., 2013, J. Gastroenterol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "KRAS exon 2 was mutated in 121 of 173 patients with advanced pancreatic cancer. Patients with KRAS wildtype had an improved OS (HR 1.68, p = 0.005)." ;
    a m2r:Evidence .

civice:918
    dct:references pbm:23340172 ;
    civico:citation "Nishi et al., 2013, Cancer Lett." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "8 gastric cancer cell lines were treated with the MTOR inhibitor everolimus. Cell proliferation was effectively inhibited in 3 cell lines by everolimus. Phosphorylated EIF4EBP1 (T37/46, T70) levels were higher in cell lines and xenografts sensitive to everolimus." ;
    a m2r:Evidence .

civice:919
    dct:references pbm:23231951 ;
    civico:citation "Floris et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Pictilisib,civic:drug_Imatinib ;
    dcterms:description "Human GISTs with different KIT mutations were grafted in 136 nude muce. Mice were then treated with control, imatinib, GDC-0941, or GDC-0941 + imatinib. The combination showed superior antitumor efficacy that was sustained after treatment withdrawal." ;
    a m2r:Evidence .

civice:920
    dct:references pbm:21576762 ;
    civico:citation "Ganguly et al., 2011, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Paclitaxel ;
    dcterms:description "High expression of class 3 beta-tubulin led to decreased effect of paclitaxel on cell motility in HeLa, MCF-7 and CHO cell lines." ;
    a m2r:Evidence .

civice:921
    dct:references pbm:23218766 ;
    civico:citation "Wang et al., 2013, Clin. Breast Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Taxane ;
    dcterms:description "High expression of betaIII-tubulin, as assessed in 85 breast cancers by IHC, was associated with better pathological response." ;
    a m2r:Evidence .

civice:922
    dct:references pbm:23060591 ;
    civico:citation "Shimizu et al., 2012, Anticancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pemetrexed ;
    dcterms:description "mRNA levels of TYMS, DHFR and GARFT were assessed (rt-PCR) in 50 patient samples of NSCLC. TYMS mRNA levels were lower in responders compared to non-responders to pemetrexed (1.671 ± 0.844 versus 5.978 ± 1.895, p=0.0142)." ;
    a m2r:Evidence .

civice:923
    dct:references pbm:22901364 ;
    civico:citation "Wang et al., 2012, J. Exp. Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "While EGFR mutation is a strong predictive factor for EGFR inhibition, some patients with EGFR wild-type also respond.  The authors investigated whether phosphorylated EGFR could be a potential predictive biomarker in patients with wild-type EGFR. Phosphorylation of Y1068 (assessed by IHC) was associated with improved progression free survival (PFS) in 205 patients with stage IIb and IV NSCLC treated with EGFR tyrosine kinase inhibitors (gefitinib or erlotinib) compared to phospho-Y1068 negative patients (median PFS 7.0 months vs. 1.2 months, P < 0.001). In this group, 92 (44.9%) were EGFR mutant. In a subgroup of patients with wild-type EGFR, phospho-Y1068 expression positive patients had a significantly prolonged PFS (4.2 months vs.1.2 months P < 0.001) compared with those without phospho-Y1068 expression." ;
    a m2r:Evidence .

civice:924
    dct:references pbm:22682017 ;
    civico:citation "Asmane et al., 2012, Eur. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_IGF1RMonoclonalAntibody ;
    dcterms:description "IGF-1R nuclear immunostaining (IHC) was observed in 9 out of 16 samples of patients with different sarcomas (osteosarcoma, ewing sarcoma, liposarcoma, synovialsarcoma, desmoplastic tumor, rhabdomyosarcoma). Exclusive nuclear immunostaining was associated with better progression free survival and overall survival after therapy with IGF1R antibodies (R1507, IMC-A12, SCH 717454 and CP-751.871)." ;
    a m2r:Evidence .

civice:925
    dct:references pbm:22623731 ;
    civico:citation "McCourt et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Bicalutamide ;
    dcterms:description "Expression of c-FLIP (CFLAR) in 50 prostate specimens (assessed by IHC) was increased in castrate-resistant prostate cancer. In-vitro, silencing of CFLAR led to sensitization of two cell lines to bicalutamide." ;
    a m2r:Evidence .

civice:926
    dct:references pbm:22596232 ;
    civico:citation "Hagiwara et al., 2012, Br. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity. Both were more highly expressed in patients not responding to sorafenib. CD133+ cells (sorted) were xenografted into mice, producing larger, more JNK inhibitor responsive tumors than CD133- xenografts." ;
    a m2r:Evidence .

civice:927
    dct:references pbm:22544540 ;
    civico:citation "Zhu et al., 2012, Med. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Paclitaxel ;
    dcterms:description "High expression of TIMP-1 was assessed by IHC in 99 primary breast cancers that had not spread beyond the breast after 6 postoperative courses of paclitaxel-based chemotherapy. High TIMP1 levels were associated with worse 5-year disease free survival (71.1%) than low levels (88.5 %; P = 0.020). High TIMP-1 levels were also associated with worse 5-year overall survival (78.9 %) than low levels (96.7 %; P = 0.004)." ;
    a m2r:Evidence .

civice:928
    dct:references pbm:22431701 ;
    civico:citation "Ladoire et al., 2012, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Epirubicin ;
    dcterms:description "1,097 patients with breast cancer were evaluated for FOXP3 expression by IHC. FOXP3 expression was found in 405 tumor samples and associated with improved OS in patients treated with anthracycline-based adjuvant chemotherapy (6 cycles of 'FEC100' aka epirubicin + cyclophosphamide + 5-fluorouracil) but not in patients treated with sequential anthracycline->taxane (3 cycles of FEC100 followed by 3 cycles of docetaxel). In-vitro experiments confirmed that FOXP3 expression enhance anthracycline efficacy. The in vitro data consisted of testing the sensitivity of various breast cancer cell lines to anthracyclines after treatment with valproic acid (which increases FOXP3 expression). The authors observed that, while valproic acid has no intrinsic cytotoxic effect on tumor cells, it enhanced the cytotoxic effect of epirubicin specifically in cell lines where FOXP3 expression was increased." ;
    a m2r:Evidence .

civice:929
    dct:references pbm:22422354 ;
    civico:citation "Shen et al., 2012, Int. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Raltitrexed ;
    dcterms:description "In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively)." ;
    a m2r:Evidence .

civice:930
    dct:references pbm:22343617 ;
    civico:citation "Yoon et al., 2012, Br. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "54 patients with advanced gastric cancer were treated with everolimus. Two patient responsed and potential biomarkers were explored. High pre-treatment expression of phosphorylated RPS6 (pS6; at Ser240/4) was associated with higher disease control rate and progression free survival (P=0.043, P=0.001 respectively; N=28)." ;
    a m2r:Evidence .

civice:931
    dct:references pbm:22333600 ;
    civico:citation "Shimokawa et al., 2012, Br. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Enzastaurin ;
    dcterms:description "Overexpression of JAK1 in 22 lung cancer cell lines was associated with sensitivity to PKC-inhibitor enzastaurin. Silencing of JAK1 (by small molecule JAK 1/2/3 inhibitor) led to resistance.  Overexpression of JAK1 (lentiviral mediated) led to sensitivity to enzastaurin." ;
    a m2r:Evidence .

civice:932
    dct:references pbm:22262166 ;
    civico:citation "Zhang et al., 2012, Cell Cycle" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_WYE354,civic:drug_BEZ235%28NVP-BEZ235,civic:drug_Dactolisib%29,civic:drug_PP242 ;
    dcterms:description "12 CRC cell lines were evaluated. 40% of these were intrinsically resistant to mTOR inhibition with  BEZ235, PP242 or WYE354. mTOR independent phosphorylation of EIF4EBP1 (T37/46) was associated with resistance to mTOR inhibitors in one analyzed cell line (SW620)." ;
    a m2r:Evidence .

civice:933
    dct:references pbm:22190288 ;
    civico:citation "Busacca et al., 2012, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vinorelbine ;
    dcterms:description "Expression of BRCA1 in 6 mesothelioma cell lines was associated with sensitivity to vinorelbine in functional studies." ;
    a m2r:Evidence .

civice:934
    dct:references pbm:22169769 ;
    civico:citation "Jing et al., 2012, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "Expression of DUSP6 was associated with sensitivity to MEK inhibitor GSK1120212 (Sensitivity: 79%; specificity: 82%: P = 0.0027) in 218 solid cancer cell lines." ;
    a m2r:Evidence .

civice:935
    dct:references pbm:22169769 ;
    civico:citation "Jing et al., 2012, Mol. Cancer Ther." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "In this screen of 218 solid cancer cell lines, KRAS and BRAF mutations were predictive of response to MEK inhibitor GSK1120212. 40 cell lines harbored a KRAS mutation. In RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic (9/10 cell lines) response rather than a cytotoxic response (1/10 cell lines)." ;
    a m2r:Evidence .

civice:936
    dct:references pbm:22169769 ;
    civico:citation "Jing et al., 2012, Mol. Cancer Ther." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "In this screen of 218 solid cancer cell lines, BRAF mutations were predictive of response to the MEK inhibitor GSK1120212. 26 of these cell lines had the BRAF V600E mutation, one cell line had a G469A mutation, one had G596R mutation and one had an unspecified mutation. Also of note, in RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic response rather than a cytotoxic response." ;
    a m2r:Evidence .

civice:937
    dct:references pbm:22025163 ;
    civico:citation "Yap et al., 2011, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_MK-2206 ;
    dcterms:description "Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements." ;
    a m2r:Evidence .

civice:938
    dct:references pbm:22025163 ;
    civico:citation "Yap et al., 2011, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_MK-2206 ;
    dcterms:description "Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements." ;
    a m2r:Evidence .

civice:939
    dct:references pbm:22004109 ;
    civico:citation "Schäfer et al., 2012, J. Cell. Mol. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gemcitabine ;
    dcterms:description "HSP27 (HSPB1) expression in pancreatic adenocarcinoma cell lines was associated with sensitivity to treatment with gemcitabine." ;
    a m2r:Evidence .

civice:940
    dct:references pbm:21964527 ;
    civico:citation "Takakuwa et al., 2011, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Amrubicin ;
    dcterms:description "Higher expression of NQO1 was correlated with decreased cytotoxicity of amrubicin (amrubicinol is the active metabolite) in 27 NSCLC and SCLC cell lines.  siRNA knockdown of NQO1 (in two cell lines) increased amrubicinol cytotoxicity." ;
    a m2r:Evidence .

civice:941
    dct:references pbm:21964527 ;
    civico:citation "Takakuwa et al., 2011, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Amrubicin ;
    dcterms:description "The presence of NQO1 C609T SNP (rs1800566) was associated with decreased protein expression and higher amrubicin sensitivity in 29 NSCLC and SCLC cell lines. 15 of these cell lines were genotyped for C609T (only 3 were T/T, and the rest were C/C or C/T). Cell lines with the T/T genotype had lower expression of NQ01 and greater response to amrubicinol." ;
    a m2r:Evidence .

civice:942
    dct:references pbm:21920589 ;
    civico:citation "Carser et al., 2011, Gynecol. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PLATINUM,civic:drug_Taxane ;
    dcterms:description "Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029)." ;
    a m2r:Evidence .

civice:943
    dct:references pbm:21890455 ;
    civico:citation "Rosa et al., 2011, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_IMO,civic:drug_EGFRInhibitor ;
    dcterms:description "TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations." ;
    a m2r:Evidence .

civice:944
    dct:references pbm:21883677 ;
    civico:citation "Meng et al., 2011, Respirology" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Paclitaxel ;
    dcterms:description "mRNA expression of ABCB1 in 17 NSCLC cell lines was associated with decreased response to paclitaxel (correlation of mRNA expression and paclitaxel IC50: r=0.5322, P=0.0279)." ;
    a m2r:Evidence .

civice:945
    dct:references pbm:21642865 ;
    civico:citation "Lee et al., 2011, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pemetrexed ;
    dcterms:description "Among 95 patients with NSCLC in this study, 15 had an ALK translocation. ORR of these patients compared to EGFR mutated or wild-type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001). TYMS expression was lower in ALK-positive cells." ;
    a m2r:Evidence .

civice:946
    dct:references pbm:21458988 ;
    civico:citation "Mutze et al., 2011, Eur. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin ;
    dcterms:description "High DNMT1 expression was found in 105/127 (83%) or patients (by qPCR assay). Low DNMT1 expression was associated with improved histopathological and clinical response and OS in patients with gastric cancer  (P=0.03/P=0.008, P(log-rank)=0.001, respectively). In one cisplatin resistant cell line, DAC treatment and cisplatin had a synergistic effect." ;
    a m2r:Evidence .

civice:947
    dct:references pbm:20956938 ;
    civico:citation "Dunn et al., 2011, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib,civic:drug_Cetuximab ;
    dcterms:description "Combined treatment with dasatinib and cetuximab, but not either agent in monotherapy, had an antitumor efficacy in-vitro and in xenografts. These results were based on three KRAS mutant cell lines (LS180, LoVo and HCT116) and two KRAS wild-type cell lines (SW48 and CaCo2)." ;
    a m2r:Evidence .

civice:948
    dct:references pbm:20826716 ;
    civico:citation "Dahabreh et al., 2011, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_EGFRInhibitor ;
    dcterms:description "A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy number), 10 (822 patients, 290 with increased gene copy number) and 5 studies (294 patients, 129 with increased gene copy number) were analyzed for overall survival (OS), progression-free survival (PFS) and time-to-progression (TTP) meta-analyses respectively. EGFR amplification was associated with increased OS (HR = 0.77; 95% CI 0.66-0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46-0.79; P<0.001) and TTP (HR = 0.50; 95% CI 0.28-0.91; P = 0.02). This effect was shown to influence survival in predominantly white patient populations but not patients of Asian descent." ;
    a m2r:Evidence .

civice:949
    dct:references pbm:20651371 ;
    civico:citation "Xie et al., 2010, Anticancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Docetaxel ;
    dcterms:description "CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019). Expression levels (by qtPCR) were also higher in resistant tumors among 25 patient samples." ;
    a m2r:Evidence .

civice:950
    dct:references pbm:20088962 ;
    civico:citation "Ojima et al., 2010, Cancer Sci." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gemcitabine ;
    dcterms:description "10 biliary tract carcinoma cell lines were sorted based on their gemcitabine sensitivity. MAGEH1 protein expression was negatively correlated with sensitivity. In a clinical validation cohort, MAGEH protein expression was found in 4/4 \"non-effective\" cases and 2/5 effective cases based on RECIST criteria after gemcitabine treatment." ;
    a m2r:Evidence .

civice:951
    dct:references pbm:18593940 ;
    civico:citation "O'Brien et al., 2008, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Paclitaxel,civic:drug_MonomethylAuristatinE ;
    dcterms:description "44 cell lines and 145 patient samples were utilized in various aspects of this study. 31 breast cancer cell lines for in vitro sensitivity to paclitaxel and Monomethyl Auristatin E (MMAE). Genome wide amplification was assessed by Affymetrix SNP arrays and expression was assessed by Affymetrix gene expression arrays. ABCC3 amplification (and expression) in ERBB2 (HER2) amplified breast cancer cell lines was associated with resistance to paclitaxel and  MMAE. Three independently derived EVSA-T cell lines overexpressing ABCC3 were at least 20-fold less sensitive to paclitaxel and MMAE based on EC50 values." ;
    a m2r:Evidence .

civice:952
    dct:references pbm:18445659 ;
    civico:citation "Oguri et al., 2008, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Paclitaxel ;
    dcterms:description "Increased expression of ABCC10 in 17 NSCLC cell lines was inversely correlated with paclitaxel sensitivity (r = 0.574; P < 0.05)." ;
    a m2r:Evidence .

civice:953
    dct:references pbm:17088436 ;
    civico:citation "Lorenzi et al., 2006, Mol. Cancer Ther." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_L-asparaginase ;
    dcterms:description "ASNS amplification and expression was associated with resistance to L-asparaginase in ovarian cancer and leukemia cell lines. ASNS silencing increased sensitivity to l-ASP in 2/3 of ovarian cancer cell lines." ;
    a m2r:Evidence .

civice:954
    dct:references pbm:16707605 ;
    civico:citation "Dziadziuszko et al., 2006, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "82 patients treated with gefitinib were retrospectively analyzed for EGFR mRNA expression (rt-PCR in 64 patients). Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas patients with low EGFR mRNA expression had 8% response probability (P = 0.006). PFS but not OS was also longer in patients with high EGFR mRNA expression." ;
    a m2r:Evidence .

civice:955
    dct:references pbm:16404430 ;
    civico:citation "Fujita et al., 2006, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "Trastuzumab was more effective in cell lines (SKBR3 vs. drug-resistant SKBR3/R) and 17 patient samples that exhibit elevated PTEN expression (by IHC)." ;
    a m2r:Evidence .

civice:956
    dct:references pbm:26789870 ;
    civico:citation "Dalerba et al., 2016, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with stage II/III colorectal cancer were analyzed for expression of CDX2 (by microarray and IHC). In the discovery (466 patients) and validation sets (314 patients), 5-year DFS was lower among patients with CDX2 negative tumors (discovery set:hazard ratio for disease recurrence, 3.44; 95% confidence interval [CI], 1.60 to 7.38; P=0.002; validation set: hazard ratio, 2.42; 95% CI, 1.36 to 4.29; P=0.003)." ;
    a m2r:Evidence .

civice:957
    dct:references pbm:22591296 ;
    civico:citation "Koskela et al., 2012, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Mutations in the Src homology 2 (SH2) domain (exon 21) of STAT3 were found in 31 of 77 patients (40%) with large granular lymphocytic leukemia. Recurrent mutational hot spots included Y640F, D661V, D661Y, and N647I. Patients with these mutations presented more often with neutropenia and rheumatoid arthritis than did patients without." ;
    a m2r:Evidence .

civice:958
    dct:references pbm:26398480 ;
    civico:citation "Wen et al., 2015, Oncol. Rep." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Oxaliplatin ;
    dcterms:description "OCT4B1 (POU5F1 splice variant) expression reduced sensitivity to oxaliplatin (via P-gp and ABCG2 differential expression) in vitro." ;
    a m2r:Evidence .

civice:959
    dct:references pbm:22325357 ;
    civico:citation "De Grève et al., 2012, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients." ;
    a m2r:Evidence .

civice:960
    dct:references pbm:19122144 ;
    civico:citation "Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Afatinib,civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "In preclinical studies of transgenic mice and xenografts, continuous expression of mutant ERBB2 (M774insAYVM or the equivalent A775insYVMA) was found to be essential for tumor maintenance. Furthermore, preclinical in vivo studies assessing erlotinib, trastuzumab, afatinib (aka BIBW2992), and/or sirolimus (aka rapamycin) revealed that the combination of afatinib and sirolimus was most effective in shrinking tumors harboring this insertion." ;
    a m2r:Evidence .

civice:961
    dct:references pbm:22418700 ;
    civico:citation "Lin et al., 2012, Breast Cancer Res. Treat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "A phase II study involving adult female patients, >=18 years, with stage IIIB or IV HER2-positive (by IHC and/or in situ fluorescence) metastatic breast cancer. All patients were previously treated with trastuzumab and a median of three chemotherapy lines. 41 patients received 50 mg afatinib once-daily until disease progression and the primary endpoint was objective response rate. 4 patients (10% of 41 treated; 11% of evaluable patients) had partial response and 15 patients (37% of 41) had stable disease as best response. Thus a total of 19 (46% of 41) achieved clinical benefit. Median progression-free survival was 15.1 weeks." ;
    a m2r:Evidence .

civice:962
    dct:references pbm:26668065 ;
    civico:citation "Huguet et al., 2016, Target Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB3 receptors. Afatinib increased the radiosensitivity of BxPC3 and Capan-2 cells. In comparison, Panc-1 cells (KRAS mut) expressing low levels of EGFR family receptors were resistant to afatinib-induced radiosensitization." ;
    a m2r:Evidence .

civice:963
    dct:references pbm:24893891 ;
    civico:citation "Cross et al., 2014, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Osimertinib ;
    dcterms:description "Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle." ;
    a m2r:Evidence .

civice:964
    dct:references pbm:25939061 ;
    civico:citation "Thress et al., 2015, Nat. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Osimertinib ;
    dcterms:description "An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expression of this mutant EGFR construct in a cell line rendered it resistant to osimertinib. ddPCR on serial cfDNA specimens collected from 15 osimertinib-treated subjects (all positive for T790M before treatment) revealed 6 cases with acquired C797S mutation." ;
    a m2r:Evidence .

civice:965
    dct:references pbm:25923549 ;
    civico:citation "Jänne et al., 2015, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Osimertinib ;
    dcterms:description "This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients." ;
    a m2r:Evidence .

civice:966
    dct:references pbm:26720284 ;
    civico:citation "Sequist et al., 2016, JAMA Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Osimertinib ;
    dcterms:description "This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR." ;
    a m2r:Evidence .

civice:967
    dct:references pbm:26515464 ;
    civico:citation "Hirano et al., 2015, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Osimertinib,civic:drug_Rociletinib ;
    dcterms:description "For cell harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay." ;
    a m2r:Evidence .

civice:968
    dct:references pbm:26515464 ;
    civico:citation "Hirano et al., 2015, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay." ;
    a m2r:Evidence .

civice:969
    dct:references pbm:26515464 ;
    civico:citation "Hirano et al., 2015, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Cells harboring an exon 19 deletion were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay." ;
    a m2r:Evidence .

civice:970
    dct:references pbm:16454808 ;
    civico:citation "Hase et al., 2006, J. Oral Pathol. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Expression of bFGF and FGFR1 were evaluated in 61 biopsy specimens of primary OSCC (IHC). Expression was evaluated in both the cancer cells and fibroblasts at the invasive front of each tumor. bFGF and FGFR1 were expressed in all tumor specimens, whereas expression of these proteins in cancer-associated fibroblasts was associated with lymph node metastasis (P < 0.05) and worse patient survival." ;
    a m2r:Evidence .

civice:971
    dct:references pbm:25586468 ;
    civico:citation "Schuster et al., 2015, Neuro-oncology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Rindopepimut ;
    dcterms:description "In a Phase II clinical trial, patients with Glioblastoma Multiforme (GBM), positive for EGFR VIII deletion mutation (N=65), were treated with the Rindopepimut cancer vaccine,  and standard adjuvant temozolomide chemotherapy.  Median progression free survival (PFS) was 9.2 months, and median overall survival (OS) was 21.8 months.  A pivotal, randomized Phase III trial is currently underway." ;
    a m2r:Evidence .

civice:972
    dct:references pbm:26811533 ;
    civico:citation "Lee et al., 2016, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. Serum HER2 (sHER2) levels measured by ELISA were higher in patients with HER2 amplification (median sHER2 levels were 25.1 ng/mL in patients with HER2-positive tumors). Serum HER2 levels were Independent predictors of lapatinib progression free survival benefit (HR per 10-ng/mL increase in serum HER2: lapatinib-containing therapies, 1.009 v nonlapatinib-containing therapies, 1.044; P interaction < .001). Tissue HER2 levels were also predictive, but within this subgroup, serum HER2 still independently predicted lapatinib PFS benefit." ;
    a m2r:Evidence .

civice:973
    dct:references pbm:26811533 ;
    civico:citation "Lee et al., 2016, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. In the control group (n = 936), higher serum HER2 (sHER2) was associated with worse prognosis in multivariable analyses (progression free survival hazard ratio per 10 ng/mL: PFS, 1.024; P < .001; and OS, 1.018; P < .001)." ;
    a m2r:Evidence .

civice:974
    dct:references pbm:26807188 ;
    civico:citation "Lin et al., 2015, Am J Transl Res" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "172 patients treated with neoadjuvant concurrent chemoradiotherapy (CCRT) were retrospectively analyzed for expression of thrombospondin 2 (THBS2) using IHC (discovery set with 46 rectal cancer patients, GSE35452). Low expression was associated with advanced pretreatment tumor, nodal status, post-treatment tumor, vascular invasion and inferior regression grade. In multivariate analysis, low expression served as negative prognostic factor for disease-free survival (Hazard ratio=3.057, P=0.002)." ;
    a m2r:Evidence .

civice:975
    dct:references pbm:26771872 ;
    civico:citation "Tokito et al., 2016, Eur. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "74 patients with stage III NSCLC treated with concurrent chemoradiotherapy were retrospectively analyzed for PD-L1 expression and CD8+ tumour-infiltrating lymphocytes (TILs) density (IHC). CD8+ TIL density was an independent predictor of progression free survival (PFS) and overall survival (OS). Only when both TIL density and PD-L1 expression were both considered, was PD-L1 expression associated with survival. The subgroup, PD-L1+/CD8 low tumors had the shortest PFS (8.6 months, p = 0.02) and shortest, but not significantly different, OS (13.9 months, p = 0.11)." ;
    a m2r:Evidence .

civice:976
    dct:references pbm:26765760 ;
    civico:citation "Yuan et al., 2016, J Clin Neurosci" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this meta-analysis of 16 Trials, TERT mutations were more common in glioblastomas (69%), oligodendrogliomas (72%) in comparison to astrocytomas (24%) and oligoastrocytomas (38%)." ;
    a m2r:Evidence .

civice:977
    dct:references pbm:26722081 ;
    civico:citation "Fiala et al., 2016, Anticancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib,civic:drug_Gefitinib ;
    dcterms:description "In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) were analzed. EGFR amplification was associated with EGFR mutation but not independently with patient benefit from EGFR TKI (overall and progression-free survival)." ;
    a m2r:Evidence .

civice:978
    dct:references pbm:26716414 ;
    civico:citation "Park et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) were identified in 2% of Korean colorectal cancer patients (147 patients). TrkA (NTRK1) protein expression was associated with presence of NTRK1 gene fusion. These fusions were mutually exclusive with other oncogenic drivers and showed in-vitro sensitivity to TrkA Inhibitor ARRY470  (Larotrectinib) (one cell line with fusion (KM12), one control cell line)." ;
    a m2r:Evidence .

civice:979
    dct:references pbm:23558169 ;
    civico:citation "Rohle et al., 2013, Science" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AGI-5198 ;
    dcterms:description "In pre-clinical studies, an IDH1 inhibitor (AG-5198) impaired growth of glioma / anaplastic oligodendroglioma cell lines with IDH1 R132H mutations.  A phase I clinical trial of the AG-120 IDH1 inhibitor in IDH1 mutant positive solid tumors, including glioma is currently underway." ;
    a m2r:Evidence .

civice:980
    dct:references pbm:26765760 ;
    civico:citation "Yuan et al., 2016, J Clin Neurosci" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Meta-analysis of 10 studies (9,411 patients, 13,708 controls) showed that TERT polymorphisms (rs2736100) were associated with an increased glioma risk (RR=1.28, 95% CI 1.23-1.33)." ;
    a m2r:Evidence .

civice:981
    dct:references pbm:24439929 ;
    civico:citation "Wu et al., 2014, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon." ;
    a m2r:Evidence .

civice:982
    dct:references pbm:24439929 ;
    civico:citation "Wu et al., 2014, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon." ;
    a m2r:Evidence .

civice:983
    dct:references pbm:25589191 ;
    civico:citation "Yang et al., 2015, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemotherapy (33.3 vs 21.1 and 31.4 vs 18.4 months in LUX-Lung 3 and LUX-Lung 6 respectively).  This effect was observed in the EGFR exon 19 deletion subgroup, but not in the L858R mutant subgroup." ;
    a m2r:Evidence .

civice:984
    dct:references pbm:26838030 ;
    civico:citation "Qiao et al., 2016, Tumour Biol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Tumor samples from 125 patients with bladder cancer were assessed by IHC for STAG2 expression. STAG2-negativity was associated with lower histological grade (p = 0.009). Complete loss of STAG2 expression was associated with a lower risk of recurrence (P = 0.023) and diminished risk of death (P = 0.034) in log-rank analysis and was a beneficial factor in uni- and multivariate analysis." ;
    a m2r:Evidence .

civice:985
    dct:references pbm:26822383 ;
    civico:citation "Johnson et al., 2016, Nat Commun" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Atezolizumab,civic:drug_Nivolumab,civic:drug_Pembrolizumab ;
    dcterms:description "Melanoma patients treated with Anti-PD1 or anti-PD-L1(nivolumab, pembrolizumab, MPDL3280A) therapy were analyzed for expression of HLA-DRA (the primary antigen-presenting molecule of the MHC-II pathway). In a discovery cohort, 30 patients underwent IHC for HLA-DRA. 11/14 (79%) patients with positive HLA-DR staining, had complete (n=3) or partial (n=8) response. 6/16 (38%) HLA-DR non-expressing melanomas responded to therapy (overall response rate 79 versus 38%, Fisher’s exact test P=0.033). This finding was confirmed in a second independent data set of 23 melanoma patients with 6/8 (75%) of HLA-DR(+) tumours in comparison to 4/15 (27%) HLA-DR(−) responding (Fisher’s exact test P=0.025). Preclinical models confirmed the result." ;
    a m2r:Evidence .

civice:986
    dct:references pbm:25853747 ;
    civico:citation "Treon et al., 2015, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Ibrutinib ;
    dcterms:description "A prospective study of ibrutinib in 63 symptomatic patients with Waldenström's macroglobulinemia who had received at least one previous treatment. The response rates were highest among patients with MYD88(L265P) and CXCR4(WT). The MYD88 L265P mutation was present in 56 patients (89%)." ;
    a m2r:Evidence .

civice:987
    dct:references pbm:26372703 ;
    civico:citation "Renaud et al., 2015, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Retrospective analysis of data from 841 patients who underwent surgery and molecular testing for NSCLC.  Mutant KRAS was observed in 265 (31.5%) cases and 90 of these were G12V. Patients with KRAS G12V exhibited worse OS and TTR compared with the entire cohort. These results were confirmed using multivariate analyses (non-G12V status, hazard ratio (HR): 0.43 (confidence interval: 0.28–0.65), P<0.0001 for OS. Risk of recurrence was significantly lower for non-KRAS G12V (HR: 0.01, (0.001–0.08), P<0.0001)." ;
    a m2r:Evidence .

civice:988
    dct:references pbm:25199829 ;
    civico:citation "Lamba et al., 2014, Cell Rep" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_RAF265,civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding could be reproduced in colorectal and lung cancer cell lines in a second, independent screen." ;
    a m2r:Evidence .

civice:989
    dct:references pbm:25199829 ;
    civico:citation "Lamba et al., 2014, Cell Rep" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_RAF265 ;
    dcterms:description "SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding was reproduced two NSCLC cell lines in a second, independent shRNA screen." ;
    a m2r:Evidence .

civice:990
    dct:references pbm:24915778 ;
    civico:citation "Infante et al., 2014, Eur. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or placebo. KRAS mutations were identified in 103 patients using cfDNA. There was no difference betweeen overall survival of KRAS Mutation-positive and -negative patients. Of note, evaluation of KRAS mutations from archival tissue from 71/143 patients identified 8 patients with mutant KRAS (wildtype by cfDNA) and 3 patients with wildtype KRAS (mutant by cfDNA)." ;
    a m2r:Evidence .

civice:991
    dct:references pbm:24685132 ;
    civico:citation "Sun et al., 2014, Cell Rep" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib,civic:drug_Afatinib ;
    dcterms:description "An shDNA Screen identified synergy betwenn ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib." ;
    a m2r:Evidence .

civice:992
    dct:references pbm:24685132 ;
    civico:citation "Sun et al., 2014, Cell Rep" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib,civic:drug_Afatinib ;
    dcterms:description "An shDNA screen identified synergy between ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib." ;
    a m2r:Evidence .

civice:993
    dct:references pbm:18946061 ;
    civico:citation "Karapetis et al., 2008, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "KRAS mutation status was assessed in 394 tumor samples from colorectal cancer patients who were randomly assigned to receive cetuximab plus best supportive care or best supportive care alone.   42% of the tumors evaluated had at least one mutation in exon 2. Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ras did benefit from cetuximab. The effectiveness of cetuximab was significantly associated with K-ras mutation status (P=0.01 for overall survival and P<0.001 for progression-free survival). In patients with wild-type K-ras tumors, treatment with cetuximab as compared with supportive care alone significantly improved overall survival. The related clinical trial ID is NCT00079066." ;
    a m2r:Evidence .

civice:994
    dct:references pbm:24947927 ;
    civico:citation "Zimmer et al., 2014, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_RO4987655 ;
    dcterms:description "Phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655. Partial response was observed in 4 of 17 patients with BRAF V600 mutated melanoma. 2 patients with prior vemurafenib treatment progressed under treatment." ;
    a m2r:Evidence .

civice:995
    dct:references pbm:24947927 ;
    civico:citation "Zimmer et al., 2014, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_RO4987655 ;
    dcterms:description "Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655. Among 12 patients with melanoma BRAF wild type and non-NRAS or NRAS unknown status, seven patients experienced partial response or stable disease." ;
    a m2r:Evidence .

civice:996
    dct:references pbm:24947927 ;
    civico:citation "Zimmer et al., 2014, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_RO4987655 ;
    dcterms:description "Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). Among 8 patients with NRAS mutated melanoma, 4 experienced SD or PR (1 Patient received study treatment for 323 days)." ;
    a m2r:Evidence .

civice:997
    dct:references pbm:24947927 ;
    civico:citation "Zimmer et al., 2014, Clin. Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_RO4987655 ;
    dcterms:description "Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). 2 PR and 8 SD among 18 patients with KRAS Mutant NSCLC." ;
    a m2r:Evidence .

civice:998
    dct:references pbm:24947927 ;
    civico:citation "Zimmer et al., 2014, Clin. Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_RO4987655 ;
    dcterms:description "Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). All 25 patients with KRAS mutant colorectal cancer experienced PD." ;
    a m2r:Evidence .

civice:999
    dct:references pbm:23200175 ;
    civico:citation "Jänne et al., 2013, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Docetaxel,civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "87 patients with KRAS mutant stage IIB-IV NSCLC after first line therapy were randomly assigned (1:1) to oral selumetunib and docetaxel or docetaxel and Placebo. Median OS was 9·4 months (6·8-13·6) in selumetinib group and 5·2 months (95% CI 3·8-non-calculable) in placebo group (hazard ratio [HR] for death 0·80, 80% CI 0·56-1·14; one-sided p=0·21). Median PFS was 5·3 months (4·6-6·4) in selumetinib group and 2·1 months (95% CI 1·4-3·7) in placebo group (HR for progression 0·58, 80% CI 0·42-0·79; one-sided p=0·014). An objective response was observed in 16 (37%) patients in the selumetinib group and none in the placebo group(p<0·0001)." ;
    a m2r:Evidence .

civice:1000
    dct:references pbm:23434733 ;
    civico:citation "Weekes et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_BAY86-9766 ;
    dcterms:description "Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 2 of 2 patients with BRAF mutant melanoma had moderate progressive disease (despite receiving the highest doses administered in the study)." ;
    a m2r:Evidence .

civice:1001
    dct:references pbm:23434733 ;
    civico:citation "Weekes et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_BAY86-9766 ;
    dcterms:description "Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 4 patients with KRAS +/- PIK3CA mutant colorectal cancer. 3 with SD, 1 with PD." ;
    a m2r:Evidence .

civice:1002
    dct:references pbm:26821351 ;
    civico:citation "Kiessling et al., 2016, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Everolimus,civic:drug_Binimetinib%28MEK162%29 ;
    dcterms:description "In-vitro study in 5 neuroblastoma cell lines (2 with NRAS Q61K mutation). The combination of mTOR and MEK Inhibitors synergistically blocked cell growth in NRAS mutant but not wild type cell lines. Single agent MEK inhibition (AZD6244/selumetinib, MEK162 or PD0325901) and single agent mTOR inhibition (Everolimus or AZD8055) also blocked cell growth in NRAS mutant cell lines, whereas single agent PI3K inhibitors or MEK Inhibitors in combination with PIK3CA/AKT inhibitors did not show synergistic effects." ;
    a m2r:Evidence .

civice:1003
    dct:references pbm:26725216 ;
    civico:citation "Hayes et al., 2016, Cancer Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_SCH772984,civic:drug_AZD8186 ;
    dcterms:description "Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either agent alone. Chemical library screen in two cell lines also identified mTOR, AKT Family Inhibitors (Temsirolimus, Everolimus) to act synergistically with ERK Inhibition." ;
    a m2r:Evidence .

civice:1004
    dct:references pbm:21985784 ;
    civico:citation "Ebi et al., 2011, J. Clin. Invest." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_R1507 ;
    dcterms:description "Preclinial data from KRAS mutant colorectal cancer cell lines show syngergistic effect on cell viability and apoptosis in vitro and in vivo when MEK and IGF-IR are inhibited concomitantly. In other cell lines, activation of other RTKs (such as MET) were observed upon MEK Inhibition and combination of RTKi and METi also showed synergistic activity. A total of 16 cell lines were used in this study. 6 were KRAS wild type, and 10 harbored various KRAS mutations (G12C, G12D, G12V, G13D, and Q61L). Additional data was obtained from xenografts." ;
    a m2r:Evidence .

civice:1005
    dct:references pbm:26678033 ;
    civico:citation "Penna et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_BEZ235%28NVP-BEZ235,civic:drug_Dactolisib%29 ;
    dcterms:description "49 BRAF-mutant melanoma cell lines from patients not previously treated with BRAF inhibition were analyzed. 21 exhibited primary resistance to BRAF inhibition using PLX4720. Inhibition of MEK1/2 (BEZ235) and PI3K/mTOR (AZD6244 [selumetinib]) was the most effective approach to counteract resistance in comparison to inhibition with the PLX4720-BEZ235 (where response was assessed by apoptosis, viability, p-ERK, p-Akt inhibition)." ;
    a m2r:Evidence .

civice:1006
    dct:references pbm:16091755 ;
    civico:citation "Xia et al., 2005, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib,civic:drug_Trastuzumab ;
    dcterms:description "In-vitro studies using ERBB2 over-expressing breast cancer cell lines BT474 and SKBR3 (with ERBB2 amplification) showed apoptosis under either labatinib or trastuzumab treatment.  A marked synergistic apoptotic effect under lapatinib and trastuzumab co-treatment was observed in BT474 cells, and a milder synergistic effect was observed in SKBR3 cells." ;
    a m2r:Evidence .

civice:1007
    dct:references pbm:22493419 ;
    civico:citation "Guarneri et al., 2012, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Lapatinib,civic:drug_Trastuzumab ;
    dcterms:description "In light of results showing increased PFS using mAB plus TKI in heavily pretreated patients, the efficacy of trastuzumab plus lapatinib in a neoadjuvant setting with untreated stage II or IIIA HER2 positive breast cancer was assessed.  In this randomized 3 arm phase II study (CHER-LOB), patients received (A) chemotherapy plus trastuzumab, (B) chemotherapy plus lapatinib, or (C) chemotherapy plus trastuzumab and lapatinib, with pathologic complete response (pCR) as endpoint.  From 121 patients, pCR rates were 25% in arm A, 26.3% in arm B, and 46.7% in arm C.  The authors conclude these results support the superiority of dual-HER2 inhibition in the neoadjuvant context of HER2 positive BC." ;
    a m2r:Evidence .

civice:1008
    dct:references pbm:26255196 ;
    civico:citation "Zardavas et al., 2015, Breast" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Lapatinib ;
    dcterms:description "This Phase III trial compared the activity of lapatinib vs. trastuzumab vs. sequential trastuzumab followed by lapatinib vs. lapatinib plus trastuzumab in an adjuvant treatment setting.  8381 women were randomized to one of four treatment arms. Patients had HER2 positive non-metastatic operable BC. The primary endpoint was disease free survival.  First results report that after median 4.5 year follow up, a non significant 16% improvement in DFS was seen in trastuzumab + lapatinib vs. trastuzumab alone.  The results are interpreted as showing no added benefit for labatinib addition to trastuzumab in the adjuvant treatment context.  This trial is ongoing but not recruiting patients (NCT00490139)." ;
    a m2r:Evidence .

civice:1009
    dct:references pbm:20124187 ;
    civico:citation "Blackwell et al., 2010, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Lapatinib,civic:drug_Trastuzumab ;
    dcterms:description "This Phase III study (EGF104900) was motivated by preclinical and other data demonstrating synergistic activity between lapatinib and trastuzumab against HER2 positive breast cancer (BC) cells.  In this study of HER2 positive metastatic BC which had progressed on trastuzumab, two arms were compared: lapatinib vs. lapatinib + trastuzumab. Progression free survival (PFS) was the primary endpoint. For 296 patients, 148 in each arm, median PFS of 8.1 weeks for lapatinib and 12.0 for combination therapy was observed (P=0.008).  The authors conclude that in the context of metastatic trastuzumab-progressed HER2 positive BC, trastuzumab with lapatinib TKI addition is a favorable treatment." ;
    a m2r:Evidence .

civice:1010
    dct:references pbm:22418700 ;
    civico:citation "Lin et al., 2012, Breast Cancer Res. Treat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "With multiple mechanisms of HER reprogramming thought to be behind trastuzumab resistance, including increased expression of ErbB members, afatinib, which broadly and irreversibly targets ErbB receptors was tested in a single arm phase II trial on advanced stage HER2 positive metastatic breast cancer. From 41 treated patients, 10% had partial response, 37% had stable disease as best response and 46% achieved clinical benefit.  Median progression free survival (PFS) was 15.1 weeks and median overall survival (OS) was 61.0 weeks. The authors conclude that Afatinib monotherapy shows promise in treatment of metastatic HER2 positive breast cancer that has progressed under trastuzumab." ;
    a m2r:Evidence .

civice:1011
    dct:references pbm:26596672 ;
    civico:citation "Cortés et al., 2015, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "This Phase II trial (LUX-Breast 3 - NCT01441596) compared afatinib, afatinib plus vinorelbine, or investigator's choice of treatment.  121 patients with HER2 overexpressing breast cancer with CNS recurrence or regression who had previously progressed on trastuzumab or lapatinib were assigned to 3 arms, with endpoint in the intention-to-treat population being patient benefit at 12 weeks defined as absence of CNS or extra CNS progression, no tumor related worsening of neurological symptoms and no increase in corticosteroid dose. Benefit was seen in 30% of 40 patients assigned to afatinib alone, 34.2% of 38 assigned to afatinib plus vinorelbine, and 41.9% of 43 assigned to investigator's treatment choice.  Differences were not statistically significant, and afatanib patients experienced more adverse effects.  While Afatanib did show response in HER2 breast cancer patients, it was not better than investigator's treatment choice and the investigators state that no further development of afatinib for HER2 breast cancer will be planned." ;
    a m2r:Evidence .

civice:1012
    dct:references pbm:26822398 ;
    civico:citation "Harbeck et al., 2016, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "LUX-Breast 1 is a phase 3 trial (NCT01125566) which enrolled 508 patients with metastatic HER2 positive BC who had progressed after adjuvant or first-line trastuzumab. It was thought that the wider range of ErbB family blocking and irreversible properties of afatinib could be beneficial in trastuzumab resistant cancer cells, since ErbB family members are thought to play a role in trastuzumab resistance. Primary endpoint was intention-to-treat group PFS. 339 patients were assigned to afatanib + vinorelbine and 169  to trastuzumab + vinorelbine.  Recruitment was stopped prematurely when it was deemed unlikely that the increased PFS would be seen in the afatinib group. Median PFS was 5.5 months in the afatinib group and 5.6 months in the trastuzumab group.  Afatanib plus vinorelbine was less well tolerated than trastuzumab plus vinorelbine, and the authors conclude that trastuzumab remains the best choice for treatment of trastuzumab-progressed HER2 positive metastatic BC." ;
    a m2r:Evidence .

civice:1013
    dct:references pbm:25370464 ;
    civico:citation "Ring et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Afatinib ;
    dcterms:description "Trastuzumab resistance is thought to consist of multiple compensatory mechanisms involving ErbB family members such as increased signaling through ErbB family heterodimers.  The irreversible TKI afatinib blocks EGFR, HER2, ErbB3 and ErbB4.  Thus afatinib was studied in this Phase I trial of trastuzumab-progressed HER2 positive metastatic BC (MBC) in combination with continued trastuzumab treatment, where trastuzumab is still the perferred treatment for trastuzumab-progressed MBC.  Objective response and disease control rates were 11% and 39%.  The authors conclude that the clinical activity observed in this trial warrants further work with afatinib and trastuzumab combination therapy." ;
    a m2r:Evidence .

civice:1014
    dct:references pbm:22077063 ;
    civico:citation "Rossi et al., 2012, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "NOTCH1 mutations were found to be associated with worse overall survival (3.77-fold increase in the hazard of death, P < .001) in a series of 309 newly diagnosed CLL and confirmed in an additional set of 230 patients. NOTCH1 mutations were mostly represented (26/34, 76.5%) by a recurrent 2-bp frameshift deletion (c.7544_7545delCT), with the remaining being other frameshift deletions or insertions." ;
    a m2r:Evidence .

civice:1015
    dct:references pbm:26256760 ;
    civico:citation "Pastore et al., 2015, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In advanced stage follicular lymphoma patients receiving rituximab + chemotherapy (R-CHOP or R-CVP), EZH2 mutations were associated with better failure free survival in patients with high-risk FLIPI scores compared to patients that were EZH2 wildtype with high-risk FLIPI scores." ;
    a m2r:Evidence .

civice:1016
    dct:references pbm:26510020 ;
    civico:citation "Mateo et al., 2015, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11, ATM, MLH3 and NBN genes and showed clinical response to PARP inhibitor olaparib (16 weeks on Treatment)." ;
    a m2r:Evidence .

civice:1017
    dct:references pbm:26778701 ;
    civico:citation "Nitta et al., 2016, Cancer Med" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nimotuzumab ;
    dcterms:description "Two human glioma cell lines (U87MG or LNZ308) overexpressing either wild-type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both in vitro. Anti-tumor effects of nimotuzumab were greater in EGFRvIII in comparison to EGFRwt (as measured by antitumor effects, growth suppression, survival elongation and EGFR and Akt phosphorylation). Combination of nimotuzumab and temozolomide further increased efficacy." ;
    a m2r:Evidence .

civice:1018
    dct:references pbm:26771088 ;
    civico:citation "Middeke et al., 2016, Br. J. Haematol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 97 patients with AML  treated with HSCT, 40 had TP53 mutations comprising a total of 44 mutations. Patients with a TP53 mutation had a reduced three year probability of overall survival and event-free survival compared to patients with the wild-type TP53." ;
    a m2r:Evidence .

civice:1019
    dct:references pbm:24162815 ;
    civico:citation "Vaishnavi et al., 2013, Nat. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lestaurtinib%28CEP-701%29,civic:drug_ARRY-470,civic:drug_Crizotinib ;
    dcterms:description "Two patients were found to harbor gene fusions maintaining the kinase domain of NTRK1 (3' partner), specifically: MPRIP-NTRK1 and CD74-NTRK1.  Both of these fusions lead to constitutive kinase activity and were found to be oncogenic. Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity (ARRY-470, CEP-701 and, to a lesser extent, crizotinib) inhibited autophosphorylation of TRKA and cell growth." ;
    a m2r:Evidence .

civice:1020
    dct:references pbm:26867820 ;
    civico:citation "Seligmann et al., 2016, JAMA Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as \"high expressor\" (either EREG or AREG mRNA level) or \"low expressor\" (neither EREG nor AREG in top tertile).  For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P < .001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P = .73; interaction test results were significant [P = .01]). Results were less clear for response rate (interaction P = .17) and OS (interaction P = .11)." ;
    a m2r:Evidence .

civice:1021
    dct:references pbm:26867820 ;
    civico:citation "Seligmann et al., 2016, JAMA Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as \"high expressor\" (either EREG or AREG mRNA level) or \"low expressor\" (neither EREG nor AREG in top tertile). For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P < .001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P = .73; interaction test results were significant [P = .01]). Results were less clear for response rate (interaction P = .17) and OS (interaction P = .11)." ;
    a m2r:Evidence .

civice:1022
    dct:references pbm:20728210 ;
    civico:citation "Bang et al., 2010, Lancet" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer." ;
    a m2r:Evidence .

civice:1023
    dct:references pbm:24868024 ;
    civico:citation "Satoh et al., 2014, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer.  Primary endpoint was Overall Survival (OS).  Participants had progressed under previous treatment and only a small percentage had seen first line trastuzumab.  Patients were a mix of those having undergone gastrectomy and not.  OS was not significantly  different in the ITT population, but certain subpopulations showed significant differences.  In the subset of patients showing a stronger immunohistochemistry result for HER2 (IHC3+), progression free survival was significantly different at 5.6 months for lapatinib + pacitaxel vs. 4.2 months for pacitaxel alone.  The authors conclude that proof of concept for lapatanib addition to chemotherapy for certain subgroups is provided in this study." ;
    a m2r:Evidence .

civice:1024
    dct:references pbm:18607592 ;
    civico:citation "Kalender et al., 2009, Cancer Chemother. Pharmacol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma. IHC was focally positive for CD117. Imatinib mesylate led to complete metabolic response (PET-CT)." ;
    a m2r:Evidence .

civice:1025
    dct:references pbm:16487996 ;
    civico:citation "Salvatierra et al., 2006, Gynecol. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "Case Report of a 41-year old patient with high-grade stromal endometrial sarcoma and a large abdominal and retroperitoneal mass progressing after chemotherapy. IHC for c-Kit was positive and treatment with imatinib led to an objective Response. Surgery was performed and the patient was free of disease two years later." ;
    a m2r:Evidence .

civice:1027
    dct:references pbm:22180162 ;
    civico:citation "Estey, 2012, Am. J. Hematol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The CBFB-MYH11 fusion has been shown to be associated with favorable prognosis in acute myeloid leukemia." ;
    a m2r:Evidence .

civice:1028
    dct:references pbm:15922892 ;
    civico:citation "Sidhu et al., 2005, Eur J Surg Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "TP53 mutation was shown to be associated with shorter overall survival in patients with adrenocortical tumors (log-rank test; P=0.098). Of 20 patients studied, 5 had coding mutation in TP53. Four of the 5 patients with a TP53 mutation had metastases at diagnosis or detected soon thereafter, and 3 of 4 died of disease within 12 months of surgical resection." ;
    a m2r:Evidence .

civice:1029
    dct:references pbm:19357394 ;
    civico:citation "Vardiman et al., 2009, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The MLL-MLLT3 translocation, along with other MLL translocations, are so common in acute myeloid leukemia that the World Health Organization has developed a sub-type of \"AML with t(9;11)(p22;q23); MLLT3-MLL\" under the AML with recurrent genetic abnormalities diagnosis." ;
    a m2r:Evidence .

civice:1030
    dct:references pbm:25667280 ;
    civico:citation "Mazières et al., 2015, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In a retrospective study, 30 patients were evaluated after crizotinib treatment for stage IV NSCLC confirmed for ROS1 rearrangement. On crizotinib, 24 of the patients achieved objective responses including 5 complete responses. Median progression free survival was 9.1 months and all patients had  been pretreated with 1 or more lines of chemotherapy." ;
    a m2r:Evidence .

civice:1031
    dct:references pbm:26872370 ;
    civico:citation "Wang et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The HIF1A rs2057482 SNP was genotyped in 410 pancreatic ductal adenocarcinoma cases and 490 healthy controls. The CC genotype was significantly correlated with PDAC risk (OR = 1.719, 95% CI: 1.293-2.286) and shorter overall survival (OS, P<0.0001), compared with the CT/TT alleles Group. After multivariate Analysis, CC-HIF1A and HIF-1α expression were still significantly associated with OS (P<0.0001).  This SNP is expected to reduce MiR-199a induced repression of HIF-1α Expression." ;
    a m2r:Evidence .

civice:1032
    dct:references pbm:20363910 ;
    civico:citation "Baba et al., 2010, Am. J. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "HIF1A overexpression was assessed by IHC in 731 colorectal cancers from two prospective cohort studies. 142 (19%) tumors showed HIF1A overexpression. Overexpression of HIF1A was associated with higher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univariate Cox regression (hazard ratio = 1.84; 95% confidence interval, 1.37 to 2.47; P < 0.0001) and multivariate analysis (adjusted hazard ratio = 1.72; 95% confidence interval, 1.26 to 2.36; P = 0.0007, adjusted for clinical and tumoral features: microsatellite instability, TP53 (p53), PTGS2 (cyclooxygenase-2), CpG island methylator phenotype, and KRAS, BRAF, PIK3CA, and LINE-1 methylation)." ;
    a m2r:Evidence .

civice:1033
    dct:references pbm:20363910 ;
    civico:citation "Baba et al., 2010, Am. J. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Expression of EPAS1 (HIF-2alpha) was assessed in 731 colorectal cancers from two prospective cohort studies. EPAS1 overexpression was found in 322 (46%) cancers by immunohistochemistry and not significantly associated with patient survival." ;
    a m2r:Evidence .

civice:1034
    dct:references pbm:17103226 ;
    civico:citation "Shintani et al., 2006, Virchows Arch." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Expression of HIF1A was analyzed by IHC in 49 soft-tissue sarcomas (29 malignant fibrous histiocytomas, 12 synovial sarcomas, 4 leiomyosarcomas and 4 malignant peripheral nerve sheath tumors). High (18.4%) or moderate (35.4%) expression of HIF-1alpha was significatnly associated with shorter overall survival rate in comparison with those with a weak or negative expression in univariate analysis (P = 0.029; log-rank test) and multivariate analysis (P = 0.018)." ;
    a m2r:Evidence .

civice:1035
    dct:references pbm:16341243 ;
    civico:citation "Thomas et al., 2006, Nat. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Temsirolimus ;
    dcterms:description "Preclinical studies linking the efficacy of mTOR inhibitor CCI-779 to VHL loss in vitro and in mouse models of kidney cancer. VHL-deficient tumors were more sensitive to mTOR inhibition than VHL-proficient tumors. Growth arrest caused by CCI-779 correlated with a block in translation of HIF1A mRNA. Expression of a VHL-resistant HIF1A cDNA lacking the 5' untranslated region rescued tumor growth." ;
    a m2r:Evidence .

civice:1036
    dct:references pbm:23430109 ;
    civico:citation "Smith et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Quizartinib%28AC220%29,civic:drug_Ponatinib ;
    dcterms:description "An in-vitro saturation mutagenesis screen of 50 independently derived FLT3-ITD clones was performed to identify mutations that confer resistance to ponatinib. Mutations at 3 AL residues (D835 [n = 31], D839 [n = 3], and Y842 [n = 16]), with varying degrees of resistance to ponatinib were identified. FLT3 D835 mutations were shown to confer resistance to the tyrosine kinase inhibitor AC220 and ponatinib.  This was especially found for D835Y and D835V mutations, whereas D835H mutations were found to confer moderate resistance to ponatinib but relatively minimal resistance to AC220." ;
    a m2r:Evidence .

civice:1037
    dct:references pbm:19318574 ;
    civico:citation "von Bubnoff et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_SU5614 ;
    dcterms:description "An in-vitro cell-based screening approach generated FLT3-ITD-expressing cell lines resistant to the FLT3 inhibitors SU5614, PKC412, and sorafenib. SU5614 resistance mutations were limited to exchanges in the second part of the kinase domain (TK2), with exchanges of D835 predominating (D835E were most common). In clones that emerged at 1,500 nmol/L SU5614 after ENU (mutagen) treatment, 127 of 179 clones (71%) displayed mutations, generating 9 different exchanges affecting 6 positions in the activation loop of FLT3." ;
    a m2r:Evidence .

civice:1038
    dct:references pbm:22504184 ;
    civico:citation "Smith et al., 2012, Nature" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sorafenib,civic:drug_Quizartinib%28AC220%29 ;
    dcterms:description "In an in-vitro study using an in vitro saturation mutagenesis assay, 4 residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. Mutations at three of these amino acid positions conferred high degrees of in vitro AC220 resistance (based on proliferation and cell-based biochemical assays). Among these residues, two within the activation loop were found (D835, Y842).  Pre-treatment and relapse samples of 8 patients (treated with AC220) with FLT3-ITD+ acute myeloid leukemia were analyzed. The activation loop mutation D835Y was detected in three cases, D835V in two, and D835F was identified in a single patient. Cross-resistance to sorafenib was identified in-vitro." ;
    a m2r:Evidence .

civice:1039
    dct:references pbm:22368270 ;
    civico:citation "Man et al., 2012, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients responded, but sorafenib response was lost in most patients after 72 (range 54-287) days. Leukemia initiating cells bearing the D835 mutation expanded during sorafenib treatment and dominated during the subsequent clinical resistance. Results were recapitulated in-vivo." ;
    a m2r:Evidence .

civice:1040
    dct:references pbm:22368270 ;
    civico:citation "Man et al., 2012, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients showed clearance or near clearance of bone marrow myeloblasts after 27 (range 21-84) days with evidence of differentiation of leukemia cells. Sorafenib response was lost in most patients after 72 (range 54-287) days." ;
    a m2r:Evidence .

civice:1041
    dct:references pbm:14679114 ;
    civico:citation "Gatzemeier et al., 2004, Ann. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "In this phase II trial with 2 arms, 103 patients with untreated stage IIIB/IV HER2 positive NSCLC were given gemcitabine-cisplatin with or without trastuzumab.  HER2 positivity was broadly defined as IHC2+/3+, positive by FISH, or increased circulating HER2 extracellular domain.  Significant differences between the treatment arms were not observed, but in a small subset of IHC3+/FISH positive patients, 5 of 6 responded to trastuzumab and had increased PFS of 8.5 months in comparison to 6.1 months in the IHC2+ group.  Although from 2004, this study remains cited in 2016 literature when discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC. The authors conclude that future studies of trastuzumab in HER2 positive NSCLC should focus on high expressing subjects." ;
    a m2r:Evidence .

civice:1042
    dct:references pbm:14967075 ;
    civico:citation "Lara et al., 2004, Clin Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "In this phase II trial a small group of patients with IHC2+ or IHC3+ HER2 NSCLC, in which primary platinum-based therapy had failed, were given either docetaxel or trastuzumab after which both groups were given docetaxel and trastuzumab together.  there was one partial response in the docetaxel group and none in the trastuzumab group.  The authors report that due to the limited clinical activity of trastuzumab-based therapy in this cohort, as well as similar results in other trastuzumab studies, that targets other than HER2 in NSCLC should be considered for future study.  This 2004 study remains cited in 2016 literature in discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC, but mutant HER2 in NSCLC has been further studied and a picture of different HER2 mutations being potentially responsive to specific targeted therapies is emerging." ;
    a m2r:Evidence .

civice:1043
    dct:references pbm:26598547 ;
    civico:citation "Mazières et al., 2016, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "This was a retrospective study of patients with advanced HER2-mutant NSCLC who had undergone varied courses of treatment.  All tumors were adenocarcinoma with in-frame HER2 exon 20 insertions.  In patients (n=57) that had been treated with trastuzumab plus chemotherapy, an overall response rate of 75% and progression free survival of 5.1 months were observed.  No standard of care currently exists for HER2-mutant NSCLC.  While trastuzumab has not shown clear benefit yet in wild-type HER2 overexpressed NSCLC, the authors conclude that further prospective studies should be done with trastuzumab plus chemotherapy in advanced HER2 mutant NSCLC, and that trastuzumab plus chemotherapy should be considered in current treatment courses of this cancer type." ;
    a m2r:Evidence .

civice:1044
    dct:references pbm:25601188 ;
    civico:citation "Kinehara et al., 2015, Lung Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Irinotecan ;
    dcterms:description "This report details 2 case studies in relapsed HER2 positive SCLC.  In the first case, a 50 pack-year patient showed intense non-mutant HER2 expression by IHC without DNA amplification, and had undergone multiple prior lines of treatment.  With induction of trastuzumab and irinotecan treatment, tumor regression was observed with progression free survival of 4.5 months.  Case 2 involved a 68 year old never-smoker with relapsed SCLC.  Tumor showed HER2 positive SCLC cells with no amplification or mutation.  Third line trastuzumab plus irinotecan brought about some symptom improvement and PFS of 3.5 months.  While the efficacy of trastuzumab against NSCLC with elevated levels of wild-type HER2 expression remains unclear, the authors conclude that trastuzumab based therapy is a promising strategy for chemo-resistant SCLC." ;
    a m2r:Evidence .

civice:1045
    dct:references pbm:26559459 ;
    civico:citation "Li et al., 2015, Lung Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "A 55 year old heavily pretreated patient with equivocal HER2 overexpression (IHC2+ and no amplification in FISH) was found to have the HER2 YMVA kinase domain insertion.  Afatinib monotherapy resulted in resolution of symptoms and 10 months before progressive disease.  The patient was subsequently given trastuzumab with no response.  The observed efficacy of afatinib against M774insAYVM, and studies reporting afatinib activity against other variants in the HER2 kinase domain, are cited by the authors as motivation for the arm of NCI-MATCH focusing on afatinib and activating HER2 mutations." ;
    a m2r:Evidence .

civice:1047
    dct:references pbm:19122144 ;
    civico:citation "Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Human HER2 with YVMA insertion was put under a clara cell specific, rtTA promoter system inducible via doxycycline.  Induction of mutant HER2 in these mice drove rapid development of adenosquamous lung tumors, where tumor maintenance was dependent on continued YMVA HER2 induction by doxycycline.  Administration of afatinib had a stronger effect than erlotinib or trastuzumab, as measured by histology and tumor volume regression.  Authors state that in the case of afatinib vs. trastuzumab, intracellular HER2 signaling may be blocked by afatanib but remain unaltered by trastuzumab." ;
    a m2r:Evidence .

civice:1048
    dct:references pbm:25899785 ;
    civico:citation "Kris et al., 2015, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dacomitinib ;
    dcterms:description "In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration between 3 and 14 months, while 13 patients with the more common HER2 p. A775_G776insYVMA showed no partial responses.  The authors conclude that in the set of activating HER2 mutations, benefits of an individual agent may be specific to certain mutations, and that \"HER2-positive lung cancers\" is not an adequate term to describe this group of distinguishable illnesses." ;
    a m2r:Evidence .

civice:1050
    dct:references pbm:24898067 ;
    civico:citation "Cretella et al., 2014, Mol. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_TrastuzumabEmtansine ;
    dcterms:description "Efficacy of trastuzumab in HER2 overexpressing NSCLC remains unclear.  In this study using a panel of NSCLC HER2 overexpressing cell lines, antiproliferative effects of trastuzumab emtansine (T-DM1) were observed in a HER2-expression dependant manner, with strongest effects in Calu-3 (high expressing) and no effects in Calu-6 (low expressing).  Trastuzumab did not show notable effects on cell growth in any tested cells.  HER2 positivity in NSCLC is fairly common at 2-20%.  A clinical trial (NCT02289833) is currently underway to asses TDM-1 in HER2 overexpressing lung cancer." ;
    a m2r:Evidence .

civice:1051
    dct:references pbm:26894977 ;
    civico:citation "Kwon et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Expression of 294 and 116 genes was enriched in good and poor prognosis subtypes, respectively. Of these genes, upregulation of proteasome subunit beta type 8 PSMB8 and PDZ binding kinase PBK was confirmed by real-time reverse transcription-PCR Analysis. IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival durations of the (-), (+), and (++) groups, classified according to nuclear PSMB8 expression, were 77.2, 70.6, and 62.2 months, respectively; P = 0.004). Cytoplasmic staining of PSMB8 and PBK were not statistically significant. In multivariate Analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively)." ;
    a m2r:Evidence .

civice:1052
    dct:references pbm:26894977 ;
    civico:citation "Kwon et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Upregulation of proteasome subunit beta type 8 (PSMB8) and PDZ binding kinase (PBK) was confirmed by real-time reverse transcription-PCR Analysis. IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival duration, months according to nuclear PBK Expression: -, 72.3 ± 1.2; +, 66.2 ± 3.4; ++, 53.1 ± 9.2; P = 0.002). Cytoplasmic staining of PSMB8 and PBK were not statistically significant. In multivariate analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively)." ;
    a m2r:Evidence .

civice:1053
    dct:references pbm:26894859 ;
    civico:citation "Schmidt et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "144 cases (discovery set: N=62 discovery; independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing, or WHO grade III). Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M). Unsupervised transcriptomic analysis in 62 meningiomas revealed a large set of differentially expressed genes in aggressive subgroups (R+M tumors and WHO grade III, n=332; p<0.01, FC>1.25). Multivariate analysis identified PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection. The patient group with the longest progression free survival was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression. IHC in 36 tumors validated these results at the protein level." ;
    a m2r:Evidence .

civice:1054
    dct:references pbm:26894859 ;
    civico:citation "Schmidt et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "144 cases (discovery set: N=62 discovery; Independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing or WHO grade III). Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M). Unsupervised transcriptomic analysis in 62 meningiomas revealed a large set of differentially expressed genes in aggressive subgroups (R+M tumors and WHO grade III, n=332; p<0.01, FC>1.25). Multivariate analysis identified PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection. The patient group with the longest PFS was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression. IHC in 36 tumors validated these results on protein level." ;
    a m2r:Evidence .

civice:1055
    dct:references pbm:26894620 ;
    civico:citation "Bauer et al., 2016, Mol. Carcinog." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "E" ;
    dcterms:description "Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg deficiency would reduce lung tumor promotion in mice. Cancerogenesis with chemical initiators/promoters (3-methylcholanthrene or control, butylated hydroxytoluene) was assessed in mice lacking Ereg (Ereg-/-) and wildtype controls (BALB/ByJ; Ereg+/+) at multiple time points and endpoints (bronchoalveolar lavage analysis, tumor analysis, mRNA expression, ELISA, wound assay). Initially a significantly reduced amount of inflammation (macrophages, PMNs) was observed in the Ereg-/- mice. At 20 wk, tumor multiplicity was also significantly decreased in the Ereg-/- mice." ;
    a m2r:Evidence .

civice:1057
    dct:references pbm:26888827 ;
    civico:citation "Sánchez-Martín et al., 2016, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Sym004 ;
    dcterms:description "An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 treatment. Subsequent treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines." ;
    a m2r:Evidence .

civice:1058
    dct:references pbm:26888827 ;
    civico:citation "Sánchez-Martín et al., 2016, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab,civic:drug_Cetuximab ;
    dcterms:description "An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 treatment. Treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. Sym004 is a 1:1 mixture of two non-overlapping anti-EGFR monoclonal antibodies. In vitro analysis in the murine fibroblast cell line NIH3T3 with ectopic expression of EGFR mutations S492R, R451C, K467T, and G465R showed that Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines. G465R mutant cell lines were resistant to treatment with panitumumab or cetuximab in-vitro." ;
    a m2r:Evidence .

civice:1059
    dct:references pbm:26893853 ;
    civico:citation "Li et al., 2016, Mol Clin Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "IHC was performed in 123 hepatocellular carcinoma tissues and their adjacent normal liver tissues for protein expression of HEF1 (NEDD9). Overexpression of HEF1 protein was observed in HCC tissue when compared with their adjacent non-malignant liver tissue. High expression of HEF1 correlated with higher advanced tumor, node, metastasis (TNM) stage and vascular invasion (P<0.05). In univariate and multivariate analysis, the expression of HEF1 was identified as an independent prognostic factor (Spearman's rank correlation, Kaplan-Meier plots and Cox regression model). In subgroup analysis, high expression of HEF1 correlated with a poorer prognosis in advanced (TNM III+IV) stages (P<0.05)." ;
    a m2r:Evidence .

civice:1060
    dct:references pbm:26893365 ;
    civico:citation "Hong et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Paclitaxel,civic:drug_Cisplatin ;
    dcterms:description "Eighty SNPs in miRNA binding sites of cancer related genes selected from 18,500 miRNA:target bindings in crosslinking, ligation, and sequencing of hybrids (CLASH) data were investigated in 379 advanced NSCLC patients using a sequenom mass spectrometry-based genotype assay. 16 SNPs were significantly associated with the clinical outcomes after chemotherapy with paclitaxel-cisplatin: ETS2 SNP: OR = 1.34, 95% CI = 1.00–1.81, P = 0.05; aHR = 0.80, 95% CI = 0.69–0.94, P = 0.006, under additive model. ETS2 rs461155A>G was significantly associated with decreased ETS2 mRNA expression in both tumor and paired normal lung tissues (Ptrend = 4 × 10-7, and 3 × 10-4, respectively)." ;
    a m2r:Evidence .

civice:1061
    dct:references pbm:26892177 ;
    civico:citation "Yin et al., 2016, Int. J. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "D" ;
    dcterms:description "Comparison of nuclear matrix protein (NMP) patterns of paclitaxel-resistant PCa cells (DU145-TxR), with that of parental cell (DU145) using two-dimensional electrophoresis, identified cytokeratin 18 (CK18) as downregulated in DU145-TxR cells (validated at mRNA, NMP and total cellular protein levels). An in-vivo assay of xenograft transplantation showed higher tumorigenicity of DU145-TxR cells. Immunohistochemistry showed that CK18 expression in PCa tissues was statistically significant inversely correlated with tumor grade." ;
    a m2r:Evidence .

civice:1062
    dct:references pbm:26891277 ;
    civico:citation "Yu et al., 2016, Int. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "243 primary PCa, 37 metastatic PCa, and  20  castration-resistant  PCa  (CRPC) specimens underwent IHC and microarray analysis. Immunohistochemistry (IHC) showed that FGF13 was detectable in the majority of human PCa samples, and FGF13 IHC scores were higher in high-grade prostatic intraepithelial neoplasia, in primary PCa, and in metastatic PCa than in benign prostatic tissue. There was a significant association between high cytoplasmic FGF13 staining and a risk of biochemical recurrence (BCR) after radical prostatectomy. Multivariate regression analysis indicated that high cytoplasmic FGF13 staining was associated with BCR. Results were recapitulated in cell lines and public databases." ;
    a m2r:Evidence .

civice:1063
    dct:references pbm:11607825 ;
    civico:citation "Ladanyi, 2001, Oncogene" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "A t(X;18) translocation resulting in the fusion SYT-SSX (SS18-SSX1 or SS18-SSX2) is detected cytogenetically in over 90% of synovial sarcomas, regardless of histologic subtype. The prevalence of this fusion in synovial sarcoma approaches 100% when there is adequate tumor RNA for RT-PCR. Its specificity for synovial sarcoma, has been confirmed by molecular screening of other morphologically similar sarcomas." ;
    a m2r:Evidence .

civice:1064
    dct:references pbm:11607825 ;
    civico:citation "Ladanyi, 2001, Oncogene" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "A t(X;18) is detected cytogenetically in over 90% of synovial sarcomas, regardless of histologic subtype. This translocation results primarily in two fusions. SYT-SSX1 (aka SS18-SSX1) and SYT-SSX2 (aka SS18-SSX2). The ratio of SYT-SSX1 to SYT-SSX2 cases is close to 2:1." ;
    a m2r:Evidence .

civice:1065
    dct:references pbm:9428816 ;
    civico:citation "Kawai et al., 1998, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. SYT (aka SS18) pairs with various 3' partners know as SSX (especially SSX1, and SSX2). In this study, 45 synovial sarcomas were assayed for SYT-SSX by RT-PCR using tumor cDNA as template. 29 (64%) had a SYT–SSX1 (SS18-SSX1) fusion transcript." ;
    a m2r:Evidence .

civice:1066
    dct:references pbm:9428816 ;
    civico:citation "Kawai et al., 1998, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. SYT (aka SS18) pairs with various 3' partners know as SSX (especially SSX1, and SSX2). In this study, 45 synovial sarcomas were assayed for SYT-SSX by RT-PCR using tumor cDNA as template. 16 (36%) contained a SYT–SSX2 (SS18-SSX2) fusion transcript." ;
    a m2r:Evidence .

civice:1067
    dct:references pbm:9428816 ;
    civico:citation "Kawai et al., 1998, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively. There was a significant relationship (P=0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had a SYT-SSX1 fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic. Kaplan-Meier analysis of 39 patients with localized tumors showed that the 15 patients with SYT-SSX2 had significantly better metastasis-free survival than the 24 patients with SYT-SSX1 (P=0.03 by multivariate analysis; relative risk, 3.0)." ;
    a m2r:Evidence .

civice:1068
    dct:references pbm:9428816 ;
    civico:citation "Kawai et al., 1998, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively. There was a significant relationship (P=0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had a SYT-SSX1 fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic. Kaplan-Meier analysis of 39 patients with localized tumors showed that the 15 patients with SYT-SSX2 had significantly better metastasis-free survival than the 24 patients with SYT-SSX1 (P=0.03 by multivariate analysis; relative risk, 3.0)." ;
    a m2r:Evidence .

civice:1069
    dct:references pbm:11122430 ;
    civico:citation "Pfeifer et al., 2000, Histopathology" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this review, the author summarize the role of this fusion in diagnosis of synovial sarcomas. Cytogenetic studies have repeatedly demonstrated the t(X;18)(p11;q11) translocation in approximately 90% of both monophasic and biphasic synovial sarcomas. The fusion has clear diagnostic value, though the authors caution that it is not perfectly specific to synovial sarcomas, and suggest that demonstration of t(X;18) in a spindle cell neoplasm should be integrated with the morphology, immunoprofile, and clinical setting of the tumour." ;
    a m2r:Evidence .

civice:1070
    dct:references pbm:11144931 ;
    civico:citation "O'Sullivan et al., 2000, Mod. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study, 141 spindle cell sarcomas were evaluated for the presence of t(X;18) by RT-PCR. 85% of the synovial sarcomas were positive for this event. The study did not indicate the specific fusion detected but from related studies we know that the majority of these fusions are SYT-SSX1 (aka SS18-SSX1)." ;
    a m2r:Evidence .

civice:1071
    dct:references pbm:11144931 ;
    civico:citation "O'Sullivan et al., 2000, Mod. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study, 141 spindle cell sarcomas were evaluated for the presence of t(X;18) by RT-PCR. 75% of the malignant peripheral nerve sheath tumors (MPNSTs) were positive for this event. The study did not indicate the specific fusion detected but from related studies we know that the majority of these fusions are SYT-SSX1 (aka SS18-SSX1)." ;
    a m2r:Evidence .

civice:1072
    dct:references pbm:11782370 ;
    civico:citation "Ladanyi et al., 2002, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma. SYT-SSX1 and SYT-SSX2 fusions were detected in 147 tumors (61%) and 91 tumors (37%), respectively. Histologically, 61 (25%) were classified as biphasic type and 180 (74%) as monophasic type based on the presence or absence of areas of glandular epithelial differentiation, respectively. Median and 5-year overall survivals for the SYT-SSX1 and SYT-SSX2 groups were 6.1 years and 53%, and 13.7 years and 73%, respectively." ;
    a m2r:Evidence .

civice:1073
    dct:references pbm:11782370 ;
    civico:citation "Ladanyi et al., 2002, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma. SYT-SSX1 and SYT-SSX2 fusions were detected in 147 tumors (61%) and 91 tumors (37%), respectively. Histologically, 61 (25%) were classified as biphasic type and 180 (74%) as monophasic type based on the presence or absence of areas of glandular epithelial differentiation, respectively. Median and 5-year overall survivals for the SYT-SSX1 and SYT-SSX2 groups were 6.1 years and 53%, and 13.7 years and 73%, respectively." ;
    a m2r:Evidence .

civice:1074
    dct:references pbm:10359553 ;
    civico:citation "Skytting et al., 1999, J. Natl. Cancer Inst." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Three synovial sarcomas were assayed for SYT-SSX fusion messenger RNA by nested RT-PCR. In a single case an SYT-SSX4 (SS18-SSX4) fusion was detected. The majority of synovial sarcomas are characterized by SS18-SSX1 or SS18-SSX2, but other rare events such as this SS18-SSX4 may explain some or all of the synovial sarcomas that are negative for the most common fusions." ;
    a m2r:Evidence .

civice:1075
    dct:references pbm:22906996 ;
    civico:citation "Kim et al., 2012, Oncology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 G2677T carriers had a longer progression-free survival (p = 0.037) along with a tendency toward a longer overall survival (p = 0.057)." ;
    a m2r:Evidence .

civice:1076
    dct:references pbm:22906996 ;
    civico:citation "Kim et al., 2012, Oncology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 C3435T carriers had a longer progression-free survival (p = 0.039) along with a tendency toward a longer overall survival (p = 0.093)." ;
    a m2r:Evidence .

civice:1077
    dct:references pbm:25693012 ;
    civico:citation "Swain et al., 2015, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pertuzumab,civic:drug_Trastuzumab,civic:drug_Docetaxel ;
    dcterms:description "CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer.  Patients were HER2-positive by IHC3+ or FISH, and patients who had received prior hormonal treatment or adjuvant/neo-adjuvant therapy with or without trastuzumab for longer than 12 months before randomization were also eligible.  The two arms of the study were trastuzumab and docetaxel with either placebo or pertuzumab.  Median PFS in the placebo arm was 12.4 months while in the petuzumab arm 18.5 months was achieved.  Median OS in the control arm was 40.8 months and 56.5 months with pertuzumab.  These strong results make a case for dual antibody blockade in first line treatments of HER2-positive metastatic breast cancer." ;
    a m2r:Evidence .

civice:1078
    dct:references pbm:22270724 ;
    civico:citation "Montagut et al., 2012, Nat. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "Tumor sequencing in pre- and post-therapy specimens from ten individuals with mCRC who experienced disease progression after a prior response to cetuximab with chemotherapy was performed. The S492R mutation was identified in two persons. One of them had already died, the other received treatment with panitumumab and had a partial response (50% tumor reduction in all liver lesions) for 5 months." ;
    a m2r:Evidence .

civice:1079
    dct:references pbm:26888827 ;
    civico:citation "Sánchez-Martín et al., 2016, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Sym004,civic:drug_Panitumumab ;
    dcterms:description "In this preclinical study of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling." ;
    a m2r:Evidence .

civice:1080
    dct:references pbm:26888827 ;
    civico:citation "Sánchez-Martín et al., 2016, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In this preclinical study of the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling." ;
    a m2r:Evidence .

civice:1081
    dct:references pbm:26888827 ;
    civico:citation "Sánchez-Martín et al., 2016, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab,civic:drug_Sym004 ;
    dcterms:description "In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The R451C mutation showed moderate drug-receptor binding with sym004, cetuximab and panitumumab treatment and inhibition of EGFR phosphorylation." ;
    a m2r:Evidence .

civice:1082
    dct:references pbm:26888827 ;
    civico:citation "Sánchez-Martín et al., 2016, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Panitumumab,civic:drug_Sym004 ;
    dcterms:description "In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor." ;
    a m2r:Evidence .

civice:1083
    dct:references pbm:26888827 ;
    civico:citation "Sánchez-Martín et al., 2016, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor." ;
    a m2r:Evidence .

civice:1084
    dct:references pbm:22906996 ;
    civico:citation "Kim et al., 2012, Oncology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR2A H131R carriers did not have a significantly different response rate, progression-free survival, or overall survival." ;
    a m2r:Evidence .

civice:1085
    dct:references pbm:22906996 ;
    civico:citation "Kim et al., 2012, Oncology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR3A V158F carriers did not have a significantly different response rate, progression-free survival, or overall survival." ;
    a m2r:Evidence .

civice:1086
    dct:references pbm:24989892 ;
    civico:citation "Norton et al., 2014, Cancer Immunol Res" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was a difference in disease-free survival for FCGR2B I232T, with I/I patients deriving benefit from trastuzumab (p<0.001) compared to the T carriers who did not (p=0.81). The interaction between FCGR2B genotype and treatment was statistically significant (p=0.03)." ;
    a m2r:Evidence .

civice:1087
    dct:references pbm:24989892 ;
    civico:citation "Norton et al., 2014, Cancer Immunol Res" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistically significant difference in disease-free survival between trastuzumab-treated patients who had the FCGR3A 158 V/V high-affinity genotype and patients without that genotype (V/F and F/F)." ;
    a m2r:Evidence .

civice:1088
    dct:references pbm:24989892 ;
    civico:citation "Norton et al., 2014, Cancer Immunol Res" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between trastuzumab-treated patients who had the FCGR2A 131 H/H high-affinity genotype and patients without that genotype." ;
    a m2r:Evidence .

civice:1089
    dct:references pbm:24934779 ;
    civico:citation "Ganesan et al., 2016, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rapamycin%28Sirolimus%29,civic:drug_Cetuximab ;
    dcterms:description "72-year old male patient presents with SCC with a mutation profile consistent with UV exposure. Sequencing revealed a number of abnormalities including P753S mutation in EGFR. Patient began therapy with cetuximab and sirolimus and continued for 9 months. Disease burden was not measurable by Response Evaluation Criteria in Solid Tumors." ;
    a m2r:Evidence .

civice:1090
    dct:references pbm:7628753 ;
    civico:citation "Diverio et al., Haematologica" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The presence of the PML-RARa fusion protein is a diagnostic marker of Acute Promyelocytic Leukemia, or M3 AML." ;
    a m2r:Evidence .

civice:1091
    dct:references pbm:11704842 ;
    civico:citation "Degos et al., 2001, Oncogene" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_ArsenicTrioxide,civic:drug_All-transRetinoicAcid ;
    dcterms:description "ATRA/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion." ;
    a m2r:Evidence .

civice:1092
    dct:references pbm:23670176 ;
    civico:citation "Tomita et al., 2013, Int. J. Hematol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_All-transRetinoicAcid ;
    dcterms:description "Mutations in the B2 domain of PML in the PML-RARa fusion have been shown to be associated with resistance to standard ATRA treatment in patients with acute promyelocytic leukemia." ;
    a m2r:Evidence .

civice:1093
    dct:references pbm:21613260 ;
    civico:citation "Goto et al., 2011, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_All-transRetinoicAcid ;
    dcterms:description "The mutation A216V in the B2 domain of PML in the PML-RARa fusion was seen in a patient with ATRA-resistant acute promyelocytic leukemia." ;
    a m2r:Evidence .

civice:1094
    dct:references pbm:21613260 ;
    civico:citation "Goto et al., 2011, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_All-transRetinoicAcid ;
    dcterms:description "The PML L218P mutation in the PML-RARa fusion was observed in a patient with previously ATRA-treated, relapsed acute promyelocytic leukemia refractory to arsenic trioxide." ;
    a m2r:Evidence .

civice:1095
    dct:references pbm:26729443 ;
    civico:citation "Awad et al., 2016, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "64-year old female (non-smoker) was diagnosed with NSCLC. A c.3028 G->A mutation was identified in exon 14 resulting in exon 14 skipping. Further, amplification of the MET gene was observed. The patient was given crizotinib and CT scans showed a positive response after 8 weeks of treatment." ;
    a m2r:Evidence .

civice:1096
    dct:references pbm:15746676 ;
    civico:citation "Santin et al., 2005, Am. J. Obstet. Gynecol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient information.  Earlier deaths were seen with heavier HER2 expression.  Multivariate Cox regression indicated that shorter survival was associated with higher HER2 expression, and not with age or ethnicity, and that observed differences in survival rates between ethnicities can be ascribed to higher rates of HER2 overexpression in African American patients.  The authors conclude that high HER2 expression in USPC is associated with poor outcome and explains observed differences in outcome between ethnicities." ;
    a m2r:Evidence .

civice:1097
    dct:references pbm:18555254 ;
    civico:citation "Santin et al., 2008, Int J Gynaecol Obstet" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer.  HER2 overexpression in USPC is more common in African American women.  This report covered 2 African American patients, the first of which presented high-grade endometrial adenocarcinoma with IHC3+ HER2-positivity as well as positivity by FISH.  Prior treatment involved surgery and chemotherapy.  Treatment with pacitaxel/carboplatin with trastuzumab showed clear clinical improvement assessed by CT scan and drop in CA-125 levels from 988 to 7.9 U/mL.  The second patient had USPC, and was treated with surgery and radiation.  Trastuzumab monotheraby was then administered.  After 7 months of treatment, the patient showed no sign of disease progression and CA-125 had dropped from 144 to 41 U/mL.  The investigators conclude there is promise in trastuzumab-based therapies in advanced endometrial cancers, including USPC." ;
    a m2r:Evidence .

civice:1098
    dct:references pbm:19840887 ;
    civico:citation "Fleming et al., 2010, Gynecol. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "This phase II single arm study assessed trastuzumab monotherapy in HER2 positive endometrial cancers with tumor response as primary endpoint.  Participants had stage III, IV or recurrent HER2 positive endometrial cancer.  During the trial's initial phase, 23 of 132 patients screened met the criteria of IHC2+ or 3+ or FISH positivity for HER2 status.  In the absence of results, the trial entered phase B, where only patients with HER2 amplification by FISH were admitted.  The trial ended early due to poor accrual with 11 of 154 screened meeting the phase B criteria. No major objective tumor responses were observed in the study.  28% of the cancers were of the serous type that had shown trastuzumab response in case studies.  The investigators note that in other HER2 cancers, such as breast and gastrointestinal, trastuzumab in combination with chemotherapy has been found most effective, and could warrant more study.  Currently a clinical trial (NCT01367002) is evaluating carboplatin/paclitaxel with or without trastuzumab in uterine serous cancer." ;
    a m2r:Evidence .

civice:1099
    dct:references pbm:22550175 ;
    civico:citation "Lee et al., 2012, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Saridegib ;
    dcterms:description "Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation." ;
    a m2r:Evidence .

civice:1100
    dct:references pbm:23724914 ;
    civico:citation "Awad et al., 2013, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. An acquired G2032R mutation in the ROS1 kinase domain was observed in the resistant tumor, and was found to confer resistance to ROS1 kinase inhibition through steric interference with drug binding." ;
    a m2r:Evidence .

civice:1101
    dct:references pbm:25351743 ;
    civico:citation "Katayama et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cabozantinib ;
    dcterms:description "Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1. It effectively inhibited the survival of CD74-ROS1 wild-type (WT) and resistant mutants harboring Ba/F3 and MGH047 cells. Furthermore, cabozantinib could overcome all the resistance by all newly identified secondary mutations." ;
    a m2r:Evidence .

civice:1102
    dct:references pbm:26789727 ;
    civico:citation "Ivey et al., 2016, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Peripheral blood from NPM1 mutated AMLs was assessed for NPM1 mutation status at multiple time points using RT-qPCR with primers designed to amplify different mutant NPM1 transcripts. The test development cohort consisted of 194 cases and an independent validation cohort consisted of 91 cases. Persistence of NPM1-mutated transcripts in blood was present in 15% of the patients after the second chemotherapy cycle. This persistence was associated with a greater risk of relapse after 3 years of follow-up than was an absence of such transcripts (82% vs. 30%; hazard ratio, 4.80; 95% confidence interval [CI], 2.95 to 7.80; P<0.001) and a lower rate of survival (24% vs. 75%; hazard ratio for death, 4.38; 95% CI, 2.57 to 7.47; P<0.001). The presence of minimal residual disease was the only independent prognostic factor for death in multivariate analysis (hazard ratio, 4.84; 95% CI, 2.57 to 9.15; P<0.001). On sequential monitoring of minimal residual disease, relapse was reliably predicted by a rising level of NPM1-mutated transcripts." ;
    a m2r:Evidence .

civice:1103
    dct:references pbm:26167872 ;
    civico:citation "Grebien et al., 2015, Nat. Chem. Biol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_OICR-9429 ;
    dcterms:description "This preclinical study establishes that the p30 isoform of CEBPA expressed as a result of N-terminal truncating mutations preferentially interacts with WRD5, a component of the SET/MLL complex. Knockdown of WRD5 in 32D cells (mouse hematopoietic cell line) or transplanted primary mouse bone marrow expressing the p30 isoform restored myeloid differentiation in these cells. OICR-9429, a small molecule inhibitor of WRD5, and anti-WRD5 siRNAs selectively inhibited colony formation of mouse fetal liver cells homozygous for N-terminal CEBPA mutations but not wildtype colony formation. Finally, OICR-9429 reduced viability of primary human AML blasts harboring N-terminal domain CEBPA mutations in culture but not AML blasts with other mutations. Taken together, WRD5 inhibition is a potential therapeutic method for patients harboring N-terminal CEBPA mutations." ;
    a m2r:Evidence .

civice:1104
    dct:references pbm:15448205 ;
    civico:citation "Chen et al., 2004, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Midostaurin ;
    dcterms:description "A t(8;13)(p11;q12) patient with ZNF198-FGFR1-induced progressive myeloproliferative disorder was treated with PKC412. Radiographic studies performed 3 months after initiation of therapy revealed marked improvement of her cervical, mediastinal, and retroperitoneal lymphadenopathy, and marked regression of splenomegaly to normal size." ;
    a m2r:Evidence .

civice:1105
    dct:references pbm:20179196 ;
    civico:citation "Turner et al., 2010, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_4-hydroxytamoxifen ;
    dcterms:description "FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1." ;
    a m2r:Evidence .

civice:1106
    dct:references pbm:19723655 ;
    civico:citation "Antonescu et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Sunitinib,civic:drug_Sorafenib ;
    dcterms:description "COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or A1065T-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib." ;
    a m2r:Evidence .

civice:1107
    dct:references pbm:19723655 ;
    civico:citation "Antonescu et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Sorafenib,civic:drug_Sunitinib ;
    dcterms:description "COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or D717V-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib." ;
    a m2r:Evidence .

civice:1108
    dct:references pbm:25295501 ;
    civico:citation "Wagle et al., 2014, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months." ;
    a m2r:Evidence .

civice:1109
    dct:references pbm:21461300 ;
    civico:citation "Hong et al., 2011, Korean J Hematol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 53 APL patients treated with combination ATRA/anthracycline chemotherapy, patients with the FLT3 ITD mutation (n=10) had higher rates of relapse (30% vs. 2.5%), lower rates of remission (70% vs 87.5%), and lower 3-year Leukemia-Free Survival (44.4% vs. 84.4%)." ;
    a m2r:Evidence .

civice:1110
    dct:references pbm:25295501 ;
    civico:citation "Wagle et al., 2014, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months, after which time resistance developed. The resistant tumor had a somatic mutation in MTOR (F2108L), that was not detected in the pretreatment tumor." ;
    a m2r:Evidence .

civice:1111
    dct:references pbm:25445424 ;
    civico:citation "Baker et al., 2015, Clin. Breast Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A healthy, 36-year-old woman presented with a palpable right breast mass upon biopsy determined to be high-grade, triple negative invasive ductal carcinoma. Her family history was notable for multiple relatives on her maternal side with breast cancer, including a distant male relative with breast cancer. Multigene panel testing with an 18-gene panel revealed a germline truncating pathogenic mutation in RAD51D (p.R186X; c. 556C>T)." ;
    a m2r:Evidence .

civice:1112
    dct:references pbm:24981688 ;
    civico:citation "Lucena-Araujo et al., 2014, Ann. Hematol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_All-transRetinoicAcid,civic:drug_Anthracycline ;
    dcterms:description "In a study of 171 APL patients treated with combination ATRA/anthracycline chemotherapy, FLT3 ITD mutations (n=35) were associated with lower 3-year OS compared to the FLT3 ITD-negative group (62% vs. 82%), as well as higher CR achievement failure and early death." ;
    a m2r:Evidence .

civice:1113
    dct:references pbm:26874901 ;
    civico:citation "Chan et al., 2016, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "In this two arm, Phase III study (NCT00878709) of the efficacy of a 12 month course of the TKI neratinib after trastuzumab-based adjuvant therapy of early stage HER2-positive breast cancer was assessed using invasive disease-free survival as primary endpoint.  HER2 positivity was assessed via FISH.  At 2 year follow-up, 70 vs. 109 disease-free survival events had occurred and disease-free survival rates were 93.9% vs. 91.6% (significant) in neratinib vs. placebo groups respectively.  Distant disease-free survival and time to distant recurrence were similar in both groups.  These results are an interesting contrast to results of long-term adjuvant therapy with trastuzumab (HERA) which did not show significant benefit." ;
    a m2r:Evidence .

civice:1114
    dct:references pbm:26634247 ;
    civico:citation "Seidensaal et al., 2015, Mol. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "IHC for expression of ALDH1A2 and CRABP2 was performed in 89 patients with squamous cell carcinoma of the head and neck. High expression of both, ALDH1A2 and CRABP2 (in comparison to ALDH1A2 low or ALDH1A2 high and CRABP2 low) was significantly associated with OS and PFS in multivariate Cox analysis (OS, HR: 0.303, 95%CI 0.14–0.63, p-value 0.002 PFS, HR: 0.395, 95%CI 0.20–0.77, p-value 0.007)." ;
    a m2r:Evidence .

civice:1115
    dct:references pbm:26634247 ;
    civico:citation "Seidensaal et al., 2015, Mol. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_All-transRetinoicAcid ;
    dcterms:description "FaDu (a high ALDH1A2 expression cell line) and Cal27 (a low expression cell line) were treated with all-trans retinoic acid (ATRA), Adapalene or Fenretinide. This led to concentration dependent decrease in the survival fraction in both cell lines with higher efficacy in Cal27 (ED50 ≈ 1 μM) as compared to FaDu cells (ED ≈ 44 μM). Treatment with 3 μM ATRA sensitized Cal27 cells to irradiation at a dose of 2 Gy, but had no or only a minor effect on ALDH1A2-postitive cells." ;
    a m2r:Evidence .

civice:1116
    dct:references pbm:23635773 ;
    civico:citation "Kostareli et al., 2013, J. Clin. Invest." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "ALDH1A2 protein levels were determined (IHC) in 115 patients with oropharyngeal squamous cell carcinoma with known HPV status (n = 89 non–HPV-driven; n = 26 HPV-driven). Low to moderate ALDH1A2 protein levels (combined as ALDH1A2low) were identified in keratinocytes of healthy mucosa as well as 73 (63.5%) primary tumors, and high ALDH1A2 protein levels in 42 (36.5%) primary tumors. Significantly higher ALDH1A2 protein levels were identified in HPV-driven than non-HPV-driven tumors. Moreover, PFS and OS strongly correlated with the ALDH1A2 protein expression level (OS, P < 0.001; PFS, P = 0.001; log-rank/Mantel-Cox test. Previous analyses in the same study identify hypermethylation of ALDH1A2 as the underlying mechanism of differential protein expression." ;
    a m2r:Evidence .

civice:1117
    dct:references pbm:26894380 ;
    civico:citation "Xu et al., 2016, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Expression of the protein CIP2A was investigated in 72 cases of pancreatic ductal adenocarcinoma and 27 cases of adjacent tissues. Immunohistochemistry revealed a significant difference in expression between tumor and adjacent normal samples. Furthermore, a statistically significant decrease in overall survival was discovered between positive and negative CIP2A expression." ;
    a m2r:Evidence .

civice:1118
    dct:references pbm:26894380 ;
    civico:citation "Xu et al., 2016, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gemcitabine ;
    dcterms:description "Researchers studied the effect of CIP2A expression in relation to  gemcitabine sensitivity via SW1990 cell lines. SW1990 cells with CIP2A expression knocked-down displayed lower IC50 (p=.024), indicating a sensitivity to gemcitabine." ;
    a m2r:Evidence .

civice:1119
    dct:references pbm:26442524 ;
    civico:citation "Li et al., 2015, Carcinogenesis" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Researchers examined the prognostic role of miR-218 expression in CRC tumor samples when receiving 5-FU based treatment. CRC samples from patients who received first-line 5-FU-based adjuvant chemotherapy were stratified into two groups (complete/partial response and stable/progressive disease) based on RECIST criteria. miR-218 expression levels were found to be significantly higher in the complete/partial response group.  Further Kaplan-Meier survival analysis revealed that in groups with higher miR-218 expression, overall survival was significantly greater." ;
    a m2r:Evidence .

civice:1121
    dct:references pbm:23181703 ;
    civico:citation "Tanaka et al., 2012, BMC Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "A 39-year-old man presented was observed to have lung acinar adenocarcinoma. Treatment with chemotherapy produced no remarkable response. A EGFR L858R point mutation was observed; the patient was therefore treated with erlotinib, but the disease progressed after 30 days. A second biopsy identified a EML4-ALK fusion, which may explain the therapeutic resistance." ;
    a m2r:Evidence .

civice:1122
    dct:references pbm:16236737 ;
    civico:citation "Piccart-Gebhart et al., 2005, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "HERA was a Phase III trial assessing application of trastuzumab in an extended adjuvant setting.  Patients were HER2 positive with completely excised invasive BC, node positive or negative, and having undergone prior adjuvant or neo-adjuvant chemotherapy.  In the 3 arm study patients were given trastuzumab courses of 1 year, 2 years, or untreated.  At the first planned interim analysis, trastuzumab treatment for one year was compared with observation alone.  A significant difference in disease-free survival was seen with 220 DFS events out of 1693 in the observation arm versus 127 DFS events out of 1694 in the 1 year trastuzumab arm.  1 year adjuvant trastuzumab is currently the standard of care." ;
    a m2r:Evidence .

civice:1123
    dct:references pbm:24137399 ;
    civico:citation "Salgado et al., 2013, Oncol Lett" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Likely Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 3020insCT/c.2901insCT in this paper, with the data shown corresponding to a GA insertion, reading left to right in the reference genome, between chr17:43092628-43092629 in GRCh38). This mutation ultimately causes a downstream premature stop codon and truncated BRCA1." ;
    a m2r:Evidence .

civice:1124
    dct:references pbm:24137399 ;
    civico:citation "Salgado et al., 2013, Oncol Lett" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 3020insCT/c.2901insCT in this paper, with the data shown corresponding to a GA insertion, reading left to right in the reference genome, between chr17:43092628-43092629 in GRCh38). This mutation ultimately causes a downstream premature stop codon and truncated BRCA1." ;
    a m2r:Evidence .

civice:1125
    dct:references pbm:25789838 ;
    civico:citation "Weiler et al., 2015, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_TrastuzumabEmtansine ;
    dcterms:description "A 51-year old female never smoker with stage IV lung adenocarcinoma carrying a HER2 insertion in exon 20 (p.A775_G776insYVMA) by sequencing archived material, HER2 overexpression by IHC (2+) and HER2 amplification by in situ hybridization was treated with T-DM1 (trastuzumab emtansine). Patient received two cycles off-label at 3.6mg/kg and was found to have morphologic response of lung and bone lesions by PET and CT. TDM-1 therapy was ongoing as of publication April 2015." ;
    a m2r:Evidence .

civice:1127
    dct:references pbm:21663470 ;
    civico:citation "Tiacci et al., 2011, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients." ;
    a m2r:Evidence .

civice:1128
    dct:references pbm:16282176 ;
    civico:citation "Mellinghoff et al., 2005, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib,civic:drug_Gefitinib ;
    dcterms:description "Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment while 19 progressed rapidly. Coexpression of EGFRvIII and PTEN was associated with clinical response (defined as 25% tumor shrinkage). These results were confirmed using IHC in an independent cohort of 33 patients (8 responders) treated with erlotinib at another institution." ;
    a m2r:Evidence .

civice:1129
    dct:references pbm:16282176 ;
    civico:citation "Mellinghoff et al., 2005, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment while 19 progressed rapidly. Coexpression of EGFRvIII and PTEN was associated with clinical response (defined as 25% tumor shrinkage). These results were confirmed using IHC in an independent cohort of 33 patients (8 responders) treated with erlotinib at another institution." ;
    a m2r:Evidence .

civice:1131
    dct:references pbm:19661358 ;
    civico:citation "Palmirotta et al., 2009, Anticancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relapsed. EGFR was assessed by immunohistochemistry, and the patient was subsequently treated with the anti-EGFR monoclonal antibody panitumumab. However, there was a rapid clinical worsening, which may possibly be attributed to a somatic mutation in KRAS (Q22*)." ;
    a m2r:Evidence .

civice:1132
    dct:references pbm:17192538 ;
    civico:citation "Geyer et al., 2006, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Lapatinib,civic:drug_Capecitabine ;
    dcterms:description "This Phase III trial took patients with locally advanced or metastatic HER2 (ERBB2) positive breast cancer that had progressed on prior trastuzumab treatment.  Patients were given capecitabine (n=161) or lapatinib plus capecitabine (n=163). The primary endpoint of the study was time to progression. Median time to progression was 4.4 months in the capecitabine group and 8.4 months in capecitabine plus lapatinib group (hazard ratio was 0.49 ; 95% confidence interval, 0.34 to 0.71; P<0.001).  The results indicated that lapatinib may be useful in addressing the problem of trastuzumab progression in HER2 breast cancer." ;
    a m2r:Evidence .

civice:1133
    dct:references pbm:19289619 ;
    civico:citation "von Minckwitz et al., 2009, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Capecitabine,civic:drug_Trastuzumab ;
    dcterms:description "In this Phase III trial, trastuzumab-based treatment was assessed in women with locally advanced or metastatic HER2 positive breast cancer who had progressed on trastuzumab.  Patients had 12 weeks or greater previous trastuzumab treatment with time since end of last cycle less than 6 weeks.  Primary endpoint was time to progression.  78 patients were assigned to each group, with median time to progression of 5.6 months in capecitabine group and 8.2 months in trastuzumab plus capecitabine group.  The results are in contrast to the principle of change of treatment on disease progression, and authors suggest that chemotherapy-sensitizing mechanisms of trastuzumab remain intact in HER2 breast cancer cells with trastuzumab progression." ;
    a m2r:Evidence .

civice:1135
    dct:references pbm:24899684 ;
    civico:citation "Ambrosini et al., 2014, Mol. Cancer Ther." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_PD0325901,civic:drug_Trametinib ;
    dcterms:description "MEK inhibitor-resistant (selumetinib, PD0325901, GSK1129212) uveal melanoma cell lines were created from two GNAQ Q209L mutant cell lines. Overexpression of DDX43 mediated RAS-induced selumetinib resistance as demonstrated by depletion of DDX43 decreasing RAS proteins and ectopic expression of DDX43 induced RAS protein levels. These results were confirmed using biopsies from liver metastases in 14 patients with uveal melanoma harboring GNAQ or GNA11 mutations who were treated on a phase II study of selumetinib. 6 patients with partial response or stable disease for ≥16 weeks, were defined as “responders” (R), 8 patients who had disease progression before 16 weeks were defined as “nonresponders” (NR). DDX43 Expression (qPCR) was higher in nonresponders (P = 0.045). Liver metastasis biopsy samples (3 R and 3 NR) were immunoblotted for DDX43, pERK and RAS proteins with consistent results." ;
    a m2r:Evidence .

civice:1136
    dct:references pbm:24178622 ;
    civico:citation "Jain et al., 2014, Clin. Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "Patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study of selumetinib and analyzed for mutations in KIT, NRAS, KRAS and FLT3. KIT mutation analysis (N=41) revealed the presence of a synonymous SNP rs3733542 (known population frequency of 20%) in exon 18 of the KIT gene in six of ten (60%) patients assessed as having a response or disease stabilization to selumetinib. In contrast, this SNP was detected in only seven of 31 (23%) patients without a response or disease stabilization (P = 0.027, Chi-squared test)." ;
    a m2r:Evidence .

civice:1137
    dct:references pbm:24178622 ;
    civico:citation "Jain et al., 2014, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "Forty-seven patients with relapsed/refractory AML or 60+ years old with untreated AML were enrolled on a phase II study. In FLT3 wild-type patients, six out of 36 (17%) had a response (1 PR, 3 MR, 2 uMR) that lasted a median of 58 days (range, 33–273 days). No patient with FLT3-ITD (n = 10) responded. One patient with unknown FLT3 status also had no response. Of note, this study did not meet its primary endpoint of 6 responses (CR, CRi, PR or MR) in the first 35 patients enrolled." ;
    a m2r:Evidence .

civice:1138
    dct:references pbm:24962318 ;
    civico:citation "Vu et al., 2014, Mol. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_AZ909 ;
    dcterms:description "Preclinical study in melanoma cell lines. TBK1 depletion (siRNA) inhibited migration and invasion, whereas its constitutive overexpression led to an increase in invasion. In MEK-resistant NRAS mutant melanoma cell lines, TBK1 depletion or inhibition (AZ909) in combination with MEK inhibitors (selumetinib) promoted apoptosis in 3D culture." ;
    a m2r:Evidence .

civice:1139
    dct:references pbm:23828442 ;
    civico:citation "Petrelli et al., 2013, Med. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab,civic:drug_Chemotherapy ;
    dcterms:description "Meta-Analysis of 12 studies with 2,266 patients (54 % were KRAS wt). The pooled response rates (RR) for KRAS wild-type (wt) versus mutated (mut) patients were 54.8 and 48.3 %, respectively (OR 1.42, P = 0.02). Median PFS in KRAS wild-type patients was significantly longer than in KRAS mut patients (HR = 0.85; 95 % confidence interval (CI) 0.74-0.98; P = 0.02). Median OS in wild-type KRAS patients compared was significantly better than in KRAS mut patients (HR = 0.65; 95 % CI 0.46-0.92; P = 0.01)." ;
    a m2r:Evidence .

civice:1140
    dct:references pbm:23934108 ;
    civico:citation "Hatzivassiliou et al., 2013, Nature" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_G-573,civic:drug_GDC-0623 ;
    dcterms:description "Preclinical study analyzing the differential response to MEK Inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Efficacy of MEK inhibitors (GDC-0623 and G-573) in KRAS-driven tumours is mediated by a hydrogen-bond interaction with S212 in MEK that is critical for blocking MEK feedback phosphorylation by wild-type RAF. This mechanism was distinct from GDC-0973 which is less potent in KRAS mutant tumors. Overall, this work indicates that MEK inhibitors with this mechanism of action will be most effective in patients with both BRAF and KRAS mutations." ;
    a m2r:Evidence .

civice:1141
    dct:references pbm:23934108 ;
    civico:citation "Hatzivassiliou et al., 2013, Nature" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cobimetinib ;
    dcterms:description "Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetinib) is required for strong inhibition of the MAPK pathway in BRAF-mutant tumours. This study provides mechanistic rationale for improved efficacy of cobimetinib in BRAF-mutant models compared to MEK inhibitors acting through an alternative mechanism (GDC-0623 and G-573)." ;
    a m2r:Evidence .

civice:1142
    dct:references pbm:26125448 ;
    civico:citation "Jänne et al., 2015, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_Docetaxel ;
    dcterms:description "83 patients from a phase II trial (docetaxel + placebo or MEK1/2 inhibitor selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations had a trend towards longer OS, PFS and ORR compared to other KRAS mutations. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo." ;
    a m2r:Evidence .

civice:1143
    dct:references pbm:26125448 ;
    civico:citation "Jänne et al., 2015, Br. J. Cancer" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Docetaxel,civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations had a trend towards longer OS, PFS and ORR compared to other KRAS mutations. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo." ;
    a m2r:Evidence .

civice:1144
    dct:references pbm:22425996 ;
    civico:citation "Chen et al., 2012, Nature" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Docetaxel,civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Lkb1 (STK11) knockout mutant mice showed only mild response to combined treatment and very low response rates to docetaxel monotherapy compared to mice with Kras(G12D) alone or Kras(G12D) and Trp53 knockout. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data." ;
    a m2r:Evidence .

civice:1145
    dct:references pbm:22425996 ;
    civico:citation "Chen et al., 2012, Nature" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Docetaxel,civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Trp53 knockout mutant mice were resistant to docetaxel monotherapy but sensitive to combined treatment. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data." ;
    a m2r:Evidence .

civice:1146
    dct:references pbm:22425996 ;
    civico:citation "Chen et al., 2012, Nature" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Docetaxel ;
    dcterms:description "A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Trp53 knockout mutant mice were resistant to docetaxel monotherapy but sensitive to combined treatment. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data." ;
    a m2r:Evidence .

civice:1147
    dct:references pbm:26899019 ;
    civico:citation "Ma et al., 2016, J Thorac Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA). Mutations (434; 36%) had no prognostic effect (OBS: HROS=0.99; [95%CI 0.77-1.28], p=0.95; HRDFS=0.99 [0.78-1.25], p=0.92) but were marginally predictive of benefit from ACT for OS (test for interaction: OS: p=0.06; DFS: p=0.11)." ;
    a m2r:Evidence .

civice:1148
    dct:references pbm:26899019 ;
    civico:citation "Ma et al., 2016, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_AdjuvantChemotherapy ;
    dcterms:description "Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with TP53wt had significantly better PFS and OS with ACT vs. OBS (p=0.005, p=0.02, respectively) whereas patients with TP53 mutations did not show significant differences in PFS and OS between ACT and OBS (p=0.86, p=0.63)." ;
    a m2r:Evidence .

civice:1149
    dct:references pbm:26899019 ;
    civico:citation "Ma et al., 2016, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_AdjuvantChemotherapy ;
    dcterms:description "Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA, 1209 patients, median follow-up 5.5 years) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with wild-type TP53 had better outcomes with ACT than OBS (HROS=0.77 [0.62-0.95], p=0.02; HRDFS=0.75 [0.62-0.92], p=0.005)." ;
    a m2r:Evidence .

civice:1150
    dct:references pbm:26883990 ;
    civico:citation "Koyama et al., 2016, Nat Commun" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_PD-1Inhibitor ;
    dcterms:description "In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody. Two patients who developed adaptive resistance to anti-PD-1 treatment also showed TIM-3 upregulation in blocking antibody-bound T cells at treatment failure." ;
    a m2r:Evidence .

civice:1151
    dct:references pbm:26883990 ;
    civico:citation "Koyama et al., 2016, Nat Commun" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PD-1Inhibitor,civic:drug_TIM-3Inhibitor ;
    dcterms:description "In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody." ;
    a m2r:Evidence .

civice:1152
    dct:references pbm:24685132 ;
    civico:citation "Sun et al., 2014, Cell Rep" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_Afatinib ;
    dcterms:description "Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen using a total of 3,530 shRNAs to target 518 human kinases identified ERBB3 knockdown to confer sensitivity of selumetinib-resistant H358 cells (NSCLC cell line) to the MEK inhibitor selumetinib. The dual EGFR-ERBB2 inhibitors afatinib and dacomitinib each showed synergy with MEK Inhibition via selumetinib in 4 KRAS mutant cell lines. Western blot evaluation of 9 NSCLC and 12 CRC cell lines showed ERBB3 expression correlated with the synergy score for combination afatinib and trametinib treatment. I.e. the synergy score was low in cells having low basal levels of ERBB3 protein and high for cells having high basal ERBB3 expression. Using selumetinib in patient-derived CRC xenografts or trametinib in NSCLC xenografts, MEK inhibition by selumetinib or trametinib in combination with afatinib more effectively inhibited increases in tumor volume than either monotherapy." ;
    a m2r:Evidence .

civice:1153
    dct:references pbm:24685132 ;
    civico:citation "Sun et al., 2014, Cell Rep" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Selumetinib%28AZD6244%29,civic:drug_CP724714 ;
    dcterms:description "Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen identified ERBB3 blockade to confer sensitivity to MEK inhibitors. The dual EGFR-ERBB2 (both forming heterodimers with ERBB3) inhibitors afatinib and dacomitinib each showed strong synergy with MEK Inhibition (trametinib or selumetinib) in several KRAS mutant cell lines. MEK Inhibitors alone or the combination with gefitinib (EGFRi) or CP724714 (ERBB2i) showed strong synergy. Results were validated in-vivo. Basal ERBB3 expression was associated with higher synergy scores." ;
    a m2r:Evidence .

civice:1155
    dct:references pbm:25892145 ;
    civico:citation "Machiels et al., 2015, Lancet Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Phase III trial to compare afatinib or metothrexate in recurrent or metastatic head and neck squamous cell carcinoma. 483 patients were randomized to either afatinib (n=322) or methotrexate (n=161). 285 patients were assessed for p16 Status (IHC). In the post-hoc analysis, benefit of afatinib compared with methotrexate was more pronounced in p16-negative disease (HR 0·69 [95% CI 0·50–0·96], p=0.022) than in p16-positive disease (HR 0·95 [CI 0·51–1·75], p=0.67, interaction test p=0·32)." ;
    a m2r:Evidence .

civice:1156
    dct:references pbm:26921265 ;
    civico:citation "Tabouret et al., 2016, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab ;
    dcterms:description "MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. High bMMP2 was correlated with better disease-free survival (DFS, p=0.001) and overall survival (OS, p=0.032). Correlation to DFS was also found after multivariate analysis (p=0.003, Hazard Ratio [HR]: 0.115). bMMP2 was associated with relapse (p=0.002) and death (p=0.049). During treatment, significant increase in MMP2 was observed in 100% of patients." ;
    a m2r:Evidence .

civice:1157
    dct:references pbm:26921265 ;
    civico:citation "Tabouret et al., 2016, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab ;
    dcterms:description "MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low bMMP9 was correlated with better OS (p=0.022) and non-significantly associated with longer DFS (p=0.071). Correlation to DFS was also found after multivariate analysis (p=0.041, HR: 3.511). bMMP9 was associated with death (p=0.035). During treatment, a significant decrease in MMP9 levels (p<0.001) was observed in 87% of patients." ;
    a m2r:Evidence .

civice:1158
    dct:references pbm:24327581 ;
    civico:citation "Tabouret et al., 2014, Neuro-oncology" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab ;
    dcterms:description "Plasma levels of 11 potential biomarkers were tested at baseline and 2 weeks after bevacizumab initiation in a prospective cohort of 26 patients with recurrent high-grade gliomas. Results were validated in a separate retrospective cohort (n = 50) and also tested in patients treated with cytotoxic agents without bevacizumab (n = 34). MMP2 level was correlated with PFS (hazard ratio, 3.92; 95% confidence interval [CI]:1.46-10.52; P = .007) and OS (hazard ratio, 4.62; 95% CI: 1.58-13.53; P = .005) in the discovery and validation cohorts but not in patients treated without bevacizumab." ;
    a m2r:Evidence .

civice:1159
    dct:references pbm:24793816 ;
    civico:citation "Krop et al., 2014, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_TrastuzumabEmtansine ;
    dcterms:description "The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated.  Patients were required to have prior exposure to trastuzumab and lapatinib as well as a taxane.  This patient population has not seen many studies, responds poorly to late-line treatment with trastuzumab, and in this study was treated with trastuzumab emtansine (T-DM1, n=404) vs. physician's choice (usually trastuzumab plus chemotherapy, n=198).  Results showed progression free survival was 6.2 months in T-DM1 treatment vs. 3.3 months under physician's choice, along with lower incidence of grade 3 or worse events with T-DM1.  The authors conclude that their findings in this heavily pretreated population, along with findings in the EMILIA trial, indicate promise for antibody-drug conjugates.  The NCI-MATCH trial with further study T-DM1 in the context of HER2 amplification." ;
    a m2r:Evidence .

civice:1160
    dct:references pbm:23020162 ;
    civico:citation "Verma et al., 2012, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_TrastuzumabEmtansine ;
    dcterms:description "The EMILIA study (NCT00829166) was a Phase II trial to assess the efficacy of trastuzumab emtansine (T-DM1, n=495) in comparison to lapatinib plus capecitabine (n=496), in treatment of advanced HER2 positive breast cancer.  Patients were required to have progressed on or after treatments involving trastuzumab and a taxane, and no prior exposure to lapatinib or T-DM1.   Primary endpoints included independently assessed progression free survival (PFS) and safety. PFS was 9.6 months in T-DM1 group vs. 6.4 months in lapatinib plus capecitabine.  Rates of adverse events of grade 3 or higher were greater with lapatinib plus capecitabine.  These results, together with other trials such as TH3RESA indicate promise for T-DM1 therapy in HER2 amplification, and this will be further studied in an arm of the NCI-MATCH trial." ;
    a m2r:Evidence .

civice:1161
    dct:references pbm:26950277 ;
    civico:citation "Hoda et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "ActA level was measured in serum and plasma samples of 64/87 lung adenocarcinoma patients and 46/66 age- and gender-matched controls (ELISA). ActA Levels were higher in patients than in controls and were significantly correlated with disease stage and metastasis. Patients were stratified as having high or low ActA levels using the median expression level. LADC patients with high serum or plasma ActA levels had significantly shorter OS than those with low circulating ActA concentrations (p < 0.0001 in both) and were identified as an independent prognostic factor (p=0.004 and p=0.002, respectively)." ;
    a m2r:Evidence .

civice:1162
    dct:references pbm:26943774 ;
    civico:citation "Kimura et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "HSP110 (HSPH1) expression was immunohistochemically assessed using a tissue microarray in 210 gastric cancer patients. The overall survival rate was significantly lower in patients with high nuclear expression (N=121, 2+ moderate/3+ strong staining) than patients with low nuclear staining (N=89, 0 no/1+ weak staining)(P = 0.0169). Multivariate regression analysis identified expression of nuclear HSP110 as an independent prognostic factor for gastric cancer outcome (P = 0.0068). This was not found for cytoplasmic expression." ;
    a m2r:Evidence .

civice:1163
    dct:references pbm:26943774 ;
    civico:citation "Kimura et al., 2016, Oncotarget" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_5-fluorouracil,civic:drug_Cisplatin ;
    dcterms:description "49 patients gastric cancer patients treated with adjuvant chemotherapy were immunohistochemically assessed for nuclear HSPH1 (HSP110) expression. Overall survival rate in the high expression group (2+ moderate/3+ strong staining) was significantly lower compared with the low expression group (0 no/1+ weak staining) (P = 0.0364). In gastric cancer cell lines (MKN7, MKN45), siRNA mediated HSP110 knockdown led to a higher sensitivity to 5-FU and cisplatin compared with the parent and control cells (p < 0.05)." ;
    a m2r:Evidence .

civice:1164
    dct:references pbm:24512910 ;
    civico:citation "Collura et al., 2014, Gastroenterology" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_5-fluorouracil,civic:drug_Oxaliplatin ;
    dcterms:description "329 consecutive patients with stage II–III colorectal tumors with MSI after surgical resection at tertiary medical centers were screened for HSP110 T(17) by PCR. Patients underwent adjuvant chemotherapy with 5-fluorouracil and oxaliplatin. Patients with large HSP110 T(17) deletions (≥5 bp; 18 of 77 patients, 23.4%) had longer times of relapse-free survival than patients with small or no deletions (≤4 bp; 59 of 77 patients, 76.6%) in multivariate analysis (hazard ratio, 0.16; 95% confidence interval, 0.012–0.8; P = .03). A significant interaction between chemotherapy and T17 deletion was found (P =.009)." ;
    a m2r:Evidence .

civice:1165
    dct:references pbm:26956051 ;
    civico:citation "Pircher et al., 2016, Oncotarget" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_AntiangiogenicTherapy ;
    dcterms:description "Biomarkers for response to antiangiogenic treatment were screened for in hepatocellular cancer (n = 11), renal cell cancer (n = 7) and non-small cell lung cancer (n = 2). Increased expression of tumor endothelial markers: Robo4 and ECSCR, nonsignificantly correlated with prolonged antiangiogenic time to progression (ECSCR high = 275 days vs. ECSCR low = 92.5 days; p = 0.07 and for Robo4 high = 387 days vs. Robo4 low = 90.0 days; p = 0.08)." ;
    a m2r:Evidence .

civice:1166
    dct:references pbm:26956051 ;
    civico:citation "Pircher et al., 2016, Oncotarget" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_AntiangiogenicTherapy ;
    dcterms:description "Biomarkers for Response to antiangiogenic treatment were screened for in hepatocellular cancer (n = 11), renal cell cancer (n = 7) and non-small cell lung cancer (n = 2). Increased expression of tumor endothelial markers: Robo4 and ECSCR, nonsignificantly correlated with prolonged antiangiogenic time to progression (ECSCR high = 275 days vs. ECSCR low = 92.5 days; p = 0.07 and for Robo4 high = 387 days vs. Robo4 low = 90.0 days; p = 0.08)." ;
    a m2r:Evidence .

civice:1167
    dct:references pbm:26918451 ;
    civico:citation "Passiglia et al., 2016, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Atezolizumab,civic:drug_Pembrolizumab,civic:drug_Nivolumab,civic:drug_Avelumab ;
    dcterms:description "Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining ≥1%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-3.68)." ;
    a m2r:Evidence .

civice:1168
    dct:references pbm:26918046 ;
    civico:citation "Jiang et al., 2016, J Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The expression of PIM1, p-STAT3, and c-MYC was tested (IHC) in 194 NSCLC archival tumor samples. High nuclear expression of PIM1 was detected in 43.3% of cases and was significantly correlated with advanced clinical stage (p<0.001) and poor pathologic differentiation (P = 0.004) and was an independent unfavorable prognostic factors for overall and disease-free survival (OS, P=0.009; DFS, P=0.034)." ;
    a m2r:Evidence .

civice:1169
    dct:references pbm:26916894 ;
    civico:citation "Vivenza et al., 2016, Int. J. Biol. Markers" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "66 HNSCC patients treated with chemoradiation were assessed for survival after a follow-up time of 10 years. Median OS was significantly shorter in patients with MDM2 SNP309 GG or GT genotypes compared with the TT genotype (p = 0.002)." ;
    a m2r:Evidence .

civice:1170
    dct:references pbm:26646755 ;
    civico:citation "Koehler et al., 2016, Ann. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pazopanib ;
    dcterms:description "19 advanced sarcoma patients treated with pazopanib were retrospectively assessed for mutations associated with response using the Foundation one sarcoma/heme panel. Progression-free survival (PFS) of patients with TP53 mutations (all predicted to be loss of function) was significantly greater than TP53 wild-type tumors with the median PFS of 208 versus 136 days, respectively [P = 0.036, hazards ratio 0.38 (95% confidence interval 0.09-0.83)]." ;
    a m2r:Evidence .

civice:1171
    dct:references pbm:16906227 ;
    civico:citation "Engelman et al., 2006, J. Clin. Invest." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "HCC827 cell lines harboring activated PI3K (HCC827 p110α E545K cells) were more resistant to gefitinib in vitro (IC50, 1 μM) compared with those harboring GFP alone (IC50, 0.01 μM). The presence of p110α E545K also protected HCC827 cells from gefitinib-mediated apoptosis." ;
    a m2r:Evidence .

civice:1172
    dct:references pbm:26970723 ;
    civico:citation "Fehrenbacher et al., 2016, Lancet" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Atezolizumab ;
    dcterms:description "Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 expression (IHC) was assessed in tumour cells (as percentage of PD-L1-expressing tumour cells TC3≥50%, TC2≥5% and <50%, TC1≥1% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3≥10%, IC2≥5% and <10%, IC1≥1% and <5%, and IC0<1%). Increasing PD-L1 Expression was associated with improved overall survival (TC3 or IC3 HR 0·49 [0·22-1·07; p=0·068], TC2/3 or IC2/3 HR 0·54 [0·33-0·89; p=0·014], TC1/2/3 or IC1/2/3 HR 0·59 [0·40-0·85; p=0·005], TC0 and IC0 HR 1·04 [0·62-1·75; p=0·871]) but not progression free survival or overall response rate." ;
    a m2r:Evidence .

civice:1173
    dct:references pbm:26739882 ;
    civico:citation "Patricelli et al., 2016, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ARS-853,civic:drug_EGFRInhibitor ;
    dcterms:description "Preclinical study to investigate mechanisms of KRAS G12C activity and inhibition with ARS-853, a covalent (irreversible) inhibitor which binds KRAS G12C in the GDP-bound state to prevent activation. Results from a mass spectrometry-based assay to evaluate KRAS activity suggests that G12C mutant KRAS is in a “hyperexcitable” rather than a “statically active” state. ARS-853 targets the inactive state and inhibited proliferation in a subset  (3/11) of KRAS G12C mutant cell lines in 2-D growth assays and 11/11 cell lines in soft-agar colony formation and 3-D assays. This effect was specific for KRAS G12C as 12/12 cell lines with other KRAS mutations (including other G12 mutations V, D and A) were not inhibited in either soft-agar assay.  Relative resistance to ARS-853 developed after epidermal growth factor (50 ng/mL) administration and the combination of erlotinib or afatinib (EGFR-inhibitors) with ARS-853 greatly potentiated growth arrest, apoptosis and decrease of PI3K and MAPK-signaling over single-agent ARS-853 treatment, even in the presence of added EGF." ;
    a m2r:Evidence .

civice:1174
    dct:references pbm:26243863 ;
    civico:citation "Kavuri et al., 2015, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib,civic:drug_Lapatinib,civic:drug_Trastuzumab ;
    dcterms:description "Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab." ;
    a m2r:Evidence .

civice:1175
    dct:references pbm:26973324 ;
    civico:citation "Kim et al., 2016, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "Updated results from ASCEND-1 trial assessing safety and activity of ceritinib in ALK rearranged locally advanced or metastatic NSCLC. 255 patients were enrolled and received at least one dose of ceritinib 750 mg/day, of whom 246 had ALK-rearranged NSCLC (Median follow-up: 11.1 months). Overall response rate was 72% [95% CI 61-82] of 83 ALK inhibitor-naive patients and 56% [49-64] of 163 ALK inhibitor-pretreated patients. Median duration of response was 17·0 months (95% CI 11.3-non-estimable [NE]) in ALK inhibitor-naive patients and 8.3 months (6.8-9.7) in ALK inhibitor-pretreated patients. Median progression-free survival was 18.4 months (95% CI 11.1-NE) in ALK inhibitor-naive patients and 6.9 months (5.6-8.7) in ALK inhibitor-pretreated patients. Brain metastases control was reported in 79% [95% CI 54-94] of 19 ALK inhibitor-naive patients and in 65% [54-76] of 75 ALK inhibitor-pretreated patients." ;
    a m2r:Evidence .

civice:1176
    dct:references pbm:26243863 ;
    civico:citation "Kavuri et al., 2015, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Neratinib,civic:drug_Lapatinib ;
    dcterms:description "Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab." ;
    a m2r:Evidence .

civice:1177
    dct:references pbm:26243863 ;
    civico:citation "Kavuri et al., 2015, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib,civic:drug_Lapatinib,civic:drug_Trastuzumab ;
    dcterms:description "Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab." ;
    a m2r:Evidence .

civice:1178
    dct:references pbm:26243863 ;
    civico:citation "Kavuri et al., 2015, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Lapatinib,civic:drug_Neratinib ;
    dcterms:description "Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab." ;
    a m2r:Evidence .

civice:1179
    dct:references pbm:26243863 ;
    civico:citation "Kavuri et al., 2015, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Neratinib,civic:drug_Lapatinib ;
    dcterms:description "Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab." ;
    a m2r:Evidence .

civice:1180
    dct:references pbm:26371285 ;
    civico:citation "Schirripa et al., 2015, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study. The primary endpoint of the trial was 4-month progression-free survival, with a benefit to treatment evaluated to be 50% of patients were progression free at this point. None of 12 patients achieved response by RECIST 1.1 criteria and three patients (25%) were progression-free at 4 months, with disease control rate at 6 months reaching 0%. Median PFS and OS were 1.9 (95% CI 1.7–3.8) and 7.2 months (95% CI 5.7–9.7)." ;
    a m2r:Evidence .

civice:1181
    dct:references pbm:26812186 ;
    civico:citation "Rowland et al., 2016, Eur. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colorectal cancer. For other KRAS MT the hazard ratio for OS benefit with addition of anti-EGFR mAb therapy was 1.06 (95% confidence interval [CI]; 0.96, 1.17), compared to 1.08 (95% CI; 0.73, 1.60) for KRAS G13D [test for interaction p=0.99]. In contrast, the hazard ratio for KRAS wild-type (WT) tumours was 0.85 (95% CI; 0.76, 0.95). Regarding PFS benefit with anti-EGFR mAbs, the hazard ratio was 1.07 (95% CI; 0.92, 1.26) for other KRAS MT, 0.96 (95% CI; 0.73, 1.27) for KRAS G13D, and 0.68 (95% CI; 0.54, 0.85) for KRAS wild-type. Again, the test for interaction (p=0.46) demonstrated no significant difference in PFS benefit for anti-EGFR mAb therapy between KRAS G13D and other KRAS MT." ;
    a m2r:Evidence .

civice:1182
    dct:references pbm:26709701 ;
    civico:citation "Chattopadhyay et al., 2015, PLoS ONE" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ixazomib ;
    dcterms:description "Preclinical study in colorectal cancer xenografts. KRAS-G13D or KRAS-G12V mutations were introduced into KRAS-WT SW48 cell line. KRAS wild-type, but not KRAS mutant tumors were sensitive to proteasome inhibitor ixazomib" ;
    a m2r:Evidence .

civice:1183
    dct:references pbm:26881434 ;
    civico:citation "Costa-Cabral et al., 2016, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD5438 ;
    dcterms:description "CDK1 was identified in a preclinical siRNA screen to identify targets in KRAS mutant tumors. Cell viability was evaluated following knockdown of 834 genes in isogenic LIM1215 colorectal cancer cell lines harboring wildtype (parental), G12S, G12D or G12V KRAS. 6 targets identified by this screen were evaluated in a second set of isogenic colorectal cancer cell lines (SW48) harboring wildtype (parental), G12S, G12D, G12V or G13D KRAS where only CDK1 knockdown more profoundly reduced survival in mutant cells compared to wildtype. Results were validated in 5 KRAS mutant (BRAF WT) and 10 KRAS WT colorectal cancer cell lines. Chemical inhibition of CDK1 by AZD5438 in KRAS mutant vs WT pancreatic and colorectal cancer cell lines showed increased efficacy in mutant cell lines. Finally, AZD5438 reduced tumor growth induced by SW620 (KRAS p.G12V) colorectal tumour cells xenografted into immunodeficient mice." ;
    a m2r:Evidence .

civice:1184
    dct:references pbm:26662432 ;
    civico:citation "Li et al., 2015, Genet. Mol. Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "D" ;
    dcterms:description "The study found mir-218 was significantly under-expressed when compared to matched adjacent normal tissue in 107 samples via qPCR. Further, low expression of mir-218 was revealed to be associated with lower overall survival (p < .001), and multivariate analysis revealed that low expression of mir-218 as an independent predictor of poor prognosis (p < .007)." ;
    a m2r:Evidence .

civice:1185
    dct:references pbm:26729443 ;
    civico:citation "Awad et al., 2016, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A single patient with a MET c.3028G>A (splice donor site of exon 14) mutation exhibited clinical sensitivity to the c-Met inhibitor crizotinib. Exon 14 skipping was detected using qRT-PCR. Response to the therapy was demonstrated by comparing CAT scans obtained before treatment to those obtained during treatment (at 2 months of crizotinib therapy)." ;
    a m2r:Evidence .

civice:1186
    dct:references pbm:25971938 ;
    civico:citation "Frampton et al., 2015, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Capmatinib ;
    dcterms:description "A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib. MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+." ;
    a m2r:Evidence .

civice:1187
    dct:references pbm:20979469 ;
    civico:citation "Kwak et al., 2010, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In the Phase I study PROFILE 1001 (NCT00585195), a recommended crizotinib dose of 250 mg twice daily for 28 day cycles was established. Among 1,500 advanced NSCLC patients who were screened for ALK-rearrangement using a break-apart FISH assay, 82 patients were eligible for crizotinib treatment.  Overall response rate was 57%, with 46 partial responses and one complete response.  Since crizotinib inhibits MET, 33 patients with available tissue were screened for MET amplification and were found negative, further indicating that patient response was due to ALK inhibition.  31 patients were tested via RT-PCR for known EML4-ALK fusions, and 13 were shown to have EML4-ALK variant 1, four cases had variant 3, and one instance of variants 2, 3b and 5 were seen.  9 were unidentified, suggesting other fusion partners in these instances.  On the basis of this and a Phase II study, accelerated approval for crizotinib in ALK-positive advanced NSCLC was granted." ;
    a m2r:Evidence .

civice:1188
    dct:references pbm:17625570 ;
    civico:citation "Soda et al., 2007, Nature" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_WHI-P154 ;
    dcterms:description "A retroviral cDNA expression library was constructed using a lung adenocarcinoma specimen from a 67 year old NSCLC patient, and transfected into mouse 3T3 fibroblasts which were assessed for transformed foci.  Analysis of clones from one transformed focus yielded a novel fusion. This fusion generated a protein with N-terminal consisting of EML4 exons 1-13 and C-terminal consisting of ALK exons 20-29, which comprise the intracellular kinase domain of ALK. In subsequent experiments using EML4-ALK or altered versions, the transforming potential of EML4-ALK was found to be dependent on a functional ALK kinase activity as well as the EML4 basic domain, which was shown to have an important role in EML4-ALK dimer formation.  BA/F3 cells expressing EML4-ALK were able to grow independently of IL3 addition, but addition of ALK inhibitor WHI-P154 induced cell death and inhibited tyrosine phosphorylation of EML4-ALK. These results indicated that EML4-ALK may be a driver mutation in NSCLC,  and a target for ALK inhibitor treatment." ;
    a m2r:Evidence .

civice:1189
    dct:references pbm:20979469 ;
    civico:citation "Kwak et al., 2010, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In the PROFILE 1001 study, from 31 NSCLC tumors positive for ALK fusions with sufficient material for RT-PCR aided exon breakpoint identification, 1 case of EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) was found. This patient had adenocarcinoma and a 9 pack year smoking history. Crizotinib treatment duration was over 16 weeks. The patient had multiple lines of prior treatment and showed a partial response to first-time crizotinib treatment. Overall, in the 82 ALK positive patients treated in the study, 46 had partial responses (including this patient) and 1 had a complete response for an overall response rate of 57%." ;
    a m2r:Evidence .

civice:1190
    dct:references pbm:18927303 ;
    civico:citation "Takeuchi et al., 2008, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Multiplex RT-PCR to detect in-frame fusions of EML4 to ALK was performed on total RNA from 253 lung adenocarcinomas, and 9 samples were found to contain such fusions, one of which was a novel fusion containing EML4 exon 2 and exon 20 of ALK. This was called variant 5. Two versions of this variant were seen: 5a consisted of EML4 exon 2 fused to ALK exon 20 while 5b contained a 117bp intronic ALK region between the two exons. Genomic PCR showed that EML4-ALK variant 5 tumor cells contained a single EML4-ALK fusion, suggesting 5a and 5b arise from alternate splicing.  5a and 5b showed in-vitro kinase activity and transformed 3T3 cells in cell culture. 5a and 5b transformed 3T3 cells formed tumors when injected in 8/8 nude mice, but 3T3 transformed with ALK alone did not.  These results suggest that EML4-ALK variant 5 is a driver mutation in lung adenocarcinoma targetable by ALK inhibitors like crizotinib." ;
    a m2r:Evidence .

civice:1191
    dct:references pbm:27004155 ;
    civico:citation "Loaiza-Bonilla et al., 2016, Cureus" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Regorafenib ;
    dcterms:description "Case Report of a 84-year-old woman with stage IVb CRC after progression under 5-fluorouracil and bevacizumab. NGS revealed a frameshift mutation in APC, a missense mutation in KRAS. Variants of uncertain significance were: a missense variant in ERBB2 and a missense variant in KDR at amino acid 961 converting the wild type residue, Arginine, to Tryptophan (frequency 28.25%). Because of the high frequency of the KDR (VEGFR2) mutation, the patient was considered a suitable candidate for a VEGFR inhibitor and received regorafenib monotherapy, which is approved for this situation, at 80mg daily which was later reduced to 40mg daily and had CEA normalization as well as partial metabolic and radiologic response. The patient remained almost asymptomatic and without disease progression after 39 weeks." ;
    a m2r:Evidence .

civice:1192
    dct:references pbm:18593892 ;
    civico:citation "Choi et al., 2008, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_2,civic:drug_4-pyrimidinediamine ;
    dcterms:description "In a cohort of 75 NSCLC patients that had tested positive for 3 EML4-ALK rearrangements, two individuals were identified via RT-PCR with a novel EML4-ALK translocation involving the first 6 exons of EML4 fused to the kinase domain of ALK. Genomic PCR resolved a single breakpoint, but 2 variants of the fusion were observed in cells. Variant 3a consisted of fusion at EML4 exon 6 and ALK exon 20, while variant 3b fused a 33 bp intronic EML4 region between EML4 exon 6 and ALK exon 20.  3a and 3b showed strong in-vitro kinase activity, transformed mouse 3T3 cells, and 3b-transformed 3T3 cells formed tumors in 8/8 nude mice.  The ALK inhibitor 2,4-pyrimidinediamine inhibited growth of the 3a/b containing NCI-H2228 NSCLC cell line.  The results indicate that 3a/b is a targetable driver-mutation as other EML4-ALK variants." ;
    a m2r:Evidence .

civice:1193
    dct:references pbm:20979469 ;
    civico:citation "Kwak et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In a set of 31 patients with NSCLC, RT-PCR was performed to test for known EML4-ALK variants.  Five patients tested positive for the 3a/3b EML4-ALK variant.  Of these, 4 had partial response (PR), and one had disease progression (DP), and this was the only DP in the group of 31.  In contrast, of the 13 testing positive for EML4-ALK variant 1, 12 showed PR, and 1 showed stable disease.  These results potentially mirror findings in the H2228 3a/3b containing NSCLC cell line where some literature indicates it does respond as strongly to ALK inhibition as other EML4-ALK NSCLC cell lines." ;
    a m2r:Evidence .

civice:1194
    dct:references pbm:18451166 ;
    civico:citation "McDermott et al., 2008, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_TAE684 ;
    dcterms:description "In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684. Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon 6 and ALK exon 20). TAE684 inhibited Akt and Erk1/2 phosphorylation in H2228 cells and appeared to induce a cytostatic response." ;
    a m2r:Evidence .

civice:1195
    dct:references pbm:18594010 ;
    civico:citation "Koivunen et al., 2008, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_TAE684 ;
    dcterms:description "Exon-array and RT-PCR was used to screen a panel of 83 NSCLC cell lines for EML4-ALK variants. The cell lines NCI-H3122 (containing EML4-ALK variant 1) and NCI-H2228 (containing the EML4 exon 6 and ALK exon 20 fusion-variant 3a/3b) were identified. TAE684 (0.1uM) appreciably inhibited growth as well as Akt and Erk1/2 phosphorylation in variant 1 containing H3122 cells. However, incomplete inhibition in 3a/3b containing H2228 cells was observed. H2228 growth inhibition by TAE684 was more similar to NSCLC cell lines harboring KRAS and EGFR mutations." ;
    a m2r:Evidence .

civice:1196
    dct:references pbm:22912387 ;
    civico:citation "Heuckmann et al., 2012, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) were expressed in Ba/F3 cells using retrovirus.  While all constructs rendered Ba/F3 cells IL3-independant, marked differences in sensitivity to ALK inhibitors TAE684 and crizotinib were observed, where v2 was most sensitized to growth inhibition and v3a the least, with v1 and v3b intermediate.  While phospho-ALK western blots indicated that the ALK inhibitors acted similarly on both v2 and v3a EML4-ALK variants, blots of cyclohexamide-treated cells showed that v2 had a shorter half-life than 3a in the transduced cells, potentially explaining increased v2 sensitivity.  Assays with a panel of mutated EML4-ALK variants of varied length suggested that longer EML4-ALK variants are less stable in cells, although this tendency was not observed across other types of ALK fusion." ;
    a m2r:Evidence .

civice:1197
    dct:references pbm:22912387 ;
    civico:citation "Heuckmann et al., 2012, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Ba/F3 cells transduced with EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) showed differential sensitivity to both crizotinib and TAE684, with variant 3a (E6;A20) being the least sensitive. The authors suggest that the type/structure of ALK fusion may have some impact on patient outcome in targeted therapy." ;
    a m2r:Evidence .

civice:1198
    dct:references pbm:23724913 ;
    civico:citation "Shaw et al., 2013, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "This two arm Phase III study named PROFILE 1007 (NCT00932893) was performed to assess crizotinib vs. established chemotherapy in non-small cell lung cancer patients positive for ALK rearrangement (assessed by break-apart FISH) with locally advanced or metastatic disease. 347 patients with disease progression after one round of platinum-based chemotherapy were randomized to receive crizotinib (N=173) or chemotherapy (N=174) consisting of pemetrexed in pemetrexed-naive patients and docetaxel for patients previously treated with pemetrexed. The primary endpoint - progression free survival (PFS) - was found to be significantly better for patients treated with crizotinib (median 7.7 months) than with chemotherapy (median 3.0 months) (hazard ratio for disease progression or death with crizotinib, 0.49; 95% CI, 0.37 to 0.64; P<0.001). Response rates were 65% for crizotinib treatment and 20% for chemotherapy (P<0.001). Improvements in quality of life were also reported." ;
    a m2r:Evidence .

civice:1199
    dct:references pbm:25470694 ;
    civico:citation "Solomon et al., 2014, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "This phase 3 trial named PROFILE 1014 (NCT01154140) compared crizotinib to established chemotherapy in first-line treatment for this disease. The study consisted of 343 patients with advanced or metastatic NSCLC that tested positive for ALK rearrangement via break-apart FISH assay, and had no prior systemic treatment. Patients were assigned in a 1:1 ratio to crizotinib (N=172) or pemetrexed with cisplatin or carboplatin (N=171). Progression free survival was significantly longer with crizotinib treatment than chemotherapy (10.9 vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% CI, 0.35 to 0.60;P<0.001), and objective response rate was higher with crizotinib treatment than chemotherapy (75% vs. 45%, P<0.001). Improvement in quality of life was also reported." ;
    a m2r:Evidence .

civice:1200
    dct:references pbm:24478318 ;
    civico:citation "Ou et al., 2014, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "This retrospective study of patients from the PROFILE 1001 and 1005 studies of crizotinib in advanced ALK-rearranged NSCLC assessed the potential benefit of crizotinib beyond progressive disease (CBPD), defined as continuation of crizotinib for 3 or more weeks after disease progression on crizotinib. 194 patients who had developed PD by data cutoff were studied, where 120 received crizotinib for a median duration of 19.4 weeks and 74 discontinued crizotinib after PD. No gross imbalances in clinicopathologic features of the two groups were evident.  Significantly longer overall survival was observed in the crizotinib continuing group from time of PD (16.4 vs. 3.9 months; hazard ratio 0.27, 95% CI: 0.17–0.42; P < 0.0001), and from the time of initial crizotinib (29.6 vs. 10.8 months; HR 0.30, 95% CI: 0.19–0.46; P < 0.0001)." ;
    a m2r:Evidence .

civice:1201
    dct:references pbm:27022118 ;
    civico:citation "Solomon et al., 2016, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "This prospective Phase III study named Profile 1014 on NSCLC ALK-rearranged patients assessed intracranial disease control rate (IC-DCR) in the subset of patients entering the study with preexisting treated brain metastasis (tBM). IC-DCR was significantly improved in the tBM group given crizotinib (N=39) over chemotherapy (pemetrexed + cisplatin or carboplatin; N=40) at 12 weeks (85% vs. 45%, P<0.001), and at 24 weeks (56% vs. 25%, P=0.006). Progression free survival was also significantly improved with crizotinib over chemotherapy in the tBM subgroup (9.0 vs. 4.0 months; HR 0.40; P<0.001), where in the intent to treat population it was 10.9 vs. 7.0 months (HR 0.45; P<0.001), indicating that the difficult to treat BM population obtained benefit from crizotinib at both the brain and systemic level." ;
    a m2r:Evidence .

civice:1202
    dct:references pbm:20940188 ;
    civico:citation "Sequist et al., 2010, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_IPI-504 ;
    dcterms:description "In this study, heavily pretreated advanced NSCLC patients with various molecular tumor makeup were treated with Hsp90 inhibitor IPI-504 to assess overall response rate. The study did not reach the targeted endpoint of 20% ORR. However, of 3/12 patients found to be ALK-rearranged via break apart FISH assay, 2 showed a partial response and the third stable disease, which was durable for 7.2 months. The authors note that the break apart FISH assay used to determine ALK-rearrangement status does not determine the identity of the ALK fusion partner and the promising results shown here may be dependent on the nature of the ALK fusion partner." ;
    a m2r:Evidence .

civice:1203
    dct:references pbm:21258415 ;
    civico:citation "Normant et al., 2011, Oncogene" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib,civic:drug_IPI-504 ;
    dcterms:description "In preclinical work using H3122 NSCLC cells which contain the EML4-ALK variant 1, administration of the Hsp90 inhibitor IPI-504 caused marked decrease of EML4-ALK protein levels at concentrations lower than those used to knock down protein levels of drivers such as HER2 or EGFR in other cell lines, making it the most sensitive Hsp90 client protein the authors had encountered.  IPI-504 treatment caused regression of H3122 tumors in nude mice, whereas Hsp90 inhibitors usually only cause growth inhibition in these models.  Combined treatment of these mice with IPI-504 and crizotinib caused an even stronger tumor regression." ;
    a m2r:Evidence .

civice:1204
    dct:references pbm:22912387 ;
    civico:citation "Heuckmann et al., 2012, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib,civic:drug_17-DMAG ;
    dcterms:description "EML4-ALK fusions occur in 2-7% of lung adenocarcinomas. Transduction of Ba/F3 cells with EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) caused the cells to grow independently of IL3 addition.  EML4-ALK may be a client protein of Hsp90. Addition of Hsp90 inhibitor 17-DMAG to the EML4-ALK variant 2 cells induced cell death which was rescued at lower 17-DMAG concentrations by IL3 addition. This result suggests that 17-DMAG specifically  targeted the EML4-ALK driver in these cells. Finally, 17-DMAG and crizotinib showed a synergistic effect in killing EML4-ALK variant 2 cells." ;
    a m2r:Evidence .

civice:1205
    dct:references pbm:22912387 ;
    civico:citation "Heuckmann et al., 2012, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_17-DMAG ;
    dcterms:description "Transduction of Ba/F3 cells with EML4-ALK variant 3a caused the cells to grow independently of IL3 addition.  While incubation of Ba/F3 cells transduced with EML4-ALK variants 1 and 2 with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, Ba/F3 cells with variant 3a were not sensitized to 17-DMAG induced death, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation. This in turn suggests that variant 3a may not rely on Hsp90 for stability in cancer cells to the extent of other variants." ;
    a m2r:Evidence .

civice:1206
    dct:references pbm:22912387 ;
    civico:citation "Heuckmann et al., 2012, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib,civic:drug_17-DMAG ;
    dcterms:description "Transduction of Ba/F3 cells with EML4-ALK variant 1 causes IL3 independent growth. Incubation of EML4-ALK variant 1 transduced Ba/F3 cells with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation, and that EML4-ALK variant 1 is a client protein of Hsp90. The degree of Hsp90 dependence, and targetability of EML4-ALK for Hsp90 inhibition, may vary among ALK fusion variants.  Addition of crizotinib to 17-DMAG caused synergistic death effects, suggesting potential clinical benefit for this inhibitor combination in targeting EML4-ALK variant 1." ;
    a m2r:Evidence .

civice:1207
    dct:references pbm:20979469 ;
    civico:citation "Kwak et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In the PROFILE 1001 study of crizotinib in 82 patients with ALK-rearranged NSCLC, 31 patients with sufficient tumor material were tested using RT-PCR for the presence of certain EML4-ALK variants.  13/31 tested patients had the EML4-ALK variant 1. Of these, 12/13 had a partial response, and 1 had stable disease. This response rate of 92% is in contrast to the 57% response rate in the overall patient population, but the numbers of patients with specific EML4-ALK breakpoints were insufficient to correlate with patient response rate." ;
    a m2r:Evidence .

civice:1208
    dct:references pbm:27037411 ;
    civico:citation "Azuara et al., 2016, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_EGFRInhibitor ;
    dcterms:description "102 mCRC patients treated with anti-EGFR therapy were analyzed for 34 hotspot mutations in KRAS, NRAS and BRAF with nanofluidic digital PCR and quantitative PCR. dPCR and qPCR results were correlated to PFS and OS. Analysis of only KRAS exon 2 hotspot mutations showed that patients with more than 1% mutant allele fraction (n = 19/83) had a hazard ratio of 3.43 for PFS (95% CI, 1.67–7.02; P=0.002) and 2.72 for OS (95% CI, 1.52–4.88; P=0.002) compared to wild-type patients or patients with less than 1% mutant allele fraction. Considering all RAS and BRAF mutations, the patients with more than 1% mutant allele fraction (n = 37/65) had a hazard ratio of 4.52 for PFS (95% CI, 2.25–9.07; P<0.001) and 2.5 for OS (95% CI, 1.57–4.02; P<0.001). ROC analysis showed that a cut-off of 1% for any mutated allele offered the best predictive value." ;
    a m2r:Evidence .

civice:1209
    dct:references pbm:27034505 ;
    civico:citation "Jennis et al., 2016, Genes Dev." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Cisplatin ;
    dcterms:description "The P47S (rs1800371) variant of TP53 is observed in 1.5% in African Americans and between 6% and 8% in certain African populations but has not been detected in Caucasian Americans. This paper reports functional studies of this variant. Mouse models with this variant show an increase in spontaneous tumor formation. 16 out of 20 (80%) of S47 homozygous mice developed cancer between 12 and 18 months of age. Cancers predominantly included hepatocellular carcinoma, B-cell lymphoma, and histiocytic sarcoma, as well as other tumor types. In S47/wild-type heterozygote mice an increased cancer incidence, with a predisposition for hepatocellular carcinoma, was also found. Mouse embryonic fibroblasts and human lymphoblastoid cell lines with S47 mutations were significantly less sensitive to cisplatinum treatment compared to TP53 wild-type cells (apoptosis and viability)." ;
    a m2r:Evidence .

civice:1210
    dct:references pbm:26397223 ;
    civico:citation "Ambrosini et al., 2015, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_JQ1 ;
    dcterms:description "Preclinical study in uveal melanoma cell lines. Cell lines (n=4) with GNAQ mutation (92.1, Omm1.3, Mel270, Mel202) were more sensitive to BRD4 inhibition with JQ1 than GNAQ/GNA11 wild type (n=3) cell line. JQ1 also inhibited growth of a GNAQ mutant cell line (92.1) in a mouse xenograft model compared to vehicle (N=5 mice/group)." ;
    a m2r:Evidence .

civice:1211
    dct:references pbm:26397223 ;
    civico:citation "Ambrosini et al., 2015, Oncotarget" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_JQ1 ;
    dcterms:description "Preclinical study in uveal melanoma cell lines. Cell lines (n=5) with GNAQ (92.1, Omm1.3, Mel270, Mel202) or GNA11 (Omm1) mutation were more sensitive to BRD4 inhibition with JQ1 than GNAQ/11 wild type (n=3) cell line." ;
    a m2r:Evidence .

civice:1212
    dct:references pbm:24938562 ;
    civico:citation "Carvajal et al., 2014, JAMA" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) vs. 15.9 weeks with selumetinib (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; P < 0.001). Most patients (80/96 evaluable harbored a mutation in exon 5 of GNAQ or GNA11) but PFS benefit from Selumetinib compared to chemotherapy was greater in the GNAQ and GNA11 wild-type population (25.9 weeks [range, 3.7-40.4 weeks] vs 15.4 weeks [range, 8.1-16.9 weeks]). However, PFS was still better with Selumetinib than chemotherapy in the GNA mutant population (hazard ratio 0.55, 95% CI, 0.34-0.87; P = 0.01). The difference was explained by potential GNAQ or GNA11 mutations outside of exon 5 in the GNA wild-type population. Another three mutations in exon 4 were retrospectively identified in the wild-type population and one had a major response." ;
    a m2r:Evidence .

civice:1213
    dct:references pbm:24938562 ;
    civico:citation "Carvajal et al., 2014, JAMA" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) vs. 15.9 weeks with selumetinib (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; P < 0.001). Most patients (80/96 evaluable harbored a mutation in exon 5 of GNAQ or GNA11) but PFS benefit from Selumetinib compared to chemotherapy was greater in the GNAQ and GNA11 wild-type population (25.9 weeks [range, 3.7-40.4 weeks] vs 15.4 weeks [range, 8.1-16.9 weeks]). However, PFS was still better with Selumetinib than chemotherapy in the GNA mutant population (hazard ratio 0.55, 95% CI, 0.34-0.87; P = 0.01). The difference was explained by potential GNAQ or GNA11 mutations outside of exon 5 in the GNA wild-type population. Another three mutations in exon 4 were retrospectively identified in the wild-type population and one had a major response." ;
    a m2r:Evidence .

civice:1214
    dct:references pbm:27001570 ;
    civico:citation "Bouffet et al., 2016, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Nivolumab ;
    dcterms:description "Two siblings (6 and 3.5 years) from nonconsanguineous parents were diagnosed with glioblastoma multiforme. Both tumors harbored TP53 mutations and lack of MGMT promoter hypermethylation as poor prognostic markers. Germline homozygous c.2117delA, p. Lys706SerfsX19 mutation in PMS2, loss of PMS2 staining in the tumor and normal tissue confirmed a diagnosis of biallelic mismatch repair deficiency (bMMRD). Both tumors harbored driver mutations in POLE and were found to harbor 24,680 and 21,919 mutations per exome. Neoantigen load was assessed in 37 bMMRD patients and all malignant tumors had high numbers of predicted neoantigens (7-16x as high as in melanoma, lung or other immunoresponsive cancers). Treatment with nivolumab was begun and both patients had radiologic response. After 9 and 5 months of therapy, respectively, the patient and her brother resumed normal schooling and daily activities." ;
    a m2r:Evidence .

civice:1215
    dct:references pbm:22948721 ;
    civico:citation "Modest et al., 2012, Oncology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 119 metastatic colorectal cancer patients treated with cetuximab-based first-line chemotherapy, KRAS G12D mutations (N=44) were associated with longer overall patient survival when compared to other KRAS G12 mutations (23.3 vs 14-18 months; G12V, A, C, S, R)." ;
    a m2r:Evidence .

civice:1216
    dct:references pbm:23313110 ;
    civico:citation "Fiala et al., Cancer Genet" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "In a study of 448 metastatic colorectal cancer patients treated with EGFR-TKIs and tested for EGFR and KRAS mutations, 69 tested positive for KRAS mutations. In 38 EGFR wildtype patients treated with erlotinib or gefitinib, those with KRAS G12C mutations (n=24) had shorter progression free survival rates compared to patients with non-G12C KRAS mutations (n=14; 4.3 vs 9 weeks; P = 0.009; HR=2.7). This was true when restricted to patients with an adenocarcinoma subtype only (n=18 vs 12; 4.1 vs 9 weeks; P = 0.007; HR=3.1). Overall survival was not different between groups." ;
    a m2r:Evidence .

civice:1217
    dct:references pbm:22247021 ;
    civico:citation "Ihle et al., 2012, J. Natl. Cancer Inst." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 48 NSCLC patients, those with G12C or G12V mutant KRAS were associated with decreased progression free survival (1.84 months) compared with other KRAS mutants or with wild-type KRAS (3.35 and 1.95 months)." ;
    a m2r:Evidence .

civice:1218
    dct:references pbm:21847063 ;
    civico:citation "Riely et al., 2011, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_FarnesylthiosalicylicAcid ;
    dcterms:description "In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival rates compared to previously untreated patients." ;
    a m2r:Evidence .

civice:1219
    dct:references pbm:21862683 ;
    civico:citation "Kim et al., 2011, Mol. Cancer Ther." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gemcitabine,civic:drug_Erlotinib ;
    dcterms:description "In a retrospective study of 136 pancreatic cancer patients, point mutations in KRAS exon 2 were associated with worse overall survival compared to that of wild-type KRAS (5.8 vs 8.0 months; P = 0.001; multivariate analysis). This difference was largely driven by the subgroup of patients with reduced response to gemcitabine-erlotinib combination therapy (7.5% vs 23.3%) with overall survival of 5.2 vs 9.7 months (N=40 vs 30) compared to those that received other therapies with an overall survival of 7.0 months for both KRAS mutated (N=31) and KRAS wildtype (N=35) patients." ;
    a m2r:Evidence .

civice:1220
    dct:references pbm:22805291 ;
    civico:citation "Infante et al., 2012, Lancet Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "In a phase 1 clinical trial for the use of trametinib for various advanced solid tumors, 22 out of 30 NSCLC patients harbored KRAS mutations. Of those 22 patients with mutant KRAS, 8 saw reductions in tumor size ranging from 6-52% including 2 partial responses." ;
    a m2r:Evidence .

civice:1221
    dct:references pbm:16624552 ;
    civico:citation "Debiec-Rychter et al., 2006, Eur. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In a phase III clinical trial comparing different doses of imatinib in GIST patients, KIT exon 9 mutations were associated with significantly improved progression free survival (P=0.0013) and a 61% relative risk reduction in response to the higher dose regimen (N=31; 800mg/daily) when compared to the lower dose regimen (N=27; 400 mg/daily; HR 0.329; 95% CI 0.218–0.706). The same dose dependent responses were not observed with KIT exon 11 mutations (N=130 vs 118; P=0.25; HR 0.821; 95% CI 0.585–1.151) or with wild-type KIT (N=25 vs 27; P=0.07; HR 1.823; 95% CI 0.938–3.543)." ;
    a m2r:Evidence .

civice:1222
    dct:references pbm:21690468 ;
    civico:citation "Guo et al., 2011, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In a phase II clinical trial of 43 melanoma patients harboring KIT mutations or amplifications, imatinib treatment exhibited significant anti-tumor activity with a median progression free survival of 3.5 months, tumor regression in 41.9% of patients, and a 1-year overall survival rate of 51%. 9/10 partial responses were in patients with exon 11 or 13 KIT mutations." ;
    a m2r:Evidence .

civice:1223
    dct:references pbm:22439647 ;
    civico:citation "Rutkowski et al., 2012, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sunitinib ;
    dcterms:description "Primary tumor genotyping of 89 patients with metastatic GIST given 2nd-line sunitinib treatment after prior imatinib therapy failure, revealed an improved response to sunitinib in patients with KIT exon 9 mutations or with wild-type KIT compared those with KIT exon 11 or PDGFRA mutations. 1-year progression free survival rates for exon 9 mutants and wild type were 68% and 57%, compared with 34% and 15% for exon 11 and PDGFRA mutants." ;
    a m2r:Evidence .

civice:1224
    dct:references pbm:22261812 ;
    civico:citation "Minor et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Sunitinib ;
    dcterms:description "10 melanoma patients were evaluated after sunitinib treatment, among which 3 out of the 4 patients with KIT exon 11 mutations showed either complete or partial response." ;
    a m2r:Evidence .

civice:1225
    dct:references pbm:25542057 ;
    civico:citation "Coupe et al., 2015, Eur. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib,civic:drug_Docetaxel ;
    dcterms:description "Phase 1 trial of trametinib and docetaxel in patients with advanced melanoma lacking BRAF V600 mutations. 15 patients were enrolled (14 BRAF wt). Six patients had a partial response, including four out of eight patients with NRAS mutations." ;
    a m2r:Evidence .

civice:1226
    dct:references pbm:23414587 ;
    civico:citation "Ascierto et al., 2013, Lancet Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Binimetinib%28MEK162%29 ;
    dcterms:description "Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9 Patients, Gln61Arg 15 Patients). Another 13 patients had stable disease (63% disease control rate)." ;
    a m2r:Evidence .

civice:1227
    dct:references pbm:22805292 ;
    civico:citation "Falchook et al., 2012, Lancet Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "Phase 1 trial in 97 patients with melanoma (81 cutaneous or unknown, 16 uveal). Seven patients were found to harbor an NRAS mutation and two of them experienced stable disease (one 48 weeks on treatment). Patients with concurrent BRAFV600wt/NRASwt (n=20) had a trend of higher response rates (20%) than BRAFV600wt/NRAS-mutant patients (n=11; RR=0%; p=0.27), as well as a trend of higher percentage of patients on study at Week 24 or at 1 year (40% vs. 18% [p=0.26] and 30% vs. 0% [p=0.07], respectively)." ;
    a m2r:Evidence .

civice:1228
    dct:references pbm:22805292 ;
    civico:citation "Falchook et al., 2012, Lancet Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks." ;
    a m2r:Evidence .

civice:1229
    dct:references pbm:22805292 ;
    civico:citation "Falchook et al., 2012, Lancet Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks." ;
    a m2r:Evidence .

civice:1230
    dct:references pbm:25504439 ;
    civico:citation "Vujic et al., 2015, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Metformin,civic:drug_Trametinib ;
    dcterms:description "Preclinical study in 16 NRAS mutant cell lines (melanoma, lung carcinoma, neuroblastoma with various Q61, G13, G12 mutations). The combination of metformin and trametinib shown synergistic effects in most tested cell lines (no antagonistic effects observed) and a melanoma xenograft model. Metformin-induced PI3K pathway suppression was identified as a potential mechanism." ;
    a m2r:Evidence .

civice:1231
    dct:references pbm:23582881 ;
    civico:citation "Templeton et al., 2013, Eur. Urol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "In a phase II trial on castration-resistant prostate cancer patients, FISH detection of PTEN deletion was associated with increased progression free survival (p=0.07) and with improved PSA response (p=0.02) in response to everolimus, an mTOR pathway inhibitor." ;
    a m2r:Evidence .

civice:1232
    dct:references pbm:23238879 ;
    civico:citation "Trédan et al., 2013, Target Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "Tumors from 35 patients (12 with partial response or stable disease) with advanced endometrial carcinoma were assessed for PTEN mutational status, revealing 12 tumors with non-identical PTEN gene mutations. No mutations found in PTEN were effective in predicting tumor response to everolimus treatment. The clinical trial associated with this study is NCT00870337." ;
    a m2r:Evidence .

civice:1233
    dct:references pbm:23434733 ;
    civico:citation "Weekes et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_BAY86-9766 ;
    dcterms:description "Phase 1 study of MAPK1/2 inhibitor BAY 86-9766. 53 patients were evaluated for efficacy, one patients achieved a PR and 11 patients had stable disease. One ocular melanoma patient with prolonged stable disease, who later went on to complete 28 courses, was positive for GNAQ Q209L and PTEN R173S mutations. The PTEN mutation was identified only in the postdose biopsy and not in the predose biopsy." ;
    a m2r:Evidence .

civice:1234
    dct:references pbm:22038994 ;
    civico:citation "Landreville et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_LBH-589,civic:drug_ValproicAcid,civic:drug_Vorinostat%28SAHA%29,civic:drug_TrichostatinA%28TSA%29 ;
    dcterms:description "Somatic and germline BAP1 mutations are associated with uveal melanoma. In this preclinical study, gene set enrichment analysis revealed HDAC inhibitors as potential drugs in BAP1 mutant uveal melanomas. HDAC inhibitors VPA, TSA, LBH-589, and SAHA (vorinostat) were tested in-vitro and led to decreased proliferation (all inhibitors) decreased viability and cytotoxicity (TSA, SAHA, LBH-589) in-vitro and in-vivo (VPA). RNAi mediated BAP1 knockdown increased sensitivity to HDAC inhibition (VPA)." ;
    a m2r:Evidence .

civice:1235
    dct:references pbm:25970771 ;
    civico:citation "Sacco et al., 2015, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Vorinostat%28SAHA%29,civic:drug_Mocetinostat,civic:drug_MC1568 ;
    dcterms:description "A siRNA screen identified BAP1 associated with HDAC1 and HDAC2 expression. HDAC2 or BAP1 depletion sensitized a mesothelioma cell line (MSTO-211H) to HDAC inhibitors MC1568, vorinostat or mocetinostat. The paper indicates however, that temporary BAP knockdown might not adequately reflect long-term BAP1 mutation." ;
    a m2r:Evidence .

civice:1236
    dct:references pbm:26574622 ;
    civico:citation "Kim et al., 2016, Cancer Biol. Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ponatinib ;
    dcterms:description "Preclinical study in endometrial cancer cell lines (MFE-296, AN3CA, MFE-280 and Ishikawa). In cell proliferation assays, the three FGFR2 mutant cell lines were more sensitive to the pan-FGFR inhibitor ponatinib (AP24534) than the FGFR2 wild type cell line (Ishikawa) and human embryonic kidney cell line (HEK293). Ponatinib also inhibited FGFR2 kinase activity and phosphorylation (MFE-296 and MFE-280) as well as cell migration and invasion (MFE-296 and AN3CA) of FGFR2 mutated cancer cell lines." ;
    a m2r:Evidence .

civice:1237
    dct:references pbm:24670165 ;
    civico:citation "Shaw et al., 2014, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "In a phase 1 clinical trial (NCT01283516) 130 patients with advanced cancers all harboring ALK alterations were treated with ceritinib.  Of 114 NSCLC patients treated with at least 400 mg/daily ceritinib, 1 had a complete response, 65 had a partial response, 25 had stable disease, 12 had progressive disease, and 11 withdrew from the study early. Ceritinib dosed at 400 mg or higher had similar results in patients who had or had not received prior crizotinib treatment. Overall response rate for patients with prior crizotinib treatment (83 out of 122) was 56% with median progression free survival of 6.9 months. For patients who had no prior crizotinib treatment, median progression free survival was 10.4 months." ;
    a m2r:Evidence .

civice:1238
    dct:references pbm:21415852 ;
    civico:citation "Walter et al., 2011, Leukemia" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "12/150 patients with de novo myelodysplastic syndrome screened for DNMT3A mutations (bone marrow and paired normal skin) had heterozygous mutations with predicted translational consequences. 1 patient was identified with 2 nonsynonymous coding mutations. R882 mutations accounted for 4/13 reported mutations, P904L for 2/13 mutations and the remaining had not been previously reported at the time of this report. Overall and event-free survival were worse for DNMT3A mutant patients although transplantation status was not considered (log-rank p=0.005 and p=0.009). Transformation to AML was increased for mutant 7/12 (58%) versus wildtype 39/138 (28%) patients (p=0.007). The authors note larger cohorts will be required to confirm these results." ;
    a m2r:Evidence .

civice:1239
    dct:references pbm:18089725 ;
    civico:citation "Christensen et al., 2007, Mol. Cancer Ther." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "NPM-ALK in anaplastic large cell lymphoma (ALCL) was the first ALK-fusion to be discovered and characterized.  In this study, targeted activity against NPM-ALK by the ALK and MET inhibitor crizotinib was assessed in cell lines and tumor xenograft models. Treatment of NPM-ALK positive ALCL cell lines Karpas299 and SU-DHL-1 potently inhibited growth, and this was seen to occur at concentrations which also inhibited NPM-ALK phosphorylation in these cells. Administration of 100mg/kg/d crizotinib resulted in complete regression of all tumors, indicating that NPM-ALK could be an effective target for crizotinib in ALCL." ;
    a m2r:Evidence .

civice:1240
    dct:references pbm:21345110 ;
    civico:citation "Gambacorti-Passerini et al., 2011, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Crizotinib at 250mg daily was given to two patients with relapsed ALK-rearranged anaplastic large cell lymphoma (ALCL). Patient one, 26 yrs old, had been treated with the CHOP-15 chemotherapy regimen, then salvage chemotherapy to prepare for autologous bone marrow transplant but ultimately relapsed. After initiation of crizotinib, PET, CT and bone marrow aspirates showed complete remission of previous lesions at 28 days. At time of publication the patient continued to show persistent response at 6 months. A 20 year old patient relapsed after one month of CHOP, and was treated with further chemotherapy and autologous bone marrow transplantation resulting in partial response of 1 month. Crizotinib was initialized, and after 12 days PET scan showed complete regression of all lesions. On day 60 bone marrow aspirates were ALK-negative (pretreatment evaluation showed 8% ALK-positive). The authors conclude these two cases indicate sensitivity to crizotinib of relapsed ALK-rearranged ALCL." ;
    a m2r:Evidence .

civice:1241
    dct:references pbm:23598171 ;
    civico:citation "Mossé et al., 2013, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In the second part of this Phase I study NCT00939770, nine patients between the ages of 12 months and 22 years with anaplastic large cell lymphoma (ALCL), who were refractory to treatment and for whom no further known treatments were available, were treated with crizotinib. Six patients with detectable NPM-ALK transcript levels responded with partial response, 1 with complete response, and 1 with stable disease.  Crizotinib was well tolerated in these children." ;
    a m2r:Evidence .

civice:1243
    dct:references pbm:23598171 ;
    civico:citation "Mossé et al., 2013, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "As part of a phase 1 dose-escalation trial (NCT00939770), seven patients between ages 12 months and 22 years with relapsed or refractory inflammatory myofibroblastic tumors with ALK-rearrangement were given crizotinib. In six patients with measurable disease, responses included 3 with partial response and 3 with stable disease. One patient with evaluable disease had stable disease with treatment ongoing at the time of publication. Crizotinib was well tolerated in this group of pediatric patients." ;
    a m2r:Evidence .

civice:1244
    dct:references pbm:20979472 ;
    civico:citation "Butrynski et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "ALK-rearrangements are seen in 50% of inflammatory myofibroblastic tumor (IMT) cases. A 44 year old man was diagnosed with IMT.  He was treated with surgery and catheter placement for administration of cisplatin, doxyrubicin and mitomycin C.  Break-apart FISH showed ALK rearrangement, and immunohistochemical staining was characteristic of RANBP2 rearrangement. After further chemotherapy along with maintenance imatinib, crizotinib was started at 200mg twice daily, and a maximal partial response was achieved 5 months later, with regrowth occurring 2 months later. After further surgery, crizotinib was restarted at 250mg twice daily and almost 2 years later the patient was in complete radiographic remission. Another patient with non-ALK rearranged IMT was administered crizotinib in this study but did not respond." ;
    a m2r:Evidence .

civice:1245
    dct:references pbm:25408655 ;
    civico:citation "Chung et al., 2014, Case Rep Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "This case study presented a 53-year-old never-smoker with a poorly differentiated malignant neoplasm. Morphology and immunohistochemistry were unable to establish the primary tumor site. Right upper extremity (RUE), scalp, and multiple lung lesions were apparent. A lung lesion sample with sufficient material for molecular profiling was not attainable but sufficient material was present from the RUE for hybrid capture genomic profiling  (FoundationOne kit was used). EML4-ALK variant 2 was found, and the patient was started on crizotinib. Rapid symptom improvement was seen. After 1 month, a CT scan showed significant size reduction in lung tumors, and after 5 months the patient was asymptomatic with an entirely negative examination." ;
    a m2r:Evidence .

civice:1246
    dct:references pbm:26179511 ;
    civico:citation "Agelopoulos et al., 2015, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Ponatinib ;
    dcterms:description "116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines." ;
    a m2r:Evidence .

civice:1247
    dct:references pbm:26179511 ;
    civico:citation "Agelopoulos et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ponatinib ;
    dcterms:description "116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines." ;
    a m2r:Evidence .

civice:1248
    dct:references pbm:26917690 ;
    civico:citation "Subbiah et al., 2016, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "Case report of a 77-year old male patient with lung adenocarcinoma (T2aN1M0, stage IIA) without EGFR, KRAS, or BRAF mutations, and no ALK gene rearrangement. CD72-ROS1 was identified in sequencing after progression on chemotherapy. Crizotinib at 250 mg orally twice daily led to resolution of metastatic disease. The patient remained disease-free for 13 months when a CT-scan showed a relapse with two nodules in the right lower lobe. Stereotactic radiation therapy, gamma knife radiosurgery, and ipilimumab did not lead to a relevant response (new pleural nodules, new intracranial metastases). The patient next received ceritinib on a “Signature Trial\" for tumors with aberrations in ALK or ROS1 that are treated with oral ceritinib (LDK378) at 750 mg daily (NCT02186821). Restaging scans after two cycles showed a partial response confirmed after four cycles (56% decrease) per RECIST1.1. MRI showed that his brain metastases decreased as well." ;
    a m2r:Evidence .

civice:1249
    dct:references pbm:26372962 ;
    civico:citation "Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cabozantinib,civic:drug_Foretinib ;
    dcterms:description "Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective." ;
    a m2r:Evidence .

civice:1250
    dct:references pbm:26372962 ;
    civico:citation "Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib,civic:drug_Brigatinib,civic:drug_Ceritinib,civic:drug_AZD3463 ;
    dcterms:description "Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective." ;
    a m2r:Evidence .

civice:1251
    dct:references pbm:25733882 ;
    civico:citation "Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lorlatinib ;
    dcterms:description "Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M mutations in ROS1." ;
    a m2r:Evidence .

civice:1252
    dct:references pbm:25733882 ;
    civico:citation "Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. BaF3 cells expressing CD74-ROS1 L2026M were more resistant to crizotinib treatment than wildtype CD74-ROS1 in both cell viability and ROS1 phosphorylation. Crizotinib was also less effective at inhibiting kinase activity in ROS1 with L2026M mutation than wildtype. In contrast, PF-06463922 was effectively inhibited the fusion harboring this mutation in these assays." ;
    a m2r:Evidence .

civice:1253
    dct:references pbm:25733882 ;
    civico:citation "Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lorlatinib ;
    dcterms:description "Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo, and in enzyme assays. After establishing that the CD74-ROS1 L2026M mutation confers crizotinib resistance in kinase activity and cell viability assays (in transduced BaF3 cells), response to PF-06463922 was tested.  Wild-type CD74-ROS1, CD74-ROS1 G2032R, and CD74-ROS1 L2026M all showed sensitivity to PF-06463922 in these assays." ;
    a m2r:Evidence .

civice:1254
    dct:references pbm:25688157 ;
    civico:citation "Song et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "ROS1 kinase domain mutations were assessed in two patients with stage IIIa/IV pulmonary adenocarcinoma and a cell line. The ROS1 G2032R mutation was identified in a crizotinib-resistant tumor from one of the patients harboring the CD74–ROS1 fusion. Expression of CD74–ROS1 G2032R in Ba/F3 cells conferred resistance to crizotinib combared to CD74–ROS1 (IC50=353.62+/-20.15 vs. 2.76+/-0.82)." ;
    a m2r:Evidence .

civice:1255
    dct:references pbm:25688157 ;
    civico:citation "Song et al., 2015, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Foretinib ;
    dcterms:description "Ba/F3 cells expressing CD74–ROS1 G2032R showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1 (~128 fold higher IC50); however, showed relative sensitivity to foretinib (only ~6 fold higher IC50 than WT)." ;
    a m2r:Evidence .

civice:1256
    dct:references pbm:25688157 ;
    civico:citation "Song et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib,civic:drug_Foretinib,civic:drug_TAE684 ;
    dcterms:description "The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2–ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib treatment and CD74–ROS1 rearrangment. Crystal structure predicted ROS1 L2155S mutation to be highly destabilizating and cause protein structural modification. HCC78CR1, 2, and 3 cells and Ba/F3 cells transfected with CD74–ROS1 L2155S, showed resistance to crizotinib compared with parental HCC78 and Ba/F3 cells. In addition, these cell lines showed resistance to foretinib, a potent ROS1 inhibitor that is effective against ROS1 G2032R-mutant cells (16), and TAE684, a potent ALK inhibitor" ;
    a m2r:Evidence .

civice:1257
    dct:references pbm:25688157 ;
    civico:citation "Song et al., 2015, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74–ROS1; however, showed similar sensitivity to foretinib." ;
    a m2r:Evidence .

civice:1258
    dct:references pbm:25688157 ;
    civico:citation "Song et al., 2015, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Foretinib ;
    dcterms:description "Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed similar sensitivity to foretinib compared with those expressing wild-type CD74–ROS1. This is in contrast to the increased resistance to crizotinib associated with this mutation in the same assay." ;
    a m2r:Evidence .

civice:1259
    dct:references pbm:25688157 ;
    civico:citation "Song et al., 2015, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib." ;
    a m2r:Evidence .

civice:1260
    dct:references pbm:25688157 ;
    civico:citation "Song et al., 2015, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Foretinib ;
    dcterms:description "Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib." ;
    a m2r:Evidence .

civice:1261
    dct:references pbm:21494621 ;
    civico:citation "Cerchietti et al., 2011, PLoS ONE" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_TAE684 ;
    dcterms:description "A cell line called LM1 was established from the bone marrow of a 13 year old female patient with relapsed CLTC-ALK positive diffuse large B-cell lymphoma (DLBCL). The patient had been heavily treated with chemotherapy before establishment of the cell line. The cell line maintained the tumor immunophenotype.  SNP analysis of patient bone marrow mononuclear cells and LM1 showed chromosomal changes associated with the cell line but 94.7% of SNPs were identically called.  ALK kinase inhibitor TAE684 induced cell death in LM1 cells at low nanomolar concentrations, while it did not significantly effect the ALK-rearrangement negative DLBCL cell line Karpas422.  LM1 cells formed tumors in 3/10 SCID and 9/10 NOD-SCID mice.  CD30 and CD138 immmunostaining were maintained between original tumor and LM1 xenografts. In mice, LM1 but not Karpas422 xenografts regressed with TAE684 administration, and complete remission for 13 weeks was observed before experiment was terminated." ;
    a m2r:Evidence .

civice:1262
    dct:references pbm:27058230 ;
    civico:citation "Barraco et al., 2016, Blood Cancer J" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a large study of patients with primary myelofibrosis evaluating mutations associated with anemia, 457 patients were evaluated for U2AF1 mutations. U2AF1 mutations were significantly associated with anemia in univariate and multivariate analysis (72 mutated vs 385 wildtype; P<0.0001). U2AF1 mutations were significantly associated with shorter overall survival in univariate analysis (P < 0.0001) but not in multivariate analysis with adjustment for age and anemia (P=0.24)." ;
    a m2r:Evidence .

civice:1263
    dct:references pbm:19636007 ;
    civico:citation "Laurent et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "C" ;
    dcterms:description "CLTC-ALK is one of the most common ALK fusions found in diffuse large B cell lymphoma (DLBCL). In a retrospective study of 38 patients with ALK-rearranged DLBCL, 3 were CD20 positive. Only one showed cytoplasmic, nuclear and nucleolar staining associated with NPM-ALK, while the others showed granular cytoplasmic ALK stain characteristic for CLTC-ALK.  Seven molecularly characterized cases were positive for CLTC-ALK.  6/7 patients were treated with CHOP chemotherapy with survival of 5, 10, 26 and 27 months, and two alive at end of study, and one CD20 positive patient was treated with CHOP chemotherapy supplemented with CD20-targeted rituximab, with survival of 8 months, resulting in median survival of 26 months for this group.  Although these numbers are not sufficient for statistical comparison, they compare unfavorably to 3.1 year overall survival and 45% 5 year survival of CHOP treated DLBCL patients, and even less favorably to R-CHOP standard of care for CD20 positive DLBCL, suggesting poor prognosis for CLTC-ALK DLBCL and need for updated treatment in this cohort." ;
    a m2r:Evidence .

civice:1264
    dct:references pbm:24330038 ;
    civico:citation "Wass et al., 2014, Eur. J. Haematol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A 27 year old female patient with advanced-stage IV, CD20 negative diffuse large B cell lymphoma (DLBCL). ALK rearrangement was determined by FISH, but the ALK fusion partner was not determined due to limited tissue. The patient underwent treatment with CHOP chemotherapy regimen and radiation but did not respond. The patient progressed following salvage chemotherapy and autologous stem cell transplant. Crizotinib was then administered at 250 mg twice daily, and LDH levels rapidly dropped along with disappearance of palpable lymphadenopathy, but progression ensued after 21 days and the patient died soon after. The authors attribute the short response to crizotinib to the possibility of this tumor having an ALK fusion variant less responsive to ALK inhibition and to a high Ki-67 index in the patient, and deem that despite the brief response, crizotinib shows promise in ALK rearranged DLBCL." ;
    a m2r:Evidence .

civice:1265
    dct:references pbm:26221234 ;
    civico:citation "Li et al., 2015, Int J Clin Exp Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A 21 year old male presented with lymphadenopathy and a low density mass in pancreas. Histopathological analysis showed diffuse tumor cell infiltrate (CD20/EMA negative) with cytoplasmic ALK. RT-PCR indicated CLTC-ALK fusion. The patient was diagnosed with splenic ALK + diffuse large B cell lymphoma (DLBCL), Stage III, Group A with an IPI of 3. CHOP-21 chemotherapy regimen was administered with improvement in abdominal lymph nodes but worsening in retroperitoneal lymph nodes assessed via standardized uptake values. Subsequent ICE chemotherapy regiment relieved some symptoms prompting the patient to refuse further treatment despite other indications of disease progression. Therapy was reinstated after worsening of disease. GEMOX chemotherapy was administered with dexamethasone and 250mg crizotinib twice daily resulting in symptom relief, decreased lymphadenopathy and LDH decline. The disease then progressed and the patient died 2 months after crizotinib initiation. The authors conclude that partial response to crizotinib was observed and that in future trials ALK rearranged DLBCL patients might see increased benefit with earlier application of targeted therapy during the treatment course." ;
    a m2r:Evidence .

civice:1266
    dct:references pbm:22252991 ;
    civico:citation "Sugawara et al., 2012, Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    dcterms:description "Adenocarcinoma cells were detected via urinary cytology in a 53 year old woman. Cancer morphology suggested papillary renal cell carcinoma (RCC), type 2A.  EML4-ALK variant 5 was discovered in tumor tissue using PCR with EML4 and ALK specific primers. The authors conclude that their findings confirm the potential for ALK targeting therapy in select cases of RCC." ;
    a m2r:Evidence .

civice:1267
    dct:references pbm:26732095 ;
    civico:citation "Chen et al., 2016, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_LY3009120 ;
    dcterms:description "Cells harboring in-frame deletions in BRAF in the L485-P490 amino acid region were found to be sensitive to the RAF dimer inhibitor LY3009120, but not sensitive to the BRAF-selective inhibitors vemurafenib or dabrafenib. These deletions were observed in KRAS wildtype pancreatic, ovarian, NSCLC, and thyroid cancers. In three cell lines H2405 (NSCLC with L485-P490>Y), BxPC-3 (pancreatic with V487-P492>A), and OV-90 (ovarian with N486-P490del), BRAF deletion–mediated MAPK activation was found to be sensitive to LY3009120 as evidenced by dose-dependent inhibition of phospho-MEK and ERK and cell growth inhibition with IC50 values of 0.04, 0.087, and 0.007 μmol/L in these three cell lines. LY3009120, but not vemurafenib, also inhibited tumor growth of both H2405 and BxPC-3 cells xenografted into mice." ;
    a m2r:Evidence .

civice:1269
    dct:references pbm:23598171 ;
    civico:citation "Mossé et al., 2013, Lancet Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "This Phase I study of crizotinib involved a cohort of pediatric neuroblastoma patients between ages 12 months and 22 years. In 11 patients with characterized ALK mutations, 4 had R1275Q mutations, and two of these were germline mutations.  Of these 2 germline patients, 1 showed stable disease (SD) and 1 complete response (CR). In contrast, in the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The authors conclude this finding is promising and merits further study." ;
    a m2r:Evidence .

civice:1270
    dct:references pbm:23598171 ;
    civico:citation "Mossé et al., 2013, Lancet Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A cohort of pediatric neuroblastoma patients ages 12 months to 22 years were assessed for response to crizotinib in a Phase I study.  11 patients in this cohort had characterized ALK mutations, 4 of which were R1275Q mutation. Two of these R1275Q mutations were germline and two were somatic. Of these 2 somatic R1275Q patients, 1 showed progressive disease (PD) and 1 showed stable disease (SD). In contrast, of the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The stable disease patient had an R1275L mutation in ALK. In general, patients with germline or somatic R1275Q mutations or R1275L mutations had 1 complete response, 3 SD and one PD, while patients with other ALK mutations had 6 PD." ;
    a m2r:Evidence .

civice:1271
    dct:references pbm:23598171 ;
    civico:citation "Mossé et al., 2013, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In a Phase I trial (NCT00939770) of the drug crizotinib in pediatric patients, a subset of 11 neuroblastoma patients were characterized for mutations in ALK. Of these 11 patients, 4 had the F1174L mutation. Among these 4 patients, stable disease (SD) was observed in one, and progressive disease (PD) was observed in 3 others after administration of crizotinib. In contrast, in the remaining 7 patients with mutations different than F1174L, 4 had PD, 2 had SD and one had complete response as best response after initiation of crizotinib." ;
    a m2r:Evidence .

civice:1272
    dct:references pbm:23639470 ;
    civico:citation "Seto et al., 2013, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "In this initial report of a single-arm Phase I and II study (JapicCTI-101264) of alectinib (CH5424802), 46 patients with advanced or metastatic ALK-rearranged non small cell lung cancer (NSCLC) were assessed for objective response during phase II. ALK positivity was assessed via IHC and verified with FISH or RT-PCR. Patients had received one or more rounds of previous chemotherapy, but no prior targeted therapy towards ALK. From the 46 patients, 41 showed partial response, and 2 showed complete response. CNS metastases in three patients which had not received prior brain irradiation showed response to alectinib. Alectinib was generally well tolerated, and the authors conclude that alectinib compared favorably to crizotinib and could be an effective and safe option in ALK-rearranged NSCLC." ;
    a m2r:Evidence .

civice:1273
    dct:references pbm:26938871 ;
    civico:citation "Yoshida et al., 2016, Anticancer Drugs" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_CH5424802 ;
    dcterms:description "In this case study of a critically ill 29 year old male nonsmoker with advanced metastatic ALK-positive NSCLC, alectinib (CH5424802), was administered as first line treatment. Where most clinical trials only admit patients with Eastern Cooperative Oncology Performance status (PS) of 0 or 1, this patient had PS 4 due to respiratory failure, multiple bone metastases and complications from disseminated intravascular coagulation (DIC). Administration of alectinib at 300 mg twice daily was followed by marked improvement seen in tests associated with DIC, pulmonary metastasis and change in PS from 4 to 0. Further improvements after a couple of months suggested a rapid complete response. Alectinib was well tolerated in this first line treatment of a critically ill ALK-positive NSCLC patient." ;
    a m2r:Evidence .

civice:1274
    dct:references pbm:27086918 ;
    civico:citation "Chowdhury et al., 2016, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody). Patients with increased PD-L1 protein had significantly shorter median DFS (36 months [membranous staining] and 49 months [cytoplasmic staining] vs. 186 months [negative], p < 0.001 and p < 0.01, respectively)." ;
    a m2r:Evidence .

civice:1275
    dct:references pbm:27009855 ;
    civico:citation "Böger et al., 2016, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein expression. PD-L1 positivity in tumor cells was defined by at least 2% tumor cells with membranous positivity, PD-L1 positivity in immune cells by at least 10% PD-L1 positive immune cells. Patients with PD-L1 positive tumor cells had a significant better overall (p=0.028) and tumor specific survival (p=0.018). The same applied for patients with PD-L1 positive immune cells (p<0.001 each)." ;
    a m2r:Evidence .

civice:1276
    dct:references pbm:27019113 ;
    civico:citation "Yasuda et al., 2016, Nat. Genet." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "D" ;
    dcterms:description "A screen for fusion genes in Ph- AYA-ALL (Philadelphia chromosome negative acute lymphoblastic leukemia in adolescents and young adults) was performed using RNA-seq from multiple cohorts of ALL patients. DUX4, ZNF384 and MEF2D fusions were the most frequent found.  DUX4 fusions were found only in AYA cases (age 15-39) and this was significant, p=0.016. DUX4 fusions clustered into groups distinct from the other fusions, and these fusions as a whole clustered with Ph- ALL cases. The authors performed extensive in vitro and in vivo experiments to demonstrate that DUX4 fusions are likely early initiating/events and that DUX4 fusion and not DUX4 wild type are tumorigenic. The authors conclude that DUX4 fusions may be a target driver resulting in AYA-ALL, and that AYA-ALL may be a distinct clinical entity." ;
    a m2r:Evidence .

civice:1277
    dct:references pbm:27019113 ;
    civico:citation "Yasuda et al., 2016, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Ph- ALL (Philadelphia chromosome negative acute lymphoblastic leukemia) gene expression profiles cluster into two main groups, Ph like and non-Ph like ALL.  Non-Ph like ALL have favorable outcomes when compared with Ph like ALL.  DUX4 fusions were discovered in a subset of Ph- ALL tumors through RNA-seq, and their mutation profile was found to cluster with non-Ph like ALL. It was found that patients with DUX4 fusions (N=9) had improved disease free survival over Ph like ALL patients (N=6) in the study. Eight years after complete remission, DUX4 fusion positive patients had over 0.8 disease free survival probability." ;
    a m2r:Evidence .

civice:1278
    dct:references pbm:27092876 ;
    civico:citation "Xie et al., 2016, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "438 patients with non-metastatic clear-cell renal carcinoma were were retrospectively analysed for B4GALT1 expression via IHC. High B4GALT1 expression was associated with poor overall survival (P<0.001 and P<0.001 in training and validation cohort) and identified as an independent adverse prognostic factor for survival (P=0.007 and P=0.002)." ;
    a m2r:Evidence .

civice:1279
    dct:references pbm:25153538 ;
    civico:citation "Gadgeel et al., 2014, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "In this Phase I trial (NCT01588028) in 47 patients, alectinib was assessed for its effectiveness in treating locally advanced or metastatic ALK-positive NSCLC that had progressed or been resistant to crizotinib treatment. ALK rearrangement was assessed via approved break apart FISH kit, and patients with asymptomatic CNS metastases were also included. Patients were divided into different cohorts receiving different doses of alectinib. In the 600 mg cohort (N=13), there were 4 confirmed partial responses, 3 unconfirmed partial responses and 3 instances of stable disease. Also, five of nine patients throughout the cohorts with measurable baseline CNS lesions showed partial response to alectinib. Cerebrospinal fluid levels of alectinib increased linearly with blood alectinib levels, indicating it effectively crossed the blood-brain barrier." ;
    a m2r:Evidence .

civice:1280
    dct:references pbm:22426421 ;
    civico:citation "Ng et al., 2012, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "DNA sequencing was performed in five Ph+ CML samples with sensitivity or resistance to imatinib. A structural variation in BIM2 (BCL2L11) with an identical 2,903-bp genomic deletion was identified in all three resistant samples. 2,597 healthy individuals were screened and the deletion polymorphism was identified in 12.3% of East Asian Population but 0% in African or European Population. In-vitro, imatinib-induced apoptosis was reduced in cells harboring the BIM deletion polymorphism. Two East Asian CML cohorts (n=203) treated with imatinib were analzed for the polymorphism. Overall odds ratio for resistant disease among subjects with the deletion polymorphism compared to those without it was 2.94 (P = 0.02, 95% CI 1.17–7.43). Patients with the polymorphism, compared to those without, were more likely to be resistant without BCR-ABL mutations than resistant with BCR-ABL mutation or sensitive (odds ratio = 1.90, 95% CI 1.08–4.35)." ;
    a m2r:Evidence .

civice:1281
    dct:references pbm:22426421 ;
    civico:citation "Ng et al., 2012, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_EGFRInhibitor ;
    dcterms:description "The BIM (BCL2L11) deletion polymorphism was identified in an EGFR Mutant NSCLC cell line with resistance to EGFR-TKI (HCC2779). Introduction of this polymorphism in a previously EGFR-inhibitor sensitive cell line led to TKI-resistance. In 141 NSCLC patients with EGFR mutations, the presence of the polymorphism (N=26) was predictive of a significantly shorter PFS under treatment with EGFR-TKI (6.6 months vs. 11.9 months, p = 0.0027). Patients received either gefitinib only (N=136) or erlotinib only (N=5)." ;
    a m2r:Evidence .

civice:1282
    dct:references pbm:26708155 ;
    civico:citation "Shaw et al., 2016, Lancet Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "In this Phase II trial of 87 patients (NCT01871805), alectinib was assayed for safety and efficacy in ALK positive NSCLC that had progressed on crizotinib. Of 69 patients with measurable disease, 35 achieved objective response, with median duration of response 13.5 months. Of 16 patients with measurable CNS disease, four achieved CNS complete response and 8 showed CNS partial response. median duration of CNS response was 11.1 months. 2 deaths were observed, and 1 was judged related to study treatment. In early 2016, alectinib was approved by the FDA partly based on this study for treatment of crizotinib-progressed ALK positive NSCLC" ;
    a m2r:Evidence .

civice:1283
    dct:references pbm:25228534 ;
    civico:citation "Katayama et al., 2014, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "The I1171T mutation in ALK fusions was found in a NSCLC patient shown positive for ALK rearrangement via break apart FISH assay, who progressed after 8 months of crizotinib, and then progressed again after 4 months of alectinib. The MGH056-1 cell line was derived from this patient, and this cell line was resistant to alectinib. Sequencing of MGH056-1 cells revealed the I1171T mutation in ALK. In cell culture studies Ba/F3 cells with EML4-ALK I1171T required more that 10x the concentration of alectinib to significantly reduce viability that was required for EML4-ALK wild-type expressing cells. Computer simulation studies indicated that the I1171T mutation interfered with alectinib binding at the ALK active site." ;
    a m2r:Evidence .

civice:1284
    dct:references pbm:25228534 ;
    civico:citation "Katayama et al., 2014, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "The MGH056-1 cell line was derived from an NSCLC patient with ALK-rearrangement who had progressed on crizotinib and then on alectinib. the cell line was also resistant to crizotinib and alectinib, and sequencing of ALK from the cell line revealed the I1171T mutation. Further testing of this mutation in BaF3 cells revealed that cells expressing EML4-ALk with I1171T mutation required 10x higher concentration to induce cell death than BaF3 cells with wild-type EML4-ALK. In contrast, ceritinib caused loss of viability in EML4-ALK wild-type and I1171T BaF3 cells at comparable concentrations. Ceritinib was also effective at killing MGH056-1 cells that were resistant to alectinib, and reduced Akt and ERK phosphorylation in these cells. Finally, administration of ceritinib to the crizotinib and alectinib resistant patient let to tumor regression and partial response lasting 7 months." ;
    a m2r:Evidence .

civice:1285
    dct:references pbm:25228534 ;
    civico:citation "Katayama et al., 2014, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_TAE684 ;
    dcterms:description "The I1171T ALK kinase domain mutaion was found in the MGH056-1 cell line which was derived from an ALK rearranged NSCLC patient who had progressed on crizotinib and then on alectinib given at lower dose (300mg twice daily).  Ectopic expression of EML4-ALK I1171T in Ba/F3 cells made these cells moderately resistant to crizotinib and resistant to alectinib. In contrast, the frequently used tool compound TAE684 was equally effective against EML4-ALK wild-type and I1171T, causing cell death at 1000x lower concentration then in unaltered Ba/F3 cells supplemented with IL3." ;
    a m2r:Evidence .

civice:1286
    dct:references pbm:25228534 ;
    civico:citation "Katayama et al., 2014, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "The EML4 ALK variant 1 containing NSCLC cell line H3122 is highly sensitive to alectinib, and an alectinib resistant derivative cell line H3122 CHR-A1 was generated by incubation of H3122 in increasing levels of alectinib culminating in 1 micro-molar, over a course of 7 months. The ALK kinase domain mutation V1180L was found in these cells, and Ba/F3 cells expressing EML4 ALK  V1180L were highly resistant to alectinib. Simulations indicated that the V1180L mutation interfered with alectinib binding. The V1180L mutation was found to be more resistant to alectinib than the I1171T mutation found in an ALK-positive NSCLC patient who developed alectinib resistance on lower dose alectinib  (300mg twice daily)." ;
    a m2r:Evidence .

civice:1287
    dct:references pbm:25228534 ;
    civico:citation "Katayama et al., 2014, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "The MGH056-1 cell line was derived from a patient with ALK rearranged NSCLC who had progressed on crizotinib and then on lower dose alectinib (300 mg twice daily). The I1171T ALK kinase domain mutation was found in this cell line (established after alectinib resistance). MGH056-1 cells were resistant to crizotinib (IC50 236nmol/L; aproximately 50x higher than for ceritinib). About 50 fold higher concentration of crizotinib was required to inhibit Ba/F3 cells expressing EML4 ALK I1171T than was required for EML4 ALK wild-type." ;
    a m2r:Evidence .

civice:1288
    dct:references pbm:25228534 ;
    civico:citation "Katayama et al., 2014, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "The alectinib resistant cell line H3122 CHR-A1 was generated by culturing of the EML4-ALK (variant 1) containing cell line H3122 with increasing levels of alectinib. Molecular characterization of H3122 CHR-A1 revealed a V1180L ALK kinase domain mutation. The H3122 CHR-A1 cell line required approximately 10 fold increase in crizotinib concentration to induce similar levels of cell death to H3122. Ectopic expression of EML4-ALK V1180L rendered Ba/F3 cells moderately less susceptible to crizotinib than ectopic EML4-ALK." ;
    a m2r:Evidence .

civice:1289
    dct:references pbm:25228534 ;
    civico:citation "Katayama et al., 2014, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "Passaging of the alectinib sensitive EML4-ALK containing H3122 NSCLC cell line with increasing levels of alectinib resulted in an alectinib resistant derivative of this cell line named H3122 CHR-A1. A V1180L missense mutation was found in the kinase domain of ALK in H3122 CHR-A1 cells. Both H3122 and H3122 CHR-A1 cells were highly and equally sensitive to ceritinib induced death. In Ba/F3 cells, ectopic expression of EML4-ALK V1180L rendered cells significantly more sensitive to ceritinib than Ba/F3 containing EML4-ALK I1171T mutant (alectinib and crizotinib resistant) or EML4-ALK wt." ;
    a m2r:Evidence .

civice:1290
    dct:references pbm:25228534 ;
    civico:citation "Katayama et al., 2014, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_TAE684 ;
    dcterms:description "The V1180L mutation in the kinase domain of rearranged ALK was found in an alectinib resistant cell line named H3122 CHR-A1, which was derived from the alectinib sensitive EML4-ALK variant 1 containing NSCLC cell line H3122 by passaging into higher concentrations of alectinib. This cell line is a model for gain of alectinib resistance, and also shows resistance to crizotinib. On the other hand, the often used tool ALK inhibitor TAE684 was highly effective in killing H3122 CHR-A1, where H3122 cells were only slightly more sensitized to TAE684-induced cell death. Ectopic expression of EML4-ALK V1180L in Ba/F3 cells caused IL3 independent growth as well as marked sensitization to TAE684, to a level greater than that seen in EML4-ALK I1171T (alectinib resistance mutation) or EML4-ALK wt, and over 1000x greater sensitivity than unaltered Ba/F3 + IL3." ;
    a m2r:Evidence .

civice:1291
    dct:references pbm:25228534 ;
    civico:citation "Katayama et al., 2014, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Brigatinib ;
    dcterms:description "ALK mutation V1180L was found in an H3122 derivative cell line that had become alectinib resistant after being passaged in increasing levels of alectinib. EML4-ALK V1180L and EML4-ALK wild-type were ectopically expressed in Ba/F3 cells, and brigatinib showed strong activity against both variants. The IC50 for brigatinib against EML4-ALK wild-type was 0.95, which is about 3x higher than the IC50 that was observed for alectinib, but about 6x lower than that for crizotinib. In contrast, the IC50 for brigatinib against the alectinib resistance variant EML4-ALK V1180L was 0.49, indicating increased sensitivity to brigatinib over non mutant EML4-ALK." ;
    a m2r:Evidence .

civice:1292
    dct:references pbm:25423555 ;
    civico:citation "Kamphues et al., 2015, Pancreas" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Absent expression of ATM, as assessed by IHC in 133 pancreatic ductal adenocarcinomas, was found to be associated with dismal prognosis (median survival, 9.6 months), whereas expression of ATM was associated with increased survival (17.7 months, P = 0.001). Furthermore loss of expression of nuclear phosphorylated Ser1981-ATM (IHC) was indicative of the worst prognosis (median survival, 10.8 vs 14.3 months [low expression] vs 31.1 months [high expression], P < 0.001)." ;
    a m2r:Evidence .

civice:1293
    dct:references pbm:24088390 ;
    civico:citation "Stenzinger et al., 2013, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Nuclear Sirt1 expression was identified by IHC in 36 (27.9%) of 129 pancreatic ductal adenocarcinoma cases. SIRT1 expression was associated with poor survival in univariate (p = 0.002) and multivariate (HR 1.65, p = 0.045) analyses. Overexpression of Sirt1 in pancreas cancer cell lines MiaPaCa-2 and PANC-1 led to increased cell viability." ;
    a m2r:Evidence .

civice:1294
    dct:references pbm:24088390 ;
    civico:citation "Stenzinger et al., 2013, BMC Cancer" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nicotinamide ;
    dcterms:description "In-vitro study with MiaPaCa-2 and PANC-1 pancreatic cancer cell lines. Inhibition of Sirt1 by increasing concentrations of nicotinamide led to a decrease in viability. Gefitinib treatment with concentrations of 50 μM showed similar effects as observed for the application of 25 mM nicotinamide. Combinatory treatment with gefitinib and nicotinamide showed a synergistic effect on cell viability. In cell lines overexpressing Sirt1, higher concentrations of nicotinamide were required to abrogate increased cell viability mediated by Sirt1 overexpression compared to controls." ;
    a m2r:Evidence .

civice:1295
    dct:references pbm:20733134 ;
    civico:citation "Fischer et al., 2010, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Midostaurin ;
    dcterms:description "In a phase 2 clinical study of 95 AML/high-risk MDS patients treated with either 50 or 100 mg midostaurin, 35 harbored FLT3 mutations (26 had FLT3 ITD, 9 had FLT3 D835Y mutations). A higher percentage of patients saw blast reductions in the FLT3 mutant group than in the FLT3 wild type group (71 vs 42%). Only one permanent response occurred in a FLT3 mutant patient receiving the 100 mg dose. No differences were observed in toxicity or response rate between the two doses of midostaurin." ;
    a m2r:Evidence .

civice:1296
    dct:references pbm:27091708 ;
    civico:citation "André et al., 2016, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combinedly analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance." ;
    a m2r:Evidence .

civice:1297
    dct:references pbm:27091708 ;
    civico:citation "André et al., 2016, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PTEN loss (as defined by IHC staining intensity and proportion of positive tumor cells) had a longer progression-free survival with everolimus compared to placebo (HR 0.54 (95%CI 0.31 to 0.96, P=0.04) whereas patients with PTEN normal status had a hazard ration of 1.00 (95%CI 0.8 to 1.26, P=0.97). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combined and analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance." ;
    a m2r:Evidence .

civice:1298
    dct:references pbm:22983505 ;
    civico:citation "Ogura et al., 2013, J. Gastroenterol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (N=17) or G12D (N=92) was associated with poorer prognosis (overall survival HR 1.6; 95% confidence interval 1.11-2.28)." ;
    a m2r:Evidence .

civice:1300
    dct:references pbm:27010960 ;
    civico:citation "Bournet et al., 2016, Clin Transl Gastroenterol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 219 patients with metastatic pancreatic ductal adenocarcinoma, a multivariate analysis identified KRAS G12D mutations as an independent predictor of poorer prognosis both in patients that have received chemotherapy (N=49/162), and the entire series (N=73/219). HR of 1.84 (P=0.02) and 1.44 (P=0.01), respectively." ;
    a m2r:Evidence .

civice:1301
    dct:references pbm:24296758 ;
    civico:citation "Aisner et al., 2014, Mol. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases. Break apart FISH assay, which does not distinguish ROS1-fusion partner, was used on the tissue microarray to determine ROS1 fusion status. 2 cases of ROS1 fusions were found. 1 case was verified by RT-PCR to be a SLC34A2-ROS1 fusion, but this case was also positive for BRAF V600E.  The second case of ROS1 fusion was of undetermined fusion partner, where known ROS1 fusion parters SLC34A2, CD74 and SDC4 were tested. This case did not have KRAS or BRAF mutations, indicating that ROS1 fusion may act in a small subset of colorectal cancer as a driver targetable by crizotinib or other inhibitors." ;
    a m2r:Evidence .

civice:1302
    dct:references pbm:17909070 ;
    civico:citation "Schmidt et al., 2007, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Large meta-analysis of 5,191 breast cancer patients and 3,834 controls did not find a conclusive link between codon 72 allele and breast cancer susceptibility. Odds ratios were 0.98 (95% CI, 0.91–1.05) for heterozygotes and 0.97 (95% CI, 0.86–1.11) in homozygotes (per-allele OR, 0.98; 95% CI, 0.91–1.04). Median age of onset was also not different between genotypes (GG: 49 years, GC: 50, CC: 50)." ;
    a m2r:Evidence .

civice:1303
    dct:references pbm:12840112 ;
    civico:citation "Matakidou et al., 2003, Mutagenesis" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Pooled data from 13 studies of patients with lung cancer found little effect of codon 72 allele on the overall survival of patients with lung cancer. Proline homozygous patients were correlated with slightly poorer outcome, odds ratio 1.18 with a 95% confidence interval of 0.99-1.41. Heterozygotes had an OR of 1.02 (95% CI 0.86-1.20). Authors conclude that the effect of these alleles on prognosis in lung cancer is inconclusive at best." ;
    a m2r:Evidence .

civice:1304
    dct:references pbm:11535556 ;
    civico:citation "Klug et al., 2001, Cancer Epidemiol. Biomarkers Prev." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a relatively small meta-analysis of 119 women with cervical cancer and 127 controls, associations with homozygosity for arginine, and heterozygosity at this locus were both associated with odds ratios above one (3.5 and 2.2, respectively) after adjusting for age and HPV infection. However, both confidence intervals had minimums below one (0.9 and 0.6, respectively). So the overall conclusion remains mixed on the significance of this polymorphism in the prognosis for cervical cancer." ;
    a m2r:Evidence .

civice:1305
    dct:references pbm:21135251 ;
    civico:citation "Villarroel et al., 2011, Mol. Cancer Ther." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_MitomycinC ;
    dcterms:description "In a patient with gemcitabine-refractory pancreatic cancer, a tumor-derived xenograft was found to be responsive to Mitomycin C. After disease progression, the patient was started on a regimen of mitomycin C, and the patient was shown to be asymptomatic after 3 years of follow-up." ;
    a m2r:Evidence .

civice:1306
    dct:references pbm:11751510 ;
    civico:citation "Tascilar et al., 2001, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis. SMAD4 was assessed by IHC in 56 of 249 (22%).  Relative hazard of mortality for cancers lacking SMAD4 after adjusting for other prognostic factors was 1.36 (95% confidence interval, 1.01-1.83; P = 0.04)." ;
    a m2r:Evidence .

civice:1307
    dct:references pbm:16243825 ;
    civico:citation "van der Heijden et al., 2005, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_MitomycinC,civic:drug_Cisplatin,civic:drug_Chlorambucil,civic:drug_Melphalan,civic:drug_Gemcitabine ;
    dcterms:description "In the pancreatic cell lines PL11 (FANCC homozygous deletion) and Hs766T (FANCG-mutated), sensitivity to DNA cross-linking agents was observed. PL11 cells (empty vector transduced) were more sensitive to mitomycin C (MMC), cisplatin, chlorambucil, and melphalan than PL11 cells transduced with a vector wildtype FANCC. Similarly, mouse xenografts of PL11 cells (empty vector) were more sensitive to MMC or gemcitabine than PL11 cells expressing a wildtype FANCC." ;
    a m2r:Evidence .

civice:1308
    dct:references pbm:16243825 ;
    civico:citation "van der Heijden et al., 2005, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_MitomycinC ;
    dcterms:description "In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and MiaPaCa2). Mitomycin C specifically led to regression in 8/11 xenografts of the CAPAN1 cell line compared to 2/9 in the CFPAC (BRCA2 wildtype) cell line." ;
    a m2r:Evidence .

civice:1309
    dct:references pbm:14645423 ;
    civico:citation "Heinrich et al., 2003, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "15/127 patients with metastatic gastrointestinal stromal tumors were tested for PDGFRA mutations. 1 patient had a deletion of I843. CHO cells expressing this variant showed similar sensitivity to imatinib as cells expressing wildtype PDGFRA. 2/3 patients with a mutation determined to be sensitive in vitro (del I843 included) achieved partial response on imatinib treatment." ;
    a m2r:Evidence .

civice:1310
    dct:references pbm:23835704 ;
    civico:citation "Weston et al., 2013, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A 10-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an EBF1-PDGFRB fusion responded to imatinib plus induction chemotherapy (vincristine, daunorubicin, prednisone, and intrathecal methotrexate). Complete remission was achieved with bone marrow MRD of 0.059% by flow cytometry and normal PDGFRB by FISH. Consolidation therapy with cyclophosphamide, cytarabine, mercaptopurine, and imatinib followed and the patient was still in remission 10 months after beginning imatinib." ;
    a m2r:Evidence .

civice:1311
    dct:references pbm:23565280 ;
    civico:citation "Rachakonda et al., 2013, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 171 patients with tumors of the exocrine pancreas, a KRAS G12D mutation (N=60) was associated with shorter overall survival than being wild-type for KRAS (N=21; Hazard Ratio: 95% CI between 1.14 and 2.67). Additionally, KRAS mutations combined with CDKN2A alterations (N=26) showed an even worse OS than those wild-type for both (N=17; HR: 95%CI 1.33-7.10)." ;
    a m2r:Evidence .

civice:1313
    dct:references pbm:22619677 ;
    civico:citation "Zhao et al., 2012, J Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Positive RB1 expression (2+ by IHC) was associated with adverse outcomes in a cohort of 73 cases with stage I and II NSCLC (P<0.001) in this retrospective study. This finding was independent from other genomic and clinical factors explored by the authors." ;
    a m2r:Evidence .

civice:1314
    dct:references pbm:22619677 ;
    civico:citation "Zhao et al., 2012, J Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a cohort of 73 patients with stage I or stage II NSCLC it was discovered that the CDKN2A protein (p16-INK4A) retrospectively evaluated via IHC was associated with adverse outcomes (p=0.004)." ;
    a m2r:Evidence .

civice:1315
    dct:references pbm:24748501 ;
    civico:citation "Li et al., 2015, Gastric Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Oxaliplatin ;
    dcterms:description "The methylation status of MLH1 was analyzed in a study of 53 paraffin-embedded gastric cancer samples. No association was found between methylation status and clinical factors. The study showed that MLH1 methylation was associated with resistance to treatment with oxaliplatin." ;
    a m2r:Evidence .

civice:1316
    dct:references pbm:24297342 ;
    civico:citation "Gu et al., 2014, Int. J. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Study explored the expression of the PTPN11 protein (SHP2) and found that expression was increased in a cohort of 112 laryngeal cancer samples. Expression was also associated with poor survival (p=.02) and in vitro models showed SHP2 expression promoted tumor growth." ;
    a m2r:Evidence .

civice:1317
    dct:references pbm:19667267 ;
    civico:citation "van Erp et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Adverse Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sunitinib ;
    dcterms:description "In 219 patients with mostly Renal Cell Carcinoma and some Gastrointestinal Stromal tumors given sunitinib treatment, FLT3 T227M (rs1933437) was associated with the development of leukopenia. 95% confidence interval of hazard ratio of between .17 and .77." ;
    a m2r:Evidence .

civice:1318
    dct:references pbm:18628482 ;
    civico:citation "Erkko et al., 2008, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Study explored the known PALB2 variant c.1592delT (p.L531C) in the context of breast cancer. The study found that among an augmented cohort of breast cancer patients with the variant, there was a hazard ratio of 6.1 (p=.01).  Further there is weak evidence to conclude that breast cancer risk for this variant decreases with age (p=.06)." ;
    a m2r:Evidence .

civice:1319
    dct:references pbm:24631838 ;
    civico:citation "Grabiner et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line JHUEM7 with the MTOR mutation S2215Y was hypersensitive to rapamycin treatment (IC50 of 0.23 nmol/L)." ;
    a m2r:Evidence .

civice:1320
    dct:references pbm:24631838 ;
    civico:citation "Grabiner et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line MOLT16, with MTOR mutation C1483Y was hypersensitive to rapamycin treatment (IC50 of 0.75 nmol/L)." ;
    a m2r:Evidence .

civice:1321
    dct:references pbm:24631838 ;
    civico:citation "Grabiner et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line SNU349, with MTOR mutation E1799K was hypersensitive to rapamycin treatment (IC50 of 0.19 nmol/L)." ;
    a m2r:Evidence .

civice:1322
    dct:references pbm:18757403 ;
    civico:citation "Byron et al., 2008, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PD173074 ;
    dcterms:description "The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wild type FGFR2.)." ;
    a m2r:Evidence .

civice:1324
    dct:references pbm:11792751 ;
    civico:citation "Plath et al., 2002, J. Natl. Cancer Inst." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_5-fluorouracil,civic:drug_Doxorubicin,civic:drug_MitomycinC,civic:drug_Gemcitabine ;
    dcterms:description "In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed. The effect was asserted to be specific to pRB depletion because, in two separate cell lines, also transfected with p16, that retained high pRB expression, chemotherapy resistance was still observed." ;
    a m2r:Evidence .

civice:1325
    dct:references pbm:27177629 ;
    civico:citation "Roh et al., 2016, J. Cancer Res. Clin. Oncol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab,civic:drug_FOLFIRIRegimen ;
    dcterms:description "Exome and RNA sequencing was performed in tumor and matched normal tissue of 19 patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. The variant PPP1R15A (rs557806) showed the most significant association (P = 0.000401) with FOLFIRI-bevacizumab-driven tumor inhibition rate in exome sequencing data and the highest correlation (r = 0.74) with the drug responses in RNA sequencing data. Patients who were homozygous for the reference alleles (GG) of PPP1R15A rs557806 exhibited greater disease control rates and a tendency toward greater overall response rate than those with homozygous or heterozygous substitution alleles (GC and CC; P = 0.027 and 0.073) when treated with bevacizumab-containing regimens. PPP1R15A rs557806 nonsignificantly correlated with DCR in multivariate analysis (P = 0.054). In HCT116 xenograft tumors, tumor growth IR with FRB was 25 % in mock cells, 24 % in clones with reference alleles (G alleles) of PPP1R15A rs557806, and 17 % in clones with substitution alleles (C alleles) of PPP1R15A rs557806 (P = 0.004, day 13). FDG-PET imaging on day 7 showed FDG uptake (mean SUV max) of 0.219 and 0.500 in HCT116 xenografts expressing the reference allele (G) and substitution allele (C) of PPP1R15A rs557806, respectively (P = 0.032)." ;
    a m2r:Evidence .

civice:1326
    dct:references pbm:25322874 ;
    civico:citation "Hochster et al., 2015, Cancer Chemother. Pharmacol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Irinotecan,civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "31 patients with KRAS exon 2 mutation (codons 12 and 13) were treated with selumetinib and irinotecan. All patients had ECOG status 0 or 1 and confirmed progression after first line therapy with oxaliplatin-based chemotherapy and bevacizumab. Patients with more than one line of therapy, MEK or B-RAF inhibitor treatment or prior irinotecan treatment were excluded. The study was terminated before full accrual due to non-protocol considerations. Three patients had a PR, 16 patients had SD >= 4 weeks. Median PFS for all patients was 105 days, median OS was 267 days." ;
    a m2r:Evidence .

civice:1327
    dct:references pbm:26786851 ;
    civico:citation "Wang et al., 2016, Sci Rep" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD3463 ;
    dcterms:description "The SH-SY5Y neuroblastoma cell line containing the F1174L ALK mutation was found to undergo cell death when treated with the ALK/IGF1R inhibitor AZD3463. These cells were more sensitive than other neuroblastoma cell lines containing wild-type ALK. Marked inhibition of soft agar colony formation of SH-SY5Y cells was also observed with drug treatment. AZD3463 inhibited Akt signaling in these cells within two hours of treatment, and activated apoptosis and autophagy pathways. Treatment of SH-SY5Y cells implanted into left kidneys of nude mice resulted in almost complete tumor regression." ;
    a m2r:Evidence .

civice:1328
    dct:references pbm:25517749 ;
    civico:citation "Bresler et al., 2014, Cancer Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "A" ;
    dcterms:description "In a cohort of 1596 neuroblastoma patients.   Five year event free survival was 74 months in non-MYCN amplified cases and 39 months in amplified cases. Differences were significant with p < 0.0001. Five year overall survival was 83 months and non-MYCN amplified cases and 46  months in amplified cases, with p < 0.0001, indicating poorer prognosis for MYCN-amplified cases." ;
    a m2r:Evidence .

civice:1329
    dct:references pbm:26554404 ;
    civico:citation "Infarinato et al., 2016, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lorlatinib ;
    dcterms:description "Efficacy of the second generation ALK inhibitor PF-06463922 was tested on ALK mutation F1174L containing neuroblastoma-derived cells.  COG-N-453x and SH-SY5Y xenografts showed some inhibition when treated with crizotinib, but showed complete growth inhibition with PF-06463922 treatment.  This corresponded to 0% event free survival (EFS) in these mice by 6 weeks with crizotinib treatment, but 100% EFS with PF-06463922 treatment. Comparison of crizotinib and PF-06463922 growth inhibition in F1174L cells SH-SY5Y, NBSD 415-IMDM and KELLY showed increased sensitivity to PF-06463922, as compared to crizotinib. Inhibition effects were not seen on neuroblastoma cells with wild type ALK (NB-EBc1, SK-N-BE(2)C). Decreased phosphorylation on ALK tyrosine 1278 was seen with PF-06463922 over crizotinib at 10 and 100 nM concentrations in SH-SY5Y cells. PF-06463922 was well tolerated in the in-vivo models." ;
    a m2r:Evidence .

civice:1330
    dct:references pbm:26554404 ;
    civico:citation "Infarinato et al., 2016, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lorlatinib ;
    dcterms:description "Patient derived xenografts of neuroblastoma Felix cells with F1245C ALK mutation in CB17 SCID mice showed growth inhibition with crizotinib treatment over control, and mice had improved duration of event-free survival (EFS) with crizotinib treatment over vehicle, but EFS with crizotinib went down to 0% by six weeks.  In contrast, PF-06463922 treatment induced complete tumor regression and EFS rate of 100% at six weeks.  PF-06463922 inhibited viability in Felix cells at 37x efficacy over crizotinib, with IC50 values of 21.8 +/- 0.4 and 814.0 +/- 119 respectively.  PF-06463922 was well tolerated in the animal models." ;
    a m2r:Evidence .

civice:1331
    dct:references pbm:26554404 ;
    civico:citation "Infarinato et al., 2016, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lorlatinib ;
    dcterms:description "In NB-1643 and LAN-5 neuroblastoma cell lines containing R1275Q mutation, PF-06463922 showed 51 and 19 fold greater effect on cell viability over crizotinib treatment respectively. ALK wild-type neuroblastoma cell lines did not show differential sensitivity to the treatments within the sensitivity range of R1275Q cells, and had IC50 values above 3800 nM to the inhibitors. NB-1653 cells induced tumors in CB17 SCID mice and crizotinib treatment inhibited tumor growth over vehicle treatment, but PF-06463922 induced complete tumor regression." ;
    a m2r:Evidence .

civice:1332
    dct:references pbm:26554404 ;
    civico:citation "Infarinato et al., 2016, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lorlatinib ;
    dcterms:description "EML4-ALK variant 1 containing H-3122 NSCLC cells were treated with second generation ALK inhibitor PF-06463922. PF-06463922 was 125x more potent at reducing cell viability than crizotinib. Control neuroblastoma cell lines with wild-type ALK did not show inhibition below 3800 nM with either drug. At values of 10 and 100 nM, PF-06463922 showed increased ability to inhibit ALK 1278 tyrosine phosphorylation in H3122 cells." ;
    a m2r:Evidence .

civice:1333
    dct:references pbm:23598171 ;
    civico:citation "Mossé et al., 2013, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily.  The patient showed progressive disease as best response after two 28-day cycles on crizotinib." ;
    a m2r:Evidence .

civice:1334
    dct:references pbm:19737969 ;
    civico:citation "Lin et al., 2009, Mol. Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "26 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potential rearrangements.  One sample showed potential rearrangement and RT-PCR demonstrated an EML4-ALK fusion where EML4 exon 21 was fused to ALK exon 13. This EML4-ALK variant is different from those commonly found in NSCLC. Genomic PCR verified the existence of the fusion breakpoint in intronic space, indicating that some colorectal adenocarcinoma may have targetable ALK-fusion driver mutations." ;
    a m2r:Evidence .

civice:1335
    dct:references pbm:19737969 ;
    civico:citation "Lin et al., 2009, Mol. Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays. A computational method was used to find potential gene fusions which assessed differential exon expression between the 3' and 5' ends of each gene. Two potential fusions were found and assessed using RNA ligase mediated rapid amplifiation of cDNA ends and RT-PCR. The fusions were EML4-ALK variants 1 and 2. Genomic PCR identified fusion breakpoints, and these differed from breakpoints for these EML4-ALK variants reported in NSCLC." ;
    a m2r:Evidence .

civice:1336
    dct:references pbm:27049722 ;
    civico:citation "Siaw et al., 2016, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Brigatinib ;
    dcterms:description "The MYCN amplification positive relapsed neuroblastoma-derived cell line CLB-BAR contains the driver ALK DEL 11-14 mutation, which removes extracellular domain exons 4 through 11. Brigatinib treatment of CLB-BAR cells reduced MYCN protein levels and ALK phosphorylation (Y1604) similar to crizotnib. Brigatinib reduced CLB-BAR cellular proliferation more effectively than crizotinib (IC50 75.2 vs 186.4nM). CLB-BAR xenografts in BalbC/NUDE mice responded to brigatinib with reduced tumor volume and weight (N=8/group) as well as reduced ALK phosphorylation and MYCN levels compared to untreated controls. Release of brigatinib administration at day 15 resulted in tumor growth (N=2)." ;
    a m2r:Evidence .

civice:1337
    dct:references pbm:22034911 ;
    civico:citation "Zhang et al., 2011, Chem Biol Drug Des" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A Ba/F3 cell line expressing EML4-ALK variant 1 was created, and then exposed to the DNA modifying agent ENU. Cells were subsequently cultured in 96 well plates at increasing concentrations of crizotinib (250, 500, 720, 1000, 1440 and 2000 nM). Cell growth occurred in all wells at 250 nM, and was absent at 2000 nM. From 500 through 1440 nM there were progressively fewer resistant clones present. 422 mutations representing 16 different sites were identified. EML4-ALK F1245C was found at 500 nM crizotinib, and was among the 10 most frequently observed mutations. Ba/F3 cells with unaltered EML4-ALK had crizotinib IC50 values for viability of 132 +/- 45 nM. EML4-ALK F1245C clones from the selection assay had IC50 viability value of 425 +/- 100 nM, while Ba/F3 cells expressing reintroduced EML4-ALK F1245C had IC50 value of 269 +/- 194 nM." ;
    a m2r:Evidence .

civice:1338
    dct:references pbm:26775591 ;
    civico:citation "Kodityal et al., 2016, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "A 52 year old male never smoker was diagnosed with stage IV NSCLC adenocarcinoma and was treated with chemotherapy with eventual disease progression. He tested positive for ALK rearrangement via break apart FISH assay, and started crizotinib with near complete response for 27 months. Progression then occurred and biopsy of a pleural nodule was performed with hybrid-capture NGS. EML4-ALK variant 3 with F1245C mutation was found with allele frequency of 2% and tumor purity 13%. Due to slow progression and low tumor burden crizotinib was maintained for additional 8 months, and then he was transitioned onto ceritinib at 750 mg daily. After 3 months ceritinib, complete radiographic response was seen and the patient was without evidence of disease at 6 months. Dose was reduced to 600 mg ceritinib daily due to gastrointestinal side effects." ;
    a m2r:Evidence .

civice:1339
    dct:references pbm:26775591 ;
    civico:citation "Kodityal et al., 2016, Lung Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A 52 year old with a non-smoking history was diagnosed with stage IV NSCLC-adenocarcinoma and treated with chemotherapy.  Upon disease progression, the initial diagnostic biopsy tested positive for ALK-rearrangement using break apart FISH, but the ALK fusion was not sequenced for mutations. Break-apart signal was positive in 66% of tumor cells. Crizotinib was initiated and a sustained near complete response for 27 months was observed, after which an FDG-avid cervical lymph node appeared along with pleural effusions and pleural nodules. A pleural nodule was biopsied and profiled using hybrid-capture next generation sequencing, and revealed EML4-ALK variant 3 with F1245C mutation at mutant allele frequency of 2% and tumor purity of 13%. Crizotinib was maintained for 8 additional months due to low tumor burden and slow progression." ;
    a m2r:Evidence .

civice:1340
    dct:references pbm:24675041 ;
    civico:citation "Friboulet et al., 2014, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "Ceritinib was 28x more potent (GI50 3.8nM) than crizotinib (GI50 107nM) at inhibiting growth of  H2228, an NSCLC cell line which harbors the EML4-ALK variant 3a/3b. SCID mice xenografted with H2228 were treated for 14 days with crizotinib (100 mg/kg) or ceritinib (25 or 50 mg/kg). All treatments caused tumor regression, but tumors recurred within 11 days after crizotinib treatment withdrawal. 4/8 mice treated with 25 mg/kg ceritinib showed regrowth after 1 month treatment withdrawal. The remaining 4/8 mice treated at 25 mg/kg ceritinib, and all mice treated at 50 mg/kg ceritinib maintained complete remission for four months. While 100 mg/kg crizotinib in mice approximates levels 3-5 times the maximal tolerated dose in humans, the authors state 25 to 50 mg/kg ceritinib in mice is predicted to approximate tolerable doses in humans." ;
    a m2r:Evidence .

civice:1341
    dct:references pbm:24675041 ;
    civico:citation "Friboulet et al., 2014, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "The crizotinib-resistant MGH045 cell line with EML4-ALK L1196M was treated with crizotinib or ceritinib. In nude mice with MGH045 xenografts, tumor response to crizotinib did not differ appreciably from vehicle, while ceritinib controlled tumor growth. Ceritinib inhibited Ba/F3 cells expressing EML4-ALK L1196M slightly stronger than ALK wild-type, but approximately double the potency as crizotinib, indicating ceritinib sensitivity in Ba/F3 EML4-ALK L1196M cells." ;
    a m2r:Evidence .

civice:1342
    dct:references pbm:24675041 ;
    civico:citation "Friboulet et al., 2014, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "The NSCLC cell line MGH021-4, harboring SQSTM1-ALK G1269A, was 6 times more sensitive to ceritinib (80nM GI50) than crizotinib (500 nM) in proliferation assays and caused notable reductions in phospho-ALK and phospho-AKT (detected by Western blot) at concentrations 10 fold lower than crizotinib. GI50 values were similar in Ba/F3 cells expressing either EML4-ALK wild-type or EML4-ALK G1269A (1.6nM and 2.2nM, respectively). In contrast, crizotinib treatment of Ba/F3 with EML4-ALK G1269A had survival GI50 of 130nM." ;
    a m2r:Evidence .

civice:1343
    dct:references pbm:24675041 ;
    civico:citation "Friboulet et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "Ba/F3 cells expressing the EML4-ALK S1206Y variant were treated with ceritinib, and survival GI50 value of 1.5 nM was obtained, which compares favorably with GI50 of 1.7 for the highly ceritinib sensitive EML4-ALK wild-type variant obtained in parallel experiments, as well as the GI50 value of 16 nM obtained for crizotinib treatment of EML4-ALK wild-type." ;
    a m2r:Evidence .

civice:1344
    dct:references pbm:24675041 ;
    civico:citation "Friboulet et al., 2014, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "Ba/F3 cells expressing EML4-ALK variant 3 with ALK I1171T mutation were treated with ceritinib, and survival IC50 of 2.6 nM was observed, which compares favorably with highly ceritinib sensitive EML4-ALK wild-type variant 1 survival IC50 of 1.7 nM reported from parallel experiments. Tumors from mice with EML4-ALK variant 3 H2228 NSCLC cell xenografts which had progressed after approximately 40 days of crizotinib treatment were sequenced for ALK mutations. I1171T was found as one of 6 ALK resistance mutations from 80 sequenced tumors. Treatment of these mouse xenograft models with ceritinib reduced tumor volume to zero, while in contrast tumor size increased with crizotinib treatment." ;
    a m2r:Evidence .

civice:1345
    dct:references pbm:24675041 ;
    civico:citation "Friboulet et al., 2014, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "Ba/F3 cells expressing EML4-ALK variant 1 with ALK G1202R mutation were assessed for ceritinib sensitivity. Crizotinib was shown to confer significantly more potency than ceritinib (43-fold decrease in IC50). EML4-ALK variant 3 NSCLC cell line H2228 was used in SCID mouse xenografts which were exposed to increasing crizotinib up to 100 mg/kg. Within 40 days tumors progressed, and progressed tumors were assayed for ALK mutation. Of 80 tumors, 6 had ALK mutation and 3 of these were G1202R. Treatment of crizotinib progressed tumors with ceritinib resulted in tumor growth which did not differ appreciably from crizotinib or vehicle treatment of these tumors." ;
    a m2r:Evidence .

civice:1346
    dct:references pbm:24675041 ;
    civico:citation "Friboulet et al., 2014, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "EML4-ALK variant 3 containing NSCLC cell line H2228 xenografts in SCID beige mice were treated with increasing doses of crizotinib up to 100 mg/kg per day by oral gavage. At approximately 40 days tumors progressed. 80 progressed tumors were tested for ALK mutations, and 6 mutant ALK variants were found. Two of the mutations were at ALK C1156Y. In Ba/F3 cells, EML4-ALK variant 3 with C1156Y was introduced and tested for crizotinib sensitivity. Survival IC50 value of 177 nM was reported, which is 9.3 times the IC50 reported for crizotinib in EML4-ALK wild-type Ba/F3 cells." ;
    a m2r:Evidence .

civice:1347
    dct:references pbm:22277784 ;
    civico:citation "Katayama et al., 2012, Sci Transl Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "Ba/F3 cells expressing EML4-ALK with 1151 Tins treated with alectinib had an IC50 of 165.7 nM, 16x higher than those expressing EML4-ALK wildtype variant 1. EML4-ALK variant 1 expressing H3122 NSCLC cell line was cultured in increasing levels of crizotinib to produce crizotinib resistant cell lines CR1, CR2 and CR3. H3122 CR2 was found to contain an 1151 insT ALK mutation and increased EML4-ALK levels. The H3122 CR2 cell line survival IC50 value for alectinib treatment was approximately 20x higher than that for H3122 cells." ;
    a m2r:Evidence .

civice:1348
    dct:references pbm:22277784 ;
    civico:citation "Katayama et al., 2012, Sci Transl Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_TAE684 ;
    dcterms:description "Treatment of Ba/F3 cells expressing EML4-ALK 1151 insT with TAE684 produced an IC50 value (28.3 nM) 20x higher cells expressing EML4-ALK wildtype variant 1. The crizotinib resistant clones were produced from parental H3122 cells (CR1, CR2, CR3). H3122 CR2 was found to contain the 1151 Tins variant as well as elevated EML4-ALK expression. H3122 CR2 cells treated with TAE684 produced IC50 values 20-30 times that of the parental H3122 cells. These results suggest possible variant resistance to the TAE684-derived compound ceritinib." ;
    a m2r:Evidence .

civice:1349
    dct:references pbm:22277784 ;
    civico:citation "Katayama et al., 2012, Sci Transl Med" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_17-AAG ;
    dcterms:description "Ba/F3 cells transduced with EML4-ALK 1151 insT were treated with 17-AAG producing an IC50 value of 44.5 nM, which was 0.4 times that reported for EML4-ALK wildtype in Ba/F3, indicating possible increased dependence of EML4-ALK 1151 insT on HSP90. 17-AAG also reduced survival of the parental IL3-dependent Ba/F3 cells (183.7 nM), indicating increased nonspecific effects of 17_AAG treatment. Crizotinib resistant clones were produced from the parental EML4-ALK variant 1 containing cell line H3122 (CR1, CR2, CR3). H3122 CR2 was found to contain the EML4-ALK InsT variant. H3122 CR2 and H3122 cells were similarly sensitized to 17-AAG death with an IC50 value of approximately 5 nM, while control cells without EML4-ALK had IC50 values approximately 10x higher." ;
    a m2r:Evidence .

civice:1350
    dct:references pbm:25727400 ;
    civico:citation "Fontana et al., 2015, Cancer Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "Ba/F3 cell line expressing EML4-ALK variant 3 with G1202R ALK mutation was assessed for alectinib sensitivity and IC50 for survival of 868 nM was reported, which was 64.4x higher than the IC50 reported for alectinib on Ba/F3 with EML4-ALK wild-type. Similar experiments using NPM-ALK instead of EML4-ALK yielded survival IC50 of 549 nM of NPM-ALK G1202R to alectinib, which was 27.9 times higher than IC50 for NPM-ALK wild-type. Western blots of Ba/F3 with NPM-ALK wild-type showed ablation of pALK levels above 100 nM alectinib, while pALK levels were essentially unchanged up to 1000 nM in NPM-ALK G1202R Ba/F3 cells." ;
    a m2r:Evidence .

civice:1351
    dct:references pbm:25727400 ;
    civico:citation "Fontana et al., 2015, Cancer Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Brigatinib ;
    dcterms:description "This study compared drug responses in Ba/F3 cells expressing either EML4-ALK or NPM-ALK fusions, with or without G1202R ALK mutation. Cells expressing the EML4-ALK variant 3 with G1202R ALK mutation were more resistant to brigatinib treatment (IC50 325 nM) than cells expressing wildtype EML4-ALK variant 3 (IC50 6 nM). These same experiments performed with the NPM-ALK fusion resulted in IC50 of 149 nM for G1202R and 11nM for wild type, consistent with resistance. In Western blots, ablation of pALK with brigatinib treatment above 100 nM was seen in Ba/F3 cells expressing NPM-ALK wildtype, but remained apparent at 1000 nM brigatinib in NPM-ALK G1202R cells, despite dose-dependent reduction." ;
    a m2r:Evidence .

civice:1352
    dct:references pbm:22277784 ;
    civico:citation "Katayama et al., 2012, Sci Transl Med" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_17-AAG ;
    dcterms:description "The G1202R ALK mutation was found in a crizotinib-resistant ALK-rearranged NSCLC, and the mutant ALK fusion was further characterized in Ba/F3 cells. EML4-ALK variant 1 with G1202R mutation was expressed in Ba/F3 and subject to 17-AAG. IC50 for cell number in response to 17-AAG was 33.4 nM, in contrast to IC50 for EML4-ALK wild-type, which was 98.9 nM, suggesting sensitization of this variant to HSP90 inhibition." ;
    a m2r:Evidence .

civice:1353
    dct:references pbm:25727400 ;
    civico:citation "Fontana et al., 2015, Cancer Med" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Brigatinib ;
    dcterms:description "EML4-ALK with ALK G1269A has been seen in crizotinib resistant NSCLC, and this mutation was tested for Brigatinib sensitivity via ectopic expression in Ba/F3 cells, where half maximal inhibitory concentration of 9 nM was seen, which was 1.5 times the IC50 of EML4-ALK wild-type to brigatinib. NPM-ALK G1269A was also tested for brigatinib sensitivity, and IC50 values of 11 nM were reported for both NPM-ALK G1269A and NPM-ALK wild-type. In western blotting, brigatinib at and above 100 nM ablated pALK signal (Y 1604), indicating sensitivity of this variant to brigatinib together with the other results." ;
    a m2r:Evidence .

civice:1354
    dct:references pbm:25727400 ;
    civico:citation "Fontana et al., 2015, Cancer Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "EML4-ALK with ALK G1269A mutation was tested for sensitivity to alectinib using Ba/F3 cells. In Ba/F3 cells with ectopic EML4-ALK variant 1 G1269A, IC50 of 84 nM was reported with alectinib, which was a 6 fold increase over IC50 for EML4-ALK wild-type. The authors considered a fold difference of 4 to 10 between the alectinib-sensitized wild-type and mutant variant to indicate a resistant mutant variant. In the background of the NPM-ALK fusion, IC50 for G1269A mutation was 104 nM, which was 5.3 fold that reported for NPM-ALK wild-type. Western blots of alectinib treated NPM-ALK G1269A were performed and reduced pALK Y1604 was seen at 300 nM alectinib, and no pALK at 1000 nM. In contrast pALK signal was ablated at and above 100 nM in NPM-ALK wild-type." ;
    a m2r:Evidence .

civice:1355
    dct:references pbm:25727400 ;
    civico:citation "Fontana et al., 2015, Cancer Med" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "EML4-ALK with G1269A mutation was tested for sensitivity to ceritinib via transduction into Ba/F3 cells and generation of survival curves varying ceritinib concentration. IC50 of 33 nM was seen, which was 1.5 times the IC50 for EML4-ALK wild-type, indicating sensitivity of the G1269A mutation to ceritinib in the context of EML4-ALK. The mutation was also tested for ceritinib sensitivity in the context of NPM-ALK, where IC50 values were reported of 19 nM and 20 nM for mutant and wild-type versions, respectively, also indicating sensitivity. In western blots,  Y1604 pALK levels for wild-type NPM-ALK were ablated at 100 nM, while at 100 nM residual pALK levels were seen in G1269A blotting, with ablation of signal at and above 300 nM, which differed somewhat from the equivalent IC50 values reported for mutant and wild-type in the NPM-ALK background, but still agrees with sensitivity to ceritinib for this mutation." ;
    a m2r:Evidence .

civice:1356
    dct:references pbm:25727400 ;
    civico:citation "Fontana et al., 2015, Cancer Med" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In Ba/F3 cells, crizotinib sensitivty of the NPM-ALK variant was compared to crizotinib sensitivity of EML4-ALK variant 3. 50% of maximal inhibitory concentration for NPM-ALK was 42 nM, which was approximately 4x greater than IC50 of 11 nM obtained for EML4-ALK. The IC50 for parental Ba/F3 supplemented with IL3 was 2299 nM, resulting in a fold difference of 209.2 for EML4-ALK and 55.1 for NPM-ALK, indicating some reduced sensitivity for NPM-ALK in direct comparison to EML4-ALK, but substantial sensitization to crizotinib for NPM-ALK in Ba/F3 cells." ;
    a m2r:Evidence .

civice:1357
    dct:references pbm:22277784 ;
    civico:citation "Katayama et al., 2012, Sci Transl Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A patient with ALK-rearranged lung adenocarcinoma responded to crizotinib treatment and then had relapse. Biopsy was taken within half a month and total DNA was extracted from the sample. Exons 20-28, which correspond to the tyrosine kinase domain of ALK, were sequenced, and ALK G1202A was found. CKIT focal amplification by FISH was also observed. Tumor sample before crizotinib treatment was not available in this case." ;
    a m2r:Evidence .

civice:1358
    dct:references pbm:25855885 ;
    civico:citation "Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Pictilisib,civic:drug_17-AAG ;
    dcterms:description "Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to class I PI3K inhibitor GDC-0941 (p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines). IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the sanger cell line screening but these results could not be reproduced in the cancer cell line encyclopedia screening." ;
    a m2r:Evidence .

civice:1359
    dct:references pbm:25855885 ;
    civico:citation "Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Pictilisib,civic:drug_17-AAG ;
    dcterms:description "Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to the class I PI3K inhibitor GDC-0941(p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines). IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the Sanger cell line screening but these results could not be reproduced in the Broad cancer cell line encyclopedia screening." ;
    a m2r:Evidence .

civice:1360
    dct:references pbm:23619167 ;
    civico:citation "Lui et al., 2013, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BEZ235%28NVP-BEZ235,civic:drug_Dactolisib%29 ;
    dcterms:description "Preclinical analysis of the predicitive value of PIK3CA mutations for mTOR/PI3K Inhibition with BEZ-235. Two cell lines with PIK3CA Mutation (H1047R) were more sensitive to BEZ-235 than two cell lines with wild-type PIK3CA (in-vitro, results from one cell line also confirmed in-vivo). Two patient-derived xenografts with PIK3CA mutations (E110K, E542K) showed sensitivity to BEZ-235." ;
    a m2r:Evidence .

civice:1361
    dct:references pbm:25855885 ;
    civico:citation "Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BEZ235%28NVP-BEZ235,civic:drug_Dactolisib%29 ;
    dcterms:description "Lentiviral transduction of PIK3CA H1047R mutation into head and neck cancer cell line SCC25 led to increased sensitivity to PI3K/mTOR inhibition with BEZ235 compared to unmanipulated cells (IC50 values 6 nM and 31 nM)." ;
    a m2r:Evidence .

civice:1362
    dct:references pbm:23619167 ;
    civico:citation "Lui et al., 2013, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BEZ235%28NVP-BEZ235,civic:drug_Dactolisib%29 ;
    dcterms:description "Two head and neck cancer cell lines with PIK3CA H1047R mutation were more sensitive to PI3K/mTOR inhibition with BEZ-235 (NVP-BEZ235, Dactolisib) than two wild type cell lines in vitro. One cell line with H1047R mutation was also found to be sensitive to BEZ-235 in vivo. PIK3CA (H1047R) mutation positive cell lines used were \"CAL-33\" and \"Detroit 562\". Wild type cell lines used here were \"SCC-9\" and \"PE/CA-PJ34(clone C12)\"." ;
    a m2r:Evidence .

civice:1363
    dct:references pbm:23619167 ;
    civico:citation "Lui et al., 2013, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab,civic:drug_BEZ235%28NVP-BEZ235,civic:drug_Dactolisib%29 ;
    dcterms:description "Xenografts from one head and neck cancer cell line (CAL-33) with a PIK3CA H1047R mutation were more sensitive to the combined inhibition of PI3K/mTOR and EGFR with BEZ-235 and cetuximab (N=9) than cetuximab (N=9, P=0.0039) or BEZ-235 alone (N=9, P=0.0002) in-vivo." ;
    a m2r:Evidence .

civice:1364
    dct:references pbm:25855885 ;
    civico:citation "Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Pictilisib,civic:drug_17-AAG,civic:drug_Trametinib ;
    dcterms:description "6 head and neck cancer cell lines were tested for Response to 17-AAG, GDC-0941. Two of the cell lines did not carry PIK3CA mutations. No clear difference was shown between PIK3CA-mutant and wild-type cell lines and there was a trend towards increased resistance. SCC25 cell line was lentivirally transduced with PIK3CA E545K or H1047R mutation. Engineered cells, compared to the parental cell line, showed decreased sensitivity to 17-AAG, GDC-0941 or trametinib." ;
    a m2r:Evidence .

civice:1365
    dct:references pbm:20368568 ;
    civico:citation "Lam et al., 2010, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "In a phase 2 clinical trial of sorafenib in patients with hereditary or sporadic advanced medullary thyroid cancer, 10 out of 12 patients genotyped in arm B (sporadic MTC) tested positive for RET mutations. In response to sorafenib, 8 patients with RET M918T mutations had stable disease, 1 RET M918T mutant had partial response, and 1 patient with a RET C634R mutation had stable disease. Prior to study entry, all patients with RET M918T mutations had progressive disease or were newly diagnosed." ;
    a m2r:Evidence .

civice:1366
    dct:references pbm:23569312 ;
    civico:citation "Dickson et al., 2013, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PD0332991 ;
    dcterms:description "In a phase 2 clinical trial, NCT01209598, 30 patients with CDK4-amplified and RB-expressing well differentiated and dedifferentiated liposarcomas (WDLS/DDLS) were treated with a selective CDK 4/6 inhibitor, PD0332991. Treatment with PD0332991 was associated with favorable progression free survival rates (66% PFS rate, primary end point being greater than 40%) suggesting that CDK4 amplification is predictive of sensitivity to CDK4 inhibitor therapy." ;
    a m2r:Evidence .

civice:1367
    dct:references pbm:25736571 ;
    civico:citation "Ou et al., 2015, Lung Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "A 51 year old female never-smoker was diagnosed with stage IV NSCLC with liver metastases. ALK rearrangement was verified via FISH. She was treated with crizotinib at 250 mg twice daily but discontinued due to adverse response. She then started alectinib at 600 mg twice daily with partial response, but new liver metastases then formed at 5 months. Liver tumor biopsy was performed and was estimated to be 15% tumor tissue. Next-generation sequencing discovered an ALK I1171N mutation. The tumor was not sequenced prior to alectinib resistance." ;
    a m2r:Evidence .

civice:1368
    dct:references pbm:25736571 ;
    civico:citation "Ou et al., 2015, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Ceritinib ;
    dcterms:description "A 51 year old female never smoker was diagnosed with stage IV NSCLC with liver metastases, and had adverse response to crizotinib treatment, after which she responded to alectinib until disease progressed after 5 months with new liver metastases. Liver tumor biopsy was taken and estimated to be 15% tumor. Hybrid capture next generation sequencing was performed and an I1171N mutation was found in rearranged ALK, and estimated to be in 33% of the tumor cells. Ceritinib was given at 750 mg once daily but dose reduction to 600 mg once daily was required due to persistent nausea. CT showed regression of liver lesions and primary lung lesion and ongoing response was seen at 3 months." ;
    a m2r:Evidence .

civice:1369
    dct:references pbm:16046528 ;
    civico:citation "Boissel et al., 2005, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In normal karyotype patients with AML (15-65 years old), complete remission rates and overall, event-free and relapse-free survival were not different for patients harboring NPM1 exon 12 mutations (N=50) than those wildtype for NPM1 (N=56)." ;
    a m2r:Evidence .

civice:1370
    dct:references pbm:19553641 ;
    civico:citation "Fong et al., 2009, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers. 19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation." ;
    a m2r:Evidence .

civice:1371
    dct:references pbm:19553641 ;
    civico:citation "Fong et al., 2009, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers.19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation." ;
    a m2r:Evidence .

civice:1372
    dct:references pbm:12777976 ;
    civico:citation "Robinson et al., 2003, Melanoma Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Flavopiridol ;
    dcterms:description "Preclinical study in 9 melanoma cell lines. Three cell lines did not have CDKN2A (p16) mutations and showed expression of the protein on western blot analysis. Two of the other six cell lines had stop codons leading to a truncated protein, and three had missense mutations with evidence of protein expression on western blot (two cell lines with a P114L mutation and one with an E88K mutation). Mean IC50s of flavopiridol were significantly lower in cell lines with a mutated or non-expressed p16 (p16-) (mean 50% inhibitory concentration [IC(50)] = 12.5 nM), than in cell lines with intact p16 (p16+) (mean IC(50) = 25 nM)." ;
    a m2r:Evidence .

civice:1373
    dct:references pbm:23898052 ;
    civico:citation "Logan et al., 2013, Anticancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion." ;
    a m2r:Evidence .

civice:1374
    dct:references pbm:23898052 ;
    civico:citation "Logan et al., 2013, Anticancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion." ;
    a m2r:Evidence .

civice:1375
    dct:references pbm:24495407 ;
    civico:citation "Young et al., 2014, Pigment Cell Melanoma Res" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "In a cohort of 143 patients with primary invasive melanoma hemizygous or homozygous loss of CDKN2A was observed (FISH) in 56% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Loss of functional p16INK4A (CDKN2A) due to gene deletion (49% of cells), methylation (4% of cells), or mutation (19% of cells) was the most prevalent alteration occurring in 71% of cell lines, and significantly correlated with PD0332991 sensitivity (Fisher's exact test P < 0.02)." ;
    a m2r:Evidence .

civice:1376
    dct:references pbm:24495407 ;
    civico:citation "Young et al., 2014, Pigment Cell Melanoma Res" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "In a cohort of 143 patients with primary invasive melanoma, copy-number gain of CDK4 was observed (FISH) in 37% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Four cell lines had an R24C activating mutation in CDK4, three of these were sensitive to PD0332991 (palbociclib)." ;
    a m2r:Evidence .

civice:1377
    dct:references pbm:21278246 ;
    civico:citation "Konecny et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "Preclinical study of the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation in a panel of 40 human ovarian cancer cell lines. Concentration-dependent antiproliferative effects of PD-0332991 were seen in all ovarian cancer cell lines, but varied significantly between individual lines. Rb-proficient cell lines with low p16 expression were significantly more sensitive to PD-0332991 (as defined by IC50 < mean) in mRNA expression (Agilent), protein level (Western Blot) and copy number (Array CGH) analyses." ;
    a m2r:Evidence .

civice:1378
    dct:references pbm:22031865 ;
    civico:citation "Metzeler et al., 2011, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In older patients (>59 years) with cytogenetically normal acute myeloid leukemia classified as ELN favorable, multivariate analysis identified ASXL1 mutations (12/99 patients) were associated with lower complete remission rates (P = 0.03), disease-free survival (P < 0.001), overall survival (P < 0.001), and event-free survival (P < 0.001). This confirmed results from univariate analysis of patients not stratified by ELN category, but cytogenetically normal and older (38/220 patients)." ;
    a m2r:Evidence .

civice:1379
    dct:references pbm:23018865 ;
    civico:citation "Schnittger et al., 2013, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with de novo AML who received intensive chemotherapy, ASXL1 mutations (N=51) were associated with shorter overall (P<0.001) and event free survival (P=0.012) compared to ASXL1 wild-type (N=430). Multivariate analysis identified ASXL1 mutations as an independent factor for adverse overall survival (P=0.032, relative risk: 1.70)." ;
    a m2r:Evidence .

civice:1380
    dct:references pbm:22802530 ;
    civico:citation "Utermark et al., 2012, Genes Dev." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Pictilisib ;
    dcterms:description "The HER2/Neu mammary tumor mouse model MMTV-NeuT was employed to demonstrate dependence of HER2 tumor formation on PIK3 p110alpha isoform. MMTV-NeuT mice were crossed with floxed p110alpha mice. Diassacociated tumors cells from these mice were treated with Cre adenovirus to delete p110alpha, or GFP adenovirus, and cells were transplanted into athymic mice. GFP treated cells formed new tumors, while p110alpha deletion blocked tumor formation indicating tumor dependence on PI3KA. Next, MMTV-NeuT tumors were dissociated and treated with pan-PI3K inhibitor GDC-0941. Reduced lipid kinase activity and reduced phospho-Akt levels were seen in these cells. Administration of 125 mg/kg GDC-0941 to athymic mice with transplantation of tumor cells caused marked reduction of tumor cell volume in comparison to control treatment." ;
    a m2r:Evidence .

civice:1381
    dct:references pbm:22802530 ;
    civico:citation "Utermark et al., 2012, Genes Dev." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_A66 ;
    dcterms:description "Pharmacologic (A66; p110alpha specific inhibitor) or genetic (cre-mediated knockout) ablation of the p110alpha PI3K isoform reduced tumor growth and tumor formation, respectively, in athymic mice transplanted with cells transduced by MMTV-NeuT (mammary specific overexpression of HER2 that effectively induces tumors). A66 treatment of cells from MMTV-NeuT mouse tumors resulted in decreased lipid kinase activity and phospho Akt levels." ;
    a m2r:Evidence .

civice:1382
    dct:references pbm:22802530 ;
    civico:citation "Utermark et al., 2012, Genes Dev." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Tgx221 ;
    dcterms:description "Treatment of cells obtained from MMTV-NeuT mouse mammary tumors with the p110beta selective inhibitor TGX-221 showed significant but minimal reductions in lipid kinase activity and negligible reductions in phospho Akt levels. In simmilar cells subjected to p110alpha isoform knockout, TGX-221 treatment fully blocked Akt activation, indicating that TGX-221 was fully inhibiting the p110beta isoform. Athymic mice recieved MMTV-NeuT tumor cell transplants and were treated with TGX-221, which resulted in significant but minimal reduction in tumor growth compared to controls." ;
    a m2r:Evidence .

civice:1383
    dct:references pbm:17936563 ;
    civico:citation "Berns et al., 2007, Cancer Cell" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in trastuzumab resistant populations was PTEN. Subsequent knockdown of PTEN in BT-474 cells increased cell survival when treated with trastuzumab, and growth curves showed partial restoration of proliferation in PTEN knockdown BT-474 cells treated with trastuzumab." ;
    a m2r:Evidence .

civice:1384
    dct:references pbm:17936563 ;
    civico:citation "Berns et al., 2007, Cancer Cell" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proliferation with trastuzumab. Sequencing of 55 HER2 breast cancer samples revealed 25% PIK3CA mutation rate and Kaplan Meier curves showed decreased time to progression for mutant PIK3CA at borderline statistical significance (p=0.052). This was potentially explained by presence of PTEN loss in wild-type PIK3CA sample and combining PTEN loss with PIK3CA mutation resulted in significant differences in time to progression (p=0.007)." ;
    a m2r:Evidence .

civice:1385
    dct:references pbm:20813970 ;
    civico:citation "Esteva et al., 2010, Am. J. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and PTEN loss alone was found to be significantly associated with resistance to trastuzumab (p=0.028) and shorter overall survival (p=0.008)." ;
    a m2r:Evidence .

civice:1386
    dct:references pbm:20813970 ;
    civico:citation "Esteva et al., 2010, Am. J. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second or greater line therapy), with 25 PTEN loss and and 25 normal samples, no association was seen between trastuzumab response and PTEN status (p=1.000) or overall survival and PTEN status (p=0.863)." ;
    a m2r:Evidence .

civice:1387
    dct:references pbm:25037629 ;
    civico:citation "Tefferi et al., 2014, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "A" ;
    dcterms:description "Study of 428 patients with primary Myelofibrosis found that those patients harboring CALR exon 9 mutations displayed significantly longer survival than those with JAK2 mutations (HR: 2.5, median survival yrs: CALR 15.9, JAK2 5.9)" ;
    a m2r:Evidence .

civice:1388
    dct:references pbm:23656643 ;
    civico:citation "Maxson et al., 2013, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)" ;
    a m2r:Evidence .

civice:1389
    dct:references pbm:23656643 ;
    civico:citation "Maxson et al., 2013, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)" ;
    a m2r:Evidence .

civice:1390
    dct:references pbm:23190221 ;
    civico:citation "Cortes et al., 2012, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Ponatinib ;
    dcterms:description "Study describes a phase 1 clinical trial of ponatinib in treatment of 81 refractory Philadelphia chromosome-positive leukemias. 43 of these patients were considered to have chronic-phase CML. All 12 chronic-phase CML patients with a T315I mutation showed a complete hematologic response. Furthermore, 91% of these patients were estimated to  remain in response at 1 year (95% CI, Kaplan-Meier analysis)." ;
    a m2r:Evidence .

civice:1391
    dct:references pbm:23470965 ;
    civico:citation "Yu et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 98 patients were found to have developed EGFR T790M mutations." ;
    a m2r:Evidence .

civice:1392
    dct:references pbm:23470965 ;
    civico:citation "Yu et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). MET amplification was seen in 4 of 75 patients tested (no baseline samples available). One patient had small cell transformation and MET amplification, two patients had EGFR T790M mutation and MET amplification." ;
    a m2r:Evidence .

civice:1393
    dct:references pbm:23470965 ;
    civico:citation "Yu et al., 2013, Clin. Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 2 of 24 patients tested were found to have HER2 amplification (but no baseline samples available for analysis). One patient of which had a metastasis sample which was reported to have only HER2 amplification whereas another autopsy specimen from the same patient was HER2 negative but EGFR T790M positive." ;
    a m2r:Evidence .

civice:1394
    dct:references pbm:25521405 ;
    civico:citation "Hellmann et al., 2014, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor samples from 2001 and 2003 were found to also harbor the S768I (but not T790M) mutation. Three-dimensional visualization showed the 768 position to be outside of the erlotinib binding position." ;
    a m2r:Evidence .

civice:1395
    dct:references pbm:20522446 ;
    civico:citation "Masago et al., 2010, Jpn. J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "Case report of an 81-year old man with lung adenocarcinoma and EGFR S768I mutation. The patient then received chemotheraoy (vinorelbine) and showed stable disease. Gefitinib was administered when disease progression was noted 4 months later and the patient was followed-up without signs of disease progression for 461 days." ;
    a m2r:Evidence .

civice:1396
    dct:references pbm:26181354 ;
    civico:citation "Yu et al., 2015, JAMA Oncol" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Osimertinib ;
    dcterms:description "Case report of a patient with stage IV lung adenocarcinoma and a 15–base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression. Repeat biopsy detected EGFRC797S mutation additionally to both aforementioned EGFR aberrations. In addition, PTEN Y27C and CTNNB1 S37F mutations were present in all 3 samples, and a TSC2 N486I was seen in the third biopsy sample only" ;
    a m2r:Evidence .

civice:1397
    dct:references pbm:26181354 ;
    civico:citation "Yu et al., 2015, JAMA Oncol" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Osimertinib ;
    dcterms:description "Case report of a patient with stage IV lung adenocarcinoma and a 15–base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression." ;
    a m2r:Evidence .

civice:1398
    dct:references pbm:24508103 ;
    civico:citation "McArthur et al., 2014, Lancet Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The BRIM-3 Phase III trial NCT01006980 assessed BRAF inhibitor vemurafenib versus dacarbazine in 598 patients with treatment naive metastatic melanoma and confirmed V600E mutation. Significant differences were seen in overall survival (13.3 months with vemurafenib vs. 10.0 months with dacarbazine) and median progression free survival (6.9 months  with vemurafenib vs. 1.6 months with dacarbazine)" ;
    a m2r:Evidence .

civice:1399
    dct:references pbm:24508103 ;
    civico:citation "McArthur et al., 2014, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In the Phase III study of vemurafenib versus dacarbazine BRIM-3 (NCT01006980) in metastatic melanoma, 57 patients were confirmed to have V600K mutation. In this subgroup of treatment-naive patients, significant differences were seen in overall survival (14.5 months with vemurafenib vs. 7.6 months with dacarbazine), as well as median progression free survival (5.9 months with vemurafenib vs. 1.7 months with dacarbazine)." ;
    a m2r:Evidence .

civice:1400
    dct:references pbm:26989536 ;
    civico:citation "Sahadudheen et al., 2016, Case Rep Oncol Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "A 53 year old male presented with a scalp lesion which was incompletely excised. Metastases were seen in lymph node biopsy and subsequently in CT. BRAF inhibitor vemurafenib was then administered at 960 mg twice daily and later at 720 mg twice daily and reduction in metastases was observed. After 2 years complete radiological response was seen, while treatment was discontinued due to cardiomyopathy. 12 months after stopping vemurafenib patient did not show evidence of metastatic melanoma." ;
    a m2r:Evidence .

civice:1401
    dct:references pbm:25550549 ;
    civico:citation "Keam et al., 2015, Anticancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BYL719%28Alpelisib%29 ;
    dcterms:description "In a panel of head and neck cancer cell lines, 2 lines containing the PIK3CA mutation H1047R (Detroit562 and SNU-1076) were more sensitive to growth inhibition (IC50 1.10 and 6.82) by the PI3Kalpha specific inhibitor BYL719 (Alepelisib) than 3 of 4 lines with wild type PI3K (SNU-1066 IC50 1.13 μM; SNU-1041, 20.65 μM; FaDu, 19.67 μM; SCC25, 49.30 μM). In the H1047R mutant cell lines and the wildtype cell line tested, phospho-Akt and phospho-S6 levels were diminished with increasing BYL719 levels." ;
    a m2r:Evidence .

civice:1402
    dct:references pbm:24608574 ;
    civico:citation "Fritsch et al., 2014, Mol. Cancer Ther." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BYL719%28Alpelisib%29 ;
    dcterms:description "A set of 474 cell lines from the Cancer Cell Line Encyclopedia was tested for responsiveness to the PI3Kalpha specific inhibitor BYL719 (Alpelisib). In the PIK3CA wild type subroup of cell lines, 22% were assessed as responsive, while in the subgroup of cell lines with PIK3CA mutations, 64% were labeled as responders. 7 patient derived xenografts with PIK3CA mutations (H1047R, E545K, M1043I, C420R, Q546K) were transplanted into mice and treated with BYL719. 6/7 mice responded with strong tumor growth inhibition or regression, while one (H1047R) responded with weak growth inhibition." ;
    a m2r:Evidence .

civice:1403
    dct:references pbm:24608574 ;
    civico:citation "Fritsch et al., 2014, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BYL719%28Alpelisib%29 ;
    dcterms:description "474 cancer cell lines from the cancer cell line encyclopedia were assessed for response to the PI3Kalpha inhibitor BYL719 (Alpelisib). PIK3CA amplification was significanly associated with BYL719 response. A gastric cancer patient derived xenograft (PDX) was transplanted into two athymic mice and one was treated with BYL719. The untreated PDX grew by over 100 percent while the BYL719 tumor was reduced by 86 percent." ;
    a m2r:Evidence .

civice:1404
    dct:references pbm:25673558 ;
    civico:citation "Pietrantonio et al., 2015, Eur. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "A quantitative synthesis was performed on nine studies comparing treatment of metastatic colorectal cancer with cetuximab or panitumumab and chemotherapy, versus chemotherapy alone, or with other targeted inhibitors. It was found that in the patient subgroup with BRAF mutation (V600E in the majority of cases), there were no benefits to overall survival, progression free survival, or overall response rate with addition of cetuximab or panitumumab to treatment. This conclusion held in the first line treatment as well as general treatment setting." ;
    a m2r:Evidence .

civice:1405
    dct:references pbm:26460303 ;
    civico:citation "Kopetz et al., 2015, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and seven patients had 8 week stable disease as best response. Median progression free survival was 2.1 months and median overall survival was 7.7 months. The authors conclude that single agent vemurafenib did not show meaningful activity in V600E CRC, in contrast to the significant vemurafenib activity against V600 in melanoma." ;
    a m2r:Evidence .

civice:1406
    dct:references pbm:22608338 ;
    civico:citation "Falchook et al., 2012, Lancet" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib ;
    dcterms:description "In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily. In nine colorectal cancer patients with established V600E mutation, 1 confirmed response, 7 instances of stable disease, and 1 case of progressive disease was seen, which contrasted strongly with a 56% confirmed response rate seen in metastatic V600E melanoma patients similarly treated in the same study." ;
    a m2r:Evidence .

civice:1407
    dct:references pbm:22608338 ;
    civico:citation "Falchook et al., 2012, Lancet" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib ;
    dcterms:description "In the NCT00880321 trial using mutant BRAF inhibitor dabrafenib in solid tumors, 10 cases of melanoma brain metastases were assessed for dabrafenib response. In nine patients a decrease in size of metastases was seen, and in four cases a complete resolution of brain lesions was observed. This subset of patients had median progression free survival of 4.2 months." ;
    a m2r:Evidence .

civice:1408
    dct:references pbm:22281684 ;
    civico:citation "Prahallad et al., 2012, Nature" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib,civic:drug_Gefitinib,civic:drug_Cetuximab ;
    dcterms:description "5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGFR as an enhancer for survival when exposed to vemurafenib.  Treatment with vemurafenib and EGFR inhibitor (cetuximab or gefitinib) in V600E CRC cells (WiDr, VACO432 and KM20) showed inhibited growth as well as induction of the cleaved PARP apoptotic marker. WiDr and VACO432 cells were injected into immunodeficient mice. Modest response was seen with vemurafenib treatment, while combination treatment showed considerable tumor growth inhibition as compared to control." ;
    a m2r:Evidence .

civice:1409
    dct:references pbm:21639808 ;
    civico:citation "Chapman et al., 2011, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. A relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression was observed with vemurafenib as compared with dacarbazine (P<0.001 for both comparisons)." ;
    a m2r:Evidence .

civice:1410
    dct:references pbm:22356324 ;
    civico:citation "Sosman et al., 2012, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E mutation.  Confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Median overall survival was 15.9 months (95% CI, 11.6 to 18.3)." ;
    a m2r:Evidence .

civice:1411
    dct:references pbm:25399551 ;
    civico:citation "Robert et al., 2015, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Trametinib,civic:drug_Dabrafenib ;
    dcterms:description "The Combi-v (NCT01597908) open-label, randomized phase 3 trial had 704 patients with metastatic melanoma with a BRAF V600 mutation. Patients were randomized to receive either a combination of dabrafenib and trametinib or vemurafenib orally as first-line therapy. At preplanned interim analysis the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P=0.005). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001). Cutaneous squamous-cell carcinoma and keratoacanthoma occurred at 1% with combination-therapy and 18% in the vemurafenib group." ;
    a m2r:Evidence .

civice:1412
    dct:references pbm:19273710 ;
    civico:citation "Iacobuzio-Donahue et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Study employed a rapid autopsy technique on a cohort of 76 patients with pancreatic cancer and explored the status of several genes. 63% (41/65) of carcinomas analyzed showed inactivation of SMAD4 (DPC4) via immunolabeling. Among the patterns of failure \"metastatic and locally destructive\", It was discovered that DPC4 loss was significantly associated with metastatic disease (p=.007)." ;
    a m2r:Evidence .

civice:1413
    dct:references pbm:25589621 ;
    civico:citation "Yaeger et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib,civic:drug_Panitumumab ;
    dcterms:description "Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy. Two patients had confirmed partial responses, and 2 showed stable disease over 6 months. The authors conclude that although some efficacy is seen, only a small subset of patients respond to this treatment and the responses are not durable." ;
    a m2r:Evidence .

civice:1414
    dct:references pbm:24987354 ;
    civico:citation "Ali et al., 2014, Case Rep Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the only genetic alteration on a near diploid genome with trisomy 1q. Vemurafenib treatment resulted in improvement of symptoms and considerable reductions in tumor mass, and after 23 months the patient remained on therapy with well controlled disease." ;
    a m2r:Evidence .

civice:1415
    dct:references pbm:26392102 ;
    civico:citation "Corcoran et al., 2015, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Trametinib ;
    dcterms:description "In clinical trial NCT01072175, 43 patients with BRAF V600 metastatic colorectal cancer (CRC) received mutant BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Only 12% of patients showed  partial response or better, with one complete response lasting 36 months and ongoing after data cutoff. 56% of patients achieved stable disease. The median progression free survival (PFS) was 3.5 months, longer than the median PFS (2.5 months) reported for metastatic CRC treated with standard chemotherapy. The authors conclude that MAPK targeting in CRC is a valid approach that can produce meaningful responses but additional work is required to more effectively inhibit the pathway." ;
    a m2r:Evidence .

civice:1416
    dct:references pbm:24345920 ;
    civico:citation "Hutchinson et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression of engineered cDNA in 293H cells showed that trametinib led to reduced ERK1/2 phosphorylation in fusion positive cells whereas vemurafenib was not effective." ;
    a m2r:Evidence .

civice:1417
    dct:references pbm:25424858 ;
    civico:citation "Maguire et al., 2015, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_SpliceostatinA ;
    dcterms:description "Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 mutant cell lines (pancreatic and endometrial with K700 and K666 mutation, respectively) and six wild-type controls showed that mutant cell lines were significantly more sensitive to spliceostatin A (SF3b complex inhibitor)." ;
    a m2r:Evidence .

civice:1418
    dct:references pbm:25424858 ;
    civico:citation "Maguire et al., 2015, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_SpliceostatinA ;
    dcterms:description "Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 mutant cell lines (pancreatic and endometrial with K700 and K666 mutation, respectively) and six wild-type controls showed that mutant cell lines were significantly more sensitive to spliceostatin A (SF3b complex inhibitor)." ;
    a m2r:Evidence .

civice:1419
    dct:references pbm:21933749 ;
    civico:citation "Shaw et al., 2011, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In a retrospective study comparing survival outcomes in a subgroup of 82 ALK-positive crizotinib-treated patients enrolled in a phase 1 clinical trial (NCT00585195), crizotinib therapy was associated with improved survival. For the crizotinib-treated, ALK-positive patient group, 1 year survival was 74% and 2 year overall survival was 54%, compared with 72% and 36% for the control group (ALK-positive crizotinib naive patients)." ;
    a m2r:Evidence .

civice:1420
    dct:references pbm:27028764 ;
    civico:citation "Qiu et al., 2016, PLoS Genet." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Study examined rare SNPs on MAP2K7 among a discovery and two validation cohorts. It was discovered that the E116K genotype was associated with a reduced median survival time of 4 and 7 months for E/K or K/K genotypes (P=2.61E-7) and an increased cancer death risk for heterozygous (HR=1.49) and homozygous (HR=1.94) genotypes for a pooled cohort. Further nude mice harboring this variant showed increased xenograft growth and metastasis." ;
    a m2r:Evidence .

civice:1421
    dct:references pbm:25265494 ;
    civico:citation "Larkin et al., 2014, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib,civic:drug_Cobimetinib ;
    dcterms:description "In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progression free survival (9.9 vs 6.2 months), increased rate of complete or partial response (68% vs 45%), and improved overall survival at 9 months ( 81% vs 73%) compared to the vemurafenib and placebo control group." ;
    a m2r:Evidence .

civice:1422
    dct:references pbm:25265494 ;
    civico:citation "Larkin et al., 2014, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib,civic:drug_Cobimetinib ;
    dcterms:description "In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progression free survival (9.9 vs 6.2 months), increased rate of complete or partial response (68% vs 45%), and improved overall survival at 9 months ( 81% vs 73%) compared to the vemurafenib and placebo control group." ;
    a m2r:Evidence .

civice:1423
    dct:references pbm:25015329 ;
    civico:citation "Iurlo et al., 2014, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In 5 patients with KIT M541L mutation-positive chronic eosinophilic leukemia (4 somatic and 1 germline mutation), treatment with low dose imatinib resulted in complete and lasting remission with a median follow up of 74 months and 1 patient relapse at 50 months." ;
    a m2r:Evidence .

civice:1424
    dct:references pbm:18955458 ;
    civico:citation "Heinrich et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sunitinib ;
    dcterms:description "In a study of 78 patients with gastrointestinal stromal tumors treated with sunitinib, patients with Kit exon 9 mutations or wildtype (lacking KIT or PDGFRA mutations) showed increased progression free survival and overall survival compared to patients with Kit exon 11 mutations." ;
    a m2r:Evidence .

civice:1425
    dct:references pbm:27069254 ;
    civico:citation "Arber et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Negative" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia." ;
    a m2r:Evidence .

civice:1426
    dct:references pbm:27069254 ;
    civico:citation "Arber et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Negative" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia." ;
    a m2r:Evidence .

civice:1427
    dct:references pbm:27069254 ;
    civico:citation "Arber et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Negative" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia." ;
    a m2r:Evidence .

civice:1428
    dct:references pbm:23549875 ;
    civico:citation "Coffee et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BEZ235%28NVP-BEZ235,civic:drug_Dactolisib%29,civic:drug_GDC-0879 ;
    dcterms:description "In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRAF inhibitor GDC-0879 and PI3K/mTOR inhibitor BEZ235 showed stronger reduction in phospho-Akt and phospho-S6 than PI3K/mTOR inhibitor alone, and combination inhibition also resulted in stronger phospho-ERK inhibition in tumors than did BRAF inhibition alone. Increased apoptosis in tumors was seen in dual treatment conditions with increased TUNEL-positive cells. In vehicle treated mice, area of colon covered by tumor increased, while treatment with single agent inhibitors caused growth inhibition resulting in no change in colon area covered by tumors. Administration of dual inhibitors induced tumor regression apparent in a decrease of colonic area covered by tumors over the course of treatment." ;
    a m2r:Evidence .

civice:1429
    dct:references pbm:23431193 ;
    civico:citation "Posch et al., 2013, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib,civic:drug_Omipalisib%28GSK2126458%29 ;
    dcterms:description "In six NRAS mutant melanoma cell lines, concomitant use of MEK inhibitor and PI3K/mTOR inhibitor resulted in greater decrease in cell viability than either alone, with the synergistic effect being marked in 4/6 cell lines. MEK inhibitor JTP-74057 and PI3K/mTOR inhibitor GSK2126458 together induced synergistic increase in apoptotic Annexin V+/PI+ cells in these cell lines. Tumor xenografts in nude mice were established with 5 of the 6 cell lines. Effects of single agent treatment with JTP-74057 or GSK2126458 ranged from minor inhibition to tumor stasis, while dual inhibitor treatment showed synergistic effects in each case, with marked tumor reductions in 2/5 cases and the authors report one compete response in a MaMel301 cell line xenograft mouse." ;
    a m2r:Evidence .

civice:1430
    dct:references pbm:27048246 ;
    civico:citation "Klempner et al., 2016, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Trametinib,civic:drug_Vemurafenib ;
    dcterms:description "BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited durable response (beyond 7 and 9 months, respectively). Urinary BRAF V600E tumor DNA correlated with disease response in one of the patients. BRAF and MEK inhibition was either dabrafenib+trametinib (case 1) or vemurafenib+trametinib (case 2)." ;
    a m2r:Evidence .

civice:1432
    dct:references pbm:23382472 ;
    civico:citation "Hurvitz et al., 2013, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_TrastuzumabEmtansine ;
    dcterms:description "In a randomized phase II study, first line treatment of HER2-positive metastatic breast cancer with trastuzumab emtansine (T-DM1) resulted in improved progression free survival and fewer serious adverse effects when compared to treatment with combination trastuzumab plus docetaxel (HT) (median follow up 14 months, median PFS with T-DM1 14.2 vs 9.2 with HT)." ;
    a m2r:Evidence .

civice:1433
    dct:references pbm:27069254 ;
    civico:citation "Arber et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2." ;
    a m2r:Evidence .

civice:1434
    dct:references pbm:27069254 ;
    civico:citation "Arber et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2." ;
    a m2r:Evidence .

civice:1435
    dct:references pbm:27069254 ;
    civico:citation "Arber et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2." ;
    a m2r:Evidence .

civice:1436
    dct:references pbm:27069254 ;
    civico:citation "Arber et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2." ;
    a m2r:Evidence .

civice:1437
    dct:references pbm:22149875 ;
    civico:citation "Baselga et al., 2012, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pertuzumab,civic:drug_Trastuzumab,civic:drug_Docetaxel ;
    dcterms:description "In a randomized phase 3 trial, HER2 positive metastatic breast cancer patients given first-line treatment of pertuzumab plus trastuzumb plus docetaxel experienced improved progression free survival (18.5 vs 12.4 months,  P<0.001) and increased objective response rate (80.2% vs 69.3%, P=0.001) than the control group given placebo plus trastuzumab plus docetaxel." ;
    a m2r:Evidence .

civice:1438
    dct:references pbm:24625776 ;
    civico:citation "Wagle et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pazopanib,civic:drug_Everolimus ;
    dcterms:description "A phase 1 clinical trial identified a patient with chemotherapy-refractory urothelial carcinoma who had complete radiographic response lasting 14 months after combined everolimus and pazopanib treatment. This patient was exome sequenced and two mutations co-occurring in MTOR were identified. Expression of these mutations in HEK293T cells demonstrated these were activating mutations. The authors propose that these two activating mutations are the reason for the dramatic response to mTOR inhibition and considered them as \"biologically plausible\" to confer sensitivity to everolimus." ;
    a m2r:Evidence .

civice:1439
    dct:references pbm:22257673 ;
    civico:citation "Baselga et al., 2012, Lancet" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Lapatinib,civic:drug_Trastuzumab ;
    dcterms:description "In a randomized open label phase 3 study (NCT00553358), women with HER2 positive primary breast cancer treated with lapatinib plus trasuzumab had higher rates of pathological complete responses than seen in control groups receiving either IV trastuzumab or oral lapatinib alone (combination treatment pCR rate of 51% vs 29.5% and 24.7% for trastuzumab and lapatinib alone, respectively)." ;
    a m2r:Evidence .

civice:1440
    dct:references pbm:26370156 ;
    civico:citation "Cheng et al., 2015, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cc-223,civic:drug_MLN0128 ;
    dcterms:description "Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma. A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alteration. RICTOR amplification was confirmed via FISH and IHC. On two separate treatments with dual mTOR1/2 inhibitors patient exhibited stable disease for more than 18 months." ;
    a m2r:Evidence .

civice:1441
    dct:references pbm:14504092 ;
    civico:citation "Klion et al., 2004, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A cohort of seven male patients with myeloproliferative hypereosinophilic syndrome and elevated serum tryptase levels were enrolled in a study of imatinib mesylate therapy. All seven patients demonstrated improvement in clinical symptoms and resolution of laboratory abnormalities and bone marrow pathology in response to treatment. Complete molecular remission of FIP1L1-PDGFRA was observed in 5 of 6 patients tested post-therapy." ;
    a m2r:Evidence .

civice:1443
    dct:references pbm:22215748 ;
    civico:citation "Bergethon et al., 2012, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Study describes a 31-year old male, never-smoker patient with advanced NSCLC with a ROS1 rearrangement. The patient was treated with crizotinib with marked response at 1 week and resolution of the tumor confirmed at 8 and 12 weeks via CT-scans. It was also demonstrated that crizotinib inhibits ROS1 phosphorylation in HEK 293 cells transfected with a CD14-ROS1 fusion gene, and crizotinib inhibited growth in the HCC78 cell line containing a ROS1 rearrangement to a similar degree as ALK-fusion positive cell lines." ;
    a m2r:Evidence .

civice:1444
    dct:references pbm:24875859 ;
    civico:citation "Lovly et al., 2014, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement. Next generation sequencing of the patient revealed a TFG-ROS1 fusion. CT scans after 3 cycles of crizotinib treatment showed a reduction of the tumor mass which continued to decrease at the time of publication after 4 months of crizonitib treatment." ;
    a m2r:Evidence .

civice:1445
    dct:references pbm:12660384 ;
    civico:citation "Cools et al., 2003, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "Of eleven patients prospectively accrued with hypereosinophilic syndrome, nine had favorable responses to imatinib that lasted >3 months post-treatment. Of these nine patients, five were found to have a FIP1L1-PDGFRA fusion." ;
    a m2r:Evidence .

civice:1446
    dct:references pbm:12660384 ;
    civico:citation "Cools et al., 2003, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A patient treated with imatinib for a FIP1L1-PDGFRA mutation relapsed during treatment. A T674I mutation in the PDGFRA split kinase domain was hypothesized to confer resistance, due to the strong evidence of this fusion in driving myeloproliferative hypereosinophilic syndrome and the contextual similarity to T315I mutations in BCR-ABL." ;
    a m2r:Evidence .

civice:1447
    dct:references pbm:19029981 ;
    civico:citation "Engelman et al., 2008, Nat. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BEZ235%28NVP-BEZ235,civic:drug_Dactolisib%29 ;
    dcterms:description "Doxycycline dependent expression of the PIK3CA H1047R mutation in mouse type II alveolar epithelial cells drove lung cancer in a reversible fashion, indicating the driver properties of this p110alpha catalytic domain mutation. Administration of pan-p110 isoform and mTOR inhibitor BEZ235 to H1047R mice with established tumors resulted in reduced tumor phospho-Akt and phosoho-S6 levels, and significant regression of tumor volume." ;
    a m2r:Evidence .

civice:1448
    dct:references pbm:23204226 ;
    civico:citation "Chakrabarty et al., 2013, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_XL147%28Pilaralisib%29 ;
    dcterms:description "In 5 trastuzumab resistant HER2 overexpressing breast cancer cell lines, combination of the pan-PI3K inhibitor XL147 and trastuzumab treatment induced cell death to similar or greater levels than XL147 alone. In three trastuzumab resistant cell lines tested, colony formation in matrigel was markedly inhibited by combination treatment. Apoptotic markers were apparent with combination treatment. In athymic mice, trastuzumab resistant cell line HR6 was used in tumor xenografts and tumors were allowed to form. Mice subsequently treated with trastuzumab or XL147 showed continued tumor growth without marked difference from control, while combination treatment essentially halted tumor growth rate." ;
    a m2r:Evidence .

civice:1449
    dct:references pbm:23204226 ;
    civico:citation "Chakrabarty et al., 2013, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "13 HER2 breast cancer patients were treated with trastuzumab and then trastuzumab + docetaxel prior to surgery. Pretreatment biopsies and post-treatment surgical samples were obtained, and microarray performed. 5 of 13 patients responded to treatment, and pretreatment biopsies from non-responders showed significantly higher survivin (BIRC5) mRNA (p=0.026) levels than responders. In HER2 positive, trastuzumab-sensitive BT474 cells, overexpression of survivin blunted sensitivity to trastuzumab. In HER2 positive trastuzumab-resistant breast cancer cell lines, knockdown of survivin with RNAi or with YM155 induced growth inhibition and apoptosis." ;
    a m2r:Evidence .

civice:1450
    dct:references pbm:8241511 ;
    civico:citation "el Rouby et al., 1993, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A study of 53 patients with B-CLL found a significant resistance to chemotherapy and corresponding poor clinical outcomes among the 7 treated patients with p53 mutations compared to the 29 treated patients without." ;
    a m2r:Evidence .

civice:1451
    dct:references pbm:18689542 ;
    civico:citation "Zenz et al., 2008, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 126 patients with long-term follow-up, TP53 mutations were significantly associated with shorter median survival in patients (P = 0.002) from time of diagnosis. The median survival from the time of first observation of a TP53 mutation was much more pronounced (P = <0.001). These findings were statistically independent of 17p deletions." ;
    a m2r:Evidence .

civice:1452
    dct:references pbm:20697090 ;
    civico:citation "Zenz et al., 2010, J. Clin. Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The authors analyzed 328 patients with CLL, of which 28 were identified to have TP53 mutations. Patients with TP53 mutations were found to have significantly shorter progression-free (HR = 3.8; P < 0.001) and overall survival (HR = 7.2; P < 0.001)." ;
    a m2r:Evidence .

civice:1453
    dct:references pbm:18829560 ;
    civico:citation "Serra et al., 2008, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "PI3K mutant E545K was overexpressed in the trastuzumab sensitive HER2 BT474 breast cancer cell line, and significant resistance to trastuzumab was induced in comparison to control cells." ;
    a m2r:Evidence .

civice:1454
    dct:references pbm:20141835 ;
    civico:citation "Heidorn et al., 2010, Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_MEKInhibitor,civic:drug_Sorafenib ;
    dcterms:description "Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers." ;
    a m2r:Evidence .

civice:1455
    dct:references pbm:15324695 ;
    civico:citation "Nagata et al., 2004, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_LY294002 ;
    dcterms:description "Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition, but co-treatment with trastuzumab and LY294002 induced growth inhibition comparable to trastuzumab alone in normal BT474 cells. BT474 mouse xenograft tumors were injected with PTEN antisense (AS) oligonucleotides and this resulted in trastuzumab resitance. Co-treatment of PTEN AS tumor mice with LY294002 and trastuzumab inhibited tumor growth in comparison to PTEN AS tumors treated with trastuzumab or LY294002 alone." ;
    a m2r:Evidence .

civice:1456
    dct:references pbm:20141835 ;
    civico:citation "Heidorn et al., 2010, Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Sorafenib,civic:drug_Trametinib ;
    dcterms:description "Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors could instead block ERK pathway hyperactivation in RAS mutated cancers." ;
    a m2r:Evidence .

civice:1457
    dct:references pbm:20141835 ;
    civico:citation "Heidorn et al., 2010, Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Sorafenib,civic:drug_MEKInhibitor ;
    dcterms:description "Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers." ;
    a m2r:Evidence .

civice:1458
    dct:references pbm:22798288 ;
    civico:citation "Dahlman et al., 2012, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib,civic:drug_Trametinib ;
    dcterms:description "Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling." ;
    a m2r:Evidence .

civice:1459
    dct:references pbm:22798288 ;
    civico:citation "Dahlman et al., 2012, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib,civic:drug_Trametinib ;
    dcterms:description "Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling." ;
    a m2r:Evidence .

civice:1460
    dct:references pbm:22798288 ;
    civico:citation "Dahlman et al., 2012, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_TAK-733 ;
    dcterms:description "Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial. A partial radiographic response with a decrease of 31% in the sum of maximum diameters of target metastatic lesions in the liver and spleen was noted after 2 cycles of therapy and remained progression free at more than 24 weeks. Follow-up sequencing analysis of DNA from the patient's tumor revealed a somatic BRAF L597S mutation." ;
    a m2r:Evidence .

civice:1461
    dct:references pbm:22798288 ;
    civico:citation "Dahlman et al., 2012, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib,civic:drug_Trametinib ;
    dcterms:description "Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling." ;
    a m2r:Evidence .

civice:1462
    dct:references pbm:22798288 ;
    civico:citation "Dahlman et al., 2012, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib,civic:drug_Vemurafenib ;
    dcterms:description "Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling." ;
    a m2r:Evidence .

civice:1463
    dct:references pbm:22805292 ;
    civico:citation "Falchook et al., 2012, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "Case report of a phase 1 study in advanced melanoma patients. 97 patients with melanoma were enrolled and treated with trametinib. One patient with a BRAF Leu597Val had a confirmed partial response with 60% tumour reduction and received study treatment for more than 2 years." ;
    a m2r:Evidence .

civice:1464
    dct:references pbm:26589432 ;
    civico:citation "Zumsteg et al., 2016, Clin. Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Taselisib%28GDC-0032%29 ;
    dcterms:description "The HNSCC cell line LB771 with PIK3CA amplification was shown to have low antiproliferative IC50 for the p110beta-sparing PI3K inhibitor taselisib. Under increasing taselisib concentrations, reduction in phospho-Akt pro-survival signal was apparent, along with increased levels of pro-apoptotic marker cleaved PARP. A general tendency for taselisib sensitivity to PI3K activation (mutation/amplification) was also seen in a panel of 26 HNSCC cell lines" ;
    a m2r:Evidence .

civice:1465
    dct:references pbm:26589432 ;
    civico:citation "Zumsteg et al., 2016, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Taselisib%28GDC-0032%29 ;
    dcterms:description "The Cal-33 HNSCC cell line with H1047R mutation was found to have a low antiproliferative IC50 value for the alpha, gamma and delta isoform-specific PI3K inhibitor taselisib. Increasing taselisib concentration induced reduction of phospho-Akt levels in Call-33 cells, while upregulating the cleaved PARP apoptotic marker. Among a panel of 26 HNSCC cell lines, activating PI3K mutations were associated with taselisib sensitivity in comparison to wild-type PI3K or PTEN mutant cell lines." ;
    a m2r:Evidence .

civice:1466
    dct:references pbm:23775962 ;
    civico:citation "Hodi et al., 2013, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "Phase 2 trial in metastatic mucosal, acral or chronically sun-damaged melanoma. Twenty-five patients were enrolled (24 evaluable). Eight patients (33%) had tumors with KIT mutations, 11 (46%) with KIT amplifications, and five (21%) with both. Median follow-up was 10.6 months. Best overall response rate was statistically significantly different by mutation status: 7 of 13 or 54% KIT mutated v 0% KIT amplified only." ;
    a m2r:Evidence .

civice:1467
    dct:references pbm:26589432 ;
    civico:citation "Zumsteg et al., 2016, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Taselisib%28GDC-0032%29 ;
    dcterms:description "In a panel of 26 HNSCC cell lines tested for sensitivity to taselisib (an alpha, delta and gamma isoform-specific PI3K inhibitor) the UD-SCC-2 cell line with homozygous PTEN deletion had considerably higher antiproliferative IC50 than taselisib sensitized cell lines. Western blots of UD-SCC-3 cells with increasing taselisib concentration showed reduction of phospho-Akt only at micro-molar doses, in contrast to nano-molar range for sensitized cells. Slight induction of the apoptotic marker cleaved PARP was only apparent at 4 micro-molar dose. Similar results were reported with the PTEN mutant HNSCC cell line UPCI-SCC-90, and 4 of the 6 most taselisib resistant cell lines had PTEN mutation." ;
    a m2r:Evidence .

civice:1468
    dct:references pbm:23171796 ;
    civico:citation "Maertens et al., 2013, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Preclinical study of mouse melanoma in-vitro and in-vivo. In-vitro treament of Braf-mutant melanomas were 10-fold more sensitive to vermurafenib (PLX4032) treatment than Braf/Nf1-mutant melanomas. In vivo treatment of mice with Braf/Nf1-mutant allografts showed less sensitivity to vemurafenib (PLX4032) than the MEK inhibitor, PD0325901." ;
    a m2r:Evidence .

civice:1469
    dct:references pbm:23171796 ;
    civico:citation "Maertens et al., 2013, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PD0325901,civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "Preclinical study of mouse melanoma both in-vitro and in-vivo. Braf/Nf1-mutant melanomas were less sensitive to vemurafenib than the MEK inhibitor PD0325901. mTOR inhibition with rapamycin had a more pronounced effect than GDC-0941 on mouse melanoma, but synergized with PD0325901(but not vemurafenib) to promote tumor regression." ;
    a m2r:Evidence .

civice:1470
    dct:references pbm:23288408 ;
    civico:citation "Whittaker et al., 2013, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. Knockdown of NF1 led to PLX4720 resistance in-vitro. MEK inhibition with AZD6244 (selumetinib) had some efficacy but was also less active than in NF1 proficient cells.  4 patients with mutant alleles of NF1 were identified among patients relapsed after vemurafenib. Of these, one was a nonsense mutation (p.R2450*) present in both pretreatment and postrelapse biopsies. The patient had a progression-free survival (PFS) of about 10 weeks. The other NF1 mutations were silent events (patient 15, c.135T>C, patient 45 c.4023G>A, and patient 50 c3018C>T) located within candidate splicing motifs. Patients 15 and 50 exhibited response rates of relatively short duration (10 and 12 weeks, respectively) and the mutations were observed in both the pretreatment and postrelapse biopsies. Patient 45 experienced a PFS of 5 months, and the NF1 mutation was only present in the postrelapse biopsy indicative of acquired resistance." ;
    a m2r:Evidence .

civice:1471
    dct:references pbm:23288408 ;
    civico:citation "Whittaker et al., 2013, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_VTX-11e,civic:drug_AZ628 ;
    dcterms:description "NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. BRAF V600E/NF1 mutant cell lines were sensitive to ERK inhibition with VTX-11e, modest resistance was observed against RAF inhibitor AZ628. Combined PLX4720 and AZD6244 (selumetinib) achieved greater efficacy than either agent alone but NF1 knockdown was still associated with residual resistance to combined RAF/MEK inhibition in vitro." ;
    a m2r:Evidence .

civice:1472
    dct:references pbm:23414587 ;
    civico:citation "Ascierto et al., 2013, Lancet Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Binimetinib%28MEK162%29 ;
    dcterms:description "Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed)." ;
    a m2r:Evidence .

civice:1473
    dct:references pbm:18390968 ;
    civico:citation "Adjei et al., 2008, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "Phase 1 trial in 57 patients with advanced cancers treated with selumetinib. 4 melanoma patients had NRAS Q61 mutations. One patient with NRAS mutation had 70% tumor shrinkage after three cycles of selumetinib (AZD6244) but developed symptomatic brain metastases before confirmatory scans could be performed." ;
    a m2r:Evidence .

civice:1474
    dct:references pbm:22194965 ;
    civico:citation "Atefi et al., 2011, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376." ;
    a m2r:Evidence .

civice:1475
    dct:references pbm:22194965 ;
    civico:citation "Atefi et al., 2011, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376." ;
    a m2r:Evidence .

civice:1476
    dct:references pbm:24950457 ;
    civico:citation "Fedorenko et al., 2014, Melanoma Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Amuvatinib ;
    dcterms:description "Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growth inhibition, tyrosine phosphorylation inhibition, cell cycle and apoptotic (Annexin V) assays." ;
    a m2r:Evidence .

civice:1477
    dct:references pbm:26546616 ;
    civico:citation "Danial et al., 2016, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_LDE225,civic:drug_Vismodegib ;
    dcterms:description "Study explored the response to the SMO inhibitor sonidegib (LDE225) in a cohort of 9 patients with advanced basal cell carcinoma  that exhibited treatment resistance with vismodegib (GDC0449). Sequencing revealed that 5 of these patients harbored SMO mutations known to confer resistance to the Smoothened inhibitors (D473G, D473H, Q477E, S533N, W535L) an additional patient harbored a SMO mutation of unknown consequence (R168H). Of these patients, 4 with a SMO mutation displayed progressive disease and 1 stable disease for 58 weeks according to RECIST v1.1 criteria." ;
    a m2r:Evidence .

civice:1478
    dct:references pbm:21483000 ;
    civico:citation "Gonzalez et al., 2011, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In the CLL4 trial assessing first line treatment with chlorambucil or fludarabine with or without cyclophosphamide, patients with TP53 mutations experienced poorer overall response rates (27% vs 83%), shorter progression free survival (5 year PFS 5% vs 17%), and overall survival (20% vs 59%) compared to patients without TP53 mutations." ;
    a m2r:Evidence .

civice:1479
    dct:references pbm:23086750 ;
    civico:citation "Oscier et al., 2013, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In the randomized UK LRF CCL4 phase 3 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, univariate analysis of patients with NOTCH1 mutations (within amino acids 2405-2525, a 399bp region of the PEST domain) demonstrated poorer overall survival (54.8 vs 74.6 months, P=0.02) and progression free survival (22 vs 26.4 months, P=0.02) compared to patients with wild-type NOTCH1. Progression-free survival was not significant (P = 0.21), however, overall survival remained significant (P = 0.03) under multivariate analysis." ;
    a m2r:Evidence .

civice:1480
    dct:references pbm:23086750 ;
    civico:citation "Oscier et al., 2013, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In the randomized phase 3 UK LRF CCL4 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, SF3B1 mutations (73/437 patients) were associated with poorer overall survival (median 54.3 vs 79 months, P <0.001), independent of treatment. Additionally, controlling for cases with TP53 deletions/mutations, SF3B1 mutations were associated with reduced progression free survival for patients in the fludarabine plus cyclophosphamide treatment arm when compared to wildtype SF3B1 (29.4 vs 46 months, P=0.002)." ;
    a m2r:Evidence .

civice:1481
    dct:references pbm:14726385 ;
    civico:citation "Lozanski et al., 2004, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Alemtuzumab ;
    dcterms:description "Thirty-six patients with CLL were treated with alemtuzumab. Partial or complete response was achieved in 6 of 15 patients with p53 mutations, compared to 4 of 21 without. These findings are not statistically significant, but the authors suggest that alemtuzumab is an effective therapy for patients with p53 mutations or deletions." ;
    a m2r:Evidence .

civice:1482
    dct:references pbm:26486786 ;
    civico:citation "Verger et al., 2015, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PegylatedIFN-alpha-2a ;
    dcterms:description "Study explored the hematologic and molecular responses in a cohort of 31 patients presenting with thrombocythemia and CALR exon 9 frameshift mutations. All 31 patients exhibited a hematologic response at the time of followup (European LeukemiaNet criteria). In regards to molecular response, before treatment the CALR mutant allele displayed a median frequency of 41% across the cohort, during treatment a significant decrease was observed in comparison to controls treated with hydroxyurea and aspirin." ;
    a m2r:Evidence .

civice:1483
    dct:references pbm:25393796 ;
    civico:citation "Ou et al., 2014, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib,civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "Case study describes a female (age 58) never-smoker presenting with stage IV NSCLC with an ALK rearrangement (confirmed by fish). Patient was treated with crizotinib (partial response) and alectinib (complete response). Liver metastasis was noted after 12 months with sequencing revealing a HIP1-ALK fusion with a I1171N variant." ;
    a m2r:Evidence .

civice:1484
    dct:references pbm:25393796 ;
    civico:citation "Ou et al., 2014, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib,civic:drug_Alectinib%28CH5424802%29 ;
    dcterms:description "Case study describes a caucasian male (age 38) never smoker presenting with stage IV non-small cell lung cancer with an ALK rearrangement. Patient was given crizotinib and exhibited a partial response after 5 months with brain metastasis occurring at 21 months. Patient then received alectinib and exhibited partial response however liver metastasis presented after 12 months on alectinib. Sequencing of this liver metastasis revealed an EML4-ALK fusion with an I1171S variant at a variant frequency of 36% (tumor purity estimated as 70%)." ;
    a m2r:Evidence .

civice:1485
    dct:references pbm:24943832 ;
    civico:citation "Baliakas et al., 2015, Leukemia" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a multivariate analysis of 774 CLL patients, TP53 aberrations were significantly correlated with shorter time to first treatment (HR=2.081; 95% CI=1.431-3.021). This finding was independent of IGHV mutation status." ;
    a m2r:Evidence .

civice:1486
    dct:references pbm:24943832 ;
    civico:citation "Baliakas et al., 2015, Leukemia" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a multivariate analysis of 774 CLL patients, NOTCH1 mutations were not significantly correlated with shorter time to first treatment (HR=1.305; 95% CI=0.923-1.847)." ;
    a m2r:Evidence .

civice:1487
    dct:references pbm:24943832 ;
    civico:citation "Baliakas et al., 2015, Leukemia" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a multivariate analysis of 774 CLL patients, SF3B1 mutations were significantly correlated with shorter time to first treatment (HR=1.644; 95% CI=1.134-2.383). This finding was independent of IGHV mutation status." ;
    a m2r:Evidence .

civice:1488
    dct:references pbm:24943832 ;
    civico:citation "Baliakas et al., 2015, Leukemia" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "BIRC3 mutations were identified in 23 of 919 screened  CLLs. They are strongly linked to non-mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for poor outcome." ;
    a m2r:Evidence .

civice:1489
    dct:references pbm:24943832 ;
    civico:citation "Baliakas et al., 2015, Leukemia" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "MYD88 mutations were identified in 24 of 1080 screened  CLLs. They were exclusively seen in instances of mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for better outcome in CLL." ;
    a m2r:Evidence .

civice:1490
    dct:references pbm:26589432 ;
    civico:citation "Zumsteg et al., 2016, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Taselisib%28GDC-0032%29,civic:drug_Radiation ;
    dcterms:description "A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensitive. Four HNSCC cell lines with activating PIK3CA alterations showed synergistic cell death response to the combination of drug with radiation treatment. This synergism was not apparent in 4 tested HNSCC cell lines with wild-type PIK3CA or PTEN mutation. Nude mouse xenografts were established with Cal-33 PIK3CA H1047R cells. Radiation and taselisib treatments alone showed some growth inhibition in comparison to control, but only the combined treatment led durable tumor regressions." ;
    a m2r:Evidence .

civice:1491
    dct:references pbm:23287563 ;
    civico:citation "Lin et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ipatasertib ;
    dcterms:description "IC50 for the pan-Akt inhibitor ipatasertib (GDC-0068) was determined over a panel of 100 cancer cell lines. Loss or mutation of PTEN (e.g. PTEN deletion, T319fsX1/Y155C, etc.) was significantly associated with ipatasertib sensitivity (p=0.000071). Non-transformed human mammary epithelial MCF10A cells were compared to an isogenic line with PTEN knockout. With low or high EGF culture conditions, a 4x or 3.5x decrease in IC50 for ipatasertib was seen in PTEN knockout cells, respectively." ;
    a m2r:Evidence .

civice:1492
    dct:references pbm:15790433 ;
    civico:citation "Lee et al., 2005, Gynecol. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cisplatin ;
    dcterms:description "A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels. Western blot showed decreased PTEN level in the resistant cell line, and siRNA against PTEN in parent OVCAR-3 cells induced cisplatin resistance." ;
    a m2r:Evidence .

civice:1493
    dct:references pbm:15900596 ;
    civico:citation "Oki et al., 2005, Int. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Chemotherapy ;
    dcterms:description "Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy. Tissue samples were divided into high grade and low grade for phospho Akt (p-Akt) expression, and tested for PTEN LOH by sequencing. Patients with PTEN LOH were significantly more likely to have elevated p-Akt (p=0.0081), and high p-Akt samples were significantly less sensitive to chemotherapy agents 5-flourouracil, adriamycin, mitomycin and cis-platinum in MTT assay." ;
    a m2r:Evidence .

civice:1494
    dct:references pbm:26304929 ;
    civico:citation "Tiffen et al., 2015, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_GSK126 ;
    dcterms:description "Preclinical study in melanoma cell lines. EZH2 expression was higher in EZH2 mutant (N=3) and wild-type melanoma cell lines (N=12) than untransformed cells (human epithelial melanocytes and human dermal fibroblasts). EZH2 mutant cell lines were the most sensitive to GSK126 compared to wild-type and untransformed." ;
    a m2r:Evidence .

civice:1495
    dct:references pbm:26307133 ;
    civico:citation "Wilson et al., 2016, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Carboplatin,civic:drug_Paclitaxel,civic:drug_Sorafenib ;
    dcterms:description "Retrospective analysis of somatic mutations and copy number changes in 119 patient treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors with CCND1 gene copy gains (HR, 0.45; P = 0.035)." ;
    a m2r:Evidence .

civice:1496
    dct:references pbm:26307133 ;
    civico:citation "Wilson et al., 2016, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Carboplatin,civic:drug_Paclitaxel,civic:drug_Sorafenib ;
    dcterms:description "Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors that were positive for RAF1 gene copy gains (HR = 0.372; P = 0.025)." ;
    a m2r:Evidence .

civice:1497
    dct:references pbm:26307133 ;
    civico:citation "Wilson et al., 2016, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Sorafenib,civic:drug_Carboplatin,civic:drug_Docetaxel ;
    dcterms:description "Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved overall survival compared with CP in patients with tumors positive for KRAS gene copy gains (HR = 0.25; P = 0.035)." ;
    a m2r:Evidence .

civice:1498
    dct:references pbm:16960151 ;
    civico:citation "David et al., 2007, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "Twelve patients with BCR-ABL-negative chronic myeloproliferative disease and reciprocal translocations involving PDGFRB received imatinib for a median of 47 months (range, 0.1-60 months). Eleven had prompt responses, 10 had complete resolution of cytogenetic abnormalities and decrease or disappearance of fusion transcripts as measured by reverse transcriptase-polymerase chain reaction (RT-PCR). Updates were sought from 8 further patients previously described in the literature; prompt responses were described in 7 and persist in 6." ;
    a m2r:Evidence .

civice:1499
    dct:references pbm:20728210 ;
    civico:citation "Bang et al., 2010, Lancet" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer." ;
    a m2r:Evidence .

civice:1500
    dct:references pbm:24088382 ;
    civico:citation "Li et al., 2013, J Transl Med" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD5363,civic:drug_Docetaxel ;
    dcterms:description "A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the commonly used gastric cancer chemotheraputic docetaxel. When used in combination, AZD5363 and docetaxel induced significant tumor growth inhibition in comparison to monotherapy and vehicle control." ;
    a m2r:Evidence .

civice:1501
    dct:references pbm:24088382 ;
    civico:citation "Li et al., 2013, J Transl Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD5363 ;
    dcterms:description "In a panel of 22 gastric cancer cell lines, 4 of 6 cell lines having the highest sensitivity to AZD5363 contained a PIK3CA mutation (E542K, E453K, E545K). A patient derived gastric cancer xenograft mouse model was established with PIK3CA H1047R mutant cells, and treatment with AZD5363 induced significant tumor growth inhibition in comparison to vehicle control." ;
    a m2r:Evidence .

civice:1502
    dct:references pbm:22294718 ;
    civico:citation "Davies et al., 2012, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD5363 ;
    dcterms:description "In a panel of 182 cell lines (162 with PIK3CA mutation status known) from solid and hematological tumors, significant correlation was found between AZD5363 (pan-Akt inhibitor) sensitivity and PIK3CA mutation status (N=33, p=0.0059). In the subpopulation free of RAS mutation (N=19) the correlation was increased." ;
    a m2r:Evidence .

civice:1503
    dct:references pbm:22294718 ;
    civico:citation "Davies et al., 2012, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD5363 ;
    dcterms:description "Sensitivity to pan-Akt inhibitor AZD5363 was assessed in a panel of 182 cell lines (160 with PTEN evaluated) derived from solid and hematological tumors. PTEN loss of function due to loss or mutation (N=32) was found to be significantly correlated with AZD5363 sensitivity (p=0.0099), and correlation improved in the subpopulation free of RAS mutation. Mouse xenografts with 786-0 (PTEN-null renal cancer) cells were established. 75 mg/kg twice daily AZD5363 caused tumor growth inhibition while 150 mg/kg twice daily induced moderate tumor regression." ;
    a m2r:Evidence .

civice:1504
    dct:references pbm:22294718 ;
    civico:citation "Davies et al., 2012, Mol. Cancer Ther." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD5363 ;
    dcterms:description "HER2 overexpressing breast cancer cell lines with PIK3CA mutation BT474c (K111N) and HCC-1954 (H1047R) were used to establish mouse tumor xenografts. In BT474c xenografts, three dosing schedules of AZD5363 caused significant tumor inhibition (200 mg/kg twice daily > 200 mg/kg once daily > 100 mg/kg once daily). In HCC-1954 xenografts two doses of AZD5363 induced significant tumor inhibition (150 mg/kg twice daily > 75 mg/kg twice daily) while 30 mg/kg twice weekly trastuzumab was inactive." ;
    a m2r:Evidence .

civice:1505
    dct:references pbm:22294718 ;
    civico:citation "Davies et al., 2012, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD5363,civic:drug_Trastuzumab ;
    dcterms:description "Tumor xenografts in mice were established with the KPL4 HER2 positive breast cancer cell line with PIK3CA H1047R mutation. KPL4 has suboptimal responses to trastuzumab and lapatinib. Xengraft treatment with trastuzumab and AZD5363 monotherapy induced moderate growth inhibition which was significant for AZD5363, but co-treatment with trastuzumab and AZD5363 induced significant tumor regression and enhanced growth delay upon removal of treatment." ;
    a m2r:Evidence .

civice:1506
    dct:references pbm:22294718 ;
    civico:citation "Davies et al., 2012, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD5363,civic:drug_Lapatinib ;
    dcterms:description "The HER2 breast cancer cell line KPL4 with PIK3CA H1047R shows sub-optimal responses to trastuzumab and lapatinib, and was used to establish mouse xenografts. Treatment of mice with monotherapy of AZD5363 or lapatinib alone induced growth inhibition (37%, not significant; 65%, P = 0.004), but treatment with AZD5363 and lapatinib together induced significant tumor regression (109%, P < 0.0001) as well as delayed tumor regrowth after removal of therapy." ;
    a m2r:Evidence .

civice:1507
    dct:references pbm:26837699 ;
    civico:citation "Nadeu et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "A" ;
    dcterms:description "In a cohort of 406 patients with CLL, those patients with clonal or sub-clonal mutations in TP53 had significantly shorter overall survival (HR: 1.71; 95% CI: 1.28-2.26; P = .0001)." ;
    a m2r:Evidence .

civice:1508
    dct:references pbm:26124496 ;
    civico:citation "Patel et al., 2015, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "An ASXL1 mutation, especially in conjunction with DNMT3A and EZH2 mutations, results in a fourfold increase in resistance to treatment with ruxolitinib and a reduced time to treatment discontinuation (TTD) for patients with myelofibrosis." ;
    a m2r:Evidence .

civice:1509
    dct:references pbm:24588908 ;
    civico:citation "Thumar et al., 2014, Mol. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Binimetinib%28MEK162%29 ;
    dcterms:description "In a panel of 7 NRAS mutant melanoma cell lines, all 7 were found to be sensitive to the MEK inhibitor MEK162, whereas 3 of 5 melanoma cell lines that were wild type for BRAF and NRAS were not sensitive to MEK162. In further tests using two of the seven NRAS mutant cell lines (YUDOSO Q16K/wt and YUKIM Q16R), colony forming capacity was reduced with increased MEK162 treatment, and MEK162 induced apoptotic markers in these cells." ;
    a m2r:Evidence .

civice:1511
    dct:references pbm:27276561 ;
    civico:citation "Papaemmanuil et al., 2016, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 1,540 patients with Acute Myeloid Leukemia, 18 patients had a mutation in IDH2(R172).  IDH2(R172) mutations rarely showed co-mutation with NPM1 (odds ratio= 0.06; P=4x10-5), whereas IDH2(R140) mutations showed strong co-mutation with NPM1 (odds ratio= 3.6; P=5x10-10).  In an absence of gene fusion products, patients with IDH2(R172) mutations showed higher survival rates when compared to mutations in NPM1, chromatin-spliceosome mutations and TP53–aneuploidy.  Patients with IDH2(R172) mutations showed worse prognosis when compared to CEBPA(biallelic) mutations." ;
    a m2r:Evidence .

civice:1512
    dct:references pbm:27276561 ;
    civico:citation "Papaemmanuil et al., 2016, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 1,540 patients with Acute Myeloid Leukemia, 66 patients (4%) had a CEBPA (biallelic) mutation.  In the absence of gene fusion products, patients with biallelic CEBPA mutations showed the highest rate of survival (~78%) when compared to IDH2 (R172) mutations, NPM1(W288fs) mutations, chromatin-spliceosome mutations and TP53–aneuploidy." ;
    a m2r:Evidence .

civice:1513
    dct:references pbm:27276561 ;
    civico:citation "Papaemmanuil et al., 2016, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with Acute Myeloid Leukemia showed an synergistic mortality rate with ASXL1 and SRSF2 co-mutations such that individual mutations of either ASXL1 or SRSF2 resulted in ~20% probability of survival after 10 years, whereas co-mutations resulted in a 100% mortality rate after 4 years." ;
    a m2r:Evidence .

civice:1514
    dct:references pbm:27276561 ;
    civico:citation "Papaemmanuil et al., 2016, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with Acute Myeloid Leukemia showed an synergistic mortality rate with ASXL1 and SRSF2 co-mutations such that individual mutations of either ASXL1 or SRSF2 resulted in ~20% probability of survival after 10 years, whereas co-mutations resulted in a 100% mortality rate after 4 years." ;
    a m2r:Evidence .

civice:1515
    dct:references pbm:27276561 ;
    civico:citation "Papaemmanuil et al., 2016, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In the absence of a FLT3 (ITD) mutation, a co-mutation of NPM1 and DNMT3A had a 50% 10-year survival rate, whereas triple-mutation of NPM1, DNMT3A, and FLT3 (ITD) had a 20% 10-year survival rate." ;
    a m2r:Evidence .

civice:1516
    dct:references pbm:27276561 ;
    civico:citation "Papaemmanuil et al., 2016, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with a triple mutation of NPM1, DNMT3A, and NRAS (G12/13) (three-way interaction p=0.04) showed a relatively benign prognosis with an 8-year survival rate of 75% and a 10-year survival rate of 55%.  Conversely, patients with a concomitant NPM1/DNMT3A co-mutation, in the absence of an NRAS (G12/13) mutation, showed a clinically unfavorable 10-year survival rate of 30%." ;
    a m2r:Evidence .

civice:1517
    dct:references pbm:22658127 ;
    civico:citation "Topalian et al., 2012, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Nivolumab ;
    dcterms:description "Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types. PD-L1 expression was tested in 42 patients by ICH from tumor FFPE biopsies. (18 melanoma, 10 NSCLC, 7 colorectal cancer, 5 renal cell cancer, 2 prostate cancer). 9 of 25 PD-L1 expressing patients showed objective response, and zero of 17 PD-L1 negative patients showed objective response (p=0.006). Biopsies were optional, and therefore not fully randomized." ;
    a m2r:Evidence .

civice:1518
    dct:references pbm:20696054 ;
    civico:citation "Jones et al., 2010, Genome Biol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Sunitinib ;
    dcterms:description "A 78-year-old man presented with oral papillary adenocarcinoma and lung metastases that were refractory to standard treatment.  Tumor sequencing showed increased MAPK activity due to RET over-expression and PTEN deletion, therefore sunitinib (RET inhibitor) was initiated.  After 28 days post-administration, the lung metastases decreased in size by 22% (28mm to 21mm) and no new metastatic lesions had appeared.  After 4 months, the patient grew resistant to treatment." ;
    a m2r:Evidence .

civice:1519
    dct:references pbm:21505136 ;
    civico:citation "Welch et al., 2011, JAMA" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_All-transRetinoicAcid ;
    dcterms:description "A 39-year old woman who presented with acute myeloid leukemia revealed a complicated genetic profile using conventional metaphase cytogenetics and FISH analysis.  Whole genome sequencing elucidated a PML-RARA fusion, which can be successfully treated with ATRA. Uncovering this mutation prevented an unnecessary allogeneic transplant and the patient remained in remission 15 months post-treatment (date of publication)." ;
    a m2r:Evidence .

civice:1520
    dct:references pbm:25802883 ;
    civico:citation "Sekulic et al., 2015, Mol Genet Genomic Med" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Ipilimumab ;
    dcterms:description "A 67-year-old Caucasian female with stage IVA Sezary syndrome presented refractory to traditional therapy and was enrolled in a whole genome study trial. Sequencing revealed a CTLA4-CD28 fusion protein such that the inhibitory CTLA4 receptor activated a stimulatory CD28 intracellular domain that promoted proliferation. The patient was treated with iplimumab, a CTLA4 receptor inhibitor, and after 10 days, there was a reduction in erythema and ulceration by 50%, a reduction in tumor size by 75%, and overall improved quality of life. However, during the sixth week of therapy, the patient rapidly developed skin tumors and died 3 months later." ;
    a m2r:Evidence .

civice:1521
    dct:references pbm:26000489 ;
    civico:citation "Robinson et al., 2015, Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bicalutamide,civic:drug_Flutamide,civic:drug_CyproteroneAcetate,civic:drug_Nilutamide ;
    dcterms:description "In a study of 150 patients with metastatic castration resistant prostate cancer (mCRPC), 71.3% of cases (n=107) harbored androgen receptor (AR) pathway aberrations.   Within the AR mutation cohort, 78 patients had AR amplification mutations, 16 patients had AR missense mutations, and 13 patients had mutations in ZBTB16, NCOR1, FOXA1, and SPOP, which are all AR regulators or downstream effectors.  All AR mutations were exclusive to mCRPC neoplasms and were not found in primary prostate cancer." ;
    a m2r:Evidence .

civice:1522
    dct:references pbm:25544636 ;
    civico:citation "Schwartz et al., 2015, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Enzalutamide,civic:drug_AZD8186,civic:drug_BYL719%28Alpelisib%29 ;
    dcterms:description "Castrated mice bearing androgen-sensitive human prostate adenocarcinomas (LNCaP tumors) were treated with PI3K inhibitors (AZD8186, BYL719) and an androgen receptor inhibitor (MDV3100).  Mice treated with single therapy of either MDV3100, BYL719, or AZD8186 resulted in mild tumor growth inhibition of 90%, 36%, and 40% respectively (n=5 mice/group).  However, triple therapy of MDV300, BYL719, and AZD8186 resulted in tumor regression of 113% (n=5 mice)." ;
    a m2r:Evidence .

civice:1523
    dct:references pbm:23569316 ;
    civico:citation "Castro et al., 2013, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 2,019 patients with prostate cancer, 18 had germline BRCA1 mutations, 61 had germline BRCA2 mutations and 1,940 were non-carriers.  Patients with BRCA1/2 mutations had a 2-fold higher incidence of poorly differentiated cancer (Gleason score >8), a higher incidence of advanced stage (37% vs. 28%; P=0.003), a higher incidence of nodal involvement (15% vs. 5%; P=0.0005), and a higher incidence of metastatic spread (18% vs. 9%; P=0.005)." ;
    a m2r:Evidence .

civice:1524
    dct:references pbm:23569316 ;
    civico:citation "Castro et al., 2013, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 2,019 patients with prostate cancer, 18 had germ-line BRCA1 mutations, 61 had germ-line BRCA2 mutations and 1,940 were non-carriers.  Patients with BRCA1/2 mutations had a 2-fold higher incidence of poorly differentiated cancer (Gleason score >8), a higher incidence of advanced stage (37% vs. 28%; P=0.003), a higher incidence of nodal involvement (15% vs. 5%; P=0.0005), and a higher incidence of metastatic spread (18% vs. 9%; P=0.005)." ;
    a m2r:Evidence .

civice:1525
    dct:references pbm:24277854 ;
    civico:citation "Liu et al., 2013, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_LGK974 ;
    dcterms:description "In an evaluation of 96 head and neck squamous cell carcinoma (HNSCC) cell lines, 31 were responsive to LGK974 (PORCN inhibitor). Of 40 cell lines (25 responsive, 15 non-responsive) that were exome sequenced, 6 cell lines had NOTCH1 loss-of-function mutations (N-terminal frameshift/nonsense) and 5/6 cell lines that had NOTCH1 mutations were susceptible to LGK974 (PORCN inhibitor)." ;
    a m2r:Evidence .

civice:1526
    dct:references pbm:27252418 ;
    civico:citation "Alves et al., 2016, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Fulvestrant ;
    dcterms:description "In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months and 3.4 vs. 8.9 months for CDK6 overexpression vs. normal expression). CDK6 expression did not correlate with other lines of treatment (N=68, tamoxifen or endocrine therapy). Four fulvestrant-resistant cell lines were derived from estrogen responsive and fulvestrant sensitive parental breast cancer cell line MCF-7/SO.5. Gene expression profiling showed upregulation of CDK6 in the fulvestrant resistant derivatives. Knockdown of CDK6 in these derivative cells resulted in fulvestrant sensitivity." ;
    a m2r:Evidence .

civice:1527
    dct:references pbm:27252418 ;
    civico:citation "Alves et al., 2016, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29,civic:drug_Fulvestrant ;
    dcterms:description "Four fulvestrant (estrogen receptor degrader) resistant cell lines were derived from parent fulvestrant sensitive ER+ MCF-7/SO.5 breast cancer cell line. Derivative cell lines showed some sensitivity to CDK4/6 inhibitor palbociclib, and increased growth inhibition when treated with fulvestrant and palbociclib together." ;
    a m2r:Evidence .

civice:1528
    dct:references pbm:27181063 ;
    civico:citation "Griffith et al., 2016, Exp. Hematol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Sunitinib ;
    dcterms:description "A 25-year-old Caucasian male presented with a second relapse of B-ALL. RNA sequencing revealed FLT3 overexpression (also confirmed by IHC). The patient was treated with 22 days of sunitinib, permitting the patient to undergo a bone marrow transplant. A bone marrow biopsy showed complete clearance by variant allele frequency and the patient remains in remission 4-years post matched-unrelated donor allograft." ;
    a m2r:Evidence .

civice:1529
    dct:references pbm:24240112 ;
    civico:citation "Pennington et al., 2014, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PLATINUM ;
    dcterms:description "In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy." ;
    a m2r:Evidence .

civice:1530
    dct:references pbm:24240112 ;
    civico:citation "Pennington et al., 2014, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PLATINUM ;
    dcterms:description "In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy." ;
    a m2r:Evidence .

civice:1531
    dct:references pbm:24240112 ;
    civico:citation "Pennington et al., 2014, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PLATINUM ;
    dcterms:description "In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum-based therapy." ;
    a m2r:Evidence .

civice:1532
    dct:references pbm:24240112 ;
    civico:citation "Pennington et al., 2014, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PLATINUM ;
    dcterms:description "In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum therapy." ;
    a m2r:Evidence .

civice:1533
    dct:references pbm:24504448 ;
    civico:citation "Turajlic et al., 2014, Ann. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors." ;
    a m2r:Evidence .

civice:1534
    dct:references pbm:24504448 ;
    civico:citation "Turajlic et al., 2014, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_MK-2206,civic:drug_PD184352 ;
    dcterms:description "A 26-year old patient presented with vemurafenib resistant BRAF V600E-mutated cutaneous melanoma. Five metastases were evaluated using whole genome sequencing and a 4-bp deletion in PTEN (frameshift mutation at V317) was identified as unanimously present in all five tumors and a pre-treatment biopsy. The other copy of PTEN was lost with a chromosome-wide loss of chr 10. Subsequently, a patient-derived tumor cell line (designated 22 092) was suspended in a solution of PD18352/MK2206 combination therapy and cell growth inhibition confirmed tumor sensitivity to MEK/AKT inhibitors compared to the BRAF V600E-containing A375P cell line. ERK inhibitor resistance was demonstrated as a result of a GNAQ Q209P mutation also identified in the patient. This cell line showed overexpression of AKT and no expression of PTEN." ;
    a m2r:Evidence .

civice:1535
    dct:references pbm:20473330 ;
    civico:citation "Dean et al., 2010, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "In 3 ER positive and 2 ER negative breast cancer cell lines with intact Rb, significant growth inhibition, as measured by BrdU incorporation, was seen with incubation in CDK4/6 inhibitor palbociclib (PD-0332991). In contrast, two ER negative cell lines lacking detectable Rb were fully resistant to palbociclib. Knockdown of Rb in 3 of the tested Rb positive cell lines led to moderate palbociclib resistance in short term incubation experiments.  In longer term (15 day) palbociclib incubations of ER negative MDA-MB-231 cells and ER positive MCF-7 cells, significant resistance to palbociclib was seen in Rb knockdown conditions while wild-type Rb cells maintained sensitivity." ;
    a m2r:Evidence .

civice:1536
    dct:references pbm:22383795 ;
    civico:citation "Leonard et al., 2012, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "A pharmacodynamic study (NCT00420056) of 17 mantle cell lymphoma MCL patients was performed using the CDK4/6 inhibitor palbociclib (PD0332991). Patients were verified by IHC, FISH or molecular testing for the t(11:14) rearrangement  causing Cyclin D overexpression in MCL. 1 patient demonstrated complete response, and 2 showed partial response for an 18% overall response rate. 7 patients showed stable disease. Patient population was heavily pretreated." ;
    a m2r:Evidence .

civice:1537
    dct:references pbm:24504448 ;
    civico:citation "Turajlic et al., 2014, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PLX4720 ;
    dcterms:description "Cells were derived from a 26-year old patient with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma (designated 20 092 cells). Five of his metastases evaluated using whole genome sequencing contained a GNAQ (Q209P) mutation. 20 092 cells were insensitive to BRAF inhibition (PLX4720) in both proliferation assays and evaluation of pERK compared to BRAF V600E mutated, GNAQ wild-type A375P cells. Using GNAQ (Q209P) siRNA in 22 092 cells, ERK activity was suppressed and cell sensitivity to PLX4720 was increased." ;
    a m2r:Evidence .

civice:1538
    dct:references pbm:26837699 ;
    civico:citation "Nadeu et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "A" ;
    dcterms:description "In a study of 406 previously untreated CLL cases, a multivariate analysis indicated clonal NOTCH1 mutations (N=55) were significantly associated with reduced overall survival (HR: 1.5; 95%CI: 1.13-1.99; P = 0.0049). Subclonal mutations (VAF <12%) were not associated with reduced OS (N=29, P=0.94, univariate analysis)." ;
    a m2r:Evidence .

civice:1539
    dct:references pbm:26837699 ;
    civico:citation "Nadeu et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "A" ;
    dcterms:description "In a study of 406 previously untreated CLL cases, a multivariate analysis indicated that aberrations (N=44; mixed pathogenic germline and somatic) in exons 2-63 of ATM were significantly associated with shorter time to first treatment (HR: 1.36; 95% CI: 1.05-1.76; P = 0.021). These mutations were not significantly associated with overall survival." ;
    a m2r:Evidence .

civice:1540
    dct:references pbm:26837699 ;
    civico:citation "Nadeu et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "A" ;
    dcterms:description "In a study of 406 previously untreated CLL cases, a multivariate analysis indicated SF3B1 mutations (N=51) were significantly associated with reduced time to first treatment (HR: 1.73; 95%CI: 1.05-2.86; P = 0.031). While clonal mutations (VAF >= 12%) were associated with reduced time to first treatment by univariate analysis (N=28, P<0.0001), subclonal mutations were not (N=21, P=0.22)." ;
    a m2r:Evidence .

civice:1541
    dct:references pbm:25524798 ;
    civico:citation "Finn et al., 2015, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29,civic:drug_Letrozole ;
    dcterms:description "A phase 2 clinical trial evaluated 165 patients with oestrogen receptor positive and HER2-negative breast cancer such that 84 patients received combination therapy of palbociclib plus letrozole and 81 patients received letrozole alone. The combination therapy arm had higher median duration of progression-free survival when compared to the letrozole only group (20.2 months vs. 10.2 months; p<0.0004). A subcategory of patients taking combination therapy, who lacked mutations in p16 or CCND1 (n=34), had an even higher median free survival of 26.1 months.  Noticeable side effects in the combination therapy group included neutropenia (54%) leucopenia (19%), fatigue (4%) back pain (2%), diarrhea (2%) and pulmonary embolism (4%)." ;
    a m2r:Evidence .

civice:1542
    dct:references pbm:21997850 ;
    civico:citation "Lin et al., 2012, Ann. Hematol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with acute myeloid leukemia, the presence of IDH2 R140Q (n = 7), IDH2 R172K (n = 3) or IDH1 R132 (N=4) mutations did not confer prognostic value (overall survival) compared to wild-type IDH1/2 patients overall (N=102; P=0.177). IDH1/2 mutations were significantly more common in cytogenetically normal AML (P=0.004). IDH1/2 mutations did also not confer an overall survival benefit in patients with an intermediate risk karyotype (N=68, P=0.484)." ;
    a m2r:Evidence .

civice:1543
    dct:references pbm:27279227 ;
    civico:citation "Rodrik-Outmezguine et al., 2016, Nature" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed. Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutations in MDA-MB-468 cells led to resistance." ;
    a m2r:Evidence .

civice:1544
    dct:references pbm:27279227 ;
    civico:citation "Rodrik-Outmezguine et al., 2016, Nature" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD8055 ;
    dcterms:description "MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Tumor volume grew more rapidly in mice with xenografts of M2327I mTOR mutant MCF7 cells treated with AZD8055 than rapamycin or RapaLink-1 treatment." ;
    a m2r:Evidence .

civice:1545
    dct:references pbm:27279227 ;
    civico:citation "Rodrik-Outmezguine et al., 2016, Nature" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_RapaLink-1,civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. These cells remained sensitive to rapamycin and RapaLink-1 in vitro and in mouse xenografts. Expression of the mutation in MDA-MB-468 cells led to AZD8055 resistance and these cells were also rapamycin and RapaLink-1 sensitive." ;
    a m2r:Evidence .

civice:1547
    dct:references pbm:27279227 ;
    civico:citation "Rodrik-Outmezguine et al., 2016, Nature" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Xenografts of these cells were more resistant to rapamycin than AZD8055 or RapaLink-1 treatment." ;
    a m2r:Evidence .

civice:1548
    dct:references pbm:27279227 ;
    civico:citation "Rodrik-Outmezguine et al., 2016, Nature" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AZD8055,civic:drug_RapaLink-1 ;
    dcterms:description "MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone (RR1). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance to rapamycin but maintained sensistivity to AZD8055. A novel mTOR inhibitor RapaLink-1 was designed and showed efficacy in A2034V mTOR mutant cell lines in-vivo and in-vitro. AZD8055 also retained efficacy in these clones in xenograft." ;
    a m2r:Evidence .

civice:1549
    dct:references pbm:26787751 ;
    civico:citation "Dolly et al., 2016, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Apitolisib ;
    dcterms:description "Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses. One of the partial responses harbored a PIK3CA E542K mutation." ;
    a m2r:Evidence .

civice:1550
    dct:references pbm:26787751 ;
    civico:citation "Dolly et al., 2016, Clin. Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Apitolisib ;
    dcterms:description "Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of 45 evaluable patients receiving 40mg, two patients with E545K PIK3CA mutation (one head and neck squamous cell carcinoma patient and a patient with ovarian cancer) had unconfirmed partial responses. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses." ;
    a m2r:Evidence .

civice:1551
    dct:references pbm:27404270 ;
    civico:citation "Amaki-Takao et al., 2016, Oncology" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 908 patients with colorectal cancer, 7 patients had BRAF (D594G) mutations and 45 patients had BRAF (V600E) mutations. Overall clinicopathological implications of BRAF V600E and D594G mutant tumors were similar but BRAF D594G mutations were more likely to be left-sided tumors (85.7% vs. 31.1%; p<0.0098) and they were more likely to present as metastatic tumors (71.4% vs. 28.9%; p<0.04) than BRAF V600E mutant tumors. The overall log-rank was p < 0.001 when all three groups were calculated simultaneously; p < 0.0001 comparing BRAF wild-type and BRAF V600E survival, p = 0.015 comparing BRAF wild-type and BRAF D594G survival, and p = 0.98 comparing BRAF V600E and BRAF D594G.  There was no statistically significant difference in OS between BRAF D594G and BRAF wt but BRAF V600E mutant patients had significantly worse survival when only stage IV patients (BRAF D594G N=5) were analyzed." ;
    a m2r:Evidence .

civice:1552
    dct:references pbm:27404270 ;
    civico:citation "Amaki-Takao et al., 2016, Oncology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 908 patients with colorectal cancer, 45 patients had BRAF V600E mutations and 589 patients were BRAF wild type.  BRAF V600E mutations were more likely to be proximal tumors (68.9%, 20.7%; p<0.0001), they were more likely to be poorly differentiated (17.7%, 1.9%; p<0.0001), they were more likely to be mucinous carcinoma type (20.0%, 4.2%; p=0.0003), they were more likely to have lymphatic invasion (77.6%, 49.9%; p=0.0003), and they had a shorter survival time (31.1 mo, 41.6 mo; p=0.001).  The 3-year survival rate was significantly poorer in the V600E group when compared to the wild type group (63.8%, 87.9%; p<0.0001)." ;
    a m2r:Evidence .

civice:1553
    dct:references pbm:27404270 ;
    civico:citation "Amaki-Takao et al., 2016, Oncology" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 908 patients with colorectal cancer (CRC), 7 patients had BRAF D595G mutations and 589 patients were BRAF wild type. The survival rate of CRC patients at 3 years was significantly poorer in the BRAF D595G mutations when compared to the wild type group (50%, 87.9%; p<0.00152)." ;
    a m2r:Evidence .

civice:1554
    dct:references pbm:27404270 ;
    civico:citation "Amaki-Takao et al., 2016, Oncology" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab,civic:drug_Cetuximab ;
    dcterms:description "Two patients with stage IV BRAF (D594G) mutations received anti-EGFR antibody therapy (cetuximab and panitumumab). The first patient was on FOLFOX plus bevacizumab and showed no signs of progression for 10 months. No response was observed after cetuximab was given as a third line therapy. The second patient received panitumumab with FOLFOX and showed no signs of progression for 8 months with reduction of the size of metastases." ;
    a m2r:Evidence .

civice:1555
    dct:references pbm:23969938 ;
    civico:citation "Baker et al., 2013, Clin. Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "Six children with relapsed or refractory FLT3-ITD-positive AML received initial therapy with sorafenib (alone or in combination with clofarabine and cytarabine).  Four of the patients initially achieved morphological complete remission (bone marrow blasts <5%), however, 3 patients developed resistance within 14-37 weeks and and 1 required a bone marrow transplant.  Two patients did not have any clinical response to sorafenib upon initial treatment." ;
    a m2r:Evidence .

civice:1556
    dct:references pbm:23969938 ;
    civico:citation "Baker et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "Three children with relapsed or refractory FLT3-ITD-positive AML were treated with sorafenib. FLT3 mutations were assessed before treatment and at the time of resistance. During the initiation of the treatment, all three patients had undetectable levels of FLT3 (D835H) mutations, however, after resistance developed, the mutation frequency rose to 33.1%, 35.7%, and 11.0% in the three patients. Ba/F3 cells expressing FLT3 mutants were resistant to sorafenib-dependent inhibition of cell viability" ;
    a m2r:Evidence .

civice:1557
    dct:references pbm:23969938 ;
    civico:citation "Baker et al., 2013, Clin. Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "Mouse Ba/F3 cells with FLT3 mutations were evaluated for sorafenib resistance.  Cells with single FLT3 (D835H/Y) mutants were resistant to sorafenib (IC50 81 nm/210 nM) whereas cells with FLT3 (ITD) mutants were not resistant to sorafenib (IC50 1.1 nM).  Cells with double mutants (ITD-D835H/Y or ITD F691L) were highly resistant to sorafenib (IC50 460-3300 nM)." ;
    a m2r:Evidence .

civice:1558
    dct:references pbm:27137476 ;
    civico:citation "Gaidzik et al., 2016, Leukemia" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with acute myeloid leukemia, those with RUNX1 mutations (n=245) had significantly worse outcomes when compared to those with RUNX1 wild-type alleles (n=2,194).  The complete remission rate for patients with RUNX1 mutations was significantly lower (48.4% vs. 68.1%; p <0.0001), the refractory disease rate was significantly higher (40.6% 23.4%; p=0.03), the 5-year event free survival rate was significantly lower (9%, 24%; p<0.0001), the 5-year relapse free survival rate was significantly lower (22%, 36%; p=0.0007), and the 5-year overall survival rate was significantly lower (22%, 37%; p=0.0001)." ;
    a m2r:Evidence .

civice:1560
    dct:references pbm:23898052 ;
    civico:citation "Logan et al., 2013, Anticancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "28 renal cell carcinoma cell lines were tested for sensitivity to CDK4/6 inhibitor Palbociclib (PD0332991). 19 were reported sensitive, and 9 resistant. 15 of the 28 cell lines had high levels of Cyclin D1 (CCND1) expression which did not correlate significantly with palbociclib sensitivity (p=0.348)." ;
    a m2r:Evidence .

civice:1561
    dct:references pbm:19874578 ;
    civico:citation "Finn et al., 2009, Breast Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "In a panel of 47 breast cancer cell lines, HER2 overexpressing cells were among those more sensitive to CDK4/6 inhibitor Palbociclib (PD0332991). In the trastuzumab sensitive cell line Bt474, palbociclib synergized with trastuzumab in growth inhibition, while in 2 trastuzumab resistant cell lines, addition of trastuzumab to palbociclib treatment resulted in increased growth inhibition over palbociclib alone." ;
    a m2r:Evidence .

civice:1562
    dct:references pbm:19874578 ;
    civico:citation "Finn et al., 2009, Breast Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "A panel of 47 breast cancer cell lines was tested for sensitivty/resistance to CDK4/6 inhibitor Palbociclib (PD0332991),  where IC50 below 150nM was sensitive, and above 1000nM resistant. Cyclin D1 had higher expression levels in sensitive cell lines." ;
    a m2r:Evidence .

civice:1563
    dct:references pbm:16690963 ;
    civico:citation "Marzec et al., 2006, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "In Mantle Cell Lymphoma (MCL), t(11:14)-induced overexpression of cyclin D1 was targeted by CDK4/6 inhibitor Palbociclib (PD0332991). Palbociclib caused Rb dephosphorylation in MCL cell lines and patient derived tumor cells. MCL cell lines overexpressing cyclin D1 showed growth inhibition with Palbociclib. The VAL DLBCL cell line was used as control to verify cyclin D1 overexpression but was not used as a control in Palbociclib inhibitor experiments. Instead, the investigators report that other publications report cell lines without cyclin D1 overexpression had higher IC50 values for palbociclib, suggesting overexpresssed cyclin D1 targetability in MCL." ;
    a m2r:Evidence .

civice:1564
    dct:references pbm:9788599 ;
    civico:citation "Starostik et al., 1998, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "43 B-CLL patients with LoH or reduced protein levels (<50% normal expression, radioimmunoassay, western blot) of ATM were found to have significantly shorter overall survival (35.6 vs. 97.3 months; P=0.003) when compared to 108 patients with normal expression levels." ;
    a m2r:Evidence .

civice:1565
    dct:references pbm:22162573 ;
    civico:citation "Chi et al., 2012, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A 62 year old female was diagnosed with glioblastoma (GBM) WHO grade 4. Treatment included radiation, temozolomide and cediranib. MET amplification was found by FISH, and ALK and MET inhibitor crizotinib treatment was started. A 40% reduction in size of contrast enhancing lesion was seen. After 6 months, progressive disease was seen and crizotinib withdrawn. The authors state this is a first report of response to prospective MET targeted therapy in GBM." ;
    a m2r:Evidence .

civice:1566
    dct:references pbm:21716144 ;
    civico:citation "Tanizaki et al., 2011, J Thorac Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "2 MET amplified NSCLC cell lines (EBC-1 and H1993), as well as 2 EGFR mutant and 2 MET and EGFR wild type cell lines were treated with ALK and MET inhibitor crizotinib, and the MET amplified cells had IC50 100 fold lower than the non MET amplified cell lines. Both crizotinib treatment and siRNA against MET increased apoptotic markers in MET amplified cells but not controls, indicating that crizotinib targeting of amplified MET was inducing the apoptotic effects. Tumors caused by MET amplified EBC-1 cells injected into mice were significantly inhibited with crizotinib treatment, while tumors from non-MET amplified cells showed no substantial effect." ;
    a m2r:Evidence .

civice:1567
    dct:references pbm:27433843 ;
    civico:citation "Zaretsky et al., 2016, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pembrolizumab ;
    dcterms:description "Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab (before prior vemurafenib treatment in patient 1). A JAK1 Q503* mutation was observed at the time of relapse in patient 1. This mutation was one of 3 new homozygous mutations in this patient (53 new mutations total) and the tumor was described to be genetically similar to the pre-treatment tumor. CRIPR-Cas9 mediated modelling of the JAK1 mutation in a melanoma cell line led to a loss of response to interferon alpha, beta and gamma." ;
    a m2r:Evidence .

civice:1568
    dct:references pbm:27433843 ;
    civico:citation "Zaretsky et al., 2016, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pembrolizumab ;
    dcterms:description "Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab. A JAK2 F547 splice site mutation was observed at the time of relapse in patient 2. RNA sequencing revealed an in-frame stop codon after exon 12. The JAK2 mutation was the only homozygous mutation (allele frequency >85%) of 76 new nonsynonymous mutations in patient 2. Cell line modelling of baseline and relapse JAK2 mutational status revealed a loss of response to interferon gamma and  loss of JAK2 protein. This loss of response was also modeled in another cell line." ;
    a m2r:Evidence .

civice:1569
    dct:references pbm:27433843 ;
    civico:citation "Zaretsky et al., 2016, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pembrolizumab ;
    dcterms:description "Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab. A B2M frame-shift deletion in exon 1 was identified as the only new homozygous mutation among 24 new relapse-specific mutations. Immunohistochemistry revealed loss of MHC1 outer-membrane localization." ;
    a m2r:Evidence .

civice:1570
    dct:references pbm:26072686 ;
    civico:citation "Menzies et al., 2015, Pigment Cell Melanoma Res" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intron 10 of BRAF). Trametinib was introduced and anemia and ECOG status improved. Imaging revealed a 90% decrease in extracranial and 19% decrease in intracranial metastases with no new metastases and no progressing sites at 6 weeks. Trametinib was stopped and pembrolizumab introduced at this time. Progressive disease was noted after 5 cycles of pembrolizumab but re-introduction of trametinib did not show an effect." ;
    a m2r:Evidence .

civice:1571
    dct:references pbm:26072686 ;
    civico:citation "Menzies et al., 2015, Pigment Cell Melanoma Res" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "A 65 yr old male patient with metastatic acral lentiginous melanoma (BRAF, NRAS, KIT negative) was found to harbor a KIAA1549-BRAF (intron 15-intron 8) fusion in a subcutaneous metastasis sample after disease progression. Trametinib was started and fatigue and ECOG status improved but imaging revealed slight disease progression after 2 weeks (15 sites measurable, 9 stable, 6 progressive). No new metastases were identified. The patient was switched to pembrolizumab and major disease progression was noted." ;
    a m2r:Evidence .

civice:1572
    dct:references pbm:18003960 ;
    civico:citation "Jonker et al., 2007, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Patients with refractory colorectal cancer expressing immunohistochemically detectable EGFR were randomly assigned to receive treatment with cetuximab (n=287) or receive supportive care alone (n=285). Patients receiving cetuximab had increased overall survival (HR=0.77, 95%CI 0.64-0.92; p=0.005), increased progression-free survival (HR=0.68, 95%CI 0.57-0.80; p<0.001), and improved quality of life at 4 months measured by survey on physical deterioration (-5.9 vs -12.5; p=0.03) and global health status (-3.6 vs. -15.2; p<0.001)." ;
    a m2r:Evidence .

civice:1573
    dct:references pbm:17522398 ;
    civico:citation "Chan et al., 2007, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Aspirin ;
    dcterms:description "Mail-in surveys conducted every two years since 1980 evaluated 82,911 woman and 47,363 men for regular aspirin use.  In this cohort, aspirin use was associated with a lower relative risk of colorectal cancer (RR=0.73; 95% CI 0.69-0.87; p<0.001).  Immunohistochemical analysis was employed on a subset of 636 cases to evaluate COX2 overexpression.  Of these tumors, 67% had moderate or strong COX2 expression and 33% had weak or absent COX-2 expression.  In tumors with COX-2 overexpression, regular aspirin use conferred significant risk reduction of colorectal cancer (RR=0.64; 95%CI 0.52-0.78) however, in tumors with reduced COX2 expression, aspirin use had no influence on colorectal cancer incidence (RR=0.96, 95%CI 0.73-1.26)." ;
    a m2r:Evidence .

civice:1574
    dct:references pbm:26287849 ;
    civico:citation "Hyman et al., 2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 20 patients with non-small-cell-lung cancer (17 with BRAF V600E, one with BRAF V600G and one with BRAF V600 unknown status), 19 were evaluable and the response rate to vemurafenib was 42%, tumor regression was observed in 14/19 patients, progression-free survival was 7.3 months, and 12-month overall survival was 66%." ;
    a m2r:Evidence .

civice:1575
    dct:references pbm:26287849 ;
    civico:citation "Hyman et al., 2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated.  Of the 14 patients with Langerhans’-cell histiocytosis, 43% of patients had a response to vemurafenib (1 complete and 5 partial responses), disease regression was observed in 12/14 patients, all patients detailed improvement in disease-related symptoms, 0 patients had progressive disease during treatment, 12-month progression free survival was 91%, and overall survival rate was 100%. Among all 18 patients with Erdheim-Chester disease or Langerhans histiocytosis, 94% had BRAF V600E mutations and the remaining 6 percent (1 patient) had an unknown V600 mutation." ;
    a m2r:Evidence .

civice:1576
    dct:references pbm:26287849 ;
    civico:citation "Hyman et al., 2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated.  Of the 10 patients with colorectal cancer (80% BRAF V600E, 20% V600 unknown status), no responses were observed and overall survival was 9.3 months with a median progression-free survival of 4.5 months." ;
    a m2r:Evidence .

civice:1577
    dct:references pbm:26466010 ;
    civico:citation "2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A phase-3 clinical trial evaluated 347 patients with ALK-positive lung cancer.  The study compared crizotinib treatment (n=173) with chemotherapy treatment of either pemetrexed or docetaxel (n=174).  In the crizotinib arm, the response rate was significantly higher (65% vs 20%; P<0.001), the progression-free survival was increased (7.7 months vs. 3.0 months; HR=0.49, 95%CI:14 months-26 months; p<0.001), however, there was no significant improvement in overall survival (HR=1.02; 95%CI:0.68-1.54; P=0.54).  Of the patients on crizotinib treatment, global quality of life was improved relative to baseline when compared to chemotherapy patients (+5 mean change, -5 mean change; P<0.001)." ;
    a m2r:Evidence .

civice:1578
    dct:references pbm:27093365 ;
    civico:citation "Nghiem et al., 2016, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pembrolizumab ;
    dcterms:description "Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression.  The response rate to pembrolizumab was 56% (95%CI: 35-76%), however, there was no correlation between PD-L1 expression (cutoff >1%) on tumor cells or on infiltrating immune cells and clinical response to pembrolizumab (P=0.61)." ;
    a m2r:Evidence .

civice:1579
    dct:references pbm:26352686 ;
    civico:citation "Tiacci et al., 2015, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia.  The overall response rate was 98% with 19/54 having a complete response and 34/54 having a partial response.  In the Italian study (n=25), the median relapse-free survival was 9 months and in the U.S. study (n=24), rate of progression-free survival was 73% with overall survival rate of 91%." ;
    a m2r:Evidence .

civice:1580
    dct:references pbm:26352686 ;
    civico:citation "Tiacci et al., 2015, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the patient’s genome revealed activating subclonal KRAS mutations (KRAS G12D, 15.2% allele frequency; KRAS K117N, 1.2%), as well as a RUNX1 A55E mutation (5.9%) that had not been seen prior to vemurafenib treatment or at remission. BRAF V600E allele frequency was detectable (2.4%) at the time of remission but dramatically increased at relapse (64.9%)." ;
    a m2r:Evidence .

civice:1581
    dct:references pbm:26359985 ;
    civico:citation "Hugo et al., 2015, Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Whole exome sequencing, transcriptome and methylome alterations in 48 melanoma samples with acquired resistance to BRAFi +/- MEKi therapy compared to patient-matched baseline melanoma tissues were analyzed. 39% of resistant melanomas were not accounted for by any validated mutational mechanism. c-MET was overexpressed in 21 of 48 (44%) resistant samples. Methylome analysis revealed three CpG clusters (C1–3) with differential methylation to be negatively correlated with differential c-MET mRNA expression. In nearly all (90%) pairwise comparisons of tumors and cell lines, differential c-MET mRNA expression could be accounted for by at least one differential CpG cluster methylation (Δβ ≥ 10% and FDR adjusted p ≤ 0.05). In contrast, only 48% displayed a concordant differential expression pattern of at least one c-MET transcription factor. In an independent study, c-MET was overexpressed in 8 of 35 (23%) MAPKi-resistant tumors from 7 of 26 (27%) patients. In two human BRAF V600E mutant cell lines, BRAFi treatment led to progressive methylation-expression changes akin to observations across MAPKi-sensitive versus resistant tumors." ;
    a m2r:Evidence .

civice:1583
    dct:references pbm:24140933 ;
    civico:citation "Surriga et al., 2013, Mol. Cancer Ther." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiRNA mediated MET-knockdown reduced cell migration but not cell growth. Crizotinib treatment led to a decrease in cell growth and migration. At 25 nmol/L of crizotinib, only the migration of G-protein mutant cells lines and not G-protein wild type cell lines was decreased. Crizotinib did not lead to a reduction in tumor volume of two cell lines in vivo but reduced the formation of macrometastases (luciferase activity, p=0.03)." ;
    a m2r:Evidence .

civice:1584
    dct:references pbm:23802768 ;
    civico:citation "Jubb et al., 2013, Histopathology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "FFPE tumours from patients enrolled in the BRIM2 (n = 59) and BRIM3 (n = 150) trials of vemurafenib in advanced BRAF mutant (V600E/K) melanoma were analyzed for MET expression (IHC). Pretreatment MET expression was frequent at the ≥1 + cutoff (BRIM3, 31%; BRIM2, 49%), but relatively infrequent at the ≥2 + cutoff (BRIM3, 9%; BRIM2, 19%). Retrospective subset analyses showed that, irrespective of the cutoff used or the treatment arm, MET expression did not show prognostic significance, in terms of objective response rate, progression-free survival, or overall survival." ;
    a m2r:Evidence .

civice:1585
    dct:references pbm:27288520 ;
    civico:citation "Metzeler et al., 2016, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In AML patients aged <60years, presence of a DNMT3A mutation associated with inferior CR rate (HR, 0.54; P=.05) and shorter OS (HR, 1.84; P<.001) in multivariate analyses. Mutated DNMT3A associated with shorter RFS (HR 1.38; P=.034) irrespective of patient age." ;
    a m2r:Evidence .

civice:1586
    dct:references pbm:27276561 ;
    civico:citation "Papaemmanuil et al., 2016, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "DNMT3A mutations associate with adverse overall survival in acute myeloid leukemia patients if they occur in the context of mutated NPM1 and  FLT3-ITD (NPM1-FLT3ITD-DNMT3A phenotype), and in the context of IDH2 codon R140 mutations." ;
    a m2r:Evidence .

civice:1587
    dct:references pbm:22124213 ;
    civico:citation "Metzeler et al., 2012, Leukemia" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Decitabine ;
    dcterms:description "Among 46 AML patients treated with decitabine, the response rate was 75% (6/8) among DNMT3A mutated and 34% (13/38) among DNMT3A wild-type patients (P=.008)" ;
    a m2r:Evidence .

civice:1588
    dct:references pbm:27325282 ;
    civico:citation "Pietrantonio et al., 2016, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib,civic:drug_Vemurafenib ;
    dcterms:description "Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months. Re-biopsy at the time of progression showed a MET amplification and overexpression (IHC, ISH) but no secondary mutations in candidate resistance genes (EGFR, KRAS, NRAS, MAP2K1). MET amplification was also present in a subset of tumor cells in the pretreatment sample. MET amplification was also identified in 3/17 (18%) chemonaive BRAF V600E colorectal cancer tumor tissues. Overexpression of MET in a BRAF mutant CRC cell line (WiDr) confered resistance to combined vemurafenib and panitumumab. The addition of crizotinib to this combination restored sensitivity in vitro. The patient was started on combined vemurafenib and crizotinib in January 2016 and had a metabolic, clinical and tumor marker response that was ongoing at the time of publication (06/16) without significant toxicity." ;
    a m2r:Evidence .

civice:1589
    dct:references pbm:27325282 ;
    civico:citation "Pietrantonio et al., 2016, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib,civic:drug_Panitumumab ;
    dcterms:description "Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subsequent disease progression." ;
    a m2r:Evidence .

civice:1590
    dct:references pbm:27226433 ;
    civico:citation "Herling et al., 2016, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In previously untreated patients with chronic lymphocytic leukemia, POT1 mutations (N=13) were associated with shorter overall survival than wildtype POT1 (N=148) in univariate and multivariate analysis (HR, 4.0; 95% CI, 1.6-10.1; P = .003) independent of IGHV mutation status, Binet stage, and serum beta-2-microglobulin." ;
    a m2r:Evidence .

civice:1591
    dct:references pbm:27460442 ;
    civico:citation "Brose et al., 2016, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort 1) previously been treated with VEGFR inhibitors. 51 patients were enrolled (26 cohort 1, 25 cohort 2). In cohort 1, partial response was achieved in ten (38.5%) patients. Nine patients achieved stable disease for at least 6 months (35%). Median PFS was 18.2 months and median OS not reached after a median follow-up pf 18.8 months. In cohort 2, six patients (27.3%) achieved a partial response and another six patients achieved stable disease for at least six months. Median PFS was 8.9 months and median OS was 14.4. months." ;
    a m2r:Evidence .

civice:1592
    dct:references pbm:26729184 ;
    civico:citation "Greig, 2016, Drugs" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Osimertinib ;
    dcterms:description "Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC." ;
    a m2r:Evidence .

civice:1593
    dct:references pbm:26341751 ;
    civico:citation "Petrelli et al., 2015, Breast Cancer Res. Treat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A quantitative meta-analysis was performed to assess optimal IHC-calculated cutoff values for the prognostic use of proliferative biomarker Ki67 in breast cancer. The studies included ER positive and negative cases, and the MIB-1 antibody was used in the large majority of studies. 25 studies that employed multivariate analysis were used, and a hazard ratio of 2.05 for overall survival was obtained when Ki67 cutoff value was set at greater or equal to 25%." ;
    a m2r:Evidence .

civice:1594
    dct:references pbm:23329234 ;
    civico:citation "Fisher et al., 2013, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "293 cases of clinically localized prostate cancer were analyzed on needle-biopsy FFPE tissue microarray, using the MIB-1 antibody against the Ki67 marker of proliferation. IHC staining was used to generate a Ki67 score, and cases were divided into 2 groups with Ki67 score greater or less than 10%. Primary endpoint was death due to prostate cancer. A hazard ratio for high Ki67 values of 3.42 was seen in univariate analysis, and  Ki67 score also added significant predictive value in multivariate analysis, with a hazard ratio of 2.78." ;
    a m2r:Evidence .

civice:1595
    dct:references pbm:20354191 ;
    civico:citation "Michaud et al., 2010, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "A panel of 21 glioblastoma cell lines harboring various mutations was treated with palbociclib. 16 of the cell lines with intact Rb showed decreased proliferation (bromodeoxyuridine incorporation, BrdU flow cytometry) and growth arrest characteristic of senescence, while the 5 cell lines that did not show a palbociclib response had homozygous deletion of Rb. Rb positive and palbociclib responsive GBM cell line U87MG was treated with shRNA against Rb. shRb treated cells showed restoration of cell proliferation (BrdU incorporation) under palbociclib treatment, indicating resistance." ;
    a m2r:Evidence .

civice:1596
    dct:references pbm:27502722 ;
    civico:citation "Pietrantonio et al., 2016, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRAS mutations were independently associated with PFS (p=0.012) after multivariate analysis." ;
    a m2r:Evidence .

civice:1597
    dct:references pbm:27499916 ;
    civico:citation "Angelika Ihle et al., 2016, J Pathol Clin Res" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vorinostat%28SAHA%29 ;
    dcterms:description "Western blot analyses were performed for HR23b (RAD23B) expression sarcoma cell lines after treatment with vorinostat, belinostat, mocetinostat and entinostat. All HDACi were able to regulate proliferation and apoptosis in vitro. Sensitivity to vorinostat correlated significantly with HR23b protein expression. IHC in 523 patient samples revealed high HR23b expression in 12.5% of sarcomas (among them malignant peripheral nerve sheath tumours, pleomorphic liposarcomas, leiomyosarcomas, dedifferentiated liposarcomas, synovial sarcomas and angiosarcomas) and 23.2% of GIST." ;
    a m2r:Evidence .

civice:1598
    dct:references pbm:26287849 ;
    civico:citation "Hyman et al., 2015, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Vemurafenib ;
    dcterms:description "Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy. 27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with BRAF V600E mutation, N=3 with V600 unknown status). One response was observed; however, approximately half the patients had tumor regression that did not meet the standard criteria for a partial response. Median progression-free survival and overall survival for patients receiving combination therapy were 3.7 months (95% CI, 1.8 to 5.1) and 7.1 months (95% CI, 4.4 to not reached), respectively. Patients were heavily pretreated, with a median of two lines of previous therapy (range, one to six)." ;
    a m2r:Evidence .

civice:1599
    dct:references pbm:21278246 ;
    civico:citation "Konecny et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "A panel of 40 ovarian cancer cell lines with varied mutation profiles was assayed for sensitivity to the cdk4/6 inhibitor palbociclib (PD0332991) via measurement of IC50 values for inhibition of proliferation. Large variation in palbociclib sensitivity was observed and cell lines (N=40) were classified as above (resistant) or below (sensitive) the mean log of all IC50 values. 6/18 (33%) of the resistant lines and in only 1/22 (5%) of the sensitive lines (P = 0.017) had CCND1 copy number gain. Increased CCND1 expression was not correlated with sensitivity to palbociclib (p=0.671)." ;
    a m2r:Evidence .

civice:1600
    dct:references pbm:25002028 ;
    civico:citation "Vora et al., 2014, Cancer Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ribociclib,civic:drug_PI3KInhibitor ;
    dcterms:description "Three PI3K mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941), and a panel of 42 inhibitor compounds was tested on the cells for ability to resensitize the cells to PI3K inhibition. The CDK4/6 inhibitor ribociclib (LEE011) acted synergistically with PI3K inhibitor to reduce viability in all three resistant cell lines. In a panel of 12 PIK3CA mutant and 10 wild type cell lines, synergistic effects between P110alpha inhibitor BYL719 and ribociclib were significantly stronger (weighted synergy score calculation, ANOVA, p=0.012) in PIK3CA mutant cells, indicating variant specific sensitization. Mouse xenografts of 4 different PIK3CA mutant breast cancer cells resistant to PI3K inhibitor showed stronger regression under dual PI3K inhibitor and ribociclib treatment than with either treatment alone." ;
    a m2r:Evidence .

civice:1601
    dct:references pbm:26787234 ;
    civico:citation "Takeda et al., 2016, Ann. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Nintedanib ;
    dcterms:description "Case report of a 60-year old woman with lung adenocarcinoma. After negative testing for EGFR mutations and ALK translocations and failure of platinum-based chemotherapy she was enrolled on a nintedanib-docetaxel trial. Docetaxel was discontinued after 22 cycles because of edema and fatigue. A total of 48 treatment cycles (26 cycles of nintedanib alone) was administered over 33 months before documentation of disease progression in March 2013. Genomic testing revealed a CCDC6-RET fusion but no other actionable mutations (confirmed by FISH)." ;
    a m2r:Evidence .

civice:1602
    dct:references pbm:21383288 ;
    civico:citation "Wagle et al., 2011, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "A patient with BRAF-mutant melanoma relapsed after treatment with PLX4032 (vemurafenib). The MAP2K1 C121S mutation was identified as a relapse-specific variant and was undetectable in the pre-treatment tumor. In vitro experiments showed that the C121S mutation increased kinase activity and conferred resistance to PLX4032." ;
    a m2r:Evidence .

civice:1603
    dct:references pbm:25766722 ;
    civico:citation "Palma et al., 2015, Eur. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pazopanib ;
    dcterms:description "Case report of a 67 year old woman with high-grade papillary urothelial carcinoma. The patient underwent chemotherapy and palliative cystectomy followed by tumor progression and pulmonary lesion enlargement. Genomic profiling of the cystectomy specimen identified FGFR3, CCND1 and FGF19 amplification as well as an FGFR3 S249C mutation (allele frequency 58%). Pazopanib was initiated on the basis of these findings and a partial response was achieved for >6 months." ;
    a m2r:Evidence .

civice:1604
    dct:references pbm:23658459 ;
    civico:citation "André et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dovitinib ;
    dcterms:description "Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model. 81 patients were enrolled in the trial and treated with dovitinib. Unconfirmed response or stable disease >6 months was observed in 25% of FGFR1-amplified/HR-positive vs. 3% FGFR1-nonamplified/HR-positive breast cancer patientes. When FGF3 and FGFR2 amplifications were also assessed, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors." ;
    a m2r:Evidence .

civice:1605
    dct:references pbm:23658459 ;
    civico:citation "André et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dovitinib ;
    dcterms:description "Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model. 81 patients were enrolled in the trial and treated with dovitinib. 2 patients were reported to harbor FGFR2 amplifications and both had a reduction in tumor size of 18.5 and 28.2%, respectively. When FGFR1, FGF3 and FGFR2 amplifications were combined, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors." ;
    a m2r:Evidence .

civice:1606
    dct:references pbm:23658459 ;
    civico:citation "André et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dovitinib ;
    dcterms:description "81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, respectively. 3 of these 4 patients also had FGFR1 amplifications (≥6 copies by qPCR) and the fourth presented with FGFR1-gene gain (3.4 copies of FGFR1 by qPCR and SISH negative)." ;
    a m2r:Evidence .

civice:1607
    dct:references pbm:25002028 ;
    civico:citation "Vora et al., 2014, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29,civic:drug_PI3KInhibitor ;
    dcterms:description "Three PIK3CA mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941) by chronic exposure. Co-treatment of all three cell lines with PI3K inhibitor and CDK4/6 inhibitor palbociclib resulted in synergistic reductions in cell viability which were not seen with treatment of either compound alone, and resulted in similar suppression to viability as seen in the respective PI3K inhibitor sensitive parental cell lines." ;
    a m2r:Evidence .

civice:1608
    dct:references pbm:27518686 ;
    civico:citation "Zhou et al., 2016, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Ruxolitinib ;
    dcterms:description "Homozygous VHL R200W mutations result in a rare congenital polycythemia known as Chuvash polycythemia. Treatment of 3 patients with this disease with the JAK1/2 inhibitor ruxolitinib led to symptomatic and hematologic improvements in all patients through 21-78 weeks of treatment." ;
    a m2r:Evidence .

civice:1609
    dct:references pbm:25002028 ;
    civico:citation "Vora et al., 2014, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Alpelisib%28NVP-BYL719%29 ;
    dcterms:description "The p110alpha-specific PI3K inhibitor BYL719 was used on a panel of five PI3K inhibitor sensitive and five resistant breast cancer cell lines. Sensitive cells (IC50<400nM) showed reduced phospho-Rb (p-Rb) western blot levels in response to BYL719 treatment, while resistant cell lines (IC50>800nM) showed significantly less reduction in p-Rb after BYL719. Paired biopsies before and after treatment were taken from a set of eight patients classified as either responder or non-responder to BYL719. Responder samples showed significantly reduced p-Rb staining after treatment in comparison to non-responder biopsies. In biopsies taken from a group of three responders who progressed, p-Rb levels were increased after progression." ;
    a m2r:Evidence .

civice:1610
    dct:references pbm:21358673 ;
    civico:citation "Weigelt et al., 2011, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PP242,civic:drug_Everolimus ;
    dcterms:description "A panel of 31 breast cancer cell lines was tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/mTORC2 inhibitor PP242. Inhibitor concentrations for 50% survival fraction (SF50) were measured and SF50 less than one micro molar was considered sensitive. PIK3CA mutant cell lines were significantly more sensitive to both everolimus and PP242 than PIK3CA wild type cell lines. Apoptotic indicators and cell cycle analysis indicated that the mTOR inhibitors induced G1 arrest instead of apoptosis in the cell lines." ;
    a m2r:Evidence .

civice:1611
    dct:references pbm:21358673 ;
    civico:citation "Weigelt et al., 2011, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Everolimus,civic:drug_PP242 ;
    dcterms:description "In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation was found between PTEN status and sensitivity to mTORC inhibition." ;
    a m2r:Evidence .

civice:1612
    dct:references pbm:21358673 ;
    civico:citation "Weigelt et al., 2011, Oncogene" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PP242 ;
    dcterms:description "Sensitivity to mTORC1/2 inhibitor PP242 was assessed in a panel of breast cancer cell lines with various mutation backgrounds. PTEN and PIK3CA mutations were heavily represented in the panel. However, a PTEN and PIK3CA wild type cell line 'HS578T' was found to harbor a mutation in the PI3K regulatory protein PIK3R1. Like PIK3CA mutant cell lines, the PIK3R1 mutant HS578T line was also determined to be sensitive to PP242. Approximately 70% of PIK3CA wild type lines were not sensitive to PP242. This suggests that mutations in the PI3K holoenzyme may be targetable by mTORC1/2 inhibition." ;
    a m2r:Evidence .

civice:1613
    dct:references pbm:21358673 ;
    civico:citation "Weigelt et al., 2011, Oncogene" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PP242 ;
    dcterms:description "In a panel of 31 breast cancer cell lines with varied mutation backgrounds, 10 cell lines harbored HER2 (ERBB2) amplification. Sensitivity to the mTORC1/2 inhibitor PP242 was assessed, and 8/10 HER2 positive cell lines were reported to be sensitive (IC50 < 1 micro molar PP242).  8/21 without HER2 amplification were reported as resistant (IC50 > 1 micro molar PP242). This pattern of HER2 positive cell sensitivity was not reported with the rapamycin analog  mTORC1 inhibitor everolimus." ;
    a m2r:Evidence .

civice:1614
    dct:references pbm:23674493 ;
    civico:citation "Weigelt et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Temsirolimus ;
    dcterms:description "A panel of 24 endometroid endometrial cancer (EEC) cell lines was characterized for mutations and 18 cell lines were found to have mutations in PTEN or absence of expression. Cell lines were assessed for sensitivity to mTORC1 allosteric inhibitor temsirolimus, and it was reported that PTEN loss had significant association with temsirolimus sensitivity. ." ;
    a m2r:Evidence .

civice:1615
    dct:references pbm:23724867 ;
    civico:citation "Wolchok et al., 2013, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Nivolumab,civic:drug_Ipilimumab ;
    dcterms:description "A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1). In the concurrent regimen cohort, 65% of patients showed clinical activity with no correlation between PD-L1 expression and response (6 of 13 patients were PD-L1 positive versus 9 of 22 patients were PD-L1 negative). In the sequential regimen cohort, 20% of patients had an objective response with a potential correlation between PD-L1 expression and response (4 of 8 patients were PD-L1 positive versus 1 of 13 patients were PD-L1 negative)." ;
    a m2r:Evidence .

civice:1616
    dct:references pbm:23674493 ;
    civico:citation "Weigelt et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Pictilisib ;
    dcterms:description "A panel of 24 endometrioid endometrial cancer (EEC) cell lines was characterized for a set of mutations and sensitivity to pan PI3K class I inhibitor GDC-0941 (pictilisib) was assessed. EEC cell lines with PIK3CA mutations were significantly more sensitive to GDC-0941 (Fisher’s exact test, two-tailed, P=0.038). Some of the PIK3CA mutant cells contained PTEN and KRAS mutations, but in these cells, these mutations did not effect sensitivity." ;
    a m2r:Evidence .

civice:1617
    dct:references pbm:21189378 ;
    civico:citation "Klümpen et al., 2011, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer. A germline STK11 D194E mutation was identified with LOH in the tumor sample. phospho-S6 ribosomal protein staining was observed in the tumor indicating mTOR pathway activation. Everolimus treatement led to partial response (but no change in phospho-S6 ribosomal protein staining) for 9 months." ;
    a m2r:Evidence .

civice:1618
    dct:references pbm:18281551 ;
    civico:citation "Wei et al., 2008, Clin. Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "Preclinical study in a mouse model of Peutz-Jeghers syndrome. Heterozygous Lkb1 (STK11) knockout mice were generated and treated with rapamycin after the onset of polyposis at 9 months of age. Rapamycin treatment significantly suppressed polyposis (p=0.017) and pS6 staining (IHC, p=0.011)." ;
    a m2r:Evidence .

civice:1619
    dct:references pbm:19541609 ;
    civico:citation "Shackelford et al., 2009, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "Treatment of mice with a heterozygous loss of Lkb1 (STK11) with rapamycin led to reduction in polyp size (p < 0.0001) and number of polyps (p=0.00022). pS6 staining was also reduced after rapamycin treatment. Rapamycin treatment abolished FDG-PET signal on imaging." ;
    a m2r:Evidence .

civice:1620
    dct:references pbm:26027660 ;
    civico:citation "Xiao et al., 2015, Acta Pharmacol. Sin." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Everolimus,civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "Preclinical study in 5 NSCLC cell lines. Two LKB1 (STK11) mutant cell lines had higher basal levels of mTOR activity (pS6K and p4EBP1 levels) but were not more sensitive to mTOR inhibitors (everolimus or rapamycin) than two wild type cell lines. Knockdown of LKB1 in one additional cell line did not lead to an increase in sensitivity to mTOR inhibitors." ;
    a m2r:Evidence .

civice:1621
    dct:references pbm:25982012 ;
    civico:citation "Subbiah et al., 2015, Lung Cancer" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vandetanib,civic:drug_Everolimus ;
    dcterms:description "Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET, as well as an AKT2 gene amplification. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well." ;
    a m2r:Evidence .

civice:1622
    dct:references pbm:25982012 ;
    civico:citation "Subbiah et al., 2015, Lung Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vandetanib,civic:drug_Everolimus ;
    dcterms:description "Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well." ;
    a m2r:Evidence .

civice:1623
    dct:references pbm:27445490 ;
    civico:citation "Sun et al., 2016, Onco Targets Ther" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Fulvestrant,civic:drug_Everolimus ;
    dcterms:description "Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC)." ;
    a m2r:Evidence .

civice:1624
    dct:references pbm:27445490 ;
    civico:citation "Sun et al., 2016, Onco Targets Ther" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Everolimus,civic:drug_Fulvestrant ;
    dcterms:description "Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC)." ;
    a m2r:Evidence .

civice:1625
    dct:references pbm:19706758 ;
    civico:citation "Liu et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Perifosine,civic:drug_Temsirolimus ;
    dcterms:description "Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, One cell line harbored a PIK3CA H1047R mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector. Perifosine treatment also increased apoptosis of a thyroid tumor xenograft with PIK3CA H1047R mutation." ;
    a m2r:Evidence .

civice:1626
    dct:references pbm:19706758 ;
    civico:citation "Liu et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Perifosine,civic:drug_Temsirolimus ;
    dcterms:description "Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, One cell line harbored a PIK3CA E542K mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector" ;
    a m2r:Evidence .

civice:1627
    dct:references pbm:19706758 ;
    civico:citation "Liu et al., 2009, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Perifosine,civic:drug_Temsirolimus ;
    dcterms:description "Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, one cell line harbored a PTEN allele deletion and R130* mutation. This cell line harbored the lowest IC50 values to both perifosine and temsirolimus and also showed increased apoptosis with perifosine in a xenograft model." ;
    a m2r:Evidence .

civice:1628
    dct:references pbm:24253377 ;
    civico:citation "Okazaki et al., 2014, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "mTOR protein levels were found to underly a circadian 24-hour rhythm regulated by time-dependent Fbxw7-mediated ubiquitination. Survival rates of tumor-bearing mice with everolimus showed time-dependency consistent with mTOR protein levels. It could be hypothesized that FBXW7 loss leads to an increase in mTOR protein levels independent of circadian regulation and higher sensitivity to mTOR inhibitors." ;
    a m2r:Evidence .

civice:1629
    dct:references pbm:27020857 ;
    civico:citation "Herrera-Abreu et al., 2016, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Cell lines with acquired resistance to palbociclib were developed. Two palbociclib-resistant cell lines were derived through chronic exposure to 1 μmol/L palbociclib during 3 to 4 months. Copy number profiling from exome sequencing of MCF-7 and MCF-7pR, confirmed relative amplification of CCNE1. Silencing of CCNE1 or CDK2 alone in MCF-7pR cells had no effect on cell-cycle arrest, but resulted in substantially increased cell-cycle arrest and reduction in cell growth in combination with palbociclib." ;
    a m2r:Evidence .

civice:1630
    dct:references pbm:27020857 ;
    civico:citation "Herrera-Abreu et al., 2016, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29 ;
    dcterms:description "Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Palbociclib-resistant xenografts from one cell line (PDX244) were developed in-vivo. In resistant xenografts, western blot analysis showed a decrease of pRb protein levels in 4 of 7 CDK4/6-acquired resistant tumors and a sustained expression of the E2F target cyclin E2, in contrast to CDK4/6 inhibitor-sensitive PDX244. Genomic characterization of PDX244LR1 showed the acquisition of an RB1 frameshift mutation (RB1 p.M695fs*26)." ;
    a m2r:Evidence .

civice:1631
    dct:references pbm:24586741 ;
    civico:citation "Jardim et al., 2014, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_MTORInhibitors ;
    dcterms:description "418 patients with advanced cancer were screened for FBXW7 mutations using a multiplex gene panel. 17 FBXW7 mutations were detected (isolated mutation in 2 patients). Ten patients were treated with an mTOR inhibitor with 7 patients having stable disease as best responses and a median time to treatment failure of 2.8 months, two patients had prolonged stable disease of >16 weeks." ;
    a m2r:Evidence .

civice:1632
    dct:references pbm:18787170 ;
    civico:citation "Mao et al., 2008, Science" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Rapamycin%28Sirolimus%29 ;
    dcterms:description "FBXW7 was shown to target mTOR for ubiquitination and degradation.  A reciprocal relationship between FBXW7 or PTEN loss was identified in breast cancer tumors and cell lines (mutual exclusivity of these two events).  In total only 4 out of 450 tumor and cell line samples had concomitant loss of both genes (p=4.9x10^-7). Cell lines (n=5) with FBXW7 mutations or deletions were significantly sensitive to rapamycin and downregulation of FBXW7 (shRNA) increased the sensitivity to rapamycin. In summary, this evidence suggests that FBXW7 may be a biomarker for cancers sensitivity to inhibitors of the mTOR pathway." ;
    a m2r:Evidence .

civice:1633
    dct:references pbm:27022066 ;
    civico:citation "Jones et al., 2016, Ann. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Irbesartan ;
    dcterms:description "A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4." ;
    a m2r:Evidence .

civice:1634
    dct:references pbm:27022066 ;
    civico:citation "Jones et al., 2016, Ann. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Irbesartan ;
    dcterms:description "A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with Irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4." ;
    a m2r:Evidence .

civice:1635
    dct:references pbm:27414035 ;
    civico:citation "Li et al., 2016, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray.  The TC/CC genotype of p14ARF at rs3814960 had decreased overall survival (HR = 2.77, 95% CI: 1.33–5.75, P = 0.006, Pc = 0.030) and decreased disease-free survival (DFS) (HR = 2.45, 95% CI: 1.30–4.61, P = 0.005) compared to patients without this mutation." ;
    a m2r:Evidence .

civice:1636
    dct:references pbm:27414035 ;
    civico:citation "Li et al., 2016, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray.  Patients with the DEL/A +AA genotype of MDM2 rs34886328 had a notably increased overall survival (HR = 0.27, 95% CI: 0.13–0.56, P = 4.7×10−4, Pc = 0.003) and increased disease free survival (HR = 0.22, 95% CI: 0.11–0.43, P < .0001) when compared to patients without this mutation." ;
    a m2r:Evidence .

civice:1637
    dct:references pbm:26732495 ;
    civico:citation "Li et al., 2016, Clin Lung Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Samples from 393 patients with NSCLC were evaluated for 3 SNPs in CBLB (rs1042852, rs2305035, and rs7649466).  Genotypes rs7649466 and rs1042852 were not associated with a change in clinical outcome compared to wildtype however, rs2305035 A genotype  (A/A or A/G) had better local recurrence-free survival, metastasis-free survival and overall survival when compared to GG genotype (n=186)." ;
    a m2r:Evidence .

civice:1638
    dct:references pbm:27568520 ;
    civico:citation "Xia et al., 2016, Leukemia" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Biopsies from 520 DLBCL patients treated with R-CHOP were evaluated for PRDM1 mutations or protein (BLIMP-1) expression. Patients with a homozygous deletion of PRDM1 (7%, N=19) had a significantly shorter overall survival and poorer progression free survival compared to heterozygous or wildtype PRDM1." ;
    a m2r:Evidence .

civice:1639
    dct:references pbm:26061751 ;
    civico:citation "2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Genomewide analysis of 250 low-grade adult gliomas revealed that patients with a wildtype IDH1/2 had significantly shorter overall survival than those with a mutated IDH gene (HR 7.4; 95%CI: 4.0-13.8). The median survival for patients with low grade gliomas was 1.7 years for patients with wild-type IDH (N=55); 6.3 years for patients with mutated IDH and no 1p/19q co-deletion (N=139); and 8.0 years for patients with IDH mutation and a 1p/19q co-deletion (N=84)." ;
    a m2r:Evidence .

civice:1640
    dct:references pbm:26061751 ;
    civico:citation "2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Genomewide analysis of 250 low-grade adult gliomas revealed that patients with a wildtype IDH1/2 had significantly shorter overall survival than those with a mutated IDH gene (HR 7.4; 95%CI: 4.0-13.8). The median survival for patients with low grade gliomas was 1.7 years for patients with wild-type IDH (N=55); 6.3 years for patients with mutated IDH and no 1p/19q co-deletion (N=139); and 8.0 years for patients with IDH mutation and a 1p/19q co-deletion (N=84)." ;
    a m2r:Evidence .

civice:1641
    dct:references pbm:22931316 ;
    civico:citation "Treon et al., 2012, N. Engl. J. Med." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_IMG-2005-5,civic:drug_IRAK-1-4Inhibitor ;
    dcterms:description "In a study of 30 patients with Waldenström’s macroglobulinemia, 87% had MYD88(L265P) mutations.  Waldenstrom macroglobulinemia cells expressing MYD88(L265P) were treated with an MYD88 homodimerization inhibitor or an IRAK 1/4 kinase inhibitor.  The cells showed a decrease in staining of NF-kappa-B p65 phosphorylation." ;
    a m2r:Evidence .

civice:1642
    dct:references pbm:25294897 ;
    civico:citation "Lim et al., 2014, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Refametinib,civic:drug_Sorafenib ;
    dcterms:description "Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was performed in 69 patients for KRAS, NRAS and BRAF mutations (BEAM technology). 4 patients were identified to harbor RAS mutations. 3 of whom still received study treatment at the cutoff date used for the final data analysis. These 3 patients had achieved confirmed PR, with duration responses ranging from 128 to 382 days. The fourth patient with a RAS mutation discontinued study treatment after 41 days on therapy due to PD. An overall of 4 (6 by modified RECIST) patients achieved PR." ;
    a m2r:Evidence .

civice:1643
    dct:references pbm:27029710 ;
    civico:citation "Griffith et al., 2016, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A DNAJB1:PRKACA fusion transcript was detected at very high expression levels by RNA-Seq in a case of mixed fibrolamellar hepatocellular carcinoma. Subsequent analysis revealed the presence of this fusion in all primary and metastatic samples, including those with mixed or conventional HCC pathology. A second case of mFL-HCC confirmed that the fusion was detectable in conventional components. An expanded screen of 112 additional HCC samples and 44 adjacent non-tumor liver samples was positive for a third case of HCC with both conventional and fibrolamellar features but negative for all conventional HCC and adjacent non-tumor liver samples." ;
    a m2r:Evidence .

civice:1644
    dct:references pbm:12237773 ;
    civico:citation "Boulay et al., 2002, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_5-fluorouracil ;
    dcterms:description "A retrospective study with 202 colorectal cancer patients found that SMAD4 deletion was associated with worse outcomes during 5-fluorouracil treatment. The hazard ratio for disease-free survival was 2.89 times greater for patients with SMAD4 deletion as compared to those  with normal SMAD4 diploidy (P = .045).  For overall survival, the hazard ratio was 3.23 times greater for SMAD4 deletion (P = .056)." ;
    a m2r:Evidence .

civice:1645
    dct:references pbm:26428308 ;
    civico:citation "Tabouret et al., 2015, J. Neurol. Sci." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A retrospective study of 178 glioblastoma patients found that LRP1B deletion (complete transcript, N=4 or focal transcript deletion of >150kb, N=13) was associated with a lower progress free survival (6.4 months vs. 10.1 months; P = 0.004) and overall free survival (13.4 months vs. 17.8 months; P = 0.001). Multivariate analysis adjusting for age and type of surgery also supported LRP1B deletion being associated with a higher hazard ratio." ;
    a m2r:Evidence .

civice:1646
    dct:references pbm:25121551 ;
    civico:citation "Liu et al., 2014, Endocr. Relat. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 308 thyroid fine-needle aspiration biopsies, 0 of the 179 benign tumors displayed either the C228T or the C250T TERT promoter mutation; however, 9 of the 129 differentiated thyroid cancers had either of these mutations. The biomarker displayed 100% diagnostic specificity and 7% sensitivity." ;
    a m2r:Evidence .

civice:1647
    dct:references pbm:23904111 ;
    civico:citation "Wiestler et al., 2013, Acta Neuropathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Temozolomide,civic:drug_Procarbazine,civic:drug_Lomustine,civic:drug_Vincristine ;
    dcterms:description "A retrospective tumor sample study found that the loss of ATRX expression (less than 10% of nuclei) in IDH-mutant astrocytomas treated with temozolomide or a combination of procarbazine, lomustine and vincristine was associated with a greater time to treatment failure (55.6 months vs. 31.8 months; P = .0168) and a greater progression-free survival (37.1 months vs. 18.1 months; P = .038)." ;
    a m2r:Evidence .

civice:1648
    dct:references pbm:26936505 ;
    civico:citation "Koschmann et al., 2016, Sci Transl Med" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "D" ;
    dcterms:description "In a glioblastoma mouse model induced by NRAS and p53 knockdown, ATRX loss was associated with a decreased median survival (69 days vs. 84 days; P = .0032). Also, the tumors grew to a larger size at earlier time points. ATRX loss was also associated with greater microsatellite instability." ;
    a m2r:Evidence .

civice:1649
    dct:references pbm:24496303 ;
    civico:citation "Tefferi et al., 2014, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In patients with primary myelofibrosis CALR mutations were associated with improved median survival. For 277 patients, CALR mutated, ASXL1 wildtype patients (median survival, 10.4 years, N=46); CALR wildtype, ASXL1 mutant patients (2.3 years; HR, 5.9; 95% CI, 3.5–10.0, N=62); and either CALR/ASXL1wildtype or CALR/ASXL1 mutant patients (5.8 years; HR, 2.5; 95% CI, 1.5–4.0, N=169). These results were independent of DIPSS-plus risk but added prognostic information to this risk categorization. These results were also validated in an independent cohort of 293 patients." ;
    a m2r:Evidence .

civice:1650
    dct:references pbm:27209210 ;
    civico:citation "Mignogna et al., 2016, J Ovarian Res" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PLATINUM ;
    dcterms:description "A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P = 0.001; HR 0.14) and platinum therapy resistance (P < 0.001). Expression of AURKA was measured using immunohistochemical techniques on tumor samples." ;
    a m2r:Evidence .

civice:1651
    dct:references pbm:26845194 ;
    civico:citation "Shea et al., 2016, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Case report of a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and major response to crizotinib." ;
    a m2r:Evidence .

civice:1652
    dct:references pbm:27343442 ;
    civico:citation "Heist et al., 2016, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation." ;
    a m2r:Evidence .

civice:1653
    dct:references pbm:25924824 ;
    civico:citation "Tamotsu et al., 2015, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin,civic:drug_5-fluorouracil ;
    dcterms:description "A retrospective study examining the expression of AURKA in tumor samples of 78 esophageal squamous cell carcinoma patients found that positive expression of AURKA (>10% of cells by IHC) was correlated with increased clinical response to chemoradiation therapy consisting of cisplatin, 5-fluorouracil, and 40 gy radiation (P = 0.0003)." ;
    a m2r:Evidence .

civice:1654
    dct:references pbm:25502557 ;
    civico:citation "Rihani et al., 2014, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "21 SNPs were analyzed using qRT-PCR genotyping assays in 500 Neuroblastoma tumor samples, and the CASP8 D302H missense variant was found to be associated with worse overall survival (P = 0.0006; Q = 0.049) and worse event-free survival (P = 0.0002; Q = 0.042) in those samples that had MYCN amplification (N = 94)." ;
    a m2r:Evidence .

civice:1655
    dct:references pbm:27172793 ;
    civico:citation "Hsieh et al., 2016, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Immunohistochemical analysis of tumors from 116 esophageal squamous cell carcinoma found that expression of AXL was associated with increased progression of the tumor (P < 0.0001), increased risk of death (HR = 2.09 ; P = 0.028), and increased risk of distant metastasis (OR = 3.96 ; P = 0.029)." ;
    a m2r:Evidence .

civice:1656
    dct:references pbm:27153245 ;
    civico:citation "Lee et al., 2016, J. Cell. Biochem." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Docetaxel ;
    dcterms:description "Prostate Cancer (PCa) cell lines were either cultured alone, co-cultured with osteoblasts expressing GAS6, or cultured in the presence of media with GAS6 to examine their response to therapy with docetaxel. Docetaxel efficiently induced apoptosis in the cells cultured without any GAS6, but it was not able to do so in the cells that were in media with GAS6 present or that were co-cultured with osteoblasts expressing GAS6. PCa cells in the presence of GAS6 were found to be in G1 phase for a greater duration which may help explain the increased resistance to docetaxel." ;
    a m2r:Evidence .

civice:1657
    dct:references pbm:26207647 ;
    civico:citation "Jiang et al., 2015, PLoS ONE" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum. OSCC patients were found to be associated with a significantly higher level of GAS6 in serum ( P = .05 ). Furthermore, within the OSCC patients, increased GAS6 serum concentration was associated with higher stage tumors ( P < .01) , poorly differentiated tumors ( P < .01 ), and increased lymph node metastasis ( OR = 2.79 ; CI = 1.72-4.48 )." ;
    a m2r:Evidence .

civice:1658
    dct:references pbm:25544710 ;
    civico:citation "Qi et al., 2015, Tumour Biol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Immunohistochemical methods were used to evaluate the expression levels of ETV4 in prostate cancer (PCa) tumor samples. Increased expression of ETV4 was associated with greater Gleason score (P = 0.045) , pathological tumor stage (P = 0.041),  and an unfavorable prognosis (P = 0.040)." ;
    a m2r:Evidence .

civice:1659
    dct:references pbm:27500726 ;
    civico:citation "Shen et al., 2016, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "A375 melanoma cells containing an inducible shRNA for STAG2 were grown as xenograft tumors in nude mice. The mice in which STAG2 was silenced had tumors that were more sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01)." ;
    a m2r:Evidence .

civice:1660
    dct:references pbm:27500726 ;
    civico:citation "Shen et al., 2016, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "A375 melanoma cells containing an inducible shRNA for STAG3 were grown as xenograft tumors in nude mice. The mice in which STAG3 was silenced had tumors that were more sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01)." ;
    a m2r:Evidence .

civice:1661
    dct:references pbm:26324360 ;
    civico:citation "Grisham et al., 2015, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer. Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years. Sequencing (MSK-IMPACT Panel) was performed on the patients tumor and germline and identified a 15-bp in-frame deletion of MAP2K1 (8.3% of tumor reads but 0% in germline). In-silico modelling suggested loss of negative feedback on kinase activity from this deletion.In-vitro expression of the MEK1 Q56_V60 deletion as well as the previously characterized MEK1 F53L mutation in 293H cells resulted in elevated levels of phosphorylated ERK and phosphorylated ribosomal protein S6 kinase as compared with wild-type MEK1 as well as increased colony formation and tumor growth in-vivo. Selumetinib treatment of MEK1-transfected cells confirmed retained sensitivity to MEK inhibition and inhibition of colony formation." ;
    a m2r:Evidence .

civice:1662
    dct:references pbm:26324360 ;
    civico:citation "Grisham et al., 2015, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_MEKInhibitor ;
    dcterms:description "One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcriptome sequencing. This patient with metastatic disease after treatment with carboplatin and paclitaxel, was enrolled onto a study of paclitaxel in combination with an oral MEK inhibitor and achieved a CR. She continued to receive therapy for 7 months, until discontinuation because of the development of pneumonitis. At publication, sustained CR had lasted > 18 months." ;
    a m2r:Evidence .

civice:1663
    dct:references pbm:26314551 ;
    civico:citation "Ross et al., 2016, Int. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "Analysis of BRAF fusions in 20,573 tumors, across 12 distinct tumor types. BRAF fusions were identified in 55 (0.3%) patients and enriched in spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers. Clinical data were available for two patients. Among them one 46-year old woman with spitzoid melanoma that  harbored  a ZKSCAN1-BRAF fusion responded to treatment with the MEK inhibitor trametinib. Subcutaneous  tumor  nodules  exhibited  clinical responses within 14 days of therapy, and her dominant bulky right lung metastases showed significant response by Day 45. Subsequent robotic-assisted lobectomy was able to remove the previously unresectable tumor with clean surgical margins." ;
    a m2r:Evidence .

civice:1664
    dct:references pbm:24422672 ;
    civico:citation "Subbiah et al., 2014, J Hematol Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Sorafenib,civic:drug_Bevacizumab,civic:drug_Temsirolimus ;
    dcterms:description "A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinase inhibitor sorafenib in combination with bevacizumab and temsirolimus, achieving stable disease after 2 cycles extending into 11 cycles at which time she expired due to co-morbidities (acute myocardial infarction, hypotension). Of note, sequencing of 236 cancer-related genes identified CDKN2A A68fs*51, SUFU E283fs*3, MAP3K1 N325fs*3 and homozygous deletion of PTEN as well." ;
    a m2r:Evidence .

civice:1665
    dct:references pbm:18509184 ;
    civico:citation "Yang et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were  treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR(median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for TTF (HR = 0.1030; P = .0004)." ;
    a m2r:Evidence .

civice:1666
    dct:references pbm:18509184 ;
    civico:citation "Yang et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild-type EGFR (median 8.9 versus 2.1). In multivariate analysis, exon 19 deletion was a significant predictive factor for TTF (HR = 0.0320; P < .0001)." ;
    a m2r:Evidence .

civice:1667
    dct:references pbm:27304188 ;
    civico:citation "Belchis et al., 2016, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib,civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (NGS failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 79%, or 31 out of the 39 patients,  had the T790M EGFR mutation present, indicating its importance in the development of resistance." ;
    a m2r:Evidence .

civice:1668
    dct:references pbm:24112705 ;
    civico:citation "Wagenaar et al., 2014, Pigment Cell Melanoma Res" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib. Analysis of the mutation in T293 cell lines found that the L505H mutant alone or with V600e had greater kinase activity and increased the levels of phospho-MEK. Finally, transduction of Ba/F3 cells with BRAF V600E/L505H IL3 independent proliferation." ;
    a m2r:Evidence .

civice:1669
    dct:references pbm:25515853 ;
    civico:citation "Hoogstraat et al., 2015, Pigment Cell Melanoma Res" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutation." ;
    a m2r:Evidence .

civice:1670
    dct:references pbm:27304188 ;
    civico:citation "Belchis et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib,civic:drug_Afatinib ;
    dcterms:description "48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 2 out of the 39 patients had the E545K PIK3CA mutation in the absence of EGFR T790M, indicating that E545K may be an alternative mutation contributing to resistance." ;
    a m2r:Evidence .

civice:1671
    dct:references pbm:25567352 ;
    civico:citation "Goutagny et al., 2015, J. Neurooncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "Ten patients with Neurofibromatosis 2 were enrolled for treatment with Everolimus.  At 12 months, no patients had reduction in tumor volume >20%, however, five patients had stable disease with a reduction in annual growth rate from 67% growth/year to 0.5% growth/year.  Growth of tumors ensued after discontinuation of Everolimus." ;
    a m2r:Evidence .

civice:1672
    dct:references pbm:23881929 ;
    civico:citation "Choueiri et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pazopanib ;
    dcterms:description "VHL mutations were evaluated in 78 tumors samples of patients with metastatic RCC treated with pazopanib as part of a clinical trial. Overall, 87% had one VHL mutation, 12% showed promoter hypermethylation, and 6 patients had both. 8 patients exhibited neither mutation nor methylation of VHL. There was no correlation between VHL status and overall response rate or progression free survival under pazopanib therapy." ;
    a m2r:Evidence .

civice:1673
    dct:references pbm:23881929 ;
    civico:citation "Choueiri et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pazopanib ;
    dcterms:description "HIF-2A (EPAS1) staining was conducted on 66 tumors.  Of the 66 patients, 25 were classified as responders and 41 were classified as non-responders.  There was no significant difference between responders and non-responders with regards to overall response rate to pazopanib (44% vs 33%; P=0.36)." ;
    a m2r:Evidence .

civice:1674
    dct:references pbm:23881929 ;
    civico:citation "Choueiri et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pazopanib ;
    dcterms:description "Immunohistochemical staining was performed on 65 patients for HIF1A such that 23 were considered responders and 42 were considered non-responders.  There was no difference between the two groups with regards to overall response rate to pazopanib.  There was no difference between the two groups with regards to progression free survival." ;
    a m2r:Evidence .

civice:1675
    dct:references pbm:26740259 ;
    civico:citation "Harter et al., 2016, Gynecol. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant." ;
    a m2r:Evidence .

civice:1676
    dct:references pbm:26740259 ;
    civico:citation "Harter et al., 2016, Gynecol. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant." ;
    a m2r:Evidence .

civice:1677
    dct:references pbm:25218906 ;
    civico:citation "Liu et al., 2014, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib,civic:drug_Cediranib ;
    dcterms:description "46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients)." ;
    a m2r:Evidence .

civice:1678
    dct:references pbm:25218906 ;
    civico:citation "Liu et al., 2014, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib,civic:drug_Cediranib ;
    dcterms:description "46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients)." ;
    a m2r:Evidence .

civice:1679
    dct:references pbm:18951446 ;
    civico:citation "Plon et al., 2008, Hum. Mutat." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "49-year old woman diagnosed with breast cancer was assessed for BRCA2 mutations.  Algorithms including Align-GVGD predicted pathogenicity, however PolyPhen predicted that this variant was benign. The author’s assessment of the factors predicts a pathogenicity probability of 0.73 and an Odds Ratio of 2.7." ;
    a m2r:Evidence .

civice:1680
    dct:references pbm:27313181 ;
    civico:citation "Rokutan et al., 2016, J. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations and MLH1 expression (immunohistochemistry). Overall survival rate of MLH1 negative cases were significantly better than MLH1 positive cases (p=0.020)." ;
    a m2r:Evidence .

civice:1681
    dct:references pbm:27313181 ;
    civico:citation "Rokutan et al., 2016, J. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations.  Overall survival rate of BCOR positive cases were significantly better than BCOR negative cases cases (p=0.038)." ;
    a m2r:Evidence .

civice:1682
    dct:references pbm:27313181 ;
    civico:citation "Rokutan et al., 2016, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "E" ;
    dcterms:description "285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  CDH1 mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001)." ;
    a m2r:Evidence .

civice:1683
    dct:references pbm:27313181 ;
    civico:citation "Rokutan et al., 2016, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "E" ;
    dcterms:description "285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  RHOA mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001)." ;
    a m2r:Evidence .

civice:1684
    dct:references pbm:25847936 ;
    civico:citation "Isakoff et al., 2015, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Carboplatin ;
    dcterms:description "In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different." ;
    a m2r:Evidence .

civice:1685
    dct:references pbm:25847936 ;
    civico:citation "Isakoff et al., 2015, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Carboplatin ;
    dcterms:description "In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different." ;
    a m2r:Evidence .

civice:1686
    dct:references pbm:22586653 ;
    civico:citation "Bertotti et al., 2011, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective patient cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab." ;
    a m2r:Evidence .

civice:1687
    dct:references pbm:22586653 ;
    civico:citation "Bertotti et al., 2011, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed resistance whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab." ;
    a m2r:Evidence .

civice:1688
    dct:references pbm:23348520 ;
    civico:citation "Martin et al., 2013, Br. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab. HER2 copy number status was significantly correlated with respoinse rate, PFS and OS. Patients with amplification in all neoplastic cells (4%) had worse outcome compared to patients without amplification (35%, intermediate outcome) or amplification in minor clones (61%, highest survival probability)" ;
    a m2r:Evidence .

civice:1689
    dct:references pbm:27108243 ;
    civico:citation "Sartore-Bianchi et al., 2016, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Lapatinib ;
    dcterms:description "Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib. After a median follow-up of 94 weeks, eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease. A total of 914 patients with KRAS wt were screened for this study, 48 patients (5%) were identified to have HER2-positive tumors." ;
    a m2r:Evidence .

civice:1690
    dct:references pbm:25922291 ;
    civico:citation "Le et al., 2015, Clin Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In an evaluation of a patient and never smoker with crizotinib-sensitive lung adenocarcinoma, an SDC4-ROS1 rearrangement was identified using comprehensive genomic profiling. The patient attained a decrease in RESIST target lesions by 26.8% (stable disease); however, the patient relapsed 4 months later. This patient also harbored a TP53 mutation, MCL1 amplification and CDKN2A deletion." ;
    a m2r:Evidence .

civice:1691
    dct:references pbm:25922291 ;
    civico:citation "Le et al., 2015, Clin Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an EML4-ALK-E13;A20 rearrangement was identified using CGP.  The patient attained a reduction in the target lesions by 14.2%, however, the patient relapsed 17 months later." ;
    a m2r:Evidence .

civice:1692
    dct:references pbm:25922291 ;
    civico:citation "Le et al., 2015, Clin Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification was identified using CGP.  The patient attained a reduction in the target lesions by 38.7%, and the patient maintained response for at least 5 months post-treatment." ;
    a m2r:Evidence .

civice:1693
    dct:references pbm:25692060 ;
    civico:citation "Barth et al., 2015, Case Rep Oncol Med" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "A 71-year old male with metastatic extramammary Paget’s disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable disease." ;
    a m2r:Evidence .

civice:1694
    dct:references pbm:25636205 ;
    civico:citation "Groenendijk et al., 2016, Eur. Urol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_PLATINUM ;
    dcterms:description "In patients with muscle-invasive bladder chancer, a cohort of complete responders to platinum chemotherapy (n=38) and non-responders to platinum chemotherapy (n=33) were evaluated for 178 cancer-associated genes. Of the complete responders, 24% had an ERBB2 missense mutations and no non-responders had ERBB2 mutations (p=0.003)." ;
    a m2r:Evidence .

civice:1695
    dct:references pbm:25625803 ;
    civico:citation "Kasaian et al., 2015, J. Clin. Endocrinol. Metab." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Two patients diagnosed with oncocytic thyroid carcinoma (hurthle cell thyroid carcinoma) were evaluated for MEN1 mutations.  One tumor showed 592-end deletion of MEN1 and the other showed a 521 frameshift mutation.  These mutations are similar to the ones seen in MEN1 syndrome inducing endocrine gland tumors." ;
    a m2r:Evidence .

civice:1696
    dct:references pbm:25303977 ;
    civico:citation "Pickering et al., 2014, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Evaluation of 39 aggressive cutaneous squamous cell carcinomas revealed that tumors with a KMT2C mutation were 5x more likely to invade the bone (53% versus 10%; p=0.008).  Patients with KMT2C mutations also had significantly shorter recurrent free survival (21.6 versus 167.5; p=0.003) and an increased hazards ratio for death (HR=5.16; 95%CI:1.55 to 17.18).  This worse prognosis did not appear to be correlated with bone invasion (p=0.98)." ;
    a m2r:Evidence .

civice:1697
    dct:references pbm:25186949 ;
    civico:citation "Crompton et al., 2014, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 96 Ewing sarcoma tumors, 15% showed heterogenous loss of STAG2 expression in IHC analysis.  Of those with STAG2 expression loss, 88% presented with metastatic disease compared to only 27% of patients who expressed STAG2 on IHC (P=0.002)." ;
    a m2r:Evidence .

civice:1698
    dct:references pbm:24997557 ;
    civico:citation "Sharman et al., 2014, Clin Lymphoma Myeloma Leuk" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "A 65-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E mutation and he was treated with vemurafenib.  After 7 weeks of treatment, the patient relapsed and died." ;
    a m2r:Evidence .

civice:1699
    dct:references pbm:24997557 ;
    civico:citation "Sharman et al., 2014, Clin Lymphoma Myeloma Leuk" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "A 54-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and received an autologous stem cell transplant.  Genomic profiling of the bone biopsy revealed BRAF V600E activating mutation and the patient was treated with vemurafenib.  At 4-months post treatment (time of case study report) the patient maintains near-resolution of hypermetabolic lesions." ;
    a m2r:Evidence .

civice:1700
    dct:references pbm:22810899 ;
    civico:citation "Johnson et al., 2013, Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 1036 patients with lung adenocarcinoma, patients with KRAS mutations (n=241) showed worse prognosis (OS: 19 months versus 23 months; HR=1.21; P=0.048)." ;
    a m2r:Evidence .

civice:1701
    dct:references pbm:22810899 ;
    civico:citation "Johnson et al., 2013, Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 1036 patients with lung adenocarcinomas, patients with EGFR mutations (n=275) showed better prognosis (OS: 34 months versus 23 months; HR=0.6; P<0.001)." ;
    a m2r:Evidence .

civice:1702
    dct:references pbm:22586653 ;
    civico:citation "Bertotti et al., 2011, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab." ;
    a m2r:Evidence .

civice:1703
    dct:references pbm:22586653 ;
    civico:citation "Bertotti et al., 2011, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab." ;
    a m2r:Evidence .

civice:1704
    dct:references pbm:22586653 ;
    civico:citation "Bertotti et al., 2011, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab." ;
    a m2r:Evidence .

civice:1705
    dct:references pbm:22586653 ;
    civico:citation "Bertotti et al., 2011, Cancer Discov" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab and only 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab." ;
    a m2r:Evidence .

civice:1706
    dct:references pbm:27276402 ;
    civico:citation "Suzuki et al., 2016, Anticancer Drugs" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_I-BET151,civic:drug_JQ1 ;
    dcterms:description "Four myeloma cell lines were treated with two different BET inhibitors (I-BET151 or JQ1). Proliferation of three cell lines (KMS11, RPMI8226 and MM1S) but not U266 (only partial inhibition) was strongly inhibited by the BET inhibitors. Microarray analysis showed a downregulation of MYC-dependent genes after treatment. qRT-PCR showed that MYCL1 but not c-MYC and MYCN was expressed in U266 cells and I-BET151 induced downregulation of MYCL1. In contrast, c-MYC but not MYCL was expressed in the other cell lines and I-BET151 induced downregulation of c-MYC." ;
    a m2r:Evidence .

civice:1707
    dct:references pbm:22203985 ;
    civico:citation "Xie et al., 2012, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_SGX523 ;
    dcterms:description "Three metastatic glioblastoma cell lines were compared with their parental cell lines with regard to differential gene expression. HGF signalling was among the top pathways identified. Exogenous HFG led to an increase in MET activity (except in one cell line with high endogenous HGF levels) which was abrogated by MET inhibitor SGX523. Three HGF autocrine cell lines were grown in mice and showed significantly increased sensitivity to SGX523 than three non-HGF autocrine cell lines (P<0.05)." ;
    a m2r:Evidence .

civice:1708
    dct:references pbm:17470858 ;
    civico:citation "Van Cutsem et al., 2007, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "463 patients with 1% or more EGFR tumor cell membrane staining, with metastatic CRC progressive after standard chemotherapy were randomized to panitumumab plus best supportive care (BSC, n = 231) or BSC alone (n = 232). Panitumumab significantly prolonged PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66, [P < .0001]). Objective response rates favored panitumumab over BSC; after a 12-month minimum follow-up, response rates were 10% for panitumumab and 0% for BSC (P < .0001). No difference was observed in OS (HR, 1.00; 95% CI, 0.82 to 1.22), but 76% of BSC patients entered the cross-over study." ;
    a m2r:Evidence .

civice:1709
    dct:references pbm:14993230 ;
    civico:citation "Saltz et al., 2004, J. Clin. Oncol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "57 patients with chemorefractory colorectal cancer expressing EGFR (IHC staining) were treated with single-agent cetuximab in this phase 2 study. Five patients (9%; 95% CI, 3% to 19%) achieved a partial response. Twenty-one additional patients had stable disease or minor responses. The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer was 6.4 months." ;
    a m2r:Evidence .

civice:1710
    dct:references pbm:24670642 ;
    civico:citation "Sun et al., 2014, Nature" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "FACS-assisted shRNA genetic screen identified SOX10 as a determinant of vemurafenib resistance. Suppression of SOX10 in melanoma cells confers resistance to BRAF and MEK inhibitors through activation of TGF-β signalling and upregulation of EGFR and PDGFRB. EGFR expression or exposure to TGF-β becomes beneficial for proliferation of melanoma cells in the presence of BRAF or MEK inhibitors. Melanoma cells with low SOX10 and consequently high EGFR expression are enriched in the presence of vemurafenib. This study finds evidence for SOX10 loss (N=2) and/or activation of TGF-β signalling (N=2) in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples." ;
    a m2r:Evidence .

civice:1711
    dct:references pbm:27671675 ;
    civico:citation "Traer et al., 2016, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Quizartinib%28AC220%29 ;
    dcterms:description "AML MOLM14 cells were cocultured with FLT3 inhibitor AC220 (10 nM) and selected proteins expressed in the bone marrow microenvironment. FL and FGF2 were the only proteins that increased viability >2 standard deviations. FGFR inhibitor PD173074 (and FGFR1 siRNA) was able to attenuate the protective effect of FGF2.  Removing FL or FGF2 from ligand-dependent resistant cultures transiently restored sensitivity to AC220, but accelerated acquisition of secondary resistance mutations. 10 FLT3-ITD AML patients treated with AC220 developed increased FGF2 expression (IHC) in marrow stromal cells, which peaked prior to overt clinical relapse and detection of resistance mutations" ;
    a m2r:Evidence .

civice:1712
    dct:references pbm:23793026 ;
    civico:citation "Martin et al., 2013, Nat. Genet." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "C" ;
    dcterms:description "EIF1AX was identified as a uveal melanoma (UM) driver gene by whole-exome sequencing. Approximately 14%–20% of UM carry a mutation in EIF1AX, with most mutations found in exons 1 and 2. EIF1AX mutations are associated with a good prognosis, and are inversely associated with metastasis. This assertion is based on observed survival for 19 EIF1AX mutant UM cases compared to 69 EIF1AX wildtype cases." ;
    a m2r:Evidence .

civice:1713
    dct:references pbm:27664533 ;
    civico:citation "Caparica et al., 2017, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Case report of two patients with MET amplification (MET:CEP7 ratio ≥5) and no concomitant MET exon 14 deletion. A response to crizotinib was observed in both cases suggesting that MET amplification may predict response to this drug even in the absence of MET exon 14 mutations." ;
    a m2r:Evidence .

civice:1714
    dct:references pbm:25232318 ;
    civico:citation "Palma et al., 2014, Case Rep Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S." ;
    a m2r:Evidence .

civice:1715
    dct:references pbm:25232318 ;
    civico:citation "Palma et al., 2014, Case Rep Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S." ;
    a m2r:Evidence .

civice:1716
    dct:references pbm:24800185 ;
    civico:citation "Heidarpour et al., 2014, Adv Biomed Res" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The authors explored the viability of PAX8 expression as a biomarker for differentiating mullerian from non-mullerian tumors. 74 tumors (37 Mullerian/37 non-Mullerian) were examined for PAX8 expression via IHC. Of these 29/37 Mullerian and 1/37 non-Mullerian tumors exhibited PAX8 expression. The sensitivity and specificity of using this as a biomarker to differentiate between the two tumor types was 78.4% and 97.3% respectively." ;
    a m2r:Evidence .

civice:1717
    dct:references pbm:27568520 ;
    civico:citation "Xia et al., 2016, Leukemia" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In 177 patients with activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), PRDM1 mutations (N=46) were associated with worse overall (P=0.016) and progression-free (P=0.023) survival compared to wildtype patients. This may have been driven by patients with exon1-2 mutations (N=15; P=0.021 for OS; P=0.024 for PFS) versus those with exon 3-7 mutations (N=31; P=0.16 for OS; P=0.24 for PFS) when compared to wildtype patients. Multivariate analysis did not identify PRDM1 mutations as an independent prognostic factor." ;
    a m2r:Evidence .

civice:1724
    dct:references pbm:24550739 ;
    civico:citation "Borad et al., 2014, PLoS Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "An ERRFI1 (E384X) was detected in a patient with metastatic, recurrent/refractory cholangiocarcinoma (allelic fraction 11%) without any mutations or amplifications in other EGFR signaling members such as EGFR and BRAF. The patient was treated with erlotinib 150 mg orally/daily. After 3 months, RECIST v1.1 partial response evidenced by a decrease of 58% in the sum of largest diameters was observed." ;
    a m2r:Evidence .

civice:1725
    dct:references pbm:27355533 ;
    civico:citation "Gotlib et al., 2016, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Midostaurin ;
    dcterms:description "In a phase II clinical trial, 60% of patients (N=89) with advanced systemic mastocytosis responded to treatment with midostaurin." ;
    a m2r:Evidence .

civice:1726
    dct:references pbm:26464169 ;
    civico:citation "Jawhar et al., 2016, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The D816V+ advanced systemic mastocytosis patients with additional mutations in SRSF2 (N=30), ASLX1 (N=20), or RUNX1 (N=16) exhibited lower overall survival over 14 years as compared to D816V+ patients with wildtype SRSF2 (N=40), ASXL1(N=50), or RUNX1 (N=54)." ;
    a m2r:Evidence .

civice:1727
    dct:references pbm:24185512 ;
    civico:citation "Toy et al., 2013, Nat. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AromataseInhibitor ;
    dcterms:description "ESR1 S463P variants were observed after extensive treatment with hormonal therapy (aromatase inhibition). Expression of the S463P mutant was found to induce modest activity in the absence of hormone. This mutation displayed elevated levels of Ser118 phosphorylation compared to wild-type ERα and appeared to possess estrogen-independent activity." ;
    a m2r:Evidence .

civice:1728
    dct:references pbm:27083334 ;
    civico:citation "Park et al., 2016, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In the LUX-LUNG 7 trial, (NCT01466660) stage IIIB or IV NSCLC patients with EGFR exon 19 deletion, (n=186) Leu858Arg mutation, (n=132) or both (n=1) were divided into equal groups and treated with first line reversible EGFR inhibitor gefitinib or irreversible pan-ErbB family inhibitor afatinib in order to obtain a direct comparison of these two approved first line treatments. Significant difference was seen in objective response with 70%  of cases with afatinib vs. 56% of cases with gefitinib. Median progression free survival was 11.0 months (10.6-12.9) with afatinib and 10.9 months (9.1-11.5) with gefitinib, HR 0.73 [0.57-0.95] p=0.017." ;
    a m2r:Evidence .

civice:1729
    dct:references pbm:27451907 ;
    civico:citation "Castel et al., 2016, Cancer Cell" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Alpelisib%28NVP-BYL719%29 ;
    dcterms:description "SGK1 mRNA expression was elevated in five breast cancer cell lines which were resistant to PI3Kalpha inhibitor alpelisib in comparison to five sensitive cell lines. Western blots showed clear elevation of protein levels in 3/5 resistant cell lines. Ectopic SGK1 expression in sensitive MDA-MB-361 cells resulted in alpelisib resistance and preservation of phopho-S6K and phospho-4EBP with alpelisib treatment. Knockdown of SGK1 in resistant HCC1954 cells increased alpelisib sensitivity and reduced p-S6K and p-4EBP levels with alpelisib treatment. Promoter methylation at SGK1 was increased in sensitive cells compared to alpelisib resistant cell lines." ;
    a m2r:Evidence .

civice:1730
    dct:references pbm:27451907 ;
    civico:citation "Castel et al., 2016, Cancer Cell" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Alpelisib%28NVP-BYL719%29 ;
    dcterms:description "A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib plus an aromatase inhbitor (NCT01870505). 3 out of 3 patients expressing high tumor SGK1 mRNA had disease progression as best response with median progression free survival (PFS) of 56 days, while 15 patients classified with low to medium SGK1 mRNA had median PFS 111 days with 4/15 having disease progression as best response." ;
    a m2r:Evidence .

civice:1731
    dct:references pbm:27451907 ;
    civico:citation "Castel et al., 2016, Cancer Cell" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BYL719%28Alpelisib%29,civic:drug_SGK1-Inh ;
    dcterms:description "The alpelisib (PI3Kalpha inhibitor) resistant breast cancer cell line HCC1954 was treated with alpelsisb alone or in combination with the SGK1 kinase inhibitor SGK1-Inh. Addition of SGK1 reduced viability over alpelisib alone, and phospho-S6K as well as phospho-4EBP1 levels decreased with combination treatment. HCC1954 xenografts showed increased tumor volume with treatment of alpelisib or SGK1-Inh alone, but only combination treatment resulted in lack of volume increase and decreased phospho-S6K levels in tumors by IHC." ;
    a m2r:Evidence .

civice:1732
    dct:references pbm:27010960 ;
    civico:citation "Bournet et al., 2016, Clin Transl Gastroenterol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Exon-2 KRAS mutation status was analyzed in 219 patients with pancreatic ductal carcinoma, excluding those who had previously undergone chemotherapy, first-line pancreatic resection, or neoadjuvant treatment with chemotherapy or radiotherapy. 72 patients had wild-type KRAS, 147 had a codon-12 KRAS mutation (G12D, G12V, or G12R) and 73 had a G12D KRAS mutation, specifically. There was no significant difference in overall survival between wild-type patients and patients with any type of exon-12 mutation. However, patients with the G12D mutation exhibited significantly lower overall survival compared to wild-type patients in univariate and multivariate analyses. This difference in overall survival between wild-type and G12D patients persisted in the subset of patients who underwent chemotherapy at any point after enrollment." ;
    a m2r:Evidence .

civice:1733
    dct:references pbm:27718847 ;
    civico:citation "Reck et al., 2016, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pembrolizumab ;
    dcterms:description "This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of EGFR or translocation of ALK. Patients in the pembrolizumab group exhibited significantly better progression-free survival and overall survival compared to patients in the chemotherapy group." ;
    a m2r:Evidence .

civice:1734
    dct:references pbm:26204491 ;
    civico:citation "Yang et al., 2015, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BMS-387032%28SNS-032%29 ;
    dcterms:description "Four ovarian cancer cell lines with elevated CCNE1 expression were 40x more sensitive to Cdk2 inhibitor SNS-032 than four cell lines without CCNE1 overexpression. SNS-032 greatly prolonged the survival of mice with CCNE1 overexpressing xenografts." ;
    a m2r:Evidence .

civice:1735
    dct:references pbm:27663592 ;
    civico:citation "Au-Yeung et al., 2016, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dinaciclib,civic:drug_MK-2206 ;
    dcterms:description "A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors" ;
    a m2r:Evidence .

civice:1736
    dct:references pbm:26124334 ;
    civico:citation "Otsuka et al., 2015, Anticancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "This small clinical (n=56) study suggests that patients with minor mutations of EGFR, like G719S, are likely to have a moderate response to Tyrosine kinase inhibitors like Gefitinib and Erlotinib. In this study 44 of 56 patients were treated with either gefitinib or erlotinib. 35 patients had a G719 mutation but the majority of these were G719S (20 with G719S, 9 with G719A, 3 with G719C)." ;
    a m2r:Evidence .

civice:1737
    dct:references pbm:12865922 ;
    civico:citation "Lim et al., 2003, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a series of 33 patients with Peutz-Jeghers Syndrome, 17 mutations in STK11/LKB1 were observed in exons 1-8 (none in exon 9). 11 of these mutations were predicted to be truncating. These mutations occurred in 10/13 patients with familial PJS and 7/20 patients with sporadic PJS." ;
    a m2r:Evidence .

civice:1738
    dct:references pbm:27577079 ;
    civico:citation "Noeparast et al., 2016, Oncotarget" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Trametinib ;
    dcterms:description "non-V600 BRAF mutations can be sensitive to clinically relevant doses of Dabrafenib and Trametinib in HEK293T cells, in lung epithelial cellular model (BEAS-2B) and in human cancer cell lines harboring non-V600 BRAF mutations" ;
    a m2r:Evidence .

civice:1739
    dct:references pbm:27391784 ;
    civico:citation "Kawano et al., 2016, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_EPZ-6438 ;
    dcterms:description "Treatment with tazemetostat , a small-molecule inhibitor of EZH2, results in concentration-dependent cell growth inhibition and cell death specifically in SS18-SSX-positive, SMARCB1-deficient synovial sarcomas." ;
    a m2r:Evidence .

civice:1740
    dct:references pbm:23620515 ;
    civico:citation "Knutson et al., 2013, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_EPZ-6438 ;
    dcterms:description "EPZ-6438 (Tazemetostat) induces apoptosis and differentiation specifically in SMARCB1-deleted malignant rhabdoid tumors (MRT) cells. This study compared in vitro EPZ-6438 treatment of four SMARCB1-deleted MRT cell lines to three control (wild-type) cell lines. These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymatic activity and suggest treatment of these genetically defined cancers with EZH2 inhibitors." ;
    a m2r:Evidence .

civice:1741
    dct:references pbm:27470558 ;
    civico:citation "Gao et al., 2016, Biomed. Pharmacother." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A meta-analysis of 26 published studies including 8097 prostate cancer patients showed that, compared to patients with normal PTEN, patients with PTEN deletion exhibited a greater aggressive Gleason score (OR: 1.284, 95% CI = 1.145–1.439), pathological stage (OR: 1.628, 95% CI = 1.270–2.087), and risk for recurrence of prostate cancer (HR: 1.738, 95% CI = 1.264–2.390)." ;
    a m2r:Evidence .

civice:1742
    dct:references pbm:26359368 ;
    civico:citation "Garcia-Rendueles et al., 2015, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "NF2 loss promotes oncogenic RAS-signaling via YAP-dependent transactivation of RAS and sensitizes to MEK inhibition. The authors demonstrate this in (A) isogenic lines derived from C643 cells (HRASG13R, NF2-WT) modified to stably express shNF2, (B) in set of 7 RAS-mutant thyroid cancer cell lines that differ in their NF2 expression levels, and (C) in a Hras-G12V/Nf2-null mouse model." ;
    a m2r:Evidence .

civice:1743
    dct:references pbm:24373973 ;
    civico:citation "Patel et al., 2014, Cell Rep" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_JQ1Compound ;
    dcterms:description "BRD4 inhibition supressess growth and tumorigenesis of NF1-/-, TP53-/- MPNST cells in mouse xenografts" ;
    a m2r:Evidence .

civice:1744
    dct:references pbm:26621817 ;
    civico:citation "Cheng et al., 2015, Sci Rep" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A genome wide association study (GWAS) meta-analysis of 13,265 cancer cases (colorectal cancer and endometrial cancer) and 40,245 controls found this variant to be associated with colorectal cancer (OR = 1.10, P = 7.23 × 10−9). The authors speculated that since this polymorphism, a missense variant in the gene SH2B3, is also associated with haematological and autoimmune disorders, it might influence cancer risk through its role in the immune response." ;
    a m2r:Evidence .

civice:1745
    dct:references pbm:26674738 ;
    civico:citation "Sun et al., 2015, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "KIF23 variant 1 was found to be expressed in the cDNA of tumor tissues from a large cohort of HCC patients of chinese descent via PCR. This expression was absent in the normal tissues of these patients for this isoform. Using IHC and custom generated antibody, the overall survival with respect to KIF23 V1 expression was evaluated using the kaplan-meier method with a log rank test. It was found that positive KIF23 V1 staining was correlated with longer overall survival over a period of 5 years (p=.0052). This pattern was seen to a lesser degree over a period of 3 years (p=.1604). KIF23 V1 expression was independent of gender, age, tumor size, or TNM stage (multivariate cox regression)." ;
    a m2r:Evidence .

civice:1746
    dct:references pbm:27044931 ;
    civico:citation "Choudhury et al., 2016, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3." ;
    a m2r:Evidence .

civice:1747
    dct:references pbm:27044931 ;
    civico:citation "Choudhury et al., 2016, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3." ;
    a m2r:Evidence .

civice:1748
    dct:references pbm:27044931 ;
    civico:citation "Choudhury et al., 2016, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3." ;
    a m2r:Evidence .

civice:1749
    dct:references pbm:20818844 ;
    civico:citation "Flaherty et al., 2010, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib). Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. Patients without the V600E mutation had evidence of tumor regression." ;
    a m2r:Evidence .

civice:1750
    dct:references pbm:22663011 ;
    civico:citation "Flaherty et al., 2012, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "Patients who had histologically confirmed, unresectable stage IIIC or IV cutaneous melanoma with a V600E or V600K BRAF mutation were eligible for the study. 322 eligible patients (281 with the V600E mutation, 40 with the V600K mutation, and 1 with both mutations) in a 2:1 ratio to receive oral trametinib (2 mg once daily) or intravenous chemotherapy consisting of either dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter), at the discretion of the investigator, every 3 weeks. The primary end point was progression-free survival; secondary end points included overall survival, overall response rate, duration of response, and safety. Treatment continued until disease progression, death, or withdrawal from the study. In the intention-to-treat population, the median duration of progression-free survival was 4.8 months in the trametinib group as compared with 1.5 months in the chemotherapy group (hazard ratio for progression, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001).  The 6-month overall survival rate in the intention-to-treat population was 81% in the trametinib group and 67% in the chemotherapy group." ;
    a m2r:Evidence .

civice:1751
    dct:references pbm:26422378 ;
    civico:citation "Yuan et al., 2015, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "GADD45A (1506T>C) association with ovarian cancer was investigated with 258 ovarian cancer patients and 332 age matched healthy women as controls using sequence analysis. A significant difference in genotype distribution was observed between cases and controls  (TT vs. TC vs. CC, P = 0.0021). A statistically significant difference in the GADD454A (1506T>C) variant between the controls groups was found in correlation with an increased risk of ovarian cancer (P<0.001, OR = 1.71, 95% CI 1.28–2.29).  Presence of the GADD45A (1506T>C) variant was also found to have higher GADD45A mRNA expression, longer ovarian cancer relapse free survival and overall survival." ;
    a m2r:Evidence .

civice:1752
    dct:references pbm:3163261 ;
    civico:citation "Turc-Carel et al., 1988, Cancer Genet. Cytogenet." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A total of 85 unrelated cases of Ewing's sarcoma were examined and 83% we found to harbor the t(11;22)(q24;q12) chromosomal abnormality (EWS/FLI)." ;
    a m2r:Evidence .

civice:1753
    dct:references pbm:9741544 ;
    civico:citation "Park et al., 1998, J. Korean Med. Sci." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The authors propose RT-PCR as a diagnostic test for Ewing sarcoma using FFPE materials.  Starting with 40 cases, intact RNA could be isolated from 6, and of these the EWS-FLI event was detected in 2 by nested PCR. Alternative diagnostic assays for this event are also considered." ;
    a m2r:Evidence .

civice:1754
    dct:references pbm:16258512 ;
    civico:citation "Bridge et al., 2006, Mod. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "An evaluation of alternative strategies for detection of EWS-FLI (FISH break apart, FISH fusion, and RT-PCR).  Of the 22 informative EWS/PNETs, 20 cases (91%) were positive by FISH break apart, FISH fusion, or both." ;
    a m2r:Evidence .

civice:1756
    dct:references pbm:27819322 ;
    civico:citation "Wu et al., 2016, Sci Rep" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Study of 1817 PCa cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T  (and c.1298A>C ) of pancreatic cancer risk in a population of Han Chinese in Shanghai.  Results indicated a lower risk for the heterozygous CT genotype and homozygous TT genotype carriers of (MTHFR)c.677C>T  which had a significantly lower risk of developing pancreatic cancer compared with the wild-type CC genotype." ;
    a m2r:Evidence .

civice:1757
    dct:references pbm:26693073 ;
    civico:citation "Nikas et al., 2015, Am J Cancer Res" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_5-fluorouracil ;
    dcterms:description "Patients with the wild type (C/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and  3.25 times more likely not to experience relapse (95% CI: [1.37, 7.72]) than patients with the heterozygous  MTHFR [rs1801133 (C>T)] mutation or  the homzygous (T/T)." ;
    a m2r:Evidence .

civice:1758
    dct:references pbm:16088935 ;
    civico:citation "Teugels et al., 2005, Hum. Mutat." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "De novo Alu element insertions were identified within the BRCA2 coding sequences in 3 out of 50 Portuguese families. However, the segregation data and mRNA results in this study were conflicting or inconclusive." ;
    a m2r:Evidence .

civice:1759
    dct:references pbm:16088935 ;
    civico:citation "Teugels et al., 2005, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Likely Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a Portuguese family with 6 cases of breast cancer and 1 of ovarian cancer, a 46 year old woman was diagnosed with breast cancer. She was negative for BRCA1/2 mutations using standard methods but a Southern blot identified a ~350bp Alu element (AluYa5 subtype) insertion in exon 3. RT-PCR revealed exon 3 was excluded from the spliced transcript in this patient. Blood samples from 24 family members were collected and the Alu element was identified in the 3 with ovarian or breast cancer that had evaluable samples." ;
    a m2r:Evidence .

civice:1760
    dct:references pbm:26108461 ;
    civico:citation "Beebe-Dimmer et al., 2015, Cancer Epidemiol. Biomarkers Prev." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "B" ;
    dcterms:description "G84E (rs138213197) substitution in HOXB13 is associated with an increased risk for prostate cancer. 49 out of 9012 male patients in the Mayo Clinic Biobank were carriers. 31% of patients were diagnosed with cancer (n=2,595). Cancer diagnosis was more common in G84E carriers than in non-carriers (51.5% vs 30.6%, P = 0.004). G84E was highly prevalent in patients with prostate cancer than those without cancer (P < 0.0001). Evidence also supported a possible link between G84E with bladder cancer (P = 0.06) and leukemia (P = 0.01). Patient family history indicated a history of prostate cancer with a first degree relative was more common when compared to non-carriers (36.2% vs. 16.0%, P = 0.0003)." ;
    a m2r:Evidence .

civice:1761
    dct:references pbm:21177507 ;
    civico:citation "Bennett et al., 2010, JAMA" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "123 patients with Cowden or Cowden-like syndrome (from the IRB8458-PTEN series) and 50 unaffected individuals without PTEN variants were analyzed for germline methylation and expression of PTEN and KILLIN. 45 out of 123 patients (37%; 95% CI, 29%-45%) showed hypermethylation of the bidirectional promoter of PTEN and KILLIN. Individuals with KILLIN-promoter methylation had a 3-fold increased prevalence of breast cancer (35/42 vs 24/64; p<0.0001) over individuals with germline PTEN mutations." ;
    a m2r:Evidence .

civice:1762
    dct:references pbm:21177507 ;
    civico:citation "Bennett et al., 2010, JAMA" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "123 patients with Cowden or Cowden-like syndrome (from the IRB8458-PTEN series) and 50 unaffected individuals without PTEN variants were analyzed for germline methylation and expression of PTEN and KILLIN. 45 out of 123 patients (37%; 95% CI, 29%-45%) showed hypermethylation of the bidirectional promoter of PTEN and KILLIN. Individuals with KILLIN-promoter methylation had a greater than 2-fold increase of kidney cancer (4/45 vs 6/155; p=0.004) over individuals with germline PTEN mutations." ;
    a m2r:Evidence .

civice:1763
    dct:references pbm:17085664 ;
    civico:citation "Balak et al., 2006, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "D761Y as a secondary mutation was reported to be associated with resistance to gefitinib and erlotinib in NSCLC cells that contain the L858R-EGFR mutation. This mutation combination was observed in a single patient with lung cancer and specifically in a metastatic brain lesion following gefitinib treatment. Functional validation of its role in drug sensitivity was examined in cell lines (293T and Ba/F3 cells)." ;
    a m2r:Evidence .

civice:1764
    dct:references pbm:21172893 ;
    civico:citation "Burris et al., 2011, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_TrastuzumabEmtansine ;
    dcterms:description "In the single arm Phase II study (TDM4258g) breast cancer patients who had progressed on previous anti-HER2 therapy were given transtuzumab emtansine (T-DM1), a HER2 monoclonal antibody and antimicrotubule drug conjugate. 95 trial participants with archival primary tumor were reassessed for HER2 status (positivity defined by FISH or IHC 3+), and 74 patients were confirmed for HER2 positivity and 21 were normal. Overall response rate was 33.8% (95% CI, 23.2% to 44.9%) in patients with confirmed HER2-positive tumors and 4.8% (95% CI, 1.0% to 21.8%) in HER2 normal patients. Median PFS was 8.2 months (95% CI, 4.4 months to not estimable) in patients with confirmed HER2-positive tumors and 2.6 months (95% CI, 1.4 to 3.9 months) in HER2 normal patients." ;
    a m2r:Evidence .

civice:1765
    dct:references pbm:26715889 ;
    civico:citation "Gao et al., 2015, Curr Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Palbociclib%28PD0332991%29,civic:drug_Letrozole ;
    dcterms:description "A patient with metastatic ER-positive, her2-negative breast cancer with CDKN2A loss experienced a short-lived (~3-month) clinical response to palbociclib when given in combination with letrozole." ;
    a m2r:Evidence .

civice:1766
    dct:references pbm:23480694 ;
    civico:citation "Egan et al., 2013, Br. J. Haematol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Lenalidomide,civic:drug_Pomalidomide ;
    dcterms:description "A 37 year old, heavily pretreated (including thalidomide and lenalidomide) patient with IgG-kappa multiple myeloma was sequenced following extramedullary relapse. A high number of alterations were observed including 38 rearrangements, 35 translocations, 4 indels, and 271 nonsynonymous point mutations. Two mutations altering CRBN (Q99* and R283K), a gene previously described as being necessary for immunomodulatory drug response, were observed and thought to be responsible for resistance to the pomalidomide and dexamethasone treatment she received but failed to respond to following sequencing." ;
    a m2r:Evidence .

civice:1767
    dct:references pbm:22238366 ;
    civico:citation "Gozgit et al., 2012, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ponatinib ;
    dcterms:description "In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 value of 7 nmol/L." ;
    a m2r:Evidence .

civice:1768
    dct:references pbm:20165957 ;
    civico:citation "Qin et al., 2010, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Deep sequencing of TSC1 and TSC2 was performed on blood from a group of 38 sporadic Tuberous Sclerosis patients who had been previously studied with no mutation identified in TSC1 or TSC2. Five patients had readily observable mutations in these genes, one of which was a previously unidentified TSC1 missense change R1062W. The authors indicate that the mutation may not be pathogenic." ;
    a m2r:Evidence .

civice:1769
    dct:references pbm:26979979 ;
    civico:citation "Jelsig et al., 2016, Int J Colorectal Dis" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Pathogenic" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Retrospective analysis of the Danish tumor bank. 43 patients with Peutz-Jeghers Syndrome were identified (clinical criteria + STK11 mutations). STK11 mutations were detected in 86% of those tested (18 of 21 probands) and included eight nonsense mutations, five frameshift mutations, two splice site mutations, two large genomic rearrangements, and one missense mutation." ;
    a m2r:Evidence .

civice:1770
    dct:references pbm:26182309 ;
    civico:citation "Maddocks et al., 2015, JAMA Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Ibrutinib ;
    dcterms:description "In a trial of 308 patients with chronic lymphocytic leukemia treated with ibrutinib, 31 discontinued treatment due to disease progression (13 CLL progression, 18 Richter’s transformation). 11/13 patients were deep sequenced for BTK and PLCG2. 9 patients were identified with BTK mutations (C481S in 8 patients). In 5 patients, C481S was the sole abnormality." ;
    a m2r:Evidence .

civice:1771
    dct:references pbm:19366796 ;
    civico:citation "McDermott et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Sunitinib ;
    dcterms:description "In the sunitinib-sensitive adenosquamous NSCLC cell line, PDGFRA expression was associated with focal PFGRA gene amplification, which was similarly detected in a small fraction of squamous cell NSCLC primary tumor specimens. Moreover, in this NSCLC cell line, focal amplification of the gene encoding the PDGFR ligand PDGFC was also detected." ;
    a m2r:Evidence .

civice:1772
    dct:references pbm:21862407 ;
    civico:citation "Gelmon et al., 2011, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib." ;
    a m2r:Evidence .

civice:1773
    dct:references pbm:21862407 ;
    civico:citation "Gelmon et al., 2011, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib." ;
    a m2r:Evidence .

civice:1774
    dct:references pbm:24456122 ;
    civico:citation "Srinivas et al., 2014, Br. J. Haematol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A patient with monoblastic myeloid sarcoma harbouring a PCR confirmed FIP1L1-PDGFRA rearrangement was treated with imatinib monotherapy. The patient demonstrated a durable response (10 wks) while on therapy which was reversed when the patient discontinued treatment. Imatinib therapy was subsequently restarted, with peripheral blood and BM analyses returning to normal after 4 weeks." ;
    a m2r:Evidence .

civice:1775
    dct:references pbm:21862407 ;
    civico:citation "Gelmon et al., 2011, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib." ;
    a m2r:Evidence .

civice:1776
    dct:references pbm:21862407 ;
    civico:citation "Gelmon et al., 2011, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib." ;
    a m2r:Evidence .

civice:1777
    dct:references pbm:24407160 ;
    civico:citation "Sadovnik et al., 2014, Exp. Hematol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ponatinib ;
    dcterms:description "In a FIP1L1-PDGFRA positive eosinophil cell line growth-inhibitory effects were seen with all PDGFR-blocking agents, (ponatinib, sorafenib, masitinib, nilotinib, dasatinib, sunitinib, midostaurin) with ponatinib found to be the most potent compound." ;
    a m2r:Evidence .

civice:1778
    dct:references pbm:8637704 ;
    civico:citation "Panagopoulos et al., 1996, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Identified two cases of myxoid liposarcoma with translocations (between 12q13 and 22q12) giving rise to EWSR1-DDIT3 (EWS-CHOP) fusions instead of the more common FUS-DDIT3." ;
    a m2r:Evidence .

civice:1779
    dct:references pbm:24407160 ;
    civico:citation "Sadovnik et al., 2014, Exp. Hematol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ponatinib ;
    dcterms:description "Ba/F3 cells expressing two clinically relevant, imatinib-resistant, mutant forms of FIP1L1-PDGFRA, namely T674I and D842V were tested for growth inhibition by 8 PDGFR-blocking TKIs. Strong inhibitory effects on both mutants were seen only with ponatinib." ;
    a m2r:Evidence .

civice:1780
    dct:references pbm:26773740 ;
    civico:citation "Klughammer et al., 2016, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a meta-analysis of 7 clinical trials of erlotinib, 10/24 patients with Exon 18 mutations harbored a G719 variant. These variants were associated with improved progression-free and overall survival. No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies." ;
    a m2r:Evidence .

civice:1781
    dct:references pbm:20871596 ;
    civico:citation "Filippakopoulos et al., 2010, Nature" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_JQ1 ;
    dcterms:description "Treatment of the patient-derived 797 NMC cell line for 48 hours with JQ1 (500 nM)  provoked terminal differentiation which was accompanied by growth arrest and sustained inhibition of proliferation.  Non-BRD4-dependent cell lines including a squamous carcinoma cell line (TE10) failed to exhibit differentiation effects when treated with JQ1." ;
    a m2r:Evidence .

civice:1782
    dct:references pbm:26773740 ;
    civico:citation "Klughammer et al., 2016, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "Efficacy of erlotinib treatment was evaluated by meta-analysis of results from seven trials and literature review. Two patients with p.S270P, and one patient with p.S720F were observed to have poor survival outcomes." ;
    a m2r:Evidence .

civice:1783
    dct:references pbm:10383129 ;
    civico:citation "Griffin et al., 1999, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT." ;
    a m2r:Evidence .

civice:1784
    dct:references pbm:24098545 ;
    civico:citation "Lum et al., 2013, PLoS ONE" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Meta-analysis of 25 studies involving 13,629 women with tamoxifen treated breast cancer. The meta-analysis investigated the association between CYP2D6 genotypes and response to tamoxifen treatment (loss/reduced function vs. unchanged/increased function). The authors examine a prevailing hypothesis that individuals carrying a reduced function CYP2D6 allele have poorer outcomes due to less metabolism of tamoxifen to active metabolites. The study concludes that there is insufficient evidence to support use of CYP2D6 genotyping as a guide for tamoxifen use in breast cancer." ;
    a m2r:Evidence .

civice:1785
    dct:references pbm:1568170 ;
    civico:citation "Sreekantaiah et al., 1992, Cancer" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "The FUS-DDIT3 fusion is pathognomonic of myxoid liposarcomas.  It encompasses parts  of the FUS gene on l6pll at its 5’ end and the DDIT3 gene at 12q13 at its 3’ ends" ;
    a m2r:Evidence .

civice:1786
    dct:references pbm:26773740 ;
    civico:citation "Klughammer et al., 2016, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation K757R from the MERIT study. Progression-free (250 days) and overall (435 days) survival suggested sensitivity in this patient. Literature analysis did not identify additional reports of patients harboring this mutation." ;
    a m2r:Evidence .

civice:1787
    dct:references pbm:26773740 ;
    civico:citation "Klughammer et al., 2016, J Thorac Oncol" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation E746G from the BeTa study. Progression-free (415 days) and overall (462 days) survival suggested sensitivity in this patient. No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies." ;
    a m2r:Evidence .

civice:1788
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also harbored a MLH1 p.G606fs*2 mutation." ;
    a m2r:Evidence .

civice:1790
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in two patients was confirmed to be a somatic mutation in both patients' microsatellite-unstable tumors (one endometrial cancer, one ovarian cancer) with suspected Lynch Syndrome (LS). These patients were therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. LOH of the WT allele was confirmed in the case of ovarian cancer." ;
    a m2r:Evidence .

civice:1791
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a patient with suspected Lynch syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting." ;
    a m2r:Evidence .

civice:1792
    dct:references pbm:26313268 ;
    civico:citation "Goey et al., 2016, J Clin Pharmacol" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Adverse Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Belinostat ;
    dcterms:description "The FDA approved package insert for Belinostat recommends dose adjustment for UGT1A1*28 allele homozygotes." ;
    a m2r:Evidence .

civice:1793
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also harbored a MLH1 p.E13fs*3 mutation." ;
    a m2r:Evidence .

civice:1794
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also harbored a p.K618del mutation." ;
    a m2r:Evidence .

civice:1795
    dct:references pbm:26313268 ;
    civico:citation "Goey et al., 2016, J Clin Pharmacol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Adverse Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Belinostat ;
    dcterms:description "In a phase 1 trial belinostat (400-800mg/m2/24h) was administered to 25 patients in combination with cisplatin and etoposide. Endpoints were associations between genotype of UGT1A1 and pharmacokinetics, toxicities and proteine lysine acetylation. Belinostat AUC and half-life was significantly increased in UGT1A1*60 carriers, and they were at greater risk for thrombocytopenia." ;
    a m2r:Evidence .

civice:1796
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in two cases of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Both patients harbored a second MLH1 mutation (c.790+1G > A and p.M1L, respectively)." ;
    a m2r:Evidence .

civice:1798
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was demonstrated. Patient also had a BRAF p.D594G mutation." ;
    a m2r:Evidence .

civice:1799
    dct:references pbm:26773740 ;
    civico:citation "Klughammer et al., 2016, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "Although EGFR exon 20 insertions may confer reduced sensitivity to erlotinib, patients with this particular mutation appeared to benefit from therapy." ;
    a m2r:Evidence .

civice:1800
    dct:references pbm:23988873 ;
    civico:citation "Caudle et al., 2013, Clin. Pharmacol. Ther." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Adverse Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_5-FU,civic:drug_Tegafur,civic:drug_Capecitabine ;
    dcterms:description "The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population." ;
    a m2r:Evidence .

civice:1801
    dct:references pbm:23988873 ;
    civico:citation "Caudle et al., 2013, Clin. Pharmacol. Ther." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Adverse Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_5-FU,civic:drug_Capecitabine,civic:drug_Tegafur ;
    dcterms:description "The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population." ;
    a m2r:Evidence .

civice:1802
    dct:references pbm:26173738 ;
    civico:citation "van IJzendoorn et al., 2015, Genes Chromosomes Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "FOS was found fused  with 3 different genes in 3 cases of bone epithelioid hemangioma. The fusion partners were not recurrent, respectively MBNL1, VIM and a lincRNA.  The truncation of the FOS gene would result in the loss of the transactivation domain (TAD) in all three cases." ;
    a m2r:Evidence .

civice:1803
    dct:references pbm:23988873 ;
    civico:citation "Caudle et al., 2013, Clin. Pharmacol. Ther." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Adverse Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_5-FU,civic:drug_Capecitabine,civic:drug_Tegafur ;
    dcterms:description "The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population." ;
    a m2r:Evidence .

civice:1804
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was confirmed." ;
    a m2r:Evidence .

civice:1805
    dct:references pbm:21584898 ;
    civico:citation "Errani et al., 2011, Genes Chromosomes Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Performed a systematic molecular analysis of 17 epithelioid hemangioendothelioma (EHE) and compared to 13 epithelioid hemangiomas, five epithelioid angiosarcomas, and four epithelioid sarcoma-like EHE. A FISH positional cloning strategy, and RT-PCR analysis identified WWTR1-CAMTA1 in all EHE cases and none of the other benign or malignant epithelioid vascular tumors examined." ;
    a m2r:Evidence .

civice:1806
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in three cases of microsatellite-unstable colorectal cancer was confirmed to be somatic in patients with suspected Lynch Syndrome (LS). The patients were therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Two patients had loss of heterozygosity effecting the wildtype allele while one patient harbored a second MLH1 mutation (p.I68S)." ;
    a m2r:Evidence .

civice:1807
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a patient with suspected Lynch syndrome (LS). The patient was therefore negative for LS. However, based on this study, we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was demonstrated." ;
    a m2r:Evidence .

civice:1808
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. The patient also harbored a second MLH1 mutation (p.D667fs) which demonstrated loss of heterozygosity." ;
    a m2r:Evidence .

civice:1809
    dct:references pbm:26051236 ;
    civico:citation "Yang et al., 2015, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In retrospective analysis of trials, afatinib conferred limited clinical benefit to patients with EGFR exon 20 insertion mutations (N=23). Only 2 patients had objective responses." ;
    a m2r:Evidence .

civice:1810
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity leading to primarily the D667fs allele detected (90% VAF). This patient also harbored a heterozygous p.V49A variant." ;
    a m2r:Evidence .

civice:1811
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity resulting in overrepresentation of the M1L allele was observed. Additionally, this patient harbored a heterozygous MLH1 p.K618del mutation." ;
    a m2r:Evidence .

civice:1812
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable villous adenomas was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. The patient also harbored an MLH1 c.453+1G > A mutation." ;
    a m2r:Evidence .

civice:1813
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was demonstrated." ;
    a m2r:Evidence .

civice:1814
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in two cases of microsatellite-unstable colorectal cancer was confirmed to be somatic in both patients with suspected Lynch Syndrome (LS). The patients were therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting." ;
    a m2r:Evidence .

civice:1815
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting." ;
    a m2r:Evidence .

civice:1816
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Patient also harbored a BRAF V600E mutation." ;
    a m2r:Evidence .

civice:1817
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also harbored MLH1 p.R226* and MSH6 p.I972F mutations at similar variant allele frequencies." ;
    a m2r:Evidence .

civice:1818
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also harbored MLH1 p.Q149* and MSH6 p.I972F mutations as similar variant allele frequencies." ;
    a m2r:Evidence .

civice:1820
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was demonstrated resulting in higher mutated allele representation (80% variant allele frequency)." ;
    a m2r:Evidence .

civice:1821
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was demonstrated." ;
    a m2r:Evidence .

civice:1822
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity leading to  p.I68S at 77% variant allele frequency was demonstrated. The patient also harbored a heterozygous MLH1 p.T117M mutation (38% VAF)." ;
    a m2r:Evidence .

civice:1823
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also had loss of heterozygosity." ;
    a m2r:Evidence .

civice:1824
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity (wildtype allele loss) was also demonstrated." ;
    a m2r:Evidence .

civice:1825
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting." ;
    a m2r:Evidence .

civice:1826
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting.  LOH of the WT allele was demonstrated." ;
    a m2r:Evidence .

civice:1827
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (LS). This patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient had two pathogenic mutations in MSH2 (E28fs, K172*)." ;
    a m2r:Evidence .

civice:1828
    dct:references pbm:10408776 ;
    civico:citation "Gallou et al., 1999, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "In a 54 year old male patient with sporadic renal cell carcinoma, a c.163_164delGA causing a p.Glu55 Stop at 130 frameshift mutation was observed. Loss of heterozygosity analysis was non-informative. Since this is a somatic variant, albeit with likely functional effect, we can only infer that if observed in a germline context, it might predispose for VHL." ;
    a m2r:Evidence .

civice:1829
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting." ;
    a m2r:Evidence .

civice:1830
    dct:references pbm:8956040 ;
    civico:citation "Zbar et al., 1996, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "This is a frameshift mutation that results in a stop at codon 66.   Family 3682 in this publication, variant segregates with disease.  VHL Type 1 disease is reported: CNS tumors, retinal angioma, renal cell carcinoma but no pheochromocytoma" ;
    a m2r:Evidence .

civice:1831
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting." ;
    a m2r:Evidence .

civice:1833
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant may predispose to LS in a germline setting. The patient also harbored PMS2 R315*, MSH2 p.E483G and MSH6 p.V352I mutations." ;
    a m2r:Evidence .

civice:1834
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient had two somatic pathogenic mutations in MSH2 (E28fs, K172*)." ;
    a m2r:Evidence .

civice:1835
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "B" ;
    dcterms:description "c.164insG causes a framehift and truncation allele. One family is described with this allele segregating with disease; 10 affected individuals: 2  patients with renal cell carcinoma, 3 with pheochromocytoma, 7 with retinal angioma, 3 with central nervous system hemangioma. ACMG evidence codes supported by this paper are possibly PVS1 and PP1." ;
    a m2r:Evidence .

civice:1836
    dct:references pbm:27626483 ;
    civico:citation "Zhang et al., 2016, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Meta-analysis of prostate cancer with sixteen case-control studies including 50,048 cases and 123,211 controls.  In a random effect model the pooled OR (3.38 (95% CI: 2.45–4.66)) of the studies supported the link between HOXB13 G84E variant and a susceptibility to prostate cancer." ;
    a m2r:Evidence .

civice:1837
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting." ;
    a m2r:Evidence .

civice:1838
    dct:references pbm:25658984 ;
    civico:citation "Chalmers et al., 2015, Blood Cancer J" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A patient harbouring a novel TNKS2–PDGFRA fusion in a myeloid neoplasm with eosinophilia demonstrated a dramatic and durable response upon treatment with Imatinib mono therapy." ;
    a m2r:Evidence .

civice:1839
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting." ;
    a m2r:Evidence .

civice:1840
    dct:references pbm:25111426 ;
    civico:citation "Geurts-Giele et al., 2014, J. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting." ;
    a m2r:Evidence .

civice:1841
    dct:references pbm:23652803 ;
    civico:citation "Radtke et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Adverse Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Methotrexate ;
    dcterms:description "499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 rs4149056 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity." ;
    a m2r:Evidence .

civice:1842
    dct:references pbm:23652803 ;
    civico:citation "Radtke et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Adverse Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Methotrexate ;
    dcterms:description "499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 RS2306283 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity." ;
    a m2r:Evidence .

civice:1843
    dct:references pbm:23652803 ;
    civico:citation "Radtke et al., 2013, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Adverse Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Methotrexate ;
    dcterms:description "499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The TYMS rs34743033 tandem repeat polymorphism was the only significant predictor of stomatitis in a multiple regression model considering sex, age, MRD class, WBC, MTX AUC0-48h, and genotypes as independent variables (B = −0.48; 95% CI, −0.84, −0.12; R2 = 0.018; P = .009)" ;
    a m2r:Evidence .

civice:1844
    dct:references pbm:15555571 ;
    civico:citation "Dahlén et al., 2004, Biochem. Biophys. Res. Commun." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Pericytoma with t(7;12) is a soft tissue tumor characterized by fusion of the ACTB and GLI genes through the translocation t(7;12)(p22;q13). In this study the genomic breakpoints of 5 cases were characterized." ;
    a m2r:Evidence .

civice:1845
    dct:references pbm:26689995 ;
    civico:citation "Umelo et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Afatinib,civic:drug_Pertuzumab ;
    dcterms:description "Case report on a novel V855A mutation located in exon 21 of the HER3 tyrosine kinase domain and found in the tumor specimen of an adolescent patient with a chemotherapy-resistant advanced NSCLC. Protein alignments indicated this mutation was analogous to EGFR-L858R and BRAF-L597V. Co-expression of wildtype HER2 and HER3-V855A in Ba/F3 cells led to sensitivity to afatinib and pertuzumab." ;
    a m2r:Evidence .

civice:1846
    dct:references pbm:24122810 ;
    civico:citation "Arai et al., 2014, Hepatology" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%)." ;
    a m2r:Evidence .

civice:1847
    dct:references pbm:24122810 ;
    civico:citation "Arai et al., 2014, Hepatology" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%)." ;
    a m2r:Evidence .

civice:1848
    dct:references pbm:16307009 ;
    civico:citation "Chim et al., 2006, Leukemia" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This study analyses 45 new acute promyelocytic leukemia patients (22 male and 23 female). CDKN2B was found to be a negative prognostic biomarker for disease free survival (DFS). The 5-year DFS was 9.6% in methylated and 62.5% in unmethylated samples. While methylation also associated with young age, a multivariate analysis found CDKN2B methylation to be the only independent marker with significance (P=0.008) for DFS." ;
    a m2r:Evidence .

civice:1850
    dct:references pbm:26629066 ;
    civico:citation "Wang et al., 2015, Int J Clin Exp Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Meta-analysis linking CHEK2 1100delC to a higher risk of prostate cancer (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00)." ;
    a m2r:Evidence .

civice:1851
    dct:references pbm:24122810 ;
    civico:citation "Arai et al., 2014, Hepatology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PD173074,civic:drug_BGJ398 ;
    dcterms:description "Expression of the FGFR2-BICC1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074." ;
    a m2r:Evidence .

civice:1852
    dct:references pbm:26629066 ;
    civico:citation "Wang et al., 2015, Int J Clin Exp Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Meta-analysis of 4 retrospective studies linked CHEK2 I157T to a higher risk of prostate cancer (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00)." ;
    a m2r:Evidence .

civice:1853
    dct:references pbm:24122810 ;
    civico:citation "Arai et al., 2014, Hepatology" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BGJ398,civic:drug_PD173074 ;
    dcterms:description "Expression of the FGFR2-AHCYL1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074." ;
    a m2r:Evidence .

civice:1854
    dct:references pbm:26629066 ;
    civico:citation "Wang et al., 2015, Int J Clin Exp Med" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Meta-analysis of 2 studies of CHEK2 and prostate cancer showing that the IVS2+1G>A mutation is irrelevant as a predictor of prostate cancer." ;
    a m2r:Evidence .

civice:1856
    dct:references pbm:23800680 ;
    civico:citation "Jiang et al., 2013, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cixutumumab,civic:drug_R1507 ;
    dcterms:description "Report of complete response to IGF1-R antibody, with or without mTOR inhibitor tensirolimus in 2/3 Ewing Sarcoma patients with germline PTPRD mutations (V253I and W775*, R995C). The third patient had stable disease (T781A mutant). Four wildtype patients had stable or progressive disease." ;
    a m2r:Evidence .

civice:1857
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A variants resulting in A56G frameshift (with stop introduced at position 131) was observed in a single patient of a VHL family. (family #146 in the publication). Neither the VHL phenotype details or segregation data were provided by this publication. Since this is a frameshift occurring early in the protein sequence we can assign an ACMG evidence code of 'PVS1'." ;
    a m2r:Evidence .

civice:1858
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "c.165G>A results in synonymous change Glu55Glu. This is family V5 in the paper (VHL Type 1, no phechromocytoma)." ;
    a m2r:Evidence .

civice:1859
    dct:references pbm:17224927 ;
    civico:citation "Nakano et al., 2007, Br. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gemcitabine ;
    dcterms:description "The mRNA expression level of RRM1 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines cultured in incrementally increased concentrations of gemcitabine. Expression levels of RRM1 progressively increased during the development of gemcitabine resistance." ;
    a m2r:Evidence .

civice:1860
    dct:references pbm:17224927 ;
    civico:citation "Nakano et al., 2007, Br. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gemcitabine ;
    dcterms:description "The mRNA expression level of RRM2 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines  cultured in incrementally increased concentrations of gemcitabine. Expression levels of RRM2 progressively increased during the development of gemcitabine resistance." ;
    a m2r:Evidence .

civice:1861
    dct:references pbm:27683556 ;
    civico:citation "Johanns et al., 2016, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pembrolizumab ;
    dcterms:description "Case report of a patient with glioblastoma multiforme and POLE germline mutation. The patient was treated with pembrolizumab and lymphocyte infiltration was noted after resection of a spinal metastasis. An objective radiographic response was noted in the intracranial lesion. A high neoantigen load was identified." ;
    a m2r:Evidence .

civice:1862
    dct:references pbm:27159395 ;
    civico:citation "Mehnert et al., 2016, J. Clin. Invest." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pembrolizumab ;
    dcterms:description "Case report of a patient with endometrial cancer and exceptional response to pembrolizumab (maintained at 14 months). POLE mutations V411L (exonuclease domain) and R114* were identified in the primary tumor as well as a resected lymph node metastasis. The tumor harbored a high mutational load as assessed by panel sequencing. Analysis of TCGA RNA-seq data revealed an association between POLE mutations and high immune marker expression." ;
    a m2r:Evidence .

civice:1863
    dct:references pbm:24035188 ;
    civico:citation "Sun et al., 2013, Lung Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01)." ;
    a m2r:Evidence .

civice:1864
    dct:references pbm:27694386 ;
    civico:citation "Bahcall et al., 2016, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cabozantinib ;
    dcterms:description "Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months)." ;
    a m2r:Evidence .

civice:1865
    dct:references pbm:27694386 ;
    civico:citation "Bahcall et al., 2016, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Savolitinib ;
    dcterms:description "Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months)." ;
    a m2r:Evidence .

civice:1866
    dct:references pbm:26802149 ;
    civico:citation "Dowlati et al., 2016, Ann. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Chemotherapy ;
    dcterms:description "Study evaluated a total of 50 small cell lung cancer patients with extensive stage disease. Multivariate analysis identified RB1 as a factor in predicting response to first-line chemotherapy (odds ratio 5.58 compared to WT, p=.038). Kaplan-Meier survival analysis revealed patients with RB1 mutations exhibited better overall survival (p = .04, 11.7 versus 9.1 months, CI = 1.1-28.2)." ;
    a m2r:Evidence .

civice:1867
    dct:references pbm:27959700 ;
    civico:citation "Mok et al., 2016, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Osimertinib ;
    dcterms:description "Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001)." ;
    a m2r:Evidence .

civice:1868
    dct:references pbm:26565381 ;
    civico:citation "Farago et al., 2015, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "In 1378 cases of NSCLC screened for NTRK1 rearrangements, 2 were identified (frequency 0.1%). One patient with SQSTM1-NTRK1 was treated with entrectinib in a phase 1 study. The patient had resolution of prior dyspnea and pain within 3 weeks. CT scans showed a partial response and complete resolution of brain metastases. The patient has continued treatment for over 6 months with ongoing PR." ;
    a m2r:Evidence .

civice:1869
    dct:references pbm:26884591 ;
    civico:citation "Drilon et al., 2016, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression." ;
    a m2r:Evidence .

civice:1870
    dct:references pbm:26884591 ;
    civico:citation "Drilon et al., 2016, Ann. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with crizotinib and had stable disease but disease progression after 18 weeks. The patient was subsequently treated with entrectinib and exhibited a partial response for 7 months followed by disease progression." ;
    a m2r:Evidence .

civice:1871
    dct:references pbm:11830488 ;
    civico:citation "Michaud et al., 2002, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A pedigree of 48 individuals with multiple instances of bleeding and platelet disorders and 8 cases of leukemia showed an A>G substitution in RUNX1 exon 3 which segregated with Familial Platelet Disorder and Acute Myeloid Leukemia. The mutation was not present in 188 unrelated control chromosomes. Functional assay suggested the mutant RUNX1 transcription factor had impaired DNA binding." ;
    a m2r:Evidence .

civice:1872
    dct:references pbm:11830488 ;
    civico:citation "Michaud et al., 2002, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A pedigree (Pedigree number 3) with 24 members with multiple instances of bleeding disorder and three cases of familial leukemia showed a C>A substitution in exon 7B of the transcription factor RUNX1.  This mutation resulted in a nonsense mutation, and the mutation segregated with familial platelet disorder and acute myeloid leukemia in the pedigree." ;
    a m2r:Evidence .

civice:1873
    dct:references pbm:11830488 ;
    civico:citation "Michaud et al., 2002, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Likely Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A pedigree (Pedigree number 2) with familial platelet disorder and acute myeloid leukemia (FPD/AML) was studied and a one-base deletion was found in RUNX1 splice donor site. This resulted in use of a cryptic donor splice site and a novel transcript with frameshift, 41 novel amino acids and termination at codon 177. This mutation segregated with FDP/AML and was not found in 184 unrelated control chromosomes." ;
    a m2r:Evidence .

civice:1874
    dct:references pbm:26884591 ;
    civico:citation "Drilon et al., 2016, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.  A NTRK3 exon 16 G623R (c.1867G>A) mutation was identified in the progressive tumor. Cell line and structural models revealed that this mutation conferred relative resistance to entrectinib." ;
    a m2r:Evidence .

civice:1875
    dct:references pbm:11675361 ;
    civico:citation "Buijs et al., 2001, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a pedigree with familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) spanning three generations, five members of generation II were sequenced at exons 3, 4 and 5 of the RUNX1 (or CBFA2) gene and the D198Y mutation (in the DNA binding RUNT domain) was found in 3/5 of the individuals with FPD/AML but not in 2/5 without FPD/AML. The mutation was not found in 108 control subjects." ;
    a m2r:Evidence .

civice:1876
    dct:references pbm:12060124 ;
    civico:citation "Walker et al., 2002, Br. J. Haematol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A pedigree of 3 generations and 8 individuals with familial platelet disease with propensity to acute myeloid leukemia (FPD/AML) was assessed for mutation in RUNX1 exons 3, 4, 5 and 6. Mutation was found in DNA binding RUNT domain at amino acid 107 from alanine to proline. This mutation was found in 5/8 individuals with FPD/AML but not in 3/8 unaffected individuals as well as 10 unrelated control samples." ;
    a m2r:Evidence .

civice:1877
    dct:references pbm:26674132 ;
    civico:citation "Castro et al., 2015, J Immunother Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_MEDI0680,civic:drug_MEDI4736 ;
    dcterms:description "Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells.  The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months." ;
    a m2r:Evidence .

civice:1878
    dct:references pbm:26674132 ;
    civico:citation "Castro et al., 2015, J Immunother Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_MEDI4736,civic:drug_MEDI0680 ;
    dcterms:description "Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells. The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months." ;
    a m2r:Evidence .

civice:1879
    dct:references pbm:27286459 ;
    civico:citation "Murakami et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib,civic:drug_Linsitinib ;
    dcterms:description "A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin. Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by authors as failing to control tumor growth." ;
    a m2r:Evidence .

civice:1880
    dct:references pbm:27286459 ;
    civico:citation "Murakami et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib,civic:drug_Linsitinib ;
    dcterms:description "A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin. Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by authors as failing to control tumor growth." ;
    a m2r:Evidence .

civice:1881
    dct:references pbm:25852058 ;
    civico:citation "Eilers et al., 2015, Mol. Cancer Ther." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib ;
    dcterms:description "An imatinib-resistant cell line, DFSP105, was established from a dermatofibrosarcoma protuberans which had progressed to a high-grade fibrosarcomatous DFSP. The disease-associated PDGFB-COL1A1 fusion was consistent with the most common form, a supernumerary ring chromosome. Genetic characterization of the cell line with a SNP array identified a homozygous CDKN2A/B deletion. Treatment of this cell line with CDK4/6 inhibitor palbociclib led to growth inhibition and reduced RB1 phosphorylation in vitro and in-vivo." ;
    a m2r:Evidence .

civice:1882
    dct:references pbm:18478040 ;
    civico:citation "Béri-Dexheimer et al., 2008, Eur. J. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A 2 year old male presented with easy bruising and bleeding. At 6 years old he was diagnosed with AML. The patients mother showed mile thrombocytopenia. Sequencing of RUNX1 exons 3-6 revealed an 8 bp deletion which was hypothesized to result in a null allele. The mutation was found in the mother and son. The patient's maternal grandparents were haematologicaly  normal. Relevant ACMG codes from this paper are 'PVS1' (frameshift/null variant) and 'PP1' (limited segregation data)." ;
    a m2r:Evidence .

civice:1887
    dct:references pbm:26712909 ;
    civico:citation "Lewinsohn et al., 2016, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Eight members of larger pedigree spanning four generations with inherited hematological cancers were sequenced with whole exome sequencing or sanger sequencing of DDX41 exons 5 and 6. A mutation c.490C>T or R164W was found in 5/5 members with Non Hodkin's lymphoma, Hodgkin lymphoma, or multiple myeloma but not in 3/3 unaffected individuals. The site of mutation is reported to potentially be important for DDX41 helicase activity." ;
    a m2r:Evidence .

civice:1888
    dct:references pbm:22325357 ;
    civico:citation "De Grève et al., 2012, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with Y772_A775dup (Case 1 in the paper), maintained a metabolic complete response for 3 months, ultimately received a total of 9 months of Afatinib, and survived one year from study entry." ;
    a m2r:Evidence .

civice:1889
    dct:references pbm:22325357 ;
    civico:citation "De Grève et al., 2012, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with G776L (Case 2 in the paper) achieved a partial response after two months of afatinib (50 mg/day). The time to progression of this single agent was four months. The patient was also noted to have a EGFR kinase domain (exon 21: p.Ala859Thr) mutation." ;
    a m2r:Evidence .

civice:1890
    dct:references pbm:22325357 ;
    civico:citation "De Grève et al., 2012, Lung Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with G778_P780dup (Case 3 in the paper), had a rapid clinical and symptomatic response to Afatinib and stable disease which lasted for 3 months. Progressive disease at 4 months led to the addition of paclitaxel, resulting in partial response. Total Afatinib treatment was 15 months (11 in combination) at which time the patient developed a brain metastasis but no other progressive disease." ;
    a m2r:Evidence .

civice:1891
    dct:references pbm:25899785 ;
    civico:citation "Kris et al., 2015, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dacomitinib ;
    dcterms:description "Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. 4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a response." ;
    a m2r:Evidence .

civice:1892
    dct:references pbm:25899785 ;
    civico:citation "Kris et al., 2015, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dacomitinib ;
    dcterms:description "Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. Two patients were identified with identical HER2 p.G778_P780dup mutations (p. P780_Y781insGSP, c. 2339_2340ins GGCTCCCCA) and no amplification. Both had a confirmed partial response lasting 11 and 14 months. Only 3/30 patients on this trial had a partial response (no complete responses)." ;
    a m2r:Evidence .

civice:1893
    dct:references pbm:25899785 ;
    civico:citation "Kris et al., 2015, Ann. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dacomitinib ;
    dcterms:description "Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). Thirteen tumors harbored identical 12 base pair exon 20 insertions [A775_G776insYVMA, alternative nomenclature p.Y772_A775dup(c.2313_2324dup)]. No partial responses were found in this subgroup even though some were on study treatment for >2 years and 3 patients with other HER2 mutations achieved PRs." ;
    a m2r:Evidence .

civice:1894
    dct:references pbm:25899785 ;
    civico:citation "Kris et al., 2015, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dacomitinib ;
    dcterms:description "Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). One patient was found to harbor a unique Exon 20 indel (p. M774delinsWLV, c.2320A>TGGCT GG; p. M774delinsWLV, c.2320delins TGGCTGG) and was among the three patients that had a partial response." ;
    a m2r:Evidence .

civice:1895
    dct:references pbm:24633157 ;
    civico:citation "Behjati et al., 2014, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Sunitinib ;
    dcterms:description "The endothelial phosphatase PTPRB, a negative regulator of vascular growth factor tyrosine kinases, harbored truncating mutations in 10 of 39 angiosarcomas (26%) which correlated with MYC amplifications. In HUVEC cell line model, silencing of PTPRB  induced features of angiogenesis which were abolished in the presence of sunitinib or vatalinib, inhibitors of VEGFR." ;
    a m2r:Evidence .

civice:1896
    dct:references pbm:9435426 ;
    civico:citation "Atuk et al., 1998, J. Clin. Endocrinol. Metab." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Study of a large kindred with von Hippel-Lindau disease (VHLD) and pheochromocytoma (spread over four generations). 25 proven cases of VHLD and 17 cases with pheochromocytoma were identified. Mutation analysis was performed in 14 family members (7 affected, 7 unaffected).  11 cases had the same mutation resulting in a predicted amino acid substitution of A149S.  The cases with mutation that appeared unaffected were all very young (before the likely age of onset). The three cases without the mutation that appeared unaffected were aged 18, 54, and 69.  ACMG evidence codes: 'PP1' based on segregation results, 'PM5' because the authors describe a prior report of a similar mutation at the same site (A149T), 'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease, and 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology." ;
    a m2r:Evidence .

civice:1897
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor Rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA mutant patients, 10 had somatic BRCA1 mutation. Confirmed objective response was seen in 79% of the BRCA1 mutant subgroup, and 74% confirmed objective response was seen in the somatic BRCA mutant subgroup. In a BRCA wild-type subgroup, with low levels of Loss of Heterozygosity, confirmed objective response was observed in 10% of the patients." ;
    a m2r:Evidence .

civice:1898
    dct:references pbm:27959684 ;
    civico:citation "Tran et al., 2016, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_AdoptiveT-cellTransfer ;
    dcterms:description "A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D. All 7 metastatic lung lesions regressed 40 days after therapy, and the patient had a 9-month partial response." ;
    a m2r:Evidence .

civice:1899
    dct:references pbm:27959684 ;
    civico:citation "Tran et al., 2016, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_AdoptiveT-cellTransfer ;
    dcterms:description "A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D and HLA-C*08:02. A single lesion that progressed after 9 months still expressed the KRAS G12D mutation. Whole-exome analysis revealed copy-neutral loss of heterozygosity at chromosome 6, encoding the HLA locus and resulting in loss of the targeted HLA-C*08:02 allele." ;
    a m2r:Evidence .

civice:1900
    dct:references pbm:26701727 ;
    civico:citation "Yang et al., 2016, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ruxolitinib ;
    dcterms:description "A JAK1 S703I mutation was found to activate the JAK-STAT signaling pathway in vitro and in vivo in hepatocellular carcinoma. Ruxolitinib causes the suppression of JAK-STAT signaling pathway in PDX models bearing JAK1 S703I mutation and delays tumor progression." ;
    a m2r:Evidence .

civice:1901
    dct:references pbm:21309036 ;
    civico:citation "Kuiper et al., 2011, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Rare but recurring germline truncating mutations of the 3’ end of EPCAM, were reported for 27 independent families, shown to lead to epigenetic silencing of a neighbouring gene, MSH2, and suggested to cause Lynch syndrome." ;
    a m2r:Evidence .

civice:1902
    dct:references pbm:27729313 ;
    civico:citation "Hong et al., 2016, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Irinotecan,civic:drug_Vemurafenib ;
    dcterms:description "Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 with appendiceal cancer). Six of 17 evaluable patients achieved an objective response, 15 patients total had either stable disease or radiographic response (the patient with appendiceal cancer had disease progression). Estimated median PFS was 7.7 months. Effect of the combined treatment was also observed in xenograft and cell line studies." ;
    a m2r:Evidence .

civice:1905
    dct:references pbm:27729313 ;
    civico:citation "Hong et al., 2016, Cancer Discov" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib,civic:drug_Irinotecan,civic:drug_Cetuximab ;
    dcterms:description "Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient had an acquired ARAF S490T mutation that was not identified before treatment initiation." ;
    a m2r:Evidence .

civice:1906
    dct:references pbm:27729313 ;
    civico:citation "Hong et al., 2016, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib,civic:drug_Cetuximab,civic:drug_Irinotecan ;
    dcterms:description "Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient acquired a novel GNAS1 R201C mutation at disease progression." ;
    a m2r:Evidence .

civice:1907
    dct:references pbm:20124459 ;
    civico:citation "Williamson et al., 2010, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Two ATM deficient mantle cell lymphoma (MCL) cell lines were more sensitive to PARP-1 inhibition with olaparib or PJ-34 than 4 other MCL cell lines. shRNA mediated ATM knockdown in a cell line increased sensitivity to olaparib. These results were confirmed in a xenograft model." ;
    a m2r:Evidence .

civice:1908
    dct:references pbm:27870574 ;
    civico:citation "Nogova et al., 2017, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_BGJ398 ;
    dcterms:description "Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. In the subgroup of FGFR1-amplified NSCLC, 36 patients were treated at doses >100mg and disease control was achieved in 50% of patients (4 PR and 14 SD) with 6 patients receiving treatment after 16 weeks." ;
    a m2r:Evidence .

civice:1909
    dct:references pbm:27870574 ;
    civico:citation "Nogova et al., 2017, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_BGJ-398 ;
    dcterms:description "Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among the 26 patients with breast cancer and FGFR1/2 amplification (n=25,  n= 21 with FGFR1 amplification only) or FGFR3 mutation (n=1) four (15.4%) had a reduced tumor burden. In total, 10 of 32 patients with breast cancer treated at doses >100mg had a best response of SD." ;
    a m2r:Evidence .

civice:1910
    dct:references pbm:27870574 ;
    civico:citation "Nogova et al., 2017, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_BGJ-398 ;
    dcterms:description "Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. In the subgroup of eight patients with FGFR3-mutated bladder/urothelial cancer treated at doses ≥ 100 mg, the disease control rate (SD + PR) was 75%. 3 patients achieved PRs and 3 patients had SD. Of the six patients with disease control, the time on treatment ranged from 15.1 to ≥ 101 weeks, with one ongoing at data cutoff." ;
    a m2r:Evidence .

civice:1911
    dct:references pbm:27870574 ;
    civico:citation "Nogova et al., 2017, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_BGJ-398 ;
    dcterms:description "Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. One patient with FGFR1 amplified bladder/urothelial carcinoma was treated with 125 mg and progressed rapidly in cycle 1 after 11 days of treatment." ;
    a m2r:Evidence .

civice:1912
    dct:references pbm:27870574 ;
    civico:citation "Nogova et al., 2017, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_BGJ-398 ;
    dcterms:description "Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among three patients with cholangiocarcinoma and FGFR2 aberrations (2 fusions, 1 mutation), all three had stable disease with a reduced tumor burden." ;
    a m2r:Evidence .

civice:1913
    dct:references pbm:27870574 ;
    civico:citation "Nogova et al., 2017, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_BGJ-398 ;
    dcterms:description "Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among three patients with cholangiocarcinoma and FGFR2 aberrations (2 fusions, 1 mutation), all three had stable disease with a reduced tumor burden." ;
    a m2r:Evidence .

civice:1914
    dct:references pbm:8187067 ;
    civico:citation "Shuin et al., 1994, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "A study of sporadic renal cell carcinoma identified this frameshift confirmed somatic variant along with LOH of the VHL gene in a case with clear cell renal carcinoma (case #152 in the study). VHL mutated clear cell carcinoma is associated with Von Hippel-Lindau Disease. Confidence in this variant being pathogenic for VHL disease is not high enough to warrant classification of Likely Pathogenic, and is therefore classified as Uncertain Significance." ;
    a m2r:Evidence .

civice:1917
    dct:references pbm:26324363 ;
    civico:citation "Tabernero et al., 2015, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_JNJ-42756493 ;
    dcterms:description "Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without known FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. In patients with FGFR2-BICC1 fusions, 1 patient with urothelial cancer harboring FGFR2-BICC1/FGFR2-CASP7 fusions had a PR." ;
    a m2r:Evidence .

civice:1918
    dct:references pbm:26324363 ;
    civico:citation "Tabernero et al., 2015, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_JNJ-42756493 ;
    dcterms:description "Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. In patients with FGFR2 fusions, 1 patient with urothelial cancer had a PR harbored FGFR2-BICC1/FGFR2-CASP7 fusions, a patient with endometrial cancer and synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR, and tumor shrinkage was observed in a patient with adrenal carcinoma and FGFR3-TACC3/FGFR2-CCDC6 fusions." ;
    a m2r:Evidence .

civice:1919
    dct:references pbm:26324363 ;
    civico:citation "Tabernero et al., 2015, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_JNJ-42756493 ;
    dcterms:description "Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 partial responses (PR) and 16 with stable disease were seen. In patients harboring FGFR3-TACC3, there were 2 urothelial cancer patients with PRs, 1 endometrial cancer patient with PR (also had FGFR2-BICC1/FGFR2-OFD1 fusions), and tumor shrinkage in a patient with adrenal carcinoma (also had FGFR2-CCDC6 fusion)." ;
    a m2r:Evidence .

civice:1920
    dct:references pbm:26324363 ;
    civico:citation "Tabernero et al., 2015, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_JNJ-42756493 ;
    dcterms:description "Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. A patient with endometrial cancer with synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR." ;
    a m2r:Evidence .

civice:1921
    dct:references pbm:21309039 ;
    civico:citation "Hoogeveen-Westerveld et al., 2011, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "D" ;
    dcterms:description "The authors used a transfection based immunoblot assay to assess the impact of TSC1 (and TSC2) variants. Numerous variants were tested independently across 4 replicates and the mean and s.e.m. were plotted relative to wild type TSC1. The R1062W variant does not display a significant functional impact relative to the wildtype.  The authors state that SIFT (an in-silico missense functional prediction program) predicts the variant is tolerated." ;
    a m2r:Evidence .

civice:1922
    dct:references pbm:27297869 ;
    civico:citation "Stottrup et al., 2016, Mol. Cancer Ther." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_MK-2206 ;
    dcterms:description "Upregulation of AKT3 due to epigenetic reprogramming may confer acquired resistance to AKT inhibitor (MK2206) in breast cancer preclinical model." ;
    a m2r:Evidence .

civice:1923
    dct:references pbm:24335962 ;
    civico:citation "Chin et al., 2014, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_AKT3Inhibitor ;
    dcterms:description "AKT3 was found to be preferentially required for the proliferation and tumor growth of TNBC. It was found to be upregulated in a set of TNBC cell lines compared to other breast cancer types. Depletion of AKT3 in TNBC sensitizes cells to the pan-Akt inhibitor GSK690693. It was found that depletion of Akt3 potentially inhibits the growth of TNBC cell lines in three-dimensional (3D) spheroid cultures and in mouse xenograft models, which imply that therapeutic targeting of AKT3 may provide a new treatment option for TNBCs." ;
    a m2r:Evidence .

civice:1924
    dct:references pbm:28211448 ;
    civico:citation "Xu et al., 2017, Nat Commun" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_CX-5461,civic:drug_CX-3543 ;
    dcterms:description "The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. Xenografts harbored both a germline BRCA and a somatic BRCA mutation leading to disruption of both. The BRCA and NHEJ pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality." ;
    a m2r:Evidence .

civice:1925
    dct:references pbm:28211448 ;
    civico:citation "Xu et al., 2017, Nat Commun" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_CX-5461,civic:drug_CX-3543 ;
    dcterms:description "The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. The BRCA and NHE J pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality." ;
    a m2r:Evidence .

civice:1930
    dct:references pbm:10866302 ;
    civico:citation "Han et al., 2000, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "D" ;
    dcterms:description "Han et al functionally tested the R173C mutation in PTEN using an expression vector construct, assessing phosphatase activity of the mutant construct with two phosphoinositide substrates (\"with[ PtdIns(3,4,5)P3] or without[ Ins(1,3,4,5)P4] a diacylglycerol chain\"). R173C resides in the NH2-terminal phosphatase domain of PTEN. R173C was one of four mutations (out of 42 tested) that displayed no significant phosphatase activity against either substrate, indicating, by this assay, that the mutation negatively impacts the function of PTEN.   However this mutation did not affect the ability of PTEN to bind lipid membranes in-vivo.  This data justifies PS3 level evidence for pathogenicity according to ACMG guidelines." ;
    a m2r:Evidence .

civice:1931
    dct:references pbm:9331072 ;
    civico:citation "Rasheed et al., 1997, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Rasheed et al. identified that PTEN mutations occur with significantly greater frequency in adults with high-grade gliomas (42 adult glioblastoma multiforme and 13 adult anaplastic astrocytoma) compared to low-grade and child gliomas (68 others, varied). Mutation analysis performed using SSCP. No further testing was done." ;
    a m2r:Evidence .

civice:1934
    dct:references pbm:9635567 ;
    civico:citation "Maxwell et al., 1998, Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "Maxwell et al identified R173C in 1 subject (of 51 endometrial hyperplasias assayed for mutations in PTEN), and identified 10 mutations of 51 in PTEN overall (20%). No additional functional testing or clinical description was given." ;
    a m2r:Evidence .

civice:1935
    dct:references pbm:22628360 ;
    civico:citation "Hopman et al., 2012, Am. J. Med. Genet. A" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Hopman et al presents a case study with an affected proband carrying PTEN R173C, and meeting the pediatric criteria for PTEN testing of Tan et al (2011). The proband died at 2 years due to a fatal chylothorax, having been seen at 1 year with progressive dyspnoea and displaying extensive lymphatic and venus malformations that displaced the right lung, as well as osteolytic lesions of the bones.  Proband's mother and two siblings (one 7 years and one 7 months) also carried the PTEN R173C mutation and were thus far asymptomatic. The mother's parents did not carry the R173C mutation. PP4 ACMG evidence criteria are met as PTEN hamartoma tumor syndrome is a disease with a single genetic etiology." ;
    a m2r:Evidence .

civice:1936
    dct:references pbm:26444240 ;
    civico:citation "Wiesner et al., 2015, Nature" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Expression of an alternative ALK transcript (ATI), encompassing exons 20–29 preceded by ~400 base pairs (bp) of intron 19, but not exons 1–19 was identified in three samples of thyroid cancer and melanoma. In TCGA samples, ALK ATI was expressed in approx. 11% of melanoma samples. Functional activity of ALK ATI was shown in-vitro. In vivo studies confirmed oncogenic activity of ALK ATI similar to other ALK mutations or fusions and sensitivity to crizotinib. A patient with metastatic melanoma and ALK ATI expression but no MET or ALK aberrations identified with FISH and a 341-gene panel sequencing  was treated with crizotinib and had symptomatic improvement and tumor shrinkage within 6 weeks of therapy" ;
    a m2r:Evidence .

civice:1937
    dct:references pbm:20022809 ;
    civico:citation "Mitsudomi et al., 2010, Lancet Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "This open label Phase 3 Trial performed across 36 centers in Japan (WJTOG3405) assessed patients with postoperative recurrent or stage IIIB/IV NSCLC and activating EGFR mutations (Exon 19 deletion and L858R).  88 patients were treated with EGFR inhibitor gefitinib, while 89 were treated with cisplatin/docetaxel. Progression free survival was significantly longer with gefitinib treatment with a median of 9.2 months vs. 6.3 with cisplatin/docetaxel (HR 0.48; 95% CI 0.336-0.710; p<0.0001). Difference in response to gefitinib between the two EGFR mutation types was not observed." ;
    a m2r:Evidence .

civice:1940
    dct:references pbm:27302369 ;
    civico:citation "Schell et al., 2016, Nat Commun" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Negative" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 468 colorectal cancer samples, 61 patients had micro-satellite instability and there was a statistically significantly better prognosis for BRAF WT patients relative to BRAF (V600E)-mutated patients (Log-rank P=0.0903)." ;
    a m2r:Evidence .

civice:1942
    dct:references pbm:20151405 ;
    civico:citation "Nordstrom-O'Brien et al., 2010, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutation detected in 4 separate cases. Two cases show CNS hemangioblastoma, pancreatic/hepatic/renal cysts, and renal cell carcinoma. One case shows CNS hemangioblastoma, pancreatic cysts, and Grawitz. ACMG evidence codes: 'PVS1' based on deletion of all exons, 'PP1' based on segregation results, 'PP4' because the patients phenotypes are highly specific for a disease with single genetic etiology." ;
    a m2r:Evidence .

civice:1943
    dct:references pbm:20151405 ;
    civico:citation "Nordstrom-O'Brien et al., 2010, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutation detected in one case. Case shows CNS hemangioblastoma. ACMG evidence codes: 'PVS1' for a single exon deletion, 'PP1' based on segregation results, 'PP4' because patients phenotypes are highly specific for a disease with single genetic etiology." ;
    a m2r:Evidence .

civice:1944
    dct:references pbm:20151405 ;
    civico:citation "Nordstrom-O'Brien et al., 2010, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutation detected in one case. Case shows renal cell carcinoma. ACMG evidence codes:Mutation detected in one case. Case shows renal cell carcinoma. ACMG evidence codes: 'PVS1' based on deletion of exon 1+2, 'PP4' since the patients phenotypes are highly specific for a disease with single genetic etiology." ;
    a m2r:Evidence .

civice:1945
    dct:references pbm:15932632 ;
    civico:citation "van Houwelingen et al., 2005, BMC Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This somatic mutation was detected in two samples from a single case with chromophobe renal cell carcinoma (a 74 year old male). The tumor also harbored a silent THR157THR (471T>A) somatic variant. Since this is a somatic variant, albeit with likely functional effect, we can only infer that if observed in a germline context, it might predispose for VHL." ;
    a m2r:Evidence .

civice:1946
    dct:references pbm:15932632 ;
    civico:citation "van Houwelingen et al., 2005, BMC Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant was detected in a single case with clear-cell renal cell carcinoma. The tumor had two somatic variants (c.1-1_20del21 and c.291_310del20). Either of these variants is predicted to be quite deleterious. While they were observed in a somatic context in an RCC, we can infer that they could be predisposing for VHL in a germline context." ;
    a m2r:Evidence .

civice:1947
    dct:references pbm:11505222 ;
    civico:citation "Gallou et al., 2001, Pharmacogenetics" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "Mutation detected in one case. Case shows clear-cell renal cell carcinoma. This case also harbored a second somatic variant in VHL: 209-210delAG (Stop130). Since this was a case of sporadic RCC, with a somatic variant observed in the tumor, we can only infer that the variant is functional and would be predisposing if it occurred in a germline context." ;
    a m2r:Evidence .

civice:1948
    dct:references pbm:11536052 ;
    civico:citation "Ma et al., 2001, Oncogene" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "A somatic mutation detected in one case, a 79ya patient with renal cell carcinoma (case '1VT'). The patient had a second in-frame deletion of 5 amino acids (41-45), but the author speculate that it could be an inherited polymorphism. Since this variant is found in renal cell carcinoma, we can make an inference that it might be relevant to VHL disease in a germline context. Grade 2 clear cell renal cess carcinoma is highly associated with VHL mutation, so PP4 label may be warranted." ;
    a m2r:Evidence .

civice:1949
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutation was detected in three unaffected members of Polish VHL families. Described as being in the non-conserved portion of the VHL coding region where mutations are not typically seen according to these authors. Possibly benign but appears to have fairly low global mutation allele frequency." ;
    a m2r:Evidence .

civice:1950
    dct:references pbm:19270817 ;
    civico:citation "Cho et al., 2009, J. Korean Med. Sci." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutation was detected in one patient. Patient shows CNS hemangioblastoma and pancreatic neuroendocrine tumors, renal and pancreatic cysts, or central nervous system tumors. ACMG evidence codes: 'PVS1' because the variant is an early frameshift and 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology." ;
    a m2r:Evidence .

civice:1951
    dct:references pbm:15932632 ;
    civico:citation "van Houwelingen et al., 2005, BMC Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "E" ;
    dcterms:description "This variant was detected in a single case with clear-cell renal cell carcinoma. The tumor had two somatic variants (c.1-1_20del21 and c.291_310del20). Either of these variants is predicted to be quite deleterious. While they were observed in a somatic context in an RCC, we can infer that they could be predisposing for VHL in a germline context." ;
    a m2r:Evidence .

civice:1952
    dct:references pbm:24141786 ;
    civico:citation "Chen et al., 2014, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PD0325901,civic:drug_AEB071 ;
    dcterms:description "Preclinical study in uveal melanoma. Increased PKC activity was found in uveal melanoma cell lines with GNA11 or GNAQ mutations (n=6) compared to GNA wt cell lines (n=4) and could be induced by introducing these mutations into wt cell lines. Cell lines carrying GNA mutations were more sensitive to PKC inhibition with AEB071 and AHT956 in vitro and in vivo. Combined inhibition of MEK and PKC with AEB071 and PD0325901led to sustained MAPK-signalling blockade and induced apoptosis." ;
    a m2r:Evidence .

civice:1953
    dct:references pbm:24141786 ;
    civico:citation "Chen et al., 2014, Oncogene" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AEB071,civic:drug_PD0325901 ;
    dcterms:description "Preclinical study in uveal melanoma. Increased PKC activity was found in uveal melanoma cell lines with GNA11 or GNAQ mutations (n=6) compared to GNA wt cell lines (n=4) and could be induced by introducing these mutations into wt cell lines. Cell lines carrying GNA mutations were more sensitive to PKC inhibition with AEB071 and AHT956 in vitro and in vivo. Combined inhibition of MEK and PKC with AEB071 and PD0325901led to sustained MAPK-signalling blockade and induced apoptosis." ;
    a m2r:Evidence .

civice:1958
    dct:references pbm:28029918 ;
    civico:citation "Dombi et al., 2016, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "Treatment with selumetinib (NCT01362803) resulted in confirmed partial, long term responses in 17 of the 24 children with NF1 associated plexiform fibromas (71%) and decreases from baseline in neurofibroma volume in 12 of 18 mice (67%)." ;
    a m2r:Evidence .

civice:1960
    dct:references pbm:26510020 ;
    civico:citation "Mateo et al., 2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Response to olaparib was observed in 4 of 5 with prostate cancer patients with ATM aberrations (2 germline)." ;
    a m2r:Evidence .

civice:1963
    dct:references pbm:26510020 ;
    civico:citation "Mateo et al., 2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "From 14 prostate cancer patients (88%) who had a response to olaparib, 7 patients had BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations), 4 of 5 with had ATM aberrations and one had a biallelic inactivation of PALB2 (frameshift mutation and deletion)." ;
    a m2r:Evidence .

civice:1971
    dct:references pbm:23729478 ;
    civico:citation "Bardelli et al., 2013, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Anti-EGFRMonoclonalAntibody ;
    dcterms:description "Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors." ;
    a m2r:Evidence .

civice:1972
    dct:references pbm:8441429 ;
    civico:citation "Nakagawara et al., 1993, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A high level of expression of the TRK proto-oncogene in a neuroblastoma is strongly predictive of a favorable outcome. A tumor with a functional nerve growth factor receptor may be dependent on the neurotrophin nerve growth factor for survival and may regress in its absence." ;
    a m2r:Evidence .

civice:1974
    dct:references pbm:24132921 ;
    civico:citation "Dai et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib,civic:drug_Crenolanib ;
    dcterms:description "Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D)  resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the  imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib." ;
    a m2r:Evidence .

civice:1975
    dct:references pbm:24132921 ;
    civico:citation "Dai et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Crenolanib,civic:drug_Imatinib ;
    dcterms:description "Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib." ;
    a m2r:Evidence .

civice:1976
    dct:references pbm:24132921 ;
    civico:citation "Dai et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib,civic:drug_Crenolanib ;
    dcterms:description "Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib." ;
    a m2r:Evidence .

civice:1977
    dct:references pbm:24132921 ;
    civico:citation "Dai et al., 2013, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib,civic:drug_Crenolanib ;
    dcterms:description "Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib." ;
    a m2r:Evidence .

civice:1979
    dct:references pbm:23729478 ;
    civico:citation "Bardelli et al., 2013, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Crizotinib ;
    dcterms:description "Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors." ;
    a m2r:Evidence .

civice:1980
    dct:references pbm:26751376 ;
    civico:citation "de Oliveira et al., 2016, PLoS ONE" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_5-Fluoropyrimidine ;
    dcterms:description "MTAP and CDKN2A gene (RT-qPCR) and protein (western-blotting) expresison as well as promoter methylation status  was analyzed in breast cancer patients and seven breast cancer cell lines. Knockdown of MTAP in one cell line increased sensitivity to inhibitors of de novo adenine synthesis (5-FU, AZA and MTX), mainly 5-FU." ;
    a m2r:Evidence .

civice:1981
    dct:references pbm:22016507 ;
    civico:citation "Wittinger et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Vps37A-deficient ovarian cancer cells become irresponsive to inhibition by the therapeutic antibody cetuximab in-vitro." ;
    a m2r:Evidence .

civice:1984
    dct:references pbm:23559153 ;
    civico:citation "Stacchiotti et al., 2013, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "18 advanced progressing chordoma patients entered this study (median age: 61 years; disease extent: metastatic 72% and locally advanced 28%). Epidermal growth factor receptor (EGFR) expression and activation were evaluated by immunohistochemistry and/or phospho-arrays, real-time polimerase chain reaction, fluorescence immunostaining. Six (33.3%) patients had PR and 7 (38.9%) SD, as their best Choi responses, corresponding to RECIST SD in all cases. Median PFS by Choi was 6 [interquartile (IQ) range 3-8] months. Median PFS by RECIST was 8 (IQ range 4-12) months, with a 22% CBR. This phase II study showed a modest antitumor activity of lapatinib in chordoma" ;
    a m2r:Evidence .

civice:1985
    dct:references pbm:27626698 ;
    civico:citation "Sharma et al., 2016, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Ibrutinib ;
    dcterms:description "Case report of a patient with CLL and Richter-transformed relapse under ibrutinib (after an initial partial response for 10 months). Sequencing of sequential samples of this patient revealed a novel BTK T316 mutation at relapse (allele frequency of 75%). Characterization of this mutation showed that is was located on the SH2 domain, not associated with Ibrutinib binding. Introduction of this mutation in an Ibrutinib-sensitive lymphoma cell line showed resistance comparable to the known C481 resistance mutations, which was also confirmed by absence of downstream signaling." ;
    a m2r:Evidence .

civice:1986
    dct:references pbm:22046346 ;
    civico:citation "Kancha et al., 2011, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 µM of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance." ;
    a m2r:Evidence .

civice:1987
    dct:references pbm:22046346 ;
    civico:citation "Kancha et al., 2011, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 µM of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance." ;
    a m2r:Evidence .

civice:1988
    dct:references pbm:22046346 ;
    civico:citation "Kancha et al., 2011, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 µM of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance." ;
    a m2r:Evidence .

civice:1989
    dct:references pbm:22046346 ;
    civico:citation "Kancha et al., 2011, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 µM of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance." ;
    a m2r:Evidence .

civice:1990
    dct:references pbm:27179038 ;
    civico:citation "Pearson et al., 2016, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_AZD4547 ;
    dcterms:description "Nine patients with FGFR2-amplified gastroesophageal cancer were treated with AZD4547.  Of these 9 patients, 3 showed confirmed responses to AZD4547. Median progression-free survival was 6.6 months (range=6.2-10.5). Two additional patients had a response in day 15 using FDG-PET but were not considered complete responders by RECIST criteria. High-level FGFR2-amplified (arbitrarily defined as FISH-ratio > 5) cancers had a higher likelihood of response and were associated with a substantially higher expression of both FGFR2 mRNA and FGFR2 protein (IHC). In vitro and in PDX models, FGFR2-amplified cell lines were sensitive to FGFR inhibition. Further preclinical analyses suggested, that FGFR2 amplification mainly signals via the PI3K pathway." ;
    a m2r:Evidence .

civice:1991
    dct:references pbm:27179038 ;
    civico:citation "Pearson et al., 2016, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_AZD4547 ;
    dcterms:description "Activity of the FGFR-selective inhibitor AZD4547 in FGFR1-amplified breast cancer and FGFR2-amplified gastroesophageal cancer was analyzed in this study. 341 patients with advanced cancer were screened by FISH, identifying FGFR1 amplification in 18% of advanced HER2-negative breast cancers and FGFR2 amplification in 9% of advanced gastroesophageal cancer. 1 patient had a confirmed response among 8 patients treated with FGFR1-amplified breast cancer. In a preclinical model, FGFR1 amplification in breast cancer cell lines was less pronounced than FGFR2-amplifications in gastroesophageal cancers, which also had a higher response rate in the trial, indicating that high level amplification is associated with response and less common in FGFR1-amplified breast cancer." ;
    a m2r:Evidence .

civice:1992
    dct:references pbm:28061634 ;
    civico:citation "Seim et al., 2017, Ann. Otol. Rhinol. Laryngol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "Case report of a 60-year old patient with p16 positive tumor of the tonsil with lung metastases after primary radiochemotherapy. The metastases were analyzed using a commercial molecular analysis and overexpression of HER2 was identified (IHC, 95% of cells, with high intensity 3+ staining) which was confirmed on RNA-level. The patient was treated with single-agent lapatinib. A locally recurrent tumor was excised (and found HER2-negative) and the patient continued on lapatinib (for 2 years) as well as 5 cycles 5-FU and irinotecan. All lung metastases decreased in size within 3 months of lapatinib mono therapy initiation. The patient remains free of local or distant disease 5 years after starting lapatinib." ;
    a m2r:Evidence .

civice:1993
    dct:references pbm:28223103 ;
    civico:citation "Jeong et al., 2017, Clin Colorectal Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "We identified 142 patients with metastatic colorectal cancer whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF. All patients received cetuximab after oxaliplatin, irinotecan, and fluoropyrimidine failure. HER2 status was determined using immunohistochemistry and silver in situ hybridization and correlated with cetuximab efficacy. Of 142 RAS and BRAF wild-type tumors, we observed 7 cases (4.9%) of HER2 amplification by SISH. After a median follow-up of 13.2 months (range, 1.4-78.1 months), median progression-free survival (PFS) was significantly different according to HER2 status: 3.1 months in patients with HER2 amplification compared with 5.6 months in those with non-amplified HER2 (HR = 2.73; 95% CI = 1.18-6.31; P = 0.019). Overall survival (OS) was not significantly different between groups, although there was a tendency towards shorter OS in patients with HER2-amplified tumors (HR = 0.31; 95% CI = 0.61-2.82; 10.1 vs. 13.5 months; P = 0.488)." ;
    a m2r:Evidence .

civice:1994
    dct:references pbm:27154293 ;
    civico:citation "Pietrantonio et al., 2016, J Transl Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Significantly shorter median progression-free survival was observed in relapsed pseudomyxoma peritonei patients with GNAS mutations (N=9; 5.3 months) as compared to wild-type (N=6; not reached; p < 0.007). The results were externally validated on a previous series of 11 peritoneal pseudomyxoma patients (5.1 vs 13 months; HR for progression 11.26, 95 % CI 3.62–35.06; log-rank test p < 0.0001). 14/15 patients evaluated also harbored KRAS exon 2 mutations but no NRAS or BRAF mutations." ;
    a m2r:Evidence .

civice:1995
    dct:references pbm:24758907 ;
    civico:citation "Hong et al., 2014, Zhongguo Fei Ai Za Zhi" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib,civic:drug_Gefitinib ;
    dcterms:description "The disease control rate of patients with GNAS1 T393C CC genotype was lower than that of patients with variant genotype (TT or CT) (46.2% vs 73.8%, P=0.039). Univariate analysis identified gender, smoking history, histology and GNAS1 T393C polymorphism as predictive marker of PFS (P=0.04, P<0.001, P<0.001 and P=0.005). Multivariate analysis of factors, including smoking history, performance status score, histology, GNAS1 T393C polymorphism demonstrated that GNAS1 T393C polymorphism was correlated independently with PFS (P=0.007). The data suggests the role of GNAS1 T393C CC genotype as a poor predictive marker both of DCR and PFS in advanced NSCLC patients treated with tyrosine kinase inhibitor." ;
    a m2r:Evidence .

civice:1996
    dct:references pbm:17356712 ;
    civico:citation "Schmitz et al., 2007, Neoplasia" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Intrahepatic cholangiocarcinomas of patients with homozygous TT genotypes revealed a higher proliferation rate and a lower apoptotic rate.This study demonstrated a significant association of both disease-specific OS and recurrence-free survival with the homozygous TT genotype of the GNAS1 gene (hazard ratio = 2.47; 95% CI = 1.03–7.28). Patients with T393 homozygosity exhibit a decreased survival time regardless of their resection status and show earlier tumor recurrence." ;
    a m2r:Evidence .

civice:1997
    dct:references pbm:17186357 ;
    civico:citation "Otterbach et al., 2007, Breast Cancer Res. Treat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This study showed that the carriers of the T allele had a significantly less favourable course of the disease when compared to carriers of the homozygous CC genotype. GNAS 393C homozygous patients of pT2-4 stages displayed a significantly lower risk for death than T393 homozygous patients, with heterozygous patients being at intermediate risk. Ten-year survival rates were 63% for CC, 40% for TC and 23% for TT genotypes, respectively." ;
    a m2r:Evidence .

civice:2001
    dct:references pbm:22392911 ;
    civico:citation "Migliardi et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_BEZ235 ;
    dcterms:description "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF, or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 8 G12V mutations (3 with PIK3CA mutations) where progressive disease occurred in only 1 tumor upon doublet treatment but 6 tumors in monotherapy." ;
    a m2r:Evidence .

civice:2004
    dct:references pbm:18316791 ;
    civico:citation "Amado et al., 2008, J. Clin. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)." ;
    a m2r:Evidence .

civice:2008
    dct:references pbm:17409929 ;
    civico:citation "Endoh et al., 2006, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)." ;
    a m2r:Evidence .

civice:2009
    dct:references pbm:19284554 ;
    civico:citation "Greco et al., 2009, J. Exp. Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)." ;
    a m2r:Evidence .

civice:2012
    dct:references pbm:11050000 ;
    civico:citation "Rowley et al., 2000, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2013
    dct:references pbm:12483530 ;
    civico:citation "Rowley et al., 2002, Oncogene" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2014
    dct:references pbm:16497971 ;
    civico:citation "Hoang et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2020
    dct:references pbm:22199315 ;
    civico:citation "Lv et al., 2011, Anticancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab ;
    dcterms:description "In a clinical study of 63 recurrent glioma patients, patients treated with bevacizumab monotherapy (n=11) and harboring IDH1 codon 132 mutation were associated with improved progression free survival (3.23 months vs. 1.37 months, p=0.05), as compared to patients with wild-type IDH1." ;
    a m2r:Evidence .

civice:2034
    dct:references pbm:20453058 ;
    civico:citation "O'Brien et al., 2010, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Pictilisib ;
    dcterms:description "Breast cancer cell lines with oncogenic PIK3CA mutations had an increased sensitivity to treatment with class I PI3K inhibitor GDC-0941 compared to wildtype PIK3CA cell lines (n=54, P=0.005)." ;
    a m2r:Evidence .

civice:2035
    dct:references pbm:21594665 ;
    civico:citation "Razis et al., 2011, Breast Cancer Res. Treat." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "In HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation was associated with an increased risk of progression (HR:2.50, 95% CI:1.35-4.61, P=0.003, univariate analysis; HR:1.86, 95% CI:1.13-3.05, P=0.014, multivariate analysis) and reduced time to progression (HR:2.50, 95% CI:1.35-4.61, P=0.003) compared to wildtype PIK3CA." ;
    a m2r:Evidence .

civice:2036
    dct:references pbm:26920887 ;
    civico:citation "Baselga et al., 2016, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Ado-trastuzumabEmtansine ;
    dcterms:description "In a phase 3 clinical trial (NCT00829166), metastatic breast cancer patients with PIK3CA mutation (n=40), including patients with PIK3CA E545K, treated with ado-trastuzumab were associated with improved median progression free survival (10.9 vs. 9.8 months), as compared to patients with wild-type PIK3CA (n=93). Further, the patients harboring PIK3CA mutations (n=79) were associated with a decrease in disease progression (ado-trastuzumab relative to standard chemotherapy; HR:0.45; 95% CI:0.25-0.82), as compared to patients with wild-type PIK3CA (n=180; HR:0.74; 95% CI:0.50-1.10). In an in vitro study, MCF7 cell lines expressing PIK3CA E545K mutation was associated with increased sensitivity to ado-trastuzumab emtansine treatment compared to trastuzumab treated MCF7 cells. Sensitivity was determined by assessing cell viability. Further, in an in vivo study, MCF7 xenografts expressing PIK3CA E545K were reportedly sensitive to ado-trastuzumab emtansine, as assessed by tumor growth." ;
    a m2r:Evidence .

civice:2037
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab,civic:drug_Cetuximab ;
    dcterms:description "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). PIK3CA E545K was the only variant noted in the primary tumor (found in the sigma-rectum junction) of one patient who experienced partial response following treatment. In the larger cohort, patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. See Patient 55 from Supplemental Table 1 for more information on this patient." ;
    a m2r:Evidence .

civice:2038
    dct:references pbm:23094721 ;
    civico:citation "Liao et al., 2012, N. Engl. J. Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Aspirin ;
    dcterms:description "In a study of 413 patients with colorectal cancer who were taking aspirin since diagnosis, the frequency of PIK3CA mutations was 17% (70/413). In 530 patients with colorectal cancer not using aspirin, the frequency of PIK3CA mutations was 17% (90/530). Patients with PIK3CA somatic mutations on aspirin treatment were associated with an improved response (cancer-specific survival : HR:0.18, 95%CI:0.06-0.61, P<0.001, multivariate analysis for cancer-related death) and an improved overall survival (HR:0.54, 95%CI:0.31-0.94, P=0.01, multivariate analysis for death from any cause) when compared to those patients with PIK3CA mutations that did not use aspirin after diagnosis." ;
    a m2r:Evidence .

civice:2040
    dct:references pbm:19513541 ;
    civico:citation "Zou et al., 2009, Int. J. Mol. Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PI103 ;
    dcterms:description "In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compared to the wildtype PIK3CA cell line A549." ;
    a m2r:Evidence .

civice:2098
    dct:references pbm:21594665 ;
    civico:citation "Razis et al., 2011, Breast Cancer Res. Treat." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "In HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation was associated with an increased risk of progression (HR:2.50, 95% CI:1.35-4.61, P=0.003, univariate analysis; HR:1.86, 95% CI:1.13-3.05, P=0.014, multivariate analysis) and reduced time to progression (HR:2.50, 95% CI:1.35-4.61, P=0.003) compared to wildtype PIK3CA." ;
    a m2r:Evidence .

civice:2100
    dct:references pbm:17202311 ;
    civico:citation "Maruyama et al., 2007, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "In Japanese invasive breast cancer patients, PIK3CA mutation was associated with improved relapse-free survival." ;
    a m2r:Evidence .

civice:2102
    dct:references pbm:20453058 ;
    civico:citation "O'Brien et al., 2010, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trastuzumab ;
    dcterms:description "Breast cancer cell lines with oncogenic PIK3CA mutations had an increased sensitivity to treatment with class I PI3K inhibitor, GDC-0941 (pictilisib), as compared to wildtype PIK3CA cell lines." ;
    a m2r:Evidence .

civice:2103
    dct:references pbm:26920887 ;
    civico:citation "Baselga et al., 2016, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Ado-trastuzumabEmtansine ;
    dcterms:description "In a phase 3 clinical trial (NCT00829166), metastatic breast cancer patients with PIK3CA mutation (n=40), including patients with PIK3CA H1047R, treated with ado-trastuzumab were associated with improved median progression free survival (10.9 vs. 9.8 months), as compared to patients with wild-type PIK3CA (n=93). Further, the patients harboring PIK3CA mutations (n=79) were associated with a decrease in disease progression (ado-trastuzumab relative to standard chemotherapy; HR:0.45; 95% CI:0.25-0.82), as compared to patients with wild-type PIK3CA (n=180; HR:0.74; 95% CI:0.50-1.10). In an in vitro study, HCC1954 and KPL-4 cell lines expressing PIK3CA H1047R mutation was associated with increased sensitivity to ado-trastuzumab emtansine treatment compared to trastuzumab treated HCC1954 and KPL-4 cells. Sensitivity was determined by assessing cell viability. Further, in an in vivo study, KPL-4 xenografts expressing PIK3CA H1047R were reportedly sensitive to ado-trastuzumab emtansine, as assessed by tumor growth." ;
    a m2r:Evidence .

civice:2105
    dct:references pbm:17590872 ;
    civico:citation "Kato et al., 2007, Int. J. Cancer" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "In colorectal cancer, PIK3CA mutations were associated with reduced relapse-free survival in stage II/III patients (HR:2.587, 95% CI:1.108-6.039, P=0.0280, univariate analysis; HR:2.478, 95% CI:1.028-5.973, P=0.0433, multivariate analysis) and reduced disease-specific survival in patients of any stage (n=18 vs. n=140, P=0.0357) compared to wildtype PIK3CA." ;
    a m2r:Evidence .

civice:2106
    dct:references pbm:19903786 ;
    civico:citation "He et al., 2009, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "Rectal cancer patients with PIK3CA mutations showed a higher risk of local recurrence (HR:3.5; 95% CI:1.3-9.3, P=0.013, univariate analysis; HR:3.4, 95% CI:1.2-9.2, P=0.017, multivariate analysis) compared to wildtype PIK3CA patients." ;
    a m2r:Evidence .

civice:2110
    dct:references pbm:19513541 ;
    civico:citation "Zou et al., 2009, Int. J. Mol. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PI103 ;
    dcterms:description "In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compared to the wildtype PIK3CA cell line A549." ;
    a m2r:Evidence .

civice:2115
    dct:references pbm:19001320 ;
    civico:citation "Di Nicolantonio et al., 2008, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Panitumumab,civic:drug_Cetuximab ;
    dcterms:description "In metastatic colorectal cancer patients with wildtype KRAS status, those with a BRAF V600E mutation were less likely to respond to treatment with cetuximab or panitumumab than  those with wildtype BRAF (0%  vs. 32% , P=0.029). Regardless of KRAS status, patients with BRAF mutations had reduced progression-free and overall survival (P=0.0107 and P <0.0001, respectively). Transfection of the colorectal cancer cell line DiFi with a BRAF V600E expression vector conferred decreased sensitivity to cetuximab and panitumumab in comparison to cells transfected with empty vector." ;
    a m2r:Evidence .

civice:2117
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Oxaliplatin ;
    dcterms:description "Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001)." ;
    a m2r:Evidence .

civice:2118
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Irinotecan ;
    dcterms:description "The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF." ;
    a m2r:Evidence .

civice:2121
    dct:references pbm:19571295 ;
    civico:citation "Tol et al., 2009, N. Engl. J. Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab ;
    dcterms:description "In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=0.003) and reduced overall survival (15.0mo vs. 24.6mo, P=0.002) compared to those with wildtype BRAF." ;
    a m2r:Evidence .

civice:2135
    dct:references pbm:22663011 ;
    civico:citation "Flaherty et al., 2012, N. Engl. J. Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "In a study of 322 advanced melanoma patients with BRAF-V600E or BRAF-V600K mutations, treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo, <0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR:0.54, 95% CI:0.32-0.92, P=0.01)." ;
    a m2r:Evidence .

civice:2137
    dct:references pbm:18682506 ;
    civico:citation "Elisei et al., 2008, J. Clin. Endocrinol. Metab." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_CI-1040 ;
    dcterms:description "In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, log-rank test). The presence of BRAF V600E was associated with poorer outcome as defined by persistent disease or death (Odds ratio:14.63, 95%CI:1.28-167.29, P=0.03, multivariate analysis." ;
    a m2r:Evidence .

civice:2148
    dct:references pbm:19692680 ;
    civico:citation "Mok et al., 2009, N. Engl. J. Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a phase 3 clinical trial of East Asian advanced pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response (HR:0.48, 95% CI:0.36-0.64, P<0.001), compared to carboplatin plus paclitaxel treatment. The frequency of mutation in exon 19 deletion and L858R was 53.6% (140/261) and 42.5% (111/261), respectively." ;
    a m2r:Evidence .

civice:2153
    dct:references pbm:22452896 ;
    civico:citation "Miller et al., 2012, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors had an EGFR mutation, of which 76 (79%) were positive for either L858R or a deletion in exon 19. These mutations were associated with improved progression-free survival (median 3.3 months  vs 1.0 month ; HR:0.51, 95% CI:0.31-0.85, P<0.009) compared to placebo control." ;
    a m2r:Evidence .

civice:2156
    dct:references pbm:24755888 ;
    civico:citation "Yu et al., 2014, Cancer Biol. Ther." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "A phase 2 study of 120 stage IIIB-IV lung adenocarcinoma patients reported improved progression free survival in patients with EGFR mutation (defined as exon 19 deletion or exon 21 mutation) when treated (n=13) with gefitinib and pemetrexed/platinum combination therapy (HR: 0.20, 95% CI: 0.05-0.75, P=0.017) as compared to treatment (n=18) with pemtrexed/platinum alone.  In the subgroup of patients without EGFR mutation (defined as all patients without the specific EGFR exon 19 deletion or L858R mutation) a difference in median PFS was not seen between the chemotherapy versus chemotherapy with gefitinib treatment groups." ;
    a m2r:Evidence .

civice:2157
    dct:references pbm:26269204 ;
    civico:citation "Planchard et al., 2015, Ann. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Osimertinib ;
    dcterms:description "In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with gefitinib and achieved a partial response, but subsequently tumor progression occurred; however, osimertinib treatment resulted a favorable tumor response with the extinguishment of the EGFR T790M mutation. In a stage IV lung adenocarcinoma patient harboring an EGFR L858R mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with erlotinib, followed by gefitinib for 12 months and achieved stable disease, but subsequently metastasis occurred; the EGFR T790M was then identified and subsequent 10 month treatment with osimertinib monotherapy resulted in a 45% disease regression." ;
    a m2r:Evidence .

civice:2158
    dct:references pbm:15737014 ;
    civico:citation "Pao et al., 2005, PLoS Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 2 patients acquired a new EGFR-T790M mutation." ;
    a m2r:Evidence .

civice:2159
    dct:references pbm:17020982 ;
    civico:citation "Kosaka et al., 2006, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study of 14 patients with progressive non-small cell lung cancer during gefitinib,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 7 patients acquired a new EGFR-T790M mutation." ;
    a m2r:Evidence .

civice:2160
    dct:references pbm:18408761 ;
    civico:citation "Li et al., 2008, Oncogene" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model" ;
    a m2r:Evidence .

civice:2161
    dct:references pbm:18089823 ;
    civico:citation "Engelman et al., 2007, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PF00299804 ;
    dcterms:description "In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation. All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 μmol/L for all three cell lines)." ;
    a m2r:Evidence .

civice:2162
    dct:references pbm:16818618 ;
    civico:citation "Shimamura et al., 2006, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 μmol/L). In an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth. Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib." ;
    a m2r:Evidence .

civice:2163
    dct:references pbm:18408761 ;
    civico:citation "Li et al., 2008, Oncogene" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone." ;
    a m2r:Evidence .

civice:2164
    dct:references pbm:21732342 ;
    civico:citation "Cha et al., 2012, Int. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs. EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment. In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib. However, IC50s were intermediate compared to a more potent pan-HER inhibitor." ;
    a m2r:Evidence .

civice:2165
    dct:references pbm:18408761 ;
    civico:citation "Li et al., 2008, Oncogene" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Canertinib ;
    dcterms:description "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib. IC50 values of canertinib were comparable to afatinib." ;
    a m2r:Evidence .

civice:2167
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F359V mutation was moderately resistant to imatinib." ;
    a m2r:Evidence .

civice:2169
    dct:references pbm:15930265 ;
    civico:citation "O'Hare et al., 2005, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F359V mutation was  moderately resistant to imatinib ." ;
    a m2r:Evidence .

civice:2170
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, a Ba/F3  cell line stably expressing the F359V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 5.16-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation." ;
    a m2r:Evidence .

civice:2183
    dct:references pbm:22392911 ;
    civico:citation "Migliardi et al., 2012, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_BEZ235 ;
    dcterms:description "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, PIK3CA or BRAF mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 mice harbored KRAS mutations including 5 G13D mutations where disease stabilization was achieved in 2/5 mice treated with AZD6244 or combination therapy and 0/5 mice treated with BEZ235 alone." ;
    a m2r:Evidence .

civice:2192
    dct:references pbm:22392911 ;
    civico:citation "Migliardi et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BEZ235,civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring mutations in KRAS, NRAS, BRAF, or PIK3CA and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. NRAS mutations were in 4/40 tumors (three Q61K, one G12D)." ;
    a m2r:Evidence .

civice:2206
    dct:references pbm:22392911 ;
    civico:citation "Migliardi et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_BEZ235 ;
    dcterms:description "In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 2 A146T tumors (1 also harboring PIK3CA E545K) which both showed disease stabilization during doublet therapy but progression on either single agent." ;
    a m2r:Evidence .

civice:2209
    dct:references pbm:22392911 ;
    civico:citation "Migliardi et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_BEZ235%28NVP-BEZ235,civic:drug_Dactolisib%29 ;
    dcterms:description "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring NRAS, KRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 2 tumors with A146V mutations which achieved stable disease with combined therapy but progressive disease in either monotherapy." ;
    a m2r:Evidence .

civice:2212
    dct:references pbm:22392911 ;
    civico:citation "Migliardi et al., 2012, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BEZ235,civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring BRAF, KRAS, NRAS or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 4 G12C mutations where disease stabilization occurred in 3/4 treated with BEZ235 or doublet therapy and 2/4 treated with AZD6244 only." ;
    a m2r:Evidence .

civice:2218
    dct:references pbm:22392911 ;
    civico:citation "Migliardi et al., 2012, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_BEZ235 ;
    dcterms:description "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors studied had KRAS mutations with 9 G12D (2 with PIK3CA H1047R) and 13 other G12 mutations." ;
    a m2r:Evidence .

civice:2225
    dct:references pbm:19603018 ;
    civico:citation "Loupakis et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free survival compared to wildtype KRAS (3.8mo vs. 5.1mo, HR:0.46, 95% CI:0.11-0.88, P=0.028). In BRAF wildtype patients, KRAS mutations in codon 61 or 146 were associated with reduced response rate (0% vs. 37%, P=0.047) and reduced progression-free survival compared to wildtype KRAS patients (3.8mo vs. 5.3mo, HR:0.45, 95% CI:0.10-0.85, P=0.023)." ;
    a m2r:Evidence .

civice:2231
    dct:references pbm:18316791 ;
    civico:citation "Amado et al., 2008, J. Clin. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)." ;
    a m2r:Evidence .

civice:2232
    dct:references pbm:18316791 ;
    civico:citation "Amado et al., 2008, J. Clin. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)." ;
    a m2r:Evidence .

civice:2236
    dct:references pbm:18316791 ;
    civico:citation "Amado et al., 2008, J. Clin. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)." ;
    a m2r:Evidence .

civice:2240
    dct:references pbm:17409929 ;
    civico:citation "Endoh et al., 2006, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)." ;
    a m2r:Evidence .

civice:2247
    dct:references pbm:19284554 ;
    civico:citation "Greco et al., 2009, J. Exp. Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)." ;
    a m2r:Evidence .

civice:2250
    dct:references pbm:11050000 ;
    civico:citation "Rowley et al., 2000, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2251
    dct:references pbm:12483530 ;
    civico:citation "Rowley et al., 2002, Oncogene" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2252
    dct:references pbm:16497971 ;
    civico:citation "Hoang et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2253
    dct:references pbm:18316791 ;
    civico:citation "Amado et al., 2008, J. Clin. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)." ;
    a m2r:Evidence .

civice:2257
    dct:references pbm:17409929 ;
    civico:citation "Endoh et al., 2006, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)." ;
    a m2r:Evidence .

civice:2258
    dct:references pbm:19284554 ;
    civico:citation "Greco et al., 2009, J. Exp. Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)." ;
    a m2r:Evidence .

civice:2261
    dct:references pbm:11050000 ;
    civico:citation "Rowley et al., 2000, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2262
    dct:references pbm:12483530 ;
    civico:citation "Rowley et al., 2002, Oncogene" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2263
    dct:references pbm:16497971 ;
    civico:citation "Hoang et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2264
    dct:references pbm:18316791 ;
    civico:citation "Amado et al., 2008, J. Clin. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)." ;
    a m2r:Evidence .

civice:2268
    dct:references pbm:17409929 ;
    civico:citation "Endoh et al., 2006, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)." ;
    a m2r:Evidence .

civice:2269
    dct:references pbm:18316791 ;
    civico:citation "Amado et al., 2008, J. Clin. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab ;
    dcterms:description "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)." ;
    a m2r:Evidence .

civice:2273
    dct:references pbm:17409929 ;
    civico:citation "Endoh et al., 2006, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)." ;
    a m2r:Evidence .

civice:2274
    dct:references pbm:19284554 ;
    civico:citation "Greco et al., 2009, J. Exp. Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)." ;
    a m2r:Evidence .

civice:2277
    dct:references pbm:11050000 ;
    civico:citation "Rowley et al., 2000, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2278
    dct:references pbm:12483530 ;
    civico:citation "Rowley et al., 2002, Oncogene" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2279
    dct:references pbm:16497971 ;
    civico:citation "Hoang et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Melphalan ;
    dcterms:description "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS." ;
    a m2r:Evidence .

civice:2286
    dct:references pbm:11595686 ;
    civico:citation "Reles et al., 2001, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Carboplatin,civic:drug_Cisplatin ;
    dcterms:description "Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53." ;
    a m2r:Evidence .

civice:2292
    dct:references pbm:14514923 ;
    civico:citation "Bataille et al., 2003, MP, Mol. Pathol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_EAPProtocol ;
    dcterms:description "In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)." ;
    a m2r:Evidence .

civice:2306
    dct:references pbm:14514923 ;
    civico:citation "Bataille et al., 2003, MP, Mol. Pathol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_EAPProtocol ;
    dcterms:description "In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)." ;
    a m2r:Evidence .

civice:2310
    dct:references pbm:14514923 ;
    civico:citation "Bataille et al., 2003, MP, Mol. Pathol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_EAPProtocol ;
    dcterms:description "In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)." ;
    a m2r:Evidence .

civice:2327
    dct:references pbm:20975057 ;
    civico:citation "Houillier et al., 2010, Neurology" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "In a study of 189 low-grade gliomas, IDH (IDH1 or IDH2) mutations were found in 132 patients (70%). IDH mutations were associated with improved rate of response to temozolomide as compared to patients with wildtype IDH (61%  vs. 17% , P=0.01)." ;
    a m2r:Evidence .

civice:2329
    dct:references pbm:23558169 ;
    civico:citation "Rohle et al., 2013, Science" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AGI-5198 ;
    dcterms:description "In an experimental in vitro study, glioma cells expressing IDH1 R132C were associated with sensitivity to AGI-5198 (IC50: 0.16M vs. IC50 > 100.00M), as compared to cells expressing wild-type IDH1. Sensitivity was determined by assessing cell growth." ;
    a m2r:Evidence .

civice:2330
    dct:references pbm:22199315 ;
    civico:citation "Lv et al., 2011, Anticancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab ;
    dcterms:description "In a clinical study of 63 recurrent glioma patients, patients treated with bevacizumab monotherapy (n=11) and harboring IDH1 codon 132 mutation were associated with improved progression free survival (3.23 months vs. 1.37 months, P=0.05), as compared to patients with wild-type IDH1." ;
    a m2r:Evidence .

civice:2331
    dct:references pbm:25583779 ;
    civico:citation "2015, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_AG-120 ;
    dcterms:description "In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, these patients were associated with response to AG-120 monotherapy; 4/7 patients who achieved a response experienced complete remission." ;
    a m2r:Evidence .

civice:2332
    dct:references pbm:24333121 ;
    civico:citation "Emadi et al., 2014, Exp. Hematol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Bis-2-%5B5-%28phenylacetamide%29-1,civic:drug_3,civic:drug_4-thiadiazol-2-yl%5DethylSulfide ;
    dcterms:description "In an experimental study of acute myeloid leukemia (AML) cell lines expressing IDH1 R132C, IDH1 R132G, or IDH1 R132H mutations were associated with increased sensitivity to small molecule glutaminase inhibitor, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) as compared to AML cell lines expressing wild-type IDH1. Sensitivity was determined by assessing cell growth." ;
    a m2r:Evidence .

civice:2339
    dct:references pbm:22199315 ;
    civico:citation "Lv et al., 2011, Anticancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab ;
    dcterms:description "In a clinical study of 63 recurrent glioma patients, patients treated with bevacizumab monotherapy (n=11) and harboring IDH1 codon 132 mutation were associated with improved progression free survival (3.23 months vs. 1.37 months, p=0.05), as compared to patients with wild-type IDH1." ;
    a m2r:Evidence .

civice:2503
    dct:references pbm:21882184 ;
    civico:citation "Kim et al., 2012, Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5%  vs. 12.8% ,  Risk ratio:2.14, 95%CI:1.67-2.74, P<0.00001)." ;
    a m2r:Evidence .

civice:2505
    dct:references pbm:21343559 ;
    civico:citation "Long et al., 2011, J. Clin. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib ;
    dcterms:description "Patients were treated with a specific RAF inhibitor (dabrafenib), which improved overall survival of patients with BRAF mutations (P<0.003), compared to non-treated patients with BRAF mutations. Patients having BRAF mutations were associated with reduced overall survival (11.1 mo vs. 46.1 mo for wild-type, P=0.006). BRAF mutations were more frequent in tumors with superficially spreading histological sub-type (43%  vs. 19% , P<0.001) compared to BRAF wild-type tumors." ;
    a m2r:Evidence .

civice:2506
    dct:references pbm:22663011 ;
    civico:citation "Flaherty et al., 2012, N. Engl. J. Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "In a study of 322 advanced melanoma patients with BRAF-V600E or BRAF-V600K mutations, treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo, <0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR:0.54, 95% CI:0.32-0.92, P=0.01)." ;
    a m2r:Evidence .

civice:2508
    dct:references pbm:20038723 ;
    civico:citation "Douillard et al., 2010, J. Clin. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study of 297 non-small cell lung cancer patients, 15% of the analyzed tumors had  EGFR mutations including deletions in exon 19 (n=22), L858R (n=16) and G719A (n=2). Patients with EGFR mutations treated with gefitinib were associated with improved response rates (42.1% vs. 6.6%, P=0.04) compared to wildtype EGFR patients." ;
    a m2r:Evidence .

civice:2512
    dct:references pbm:19692680 ;
    civico:citation "Mok et al., 2009, N. Engl. J. Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a phase 3 clinical trial of East Asian pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response (HR:0.48, 95% CI:0.36-0.64, P<0.001), compared to carboplatin plus paclitaxel treatment. The frequency of mutation in exon 19 deletion and L858R was 53.6% (140/261) and 42.5% (111/261), respectively." ;
    a m2r:Evidence .

civice:2519
    dct:references pbm:22370314 ;
    civico:citation "Han et al., 2012, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort." ;
    a m2r:Evidence .

civice:2559
    dct:references pbm:15329413 ;
    civico:citation "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical imporvement in response to gefitinib, and in 8 patients who had not shown gefitinib response. 7 of 10 sensitive patients had mutations in EGFR, while none of the 8 gefitinib refractory patients showed EGFR mutation in these exons (p=0.004)" ;
    a m2r:Evidence .

civice:2621
    dct:references pbm:20038723 ;
    civico:citation "Douillard et al., 2010, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations." ;
    a m2r:Evidence .

civice:2624
    dct:references pbm:15329413 ;
    civico:citation "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was L858R. The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months." ;
    a m2r:Evidence .

civice:2625
    dct:references pbm:24893891 ;
    civico:citation "Cross et al., 2014, Cancer Discov" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib  (IC50: 23.0 nmol/L vs 200.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type)." ;
    a m2r:Evidence .

civice:2626
    dct:references pbm:18408761 ;
    civico:citation "Li et al., 2008, Oncogene" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Lapatinib ;
    dcterms:description "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells." ;
    a m2r:Evidence .

civice:2627
    dct:references pbm:18089823 ;
    civico:citation "Engelman et al., 2007, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PF00299804 ;
    dcterms:description "In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to PF 00299804  (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L)." ;
    a m2r:Evidence .

civice:2628
    dct:references pbm:16818618 ;
    civico:citation "Shimamura et al., 2006, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "In an in vitro study using NCI-H1781 cells (EGFR wild-type) and NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to neratinib (IC50: 0.0049umol/L vs. 0.085umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug erlotinib (IC50: 0.031umol/L vs. wildtype >1umol/L)." ;
    a m2r:Evidence .

civice:2629
    dct:references pbm:18408761 ;
    civico:citation "Li et al., 2008, Oncogene" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells." ;
    a m2r:Evidence .

civice:2631
    dct:references pbm:18408761 ;
    civico:citation "Li et al., 2008, Oncogene" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Canertinib ;
    dcterms:description "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells." ;
    a m2r:Evidence .

civice:2632
    dct:references pbm:15329413 ;
    civico:citation "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end." ;
    a m2r:Evidence .

civice:2633
    dct:references pbm:24893891 ;
    civico:citation "Cross et al., 2014, Cancer Discov" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_MEDI4736 ;
    dcterms:description "EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib.In an in vitro study using PC9 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib  (IC50: 11.0-12.0 nmol/L vs 61.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type)." ;
    a m2r:Evidence .

civice:2634
    dct:references pbm:22370314 ;
    civico:citation "Han et al., 2012, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort." ;
    a m2r:Evidence .

civice:2638
    dct:references pbm:15930265 ;
    civico:citation "O'Hare et al., 2005, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The M244V mutation was  sensitive to imatinib ." ;
    a m2r:Evidence .

civice:2641
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The L248V mutation was moderately resistant to imatinib." ;
    a m2r:Evidence .

civice:2644
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib,civic:drug_Nilotinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L248V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 2 μM imatinib (3 clones recovered, ~2% of viable clones in this treatment), 50nM nilotinib (1 clone, ~2%), and 5nM dasatinib (3 clones, ~9%). In a review of 20 publications, this mutation was described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:2645
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The G250E mutation was resistant to imatinib." ;
    a m2r:Evidence .

civice:2647
    dct:references pbm:15930265 ;
    civico:citation "O'Hare et al., 2005, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The G250E mutation was  resistant to imatinib ." ;
    a m2r:Evidence .

civice:2648
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 4.56-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation." ;
    a m2r:Evidence .

civice:2650
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Q252H mutation was sensitive to imatinib." ;
    a m2r:Evidence .

civice:2654
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The Y253H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 50nM nilotinib (14 clones recovered, ~30% of viable clones in this treatment), 500nM nilotinib (50 clones, ~63%), and 16 nM imatinib (16 clones; ~48%). Resistant clones were also found at 2, 4, and 8 μM imatinib. In a review of 20 publications, this mutation was described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:2655
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Y253F mutation was moderately resistant to imatinib." ;
    a m2r:Evidence .

civice:2657
    dct:references pbm:15930265 ;
    civico:citation "O'Hare et al., 2005, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Y253F mutation was  moderately resistant to imatinib ." ;
    a m2r:Evidence .

civice:2659
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The E255K mutation was resistant to imatinib." ;
    a m2r:Evidence .

civice:2661
    dct:references pbm:15930265 ;
    civico:citation "O'Hare et al., 2005, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 16 mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and evaluated for anti-proliferative activity and substrate or auto-phosphorylation assays. The E255K mutation was resistant to imatinib (20-fold IC50 increase for the proliferation assay)." ;
    a m2r:Evidence .

civice:2662
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, Ba/F3 cell line stably expressing the E255K mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 6.69-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation." ;
    a m2r:Evidence .

civice:2663
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The D276G mutation was moderately resistant to imatinib." ;
    a m2r:Evidence .

civice:2666
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, a Ba/F3  cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 2.00-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation." ;
    a m2r:Evidence .

civice:2667
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The T315I mutation was resistant to imatinib." ;
    a m2r:Evidence .

civice:2669
    dct:references pbm:15930265 ;
    civico:citation "O'Hare et al., 2005, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The T315I mutation was  resistant to imatinib ." ;
    a m2r:Evidence .

civice:2670
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, a Ba/F3  cell line stably expressing the T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 39.41-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation." ;
    a m2r:Evidence .

civice:2674
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F317L mutation was moderately resistant to imatinib." ;
    a m2r:Evidence .

civice:2676
    dct:references pbm:15930265 ;
    civico:citation "O'Hare et al., 2005, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F317L mutation was  moderately resistant to imatinib ." ;
    a m2r:Evidence .

civice:2680
    dct:references pbm:15930265 ;
    civico:citation "O'Hare et al., 2005, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F317L mutation was  moderately resistant to imatinib ." ;
    a m2r:Evidence .

civice:2682
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The M351T mutation was sensitive to imatinib." ;
    a m2r:Evidence .

civice:2684
    dct:references pbm:15930265 ;
    civico:citation "O'Hare et al., 2005, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The M351T mutation was  sensitive to imatinib ." ;
    a m2r:Evidence .

civice:2685
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.44-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation." ;
    a m2r:Evidence .

civice:2687
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The H396R mutation was resistant to imatinib." ;
    a m2r:Evidence .

civice:2689
    dct:references pbm:15930265 ;
    civico:citation "O'Hare et al., 2005, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The H396R mutation was  resistant to imatinib ." ;
    a m2r:Evidence .

civice:2697
    dct:references pbm:11595686 ;
    civico:citation "Reles et al., 2001, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "p53 overexpression (>10% positive stained nuclei) was found in 110 cases from a 178 patient cohort with invasive ovarian carcinoma who had undergone surgery. Overexpression of p53 was correlated with poor differentiation (p<0.001) and high S-phase fraction (p<0.001)." ;
    a m2r:Evidence .

civice:2745
    dct:references pbm:11595686 ;
    civico:citation "Reles et al., 2001, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Carboplatin ;
    dcterms:description "Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53." ;
    a m2r:Evidence .

civice:2771
    dct:references pbm:11595686 ;
    civico:citation "Reles et al., 2001, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Carboplatin,civic:drug_Cisplatin ;
    dcterms:description "In a group of patients with invasive ovarian carcinoma who had undergone surgery, a subset of 74 patients treated with platinum based chemotherapy were assessed for  p53 alteration (p53 mutation or p53 overexpression by immunostaining >10% positive). Significant decreased time to progression (p=0.037) was seen in the subset of  patients with p53 alteration (n=54) in comparison to the group with normatl p53 (n=20)" ;
    a m2r:Evidence .

civice:2783
    dct:references pbm:10786679 ;
    civico:citation "Berns et al., 2000, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Tamoxifen ;
    dcterms:description "In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population a 66% response rate was reported, where response was considered as complete response, partial response or stable disease. In a patient subgroup with mutations in p53 amino acids that directly interact with DNA, 2 of 11 (18%) of patients responded to tamoxifen." ;
    a m2r:Evidence .

civice:2784
    dct:references pbm:10786679 ;
    civico:citation "Berns et al., 2000, Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Tamoxifen ;
    dcterms:description "In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31%, odds ratio (OR):0.22, 95CI:0.12-0.42, P<0.0001, univariate analysis; OR:0.29, 95% CI:0.12-0.42, P=0.0014, multivariate analysis). The median survival after start of therapy was shorter in patients with mutations in TP53 than for patients with wild-type TP53 (20mo vs. 29mo, HR:1.99,95% CI:1.43-2.75, P<0.001). Breast cancer patients with TP53 mutations also had a decrease in progression-free survival (HR:2.61, 95% CI:1.90-3.6, P<0.001)." ;
    a m2r:Evidence .

civice:2799
    dct:references pbm:14514923 ;
    civico:citation "Bataille et al., 2003, MP, Mol. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Mitomycin,civic:drug_Etoposide ;
    dcterms:description "In a Phase II trial of 25 patients with metastaic gastric cancer, patients received preoperative high dose chemotherapy (HDCT) consisting of etoposide, cisplatin and mitomycin. Patients with greater than 50% regression in response to HDCT received surgery. TP53 overexpression was assayed by immunohistochemistry. 14 patients showed p53 overexpression, and 12 of these qualified for resection. Overall survival in patients with p53 overexpression was 17.3 months in contrast to patients with negative p53 immunohistochemistry, where it was 7.2 months (p=0.0003)." ;
    a m2r:Evidence .

civice:2818
    dct:references pbm:14514923 ;
    civico:citation "Bataille et al., 2003, MP, Mol. Pathol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_EAPProtocol ;
    dcterms:description "In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)." ;
    a m2r:Evidence .

civice:2819
    dct:references pbm:14514923 ;
    civico:citation "Bataille et al., 2003, MP, Mol. Pathol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_EAPProtocol ;
    dcterms:description "In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)." ;
    a m2r:Evidence .

civice:2820
    dct:references pbm:14514923 ;
    civico:citation "Bataille et al., 2003, MP, Mol. Pathol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_EAPProtocol ;
    dcterms:description "In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)." ;
    a m2r:Evidence .

civice:2829
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.85-fold), comparable to Ba/F3 cells expressing BCR-ABL fusion protein. Sensitivity was determined by assessing cell proliferation." ;
    a m2r:Evidence .

civice:2850
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, a Ba/F3  cell line stably expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 10.31-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation." ;
    a m2r:Evidence .

civice:2851
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate,civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to imatinib (1 clone, 0.43% of viable clones in this treatment, recovered in 4 μM but none at 2, 8, or 16 μM) and nilotinib (1 clone, 1.25%, recovered at 500nM but none at 50, 2000 or 5000nM). In a review of 20 publications, this mutation was described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:2853
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The E292V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to nilotinib treatment (1 clone recovered at 50nM). In a review of 20 publications, this mutation was not previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:2854
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The F359C mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 50nM nilotinib (6 clones recovered, ~13% of viable clones in this treatment) and 2 μM imatinib (6 clones, ~4%). In a review of 20 publications, this mutation was described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:2861
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L384M mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance in 50nM nilotinib (1 clone recovered, ~2% of viable clones in this treatment) and 2 μM imatinib (1 clone, ~0.7%). L384M was one of 3 novel mutations that were not identified in imatinib resistant patients from a review of 20 publications." ;
    a m2r:Evidence .

civice:2862
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line stably expressing the V299L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.34-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation." ;
    a m2r:Evidence .

civice:2863
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The L387F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to nilotinib treatment (1 clone recovered at 50nM)." ;
    a m2r:Evidence .

civice:2864
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.49-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation." ;
    a m2r:Evidence .

civice:2868
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2869
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2870
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2871
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2872
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2873
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2874
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2875
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2876
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2877
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2878
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2879
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2880
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2881
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2882
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2883
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2884
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2885
    dct:references pbm:27908594 ;
    civico:citation "Swisher et al., 2017, Lancet Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Rucaparib ;
    dcterms:description "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)." ;
    a m2r:Evidence .

civice:2886
    dct:references pbm:21642685 ;
    civico:citation "Carvajal et al., 2011, JAMA" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "FFPE tumor specimens from 295 melanoma patients were screened for KIT amplification and mutation. Of these, 51 patients had variants in KIT and 28 of these were treated with imatinib mesylate at 400 mg orally, twice daily with 25 patients eligible for response evaluation. None of the patients had mutations in BRAF, NRAS, or GNAQ. Two patients achieved a durable complete response, two achieved a durable partial response, and 5 achieved stable disease >12 weeks with a median survival of 46.3 weeks. One patient harboring a somatic D820Y mutation at roughly 50% variant allele frequency (1:1 with wild type) displayed Imatinib mesylate–resistance and disease progression, which is consistent with resistant mechanisms described in Gastro-Intestinal Stromal Tumors." ;
    a m2r:Evidence .

civice:2888
    dct:references pbm:19035443 ;
    civico:citation "Ashida et al., 2009, Int. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "C" ;
    dcterms:description "28 acral or mucosal melanomas from Shinshu University Hospital in Japan were examined for KIT expression and mutations. 13 tumors displayed strong KIT expression and KIT exons 11, 13,17, and 18 were examined for mutations. Two of 19 melanomas examined harbored KIT mutations, with one subject harboring mutation at D820Y.  The SM3 cell line harboring a D820Y mutation showed significant growth inhibition with sunitinib exposures of 1uM and 10uM. The authors comment that this indicates a potential role for sunitinib in growth inhibition of acral melanomas." ;
    a m2r:Evidence .

civice:2889
    dct:references pbm:18510589 ;
    civico:citation "Lutzky et al., 2008, Pigment Cell Melanoma Res" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A 69 y.o. woman presented with metastatic mucuosal melanoma of the anus. KIT was amplified in the tumor and harbored the K642E mutation. Post surgery with extensive margins, she was given a dose of anti-CTLA-4 antibody and adjuvant radiation therapy for 2.5 weeks.  Two weeks post radiation she developed nodules in the same region and testing indicated they were malignant melanoma with high KIT expression. She enrolled in a clinical trial with a dose of 400mg imatinib per day (Nov 2006). Less than 4 weeks later, all nodules had disappeared. Upon a lowered dosage to 200mg of imatinib, the nodules returned and subsequently the dosage was increased to 600mg/day. The patient remained melanoma-free on 600mg imatinib until a follow up in Jan 2008. The authors do not provide further details on patient outcome." ;
    a m2r:Evidence .

civice:2892
    dct:references pbm:15824158 ;
    civico:citation "Frey et al., 2005, Cancer Epidemiol. Biomarkers Prev." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This study demostrated that the progression-free survival, metastasis-free survival, and cancer-specific survival was significantly increased in patients with T393 homozygosity i.e. TT genotypes (56%, 84%, 82%) compared with CC genotypes (35%, 53%, 58%). In multivariate Cox proportional hazard analysis, the T393C polymorphism was an independent prognostic factor for clinical outcome. Homozygous CC patients were at highest risk for progression [odds ratio (OR), 1.94; P = 0.020], metastasis (OR, 3.49; P = 0.005), and tumor-related death (OR, 2.49; P = 0.031) compared with TT genotypes." ;
    a m2r:Evidence .

civice:2893
    dct:references pbm:16033819 ;
    civico:citation "Frey et al., 2005, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a retrospective study of 151 patients with sporadic colorectal cancer, 5-year survival rate was significantly higher in patients with International Union Against Cancer (UICC) stages I to II (mean follow-up, 43 months) and the GNAS1 T393C polymorphism-associated TT genotypes (87.8%) compared with TC (71.0%) and CC genotypes (50.0%; P = 0.009). No genotype effect could be observed for UICC stages III to IV. In multivariate Cox proportional analysis the T393C polymorphism was an independent prognostic factor for survival. Compatible with a gene-dose effect, homozygous CC patients were at highest risk for death (hazard ratio, 12.1; P = 0.006) compared with TT genotypes and heterozygous patients had an intermediate risk." ;
    a m2r:Evidence .

civice:2895
    dct:references pbm:19274060 ;
    civico:citation "Alakus et al., 2009, Pharmacogenomics J." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin,civic:drug_5-fluorouracil ;
    dcterms:description "Overall, 63% of the patients in the T-allele group (TT + CT), i.e with the T393C genotype, were minor responders with more than 10% residual vital tumor cells in resection specimens, whereas T(-) genotypes (CC) showed a major histopathological response with less than 10% residual vital tumor cells in 80%." ;
    a m2r:Evidence .

civice:2896
    dct:references pbm:16467086 ;
    civico:citation "Frey et al., 2006, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study, Kaplan-Meier curves for tumor progression, development of metastasis, and tumor-related death showed a significant association of the T393C polymorphism with outcome (5-year cancer-specific survival rates: TT, 91%; TC, 81%; CC, 69%; P = 0.015). Multivariate Cox proportional analysis of a 10-year follow-up confirmed the T393C polymorphism as an independent prognostic factor in clear cell renal cell carcinoma. Homozygous CC patients were at highest risk for progression (hazard ratio, 2.48; P = 0.009) or tumor-related death (hazard ratio, 3.15; P = 0.018) compared with T-allele carriers." ;
    a m2r:Evidence .

civice:2897
    dct:references pbm:17020971 ;
    civico:citation "Frey et al., 2006, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a retrospective study of 144 patients with B-cell chronic lymphocytic leukemia, the median progression-free survival was significantly different between GNAS T393C genotypes (TT 130 months; TC 100 months; CC 31 months; P = 0.0066) and an independent prognostic factor for progression-free survival by multivariable analysis [hazard ratio (HR) CC versus TT 2.7; P = 0.010]. CC genotypes were at highest risk for death compared with T-alleles (median overall survival 197 vs 310 months, respectively) in both univariate (HR, 4.8; P < 0.0001) and multivariable analysis (HR, 5.6; P = 0.002)." ;
    a m2r:Evidence .

civice:2898
    dct:references pbm:21156401 ;
    civico:citation "Frey et al., 2010, Eur. J. Med. Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This study showed that GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression in patients with malignant melanoma. Carriers of the C-allele showed a significantly more severe tumor progression as estimated from the time period to develop metastasis (HR 2.2, 95% CI 1.1-3.2, p = 0.017). Proportions of 5-year metastasis-free intervals were 87.1% for TT genotypes and 66.0% for C-allele carriers. Moreover, multivariable Cox regression analysis including tumor stage and melanoma subtype proved the T393C polymorphism to be an independent factor for metastasis (p = 0.012)." ;
    a m2r:Evidence .

civice:2899
    dct:references pbm:17442989 ;
    civico:citation "Chinot et al., 2007, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "In this study, patients with low MGMT expression, compared with patients with high MGMT expression, had a significantly higher response rate (55% v 7%, respectively; P = .004) and improved PFS (median, 5.5 v 1.9 months, respectively; P = .009) and OS (median, 16 v 5 months, respectively; P = .003). Among patients with MGMT data available for analysis, radiotherapy was started and completed in 91% of patients with low MGMT expression. In contrast, among patients with high MGMT expression, only 64% started radiotherapy, and 43% completed it. These results suggest that neoadjuvant chemotherapy may be feasible for inoperable glioblastoma patients expressing low levels of MGMT without compromising subsequent treatment with radiotherapy, whereas patients with high MGMT expression are less likely to respond and more likely to experience progression before or during radiotherapy." ;
    a m2r:Evidence .

civice:2901
    dct:references pbm:21365007 ;
    civico:citation "Kreth et al., 2011, PLoS ONE" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "This study showed that low MGMT mRNA expression was strongly predictive for prolonged time to progression, treatment response, and length of survival in univariate and multivariate models (p<0.0001). The degree of MGMT mRNA expression was highly correlated with the MGMT promoter methylation status (p<0.0001); however, discordant findings were seen in 12 glioblastoma patients. Patients with methylated tumors with high MGMT mRNA expression (N = 6) did significantly worse than those with low transcriptional activity (p<0.01). Conversely, unmethylated tumors with low MGMT mRNA expression (N = 6) did better than their counterparts." ;
    a m2r:Evidence .

civice:2902
    dct:references pbm:16541434 ;
    civico:citation "Levin et al., 2006, Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "In this study, loss of chromosome 1p and low MGMT protein expression were associated with objective response (P < .003 and P < .04, respectively). However, only 54% of the study group had evaluation of 1p/19q status, and MGMT protein expression was studied in only 33%. Therefore, the association between 1p deletion and low MGMT protein expression was statistically significant when evaluated further and verified in the extended group of 31 patients with low-grade oligodendrogliomas." ;
    a m2r:Evidence .

civice:2903
    dct:references pbm:21331613 ;
    civico:citation "Watanabe et al., 2011, Brain Tumor Pathol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "In 41 glioblastomas treated with temozolomide (TMZ) therapy (MGMT-immunopositive: n = 22, negative: n = 19), both progression free survival and overall survival were significantly better in MGMT-immunonegative glioblastomas. (PFS: P = 0.0015, OS: P = 0.0384)." ;
    a m2r:Evidence .

civice:2904
    dct:references pbm:19118063 ;
    civico:citation "Kulke et al., 2009, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Temozolomide ;
    dcterms:description "Among those patients who received temozolomide-based therapy in this study, the median progression-free survival for patients whose tumors showed intact MGMT expression was 9.3 months compared with 19.2 months for patients with MGMT-deficient tumors (P = 0.11). The median overall survival for patients whose tumors showed intact MGMT expression was 19.1 months; the median overall survival for patients with MGMT deficient tumors was not reached." ;
    a m2r:Evidence .

civice:2905
    dct:references pbm:24595080 ;
    civico:citation "Nie et al., 2013, Cancer Biomark" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Gemcitabine ;
    dcterms:description "In the personalized therapy group of this study, patients received chemotherapy based on RRM-1 IHC expression levels, whereas the standard therapy group received non-customized chemotherapy. There were statistically significant improvements between the personalized therapy group versus the standard therapy group in disease control rate (82.9% vs 55.3%, P=0.004), and progression-free survival (median: 5.5 months vs 3.0 months, P=0.005). Besides, the overall survival had a tendency to become more prolonged (median: 16.0 months vs 12.4 months, P=0.286)." ;
    a m2r:Evidence .

civice:2906
    dct:references pbm:27211795 ;
    civico:citation "Leventakos et al., 2016, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treated cases, its exact prognostic and predictive role is not fully understood. In our experience, S768I mutations in isolation do not necessarily confer sensitivity to erlotinib, but in conjunction with sensitizing EGFR mutations, S768I mutations do not restrict efficacy." ;
    a m2r:Evidence .

civice:2907
    dct:references pbm:23515407 ;
    civico:citation "Ohashi et al., 2013, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_Trametinib ;
    dcterms:description "Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations (one harboring Q61L, two Q61R, and three Q61K mutations) and 5/6 were sensitive to MEK inhibitors selumetinib and trametinib. One Q61K line was not sensitive to these inhibitors." ;
    a m2r:Evidence .

civice:2913
    dct:references pbm:19472011 ;
    civico:citation "Calva et al., 2009, Ann. Surg. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Pathogenic" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Study of a family with three generations of history indicating co-segregation of RET C609Y and multiple endocrine neoplasia type 2A, many of whom exhibited medullary thyroid cancers specifically.  22 individuals in this family were carriers of C609Y. Of these, 9 exhibited medullary thyroid cancers. While the variant is strongly suspected of being pathogenic for these tumors, this variant appears to result in later onset of cancer than some other variants and the authors recommend delaying prophylactic thyroidectomy until 10-15 years of age. In addition to this large family, the authors also provide an extensive review of prior reports of C609 variants, identifying a total of 111 patients from 19 publications, representing 21 affected kindreds and 15 sporadic cases. 89 of these cases had C609Y specifically.  The authors also summarize prior functional work that suggests that C609Y has transforming activity that is significant but not as strong as some other variants. Based on all of this analysis, the authors conclude that C609Y causes medullary thyroid cancers but a milder form than some other variants. Based on this paper, the following ACMG evidence codes seem potentially valid: 'PS1', 'PS3',  'PM5', 'PP1', 'PP4', and 'PP5'." ;
    a m2r:Evidence .

civice:2915
    dct:references pbm:27535980 ;
    civico:citation "Chudasama et al., 2017, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BGJ398,civic:drug_AZD4547,civic:drug_FGF-VEGFReceptorTyrosineKinaseInhibitor,civic:drug_PD173074 ;
    dcterms:description "Targeting of FGFR1 by RNA interference and small-molecule inhibitors (PD173074, AZD4547, BGJ398) revealed that the requirement for FGFR1 signaling in STS cells is dictated by FGFR1 expression levels, and identified the MAPK-ERK1/2 axis as critical FGFR1 effector pathway." ;
    a m2r:Evidence .

civice:2918
    dct:references pbm:16954519 ;
    civico:citation "Heinrich et al., 2006, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. N822K was observed as a secondary KIT mutation in two patients with secondary imatinib resistance and one patient with primary resistance, and also as a primary mutation in a patient with primary resistance. The mutation was shown to occur at a hotspot (N822) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro N822K showed moderate imatinib resistance." ;
    a m2r:Evidence .

civice:2919
    dct:references pbm:16954519 ;
    civico:citation "Heinrich et al., 2006, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. Y823D was observed as a secondary KIT mutation in five patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (Y823) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro Y823D showed \"extreme\" imatinib resistance." ;
    a m2r:Evidence .

civice:2920
    dct:references pbm:16954519 ;
    civico:citation "Heinrich et al., 2006, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. C809G was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. In vitro, C809G showed imatinib resistance both in isolation and when coexpressed with K642E + N822H (the primary KIT mutations, found on the same allele, for this patient)." ;
    a m2r:Evidence .

civice:2921
    dct:references pbm:16954519 ;
    civico:citation "Heinrich et al., 2006, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820A was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. A cell line derived from a separate patient with the same primary (V560D) and secondary (D820A) mutations showed moderately increased resistance to imatinib compared to reports for GIST lines with primary exon 11 KIT mutations alone." ;
    a m2r:Evidence .

civice:2922
    dct:references pbm:16954519 ;
    civico:citation "Heinrich et al., 2006, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820G was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D820G showed \"extreme\" imatinib resistance." ;
    a m2r:Evidence .

civice:2923
    dct:references pbm:16954519 ;
    civico:citation "Heinrich et al., 2006, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D816H was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D816) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D816H showed \"extreme\" imatinib resistance. It was also highly resistant in isolation." ;
    a m2r:Evidence .

civice:2924
    dct:references pbm:16954519 ;
    civico:citation "Heinrich et al., 2006, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. T670I was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (T670) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro T670I showed \"extreme\" imatinib resistance. It also showed resistance in isolation." ;
    a m2r:Evidence .

civice:2926
    dct:references pbm:28351930 ;
    civico:citation "Kato et al., 2017, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pembrolizumab,civic:drug_Atezolizumab,civic:drug_Nivolumab ;
    dcterms:description "A subset of patients receiving PD1/PD-L1 inhibition appear to be \"hyper-progressors,\" with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy. The current study investigated potential genomic markers associated with \"hyper-progression\". Consecutive stage IV cancer patients who received immunotherapies (CTLA-4, PD-1/PD-L1 inhibitors or other [investigational] agents) and had their tumor evaluated by next-generation sequencing Amongst 155 patients, TTF (time to treatment failure) <2 months was seen in 4/5 individuals harbouring DNMT3A alteration." ;
    a m2r:Evidence .

civice:2927
    dct:references pbm:21993670 ;
    civico:citation "Guarini et al., 2012, Haematologica" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "ATM point mutations were found in 8/57 patients with CLL and were associated with a shorter treatment-free interval, suggesting a more aggressive course." ;
    a m2r:Evidence .

civice:2929
    dct:references pbm:25673644 ;
    civico:citation "Ahronian et al., 2015, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Panitumumab ;
    dcterms:description "Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed. Alterations in MAPK pathway genes were found in resistant tumors not present in matched pre-treatment tumors, including KRAS amplification, BRAF amplification, and a MEK1 mutation." ;
    a m2r:Evidence .

civice:2931
    dct:references pbm:26987942 ;
    civico:citation "Vu et al., 2016, Pharmacol. Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Ribociclib,civic:drug_Binimetinib ;
    dcterms:description "Inhibition of CDK4 and 6, regulators of the G1/S cell cycle checkpoint, arrests the cell cycle in the G1 phase, suppresses DNA synthesis, and inhibits cancer cell growth. There is an ongoing phase 1/2 trial of binimetinib with the CDK4/6 inhibitor ribociclib (LEE011) in mutant NRAS melanoma patients (NCT01781572). Early results from the 21 evaluable patients were very promising, with 7 patients achieving a partial response (33%) and 11 patients with stable disease (52%)" ;
    a m2r:Evidence .

civice:2933
    dct:references pbm:28148839 ;
    civico:citation "Sulkowski et al., 2017, Sci Transl Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Mutations in isocitrate dehydrogenase 1 and 2, which result in overproduction of 2-hydroxyglutarate (2HG). 2HG is considered to be an oncometabolite, or a metabolite that promotes carcinogenesis, and inhibitors of mutant isocitrate dehydrogenase are in development to target this process. The authors discovered that 2HG overproduction impairs homologous recombination used in DNA repair and sensitizes cancer cells to treatment with PARP inhibitors, another class of cancer drugs that are already in clinical use." ;
    a m2r:Evidence .

civice:2934
    dct:references pbm:23724914 ;
    civico:citation "Awad et al., 2013, N. Engl. J. Med." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. A biopsy of a resistant tumor showed an acquired G2032R mutation in the ROS1 kinase domain. Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding. The same resistance mutation was observed at all the metastatic sites that were examined at autopsy, suggesting that this mutation was an early event in the clonal evolution of resistance." ;
    a m2r:Evidence .

civice:2935
    dct:references pbm:25351745 ;
    civico:citation "Arcila et al., 2015, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "This report identified 36 MEK1-mutated cases among 6,024 Lung adecarcinomas. The majority of patients were smokers (97%). There was no association with age, sex, race, or stage. The most common mutations were K57N (64%, 23/36) followed by Q56P (19%, 7/36), all mutually exclusive with other driver mutations in the targeted panel.  MEK1 mutations define a distinct subset of lung cancers (∼1%) with potential sensitivity to MEK inhibitors. Mutations are predominantly transversions, in keeping with a strong association with smoking." ;
    a m2r:Evidence .

civice:2936
    dct:references pbm:18632602 ;
    civico:citation "Marks et al., 2008, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "Mutational profiling of a large cohort of lung adenocarcinomas  identified in 2 of 207 primary lung tumors a somatic activating mutation in exon 2 of MEK1 (i.e., mitogen-activated protein kinase kinase 1 or MAP2K1) that substitutes asparagine for lysine at amino acid 57 (K57N) in the nonkinase portion of the kinase. Neither of these two tumors harbored known mutations in other genes encoding components of the EGFR signaling pathway (i.e., EGFR, HER2, KRAS, PIK3CA, and BRAF). Expression of mutant, but not wild-type, MEK1 leads to constitutive activity of extracellular signal-regulated kinase (ERK)-1/2 in human 293T cells and to growth factor-independent proliferation of murine Ba/F3 cells. A selective MEK inhibitor, AZD6244, inhibits mutant-induced ERK activity in 293T cells and growth of mutant-bearing Ba/F3 cells." ;
    a m2r:Evidence .

civice:2937
    dct:references pbm:28284557 ;
    civico:citation "Dummer et al., 2017, Lancet Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Binimetinib ;
    dcterms:description "NEMO is an ongoing, randomised, open-label phase 3 study of patients with advanced, unresectable, AJCC IIIC/IV NRAS-mutant melanoma. 402 patients that were previously untreated or progressed on or after previous immunotherapy were randomised to receive either binimetinib (269) or dacarbazine (133). The study's primary endpoint was progression free survival. Median follow-up was 1.7 months (IQR 1.4-4.1). Median progression-free survival was 2.8 months (95% CI 2.8-3.6) in the binimetinib group and 1.5 months (1.5-1.7) in the dacarbazine group, demonstrating improved progression-free survival of binimetinib compared with dacarbazine." ;
    a m2r:Evidence .

civice:2939
    dct:references pbm:17409929 ;
    civico:citation "Endoh et al., 2006, J Thorac Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study of 52 patients with recurrent lung cancer, 27 individuals had EGFR mutation including 2 point mutations in exon 18 (G719A and G1719C), 23 deletions in exon 19, two insertions in exon 19 (I744KIPVAI), on mutation in exon 20 (S768I), and 16 point mutations in exon 21 (L858R and E709H). Patients were treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, and tumors harboring an EGFR mutation had an increased frequency of partial response (PR) and a lower rate of progressive disease (PD) (PR:22, PD:2 vs. PR:2, PD:17; P<0.0001) compared to wildtype EGFR patients. Patients with KRAS mutations also had a longer overall survival compared to wildtype EGFR patients (HR:2.526, 95% CI:1.314-4.858, P=0.0055)." ;
    a m2r:Evidence .

civice:2943
    dct:references pbm:20570890 ;
    civico:citation "Janakiraman et al., 2010, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901. This study involved treatment of mice bearing A146T KRAS xenografts treated with PD0325901 or cetuximab." ;
    a m2r:Evidence .

civice:2948
    dct:references pbm:28183697 ;
    civico:citation "Drilon et al., 2017, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer." ;
    a m2r:Evidence .

civice:2949
    dct:references pbm:28183697 ;
    civico:citation "Drilon et al., 2017, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer." ;
    a m2r:Evidence .

civice:2950
    dct:references pbm:28183697 ;
    civico:citation "Drilon et al., 2017, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer." ;
    a m2r:Evidence .

civice:2951
    dct:references pbm:28183697 ;
    civico:citation "Drilon et al., 2017, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer." ;
    a m2r:Evidence .

civice:2952
    dct:references pbm:28183697 ;
    civico:citation "Drilon et al., 2017, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer." ;
    a m2r:Evidence .

civice:2955
    dct:references pbm:26216294 ;
    civico:citation "Doebele et al., 2015, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Larotrectinib%28LOXO-101%29 ;
    dcterms:description "LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors. The tumor of a 41-year-old woman with soft-tissue sarcoma metastatic to the lung was found to harbor an LMNA-NTRK1 gene fusion encoding a functional LMNA-TRKA fusion oncoprotein.  This patient's tumors underwent rapid and substantial tumor regression, with an accompanying improvement in pulmonary dyspnea, oxygen saturation, and plasma tumor markers." ;
    a m2r:Evidence .

civice:2956
    dct:references pbm:26216294 ;
    civico:citation "Doebele et al., 2015, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Larotrectinib%28LOXO-101%29 ;
    dcterms:description "LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors. The tumor of a 41-year-old woman with soft-tissue sarcoma metastatic to the lung was found to harbor an LMNA-NTRK1 gene fusion encoding a functional LMNA-TRKA fusion oncoprotein.  This patient's tumors underwent rapid and substantial tumor regression, with an accompanying improvement in pulmonary dyspnea, oxygen saturation, and plasma tumor markers." ;
    a m2r:Evidence .

civice:2958
    dct:references pbm:28183697 ;
    civico:citation "Drilon et al., 2017, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. No objective responses (per RECIST v1.1; ref. 38) were observed in patients whose tumors did not harbor gene fusions involving NTRK1/2/3, ROS1, or ALK, with the exception of 1 patient with an ALKF1245V mutant neuroblastoma." ;
    a m2r:Evidence .

civice:2959
    dct:references pbm:28183697 ;
    civico:citation "Drilon et al., 2017, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. No objective responses (per RECIST v1.1; ref. 38) were observed in patients whose tumors did not harbor gene fusions involving NTRK1/2/3, ROS1, or ALK, with the exception of 1 patient with an ALKF1245V mutant neuroblastoma." ;
    a m2r:Evidence .

civice:2960
    dct:references pbm:26546295 ;
    civico:citation "Russo et al., 2016, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months." ;
    a m2r:Evidence .

civice:2961
    dct:references pbm:26546295 ;
    civico:citation "Russo et al., 2016, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Entrectinib ;
    dcterms:description "A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months. Longitudinal analysis of ctDNA in plasma samples revealed a p.G595R- and p.G667C mutation in NTRK1 that were absent before treatment initiation but  emerged 4 weeks upon initiation of treatment with entrectinib. These mutations were also validated using xenograft, in vitro and 3D-modeling." ;
    a m2r:Evidence .

civice:2963
    dct:references pbm:17671205 ;
    civico:citation "Efeyan et al., 2007, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nutlin-3a ;
    dcterms:description "MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. Cells lacking functional TP53 were completely insensitive to the drug." ;
    a m2r:Evidence .

civice:2964
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53  status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor." ;
    a m2r:Evidence .

civice:2965
    dct:references pbm:26459177 ;
    civico:citation "Andreeff et al., 2016, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_RG7112 ;
    dcterms:description "Phase I Trial of RG7112 in 116 heavily pretreated patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53. 96 patients were tested for TP53 mutation and 19 cases of mutation were detected. No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53." ;
    a m2r:Evidence .

civice:2966
    dct:references pbm:26459177 ;
    civico:citation "Andreeff et al., 2016, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_RG7112 ;
    dcterms:description "Phase I Trial of MDM2 inhibitor RG7112 in 116 patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53. No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53." ;
    a m2r:Evidence .

civice:2967
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor AMGMDS3, while those with p53 mutations demonstrated resistance." ;
    a m2r:Evidence .

civice:2968
    dct:references pbm:17671205 ;
    civico:citation "Efeyan et al., 2007, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nutlin-3a ;
    dcterms:description "MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. TP53 mutant cells lacking functional TP53 were completely insensitive to the drug." ;
    a m2r:Evidence .

civice:2972
    dct:references pbm:8929264 ;
    civico:citation "Shibata et al., 1996, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Expression of DCC was a strong positive predictive factor for survival in both stage II and stage III colorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001). In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P=0.03)." ;
    a m2r:Evidence .

civice:2973
    dct:references pbm:18832571 ;
    civico:citation "Lazar et al., 2008, Am. J. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches." ;
    a m2r:Evidence .

civice:2974
    dct:references pbm:18832571 ;
    civico:citation "Lazar et al., 2008, Am. J. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (S45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches." ;
    a m2r:Evidence .

civice:2975
    dct:references pbm:18832571 ;
    civico:citation "Lazar et al., 2008, Am. J. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors." ;
    a m2r:Evidence .

civice:2976
    dct:references pbm:18832571 ;
    civico:citation "Lazar et al., 2008, Am. J. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (S45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches." ;
    a m2r:Evidence .

civice:2982
    dct:references pbm:27364904 ;
    civico:citation "Miller et al., 2016, Mol. Cancer Ther." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "High-throughput  drug screens in OCCC tumor cell model identified synthetic lethal (SL) interaction between the kinase inhibitor dasatinib and ARID1A mutation. Imposing ARID1A deficiency upon a variety of human or mouse cells induced dasatinib sensitivity, both in vitro and in vivo." ;
    a m2r:Evidence .

civice:2983
    dct:references pbm:25686104 ;
    civico:citation "Bitler et al., 2015, Nat. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_GSK126 ;
    dcterms:description "Inhibition of the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A mutated ovarian cancer cells. ARID1A mutational status correlates with response to the EZH2 inhibitor. Significantly, EZH2 inhibition causes regression of ARID1A mutated ovarian tumors in vivo." ;
    a m2r:Evidence .

civice:2988
    dct:references pbm:25970248 ;
    civico:citation "Spranger et al., 2015, Nature" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PD-L1Antibody,civic:drug_CTLA-4Antibody ;
    dcterms:description "Activation of melanoma-cell-intrinsic WNT/β-catenin signalling pathway contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. In autochthonous mouse melanoma models active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy." ;
    a m2r:Evidence .

civice:2991
    dct:references pbm:23585477 ;
    civico:citation "Schlegel et al., 2013, J. Clin. Invest." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_UNC1062 ;
    dcterms:description "Highest MERTK expression was observed in metastatic melanomas, followed by primary melanomas, and lowest in benign nevi. Over half of melanoma cell lines overexpressed MERTK compared with normal human melanocytes; however, overexpression did not correlate with mutations in BRAF or RAS. MERTK inhibition via shRNA reduced MERTK-mediated downstream signaling, reduced colony formation by up to 59%, and diminished tumor volume by 60% in a human melanoma murine xenograft model. Treatment of melanoma cells with UNC1062, a novel MERTK-selective small-molecule tyrosine kinase inhibitor, reduced activation of MERTK-mediated downstream signaling, induced apoptosis in culture, reduced colony formation in soft agar, and inhibited invasion of melanoma cells." ;
    a m2r:Evidence .

civice:2993
    dct:references pbm:11595686 ;
    civico:citation "Reles et al., 2001, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Patients with conserved domain p53 mutation (n=61) were compared with those with wild type or non-conserved domain p53 mutation (n=117) in a cohort of 178 invasive ovarian carcinoma patients who had undergone surgery. Overall survival was decreased in the cohort with conserved domian mutation (p=0.005).  Conserved domain mutation was an independent factor in univariate (but not multivariate) analysis of overall survival with relative risk 1.70 (1.17-2.47, p<0.007)." ;
    a m2r:Evidence .

civice:2994
    dct:references pbm:24868098 ;
    civico:citation "Khozin et al., 2014, Oncologist" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations." ;
    a m2r:Evidence .

civice:2995
    dct:references pbm:24868098 ;
    civico:citation "Khozin et al., 2014, Oncologist" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations." ;
    a m2r:Evidence .

civice:2996
    dct:references pbm:23982599 ;
    civico:citation "Dungo et al., 2013, Drugs" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test" ;
    a m2r:Evidence .

civice:2997
    dct:references pbm:23982599 ;
    civico:citation "Dungo et al., 2013, Drugs" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test" ;
    a m2r:Evidence .

civice:2998
    dct:references pbm:28492898 ;
    civico:citation "Jänne et al., 2017, JAMA" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Selumetinib%28AZD6244%29,civic:drug_Docetaxel ;
    dcterms:description "A phase 3 study of selumetinib and docetaxel in KRAS mutant, previously treated NSCLC. 866 were enrolled and 510 randomized. Median progression-free survival was 3.9 months with selumetinib + docetaxel and 2.8 months with placebo + docetaxel. Median overall survival was 8.7 months with selumetinib + docetaxel and 7.9 months with placebo + docetaxel. Objective response rate was 20.1% with selumetinib + docetaxel and 13.7% with placebo + docetaxel." ;
    a m2r:Evidence .

civice:2999
    dct:references pbm:28453411 ;
    civico:citation "Shepherd et al., 2017, J. Clin. Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A pooled analysis to investigate the prognostic and predictive roles of TP53/KRAS and TP53/EGFR comutations (cm) in randomized trials of adjuvant chemotherapy compared to observational therapy encompassing a total of 3,553 patients. TP53/KRAS cm showed no prognostic effects but a borderline predictive effect (p=0,04) for negative effect of chemotherapy as compared to tp53/KRAS wt/wt. TP53/EGFR cm in was neither prognostic ( P = .83), nor significantly predictive ( P = .86). Similar results were observed for both groups for disease-free survival." ;
    a m2r:Evidence .

civice:3000
    dct:references pbm:28476872 ;
    civico:citation "Skinner et al., 2017, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Radiation ;
    dcterms:description "Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamous cell carcinoma patient samples evaluated with different methods [reverse phase protein array (N=68), mRNA expression array (N=97) or immunohistochemistry (N=114), respectively], increased expression of PD-L1 was also correlated with local failure following radiotherapy as compared to the PD-L1–low expression group (P = 0.01, 1.9 × 10−3, and 9 × 10−4, respectively)." ;
    a m2r:Evidence .

civice:3003
    dct:references pbm:28490518 ;
    civico:citation "Sen et al., 2017, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Olaparib,civic:drug_Prexasertib,civic:drug_Cisplatin ;
    dcterms:description "A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexasertib had strong single agent efficacy and augmented the effect of Olaparib or Cisplatin in either combination, including platinum-resistant models. CHEK1 and MYC overexpression were predictors of response." ;
    a m2r:Evidence .

civice:3007
    dct:references pbm:15256420 ;
    civico:citation "Clark et al., 2004, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_MLN518 ;
    dcterms:description "Murine Ba/F3 cells with FLT3-D835V mutations were evaluated as non-responsive to MLN518. Cells with single FLT3 (D835V) mutants were resistant to MLN518(IC50 > 10uM) whereas cells with FLT3 (ITD) mutants were not resistant to MLN518 (IC50 0.55uM)." ;
    a m2r:Evidence .

civice:3008
    dct:references pbm:15304385 ;
    civico:citation "Yee et al., 2004, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_SU11248 ;
    dcterms:description "Murine Ba/F3 cells with FLT3 D835V mutation were assessed as not sensitive to SU11248.(IC50 = 110nm)" ;
    a m2r:Evidence .

civice:3009
    dct:references pbm:15304385 ;
    civico:citation "Yee et al., 2004, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_SU11248,civic:drug_Cytarabine ;
    dcterms:description "SU11248 + Cytarabin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation (Combination Index = 0.59 for ED50, Combination Index = 0.71 for ED75, Combination Index = 0.82 for ED90)" ;
    a m2r:Evidence .

civice:3010
    dct:references pbm:15304385 ;
    civico:citation "Yee et al., 2004, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_SU11248,civic:drug_Daunorubicin ;
    dcterms:description "SU11248 + Daunorubicin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation. (Combination Index = 0.82 for ED50, Combination Index = 0.72 for ED75, Combination Index = 0.64 for ED90)" ;
    a m2r:Evidence .

civice:3012
    dct:references pbm:23497317 ;
    civico:citation "Kampa-Schittenhelm et al., 2013, Mol. Cancer" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Quizartinib ;
    dcterms:description "Murine Ba/F3 cell line has a restrictive sensitivity to Quizartinib(AC220), a second generation class II tyrosine kinase inhibitor. (IC50 for proliferation = 172nM, IC50 for induction of apoptosis = 888nM)" ;
    a m2r:Evidence .

civice:3013
    dct:references pbm:11595686 ;
    civico:citation "Reles et al., 2001, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cisplatin,civic:drug_Carboplatin ;
    dcterms:description "In a study involving patients with invasive ovarian carcinoma who had undergone surgery, a subset of 73 patients were classified via response to platinum-based chemotherapy as sensitive or resistant/refractory and tested for p53 overexpression (>10% postive stained nuclei). 78% of p53 negative patients were classified as sensitive, in compariston to 39% of p53 positive patients (p=0.001)." ;
    a m2r:Evidence .

civice:3014
    dct:references pbm:11595686 ;
    civico:citation "Reles et al., 2001, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of invasive ovarian carcinoma patients who had undergone surgery, the p53 alteration variant was defined as p53 mutation or p53 overexpression by immunostain (>10% positive). Patients with p53 alterations showed increase in poor tumor cell differentiation (p<0.001) and increase in tumor cellular S-phase fraction (p<0.001). Out of 178 patients, p53 alteration (n=132) was associated with decreased overall survival in comparison to normal p53 (n=46), p=0.007." ;
    a m2r:Evidence .

civice:3015
    dct:references pbm:28202511 ;
    civico:citation "Nukaga et al., 2017, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Osimertinib,civic:drug_Rociletinib ;
    dcterms:description "Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. This study reports that the Src-AKT pathway contributes to acquired resistance to third generation EGFR TKIs. In addition, amplification of EGFR wild-type alleles but not mutant alleles was sufficient to confer acquired resistance." ;
    a m2r:Evidence .

civice:3016
    dct:references pbm:20038723 ;
    civico:citation "Douillard et al., 2010, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations." ;
    a m2r:Evidence .

civice:3017
    dct:references pbm:27283860 ;
    civico:citation "Planchard et al., 2016, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Trametinib ;
    dcterms:description "Patients with BRAF V600E-mutant NSCLC (n=57) were enrolled into a phase 2, multicentre, non-randomised, open-label study, administering dabrafenib plus trametinib. The overall response rate was 36/57 (63.2%, [95% CI 49.3-75.6]) and the median progression-free survival was 9.7 months (95% CI 6.9-19.6). At data cutoff (11.6 months of follow-up), 18/36  (50%) confirmed responses were ongoing and 23/57 (40%) of patients had died." ;
    a m2r:Evidence .

civice:3027
    dct:references pbm:27315356 ;
    civico:citation "Lim et al., 2016, Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dovitinib ;
    dcterms:description "Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partial response, 38.5% exhibited stable disease. Median PFS was 2.9 months, median OS was 5 months, this trend was worse with increases in FGFR1 amplification above average." ;
    a m2r:Evidence .

civice:3028
    dct:references pbm:22114577 ;
    civico:citation "Cameron et al., 2011, Case Rep Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Imatinib ;
    dcterms:description "Patient with c-kit-positive mesenchymal tumor in descending part of the duodenum. The patient has received 400mg Imatinib daily for 10 years. He responded well to therapy (Karnofsky index 90%). V559D is a positive predictor of imatinib response with long term usage." ;
    a m2r:Evidence .

civice:3029
    dct:references pbm:16046538 ;
    civico:citation "Carter et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_BMS-354825,civic:drug_PD-180970,civic:drug_Imatinib,civic:drug_MLN518,civic:drug_SU11248 ;
    dcterms:description "KIT(V559D) were expressed in HEK-293 cells (in vitro). Imatinib, BMS-354825, PD-180970, MLN-518, and SU-11248 bind variant V559D with high affinity (Kd =< 20 nM), and inhibit KIT autophosphorylation. Despite similar binding affinities, the cellular activity of BMS-354825 was >10-fold greater than that of SU-11248 or PD-180970, and the authors hypothesize that additional pharmaceutical properties may contribute to the greater cellular potency." ;
    a m2r:Evidence .

civice:3034
    dct:references pbm:17330097 ;
    civico:citation "Griessinger et al., 2007, Leukemia" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AS602868,civic:drug_AG1296 ;
    dcterms:description "Murine Ba/F3 cells with FLT3 D835V mutation were assessed as sensitive to both AS602868 and AG1296.(IC50 = 1.85uM and IC50 = 4.55uM, respectively)" ;
    a m2r:Evidence .

civice:3038
    dct:references pbm:25952648 ;
    civico:citation "Cheng et al., 2015, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib,civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "In this study the authors screened for growth factors that elicited resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibitors, trametinib and selumetinib, showing that neuregulin 1 (NRG1) and hepatocyte growth factor (HGF) provide resistance to MEK inhibition. Trametinib enhances the responsiveness to NRG1 and sustained HGF-mediated activation of AKT. Targeting ERBB3 and cMET could overcome resistance to trametinib." ;
    a m2r:Evidence .

civice:3039
    dct:references pbm:28489509 ;
    civico:citation "Hyman et al., 2017, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_AZD-5363 ;
    dcterms:description "AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363. 58 patients with advanced solid tumors were treated. In patients with AKT1 E17K-mutant tumors (n = 52) and a median of 5 lines of prior therapy, the median PFS was 5.5 months , 6.6 months and 4.2 months in patients with ER+ breast, gynecologic, and other solid tumors, respectively. In an exploratory biomarker analysis, imbalance of the AKT1 E17K-mutant allele, most frequently caused by copy-neutral loss-of-heterozygosity targeting the wild-type allele, was associated with longer PFS as was the presence of coincident PI3K pathway hotspot mutations. Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS and response. Responses were not restricted to patients with detectable AKT1 E17K in pretreatment cfDNA." ;
    a m2r:Evidence .

civice:3040
    dct:references pbm:28489509 ;
    civico:citation "Hyman et al., 2017, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study of 37 patients with AKT1 (E13K) mutations, 5 patients harbored a concurrent PI3K/mTOR pathway alteration. The PFS of patients with a concurrent PI3K/mTOR pathway alteration was significantly longer than those without when treated with AZD-5363 (median PFS, not reached v 4.3 months, respectively; HR, 0.21; P = 0.045)." ;
    a m2r:Evidence .

civice:3042
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248Q loss of function mutation is present in 5 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:3043
    dct:references pbm:18832571 ;
    civico:citation "Lazar et al., 2008, Am. J. Pathol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). Because of their low frequency, patients with S45P mutations were excluded from these analyses but showed a recurrence course similar to T41A or wild type patients." ;
    a m2r:Evidence .

civice:3044
    dct:references pbm:18832571 ;
    civico:citation "Lazar et al., 2008, Am. J. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In an analysis of 138 desmoid fibromatosis tumors, which is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence, 117 tumors (85%) had CTNNB1 mutations. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors." ;
    a m2r:Evidence .

civice:3045
    dct:references pbm:26788326 ;
    civico:citation "Lu et al., 2016, Endocrinol Diabetes Metab Case Rep" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_RadioactiveIodine ;
    dcterms:description "A 79 year old patient with prior history of graves' disease presented with follicular thyroid carcinoma. Two mutations NRAS p.Q61K and GNAS p.R201H were detected. The thyroid cancer manifested as a 13.5 cm mass. There were minimal lung, humerus and T9 spine metastases, and exhibited a very good response to the radioactive iodine treatment after he had underwent total thyroidectomy and bilateral neck dissection. They also screened other 23 fatal cases and revealed that none of them had GNAS p.R201H mutation. But two of them had NRAS p.Q61K mutation." ;
    a m2r:Evidence .

civice:3046
    dct:references pbm:28486044 ;
    civico:citation "Jones et al., 2017, J. Clin. Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This study of  9,643 patients characterized clinical implications of non-V600 BRAF mutations in metastatic CRC. Of the patients with metastatic CRC that underwent NGS testing, 208 patients had non-V600 BRAF mutations (22% of BRAF mutations identified and 2.2% of total patients tested ). When compared to V600 BRAF mutations, tumors without V600 BRAF mutations were more prevalent in younger patients (58 v 68 years, respectively) and male patients (65% vs 46%, respectively). Additionally, non-V600 BRAF mutations were less prevalent in high-grade tumors (13% v 64%, respectively) and right-sided primary tumors (36% v 81%, respectively). Median overall survival was significantly longer in patients with non-V600 BRAF-mutant metastatic CRC compared with those with both V600E BRAF-mutant and wild-type BRAF metastatic CRC (60.7 v 11.4 v 43.0 months)." ;
    a m2r:Evidence .

civice:3049
    dct:references pbm:28103611 ;
    civico:citation "Daud et al., 2017, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cabozantinib ;
    dcterms:description "A randomized phase II trial assessing the efficacy of Cabozantinib in metastatic melanoma. 77 patients (62% cutaneous, 30% uveal, 8% mucosal). Patients received cabozantinib 100 mg/d during a 12-week lead-in. Patients with stable disease (SD; RECIST) at week 12 were randomised to cabozantinib or placebo. During lead-in phase 55% of evaluable patients showed reduction in target lesion size (59% uveal melanoma). Uveal melanoma cohort included 23 patients, 9 with GNAQ (n=5) and GNA11 (n=4) mutations. Responses were reported in mutational patients. In the uveal melanoma cohort, 61% of patients (14/23) had SD at week 12, and no patient had a PR, resulting in an overall disease control rate of 61%. The median PFS for the 23 patients with uveal melanoma was 4.8 months." ;
    a m2r:Evidence .

civice:3693
    dct:references pbm:25666295 ;
    civico:citation "Kaczirek et al., 2015, Clin Colorectal Cancer" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS." ;
    a m2r:Evidence .

civice:3710
    dct:references pbm:26161928 ;
    civico:citation "Camaj et al., 2015, Future Oncol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Regorafenib ;
    dcterms:description "In an in vitro study, a SW48 cell line expressing KRAS G12A mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 330.13 nmol vs. 114.28 nmol, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability." ;
    a m2r:Evidence .

civice:3715
    dct:references pbm:21969500 ;
    civico:citation "Brugger et al., 2011, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherpy. The study was not powered for prognostic tests, but it was still found that KRAS Mutant status was a significant negative prognostic factor on progression free survival. (HR, 1.50; 95% CI, 1.06 to 2.12; P=0.20)" ;
    a m2r:Evidence .

civice:3722
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) used PIK3CA E545K as a positive control for testing resistance to BRAF inhibition by vemurafenib. M229 cells virally transduced with PIK3CA E545K were significantly more resistant to vemurafenib-mediated growth suppression than cells transduced with empty vectors (50% vs 20% survival at the highest concentration, p <.0001). Furthermore, E545K appears to confer more resistance to vemurafenib than PIK3CA D350G and similar levels of resistance as E545G. Resistance was determined by assessing cell survival." ;
    a m2r:Evidence .

civice:3724
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA E545G were significantly more resistant to BRAF inhibition by vemurafenib than cells transduced with an empty vector (50% vs 20% survival at the highest concentration, p < .0001). Though statistics were not provided, E545G appears to confer similar levels of resistance to vemurafenib as the positive control variant, PIK3CA E545K." ;
    a m2r:Evidence .

civice:3739
    dct:references pbm:25666295 ;
    civico:citation "Kaczirek et al., 2015, Clin Colorectal Cancer" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with BRAF V600E (n=14) mutation treated with FOLFOX4 plus cetuximab were associated with a decreased progression free survival (7.2mo vs. 9.7mo, HR:0.39, 95% CI:0.21-0.72, P=0.0017), and decreased overall survival (11.7mo vs. 28.5mo, HR:0.23, 95% CI:0.12-0.41, P<0.0001), as compared to patients with wildtype BRAF." ;
    a m2r:Evidence .

civice:3750
    dct:references pbm:23569304 ;
    civico:citation "Trunzer et al., 2013, J. Clin. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In a phase 2 clinical trial (NCT00949702) of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, patients harboring BRAF V600E (n=123) or V600K (n=9) mutations were associated with a favorable objective response rate (53% per RECIST v1.1 criteria, 70/132), with 6% (8/132) and 47% (62/132) of patients achieving complete response and partial response, respectively." ;
    a m2r:Evidence .

civice:3755
    dct:references pbm:26557775 ;
    civico:citation "Rutkowski et al., 2015, Contemp Oncol (Pozn)" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In a  clinical study of Polish, stage IIIC/IV, melanoma patients with metastases (n=75) harboring BRAF V600 mutation (as detected by cobas 4800 BRAF V600 Mutation Test), patients were associated with a 61.9% (95% CI: 50.1-73.6) median overall survival, a 7.4 months (95% CI: 5.5-9.2) median progression free survival; a median duration response of 7.4 months was reported, with 3% (2/75) and 43% (29/75) of patients achieving a complete and partial response, respectively." ;
    a m2r:Evidence .

civice:3757
    dct:references pbm:25524477 ;
    civico:citation "Ugurel et al., 2015, Ann. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600E mutation (n=175) were associated with a 4.8% (8/167) complete response, a 58.1% (97/167) partial response and stable disease in 22.2% (37/167) of cases; however, 15% (25/167) of patients harboring BRAF V600E experienced progressive disease." ;
    a m2r:Evidence .

civice:3758
    dct:references pbm:25399551 ;
    civico:citation "Robert et al., 2015, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib,civic:drug_Dabrafenib ;
    dcterms:description "In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600E mutation and treated with vemurafenib (n=317) were associated with a 52% response rate, as compared to a 64% response rate in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=312)." ;
    a m2r:Evidence .

civice:3777
    dct:references pbm:25524464 ;
    civico:citation "del Bufalo et al., 2014, J Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In a case report, a cervicomedullary ganglioglioma patient harboring BRAF V600E mutation was associated with radiological and clinical response to vemurafenib monotherapy after 3 months of treatment, which was sustained after 6 months of therapy. Prior to vemurafenib treatment, the patient had undergone tracheotomy, was treated with standard chemotherapy and underwent another surgery, but had developed progressive disease." ;
    a m2r:Evidence .

civice:3787
    dct:references pbm:26490654 ;
    civico:citation "Combe et al., 2015, Invest New Drugs" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy, hormone therapy and bevacizumab prior to the identification of the BRAF V600E mutation; next, the patient was treated with paclitaxel and an anti-HER3 antibody and finally with vemurafenib, obtaining a partial response of greater than 1 year." ;
    a m2r:Evidence .

civice:3791
    dct:references pbm:22285168 ;
    civico:citation "Rosell et al., 2012, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "The phase 3 (EURTAC) study consisted of of 173 non-small cell lung cancer patients who had not had prior chemotherapy for metastatic disease (although adjuvant or neoadjuvant chemotherapy was permitted) and included 160 patients with lung adenocarcinoma subtype. The patients had EGFR mutations (exon 19 deletions or L858R), and improved progression-free survival was reported in the erlotinib treated cohort as compared to the cohort that was treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis)." ;
    a m2r:Evidence .

civice:3792
    dct:references pbm:21969500 ;
    civico:citation "Brugger et al., 2011, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy. It was found that EGFR Mutant status was a significant positive prognostic factor for overall survival. (HR, 0.33; 95% CI, 0.19 to 0.59; P<0.01)" ;
    a m2r:Evidence .

civice:3794
    dct:references pbm:15329413 ;
    civico:citation "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a phase II trial for Bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to Erlotinib, and 10 patients who did not.  EGFR mutations were seen in 5/7 responders but not in any of the non-responders, which was a significant result (p=0.003)." ;
    a m2r:Evidence .

civice:3802
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21. All patients had L861Q mutation and were treated with the 1st generation TKI gefitinib. 4 patients had partial response with progression free survival (PFS) of 4.3, 19.3, 10.0, 8.7 months; overall survival (OS) of 4.3, 34.9, 15.7, 15.7 months; and all 4 were alive at study end. One patient had stable disease, PFS 6.5 months, OS 15.2 months, and was not alive at study end. One patient had progressive disease as response, with PFS of 2.8 months, OS of 10.7 months, and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:3810
    dct:references pbm:19147750 ;
    civico:citation "Kancha et al., 2009, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "Experimental - EGFR T790M mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study, Ba/F3 cells stably expressing EGFR T790M demonstrated  resistance to gefitinib and erlotinib and the tool construct AEE788. These cells had very high IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib>2000, Erlotinib>2000, AEE788>2000), indicating resitance to all three inhibitors." ;
    a m2r:Evidence .

civice:3811
    dct:references pbm:19147750 ;
    civico:citation "Kancha et al., 2009, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib,civic:drug_AEE788 ;
    dcterms:description "EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors Gefitinib, Erlotinib, or the the tool compound AEE788, and IC50 values were measured. L858R EGFR cells had very low IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib=12, Erlotinib=6, AEE788=6), indicating sensitivity to all three constructs." ;
    a m2r:Evidence .

civice:3815
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F359V evaluated, 6/6 had complete hematologic responses and 4/7 had major cytogenetic responses." ;
    a m2r:Evidence .

civice:3819
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase) patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of the 27 with F359V mutations, 14, 17, and 25 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:3851
    dct:references pbm:22256804 ;
    civico:citation "Su et al., 2012, N. Engl. J. Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy, a patient harboring HRAS G13D co-mutation (n=1) was reported to be resistant to vemurafenib treatment." ;
    a m2r:Evidence .

civice:3852
    dct:references pbm:26561417 ;
    civico:citation "Boidot et al., 2016, Int J Colorectal Dis" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressing wild-type HRAS." ;
    a m2r:Evidence .

civice:3858
    dct:references pbm:25666295 ;
    civico:citation "Kaczirek et al., 2015, Clin Colorectal Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_FOLFOX4,civic:drug_Cetuximab ;
    dcterms:description "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations and wildtype BRAF (n=10), including A146T (N=3), G15D (N=1), and V152M/NRAS V160A, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS, NRAS and BRAF." ;
    a m2r:Evidence .

civice:3862
    dct:references pbm:22722830 ;
    civico:citation "Misale et al., 2012, Nature" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In a colorectal cancer patient with a KRAS Q61H mutation, KRAS Q61H was reported to be refractory to cetuximab treatment. The patient was treated with cetuximab and irinotecan for 18 months, had a partial response to therapy and then experienced progressive disease with a re-biopsy of the tumor identifying a KRAS Q61H mutation." ;
    a m2r:Evidence .

civice:3878
    dct:references pbm:22722830 ;
    civico:citation "Misale et al., 2012, Nature" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability." ;
    a m2r:Evidence .

civice:3882
    dct:references pbm:25666295 ;
    civico:citation "Kaczirek et al., 2015, Clin Colorectal Cancer" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS." ;
    a m2r:Evidence .

civice:3895
    dct:references pbm:21969500 ;
    civico:citation "Brugger et al., 2011, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, KRAS mutation was assessed. In the KRAS wildtype group, erlotinib showed a significant benefit for progression free survival (PFS) over placebo (HR, 0.70; 95% CI, 0.57 to 0.87, P<0.001). No statistically significant improvement in PFS was seen with erlotinib in the KRAS mutant group over placebo. Significant difference in PFS between erlotinib treated KRAS WT and MUT patients was not seen.  Overall, in the intent to treat population erlotinib significantly improved PFS over placebo (HR, 0.71; 95% CI, 0.62 to 0.82; P<0.001)." ;
    a m2r:Evidence .

civice:3924
    dct:references pbm:26161928 ;
    civico:citation "Camaj et al., 2015, Future Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Regorafenib ;
    dcterms:description "In an in vitro study,  a SW48 cell line expressing KRAS G12V mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 241.90 nmol vs. 114.28 nmol, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability." ;
    a m2r:Evidence .

civice:3946
    dct:references pbm:26161928 ;
    civico:citation "Camaj et al., 2015, Future Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Regorafenib ;
    dcterms:description "In an in vitro study, a SW48 cell line expressing KRAS G12D mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 195.01nmol vs. 114.28 nmol P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability." ;
    a m2r:Evidence .

civice:3957
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express KRAS4a G12D or KRAS4b G12D  were more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with empty vectors (90% vs 10% survival)." ;
    a m2r:Evidence .

civice:3958
    dct:references pbm:22246397 ;
    civico:citation "Sato et al., 2012, Oncol. Rep." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In an in vitro study, a MCAS cell line expressing KRAS G12D mutation was associated with reduced sensitivity to cetuximab treatment as compared to RMUG-L and OMC-1 cells expressing wild-type KRAS. Resistance was determined by assessing cell growth. Further, in an in vivo experiment, KRAS G12D expressing MCAS xenografts in nude mice had reduced response to cetuximab, as compared to KRAS wild-type expressing RMUG-L xenografts. Resistance was determined by assessing tumor growth." ;
    a m2r:Evidence .

civice:3973
    dct:references pbm:26161928 ;
    civico:citation "Camaj et al., 2015, Future Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Regorafenib ;
    dcterms:description "In an in vitro study, a SW48 cell line expressing KRAS G12C mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 386.22 nmol vs. 114.28 nmol, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability." ;
    a m2r:Evidence .

civice:3989
    dct:references pbm:22722830 ;
    civico:citation "Misale et al., 2012, Nature" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In an in vitro study to identify cetuximab-resistant clones following continuous drug treatment, a resistant clone of the Lim1215 colorectal cancer cell line was identified to have the KRAS G12R mutation. No G12R was detected in the parental line despite high-resolution evaluation. Additionally, endogenously expressing KRAS G12R (knock-in) mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability." ;
    a m2r:Evidence .

civice:3991
    dct:references pbm:26161928 ;
    civico:citation "Camaj et al., 2015, Future Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Regorafenib ;
    dcterms:description "In an in vitro study, a SW48 cell line expressing KRAS G12R mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 181.77 nmol vs. 114.28 nmol, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability." ;
    a m2r:Evidence .

civice:4012
    dct:references pbm:26161928 ;
    civico:citation "Camaj et al., 2015, Future Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Regorafenib ;
    dcterms:description "In an in vitro study, a SW48 cell line expressing KRAS G12S mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 264.23 nmol vs. 114.28 nmol, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability." ;
    a m2r:Evidence .

civice:4022
    dct:references pbm:15459012 ;
    civico:citation "Fiedler et al., 2005, Blood" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Sunitinib ;
    dcterms:description "In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 D835 mutation (n=2) were associated with improved response to sunitinib treatment (2/2 vs. 2/7) compared to FLT3 wild-type patients. The FLT3 D835 mutation positive patients were treated with sunitinib after failure of standard chemotherapy. After 4wk of sunitinib therapy, one patient showed morphological response and the other patient showed partial response to sunitinib therapy." ;
    a m2r:Evidence .

civice:4029
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 E17K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival." ;
    a m2r:Evidence .

civice:4032
    dct:references pbm:22199315 ;
    civico:citation "Lv et al., 2011, Anticancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In a  clinical study of 63 recurrent glioma patients, de novo glioblastoma patients treated with cetuximab monotherapy (n=27) and harboring IDH1 codon 132 mutation were associated with improved overall survival (5.13 months vs. 0.90 months, 95% CI: 1.8, P=0.035), as compared to patients with wild-type IDH1." ;
    a m2r:Evidence .

civice:4060
    dct:references pbm:18955458 ;
    civico:citation "Heinrich et al., 2008, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Sunitinib ;
    dcterms:description "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to sunitinib treatment (IC50>1000 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation." ;
    a m2r:Evidence .

civice:4180
    dct:references pbm:25524477 ;
    civico:citation "Ugurel et al., 2015, Ann. Oncol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600K mutation (n=18) were associated with a 5.6% (1/18) complete response, a 22.2% (4/18) partial response and stable disease in 44.4% (8/18) of cases; however, 27.8% (5/18) of patients harboring BRAF V600K experienced progressive disease and patients with BRAF V600E mutation achieved a more impressive clinical benefit, as compared to patients with BRAF V600K mutation (P=0.016)." ;
    a m2r:Evidence .

civice:4181
    dct:references pbm:25399551 ;
    civico:citation "Robert et al., 2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib,civic:drug_Dabrafenib ;
    dcterms:description "In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600K mutation and treated with vemurafenib (n=34) were associated with a 44% response rate, as compared to a 65% response rate in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=34)." ;
    a m2r:Evidence .

civice:4186
    dct:references pbm:17177598 ;
    civico:citation "Lee et al., 2006, PLoS Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4187
    dct:references pbm:17177598 ;
    civico:citation "Lee et al., 2006, PLoS Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR T263P demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4188
    dct:references pbm:17177598 ;
    civico:citation "Lee et al., 2006, PLoS Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR A289V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0–10 uM)." ;
    a m2r:Evidence .

civice:4189
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib,civic:drug_Gefitinib ;
    dcterms:description "EGFR G719 mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In a study of patients treated with erlotinib or gefitinib, a subset of patients with EGFR mutation at codons G719 or L861 (n=30) was associated with improved response rate (47.5% vs 16.5%, P<0.001) median progression free survival (5.0 vs 2.0 months, P<0.001), and overall survival (15.0 vs. 10.4 months, P =0.030), compared to patients with wild-type EGFR (n=272)." ;
    a m2r:Evidence .

civice:4190
    dct:references pbm:19147750 ;
    civico:citation "Kancha et al., 2009, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR G719S and EGFR L858R expressing cells were 16 nmol/L and 6 nmol/L, respectively." ;
    a m2r:Evidence .

civice:4197
    dct:references pbm:19147750 ;
    civico:citation "Kancha et al., 2009, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 21 nmol/L and 6 nmol/L, respectively." ;
    a m2r:Evidence .

civice:4201
    dct:references pbm:21969500 ;
    civico:citation "Brugger et al., 2011, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, EGFR mutation was assessed. In patients with EGFR mutation, erlotinib maintenance reduced progression and death significantly with median progression free survival (PFS) of 44.6 vs. 13 weeks over placebo. Erlotinib also significantly improved PFS in EGFR wildtype patients, but EGFR mutant tumors treated with erlotinib had significant better PFS than EGFR wildtype. Overall, in the intent to treat population erlotinib significantly improved PFS over placebo (HR, 0.71; 95% CI, 0.62 to 0.82; P<0.001)." ;
    a m2r:Evidence .

civice:4210
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib,civic:drug_Gefitinib ;
    dcterms:description "In a study, 2 participants with stage IV lung adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have G719D mutation and were treated with the 1st generation TKIs gefitinib or erlotinib. The first patient (M, 81, smoker) was treated with gefitinib and had a partial response, progression free survival (PFS) of 21.7 months, overall survival (OS) of 22.5 months and was alive at study end. The second patient (M, 76, smoker) was treated with erlotinib and had stable disease as response, PFS of 2.6 months, OS of 2.6 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:4220
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a study, 2 participants with stage IV adenocarcinoma were sequenced at EGFR exons 18 to 21.  Both patients were found to have L747P mutation and were treated with the 1st generation TKIs gefitinib or erlotinib. The first patient (M, 62, nonsmoker) was treated with gefitinib and had progressive disease, progression free survival (PFS) of 1.0 months, overall survival (OS) of 7.7 months and was not alive at study end. The second patient (M, 39, nonsmoker) was treated with erlotinib and had progressive disease as response, PFS of 2.3 months, OS of 7.2 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:4226
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774A mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 51, nonsmoker) had a partial response, progression free survival (PFS) of 6.9 months, overall survival (OS) of 29.7 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:4231
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib. The patient (M, 80, smoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 6.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:4239
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have K806E mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, nonsmoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 28.1 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:4244
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N826Y mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 46, nonsmoker) had progressive disease as response, progression free survival (PFS) of 3.3 months, overall survival (OS) of 13.9 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:4248
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V834I mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 79, nonsmoker) had a partial response, progression free survival (PFS) of 5.0 months, overall survival (OS) of 15.0 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:4252
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L838P mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 66, nonsmoker) had a partial response, progression free survival (PFS) of 15.2 months, overall survival (OS) of 29.3 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:4256
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N842S mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 73, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.9 months, overall survival (OS) of 9.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:4260
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have T847I mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, smoker) progressive disease as response, progression free survival (PFS) of 1.1 months, overall survival (OS) of 1.1 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:4264
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplications in exon 20 (n=25). Patients with EGFR deletions in exon 19 or L858R mutations were associated with an improved response to erlotinib or gefitinib with partial or complete response (74.1% vs. 16.5%, P<0.001) when compared to wildtype EGFR patients. Additionally, tumors with EGFR mutations in L858R or deletions in exon 19 were associated with increased overall survival (19.6mo vs. 10.4mo) compared to wildtype (all patients were treated with either erlotinib or gefitinib)." ;
    a m2r:Evidence .

civice:4265
    dct:references pbm:17877814 ;
    civico:citation "de Gunst et al., 2007, Mol. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells. Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM). Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.  These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib." ;
    a m2r:Evidence .

civice:4266
    dct:references pbm:19147750 ;
    civico:citation "Kancha et al., 2009, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR L747_P753>S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L747_P753>S and EGFR L858R expressing cells were 5 nmol/L and 6 nmol/L, respectively." ;
    a m2r:Evidence .

civice:4273
    dct:references pbm:22895145 ;
    civico:citation "Lund-Iversen et al., 2012, J Thorac Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously treated with standard chemotherapy." ;
    a m2r:Evidence .

civice:4274
    dct:references pbm:19147750 ;
    civico:citation "Kancha et al., 2009, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR S768I demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR S768I and EGFR L858R expressing cells were 250 nmol/L and 6 nmol/L, respectively." ;
    a m2r:Evidence .

civice:4275
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment (IC50=3.187�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155�M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation." ;
    a m2r:Evidence .

civice:4276
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR H773_V774insH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.902�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155�M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation." ;
    a m2r:Evidence .

civice:4279
    dct:references pbm:20942962 ;
    civico:citation "Foster et al., 2010, World J Surg Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a COS-7 cell line expressing EGFR R831H demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4280
    dct:references pbm:19147750 ;
    civico:citation "Kancha et al., 2009, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L838V and EGFR L858R expressing cells were 160 nmol/L and 6 nmol/L, respectively." ;
    a m2r:Evidence .

civice:4284
    dct:references pbm:18408761 ;
    civico:citation "Li et al., 2008, Oncogene" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells." ;
    a m2r:Evidence .

civice:4285
    dct:references pbm:21132006 ;
    civico:citation "Harada et al., 2011, Oncogene" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation." ;
    a m2r:Evidence .

civice:4286
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006�M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability." ;
    a m2r:Evidence .

civice:4287
    dct:references pbm:27612423 ;
    civico:citation "Ray et al., 2016, Oncotarget" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density." ;
    a m2r:Evidence .

civice:4288
    dct:references pbm:22235099 ;
    civico:citation "Doebele et al., 2012, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In a non-small cell lung cancer patient with an EGFR L858R mutation, EGFR L858R was reported to be refractory to 61-day crizotinib treatment." ;
    a m2r:Evidence .

civice:4290
    dct:references pbm:27032107 ;
    civico:citation "De Grève et al., 2016, PLoS ONE" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR L858R mutation was associated with resistance to erlotinib treatment; the patient survived 3.9 months, as compared to the overall 24 months median overall survival of the other patients who were not resistant to erlotinib treatment." ;
    a m2r:Evidence .

civice:4291
    dct:references pbm:27102076 ;
    civico:citation "Konduri et al., 2016, Cancer Discov" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation, and EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4292
    dct:references pbm:27102076 ;
    civico:citation "Konduri et al., 2016, Cancer Discov" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to cetuximab treatment. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation and EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4293
    dct:references pbm:24893891 ;
    civico:citation "Cross et al., 2014, Cancer Discov" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated an sensitivity to erlotinib (IC50: 8.0-11.0 nmol/L vs 108.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type)." ;
    a m2r:Evidence .

civice:4294
    dct:references pbm:24893891 ;
    civico:citation "Cross et al., 2014, Cancer Discov" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to erlotinib (IC50: 8.0-11.0 nmol/L vs 108.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type)." ;
    a m2r:Evidence .

civice:4295
    dct:references pbm:17177598 ;
    civico:citation "Lee et al., 2006, PLoS Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4298
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib,civic:drug_Gefitinib ;
    dcterms:description "EGFR L861 mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In a study of patients treated with erlotinib or gefitinib, a subset of patients with EGFR mutation at codons G719 or L861 (n=30) was associated with improved response rate (47.5% vs 16.5%, P<0.001) median progression free survival (5.0 vs 2.0 months, P<0.001), and overall survival (15.0 vs. 10.4 months, P =0.030), compared to patients with wild-type EGFR (n=272)." ;
    a m2r:Evidence .

civice:4299
    dct:references pbm:17177598 ;
    civico:citation "Lee et al., 2006, PLoS Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR L861Q demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4301
    dct:references pbm:20942962 ;
    civico:citation "Foster et al., 2010, World J Surg Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a COS-7 cell line expressing EGFR E868G demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4302
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 46 patients with M244V mutations,  20, 27, and 45 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4307
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with M244V evaluated, 2/2 had complete hematologic responses and 2/3 had major cytogenetic responses." ;
    a m2r:Evidence .

civice:4310
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L248V evaluated, 3/3 had complete hematologic responses and 2/3 had major cytogenetic responses." ;
    a m2r:Evidence .

civice:4313
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with G250E evaluated, 1/1 had a complete hematologic response and 2/2 had major cytogenetic responses." ;
    a m2r:Evidence .

civice:4316
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of 60 patients with G250E mutations, 20, 29, and 56 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4327
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of 6 patients with  Q252H mutations, 1, 1, and 3 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations. The authors identify Q252H as one of 4 variants with a low CCyR but advise caution when interpreting these results due to low sample size." ;
    a m2r:Evidence .

civice:4331
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with Y253H evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4335
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 23 patients with the Y253H mutation, 14, 15, and 20 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4340
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with Y253F evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4348
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E255K evaluated, 2/2 had complete hematologic responses and 1/2 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4350
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 16 patients with E255K mutations, 6, 9, and 14 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4357
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with D276G evaluated, 1/1 had a complete hematologic responses and 0/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4359
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 8 patients with D276G mutations, 3, 4, and 7 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4364
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with T315I evaluated, 1/2 had a complete hematologic response and 0/3 had major cytogenetic responses." ;
    a m2r:Evidence .

civice:4365
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 21 patients with T315I mutations, 0, 2, and 6 achieved CCyR, MCyR, and CHR to dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations. Of the 63 variants considered, the authors associate T315I, F317L, and V299L with resistance to dasatinib or lower levels of response due to clinical resistance and low in vitro sensitivity. They suggest considering alternative treatment options for patients with these variants." ;
    a m2r:Evidence .

civice:4381
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F317L evaluated, 3/3 had major cytogenetic responses." ;
    a m2r:Evidence .

civice:4396
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 54 patients with M351T mutations, 25, 28, and 51 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4400
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E355G evaluated, 2/2 had complete hematologic responses and 1/2 had major cytogenetic responses." ;
    a m2r:Evidence .

civice:4403
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 19 patients with E355G mutations, 4, 9, and 17 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4406
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 5 patients with L387M mutations, 4, 4, and 5 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4411
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with H396R evaluated, 1/1 had a complete hematologic response." ;
    a m2r:Evidence .

civice:4413
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 33 patients with H396R mutations, 13, 17, and 30 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4443
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E255V evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4447
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 11 patients with E255V mutations, 4, 4, and 9 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4468
    dct:references pbm:19147750 ;
    civico:citation "Kancha et al., 2009, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 47 nmol/L and 6 nmol/L, respectively." ;
    a m2r:Evidence .

civice:4472
    dct:references pbm:26989027 ;
    civico:citation "Hsu et al., 2016, Oncotarget" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to be non-responders to cetuximab in combination with irinotecan, (BRAF mutation positive: responders vs. non-responders = 0 vs. 6; BRAF wild-type: responders vs. non-responders 30 vs. 17; P=0.004), as compared to patients with wild-type BRAF." ;
    a m2r:Evidence .

civice:4475
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L298V evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4478
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F311I evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4482
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 5 patients with F359C mutations, 3, 3, and 4 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4486
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E453Q evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4487
    dct:references pbm:27364904 ;
    civico:citation "Miller et al., 2016, Mol. Cancer Ther." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, a HCT116 cell line expressing ARID1A Q456* mutation demonstrated increased sensitivity to dasatinib treatment, compared to HCT116 cells expressing wild-type ARID1A. Sensitivity was determined by assessing cell survival." ;
    a m2r:Evidence .

civice:4488
    dct:references pbm:18287029 ;
    civico:citation "Tsai et al., 2008, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In an in vitro study, WM2664, a BRAF V600D expressing cell line, demonstrated improved sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells. Sensitivity was determined by assessing cell proliferation (WM2664, GI50: 1.5uM; vs. BRAF expressing cells (n=9) GI50: 10-41uM)." ;
    a m2r:Evidence .

civice:4489
    dct:references pbm:20551065 ;
    civico:citation "Yang et al., 2010, Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In an in vitro study, the WM2664 and WM239A cell lines expressing BRAF V600D were associated with increased sensitivity to vemurafenib treatment, as compared to cell lines expressing BRAF wild-type. Sensitivity was determined by proliferation assay." ;
    a m2r:Evidence .

civice:4493
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a lung adenocarcinoma patient harboring EGFR H773_V774insNPH mutation, EGFR H773_V774insNPH was associated with progressive disease in response to erlotinib monotherapy." ;
    a m2r:Evidence .

civice:4494
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and treated with erlotinib monotherapy, patients with EGFR D770_N771insGL mutation (n=3) experienced progressive disease." ;
    a m2r:Evidence .

civice:4495
    dct:references pbm:19147750 ;
    civico:citation "Kancha et al., 2009, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR A864T and EGFR L858R expressing cells were 49 nmol/L and 6 nmol/L, respectively." ;
    a m2r:Evidence .

civice:4496
    dct:references pbm:19147750 ;
    civico:citation "Kancha et al., 2009, Clin. Cancer Res." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR N826S and EGFR L858R expressing cells were 505 nmol/L and 6 nmol/L, respectively." ;
    a m2r:Evidence .

civice:4497
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, Ba/F3 and BID007 cell lines expressing EGFR A763_Y764insFQEA demonstrated increased sensitivity to erlotinib treatment (IC50=0.048�M and 0.082�M, respectively), comparable to Ba/F3 and NCI-H3255 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=0.006�M and 0.068�M, respectively). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability." ;
    a m2r:Evidence .

civice:4498
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 Q79K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival." ;
    a m2r:Evidence .

civice:4500
    dct:references pbm:17177598 ;
    civico:citation "Lee et al., 2006, PLoS Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR vIII demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4521
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express AKT3 E17K were significantly more resistant to BRAF inhibition via vemurafenib than cells transduced with empty vectors (40% vs 20% survival, p = .0033)." ;
    a m2r:Evidence .

civice:4527
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, a majority of patients with and without ABL1 mutation had comparable complete hematologic response, major cytogenetic response, complete cytogenetic response (CCyR), and major molecular response. However, out of 2 patients with the L384M mutation, 0 achieved CCyR with dasatinib monotherapy. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4530
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F359I evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4532
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 12 patients with F359I mutations, 7, 10, and 12 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4540
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response, major cytogenetic response, complete cytogenetic response (CCyR), and major molecular response. There was 1 patient with a V299L mutation who did not achieved CCyR with dasatinib monotherapy. Analyses by variant included patients with multiple kinase domain mutations. Of the 63 variants considered, the authors associate T315I, F317L, and V299L with resistance to dasatinib or lower levels of response due to clinical resistance and low in vitro sensitivity. They suggest considering alternative treatment options for patients with these variants." ;
    a m2r:Evidence .

civice:4543
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 8 patients with E279K mutations, 5, 5, and 8 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4546
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F311L evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4549
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with N331S evaluated, 1/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4551
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L364P evaluated, 1/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4554
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with H396P evaluated, 1/1 had a complete hematologic response and 2/2 had major cytogenetic responses." ;
    a m2r:Evidence .

civice:4559
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with D421G evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4561
    dct:references pbm:19075254 ;
    civico:citation "Redaelli et al., 2009, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, a Ba/F3  cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.27nM vs. IC50: 1.83nM), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation." ;
    a m2r:Evidence .

civice:4563
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E450V evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4565
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E453K evaluated, 1/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4568
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with P480A evaluated, 1/1 had a major cytogenetic response." ;
    a m2r:Evidence .

civice:4571
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 13 patients with F486S mutations, 5, 6, and 12 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:4623
    dct:references pbm:23415752 ;
    civico:citation "Stordal et al., 2013, Mol Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines expressing BRCA1 wild-type. Sensitivity was determined by assessing cytotoxicity and doubling time." ;
    a m2r:Evidence .

civice:4643
    dct:references pbm:23371856 ;
    civico:citation "Arcila et al., 2013, Mol. Cancer Ther." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a lung adenocarcinoma patient harboring EGFR D770_N771insGT mutation, EGFR D770_N771insGT was associated with lack of response to treatment with erlotinib monotherapy." ;
    a m2r:Evidence .

civice:4650
    dct:references pbm:22895145 ;
    civico:citation "Lund-Iversen et al., 2012, J Thorac Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In stage IV lung adenocarcinoma patients (n=2) harboring EGFR inframe exon 20 insertion mutation, EGFR exon 20 insertion was associated with progressive disease after 1 and 3 months of erlotinib monotherapy, respectively; both patients were previously treated with standard chemotherapy." ;
    a m2r:Evidence .

civice:4653
    dct:references pbm:25759020 ;
    civico:citation "Atwood et al., 2015, Cancer Cell" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vismodegib ;
    dcterms:description "In an in vitro study, mouse embryonic fibroblasts (MEFs), null for the Smo mouse gene expressing SMO L412F mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L) compared to MEFs expressing wild-type SMO. Resistance was determined by assessing GLI1 mRNA expression levels." ;
    a m2r:Evidence .

civice:4654
    dct:references pbm:26822128 ;
    civico:citation "Khamaysi et al., 2016, Br. J. Dermatol." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vismodegib ;
    dcterms:description "An Arab basal cell carcinoma patient harboring SMO L412F mutation was associated with response to vismodegib monotherapy. Prior to the identification of the mutation, the patient was treated with acitretin, but did not achieve any response." ;
    a m2r:Evidence .

civice:4655
    dct:references pbm:20942962 ;
    civico:citation "Foster et al., 2010, World J Surg Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a COS-7 cell line expressing EGFR W731L demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4656
    dct:references pbm:20942962 ;
    civico:citation "Foster et al., 2010, World J Surg Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a COS-7 cell line expressing EGFR E734Q demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4657
    dct:references pbm:20942962 ;
    civico:citation "Foster et al., 2010, World J Surg Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a COS-7 cell line expressing EGFR T785A demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4658
    dct:references pbm:20942962 ;
    civico:citation "Foster et al., 2010, World J Surg Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a COS-7 cell line expressing EGFR C797Y demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4659
    dct:references pbm:20942962 ;
    civico:citation "Foster et al., 2010, World J Surg Oncol" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a COS-7 cell line expressing EGFR Y801H demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation." ;
    a m2r:Evidence .

civice:4665
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutations and treated with erlotinib monotherapy, patients with EGFR A767_V769dupASV mutation (n=3) experienced progressive disease." ;
    a m2r:Evidence .

civice:4669
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L861R mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 83, nonsmoker) had a partial response, progression free survival (PFS) of 37.5 months, overall survival (OS) of 53.3 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type." ;
    a m2r:Evidence .

civice:4755
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib,civic:drug_Gefitinib ;
    dcterms:description "In a cohort of NSCLC patients treated with tyrosine kinase inhibitors erlotinib or gefitinib, 61 patients with uncommon mutations of unknown clinical significance (UMUCS) in EGFR exons 18-21 responded at a rate of 47.5% (primarily G719 and L861, N=30/61). This was significantly greater (p<0.001) than a response rate of 16.5% in EGFR wild type patients but significantly smaller (p<0.001) than a 74.1% response in EGFR mutant patients with canonical exon 19 deletion or L858R mutation. Uncommon mutations also had greater median PFS (5.0 vs. 2.0 months, P < 0.001) and median overall survival (15.0 vs. 10.4 months, P = 0.030) than in patients with the wild-type EGFR." ;
    a m2r:Evidence .

civice:4759
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib,civic:drug_Gefitinib ;
    dcterms:description "In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplications in exon 20 (n=25). Patients with EGFR deletions in exon 19 or L858R mutations were associated with an improved response to erlotinib or gefitinib with partial or complete response (74.1% vs. 16.5%, P<0.001) when compared to wildtype EGFR patients. Additionally, tumors with EGFR mutations in L858R or deletions in exon 19 were associated with increased overall survival (19.6mo vs. 10.4mo) compared to wildtype (all patients were treated with either erlotinib or gefitinib). From 61 patients with uncommon EGFR mutations of unknown clinical significance, 47.5% were responders in contrast to the 74.1% responders in the exon 19 deletion/L858R group." ;
    a m2r:Evidence .

civice:4762
    dct:references pbm:21531810 ;
    civico:citation "Wu et al., 2011, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib,civic:drug_Gefitinib ;
    dcterms:description "In a cohort of NSCLC patients tested for mutation in EGFR exons 18-21 a subset had uncommon mutations of unknown clinical significance (UMUCS). The most commonly occurring UMUCS were G719 and L861 mutations. Among patients that had UMUCS but not G719 or L861, the response rate to tyrosine kinase inhibitors erlotinib or gefitinib, progression free survival, and overall survival were 20%, 1.6 month and 11.1 months, which was similar for wild type EGFR (16.5%, 2.0 months and 10.4 months), which contrasted to higher response for more commonly occurring G719 and L861 mutations (53.3% and 60.0%, respectively)." ;
    a m2r:Evidence .

civice:4766
    dct:references pbm:27566387 ;
    civico:citation "Kanemaru et al., 2016, Respir Investig" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response." ;
    a m2r:Evidence .

civice:4776
    dct:references pbm:25765070 ;
    civico:citation "Rizvi et al., 2015, Science" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pembrolizumab ;
    dcterms:description "In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in any patients who did not experience a durable clinical benefit." ;
    a m2r:Evidence .

civice:4777
    dct:references pbm:25765070 ;
    civico:citation "Rizvi et al., 2015, Science" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pembrolizumab ;
    dcterms:description "In a retrospective study of 34 non-small cell lung cancer patients, a patient, who never smoked, with POLD1 deleterious E374K mutation (as determined by Polyphen or SIFT) and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in patients who did not experience a durable clinical benefit." ;
    a m2r:Evidence .

civice:4783
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "An in vitro study of WM2664 (a human melanoma cell line) endogenously expressing wildtype PIK3R2 and BRAF V600D (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3R2 N561D were significantly more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with an empty vector (40% vs 0% survival at the highest concentration, p < .0001)." ;
    a m2r:Evidence .

civice:4784
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA D350G were significantly more resistant to BRAF inhibition by vemurafenib  than cells transduced with empty vectors (40% vs 20% survival at the highest concentration, p=.0148). Though statistics were not provided, D350G appears to confer less resistance to vemurafenib than the positive control variant, PIK3CA E545K." ;
    a m2r:Evidence .

civice:4785
    dct:references pbm:25666295 ;
    civico:citation "Kaczirek et al., 2015, Clin Colorectal Cancer" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS." ;
    a m2r:Evidence .

civice:4786
    dct:references pbm:25769807 ;
    civico:citation "Jenkins et al., 2015, Clin Lung Cancer" ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "In a never-smoking metastatic lung adenocarcinoma patient harboring a MET splice site mutation (c.2887-18_2887-7del12)  treated with crizotinib monotherapy, was  associated with a response as evident by the reduced size of tumors. Prior to identification of the MET splice site mutation, the patient was treated with stereotactic radiotherapy, palliative radiation, and a single cycle of pemetrexed; subsequently, the patient was treated with crizotinib, but progressed at 8 weeks of treatment." ;
    a m2r:Evidence .

civice:4788
    dct:references pbm:26758680 ;
    civico:citation "Testoni et al., 2016, EMBO Mol Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate,civic:drug_Dasatinib ;
    dcterms:description "In this in vitro study, the H2110 non-small cell lung cancer cell line (heterozygous for a G340L mutation) was shown to be susceptible to imatinib and dasatinib monotherapies. This line showed a significant reduction in colony formation (P = 0.0001) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. A significant reduction in colony formation (P < 0.001) with dasatinib treatment vs vehicle was also observed. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Moreover, a significant increase in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.001) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target." ;
    a m2r:Evidence .

civice:4799
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR M766_A767insAI demonstrated reduced sensitivity to erlotinib treatment (IC50=3.403�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155�M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation." ;
    a m2r:Evidence .

civice:4800
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In an in vitro study, a Ba/F3 cell line expressing EGFR Y764_V765insHH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.845�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generations EGFR tyrosine kinase inhibitors; IC50=4.155�M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation." ;
    a m2r:Evidence .

civice:4801
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and treated with erlotinib monotherapy, patients with EGFR delD770insGY mutation (n=2) experienced progressive disease." ;
    a m2r:Evidence .

civice:4802
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a non-small cell lung cancer patient harboring EGFR P772_H773insYNP mutation, EGFR P772_H773insYNP was associated with progressive disease in response to erlotinib monotherapy." ;
    a m2r:Evidence .

civice:4803
    dct:references pbm:24353160 ;
    civico:citation "Yasuda et al., 2013, Sci Transl Med" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Erlotinib ;
    dcterms:description "In a lung adenocarcinoma patient harboring EGFR P772_V774insPHV mutation, EGFR P772_V774insPHV was associated with progressive disease in response to erlotinib monotherapy." ;
    a m2r:Evidence .

civice:4814
    dct:references pbm:27556863 ;
    civico:citation "Gyanchandani et al., 2016, Oncotarget" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Letrozole,civic:drug_Palbociclib ;
    dcterms:description "In a study of 16 patients with metastatic breast cancer (NCT02142868) treated with palbociclib in combination with letrozole, patients with ESR1 mutations (5/16), including ESR1 D538G (n=2), detected at any time or at initial blood draw, were associated with reduced progression free survival (HR=0.31, 95% CI: 0.05-0.95, P=0.047), as compared with patients with wildtype ESR1 (n=11). There was no significant difference in overall survival (median; 14.1 versus 12.8 months, HR=0.40; 95% CI: 0.06-2.0, P-value=0.24)." ;
    a m2r:Evidence .

civice:4825
    dct:references pbm:27433843 ;
    civico:citation "Zaretsky et al., 2016, N. Engl. J. Med." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pembrolizumab ;
    dcterms:description "In a retrospective study of four relapsed, malignant melanoma patients, JAK2 (c.1641+2T>G) F547 splice site mutation was associated with acquired resistance to pembrolizumab monotherapy in one patient." ;
    a m2r:Evidence .

civice:4826
    dct:references pbm:27364904 ;
    civico:citation "Miller et al., 2016, Mol. Cancer Ther." ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, a HCH1 cell line expressing ARID1A P1175fs*5 mutation demonstrated increased sensitivity to dasatinib treatment, compared to ES2, KK and RMG-1 cells expressing wild-type ARID1A. Sensitivity was determined by assessing cell survival." ;
    a m2r:Evidence .

civice:4830
    dct:references pbm:28103578 ;
    civico:citation "Kim et al., 2017, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_VEGFInhibition ;
    dcterms:description "A meta-analysis to evaluate the association between the VHL alteration and clinical outcomes in patients with RCC. Six studies (total of 633 patients) were included. 61,8% had a VHL mutation. The meta-analysis showed no association between the VHL gene alteration and overall response rate or progression free survival. There was also no correlation to overall survival. VEGFR inhibition included: Sunitinib, Sorafenib, Axitinib, Pazopanib, Bevacizumab." ;
    a m2r:Evidence .

civice:4832
    dct:references pbm:28103578 ;
    civico:citation "Kim et al., 2017, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_VEGFInhibition ;
    dcterms:description "A meta-analysis to evaluate the association between the VHL alteration and clinical outcomes in patients with RCC. There were six studies including a total of 633 patients: 244 patients who received anti-VEGF therapy in the predictive value analysis and 419 in the prognostic value analysis. 410 (61.8%) had VHL alteration. The meta-analysis showed no association between the VHL gene alteration and ORR or PFS, as well as no correlation to OS. VEGFR inhibition included: Sunitinib, Sorafenib, Axitinib, Pazopanib, Bevacizumab." ;
    a m2r:Evidence .

civice:4833
    dct:references pbm:28193778 ;
    civico:citation "Yen et al., 2017, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Enasidenib%28AG-221%29 ;
    dcterms:description "Mutations in IDH1 or IDH2 are identified in approximately 20% of patients with AML.This study report the discovery and characterization of AG-221, orally available, selective, potent inhibitor of the mutant IDH2 enzyme. AG-221 suppressed oncometobolite 2HG production and induced cellular differentiation in primary human IDH2 mutated AML cells in vivo and in xenograft mouse models, providing a statistically significant benefit in an aggressive IDH2 R140Q-mutant AML xenograft mouse model. Clinical trials are ongoing." ;
    a m2r:Evidence .

civice:4835
    dct:references pbm:28475456 ;
    civico:citation "Kim et al., 2017, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Brigatinib ;
    dcterms:description "In a phase II randomized trial we evaluated two regimens of Brigatinib in Crizotinib-refractory ALK-pos. NSCLC. They were randomly assigned (1:1) to oral Brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg. Of 222 patients enrolled (arm A: n = 112, arm B: n = 110), 154 (69%) had baseline brain metastases and 164 of 222 (74%) had received prior chemotherapy. investigator-assessed confirmed ORR was 45 (arm A) and 54% (B). Investigator-assessed median PFS was 9.2 months (A) and 12.9 months (B). Independent review committee-assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11/26, A) and 67% (12/18, B). Brigatinib yielded substantial whole-body and intracranial responses as well as robust PFS; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety." ;
    a m2r:Evidence .

civice:4838
    dct:references pbm:28242752 ;
    civico:citation "de Bono et al., 2017, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Talazoparib ;
    dcterms:description "In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively." ;
    a m2r:Evidence .

civice:4839
    dct:references pbm:28242752 ;
    civico:citation "de Bono et al., 2017, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Talazoparib ;
    dcterms:description "In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively." ;
    a m2r:Evidence .

civice:4840
    dct:references pbm:28526536 ;
    civico:citation "Diéras et al., 2017, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Ado-trastuzumabEmtansine ;
    dcterms:description "Trastuzumab emtansine has its indication for patients with HER2-positive metastatic breast cancer after therapy with Trastuzumab and Taxane, approval based on PFS and preliminary OS data. EMILIA was a randomised open-label, phase III study for patients with HER2-positive, unresectable, locally advanced, or metastatic breast cancer previously treated with Trastuzumab and a Taxane, randomized 1:1 to Trastuzumab-emtansine or Capecitabine plus Lapatinib. 991 patients were enrolled. Median OS was 29.9m vs. 25.9m. Fewer grade 3 or worse AE occurred with trastuzumab emtansine than with capecitabine plus lapatinib control treatment." ;
    a m2r:Evidence .

civice:4841
    dct:references pbm:27124835 ;
    civico:citation "Dickson et al., 2016, JAMA Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Palbociclib ;
    dcterms:description "More than 90% of well-differentiated or dedifferentiated liposarcomas (WD/DDLS) have CDK4 amplification.  A prior phase 2 study demonstrated that treatment with palbociclib (200 mg/d for 14 days every 21 days) resulted in clinical benefit in WD/DDLS but moderate hematologic toxic effects. In this phase 2, nonrandomized, open-label clinical trial conducted at the Memorial Sloan Kettering Cancer Center, 60 patients 18 years and older with advanced WD/DDLS and measurable disease by RECIST 1.1 were enrolled from December 2011 to January 2014 and followed to March 2015. Patients received oral palbociclib at new dose scheme, 125 mg/d for 21 days in 28-day cycles. Progression-free survival at 12 weeks was 57.2% and overall median PFS was 17.9 weeks. There was 1 complete response. Toxic effects were primarily hematologic and included neutropenia (grade 3, n = 20 [33%]; grade 4, n = 2 [3%]) but no neutropenic fever.  Compared to other dose scheme in PMID 23569312 with 200mg/d: 12week PFS 66%, overall median PFS 18 weeks." ;
    a m2r:Evidence .

civice:4842
    dct:references pbm:27217383 ;
    civico:citation "Patnaik et al., 2016, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Abemaciclib ;
    dcterms:description "In this multicenter phase I study of abemaciclib, a total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma. The disease control rate for the KRAS-mutant population was 55% (16/29) compared to 39% (13/33)  in KRAS wildtype cohort. Stable disease lasting ≥24 weeks was achieved for 31% (9/29) with KRAS-mutant disease vs 12% (4/33) with KRAS wild-type disease. Median PFS was 2.8 months and 1.9 months for the KRAS-mutant and KRAS wild-type populations, respectively." ;
    a m2r:Evidence .

civice:4844
    dct:references pbm:28079291 ;
    civico:citation "Wang et al., 2017, Breast J" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A meta-analysis of the role of PD-L1 expression in breast cancer found nine relevant studies with a total 8583 patients. PD-L1 expression was found to be associated with several poor prognostic indicators, such as ductal cancer, high tumor grade, ER negativity, PR negativity, HER2 positivity and aggressive molecular subtypes. PD-L1 overexpression had no significant impact on metastasis-free survival (HR 0.924, 95% CI = 0.747-1.141, p = 0.462), disease-free survival (HR 1.122, 95% CI = 0.878-1.434, p = 0.357) and overall specific survival (HR 0.837, 95% CI = 0.640-1.093, p = 0.191), but significantly correlated with shortened overall survival (HR 1.573, 95% CI = 1.010-2.451, p = 0.045)." ;
    a m2r:Evidence .

civice:4845
    dct:references pbm:24705250 ;
    civico:citation "Fontebasso et al., 2014, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "The authors used whole exome sequencing on 39 midline pediatric high-grade astrocytomas (pHGAs) and identified 5 with mutations in ACVR1, with 2 occurring at G328 (G328V and G328E). The authors state that somatic mutations are specific to tumor location -- gain-of-function mutations in ACVR1 (such as G328V) occur in tumors of the pons in conjunction with H3.1 K27M (as compared to thalamic tumors with FGFR1 mutations)." ;
    a m2r:Evidence .

civice:4846
    dct:references pbm:24705250 ;
    civico:citation "Fontebasso et al., 2014, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Sequencing of 39 pediatric midline high-grade astrocytomas identified 5 patients with ACVR1 mutations. The authors identified an increase in endogenous phospho-SMAD1/5/8 signal in diffuse intrinsic pontine glioma (DIPG) cells harboring ACVR1 G328V, with corresponding increase in phospho-SMAD1/5/8 staining as well. By PCR, the authors show strong increase in fold change of mRNA expression in downstream proteins of the ACVR1/BMP pathway, ID, ID2, ID3 and SNAI1 in ACVR1-mutant DIPG cell line compared to glioblastoma cells (KNS42 cells). These activating ACVR1 mutations were exclusively in midline high grade astrocytomas (P = 0.0040, Fisher's exact test)." ;
    a m2r:Evidence .

civice:4847
    dct:references pbm:27825636 ;
    civico:citation "Drilon et al., 2016, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cabozantinib ;
    dcterms:description "RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. An open-label, two-stage, single-centre, phase 2, single-arm trial in the USA in metastatic/unresectable lung cancer harbouring RET rearrangement. 26 Patients were given 60 mg of cabozantinib orally per day. The primary objective was overall response, 25 patients assessable. KIF5B-RET was the predominant fusion in 16 (62%) patients. With confirmed PR seen in 7/25 (28%) response-assessable patients. The reported activity of cabozantinib in patients with RET-rearranged lung cancers defines RET rearrangements as actionable drivers in patients with lung cancers" ;
    a m2r:Evidence .

civice:4848
    dct:references pbm:27803005 ;
    civico:citation "Lee et al., 2017, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vandetanib ;
    dcterms:description "RET rearrangements involving RET are found in about 1% of NSCLC and define a unique molecular subset.  This study was a multi-center, open-label, phase II clinical trial to examine the safety and efficacy of Vandetanib (300 mg/d) in RET positive NSCLC patients (confirmed by FISH), Primary endpoint was the objective response rate. 18 patients were enrolled, the majority were a heavily pretreated population. Among the 17 evaluable patients, three had a partial response (ORR = 18%) and eight had a stable disease (DCR = 65%). Among these patients, the PR or SD was durable for more than 6 months in 8 patients. Vandetanib also showed a PFS of 4.5 months, and an OS of 11.6 months during a median follow-up duration of 14 months." ;
    a m2r:Evidence .

civice:4849
    dct:references pbm:27825616 ;
    civico:citation "Yoh et al., 2017, Lancet Respir Med" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vandetanib ;
    dcterms:description "We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged NSCLC continuously received 300 mg of oral vandetanib daily. 1536 patients with EGFR mutation-negative NSCLC were screened,, 34 were RET-positive (2%), 19 were enrolled and 17 patients were eligible for primary analysis.   9 patients (53%) achieved and objective response, in the intention to treat population of 19 patients, 9 patients (47% achieved an OR. At data cutoff, median PFS was 4,7 months. The results define RET rearrangement as a new molecular subgroup of NSCLC suitable for targeted therapy." ;
    a m2r:Evidence .

civice:4850
    dct:references pbm:27544060 ;
    civico:citation "Lin et al., 2016, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Alectinib ;
    dcterms:description "Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. The clinical activity of alectinib in patients with RET-rearranged NSCLC has not yet been reported. 4 patients with metastatic RET-rearranged NSCLC were identified. 3 of 4 had received prior RET TKIs, including cabozantinib and experimental RET inhibitors. We observed two (50%) objective radiographic responses after treatment with alectinib (one confirmed and one unconfirmed), with durations of therapy of 6 months and more than 5 months (treatment ongoing). Notably, one of these two patients had his dose of alectinib escalated to 900 mg twice daily and had clinical improvement in central nervous system metastases. In addition, one patient (25%) experienced a best response of stable disease lasting approximately 6 weeks. A fourth patient who was RET TKI-naive had primary progression while receiving alectinib." ;
    a m2r:Evidence .

civice:4855
    dct:references pbm:28430626 ;
    civico:citation "Zhang et al., 2017, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this meta-analysis, 5 studies totalling 2,546 cases were combined to assess the prognostic association of PD-L1 expression in breast cancer. The combined hazard ratio (HR) for PD-L1 overexpression was 1.76 (OS). The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph node metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast cancer (TNBC)." ;
    a m2r:Evidence .

civice:4856
    dct:references pbm:28453554 ;
    civico:citation "Zhao et al., 2017, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "PD-L1 is not only expressed in tumor cells (TCs) but also upregulated in tumor-infiltrating immune cells (TIICs). This meta-analysis evaluated the prognostic value of PD-L1 expression in TIICs in different types of cancers. 18 studies involving 3674 patients were included. PD-L1 positivity in TIICs related to a lower risk of death (HR = 0.784, p=0.047), and TIICs indicated a better prognosis especially in breast cancer patients (HR = 0.359, p=0.002)." ;
    a m2r:Evidence .

civice:4857
    dct:references pbm:28472902 ;
    civico:citation "Aguiar et al., 2017, Immunotherapy" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Nivolumab,civic:drug_Pembrolizumab,civic:drug_Atezolizumab,civic:drug_Avelumab,civic:drug_Durvalumab ;
    dcterms:description "In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89)." ;
    a m2r:Evidence .

civice:4858
    dct:references pbm:28586279 ;
    civico:citation "Peters et al., 2017, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Alectinib,civic:drug_Crizotinib ;
    dcterms:description "In a randomized, open-label phase 3 trial 303 patients with ALK-positive, previously untreated NSCLC (including asympt. CNS disease) were randomized to reiceive either Alectinib or Crizotinib. During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression/death occurred in 41% (62/152  pt) in the alectinib group and 68% (102/151 patients) in the crizotinib group. 12-month event-free survival rate 68.4% with alectinib vs. 48.7% with crizotinib. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, compared to 68 patients (45%) in the crizotinib group. Response rates were 82.9% (Alectinib) and 75.5% (crizotinib)." ;
    a m2r:Evidence .

civice:4859
    dct:references pbm:26768165 ;
    civico:citation "Ramalingam et al., 2016, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib,civic:drug_Dacomitinib ;
    dcterms:description "Non-small cell cancer patients from two studies [The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)] with exon 19 deletion and L858R EGFR (Exon 21) mutations were pooled to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. Median progression-free survival and median survival were better following dacomitinib treatment (14.6 and 26.6 months, N=53) than erlotinib (9.6 and 23.2, P = 0.146 and P = 0.265, N=48). In exon 19 mutated patients (N=32 and 36) PFS was better for dacomitinib treated patients (HR of 0.585 [95% CI 0.335–1.024], two-sided log-rank, P = 0.058) but did not reach significance." ;
    a m2r:Evidence .

civice:4860
    dct:references pbm:26768165 ;
    civico:citation "Ramalingam et al., 2016, Ann. Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dacomitinib ;
    dcterms:description "The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib." ;
    a m2r:Evidence .

civice:4862
    dct:references pbm:27876675 ;
    civico:citation "Gandara et al., 2017, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib,civic:drug_Docetaxel,civic:drug_Pemetrexed ;
    dcterms:description "This phase I/Ib two-part study evaluated trametinib in combination with anticancer agents docetaxel or pemetrexed in NSCLC with and without KRAS mutations. Confirmed partial response (PR) was observed in 21% (10/47) patients receiving trametinib/docetaxel. The ORR was 18% (4 PR in 22 patients) in KRAS wild-type versus 24% (six PR in 25 patients) in KRAS-mutant NSCLC. Of the 42 patients treated with trametinib/pemetrexed, 14% (6/42) had a PR; the ORR was 17% (4/23) in KRAS-mutated NSCLC versus 11% (2/19) in KRAS wild-type NSCLC." ;
    a m2r:Evidence .

civice:4863
    dct:references pbm:28525386 ;
    civico:citation "Kim et al., 2017, Oncotarget" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Nivolumab,civic:drug_Atezolizumab ;
    dcterms:description "A meta-analysis of randomized trials to investigate if KRAS mutation status affects survival benefits of immune checkpoint inhibition (ICI) in patients with advanced NSCLC. Of 3 eligible studies using either nivolumab or atezolizumab, 138 patients with KRAS mutant NSCLC and 371 with KRAS wild-type were included. ICI improved overall survival over that with docetaxel in KRAS mutant, previously-treated advanced NSCLC (hazard ratio=0.64 [95% confidence interval, 0.43-0.96], P = 0.03) but not in those with KRAS wild-type tumor (HR = 0.88 [95% CI, 0.68-1.13], P = 0.30). These results suggest that KRAS mutation status may be a potential biomarker for survival benefits to ICIs." ;
    a m2r:Evidence .

civice:4864
    dct:references pbm:28259530 ;
    civico:citation "Li et al., 2017, Eur J Surg Oncol" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "A" ;
    dcterms:description "In this meta-analysis of nine studies querying the association between KRAS status and PD-L1expression, KRAS-mutant tumors were more likely to be PD-L1 positive than KRAS-wild type tumors (51% vs 36%; OR 1.69; 95% CI 1.01-2.84; p = 0.045)." ;
    a m2r:Evidence .

civice:4866
    dct:references pbm:26666244 ;
    civico:citation "Deming et al., 2016, Invest New Drugs" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "A phase I study  to determine the tolerability and pharmacokinetics of Selumetinib and Cetuximab with an expanded cohort in KRAS-mutant CRC. In the KRAS-mutant CRC dose expansion cohort 14 patients were evaluable for response. Five patients experienced stable disease, nine had progressive disease.  Minimal anti-tumor activity was observed in KRAS-mutant refractory metastatic CRC." ;
    a m2r:Evidence .

civice:4867
    dct:references pbm:25722381 ;
    civico:citation "Blumenschein et al., 2015, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "In this phase II trial, trametinib or docetaxel was given to patients with advanced KRAS-mutant NSCLC. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (HR 1.14; p = 0.5197). Median OS, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P = 1.0000). These data suggest that trametinib is associated with similar PFS and response rates as docetaxel." ;
    a m2r:Evidence .

civice:4868
    dct:references pbm:26802155 ;
    civico:citation "Carter et al., 2016, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Erlotinib,civic:drug_Selumetinib%28AZD6244%29 ;
    dcterms:description "38 KRAS wild-type patients were randomized to erlotinib or combination of selumetinib with erlotinib. 41 KRAS mutant patients were randomized to selumetinib or the combination. The primary end points were progression-free survival (PFS) for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Median PFS in the KRAS wild-type arm was 2.4 months for erlotinib alone and 2.1 months for the combination. The ORR in the KRAS mutant group was 0% for selumetinib alone and 10% for the combination. These data suggest no difference in ORR or PFS with combination therapy of over monotherapy in KRAS mutant and KRAS wild-type advanced NSCLC." ;
    a m2r:Evidence .

civice:4869
    dct:references pbm:27167191 ;
    civico:citation "Lee et al., 2016, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Binimetinib,civic:drug_Palbociclib ;
    dcterms:description "A preclinical study to investigate the efficacy of Binimetinib, Palbociclib and the combination on KRAS mutant colorectal cancer cell lines, cell line-derived and patient-derived xenografts.   The combination of MEK and CDK4/6 inhibition inhibited cancer cell growth and caused cell regression in a synergistic manner Combination therapy markedly decreased levels of phosphorylated ribosomal protein S6 both in vitro and in vivo and decreased Ki67 staining in vivo." ;
    a m2r:Evidence .

civice:4872
    dct:references pbm:26528855 ;
    civico:citation "Perez et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Palbociclib ;
    dcterms:description "A preclinical study to explore the efficacy of CDK4/6 inhibition with palbociclib, in a panel of sarcoma cell lines and sarcoma tumor xenografts (PDXs). The responsiveness of these cell lines correlated with their levels of CDK4 mRNA as well as in vivo PDX, but not against sarcomas displaying low levels of CDK4 and high levels of p16ink4a (CDKN2A)." ;
    a m2r:Evidence .

civice:4874
    dct:references pbm:28490518 ;
    civico:citation "Sen et al., 2017, Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Prexasertib,civic:drug_Olaparib,civic:drug_Cisplatin ;
    dcterms:description "A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexasertib had strong single agent efficacy and augmented the effect of Olaparib or Cisplatin in either combination, including platinum-resistant models. CHEK1 and MYC overexpression were predictors of response." ;
    a m2r:Evidence .

civice:4875
    dct:references pbm:28242752 ;
    civico:citation "de Bono et al., 2017, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Talazoparib ;
    dcterms:description "In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively." ;
    a m2r:Evidence .

civice:4876
    dct:references pbm:28242752 ;
    civico:citation "de Bono et al., 2017, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Talazoparib ;
    dcterms:description "In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively." ;
    a m2r:Evidence .

civice:4877
    dct:references pbm:12748244 ;
    civico:citation "Fukuoka et al., 2003, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "Double blind Phase II clinical trial found an objective response rate of 18.4% and 19% for two groups of patients treated with 250mg/d and 500mg/d respectively. The disease control rate was found to be 54.4% and 51.4% for the two groups." ;
    a m2r:Evidence .

civice:4879
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248W loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4880
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R175H loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4881
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273C loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4882
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273H loss of function mutation is present in 7 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4883
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 G245S loss of function mutation is present in 3 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4884
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 Y220C loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4885
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 M237I loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4886
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158H loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4887
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 V157F loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4888
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R249S loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4889
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R280K loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4890
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R280T loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4891
    dct:references pbm:25730903 ;
    civico:citation "Saiki et al., 2015, Oncotarget" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_AMGMDS3 ;
    dcterms:description "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158L loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3." ;
    a m2r:Evidence .

civice:4895
    dct:references pbm:12202531 ;
    civico:citation "Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Likely Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Frameshift truncation mutation found in a single patient with VHL retinal manifestation, which coincides with mutations confirmed to be associated with VHL type 1 in this study. Only moderate evidence of pathogenicity since the protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants (AMCG code: PM4)." ;
    a m2r:Evidence .

civice:4905
    dct:references pbm:24933606 ;
    civico:citation "Bowyer et al., 2014, Melanoma Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "Case study report including one patient with L597Q mutation-positive metastatic melanoma (M1b disease) treated with the MEK inhibitor trametinib. The L597Q patient achieved a RECIST partial response and showed maximum tumor shrinkage of 33% with trametinib as the first-line treatment and had a partial response for 6.2 months." ;
    a m2r:Evidence .

civice:4906
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. Missense mutation found in two VHL type 2A families of 55 individuals altogether (family IDs 3476, 3127). 26 of 55 individuals were identified with retinal hemangioblastomas, 5 with cerebellar hemangioblastomas, and 30 with pheochromocytomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4907
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 2B family of 12 individuals (Family ID 4486 in publication). All 12 family members identified with cerebellar hemangioblastomas, 2 of 12 family members with retinal hemangioblastomas, one with renal cell carcinoma and one with pheochromocytoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma, Pheochromocytoma." ;
    a m2r:Evidence .

civice:4908
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 2B family of 7 individuals (Family ID 4414 in publication).Two of seven individuals were identified with retinal hemangioblastomas, 3 with cereballar hemangioblastomas, one with renal cell carcinoma, and one with pheochromocytomas.Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma, Pheochromocytoma." ;
    a m2r:Evidence .

civice:4909
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL (Family ID 3969 in publication). One carried pheochromocytoma, while both carried angiomas." ;
    a m2r:Evidence .

civice:4910
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This mutation was found in 2 family members with VHL disease (family ID 4402). One carried pheochromocytoma and both carried retinal hemangioblastoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4911
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a VHL type 2B patient with retinal hemangioblastoma, renal cell carcinoma, and pheochromocytoma (family ID 4422). Only supporting evidence for pathogenicity because patient's phenotyoe is highly specific for a disease with a single genetic etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:4912
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in four VHL type 2 families of 51 individuals altogether (family IDs 2338, 3490, 4477, 4405). 36 of 51 individuals had retinal hemangioblastomas, 17 had cerebellar hemangioblastomas, 16 with renal cell carcinoma, and 36 with pheochromocytomas. This mutation was also detected in a VHL type 1 patient with angiomas (family ID 3699). Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4913
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in six VHL type 2 families (including one family with 9 affected individuals) and one VHL type 1 family totaling 23 individuals altogether (family IDs 4421, 3718, 3767, 3493, 3731, 3517, 3739). Twelve of 23 individuals had retinal hemangioblastomas, 12 carried cerebellar hemangioblastomas, 8 carried renal cell carcinoma and 13 carried pheochromocytomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4914
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL disease type 2A, who both had retinal hemangioblastomas and cerebellar hemangioblastomas (family ID 3786). One of 2 individuals carried pheochromocytomas as well. Mutation also found in 8 individuals with VHL type 1 phenotype (family IDs 3314, 4419, 4403, 3708). Three of 8 individuals were identified with retinal hemangioblastomas, 5 with cerebellar hemangioblastomas, and 2 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4916
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This frameshift mutation was found in a VHL type 1 family of 8 individuals (family ID 3563). Two of 8 individuals were identified with retinal hemangioblastomas, 3 with cerebellar hemangioblastomas and 3 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4917
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 1 family of four individuals (family ID 4325). Three of 4 individuals were identified with retinal hemangioblastomas and one with cerebellar hemangioblastomas. Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:4918
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense mutation was found in a VHL type 1 family of 7 individuals (family ID 2753). Six of 7 individuals were identified with retinal hemangioblastomas, 3 with cerebellar hemangioblastomas and one with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4919
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "This deletion mutation was found in two VHL type 1 families of 15 individuals altogether (Family IDs 2693 and 2956 in publication). Five of 7 individuals were identified with retinal hemangioblastomas, 8 with cerebellar hemangioblastomas, and 7 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4920
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a type 1 VHL patient (family ID 4389) with retinal hemangioblastomas, cerebellar hemangioblastomas, and renal cell carcinoma. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:4921
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 4327). All 3 individuals carried cerebellar hemangioblastomas and one also carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4922
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 3101). One of 3 members carried retinal hemangioblastomas and 2 carried cerebellar hemangioblastomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:4923
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a type 1 VHL patient with retinal hemangioblastomas and cerebellar hemangioblastomas (family ID 3630). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:4924
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This frameshift mutation was found in 3 family members with VHL type 1 phenotype (family ID 3312). All 3 individuals carried retinal hemangioblastomas, 2 of 3 carried cerebellar hemangioblastomas and one carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4926
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in two VHL type 1 families of 12 individuals altogether (family IDs 2612 and 3568). Nine of 12 individuals were identified with cerebellar hemangioblastomas, 6 with retinal hemangioblastomas, and 6 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:4927
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 1255). All 3 individuals carried cerebellar hemangioblastomas and retinal hemangioblastomas. Two of 3 also carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:4928
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This frameshift mutation was detected in a VHL type 1 patient with cerebellar hemangioblastomas (family ID 3669). Only supporting evidence for pathogenicity because the patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Cerebellar hemangioblastoma." ;
    a m2r:Evidence .

civice:4929
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 1 family of 4 individuals (family ID 3315). One of the 4 individuals was identified with retinal hemangioblastomas, 2 with cerebellar hemangioblastomas and 2 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4930
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a VHL type 1 patient with cerebellar hemangioblastomas (family ID 4401). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:4931
    dct:references pbm:15118073 ;
    civico:citation "Lynch et al., 2004, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "Study found Somatic EGFR mutations localized to exons 19,21 in 8/9 patients who exhibited a response to Gefitinib treatment. Of these mutations 7/8 were localized near the ATP cleft Gefitinib targets. No EGFR mutations were observed in 7 patients with no response to Gefitinib. An expansion cohort independent of the Gefitinib study showed 2/25 patients harbored EGFR mutations. A second expansion independent of Gefitinib consisting of 95 tumors and 108 cell lines showed no mutations in exons 19,21." ;
    a m2r:Evidence .

civice:4932
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense mutation was found in a VHL type 1 patient and familiy of 4 individuals (family IDs 3759 and 3760). Four of 5 individuals were identified with angiomas, 2 with cerebellar hemangioblastomas, and one with renal cell carcinoma. ACMG codes as follows: Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Patient's phenotype is highly specific for a disease with a single genetic etiology (PP4)." ;
    a m2r:Evidence .

civice:4933
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 1 family of 10 individuals (family ID 1239). Seven of 10 individuals were identified with cerebellar hemangioblastomas and renal cell carcinoma. One identified with retinal hemangioblastomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4934
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This insertion mutation was detected in a VHL type 1 patient (family ID 4410 in publication) with retinal hemangioblastomas, cerebellar hemangioblastomas, and renal cell carcinoma. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:4935
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense mutation was found in a VHL type 1 family of 6 individuals (family ID 3720). All 6 individuals were identified with cerebellar hemangioblastomas, 4 with angiomas and 3 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4936
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This mutation causes a stop codon at amino acid 158. Mutation also found in 3 family members with VHL type 1 phenotype (family ID 3575). Two of 3 members carried retinal hemangioblastomas, one carried cerebellar hemangioblastomas and one with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:4937
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. Mutation causes a stop codon at amino acid 158. This mutation was also found in 4 family members with VHL type 1 phenotype (family ID 3616). Two of 4 members carried retinal hemangioblastomas and 2 with renal cell carcinoma. Supporting evidence of pathogenicity because of the introduction of an early stop codon in a gene where loss of function is an established mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:4939
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. Missense mutation detected in a VHL type 1 patient (Family ID 3509 in publication) with angiomas, cerebellar hemangioblastomas, and renal cell carcinoma. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:4940
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 4 family members with VHL type 1 phenotype (Family ID 3820 in publication). All 4 family members carried cerebellar hemangioblastomas, 2 of 4 carried retinal hemangioblastomas and one carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:4941
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in VHL type 1 patient (Family ID 3618 in publication) with cerebellar hemangioblastomas. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Cerebellar hemangioblastoma." ;
    a m2r:Evidence .

civice:4942
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL type 1 phenotype (family ID 4480). Both individuals were identified with cerebellar hemangioblastomas and one with retinal hemangioblastoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:4943
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL type 1 phenotype (family ID 3708). Both individuals were identified with renal cell carcinoma and one who also carried cerebellar hemangioblastomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:4944
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals .This nonsense mutation was found in a VHL type 1 family of 6 individuals (Family ID 3770 in publication). All 6 individuals were identified with cerebellar hemangioblastomas, 4 with retinal hemangioblastomas, and 5 with renal cell carcinoma. Supporting evidence of pathogenicity because of the introduction of an early stop codon in a gene where loss of function is an established mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:4945
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL type 1 phenotype (Family ID 3736 in publication). One of 2 individuals were identified with retinal hemangioblastomas, one with cerebellar hemangioblastomas, and one with renal cell carcinoma. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:4956
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation causes a frameshift and premature stop codon at amino acid 131 and was found in a VHL type 1 patient (kindred no. 110). This variant is likely to cause a dramatic alteration in protein function in a gene where loss-of-function mutations are a known mechanism (ACMG code: PVS1). Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:4958
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those in which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 25)." ;
    a m2r:Evidence .

civice:4959
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 52)." ;
    a m2r:Evidence .

civice:4961
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation causes a stop codon at amino acid 131 and was found in a VHL type 2 and a VHL type 1 patient (kindred no. 71, 85). A frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:4962
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those in which pheochromocytoma had not occurred (VHL type1). This mutation was found in a VHL type 1 patient (kindred no. 34)." ;
    a m2r:Evidence .

civice:4963
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those in which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL patient (kindred no. 150). The presence of pheochromocytoma was not indicated." ;
    a m2r:Evidence .

civice:4964
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 103)." ;
    a m2r:Evidence .

civice:4965
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in VHL type 1 patient (kindred no. 59)." ;
    a m2r:Evidence .

civice:4967
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL family (kindred no. 22). Incidence of pheochromocytoma was unknown. Supporting evidence for pathogenicity because of a missense mutation in a gene where missense variants are a common mechanism of disease (ACMG code: PP2)." ;
    a m2r:Evidence .

civice:4970
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in 2 unrelated VHL families (kindred no. 40, 133). One was identified with pheochromocytoma, the other was unknown. Supporting evidence for pathogenicity because of a missense mutation in a gene where missense variants are a common mechanism of disease (ACMG code: PP2). Relevant HPO term: pheochromocytoma." ;
    a m2r:Evidence .

civice:4971
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 19)." ;
    a m2r:Evidence .

civice:4973
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation causes stop codon at amino acid 133 and was found in VHL type 1 patient (kindred no. 64). Only moderate support for pathogenicity because protein length changes as a result of in-frame deletion in a nonrepeat region and stop-loss variant (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:4974
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL patient (kindred no. 27)." ;
    a m2r:Evidence .

civice:4975
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation causes stop codon at amino acid 158 and was found in  2 unrelated VHL patients (kindred no. 41, 99). One patient did not have pheochromocytoma." ;
    a m2r:Evidence .

civice:4976
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in VHL type 2 patient (kindred no. 49)." ;
    a m2r:Evidence .

civice:4977
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in VHL type 1 patient (kindred no. 91)." ;
    a m2r:Evidence .

civice:4982
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 2 patient (kindred no. 26). Supporting evidence of pathogenicity because of a missense mutation in a gene in which missense variants are a common mechanism of disease. Relevant HPO terms: Pheochomocytoma." ;
    a m2r:Evidence .

civice:4983
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 44)." ;
    a m2r:Evidence .

civice:4984
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 79)." ;
    a m2r:Evidence .

civice:4996
    dct:references pbm:26209642 ;
    civico:citation "Rulli et al., 2015, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Docetaxel ;
    dcterms:description "In this study, KRAS was neither prognostic nor predictive of benefit for either docetaxel or erlotinib." ;
    a m2r:Evidence .

civice:4997
    dct:references pbm:20038723 ;
    civico:citation "Douillard et al., 2010, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Docetaxel ;
    dcterms:description "Of the 275 patients assessable for KRAS mutation status, 49 (18%) were positive for KRAS mutation. There were no differences between treatments in OS, PFS, or response rates according to KRAS mutation status, and no evidence that KRAS mutation is a predictive factor for a differential survival effect between gefitinib and docetaxel." ;
    a m2r:Evidence .

civice:5013
    dct:references pbm:8730290 ;
    civico:citation "Maher et al., 1996, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 138 unrelated VHL families, 109 germline mutations were found. Missense mutations were more frequently found in families with pheochromocytoma (PC). Deletions. Nonsense, and frameshift mutations were more frequently found in families without PC. Large deletions and mutations predicted to cause truncated protein were associated with lower risk of PC. This missense mutation was found in a VHL family (family ID 77). No phenotype described." ;
    a m2r:Evidence .

civice:5017
    dct:references pbm:28404093 ;
    civico:citation "Domingo et al., 2016, Lancet Gastroenterol Hepatol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis." ;
    a m2r:Evidence .

civice:5018
    dct:references pbm:28404093 ;
    civico:citation "Domingo et al., 2016, Lancet Gastroenterol Hepatol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis." ;
    a m2r:Evidence .

civice:5019
    dct:references pbm:28404093 ;
    civico:citation "Domingo et al., 2016, Lancet Gastroenterol Hepatol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis." ;
    a m2r:Evidence .

civice:5020
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of VHL gene product (pVHL). Missense mutation, affecting an amino acid within pVHL protein core, was found in 6 VHL type 1 families with 12 affected individuals altogether. Nine of 12 patients had retinal angioma, 5 had cerebellar hemangioblastoma, and 2 had renal cell carcinoma." ;
    a m2r:Evidence .

civice:5022
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue with pVHL protein core, was detected in a VHL type 1 family with 3 affected individuals. All 3 patients had retinal angioma." ;
    a m2r:Evidence .

civice:5024
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting surface residue of pVHL protein core, was found in 2 VHL type 2A families with 5 affected individuals altogether. Two of 5 patients had retinal angioma, 2 had cerebellar hemangioblastoma, and 4 had pheochromocytoma." ;
    a m2r:Evidence .

civice:5026
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was detected in a VHL type 1 patient with retinal and cerebellar hemangioblastoma, renal cell carcinoma, and pancreatic cysts (family no. 3)." ;
    a m2r:Evidence .

civice:5027
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was detected in a VHL type 1 patient with cerebellar hemangioblastoma, renal cysts and pancreatic cysts (family no. 6)." ;
    a m2r:Evidence .

civice:5029
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was identified in 14 VHL patients (family no. 18). Six had retinal hemangioblastoma, 9 had cerebellar hemangioblastoma, 7 had renal cell carcinoma, 8 had renal cysts, 4 had pheochromocytoma, and 5 had pancreatic cysts." ;
    a m2r:Evidence .

civice:5033
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation found in VHL type 1 family (lineage 80). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5034
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 53)." ;
    a m2r:Evidence .

civice:5035
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 179). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1). Relevant HPO terms: hemangioblastoma,  Renal cell carcinoma, Pheochromocytoma." ;
    a m2r:Evidence .

civice:5037
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 132)." ;
    a m2r:Evidence .

civice:5040
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 103)." ;
    a m2r:Evidence .

civice:5041
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in VHL type 1 family (lineage 208)." ;
    a m2r:Evidence .

civice:5042
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 76)." ;
    a m2r:Evidence .

civice:5043
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 81). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5044
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in 2 VHL type 1 families (lineage 83 and 146).Discovered the presence of the same missense mutation in another VHL type 1 family, so I changed evidence statement to include findings from both VHL families." ;
    a m2r:Evidence .

civice:5045
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes stop codon at amino acid 131 and was found in a VHL type 1 family (lineage 13). Only moderate evidence for pathogenicity because protein length changes as a result of insertion in a nonrepeat region (ACMG code: PM4). Relevant HPO terms: hemangioblastoma, Renal cell carcinoma, Pheochromocytoma." ;
    a m2r:Evidence .

civice:5046
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 86)." ;
    a m2r:Evidence .

civice:5047
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes an early stop codon at position 158 and was found in a VHL type 1 family (lineage 64). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5048
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes an early stop codon at position 158 and was found in a VHL type 1 family (lineage 119). Only moderate evidence for pathogenicity because protein length changes as a result of deletion in a nonrepeat region and stop-loss variant (ACMG code: PM4).  Relevant HPO terms: hemangioblastoma, Renal cell carcinoma, Pheochromocytoma." ;
    a m2r:Evidence .

civice:5049
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in 3 VHL type 1 families and one VHL type 2 family (lineages 184, 93, 22, 92). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5050
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 69)." ;
    a m2r:Evidence .

civice:5051
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 141). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5052
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in two VHL type 1 families and six VHL type 2 families (lineages 202, 47, 102, 106, 153, 109)." ;
    a m2r:Evidence .

civice:5053
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 7)." ;
    a m2r:Evidence .

civice:5054
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes an early stop codon at amino acid 200 and was found in a VHL type 1 family (lineage 25). Only moderate evidence for pathogenicity because protein length changes as a result of deletions in a nonrepeat region and stop-loss variant (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5055
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 14)." ;
    a m2r:Evidence .

civice:5056
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 50). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5057
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 78). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5058
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 48). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5059
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 128)." ;
    a m2r:Evidence .

civice:5061
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 2 family (lineage 3)." ;
    a m2r:Evidence .

civice:5062
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in six VHL type 2 families (lineages 100, 42, 44, 88, 105, 135). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:5064
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 2 family (lineage 65). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).   Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:5066
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 2 family (lineage 73)." ;
    a m2r:Evidence .

civice:5067
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 2 family (lineage 174)." ;
    a m2r:Evidence .

civice:5068
    dct:references pbm:28103611 ;
    civico:citation "Daud et al., 2017, Br. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cabozantinib ;
    dcterms:description "Patients with metastatic melanoma (n=77; 48 cutaneous, 23 uveal, 6 mucosal) were enrolled in a phase II randomised discontinuation trial assessing cabozantinib. Patients received 100 mg cabozantinib daily for 12 weeks. Patients with stable disease (SD; RECIST; n=26) were randomly assigned to cabozantinib (n=13) or placebo (n=13). In the uveal melanoma cohort, 61% of patients (14/23, 61%) had SD at week 12. 9 patients had either a GNAQ (n=5) or GNA11 (n=4) mutation; only 10 patients were analyzed. Patients with GNAQ mutations remained on the study treatment from 1.4-10.3 months. The median PFS for the 23 patients with uveal melanoma was 4.8 months (41% PFS at 6 months) and median OS was 12.6 months. In the entire cohort, median overall PFS was 3.8 months (33% PFS at 6 months). After randomisation, median PFS for cabozantinib patients was 4.1 months and 2.8 months for placebo (HR 0.59, p=0.284)." ;
    a m2r:Evidence .

civice:5069
    dct:references pbm:28588020 ;
    civico:citation "Stein et al., 2017, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Enasidenib ;
    dcterms:description "A first-in-human phase 1/2 trial assessing the pharmacology, safety and activity of Enasidenib in IDH2-mutant myeloid hematoblastosis patients. In the AML subgroup (n=176) of included patients (n=239) the overall response rate was 40.3%, with median response duration of 5.8 months. Responses were associated with cellular differentiation and maturation, typically without evidence of aplasia. Median overall survival among relapsed/refractory patients was 9.3 months, and for the 34 patients (19.3%) with complete response was 19.7 months." ;
    a m2r:Evidence .

civice:5070
    dct:references pbm:22766794 ;
    civico:citation "Le Guellec et al., 2012, Mod. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations." ;
    a m2r:Evidence .

civice:5071
    dct:references pbm:22766794 ;
    civico:citation "Le Guellec et al., 2012, Mod. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations." ;
    a m2r:Evidence .

civice:5072
    dct:references pbm:22766794 ;
    civico:citation "Le Guellec et al., 2012, Mod. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations." ;
    a m2r:Evidence .

civice:5092
    dct:references pbm:8956040 ;
    civico:citation "Zbar et al., 1996, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutation analysis of 469 VHL families reveled 300 mutations. The most common germline mutations were identified between codons 75-82, between codons 157-189 (Elongin binding domain) and at the splice site between exons 2 and 3. The association between mutations in codon 167 and pheochromocytoma was detected in all nationalities tested. This missense mutation was found in a VHL type 2 family (family ID R-D)." ;
    a m2r:Evidence .

civice:5094
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was found in a VHL type 2B family of 6 patients with the mutation, but incomplete penetrance (family no. 1; pedigree in Figure 2). A 59 yo carrier had no VHL manifestations but 2 unaffected children without the mutation and 2 children with the mutation, 1 with pheochromocytoma aged 32 and a 40 yo with no clinical manifestations. The 59 year old also had an affected family with the mutation - a parent (renal cell carcinoma) and a affected sibling (pheochromocytoma) and their child (paraganglioma) - and 4 unaffected siblings without the mutation. Only supporting evidence for pathogenicity because of cosegregation of the disease with multiple affected family in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:5096
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in a VHL type 1 patient with cerebellar hemangioblastomas and renal cell carcinoma (family no. 21)." ;
    a m2r:Evidence .

civice:5097
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 VHL type 2A family members (family no. 23). Both had retinal hemangioblastomas, one had cerebellar hemangioblastomas, and one had pheochromocytoma.  Only supportive evidence for pathogenicity because patient’s phenotype or family history is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Pheochromocytoma." ;
    a m2r:Evidence .

civice:5098
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation causes an early stop codon at amino acid 201 and was found in a VHL type 1 patient with cerebellar hemangioblastomas and renal cysts (family no. 27)." ;
    a m2r:Evidence .

civice:5099
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was detected in a VHL patient with renal cell carcinoma (family no. 31)." ;
    a m2r:Evidence .

civice:5100
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 VHL type 2C family members (family no. 9)" ;
    a m2r:Evidence .

civice:5101
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was detected in a VHL patient with cerebellar hemangioblastomas and renal cell carcinoma (family no. 11). Only supporting evidence for pathogenicity because Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Cerebellar hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:5103
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 VHL family members with retinal hemangioblastomas (family no.13)." ;
    a m2r:Evidence .

civice:5104
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended.  This mutation was found in a VHL type 1 patient with cerebellar hemangioblastomas, renal cell carcinoma, renal cysts, epididymal cyst, and pancreatic cysts (family no. 2)." ;
    a m2r:Evidence .

civice:5105
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was detected in a VHL family with 2 individuals with retinal hemangioblastomas (family no. 4)." ;
    a m2r:Evidence .

civice:5125
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting a residue on surface of pVHL protein core, was found in 2 VHL type 2C families with 4 patients altogether. All 4 patients had pheochromocytoma." ;
    a m2r:Evidence .

civice:5128
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other  loss of function mutations (either germline deletions or truncating mutations). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation causes an early stop codon at amino acid 133 and was found in a VHL patient with cerebellar hemangioblastomas. This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). Relevant HPO terms: Cerebellar hemangioblastoma." ;
    a m2r:Evidence .

civice:5130
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting a residue within the pVHL protein core, was found in 2 VHL family members. Both had retinal angiomas and cerebellar hemangioblastomas. One had renal cell carcinoma." ;
    a m2r:Evidence .

civice:5131
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting a residue on surface of pVHL, was found in a VHL family with retinal angiomas, cerebellar hemangioblastomas, and renal cell carcinoma." ;
    a m2r:Evidence .

civice:5133
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in a VHL patient with retinal hemangioblastomas and pheochromocytoma. Relevant HPO terms: Retinal hemangioblastoma, Pheochromocytoma." ;
    a m2r:Evidence .

civice:5134
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in 2 VHL families with 9 patients altogether. Eight had retinal hemangioblastomas, one had cerebellar hemangioblastomas, 3 had renal cell carcinoma, and 5 had pheochromcytoma. Only moderate evidence of pathogenicity since the protein length changes as a result of a stop-loss variant (ACMG code: PM4). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma, Pheochromocytoma." ;
    a m2r:Evidence .

civice:5135
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in 3 VHL families with 9 patients altogether. Seven had retinal hemangioblastomas, 3 had cerebellar hemangioblastomas, and 5 had renal cell carcinoma. Only moderate evidence of pathogenicity since the protein length changes as a result of a stop-loss variants (ACMG code: PM4). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:5137
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in 2 VHL families with 6 patients altogether. All six had retinal hemangioblastomas and 2 had cerebellar hemangioblastomas. Only moderate evidence of pathogenicity since the protein length changes as a result of a stop-loss variant (ACMG code: PM4). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5138
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation causes an early stop codon at amino acid 130 and was found in a VHL type 1 family of 16 patients. Six patients had retinal hemangioblastomas, 10 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma. This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5139
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other  loss of function mutations (either germline deletions or truncating mutations). This missense mutation, affecting residue within the pVHL protein core, was found in a VHL patient with cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease." ;
    a m2r:Evidence .

civice:5140
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma" ;
    a m2r:Evidence .

civice:5141
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other loss of function mutations (either germline deletions or truncating mutations). A missense mutation, affecting residue within the pVHL protein core, was found in 2 VHL families with 4 patients. Two had retinal hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2). Relevant HPO terms: Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5143
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in 3 VHL families of 7 patients altogether. Six had retinal hemangioblastomas, one had renal cell carcinoma, 6 had cerebellar hemangioblastomas, and 4 pheochromocytoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2). Relevant HPO terms: Renal cell carcinoma. retinal hemangioblastoma cerebellar hemangioblastoma, pheochromocytoma." ;
    a m2r:Evidence .

civice:5144
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2). Relevant HPO terms: Cerebellar hemanioblastoma and retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5145
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation causes an early stop codon at amino acid 158 and was found in 2 VHL families with 5 patients altogether. Three had retinal angiomas, 5 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma." ;
    a m2r:Evidence .

civice:5146
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This mutation was found in a VHL type 1 patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2).Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5147
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 family with retinal hemangioblastomas and renal cell carcinoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma" ;
    a m2r:Evidence .

civice:5148
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL protein core, was found in a VHL type 1 patient with retinal hemanioblastomas and cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2). Relevant HPO terms: Cerebellar hemangioblastoma." ;
    a m2r:Evidence .

civice:5149
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 family of 3. All family members had retinal hemangioblastomas and cerebellar hemangioblastomas. Two had renal cell carcinoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:5150
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 patient with retinal hemangioblastomas, cerebellar hemangioblastomas, and renal cell carcinoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:5151
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This mutation was found in 2 VHL type 1 family members with cerebellar hemangioblastomas. ACMG codes as follows: Protein length changes as a result of insertion in a nonrepeat region and stop-loss variant (PM4). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Relevant HPO terms: Cerebellar hemangioblastoma." ;
    a m2r:Evidence .

civice:5152
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in 2 VHL families of 5 patients altogether. Three had retinal hemangioblastomas, 4 had cerebellar hemangioblastomas, 3 had renal cell carcinoma. ACMG codes as follows:  supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2)." ;
    a m2r:Evidence .

civice:5153
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastoma and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in a VHL with retinal hemangio blstomas and cerebellar hemangioblastomas. Missense mutation at codon 273 (C>A), resulting in the same amino acid change, was also found. Only moderate evidence of pathogenicity since the protein length changes as a result of a stop-loss variant (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5154
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in a VHL type 2B family with 6 patients. One patient had retinal hemangioblastomas, 2 had cerebellar hemangioblastomas, 3 had renal cell carcinoma, 2 had pheochromocytoma. Only supporting evidence of pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma and pheochromocytoma." ;
    a m2r:Evidence .

civice:5155
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family of 5 patients. Three had retinal hemangioblastomas, 4 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma. This mutation also causes an early stop codon at amino acid 66. ACMG codes as follows: Protein length changes as a result of in-frame deletions in a nonrepeat region and stop-loss variant (PM4). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:5156
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family with retinal hemangiolastomas and renal cell carcinoma. Only supporting evidence of pathogenicity because of cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  Relevant HPO terms: retinal hemangioblastoma and renal cell carcinoma." ;
    a m2r:Evidence .

civice:5157
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5158
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL patient with cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma." ;
    a m2r:Evidence .

civice:5159
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in 4 VHL families of 11 patients altogether. Ten had retinal hemangioblastomas, 4 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma. ACMG codes as follows:  supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)." ;
    a m2r:Evidence .

civice:5160
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in a VHL patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5161
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family with retinal hemangioblastomas, cerebellar hemangioblastomas, and renal cell carcinoma. ACMG codes as follows:  supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:5162
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in two VHL families of 4 patients altogether. One patient had retinal hemagioblastomas and two had cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5163
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastoma and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation causes a frameshift, an early stop codon at amino acid 158, and was found in a VHL type 1 family with retinal hemangioblastoma, cerebellar hemangioblastomas, and renal cell carcinoma. There is very strong evidence for pathogenicity in the form of  a frameshift variant in a gene where loss-of-function is  known mechanism of disease (ACMG code: PSV1).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:5164
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation results in a frameshift, a premature stop codon at amino acid 158, and was found in a VHL patient with retinal hemangioblastomas, There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).  Relevant HPO terms: Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5165
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation results in a frameshift, an early stop codon at amino acid 158, and was found in a VHL type 1 family with retinal hemangioblastomas and cerebellar hemangioblastomas. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5166
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation causes a frameshift, an early stop codon at amino acid 201, and was found in two VHL families of 3 patients. One patient had retinal hemangioblastomas, three had cerebellar hemangioblastomas, and one with renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).   Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:5167
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation causes a frameshift, a stop codon at amino acid 217, and was found in a VHL type 1 family with cerebellar hemangioblastomas and renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). Relevant HPO terms: Cerebellar hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:5168
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 patient with retinal hemangioblastoms, cerebellar hemangioblastomas, and renal cell carcinoma. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:5169
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangoblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in a VHL family with retinal hemangioblastomas, cerebellar hemangioblastomas, renal cell carcinoma, and pheochromocytoma. There is very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)." ;
    a m2r:Evidence .

civice:5170
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal hemangiobastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 3 VHL families with 4 patients altogether. All four had retinal hemangioblastomas and cerebellar hemangioblastomas. Two had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5171
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in a VHL type 2B family with retinal hemangioblastomas, cerebellar hemangioblastomas, and pheochromocytoma. ACMG codes as follows:   Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Pheochromocytoma." ;
    a m2r:Evidence .

civice:5172
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other loss of function mutations (either germline deletions or truncating mutations). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL family of 4, 3 with retinal hemangioblastomas, 1 with renal cell carcinoma, and 1 with pheochromocytoma. ACMG codes as follows:  supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Supporting evidence of pathogenicity because missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)." ;
    a m2r:Evidence .

civice:5174
    dct:references pbm:19270817 ;
    civico:citation "Cho et al., 2009, J. Korean Med. Sci." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline VHL mutations were found in all Korean patients who fulfilled clinical criteria for VHL disease. No mutation of VHL was detected in other patients who did not meet clinical criteria. In all cases, samples from both parents were not available and evidence of de novo mutations could not further be evaluated. This variant is predicted to cause a frameshift and premature stop codon. This variant was found in a 24 year old Korean female with hemangioblastomas of the central nervous system and retinal hemangioblastomas (patient no. 4). There is very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)." ;
    a m2r:Evidence .

civice:5175
    dct:references pbm:19270817 ;
    civico:citation "Cho et al., 2009, J. Korean Med. Sci." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline VHL mutations were found in all Korean patients who fulfilled clinical criteria for VHL disease. No mutation of VHL was detected in other patients who did not meet clinical criteria. In all cases, samples from both parents were not available and evidence of de novo mutations could not further be evaluated. This missense mutation (p.C162R) was found in a 30 year old Korean female with hemangioblastomas of the central nervous system, retinal hemangioblastomas, and renal cell carcinoma (patient no. 7). This patient's phenotype is highly specific for a disease with a single etiology (ACMG code: PP4). Relevant HPO terms: hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma." ;
    a m2r:Evidence .

civice:5176
    dct:references pbm:19270817 ;
    civico:citation "Cho et al., 2009, J. Korean Med. Sci." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline VHL mutations were found in all Korean patients who fulfilled clinical criteria for VHL disease. No mutation of VHL was detected in other patients who did not meet clinical criteria. In all cases, samples from both parents were not available and evidence of de novo mutations could not further be evaluated. This nonsense mutation was found in a 22 year old Korean female with hemangioblastomas of the central nervous system (patient no. 3). There is very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5179
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 8 year old VHL patient with pheochromocytoma (index case 244). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)." ;
    a m2r:Evidence .

civice:5183
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. A novel, missense mutation, was found in 57 year old and 31 year old patients with hemangioblastomas of the central nervous system, retinal hemangioblastomas and pheochromocytoma (index cases 24, 232). This mutation was predicted to alter the linker region between beta and alpha domains of VHL protein. ACMG codes as follows: Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before (PM5). Patient's phenotype is highly specific for a disease with a single genetic etiology (PP4)." ;
    a m2r:Evidence .

civice:5184
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in five VHL patients. The 13 yr old patient had pheochromocytoma (PH) (index case 164). The 25 yr old patient had pheochromocytoma and multiple renal cysts (index case 260). The 27 yr old patient had pheochromocytoma, hemangioblastomas of the central nervous system (CNS) and retinal hemangioblastoma (index case 6). The 30 yr old patient had CNS hemangioblastomas and pheochromocytoma (index case 217). The 33 yr old patient had retinal hemangioblastomas and multiple renal cysts (index case 44). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:5188
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This de novo frameshift mutation was found in a 24 yr old VHL patient with no family history and central nervous system and retinal hemangioblastomas (index case 107). This variant also potentially alters the beta domain of the VHL protein. ACMG codes as follows: Frameshift variant in a gene where loss-of-function is a known mechanism of disease (PVS1). De novo in a patient with the disease and no family history (PS2)." ;
    a m2r:Evidence .

civice:5189
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 34 yr old VHL patient with multiple pancreatic cysts, pheochromocytoma, multiple renal cysts, and central nervous system and retinal hemangioblastomas (index case 74). There is supporting evidence for pathogenicity because the patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Hemangioblastoma, retinal hemangioblastoma, multiple renal cysts, multiple pancreatic cysts, pheochromocytoma." ;
    a m2r:Evidence .

civice:5191
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This frameshift mutation introduces a premature stop codon at amino acid 172 and was found in a 35 yr old VHL patient with hemangioblastomas of the central nervous system and clear cell renal cell carcinoma (index case 182). There is very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code : PVS1). Relevant HPO terms: hemangioblastoma, clear cell renal cell carcinoma." ;
    a m2r:Evidence .

civice:5193
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 36 yr old VHL patient with multiple pancreatic cysts as well as central nervous system and retinal hemangioblastomas (index case 118). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)." ;
    a m2r:Evidence .

civice:5196
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 36 yr old VHL patient with multiple renal cysts as well as central nervous system and retinal hemangioblastoma (index case 191). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2). Relevant HPO terms: hemangioblastoma, retinal hemangioblastoma, multiple renal cysts" ;
    a m2r:Evidence .

civice:5197
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 21 yr old VHL patient with retinal hemangioblastomas (index case 344). ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)." ;
    a m2r:Evidence .

civice:5198
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 14 yr old VHL patient with retinal hemangioblastomas, multiple pancreatic cysts, pheochromocytoma, and multiple renal cysts (index case 160). This patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:5199
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 44 yr old VHL patient with clear cell renal cell carcinoma as well as central nervous system and retinal hemangioblastomas (index case 363). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)." ;
    a m2r:Evidence .

civice:5200
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This novel, missense mutation was found in a 48 yr old VHL patient with multiple renal cysts and hemangioblastomas of the central nervous system (index case 109). This variant potentially alters the alpha domain core of the VHL protein. ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)." ;
    a m2r:Evidence .

civice:5202
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 30 yr old VHL patient with hemangioblastomas of the central nervous system (index case 207). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)." ;
    a m2r:Evidence .

civice:5203
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This deletion mutation was found in a 25 yr old VHL patient with multiple pancreatic cysts and hemangioblastomas of the central nervous system (index case 280). This study contains moderate support for pathogenicity because the protein length changes as a result changes as a result of in-frame deletions in a nonrepeat region (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5205
    dct:references pbm:21463266 ;
    civico:citation "Leonardi et al., 2011, Ann. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This novel, missense mutation was found in a 21 yr old VHL patient with retinal hemangioblastomas and pheochromocytoma (index case 115). This variant potentially alters the beta domain core of the VHL protein. ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)." ;
    a m2r:Evidence .

civice:5215
    dct:references pbm:26282658 ;
    civico:citation "Bang et al., 2015, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A randomized phase 2 trial investigating the efficiency of Olaparib plus Paclitaxel vs. Placebo plus Paclitaxel in recurrent or metastatic gastric cancer patients. 123 patients received treatment. Combination treatment did not significantly improve ORR (26,4% vs 19,1%) or PFS (3,91m vs 3,55 m) but OS (13,8 m vs. 8,3 m) in the overall cohort.  A subcohort of ATM low expressing tumours (14%) experienced improvement of OS (not reached vs. 8,2 m) and a trend towards improved PFS (5,29 m vs 3,68 m)." ;
    a m2r:Evidence .

civice:5245
    dct:references pbm:21972040 ;
    civico:citation "Huang et al., 2012, Int. J. Mol. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This mutation was found in a VHL type 1 male patient with hemangioblastomas of the central nervous system, retinal angiomas, and renal cell carcinomas (family G)." ;
    a m2r:Evidence .

civice:5246
    dct:references pbm:21972040 ;
    civico:citation "Huang et al., 2012, Int. J. Mol. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This splice-site alteration was found in two VHL type 2A female family members with hemangioblastomas of the central nervous system. Mutation was also found in a male VHL type 2A family member with hemangioblastomas of the central nervous system and pheochromocytomas (family C). This study contains very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5247
    dct:references pbm:21972040 ;
    civico:citation "Huang et al., 2012, Int. J. Mol. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This novel mutation was found in 2 male VHL type 1 family members with hemangioblastomas of the central nervous system (family B). Family also contained 5 asymptomatic individuals. This study contains very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5248
    dct:references pbm:21972040 ;
    civico:citation "Huang et al., 2012, Int. J. Mol. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This nonsense mutation was found in two separate families. One female VHL type 1 patient with hemangioblastomas of the central nervous system and an asymptomatic son (family D). Two male VHL type 1 family members with hemangioblastomas of the central nervous system and pancreatic cysts (family F). This study contains very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5249
    dct:references pbm:21972040 ;
    civico:citation "Huang et al., 2012, Int. J. Mol. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This mutation was found two separate VHL families. One family contained a male VHL type 1 patient with hemangioblastomas of the central nervous system and a male asymptomatic patient (family A). The other family contained two male VHL type patients with hemangioblastomas of the central nervous system and 4 asymptomatic family members (family E). This study contains very strong evidence for pathogenicity in the form of a single exon deletion variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5250
    dct:references pbm:19464396 ;
    civico:citation "Ciotti et al., Eur J Med Genet" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 Italian patients were molecularly analyzed for Von Hippel-Lindau disease based on clinical suspicion. 2 of the 43 patients were found to have the above mutation. Clinical manifestations associated with this mutation include: CNS hemangioblastomas, pancreatic cysts, and retinal hemangioblastomas. ACMG evidence codes:  'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease. Relevant HPO terms: Hemangioblastoma, Retinal hemangioblastoma, Multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5260
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient V59). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5261
    dct:references pbm:28546144 ;
    civico:citation "Levis, 2017, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Midostaurin ;
    dcterms:description "Midostaurin is FDA-approved for the treatment of newly-diagnosed acute myeloid leukemia patients harboring FLT3 mutations." ;
    a m2r:Evidence .

civice:5262
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 3 unrelated VHL type 2A patients (patients V32, V60, V97). This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence In controls (ACMG code: PS4)." ;
    a m2r:Evidence .

civice:5263
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in 2 unrelated VHL type 1 patients (patient V3, V46). ACMG codes as follows: A null, nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4)." ;
    a m2r:Evidence .

civice:5264
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient and two VHL type 2B patients (patient no. V322, V36, V262). This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence In controls (ACMG code: PS4). No additional family members were screened in all 3 cases." ;
    a m2r:Evidence .

civice:5265
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient and 5 VHL type 2B patients (patient no. V30, V1). This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence In controls (ACMG code: PS4)." ;
    a m2r:Evidence .

civice:5266
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient (patient no. V233)." ;
    a m2r:Evidence .

civice:5267
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2B patient (patient no. V345). No additional family was screened for this mutation." ;
    a m2r:Evidence .

civice:5268
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 2B patient (patient no. V89). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5269
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V96). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5270
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V64). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5271
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V77). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5272
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V285)." ;
    a m2r:Evidence .

civice:5273
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V374). This patient was further described in Hes et al 2007 (family no. 5) to have bilateral, retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5274
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V48)." ;
    a m2r:Evidence .

civice:5275
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation causes a premature stop codon at amino acid 201 and was found in a VHL type 2B patient (patient no. V51). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)" ;
    a m2r:Evidence .

civice:5276
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 3 VHL type 1 family members (patient no. V27). This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (ACMG code: PS4)." ;
    a m2r:Evidence .

civice:5279
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. ACMG codes as follows. This mutation causes a premature stop codon at amino acid 142 and was found in a VHL type 1 patient and a VHL type 2B patient (patient no. V73, V80). A null, nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4)." ;
    a m2r:Evidence .

civice:5280
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation causes a premature stop codon at amino acid 173 and was found in a VHL type 1 patient (patient no. V235). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5281
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in two VHL type 1 family members (patient no. V252)." ;
    a m2r:Evidence .

civice:5282
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V269)." ;
    a m2r:Evidence .

civice:5283
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation causes a premature stop codon at amino acid 131 and was found in a VHL type 2A patient (patient no. V69). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5284
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in two unrelated VHL type 1 patients (patient no. V53, V94)." ;
    a m2r:Evidence .

civice:5285
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This silent mutation was found in two VHL type 2A family members (patient no. V78). Two unaffected family members did not harbor this synonymous mutation." ;
    a m2r:Evidence .

civice:5286
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 3 VHL type 2B family members (patient no. V11)." ;
    a m2r:Evidence .

civice:5287
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2 patient (patient no. V209)." ;
    a m2r:Evidence .

civice:5288
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V259)." ;
    a m2r:Evidence .

civice:5289
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in two VHL type 1 family members (patient no. V19)." ;
    a m2r:Evidence .

civice:5290
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation causes a premature stop codon at amino acid 66 and was found in a VHL type 1 patient (patient no. V9). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5293
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 14 VHL type 1 family members (patient no. V8).  This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members (14 affected, 13 unaffected) in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:5294
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient (patient no. V240)." ;
    a m2r:Evidence .

civice:5295
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 4 VHL type 1 family members (patient no. V13). This study contains supporting evidence of pathogenicity for this variant due to cosegregation of disease with multiple family members in a gene definitively known to cause disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:5296
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V266)." ;
    a m2r:Evidence .

civice:5297
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2B patient (patient no.V87). No unaffected family members were evaluated. An additional type 1 patient had a similar missense mutation (Y156C, patient no. V265)." ;
    a m2r:Evidence .

civice:5298
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V265)." ;
    a m2r:Evidence .

civice:5299
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V41). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5300
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V63). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5301
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V91)." ;
    a m2r:Evidence .

civice:5302
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient (patient no. V49)." ;
    a m2r:Evidence .

civice:5303
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V81)." ;
    a m2r:Evidence .

civice:5305
    dct:references pbm:19464396 ;
    civico:citation "Ciotti et al., Eur J Med Genet" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 Italian patients were molecularly analyzed for Von Hippel-Lindau disease based on clinical suspicion. 2 of the 43 patients (VHL-6 and -16) were found to have the above mutation. Clinical manifestations associated with this mutation include: CNS hemangioblastomas and pancreatic cysts. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease." ;
    a m2r:Evidence .

civice:5323
    dct:references pbm:26951309 ;
    civico:citation "Powles et al., 2016, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "A randomized, open-label phase 2 study, encompassing 85 patients, to compare the efficacy of dual PIK3/mTOR Inhibitor Apitolisib and mTORC1 inhibitor Everolimus in patients who progressed on or after antiangiogenetic therapy (VEGFR). There was a trend towards association between deleterious VHL alterations and progression-free-survival in the Everolimus arm only." ;
    a m2r:Evidence .

civice:5331
    dct:references pbm:20518900 ;
    civico:citation "Zhou et al., 2010, Pathol. Int." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "14 Chinese patients from 10 VHL Type I families were diagnosed with Von Hippel-Lindau disease based on clinical criteria. Germline mutations were identified in 7/10 families. In all 14 patients, the first manifestation of VHL disease was a central nervous system hemangioblastoma. Their mean age of neurological symptom onset was 24.5 years (range: 12–58 years). Genetic testing demonstrated that Patient 10 (from family VI) and Patient 11 (from family VII) carried this mutation. Patient 10 was reported to have a retinal hemangioblastoma, and patient 11 had a pancreatic tumor. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology." ;
    a m2r:Evidence .

civice:5332
    dct:references pbm:20518900 ;
    civico:citation "Zhou et al., 2010, Pathol. Int." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "14 Chinese patients from 10 families were diagnosed with Von Hippel-Lindau disease based on clinical criteria. Genetic testing demonstrated 1 member of a single family harbored the above mutation. Clinical manifestations in this family included: CNS hemangioblastoma. ACMG evidence codes: 'PVS1' because they observe a canonical +1 splice site variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Hemangioblastoma." ;
    a m2r:Evidence .

civice:5334
    dct:references pbm:20560986 ;
    civico:citation "Sorrell et al., 2011, Clin. Genet." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "This paper identified run-on mutations in 5 members of 4 distinct families. More specifically, genetic testing demonstrated the above mutation (X214LextX15) in 3 individuals in 2 separate families. Clinical evidence suggested an additional 1 family member was affected with VHL, but genetic testing was not conducted on this individual. Clinical manifestations associated with this mutation include: pheochromocytoma, retinal hemangioblastoma, and pancreatic neuroendocrine tumor. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology, 'PP1' because of segregation results, and 'PS3' because in-vitro studies demonstrated this variant was unable to perform normal cellular functions (downregulate JunB)." ;
    a m2r:Evidence .

civice:5335
    dct:references pbm:20560986 ;
    civico:citation "Sorrell et al., 2011, Clin. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "This paper identified run-on mutations in 5 members of 4 distinct families. More specifically, genetic testing demonstrated the above mutation (X214WextX15) in 1 individual in a single family. Clinical manifestations included: pheochromocytoma and pancreatic cysts." ;
    a m2r:Evidence .

civice:5336
    dct:references pbm:20560986 ;
    civico:citation "Sorrell et al., 2011, Clin. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "This paper identified run-on mutations in 5 members of 4 distinct families. More specifically, genetic testing demonstrated the above mutation (X214CextX15) in 1 individual in a single family. Clinical manifestations included: pheochromocytoma, CNS hemangioblastoma, retinal hemangioblastoma, clear cell renal cell carcinoma, and pancreatic neuroendocrine tumor. Relevant HPO terms: Pheochromocytoma, Hemangioblastoma, Retinal hemangioblastoma, Clear cell renal cell carcinoma, Neuroendocrine neoplasm." ;
    a m2r:Evidence .

civice:5338
    dct:references pbm:28679771 ;
    civico:citation "Ma et al., 2017, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Neratinib ;
    dcterms:description "16 patients with HER2-mutated metastatic breast cancer were treated with neratinib monotherapy. Of these 16 patients, 14 had known-activating mutations and 2 had mutations of unknown significance. Five of the 16 patients achieved clinical benefit including 1 complete response (6%), 1 partial response (6%) and 3 with stable disease >24 weeks (19%). Clinical benefit was observed across different HER2 mutations including L755S, V777_G778 insGSP, P780_Y781 insGSP, V842I, S310F, and L869R." ;
    a m2r:Evidence .

civice:5339
    dct:references pbm:27751729 ;
    civico:citation "Hsieh et al., 2017, Eur. Urol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Everolimus,civic:drug_Sunitinib ;
    dcterms:description "This study evaluated the effects of everolimus and sunitinib on patients with metastatic renal cell carcinoma. A total of 220 patients with RCC were evaluated for 341 genes at 540x coverage. Of all 220 patients, 19% of had BAP1 mutations. Patients with BAP1 mutations treated with first line everolimus followed by sunitinib (N=87 wildtype, 22 mutant) were associated with shorter progression free survival (median [95% CI] 4.9 [2.9 - 8.1] vs 10.5 [7.3 - 12.9] mo; HR 1.84 [1.1-3.2]; P=0.02). For patients treated with sunitinib followed by everolimus (N=91 wildtype, 20 mutant) were associated with a trend towards shorter progression free survival (median [95% CI] 8.1 [3.1-11.3] vs 11.0 [8.3-13.8] mo; HR 1.69 [0.9-3.2]; P=0.06)." ;
    a m2r:Evidence .

civice:5340
    dct:references pbm:8641976 ;
    civico:citation "Kanno et al., 1996, Jpn. J. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Blood samples from 5 Japanese families revealed 4 germline mutations. This mutation was found in a family of 3 individuals. Only one VHL patient identified with brain stem hemangioblastomas and retinal angiomas (family B). Parents showed no manifestations of VHL disease. This study contains moderate evidence of pathogenicity because the protein length changes as a result of an in-frame deletion in a nonrepeat region (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5341
    dct:references pbm:8641976 ;
    civico:citation "Kanno et al., 1996, Jpn. J. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Blood samples from 5 Japanese families revealed 4 germline mutations. This missense mutation was found in a family of five individuals. Only one VHL patient was identified with hemangioblastomas of the cerebellum and spinal cord, retinal angiomas, and renal cysts (family A)." ;
    a m2r:Evidence .

civice:5343
    dct:references pbm:8641976 ;
    civico:citation "Kanno et al., 1996, Jpn. J. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Blood samples from 5 Japanese families revealed 4 germline mutations. This mutation was found in a family of 10 individuals. Three VHL patients were identified with hemangioblastomas of the central nervous system and retinal angiomas (family C). The eldest patient also had renal cell carcinoma (listed as C-1 in publication). This study contains very strong evidence of pathogenicity in the form of a canonical -1 splice site mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5344
    dct:references pbm:28275037 ;
    civico:citation "Benson et al., 2017, J Natl Compr Canc Netw" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "NCCN guidelines indicate colorectal cancer patients with NRAS mutations should not be treated with EGFR inhibitors cetuximab or panitumumab." ;
    a m2r:Evidence .

civice:5345
    dct:references pbm:28275037 ;
    civico:citation "Benson et al., 2017, J Natl Compr Canc Netw" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "NCCN guidelines indicate colorectal cancer patients with KRAS mutations should not be treated with the anti-EGFR therapies cetuximab or panitumumab." ;
    a m2r:Evidence .

civice:5349
    dct:references pbm:8641976 ;
    civico:citation "Kanno et al., 1996, Jpn. J. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Blood samples from 5 Japanese families revealed 4 germline mutations. This missense mutation was found in a family of 7 individuals. Two VHL patients were identified, 1 with brain stem hemangioblastomas and retinal angiomas, the other with renal cell carcinoma (family D). Single-strand conformational polymorphism (SSCP) analysis showed bands for the 2 affected individuals that were absent from 5 normal individuals. Direct sequencing was performed on SSCP positive patients. Supporting evidence for pathogenicity due to cosegregation with disease in multiple affected family members (ACMG code: PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma" ;
    a m2r:Evidence .

civice:5351
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 family. Only one affected patient was identified with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts. (family VHL 57). This study contains very strong evidence of pathogenicity in the form of a canonical -2 splice variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5352
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in a German, VHL type 1 family (family VHL 55). Two patients were identified with retinal angiomas and hemangioblastomas of the central nervous system. This study contains very strong evidence of pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5353
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 2B family. Only one patient was identified with retinal angiomas, hemangioblastomas of the central nervous system, pheochromocytoma, and renal cell carcinoma. This patient's phenotype is highly specific for a disease with a single etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:5354
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 2B family with 5 affected individuals (family VHL 43). Each patient had retinal angiomas, 2 had hemangioblastomas of the central nervous system, and 2 had renal cell carcinoma. The patients phenotype and family history are highly specific for a disease with a single gene etiology (ACMG code: PP4)." ;
    a m2r:Evidence .

civice:5355
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 42). HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5356
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a Croatian, VHL type 1 family of 3. Each individual had retinal angiomas, one had hemangioblastomas of the central nervous system, one had renal cell carcinoma, and one had pancreatic cysts (family VHL 7). This study contains very strong evidence of pathogenicity in the form of a canonical +2 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5357
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 patient with hemangioblastomas of the central nervous system (family VHL 48). This study contains very strong evidence of pathogenicity in the form of a canonical -1 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma." ;
    a m2r:Evidence .

civice:5358
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, and pancreatic cysts (family VHL 30). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: retinal hemangioblastoma, hemangioblastoma, multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5359
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in an Iranian, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and pancreatic islet cell tumors (family VHL 65). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts, neuroendocrine neoplasm." ;
    a m2r:Evidence .

civice:5360
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in 2 German, VHL type 1 family members with retinal angiomas and hemangioblastomas of the central nervous system (family VHL 56). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: retinal hemangioblastoma, hemangioblastoma." ;
    a m2r:Evidence .

civice:5361
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in a Filipino, VHL type 1 patient with hemangioblastomas of the central nervous system (family VHL 50). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma." ;
    a m2r:Evidence .

civice:5363
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 patient with retinal angiomas (family VHL 59)." ;
    a m2r:Evidence .

civice:5364
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations.  This mutation was found in 2 Croatian, VHL type 1 family members (family VHL 26). Both have hemangioblastomas of the central nervous system, one has renal cell carcinoma, and one with pancreatic cysts." ;
    a m2r:Evidence .

civice:5365
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This mutation was found in 2 German, VHL type 1 family members with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 44). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5366
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in 2 German, VHL type 2 family members with retinal angiomas, hemangioblastomas of the central nervous system, and pheochromocytomas (family VHL 29). Each patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).  HPO terms: retinal hemangioblastoma, hemangioblastoma, pheochromocytoma." ;
    a m2r:Evidence .

civice:5368
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 family of 11. Three patients had retinal angiomas, 7 hand hemangioblastomas of the central nervous system, 7 had renal cell carcinoma, and 6 had pancreatic cysts (family VHL 3). This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5369
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 23).  HPO terms: hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5370
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in 3 Italian, VHL type 1 family members. Two had retinal angiomas, 2 had hemangioblastomas of the central nervous system, 2 had renal cell carcinoma, and all three had pancreatic cysts. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5371
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a Slovakian, VHL type 1 family of 13 affected individuals. Seven had retinal angiomas, 7 had hemangioblastomas of the central nervous system, 5 had renal cell carcinoma, one had pancreatic cysts, and one had  pancreatic islet cell tumors (family VHL 39). This study contains supporting evidence for pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts, neuroendocrine neoplasm." ;
    a m2r:Evidence .

civice:5372
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found 3 unrelated, German families, 2 of which had been previously described (Neumann et al. 1995). The newly-identified VHL type 2 patient had retinal angiomas and pheochromocytoma (family VHL 54). As previously described, one VHL type 2A family of 52 affected individuals had 26 patients with retinal angiomas, 6 with hemangioblastomas of the central nervous system, and 41 with pheochromocytoma (family VHL*). A VHL type 1 family of 3 had 2 patients with retinal angiomas and one with renal cell carcinoma (family VHL 47). This study contains supporting evidence for pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:5373
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 45). This study contains very strong evidence of pathogenicity in the form of a canonical +1 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5374
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in 2 unrelated, German families. The VHL type 1 family of 4 affected individuals had 2 patients with retinal angiomas, 5 with hemangioblastomas of the central nervous system, and one with renal cell carcinoma (family VHL 53). The VHL type 2B family of 3 affected individuals had one patient with retinal angioma, 3 with hemangioblastomas of the central nervous system, one with pheochromocytoma, one with renal cell carcinoma, one with pancreatic cysts, and one with cystadenomas of the epididymis (family VHL 9). This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: papillary cystadenomas of the broad ligament, retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, pheochromocytoma, multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5375
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in 2 unrelated, German families. One VHL type 1 family of 2 affected individuals had one patient with retinal angiomas, 2 with hemangioblastomas of the central nervous system, one with renal cell carcinoma, one with pancreatic cysts, and  one with cystadenomas of the epididymis (family VHL 32). Another VHL type 1 family of 3 affected individuals had 3 patients with retinal angiomas, one with hemangioblastomas of the central nervous system, 2 with renal cell carcinoma, one with pancreatic cysts, and one with cystadenomas of the epididymis (family VHL 49). ACMG codes as follows: A nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). HPO terms:  papillary cystadenomas of the broad ligament." ;
    a m2r:Evidence .

civice:5376
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 family of 6. Each patient had hemangioblastomas of the central nervous system and 4 had cystadenomas of the epididymis (family VHL 51). This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: hemangioblastoma, papillary cystadenomas of the broad ligament." ;
    a m2r:Evidence .

civice:5377
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 family of 2. Both patients had hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and cystadenomas of the epididymis (family VHL 60). One patient also had retinal angiomas. This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts, papillary cystadenomas of the broad ligament." ;
    a m2r:Evidence .

civice:5399
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5400
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and two patients with pheochromocytoma." ;
    a m2r:Evidence .

civice:5401
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5402
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma. HPO terms: pheochromocytoma." ;
    a m2r:Evidence .

civice:5403
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This nonsense mutation was found in the VHL gene and one patient with pheochromocytoma. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5404
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This nonsense mutation was found in the VHL gene and one patient with pheochromocytoma. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5405
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This nonsense mutation was found in the VHL gene and one patient with pheochromocytoma. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: pheochromocytoma." ;
    a m2r:Evidence .

civice:5406
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5407
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and two patients with pheochromocytoma." ;
    a m2r:Evidence .

civice:5408
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5409
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma.  HPO terms: pheochromocytoma." ;
    a m2r:Evidence .

civice:5410
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5411
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5412
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5413
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5414
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5415
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5416
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5417
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and two patients with pheochromocytoma." ;
    a m2r:Evidence .

civice:5418
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations. This missense mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:5420
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was detected in a previously diagnosed VHL patient by DHPLC (VHL 73). This frameshift mutation provides strong evidence of pathogenicity (PVS1)." ;
    a m2r:Evidence .

civice:5422
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 83). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5424
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 92). This was the same missense mutation as was described in the previously published Glavač et al. (1996) study included in this study (VHL 9 and 53)." ;
    a m2r:Evidence .

civice:5426
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in 2  previously diagnosed VHL patients and a suspect VHL mutation carrier by DHPLC (family VHL 26, VHL 63, VHL 77). This variant results in an in frame deletion providing moderate evidence for pathogenicity (PM4)." ;
    a m2r:Evidence .

civice:5427
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 82)." ;
    a m2r:Evidence .

civice:5428
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 104)." ;
    a m2r:Evidence .

civice:5430
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a suspect VHL mutation carrier by DHPLC (family VHL 110)." ;
    a m2r:Evidence .

civice:5431
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 66)." ;
    a m2r:Evidence .

civice:5432
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a suspected VHL mutation carrier by DHPLC (family VHL 106)." ;
    a m2r:Evidence .

civice:5433
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 85). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5434
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 86). Protein length changes as a result of in-frame insertion in a nonrepeat region (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5435
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 94)." ;
    a m2r:Evidence .

civice:5436
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 99)." ;
    a m2r:Evidence .

civice:5437
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 105)." ;
    a m2r:Evidence .

civice:5440
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 103). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5441
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 79). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5442
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 75). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5443
    dct:references pbm:11409863 ;
    civico:citation "Klein et al., 2001, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 80)." ;
    a m2r:Evidence .

civice:5445
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes:  'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease." ;
    a m2r:Evidence .

civice:5446
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5447
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. More specifically, the mutation causes the following protein change: F76Cfs*83. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease." ;
    a m2r:Evidence .

civice:5448
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5449
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5450
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5451
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5452
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5453
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. More specifically, the mutation causes the following protein change W117LfsX1. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease." ;
    a m2r:Evidence .

civice:5454
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5455
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5456
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the A122I mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease." ;
    a m2r:Evidence .

civice:5457
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5458
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease." ;
    a m2r:Evidence .

civice:5459
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. More specifically, this mutation causes the following protein change: N150SfsX19. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Neuroendocrine neoplasm." ;
    a m2r:Evidence .

civice:5460
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5461
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5462
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed." ;
    a m2r:Evidence .

civice:5463
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5464
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5465
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. More specifically, this mutation causes the following protein change: E160AfsX12. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease ." ;
    a m2r:Evidence .

civice:5466
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 5 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5467
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5468
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 7 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5469
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 4 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease." ;
    a m2r:Evidence .

civice:5470
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5471
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease ." ;
    a m2r:Evidence .

civice:5472
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease ." ;
    a m2r:Evidence .

civice:5473
    dct:references pbm:20660572 ;
    civico:citation "Erlic et al., 2010, Endocr. Relat. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ." ;
    a m2r:Evidence .

civice:5474
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease." ;
    a m2r:Evidence .

civice:5475
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease. Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:5476
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease. Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:5477
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease. Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:5478
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease. Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:5479
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease. Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:5480
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients, from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease. Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:5481
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients, from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease. Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:5482
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients, from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. More specifically, this mutation causes the following protein change: C162AfsX8. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:5483
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This nonsense mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina, and renal cell carcinoma (family no. 15). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5484
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 2 patients from 2 families were confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease. Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:5485
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 12 patients from 4 families were confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease." ;
    a m2r:Evidence .

civice:5486
    dct:references pbm:20846682 ;
    civico:citation "Benhammou et al., 2010, J. Urol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 3 patients from 3 families were confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a multiexon deletion variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Pheochromocytoma." ;
    a m2r:Evidence .

civice:5487
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). Arg167Trp and Arg167Gln mutations conferred a high (62%) risk for pheochromocytoma. Pheochromocytoma was diagnosed in all families with Arg167Gln mutation. This missense mutation was found in a VHL patient with retinal hemangioblastomas and pheochromocytoma (family no. 17). This mutation was also found in a VHL family of 8 affected patients (family no. 18). Seven had retinal hemangioblastomas, six had hemangioblastomas of the central nervous system, and 2 had pheochromocytoma. Cosegregation of the disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:5489
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHLD family of 4 affected patients (family no. 10). All 4 patients had retinal hemangioblastomas, 3 had hemangioblastomas of the central nervous system, and one had renal cell carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5491
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHL patient and 2 VHL family members. The single patient had hemangioblastomas of the central nervous system and retina (family no. 8). One of the family members had retinal hemangioblastomas and the other had renal cell carcinoma (family no. 9).  HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5493
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHL family of 5 affected patients (family no. 16). Four had retinal hemangioblastomas and 4 had hemangioblastomas of the central nervous system. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5495
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina (family no. 11). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma, retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5496
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in VHL patient with hemangioblastomas of the retina and central nervous system (family no. 14). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma, retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5498
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina (family no. 12). HPO terms: hemangioblastoma, retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5499
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in one VHL patient and 2 VHL families. The patient had hemangioblastomas of the central nervous system (family no. 1). A VHL family of 4 affected individuals had one patient with retinal hemangioblastomas, 3 with hemangioblastomas of the central nervous system, and one with renal cell carcinoma (family no. 2). A VHL family of 12 individuals had 10 with retinal hemangioblastomas, 3 with renal cell carcinoma, and 13 with hemangioblastomas of the central nervous system (family no. 3). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5500
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina (family no. 4). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma, retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5501
    dct:references pbm:12114495 ;
    civico:citation "Cybulski et al., 2002, J. Med. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in a VHL family of 3 individuals. All 3 had retinal hemangioblastomas, 2 had hemangioblastomas of the central nervous system, and one had renal cell carcinoma (family no. 13). ACMG codes as follows: A frameshift variant in a gene where loss-of-function is a known mechanism of disease (PVS1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5505
    dct:references pbm:21889194 ;
    civico:citation "Delmore et al., 2011, Cell" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_JQ-1 ;
    dcterms:description "BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes. In experimental models of multiple myeloma, a Myc-dependent hematologic malignancy, JQ1 produces a potent antiproliferative effect associated with cell-cycle arrest and cellular senescence." ;
    a m2r:Evidence .

civice:5506
    dct:references pbm:19543324 ;
    civico:citation "Akita et al., 2009, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gemcitabine ;
    dcterms:description "There were 68 patients enrolled in this study, 28 of which were treated with gemcitabine.  Of those 28, 14 patients had a low RRM1 expression and 14 had a high RRM1 expression. Only the patients with low RRM1 expression received a significant benefit from gemcitabine (p=0.0010) whereas the benefit for those with a high RRM1 expression was not significantly better (p=0.3309).  The study also tested the role of ERCC1 expression and its correlation to RRM1 expression. It was found that patients with a combined high RRM1 and ERCC1 expression had good prognosis with the highest survival rate (P=0.0127)." ;
    a m2r:Evidence .

civice:5507
    dct:references pbm:28471952 ;
    civico:citation "Wang et al., 2017, Medicine (Baltimore)" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A meta analysis of 60 research studies involving 10,310 solid tumors indicated that CD274 over expression results in poor overall survival (HR = 1.58, P <.001) and poor disease free/progression free survival (DFS/PFS) (HR = 1.72, P =0 .001). When split into sub groups by cancer type overall survival  was poor for breast (HR = 1.98, P =0 .014), urothelial (HR = 2.24, P <0.001), renal (HR = 3.30,  P <0.001), and gastric cancers (HR = 1.56, P =0 .040). DFS/PFS was poor in patients with hepatocellular carcinoma (HR = 1.72,  P = 0.003), melanoma (HR = 3.39,  P <0.001), and renal carcinoma, (HR = 5.04,  P <0.001)." ;
    a m2r:Evidence .

civice:5508
    dct:references pbm:17131328 ;
    civico:citation "Nakahira et al., 2007, Int. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gemcitabine ;
    dcterms:description "In this study, human pancreatic carcinoma cell line MiaPaCa2, which is a gemcitabine-sensitive cell line, was used for the establishment of chemoresistant cells MiaPaCa2-RG. Analysis for identifying genetic alterations relating to gemcitabine resistance revealed that RRM1 was the most upregulated gene with a 4.5 fold expression. RRM1-speciﬁc RNAi transfection significantly reduced the gemcitabine chemoresistance of MiaPaCa2-RG to the same level as that of gemcitabine sensitive MiaPaCa2. Moreover, gemcitabine response of MiaPaCa2 also became more sensitive.  Next, patients with pancreatic cancer were recruited and 18 tissue samples were taken. The patients with a low RRM1 expression had a significantly better outcome after gemcitabine treatment than those patients with high RRM1 expression (P=0.016)." ;
    a m2r:Evidence .

civice:5530
    dct:references pbm:24647522 ;
    civico:citation "Dong et al., 2014, PLoS ONE" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gemcitabine,civic:drug_Docetaxel,civic:drug_Vinorelbine ;
    dcterms:description "In this study, 229 tumors were analyzed for RRM1 expression. This resulted in 146 that were negative for RRM1 expression and 83 that were positive. These tumors were studied for a relationship between RRM1 expression and chemotherapy regimens, gemcitabine, docetaxel and carboplatin, and vinorelbine and carboplatin. In the patients receiving gemcitabine treatment, the progression-free survival of RRM1-negative patients was significantly higher than that of RRM1-positive patients (8.8 months vs. 7.6 months, P = 0.01). The patients that were positive for RRM1 expression, had a better response to docetaxel or vinorelbine treatment than gemcitabine (P=0.047 and P=0.047). However, there were no differences of response to docetaxel and vinorelbine in regards to RRM1 expression." ;
    a m2r:Evidence .

civice:5533
    dct:references pbm:26428316 ;
    civico:citation "Conlon et al., 2015, Mod. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Sanger sequencing identified DICER1 hotspot mutations in 20 of 32 (63%) ovarian Sertoli–Leydig cell tumors. These mutations were unrelated to tumor differentiation and mostly (16/20, 80%) were E1705K. Additionally, DICER1 E1705K mutations were identified in 5/8 (63%) Sertoli cell tumors and 2/5 (40%) gynandroblastomas. However, no mutations were identified in 15 testicular sex cord-stromal tumors (8 classical Sertoli cell tumors, 3 Sertoli cell tumors-large cell calcifying variant, 4 sex cord-stromal tumors not otherwise specified)." ;
    a m2r:Evidence .

civice:5534
    dct:references pbm:26428316 ;
    civico:citation "Conlon et al., 2015, Mod. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was previously believed." ;
    a m2r:Evidence .

civice:5535
    dct:references pbm:26428316 ;
    civico:citation "Conlon et al., 2015, Mod. Pathol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was previously believed. " ;
    a m2r:Evidence .

civice:5543
    dct:references pbm:12624160 ;
    civico:citation "Rocha et al., 2003, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 1 family of 8 affected individuals (VHL family 12). Seven had hemangioblastomas of the central nervous system, one had retinal angiomas, and 2 had renal carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5544
    dct:references pbm:12624160 ;
    civico:citation "Rocha et al., 2003, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in 20 Brazilian, VHL probands and their families. This mutation causes a premature stop codon at amino acid 158 and was found in a VHL type 1 patient with hemangioblastomas of the central nervous system, retinal angiomas, and renal carcinoma (VHL family 13). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5545
    dct:references pbm:12624160 ;
    civico:citation "Rocha et al., 2003, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in 2 affected family members with pheochromocytoma (VHL family 15). One also had hemangioblastomas of the central nervous system. Patient's phenotype is highyl specific for a disease with a single genetic etiology (ACMG code: PP1). HPO terms: hemangioblastoma, pheochromocytoma." ;
    a m2r:Evidence .

civice:5546
    dct:references pbm:12624160 ;
    civico:citation "Rocha et al., 2003, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 2 family of 4 affected individuals (VHL family 16). Two patients had hemangioblastomas of the central nervous system and three had pheochromocytoma. ACMG codes as follows: Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Patients' phenotypes are highly specific for a disease with a single genetic etiology (PP4)." ;
    a m2r:Evidence .

civice:5547
    dct:references pbm:12624160 ;
    civico:citation "Rocha et al., 2003, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 1 family of 10 affected individuals (VHL family 2). Seven had hemangioblastomas of the central nervous system, 3 had retinal angiomas, and 3 had renal carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5548
    dct:references pbm:12624160 ;
    civico:citation "Rocha et al., 2003, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 1 family of 10 affected individuals (VHL family 2). Seven had hemangioblastomas of the central nervous system, 3 had retinal angiomas, and 3 had renal carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5549
    dct:references pbm:12624160 ;
    civico:citation "Rocha et al., 2003, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in 2 VHL family members (VHL family 3). One had hemangioblastomas of the central nervous system and the other had retinal angiomas. HPO terms: hemangioblastoma, retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5550
    dct:references pbm:12624160 ;
    civico:citation "Rocha et al., 2003, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in 20 Brazilian, VHL probands and their families. This nonsense mutation was found in a VHL type 1 family of 3 affected individuals. All three family members had retinal angiomas and 2 also had hemangioblastomas of the central nervous system (VHL family 4). A nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). HPO terms: hemangioblastoma, retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5553
    dct:references pbm:12624160 ;
    civico:citation "Rocha et al., 2003, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in 20 Brazilian, VHL probands and their families. This mutstaion was found in a VHL type 1 family of 3 affected individuals (VHL family 9). One had hemangioblastomas of the central nervous system, one with retinal angiomas, and one with renal carcinoma. ACMG codes as follows: A frameshift mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5554
    dct:references pbm:12624160 ;
    civico:citation "Rocha et al., 2003, J. Med. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in 20 Brazilian, VHL probands and their families. This mutation causes a premature stop codon at amino acid 142 and was found in a VHL type 1 patient with hemangioblastomas of the central nervous system (VHL family 6). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). HPO terms: hemangioblastoma." ;
    a m2r:Evidence .

civice:5561
    dct:references pbm:22133049 ;
    civico:citation "Sun et al., 2012, Br J Neurosurg" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Case report of a female VHL patient presenting with spinal hemangioblastoma at the age of 32. Further workup showed the presence of pancreatic cysts and a history of spinal hemangioblastoma in the mother. Genetic testing confirmed the presence of the above mutation in the proband. ACMG evidence codes:  'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease, 'PP4' because the patients' phenotypes or family history are highly specific for a disease with single genetic etiology. Relevant HPO terms: Spinal hemangioblastoma, Multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5582
    dct:references pbm:14722919 ;
    civico:citation "Ruiz-Llorente et al., 2004, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Thirty-five unrelated patients suspected of having von Hippel-Lindau disease were analyzed and 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered. This missense mutation was found in a patient with cerebellar hemangioblastomas and clear cell renal carcinoma (patient no. F62). HPO terms: hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5599
    dct:references pbm:23038758 ;
    civico:citation "Vilmar et al., 2013, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Paclitaxel,civic:drug_Vinorelbine,civic:drug_Gemcitabine ;
    dcterms:description "The study began with a total of 443 patients that were randomly assigned to either regimen A (Paclitaxel and cisplatin with gemcitabine) or regimen B ( cisplatin and vinorelbine). Of those patients, 261 had tissue available for RRM1 evaluation.  In regimen B, survival increased significantly in patients with low RRM1 expression as compared to those with a high expression (P=0.046). However, in regimen A, the increase in survival for patients with low RRM1 expression as opposed to those with a high RRM1 expression was not as significant (P=0.366)." ;
    a m2r:Evidence .

civice:5637
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation was found in a VHL type 1 patient (kindred no. 35). Only moderate support for pathogenicity because protein length changes as a result of in-frame deletions in a nonrepeat region (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5638
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation was found in a VHL type 1 patient (kindred no. 46)." ;
    a m2r:Evidence .

civice:5639
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 1 patient (kindred no. 151). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5640
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 1 patient (kindred no. 76)." ;
    a m2r:Evidence .

civice:5641
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in 2 VHL type 1 patients (kindred no. 48, 75). Only moderate support for pathogenicity because protein length changes as a result of in-frame deletion in a nonrepeat region (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5642
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This splice mutation was found in a VHL type 1 patient (kindred no. 143). This study contains very strong evidence for pathogenicity in the form of a canonical -1 splice site mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5643
    dct:references pbm:7987306 ;
    civico:citation "Crossey et al., 1994, Hum. Mol. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation was found in a VHL type 1 patient (kindred no. 54). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5649
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation was found in VHL type 1 family (lineage 11). Only moderate evidence for pathogenicity because protein length changes as a result of in-frame insertions in a nonrepeat region (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5650
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation was found in 2 VHL type 1 families (lineages 136, 183). Only moderate evidence for pathogenicity because protein length changes as a result of in-frame deletion in a nonrepeat region (ACMG code: PM4)." ;
    a m2r:Evidence .

civice:5651
    dct:references pbm:9829911 ;
    civico:citation "Stolle et al., 1998, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes a premature stop codon at amino acid 170 and was found in a VHL type 1 family (lineage 16). There is very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5653
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V287). Only moderate evidence of pathogenicity since the protein length changes as a result of an in-frame deletion in a nonrepeat region  (AMCG code: PM4)." ;
    a m2r:Evidence .

civice:5654
    dct:references pbm:9829912 ;
    civico:citation "Olschwang et al., 1998, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V67). Only moderate evidence of pathogenicity since the protein length changes as a result of an in-frame deletion in a nonrepeat region (AMCG code: PM4)." ;
    a m2r:Evidence .

civice:5675
    dct:references pbm:22808142 ;
    civico:citation "Wang et al., 2012, PLoS ONE" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "D" ;
    dcterms:description "In this study, real-time quantitative RT-PCR assays were used in 66 pairs of cancerous and matched adjacent normal tissues. In 43 of those pairs, the expression level of ARID1A was significantly lower in the cancerous tissue than in the normal tissue (P=0.0029). This was then again tested using Western Blotting. Consistent with the real-time PCR results, there was a lower expression of ARID1A in 13 of the tumor tissue samples compared to the normal tissue samples (P=0.0015). In an immunohistochemical analysis of 224 tissue blocks, 115 of those had a decreased ARID1A expression. The data conveyed that lower ARID1A expression was correlated with depth of tumor infiltration (P=0.001). Lastly, cell proliferation in regards to ARID1A expression was tested in cell lines. The cells with silenced expression of ARID1A had a much greater growth than those with greater expression of the protein." ;
    a m2r:Evidence .

civice:5676
    dct:references pbm:25628030 ;
    civico:citation "Park et al., 2015, Hum. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed. These samples were then divided according to ARID1A expression after immunohistochemical staining. Of the 290 patients, 213 had a low ARID1A expression and 77 patients had a high expression. There was a significant correlation between low ARID1A expression and large tumors as well as shorter survival. After a multivariate analysis using Cox proportional hazards, it was found that ARID1A expression levels are an independent predictor of progression-free survival in patients with CCRCC, although no significant correlation was found between the expression levels and cancer-specific survival." ;
    a m2r:Evidence .

civice:5679
    dct:references pbm:23673869 ;
    civico:citation "Mete et al., 2014, Endocrine" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "49 family members from three generations of a Turkish family were examined. A clinical presentation of VHL type 2B was noted. Genetic testing was performed on 17 family members. 11 members with the mutation had manifestations, while 6 members with the mutation were asymptomatic. 1 of the asymptomatic individuals belonged to generation 2, while the remaining 5 belonged to the fourth generation, suggesting they may be too young to present manifestations. From the members that had manifestations: 9 had pheochromocytoma (5 bilateral),  1 had lumbar spine hemangioblastoma, 1 had retinal hemangioblastoma, 4 had renal cell carcinoma (2 bilateral), and 3 had pancreatic neuroendocrine tumours (1 also had a serous cystadenoma in addition to the neuroendocrine tumour). ACMG evidence codes: 'PP1' because of segregation results, 'PP2' because there is a missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease, 'PP4' because the patient's phenotype or family history is highly specific for a disease with a single genetic etiology. Relevant HPO terms: Renal cell carcinoma, Spinal hemangioblastoma, Multiple pancreatic cysts, Pheochromocytoma, Neuroendocrine neoplasm, Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5682
    dct:references pbm:23143947 ;
    civico:citation "Chen et al., 2013, Clin Transl Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "This paper reports on 4 Chinese kindreds with VHL. The VHL gene was screened using direct DNA sequencing and MLPA in 44 volunteers among the 4 families. The above mutation was found in 1 kindred; 10 members were tested and 3 were found to harbour the mutation. More specifically, this mutation is believed to cause the following protein change: F76Cfs*83. The 7 members without a mutation were asymptomatic, while the 3 members with a mutation had manifestations. In addition to the 3 members who tested positive, there were 2 additional members who displayed manifestations, but died before testing could be performed. Clinical manifestations in this kindred included: renal cell carcinoma, CNS hemangioblastoma, pancreatic cysts, renal cysts, and retinal hemangioblastoma. ACMG evidence codes: 'PP1' because of segregation results, 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology, 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Renal cell carcinoma, Multiple renal cysts, Multiple pancreatic cysts, Hemangioblastoma, Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5689
    dct:references pbm:23298237 ;
    civico:citation "Losonczy et al., 2013, BMC Med. Genet." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genetic analysis of 7 Hungarian individuals from 5 unrelated families affected with von Hippel-Lindau disease revealed 5 different mutations, 3 of which were novel. The mutations could not be found within 100 healthy controls. The above mutation was found in 2 members (father and daughter) of a single family. The mutation was absent in two healthy family members. The mutation destroys the conserved intronic donor splice site and likely leads to premature protein termination (G114Dfs*6). The 12-year-old daughter had retinal and spinal hemangioblastoma, while the 34-year-old father had retinal, spinal, and cerebellar hemangioblastoma, and bilateral clear cell renal cell carcinoma. ACMG evidence codes: 'PVS1' because they observe a canonical +1 splice site variant in a gene where loss of function is a known mechanism of disease, 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology, 'PP1' because of segregation results. Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Spinal hemangioblastoma, Clear cell renal cell carcinoma." ;
    a m2r:Evidence .

civice:5720
    dct:references pbm:10567493 ;
    civico:citation "Gläsker et al., 1999, J. Neurol. Neurosurg. Psychiatr." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A cohort of 141 patients with hemangioblastomas of the central nervous system was analyzed. 81 patients had germline mutations in the VHL gene. This missense mutation was found in one patient with hemangioblastomas of the central nervous system. No other phenotype described.  HPO terms: hemangioblastoma." ;
    a m2r:Evidence .

civice:5724
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This splice mutation was found in a VHL type 1 family of 3 individuals. One family member had retinal angiomas and 2 had hemangioblastomas of the central nervous system. There is very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: retinal hemangioblastoma, hemangioblastoma." ;
    a m2r:Evidence .

civice:5725
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This mutation was found in 2 VHL type 1 family members with retinal angiomas and hemangioblastomas of the central nervous system. HPO terms: retinal hemangioblastoma, hemangioblastoma." ;
    a m2r:Evidence .

civice:5726
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This mutation was found in a VHL type 1 family of 5 individuals. Four family members had retinal angiomas and 3 had hemangioblastomas of the central nervous system. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: retinal hemangioblastoma, hemangioblastoma." ;
    a m2r:Evidence .

civice:5727
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 2 family of 7 individuals. Three family members had retinal angiomas, 2 had hemangioblastomas of the central nervous system, 2 had renal cell carcinoma, and one had pheochromocytoma. ACMG codes as follows: A frameshift variant in a gene where loss-of-function is known mechanism of disease (PSV1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma, pheochromocytoma." ;
    a m2r:Evidence .

civice:5728
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 family of 3. All three had retinal angiomas and hemangioblastomas of the central nervous system. One also had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5729
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 3 VHL type 1 families of 7 individuals total. Five patients had retinal angiomas, 3 had hemangioblastomas of the central nervous system, and 6 had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5730
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 2 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, and pheochromocytoma. There is very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)." ;
    a m2r:Evidence .

civice:5731
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. This mutation was found in a VHL type 1 family of 3. All three family members had retinal angiomas. One also had renal cell carcinoma. HPO terms: retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5733
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 family of 3. One family member had retinal angiomas, one had hemangioblastomas of the central nervous system, and one had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5734
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 patient with retinal angiomas. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5735
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 family of 5 individuals. Three had hemangioblastomas of the central nervous system and one had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5736
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 2 family members. One family member had retinal angiomas and the other had hemangioblastomas of the central nervous system. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1)." ;
    a m2r:Evidence .

civice:5737
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 2 family members with renal cell carcinomas. One relative also had retinal angiomas, while the other had hemangioblastomas of the central nervous system. HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5738
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, and renal cell carcinoma. HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5739
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 family retinal angiomas and renal cell carcinoma. HPO terms: retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5740
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a patient with hemangioblastomas of the central nervous system. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss-of-function is known mechanism of disease." ;
    a m2r:Evidence .

civice:5741
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a patient with retinal hemangioblastomas. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). Relevant HPO terms: Retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5742
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL patient with retinal angiomas and hemangioblastomas of the central nervous system. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: retinal hemangioblastoma, hemangioblastoma." ;
    a m2r:Evidence .

civice:5743
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL patient with retinal angiomas and hemangioblastomas of the central nervous system. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, retinal hemangioblastoma." ;
    a m2r:Evidence .

civice:5744
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 4 unrelated families of 8 individuals total. 5 individuals had retinal hemangioblastomas, 4 had hemangioblastomas of the central nervous system, and 3 had renal cell carcinoma. ACMG evidence codes: 'PM4' because they observe a protein length change as a result of an in-frame deletion in a nonrepeat region or stop-loss variants, 'PP4' because the patients' phenotypes or family history are highly specific for a disease with single genetic etiology." ;
    a m2r:Evidence .

civice:5745
    dct:references pbm:17024664 ;
    civico:citation "Ong et al., 2007, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 2 unrelated VHL families with 4 individuals total. Three had hemangioblastomas of the central nervous system, 4 had retinal angiomas, and 2 had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma." ;
    a m2r:Evidence .

civice:5748
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This splice mutation was found in VHL patient with hemangioblastomas of the retina and central nervous system, renal cell carcinoma, and pancreatic cysts (family no. 32). ACMG evidence codes: 'PSV1' because they observe a splice-site variant in a gene where loss-of-function is known mechanism of disease, 'PP4' because the patients' phenotypes or family history are highly specific for a disease with single genetic etiology." ;
    a m2r:Evidence .

civice:5749
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 family members with retinal hemangioblastomas and renal cell carcinoma (family no. 25). One family member also had central nervous system hemangioblastoma. ACMG evidence codes: 'PM4' because they observe a protein length change as a result of an in-frame deletion in a nonrepeat region." ;
    a m2r:Evidence .

civice:5765
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 40 year old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 1)." ;
    a m2r:Evidence .

civice:5766
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This mutation was found in a 42-year-old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 12). ACMG evidence codes: 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology." ;
    a m2r:Evidence .

civice:5767
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This mutation was found in 3 family members and an unrelated patient. All three family members had hemangioblastomas of the central nervous system (proband no. 13). The 32-year-old sister and 27-year-old proband had renal cell carcinoma and pancreatic cysts. The proband also had retinal angiomas. The unrelated, 45-year-old VHL patient had hemangioblastomas of the central nervous system and retina, renal cell carcinoma, and pancreatic cysts (proband no. 14). ACMG codes as follows: A single exon deletion variant in a gene where loss-of-function is known mechanism of disease (PSV1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1)." ;
    a m2r:Evidence .

civice:5768
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This silent mutation was found in a 34-year-old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 15)." ;
    a m2r:Evidence .

civice:5769
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in 4 VHL family members (proband no. 6). The 65-year-old father had renal cell carcinoma; The 37-year old sister had pancreatic cysts and the 33-year old sister had retinal angiomas. The 38-year-old proband had hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and epididymal cystadenoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:5771
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This nonsense mutation was found in 2 unrelated families. One family of 3 had a asymptomatic 27-year-old female, a 27-year-old male with epididymal cystadenoma, and a 55-year old with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 10). The other VHL family had 2 individuals with hemangioblastomas of the central nervous system (proband no. 11). ACMG codes as follows: A nonsense variant in a gene where loss-of-function is a known mechanism of disease (PSV1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1)." ;
    a m2r:Evidence .

civice:5772
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 45-year-old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 4)." ;
    a m2r:Evidence .

civice:5773
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 43-year-old VHL patient with renal cell carcinoma, pancreatic cysts, an endolymphatic sac tumor, and an epididymal /ovarian cystadenoma (proband no. 5)." ;
    a m2r:Evidence .

civice:5774
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a VHL family of 6 individuals (proband no. 7). A 62-year-old female carrying the mutation and a male with an unknown mutation had hemangioblastomas of the central nervous system (CNS). A 58-year-old male family member had retinal angiomas and renal cell carcinoma. The 60 year-old proband had CNS hemangioblastomas, retinal angiomas, renal cell carcinoma, and pancreatic cysts. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)." ;
    a m2r:Evidence .

civice:5775
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 2 VHL family members (proband no. 2). The 33-year-old proband had retinal angiomas, renal cell carcinoma, pancreatic cysts, and pheochromocytoma. The proband's 8-year-old had no clinical manifestations of VHL disease." ;
    a m2r:Evidence .

civice:5776
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This nonsense mutation was found in 2 unrelated families. One family had a 32-year-old with hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and epididymal cystadenoma, and their 8-year-old asymptomatic son (proband no. 8). The other family had a 39-year-old with renal cell carcinoma and pancreatic cysts and their 81-year-old mother with CNS hemangioblastomas (proband no. 9). There is very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)." ;
    a m2r:Evidence .

civice:5777
    dct:references pbm:22357542 ;
    civico:citation "Wu et al., 2012, J. Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This mutation was found in a 30-year-old VHL patient with hemangioblastomas of the central nervous system, retinal angiomas, renal cell carcinoma, and pancreatic cysts (proband no. 16). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5780
    dct:references pbm:25562111 ;
    civico:citation "Park et al., 2015, Scand. J. Gastroenterol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In the analysis of 63 clinically diagnosed VHL patients, 55 patients were found with pancreatic involvement. Genetic tests on 35 of 55 VHL patients revealed VHL variants in 28 patients. Of the 55 enrolled patients, hemangioblastomas of the central nervous system were previously documented in 47 patients, renal cell carcinoma in 25, and pheochromocytoma in 11 patients. This missense variant was found in 37-year-old female with reported VHL type 1 phenotype and pancreatic lesions (case no. 1). ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease." ;
    a m2r:Evidence .

civice:5787
    dct:references pbm:22101352 ;
    civico:citation "Katagiri et al., 2012, Mod. Pathol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study, tissue sampling began with 77 ovarian cancer patients. Following, 60 of those samples, the patients withe clear cell ovarian cancer, were analyzed for ARID1A expression using immunohistochemistry.  Of those 60, 9 patients had a loss of ARID1A expression. Also, 17 high-grade serous adenocarcinomas were also analyzed and none of them showed a loss of ARID1A expression. The loss was more frequent in clear cell ovarian carcinoma than in the high-grade serous adenocarcinoma. Results showed that a low ARID1A expression was significantly related to advanced FIGO stages and high CAI25 levels (P=0.02). Those patients with a low expression experienced shorter progression free survival than those with no loss of expression (P<0.01). In a multivariate analysis it was found that a loss of ARID1A expression was significant for shorter disease free survival (P=0.03) and shorter overall survival for patients whose ovarian clear cell carcinoma was treated with platinum-based chemotherapy (P=0.015). Lastly, tumors with low expression were significantly more likely to be resistant to primary adjuvant chemotherapy than tumors with a higher expression (P=0.04)." ;
    a m2r:Evidence .

civice:5794
    dct:references pbm:24396697 ;
    civico:citation "Ku et al., 2013, Endocrinol Metab (Seoul)" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A case report of a female Korean patient with VHL. She presented initially with gestational diabetes mellitus, and on routine abdominal scan displayed renal and pancreatic cysts. Family history demonstrated 2 family members with features consistent with VHL (cerebellar hemangioblastoma), which prompted genetic testing. Molecular analysis revealed the presence of the above mutation. Subsequently, she developed spinal hemangioblastoma and clear cell renal cell carcinoma. ACMG evidence codes: 'PP4' because the patient's phenotype or family history is highly specific for a disease with a single genetic etiology, 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease." ;
    a m2r:Evidence .

civice:5798
    dct:references pbm:25586603 ;
    civico:citation "Sidhu et al., 2015, Pediatr Blood Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "This is a case report on a 9-month-old female with polycythemia. The patient carries a paternally inherited missense mutation (EID5799) and this de novo, nonsense mutation. ACMG codes as follows: A nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). Assumed de novo, but without confirmation of paternity and maternity (PM6)." ;
    a m2r:Evidence .

civice:5799
    dct:references pbm:25586603 ;
    civico:citation "Sidhu et al., 2015, Pediatr Blood Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "This is a case report on a 9-month-old female with polycythemia. The patient carries a de novo nonsense mutation [Q145* (c.433C>T)] and this paternally inherited, missense mutation. The authors of this paper believed this missense mutation was the cause of the aforementioned clinical manifestations. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease." ;
    a m2r:Evidence .

civice:5811
    dct:references pbm:25891174 ;
    civico:citation "Garon et al., 2015, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pembrolizumab ;
    dcterms:description "PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab." ;
    a m2r:Evidence .

civice:5815
    dct:references pbm:28578601 ;
    civico:citation "Robson et al., 2017, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA1 patients specifically, the hazard ratio was 0.54, 95% CI 0.37-0.79)." ;
    a m2r:Evidence .

civice:5816
    dct:references pbm:28578601 ;
    civico:citation "Robson et al., 2017, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA2 patients specifically, the hazard ratio was 0.68, 95% CI 0.45-0.1.07." ;
    a m2r:Evidence .

civice:5829
    dct:references pbm:24934408 ;
    civico:citation "Al-Ahmadie et al., 2014, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Irinotecan,civic:drug_AZD7762 ;
    dcterms:description "The publication describes a patient with a somatic RAD50 L1237F mutation in combination with LOH and a TP53 A161T mutation that showed a complete response to a combination treatment with Irinotecan and the CHK1 inhibitor AZD7762." ;
    a m2r:Evidence .

civice:5830
    dct:references pbm:28792849 ;
    civico:citation "2017, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group." ;
    a m2r:Evidence .

civice:5831
    dct:references pbm:28792849 ;
    civico:citation "2017, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group." ;
    a m2r:Evidence .

civice:5833
    dct:references pbm:28418267 ;
    civico:citation "Woyach et al., 2017, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "A patient cohort of 308 individuals was created from trails of Ibrutinib in CLL (see Maddocks 2015 PMID 26182309).  A secondary cohort was created from a prospective collection of  112 patients.  83/308 patients discontinued because of disease progression (27 Richter's transformation; 1 prolymphocytic leukemia; 55 progressive CLL).  46/55 progressive patients had a relapse sample available for sequencing of BTK and PLCG2. 31 patients only had BTK C481(F/R/A/S)  mutations, 3 patients only had PLCG2 mutations, and 6 patients had both BTK C481 and PLCG2 mutations.  In the 112 patients sequencing of BTK and PLGC2 coding regions was performed every 3 months. At publication at 8 patients had experienced relapse. All 8 had BTK C481S  mutations with clonal expansion before relapse.  8 additional patients did not have clinical relapse but had  BTK  C481S  mutations with VAF >1% and increasing CLL cells in peripheral blood." ;
    a m2r:Evidence .

civice:5834
    dct:references pbm:24869598 ;
    civico:citation "Woyach et al., 2014, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Whole exome sequencing was performed on baseline and relapse samples from six patients with CLL.  One relapse sample had mutations in BTK and PLCG2, and a second relapse sample only had a mutation in PLCG2.  Both samples with PLCG2 mutations had a mutation at R665W.  Mutations in PLCG2 at L845F and S707Y were observed in the relapse samples with an additional BTK C481S mutation." ;
    a m2r:Evidence .

civice:5835
    dct:references pbm:28958504 ;
    civico:citation "Catenacci et al., 2017, Lancet Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Rilotumumab ;
    dcterms:description "In this randomised, double-blind, placebo-controlled phase 3 trial, 609 patients with MET+ (expression of at least 1+ intensity on 25% or more tumor cells) gastric cancer or gastroesophageal adenocarcinoma were randomized to chemotherapy (epirubicin, cisplatin, capecitabine) with placebo or MET inhibitor rilotumumab. Study treatment was stopped early because of a higher number of deaths in the rilotumumab arm. Median overall survival was 8·8 months (95% CI 7·7-10·2) in the rilotumumab group compared with 10·7 months (9·6-12·4) in the placebo group (stratified hazard ratio 1·34, 95% CI 1·10-1·63; p=0·003)." ;
    a m2r:Evidence .

civice:5836
    dct:references pbm:23099803 ;
    civico:citation "Birkeland et al., 2012, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In this study, KRAS gain (KRAS/CEP12q ratio >1 and <2) or amplification (ratio >2) was detected in 3% (13 of 414) of the primary endometrial carcinomas investigated. Presence of KRAS gain or amplification were highly significantly associated with poor prognosis with a 46% 5-year survival compared with 87% for patients with unamplified status (P<0.001). Amplification of KRAS maintains its independent prognostic impact in Cox multivariate analysis when adjusted for age, histological subtype, grade and FIGO stage (HR=2.6, 95% CI: 1.2–5.8, P=0.02). In contrast, presence of KRAS mutation did not influence prognosis (P=0.67)" ;
    a m2r:Evidence .

civice:5840
    dct:references pbm:28330462 ;
    civico:citation "Kim et al., 2017, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Everolimus ;
    dcterms:description "In a single-arm, open label phase 2 trial in PIK3CA amplified/mutated and/or PTEN loss encompassing 10 patients, no objective responses were observed but a stable disease response in 4 patients, resulting in a median PFS of 1.4 months. Everolimus failed to meet its enpoint." ;
    a m2r:Evidence .

civice:5845
    dct:references pbm:25952756 ;
    civico:citation "Vikkath et al., 2015, Fam. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A study describing phenotypic and genotypic characteristics of VHL in an Indian population of 31 subjects, from 15 families diagnosed with VHL. Multi-cystic pancreas and CNS hemangioblastomas were the most common manifestations in this population. This splice site mutation was found in a VHL family of 8 individuals(family ID AD). 3 family members had renal cell carcinoma, 4 had hemangioblastomas of the central nervous system, 7 had multi-cystic pancreatic lesions, and 1 had retinal hemangioblastomas. ACMG codes as follows: A splice-site variant in a gene where loss-of-function is a known mechanism of disease (PVS1), patient's phenotypes or family history are highly specific for a disease with single genetic etiology (PP4), cosegregation with the disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Relevant HPO terms: Hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma, Multiple pancreatic cysts." ;
    a m2r:Evidence .

civice:5851
    dct:references pbm:8707293 ;
    civico:citation "Glavac et al., 1996, Hum. Genet." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 family. Only one affected patient was identified with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts and cystadenomas of the epididymis. (family VHL 31).  HPO terms: hemangioblastomas, retinal hemangioblastomas, renal cell carcinoma, multiple pancreatic cysts, papillary cystadenomas of the broad ligament." ;
    a m2r:Evidence .

civice:5858
    dct:references pbm:28950338 ;
    civico:citation "Jones et al., 2017, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In a single patient with presumed cholangiocarcinoma a novel ATP1B1-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the gene fusion, prioritizing a therapeutic strategie targeting the HER-family of growth factor receptors with afatinib. This patient was treated with the pan HER-family kinase inhibitor afatinib and displayed significant and durable response to treatment." ;
    a m2r:Evidence .

civice:5859
    dct:references pbm:28950338 ;
    civico:citation "Jones et al., 2017, Ann. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Afatinib ;
    dcterms:description "In patient with lung adenocarcinoma an SDC4-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the detected gene fusion, prioritizing therapeutic strategies targeting the HER-family of growth factor receptors. This patient was treated with the pan HER-family kinase inhibitor afatinib and displayed a significant and durable response to treatment." ;
    a m2r:Evidence .

civice:5863
    dct:references pbm:9681858 ;
    civico:citation "Wittebol-Post et al., 1998, J. Intern. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "20 patients from 6 families in the Netherlands were analyzed for Von Hippel Lindau manifestations. 1 family consisting of 12 members had the above mutation. Manifestations in this family included: renal cell carcinoma, cerebellar hemangioblastoma, pancreatic cyst, retinal hemangioblastoma, and pheochromocytoma. ACMG evidence codes: 'PP1' based on segregation results, 'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease, 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology. Relevant HPO terms: Renal cell carcinoma, Cerebellar hemangioblastoma, Multiple pancreatic cysts, Retinal hemangioblastoma, Pheochromocytoma." ;
    a m2r:Evidence .

civice:5886
    dct:references pbm:22187960 ;
    civico:citation "Heravi-Moussavi et al., 2012, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Likely Pathogenic" ;
    civico:evidenceLevel "B" ;
    dcterms:description "DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were ten mutations in D1709N." ;
    a m2r:Evidence .

civice:5887
    dct:references pbm:22187960 ;
    civico:citation "Heravi-Moussavi et al., 2012, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Likely Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1709G." ;
    a m2r:Evidence .

civice:5888
    dct:references pbm:22187960 ;
    civico:citation "Heravi-Moussavi et al., 2012, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Likely Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two mutations in D1709E." ;
    a m2r:Evidence .

civice:5892
    dct:references pbm:22187960 ;
    civico:citation "Heravi-Moussavi et al., 2012, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Likely Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two mutations in E1813Q." ;
    a m2r:Evidence .

civice:5897
    dct:references pbm:22187960 ;
    civico:citation "Heravi-Moussavi et al., 2012, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Likely Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with one mutation in a Juvenile ovarian granulosa-cell tumor (1/14; 7%). This individual had a germline mutation in D1709G." ;
    a m2r:Evidence .

civice:5899
    dct:references pbm:22187960 ;
    civico:citation "Heravi-Moussavi et al., 2012, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Likely Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). There was one Yolk sac tumor that had a germline mutation in D1709N." ;
    a m2r:Evidence .

civice:5900
    dct:references pbm:22187960 ;
    civico:citation "Heravi-Moussavi et al., 2012, N. Engl. J. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Likely Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). There was one Yolk sac tumor that had a germline mutation in D1709E." ;
    a m2r:Evidence .

civice:5902
    dct:references pbm:28480077 ;
    civico:citation "Kocsis et al., 2017, J Gastrointest Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_TrametinibDMSO ;
    dcterms:description "Chemotherapy-refractory, metastatic cholangiocarcinoma with BRAF V600E showed dramatically response for Dabrafenib and Trametinib combination." ;
    a m2r:Evidence .

civice:5903
    dct:references pbm:28078132 ;
    civico:citation "Lavingia et al., 2016, J Gastrointest Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_TrametinibDMSO ;
    dcterms:description "Two cases of patients with BRAF V600E positive cholangiocarcinoma showed excellent response for Dabrafenib and Trametinib." ;
    a m2r:Evidence .

civice:5904
    dct:references pbm:25435907 ;
    civico:citation "Loaiza-Bonilla et al., 2014, Ecancermedicalscience" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_TrametinibDMSO ;
    dcterms:description "Dabrafenib and trametinib combination showed durable response for patients with standard chemotherapy refractory cholangiocarcinoma havoring BRAF V600E." ;
    a m2r:Evidence .

civice:5905
    dct:references pbm:26287849 ;
    civico:citation "Hyman et al., 2015, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "Eight patients with BRAF V600 (7 with V600E, 1 with V600 unknown) mutated cholangiocarcinoma received vemurafenib. Only one patients showed partial response and duration of response of this patient was longer than 12 months." ;
    a m2r:Evidence .

civice:5906
    dct:references pbm:26687137 ;
    civico:citation "Silkin et al., 2016, J Gastrointest Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Irinotecan,civic:drug_Vemurafenib,civic:drug_Panitumumab ;
    dcterms:description "Patients with metastatic cholangiocarcinoma havoring with BRAF V600E was treated with vemurafenib, panitumumab and irinotecan triplet therapy. Multiple lung metastasis was dramatically regressed and this treatment was continued." ;
    a m2r:Evidence .

civice:5908
    dct:references pbm:29182496 ;
    civico:citation "Javle et al., 2017, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_BGJ398 ;
    dcterms:description "This Phase II trial of BGJ398 for FGFR2 aberant cholangiocarcinoma included 48 patients with FGFR2 fusions. Among these patients with FGFR2 fusions, eight showed tumor response (18.8%) and thirty-six showed tumor shrinkage (75%)." ;
    a m2r:Evidence .

civice:5912
    dct:references pbm:29182496 ;
    civico:citation "Javle et al., 2017, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_BGJ398 ;
    dcterms:description "Eight patients with cholangiocarcinoma haboring FGFR2 mutations received BGJ398. No response was observed, but one tumor showed a 23% reduction in  size. Water fall plot of this article showed 5 patients with stable disease." ;
    a m2r:Evidence .

civice:5913
    dct:references pbm:25366685 ;
    civico:citation "Kaufman et al., 2015, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. All but one had received gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%." ;
    a m2r:Evidence .

civice:5914
    dct:references pbm:25366685 ;
    civico:citation "Kaufman et al., 2015, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. All but one had received gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%." ;
    a m2r:Evidence .

civice:5915
    dct:references pbm:25072261 ;
    civico:citation "Golan et al., 2014, Br. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PLATINUM ;
    dcterms:description "Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)" ;
    a m2r:Evidence .

civice:5916
    dct:references pbm:25072261 ;
    civico:citation "Golan et al., 2014, Br. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_PLATINUM ;
    dcterms:description "Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)" ;
    a m2r:Evidence .

civice:5923
    dct:references pbm:20942962 ;
    civico:citation "Foster et al., 2010, World J Surg Oncol" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_CRS-IPHC ;
    dcterms:description "25 patients with metastatic peritoneal mesothelioma were treated with surgical cytoreduction consolidated with intraperitoneal hyperthermic chemotherapy (CRS/IPHC). 8 of the patients carried EGFR mutations in the tyrosine kinase domain. Each mutation was not found in 100 unrelated controls. At study end 10/18 wildtype patients had died with median survival of 14 months, while 2/7 EGFR mutant patients had died and median survival was not yet reached. Median time to progression (TTP) was 12 months in the wildtype group and in the mutant group median TTP was not yet reached. 3 year progression free survival was 71% in the mutant group and 28% in the wildtype group." ;
    a m2r:Evidence .

civice:5924
    dct:references pbm:20826716 ;
    civico:citation "Dahabreh et al., 2011, Ann. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "The result of the analysis found that EGFR gene copy number was associated with increased OS and PFS, supporting the idea that EGFR gene copy number is a biomarker for response to EGFR-TKI therapy in patients with advanced NSCLC." ;
    a m2r:Evidence .

civice:5925
    dct:references pbm:27664271 ;
    civico:citation "Zhang et al., 2017, J. Investig. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "Among TKI-treated patients, increased EGFR gene copy number appears to be associated with improved survival outcomes." ;
    a m2r:Evidence .

civice:5929
    dct:references pbm:28389374 ;
    civico:citation "Parrotta et al., 2017, J Thorac Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Olaparib,civic:drug_GDC-0980 ;
    dcterms:description "Novel alternative splice isoform of BAP1 (BAP1Δ) that misses part of the catalytic domain showed reduced deubiquitinating activity compared with full-length BAP1. MPM cell lines expressing more than 20% of BAP1Δ are more sensitive to olaparib (a PARP1 inhibitor), and this sensitivity is enhanced when olaparib treatment is combined with GDC0980 (a dual PI3K-mTOR inhibitor)." ;
    a m2r:Evidence .

civice:5932
    dct:references pbm:29338080 ;
    civico:citation "O'Reilly et al., 2018, Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gemcitabine,civic:drug_Veliparib,civic:drug_Cisplatin ;
    dcterms:description "In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease." ;
    a m2r:Evidence .

civice:5933
    dct:references pbm:29338080 ;
    civico:citation "O'Reilly et al., 2018, Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gemcitabine,civic:drug_Cisplatin,civic:drug_Veliparib ;
    dcterms:description "In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease." ;
    a m2r:Evidence .

civice:5934
    dct:references pbm:29223478 ;
    civico:citation "Lowery et al., 2018, Eur. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Veliparib ;
    dcterms:description "Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy. No confirmed PR was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR." ;
    a m2r:Evidence .

civice:5935
    dct:references pbm:29223478 ;
    civico:citation "Lowery et al., 2018, Eur. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Veliparib ;
    dcterms:description "Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy. No confirmed PR was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR." ;
    a m2r:Evidence .

civice:5953
    dct:references pbm:27197561 ;
    civico:citation "Ozden et al., 2016, Sci Rep" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "Loss of BARD1 function through the expression of a BARD1 splice variant, BARD1β, results in a more malignant phenotype with decreased RAD51 foci formation, reduced BRCA1 E3 ubiquitin ligase activity, and decreased nuclear BRCA1 protein localization. BARD1β sensitizes colon cancer cells to poly ADP ribose polymerase 1 (PARP-1) inhibition even in a BRCA1 WT background." ;
    a m2r:Evidence .

civice:5954
    dct:references pbm:24687827 ;
    civico:citation "Godbert et al., 2015, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor volume, and her response has been stable on follow-up." ;
    a m2r:Evidence .

civice:5955
    dct:references pbm:22374460 ;
    civico:citation "Harder et al., 2012, Br. J. Cancer" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Capecitibine ;
    dcterms:description "This is Phase II trial of Trastuzumab and capecitabine as first line treatment in patients with IHC 3+ HER2 expressing advanced pancreatic cancer or cancer with HER2 gene amplification of stage IVB. Total 207 patients could be assessed for HER2 expression. From the 23 patient with IHC 3+ HER2 expression or IHC 2+ and HER2 gene amplification, 17 patients were included in the study and could be assessed for response to the treatment. Contrary to breast and gastric cancer, only 7 out of 11 (64%) patients with IHC 3+ HER2 expression showed gene amplification. PFS rate at 12 weeks was estimated as 23.5%. Median PFS was 65 days. Median OS was 6.9 months. Authors concluded not to recommend further evaluation of anti-HER2 treatment in patients with metastatic pancreatic cancer." ;
    a m2r:Evidence .

civice:5956
    dct:references pbm:15581051 ;
    civico:citation "Safran et al., 2004, Cancer Invest." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Gemcitabine ;
    dcterms:description "Patients with metastatic pancreatic cancer with IHC 2+/3+ HER2 received gemcitabine and Trastuzumab combination. Screening logs demonstrated the rate of HER2 overexpression was 16%. Thirty-four patients were enrolled. Thirty patients (88%) had pancreatic cancers with 2+ overexpression and 4 patients (12%) had 3+ overexpression. Confirmed partial responses were observed in 2 of 32 patients (6%). The median survival for all 34 patients was 7 months." ;
    a m2r:Evidence .

civice:5957
    dct:references pbm:28281183 ;
    civico:citation "Smyth et al., 2017, Invest New Drugs" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Buparlisib,civic:drug_Paclitaxel,civic:drug_Carboplatin ;
    dcterms:description "No objective responses were observed in the PTEN deficient cohort. Four out of 6 patients with stable disease (SD) had SD or better for ≥6 cycles, 2 of which had PTEN deficient tumors. Conclusion The addition of buparlisib to high dose carboplatin and paclitaxel was not tolerable. The combination did not reveal significant clinical activity amongst a small and heterogenous group of PTEN deficient tumors." ;
    a m2r:Evidence .

civice:5958
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Within the BRAF mutant group, fourteen patients had refractory BRAF V600E-mutated NSCLC (adenocarcinoma, n = 13; sarcomatoid, n = 1). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD > 120 days. The median DOR was 5 months (range, 4 to 14 months)." ;
    a m2r:Evidence .

civice:5959
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 4 patients with BRAF V600E mutant ovarian cancer, 2 had a partial response and one had stable disease > 120days." ;
    a m2r:Evidence .

civice:5960
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 2 patients with BRAF V600E mutant colorectal cancer, 1 had a partial response." ;
    a m2r:Evidence .

civice:5961
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Pertuzumab,civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant anaplastic thyroid cancer had a complete response." ;
    a m2r:Evidence .

civice:5962
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant laryngeal cancer had a partial response with vemurafenib." ;
    a m2r:Evidence .

civice:5964
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5965
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5966
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5967
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5968
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5969
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5970
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5971
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5972
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5973
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5974
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5975
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5976
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion." ;
    a m2r:Evidence .

civice:5977
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion)." ;
    a m2r:Evidence .

civice:5978
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vismodegib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one patients had mutations in the Hedgehog pathway (PTCH-1, n = 18; SMO, n = 3). Three patients with PTCH1 mutations had PRs to vismodegib (17%; unknown primary cancer, n = 1; squamous skin cancer, n = 1; salivary gland cancer, n = 1)." ;
    a m2r:Evidence .

civice:5979
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vismodegib ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one patients had mutations in the Hedgehog pathway (PTCH-1, n = 18; SMO, n = 3). None of the patients with SMO mutations responded to SHH-inhibition with vismodegib." ;
    a m2r:Evidence .

civice:5980
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pertuzumab,civic:drug_Trastuzumab ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among thirty-six patients that received treatment with trastuzumab plus pertuzumab because of a HER2 mutation (without amplification/overexpression) four patients (11%; 95% CI, 3% to 26%) had objective responses.  Fourteen of the 36 patients with HER2-mutated tumors had NSCLC (adenocarcinoma, n = 13; adenosquamous, n = 1); in this group, three patients (21%; 95% CI, 5% to 51%) had PR and three had SD > 120 days. Only one of the other 22 patients with HER2-mutated tumors responded to treatment with pertuzumab plus trastuzumab (biliary cancer)." ;
    a m2r:Evidence .

civice:5981
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Pertuzumab ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.  Thirty of 114 patients (26%; 95% CI, 19% to 35%) with HER2 amplification/overexpression had objective responses to treatment with trastuzumab plus pertuzumab (two CR, 28 PR).  Patients with HER2-amplified/overexpressing metastatic colorectal cancer composed the largest tumor-pathway cohort. In this group of 37 patients with refractory disease (median, four previous lines of therapy), treatment with trastuzumab plus pertuzumab produced PRs in 14 patients (38%; 95% CI, 23% to 55%; Fig 2A). An additional four patients had SD > 120 days. The median DOR was 11 months (range, < 1 to 16+ months; 95% CI, 2.8 months to not estimable)." ;
    a m2r:Evidence .

civice:5982
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Pertuzumab ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Three of nine patients (33%; 95% CI, 8% to 70%) with advanced bladder cancer and HER2 amplification/overexpression had responses (one CR ongoing at 15 months; two PR lasting 1 and 6 months), and two patients had SD > 120 days." ;
    a m2r:Evidence .

civice:5983
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Pertuzumab ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of seven patients (29%; 95% CI, 4% to 71%) with biliary cancer and HER2 amplification/overexpression had PR, and three had SD > 120 days" ;
    a m2r:Evidence .

civice:5984
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pertuzumab,civic:drug_Trastuzumab ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five patients with HER2 amplified/overexpressing salivary gland carcinoma (80%; 95% CI, 28% to > 99%) had responses (all PR)." ;
    a m2r:Evidence .

civice:5985
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Pertuzumab,civic:drug_Trastuzumab ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of nine patients (22%) with HER2 amplified/overexpressing pancreatic cancer had a PR with trastuzumab/pertuzumab combination. Another patient had SD > 120days." ;
    a m2r:Evidence .

civice:5986
    dct:references pbm:29320312 ;
    civico:citation "Hainsworth et al., 2018, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trastuzumab,civic:drug_Pertuzumab ;
    dcterms:description "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. None of the 7 patients with HER2 amplified/overexpressing uterus cancer responded to pertuzumab/trastuzumab." ;
    a m2r:Evidence .

civice:5987
    dct:references pbm:27466707 ;
    civico:citation "Brody et al., 2016, Cancer Biol. Ther." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_AG-120 ;
    dcterms:description "A 48-year-old female was diagnosed with metastatic pancreatic ductal adenocarcinoma and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed. Detailed molecular profiling was performed on a biopsy from a liver lesion that demonstrated an IDH1 mutation, R132H. The patient subsequently received a mutant IDH1 inhibitor (AG-120), but with no response." ;
    a m2r:Evidence .

civice:5988
    dct:references pbm:27735949 ;
    civico:citation "Bean et al., 2016, Cell Death Dis" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Chloroquine,civic:drug_ADI-PEG20 ;
    dcterms:description "90% out of 700 sarcoma samples (comprising 45 histologies) demonstrated loss or reduction of argininosuccinate synthetase 1 expression. Arginine auxotrophy confers sensitivity to arginine deprivation. In sarcoma models, arginine deprivation therapy with pegylated arginine deiminase (ADI-PEG20) maintains a prolonged state of arginine starvation without causing cell death. Combination of ADI-PEG20 and chloroquine led to synergistic cell death via necroptosis and apoptosis." ;
    a m2r:Evidence .

civice:5989
    dct:references pbm:19533750 ;
    civico:citation "Nicholson et al., 2009, Int. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PLATINUM ;
    dcterms:description "Preclinical evidence for epigenetic inactivation of ASS1 as a determinant of response to platinum chemotherapy suggesting that silencing of ASS1 contributes to treatment failure and clinical relapse in ovarian cancer." ;
    a m2r:Evidence .

civice:5992
    dct:references pbm:25452615 ;
    civico:citation "Correia et al., 2015, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a multivariate analysis, BCL2 mutations and high FL international prognostic index were independent risk factors for transformation and death due to lymphoma. Some mutant Bcl-2 proteins exhibited enhanced antiapoptotic capacity in vitro." ;
    a m2r:Evidence .

civice:5994
    dct:references pbm:29127119 ;
    civico:citation "Hayashi et al., 2017, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Trametinib ;
    dcterms:description "Approximately 2% of NSCLCs had RASA1 truncating mutations, and this alteration was statistically, but not completely, mutually exclusive with known activating EGFR (p=0.02) and KRAS (p=0.02) mutations. Unexpectedly, RASA1 truncating mutations had a strong tendency to co-occur with NF1 truncating mutations (p<0.001). While growth of cell lines with inactivation of only one of these two RasGAPs showed moderate and variable sensitivity to inhibitors of MEK or PI3K, cells with concurrent RASA1/NF1 mutations were profoundly more sensitive (IC50: 0.040μM trametinib)." ;
    a m2r:Evidence .

civice:6000
    dct:references pbm:27694828 ;
    civico:citation "Kim et al., 2016, Nat Commun" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_GF109203X,civic:drug_Go6983 ;
    dcterms:description "TLK2 inhibition selectively inhibits the growth of TLK2-high breast cancer cells, downregulates ERα, BCL2 and SKP2, impairs G1/S cell cycle progression, induces apoptosis and significantly improves progression-free survival in vivo." ;
    a m2r:Evidence .

civice:6001
    dct:references pbm:18794803 ;
    civico:citation "Smalley et al., 2009, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib." ;
    a m2r:Evidence .

civice:6002
    dct:references pbm:18794803 ;
    civico:citation "Smalley et al., 2009, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_U0126 ;
    dcterms:description "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib." ;
    a m2r:Evidence .

civice:6003
    dct:references pbm:18794803 ;
    civico:citation "Smalley et al., 2009, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Sorafenib ;
    dcterms:description "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib." ;
    a m2r:Evidence .

civice:6004
    dct:references pbm:18794803 ;
    civico:citation "Smalley et al., 2009, Oncogene" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_U0126 ;
    dcterms:description "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition (U0126) but underwent apoptosis after shRNA-mediated CRAF knowdown or treatment with the pan-RAF inhibitor sorafenib." ;
    a m2r:Evidence .

civice:6034
    dct:references pbm:26033501 ;
    civico:citation "Goulvent et al., 2016, Histopathology" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "FOXL2 mutations were found in 94% of pathologically confirmed A-GCTs (95/101), in one of eight juvenile granulosa cell tumours (J-GCTs), and in two of 19 SLCTs." ;
    a m2r:Evidence .

civice:6042
    dct:references pbm:26942346 ;
    civico:citation "Forde et al., 2016, Obstet Gynecol" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "Patient was 34-year-old woman with vaginal sarcoma, which was excised with positive surgical margins. Fluorescence in situ hybridization testing of her tumor revealed  anaplastic lymphoma kinase gene rearrangements. A 3-cm mass recurred 1 month later. Treatment with crizotinib resulted in complete regression of all visible or palpable tumor within 3 weeks." ;
    a m2r:Evidence .

civice:6043
    dct:references pbm:25028698 ;
    civico:citation "Kimbara et al., 2014, Jpn. J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Crizotinib ;
    dcterms:description "This is a case report of a  22-year-old Japanese man with a pelvic mesenchymal neoplasm. Tumor analysis include IHC and RT-PCR led to diagnosis of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion. Despite two surgical excision procedures, local recurrence rapidly occurred, and the tumor developed resistance to conventional chemotherapy with doxorubicin. Subsequent administration of crizotinib resulted in relief of severe pain and durable tumor shrinkage at least 10 months." ;
    a m2r:Evidence .

civice:6044
    dct:references pbm:27480103 ;
    civico:citation "Ascierto et al., 2016, Lancet Oncol." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "A" ;
    civico:drug civic:drug_Cobimetinib,civic:drug_Vemurafenib ;
    dcterms:description "In this double-blind, randomised, placebo-controlled, multicentre study, adult patients with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma were randomly assigned (1:1) to receive cobimetinib or placebo, in combination with oral vemurafenib. Progression-free was primary endpoint. Between Jan 8, 2013, and Jan 31, 2014, 495 eligible adult patients were enrolled and randomly assigned to the cobimetinib plus vemurafenib group (n=247) or placebo plus vemurafenib group (n=248). Investigator-assessed median progression-free survival was 12·3 months for cobimetinib and vemurafenib versus 7·2 months for placebo and vemurafenib (HR 0·58 [95% CI 0·46-0·72], p<0·0001).Median overall survival was 22·3 months for cobimetinib and vemurafenib versus 17·4 months for placebo and vemurafenib (HR 0·70, 95% CI 0·55-0·90; p=0·005). The safety profile for cobimetinib and vemurafenib was tolerable and manageable, and no new safety signals were observed with longer follow-up." ;
    a m2r:Evidence .

civice:6045
    dct:references pbm:26287849 ;
    civico:citation "Hyman et al., 2015, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In a phase 2 “basket” study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete response and one partial response was observed, for a response rate of 29%." ;
    a m2r:Evidence .

civice:6046
    dct:references pbm:28363909 ;
    civico:citation "van Geel et al., 2017, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Encorafenib ;
    dcterms:description "In a Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab, Twenty-six patients with refractory BRAF V600 mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab).  Confirmed overall response rates of 19% were observed and median progression-free survival was 3.7 months." ;
    a m2r:Evidence .

civice:6047
    dct:references pbm:28363909 ;
    civico:citation "van Geel et al., 2017, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Encorafenib,civic:drug_Cetuximab,civic:drug_Alpelisib ;
    dcterms:description "In a Phase Ib Dose-Escalation Study of Encorafenib, Cetuximab and Alpelisib, Twenty-eight patients with refractory BRAFV600 mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab) with a PI3Kα inhibitor (alpelisib).  Confirmed overall response rates of 18% were observed and median progression-free survival was 4.2 months" ;
    a m2r:Evidence .

civice:6049
    dct:references pbm:24788118 ;
    civico:citation "Hamada et al., 2014, PLoS ONE" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Meloxicam ;
    dcterms:description "Of the 33 patients with desmoid fibromatosis treated with meloxicam, a COX-2 selective inhibitor, one showed complete remission (CR), 7 partial remission (PR), 12 stable disease (SD), and 13 progressive disease (PD). The following 3 point mutations were identified in 21 of the 33 cases (64%): T41A (16 cases), S45F (4 cases) and S45P (one case). All four cases with S45F mutation exhibited strong nuclear expression of β-catenin. S45F mutation was significantly associated with a poor response (all cases; PD) (p = 0.017)" ;
    a m2r:Evidence .

civice:6059
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense variant was found in a VHL type 1 patient  with CNS hemangioblastomas (family ID 4479)." ;
    a m2r:Evidence .

civice:6060
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This in-frame deletion was  found in a VHL type 1 family of 6 individuals (family ID 3177). Four of 6 individuals were identified with angiomas and 3 had CNS hemangioblastomas." ;
    a m2r:Evidence .

civice:6061
    dct:references pbm:7728151 ;
    civico:citation "Chen et al., 1995, Hum. Mutat." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense variant was found in 2 family members with VHL type 1 phenotype (family ID 3513). Both individuals were identified with cerebellar hemangioblastomas and renal cell carcinoma. One also had angiomas." ;
    a m2r:Evidence .

civice:6062
    dct:references pbm:7977367 ;
    civico:citation "Whaley et al., 1994, Am. J. Hum. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Tissue analysis from 61 VHL patients, 30 sporadic renal cell carcinoma (RCC) tumor samples, and 6 sporadic RCC cell lines revealed 22 variants within VHL patients, 10 variants in tumor samples and variants in all cell lines. All mutations cluster to the 3’ end of the VHL gene open reading frame, implicating this region as important for the tumor-suppressor function of the VHL protein. From findings VHL gene was concluded to have \"an important and specific role in the etiology of sporadic RCCs.\" This in-frame deletion results in a premature stop codon at amino acid 62 and was found in one of the tumor samples (tumor no. 22). No phenotype described." ;
    a m2r:Evidence .

civice:6075
    dct:references pbm:25366685 ;
    civico:citation "Kaufman et al., 2015, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "In multicenter phase II study included individuals with a germline BRCA1/2 mutation and pancreatic cancer after gemcitabine treatment. Olaparib was administered at 400 mg twice per day.  Tumor response rate was 21.7% (five of 23 patients).Stable disease more than 8 weeks was observed in 35% of patients." ;
    a m2r:Evidence .

civice:6076
    dct:references pbm:25366685 ;
    civico:citation "Kaufman et al., 2015, J. Clin. Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Olaparib ;
    dcterms:description "In multicenter phase II study included individuals with a germline BRCA1/2 mutation and pancreatic cancer after gemcitabine treatment. Olaparib was administered at 400 mg twice per day.  Tumor response rate was 21.7% (five of 23 patients).Stable disease more than 8 weeks was observed in 35% of patients." ;
    a m2r:Evidence .

civice:6091
    dct:references pbm:24705252 ;
    civico:citation "Taylor et al., 2014, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Sequencing (whole genome or exome) was performed on a series of 26 pediatric patients (1.7 to 13.6 years old), 7 had missense mutations in ACVR1. Two patients with G328E mutation were identified. This mutation had not been previously reported in other cancer types, indicating it was supportive of a diagnosis of high grade pontine glioma. PEDIATRIC" ;
    a m2r:Evidence .

civice:6098
    dct:references pbm:29606586 ;
    civico:citation "Laetsch et al., 2018, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "One Patient with soft tissue sarcoma and a NTRK2-STRN fusion had a partial Response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response." ;
    a m2r:Evidence .

civice:6099
    dct:references pbm:29606586 ;
    civico:citation "Laetsch et al., 2018, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "Four out of six patients with infantile fibrosarcoma and a NTRK3-ETV6 fusion had a partial response, the remaining two had a complete response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response." ;
    a m2r:Evidence .

civice:6100
    dct:references pbm:29606586 ;
    civico:citation "Laetsch et al., 2018, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "One Patient with soft tissue sarcoma and a NTRK1-LMNA fusion had a partial response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response." ;
    a m2r:Evidence .

civice:6101
    dct:references pbm:29606586 ;
    civico:citation "Laetsch et al., 2018, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "Four patients with infantile fibrosarcoma and soft tissue sarcoma and a NTRK1-TMP3 fusion were treated with larotrectinib. Two had a partial, and two had a complete response. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response." ;
    a m2r:Evidence .

civice:6102
    dct:references pbm:29606586 ;
    civico:citation "Laetsch et al., 2018, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "One Patient with soft tissue sarcoma and a NTRK1-PDE4DIP fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response." ;
    a m2r:Evidence .

civice:6103
    dct:references pbm:29606586 ;
    civico:citation "Laetsch et al., 2018, Lancet Oncol." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "One patient with infantile fibrosarcoma and a NTRK1-SQSTM1 fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response." ;
    a m2r:Evidence .

civice:6106
    dct:references pbm:9663592 ;
    civico:citation "van der Harst et al., 1998, Int. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 68 patients, who had been operated on for apparently sporadic pheochromocytomas, for germline mutations in the VHL gene. This missense mutation was found in a 51 year-old female with unilateral, benign, adrenal pheochromocytoma (patient no. 48)." ;
    a m2r:Evidence .

civice:6108
    dct:references pbm:9663592 ;
    civico:citation "van der Harst et al., 1998, Int. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Screening of 68 patients, who had been operated on for apparently sporadic pheochromocytomas, for germline mutations in the VHL gene. This splice variant causes a premature stop codon at amino acid 66 and was found in a 33 year-old male with unilateral, benign, adrenal pheochromocytoma (patient no. 54)." ;
    a m2r:Evidence .

civice:6121
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This in-frame deletion variant was detected in a VHL type 2 patient with cerebellar hemangioblastoma, pheochromocytoma, renal cell carcinoma, and epididymal cysts (family no. 24)." ;
    a m2r:Evidence .

civice:6122
    dct:references pbm:17661816 ;
    civico:citation "Hes et al., 2007, Clin. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This variant was detected in a VHL type 1 patient with cerebellar hemangioblastoma, retinal hemangioblastomas, and renal cell carcinoma (family no. 28)." ;
    a m2r:Evidence .

civice:6123
    dct:references pbm:29431699 ;
    civico:citation "Corcoran et al., 2018, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Panitumumab,civic:drug_Trametinib ;
    dcterms:description "In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively." ;
    a m2r:Evidence .

civice:6124
    dct:references pbm:29431699 ;
    civico:citation "Corcoran et al., 2018, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib,civic:drug_Panitumumab ;
    dcterms:description "In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively." ;
    a m2r:Evidence .

civice:6170
    dct:references pbm:23826550 ;
    civico:citation "Firwana et al., 2012, Avicenna J Med" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Paclitaxel,civic:drug_Trastuzumab ;
    dcterms:description "Case report of a 61-year-old caucasian male with a renal mass and subsequent liver metastases. Histopathological examination of the liver led to the diagnosis of metastastic adenocarcinoma of the salivary Gland, which had been diagnosed and treated in the Patient 20 years earlier. IHC revealed Her2/neu, 3+. The patient was treated successfully with trastuzumab/paclitaxel with near-complete response as measured by PET-CT scans for more than a year." ;
    a m2r:Evidence .

civice:6171
    dct:references pbm:20504363 ;
    civico:citation "Sharon et al., 2010, Head Neck Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_ZoledronicAcid,civic:drug_Trastuzumab,civic:drug_Capecitabin ;
    dcterms:description "Case report of a a 58 year old man with multiple bone metastases after local therapy of a carcinoma ex pleomorphic adenoma one year earlier. The original tumor tested strongly positive for HER2/neu by immunohistochemistry. The patient was treated with trastuzumab, capecitabine, and zoledronic acid. He experienced total resolution of symptoms and repeat FDG-PET scan after three cycles revealed interval disease resolution. Continued treatment resulted in maintenance of disease control for over 2 years." ;
    a m2r:Evidence .

civice:6178
    dct:references pbm:28891408 ;
    civico:citation "Long et al., 2017, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Trametinib ;
    dcterms:description "Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (COMBO-AD, NCT01682083). 792 (91%) patients had V600E, and were administered dabrafenib and trametinib or placebo for 12 months. In subsequent analysis, relapse or death occurred in 150/397 patients (38%) in the treatment group and 229/395 patients (58%) in the placebo group for a 95% CI Hazard Ratio of 0.48 (0.39-0.58)." ;
    a m2r:Evidence .

civice:6179
    dct:references pbm:28891408 ;
    civico:citation "Long et al., 2017, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Trametinib,civic:drug_Dabrafenib ;
    dcterms:description "Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (COMBO-AD, NCT01682083). 78 (9%) patients had V600K, and were administered dabrafenib and trametinib or placebo for 12 months. In subsequent analysis, relapse or death occurred in 16/41 patients (39%) in the treatment group and 19/37 patients (51%) in the placebo group for a 95% CI Hazard Ratio of 0.54 (0.27-1.06)." ;
    a m2r:Evidence .

civice:6180
    dct:references pbm:28891408 ;
    civico:citation "Long et al., 2017, N. Engl. J. Med." ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Trametinib ;
    dcterms:description "Combination Dabrafenib and Trametinib treatment was assessed for adjuvant treatment of stage III resected BRAF V600 mutant melanoma in the COMBI-AD trial NCT01682083. Patients were treated with combination therapy or placebo for 12 months. The estimated 3-year rate of relapse-free survival was 58% in the treated group and 39% in the placebo group  with hazard ratio for relapse or death of 0.47 (95% CI, 0.39 to 0.58; P<0.001). 3-year overall survival rate for treated group was 86%, and 77% in the placebo group (hazard ratio for death, 0.57; 95% CI, 0.42-0.79; P=0.0006). The level of improvement observed did not cross the prespecified interim analysis boundary of P=0.000019. Distant metastasis-free survival and freedom from relapse was higher in the combination-treated group." ;
    a m2r:Evidence .

civice:6181
    dct:references pbm:23749122 ;
    civico:citation "Locatelli-Sanchez et al., 2013, Lung" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generation TKIs erlotinib or gefitinib were administered. One patient was found to have a G719A mutation, was administered a TKI, and an NSCLC progression was observed." ;
    a m2r:Evidence .

civice:6182
    dct:references pbm:23749122 ;
    civico:citation "Locatelli-Sanchez et al., 2013, Lung" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib,civic:drug_Erlotinib ;
    dcterms:description "In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generation TKIs erlotinib or gefitinib were administered. One patient was found to have a R705K mutation, was administered a TKI, and an NSCLC progression was observed." ;
    a m2r:Evidence .

civice:6183
    dct:references pbm:27022112 ;
    civico:citation "Urata et al., 2016, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Reduced Sensitivity" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704)." ;
    a m2r:Evidence .

civice:6186
    dct:references pbm:27022112 ;
    civico:citation "Urata et al., 2016, J. Clin. Oncol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Reduced Sensitivity" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Gefitinib ;
    dcterms:description "A Japanese Phase III clinical study assessed the noninferiority of gefitinib as compared to erlotinib in 561 advanced stage (IIIB and IV) postoperative lung adenocarcinoma patients. All patients had prior chemotherapy but no treatment with TKIs. 19 patients had unspecified uncommon EGFR mutations, including single mutations other than ex19del and L858R and double mutations. Of those 19 patients, 7 were treated with erlotinib and 12 were treated with gefitinib. Objective response and disease control rate between erlotinib and gefitinib were not significantly different. The study failed to satisfy the primary endpoint of demonstrating statistical noninferiority in PFS of gefitinib." ;
    a m2r:Evidence .

civice:6188
    dct:references pbm:17575221 ;
    civico:citation "Pérez-Tenorio et al., 2007, Clin. Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This was a Swedish study of 270 breast tumors removed from patients with unilateral operable breast cancer, and either lymph node metastases or a tumor diameter >30mm. PIK3CA missense mutations were found in 66/270 (24%) tumors. Of these, 36 tumors (55%) harbored mutations in exon 20— 33 H1047R, 1 Y1021C, 1 G1049R, and 1 H1047P. The other 30 were missense mutations in exon 9— 11 E542K, 18 E545K, 1 Q546P. The study found that the risk of relapse with a local recurrence was significantly lower among patients with a PIK3CA mutation in comparison with those who carried wild-type PIK3CA (p= 0.023). When adjusting for other factors, including ER status, node status, tumor size, and treatment (tamoxifen vs no tamoxifen or radiotherapy vs chemotherapy), mutations in the PIK3CA gene were associated with approximately half the risk for local recurrence in comparison with wtPIK3CA (p = .07)." ;
    a m2r:Evidence .

civice:6189
    dct:references pbm:21676217 ;
    civico:citation "Wang et al., 2011, BMC Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Tamoxifen ;
    dcterms:description "This was a Swedish study of 270 breast tumors removed from patients with unilateral operable breast cancer, and either lymph node metastases or a tumor diameter >30mm. PIK3CA missense mutations were found in 65/270 (24%) tumors. Of these, 36 (55%) were in exon 20— 33 H1047R, 1 Y10121C, 1 G1049R, and 1 H1047P. The other 30 were missense mutations in exon 9— 11 E542K, 18 E545K, 1 Q546P. Within the group of 188 patients with ER+ tumors, PIK3CA mutation status did not predict response to tamoxifen." ;
    a m2r:Evidence .

civice:6190
    dct:references pbm:15705718 ;
    civico:citation "Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ﻿50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 60 of these clones had T315A mutations. To validate resistance to dasatinib, Ba/F3 cell lines stably expressing a T315A mutation in the ABL1 region of the BCR-ABL fusion were generated. T315A was associated with higher dasatinib IC50 of 125 nM vs 1.34 nM in wildtype as determined by dose response curves." ;
    a m2r:Evidence .

civice:6191
    dct:references pbm:18371219 ;
    civico:citation "Liedtke et al., 2008, Breast Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Epirubicin,civic:drug_5-fluorouracil,civic:drug_Doxorubicin,civic:drug_Cyclophosphamide,civic:drug_Paclitaxel ;
    dcterms:description "This study of 140 patients with stage II-III breast cancer assessed the response of patients with PIK3CA mutations to 6 months of preoperative chemotherapy. 23/170 patients had PIK3CA mutations. Of those patients, 12 received six courses of 5-fluorouracil, doxorubicin (or epirubicin), and cyclophosphamide; this treatment group contained 7 patient with E545K mutations, 1 with E542K, and 4 with H1047R. The other 11 patients received 12 weekly courses of paclitaxel followed by four courses of 5-fluorouracil, doxorubicin (or epirubicin), and cyclophosphamide; this treatment group contained 1 patient with an E545K mutation, 1 with Q546R, 1 with E542K, 1 with E542V, 5 with H1047R, 1 with G1049R, and 1 with H1047T. The study did not find evidence that PIK3CA mutations are associated with preoperative chemotherapy sensitivity in breast cancer treated with an anthracycline (doxorubicin or epirubicin), 5-fluorouracil and cyclophosphamide regardless of whether paclitaxel was also administered. The lack of association was true of estrogen receptor (ER)-positive and ER-negative tumors." ;
    a m2r:Evidence .

civice:6192
    dct:references pbm:15705718 ;
    civico:citation "Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate,civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations in the ABL1 region of the p210 BCR-ABL fusion were generated and stably expressed in Ba/F3 cell lines from mutagenized libraries. Combination therapy with 10﻿ μM imatinib and 50 nM dasatinib resulted in a single clone with the T315I variant. Combination therapy with 25 nM dasatinib resulted in 11 clones, 6 of which had the T315I variant." ;
    a m2r:Evidence .

civice:6193
    dct:references pbm:15705718 ;
    civico:citation "Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations in the ABL1 region of the p210 BCR-ABL fusion were generated and stably expressed in Ba/F3 cell lines from mutagenized libraries. Combination therapy with 10﻿ μM imatinib and 50 nM Dasatinib resulted in 11 clones, 5 of which had the E255K variant." ;
    a m2r:Evidence .

civice:6194
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. The E255V mutation was associated with resistance in 4 μM imatinib ( 1 clone, 0.43%) and 500 nM nilotinib (1 clone, 1.25%) tyrosine kinase inhibitors." ;
    a m2r:Evidence .

civice:6196
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate,civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. The T315I mutation was associated with resistance in 400 nM imatinib + 50 nM nilotinib (3 clones, ~16%), 2 μM imatinib + 1 μM nilotinib (8 clones, 100%), and 4 μM imatinib + 2 μM nilotinib (2 clones, 100%) combination treatments." ;
    a m2r:Evidence .

civice:6198
    dct:references pbm:17947469 ;
    civico:citation "Barbareschi et al., 2007, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Better Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "An Italian study of 163 malignant breast tumors assessed the association between PIK3CA mutations and clinical outcome. Of the 163 tumors sequenced, 118 had wild-type (wt) PIK3CA, 24 had exon 9 (helical domain) missense mutations, and 21 had exon 20 (kinase domain) missense mutations. The study found that patients with exon 20 mutations showed significantly better 5-year overall survival (OS) and 5-year disease free survival (DFS) compared to patients with wt PIK3CA (P=.011 and P = .01, respectively).  Furthermore, patients with exon 20 mut showed especially better OS and DFS than patients with exon 9 mutations (P=.0018 and P=.0017, respectively). The 21 cases with exon 20 mutations had excellent prognosis with no recurrences or deaths, whereas there were 10 recurrences and 9 deaths among the 24 cases of exon 9 mutations, in observed period." ;
    a m2r:Evidence .

civice:6199
    dct:references pbm:17947469 ;
    civico:citation "Barbareschi et al., 2007, Clin. Cancer Res." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "An Italian study of 163 malignant breast tumors assessed the association between PIK3CA mutations and clinical outcome. Of the 163 tumors sequenced, 118 had wild-type (wt) PIK3CA, 24 had exon 9 (helical domain) missense mutations, and 21 had exon 20 (kinase domain) missense mutations. The study found that patients with exon 9 mutations showed significantly worse 5-year overall survival (OS) and 5-year disease free survival (DFS) compared to patients with wt PIK3CA (P=.018 and P = .04, respectively).  Furthermore, patients with exon 9 mut showed especially worse OS and DFS than patients with exon 20 mutations (P=.0018 and P=.0017, respectively). The 21 cases with exon 20 mutations had excellent prognosis with no recurrences or deaths, whereas there were 10 recurrences and 9 deaths among the 24 cases of exon 9 mutations, in observed period." ;
    a m2r:Evidence .

civice:6208
    dct:references pbm:15705718 ;
    civico:citation "Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ﻿50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 83 of these clones had F317V mutations. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the F317V mutation in the ABL1 region of the BCR-ABL fusion was generated and associated with higher dasatinib IC50 of 53 nM vs 1.34 nM in wildtype as determined by dose response curves." ;
    a m2r:Evidence .

civice:6210
    dct:references pbm:15705718 ;
    civico:citation "Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ﻿50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an L248R mutation. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the L248R mutation in the ABL1 region of the BCR-ABL fusion was generated. The L248R variants was associated with higher dasatinib IC50 of 16 nM vs 1.34 nM in wildtype and higher imatinib IC50 of >10,000 nM vs 323 nM in wildtype as determined by dose response curves." ;
    a m2r:Evidence .

civice:6214
    dct:references pbm:15705718 ;
    civico:citation "Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ﻿50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 4 of these clones had E255K mutations. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the E255K mutation in the ABL1 region of the BCR-ABL fusion was generated. The E255K variants was associated with higher dasatinib IC50 of 13 nM vs 1.34 nM in wildtype and higher imatinib IC50 of 8,400 nM vs 323 nM in wildtype as determined by dose response curves." ;
    a m2r:Evidence .

civice:6215
    dct:references pbm:15705718 ;
    civico:citation "Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ﻿50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 10 of these clones had F317L mutations. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the F317L mutation in the ABL1 region of the BCR-ABL fusion was generated and associated with higher dasatinib IC50 of 18 nM vs 1.34 nM in wildtype as determined by dose response curves." ;
    a m2r:Evidence .

civice:6216
    dct:references pbm:15705718 ;
    civico:citation "Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ﻿50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an V299L mutation. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the V299L mutation in the ABL1 region of the BCR-ABL fusion was generated and associated with higher dasatinib IC50 of 18 nM vs 1.34 nM in wildtype as determined by dose response curves." ;
    a m2r:Evidence .

civice:6217
    dct:references pbm:15705718 ;
    civico:citation "Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ﻿50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an F317I mutation." ;
    a m2r:Evidence .

civice:6218
    dct:references pbm:15705718 ;
    civico:citation "Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ﻿50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an F317S mutation." ;
    a m2r:Evidence .

civice:6219
    dct:references pbm:15705718 ;
    civico:citation "Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ﻿50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an Q252H mutation." ;
    a m2r:Evidence .

civice:6222
    dct:references pbm:29396065 ;
    civico:citation "Taylor et al., 2018, J Clin Neurosci" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A case report of a 51Y male patient presenting with headaches and a family history of VHL disease revealed multiple CNS Hemangioblastomas, bilateral ccRCC, pheochromocytoma, and a pancreatic neuroendocrine tumour. A germline mutation of p.Arg167Trp was confirmed in the patient's VHL gene. ACMG: PM1, PP1, PP4" ;
    a m2r:Evidence .

civice:6234
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The T315I mutation was associated with resistance in 400 nM imatinib + 10 nM dasatinib (10 clones, ~91%), 2 μM imatinib + 50 nM dasatinib (8 clones, 100%), and 4 μM imatinib + 100 nM dasatinib (8 clones, 100%) combination treatments." ;
    a m2r:Evidence .

civice:6235
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib,civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The T315I mutation was associated with resistance in 50 nM nilotinib + 10 nM dasatinib (7 clones, 100% of viable clones in this treatment), 1 μM nilotinib + 50 nM dasatinib (9 clones, 100%), and 2 μM nilotinib + 100 nM dasatinib (2 clones, 100%) combination treatments." ;
    a m2r:Evidence .

civice:6236
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate,civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 2 (~11%) were found to have L248V mutations." ;
    a m2r:Evidence .

civice:6237
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 5 (~26%) were found to have Y253H mutations." ;
    a m2r:Evidence .

civice:6238
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 1 (~5%) was found to have an F311L mutation." ;
    a m2r:Evidence .

civice:6239
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 7 (~37%) were found to have F359C mutations." ;
    a m2r:Evidence .

civice:6240
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate,civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 1 (~5%) was found to have an H396P mutation." ;
    a m2r:Evidence .

civice:6241
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib,civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. Of the 11 clones that grew in a combination of 400 nM imatinib and 10 nM dasatinib, 1 (9%) was found to have a V299L mutation." ;
    a m2r:Evidence .

civice:6242
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The M244V mutation was associated with resistance in 2 μM imatinib (1 clone recovered, 0.71%). In a review of 20 publications, this mutation was described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6243
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The L248R mutation was associated with resistance in 2 μM imatinib (1 clone recovered, ~1%) and 8 μM imatinib (1 clone, ~2%). In a review of 20 publications, this mutation had not been described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6244
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The G250E mutation was associated with resistance in 2 μM imatinib (3 clone recovered, ~2%), 4 μM imatinib (1 clone recovered, ~0.74%), and 50 nM nilotinib (5 clone, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6245
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The Q252H mutation was associated with resistance to 4 μM and 16 μM imatinib (4 clones [~3%] and 1 clone [~3%] recovered, respectively) as well as 10 nM dasatinib (1 clone [~2%]). No clones recovered at 2 μM/8 μM imatinib or 5 nM dasatinib. In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6246
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The D276G mutation was associated with resistance in 2 μM imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6247
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The V299L mutation was associated with resistance in 10 nM dasatinib (3 clone recovered, ~5%). No clones were recovered in 5 nM dasatinib. In a review of 20 publications, this mutation was described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6250
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317C mutation was associated with resistance in 5 nM dasatinib (1 clone recovered, ~ 3%) and 10 nM dasatinib (6 clones, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6251
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317I mutation was associated with resistance in 5 nM dasatinib (2 clone recovered, ~ 6%) and 10 nM dasatinib (10 clones, ~18%)." ;
    a m2r:Evidence .

civice:6252
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317L mutation was associated with resistance in 2 μM imatinib (2 clones recovered, ~1%), 5 nM dasatinib (6 clones, ~ 17%), and 10 nM dasatinib (4 clones, ~7%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6253
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317V mutation was associated with resistance in 5 nM dasatinib (1 clone recovered,  ~ 3%) and 25 nM dasatinib (1 clone, ~3%). No clones were recovered at 10 nM dasatinib." ;
    a m2r:Evidence .

civice:6254
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The M351T mutation was associated with resistance in 2 μM imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6255
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The E355G mutation was associated with resistance in 2 μM imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6256
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F359V mutation was associated with resistance in 2 μM imatinib (3 clones recovered, ~2%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6257
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The V379I mutation was associated with resistance in 2 μM imatinib (2 clones recovered, ~1%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6258
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The H396R mutation was associated with resistance in 2 μM imatinib (1 clone recovered, ~0.71%) and 4 μM imatinib (1 clone, ~0.74%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6259
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wild-type AKT1 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express AKT1 (via viral transduction with additional copies of AKT1) were not significantly more resistant to vemurafenib (a BRAFi) than cells transduced with empty vectors, which served as the negative controls." ;
    a m2r:Evidence .

civice:6260
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Dabrafenib ;
    dcterms:description "In a retrospective study of 44 relapsed melanoma patients with BRAF V600E/K (known BRAF inhibitor sensitizing mutations), AKT1 Q79K was associated with acquired resistance to BRAF inhibitor (dabrafenib) monotherapy in one patient. This patient was a 38 year old female with stage IV M1a melanoma who took dabrafenib (35 mg twice daily to 100 mg three times a day). The best overall response was a 100% reduction in the sum of target lesions, and progression free survival lasted 119 days. Prior to dabrafenib monotherapy, this patient's baseline tumor harbored BRAF V600K—no other somatic alterations were noted. Following relapse, the patient gained AKT1 Q79K in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors hypothesized that disruptions in the PI3K-PTEN-AKT pathway represent a core mechanism of acquired resistance to BRAF inhibitor therapy." ;
    a m2r:Evidence .

civice:6261
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express AKT3 (via viral transduction of additional copies of wild type AKT3) were significantly more resistant to BRAF inhibition by vemurafenib than cells transduced with empty vectors (30% vs 20% survival, p = .0064)." ;
    a m2r:Evidence .

civice:6262
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Vemurafenib ;
    dcterms:description "In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA." ;
    a m2r:Evidence .

civice:6263
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Vemurafenib ;
    dcterms:description "In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA." ;
    a m2r:Evidence .

civice:6264
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Vemurafenib ;
    dcterms:description "In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA." ;
    a m2r:Evidence .

civice:6266
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "An in vitro study of WM2664 (a human melanoma cell line) endogenously expressing wildtype PIK3R2 and BRAF V600D (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express PIK3R2 (via viral transduction with additional copies of wildtype PIK3R2) were not significantly more resistant to vemurafenib (a BRAFi) than cells transduced with empty vectors, which served as the negative controls." ;
    a m2r:Evidence .

civice:6267
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The G250E mutation was associated with resistance in 2 μM imatinib (3 clone recovered, ~2%), 4 μM imatinib (1 clone recovered, ~0.74%), and 50 nM nilotinib (5 clone, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6268
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E/K (known BRAF inhibitor sensitizing mutations), PREX2 R172I was associated with a case of acquired resistance to BRAF inhibitor (vemurafenib) monotherapy in one patient. This patient was an 83 year old male with stage IV M1c melanoma who took vemurafenib (960mg twice daily). The best overall response was a 5% increase in sum of target lesions, and progression free survival lasted 132 days. Prior to vemurafenib monotherapy, this patient harbored BRAF V600K and no other somatic genetic alterations noted in the baseline tumor. Following relapse, the patient gained PREX2 R172I in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors indicated that the biology behind this potential resistance mutation was unknown." ;
    a m2r:Evidence .

civice:6270
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317L mutation was associated with resistance in 2 μM imatinib (2 clones recovered, ~1%), 5 nM dasatinib (6 clones, ~ 17%), and 10 nM dasatinib (4 clones, ~7%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6271
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PTEN and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that PTEN knockdown cells (achieved via lentiviral transduction of shPTEN) were more resistant to vemurafenib (a BRAF inhibitor) than cells expressing wildtype PTEN. Lentiviral mediated reintroduction of PTEN restored vemurafenib sensitivity in WM2664, a vemurafenib resistant, PTEN non-expressing and BRAF V600D mutated human melanoma cell line." ;
    a m2r:Evidence .

civice:6273
    dct:references pbm:29802158 ;
    civico:citation "Heining et al., 2018, Cancer Discov" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Afatinib,civic:drug_Erlotinib-Pertuzumab ;
    dcterms:description "In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberrant ERBB receptor-mediated signaling, and pharmacologic ERBB inhibition resulted in clinical improvement and remission of liver metastases in two patients with NRG1-rearranged tumors that had proved resistant to standard treatment." ;
    a m2r:Evidence .

civice:6274
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The Q252H mutation was associated with resistance to 4 μM and 16 μM imatinib (4 clones [~3%] and 1 clone [~3%] recovered, respectively) as well as 10 nM dasatinib (1 clone [~2%]). No clones recovered at 2 μM/8 μM imatinib or 5 nM dasatinib. In a review of 20 publications, this mutation was previously described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6275
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express PIK3CA (via viral transduction with additional copies of wild type PIK3CA) were significantly more resistant to vemurafenib (a BRAFi) than cells transduced with an empty vector (30% vs 20% survival, p < .0001). Though statistics were not provided, it appears that amplification of wildtype PIK3CA confers less resistance than the positive control variant, PIK3CA E545K." ;
    a m2r:Evidence .

civice:6282
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The E255K mutation was associated with resistance in 16 μM imatinib ( 1 clone recovered, ~3%) and all lower concentrations as well as in 50 nM nilotinib (5 clones, ~11%) and 5 nM dasatinib (2 clones, ~6%), the lowest concentrations tested for these two drugs. In a review of 20 publications, this mutation was described in imatinib resistant patients." ;
    a m2r:Evidence .

civice:6285
    dct:references pbm:16772610 ;
    civico:citation "Bradeen et al., 2006, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_ImatinibMesylate,civic:drug_Dasatinib,civic:drug_Nilotinib ;
    dcterms:description "In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The T315I mutation was associated with resistance in 16 μM imatinib ( 15 clones, 45% of viable clones in this treatment), 5000 nM nilotinib (10 clones, 100%), and 25 nM dasatinib (32 clones, 100%) which were the highest concentrations used. T315I resistant clones were also found at all lower concentrations tested." ;
    a m2r:Evidence .

civice:6287
    dct:references pbm:26365017 ;
    civico:citation "Suzuki-Muromoto et al., 2016, Brain Dev." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A case report of a woman with de novo 3p deletion syndrome (encompassing the VHL gene) was associated with cerebellar hemangioblastoma at the age of 16 years old. This is the first report of a patient with 3p- with cerebral hemangioblastoma that may be associated with VHL disease. ACMG: PVS1, PS2, PP4" ;
    a m2r:Evidence .

civice:6288
    dct:references pbm:25715769 ;
    civico:citation "Heo et al., 2016, Cancer Res Treat" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "C" ;
    dcterms:description "74-year-old man admitted to the  Department of Neurosurgery at Yonsei University College of Medicine was found carry a p.Glu70Lys VHL gene mutation and presented with colorectal adenocarcinoma, renal clear cell carcinoma, and hemangioblastomas of CNS. Patient's mother suffered from a brain tumor of unconfirmed pathology, and both brothers  (79Y and 70Y) presented with renal cell carcinoma and the same VHL gene mutation. One of the patient's son tested positive for the mutation without any clinical manifestations of disease. ACMG:PP2, PP1, PP4" ;
    a m2r:Evidence .

civice:6289
    dct:references pbm:26984080 ;
    civico:citation "Kobayashi et al., 2016, Intern. Med." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A male patient with Type 1 VHL disease  presented with vision loss and retinal angiomatosis in the right eye at 19Y, left retinal angiomatosis at 23Y as well as CNS hemangioblastomas, neuroendocrine tumor of the pancreas which metastases to the liver, and renal tumors at 25Y. Patient was found to carry c.233A>G (p.Asn78Ser) mutation in the VHL gene. Patient had a positive family history of VHL clinical manifestations, although the genotype of affected family members was not confirmed. His mother presented with pancreatic and renal cysts at 37Y and retinal angiomatosis at 47Y. Patient's grandmother suffered from loss of vision  in her 30s, and renal cancer and brain tumour at 58Y. ACMG: PP2, PP4" ;
    a m2r:Evidence .

civice:6292
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between KRAS mutation status in primary tumors and post treatment progression free survival (PFS) and overall survival (OS). Of the 168 patients, 106 had wildtype KRAS and 62 had mutations in KRAS—including G12A, G12C, G12D, G12R, G12S, G12V, and G13D. Regardless of first line chemotherapy regimen or use of monoclonal antibody treatment, patients with KRAS-mutated tumors did not have a significantly worse outcome than patients with wtKRAS tumors,  as evidenced by non-significant differences in PFS (12.3 vs 11.8 months, respectively) and OS (35.8 and 40.5 months, respectively)." ;
    a m2r:Evidence .

civice:6293
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Oxaliplatin ;
    dcterms:description "This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between KRAS mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 61 had wildtype KRAS and 39 had mutations in KRAS—including G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients with KRAS-mutated tumors were not significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype KRAS, as evidenced by a nonsignificant difference in PFS (11.7 and 11.4 months, respectively)." ;
    a m2r:Evidence .

civice:6294
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Irinotecan ;
    dcterms:description "This was a retrospective clinical study of 44 metastatic colorectal cancer patients who recieved FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between KRAS mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 26 had wildtype KRAS and 18 had mutations in KRAS—including G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients harboring a KRAS mutation were not significantly more resistant to irinotecan-based first-line therapy than patients with wildtype KRAS. The difference in PFS between patients with KRAS-mutated tumors and the patients with wtKRAS tumors was nonsignificant (PFS: 13.7 and 12.0 months; p= 0.074)." ;
    a m2r:Evidence .

civice:6295
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab ;
    dcterms:description "This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between KRAS mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients, 58 had wildtype KRAS and 39 had mutations in KRAS—including G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients with KRAS-mutated tumors were not significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype KRAS, as evidenced by a non-significant difference in PFS between the two groups (12.1 and 11.7 months, respectively)." ;
    a m2r:Evidence .

civice:6296
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between KRAS mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 60 had wildtype KRAS and 32 had mutations in KRAS—including G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients harboring a KRAS mutation were trending toward resistance to cetuximab-containing salvage chemotherapy as compared to patients with wildtype KRAS (p=0.094). Note: while differences in PFS were nonsignificant between patients with wildtype or mutant KRAS, differences in objective response (defined as reduction by at least 30% in the sum of the longest diameters of target lesions compared to baseline) were significantly different. Of the 32 patients with mutant KRAS, none responded to cetuximab-containing salvage therapy, while 14/60 of the patients with wildtype KRAS (23%) responded (p=.002)." ;
    a m2r:Evidence .

civice:6297
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between PIK3CA mutation status in primary tumors and post treatment PFS. Of 168 patients, 142 had wildtype PIK3CA and 26 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation did not have a significantly worse outcome than patients expressing wildtype PIK3CA, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment." ;
    a m2r:Evidence .

civice:6298
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Oxaliplatin ;
    dcterms:description "This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between PIK3CA mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 81 had wildtype PIK3CA and 19 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups (10.7 and 11.7 months, respectively)." ;
    a m2r:Evidence .

civice:6299
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Irinotecan ;
    dcterms:description "This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between PIK3CA mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 40 had wildtype PIK3CA and 4 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to irinotecan-based first-line therapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups." ;
    a m2r:Evidence .

civice:6300
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab ;
    dcterms:description "This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between PIK3CA mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients, 83 had wildtype PIK3CA and 14 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups." ;
    a m2r:Evidence .

civice:6301
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between PIK3CA mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 79 had wildtype PIK3CA and 19 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were significantly more resistant to cetuximab-containing salvage chemotherapy than patients with wildtype PIK3CA (Median PFS: 2.5 and 3.9 months, respectively; p = .014)." ;
    a m2r:Evidence .

civice:6302
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and post treatment PFS. Of 168 patients, 155 had wildtype BRAF and 13 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation had a significantly worse outcome than patients expressing wildtype BRAF, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment (Median PFS: 4.3 and 12.5 months, respectively; p <.0001)." ;
    a m2r:Evidence .

civice:6303
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Oxaliplatin ;
    dcterms:description "This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 94 had wildtype BRAF and 6 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype BRAF (Median PFS: 5.0 and 11. 7 months, respectively; p < .0001)." ;
    a m2r:Evidence .

civice:6304
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Irinotecan ;
    dcterms:description "This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between BRAF mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 39 had wildtype BRAF and 5 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to irinotecan-based first-line therapy than patients with wildtype BRAF (Median PFS: 3.5 and 12.8 months, respectively; p = .006)." ;
    a m2r:Evidence .

civice:6305
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bevacizumab ;
    dcterms:description "This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between BRAF mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients,89 had wildtype BRAF and 8 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype BRAF (Median PFS: 4.2 and 12.5 months, respectively; p < .0001)." ;
    a m2r:Evidence .

civice:6306
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab ;
    dcterms:description "This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between BRAF mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 83 had wildtype BRAF and 9 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to cetuximab-containing salvage chemotherapy than patients with wildtype BRAF (Median PFS: 2.0 and 3.9, respectively; p = .0005)." ;
    a m2r:Evidence .

civice:6307
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and post treatment OS. Of 168 patients, 155 had wildtype BRAF and 13 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation had a significantly worse outcome than patients expressing wildtype BRAF, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment (Median OS: 10.9 and 40.5 months, respectively; p <.0001)." ;
    a m2r:Evidence .

civice:6308
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 15 patients with L248V mutations, 6, 10, and 15 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:6309
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase) patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 14 patients with F317L mutations, 1, 2, and 13 achieved CCyR, MCyR, and CHR to dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations. Despite high CHR in patients with the F317L variant, of the 63 variants considered, the authors associate T315I, F317L, and V299L with resistance or lower levels of response to dasatinib due to clinical resistance and low in vitro sensitivity. They suggest considering alternative treatment options for patients with these three variants." ;
    a m2r:Evidence .

civice:6310
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 12 patients with the E459K mutations, 4, 6, and 11 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations." ;
    a m2r:Evidence .

civice:6311
    dct:references pbm:19779040 ;
    civico:citation "Müller et al., 2009, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dasatinib ;
    dcterms:description "This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, imatinib-resistant patients with and without ABL1 mutation  had comparable complete hematologic response [CHR= 90% (345/384) vs. 93% (390/421)], major cytogenetic response [MCyR= 56% (211/384) vs. 58% (243/421)], complete cytogenetic response [CCyR= 43% (164/384) vs. 47% (196/421)], and major molecular response [MMR= 31% (115/367) vs. 36% (145/404)]. Of the 63 imatinib-resistant variants observed (see comment), the authors associate T315I, F317L, and V299L with resistance to dasatinib or lower levels of response due to clinical resistance and low in vitro sensitivity. However, F317L does have a high CHR. They suggest considering alternative treatment options for patients with these three variants." ;
    a m2r:Evidence .

civice:6314
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G12S was the only variant noted in the primary tumor of one patient who experienced disease progression following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant." ;
    a m2r:Evidence .

civice:6315
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). PTEN protein expression loss was the only variant noted in the primary tumors of 11 patients who experienced disease progression following treatment. In the larger cohort, patients with PTEN nonexpressiong tumors had significantly shorter overall survival and decreased incidence of objective response than patients with PTEN protein expressing tumors." ;
    a m2r:Evidence .

civice:6316
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G12D was the only variant noted in the primary tumor of one patient who experienced disease progression following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant." ;
    a m2r:Evidence .

civice:6317
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Vemurafenib ;
    dcterms:description "In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF sensitizing mutation) found that cells induced to stably over-express wildtype KRAS4a or KRAS4b (via viral transduction with additional copies of KRAS4a or KRAS4b) were more resistant to vemurafenib (a BRAFi) than cells transduced with empty vectors. Resistance was determined by assessing cell survival." ;
    a m2r:Evidence .

civice:6319
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G12A was the only variant noted in the both the primary tumor and metastatic tumor of one patient, and the primary tumor of another patient,  who experienced stable disease following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant." ;
    a m2r:Evidence .

civice:6320
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G13D was the only variant noted in the primary tumor of two patients who experienced partial response following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant." ;
    a m2r:Evidence .

civice:6322
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab,civic:drug_Cetuximab ;
    dcterms:description "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G13D was the only variant noted in the primary tumor of one patient who experienced disease progression following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant." ;
    a m2r:Evidence .

civice:6323
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Panitumumab,civic:drug_Cetuximab ;
    dcterms:description "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G12V was the only variant noted in the primary tumor of one patient who experienced disease progression following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant." ;
    a m2r:Evidence .

civice:6324
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "1.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G12S was the only variant noted in the primary tumor of one patient who experienced stable disease following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant." ;
    a m2r:Evidence .

civice:6329
    dct:references pbm:15709172 ;
    civico:citation "Lee et al., 2005, Clin. Cancer Res." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Eleven RCCs and 16 renal cysts from eight patients with VHL were analyzed. All patients had known germline VHL mutations. One male patient had a germline deletion (c.128−?_250+?) in the VHL gene and presented with bilateral RCC and cysts, CNS hemangioblastoma, and pancreatic cysts. Family history was not described for the patient." ;
    a m2r:Evidence .

civice:6335
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysis at baseline, subsets were evaluated for complete hematologic response (CHR) and major cytogenetic response (MCyR). Both were comparable for patients with Abl1 mutation versus without [CHR = 33/34 vs. 27/27; MCyR = 41/59 (69%) vs. 19/35 (54%)]. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I." ;
    a m2r:Evidence .

civice:6336
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysis at baseline, subsets were evaluated for complete hematologic response (CHR) and major cytogenetic response (MCyR). Both were comparable for patients with P-loop mutations versus patients without Abl1 mutations [ CHR = 9/9 vs. 27/27; MCyR = 7/10 vs. 19/35 (54%)]. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I." ;
    a m2r:Evidence .

civice:6337
    dct:references pbm:21865346 ;
    civico:citation "Cortes et al., 2011, Blood" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Does Not Support" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Bosutinib ;
    dcterms:description "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysis at baseline, subsets were evaluated for complete hematologic response (CHR) and major cytogenetic response (MCyR). Both were comparable for patients with non-P-loop mutations versus patient without Abl1 mutations [ CHR = 22/23 (96%) vs. 27/27; MCyR = 26/39 (67%) vs. 19/35 (54%)]. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I." ;
    a m2r:Evidence .

civice:6362
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "Mutational analysis of 110 metastatic colorectal cancer patients was used to examine objective tumor response, progression free survival (PFS), and overall survival (OS) following treatment with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). In univariate analysis, PIK3CA mutations (H1047R or E545K) were significantly associated with lack of response to panitumumab or cetuximab (objective response rate: 0/15 vs 22/95 for patients harboring PIK3CA mutated or wildtype tumors, respectively; P = 0.038). Multivariate logistic regression of KRAS mutations, PIK3CA mutations and PTEN protein expression also confirmed an independent effect of PIK3CA mutation on objective response (P = 0.0337; OR = 0.1153; CI for OR: 0.000–0.865). Patients with tumors harboring either PIK3CA H1047R or E545K mutations (15/109) had decreased PFS, compared to those with wild-type tumors (P = 0.0035), though they had a nonsignificant difference in OS. Authors note a trend in decreasing OS in patients with PIK3CA mutated tumors." ;
    a m2r:Evidence .

civice:6363
    dct:references pbm:19223544 ;
    civico:citation "Sartore-Bianchi et al., 2009, Cancer Res." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Cetuximab,civic:drug_Panitumumab ;
    dcterms:description "Mutational analysis of 109 metastatic colorectal cancer patients was used to examine objective tumor response, progression free survival (PFS), and overall survival (OS) following treatment with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). In univariate analysis, KRAS mutations (G12V, G12S, G12D, G12A, G13V, G13D) were significantly associated with lack of response to panitumumab or cetuximab (objective response rate: 2/32 vs 20/77 for patients harboring KRAS mutated or wildtype tumors, respectively; P = 0.019). Multivariate logistic regression of KRAS mutations, PIK3CA mutations and PTEN protein expression also confirmed an independent effect of KRAS mutations on objective response (p = 0.0029). Authors noted that patients with tumors harboring KRAS mutations (32/108) tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant." ;
    a m2r:Evidence .

civice:6375
    dct:references pbm:23094721 ;
    civico:citation "Liao et al., 2012, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Aspirin ;
    dcterms:description "This was a retrospective study of 964 colorectal cancer patients who participated in the Nurses' Health Study and the Health Professionals Follow-up Study. Of 964 patients, 803 patients had wildtype PIK3CA (aspirin use: 337/803, no aspirin use: 466/803)  and 161 had mutated PIK3CA (aspirin use: 66/161, no aspirin use: 95/161). This study found that—among patients with mutated PIK3CA cancer— regular use of aspirin following diagnosis was correlated with superior colorectal cancer specific survival (multivariate hazard ratio, 0.18; 95% CI, 0.06-0.61; P<0.001) and overall survival (multivariate hazard ratio, 0.54; 95% CI, 0.31-0.94; P = 0.01). Conversely, among patients with wild-type PIK3CA, regular use of aspirin after diagnosis was not significantly associated with colorectal cancer–specific survival or overall survival. Among patients with mutated-PIK3CA tumors, 23 of 90 patients who did not use aspirin after diagnosis (26%) died within 5 years after diagnosis, whereas only 2 of 62 regular users of aspirin after diagnosis (3%) died within 5 years after diagnosis (P<0.001). In contrast, among patients with wild-type PIK3CA tumors, the 5-year cumulative colorectal cancer–specific mortality was the same (15%) for users and nonusers of aspirin after diagnosis (P = 0.92). The authors conclude that PIK3CA mutation may predict response to aspirin therapy in patients with newly diagnosed colorectal cancer." ;
    a m2r:Evidence .

civice:6380
    dct:references pbm:24081659 ;
    civico:citation "Fleischman et al., 2013, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_Ruxolitinib ;
    dcterms:description "Demonstrates that activating mutations in CSF3R are sufficient to drive a myeloproliferative disorder resembling aCML and CNL that is sensitive to pharmacologic JAK inhibition." ;
    a m2r:Evidence .

civice:6381
    dct:references pbm:25180155 ;
    civico:citation "Dao et al., 2014, Leuk Res Rep" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Ruxolitinib ;
    dcterms:description "Case report of a patient treated with ruxolitinib, an FDA-approved JAK1/2 inhibitor, which resulted in dramatic improvement of his blood counts. He also had significant reduction of spleen volume and constitutional symptoms." ;
    a m2r:Evidence .

civice:6382
    dct:references pbm:27069254 ;
    civico:citation "Arber et al., 2016, Blood" ;
    civico:rating "5.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "A" ;
    dcterms:description "Diagnostic criterion for essential thrombocytemia according to the World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues 2016." ;
    a m2r:Evidence .

civice:6392
    dct:references pbm:29683819 ;
    civico:citation "Lezcano et al., 2018, Am. J. Surg. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas analyzed by next-generation sequencing, 4 metastatic melanomas were identified with NTRK fusions, 3 involving NTRK1 (TRIM63, DDR2, and GON4L), 1 involving NTRK2 (TRAF2). All tumors were cytologically characterized by the presence of large epithelioid melanocytes and were immunoreactive with anti-Trk antibody. The NTRK1-TRIM63 fusion occurred in a 63 yo man with a nodular melanoma with the primary tumor on the shin and skin and lymph node metastases. No known melanoma drivers were identified as co-occurring in this patient. Thus, the presence of an NTRK family fusion in nonspitzoid metastasizing melanomas of adults may provide a therapeutic opportunity for NTRK inhibitors such as larotrectinib in a small subset of patients with metastatic melanoma." ;
    a m2r:Evidence .

civice:6393
    dct:references pbm:29683819 ;
    civico:citation "Lezcano et al., 2018, Am. J. Surg. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas analyzed by next-generation sequencing, 4 metastatic melanomas were identified with NTRK fusions, 3 involving NTRK1 (TRIM63, DDR2, and GON4L), 1 involving NTRK2 (TRAF2). All tumors were cytologically characterized by the presence of large epithelioid melanocytes and were immunoreactive with anti-Trk antibody. The NTRK1-DDR2 fusion occurred in a 55 yo woman with a nodular melanoma. Her primary tumor was umbilical with a metastasis to the colon. NF1 truncation and RAC1 p295 were identified as co-occurring melanoma drivers in this patient. Thus, the presence of an NTRK family fusion in nonspitzoid metastasizing melanomas of adults may provide a therapeutic opportunity for NTRK inhibitors such as larotrectinib in a small subset of patients with metastatic melanoma." ;
    a m2r:Evidence .

civice:6394
    dct:references pbm:29683819 ;
    civico:citation "Lezcano et al., 2018, Am. J. Surg. Pathol." ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "E" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas analyzed by next-generation sequencing, 4 metastatic melanomas were identified with NTRK fusions, 3 involving NTRK1 (TRIM63, DDR2, and GON4L), 1 involving NTRK2 (TRAF2). All tumors were cytologically characterized by the presence of large epithelioid melanocytes and were immunoreactive with anti-Trk antibody. The NTRK1-GON4L fusion occurred in a 36 yo woman with a nodular melanoma. Her primary tumor was on her back with a metastasis to the duodenum. NRAS Q61L was identified as a co-occurring melanoma driver in this patient. Thus, the presence of an NTRK family fusion in nonspitzoid metastasizing melanomas of adults may provide a therapeutic opportunity for NTRK inhibitors such as larotrectinib in a small subset of patients with metastatic melanoma." ;
    a m2r:Evidence .

civice:6396
    dct:references pbm:29920189 ;
    civico:citation "Taylor et al., 2018, J. Clin. Invest." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. Although TRK fusions occur in <1% of all solid tumors, inhibition of TRK results in profound therapeutic responses resulting in breakthrough FDA-approval of the TRK inhibitor larotrectinib for adult and pediatric solid tumor patients regardless of histology. In contrast to solid tumors, the frequency of TRK fusions and clinical effects of targeting TRK in hematologic malignancies is unknown. Here, through an evaluation for TRK fusions across > 7,000 patients with hematologic malignancies, we identified TRK fusions in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), histiocytosis, multiple myeloma and dendritic cell neoplasms. Although TRK fusions occurred in only 0.1% of patients (8 out of 7,311 patients), they conferred responsiveness to TRK inhibition in vitro and in vivo in a patient-derived xenograft and a corresponding AML patient with ETV6-NTRK2 fusion. These data identify that despite their individual rarity, collectively TRK fusions are present in a wide variety of hematologic malignancies and predict clinically significant therapeutic responses to TRK inhibition." ;
    a m2r:Evidence .

civice:6400
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Dabrafenib,civic:drug_Vemurafenib ;
    dcterms:description "In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA." ;
    a m2r:Evidence .

civice:6401
    dct:references pbm:24265155 ;
    civico:citation "Shi et al., 2014, Cancer Discov" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Vemurafenib,civic:drug_Dabrafenib ;
    dcterms:description "In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA." ;
    a m2r:Evidence .

civice:6402
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Irinotecan ;
    dcterms:description "The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF." ;
    a m2r:Evidence .

civice:6403
    dct:references pbm:19603024 ;
    civico:citation "Souglakos et al., 2009, Br. J. Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Resistance" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Oxaliplatin ;
    dcterms:description "Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001)." ;
    a m2r:Evidence .

civice:6417
    dct:references pbm:12000816 ;
    civico:citation "Neumann et al., 2002, N. Engl. J. Med." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This mutation was found in the VHL gene and one patient with pheochromocytoma." ;
    a m2r:Evidence .

civice:6442
    dct:references pbm:20193854 ;
    civico:citation "Musil et al., 2010, Cancer Genet. Cytogenet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:clinicalSignificance "Pathogenic" ;
    civico:evidenceLevel "C" ;
    dcterms:description "This variant is associated with Paragangliona. This Variant can be using as a predisposing marker for family members." ;
    a m2r:Evidence .

civice:6473
    dct:references pbm:27093299 ;
    civico:citation "Nagasubramanian et al., 2016, Pediatr Blood Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_LOXO-101 ;
    dcterms:description "Nagasubramanian et al reports on a case of refractory infantile fibrosarcoma (IFS) with constitutive activation of the tropomyosin‐related kinase (TRK) signaling pathway from an ETS variant gene 6–neurotrophin 3 receptor gene (ETV6–NTRK3) gene fusion. The patient was diagnosed with IFS at 6 months of age. At 16 months the patient enrolled in a pediatric Phase 1 trial of LOXO‐101, an experimental, highly selective inhibitor of TRK. The patient experienced a rapid, radiographic response, demonstrating the potential for LOXO‐101 to provide benefit for IFS harboring NTRK gene fusions." ;
    a m2r:Evidence .

civice:6474
    dct:references pbm:26784937 ;
    civico:citation "Prasad et al., 2016, Cancer" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Prognostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Poor Outcome" ;
    civico:evidenceLevel "B" ;
    dcterms:description "Prasad et al queried the histopathology of 28 Papillary Thyroid Carcinomas (PTCs) from patients ages 6-18 years (20 females, 8 males). None had significant exposure to radiation. 5 / 27 PTCs (18.5%) had NTRK3-ETV6 fusion oncogenes. The authors compare NTRK3-ETV6 (and include 2 other NTRK fusion samples) to PTCs with BRAF(V) (600E) and find they are associated with large size (mean, 2.2 cm vs 1.5 cm, respectively; P = .05), solid and diffuse variants (11 of 13 vs 0 of 13 tumors, respectively; P < .001), and lymphovascular invasion (12 of 13 vs 6 of 13 tumors, respectively; P = .02); The authors conclude that NTRK fusion oncogene PTC presents with more extensive disease and aggressive pathology than BRAF(V) (600E) PTC in the pediatric population." ;
    a m2r:Evidence .

civice:6475
    dct:references pbm:29623306 ;
    civico:citation "Shukla et al., 2017, JCO Precis Oncol" ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "C" ;
    civico:drug civic:drug_Larotrectinib,civic:drug_LOXO-101 ;
    dcterms:description "Shukla et al report on a remarkable case study of a 14 year old pediatric patient with refractory secretory breast carcinoma first presenting as a fibroadenoma at 8 yo. Over the next years, she experienced recurrence, multiple rounds of chemotherapy and metastasis -- until her case was presented at a virtual multidisciplinary tumor board organized by the Global Cancer Institute which recommended testing for ETV6-NTRK3 fusion. This fusion was confirmed by RNA-seq, targeted DNA and WGS sequencing as well as immunohistochemistry staining with a TRK antibody. The patient was treated with LOXO-101 (larotrectinib) in a single patient use protocol. Within two months, she experienced near complete resolution of a 10.4 × 8.5 cm fungating chest mass with multiple satellite lesions (See Figure 2). The authors note that TERT promoter mutation and a reciprocal inversion including CDKN2A were also identified, but given what is known about LOXO-101 and ETV6-NTRK3, they  infer ETV6-NTRK3 fusion as the primary mitogenic driver in this patient." ;
    a m2r:Evidence .

civice:6567
    dct:references pbm:29466156 ;
    civico:citation "Drilon et al., 2018, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall response rate was 75% according to independent review and 80% according to investigator assessment. Authors state that Larotrectinib had durable anti tumor activity regardless of age or tumor type. 17/23 patients with NTRK1-fusion showed maximum percent change in tumor size between -30% and -100%." ;
    a m2r:Evidence .

civice:6568
    dct:references pbm:29466156 ;
    civico:citation "Drilon et al., 2018, N. Engl. J. Med." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall response rate was 75% according to independent review and 80% according to investigator assessment. Authors state that Larotrectinib had durable anti tumor activity regardless of age or tumor type. 26/27 patients with NTRK3-fusion showed maximum percent change in tumor size between -30% and -100%." ;
    a m2r:Evidence .

civice:6569
    dct:references pbm:29606586 ;
    civico:citation "Laetsch et al., 2018, Lancet Oncol." ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "B" ;
    civico:drug civic:drug_Larotrectinib ;
    dcterms:description "In a Phase 1/2 study involving 15 pediatric patients with infantile fibrosarcoma or soft tissue sarcoma, 8 patients had NTRK1 fusions. The patients were administered Larotrectinib, and 7 out of 8 patients showed objective response, with 2 complete and 5 partial responses. The patient without objective response had soft tissue sarcoma, and showed stable disease." ;
    a m2r:Evidence .

civice:6654
    dct:references pbm:26437031 ;
    civico:citation "Kataoka et al., 2015, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "D" ;
    dcterms:description "PRKCB was mutated in 33% of ATLL cases. 93% of these mutations were within the catalytic domain at Asp427. This gene has not been reported to be significantly mutated in any other cancers.  Indeed this is the first known example in any cancer that appears to involve activation by the PKC gene family.  Nearly all occurrences of this mutation in COSMIC correspond to ATLL." ;
    a m2r:Evidence .

civice:6723
    dct:references pbm:12673678 ;
    civico:citation "Dannenberg et al., 2003, Int. J. Cancer" ;
    civico:rating "2.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predisposing" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Uncertain Significance" ;
    civico:evidenceLevel "C" ;
    dcterms:description "A 49 year old female from Europe presented with pheochromocytoma. Genetic testing confirmed a germline missense mutation found at c.639T>G in the VHL gene. Family history and patient demographic is unknown. This patient underwent surgical resection." ;
    a m2r:Evidence .

civice:6930
    dct:references pbm:29880614 ;
    civico:citation "Roberts et al., 2018, Blood" ;
    civico:rating "4.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Predictive" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Sensitivity/Response" ;
    civico:evidenceLevel "D" ;
    civico:drug civic:drug_PLX7486,civic:drug_Larotrectinib ;
    dcterms:description "In this manuscript, the authors describe the first genetically engineered mouse model of ETV6-NTRK3 ALL and report remarkable efficacy of TRK inhibitors, which induce complete suppression of leukemic cell proliferation when administered as a monotherapy. They also show in vivo efficacy of TRK inhibition in a PDX model of ETV6-NTRK3 ALL. TRK-targeting compounds including PLX7486 and larotrectinib are predicted to show efficacy in B-ALL with ETV6-NTRK3 fusion which accounts for approximately 1% of Ph-like B-ALL." ;
    a m2r:Evidence .

civice:6955
    dct:references pbm:24705254 ;
    civico:citation "Buczkowicz et al., 2014, Nat. Genet." ;
    civico:rating "3.0" ;
    civico:evidenceStatus "accepted" ;
    civico:evidenceType "Diagnostic" ;
    civico:evidenceDirection "Supports" ;
    civico:clinicalSignificance "Positive" ;
    civico:evidenceLevel "B" ;
    dcterms:description "In a study sequencing 61 patients (median age 6.3) with diffuse intrinsic pontine glioma (DIPG), 12 variants affecting ACVR1 were observed. Five patients had G328V within the kinase domain. The ACVR1 G328V mutation was expressed using the pCDH511b vector in immortalized normal human astrocytes (iNHAs) where it activated downstream BMP signaling and enhanced cell growth. Activating ACVR1 mutations are recurrent and support diagnosis of high grade glioma. PEDIATRIC" ;
    a m2r:Evidence .

civic:LymphoidLeukemia
    rdfs:seeAlso obo:DOID_10747 ;
    rdfs:label "Lymphoid Leukemia" ;
    a m2r:Disease .

civic:GastrointestinalStromalTumor
    rdfs:seeAlso obo:DOID_9253 ;
    rdfs:label "Gastrointestinal Stromal Tumor" ;
    a m2r:Disease .

civic:AcuteMyeloidLeukemia
    rdfs:seeAlso obo:DOID_9119 ;
    rdfs:label "Acute Myeloid Leukemia" ;
    a m2r:Disease .

civic:ChronicMyeloidLeukemia
    rdfs:seeAlso obo:DOID_8552 ;
    rdfs:label "Chronic Myeloid Leukemia" ;
    a m2r:Disease .

civic:BoneMarrowCancer
    rdfs:seeAlso obo:DOID_4960 ;
    rdfs:label "Bone Marrow Cancer" ;
    a m2r:Disease .

civic:AcuteLeukemia
    rdfs:seeAlso obo:DOID_12603 ;
    rdfs:label "Acute Leukemia" ;
    a m2r:Disease .

civic:Melanoma
    rdfs:seeAlso obo:DOID_1909 ;
    rdfs:label "Melanoma" ;
    a m2r:Disease .

civic:Non-smallCellLungCarcinoma
    rdfs:seeAlso obo:DOID_3908 ;
    rdfs:label "Non-small Cell Lung Carcinoma" ;
    a m2r:Disease .

civic:PolycythemiaVera
    rdfs:seeAlso obo:DOID_8997 ;
    rdfs:label "Polycythemia Vera" ;
    a m2r:Disease .

civic:ColorectalCancer
    rdfs:seeAlso obo:DOID_9256 ;
    rdfs:label "Colorectal Cancer" ;
    a m2r:Disease .

civic:InflammatoryMyofibroblasticTumor
    rdfs:seeAlso obo:DOID_50905 ;
    rdfs:label "Inflammatory Myofibroblastic Tumor" ;
    a m2r:Disease .

civic:Neuroblastoma
    rdfs:seeAlso obo:DOID_769 ;
    rdfs:label "Neuroblastoma" ;
    a m2r:Disease .

civic:ThyroidMedullaryCarcinoma
    rdfs:seeAlso obo:DOID_3973 ;
    rdfs:label "Thyroid Medullary Carcinoma" ;
    a m2r:Disease .

civic:ThyroidCancer
    rdfs:seeAlso obo:DOID_1781 ;
    rdfs:label "Thyroid Cancer" ;
    a m2r:Disease .

civic:PapillaryThyroidCarcinoma
    rdfs:seeAlso obo:DOID_3969 ;
    rdfs:label "Papillary Thyroid Carcinoma" ;
    a m2r:Disease .

civic:BladderCarcinoma
    rdfs:seeAlso obo:DOID_4007 ;
    rdfs:label "Bladder Carcinoma" ;
    a m2r:Disease .

civic:GlioblastomaMultiforme
    rdfs:seeAlso obo:DOID_3068 ;
    rdfs:label "Glioblastoma Multiforme" ;
    a m2r:Disease .

civic:OvarianCancer
    rdfs:seeAlso obo:DOID_2394 ;
    rdfs:label "Ovarian Cancer" ;
    a m2r:Disease .

civic:StomachCancer
    rdfs:seeAlso obo:DOID_10534 ;
    rdfs:label "Stomach Cancer" ;
    a m2r:Disease .

civic:BreastCancer
    rdfs:seeAlso obo:DOID_1612 ;
    rdfs:label "Breast Cancer" ;
    a m2r:Disease .

civic:LungCancer
    rdfs:seeAlso obo:DOID_1324 ;
    rdfs:label "Lung Cancer" ;
    a m2r:Disease .

civic:LungAdenocarcinoma
    rdfs:seeAlso obo:DOID_3910 ;
    rdfs:label "Lung Adenocarcinoma" ;
    a m2r:Disease .

civic:T-cellLeukemia
    rdfs:seeAlso obo:DOID_715 ;
    rdfs:label "T-cell Leukemia" ;
    a m2r:Disease .

civic:Estrogen-receptorPositiveBreastCancer
    rdfs:seeAlso obo:DOID_60075 ;
    rdfs:label "Estrogen-receptor Positive Breast Cancer" ;
    a m2r:Disease .

civic:Cholangiocarcinoma
    rdfs:seeAlso obo:DOID_4947 ;
    rdfs:label "Cholangiocarcinoma" ;
    a m2r:Disease .

civic:MalignantAnusMelanoma
    rdfs:seeAlso obo:DOID_14145 ;
    rdfs:label "Malignant Anus Melanoma" ;
    a m2r:Disease .

civic:AcutePromyelocyticLeukemia
    rdfs:seeAlso obo:DOID_60318 ;
    rdfs:label "Acute Promyelocytic Leukemia" ;
    a m2r:Disease .

civic:InvasiveBladderTransitionalCellCarcinoma
    rdfs:seeAlso obo:DOID_6477 ;
    rdfs:label "Invasive Bladder Transitional Cell Carcinoma" ;
    a m2r:Disease .

civic:MyelodysplasticSyndrome
    rdfs:seeAlso obo:DOID_50908 ;
    rdfs:label "Myelodysplastic Syndrome" ;
    a m2r:Disease .

civic:Astrocytoma
    rdfs:seeAlso obo:DOID_3069 ;
    rdfs:label "Astrocytoma" ;
    a m2r:Disease .

civic:HeadAndNeckSquamousCellCarcinoma
    rdfs:seeAlso obo:DOID_5520 ;
    rdfs:label "Head And Neck Squamous Cell Carcinoma" ;
    a m2r:Disease .

civic:MantleCellLymphoma
    rdfs:seeAlso obo:DOID_50746 ;
    rdfs:label "Mantle Cell Lymphoma" ;
    a m2r:Disease .

civic:GastricAdenosquamousCarcinoma
    rdfs:seeAlso obo:DOID_5635 ;
    rdfs:label "Gastric Adenosquamous Carcinoma" ;
    a m2r:Disease .

civic:MultipleMyeloma
    rdfs:seeAlso obo:DOID_9538 ;
    rdfs:label "Multiple Myeloma" ;
    a m2r:Disease .

civic:AcuteLymphocyticLeukemia
    rdfs:seeAlso obo:DOID_9952 ;
    rdfs:label "Acute Lymphocytic Leukemia" ;
    a m2r:Disease .

civic:HepatocellularFibrolamellarCarcinoma
    rdfs:seeAlso obo:DOID_5015 ;
    rdfs:label "Hepatocellular Fibrolamellar Carcinoma" ;
    a m2r:Disease .

civic:DiffuseLargeB-cellLymphoma
    rdfs:seeAlso obo:DOID_50745 ;
    rdfs:label "Diffuse Large B-cell Lymphoma" ;
    a m2r:Disease .

civic:ProstateCancer
    rdfs:seeAlso obo:DOID_10283 ;
    rdfs:label "Prostate Cancer" ;
    a m2r:Disease .

civic:OvarianCarcinoma
    rdfs:seeAlso obo:DOID_4001 ;
    rdfs:label "Ovarian Carcinoma" ;
    a m2r:Disease .

civic:ClearCellRenalCellCarcinoma
    rdfs:seeAlso obo:DOID_4467 ;
    rdfs:label "Clear Cell Renal Cell Carcinoma" ;
    a m2r:Disease .

civic:EwingSarcoma
    rdfs:seeAlso obo:DOID_3369 ;
    rdfs:label "Ewing Sarcoma" ;
    a m2r:Disease .

civic:FollicularLymphoma
    rdfs:seeAlso obo:DOID_50873 ;
    rdfs:label "Follicular Lymphoma" ;
    a m2r:Disease .

civic:ChronicLymphocyticLeukemia
    rdfs:seeAlso obo:DOID_1040 ;
    rdfs:label "Chronic Lymphocytic Leukemia" ;
    a m2r:Disease .

civic:ColonCarcinoma
    rdfs:seeAlso obo:DOID_1520 ;
    rdfs:label "Colon Carcinoma" ;
    a m2r:Disease .

civic:ProstateCarcinoma
    rdfs:seeAlso obo:DOID_10286 ;
    rdfs:label "Prostate Carcinoma" ;
    a m2r:Disease .

civic:Cancer
    rdfs:seeAlso obo:DOID_162 ;
    rdfs:label "Cancer" ;
    a m2r:Disease .

civic:HematologicCancer
    rdfs:seeAlso obo:DOID_2531 ;
    rdfs:label "Hematologic Cancer" ;
    a m2r:Disease .

civic:EsophagusAdenocarcinoma
    rdfs:seeAlso obo:DOID_4914 ;
    rdfs:label "Esophagus Adenocarcinoma" ;
    a m2r:Disease .

civic:CervicalAdenocarcinoma
    rdfs:seeAlso obo:DOID_3702 ;
    rdfs:label "Cervical Adenocarcinoma" ;
    a m2r:Disease .

civic:UvealMelanoma
    rdfs:seeAlso obo:DOID_6039 ;
    rdfs:label "Uveal Melanoma" ;
    a m2r:Disease .

civic:Myeloma
    rdfs:seeAlso obo:DOID_70004 ;
    rdfs:label "Myeloma" ;
    a m2r:Disease .

civic:EpithelialOvarianCancer
    rdfs:seeAlso obo:DOID_2152 ;
    rdfs:label "Epithelial Ovarian Cancer" ;
    a m2r:Disease .

civic:T-cellAcuteLymphoblasticLeukemia
    rdfs:seeAlso obo:DOID_5603 ;
    rdfs:label "T-cell Acute Lymphoblastic Leukemia" ;
    a m2r:Disease .

civic:Barrett%27sAdenocarcinoma
    rdfs:seeAlso obo:DOID_7941 ;
    rdfs:label "Barrett's Adenocarcinoma" ;
    a m2r:Disease .

civic:CervicalSquamousCellCarcinoma
    rdfs:seeAlso obo:DOID_3744 ;
    rdfs:label "Cervical Squamous Cell Carcinoma" ;
    a m2r:Disease .

civic:SupratentorialGlioblastomaMultiforme
    rdfs:seeAlso obo:DOID_3073 ;
    rdfs:label "Supratentorial Glioblastoma Multiforme" ;
    a m2r:Disease .

civic:OvarianGranulosaCellTumor
    rdfs:seeAlso obo:DOID_2999 ;
    rdfs:label "Ovarian Granulosa Cell Tumor" ;
    a m2r:Disease .

civic:PrecursorBLymphoblasticLymphoma-leukemia
    rdfs:seeAlso obo:DOID_7061 ;
    rdfs:label "Precursor B Lymphoblastic Lymphoma/leukemia" ;
    a m2r:Disease .

civic:ThymicCarcinoma
    rdfs:seeAlso obo:DOID_3284 ;
    rdfs:label "Thymic Carcinoma" ;
    a m2r:Disease .

civic:AnaplasticOligodendroglioma
    rdfs:seeAlso obo:DOID_3181 ;
    rdfs:label "Anaplastic Oligodendroglioma" ;
    a m2r:Disease .

civic:FollicularThyroidCarcinoma
    rdfs:seeAlso obo:DOID_3962 ;
    rdfs:label "Follicular Thyroid Carcinoma" ;
    a m2r:Disease .

civic:RenalCellCarcinoma
    rdfs:seeAlso obo:DOID_4450 ;
    rdfs:label "Renal Cell Carcinoma" ;
    a m2r:Disease .

civic:GastricAdenocarcinoma
    rdfs:seeAlso obo:DOID_3717 ;
    rdfs:label "Gastric Adenocarcinoma" ;
    a m2r:Disease .

civic:ProstateAdenocarcinoma
    rdfs:seeAlso obo:DOID_2526 ;
    rdfs:label "Prostate Adenocarcinoma" ;
    a m2r:Disease .

civic:PancreaticAdenocarcinoma
    rdfs:seeAlso obo:DOID_4074 ;
    rdfs:label "Pancreatic Adenocarcinoma" ;
    a m2r:Disease .

civic:SmallCellCarcinomaOfTheOvaryHypercalcemicType
    rdfs:seeAlso obo:DOID_7651 ;
    rdfs:label "Small Cell Carcinoma Of The Ovary Hypercalcemic Type" ;
    a m2r:Disease .

civic:AcralLentiginousMelanoma
    rdfs:seeAlso obo:DOID_6367 ;
    rdfs:label "Acral Lentiginous Melanoma" ;
    a m2r:Disease .

civic:SkinMelanoma
    rdfs:seeAlso obo:DOID_8923 ;
    rdfs:label "Skin Melanoma" ;
    a m2r:Disease .

civic:EsophagusSquamousCellCarcinoma
    rdfs:seeAlso obo:DOID_3748 ;
    rdfs:label "Esophagus Squamous Cell Carcinoma" ;
    a m2r:Disease .

civic:Her2-receptorPositiveBreastCancer
    rdfs:seeAlso obo:DOID_60079 ;
    rdfs:label "Her2-receptor Positive Breast Cancer" ;
    a m2r:Disease .

civic:OvarianSerousCarcinoma
    rdfs:seeAlso obo:DOID_50933 ;
    rdfs:label "Ovarian Serous Carcinoma" ;
    a m2r:Disease .

civic:PeripheralT-cellLymphoma
    rdfs:seeAlso obo:DOID_50749 ;
    rdfs:label "Peripheral T-cell Lymphoma" ;
    a m2r:Disease .

civic:OralSquamousCellCarcinoma
    rdfs:seeAlso obo:DOID_50866 ;
    rdfs:label "Oral Squamous Cell Carcinoma" ;
    a m2r:Disease .

civic:PeritonealMesothelioma
    rdfs:seeAlso obo:DOID_1788 ;
    rdfs:label "Peritoneal Mesothelioma" ;
    a m2r:Disease .

civic:ColonCancer
    rdfs:seeAlso obo:DOID_219 ;
    rdfs:label "Colon Cancer" ;
    a m2r:Disease .

civic:ParietalLobeEpendymoma
    rdfs:seeAlso obo:DOID_50903 ;
    rdfs:label "Parietal Lobe Ependymoma" ;
    a m2r:Disease .

civic:CervicalCancer
    rdfs:seeAlso obo:DOID_4362 ;
    rdfs:label "Cervical Cancer" ;
    a m2r:Disease .

civic:Osteosarcoma
    rdfs:seeAlso obo:DOID_3347 ;
    rdfs:label "Osteosarcoma" ;
    a m2r:Disease .

civic:LungSquamousCellCarcinoma
    rdfs:seeAlso obo:DOID_3907 ;
    rdfs:label "Lung Squamous Cell Carcinoma" ;
    a m2r:Disease .

civic:EndometrialCancer
    rdfs:seeAlso obo:DOID_1380 ;
    rdfs:label "Endometrial Cancer" ;
    a m2r:Disease .

civic:MerkelCellCarcinoma
    rdfs:seeAlso obo:DOID_3965 ;
    rdfs:label "Merkel Cell Carcinoma" ;
    a m2r:Disease .

civic:BrainMedulloblastoma
    rdfs:seeAlso obo:DOID_60105 ;
    rdfs:label "Brain Medulloblastoma" ;
    a m2r:Disease .

civic:BasalCellCarcinoma
    rdfs:seeAlso obo:DOID_2513 ;
    rdfs:label "Basal Cell Carcinoma" ;
    a m2r:Disease .

civic:OropharynxCancer
    rdfs:seeAlso obo:DOID_8557 ;
    rdfs:label "Oropharynx Cancer" ;
    a m2r:Disease .

civic:PapillaryRenalCellCarcinoma
    rdfs:seeAlso obo:DOID_4465 ;
    rdfs:label "Papillary Renal Cell Carcinoma" ;
    a m2r:Disease .

civic:HeadAndNeckCarcinoma
    rdfs:seeAlso obo:DOID_1542 ;
    rdfs:label "Head And Neck Carcinoma" ;
    a m2r:Disease .

civic:MalignantPleuralMesothelioma
    rdfs:seeAlso obo:DOID_7474 ;
    rdfs:label "Malignant Pleural Mesothelioma" ;
    a m2r:Disease .

civic:BoneEwing%27sSarcoma
    rdfs:seeAlso obo:DOID_3368 ;
    rdfs:label "Bone Ewing's Sarcoma" ;
    a m2r:Disease .

civic:EndometrialCarcinoma
    rdfs:seeAlso obo:DOID_2871 ;
    rdfs:label "Endometrial Carcinoma" ;
    a m2r:Disease .

civic:PancreaticDuctalAdenocarcinoma
    rdfs:seeAlso obo:DOID_3498 ;
    rdfs:label "Pancreatic Ductal Adenocarcinoma" ;
    a m2r:Disease .

civic:UterineCorpusEndometrialCarcinoma
    rdfs:seeAlso obo:DOID_50939 ;
    rdfs:label "Uterine Corpus Endometrial Carcinoma" ;
    a m2r:Disease .

civic:EsophagealCarcinoma
    rdfs:seeAlso obo:DOID_1107 ;
    rdfs:label "Esophageal Carcinoma" ;
    a m2r:Disease .

civic:PancreaticCarcinoma
    rdfs:seeAlso obo:DOID_4905 ;
    rdfs:label "Pancreatic Carcinoma" ;
    a m2r:Disease .

civic:Sarcoma
    rdfs:seeAlso obo:DOID_1115 ;
    rdfs:label "Sarcoma" ;
    a m2r:Disease .

civic:HepatocellularCarcinoma
    rdfs:seeAlso obo:DOID_684 ;
    rdfs:label "Hepatocellular Carcinoma" ;
    a m2r:Disease .

civic:MalignantMesothelioma
    rdfs:seeAlso obo:DOID_1790 ;
    rdfs:label "Malignant Mesothelioma" ;
    a m2r:Disease .

civic:BileDuctAdenocarcinoma
    rdfs:seeAlso obo:DOID_4896 ;
    rdfs:label "Bile Duct Adenocarcinoma" ;
    a m2r:Disease .

civic:T-cellLargeGranularLymphocyteLeukemia
    rdfs:seeAlso obo:DOID_50751 ;
    rdfs:label "T-cell Large Granular Lymphocyte Leukemia" ;
    a m2r:Disease .

civic:BrainGlioma
    rdfs:seeAlso obo:DOID_60108 ;
    rdfs:label "Brain Glioma" ;
    a m2r:Disease .

civic:Waldenstr%C3%B6m%27sMacroglobulinemia
    rdfs:label "Waldenström's Macroglobulinemia" ;
    a m2r:Disease .

civic:AdrenocorticalCarcinoma
    rdfs:seeAlso obo:DOID_3948 ;
    rdfs:label "Adrenocortical Carcinoma" ;
    a m2r:Disease .

civic:RenalCarcinoma
    rdfs:seeAlso obo:DOID_4451 ;
    rdfs:label "Renal Carcinoma" ;
    a m2r:Disease .

civic:LungSmallCellCarcinoma
    rdfs:seeAlso obo:DOID_5409 ;
    rdfs:label "Lung Small Cell Carcinoma" ;
    a m2r:Disease .

civic:LungCarcinoma
    rdfs:seeAlso obo:DOID_3905 ;
    rdfs:label "Lung Carcinoma" ;
    a m2r:Disease .

civic:Meningioma
    rdfs:seeAlso obo:DOID_3565 ;
    rdfs:label "Meningioma" ;
    a m2r:Disease .

civic:SynovialSarcoma
    rdfs:seeAlso obo:DOID_5485 ;
    rdfs:label "Synovial Sarcoma" ;
    a m2r:Disease .

civic:MalignantPeripheralNerveSheathTumor
    rdfs:seeAlso obo:DOID_5940 ;
    rdfs:label "Malignant Peripheral Nerve Sheath Tumor" ;
    a m2r:Disease .

civic:SkinSquamousCellCarcinoma
    rdfs:seeAlso obo:DOID_3151 ;
    rdfs:label "Skin Squamous Cell Carcinoma" ;
    a m2r:Disease .

civic:UterineCorpusSerousAdenocarcinoma
    rdfs:seeAlso obo:DOID_5750 ;
    rdfs:label "Uterine Corpus Serous Adenocarcinoma" ;
    a m2r:Disease .

civic:ChronicMyeloproliferativeDisease
    rdfs:seeAlso obo:DOID_2226 ;
    rdfs:label "Chronic Myeloproliferative Disease" ;
    a m2r:Disease .

civic:Angiosarcoma
    rdfs:seeAlso obo:DOID_1816 ;
    rdfs:label "Angiosarcoma" ;
    a m2r:Disease .

civic:ThyroidCarcinoma
    rdfs:seeAlso obo:DOID_3963 ;
    rdfs:label "Thyroid Carcinoma" ;
    a m2r:Disease .

civic:LungAcinarAdenocarcinoma
    rdfs:seeAlso obo:DOID_6482 ;
    rdfs:label "Lung Acinar Adenocarcinoma" ;
    a m2r:Disease .

civic:HairyCellLeukemia
    rdfs:seeAlso obo:DOID_285 ;
    rdfs:label "Hairy Cell Leukemia" ;
    a m2r:Disease .

civic:ColonMucinousAdenocarcinoma
    rdfs:seeAlso obo:DOID_3029 ;
    rdfs:label "Colon Mucinous Adenocarcinoma" ;
    a m2r:Disease .

civic:InflammatoryBreastCarcinoma
    rdfs:seeAlso obo:DOID_6263 ;
    rdfs:label "Inflammatory Breast Carcinoma" ;
    a m2r:Disease .

civic:HeadAndNeckCancer
    rdfs:seeAlso obo:DOID_11934 ;
    rdfs:label "Head And Neck Cancer" ;
    a m2r:Disease .

civic:PancreaticCancer
    rdfs:seeAlso obo:DOID_1793 ;
    rdfs:label "Pancreatic Cancer" ;
    a m2r:Disease .

civic:ColorectalAdenocarcinoma
    rdfs:seeAlso obo:DOID_50861 ;
    rdfs:label "Colorectal Adenocarcinoma" ;
    a m2r:Disease .

civic:AnaplasticLargeCellLymphoma
    rdfs:seeAlso obo:DOID_50744 ;
    rdfs:label "Anaplastic Large Cell Lymphoma" ;
    a m2r:Disease .

civic:Myelofibrosis
    rdfs:seeAlso obo:DOID_4971 ;
    rdfs:label "Myelofibrosis" ;
    a m2r:Disease .

civic:StomachCarcinoma
    rdfs:seeAlso obo:DOID_5517 ;
    rdfs:label "Stomach Carcinoma" ;
    a m2r:Disease .

civic:PancreaticDuctalCarcinoma
    rdfs:seeAlso obo:DOID_3587 ;
    rdfs:label "Pancreatic Ductal Carcinoma" ;
    a m2r:Disease .

civic:TumorOfExocrinePancreas
    rdfs:seeAlso obo:DOID_1795 ;
    rdfs:label "Tumor Of Exocrine Pancreas" ;
    a m2r:Disease .

civic:LaryngealCarcinoma
    rdfs:seeAlso obo:DOID_2600 ;
    rdfs:label "Laryngeal Carcinoma" ;
    a m2r:Disease .

civic:EndometrialAdenocarcinoma
    rdfs:seeAlso obo:DOID_2870 ;
    rdfs:label "Endometrial Adenocarcinoma" ;
    a m2r:Disease .

civic:Liposarcoma
    rdfs:seeAlso obo:DOID_3382 ;
    rdfs:label "Liposarcoma" ;
    a m2r:Disease .

civic:ChronicNeutrophilicLeukemia
    rdfs:label "Chronic Neutrophilic Leukemia" ;
    a m2r:Disease .

civic:AtypicalChronicMyeloidLeukemia
    rdfs:seeAlso obo:DOID_60597 ;
    rdfs:label "Atypical Chronic Myeloid Leukemia" ;
    a m2r:Disease .

civic:ChronicLeukemia
    rdfs:seeAlso obo:DOID_1036 ;
    rdfs:label "Chronic Leukemia" ;
    a m2r:Disease .

civic:ChronicMyelomonocyticLeukemia
    rdfs:label "Chronic Myelomonocytic Leukemia" ;
    a m2r:Disease .

civic:GastrointestinalNeuroendocrineTumor
    rdfs:seeAlso obo:DOID_50626 ;
    rdfs:label "Gastrointestinal Neuroendocrine Tumor" ;
    a m2r:Disease .

civic:MyeloidAndLymphoidNeoplasmsWithEosinophiliaAndAbnormalitiesOfPDGFRA%2CPDGFRB%2CAndFGFR1
    rdfs:seeAlso obo:DOID_80164 ;
    rdfs:label "Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1" ;
    a m2r:Disease .

civic:UrothelialCarcinoma
    rdfs:seeAlso obo:DOID_2671 ;
    rdfs:label "Urothelial Carcinoma" ;
    a m2r:Disease .

civic:Bronchiolo-alveolarAdenocarcinoma
    rdfs:seeAlso obo:DOID_4926 ;
    rdfs:label "Bronchiolo-alveolar Adenocarcinoma" ;
    a m2r:Disease .

civic:MucosalMelanoma
    rdfs:seeAlso obo:DOID_50929 ;
    rdfs:label "Mucosal Melanoma" ;
    a m2r:Disease .

civic:PapillaryAdenocarcinoma
    rdfs:seeAlso obo:DOID_3112 ;
    rdfs:label "Papillary Adenocarcinoma" ;
    a m2r:Disease .

civic:Sezary%27sDisease
    rdfs:seeAlso obo:DOID_8541 ;
    rdfs:label "Sezary's Disease" ;
    a m2r:Disease .

civic:AdultB-LymphoblasticLeukemia
    rdfs:seeAlso obo:DOID_60592 ;
    rdfs:label "Adult B-Lymphoblastic Leukemia" ;
    a m2r:Disease .

civic:Langerhans-CellHistiocytosis
    rdfs:seeAlso obo:DOID_2571 ;
    rdfs:label "Langerhans-Cell Histiocytosis" ;
    a m2r:Disease .

civic:PseudomyxomaPeritonei
    rdfs:seeAlso obo:DOID_3559 ;
    rdfs:label "Pseudomyxoma Peritonei" ;
    a m2r:Disease .

civic:ChuvashPolycythemia
    rdfs:seeAlso obo:DOID_60474 ;
    rdfs:label "Chuvash Polycythemia" ;
    a m2r:Disease .

civic:Peutz-JeghersSyndrome
    rdfs:seeAlso obo:DOID_3852 ;
    rdfs:label "Peutz-Jeghers Syndrome" ;
    a m2r:Disease .

civic:ColonAdenocarcinoma
    rdfs:seeAlso obo:DOID_234 ;
    rdfs:label "Colon Adenocarcinoma" ;
    a m2r:Disease .

civic:HepatocellularMixedFibrolamellarCarcinoma
    rdfs:label "Hepatocellular Mixed Fibrolamellar Carcinoma" ;
    a m2r:Disease .

civic:AcousticNeuroma
    rdfs:seeAlso obo:DOID_12689 ;
    rdfs:label "Acoustic Neuroma" ;
    a m2r:Disease .

civic:Triple-receptorNegativeBreastCancer
    rdfs:seeAlso obo:DOID_60081 ;
    rdfs:label "Triple-receptor Negative Breast Cancer" ;
    a m2r:Disease .

civic:ScrotumPaget%27sDisease
    rdfs:seeAlso obo:DOID_3444 ;
    rdfs:label "Scrotum Paget's Disease" ;
    a m2r:Disease .

civic:ThyroidHurthleCellCarcinoma
    rdfs:seeAlso obo:DOID_8161 ;
    rdfs:label "Thyroid Hurthle Cell Carcinoma" ;
    a m2r:Disease .

civic:FemaleReproductiveOrganCancer
    rdfs:seeAlso obo:DOID_120 ;
    rdfs:label "Female Reproductive Organ Cancer" ;
    a m2r:Disease .

civic:SystemicMastocytosis
    rdfs:seeAlso obo:DOID_349 ;
    rdfs:label "Systemic Mastocytosis" ;
    a m2r:Disease .

civic:OvarianSerousCystadenocarcinoma
    rdfs:seeAlso obo:DOID_5746 ;
    rdfs:label "Ovarian Serous Cystadenocarcinoma" ;
    a m2r:Disease .

civic:RhabdoidCancer
    rdfs:seeAlso obo:DOID_3672 ;
    rdfs:label "Rhabdoid Cancer" ;
    a m2r:Disease .

civic:RectumCancer
    rdfs:seeAlso obo:DOID_1993 ;
    rdfs:label "Rectum Cancer" ;
    a m2r:Disease .

civic:Her2-receptorNegativeBreastCancer
    rdfs:seeAlso obo:DOID_60080 ;
    rdfs:label "Her2-receptor Negative Breast Cancer" ;
    a m2r:Disease .

civic:TuberousSclerosis
    rdfs:seeAlso obo:DOID_13515 ;
    rdfs:label "Tuberous Sclerosis" ;
    a m2r:Disease .

civic:MyxoidLiposarcoma
    rdfs:seeAlso obo:DOID_5363 ;
    rdfs:label "Myxoid Liposarcoma" ;
    a m2r:Disease .

civic:NUTMidlineCarcinoma
    rdfs:seeAlso obo:DOID_60463 ;
    rdfs:label "NUT Midline Carcinoma" ;
    a m2r:Disease .

civic:LynchSyndrome
    rdfs:seeAlso obo:DOID_3883 ;
    rdfs:label "Lynch Syndrome" ;
    a m2r:Disease .

civic:BoneEpithelioidHemangioma
    rdfs:seeAlso obo:DOID_6610 ;
    rdfs:label "Bone Epithelioid Hemangioma" ;
    a m2r:Disease .

civic:EpithelioidHemangioendothelioma
    rdfs:label "Epithelioid Hemangioendothelioma" ;
    a m2r:Disease .

civic:VonHippel-LindauDisease
    rdfs:seeAlso obo:DOID_14175 ;
    rdfs:label "Von Hippel-Lindau Disease" ;
    a m2r:Disease .

civic:Pericytoma
    rdfs:label "Pericytoma" ;
    a m2r:Disease .

civic:SalivaryGlandCarcinoma
    rdfs:seeAlso obo:DOID_50904 ;
    rdfs:label "Salivary Gland Carcinoma" ;
    a m2r:Disease .

civic:DermatofibrosarcomaProtuberans
    rdfs:seeAlso obo:DOID_3507 ;
    rdfs:label "Dermatofibrosarcoma Protuberans" ;
    a m2r:Disease .

civic:EndometrialHyperplasia
    rdfs:label "Endometrial Hyperplasia" ;
    a m2r:Disease .

civic:PTENHarmatomaTumorSyndrome
    rdfs:label "PTEN Harmatoma Tumor Syndrome" ;
    a m2r:Disease .

civic:PlexiformNeurofibroma
    rdfs:seeAlso obo:DOID_5151 ;
    rdfs:label "Plexiform Neurofibroma" ;
    a m2r:Disease .

civic:Chordoma
    rdfs:seeAlso obo:DOID_3302 ;
    rdfs:label "Chordoma" ;
    a m2r:Disease .

civic:IntrahepaticCholangiocarcinoma
    rdfs:seeAlso obo:DOID_4928 ;
    rdfs:label "Intrahepatic Cholangiocarcinoma" ;
    a m2r:Disease .

civic:BreastCarcinoma
    rdfs:seeAlso obo:DOID_3459 ;
    rdfs:label "Breast Carcinoma" ;
    a m2r:Disease .

civic:MalignantGlioma
    rdfs:seeAlso obo:DOID_3070 ;
    rdfs:label "Malignant Glioma" ;
    a m2r:Disease .

civic:BladderUrothelialCarcinoma
    rdfs:seeAlso obo:DOID_4006 ;
    rdfs:label "Bladder Urothelial Carcinoma" ;
    a m2r:Disease .

civic:EsophagealCancer
    rdfs:seeAlso obo:DOID_5041 ;
    rdfs:label "Esophageal Cancer" ;
    a m2r:Disease .

civic:Oligodendroglioma
    rdfs:seeAlso obo:DOID_3181 ;
    rdfs:label "Oligodendroglioma" ;
    a m2r:Disease .

civic:NeuroendocrineTumor
    rdfs:seeAlso obo:DOID_169 ;
    rdfs:label "Neuroendocrine Tumor" ;
    a m2r:Disease .

civic:Leukemia
    rdfs:seeAlso obo:DOID_1240 ;
    rdfs:label "Leukemia" ;
    a m2r:Disease .

civic:DesmoidFibromatosis
    rdfs:label "Desmoid Fibromatosis" ;
    a m2r:Disease .

civic:OvarianClearCellCarcinoma
    rdfs:seeAlso obo:DOID_50934 ;
    rdfs:label "Ovarian Clear Cell Carcinoma" ;
    a m2r:Disease .

civic:Ganglioglioma
    rdfs:seeAlso obo:DOID_5078 ;
    rdfs:label "Ganglioglioma" ;
    a m2r:Disease .

civic:OvarianCystadenocarcinoma
    rdfs:seeAlso obo:DOID_3605 ;
    rdfs:label "Ovarian Cystadenocarcinoma" ;
    a m2r:Disease .

civic:DiffuseIntrinsicPontineGlioma
    rdfs:label "Diffuse Intrinsic Pontine Glioma" ;
    a m2r:Disease .

civic:AdrenalGlandPheochromocytoma
    rdfs:seeAlso obo:DOID_50892 ;
    rdfs:label "Adrenal Gland Pheochromocytoma" ;
    a m2r:Disease .

civic:MalignantSertoli-LeydigCellTumor
    rdfs:seeAlso obo:DOID_50618 ;
    rdfs:label "Malignant Sertoli-Leydig Cell Tumor" ;
    a m2r:Disease .

civic:UreterSmallCellCarcinoma
    rdfs:seeAlso obo:DOID_6886 ;
    rdfs:label "Ureter Small Cell Carcinoma" ;
    a m2r:Disease .

civic:GlandularPatternOvarianYolkSacTumor
    rdfs:seeAlso obo:DOID_6511 ;
    rdfs:label "Glandular Pattern Ovarian Yolk Sac Tumor" ;
    a m2r:Disease .

civic:SolidTumor
    rdfs:label "Solid Tumor" ;
    a m2r:Disease .

civic:AnaplasticThyroidCarcinoma
    rdfs:label "Anaplastic Thyroid Carcinoma" ;
    a m2r:Disease .

civic:LaryngealSquamousCellCarcinoma
    rdfs:seeAlso obo:DOID_2876 ;
    rdfs:label "Laryngeal Squamous Cell Carcinoma" ;
    a m2r:Disease .

civic:BiliaryTractCancer
    rdfs:seeAlso obo:DOID_4607 ;
    rdfs:label "Biliary Tract Cancer" ;
    a m2r:Disease .

civic:UterineCancer
    rdfs:seeAlso obo:DOID_363 ;
    rdfs:label "Uterine Cancer" ;
    a m2r:Disease .

civic:OvarianSexCord-stromalTumours
    rdfs:label "Ovarian Sex Cord-stromal Tumours" ;
    a m2r:Disease .

civic:VaginaSarcoma
    rdfs:seeAlso obo:DOID_1901 ;
    rdfs:label "Vagina Sarcoma" ;
    a m2r:Disease .

civic:EpithelioidInflammatoryMyofibroblasticSarcoma
    rdfs:label "Epithelioid Inflammatory Myofibroblastic Sarcoma" ;
    a m2r:Disease .

civic:AnaplasticThyroidCancer
    rdfs:label "Anaplastic Thyroid Cancer" ;
    a m2r:Disease .

civic:PediatricFibrosarcoma
    rdfs:seeAlso obo:DOID_3520 ;
    rdfs:label "Pediatric Fibrosarcoma" ;
    a m2r:Disease .

civic:SalivaryGlandCancer
    rdfs:seeAlso obo:DOID_8850 ;
    rdfs:label "Salivary Gland Cancer" ;
    a m2r:Disease .

civic:EssentialThrombocythemia
    rdfs:label "Essential Thrombocythemia" ;
    a m2r:Disease .

civic:Paraganglioma
    rdfs:seeAlso obo:DOID_50773 ;
    rdfs:label "Paraganglioma" ;
    a m2r:Disease .

civic:CongenitalFibrosarcoma
    rdfs:seeAlso obo:DOID_8418 ;
    rdfs:label "Congenital Fibrosarcoma" ;
    a m2r:Disease .

civic:BreastSecretoryCarcinoma
    rdfs:seeAlso obo:DOID_4922 ;
    rdfs:label "Breast Secretory Carcinoma" ;
    a m2r:Disease .

civic:AdultT-cellLeukemia
    rdfs:seeAlso obo:DOID_50523 ;
    rdfs:label "Adult T-cell Leukemia" ;
    a m2r:Disease .

civic:PediatricB-lymphoblasticLeukemia
    rdfs:label "Pediatric B-lymphoblastic Leukemia" ;
    a m2r:Disease .

civic:drug_
    rdfs:label "" ;
    a m2r:Drug .

civic:drug_Lomustine
    rdfs:label "Lomustine" ;
    a m2r:Drug .

civic:drug_G-573
    rdfs:label "G-573" ;
    a m2r:Drug .

civic:drug_AZD4547
    rdfs:label "AZD4547" ;
    a m2r:Drug .

civic:drug_Chemotherapy
    rdfs:label "Chemotherapy" ;
    a m2r:Drug .

civic:drug_PLX4720
    rdfs:label "PLX4720" ;
    a m2r:Drug .

civic:drug_Alpelisib%28NVP-BYL719%29
    rdfs:label "Alpelisib (NVP-BYL719)" ;
    a m2r:Drug .

civic:drug_Anti-CD33
    rdfs:label "Anti-CD33" ;
    a m2r:Drug .

civic:drug_Ixazomib
    rdfs:label "Ixazomib" ;
    a m2r:Drug .

civic:drug_Aspirin
    rdfs:label "Aspirin" ;
    a m2r:Drug .

civic:drug_I-BET151
    rdfs:label "I-BET151" ;
    a m2r:Drug .

civic:drug_Everolimus
    rdfs:label "Everolimus" ;
    a m2r:Drug .

civic:drug_Arabinosylguanine
    rdfs:label "Arabinosylguanine" ;
    a m2r:Drug .

civic:drug_Lenalidomide
    rdfs:label "Lenalidomide" ;
    a m2r:Drug .

civic:drug_Binimetinib
    rdfs:label "Binimetinib" ;
    a m2r:Drug .

civic:drug_PD184352
    rdfs:label "PD184352" ;
    a m2r:Drug .

civic:drug_Oxaliplatin
    rdfs:label "Oxaliplatin" ;
    a m2r:Drug .

civic:drug_Dacarbazine
    rdfs:label "Dacarbazine" ;
    a m2r:Drug .

civic:drug_LBH-589
    rdfs:label "LBH-589" ;
    a m2r:Drug .

civic:drug_Letrozole
    rdfs:label "Letrozole" ;
    a m2r:Drug .

civic:drug_Rapamycin%28Sirolimus%29
    rdfs:label "Rapamycin (Sirolimus)" ;
    a m2r:Drug .

civic:drug_Cetuximab
    rdfs:label "Cetuximab" ;
    a m2r:Drug .

civic:drug_CH5132799
    rdfs:label "CH5132799" ;
    a m2r:Drug .

civic:drug_Nintedanib
    rdfs:label "Nintedanib" ;
    a m2r:Drug .

civic:drug_Pembrolizumab
    rdfs:label "Pembrolizumab" ;
    a m2r:Drug .

civic:drug_BEZ235
    rdfs:label "BEZ235" ;
    a m2r:Drug .

civic:drug_Bis-2-%5B5-%28phenylacetamide%29-1
    rdfs:label "Bis-2-[5-(phenylacetamide)-1" ;
    a m2r:Drug .

civic:drug_GDC0941
    rdfs:label "GDC0941" ;
    a m2r:Drug .

civic:drug_Bortezomib
    rdfs:label "Bortezomib" ;
    a m2r:Drug .

civic:drug_Dactolisib%29
    rdfs:label " Dactolisib)" ;
    a m2r:Drug .

civic:drug_Afatinib
    rdfs:label "Afatinib" ;
    a m2r:Drug .

civic:drug_Alpelisib
    rdfs:label "Alpelisib" ;
    a m2r:Drug .

civic:drug_Nelarabine
    rdfs:label "Nelarabine" ;
    a m2r:Drug .

civic:drug_Crizotinib
    rdfs:label "Crizotinib" ;
    a m2r:Drug .

civic:drug_CH5424802
    rdfs:label "CH5424802" ;
    a m2r:Drug .

civic:drug_FGF-VEGFReceptorTyrosineKinaseInhibitor
    rdfs:label "FGF/VEGF Receptor Tyrosine Kinase Inhibitor" ;
    a m2r:Drug .

civic:drug_SpliceostatinA
    rdfs:label "Spliceostatin A" ;
    a m2r:Drug .

civic:drug_AKT3Inhibitor
    rdfs:label "AKT3 Inhibitor" ;
    a m2r:Drug .

civic:drug_NU7441
    rdfs:label "NU7441" ;
    a m2r:Drug .

civic:drug_Lorlatinib
    rdfs:label "Lorlatinib" ;
    a m2r:Drug .

civic:drug_Go6983
    rdfs:label "Go6983" ;
    a m2r:Drug .

civic:drug_Docetaxel
    rdfs:label "Docetaxel" ;
    a m2r:Drug .

civic:drug_Gefitinib
    rdfs:label "Gefitinib" ;
    a m2r:Drug .

civic:drug_Savolitinib
    rdfs:label "Savolitinib" ;
    a m2r:Drug .

civic:drug_Erlotinib
    rdfs:label "Erlotinib" ;
    a m2r:Drug .

civic:drug_Ibrutinib
    rdfs:label "Ibrutinib" ;
    a m2r:Drug .

civic:drug_Melphalan
    rdfs:label "Melphalan" ;
    a m2r:Drug .

civic:drug_AZD8186
    rdfs:label "AZD8186" ;
    a m2r:Drug .

civic:drug_Pomalidomide
    rdfs:label "Pomalidomide" ;
    a m2r:Drug .

civic:drug_Neratinib
    rdfs:label "Neratinib" ;
    a m2r:Drug .

civic:drug_Talazoparib
    rdfs:label "Talazoparib" ;
    a m2r:Drug .

civic:drug_MK-2206
    rdfs:label "MK-2206" ;
    a m2r:Drug .

civic:drug_Belinostat
    rdfs:label "Belinostat" ;
    a m2r:Drug .

civic:drug_AS602868
    rdfs:label "AS602868" ;
    a m2r:Drug .

civic:drug_Nivolumab
    rdfs:label "Nivolumab" ;
    a m2r:Drug .

civic:drug_Alectinib
    rdfs:label "Alectinib" ;
    a m2r:Drug .

civic:drug_Fulvestrant
    rdfs:label "Fulvestrant" ;
    a m2r:Drug .

civic:drug_SN-38
    rdfs:label "SN-38" ;
    a m2r:Drug .

civic:drug_TAK-733
    rdfs:label "TAK-733" ;
    a m2r:Drug .

civic:drug_Atezolizumab
    rdfs:label "Atezolizumab" ;
    a m2r:Drug .

civic:drug_Flavopiridol
    rdfs:label "Flavopiridol" ;
    a m2r:Drug .

civic:drug_17-DMAG
    rdfs:label "17-DMAG" ;
    a m2r:Drug .

civic:drug_MitomycinC
    rdfs:label "Mitomycin C" ;
    a m2r:Drug .

civic:drug_GDC-0879
    rdfs:label "GDC-0879" ;
    a m2r:Drug .

civic:drug_Cytarabine
    rdfs:label "Cytarabine" ;
    a m2r:Drug .

civic:drug_AdjuvantChemotherapy
    rdfs:label "Adjuvant Chemotherapy" ;
    a m2r:Drug .

civic:drug_Ado-trastuzumabEmtansine
    rdfs:label "Ado-trastuzumab Emtansine" ;
    a m2r:Drug .

civic:drug_AZD1480
    rdfs:label "AZD1480" ;
    a m2r:Drug .

civic:drug_L-asparaginase
    rdfs:label "L-asparaginase" ;
    a m2r:Drug .

civic:drug_Taselisib%28GDC-0032%29
    rdfs:label "Taselisib (GDC-0032)" ;
    a m2r:Drug .

civic:drug_ImatinibMesylate
    rdfs:label "Imatinib Mesylate" ;
    a m2r:Drug .

civic:drug_PD173074
    rdfs:label "PD173074" ;
    a m2r:Drug .

civic:drug_PLATINUM
    rdfs:label "PLATINUM" ;
    a m2r:Drug .

civic:drug_4-pyrimidinediamine
    rdfs:label "4-pyrimidinediamine" ;
    a m2r:Drug .

civic:drug_LY294002
    rdfs:label "LY294002" ;
    a m2r:Drug .

civic:drug_Linsitinib
    rdfs:label "Linsitinib" ;
    a m2r:Drug .

civic:drug_Avelumab
    rdfs:label "Avelumab" ;
    a m2r:Drug .

civic:drug_MEDI4736
    rdfs:label "MEDI4736" ;
    a m2r:Drug .

civic:drug_SCH772984
    rdfs:label "SCH772984" ;
    a m2r:Drug .

civic:drug_Quizartinib%28AC220%29
    rdfs:label "Quizartinib (AC220)" ;
    a m2r:Drug .

civic:drug_Conatumumab
    rdfs:label "Conatumumab" ;
    a m2r:Drug .

civic:drug_MLN518
    rdfs:label "MLN518" ;
    a m2r:Drug .

civic:drug_Vincristine
    rdfs:label "Vincristine" ;
    a m2r:Drug .

civic:drug_CX-5461
    rdfs:label "CX-5461" ;
    a m2r:Drug .

civic:drug_PF00299804
    rdfs:label "PF 00299804" ;
    a m2r:Drug .

civic:drug_Mitomycin
    rdfs:label "Mitomycin" ;
    a m2r:Drug .

civic:drug_Foretinib
    rdfs:label "Foretinib" ;
    a m2r:Drug .

civic:drug_WYE354
    rdfs:label "WYE354" ;
    a m2r:Drug .

civic:drug_PD-1Inhibitor
    rdfs:label "PD-1 Inhibitor" ;
    a m2r:Drug .

civic:drug_Pemetrexed
    rdfs:label "Pemetrexed" ;
    a m2r:Drug .

civic:drug_Trastuzumab
    rdfs:label "Trastuzumab" ;
    a m2r:Drug .

civic:drug_Cyclophosphamide
    rdfs:label "Cyclophosphamide" ;
    a m2r:Drug .

civic:drug_Anthracycline
    rdfs:label "Anthracycline" ;
    a m2r:Drug .

civic:drug_PSI
    rdfs:label "PSI" ;
    a m2r:Drug .

civic:drug_Larotrectinib%28LOXO-101%29
    rdfs:label "Larotrectinib (LOXO-101)" ;
    a m2r:Drug .

civic:drug_Nicotinamide
    rdfs:label "Nicotinamide" ;
    a m2r:Drug .

civic:drug_AZD7762
    rdfs:label "AZD7762" ;
    a m2r:Drug .

civic:drug_JQ1Compound
    rdfs:label "JQ1 Compound" ;
    a m2r:Drug .

civic:drug_Olaparib
    rdfs:label "Olaparib" ;
    a m2r:Drug .

civic:drug_Anti-EGFRMonoclonalAntibody
    rdfs:label "Anti-EGFR Monoclonal Antibody" ;
    a m2r:Drug .

civic:drug_Panitumumab
    rdfs:label "Panitumumab" ;
    a m2r:Drug .

civic:drug_Idelalisib
    rdfs:label "Idelalisib" ;
    a m2r:Drug .

civic:drug_PD-180970
    rdfs:label "PD-180970" ;
    a m2r:Drug .

civic:drug_TrastuzumabEmtansine
    rdfs:label "Trastuzumab Emtansine" ;
    a m2r:Drug .

civic:drug_AZD5438
    rdfs:label "AZD5438" ;
    a m2r:Drug .

civic:drug_FarnesylthiosalicylicAcid
    rdfs:label "Farnesylthiosalicylic Acid" ;
    a m2r:Drug .

civic:drug_Enzastaurin
    rdfs:label "Enzastaurin" ;
    a m2r:Drug .

civic:drug_GF109203X
    rdfs:label "GF109203X" ;
    a m2r:Drug .

civic:drug_Salinomycin
    rdfs:label "Salinomycin" ;
    a m2r:Drug .

civic:drug_IMO
    rdfs:label "IMO" ;
    a m2r:Drug .

civic:drug_NOTCH1Antibody
    rdfs:label "NOTCH1 Antibody" ;
    a m2r:Drug .

civic:drug_Bevacizumab
    rdfs:label "Bevacizumab" ;
    a m2r:Drug .

civic:drug_SB202190
    rdfs:label "SB202190" ;
    a m2r:Drug .

civic:drug_Etoposide
    rdfs:label "Etoposide" ;
    a m2r:Drug .

civic:drug_AZD5363
    rdfs:label "AZD5363" ;
    a m2r:Drug .

civic:drug_FolfoxProtocol
    rdfs:label "FolfoxProtocol" ;
    a m2r:Drug .

civic:drug_Sym004
    rdfs:label "Sym004" ;
    a m2r:Drug .

civic:drug_MonomethylAuristatinE
    rdfs:label "Monomethyl Auristatin E" ;
    a m2r:Drug .

civic:drug_Ceritinib
    rdfs:label "Ceritinib" ;
    a m2r:Drug .

civic:drug_ACLYSiRNA
    rdfs:label "ACLY SiRNA" ;
    a m2r:Drug .

civic:drug_TrametinibDMSO
    rdfs:label "Trametinib DMSO" ;
    a m2r:Drug .

civic:drug_LY3009120
    rdfs:label "LY3009120" ;
    a m2r:Drug .

civic:drug_Daunorubicin
    rdfs:label "Daunorubicin" ;
    a m2r:Drug .

civic:drug_Enasidenib%28AG-221%29
    rdfs:label "Enasidenib (AG-221)" ;
    a m2r:Drug .

civic:drug_Rindopepimut
    rdfs:label "Rindopepimut" ;
    a m2r:Drug .

civic:drug_Anti-ERBB3Agents
    rdfs:label "Anti-ERBB3 Agents" ;
    a m2r:Drug .

civic:drug_PP242
    rdfs:label "PP242" ;
    a m2r:Drug .

civic:drug_Pertuzumab
    rdfs:label "Pertuzumab" ;
    a m2r:Drug .

civic:drug_GNE-617
    rdfs:label "GNE-617" ;
    a m2r:Drug .

civic:drug_Cixutumumab
    rdfs:label "Cixutumumab" ;
    a m2r:Drug .

civic:drug_SGX523
    rdfs:label "SGX523" ;
    a m2r:Drug .

civic:drug_Staurosporine
    rdfs:label "Staurosporine" ;
    a m2r:Drug .

civic:drug_Larotrectinib
    rdfs:label "Larotrectinib" ;
    a m2r:Drug .

civic:drug_JQ1
    rdfs:label "JQ1" ;
    a m2r:Drug .

civic:drug_Idarubicin
    rdfs:label "Idarubicin" ;
    a m2r:Drug .

civic:drug_BAY86-9766
    rdfs:label "BAY 86-9766" ;
    a m2r:Drug .

civic:drug_Tegafur
    rdfs:label "Tegafur" ;
    a m2r:Drug .

civic:drug_Nilutamide
    rdfs:label "Nilutamide" ;
    a m2r:Drug .

civic:drug_Nilotinib
    rdfs:label "Nilotinib" ;
    a m2r:Drug .

civic:drug_Ipatasertib
    rdfs:label "Ipatasertib" ;
    a m2r:Drug .

civic:drug_4-thiadiazol-2-yl%5DethylSulfide
    rdfs:label "4-thiadiazol-2-yl]ethyl Sulfide" ;
    a m2r:Drug .

civic:drug_Temsirolimus
    rdfs:label "Temsirolimus" ;
    a m2r:Drug .

civic:drug_CRS-IPHC
    rdfs:label "CRS/IPHC" ;
    a m2r:Drug .

civic:drug_Alectinib%28CH5424802%29
    rdfs:label "Alectinib (CH5424802)" ;
    a m2r:Drug .

civic:drug_Paclitaxel
    rdfs:label "Paclitaxel" ;
    a m2r:Drug .

civic:drug_Saridegib
    rdfs:label "Saridegib" ;
    a m2r:Drug .

civic:drug_9F7-F11
    rdfs:label "9F7-F11" ;
    a m2r:Drug .

civic:drug_Buparlisib
    rdfs:label "Buparlisib" ;
    a m2r:Drug .

civic:drug_SGK1-Inh
    rdfs:label "SGK1-Inh" ;
    a m2r:Drug .

civic:drug_Rucaparib
    rdfs:label "Rucaparib" ;
    a m2r:Drug .

civic:drug_Dinaciclib
    rdfs:label "Dinaciclib" ;
    a m2r:Drug .

civic:drug_BGJ398
    rdfs:label "BGJ398" ;
    a m2r:Drug .

civic:drug_VEGFInhibition
    rdfs:label "VEGF Inhibition" ;
    a m2r:Drug .

civic:drug_EGFRInhibitor
    rdfs:label "EGFR Inhibitor" ;
    a m2r:Drug .

civic:drug_PD0332991
    rdfs:label "PD0332991" ;
    a m2r:Drug .

civic:drug_Trametinib
    rdfs:label "Trametinib" ;
    a m2r:Drug .

civic:drug_Durvalumab
    rdfs:label "Durvalumab" ;
    a m2r:Drug .

civic:drug_MLN0128
    rdfs:label "MLN0128" ;
    a m2r:Drug .

civic:drug_IMG-2005-5
    rdfs:label "IMG-2005-5" ;
    a m2r:Drug .

civic:drug_5-fluorouracil
    rdfs:label "5-fluorouracil" ;
    a m2r:Drug .

civic:drug_BMN-673
    rdfs:label "BMN-673" ;
    a m2r:Drug .

civic:drug_CX-3543
    rdfs:label "CX-3543" ;
    a m2r:Drug .

civic:drug_NSC348884
    rdfs:label "NSC348884" ;
    a m2r:Drug .

civic:drug_Nimotuzumab
    rdfs:label "Nimotuzumab" ;
    a m2r:Drug .

civic:drug_Patritumab
    rdfs:label "Patritumab" ;
    a m2r:Drug .

civic:drug_Irinotecan
    rdfs:label "Irinotecan" ;
    a m2r:Drug .

civic:drug_Vismodegib
    rdfs:label "Vismodegib" ;
    a m2r:Drug .

civic:drug_Dacomitinib
    rdfs:label "Dacomitinib" ;
    a m2r:Drug .

civic:drug_RO4987655
    rdfs:label "RO4987655" ;
    a m2r:Drug .

civic:drug_Amuvatinib
    rdfs:label "Amuvatinib" ;
    a m2r:Drug .

civic:drug_VTX-11e
    rdfs:label "VTX-11e" ;
    a m2r:Drug .

civic:drug_Selumetinib%28AZD6244%29
    rdfs:label "Selumetinib (AZD6244)" ;
    a m2r:Drug .

civic:drug_Gemcitabine
    rdfs:label "Gemcitabine" ;
    a m2r:Drug .

civic:drug_FOLFIRIRegimen
    rdfs:label "FOLFIRI Regimen" ;
    a m2r:Drug .

civic:drug_JSI-124
    rdfs:label "JSI-124" ;
    a m2r:Drug .

civic:drug_CBL0137
    rdfs:label "CBL0137" ;
    a m2r:Drug .

civic:drug_HormoneTherapy
    rdfs:label "Hormone Therapy" ;
    a m2r:Drug .

civic:drug_SU11248
    rdfs:label "SU11248" ;
    a m2r:Drug .

civic:drug_Cabozantinib
    rdfs:label "Cabozantinib" ;
    a m2r:Drug .

civic:drug_O%286%29-benzylguanine
    rdfs:label "O(6)-benzylguanine" ;
    a m2r:Drug .

civic:drug_Cediranib
    rdfs:label "Cediranib" ;
    a m2r:Drug .

civic:drug_Dabrafenib
    rdfs:label "Dabrafenib" ;
    a m2r:Drug .

civic:drug_IRAK-1-4Inhibitor
    rdfs:label "IRAK-1/4 Inhibitor" ;
    a m2r:Drug .

civic:drug_IGF1RMonoclonalAntibody
    rdfs:label "IGF1R Monoclonal Antibody" ;
    a m2r:Drug .

civic:drug_Stattic
    rdfs:label "Stattic" ;
    a m2r:Drug .

civic:drug_TG101348
    rdfs:label "TG101348" ;
    a m2r:Drug .

civic:drug_AZD3463
    rdfs:label "AZD3463" ;
    a m2r:Drug .

civic:drug_Pazopanib
    rdfs:label "Pazopanib" ;
    a m2r:Drug .

civic:drug_A66
    rdfs:label "A66" ;
    a m2r:Drug .

civic:drug_Palbociclib%28PD0332991%29
    rdfs:label "Palbociclib (PD0332991)" ;
    a m2r:Drug .

civic:drug_Lestaurtinib%28CEP-701%29
    rdfs:label "Lestaurtinib (CEP-701)" ;
    a m2r:Drug .

civic:drug_Imatinib
    rdfs:label "Imatinib" ;
    a m2r:Drug .

civic:drug_SU5614
    rdfs:label "SU5614" ;
    a m2r:Drug .

civic:drug_InductionTherapy
    rdfs:label "Induction Therapy" ;
    a m2r:Drug .

civic:drug_Chlorambucil
    rdfs:label "Chlorambucil" ;
    a m2r:Drug .

civic:drug_Dasatinib
    rdfs:label "Dasatinib" ;
    a m2r:Drug .

civic:drug_Abemaciclib
    rdfs:label "Abemaciclib" ;
    a m2r:Drug .

civic:drug_AG1296
    rdfs:label "AG1296" ;
    a m2r:Drug .

civic:drug_Exemestane
    rdfs:label "Exemestane" ;
    a m2r:Drug .

civic:drug_5-FU
    rdfs:label "5-FU" ;
    a m2r:Drug .

civic:drug_Carmustine
    rdfs:label "Carmustine" ;
    a m2r:Drug .

civic:drug_XL147%28Pilaralisib%29
    rdfs:label "XL147 (Pilaralisib)" ;
    a m2r:Drug .

civic:drug_Vorinostat%28SAHA%29
    rdfs:label "Vorinostat (SAHA)" ;
    a m2r:Drug .

civic:drug_PD-L1Antibody
    rdfs:label "PD-L1 Antibody" ;
    a m2r:Drug .

civic:drug_AZD8055
    rdfs:label "AZD8055" ;
    a m2r:Drug .

civic:drug_Palbociclib
    rdfs:label "Palbociclib" ;
    a m2r:Drug .

civic:drug_AZ628
    rdfs:label "AZ628" ;
    a m2r:Drug .

civic:drug_JW55
    rdfs:label "JW55" ;
    a m2r:Drug .

civic:drug_Alemtuzumab
    rdfs:label "Alemtuzumab" ;
    a m2r:Drug .

civic:drug_Alisertib
    rdfs:label "Alisertib" ;
    a m2r:Drug .

civic:drug_Nutlin-3a
    rdfs:label "Nutlin-3a" ;
    a m2r:Drug .

civic:drug_Enasidenib
    rdfs:label "Enasidenib" ;
    a m2r:Drug .

civic:drug_BYL719%28Alpelisib%29
    rdfs:label "BYL719 (Alpelisib)" ;
    a m2r:Drug .

civic:drug_Meloxicam
    rdfs:label "Meloxicam" ;
    a m2r:Drug .

civic:drug_Veliparib
    rdfs:label "Veliparib" ;
    a m2r:Drug .

civic:drug_U0126
    rdfs:label "U0126" ;
    a m2r:Drug .

civic:drug_MTORInhibitors
    rdfs:label "MTOR Inhibitors" ;
    a m2r:Drug .

civic:drug_Nutlin-3
    rdfs:label "Nutlin-3" ;
    a m2r:Drug .

civic:drug_GSK2141795
    rdfs:label "GSK2141795" ;
    a m2r:Drug .

civic:drug_MEDI0680
    rdfs:label "MEDI0680" ;
    a m2r:Drug .

civic:drug_MEKInhibitor
    rdfs:label "MEK Inhibitor" ;
    a m2r:Drug .

civic:drug_Aminoglutethimide
    rdfs:label "Aminoglutethimide" ;
    a m2r:Drug .

civic:drug_WHI-P154
    rdfs:label "WHI-P154" ;
    a m2r:Drug .

civic:drug_OICR-9429
    rdfs:label "OICR-9429" ;
    a m2r:Drug .

civic:drug_Doxorubicin
    rdfs:label "Doxorubicin" ;
    a m2r:Drug .

civic:drug_Lonafarnib
    rdfs:label "Lonafarnib" ;
    a m2r:Drug .

civic:drug_AV-203
    rdfs:label "AV-203" ;
    a m2r:Drug .

civic:drug_Capecitibine
    rdfs:label "Capecitibine" ;
    a m2r:Drug .

civic:drug_CP724714
    rdfs:label "CP724714" ;
    a m2r:Drug .

civic:drug_Ruxolitinib
    rdfs:label "Ruxolitinib" ;
    a m2r:Drug .

civic:drug_G007-LK
    rdfs:label "G007-LK" ;
    a m2r:Drug .

civic:drug_RadioactiveIodine
    rdfs:label "Radioactive Iodine" ;
    a m2r:Drug .

civic:drug_Onartuzumab
    rdfs:label "Onartuzumab" ;
    a m2r:Drug .

civic:drug_GDC-0980
    rdfs:label "GDC-0980" ;
    a m2r:Drug .

civic:drug_Epirubicin
    rdfs:label "Epirubicin" ;
    a m2r:Drug .

civic:drug_Lapatinib
    rdfs:label "Lapatinib" ;
    a m2r:Drug .

civic:drug_GSK126
    rdfs:label "GSK126" ;
    a m2r:Drug .

civic:drug_Dovitinib
    rdfs:label "Dovitinib" ;
    a m2r:Drug .

civic:drug_KU-0060648
    rdfs:label "KU-0060648" ;
    a m2r:Drug .

civic:drug_Methotrexate
    rdfs:label "Methotrexate" ;
    a m2r:Drug .

civic:drug_Taxane
    rdfs:label "Taxane" ;
    a m2r:Drug .

civic:drug_Sunitinib
    rdfs:label "Sunitinib" ;
    a m2r:Drug .

civic:drug_BGJ-398
    rdfs:label "BGJ-398" ;
    a m2r:Drug .

civic:drug_Rociletinib
    rdfs:label "Rociletinib" ;
    a m2r:Drug .

civic:drug_ValproicAcid
    rdfs:label "Valproic Acid" ;
    a m2r:Drug .

civic:drug_Entrectinib
    rdfs:label "Entrectinib" ;
    a m2r:Drug .

civic:drug_Mocetinostat
    rdfs:label "Mocetinostat" ;
    a m2r:Drug .

civic:drug_17-AAG
    rdfs:label "17-AAG" ;
    a m2r:Drug .

civic:drug_Apitolisib
    rdfs:label "Apitolisib" ;
    a m2r:Drug .

civic:drug_GSK321
    rdfs:label "GSK321" ;
    a m2r:Drug .

civic:drug_EAPProtocol
    rdfs:label "EAP Protocol" ;
    a m2r:Drug .

civic:drug_TrichostatinA%28TSA%29
    rdfs:label "Trichostatin A (TSA)" ;
    a m2r:Drug .

civic:drug_AEE788
    rdfs:label "AEE788" ;
    a m2r:Drug .

civic:drug_Fasudil
    rdfs:label "Fasudil" ;
    a m2r:Drug .

civic:drug_LY2835219
    rdfs:label "LY2835219" ;
    a m2r:Drug .

civic:drug_CI-1040
    rdfs:label "CI-1040" ;
    a m2r:Drug .

civic:drug_Cisplatin
    rdfs:label "Cisplatin" ;
    a m2r:Drug .

civic:drug_LGK974
    rdfs:label "LGK974" ;
    a m2r:Drug .

civic:drug_Pictilisib
    rdfs:label "Pictilisib" ;
    a m2r:Drug .

civic:drug_Procarbazine
    rdfs:label "Procarbazine" ;
    a m2r:Drug .

civic:drug_5-Fluoropyrimidine
    rdfs:label "5-Fluoropyrimidine" ;
    a m2r:Drug .

civic:drug_All-transRetinoicAcid
    rdfs:label "All-trans Retinoic Acid" ;
    a m2r:Drug .

civic:drug_MC1568
    rdfs:label "MC1568" ;
    a m2r:Drug .

civic:drug_ARS-853
    rdfs:label "ARS-853" ;
    a m2r:Drug .

civic:drug_Sorafenib
    rdfs:label "Sorafenib" ;
    a m2r:Drug .

civic:drug_Decitabine
    rdfs:label "Decitabine" ;
    a m2r:Drug .

civic:drug_Quizartinib
    rdfs:label "Quizartinib" ;
    a m2r:Drug .

civic:drug_Capmatinib
    rdfs:label "Capmatinib" ;
    a m2r:Drug .

civic:drug_Raltitrexed
    rdfs:label "Raltitrexed" ;
    a m2r:Drug .

civic:drug_Encorafenib
    rdfs:label "Encorafenib" ;
    a m2r:Drug .

civic:drug_GW-2580
    rdfs:label "GW-2580" ;
    a m2r:Drug .

civic:drug_Topotecan
    rdfs:label "Topotecan" ;
    a m2r:Drug .

civic:drug_Ipilimumab
    rdfs:label "Ipilimumab" ;
    a m2r:Drug .

civic:drug_Motesanib
    rdfs:label "Motesanib" ;
    a m2r:Drug .

civic:drug_WZ4002
    rdfs:label "WZ4002" ;
    a m2r:Drug .

civic:drug_Binimetinib%28MEK162%29
    rdfs:label "Binimetinib (MEK162)" ;
    a m2r:Drug .

civic:drug_Tgx221
    rdfs:label "Tgx 221" ;
    a m2r:Drug .

civic:drug_ARRY-470
    rdfs:label "ARRY-470" ;
    a m2r:Drug .

civic:drug_Metformin
    rdfs:label "Metformin" ;
    a m2r:Drug .

civic:drug_PI103
    rdfs:label "PI103" ;
    a m2r:Drug .

civic:drug_Anti-CD123
    rdfs:label "Anti-CD123" ;
    a m2r:Drug .

civic:drug_Brigatinib
    rdfs:label "Brigatinib" ;
    a m2r:Drug .

civic:drug_Ganetespib
    rdfs:label "Ganetespib" ;
    a m2r:Drug .

civic:drug_PegylatedIFN-alpha-2a
    rdfs:label "Pegylated IFN-alpha-2a" ;
    a m2r:Drug .

civic:drug_Amrubicin
    rdfs:label "Amrubicin" ;
    a m2r:Drug .

civic:drug_ARRY-142886
    rdfs:label "ARRY-142886" ;
    a m2r:Drug .

civic:drug_JNJ-42756493
    rdfs:label "JNJ-42756493" ;
    a m2r:Drug .

civic:drug_CyproteroneAcetate
    rdfs:label "Cyproterone Acetate" ;
    a m2r:Drug .

civic:drug_TAE684
    rdfs:label "TAE684" ;
    a m2r:Drug .

civic:drug_CTLA-4Antibody
    rdfs:label "CTLA-4 Antibody" ;
    a m2r:Drug .

civic:drug_AntiangiogenicTherapy
    rdfs:label "Antiangiogenic Therapy" ;
    a m2r:Drug .

civic:drug_Ribociclib
    rdfs:label "Ribociclib" ;
    a m2r:Drug .

civic:drug_Perifosine
    rdfs:label "Perifosine" ;
    a m2r:Drug .

civic:drug_DovitinibDilacticAcid%28TKI258DilacticAcid%29
    rdfs:label "Dovitinib Dilactic Acid (TKI258 Dilactic Acid)" ;
    a m2r:Drug .

civic:drug_AG-120
    rdfs:label "AG-120" ;
    a m2r:Drug .

civic:drug_TIM-3Inhibitor
    rdfs:label "TIM-3 Inhibitor" ;
    a m2r:Drug .

civic:drug_AZD-5363
    rdfs:label "AZD-5363" ;
    a m2r:Drug .

civic:drug_Irbesartan
    rdfs:label "Irbesartan" ;
    a m2r:Drug .

civic:drug_AGI-5198
    rdfs:label "AGI-5198" ;
    a m2r:Drug .

civic:drug_PLX7486
    rdfs:label "PLX7486" ;
    a m2r:Drug .

civic:drug_BMS-354825
    rdfs:label "BMS-354825" ;
    a m2r:Drug .

civic:drug_Chloroquine
    rdfs:label "Chloroquine" ;
    a m2r:Drug .

civic:drug_Refametinib
    rdfs:label "Refametinib" ;
    a m2r:Drug .

civic:drug_Rilotumumab
    rdfs:label "Rilotumumab" ;
    a m2r:Drug .

civic:drug_Vinorelbine
    rdfs:label "Vinorelbine" ;
    a m2r:Drug .

civic:drug_AUY922
    rdfs:label "AUY922" ;
    a m2r:Drug .

civic:drug_4-hydroxytamoxifen
    rdfs:label "4-hydroxytamoxifen" ;
    a m2r:Drug .

civic:drug_ZoledronicAcid
    rdfs:label "Zoledronic Acid" ;
    a m2r:Drug .

civic:drug_Cc-223
    rdfs:label "Cc-223" ;
    a m2r:Drug .

civic:drug_AKTi-1-2
    rdfs:label "AKTi-1/2" ;
    a m2r:Drug .

civic:drug_JQ-1
    rdfs:label "JQ-1" ;
    a m2r:Drug .

civic:drug_Flutamide
    rdfs:label "Flutamide" ;
    a m2r:Drug .

civic:drug_Vandetanib
    rdfs:label "Vandetanib" ;
    a m2r:Drug .

civic:drug_ArsenicTrioxide
    rdfs:label "Arsenic Trioxide" ;
    a m2r:Drug .

civic:drug_OSI-906%28Linsitinib%29
    rdfs:label "OSI-906 (Linsitinib)" ;
    a m2r:Drug .

civic:drug_FOLFOX4
    rdfs:label "FOLFOX4" ;
    a m2r:Drug .

civic:drug_6-mercaptopurine
    rdfs:label "6-mercaptopurine" ;
    a m2r:Drug .

civic:drug_Carboplatin
    rdfs:label "Carboplatin" ;
    a m2r:Drug .

civic:drug_Abiraterone
    rdfs:label "Abiraterone" ;
    a m2r:Drug .

civic:drug_ARN-509
    rdfs:label "ARN-509" ;
    a m2r:Drug .

civic:drug_BMS-387032%28SNS-032%29
    rdfs:label "BMS-387032 (SNS-032)" ;
    a m2r:Drug .

civic:drug_Crenolanib
    rdfs:label "Crenolanib" ;
    a m2r:Drug .

civic:drug_AZ909
    rdfs:label "AZ909" ;
    a m2r:Drug .

civic:drug_UNC1062
    rdfs:label "UNC1062" ;
    a m2r:Drug .

civic:drug_Capecitabin
    rdfs:label "Capecitabin" ;
    a m2r:Drug .

civic:drug_Ponatinib
    rdfs:label "Ponatinib" ;
    a m2r:Drug .

civic:drug_ADI-PEG20
    rdfs:label "ADI-PEG20" ;
    a m2r:Drug .

civic:drug_AEB071
    rdfs:label "AEB071" ;
    a m2r:Drug .

civic:drug_Canertinib
    rdfs:label "Canertinib" ;
    a m2r:Drug .

civic:drug_Osimertinib
    rdfs:label "Osimertinib" ;
    a m2r:Drug .

civic:drug_Prexasertib
    rdfs:label "Prexasertib" ;
    a m2r:Drug .

civic:drug_GDC-0623
    rdfs:label "GDC-0623" ;
    a m2r:Drug .

civic:drug_PD0325901
    rdfs:label "PD0325901" ;
    a m2r:Drug .

civic:drug_LDE225
    rdfs:label "LDE225" ;
    a m2r:Drug .

civic:drug_Bosutinib
    rdfs:label "Bosutinib" ;
    a m2r:Drug .

civic:drug_Capecitabine
    rdfs:label "Capecitabine" ;
    a m2r:Drug .

civic:drug_L-FolinicAcid
    rdfs:label "L-Folinic Acid" ;
    a m2r:Drug .

civic:drug_Midostaurin
    rdfs:label "Midostaurin" ;
    a m2r:Drug .

civic:drug_SU-5402
    rdfs:label "SU-5402" ;
    a m2r:Drug .

civic:drug_Temozolomide
    rdfs:label "Temozolomide" ;
    a m2r:Drug .

civic:drug_RG7112
    rdfs:label "RG7112" ;
    a m2r:Drug .

civic:drug_AdoptiveT-cellTransfer
    rdfs:label "Adoptive T-cell Transfer" ;
    a m2r:Drug .

civic:drug_AromataseInhibitor
    rdfs:label "Aromatase Inhibitor" ;
    a m2r:Drug .

civic:drug_PI3KInhibitor
    rdfs:label "PI3K Inhibitor" ;
    a m2r:Drug .

civic:drug_Ridaforolimus
    rdfs:label "Ridaforolimus" ;
    a m2r:Drug .

civic:drug_Erlotinib-Pertuzumab
    rdfs:label "Erlotinib/Pertuzumab" ;
    a m2r:Drug .

civic:drug_R1507
    rdfs:label "R1507" ;
    a m2r:Drug .

civic:drug_3
    rdfs:label "3" ;
    a m2r:Drug .

civic:drug_BEZ235%28NVP-BEZ235
    rdfs:label "BEZ235 (NVP-BEZ235" ;
    a m2r:Drug .

civic:drug_RG7356
    rdfs:label "RG7356" ;
    a m2r:Drug .

civic:drug_Bicalutamide
    rdfs:label "Bicalutamide" ;
    a m2r:Drug .

civic:drug_Cobimetinib
    rdfs:label "Cobimetinib" ;
    a m2r:Drug .

civic:drug_IPI-504
    rdfs:label "IPI-504" ;
    a m2r:Drug .

civic:drug_LOXO-101
    rdfs:label "LOXO-101" ;
    a m2r:Drug .

civic:drug_Regorafenib
    rdfs:label "Regorafenib" ;
    a m2r:Drug .

civic:drug_6-thioguanine
    rdfs:label "6-thioguanine" ;
    a m2r:Drug .

civic:drug_Tamoxifen
    rdfs:label "Tamoxifen" ;
    a m2r:Drug .

civic:drug_Radiation
    rdfs:label "Radiation" ;
    a m2r:Drug .

civic:drug_EPZ-6438
    rdfs:label "EPZ-6438" ;
    a m2r:Drug .

civic:drug_Vemurafenib
    rdfs:label "Vemurafenib" ;
    a m2r:Drug .

civic:drug_RapaLink-1
    rdfs:label "RapaLink-1" ;
    a m2r:Drug .

civic:drug_Cabazitaxel
    rdfs:label "Cabazitaxel" ;
    a m2r:Drug .

civic:drug_Enzalutamide
    rdfs:label "Enzalutamide" ;
    a m2r:Drug .

civic:drug_AMGMDS3
    rdfs:label "AMGMDS3" ;
    a m2r:Drug .

civic:drug_RAF265
    rdfs:label "RAF265" ;
    a m2r:Drug .

civic:drug_Omipalisib%28GSK2126458%29
    rdfs:label "Omipalisib (GSK2126458)" ;
    a m2r:Drug .

civic:drug_2
    rdfs:label "2" ;
    a m2r:Drug .


